<SEC-DOCUMENT>0001437749-12-003276.txt : 20120403
<SEC-HEADER>0001437749-12-003276.hdr.sgml : 20120403
<ACCEPTANCE-DATETIME>20120403143847
ACCESSION NUMBER:		0001437749-12-003276
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		15
FILED AS OF DATE:		20120403
DATE AS OF CHANGE:		20120403

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-180535
		FILM NUMBER:		12736964

	BUSINESS ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080
		BUSINESS PHONE:		678-384-7220

	MAIL ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>geovax_s1-032812.htm
<DESCRIPTION>FORM S-1
<TEXT>
<html>
<head>
    <title>geovax_s1-032812.htm</title>
    <!--Licensed to: RDG-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">As Filed with the Securities and Exchange Commission on April 3, 2012.</font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Registration No.&#160;&#160;333-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>

<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%">
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 1pt">&#160;</font></div>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Washington, D.C.&#160;&#160;20549</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">FORM&#160;S-1</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">REGISTRATION STATEMENT</font></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNDER THE SECURITIES ACT OF 1933</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">GEOVAX LABS, INC.</font></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="33%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware</font></div>
</td>
<td valign="top" width="34%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2834</font></div>
</td>
<td valign="top" width="33%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">87-0455038</font></div>
</td>
</tr><tr>
<td valign="top" width="33%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or other jurisdiction of incorporation&#160;or&#160;organization)</font></div>
</td>
<td valign="top" width="34%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Primary Standard Industrial Classification&#160;Code&#160;Number)</font></div>
</td>
<td valign="top" width="33%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(I.R.S.&#160;&#160;Employer Identification&#160;Number)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1900 Lake Park Drive, Suite 380, Smyrna, Georgia 30080, (678) 384-7220</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="25%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="top" width="31%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Robert T. McNally, Ph.D.</font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">President&#160;&amp; Chief Executive Officer</font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GeoVax Labs,&#160;Inc.</font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1900 Lake Park Drive, Suite 380</font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Smyrna, Georgia 30080</font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Tel: (678) 384-7220</font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fax: (678) 384-7283</font></div>
</td>
<td valign="top" width="44%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline"><font style="DISPLAY: inline">With a copy to</font>:</font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">T. Clark Fitzgerald III</font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Womble Carlyle Sandridge &amp; Rice, LLP</font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">271 17<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Street NW, Suite 2400</font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Atlanta, Georgia 30363</font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Tel: (404) 879-2455</font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fax: (404) 870-4869</font></div>
</td>
</tr><tr>
<td colspan="3" valign="top" width="25%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Name, address, including zip code, and telephone number, including area code, of agent for service)</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Approximate date of commencement of proposed sale to the public: </font>From time to time after the effective date of this registration statement.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If any of the securities being registered on this Form&#160;are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act, check the following box. <font style="DISPLAY: inline;" face="Wingdings">x</font><a name="Check1"><!--EFPlaceholder--></a></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="DISPLAY: inline;" face="Wingdings">o</font><a name="Check2"><!--EFPlaceholder--></a></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If this form is a post-effective amendment filed pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font style="DISPLAY: inline;" face="Wingdings">o</font><a name="BM__________"><!--EFPlaceholder--></a></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.&#160;&#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Large accelerated filer&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accelerated filer&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Non-accelerated filer&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Smaller reporting company <font style="DISPLAY: inline;" face="Wingdings">x</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Calculation of Registration Fee</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="2" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="23%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Title of Each Class Of Securities To Be Registered</font></div>
</div>
</td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amount To Be Registered (1)</font></div>
</div>
</td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Proposed Maximum Offering Price Per Unit</font></div>
</div>
</td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Proposed Maximum Aggregate Offering Price</font></div>
</div>
</td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amount of Registration Fee</font></div>
</div>
</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="middle" width="23%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -27pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock, $0.001 par value per share underlying Series A convertible preferred stock, $0.001 par value per share</font></div>
</td>
<td align="left" valign="middle" width="14%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,933,333<font style="DISPLAY: inline; FONT-FAMILY: times new roman">(2)</font></font></div>
</td>
<td align="left" valign="middle" width="14%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$0.99(<font style="DISPLAY: inline; FONT-FAMILY: times new roman">3)</font></font></div>
</td>
<td align="left" valign="middle" width="14%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$2,904,000(<font style="DISPLAY: inline; FONT-FAMILY: times new roman">3)</font></font></div>
</td>
<td align="left" valign="middle" width="14%" style="BORDER-BOTTOM: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$332.80</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="middle" width="23%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -27pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock underlying Outstanding Series A and Series C Warrants</font></div>
</td>
<td align="left" valign="middle" width="14%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,866,666<font style="DISPLAY: inline; FONT-FAMILY: times new roman">(4)</font></font></div>
</td>
<td align="left" valign="middle" width="14%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.00<font style="DISPLAY: inline; FONT-FAMILY: times new roman">(5)</font></font></div>
</td>
<td align="left" valign="middle" width="14%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,866,666(5)</font></div>
</td>
<td align="left" valign="middle" width="14%" style="BORDER-BOTTOM: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">672.32</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="middle" width="23%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -27pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock underlying outstanding Series B Warrants</font></div>
</td>
<td align="left" valign="middle" width="14%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,933,333<font style="DISPLAY: inline; FONT-FAMILY: times new roman">(4)</font></font></div>
</td>
<td align="left" valign="middle" width="14%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$0.75<font style="DISPLAY: inline; FONT-FAMILY: times new roman">(5)</font></font></div>
</td>
<td align="left" valign="middle" width="14%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,200,000<font style="DISPLAY: inline; FONT-FAMILY: times new roman">(5)</font></font></div>
</td>
<td align="left" valign="middle" width="14%" style="BORDER-BOTTOM: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">252.12</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="middle" width="23%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -27pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font></div>
</td>
<td align="left" valign="middle" width="14%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,733,332</font></div>
</td>
<td valign="middle" width="14%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="14%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$10,970,666</font></div>
</td>
<td align="left" valign="middle" width="14%" style="BORDER-BOTTOM: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$1,257.24(6)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1) In accordance with Rule 416(a<font style="DISPLAY: inline; FONT-SIZE: 10pt">)</font>, the Registrant is also registering hereunder an indeterminate number of shares that may be issued and resold resulting from stock splits, stock dividends or similar transactions.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2) Represents shares of the Registrant&#8217;s common stock underlying shares of Series A convertible preferred stock being registered for resale that have been issued to the selling stockholders named in this registration statement.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(3) Estimated pursuant to Rule 457(c) of the Securities Act of 1933 solely for the purpose of computing the amount of the registration fee based on the average of the bid and asked prices reported on the over-the-counter bulletin board on March 30, 2012, which was $.99 per share.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(4) Represents shares of common stock issuable upon exercise of warrants to purchase shares of common stock held by selling stockholders named in this registration statement.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(5) Calculated in accordance with Rule 457(g) based upon the aggregate exercise price of the warrants held by selling stockholders named in this registration statement.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(6) The Registrant previously filed Form S-1 (333-165825) on March 31, 2010, and paid a filing fee of $2,852.&#160;&#160;The Registrant did not sell any securities pursuant to that Form S-1, and it was withdrawn in December, 2011. Pursuant to Rule 457(p), the Registrant hereby applies $1,257.24 of the previously paid filing fee against amounts due herewith.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to Section&#160;8(a), may determine.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The information in this prospectus is not complete and may be changed.&#160;&#160;The selling stockholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective.&#160;&#160;This prospectus is not an offer to sell these securities and it is not soliciting offers to buy these securities in any state where the offer or sale is not permitted.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SUBJECT TO COMPLETION, DATED APRIL 3, 2012.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 7.2pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PROSPECTUS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 7.2pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GEOVAX LABS, INC.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 7.2pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Up to 11,733,332 Shares of Common Stock</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="85%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">This prospectus relates to up to 11,733,332 shares of common stock, $0.001 par value, of GeoVax Labs, Inc. that may be sold from time to time by the selling stockholders named in this prospectus, which includes up to:&#160;</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="85%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="85%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif">&#183; </font>2,933,333 shares of common stock underlying Series A convertible preferred stock, par value $0.01 per share, and</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="85%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="middle" width="85%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: symbol, serif">&#183; </font>8,799,999 shares of common stock issuable to the selling stockholders upon the exercise of Series A, B and C Warrants.</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="85%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="middle" width="85%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The prices at which the Selling Stockholders may sell the shares will be determined by the prevailing market price for the shares or in negotiated transactions.&#160;&#160;The shares included in this prospectus may be reoffered and sold directly by the selling stockholders in accordance with one or more of the methods described in the plan of distribution, which begins on page 46 of this prospectus.&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We will not receive any proceeds from the sales of outstanding shares of common stock by the selling stockholders, but we will receive funds from the exercise of Series A, B or C Warrants held by the selling stockholders, if exercised for cash.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Our common stock is registered under Section&#160;12(g) of the Securities Exchange Act of 1934 and quoted on the over-the-counter bulletin board under the symbol &#8220;GOVX.&#8221; On March 30, 2012, the last reported sale price for our common stock as reported on the over-the-counter bulletin board was $.97 per share.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">This prospectus may only be used where it is legal to offer and sell the shares covered by this prospectus. We have not taken any action to register or obtain permission for this offering or the distribution of this prospectus in any country other than the United States.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">____________________</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Investing in the common stock involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page&#160;3 for a discussion of these risks.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">____________________</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">____________________</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The date of this Prospectus is April&#160;____, 2012</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">TABLE OF CONTENTS</font></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#c0ffff">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">PROSPECTUS SUMMARY</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">RISK FACTORS</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">FORWARD-LOOKING STATEMENTS</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">USE OF PROCEEDS</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">MARKET FOR OUR COMMON STOCK AND RELATED STOCKHOLDER MATTERS</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">BUSINESS</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">SELECTED FINANCIAL DATA</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">DIRECTORS AND EXECUTIVE OFFICERS</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">34</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">EXECUTIVE COMPENSATION</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">36</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">DIRECTOR COMPENSATION</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">40</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">41</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">SECURITY OWNERSHIP OF PRINCIPAL STOCKHOLDERS, DIRECTORS AND OFFICERS</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">SELLING STOCKHOLDERS</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">44</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">PLAN OF DISTRIBUTION</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">46</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">DESCRIPTION OF SECURITIES</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">48</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">52</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">WHERE YOU CAN FIND MORE INFORMATION</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">EXPERTS</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">LEGAL MATTERS</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">INDEX TO THE FINANCIAL STATEMENTS</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-1</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="96%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">PART II &#8211; INFORMATION NOT REQUIRED IN PROSPECTUS</font></div>
</td>
<td align="right" valign="top" width="4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">II-1</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">You should rely only on the information contained in this prospectus and in any accompanying prospectus supplement.&#160;&#160;We have not authorized anyone to provide you with different information.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We have not authorized the selling stockholders to make an offer of these shares of common stock in any jurisdiction where the offer is not permitted.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">You should not assume that the information in this prospectus or prospectus supplement is accurate as of any date other than the date on the front of this prospectus.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PROSPECTUS SUMMARY</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This summary highlights information contained elsewhere in this prospectus. It does not contain all of the information that you should consider before investing in our securities. Please read the entire prospectus carefully, including the section entitled &#8220;Risk Factors&#8221; and our consolidated financial statements and the related notes. We have not authorized anyone else to provide you with different information, and if you receive any unauthorized information you should not rely on it. The information appearing in this prospectus is accurate only as of its date. Our business, financial condition, results of operations and prospects may have changed since that date.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">You should not invest unless you can afford to lose your entire investment.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Company Overview</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">GeoVax Labs, Inc. is a biotechnology company developing vaccines that prevent and fight Human Immunodeficiency Virus (&#8220;HIV&#8221;) infections.&#160;&#160;HIV infections result in Acquired Immunodeficiency Syndrome (&#8220;AIDS&#8221;).&#160;&#160;We have exclusively licensed from Emory University (&#8220;Emory&#8221;) vaccine technology which was developed in collaboration with the United States National Institutes of Health (&#8220;NIH&#8221;) and the United States Centers for Disease Control and Prevention (&#8220;CDC&#8221;).</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our current vaccines under development address the clade B subtype of the HIV virus that is most prevalent in the United States and the developed world.&#160;&#160;Our vaccines are being evaluated to determine their potential to (a) prevent HIV infection and (b) to serve as a therapy for individuals who are already infected with HIV.&#160;&#160;These vaccines are currently being evaluated in humans -- both in those infected with HIV and those who are not.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our vaccines incorporate two delivery components: a recombinant deoxyribonucleic acid, or DNA vaccine, and a recombinant poxvirus designated modified vaccinia Ankara, or MVA vaccine. Both the DNA and MVA vaccines contain sufficient HIV genes to support the production of non-infectious virus-like particles.&#160;&#160;These particles display the native trimeric-membrane-bound form of the viral envelope glycoprotein that mediates entry into cells and is the target for protective antibody. When used together, the recombinant DNA component primes immune responses, which are boosted by administration of the recombinant MVA component.&#160;&#160;We are also testing a new version of our preventive vaccine that co-expresses granulocyte-macrophage colony-stimulating factor (GM-CSF) in the DNA vaccine used to prime the immune response.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Work on our vaccines began during the 1990s at Emory University in Atlanta, Georgia, under the direction of Dr.&#160;Harriet L. Robinson, who is now our Chief Scientific Officer. The vaccine technology was developed in collaboration with researchers at the&#160;NIH and the CDC. The technology developed by the collaboration is exclusively licensed to us from Emory University.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our common stock is quoted on the OTC Bulletin&#160;Board under the symbol &#8220;GOVX.&#8221; On March 30, 2012, the last reported sale price for our common stock on the OTC Bulletin&#160;Board was $0.97 per share.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As used herein, &#8220;GeoVax,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and similar terms include GeoVax Labs, Inc., and its operating subsidiary, GeoVax, Inc., unless the context indicates otherwise.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are incorporated under the laws of the State of Delaware. Our principal executive offices are located at 1900 Lake Park Drive, Suite&#160;380, Smyrna, Georgia 30080 (metropolitan Atlanta). Our telephone number is (678)&#160;384-7220. The address of our website is www.geovax.com. Information on our website is not part of this prospectus.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The Offering</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#c0ffff">
<td align="left" colspan="2" valign="top" width="48%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock offered by selling stockholders</font></div>
</td>
<td colspan="2" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="46%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Up to 11,733,332 shares, consisting of 2,933,333 shares of common stock underlying Series A Preferred Stock owned by selling stockholders and 8,799,999 shares of common stock issuable upon the exercise of Series A, B or C Warrants held by the selling stockholders. This number represents approximately 41% of our current outstanding common stock, on a fully diluted basis.<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(1)</font></font></div>
</td>
</tr><tr bgcolor="white">
<td colspan="2" valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="46%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" colspan="2" valign="top" width="48%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock outstanding before the offering</font></div>
</td>
<td colspan="2" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="46%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,850,610 shares (1)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" colspan="2" valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="top" width="46%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" colspan="2" valign="top" width="48%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock outstanding after the offering, assuming all the shares of Series A Preferred Stock are converted into common stock and the Series A, B and C Warrants are exercised for cash.</font></div>
</td>
<td colspan="2" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="46%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28,583,942 shares (1)</font></div>
</td>
</tr><tr bgcolor="white">
<td colspan="2" valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="46%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" colspan="2" valign="top" width="48%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds to us</font></div>
</td>
<td colspan="2" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="46%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">We will not receive any proceeds from the sale of common stock covered by this prospectus. We will, however, receive approximately $8.1 million from the exercise of the Series A, B, and C Warrants held by the selling stockholders, if they are exercised in full for cash.</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" colspan="2" valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="top" width="46%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" colspan="2" valign="top" width="48%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Trading Symbol</font></div>
</td>
<td align="left" colspan="2" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="46%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">GOVX</font></div>
</td>
</tr><tr bgcolor="white">
<td colspan="2" valign="top" width="48%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="46%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#c0ffff">
<td colspan="2" valign="top" width="48%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Risk Factors</font></div>
</td>
<td colspan="2" valign="top" width="6%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="46%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">There are significant risks involved in investing in our Company.&#160;&#160;For a discussion of risk factors you should consider before buying our common stock.&#160;&#160;See &#8220;Risk Factors&#8221; beginning on page 3.</font></font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">____________________</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1) The number of shares of our common stock to be outstanding after this offering is based on the number of shares outstanding as of March 30, 2012 and excludes:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1,197,529 shares of common stock reserved for future issuance under our equity incentive plans.&#160;&#160;As of March 30, 2012, there were options to purchase 922,042 shares of our common stock outstanding under our equity incentive plans with a weighted average exercise price of $5.45 per share;</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2,482,560 shares of common stock issuable upon exercise of currently outstanding warrants (but not including the Series A, B and C Warrants) as of March 30, 2012, with a weighted average exercise price of $6.24 per share;</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">RISK FACTORS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">You should carefully consider the risks, uncertainties and other factors described below before you decide whether to buy shares of our common stock.&#160;&#160;Any of the factors could materially and adversely affect our business, financial condition, operating results and prospects and could negatively impact the market price of our common stock.&#160;&#160;Also, you should be aware that the risks and uncertainties described below are not the only ones we face.&#160;&#160;Additional risks and uncertainties, of which we are not yet aware, or that we currently consider to be immaterial, may also impair our business operations.&#160;&#160;You should also refer to the other information contained in and incorporated by reference into this prospectus, including our financial statements and the related notes.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a name="tx35073_26"><!--EFPlaceholder--></a>Risks Related to Our Financial Results and Need for Additional Financing</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We have a history of operating losses, and we expect losses to continue for the foreseeable future.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have had no product revenue to date and there can be no assurance that we will ever generate any product revenue. We have experienced operating losses since we began operations in 2001. As of December 31, 2011, we had an accumulated deficit of approximately $22.6 million. We expect to incur additional operating losses and expect cumulative losses to increase as our research and development, pre-clinical, clinical, manufacturing and marketing efforts expand. Our ability to generate revenue and achieve profitability depends on our ability to successfully complete the development of our product candidates, conduct pre-clinical tests and clinical trials, obtain the necessary regulatory approvals, and manufacture and market the resulting products. Unless we are able to successfully meet these challenges, we will not be profitable and may not remain in business.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our business will require continued funding. If we do not receive adequate funding, we will not be able to continue our operations.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To date, we have financed our operations principally through the private placement of equity securities and through NIH grants. We will require substantial additional financing at various intervals for our operations, including clinical trials, operating expenses, intellectual property protection and enforcement, for pursuit of regulatory approvals, and for establishing or contracting out manufacturing, marketing and sales functions. There is no assurance that such additional funding will be available on terms acceptable to us or at all. If we are not able to secure the significant funding that is required to maintain and continue our operations at current levels, or at levels that may be required in the future, we may be required to delay clinical studies or clinical trials, curtail operations, or obtain funds through collaborative arrangements that may require us to relinquish rights to some of our products or potential markets.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The costs of conducting all of our human clinical trials to date have been borne by the HIV Vaccine Trials Network (&#8220;HVTN&#8221;), funded by the NIH, with GeoVax incurring costs associated with manufacturing the clinical vaccine supplies and other study support. This includes the cost of conducting the ongoing Phase 2a human clinical study of our preventive vaccine. We cannot predict the level of support we will receive from the HVTN or the NIH for any additional clinical trials. We are currently not receiving any governmental support for our Phase 1/2 therapeutic vaccine human clinical trial.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our operations are also partially supported by the&#160;Integrated Preclinical/Clinical AIDS Vaccine Development&#160;(&#8220;IPCAVD&#8221;) grant awarded to us to support our HIV/AIDS vaccine program. The project period for the grant covers a five year period which commenced October 2007, with an aggregate award of $20.4 million. As of December 31, 2011, there is approximately $3.9 million of unused grant funds remaining and available for use through August 31, 2012 (the end of the original project period). We intend to pursue additional grants from the federal government. However, as we progress to the later stages of our vaccine development activities, government financial support may be more difficult to obtain, or may not be available at all. Therefore, it will be necessary for us to look to other sources of funding in order to finance our development activities.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our current working capital, combined with proceeds from the IPCAVD grant awarded from the NIH will be sufficient to support our planned level of operations into the first quarter of 2013, without giving consideration to the potential proceeds from exercise of the Series A, B or C Warrants.&#160;&#160;In order to meet our operating cash flow requirements we plan additional offerings of our equity securities, debt, or convertible debt instruments.&#160;&#160;Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive when we require it, the consequences could have a material adverse effect on our business, operating results, financial condition and prospects.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The current economic conditions may adversely impact our ability to raise capital.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The recession and adverse conditions in the national and global markets may negatively affect both our ability to raise capital and our operations in the future. The volatile equity markets and adverse credit markets may make it difficult for us to raise capital or procure credit in the future to fund the growth of our business, which could have a negative impact on our business and results of operations.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks Related to Development and Commercialization of Product Candidates and Dependence on Third Parties</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our products are still being developed and are unproven. These products may not be successful.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To become profitable, we must generate revenue through sales of our products. However our products are in varying stages of development and testing. Our products have not been proven in human clinical trials and have not been approved by any government agency for sale. If we cannot successfully develop and prove our products and processes, or if we do not develop other sources of revenue, we will not become profitable and at some point we would discontinue operations.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Whether we are successful will be dependent, in part, upon the leadership provided by our management. If we were to lose the services of any of these individuals, our business and operations may be adversely affected. Further, we may not carry key man life insurance on our executive officers or directors.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Whether our business will be successful will be dependent, in part, upon the leadership provided by our officers, particularly our President and Chief Executive Officer and our Chief Scientific Officer. The loss of the services of these individuals may have an adverse effect on our operations. Although we carry some key man life insurance on Dr.&#160;Harriet L. Robinson, the amount of such coverage may not be sufficient to offset any adverse economic effects on our operations and we do not carry key man insurance on any of our other executive officers or directors. Further, our employees, including our executive officers and directors, are not subject to any covenants not to compete against the Company, and our business could be adversely affected if any of our employees or directors engaged in an enterprise competitive with the Company.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Regulatory and legal uncertainties could result in significant costs or otherwise harm our business.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To manufacture and sell our products, we must comply with extensive domestic and international regulation. In order to sell our products in the United States, approval from the FDA is required. Satisfaction of regulatory requirements, including FDA requirements, typically takes many years, and if approval is obtained at all, it is dependent upon the type, complexity and novelty of the product, and requires the expenditure of substantial resources. We cannot predict whether our products will be approved by the FDA. Even if they are approved, we cannot predict the time frame for approval. Foreign regulatory requirements differ from jurisdiction to jurisdiction and may, in some cases, be more stringent or difficult to meet than FDA requirements. As with the FDA, we cannot predict if or when we may obtain these regulatory approvals. If we cannot demonstrate that our products can be used safely and successfully in a broad segment of the patient population on a long-term basis, our products would likely be denied approval by the FDA and the regulatory agencies of foreign governments.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We will face intense competition and rapid technological change that could result in products that are superior to the products we will be commercializing or developing.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The market for vaccines that protect against or treat HIV/AIDS is intensely competitive and is subject to rapid and significant technological change. We will have numerous competitors in the United States and abroad, including, among others, large companies with substantially greater resources than us. These competitors may develop technologies and products that are more effective or less costly than any of our future technology or products or that could render our technology or products obsolete or noncompetitive. If our technology or products are not competitive, we may not be able to remain in business.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our product candidates are based on new medical technology and, consequently, are inherently risky. Concerns about the safety and efficacy of our products could limit our future success.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are subject to the risks of failure inherent in the development of product candidates based on new medical technologies. These risks include the possibility that the products we create will not be effective, that our product candidates will be unsafe or otherwise fail to receive the necessary regulatory approvals, and that our product candidates will be hard to manufacture on a large scale or will be uneconomical to market.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Many pharmaceutical products cause multiple potential complications and side effects, not all of which can be predicted with accuracy and many of which may vary from patient to patient. Long term follow-up data may reveal additional complications associated with our products. The responses of potential physicians and others to information about complications could materially affect the market acceptance of our products, which in turn would materially harm our business.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may experience delays in our clinical trials that could adversely affect our financial results and our commercial prospects.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We do not know whether planned clinical trials will begin on time or whether we will complete any of our clinical trials on schedule, if at all. Product development costs will increase if we have delays in testing or approvals or if we need to perform more or larger clinical trials than planned. Significant delays may adversely affect our financial results and the commercial prospects for our products, and delay our ability to become profitable.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We rely heavily on the HVTN, independent clinical investigators, and other third party service providers for successful execution of our clinical trials, but do not control many aspects of their activities. We are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as Good Clinical Practices, for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. Third parties may not complete activities on schedule, or may not conduct our clinical trials in accordance with regulatory requirements or our stated protocols. The failure of these third parties to carry out their obligations could delay or prevent the development, approval and commercialization of our product candidates.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Failure to obtain timely regulatory approvals required to exploit the commercial potential of our products could increase our future development costs or impair our future sales.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">None of our vaccines are approved by the FDA for sale in the United States or by other regulatory authorities for sale in foreign countries. To exploit the commercial potential of our technologies, we are conducting and planning to conduct additional pre-clinical studies and clinical trials. This process is expensive and can require a significant amount of time. Failure can occur at any stage of testing, even if the results are favorable. Failure to adequately demonstrate safety and efficacy in clinical trials could delay or preclude regulatory approval and restrict our ability to commercialize our technology or products. Any such failure may severely harm our business. In addition, any approvals we obtain may not cover all of the clinical indications for which approval is sought, or may contain significant limitations in the form of narrow indications, warnings, precautions or contraindications with respect to conditions of use, or in the form of onerous risk management plans, restrictions on distribution, or post-approval study requirements.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">State pharmaceutical marketing compliance and reporting requirements may expose us to regulatory and legal action by state governments or other government authorities.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In recent years, several states have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs and file periodic reports on sales, marketing, pricing and other activities. Similar legislation is being considered in other states. Many of these requirements are new and uncertain, and available guidance is limited. Unless we are in full compliance with these laws, we could face enforcement action and fines and other penalties and could receive adverse publicity, all of which could harm our business.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may be subject to new federal and state legislation to submit information on our open and completed clinical trials to public registries and databases.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In 1997, a public registry of open clinical trials involving drugs intended to treat serious or life-threatening diseases or conditions was established under the FDA Modernization Act, or the FDMA, to promote public awareness of and access to these clinical trials. Under the FDMA, pharmaceutical manufacturers and other trial sponsors are required to post the general purpose of these trials, as well as the eligibility criteria, location and contact information of the trials. Since the establishment of this registry, there has been significant public debate focused on broadening the types of trials included in this or other registries, as well as providing for public access to clinical trial results. A voluntary coalition of medical journal editors has adopted a resolution to publish results only from those trials that have been registered with a no-cost, publicly accessible database, such as www.clinicaltrials.gov. Federal legislation was introduced in the fall of 2004 to expand www.clinicaltrials.gov and to require the inclusion of trial results in this registry. The Pharmaceutical Research and Manufacturers of America also issued voluntary principles for its members to make results from certain clinical trials publicly available and established a website for this purpose. Other groups have adopted or are considering similar proposals for clinical trial registration and the posting of clinical trial results. Failure to comply with any clinical trial posting requirements could expose us to negative publicity, fines and other penalties, all of which could materially harm our business.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We will face uncertainty related to pricing and reimbursement and health care reform.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In both domestic and foreign markets, sales of our products will depend in part on the availability of reimbursement from third-party payers such as government health administration authorities, private health insurers, health maintenance organizations and other health care-related organizations. Reimbursement by such payers is presently undergoing reform and there is significant uncertainty at this time how this will affect sales of certain pharmaceutical products.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Medicare, Medicaid and other governmental healthcare programs govern drug coverage and reimbursement levels in the United States. Federal law requires all pharmaceutical manufacturers to rebate a percentage of their revenue arising from Medicaid-reimbursed drug sales to individual states. Generic drug manufacturers&#8217; agreements with federal and state governments provide that the manufacturer will remit to each state Medicaid agency, on a quarterly basis, 11% of the average manufacturer price for generic products marketed and sold under abbreviated new drug applications covered by the state&#8217;s Medicaid program. For proprietary products, which are marketed and sold under new drug applications, manufacturers are required to rebate the greater of (a)&#160;15.1% of the average manufacturer price or (b)&#160;the difference between the average manufacturer price and the lowest manufacturer price for products sold during a specified period.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Both the federal and state governments in the United States, and foreign governments, continue to propose and pass new legislation, rules and regulations designed to contain or reduce the cost of health care. Existing regulations that affect the price of pharmaceutical and other medical products may also change before any of our products are approved for marketing. Cost control initiatives could decrease the price that we receive for any product developed in the future. In addition, third-party payers are increasingly challenging the price and cost-effectiveness of medical products and services and litigation has been filed against a number of pharmaceutical companies in relation to these issues. Additionally, some uncertainty may exist as to the reimbursement status of newly approved injectable pharmaceutical products. Our products may not be considered cost-effective or adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an adequate return on our investment.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may not be successful in establishing collaborations for product candidates we may seek to commercialize, which could adversely affect our ability to discover, develop, and commercialize products.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We expect to seek collaborations for the development and commercialization of product candidates in the future. The timing and terms of any collaboration will depend on the evaluation by prospective collaborators of the clinical trial results and other aspects of our vaccine&#8217;s safety and efficacy profile. If we are unable to reach agreements with suitable collaborators for any product candidate, we will be forced to fund the entire development and commercialization of such product candidates, ourselves, and we may not have the resources to do so. If resource constraints require us to enter into a collaboration agreement early in the development of a product candidate, we may be forced to accept a more limited share of any revenues this product may eventually generate. We face significant competition in seeking appropriate collaborators. Moreover, these collaboration arrangements are complex and time-consuming to negotiate and document. We may not be successful in our efforts to establish collaborations or other alternative arrangements for any product candidate. Even if we are successful in establishing collaborations, we may not be able to ensure fulfillment by collaborators of their obligations or our expectations.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We do not have manufacturing, sales or marketing experience.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We do not have experience in manufacturing, selling, or marketing vaccines. To obtain the expertise necessary to successfully manufacture, market, and sell our vaccines, we will require the development of our own commercial infrastructure and/or collaborative commercial arrangements and partnerships. Our ability to execute our current operating plan is dependent on numerous factors, including, the performance of third party collaborators with whom we may contract.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our vaccines under development may not gain market acceptance.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our vaccines may not gain market acceptance among physicians, patients, healthcare payers and the medical community. Significant factors in determining whether we will be able to compete successfully include:</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the efficacy and safety of our vaccines;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the time and scope of regulatory approval;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">reimbursement coverage from insurance companies and others;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the price and cost-effectiveness of our products, and</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the ability to maintain patent protection.</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We may be required to defend lawsuits or pay damages for product liability claims.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Product liability is a major risk in testing and marketing biotechnology and pharmaceutical products. We may face substantial product liability exposure in human clinical trials and for products that we sell after regulatory approval. We carry product liability insurance and we expect to continue such policies. However, product liability claims, regardless of their merits, could exceed policy limits, divert management&#8217;s attention, and adversely affect our reputation and the demand for our products.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks Related to Our Intellectual Property</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We could lose our license rights to our important intellectual property if we do not fulfill our contractual obligations to our licensors.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our rights to significant parts of the technology we use in our vaccines are licensed from third parties and are subject to termination if we do not fulfill our contractual obligations to our licensors. Termination of intellectual property rights under any of our license agreements could adversely impact our ability to produce or protect our vaccines. Our obligations under our license agreements include requirements that we make milestone payments to our licensors upon the achievement of clinical development and regulatory approval milestones, royalties as we sell commercial products, and reimbursement of patent filing and maintenance expenses. Should we become bankrupt or otherwise unable to fulfill our contractual obligations, our licensors could terminate our rights to critical technology that we rely upon.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other parties may claim that we infringe their intellectual property or proprietary rights, which could cause us to incur significant expenses or prevent us from selling products.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our success will depend in part on our ability to operate without infringing the patents and proprietary rights of third parties. The manufacture, use and sale of new products have been subject to substantial patent rights litigation in the pharmaceutical industry. These lawsuits generally relate to the validity and infringement of patents or proprietary rights of third parties. Infringement litigation is prevalent with respect to generic versions of products for which the patent covering the brand name product is expiring, particularly since many companies that market generic products focus their development efforts on products with expiring patents. Pharmaceutical companies, biotechnology companies, universities, research institutions or other third parties may have filed patent applications or may have been granted patents that cover aspects of our products or our licensors&#8217; products, product candidates or other technologies.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Future or existing patents issued to third parties may contain patent claims that conflict with our products. We expect to be subject to infringement claims from time to time in the ordinary course of business, and third parties could assert infringement claims against us in the future with respect to our current products or with respect to products that we may develop or license. Litigation or interference proceedings could force us to:</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">stop or delay selling, manufacturing or using products that incorporate, or are made using the challenged intellectual property;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">pay damages; or</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">enter into licensing or royalty agreements that may not be available on acceptable terms, if at all.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Any litigation or interference proceedings, regardless of their outcome, would likely delay the regulatory approval process, be costly and require significant time and attention of our key management and technical personnel.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Any inability to protect intellectual property rights in the United States and foreign countries could limit our ability to manufacture or sell products.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We will rely on trade secrets, unpatented proprietary know-how, continuing technological innovation and, in some cases, patent protection to preserve our competitive position. Our patents and licensed patent rights may be challenged, invalidated, infringed or circumvented, and the rights granted in those patents may not provide proprietary protection or competitive advantages to us. We and our licensors may not be able to develop patentable products. Even if patent claims are allowed, the claims may not issue, or in the event of issuance, may not be sufficient to protect the technology owned by or licensed to us. If patents containing competitive or conflicting claims are issued to third parties, we may be prevented from commercializing the products covered by such patents, or may be required to obtain or develop alternate technology. In addition, other parties may duplicate, design around or independently develop similar or alternative technologies.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We may not be able to prevent third parties from infringing or using our intellectual property, and the parties from whom we may license intellectual property may not be able to prevent third parties from infringing or using the licensed intellectual property. We generally will attempt to control and limit access to, and the distribution of, our product documentation and other proprietary information. Despite efforts to protect this proprietary information, unauthorized parties may obtain and use information that we may regard as proprietary. Other parties may independently develop similar know-how or may even obtain access to these technologies.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The laws of some foreign countries do not protect proprietary information to the same extent as the laws of the United States, and many companies have encountered significant problems and costs in protecting their proprietary information in these foreign countries.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Neither the U.S.&#160;Patent and Trademark Office nor the courts have established a consistent policy regarding the breadth of claims allowed in pharmaceutical patents. The allowance of broader claims may increase the incidence and cost of patent interference proceedings and the risk of infringement litigation. On the other hand, the allowance of narrower claims may limit the value of our proprietary rights.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Risks Related to Our Common Stock</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The market price of our common stock is highly volatile.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The market price of our common stock has been, and is expected to continue to be, highly volatile. Certain factors, including announcements of new developments by us or other companies, regulatory matters, new or existing medicines or procedures, concerns about our financial position, operating results, litigation, government regulation, developments or disputes relating to agreements, patents or proprietary rights, may have a significant impact on the market price of our stock. In addition, potential dilutive effects of future sales of shares of common stock by us, and subsequent sales of common stock by the holders of warrants and options could have an adverse effect on the market price of our shares.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our common stock does not have a vigorous trading market and investors may not be able to sell their securities when desired.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have a limited active public market for our common shares.&#160;&#160;A more active public market, allowing investors to sell large quantities of our common stock, may never develop. Consequently, investors may not be able to liquidate their investments in the event of an emergency or for any other reason.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We have never paid dividends and have no plans to do so.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Holders of shares of our common stock are entitled to receive such dividends as may be declared by our Board of Directors. To date, we have paid no cash dividends on our shares of common stock and we do not expect to pay cash dividends on our common stock in the foreseeable future. We intend to retain future earnings, if any, to provide funds for operations of our business. Therefore, any potential return investors in our common stock may have will be in the form of appreciation, if any, in the market value of their shares of common stock.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent fraud.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are subject to reporting obligations under the United States securities laws. The Securities and Exchange Commission, or the SEC, as required by the Sarbanes-Oxley Act of 2002, adopted rules requiring every public company to include a management report on such company&#8217;s internal controls over financial reporting in its annual report. Effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent fraud. As a result, our failure to achieve and maintain effective internal controls over financial reporting could result in the loss of investor confidence in the reliability of our financial statements, which in turn could negatively impact the trading price of our stock.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">If we fail to remain current in our reporting requirements, our securities could be removed from the OTC Bulletin&#160;Board, which would limit the ability of broker-dealers to sell our securities and the ability of stockholders to sell their securities in the secondary market.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">United States companies trading on the OTC Bulletin&#160;Board must be reporting issuers under Section&#160;12 of the Exchange Act, and must be current in their reports under Section&#160;13. If we fail to remain current on our reporting requirements, we could be removed from the OTC Bulletin&#160;Board. As a result, the market liquidity for our securities could be severely adversely affected by limiting the ability of broker-dealers to sell our securities and the ability of stockholders to sell their securities in the secondary market.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">We expect to need additional capital, and the sale of additional shares or other equity securities could result in additional dilution to our stockholders.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We believe that our current cash and cash equivalents, combined with anticipated cash flow from the IPCAVD grant, will be sufficient to meet our anticipated cash needs into the first quarter of 2013, without giving consideration to the potential proceeds from exercise of the Series A, B or C Warrants.&#160;&#160;In order to meet our operating cash flow requirements we plan additional offerings of our equity securities, debt, or convertible debt instruments. The sale of additional equity securities could result in additional dilution to our stockholders.&#160;&#160;Certain equity securities, such as convertible preferred stock, or warrants, may contain anti-dilution provisions which could result in the issuance of additional shares at lower prices if we sell other shares below specified prices.&#160;&#160;The incurrence of indebtedness would result in debt service obligations and could result in operating and financing covenants that would restrict our operations. We cannot assure investors that financing will be available in amounts or on terms acceptable to us, if at all.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our directors and executive officers beneficially own a significant amount of our common stock and will be able to exercise significant influence on matters requiring stockholder approval.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our directors and executive officers collectively beneficially own approximately 14.3% of our common stock as of March 30, 2012.&#160;&#160;Consequently, our directors and executive officers as a group are able to exert significant influence over the election of directors and the outcome of most corporate actions requiring stockholder approval and our business, which may have the effect of delaying or precluding a third party from acquiring control of us. Furthermore, Emory University beneficially owns 27.4% of our common stock as of March 30, 2012. If our directors and executive officers move to act in concert with Emory University, their ability to influence stockholder actions will be even more significant.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The exercise of warrants or options or conversion of our Series A Convertible Preferred Stock may depress our stock price and may result in significant dilution to our common stockholders.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There are a significant number of outstanding warrants and options to purchase our stock and we have issued Series A Convertible Preferred Stock that is convertible into our Common Stock. If the market price of our Common Stock exceeds the exercise price of outstanding warrants and options or the conversion price of the Series A Convertible Preferred Stock, holders of those securities may be likely to exercise their warrants and options or convert their preferred shares and sell the Common Stock acquired upon exercise or conversion of such securities, as applicable, in the open market. Sales of a substantial number of shares of our Common Stock in the public market by holders of warrants, options, or preferred shares may depress the prevailing market price for our Common Stock and could impair our ability to raise capital through the future sale of our equity securities. Additionally, if the holders of outstanding options, warrants, or preferred shares exercise those options or warrants or convert those preferred shares, as applicable, our common stockholders will incur dilution in their relative percentage ownership.&#160;&#160;The prospect of this possible dilution may also impact the price of our Common Stock.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our outstanding warrants include the Series A, B, and C Warrants to purchase up to 8,799,999 shares of our Common Stock that were issued in March 2012.&#160;&#160;Of these, warrants to purchase up to 2,933,333 shares have an exercise price of $0.75 per share, and warrants to purchase up to 5,866,666 shares have an exercise price of $1.00 per share. These warrants contain anti-dilution provisions, which may, under certain circumstances, reduce the exercise price (but have no effect on the number of shares subject to the warrants) to match if we sell or grant options to purchase, including rights to reprice, our common stock or common stock equivalents at a price lower than the exercise price of the warrants, or if we announce plans to do so.&#160;&#160;This potential reduction in exercise price could reduce the funds the Company receives upon exercise of the warrants, and increase the likelihood that a dilutive issuance will occur.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Series A Convertible Preferred Stock provides for an adjustment to the conversion price if on specified dates certain conditions relating to the ability of the holders to sell the Common Stock issuable upon conversion of the preferred shares pursuant to either an effective registration statement under the Securities Act of 1933 or Rule 144 are not satisfied, then the conversion price shall be reduced to the lesser of (a) the then conversion price, as adjusted and taking into consideration any prior resets, (b) 85% of the volume weighted average price of the Common Stock for the 5 trading days immediately following each such date, as calculated pursuant to the AQR function on Bloomberg L.P., (c) 85% of the average of the volume weighted average prices for the Common Stock for each of the 5 trading days immediately following the date and (d) 85% of the closing bid price on the last trading day of the 5 trading days immediately following each such date, which shall thereafter be the new conversion price. The adjusted Conversion Price shall not be lower than $0.32.&#160;&#160;This potential reduction in conversion price could increase the number of shares that could be issued upon conversion of the preferred shares and the resulting dilution to the other holders of Common Stock.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our Common Stock is and likely will remain subject to the SEC&#8217;s &#8220;Penny Stock&#8221; rules, which may make its shares more difficult to sell.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our Common Stock is currently and may remain classified as a &#8220;penny stock.&#8221; The SEC rules regarding penny stocks may have the effect of reducing trading activity in our shares, making it more difficult for investors to sell. Under these rules, broker-dealers who recommend such securities to persons other than institutional accredited investors must:</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 14.4pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8226;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">make a special written suitability determination for the purchaser;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 14.4pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8226;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">receive the purchaser&#8217;s written agreement to a transaction prior to sale;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 14.4pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8226;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">provide the purchaser with risk disclosure documents which identify certain risks associated with investing in &#8220;penny stocks&#8221; and which describe the market for these &#8220;penny stocks&#8221; as well as a purchaser&#8217;s legal remedies;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 14.4pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8226;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">obtain a signed and dated acknowledgment from the purchaser demonstrating that the purchaser has received the required risk disclosure document before a transaction in a &#8220;penny stock&#8221; can be completed; and</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 14.4pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8226;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">give bid and offer quotations and broker and salesperson compensation information to the customer orally or in writing before or with the confirmation.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These rules make it more difficult for broker-dealers to effectuate customer transactions and trading activity in our securities and may result in a lower trading volume of our common stock and lower trading prices.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Certain provisions of our certificate of incorporation which authorize the issuance of additional shares of preferred stock may make it more difficult for a third party to effect a change in control.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our certificate of incorporation authorizes our Board of Directors to issue up to 10,000,000&#160;shares of preferred stock. We have issued 2,200 shares of Series A Convertible Preferred Stock.&#160;&#160;We believe the terms of these preferred shares would not have a substantial impact on the ability of a third party to effect a change in control. The remaining shares of preferred stock may be issued in one or more series, the terms of which may be determined at the time of issuance by our Board of Directors without further action by the stockholders. These terms may include voting rights including the right to vote as a series on particular matters, preferences as to dividends and liquidation, conversion rights, redemption rights and sinking fund provisions. The issuance of any preferred stock could diminish the rights of holders of our common stock, and therefore could reduce the value of our common stock. In addition, specific rights granted to future holders of preferred stock could be used to restrict our ability to merge with, or sell assets to, a third party. The ability of our Board of Directors to issue preferred stock could make it more difficult, delay, discourage, prevent or make it more costly to acquire or effect a change-in-control, which in turn could prevent the stockholders from recognizing a gain in the event that a favorable offer is extended and could materially and negatively affect the market price of our common stock.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Certain provision of the warrants we issued in March 2012 may make it more difficult for a third party to effect a change in control.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Series A, B and C Warrants contain provisions which permit the holders to require the payment&#160;&#160;to them of an amount of cash equal to the value (based on a Black-Scholes computation) of the remaining unexercised portion of the warrants on the date of the consummation of a fundamental transaction (as defined, but generally a change in control of the Company) that is (i) an all cash transaction, (ii) a &#8220;going private&#8221; transaction, or (ii) a transacting involving a person or entity not traded on a national securities exchange.&#160;&#160;The prospect of making such payments may discourage a potential third party acquirer.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">FORWARD-LOOKING STATEMENTS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The information contained in this prospectus, includes forward-looking statements as defined in the Private Securities Reform Act of 1995. These forward-looking statements are often identified by words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;plan,&#8221; their negatives, and similar expressions, although not all forward-looking statements contain these identifying words. These statements involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed for the reasons described in this prospectus. You should not place undue reliance on these forward-looking statements.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The forward-looking statements contained in this prospectus are based on our expectations, which reflect estimates and assumptions made by our management. These estimates and assumptions reflect our best judgment based on currently known industry developments, our scientific work, contractual arrangements, and other factors. Although we believe such estimates and assumptions to be reasonable, they are inherently uncertain and involve a number of risks and uncertainties that are beyond our control. In addition, our assumptions about future events may prove to be inaccurate. We caution all readers that the forward-looking statements contained in this prospectus are not guarantees of future performance, and we cannot assure any reader that such statements will be realized or the forward-looking events and circumstances will occur. Actual results may differ materially from those anticipated or implied in the forward-looking statements due to the factors listed in the &#8220;Risk Factors&#8221; section and elsewhere in this prospectus. All forward-looking statements speak only as of the date of this prospectus. We do not intend to publicly update or revise any forward-looking statements as a result of new information, future events or otherwise. These cautionary statements qualify all forward-looking statements attributable to us, or persons acting on our behalf. The risks, contingencies and uncertainties relate to, among other matters, the following: our history of operating losses, our need for continued funding, the development stage of our vaccines, regulatory and legal uncertainties, competition, the difficulty of obtaining timely regulatory approvals, uncertainty as to third party reimbursements, the impact of healthcare reform, difficulties related to our intellectual property, and other factors discussed under &#8220;Risk Factors.&#8221;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Other factors besides those described in this prospectus and any prospectus supplement could also affect our actual results. These forward-looking statements are largely based on our expectations and beliefs concerning future events, which reflect estimates and assumptions made by our management. These estimates and assumptions reflect our best judgment based on currently known market conditions and other factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">USE OF PROCEEDS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We will not receive proceeds from the sales by the selling stockholders. If the Series A, B or C Warrants are exercised for cash, then we will receive the proceeds payable by the selling stockholders upon exercise of those warrants. If all of Series A, B, and C Warrants are exercised in full for cash, we will receive approximately $8.1 million.&#160;&#160;We will use these proceeds, if received, for general working capital purposes.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">MARKET FOR OUR COMMON STOCK AND RELATED STOCKHOLDER MATTERS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Market Information</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our common stock is currently traded on the over-the-counter bulletin board market under the symbol &#8220;GOVX&#8221;.&#160;&#160;The following table sets forth the high and low bid prices for our common stock for the periods indicated.&#160;&#160;The prices represent quotations between dealers and do not include retail mark-up, markdown, or commission, and do not necessarily represent actual transactions:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">High</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Low</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">2012</font></font></div>
</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="68%" style="PADDING-LEFT: 5%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">First Quarter</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.24</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.77</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="68%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="68%" style="PADDING-LEFT: 5%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fourth Quarter</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.94</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.82</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="68%" style="PADDING-LEFT: 5%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Third Quarter</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.10</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.80</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="68%" style="PADDING-LEFT: 5%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Second Quarter</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.40</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.76</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="68%" style="PADDING-LEFT: 5%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">First Quarter</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.53</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.10</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="68%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="68%" style="PADDING-LEFT: 5%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fourth Quarter</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.18</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.63</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="68%" style="PADDING-LEFT: 5%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Third Quarter</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.35</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.52</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="68%" style="PADDING-LEFT: 5%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Second Quarter</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.50</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.25</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="68%" style="PADDING-LEFT: 5%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">First Quarter</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9.00</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="13%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.00</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 30, 2012, the last reported sale price for our common stock as reported in the over-the-counter bulletin board was $0.97 per share.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Holders</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 30, 2012, there were approximately 1,000 holders of record of our common stock.&#160;&#160;The number of record holders does not reflect the number of beneficial owners of our common stock for whom shares are held by brokerage firms and other institutions.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Dividends</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have not paid any dividends since our inception and do not contemplate paying dividends in the foreseeable future.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">BUSINESS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Company Overview</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">GeoVax, Labs, Inc. was formed in 2001 and is a biotechnology company developing vaccines that prevent and fight human immunodeficiency virus (HIV).&#160;&#160;HIV infections result in acquired immunodeficiency syndrome (AIDs).&#160;&#160;We are incorporated in Delaware, and our offices and laboratory facilities are located in<font style="DISPLAY: inline; FONT-WEIGHT: bold"> S</font>myrna, Georgia (metropolitan Atlanta).</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our vaccines are being evaluated to determine their potential to (a) prevent HIV infection and (b) to serve as a treatment for individuals who are already infected with HIV.&#160;&#160;These vaccines are currently being evaluated in humans -- both in those infected with HIV and those who are not.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our current vaccines under clinical development are designed to function against the clade B subtype of the HIV virus that is prevalent in the United States and the developed world.&#160;&#160;An estimated 3.5 million people are infected with clade B HIV virus and between 55,000 and 58,000 new infections occur in the U.S. every year.&#160;&#160;The cost of treating HIV infected individuals in the United States is estimated at $500,000 for each infected individual over their lifetime.&#160;&#160;We estimate the worldwide market opportunity for a clade B HIV vaccine (preventive and therapeutic) to be approximately $5 billion annually.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Subject to the availability of funding support from governmental or nongovernmental organizations, we also plan to develop vaccines designed for use to combat the subtypes of HIV that predominate in the developing countries.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Work on our vaccines began during the 1990s at Emory University in Atlanta, Georgia, under the direction of Dr. Harriet L. Robinson, who is now our Chief Scientific Officer. The vaccine technology was developed in collaboration with researchers at Emory University, the U.S. National Institutes of Health (NIH), and the U.S.&#160;&#160;Centers for Disease Control and Prevention (CDC). The technology developed by the collaboration is exclusively licensed to us from Emory University. We also have nonexclusive licenses to certain patents owned by the NIH and exclusive license rights to certain manufacturing process patents of MFD, Inc.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our Vaccine Pipeline</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table summarizes key information regarding our vaccine candidates:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="20%">
<div><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Vaccine</font></font></div>

<div><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Candidate</font></font></font></div>
</td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="37%"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Indication</font></font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="20%">
<div><font style="DISPLAY: inline; FONT-WEIGHT: bold">Stage of</font></div>

<div><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Development</font></font></div>
</td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="20%">
<div><font style="DISPLAY: inline; FONT-WEIGHT: bold">Clinical</font></div>

<div><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Trial Sponsor</font></font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td width="20%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">B &#8211; DNA/MVA</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="37%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">HIV &#8211; Preventive Vaccine (Clade B)</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Clinical &#8211; Phase 2a</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">NIH/HVTN</font></td>
</tr><tr bgcolor="white">
<td width="20%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">B &#8211; DNA-GM/MVA</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="37%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">HIV &#8211; Preventive Vaccine (Clade B)</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Clinical &#8211; Phase 1</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">NIH/HVTN</font></font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td width="20%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">B &#8211; DNA/MVA</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="37%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">HIV &#8211; Treatment Vaccine (Clade B)</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Clinical &#8211; Phase 1/2</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">GeoVax</font></td>
</tr><tr bgcolor="white">
<td width="20%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">B &#8211; DNA-GM/MVA</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="37%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">HIV &#8211; Treatment Vaccine (Clade B)</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Planning &#8211; Phase 1/2</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">NIH/IMPAACT</font></td>
</tr><tr bgcolor="#c0ffff">
<td width="20%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">C &#8211; DNA/MVA&#160;</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="37%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">HIV &#8211; Preventive Vaccine (Clade C)</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Preclinical</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">n/a</font></td>
</tr><tr bgcolor="white">
<td width="20%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">C &#8211; MVA</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="37%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">HIV &#8211; Preventive Vaccine (Clade C)</font></td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%">Preclinical</td>
<td width="1%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="20%">n/a</td>
</tr></table>
</div>

<div>&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our preventive vaccines are being tested in humans by the HVTN and are funded by the NIH. The first generation of our preventive vaccine is one of only 5 vaccine candidates out of more than 80 tested by the HVTN to have successfully progressed to Phase 2 testing.&#160;&#160;In Phase 1 human trials in uninfected people, our vaccines have shown excellent safety and induced both anti-viral antibodies and anti-viral T cells. The results of a two group, 30 participant, Phase 1 trial (designated HVTN 048) are published in <font style="FONT-STYLE: italic; DISPLAY: inline">AIDS RESEARCH AND HUMAN RETROVIRUSES </font>22:678 (2006) and of a four group 120 participant trial (HVTN 065) in <font style="FONT-STYLE: italic; DISPLAY: inline">The Journal of Infectious Diseases</font> 203:610 (2011).&#160;&#160;Our Phase 1 trials have tested both safety and dosing regimens.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The 300 participant Phase 2a clinical trial of our preventive vaccine (HVTN 205) further tested safety and immunogenicity of the two most promising regimens evaluated in phase 1:&#160;&#160;(1) Priming with DNA at months 0 and 2 and boosting with MVA at months 4 and 6 and (2) priming and boosting with MVA at months 0, 2 and 6.&#160;&#160;The HVTN 205 trial is fully enrolled and patient inoculations were completed in January 2012.&#160;&#160;We expect study analysis and completion of the trial during 2012.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The HVTN has also agreed to sponsor and conduct clinical testing in humans of a new version of our preventive vaccine that co-expresses granulocyte-macrophage colony-stimulating factor (GM-CSF) in the DNA vaccine used to prime the vaccine response.&#160;&#160;In preclinical studies in non-human primates, co-expression of GM-CSF in a simian prototype of the DNA vaccine improved the ability of the vaccine to prevent infection. In a study employing 12 successive weekly exposures to simian immunodeficiency virus (SIV), vaccinating in the presence of co-expressed GM-CSF prevented infection in 70% of the animals for a 90% reduction in per exposure risk of transmission, whereas vaccinating in the absence of the co-expressed GM-CSF prevented infection in only 25% of animals and achieved a less effective&#160;&#160;60% reduction in the per exposure risk of transmission (<font style="FONT-STYLE: italic; DISPLAY: inline">The Journal of Infectious Diseases, </font>204:164 (2011)). In normal humans, GM-CSF stimulates the expansion and differentiation of cells in the macrophage and dendritic cell lineages that promote immune responses. The use of GM-CSF in humans is anticipated to have good safety based on its licensure for stimulating production of white blood cells after autologous bone marrow transplantation, as a treatment for fungal infections, and as an adjuvant for the Provenge&#174;&#160;&#160;prostate cancer vaccine.&#160;&#160;&#160;Research into the potential benefits of adding GM-CSF to our vaccine has been supported by a $20.4 million IPCAVD grant awarded by the NIH to GeoVax in 2007 and covering a five year period ending in 2012.&#160;&#160;Clinical testing of the GM-CSF co-expressing vaccine is expected to commence in the second quarter of 2012.&#160;&#160;Pending successful outcome of this trial, we expect to carry forward this version of our preventive vaccine into Phase 2b efficacy testing. We have scheduled vaccine production and have begun discussions about protocol development with potential government sponsors.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our therapeutic (treatment) vaccine is in Phase 1/2 human clinical testing that we are sponsoring. These trials were initiated based on promising preclinical data from therapeutic trials in HIV-infected non-human primates. In these studies, non-human primates were infected, drug-treated, vaccinated and then drug-interrupted. Following treatment interruption, median levels of virus in blood, measured as viral RNA, were 10 to 1000-times lower (overall median of 100-times lower) than those measured prior to drug and vaccine treatment. The therapeutic reductions in virus levels were associated with the vaccination regimen eliciting T-cells (a form of white blood cell) with functional characteristics known to successfully control viral infections. We expect to complete patient enrollment of the Phase 1/2 human trial of our therapeutic vaccine during 2012 and to generate data in 2013.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are also planning a Phase 1 therapeutic clinical trial to investigate the use of our vaccine in combination with standard-of-care drug therapy in young adults.&#160;&#160;This trial would be supported by the International Maternal Pediatric Adolescent AIDS Clinical Trial Group (IMPAACT).&#160;&#160;The NIH has recently prioritized searching for a cure for those individuals who are HIV positive. Because of the mechanisms by which current oral drugs&#160;&#160;work, if the virus is in a latent phase these drugs are not effective, thus it is impossible to totally eradicate the virus. Current approaches to a cure include using an effective vaccine and oral medication together to more effectively eradicate virus. This trial has been assigned a clinical study number (P-1082) and, pending successful committee reviews and FDA approval, we are hopeful that this study will commence in late 2012.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Background &#8211; Viruses and Vaccines</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">What are Viruses?</font>&#160;&#160;Viruses are microscopic organisms consisting of genetic material comprised of deoxyribonucleic acid (&#8220;DNA&#8221;) or ribonucleic acid (&#8220;RNA&#8221;), surrounded by a protein, lipid (fat), or glycoprotein coat. Viruses invade healthy, living host cells in order to replicate and spread. In many cases, the body&#8217;s immune system can recognize and effectively combat an infection caused by a virus. However, with certain viral infections, the body&#8217;s immune system is unable to fully destroy or inhibit the replication of the virus, which results in persistent and ongoing viral replication resulting in disease.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Infections caused by viruses can be chronic or acute. Chronic infections, such as those caused by HIV, do not typically self-resolve with time and can cause chronic disease. Acute infections associated with viruses, such as influenza, generally last for a relatively short period of time, and self-resolve in most immuno-competent individuals.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Viruses can also be characterized as either active or latent. An active virus can cause a persistent infection or disease over an extended period of time. A latent virus will remain in the body for very long periods of time after the initial infection and generally will only cause disease when the body&#8217;s immune system weakens, fails or is suppressed, allowing the virus to once again replicate. Vaccines have been widely used to prevent active viral infections from occurring.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Viruses that develop resistance to antiviral drugs are increasingly becoming a challenge in the treatment of viral infections, particularly those that are chronic in nature. The ability of viruses to mutate spontaneously during replication allows drug-resistant strains to emerge when patients are using drugs that are not potent enough to quickly and completely inhibit viral replication. Drug resistance occurs because viruses continually replicate making millions of copies of themselves, some of which contain mutations in their genetic material. Mutations that emerge in the presence of a suppressive antiviral drug will give rise to mutant strains that are wholly or partially resistant to that drug. These mutant viruses, while initially low in number, eventually become the predominant strain in an infected patient as those strains that remain susceptible to the drug are inhibited from replicating. Once this occurs, the treatment benefit of that particular antiviral drug often diminishes, resulting in treatment failure and the need for an alternate therapy with different or possibly new drugs, or classes of drugs. In general, viruses that cause chronic infections, such as HIV, are more likely to develop drug resistance due to the long-term and persistent exposure of the virus to the antiviral therapy.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">14</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">What are Vaccines?</font>&#160;&#160;Vaccines represent an approach to broaden the ability to prevent serious infectious diseases caused by both viruses and bacteria.&#160;&#160;A vaccine is a substance introduced into the human body that teaches the immune system to detect and destroy a pathogen (a virus or bacterium that causes disease). All vaccines contain some harmless form or part of the pathogen they target. They exert their effects through the adaptive immune response, an arm of the immune system that learns to recognize and neutralize specific pathogens.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There are several types of vaccines:</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Whole-killed/Whole-inactivated vaccines</font>: The active ingredient in these vaccines is an intact virus or bacterium that has been killed or otherwise stripped of its ability to infect humans. Examples include the cholera and injectable polio vaccines. This approach has not been applied to the development of vaccines against HIV due to the small but inevitable risk that the viruses harvested for such preparations may not all have been killed or adequately inactivated.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Live attenuated vaccines</font>:&#160; These vaccines use a form of the targeted pathogen that is highly unlikely to be harmful&#8212;one capable, say, of multiplying, but not causing disease. Examples include the measles vaccine and the oral vaccine against polio, which has been widely deployed in global eradication efforts. Such vaccines can be very effective because they closely mimic the behavior of the targeted pathogen, giving the immune system a truer picture of what it would be up against. Due to the risk that attenuated HIV might revert to its disease-causing form, this approach has not been applied to the development of human AIDS vaccines.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Subunit vaccines:</font> Vaccines of this variety are composed of purified pieces of the pathogen (known as antigens) that generate a vigorous, protective immune response. Common subunit vaccines include the seasonal flu and hepatitis B vaccines. This approach was employed to devise the first AIDS vaccine candidate tested in humans, which failed to induce protection from HIV infection.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">DNA vaccines</font>: These vaccine candidates are also designed to train the immune system to recognize a piece of the targeted bacterium or virus. The difference is that the active ingredients are not the purified antigens themselves but circles of DNA, called plasmids, that carry genes encoding those antigens. Human cells passively take up these plasmids and produce the antigens that, in turn, train the immune system to recognize the targeted pathogen.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Recombinant vector vaccines</font>: These vaccines, like DNA vaccines, introduce genes for targeted antigens into the body. But the genes are inserted into a virus that actively infects human cells. The viruses chosen as vectors are safe to use because they do not ordinarily cause disease in humans and/or have been stripped of their ability to proliferate.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Overview of HIV/AIDS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">What is HIV? </font>HIV is a retrovirus that carries its genetic code in the form of ribonucleic acid, or RNA. Retroviruses use RNA and the reverse transcriptase enzyme to create DNA from the RNA template. The HIV-1 virus invades human cells and produces its viral DNA that is subsequently inserted into the chromosomes, which are the genetic material of a cell. HIV preferentially infects and replicates in T-cells, which are a type of white blood cell. Infection of T-cells alters them from immunity mediating cells to cells that produce and release HIV. This process results in the destruction of the immune defense system of infected individuals and ultimately, the development of AIDS.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There are several AIDS-causing HIV virus subtypes, or clades, that are found in different regions of the world. These clades are identified as clade A, clade B and so on. The predominant clade found in Europe, North America, parts of South America, Japan and Australia is clade B whereas the predominant clades in Africa are clades A and C. In India the predominant clade is clade C. Each clade differs by at least 20% with respect to its genetic sequence from other clades. These differences may mean that vaccines or treatments developed against HIV of one clade may only be partially effective or ineffective against HIV of other clades. Thus there is often a geographical focus to designing and developing vaccines suited for the local clade.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">HIV, even within clades, has a high rate of mutation that supports a significant level of genetic variation. In drug treatment programs, virus mutation can result in the development of drug resistance, referred to as virus drug escape, thereby rendering drug therapy ineffective. Hence, we believe that multi-drug therapy is very important. If several drugs are active against virus replication, the virus must undergo multiple simultaneous mutations to escape, which is less likely. The same is true for immune responses. HIV can escape single targeted immune responses. However, our scientists believe if an immune response is directed against multiple targets, which are referred to as epitopes, virus escape is much less frequent. Vaccination against more than one of the proteins found in HIV increases the number of targets for the immune response as well as the chance that HIV will not escape the vaccine-stimulated immune response, thus resulting in protection against infection or the development of clinical AIDS once infection occurs.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">What is AIDS?</font> AIDS is the final, life-threatening stage of infection with the virus known as HIV. Infection with HIV severely damages the immune system, the body&#8217;s defense against disease. HIV infects and gradually destroys T-cells and macrophages, which are white blood cells that play key roles in protecting humans against infectious disease caused by viruses, bacteria, fungi and other micro-organisms.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">15</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Opportunistic infections by organisms, normally posing no problem for control by a healthy immune system, can ravage persons with immune systems damaged by HIV infections. Destruction of the immune system occurs over years. The average onset of the clinical disease recognized as AIDS occurs after three to ten years of HIV infection if the virus is not treated effectively with drugs, but the time to developing AIDS is highly variable.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">AIDS in humans was first identified in the United States in 1981, but researchers believe that it was present in Central Africa as early as 1959. AIDS is most often transmitted sexually from one person to another but it is also transmitted by blood in shared needles and through pregnancy and childbirth. Heterosexual activity is the most frequent route of transmission worldwide.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The level of virus in blood, known as viral load, is the best indicator of the speed with which an individual will progress to AIDS and the frequency with which an individual will spread infection. An estimated 1% or fewer of those infected have low enough levels of the virus to preclude progression to AIDS and to not transmit the infection. These individuals are commonly called elite controllers or long-term non-progressors.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">AIDS is considered by many in the scientific and medical community to be the most lethal infectious disease in the world. According to the 2011 World AIDS Day Report published by UNAIDS, the Joint United Nations Programme on HIV/AIDS, at the end of 2010, an estimated 34 million people were living with HIV worldwide, with approximately 2.7&#160;million newly infected in 2010 alone. Approximately 25&#160;million people infected with HIV have died since the 1981 start of the HIV pandemic. The United States currently suffers about 56,000 infections per year with the highest rates found in Washington, D.C., where an estimated 3% of the population is infected, a prevalence rate higher than in some developing countries.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">According to the International AIDS Vaccine Initiative (IAVI) in a model developed with Advanced Marketing Commitment dated June 2005, the annual global market for a safe and effective preventive AIDS vaccine (all clades) is estimated at approximately $4 billion or more.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At present, the standard approach to treating HIV infection is to inhibit viral replication through the use of combinations of drugs. Available drugs include reverse transcriptase inhibitors, protease inhibitors, integration inhibitors and inhibitors of cell entry to block multiple essential steps in virus replication. However, HIV is prone to genetic changes that can produce strains that are resistant to currently approved drugs. When HIV acquires resistance to one drug within a class, it can often become resistant to the entire class, meaning that it may be impossible to re-establish control of a genetically altered strain by substituting different drugs in the same class. Furthermore, these treatments continue to have significant limitations which include toxicity, patient non-adherence to the treatment regimens and cost. As a result, over time, many patients develop intolerance to these medications or simply give up taking the medications due to the side effects.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">According to the IAVI, the cost and complexity of new treatment advances for AIDS puts them out of reach for most people in the countries where treatment is most needed, and as noted above, in industrialized nations, where drugs are more readily available, side effects and increased rates of viral resistance have raised concerns about their long term use. AIDS vaccines, therefore, are seen by many as the most promising way to end the HIV/AIDS pandemic. It is expected that vaccines for HIV/AIDS, once developed, will be used universally and administered worldwide by organizations that provide health care services, including hospitals, medical clinics, the military, prisons and schools.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our Vaccine Candidates</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our vaccines, initially developed by our Chief Scientific Officer, Dr. Harriet L. Robinson at Emory University in collaboration with scientists at the NIH and the CDC, incorporate two vaccine delivery components: (1) a recombinant DNA (deoxyribonucleic acid) and (2) a recombinant poxvirus, known as MVA (modified vaccinia Ankara), both of which deliver genes that encode inactivated HIV derived proteins to the immune system. Both the DNA and MVA vaccines contain sufficient HIV genes to support the production of non-infectious virus-like particles which display the native trimeric membrane-bound form of the viral envelope glycoprotein that appears authentic to the immune system. When used together, the recombinant DNA component is used to prime the immune response, which is then boosted by administration of the recombinant MVA component. However, in certain settings the recombinant MVA alone may be sufficient for priming and boosting the immune responses.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our initial work focused on the development of a preventive vaccine for use in uninfected humans to prevent infection should they be exposed to the virus. Later,&#160;based on&#160;encouraging data in preclinical primate models, we undertook the development of a therapeutic vaccine for use in HIV infected humans to supplement approved drug regimens. For both preventive and therapeutic applications, our current focus is on a vaccine for use against clade B, which is common in the United States and the industrially developed world. However, if efficacy is documented against clade B, we plan to develop vaccines designed for use to combat the subtypes of HIV that predominate in developing countries, including clades A, C and an AG recombinant.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">16</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Induction of T-cell and Antibody Immune Responses. </font>In both preclinical and clinical trials, our vaccines induce both anti-viral antibody and T-cell responses. The induction of both antibodies and T-cells is beneficial because these immune responses work through different mechanisms. Antibodies can prevent infection by blocking viruses from infecting cells.&#160;&#160;In preclinical vaccine studies using repeated rectal challenges with moderate doses of virus, the avidity, or tightness, of antibody binding to the surface envelope glycoprotein of HIV correlates with the prevention of infection (<font style="FONT-STYLE: italic; DISPLAY: inline">The Journal of Infectious Diseases, </font>204:164 (2011)).&#160;&#160;In high dose challenges that infect all&#160;&#160;animals at the first exposure, the avidity of the antibody for envelope glycoprotein correlates with reduced levels of virus replication (<font style="FONT-STYLE: italic; DISPLAY: inline">Journal of Virology</font>, 83:4102 (2009)).&#160;&#160;These results likely reflect the tightly binding antibody both blocking infection as well as tagging the virus and infected cells for destruction.&#160;&#160;Our vaccines elicit CD8 T-cells, a type of T-cell that can recognize and kill cells that become infected by virus. CD8 T-cells are important for the control of the virus that has established an infection.&#160;&#160;In our therapeutic vaccinations, our vaccines elicit high frequencies of CD8 T-cells with the functional characteristics of CD8 T-cells associated with control of viral infections in individuals termed &#8220;elite controllers&#8221;.&#160;&#160;Elite controllers, who constitute less than 1% of all HIV-infected individuals, enjoy years of disease-free life without the use of drugs.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">DNA and MVA as Vaccine Vectors. </font>Both the DNA and MVA vaccines produce virus-like particles containing the three major proteins of HIV.&#160;&#160;The virus-like particles cannot cause disease because they were designed with mutated or deleted enzymatic functions that are essential for virus replication.&#160;&#160;The virus-like particles display trimeric membrane bound forms of the HIV envelope glycoprotein (Env).&#160;&#160;This is important because the natural form of the envelope glycoprotein elicits antibody capable of recognizing incoming virus and blocking infections.&#160;&#160;Expression of multiple proteins by the vaccine is important because each protein provides targets for cytotoxic T-cells.&#160;&#160;Elicitation of a multi-target T-cell response limits immune escape, just as multi-drug therapies limit drug escape.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="85%" style="TEXT-ALIGN: center"><img src="img1.jpg" alt=""></td>
</tr><tr>
<td valign="top" width="85%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 34.2pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Figure 1. Electron micrographs showing the virus-like-particles (VLPs) produced by GeoVax recombinant DNA and recombinant MVA vaccines.</font> For the DNA Prime, VLPs are seen budding from a DNA-expressing cell.&#160;&#160;For the MVA boost, fully formed particles as well as a budding particle are shown.&#160;&#160;The VLPs display trimeric membrane-bound forms of the viral envelope glycoprotein (Env).&#160;&#160;This is an important feature of the vaccine because display of the normal Env means that the antibody elicited by the vaccine can recognize the Env on incoming viruses. The VLPs are immature and are rendered non-infectious by deletion of essential genes and introduction of inactivating mutations in essential viral enzymes.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">MVA was selected for use as the live viral component of our vaccines because of its well established safety record and because of the ability of this vector to carry sufficient HIV proteins to produce virus-like particles. MVA was originally developed as a safer smallpox vaccine for use in immune compromised humans.&#160;&#160;It was developed by attenuating the standard smallpox vaccine by making over 500 passages of the virus in chicken embryos or chick embryo fibroblasts which resulted in large genomic deletions. These deletions limited the ability of MVA to replicate in human cells, which can cause safety problems, but did not compromise the ability of MVA to grow on avian cells that are used for manufacturing the virus. The deletions also resulted in the loss of immune evasion genes which assist the spread of wild type smallpox infections, even in the presence of human immune responses. MVA was safely administered to over 120,000&#160;people in the 1970s as a smallpox vaccine.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The availability of DNA and MVA vaccine delivery vectors provides GeoVax with the means to use combination vaccines that induce different patterns of T-cell and antibody responses. Specifically, the use of DNA to prime immune responses and MVA to boost immune responses elicits high levels of T-cells and thus could be particularly well-suited for therapeutic uses. Alternatively, the use of MVA to both prime and boost the immune response elicits higher levels of antibodies and therefore could be well-suited for use in prevention.&#160;&#160;The DNA prime also facilitates expressing genetic adjuvants, which are co-expressed by the vaccine vector with HIV proteins, at the site of immunization.&#160;&#160;This has proven to be particularly effective in our work using GM-CSF as an adjuvant in which a single DNA expresses both virus-like particles and GM-CSF.&#160;&#160;By co-expressing GM-CSF and HIV proteins in the DNA vaccine, GM-CSF is present at the site of the HIV vaccination where it enhances the ability of the vaccine to elicit blocking antibodies for the HIV virus.&#160;&#160;Blocking antibodies can stop a virus before it infects cells.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">17</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Pre-clinical Studies. </font>During the development of our preventive vaccines, preclinical efficacy trials were conducted by vaccinating non-human primates with simian immunodeficiency virus prototypes of our HIV vaccines and then testing them for resistance to simian immunodeficiency virus. The experimental data produced by these trials documented the ability of the simian prototypes of our vaccines to induce immune responses that can prevent infection as well as reduce the levels of viral replication in those animals that become infected.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">GeoVax&#8217;s research pipeline includes the use of adjuvants together with our DNA/MVA vaccine.&#160;&#160;Adjuvants are additives to vaccines that improve vaccine efficacy.&#160;&#160;One of these, GM-CSF, a normal human protein that stimulates the first stages of immune responses, has shown particular promise.&#160;&#160;When GM-CSF is co-expressed in the DNA prime for the MVA boost, the vaccine achieved 70% prevention of infection with a &gt;90% reduction in the per exposure risk of transmission in a study employing 12 successive weekly exposures to simian immunodeficiency virus, whereas vaccinating in the absence of the co-expressed GM-CSF achieved 25% prevention of infection and a less effective 60% reduction in the per exposure risk of transmission (<font style="FONT-STYLE: italic; DISPLAY: inline">The Journal of Infectious Diseases 204:164 (2011))</font>.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Survivors from this first series of exposures were rested a year, boosted once with the MVA vaccine, and then exposed to a 2<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">nd</font> series of challenges (Figure 2). Greater than 90% reduction in risk of infection per exposure was achieved against the 2<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">nd</font> series of exposures. Survivors of this 2<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">nd</font> series of exposures were again rested for 6 months and are being exposed to a 3<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">rd</font> series of challenges. Again, 94% reduction in risk of infection per exposure was achieved.&#160;&#160;The 1<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">st</font> two series of exposures were to SIVE660, a virus that has neutralization characteristics like viruses undergoing transmission in the current epidemic.&#160;&#160;The 3<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">rd</font> series of challenges is with SIV251, a virus that is considered the most potent SIV used in nonhuman primate studies and is an outlier in its high resistance to neutralization.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><img src="img02.jpg" alt=""></font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 43.2pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Figure 2.&#160;&#160;Schematic of serial exposures testing vaccine efficacy.</font>&#160;&#160;Heavy vertical arrows indicate vaccinations, clusters of thin arrows, serial exposures.&#160;&#160;Exposures to virus were rectal to mimic mucosal transmissions.&#160;&#160;&#160;Protection against the 3<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">rd</font> series of exposures is shown in Figure 3C below.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To our knowledge, the level of protection achieved by the simian prototype for the GeoVax GM-CSF-adjuvanted HIV vaccine is unprecedented and far better than has been achieved with simian prototypes of other vaccines currently in, or slated for efficacy trials (see Figure 3 below).&#160;&#160;Figure 3A shows prevention of serial infections by the vaccine currently in efficacy trials that was developed by the NIH Vaccine Research Center.&#160;&#160;This vaccine consists of priming with a DNA vaccine and boosting with a recombinant Adenovirus 5 vaccine (DNA/Ad5).&#160;&#160;When challenged with SIV251, vaccinated animals were infected more rapidly than the unvaccinated animals.&#160;&#160;Figure 3B shows a Johnson and Johnson (Crucell) vaccine developed at Harvard and tested in conjunction with the US military.&#160;&#160;This vaccine initially provides some protection, however only 13% of the animals remained protected after 6 exposures to SIV251.&#160;&#160;Figure 3C shows data from serial exposures to the simian prototype for the GeoVax GM-CSF-co-expressing vaccine. This vaccine has a 72% per exposure reduction in risk of infection over 12 serial exposures.&#160;&#160;We are very pleased with the reduction in risk of infection per exposure that the GeoVax prototype vaccine has achieved.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">18</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><img src="img3.jpg" alt=""></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="85%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 43.2pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Figure 3. Comparison of protection against serial exposures to SIV251 induced by vaccines undergoing or slated for efficacy trials.</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 43.2pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">A. Vaccine consisting of priming with a DNA vaccine and boosting with and adenovirus5 vaccine (Ad5) developed by the NIH Vaccine Research Center and currently in an efficacy trial in North America.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 43.2pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">B. Vaccine consisting of priming with an adenovirus 26 vaccine (Ad26) and boosting with an MVA vaccine developed by Harvard and the U.S. Military, owned by Johnson and Johnson (Crucell) and slated for an efficacy trial in South Africa.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 43.2pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">C. GeoVax vaccine consisting of priming with a GM-CSF co-expressing DNA and boosting with MVA..</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Preventive Vaccine &#8212; Phase 1 Human Clinical Trials. </font>All of our preventive vaccination trials in humans have been conducted by the HVTN, a network that is funded and supported by the NIH. The HVTN is the largest worldwide clinical trials network focused on the development and testing of HIV/AIDS vaccines. Figure 4 below summarizes our clinical trials conducted by the HVTN. In our first Phase 1 clinical trial, HVTN 045, our DNA vaccine was tested without MVA boosting to document the safety of the DNA. Our second Phase 1 clinical trial, HVTN 065, was designed to test the combined use of DNA and MVA and consisted of a dose escalation as well as regimen studies. The low dose consisted of 0.3&#160;mg of DNA and 1x10<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">7</font> tissue culture infectious doses (TCID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: sub">50</font>) of MVA. Once safety was demonstrated for the low dose in 10 participants, the full dose (3 mg of DNA and 1x10<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">8</font> TCID<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: sub">50 </font>of MVA) was administered to 30 participants. A single dose of DNA at time 0 followed by MVA at weeks 8 and 24, a DMM regimen, and three doses of MVA administered at weeks 0, 8 and 24, an MMM regimen, were also tested in 30 participants each. Participants were followed for 12 months to assess vaccine safety and to measure vaccine-induced immune responses.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Data from the HVTN 065 trial again documented the safety of the vaccine products but also showed that the DDMM and MMM regimens induced different patterns of immune responses (<font style="FONT-STYLE: italic; DISPLAY: inline">Journal of Infectious Diseases</font> 203: 610 (2011)). The full dose DDMM regimen induced higher response rates of CD4+ T-cells (77%) and CD8+ T-cells (42%) compared to the MMM regimen (43% CD4 and 17% CD8 response rates). In contrast, the highest response rates and highest titers of antibodies to the HIV Env protein were induced in the group that received only the MVA using the MMM regimen. Antibody response rates were documented to be higher for the MMM group using three different assays designed to measure total binding antibody levels for an immune dominant portion of the Env protein (27% for DDMM and 75% for MMM), binding of antibodies to the gp120 subunit of the envelope glycoprotein (81% for DDMM and 86% for MMM)&#160;and neutralizing antibodies (7% for DDMM and 30% for MMM). The 1/10th&#160;dose DDMM regimen induced overall similar T-cell responses but reduced antibody responses while the response rates were intermediate in the DMM group.&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">19</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><img src="img4.jpg" alt=""></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="85%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 43.2pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Figure 4.&#160;&#160;Overview of GeoVax human clinical trials supported by HVTN.</font>&#160;&#160;The efficacy trial is indicated with a dashed line, because it has yet to be assigned a HVTN trial number.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Preventive Vaccine &#8212; Phase 2 Human Clinical Trials. </font>Based on the safety and the immunogenicity results in the HVTN 045 and HVTN 065 trials, the full dose DNA/MVA and MVA-only regimens were selected for testing by the HVTN in a Phase 2a trial (designated HVTN 205) which commenced patient enrollment in February 2009.&#160;&#160;Because the Merck STEP trial had recently shown the Merck adeno virus vectored vaccine increased patient susceptibility to HIV infection, HVTN undertook the trial in low risk individuals to gain additional safety and immunogenicity data. The HVTN 205 trial is fully enrolled and patient inoculations were completed in January 2012.&#160;&#160;We expect study analysis and publication to occur during 2012. Preliminary analysis of data for neutralizing antibody responses have shown elicitation of unexpectedly high response rates for tier 2 isolates of HIV.&#160;&#160;In the DNA/MVA regimen, of 46 tested vaccine recipients, 50% responded with neutralizing activity for tier 2 clade B isolate RHPA, 26% with neutralizing antibody for tier 2 clade B isolate SC22.3C2 and 20% with neutralizing activity for 9020.A3 and CH77.&#160;&#160;In the MVA-only regimen 72% responded with neutralizing Ab for RHPA and 40% with neutralizing Ab for 9020.A3 and CH77. Neutralizing antibodies can block virus from infecting cells by binding to regions of the virus that mediate entry into cells. The elicitation of neutralizing antibody for tier 2 viruses is an important result because tier 2 viruses represent viruses that undergo the most frequent transmission from an infected person to an uninfected person.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Preventive Vaccine &#8212; Adjuvanted Vaccine &#8211; Phase 1 to Phase 2b Efficacy Trials </font><font style="FONT-STYLE: italic; DISPLAY: inline">. </font>The HVTN is also sponsoring and conducting clinical testing in humans of a new version of our preventive vaccine that has substantially enhanced prevention of infection in non-human primates (see above).&#160;&#160;This vaccine co-expresses GM-CSF as an adjuvant and achieved a much higher level of prevention of infection than our unadjuvanted vaccine in non-human primate testing.&#160;&#160;Prevention of infection is seen for serial challenges with tested animals being protected against more than 34 challenges administered over two and one-half years in a &gt;3 year vaccine trial.&#160;&#160;&#160;The co-expressed GM-CSF enhances antibody responses with the enhanced prevention of infection correlating with enhanced tightness of binding of the antibody to the viral envelope glycoprotein that mediates HIV entry into cells. Commencement of Phase 1 clinical testing of the GM-CSF co-expressing vaccine in a trial designated HVTN 094 is expected to begin in April 2012.&#160;&#160;The study will be conducted in 48 volunteers and will assess safety and immunogenicity of the adjuvanted vaccine at low-dose and full-dose regimens.&#160;&#160;Pending successful outcome of this trial, we expect to carry forward this version of our preventive vaccine into Phase 2b efficacy testing. The Phase 2b trial is anticipated to have approximately 4000 participants equally divided between placebo and vaccine groups and to be conducted in the Americas. GeoVax is currently manufacturing product to support the Phase 2b clinical trial so that progression through the development path can proceed as soon as results are available from Phase 1 testing in HVTN 094.&#160;&#160;We have begun conversations with the HVTN regarding protocol development for efficacy testing of the GeoVax vaccine.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Therapeutic Vaccine &#8212; Phase 1/2 Human Clinical Trials. </font>To help treat those people who are already infected with HIV, the Company is testing its vaccine for the ability to supplement, or even supplant, the need for antiretroviral therapeutic drugs in HIV-infected individuals. Antiretroviral therapeutic drugs, which are taken for life by individuals once infected with HIV, have side effects and are expensive, costing $12,000 - $15,000 per year (drug cost only, not including physician visits and related costs).&#160;&#160;And according to a 2010 study by the CDC, of those individuals in the United States who are diagnosed with HIV, only 35% ultimately achieve stable viral load suppression through drug treatment.&#160; Thus, even in the United States where the availability of drugs and treatment is good, there is still obvious compelling need for therapies that complement drugs.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">20</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In 2007-2008, data were generated in three pilot studies on therapeutic vaccination in simian immunodeficiency virus-infected non-human primates. The vaccine used in these pilot studies was specific for simian immunodeficiency virus but with the design features of our HIV/AIDS vaccine. In these pilot studies, conducted at Yerkes National Primate Research Center of Emory University, the immune systems of most infected and then vaccinated animals were able to control the infection.&#160;&#160;This control resulted in median levels of viral replication following post vaccination treatment interruption being 100-times lower than the median for viral replication prior to vaccination.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have received permission from the FDA for a Phase 1/2 clinical trial in HIV-infected individuals and are currently enrolling patients. This initial trial is being conducted in Atlanta, Birmingham, and Los Angeles and will enroll individuals who began successful antiretroviral therapeutic drug treatment within 18 months of a negative HIV-1 antibody test. The primary goals of this clinical trial are to document the safety and immunogenicity of the vaccine using the DDMM regimen in patients with well-controlled infections.&#160;&#160;However, vaccine efficacy will be directly assessed through a brief period of anti-retroviral drug cessation. We expect to complete patient enrollment for this Phase 1/2 clinical trial during 2012 and to begin generating data in 2013.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are also planning a Phase 1 therapeutic clinical trial to investigate the use of our vaccine in combination with standard-of-care drug therapy in young adults.&#160;&#160;This trial would be supported by IMPAACT. The NIH has recently prioritized searching for a cure for those individuals who are HIV positive. Because of the mechanisms by which current oral drugs&#160;&#160;work, if the virus is in a latent phase these drugs are not effective, thus it is impossible to totally eradicate the virus. Current approaches to a cure include using an effective vaccine and oral medication together to more effectively eradicate virus.&#160;&#160;&#160;This trial is planned to have two groups of 20 participants, one of which will remain on drugs while being vaccinated and the second of which will remain on drugs but receive placebo.&#160;&#160;The participants will be monitored for vaccine-associated reductions in viral reservoirs. This trial has been assigned a clinical study number (P-1082) and, pending successful committee reviews and FDA approvals, should initiate before the end of 2012.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Support from the Government</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">With the exception of the Phase 1/2 therapeutic trial, all of our Phase 1 human clinical trials, as well as our ongoing Phase 2a clinical trial, have been conducted by the HVTN and funded by NIH.&#160;&#160;The HVTN will also support Phase 1 human clinical testing of our GM-CSF adjuvanted vaccine, and we anticipate their support for the Phase 1 therapeutic trial with IMPAACT. Our responsibility for these clinical trials has been to provide sufficient supplies of vaccine materials and technical expertise when necessary.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In September 2007, we were the recipient of an NIH <font style="FONT-STYLE: italic; DISPLAY: inline">Integrated Preclinical-Clinical AIDS Vaccine Development</font>&#160;&#160;grant to support our HIV/AIDS vaccine program, which was subsequently amended such that the total award now totals approximately $20.4&#160;million. The project period for the grant covers a five-year period that commenced October 1, 2007.&#160;&#160;Only meritorious HIV/AIDS prevention vaccine candidates are considered to receive an IPCAVD award. Candidate companies are highly scrutinized and must supply substantial positive AIDS vaccine data to support their application. IPCAVD grants are awarded on a competitive basis and are designed to support later stage vaccine research, development and human trials. We are utilizing this funding to further our HIV/AIDS vaccine development, optimization and production, including the GM-CSF adjuvant program.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Regulations</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Regulation by governmental authorities in the United States and other countries is a significant factor in our ongoing research and development activities and in the manufacture of our products under development. Complying with these regulations involves a considerable amount of time and expense.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the United States, drugs are subject to rigorous federal and state regulation. The Federal Food, Drug and Cosmetic Act, as amended, or the FDC Act, and the regulations promulgated thereunder, and other federal and state statutes and regulations govern, among other things, the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of medications and medical devices. Product development and approval within this regulatory framework is difficult to predict, takes a number of years and involves great expense.&#160;&#160;The steps required before a pharmaceutical agent may be marketed in the United States include:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">pre-clinical laboratory tests, in vivo pre-clinical studies and formulation studies;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the submission to the FDA of an IND application for human clinical testing which must become effective before human clinical trials can commence;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">adequate and well-controlled human clinical trials to establish the safety and efficacy of the product;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the submission of a New Drug Application to the FDA;&#160;and</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">FDA approval of the New Drug Application prior to any commercial sale or shipment of the product.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">21</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Each of these steps is described further below. In addition to obtaining FDA approval for each product, each domestic manufacturing establishment must be registered with, and approved by, the FDA. Domestic manufacturing establishments are subject to biennial inspections by the FDA and must comply with the FDA&#8217;s Good Manufacturing Practices for products, drugs and devices.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Pre-Clinical Testing. </font>Pre-clinical testing includes laboratory evaluation of chemistry and formulation, as well as cell culture and animal studies to assess the safety and potential efficacy of the product. Pre-clinical safety tests must be conducted by laboratories that comply with the FDA&#8217;s Good Laboratory Practices, or GLP. The results of pre-clinical testing are submitted to the FDA as part of the IND application and are reviewed by the FDA prior to the commencement of human clinical trials. Unless the FDA objects to an IND, the IND becomes effective 30&#160;days following its receipt by the FDA.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Clinical Trials. </font>Clinical trials involve the administration of the HIV vaccines to volunteers or to patients under the supervision of a qualified, medically trained principal investigator. Clinical trials are conducted in accordance with Good Clinical Practices under protocols that detail the objectives of the trial, the parameters to be used to monitor safety and the efficacy criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND. Further, each clinical trial must be conducted under the auspices of an independent institutional review board at the institution where the trial will be conducted. The institutional review board will consider, among other things, ethical factors, the safety of human subjects and the possible liability of the institution.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Clinical trials are typically conducted in three sequential phases, but the phases may overlap. In the Phase 1 clinical trial, the initial introduction of the product into healthy human subjects, the vaccine is tested for safety (including adverse side effects) and dosage tolerance. The Phase 2 clinical trial is the proof of principal stage and involves trials in a limited patient population to determine whether the product induces the desired effect (for our vaccines this means immune responses) and to better determine optimal dosage. The continued identification of possible safety risks is also a focus. When there is evidence that the product may be effective and has an acceptable safety profile in Phase 2 clinical trials, Phase 3 clinical trials are undertaken to evaluate clinical efficacy and to test for safety within an expanded patient population. Phase&#160;3 trials are completed using multiple clinical study sites which are geographically dispersed. The manufacturer or the FDA may suspend clinical trials at any time if either believes that the individuals participating in the trials are being exposed to unacceptable health risks.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">New Drug Application and FDA Approval Process. </font>The results and details of the pre-clinical studies and clinical trials are submitted to the FDA in the form of a New Drug Application. If the New Drug Application is approved, the manufacturer may market the product in the United States.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">International Approval. </font>Whether or not the FDA has approved the drug, approval of a product by regulatory authorities in foreign countries must be obtained prior to the commencement of commercial sales of the drug in such countries. The requirements governing the conduct of clinical trials and drug approvals vary widely from country to country, and the time required for approval may be longer or shorter than that required for FDA approval.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Other Regulations. </font>In addition to FDA regulations, our business activities may also be regulated by the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential future federal, state or local regulations. Violations of regulatory requirements at any stage may result in various adverse consequences, including regulatory delay in approving or refusal to approve a product, enforcement actions, including withdrawal of approval, labeling restrictions, seizure of products, fines, injunctions and/or civil or criminal penalties. Any product that we develop must receive all relevant regulatory approvals or clearances before it may be marketed.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our Strategy</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our immediate goal is to bring both our preventive and therapeutic HIV/AIDS vaccines into efficacy testing, with the ultimate goal of becoming a leading biopharmaceutical company that develops differentiated products to prevent and treat serious infections, focusing on unmet medical needs. To achieve these strategic goals, we intend to employ the following strategies:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">22</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Focus Our Resources on the Development of Our Therapeutic Vaccine Candidates</font>.&#160;&#160;In the near-term, we plan to focus our resources on developing our therapeutic vaccines to show initial proof of efficacy in humans.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Leverage the Support of Federal Government Agencies for Trials of our Preventive Vaccine</font>.&#160;&#160;The NIH and HVTN have been very supportive of our efforts to date in developing our preventive vaccines, and we intend to continue to solicit their assistance and financial support for the efficacy testing of our preventive vaccines.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Seek the Support of Nongovernmental Organizations</font>.&#160;&#160;We also intend to solicit the support of Nongovernmental Organizations (NGOs) toward the development of our vaccine candidates for the versions of the HIV virus prevalent in the developing world.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Seek Strategic Collaborations to Accelerate the Development of Our Vaccine Candidates to Optimize Economic Returns while Managing Risk</font>.&#160;&#160;We intend to establish strategic licenses and collaborations, partnerships, alliances or enter into other transactions in the future with pharmaceutical or biopharmaceutical companies with greater clinical development, manufacturing and commercialization capabilities that we believe can accelerate the development and/or commercialization of our vaccine candidates.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Seek New Business Opportunities</font>.&#160;&#160;We plan to seek out new business development opportunities to potentially expand our technology and product pipeline or to otherwise provide additional revenue sources.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Manufacturing</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We do not have the facilities or expertise to manufacture any of the clinical or commercial supplies of any of our products. To be successful, our products must be manufactured in commercial quantities in compliance with regulatory requirements and at an acceptable cost. To date, we have not commercialized any products, nor have we demonstrated that we can manufacture commercial quantities of our product candidates in accordance with regulatory requirements. If we cannot manufacture products in suitable quantities and in accordance with regulatory standards, either on our own or through contracts with third parties, it may delay clinical trials, regulatory approvals and marketing efforts for such products. Such delays could adversely affect our competitive position and our chances of achieving profitability. We cannot be sure that we can manufacture, either on our own or through contracts with third parties, such products at a cost or in quantities which are commercially viable.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We currently rely and intend to continue to rely on third-party contract manufacturers to produce vaccines needed for research and clinical trials. We have entered into arrangements with third party manufacturers for the supply of our DNA and MVA vaccines for use in our planned clinical trials. These suppliers operate under the FDA&#8217;s Good Manufacturing Practices and similar regulations of the European Medicines Agency. We anticipate that these suppliers will be able to provide sufficient vaccine supplies to complete our currently planned clinical trials. Various contractors are generally available in the United States and Europe for manufacture of vaccines for clinical trial evaluation, however, it may be difficult to replace existing contractors for certain manufacturing and testing activities and costs for contracted services may increase substantially if we switch to other contractors.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Development of Improved Manufacturing Techniques for MVA &#8211; </font>The MVA component of our vaccine is currently manufactured in cells that are cultured from embryonated eggs.&#160;&#160;&#160;This is cumbersome and prone to contamination during the processing of the eggs required to make a large batch of vaccine.&#160;&#160;GeoVax has explored a number of approaches to growing MVA in continuous cell lines that can be grown in bioreactors. In this process we have identified a duck stem-cell-derived line (termed EB66), that is proprietary to Vivalis, Ltd, Nantes France. We are currently working with Vivalis on the use of EB66 cells for the growth of our MVA vaccines and are pleased with the results the collaboration is obtaining. We anticipate that by the time process development is complete we will be producing at least 10-times higher titers of virus per ml than we currently achieve.&#160;&#160;The U.S. FDA has reviewed our plans for transitioning from MVA growth in egg-derived cells to a continuous cell line.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Competition</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There currently is no FDA licensed and commercialized HIV/AIDS vaccine or competitive vaccine available in the world market. However, the market for vaccines that protect against or treat HIV/AIDS is intensely competitive and is subject to rapid and significant technological change. We will have numerous competitors in the United States and abroad, including large companies with substantially greater resources than us. These competitors may develop technologies and products that are more effective or less costly than any of our future technology or products or that could render our technology or products obsolete or noncompetitive.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There are several small and large biopharmaceutical companies pursuing HIV/AIDS vaccine research and development, including Novartis, Sanofi-Aventis and GlaxoSmithKline. Other HIV/AIDS vaccines are in varying stages of research, testing and clinical trials including those supported by the NIH Vaccine Research Center, the U.S. Military, IAVI, the European Vaccine Initiative, and the South African AIDS Vaccine Initiative. Following the reported failure of the vaccine developed by Merck&#160;&amp; Co., Inc. in September 2007, Merck&#160;&amp; Co., Inc.&#8217;s vaccine program and the NIH Vaccine Research Center vaccine program, both of which use Ad5 vectors, were placed on hold. Since then, the NIH Vaccine Research Center product has moved into an experimental Phase 2b clinical trial to learn more about immune responses and AIDS control. This clinical trial has been restricted to individuals who do not have high levels of antibodies to the Ad5 vector used in the vaccine (approximately 50% of U.S.&#160;citizens) and to men who are circumcised.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">23</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In October 2009, the results from a Phase 3 community-based clinical trial in Thailand using a recombinant canarypox (designated ALVAC and produced by Sanofi Pasteur) as a priming vaccine and a bivalent mixture of the gp120 subunit of Env from HIV clades&#160;B and C (produced by VaxGen, Inc. and currently licensed to Global Solutions for Infectious Diseases) as a protein booster vaccine were reported. In this clinical trial, protection against HIV infection at the rate of 31% was reported. This level of protection was significant in a &#8220;modified intent to treat&#8221; analysis in which the seven participants in the 16,500&#160;person trial who had become infected by the day of the first inoculation were excluded. The results of this clinical trial are encouraging because they represent the first success of an AIDS vaccine in humans and demonstrate that a vaccine can provide protection against HIV infections.&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To our knowledge, none of our competitors&#8217; products have been tested in large scale non-human primate trials that have included experimental infection through the rectal site and shown to induce levels of protection or duration of protection comparable to that achieved using experimental prototypes of GeoVax&#8217;s vaccines. Furthermore, many of our competitors&#8217; vaccine development programs require vaccine compositions which are more complicated than ours. For these reasons, we believe that it may be possible for our vaccine to compete successfully in the marketplace if licensed.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Overall, the biopharmaceutical industry is competitive and subject to rapid and substantial technological change. Developments by others may render our proposed vaccination technologies noncompetitive or obsolete, or we may be unable to keep pace with technological developments or other market factors. Technological competition in the industry from pharmaceutical and biotechnology companies, universities, governmental entities and others diversifying into the field is intense and is expected to increase. Many of the pharmaceutical companies that compete with us have significantly greater research and development capabilities than we have, as well as substantially more marketing, manufacturing, and financial resources. In addition, acquisitions of, or investments in, small pharmaceutical or biotechnology companies by such large corporations could increase their research, financial, marketing, manufacturing and other resources. Competitive technologies may ultimately prove to be safer, more effective or less costly than any vaccine that we develop.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">FDA and other regulatory approvals of our vaccines have not yet been obtained and we have not yet generated any revenues from product sales. Our future competitive position depends on our ability to obtain FDA and other regulatory approvals of our vaccines and to license or sell the vaccines to third parties on favorable terms.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Our Intellectual Property</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary rights are described by valid and enforceable patents or are effectively maintained as trade secrets. Accordingly, we are pursuing and will continue to pursue patent protection for our proprietary technologies developed through our collaborations with Emory University, the NIH, and the CDC, or developed by us alone. Patent applications have been filed with the U.S. Patent and Trademark Office and in specific international markets (countries). Patent applications include provisions to cover our DNA and MVA based HIV vaccines, their genetic inserts expressing multiple HIV protein components, composition, structure, claim of immunization against multiple subtypes of HIV, routes of administration, safety and other related factors. Patent claims filed for our vaccines include provisions for their therapeutic and prophylactic use against HIV and smallpox.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are the exclusive, worldwide licensee of a number of patents and patent applications, which we refer to as the Emory Technology, owned, licensed or otherwise controlled by Emory University for HIV or smallpox vaccines pursuant to a License Agreement originally entered into on August&#160;23, 2002 and restated on June&#160;23, 2004, which we refer to as the Emory License. Through the Emory License we are also a non-exclusive licensee of four issued United States patents owned by the NIH related to the ability of our MVA vector vaccine to operate as a vehicle to deliver HIV virus antigens, and also to induce an immune response in humans. The four issued United States patents owned by the NIH expire in 2023. All of our obligations with respect to the NIH-owned MVA patents are covered by the Emory License. In addition to the issued United States patents owned by the NIH, and a recently issued patent owned by Emory&#160;University, there are six issued and five pending United States patent applications, 29&#160;issued or pending patents in countries other than the United States. The Emory License expires on the expiration date of the last to expire of the patents licensed thereunder including those that are issued on patents currently pending. We will not know the final termination date of the Emory License until such patents are issued. The Company may terminate the Emory University License upon 90&#160;days&#8217; written notice. The Emory License also contains standard provisions allowing Emory University to terminate upon breach of contract by the Company or upon the Company&#8217;s bankruptcy.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">24</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Emory License, among other contractual obligations, requires payments based on the following:</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Milestone Payments.</font>&#160;&#160;An aggregate of $3,450,000 is potentially due to Emory University in the future upon the achievement of clinical development and regulatory approval milestones as defined in the Emory License. To date, we have paid a nominal milestone fee upon entering Phase 2 clinical trials for our preventive HIV/AIDS vaccine.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Maintenance Fees.</font>&#160;&#160;The Company has achieved the specified milestones and met its obligations with regard to the related payments, and no maintenance fees are (or will be) owed to Emory University.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Royalties.</font>&#160;&#160;Upon commercialization of products covered by the Emory License, we will owe royalties to Emory University of between 5% and 7.5%, depending on annual sales volume, of net sales made directly by GeoVax. The Emory License also requires minimum annual royalty payments of $3&#160;million in the third year following product launch, increasing annually to $12&#160;million in the sixth year.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Sublicense Royalties.</font>&#160;&#160;In the event that we sublicense a covered product to a third party, we will owe royalties to Emory University based on all payments, cash or noncash, that we receive from our sublicensees. Those royalties will be 19% of all sublicensing consideration we receive prior to the first commercial sale of a related product. Commencing with the first commercial sale, the royalty owed to Emory University will be 27.5% of all sublicensing consideration we receive.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Patent Reimbursements.</font>&#160;&#160;During the term of the Emory License we are obligated to reimburse Emory University for ongoing third party costs in connection with the filing, prosecution and maintenance of patent applications subject to the Emory License. The expense associated with these ongoing patent cost reimbursements to Emory University amounted to $249,907, $193,674, and $85,673 for the years ended December 31, 2011, 2010 and 2009, respectively.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We may only use the Emory Technology for therapeutic or prophylactic HIV or smallpox vaccines. Emory University also reserved the right to use the Emory Technology for research, educational and non-commercial clinical purposes. Due to the use of federal funds in the development of the Emory Technology, the U.S. Government has the irrevocable, royalty-free, paid-up right to practice and have practiced certain patents throughout the world, should it choose to exercise such rights.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are not a party to any litigation, opposition, interference, or other potentially adverse proceeding with regard to our patent positions. However, if we become involved in litigation, interference proceedings, oppositions or other intellectual property proceedings, for example as a result of an alleged infringement or a third-party alleging an earlier date of invention, we may have to spend significant amounts of money and time and, in the event of an adverse ruling, we could be subject to liability for damages, invalidation of our intellectual property and injunctive relief that could prevent us from using technologies or developing products, any of which could have a significant adverse effect on our business, financial conditions or results of operations. In addition, any claims relating to the infringement of third-party proprietary rights, or earlier date of invention, even if not meritorious, could result in costly litigation, lengthy governmental proceedings, divert management&#8217;s attention and resources and require us to enter royalty or license agreements which are not advantageous if available at all.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are also the exclusive licensee of five patents from MFD, Inc., which we refer to as the MFD Patents, pursuant to a license agreement dated December 26, 2004 with MFD, Inc., which we refer to as the MFD license agreement, related to certain manufacturing processes used in the production of our vaccines. Pursuant to the MFD license agreement, we obtained a fully paid, worldwide, irrevocable, exclusive license in and to the MFD Patents to use, market, offer for sale, sell, lease and import any AIDS and smallpox vaccine made with GeoVax Technology, as such term is defined in the MFD license agreement, and non-exclusive rights for other products. The term of the MFD license agreement ends on the expiration date of the last to expire of the MFD Patents, one of which expires in 2017. The license granted also extends to any and all current or future customers of GeoVax the right to commercially practice the GeoVax Technology, as such term is defined in the MFD license agreement, or any portion thereof. The license also extends to any and all current or future GeoVax Users, as such term is defined in the MFD license agreement, the right to use any GeoVax Technology, as such term is defined in the MFD license agreement.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition to patent protection, we also attempt to protect our proprietary products, processes and other information by relying on trade secrets and non-disclosure agreements with our employees, consultants and certain other persons who have access to such products, processes and information. Under these agreements, all inventions conceived by employees are our exclusive property. Nevertheless, there can be no assurance that these agreements will afford significant protection against misappropriation or unauthorized disclosure of our trade secrets and confidential information.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">25</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We cannot be certain that any of the current pending patent applications we have licensed, or any new patent applications we may file or license, will ever be issued in the United States or any other country. Even if issued, there can be no assurance that those patents will be sufficiently broad to prevent others from using our products or processes. Furthermore, our patents, as well as those we have licensed or may license in the future, may be held invalid or unenforceable by a court, or third parties could obtain patents that we would need to either license or to design around, which we may be unable to do. Current and future competitors may have licensed or filed patent applications or received patents, and may acquire additional patents or proprietary rights relating to products or processes competitive to ours. In addition, any claims relating to the infringement of third-party proprietary rights, or earlier date of invention, even if not meritorious, could result in costly litigation, lengthy governmental proceedings, divert management&#8217;s attention and resources and require us to enter royalty or license agreements which are not advantageous to us, if available at all.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Research and Development</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our expenditures for research and development activities were $4,276,375, $4,793,956, and $4,068,682 during the years ended December 31, 2011, 2010 and 2009, respectively. As our vaccines continue to go through the process to obtain regulatory approval, we expect our research and development costs to continue to increase significantly as even larger human clinical trials proceed in the United States and foreign countries. We have not yet formulated any plans for marketing and sales of any vaccine candidate we may successfully develop. Compliance with environmental protection laws and regulations has not had a material effect on our capital expenditures, earnings or competitive position to date.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Properties and Employees</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We lease approximately 8,400 square feet of office and laboratory space located at 1900 Lake Park Drive, Suite 380, Smyrna, Georgia under a 62 month lease agreement which began November 1, 2009.&#160;&#160;We believe this space is adequate for our current needs. As of March 30, 2012, we had thirteen full-time and one part-time employees.&#160;&#160;None of our employees are covered by collective bargaining agreements and we believe that our employee relations are good.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Background and Structure</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our primary business is conducted by our subsidiary, GeoVax, Inc., which was incorporated under the laws of Georgia in June 2001.&#160;&#160;The predecessor of our parent company, GeoVax Labs, Inc. (the reporting entity) was originally incorporated in June 1988 under the laws of Illinois as Dauphin Technology, Inc. (&#8220;Dauphin&#8221;).&#160;&#160;In September 2006, Dauphin completed a merger (the &#8220;Merger&#8221;) with GeoVax, Inc.&#160;&#160;As a result of the Merger, GeoVax, Inc. became a wholly-owned subsidiary of Dauphin, and Dauphin changed its name to GeoVax Labs, Inc.&#160;&#160;Unless otherwise indicated, information for periods prior to the September 2006 merger is that of GeoVax, Inc.&#160;&#160;In June 2008, the Company was reincorporated under the laws of Delaware.&#160;&#160;We currently do not conduct any business other than GeoVax, Inc.&#8217;s business of developing new products for the treatment or prevention of human diseases.&#160;&#160;Our principal offices are located in Smyrna, Georgia (metropolitan Atlanta).</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Available Information</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our website address is www.geovax.com.&#160;&#160;We make available on this website under &#8220;Investors &#8211; SEC Reports,&#8221; free of charge, our proxy statements, annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports as soon as reasonably practicable after we electronically file or furnish such materials to the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).&#160;&#160;We also make available our Code of Ethics on this website under the heading &#8220;Investors&#8211;Corporate Governance&#8221;.&#160;&#160;Information contained on our website is not incorporated into this prospectus.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">26</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SELECTED FINANCIAL DATA</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following selected financial data are derived from our audited consolidated financial statements.&#160;&#160;The historical results presented below are not necessarily indicative of the results to be expected for any future period.&#160;&#160;The information set forth below should be read in conjunction with the information contained in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;, and our consolidated financial statements and the related notes, beginning on page F-1 of this prospectus.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<div align="center">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="18" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Years Ended December 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2008</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2007</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Statement of Operations Data:</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="45%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total revenues (grant income)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,899,885</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,185,257</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,668,195</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,910,170</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">237,004</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="45%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,346,826</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,747,328</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,284,252</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,728,187</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,241,796</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="45%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Basic and diluted net loss per common share</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.15</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.18</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.22</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.25</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.30</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="45%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="18" valign="bottom" width="53%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As of December 31,</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" width="45%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2008</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2007</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="45%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance Sheet Data:</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="45%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total assets</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,645,142</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,357,834</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,315,597</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,056,241</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,246,404</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="45%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total stockholders&#8217; equity</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">703,607</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,836,226</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,744,232</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,709,819</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,647,866</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION</font></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AND RESULTS OF OPERATIONS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following discussion and analysis of our financial condition and results of operations should be read together with the discussion under &#8220;Selected Financial Data&#8221; and our consolidated financial statements included in this prospectus.&#160;&#160;This discussion contains forward-looking statements that involve risks and uncertainties because they are based on current expectations and relate to future events and our future financial performance. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many important factors, including those set forth under &#8220;Risk Factors,&#8221; &#8220;Forward Looking Statements,&#8221; and elsewhere in this prospectus.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Overview</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">GeoVax is a biotechnology company developing vaccines that prevent and fight HIV/AIDS. We have exclusively licensed from Emory University vaccine technology which was developed in collaboration with the NIH and the CDC.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our current vaccines under development address the clade B subtype of the HIV virus that is most prevalent in the United States and the developed world.&#160;&#160;Our vaccines are being evaluated to determine their potential to (a) prevent HIV infection and (b) to serve as a therapy for individuals who are already infected with HIV.&#160;&#160;These vaccines are currently being evaluated in human clinical trials -- both in those infected with HIV and those who are not.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have neither received regulatory approval for any of our vaccine candidates, nor do we have any commercialization capabilities; therefore, it is possible that we may never successfully derive significant product revenues from any of our existing or future development programs or product candidates.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We expect for the foreseeable future our operations will result in a net loss on a quarterly and annual basis.&#160;&#160;As of December 31, 2011, we had an accumulated deficit of $22.6 million.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Critical Accounting Policies and Estimates</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates and adjusts the estimates as necessary. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">27</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our significant accounting policies are summarized in Note&#160;2 to our consolidated financial statements for the year ended December&#160;31, 2011. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our consolidated financial statements:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Impairment of Long-Lived Assets</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future net cash flows expected to be generated by such assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the discounted expected future net cash flows from the assets.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Revenue Recognition</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We recognize revenue in accordance with the SEC&#8217;s Staff Accounting Bulletin&#160;No.&#160;101, <font style="FONT-STYLE: italic; DISPLAY: inline">Revenue Recognition in Financial Statements,</font> as amended by Staff Accounting Bulletin&#160;No.&#160;104, <font style="FONT-STYLE: italic; DISPLAY: inline">Revenue Recognition</font> (&#8220;SAB 104&#8221;).&#160;&#160;SAB&#160;104 provides guidance in applying U.S.&#160;generally accepted accounting principles to revenue recognition issues, and specifically addresses revenue recognition for upfront, non-refundable fees received in connection with research collaboration agreements. Our revenue consists solely of grant funding received from the NIH. Revenue from this arrangement is approximately equal to the costs incurred and is recorded as income as the related costs are incurred.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Stock-Based Compensation</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Compensation cost for stock options or warrants is estimated at the grant date based on each instrument&#8217;s fair-value as calculated by the Black-Scholes option pricing model. The Company recognizes stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Liquidity and Capital Resources</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At December 31, 2011, we had cash and cash equivalents of $1,167,980 and total assets of $1,645,142, as compared to $1,079,087 and $2,357,834, respectively, at December&#160;31, 2010. Working capital totaled $476,468 at December 31, 2011, compared to $1,080,584 at December&#160;31, 2010.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Sources and Uses of Cash</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are a development-stage company as defined by Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 915,&#160;&#160;&#8220;Development Stage Entities&#8221;&#160;&#160;and do not have any products approved for sale. Due to our significant research and development expenditures, we have not been profitable and have generated operating losses since our inception in 2001. Our primary sources of cash are from sales of our equity securities and from government grant funding.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cash Flows from Operating Activities</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net cash used in operating activities was $303,621, $2,007,169, and $1,425,150 for the years ended December&#160;31, 2011, 2010 and 2009, respectively. Generally, the differences between periods are due to fluctuations in our net losses which, in turn, result from fluctuations in expenditures for our research activities, offset by government grant revenues and net changes in our assets and liabilities.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The costs of conducting all of our human clinical trials to date, except for our ongoing Phase 1/2&#160;&#160;therapeutic trial, have been borne by the HVTN, funded by the NIH, with GeoVax incurring costs associated with manufacturing the clinical vaccine supplies and other study support. The HVTN and the NIH are bearing the cost of conducting our ongoing Phase 2a preventive trial and have indicated their support for the planned Phase 1 clinical trial of the GM-CSF adjuvanted version of our vaccine.&#160;&#160;We are also having discussions with the HVTN and NIH with regard to the conduct of a planned Phase 2b clinical trial of our preventive vaccine, and we expect the NIH will support this trial as well.&#160;&#160;We cannot, however, predict the level of support we will receive from the HVTN or the NIH for any additional clinical trials.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">28</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our operations are partially funded by the IPCAVD grant awarded to us in September 2007 by the NIH to support our HIV/AIDS vaccine program. The project period for the grant covers a five-year period which commenced in October 2007, with an aggregate award of $20.4 million.&#160;&#160;As of December 31, 2011, there is approximately $3.9 million of unused grant funds remaining and available for use through August 31, 2012 (the end of the original project period).&#160;&#160;The funding we receive pursuant to this grant is recorded as revenue at the time the related expenditures are incurred, and thus partially offsets our net losses.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are pursuing additional grants from the federal government. However, as we progress to the later stages of our vaccine development activities, government financial support may be more difficult to obtain, or may not be available at all. Therefore, it will be necessary for us to look to other sources of funding in order to finance our development activities.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cash Flows from Investing Activities</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our investing activities have consisted predominantly of capital expenditures. Capital expenditures for the years ended December&#160;31, 2011, 2010 and 2009, were $11,896, $4,706, and $270,246, respectively, and during 2010, we received $5,580 in proceeds from the sale of equipment.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cash Flows from Financing Activities</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net cash provided by financing activities was $404,410 for the year ended December 31, 2011, as compared to net cash used by financing activities of $430,402 for 2010, and net cash provided by operating activities of $3,020,000 for 2009. The cash generated by our financing activities during 2011 relates to the sale of our common stock to individual accredited investors in a private placement offering initiated during December 2011.&#160;&#160;During January 2012, we received an additional $310,160 from stock sales pursuant to this offering (including $36,800 received in payment of a stock subscription receivable from December 2011).&#160;&#160;The net cash used by financing activities during 2010 relates to costs associated with our previous efforts to raised funds.&#160;&#160;During 2009, we received $1,500,000 from the exercise of a stock purchase warrant and $1,520,000 from the sale of our common stock pursuant to a stock purchase agreement.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In March 2012, we sold shares of Series A convertible preferred stock to certain institutional investors for an aggregate purchase price of $2.2 million, and five-year Class A warrants to purchase an aggregate of 2,933,333 shares of our common stock at $1.00 per share.&#160;&#160;The preferred stock is convertible at any time into shares of our common stock at $0.75 per share (2,933,333 shares in the aggregate), subject to adjustment as provided in the certificate of designation.&#160;&#160;We also granted to the investors a one-year additional purchase right, evidenced in the form of Class B warrants to purchase up to 2,933,333 of our common stock for one year with an exercise price of $0.75 per share, and five-year Class C warrants to purchase up to 2,933,333 shares of our common stock at $1.00 per share.&#160;&#160;The Class B warrants are immediately exercisable.&#160;&#160;The Class C warrants only become exercisable at the time, and to the extent, that the Class B warrants are exercised.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our capital requirements, particularly as they relate to product research and development, have been and will continue to be significant. We anticipate incurring additional losses for several years as we expand our drug development and clinical programs and proceed into higher cost human clinical trials. Conducting clinical trials for our vaccine candidates in development is a lengthy, time-consuming and expensive process. We will not generate revenues from the sale of our technology or products for at least several years, if at all. For the foreseeable future, we will be dependent on obtaining financing from third parties in order to maintain our operations, including our clinical program. Due to the existing uncertainty in the capital and credit markets, and adverse regional and national economic conditions that may persist or worsen, capital may not be available on terms acceptable to the Company or at all. If we fail to obtain additional funding when needed, we would be forced to scale back or terminate our operations, or to seek to merge with or to be acquired by another company.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our current working capital combined with the proceeds from the IPCAVD grant awarded from the NIH is currently sufficient to support our planned level of operations into the first quarter of 2013, without giving consideration to the potential proceeds from exercise of the Series A, B or C Warrants.&#160;&#160;We anticipate raising additional capital during 2012 or 2013, although there can be no assurance that we will be able to do so. While we believe that we will be successful in obtaining the necessary financing to fund our operations through grants, exercise of options and warrants, and/or other sources, there can be no assurances that such additional funding will be available to us on reasonable terms or at all.&#160;&#160;Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive when we require it, the consequences could have a material adverse effect on our business, operating results, financial condition and prospects.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have no off-balance sheet arrangements that are likely or reasonably likely to have a material effect on our financial condition or results of operations.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">29</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractual Obligations</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude contingent liabilities for which we cannot reasonably predict future payment. Additionally, the expected timing of payment of the obligations presented below is estimated based on current information. Timing of payments and actual amounts paid may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some obligations.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table represents our contractual obligations as of December 31, 2011, aggregated by type (in thousands):</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="18" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Payments Due by Period</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contractual Obligations</font></div>
</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Less than</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1 Year</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1-3</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Years</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4-5</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Years</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">More than</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5 years</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operating Lease Obligations <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(1)</font></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">376</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">122</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">254</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">--</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">--</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Firm Purchase Commitments <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(2)</font></font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">478</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">445</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">33</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">--</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">--</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Emory University </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8211; License Agreement <font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">(3)</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;--</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;--</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;--</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;--</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;--</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">854</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">567</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">287</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">--</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">--</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our operating lease obligations relate to the facility lease for our 8,430 square foot facility in Smyrna, Georgia, which houses our laboratory operations and our administrative offices.&#160;&#160;The lease, which was effective November 1, 2009, expires on December 31, 2014.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Firm purchase commitments relate to contracts for production and testing of our vaccine products, conduct of clinical trials, and other research-related activities.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 9pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(3)</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the Emory License, we have committed to make potential future milestone and royalty payments which are contingent upon the occurrence of future events.&#160;&#160;Such events include development milestones, regulatory approvals and product sales.&#160;&#160;Because the achievement of these milestones is currently neither probable nor reasonably estimable, the contingent payments have not been included in the table above or recorded on our Consolidated Balance Sheets.&#160;&#160;The aggregate total of all potential milestone payments included in the Emory License (excluding royalties on net sales) is approximately $3.5 million.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of December&#160;31, 2011, except as disclosed in the table above, we had no other material firm purchase obligations or commitments for capital expenditures and no committed lines of credit or other committed funding or long-term debt. We have employment agreements with our executive officers and a consulting agreement with a member of our Board of Directors, each of which may be terminated with no more than 90&#160;days advance written notice. The table also excludes budgeted expenses under our two Research Agreements with Emory University which are fully reimbursable to us pursuant to the IPCAVD grant from the NIH and cover a period of less than one year.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Net Operating Loss Carryforwards</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At December&#160;31, 2011, we had consolidated net operating loss carryforwards for income tax purposes of $71.3 million, which will expire in 2012 through 2031 if not utilized. Approximately $55.8 million of our net operating loss carryforwards relate to the operations of our predecessor, Dauphin Technology, Inc. prior to the 2006 merger between Dauphin Technology, Inc. and GeoVax, Inc. We also have research and development tax credits of approximately $764,000 available to reduce income taxes, if any, which will expire in 2022 through 2031 if not utilized. The amount of net operating loss carryforwards and research tax credits available to reduce income taxes in any particular year may be limited in certain circumstances. Based on an assessment of all available evidence including, but not limited to, our limited operating history in our core business and lack of profitability, uncertainties of the commercial viability of our technology, the impact of government regulation and healthcare reform initiatives, and other risks normally associated with biotechnology companies, we have concluded that it is more likely than not that these net operating loss carryforwards and credits will not be realized and, as a result, a 100% deferred tax valuation allowance has been recorded against these assets.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">30</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Results of Operations</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net Loss</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We recorded net losses of $2,346,826, $2,747,328, and $3,284,252 for the years ended December 31, 2011, 2010 and 2009, respectively. Our operating results typically fluctuate due to the timing of activities and related costs associated with our vaccine research and development activities and our general and administrative costs, as described in more detail below.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Grant Revenue</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We recorded grant revenues of $4,899,885, $5,185,257, and $3,668,195 for the years ended December 31, 2011, 2010 and 2009, respectively.&#160;&#160;Grant revenues for all three years relate to our IPCAVD grant, except that 2010 includes $244,479 related to our receipt of a Qualified Therapeutic Discover Program (QTDP) grant.&#160;&#160;During 2007, we were awarded the IPCAVD grant by the NIH to support our HIV/AIDS vaccine program.&#160;&#160;The project period for the grant covers a five-year period which commenced in October 2007, with an aggregate award of $20.4 million.&#160;&#160;As of December 31, 2011, there is approximately $3.9 million of unused grant funds remaining and available for use through August 31, 2012 (the end of the original project period).</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and Development</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our research and development expenses were $4,276,375, $4,793,956, and $4,068,682 for the years ended December&#160;31, 2011, 2010 and 2009, respectively. Research and development expense for these periods includes stock-based compensation expense of $179,400, $206,501, and $304,654 for 2011, 2010 and 2009, respectively (see discussion under &#8220;Stock-Based Compensation Expense&#8221; below).&#160;&#160;Our research and development costs do not include costs incurred by HVTN in conducting trials of GeoVax vaccines.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our research and development expenses can fluctuate considerably on a period-to-period basis, depending on our need for vaccine manufacturing by third parties, the timing of expenditures related to our IPCAVD grant from the NIH, and the timing of costs associated with clinical trials being funding directly by us.&#160;&#160;Our Phase 2a clinical trial for our preventive vaccine is being conducted and funded by the HVTN, but we are responsible for the manufacture of vaccine product to be used in the trial, and we are not currently receiving any government support for the Phase 1 clinical trial of our therapeutic vaccine.&#160;&#160;We cannot predict the level of support we may receive from HVTN or other federal agencies (or divisions thereof) for our future clinical trials.&#160;&#160;We expect that our research and development costs, including costs of conducting clinical trials for our therapeutic vaccine not currently being supported by HVTN, will continue to increase during 2012 and beyond as we progress through the human clinical trial process leading up to possible product approval by the FDA.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Since our inception, all of our research and development efforts have been focused on development of our HIV/AIDS vaccines, which we have managed and evaluated to date as a single project.&#160;&#160;Upon receipt of the IPCAVD grant in late 2007, we began incurring additional costs associated with the grant, and reallocated personnel and other internal resources toward activities supported by the grant.&#160;&#160;The table below summarizes our research and development expenses for each of the years in the three year period ended December&#160;31, 2011. The amounts shown related to the IPCAVD grant represent all direct costs associated with the grant activities, including salaries and personnel-related expenses, supplies, consulting, contract services and travel. The remainder of our research and development expense is allocated to our general HIV/AIDS vaccine program.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-DECORATION: underline"><font style="DISPLAY: inline">R&amp;D Project</font></font></div>
</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="55%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">IPCAVD Grant &#8211; Vaccine Adjuvants</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,015,812</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,385,193</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,772,397</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="55%" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">DNA/MVA Vaccines &#8211; HIV/AIDS</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,260,563</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,408,763</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,296,285</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="55%" style="PADDING-BOTTOM: 4px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total Research and Development Expense</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,276,375</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,793,956</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,068,682</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our vaccine candidates still require significant, time-consuming and costly research and development, testing and regulatory clearances. Completion of clinical development will take several years or more, but the length of time generally varies substantially according to the type, complexity, novelty and intended use of a product candidate. The cost of the ongoing Phase 2a clinical trial for our preventive vaccine is being funded by the HVTN, but we cannot be certain whether the HVTN or any other external source will provide funding for further development. We intend to seek government and/or third party support for future clinical human trials, but there can be no assurance that we will be successful. The duration and the cost of future clinical trials may vary significantly over the life of the project as a result of differences arising during development of the human clinical trial protocols, including, among others:</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the number of patients that ultimately participate in the clinical trial;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the duration of patient follow-up that seems appropriate in view of the results;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the number of clinical sites included in the clinical trials; and</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">the length of time required to enroll suitable patient subjects.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Due to the uncertainty regarding the timing and regulatory approval of clinical trials and pre-clinical studies, our future expenditures are likely to be highly volatile in future periods depending on the outcomes of the trials and studies. From time to time, we will make determinations as to how much funding to direct to these programs in response to their scientific, clinical and regulatory success, anticipated market opportunity and the availability of capital to fund our programs.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">31</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In developing our product candidates, we are subject to a number of risks that are inherent in the development of products based on innovative technologies. For example, it is possible that our vaccines may be ineffective or toxic, or will otherwise fail to receive the necessary regulatory clearances, causing us to delay, extend or terminate our product development efforts. Any failure by us to obtain, or any delay in obtaining, regulatory approvals could cause our research and development expenditures to increase which, in turn, could have a material adverse effect on our results of operations and cash flows. Because of the uncertainties of clinical trials, estimating the completion dates or cost to complete our research and development programs is highly speculative and subjective. As a result of these factors, we are unable to accurately estimate the nature, timing and future costs necessary to complete the development of our product candidates. In addition, we are unable to reasonably estimate the period when material net cash inflows could commence from the sale, licensing or commercialization of such product candidates, if ever.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">General and Administrative Expense</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our general and administrative expenses were $2,972,555, $3,162,134, and $2,914,845 for the years ended December&#160;31, 2011, 2010 and 2009, respectively. General and administrative costs include officers&#8217; salaries, legal and accounting costs, patent costs, amortization expense associated with intangible assets, and other general corporate expenses. General and administrative expense includes stock-based compensation expense of $593,597, $544,031, and $994,011 for 2011, 2010 and 2009, respectively (see discussion under &#8220;Stock-Based Compensation Expense&#8221; below). We expect that our general and administrative costs may increase in the future in support of expanded research and development activities and other general corporate activities.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Stock-Based Compensation Expense</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We recorded total stock-based compensation expense of $772,997, $750,532, and $1,298,665 during the years ended December&#160;31, 2011, 2010 and 2009, respectively, which was allocated to research and development expense or general and administrative expense according to the classification of cash compensation paid to the employee, consultant or director to whom the stock compensation was granted. In addition to amounts related to the issuance of stock options to employees, the figures include amounts related to common stock and stock purchase warrants issued to consultants and non-employee directors. For the three years ended December&#160;31, 2011, stock-based compensation expense was allocated as follows:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="55%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">593,597</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">544,031</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">994,011</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="55%" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development expense</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">179,400</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">206,501</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">304,654</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="55%" style="PADDING-BOTTOM: 4px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total stock option expense</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">772,997</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">750,532</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,298,665</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Other Income</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Interest income was $2,219, $23,505, and $31,080 for the years ended December&#160;31, 2011, 2010 and 2009, respectively. The variances between years are primarily attributable to the cash available for investment and to interest rate fluctuations.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Impact of Inflation</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the three year period ended December&#160;31, 2011, we do not believe that inflation and changing prices had a material impact on our operations or on our financial results.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">32</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Off-Balance Sheet Arrangements</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have not entered into off-balance sheet financing arrangements, other than operating leases.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Quantitative and Qualitative Disclosures about Market Risk</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our exposure to market risk is limited primarily to interest income sensitivity, which is affected by changes in the general level of United States interest rates, particularly because a significant portion of our investments are in short-term debt securities issued by the U.S. government and institutional money market funds. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income received without significantly increasing risk. Due to the nature of our short-term investments, we believe that we are not subject to any material market risk exposure. We do not have any derivative financial instruments or foreign currency instruments.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">33</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DIRECTORS AND EXECUTIVE OFFICERS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table sets forth certain information with respect to our directors and executive officers.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Name</font></font></div>
</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Age</font></font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline">Current Position</font></font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="39%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">David A. Dodd (1)(2)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">62</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="46%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chairman of the Board of Directors</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="39%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Robert T. McNally, Ph.D.</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">64</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="46%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">President and Chief Executive Officer, Director</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="39%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Mark W. Reynolds, CPA</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">50</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="46%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Financial Officer and Corporate Secretary</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="39%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Harriet L. Robinson, Ph.D.</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">74</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="46%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Scientific Officer, Director</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="39%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Steven S. Antebi (1)(3)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">68</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="46%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="39%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dean G. Kollintzas (1)(2)(3)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">38</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="46%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="39%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">John N. Spencer, Jr. CPA (2)(3)</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">71</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="46%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="39%">___________________</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="46%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(1)</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Member of the Compensation Committee of the Board of Directors.</font></div>
</td>
</tr></table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(2)</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Member of the Nominating and Governance Committee of the Board of Directors.</font></div>
</td>
</tr></table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">(3)</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Member of the Audit Committee of the Board of Directors.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">David A. Dodd</font>.&#160;&#160;Mr.&#160;Dodd joined the Board of Directors in March 2010 and became Chairman of our Board of Directors on January&#160;1, 2011. He is the Chief Executive Officer of RiversEdge BioVentures, an investment and advisory firm focused on the life sciences and pharmaceuticals industries, which he founded in 2009.&#160;&#160;Mr. Dodd is also the Chief Executive Officer of VaxyGen Holdings, LLC, a group of companies providing bio-assay and biopharmaceutical manufacturing services, and which holds exclusive rights to commercialize the Serum Institute of India&#8217;s vaccine products in North America and the European Union.&#160;&#160;He has more than 35&#160;years of executive experience in the healthcare industry. From December 2007 to June 2009, Mr.&#160;Dodd was President, Chief Executive officer and Chairman of BioReliance Corporation, an organization that provided biological safety testing, viral clearance testing, genetic and mammalian technology testing and laboratory animal diagnostic services testing. From October 2006 to April 2009, he served as non-executive chairman of Stem Cell Sciences Plc. Before that, Mr.&#160;Dodd served as President, Chief Executive Officer and Director of Serologicals Corporation (Nasdaq: SERO) before it was sold to Millipore Corporation in July 2006 for $1.5&#160;billion. For five years prior to his employment by Serologicals Corporation, Mr.&#160;Dodd served as President and Chief Executive Officer of Solvay Pharmaceuticals, Inc. and Chairman of its subsidiary Unimed Pharmaceuticals, Inc. The Board of Directors concluded Mr.&#160;Dodd should serve on the Board of Directors due to his experience in the pharmaceutical industry, as well as his background in general management, business transformation, corporate partnering, and mergers and acquisitions.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Robert T. McNally,&#160;Ph.D</font>.&#160;&#160;Dr.&#160;McNally joined the Board of Directors in December 2006 and was appointed as our President and Chief Executive Officer effective April&#160;1, 2008. From 2000 to March 2008, Dr.&#160;McNally served as Chief Executive Officer of Cell Dynamics LLC, a cGMP laboratory services company. Previously, Dr.&#160;McNally was a co-founder and Senior Vice President of Clinical Research for CryoLife, Inc., a pioneering company in transplantable human tissues. He has over 34 years of experience in academic and corporate clinical investigations, management, research, business, quality and regulatory affairs Dr.&#160;McNally is a Fellow of the American Institute for Medical and Biological Engineering, serves on the advisory boards of the Petit Institute for Bioengineering and Dupree College of Management at the Georgia Institute of Technology, and is a former Chairman of Georgia Bio, a trade association. Dr.&#160;McNally graduated with a Ph.D. in biomedical engineering from the University of Pennsylvania. The Board of Directors has concluded that Dr.&#160;McNally should serve on its Board of Directors by virtue of his prior business and scientific experience, including his experience as Chief Executive Officer of Cell Dynamics, LLC and as Senior Vice President of Clinical Research for CryoLife, Inc., and due to his intimate involvement with the Company&#8217;s ongoing operations as its President and Chief Executive Officer.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Mark W. Reynolds, CPA</font>&#160;&#160;Mr.&#160;Reynolds joined the Company on a part-time basis in October 2006 as Chief Financial Officer and Corporate Secretary, becoming a full-time employee in January 2010. From 2003 to 2006, before being named Chief Financial Officer of GeoVax Labs, Inc., Mr.&#160;Reynolds provided financial and accounting services to GeoVax, Inc. as an independent contractor. From 2004 to 2008, Mr.&#160;Reynolds served as Chief Financial Officer for Health Watch Systems, Inc. a privately-held company in the consumer healthcare industry. From 2004 to 2006, he served as Chief Financial Officer for Duska Therapeutics, Inc., a publicly-held biotechnology company. From 1988 to 2002, Mr.&#160;Reynolds was first Controller and later Chief Financial Officer and Corporate Secretary of CytRx Corporation, a publicly-held biopharmaceutical company. Mr.&#160;Reynolds began his career as an auditor with Arthur Andersen&#160;&amp; Co. from 1985 to 1988. He is a certified public accountant and earned a masters of accountancy degree from the University of Georgia.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">34</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Harriet L. Robinson,&#160;Ph.D</font>.&#160;&#160;Dr.&#160;Robinson joined the Company as Senior Vice President, Research and Development on a part-time basis in November 2007 and on a full-time basis in February 2008, and was elected to the Board of Directors in June 2008. She is a co-founder of GeoVax, Inc. and has served as chief of its scientific advisory board since formation of the company in 2001. From 1999 to February 2008, Dr.&#160;Robinson served as the Asa Griggs Candler Professor of Microbiology and Immunology at Emory University in Atlanta, Georgia, and from 1998 to February 2008 as Chief, Division of Microbiology and Immunology, Yerkes National Primate Center and Professor at the Emory University School of Medicine. She was Professor, Department of Microbiology&#160;&amp; Immunology, at the University of Massachusetts Medical Center from 1988 to 1997 and Staff, then Senior, then Principal Scientist at the University of Massachusetts Worcester Foundation for Experimental Biology from 1977 to 1987.<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Dr.&#160;Robinson received a bachelor of arts degree from Swarthmore College and M.S. and Ph.D. degrees from the Massachusetts Institute of Technology. The Board of Directors has concluded that Dr.&#160;Robinson should serve on its Board of Directors by virtue of her extensive knowledge of the Company&#8217;s technology as its scientific founder.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Steven S. Antebi</font>.&#160;&#160;Mr.&#160;Antebi joined the Board of Directors in March 2010. During the last five years, he has served as President of Maple Capital Management, a fund focusing on debt and equity investments in North America (May 2007 to present), President and Chief Executive Officer of Galileo Partners LLC (2006 to present), and President of Blue and Gold Enterprises Inc. (2002-2009), funds that invest in registered direct investments, PIPE transactions, private placements, and open market equity transactions. Prior to that, he served for twenty years in various senior positions at Bear Stearns and Company, including institutional sales, trading the firm&#8217;s capital in the over the counter market, syndicate distribution, and outside investment banking. He has served as a member of the Board of Governors of Cedars Sinai Medical Center in Los Angeles, California, one of the largest hospital/research centers in the world, for over ten years. Mr.&#160;Antebi is also the Chairman of the Board of the Royalty Review Council, a company doing royalty accounting for web casting and digital media; a co-founder and Chairman of the Board of Crunch Digital, a provider of business intelligence services for the music industry; and a member of the Advisory Board of MediaPass, a provider of subscription services for online publishers. The Board of Directors concluded that Mr.&#160;Antebi should serve on the Board of Directors because of his substantial experience in finance and his experience in healthcare and technology.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Dean G. Kollintzas.</font>&#160;&#160;Mr.&#160;Kollintzas joined the Board of Directors upon consummation of the merger with GeoVax, Inc. in September 2006. Since 2001 Mr.&#160;Kollintzas has been an intellectual property attorney specializing in biotechnology and pharmaceutical licensing, FDA regulation, and corporate/international transactions. Mr.&#160;Kollintzas received a microbiology degree from the University of Illinois and a J.D. from Franklin Pierce Law Center. He is a member of the Wisconsin and American Bar Associations.&#160;&#160;Since 2004, Mr.&#160;Kollintzas has also owned and operated a restaurant in Joliet, Illinois called The Metro Grill. The Board of Directors has concluded that Mr.&#160;Kollintzas should serve on the Board of Directors by virtue of his experience with intellectual property matters, biotechnology and pharmaceutical licensing, and FDA regulation.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">John N. (Jack) Spencer,&#160;Jr., CPA</font>&#160;&#160;Mr.&#160;Spencer joined the Board of Directors upon consummation of the merger with GeoVax, Inc. in September 2006. Mr.&#160;Spencer is a certified public accountant and was a partner of Ernst&#160;&amp; Young LLP where he spent more than 38&#160;years until he retired in 2000. Mr.&#160;Spencer also serves as a director MRI Interventions, Inc., a medical device company, where he also chairs the audit committee, and served as a director of Firstwave Technologies (Nasdaq: FSTW) from November 2003 until April 2009. He also serves as a consultant to various companies primarily relating to financial accounting and reporting matters. Mr.&#160;Spencer received a bachelor of science degree from Syracuse University, and he earned an M.B.A. degree from Babson College. He also attended the Harvard Business School Advanced Management Program. The Board of Directors has concluded that Mr.&#160;Spencer should serve on the Board of Directors by virtue of his experience at Ernst&#160;&amp; Young LLP where he was the partner in charge of that firm&#8217;s life sciences practice for the southeastern United States, and his clients included a large number of publicly-owned and privately-held medical technology companies, together with his continuing expertise as a director of, and a consultant to, other publicly owned and privately held companies.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Compensation Committee Interlocks and Insider Participation</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During 2011, Mr. Antebi, Mr. Dodd, and Mr.&#160;Kollintzas served on our Compensation Committee. None of these individuals were officers or employees of the Company or any of its subsidiaries during the fiscal year ended December&#160;31, 2011, nor at any time prior thereto.&#160;&#160;During the fiscal year ended December&#160;31, 2011, none of the members of the Compensation Committee had any relationship with the Company requiring disclosure under Item&#160;404 of Regulation&#160;S-K, and none of the Company&#8217;s executive officers served on the compensation committee (or equivalent), or the Board of Directors, of another entity whose executive officer(s) served on our Board of Directors or Compensation Committee.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">35</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXECUTIVE COMPENSATION</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The tables and disclosures that follow set forth the compensation and certain other information with respect to our &#8220;Named Executive Officers&#8221;. The Named Executive Officers for 2011 include our chief executive officer and the two other most highly compensated individuals who were serving as executive officers as of December 31, 2011. Our Named Executive Officers for 2011 were:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Robert T. McNally, Ph.D., President and Chief Executive Officer</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Mark W. Reynolds, Chief Financial Officer</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Harriet L. Robinson, Ph.D., Chief Scientific Officer</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Employment Agreements</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Robert T. McNally.</font>&#160;&#160;On March&#160;20, 2008, GeoVax entered into an employment agreement with Robert T. McNally,&#160;Ph.D. to become our President and Chief Executive Officer effective April&#160;1, 2008. The employment agreement has no specified term. The employment agreement provided for an initial annual salary of $200,000 to Dr.&#160;McNally, subject to periodic increases as determined by the Compensation Committee. The Board of Directors may also approve the payment of a discretionary bonus annually. Dr.&#160;McNally is eligible for grants of awards from our 2006 Equity Incentive Plan (the &#8220;Plan&#8221;) and is entitled to participate in any and all benefits in effect from time-to-time for employees generally. We may terminate the employment agreement, with or without cause. If we terminate the employment agreement without cause, we will be required to provide Dr.&#160;McNally at least 30&#160;days prior notice of the termination and one week of severance pay for each full year of service as President and Chief Executive Officer ($15,865 as of December 31, 2011, paid as salary continuance). Dr.&#160;McNally may terminate the employment agreement at any time by giving us 60&#160;days notice. In that event, he would not receive severance.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Mark W. Reynolds.</font>&#160;&#160;On February&#160;1, 2008, GeoVax entered into an amended and restated employment agreement with Mark W. Reynolds, our Chief Financial Officer. The employment agreement has no specified term. The employment agreement provided for an initial annual salary of $115,000 to Mr.&#160;Reynolds, which was increased to $150,000 by the Compensation Committee and the Board of Directors effective January&#160;1, 2009, commensurate with an increased time commitment provided by Mr.&#160;Reynolds (50% to 75%). The employment agreement was again amended and restated, effective January&#160;1, 2010, to reflect a further adjustment for Mr.&#160;Reynolds time commitment (from 75% to 100%) together with a base salary increase to $212,600. The Board of Directors may also approve the payment of a discretionary bonus annually. Mr.&#160;Reynolds is eligible for grants of awards from our Plan and is entitled to participate in any and all benefits in effect from time-to-time for employees generally. We may terminate the employment agreement, with or without cause. If we terminate the employment agreement without cause, we will be required to provide Mr.&#160;Reynolds at least 30&#160;days prior notice of the termination and one week of severance pay for each full year of service as Chief Financial Officer ($20,442 as of December 31, 2011, paid as salary continuance). Mr.&#160;Reynolds may terminate the employment agreement at any time by giving us 60&#160;days notice. In that event, he would not receive severance.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Harriet L. Robinson.</font>&#160;&#160;On November&#160;19, 2007, GeoVax entered into an employment agreement with Harriet L. Robinson, our Chief Scientific Officer. The employment agreement has no specified term. The employment agreement provided for an initial base salary of $250,000 to Dr.&#160;Robinson, subject to periodic increases as determined by the Compensation Committee. Dr.&#160;Robinson initially worked part-time for the Company, and became a full-time employee in February 2008. The Board of Directors may also approve the payment of a discretionary bonus annually. Dr.&#160;Robinson is eligible for grants of awards from our Plan and is entitled to participate in any and all benefits in effect from time-to-time for employees generally. We may terminate the employment agreement, with or without cause. If we terminate the employment agreement without cause, we will be required to provide Dr.&#160;Robinson at least 30&#160;days prior notice of the termination and one week of severance pay for each full year of service ($20,442 as of December 31, 2011, paid as salary continuance). Dr.&#160;Robinson may terminate the employment agreement at any time by giving us 60&#160;days notice. In that event, she would not receive severance.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In October 2006 GeoVax Labs, Inc. and our subsidiary, GeoVax, Inc. entered into indemnification agreements with Messrs. McNally, Reynolds, Kollintzas and Spencer.&#160;&#160;Pursuant to these agreements, we have agreed to indemnify them to the full extent permitted by Illinois and Georgia law against certain liabilities incurred by these individuals in connection with specified proceedings if they acted in a manner they believed in good faith to be in or not opposed to the best interests of the Company and, with respect to any criminal proceeding, had no reasonable cause to believe that such conduct was unlawful.&#160;&#160;The agreements also provide for the advancement of expenses to these individuals subject to specified conditions.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">36</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Potential Payments Upon Change-in-Control</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our 2006 Equity Incentive Plan contains provisions that could lead to an accelerated vesting of options or other awards.&#160;&#160;In the event of certain change-in-control transactions described in the Plan, (i)&#160;outstanding options or other awards under the Plan may be assumed, converted or replaced; (ii)&#160;the successor corporation may substitute equivalent options or other awards or provide substantially similar consideration to Plan participants as were provided to stockholders (after taking into account the existing provisions of the options or other awards); or (iii) the successor corporation may replace options or awards with substantially similar shares or other property.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the event the successor corporation (if any) refuses to assume or substitute options or other awards as described (i)&#160;the vesting of any or all options or awards granted pursuant to the Plan will accelerate upon the change-in-control transaction, and (ii)&#160;any or all options granted pursuant to the Plan will become exercisable in full prior to the consummation of the change-in-control transaction at such time and on such conditions as the Compensation Committee determines.&#160;&#160;If the options are not exercised prior to the consummation of the change-in-control transaction, they shall terminate at such time as determined by the Compensation Committee.&#160;&#160;Subject to any greater rights granted to Plan participants under the Plan, in the event of the occurrence of a change-in-control transaction any outstanding options or other awards will be treated as provided in the applicable agreement or plan of merger, consolidation, dissolution, liquidation, or sale of assets.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">If the Company experienced a change-in-control transaction described in the Plan on December&#160;31, 2011, the value of accelerated options for each Named Executive Officer, based on the difference between $0.91, the closing price of our common stock on the over-the-counter bulletin board on December&#160;30, 2011, and, if lower, the exercise price per share of each option for which vesting would be accelerate for each Named Executive Officer, would be as follows: Dr. McNally - $-0-; Mr. Reynolds - $-0-; and Dr. Robinson - $-0-.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Additionally, our employment agreements with each Named Executive Officer provide for payment to each Named Executive Officer if we terminate such Named Executive Officer&#8217;s employment without cause.&#160;&#160;If each Named Executive Officer was terminated without cause on December&#160;31, 2011, the following amounts, which represent one week of pay for each full year of service to the Company, would be payable to each Named Executive Officer as salary continuance under the terms of such Named Executive Officer&#8217;s employment agreement:&#160;&#160;Dr. McNally - $10,577; Mr. Reynolds - $16,354; and Dr. Robinson - $15,332; .</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Summary Compensation Table</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following narrative, table, and footnotes set forth information concerning the total compensation earned during the fiscal years ended December 31, 2011 and 2010 by our Named Executive Officers.&#160;&#160;The individual components of the total compensation reflected in the table are broken out as follows:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Salary</font>.&#160;&#160;Base salary earned during 2011 and 2010.&#160;&#160;The terms of the Employment Agreements governed the base salaries for Dr. McNally, Mr. Reynolds, and Dr. Robinson.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Bonus</font>.&#160;&#160;The amount of cash bonuses paid during 2011 and 2011.&#160;&#160;No bonuses were paid to Dr. McNally, Mr. Reynolds, or Dr. Robinson during these periods.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">Option Awards.</font>&#160;&#160;The awards disclosed under the heading &#8220;Option Awards&#8221; consist of the aggregate grant date fair value of the stock option grants during 2011 and 2010 computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, <font style="FONT-STYLE: italic; DISPLAY: inline">Compensation &#8211; Stock Compensation</font> (&#8220;FASB ASC Topic 718&#8221;).&#160;&#160;For a discussion of the various assumptions made and methods used for determining such amounts, see footnotes 2 and 6 to our 2011 consolidated financial statements contained elsewhere in this prospectus.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">37</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline">All Other Compensation.</font>&#160;&#160;The amounts include under &#8220;All Other Compensation&#8221; are described in the footnotes to the table.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="2" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="43%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 0.5pt solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Name and</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Principal Position</font></div>
</td>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center; BORDER-LEFT: black 2px solid; BORDER-TOP: black 0.5pt solid; BORDER-RIGHT: black 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Year</font></div>
</td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 0.5pt solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Salary</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">($)</font></div>
</td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center; BORDER-LEFT: black 2px solid; BORDER-TOP: black 0.5pt solid; BORDER-RIGHT: black 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Bonus</font></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">($)</font></div>
</td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 0.5pt solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Option</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Awards</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">($)</font></div>
</td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 0.5pt solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">All Other</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Compensation ($)(4)</font></div>
</td>
<td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 0.5pt solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">($)</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="top" width="43%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Robert T. McNally</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;President and </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Executive Officer</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$275,000</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">275,000</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$ -</font></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$ 23,610 (1)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,600 (2)</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$9,800</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,800</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$308,410</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">302,400</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="43%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Mark W. Reynolds</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;Chief Financial Officer</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">212,600</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">212,600</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,675 (3)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,600 (2)</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,504</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,063</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">240,779</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">231,263</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="top" width="43%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Harriet L. Robinson</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;Chief Scientific Officer</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">265,750</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">265,750</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,675 (3)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17,600 (2)</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,800</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9,800</font></div>
</td>
<td valign="top" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">295,225</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">293,150</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Grant date fair value of stock option grant on December 30, 2011 for 30,000 shares with an exercise price of $0.91 per share, vesting over a three-year period.&#160;&#160;As of March 30, 2012, none of these shares have vested and are exercisable.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Grant date fair value of stock option grant on December 10, 2010 for 10,000 shares with an exercise price of $1.98 per share, vesting over a three-year period.&#160;&#160;As of March 30, 2012, 3,333 of these shares have vested and are exercisable.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(3)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Grant date fair value of stock option grant on December 30, 2011 for 25,000 shares with an exercise price of $0.91 per share, vesting over a three-year period.&#160;&#160;As of March 30, 2012, none of these shares have vested and are exercisable.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: normal">(4)</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt">Amounts shown in the &#8220;All Other Compensation&#8221; column represent employer contributions to the Company&#8217;s 401(k) retirement plan.</font></font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Outstanding Equity Awards at Fiscal Year-End</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">GeoVax has awarded stock options to its senior management and other employees.&#160;&#160;The terms of these awards typically provide for vesting over a defined period of time, generally three years.&#160;&#160;The options expire if not exercised within ten years from the date of grant.&#160;&#160;The Company does not have a formula for determining stock option awards.&#160;&#160;Awards are generally based on the subjective judgment of the President and Chief Executive Officer and on the Compensation Committee&#8217;s subjective judgment.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table sets forth certain information with respect to unexercised options previously awarded to our Named Executive Officers that were outstanding as of December 31, 2011.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="2" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="8" valign="bottom" width="100%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Option Awards</font></div>
</td>
</tr><tr>
<td valign="bottom" width="27%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="4" valign="bottom" width="38%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Number of Securities</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Underlying Unexercised Options</font></div>
</td>
<td colspan="2" valign="bottom" width="19%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="16%" style="BORDER-BOTTOM: black 2px solid; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="27%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Name</font></div>
</td>
<td colspan="2" valign="bottom" width="19%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center; BORDER-RIGHT: black 2px solid">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(#) Exercisable</font></div>
</td>
<td colspan="2" valign="bottom" width="19%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;(#) Unexercisable</font></div>
</td>
<td colspan="2" valign="bottom" width="19%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Option Exercise Price ($)</font></div>
</td>
<td valign="bottom" width="16%" style="BORDER-BOTTOM: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Option Expiration Date</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Robert McNally</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font> </font>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,333</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,667</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,000</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">48,000</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,000</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26,400</font></font></div>
</td>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 2px solid; BORDER-RIGHT: black 2px solid">&#160;</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">30,000 (1)</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,667 (2)</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,333 (3)</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$&#160;&#160;&#160;&#160;0.91</font> </font>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.98</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.00</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.50</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8.50</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8.05</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17.75</font></font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 2px solid; BORDER-RIGHT: black 2px solid">&#160;</td>
<td valign="top" width="16%" style="BORDER-BOTTOM: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12/30/21</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12/10/20</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12/2/19</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12/11/18</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6/17/18</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12/5/17</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3/14/17</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Mark Reynolds</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,333</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,667</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,000</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,000</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">36,000</font></font></div>
</td>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 2px solid; BORDER-RIGHT: black 2px solid">&#160;</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,000 (1)</font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,667 (2)</font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,333 (3)</font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right; BORDER-LEFT: black 2px solid">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.91</font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.98</font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.00</font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.50</font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8.05</font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">17.75</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 2px solid; BORDER-RIGHT: black 2px solid">&#160;</td>
<td valign="top" width="16%" style="BORDER-BOTTOM: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12/30/21</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12/10/20</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12/2/19</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12/11/18</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12/5/17</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3/14/17</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td valign="top" width="27%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Harriet Robinson</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td valign="top" width="11%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,333</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,667</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,000</font></font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">177,912</font></font></div>
</td>
<td valign="top" width="8%" style="BORDER-BOTTOM: black 2px solid; BORDER-RIGHT: black 2px solid">&#160;</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,000 (1)</font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,667 (2)</font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,333 (3)</font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 2px solid">&#160;</td>
<td valign="top" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right; BORDER-LEFT: black 2px solid">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.91</font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.98</font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.00</font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.50</font></div>

<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.024</font></div>
</td>
<td valign="top" width="7%" style="BORDER-BOTTOM: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="16%" style="BORDER-BOTTOM: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12/30/21</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12/10/20</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12/2/19</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">12/11/18</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2/5/14</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These stock options vest and become exercisable in three equal installments on December 30, 2012, 2013 and 2014.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These stock options vest and become exercisable in two equal installments on December 10, 2012 and 2013.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(3)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These stock options vest and become exercisable on December 2, 2012.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">38</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other Benefits Provided to Executive Officers</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dr.&#160;McNally, Mr.&#160;Reynolds and Dr.&#160;Robinson are eligible for health insurance and 401(k) benefits at the same level and subject to the same conditions as provided to all other employees.&#160;&#160;GeoVax participates in a multi-employer defined contribution retirement plan (the &#8220;401k Plan&#8221;) administered by a third party service provider; and the Company contributes to the 401k Plan on behalf of all its eligible employees based upon the same matching formula.&#160;&#160;The amounts shown in the Summary Compensation Table under the heading &#8220;Other Compensation&#8221; represent the value of the Company&#8217;s matching contributions to the 401(k) accounts of these executive officers. Executive officers did not receive any other perquisites or other personal benefits or property from the Company or any other source.&#160;&#160;The Company has also entered into indemnification agreements with certain executive officers as discussed as &#8220;Directors and Executive Officers.&#8221;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">39</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DIRECTOR COMPENSATION</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table sets forth information concerning the compensation earned for service on our Board of Directors during the fiscal year ending December 31, 2011 by each individual who served as a director at any time during the fiscal year.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="2" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Name</font></div>
</td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Fees</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Earned or Paid in Cash</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">($)</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-TOP: black 2px solid; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Stock</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Awards</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">($)</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-TOP: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(3)(4)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Option</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Awards</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">($)</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-TOP: black 2px solid; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Non-Equity</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Incentive</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Plan</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Compensation</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">($)</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-TOP: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Non-qualified</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Deferred</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Compensation Earnings</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">($)</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-TOP: black 2px solid; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">All</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Compensation</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">($)</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-TOP: black 2px solid; BORDER-RIGHT: black 2px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Total</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">($)</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-TOP: black 2px solid; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="16%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Steven S. Antebi</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,600</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,675</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,275</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="16%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">David A. Dodd</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">43,750</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,675</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">63,425</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="16%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Donald G. Hildebrand (1)</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,500</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,000</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31,500</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="16%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dean G. Kollintzas</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">26,900</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,675</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">46,575</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="16%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Robert T. McNally (2)</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="16%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Harriet L. Robinson (2)</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="16%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">John N. Spencer, Jr.</font></div>
</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">33,450</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,675</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px double"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53,125</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Mr. Hildebrand served as a director until our August 16, 2011 annual meeting of stockholders.&#160;&#160;He now serves as Chairman Emeritus in an advisory role and not as a director or as an executive officer.&#160;&#160;The amount shown in the &#8220;All Other Compensation&#8221; column represents the amount paid to Mr. Hildebrand for the year ended December 31, 2011 pursuant to his consulting agreement with the Company.&#160;&#160;See &#8220;Certain Relationships and Related Transactions &#8211; Consulting Agreement with Donald Hildebrand.&#8221;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dr. McNally and Dr. Robinson, who were employees of the Company during the fiscal year ended December 31, 2011, received no compensation for their service as directors. All amounts related to their compensation as Named Executive Officers during the fiscal year ended December 31, 2011 and prior years are included in the &#8220;Summary Compensation Table&#8221;.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(3)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Amounts shown in the &#8220;Option Awards&#8221; column represent the aggregate grant date fair value of awards computed in accordance with FASB ASC Topic 718.&#160;&#160;For a discussion of the various assumptions made and methods used for determining such amounts, see footnotes 2 and 6 to our 2011 consolidated financial statements contained elsewhere in this prospectus.&#160;&#160;On December 30, 2011, Messrs. Antebi, Dodd, Kollintzas and Spencer were each granted options to purchase 25,000 shares of our common stock, with an exercise price of $0.91 per share.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(4)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The table below shows the aggregate numbers of option awards outstanding for each non-employee director as of December 31, 2011.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-TOP: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Name</font></div>
</td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid; BORDER-TOP: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aggregate Option Awards</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">as of December 31, 2011</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(#)</font></div>
</td>
<td nowrap valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-TOP: black 2px solid; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="83%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Steven S. Antebi</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">61,400</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="83%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">David A. Dodd</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">61,400</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="83%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dean G. Kollintzas</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">91,400</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="83%" style="BORDER-BOTTOM: black 2px solid; BORDER-LEFT: black 2px solid; BORDER-RIGHT: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">John N. Spencer, Jr.</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">91,400</font></td>
<td nowrap valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left; BORDER-RIGHT: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Director Compensation Plan</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In March 2007, the Board of Directors approved a recommendation from the Compensation Committee for director compensation, which we refer to as the &#8220;Director Compensation Plan.&#8221; It was subsequently amended in March 2008, December 2009, and in December 2010. The Director Compensation Plan applies only to non-employee directors. Directors who are employees of the Company receive no compensation for their service as directors or as members of committees.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cash Fees</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For 2011, each non-employee director received an annual retainer of $5,000 (paid quarterly) for service as a member of the Audit Committee and $3,300 for service as a member of the Compensation Committee. The Chairman of the Audit Committee received an annual retainer of $9,000, and the Chairman of each of the Compensation Committee and the Nominating and Corporate Governance Committee received an annual retainer of $6,000.&#160;&#160;These retainers were also paid quarterly. Non-employee directors also received fees for each Board of Directors or Committee meeting attended as follows: $3,000 for in person Board of Directors meetings and $1,500 for telephonic Board of Directors meetings, $1,000 per Committee meeting chaired, and $500 per Committee meeting attended as a non-chair member.&#160;&#160;Mr. Dodd, the non-employee Chairman of the Board during 2011, received an annual retainer of $30,000 (paid quarterly) and was not entitled to additional fees for Board meetings attended, but did receive additional fees for committees on which he serves.&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">40</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Stock Option Grants</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Each of our current non-employee directors received a grant of options to purchase 26,400 shares of common stock on the date that such non-employee director was first elected or appointed. We currently do not have a formula for determining annual stock option grants to directors (upon their re-election to the Board of Directors, or otherwise). Such option grants are currently determined by the Board of Directors, upon recommendation by the Compensation Committee based on the Compensation Committee&#8217;s annual deliberations and review of the director compensation structure of similar companies. At its meeting in December 2011, upon a recommendation of the Compensation Committee, the Board of Directors approved an annual stock option grant of 25,000&#160;shares to its non-employee members.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Expense Reimbursement</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All directors are reimbursed for expenses incurred in connection with attending meetings of the Board of Directors and committees.<a name="gmnh118"><!--EFPlaceholder--></a></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Policies and Procedures for Approval of Related Party Transactions</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our Audit Committee is responsible for reviewing and approving all transactions or arrangements between the Company and any of our directors, officers, principal stockholders or any of their respective affiliates, associates or related parties, other than transactions with officers which are covered by the duties of the Compensation Committee. In determining whether to approve or ratify a related party transaction, the Audit Committee will discuss the transaction with management and will consider all relevant facts and circumstances available to it including:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;</font></div>
</td>
<td align="left" valign="top" width="77%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">whether the terms of the transaction are fair to the Company and at least as favorable to the Company as would apply if the transaction did not involve a related party;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;</font></div>
</td>
<td align="left" valign="top" width="77%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">whether there are demonstrable business reasons for the Company to enter into the transaction;</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;</font></div>
</td>
<td align="left" valign="top" width="77%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">whether the transaction would impair the independence of a non-employee director;&#160;and</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="7%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;</font></div>
</td>
<td align="left" valign="top" width="77%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">whether the transaction would present an improper conflict of interest for any director or executive officer, taking into account the size of the transaction, the direct or indirect nature of the related party&#8217;s interest in the transaction and the ongoing nature of any proposed relationship, and any other factors the Audit Committee deems relevant.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">These policies are in writing and included in the Company&#8217;s minute book.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our Board of Directors has made the following findings and adopted the following policies (in writing) regarding related party transactions:</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has not made and will not make loans or loan guarantees on behalf of any director, officer, beneficially owner of more than 5% of our common stock, or other person constituting a Promoter, as such term is defined in the NASAA Statement of Policy Regarding Corporate Securities Definitions.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company has not engaged and will not engage in material transactions with any director, officer, beneficial owner of more than 5% of our common stock, or other person constituting a Promoter, as such term is defined in the NASAA Statement of Policy Regarding Corporate Securities Definitions, except as described below or as otherwise approved by our Audit Committee consistent with the policies and procedures described below.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company will make any future material affiliated transactions on terms that are no less favorable to the Company than those that can be obtained from unaffiliated third parties.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A majority of the Company&#8217;s Audit Committee will approve all future material transactions.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company&#8217;s officers, directors, and counsel will:</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">consider their due diligence and assure that there is a reasonable basis for these representations, and</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">consider whether to embody the representations in the issuer&#8217;s charter or bylaws.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Consulting Agreement with Donald Hildebrand</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In March 2008, we entered into a consulting agreement with Donald Hildebrand, our former Chairman of the Board of Directors, President and Chief Executive Officer, pursuant to which Mr.&#160;Hildebrand provides business and technical advisory services to the Company.&#160;&#160;Mr. Hildebrand served as a director until August 16, 2011, and is the beneficial owner of more than 5% of our common stock.&#160;&#160;The term of the consulting agreement, as amended, began on April&#160;1, 2008 and ends on December&#160;31, 2012.&#160;&#160;During 2011, 2010 and 2009, Mr.&#160;Hildebrand received $24,000, $57,600, and $57,600, respectively, for his services pursuant to the consulting agreement. We also paid Mr.&#160;Hildebrand&#8217;s medical and dental coverage during 2009.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">41</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Transactions with Emory University</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Emory University is a significant stockholder of the Company, and our primary product candidates are based on technology rights subject to a license agreement with Emory University, which we refer to as the Emory License. The Emory License, among other contractual obligations, requires payments based on milestone achievements, royalties on sales by the Company or on payments to the Company by our sublicensees, and payment of maintenance fees in the event certain milestones are not met within the time periods specified in the Emory License. We may terminate the Emory License upon 90&#160;days prior written notice. In any event, the Emory License expires on the date of the latest expiration date of the underlying patents. We are also obligated to reimburse Emory University for certain ongoing costs in connection with the filing, prosecution and maintenance of patent applications subject to the Emory License. The expense associated with these ongoing patent reimbursements to Emory University amounted to $249,907, $193,674, and $85,673 for the years ended December&#160;31, 2011, 2010, and 2009, respectively.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Through November 2009, we leased office and laboratory space on a month-to-month basis from Emtech Biotechnology Development, Inc., a related party associated with Emory University. Rent expense associated with this lease totaled $43,112 for the year ended December&#160;31, 2009.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have entered into two research agreements with Emory University for the purpose of conducting research and development activities associated with our IPCAVD grant from the NIH. During the years ended 2011, 2010 and 2009, we recorded $1,172,758, $1,391,203, and $816,651, respectively, of expense associated with these contracts. All amounts paid to Emory under these agreements are reimbursable to us pursuant to the IPCAVD grant from the NIH.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other Transactions</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In December 2011 and January 2012, members of our management and Board of Directors participated in a private placement offering of units of our common stock and warrants.&#160;&#160;Each unit, which was priced at $0.67 per unit, consisted of one share of our common stock and a five-year warrant to purchase 1.5 shares at $1.00 per share.&#160;&#160;The purchases by management and members of our Board of Directors were as follows: Dr. McNally $20,000 (29,850 units); Dr. Robinson $100,000 (149,254&#160;units); Mr. Dodd $75,040 (112,000 units); Mr. Reynolds $20,100 (30,000 units); Mr. Spencer $10,000 (14,925 units); Mr. Kollintzas $10,000 (14,925 units); and Mr. Antebi $20,100 (30,000 units).</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">42</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITY OWNERSHIP OF PRINCIPAL STOCKHOLDERS, DIRECTORS AND EXECUTIVE OFFICERS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based solely upon information made available to us, the following table sets forth information with respect to the beneficial ownership of our common stock as of March 30, 2012 by (1) each director; (2) each of our Named Executive Officers; (3) all executive officers and directors as a group; and (4) each additional person who is known by us to beneficially own more than 5% of our common stock.&#160;&#160;Except as otherwise indicated, the holders listed below have sole voting and investment power with respect to all shares of common stock beneficially owned by them.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="54%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Name of Beneficial Owner (1)</font></div>
</td>
<td align="left" valign="bottom" width="17%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="3" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Amount and Nature</font></font></font></div>

<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of Beneficial</font></font></div>

<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Ownership</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="3" valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Percent</font></font></div>

<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of Class (2)</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="54%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Directors and Executive Officers:</font></div>
</td>
<td align="left" valign="bottom" width="17%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="12%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="12%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="54%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Steven S. Antebi (3)</font></div>
</td>
<td valign="bottom" width="17%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td align="right" valign="bottom" width="12%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">87,133</font></div>
</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="12%">&#160;</td>
<td align="left" valign="bottom" width="1%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="54%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">David A. Dodd (4)</font></div>
</td>
<td align="left" valign="bottom" width="17%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="right" valign="bottom" width="12%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">307,858</font></div>
</td>
<td valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="right" valign="bottom" width="12%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.8</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="54%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dean G. Kollintzas (5)</font></div>
</td>
<td align="left" valign="bottom" width="17%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="right" valign="bottom" width="12%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">93,712</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="right" valign="bottom" width="12%">&#160;</td>
<td align="left" valign="bottom" width="1%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="54%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Robert T. McNally (6)</font></div>
</td>
<td align="left" valign="bottom" width="17%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="right" valign="bottom" width="12%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">191,379</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="right" valign="bottom" width="12%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.1</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="54%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Mark W. Reynolds (7)</font></div>
</td>
<td valign="bottom" width="17%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td align="right" valign="bottom" width="12%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">146,999</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="right" valign="bottom" width="12%">&#160;</td>
<td align="left" valign="bottom" width="1%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="54%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Harriet L. Robinson (8)</font></div>
</td>
<td align="left" valign="bottom" width="17%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="right" valign="bottom" width="12%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,623,018</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="right" valign="bottom" width="12%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">9.4</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="54%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">John N. Spencer, Jr. (9)</font></div>
</td>
<td align="left" valign="bottom" width="17%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="right" valign="bottom" width="12%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">107,412</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="12%">&#160;</td>
<td align="left" valign="bottom" width="1%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="54%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">All executive officers and directors as a group (7 persons) (10)</font></div>
</td>
<td align="left" valign="bottom" width="17%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="right" valign="bottom" width="12%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,557,511</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td align="right" valign="bottom" width="12%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14.3</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="54%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Other 5% Stockholders:</font></div>
</td>
<td align="left" valign="bottom" width="17%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="12%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="middle" width="12%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="54%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Emory University (11)</font></div>
</td>
<td align="left" valign="bottom" width="17%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="right" valign="top" width="12%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,621,405</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="right" valign="top" width="12%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27.4</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="54%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Donald G. Hildebrand (12)</font></div>
</td>
<td align="left" valign="bottom" width="17%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="right" valign="bottom" width="12%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,071,400</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td align="right" valign="bottom" width="12%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.4</font></div>
</td>
<td align="left" valign="bottom" width="1%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="54%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Welch &amp; Forbes LLC (13)</font></div>
</td>
<td valign="top" width="17%">&#160;</td>
<td valign="top" width="1%">&#160;</td>
<td align="right" valign="top" width="12%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,503,523</font></div>
</td>
<td valign="top" width="1%">&#160;</td>
<td valign="top" width="1%">&#160;</td>
<td valign="top" width="1%">&#160;</td>
<td align="right" valign="middle" width="12%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8.9</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">___________</font></div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-WEIGHT: bold">* </font><font style="DISPLAY: inline; FONT-SIZE: 10pt">Less than 1%</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Except as otherwise indicated, the business address of each director and executive officer listed is c/o GeoVax Labs, Inc., 1900 Lake Park Drive, Suite 380, Smyrna, Georgia 30080.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This table is based upon information supplied by officers and directors, and with respect to principal stockholders, Schedules 13D and 13G filed with the SEC. Beneficial ownership is determined in accordance with the rules of the SEC. Applicable percentage ownership is based on 16,850,610 shares of common stock outstanding as of March 30, 2012.&#160;&#160;In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of common stock subject to options currently exercisable, or exercisable within 60&#160;days of March 30, 2012, are deemed outstanding.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(3)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Includes options and warrants to purchase 57,133 shares of common stock exercisable within 60&#160;days of March 30, 2012.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(4)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Includes options and warrants to purchase 180,133 shares of common stock exercisable within 60&#160;days of March 30, 2012.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(5)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Includes options and warrants to purchase 78,787 shares of common stock exercisable within 60&#160;days of March 30, 2012.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(6)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Includes options and warrants to purchase 149,174 shares of common stock exercisable within 60&#160;days of March 30, 2012.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(7)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Includes options and warrants to purchase 110,999 shares of common stock exercisable within 60&#160;days of March 30, 2012.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(8)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Dr. Robinson shares voting and investment power over 1,051,972 shares with Welch &amp; Forbes LLC, whose ownership is described below.&#160;&#160;Includes options and warrants to purchase 421,792 shares of common stock exercisable within 60&#160;days of March 30, 2012.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(9)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Includes options and warrants to purchase 78,777 shares of common stock exercisable within 60&#160;days of March 30, 2012.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(10)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Includes warrants to purchase 1,076,805 shares of common stock exercisable within 60&#160;days of March 30, 2012.&#160;&#160;Mr. Spencer shares voting and investment power with his spouse with respect to 28,625 shares and a warrant for 22,388 shares which are owned jointly by them.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(11)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The address for this stockholder is Administration Building, 201 Dowman Drive, Atlanta, Georgia 30322.&#160;&#160;Ownership information has been derived from this stockholder&#8217;s SEC filing on Form 4 filed on January 29, 2010.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(12)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The address for the stockholder is c/o GeoVax Labs, Inc., 1900 Lake Park Drive, Suite 380, Smyrna, Georgia 30080</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(13)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The address for this stockholder is 45 School Street, Boston, Massachusetts 02108.&#160;&#160;This stockholder shares voting and investment power with respect to all of these shares.&#160;&#160;Includes 1,051,972 shares held by Dr. Robinson.&#160;&#160;Ownership information has been derived from this stockholder&#8217;s Schedule 13G filed January 6, 2012.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">43</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SELLING STOCKHOLDERS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This prospectus relates to the resale by the selling stockholders named below from time to time of up to a total of 11,733,332 shares that are issuable to the selling stockholders. The number of shares is subject to adjustment as described at &#8220;Description of Securities.&#8221;&#160;&#160;The common stock offered by this prospectus is being offered by the selling stockholders for their own accounts.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Private Placement Transaction</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 21, 2012, we completed a private placement transaction and issued to a total of 2,200 shares of Series&#160;A convertible preferred stock, with a stated value of $1,000 per share and a conversion price of $0.75, to three accredited investors.&#160;&#160;Each share of Series&#160;A convertible preferred stock is convertible into 1,333.33 shares of our common stock.&#160;&#160;Each purchaser of a share of Series&#160;A convertible preferred stock also acquired a Series A, a Series B, and a Series C Warrant to purchase a share of our common stock.&#160;&#160;The Series A convertible preferred shares and related warrants were issued in reliance upon exemptions provided by Section 4(2) of the Securities Act for the offer and sale of securities not involving a public offering and Regulation D promulgated thereunder.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Selling Stockholders</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The table below, which was prepared based on information supplied to us by the selling stockholders, sets forth information regarding the beneficial ownership of outstanding shares of our common stock owned by the selling stockholders and the shares that they may sell or otherwise dispose of from time to time under this prospectus. Each of the selling stockholders, or their respective transferees, donees or their successors, may resell, from time to time, all, some or none of the shares of our common stock covered by this prospectus, as provided in this prospectus under the section entitled &#8220;Plan of Distribution&#8221; and in any applicable prospectus supplement. However, we do not know when, in what amount, or at what specific prices the selling stockholders may offer their shares for sale under this prospectus, if any.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The number of shares disclosed in the table below as &#8220;beneficially owned&#8221; are those beneficially owned as determined under the rules of the SEC. Such information is not necessarily indicative of ownership for any other purpose. Under the rules of the SEC, a person is deemed to be a &#8220;beneficial owner&#8221; of a security if that person has or shares &#8220;voting power,&#8221; which includes the power to vote or to direct the voting of such security, or &#8220;investment power,&#8221; which includes the power to dispose of or to direct the disposition of such security. In computing the number of shares beneficially owned by a selling stockholder and the percentage of ownership of that selling stockholder, shares of common stock underlying shares of Series&#160;A convertible preferred stock, options or warrants held by that selling stockholder that are convertible or exercisable, as the case may be, within 60 days of March 30, 2012 are included. Those shares, however, are not deemed outstanding for the purpose of computing the percentage ownership of any other selling stockholder. Each selling stockholder&#8217;s percentage of ownership in the following table is based upon 16,850,610 shares of our common stock outstanding as of March 30, 2012.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Unless otherwise indicated and subject to community property laws where applicable, the selling stockholders named in the following table have, to our knowledge, sole voting and investment power with respect to the shares beneficially owned by them. In addition, none of the selling stockholders has any family relationships with our officers, directors or controlling stockholders. Furthermore, no selling stockholder is a registered broker-dealer or an affiliate of a registered broker-dealer.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Information concerning any of the selling stockholders may change from time to time, and any changed information will be presented in a prospectus supplement as necessary. Please carefully read the footnotes located below the table in conjunction with the information presented in the table.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">44</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<div align="center">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="41%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Selling&#160;Stockholder Name</font></div>
</td>
<td align="right" valign="bottom" width="9%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Beneficial</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Ownership</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Prior&#160;to&#160;this</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Offering&#160;</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(1), (2)</font></font></div>
</td>
<td align="right" valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Shares&#160;that</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">may&#160;be</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Offered&#160;and</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Sold&#160;Hereby</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(2)</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Beneficial</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Ownership</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">After&#160;this</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Offering</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">%&#160;Holding</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">After</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Completion</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">of&#160;this</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Offering</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="41%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Sabby Volatility Warrant Master Fund, Ltd.</font></div>
</td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,333,332</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,333,332</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="41%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Sabby Healthcare Volatility Master Fund, Ltd.</font></div>
</td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,333,332</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,333,332</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="41%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;Brio Capital LP.</font></div>
</td>
<td align="right" valign="bottom" width="9%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,066,668</font></td>
<td valign="bottom" width="2%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,066,668</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">______________________</font></div>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">*</font></div>
</td>
<td align="left" valign="top" width="82%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Less than 1.0%</font></font></div>
</td>
</tr><tr>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="82%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1)</font></div>
</td>
<td align="left" valign="top" width="82%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes all shares beneficially owned by the Selling Stockholders as of March 21, 2012.</font></div>
</td>
</tr><tr>
<td colspan="3" valign="middle" width="85%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td align="left" valign="top" width="82%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes all of the shares of common stock issuable upon exercise of the Series A convertible preferred stock owned by this stockholder, as well as all of the shares issuable upon exercise of the Series A, B and C Warrants held by this stockholder.&#160;&#160;The number of shares offered by the Selling Stockholders in the table above reflects 100% of the shares issuable upon conversion of the Series A convertible preferred stock and upon exercise of the Series A, B, and C Warrants.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">The Series A convertible preferred stock and the Series A, B, and C Warrants contain exercise and conversion limitations providing that a holder thereof may not convert or exercise (as the case may be) to the extent (but only to the extent) that, if after giving effect to such conversion or exercise (as the case may be), the holder or any of its affiliates would beneficially own in excess of 4.99% or 9.99%, as applicable (the &#8220;Maximum Percentage&#8221;) of the outstanding shares of common stock immediately after giving effect to such conversion or exercise (as the case may be). To the extent the above limitation applies, the determination of whether a share of preferred stock or warrant shall be exercisable or convertible (vis-&#224;-vis other convertible, exercisable or exchangeable securities owned by the holder) shall, subject to such Maximum Percentage limitation, be determined on the basis of the first submission to the Company for conversion, exercise or exchange (as the case may be).&#160;&#160;Accordingly, the number of shares of common stock set forth in the table as being registered for a Selling Stockholder may exceed the number of shares of common stock that the Selling Stockholder could own beneficially at any given time through its ownership of the Series A convertible preferred stock and the Series A, B, and C Warrants.</font></div>
</td>
</tr><tr>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="82%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3)</font></div>
</td>
<td align="left" valign="top" width="82%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes 1,333,333 shares of common stock issuable upon conversion of the 1,000 shares of the Series A convertible preferred stock held by this selling stockholder and 1,333,333 shares issuable upon exercise of each of the Series A, B. and C Warrants (3,999,999 in the aggregate for all three warrants).&#160;&#160;Sabby Management, LLC shares voting and investment power with respect to these shares on behalf of this stockholder as well as Sabby Healthcare Volatility Master Fund, Ltd.&#160; </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As manager of Sabby Management, LLC, Hal Mintz also shares voting and investment power on behalf of this stockholder.&#160;&#160;Each of Sabby Management, LLC and Hal Mintz disclaim beneficial ownership over the securities covered by this prospectus except to the extent of their pecuniary interest therein.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27.35pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4)</font></div>
</td>
<td align="left" valign="top" width="82%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes 1,333,333 shares of common stock issuable upon conversion of the 1,000 shares of the Series A convertible preferred stock held by this stockholder and 1,333,333 shares issuable upon exercise of each of the Series A, B. and C Warrants (3,999,999 in the aggregate for all three warrants).&#160;&#160;Sabby Management, LLC shares voting and investment power with respect to these shares on behalf of this stockholder as well as Sabby Volatility Warrant Master Fund, Ltd.&#160; <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">As manager of Sabby Management, LLC, Hal Mintz also shares voting and investment power on behalf of this stockholder.&#160;&#160;Each of Sabby Management, LLC and Hal Mintz disclaim beneficial ownership over the securities covered by this prospectus except to the extent of their pecuniary interest therein.</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27.35pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
</tr></table>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5)</font></div>
</td>
<td align="left" valign="top" width="82%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Includes 266,667 shares of common stock issuable upon conversion of the 200 shares of the Series A convertible preferred stock held by this stockholder and 266,667 shares issuable upon exercise of each of the Series A, B. and C Warrants (800,001 in the aggregate for all three warrants).&#160; </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Brio Capital Management. LLC shares voting and investment power with respect to these shares.&#160;&#160;As manager of Brio Capital Management, LLC, Shaye Hirsch also shares voting and investment power on behalf of this stockholder.&#160; Each of Brio Capital Management. LLC and Shaye Hirsch disclaim beneficial ownership over the securities covered by this prospectus except to the extent of their pecuniary interest therein.</font></div>
</td>
</tr></table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">45</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PLAN OF DISTRIBUTION</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Each selling stockholder of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the OTC Bulletin Board or any other stock exchange, market or trading facility on which the securities are traded or in private transactions.&#160;&#160;These sales may be at fixed or negotiated prices.&#160;&#160;A selling stockholder may use any one or more of the following methods when selling securities:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">an exchange distribution in accordance with the rules of the applicable exchange;</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">privately negotiated transactions;</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part;</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">in transactions through broker-dealers that agree with the selling stockholders to sell a specified number of such securities at a stipulated price per security;</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">a combination of any such methods of sale; or</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">any other method permitted pursuant to applicable law.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The selling stockholders may also sell securities under Rule 144 under the Securities Act of 1933, as amended (the &#8220;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Securities Act</font>&#8221;), if available, rather than under this prospectus.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Broker-dealers engaged by the selling stockholders may arrange for other brokers-dealers to participate in sales.&#160;&#160;Broker-dealers may receive commissions or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance with FINRA IM-2440.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with the sale of the securities or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume.&#160;&#160;The selling stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities.&#160;&#160;The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The selling stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales.&#160;&#160;In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.&#160;&#160;Each selling stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities. In no event shall any broker-dealer receive fees, commissions and markups which, in the aggregate, would exceed eight percent (8%).</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">46</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities.&#160;&#160;The Company has agreed to indemnify the selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Because selling stockholders may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act, they will be subject to the prospectus delivery requirements of the Securities Act including Rule 172 thereunder.&#160;&#160;In addition, any securities covered by this prospectus which qualify for sale pursuant to Rule 144 under the Securities Act may be sold under Rule 144 rather than under this prospectus. The selling stockholders have advised us that there is no underwriter or coordinating broker acting in connection with the proposed sale of the resale securities by the selling stockholders.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the selling stockholders without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144 (assuming a cashless exercise of each Series A, B, and C Warrant), without the requirement for the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule&#160;144 under the Securities Act or any other rule of similar effect.&#160;&#160;The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M under the Securities Act, prior to the commencement of the distribution.&#160;&#160;In addition, the selling stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of securities of the common stock by the selling stockholders or any other person.&#160;&#160;We will make copies of this prospectus available to the selling stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">47</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DESCRIPTION OF SECURITIES</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Capital Stock</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following description of our capital stock is summarized from, and qualified in its entirety by reference to, our certificate of incorporation, as amended, including the certificate of designation setting forth the terms of our Series A convertible preferred stock, all of which have been previously filed with the SEC and are incorporated herein by reference. This summary is not intended to give full effect to provisions of statutory or common law. We urge you to review the following documents because they, and not this summary, define the rights of a holder of shares of common stock or Series&#160;A convertible or preferred stock:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;</font></div>
</td>
<td align="left" valign="top" width="79%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the General Corporation Law of the State of Delaware, or the &#8220;DGCL&#8221;, as it may be amended from time to time;</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;</font></div>
</td>
<td align="left" valign="top" width="79%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">our certificate of incorporation, as it may be amended or restated from time to time,&#160;and</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;</font></div>
</td>
<td align="left" valign="top" width="79%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">our bylaws, as they may be amended or restated from time to time.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">General</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our authorized capital stock currently consists of 50,000,000&#160;shares, which are divided into two classes consisting of 40,000,000&#160;shares of common stock, par value $0.001 per share, and 10,000,000&#160;shares of preferred stock, par value $0.01 per share.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Common Stock</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of March 30, 2012, there were issued and outstanding 16,850,610 shares of common stock, options to purchase 922,042 shares of common stock and warrants to purchase 11,282,559 shares of common stock, including the 8,799,999 shares in the aggregate subject to the Series A, B, and C Warrants.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Holders of our common stock are entitled to one vote for each share held in the election of directors and in all other matters to be voted on by the stockholders. There is no cumulative voting in the election of directors. Holders of common stock are entitled to receive dividends as may be declared from time to time by our Board of Directors out of funds legally available therefor, and subject to the rights of holders of our Series&#160;A convertible preferred stock. In the event of liquidation, dissolution or winding up of the Company, holders of common stock are to share in all assets remaining after the payment of liabilities, and satisfaction of the liquidation preference of our outstanding Series&#160;A convertible preferred stock. Holders of common stock have no pre-emptive or conversion rights and are not subject to further calls or assessments. There are no redemption or sinking fund provisions applicable to the common stock. The rights of the holders of the common stock are subject to any rights that may be fixed for holders of preferred stock, such as the Series A convertible preferred stock. All of the outstanding shares of common stock are fully paid and non-assessable.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Series A Convertible Preferred Stock</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are authorized to issue up to 2,200 shares of our Series A convertible preferred stock.&#160;&#160;As of March 30, 2012, 2,200 shares of our Series A convertible preferred stock were outstanding.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Series A convertible preferred stock is convertible at the option of the holder at any time into shares of common stock at a conversion ratio determined by dividing the $1,000 stated value of the Series A convertible preferred stock by a conversion price of $0.75 per share. As of March&#160;30, 2012, an aggregate of 2,933,333 shares of our common stock are issuable upon conversion of the 2,200 outstanding shares of Series&#160;A convertible preferred stock. The conversion price of the Series A convertible preferred stock is subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On each of (i) the effective date of the registration statement of which this prospectus is a part and (ii)&#160;if the registration statement required to be filed pursuant to the registration rights agreement is not declared effective on or before September&#160;21, 2012 or if one or more registration statements do not register for resale by the selling stockholders all of the common stock issuable to them upon conversion of their Series A convertible preferred stock, the date that all common stock issuable pursuant to the conversion of their Series A convertible preferred stock may be resold by the holders pursuant to Rule 144 without volume or manner restrictions (each such date, a &#8220;Trigger Date&#8221;), the conversion price shall be reduced to the lesser of (a) the then conversion price, as adjusted and taking into consideration any prior resets (b) 85% of the Volume Weighted Average Price (&#8220;VWAP&#8221; as defined) for the 5 trading days immediately following each such Trigger Date, as calculated pursuant to the AQR function on Bloomberg L.P., (c) 85% of the average of the VWAPs for each of the 5 trading days immediately following the Trigger Date and (d) 85% of the closing bid price on the last trading day of the 5 trading days immediately following each such Trigger Date, which shall thereafter be the new conversion price.&#160;&#160;The adjusted conversion price shall not be lower than $0.32.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">48</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Subject to limited exceptions, a holder of the Series A convertible preferred stock will not have the right to convert any portion of its Series A convertible preferred stock if the holder, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect to its conversion.&#160;&#160;Upon 61 days&#8217; prior notice from a holder, the 4.99% limitation may be increased to 9.99% for that holder.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The holders of Series A convertible preferred stock will be entitled to receive any securities or rights to acquire securities or property granted or issued by us pro rata to the holders of our common stock to the same extent as if such holders had converted all of their shares of Series A convertible preferred stock. No distribution may be made on the common stock so long as any dividend due on the Series&#160;A convertible preference stock remains unpaid. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations, the holders of Series A convertible preferred stock will be entitled to receive, upon conversion of their shares, any securities or other consideration received by the holders of our common stock pursuant to the fundamental transaction.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Except as required by law, holders of the Series A convertible preferred stock are not entitled to voting rights; provided, however, that the affirmative vote of the holders of a majority of the outstanding shares of Series A convertible preferred stock is required to take certain actions that may alter or change adversely the rights or preferences of the holders of Series A convertible preferred stock, increase the number of shares of Series&#160;A convertible preferred stock, or authorize a new class ranking senior or <font style="DISPLAY: inline; TEXT-DECORATION: underline">pari</font> <font style="DISPLAY: inline; TEXT-DECORATION: underline">passu</font> to the Series&#160;A convertible preferred stock.&#160;&#160;The Series A convertible preferred stock has a liquidation preference equal to $1,000 per share.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The securities purchase agreement and related registration rights agreement, as well as the certificate of designation authorizing the Series A convertible preferred stock include certain other agreements and covenants for the benefit of the holders of the Series A convertible preferred stock, including restrictions on our ability to issue additional equity securities for a period of 45 days after the effective date of this prospectus, issue additional debt or equity securities with a variable conversion or exercise price for a period of nine months after the initial closing, and undertake a reverse or forward stock split or reclassification of our common stock until March 21, 2013 (unless such reverse split is made in conjunction with the listing of the common stock on a national securities exchange), and a requirement to use our best efforts to maintain the listing or trading of our common stock on one or more specified United States securities exchanges or regulated quotation services.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-WEIGHT: bold">Undesignated Preferred Stock</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Subject to the restrictions set forth in the certificate of designation for our Series A convertible preferred stock, our Board of Directors has the authority to issue up to 9,997,800 additional shares of preferred stock in one or more series and fix the number of shares constituting any such series, the voting powers, designations, preferences and relative, participating, optional or other special rights and qualifications, limitations or restrictions thereof, including the dividend rights, dividend rate, terms of redemption (including sinking fund provisions), redemption price or prices, conversion rights and liquidation preferences of the shares constituting any series, without any further vote or action by the stockholders. For example, the Board of Directors is authorized to issue a stockholder of preferred stock that would have the right to vote, separately or with any other stockholder of preferred stock, on any proposed amendment to our certificate of incorporation, or on any other proposed corporate action, including business combinations and other transactions.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We will not offer preferred stock unless the offering is approved by a majority of our independent directors. The independent directors will have access, at our expense, to our counsel or independent counsel.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">The Series A, B and C Warrants</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the terms of the securities purchase agreement for the sale of the Series A convertible preferred stock, each purchaser was also issued a Series A Warrant, a Series B Warrant and a Series C Warrant, each to purchase up to a number of shares of the Company&#8217;s Common Stock equal to 100% of the Common Stock underlying the preferred shares issued to such purchaser pursuant to the securities purchase agreement (up to 2,933,333 shares in the aggregate for each series of warrants, or 8,799,999 shares in total).&#160;&#160;The Series A Warrants have an exercise price of $1.00 per share, are exercisable immediately, and have a term of exercise equal to five years from the date of issuance.&#160;&#160;The Series B Warrants have an exercise price of $0.75 per share, are exercisable immediately, and have a term of exercise equal to one year from the date of issuance.&#160;&#160;The Series C Warrants have an exercise price of $1.00 per share and have a term of exercise equal to five years from the date of issuance, but only vest and become exercisable upon, and in proportion to, the exercise of the one-year Series B Warrants held by each purchaser (or its assigns).</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">49</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The exercise price of the warrants and, in some cases, the number of shares issuable upon exercise, are subject to adjustment in the case of stock splits, stock dividends, combinations of shares, similar recapitalization transactions and certain pro-rata distributions to common stockholders. The exercise price, but not the number of shares of common stock issuable upon exercise, will also be adjusted to match the lower price if we sell or grant (or announce a sale or grant) of any shares of common stock or securities convertible into, or rights to acquire, common stock at an effective price per share that is lower than the then exercise price, except in the event of certain exempt issuances. In addition, upon exercise of the warrants the warrant holders will be entitled to receive any securities or rights to acquire securities or property granted or issued by us pro rata to the holders of our common stock to the same extent as if such holders had then exercised the warrants. In the event of a fundamental transaction, such as a merger, consolidation, sale of substantially all assets and similar reorganizations or recapitalizations, the warrant holders will be entitled to receive, upon exercise of their warrants, any securities or other consideration received by the holders of common stock pursuant to the fundamental transaction.&#160;&#160;Under certain circumstance, after a fundamental transaction, holders may be entitled to receive a cash payment equal to the value of the Series&#160;A, B or C Warrants, computed as provided in those warrants.&#160;&#160;Any successor to us or surviving entity shall assume the obligations under the warrants.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The warrant holders must surrender payment in cash of the aggregate exercise price of the shares being acquired upon exercise of the warrants. If at any time after the six month anniversary of the initial exercise date (March 21, 2012), there is no effective registration statement registering, or no current prospectus available for the resale of the shares issuable upon exercise of the warrants, then the warrants may be exercised on a &#8220;net&#8221; or &#8220;cashless&#8221; basis. No fractional shares of common stock will be issued in connection with the exercise of a warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Subject to limited exceptions, a holder of the Series A, B, or C Warrants will not have the right to exercise the warrant if the holder, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect to its conversion. Upon 61 days&#8217; prior notice from a holder, the 4.99% limitation may be increased to 9.99% for that holder.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Delaware Anti-Takeover Law</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have elected not to be subject to certain provisions of Delaware law that could make it more difficult to acquire us by means of a tender offer, a proxy contest, open market purchases, removal of incumbent directors and otherwise. These provisions, summarized below, are expected to discourage types of coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control of us to first negotiate with our Board of Directors.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In general, Section&#160;203 of the DGCL prohibits a publicly held Delaware corporation from engaging in various &#8220;business combination&#8221; transactions with any interested stockholder for a period of three years after the date of the transaction in which the person became an interested stockholder, unless:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;</font></div>
</td>
<td align="left" colspan="2" valign="top" width="79%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the transaction is approved by the corporation&#8217;s board of directors prior to the date the interested stockholder obtained interested stockholder status;</font></div>
</td>
</tr><tr>
<td align="left" colspan="2" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;</font></div>
</td>
<td align="left" colspan="2" valign="top" width="79%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">upon consummation of the transaction that resulted in the stockholder&#8217;s becoming an interested stockholder, the stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding those shares owned by (a)&#160;persons who are directors and also officers and (b)&#160;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer;&#160;or</font></div>
</td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="top" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" colspan="2" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;</font></div>
</td>
<td align="left" colspan="2" valign="top" width="79%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">on or subsequent to the date the business combination is approved by the corporation&#8217;s board of directors and authorized at an annual or special meeting of stockholders by the affirmative vote of at least 66 2 / 3 % of the outstanding voting stock that is not owned by the interested stockholder.</font></font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A &#8220;business combination&#8221; is defined to include mergers, asset sales and other transactions resulting in financial benefit to a stockholder. In general, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns or within three years, did own, 15% or more of a corporation&#8217;s voting stock.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">50</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Section&#160;203 applies to Delaware corporations that have a class of voting stock that is listed on a national securities exchange or held of record by more than 2,000 stockholders; provided, however, the restrictions of this statute will not apply to a corporation if:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;</font></div>
</td>
<td align="left" valign="top" width="79%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the corporation&#8217;s original charter contains a provision expressly electing not to be governed by the statute;</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;</font></div>
</td>
<td align="left" valign="top" width="79%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the corporation&#8217;s board of directors adopts an amendment to the corporation&#8217;s bylaws within 90&#160;days of the effective date of the statute expressly electing not to be governed by it;</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;</font></div>
</td>
<td align="left" valign="top" width="79%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the stockholders of the corporation adopt an amendment to its charter or bylaws expressly electing not to be governed by the statute (so long as such amendment is approved by the affirmative vote of a majority of the shares entitled to vote);</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;</font></div>
</td>
<td align="left" valign="top" width="79%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">a stockholder becomes an interested stockholder inadvertently and as soon as practicable divests himself of ownership of a sufficient number of shares so that he ceases to be an interested stockholder, and during the three year period immediately prior to a business combination, would not have been an interested stockholder but for the inadvertent acquisition;</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;</font></div>
</td>
<td align="left" valign="top" width="79%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the business combination is proposed prior to the consummation or abandonment of a merger or consolidation, a sale, lease, exchange, mortgage, pledge, transfer or other disposition of assets of the corporation or a proposed tender or exchange offer for 50% or more of the outstanding voting shares of the corporation;&#160;or</font></div>
</td>
</tr><tr>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="middle" width="79%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#8226;&#160;</font></div>
</td>
<td align="left" valign="top" width="79%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">the business combination is with an interested stockholder who became an interested stockholder at a time when the restrictions contained in the statutes did not apply.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our certificate of incorporation includes a provision electing not to be governed by Section&#160;203 of the DCGL. Accordingly, our board of directors does not have the power to reject certain business combinations with interested stockholders based on Section&#160;203 of the DCGL.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Indemnification</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Section&#160;145 of the Delaware General Corporation Law, or DGCL, provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to an action, suit or proceeding (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the corporation&#8217;s request in such a capacity for another entity against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with the action, suit or proceeding. The power to indemnify applies (i)&#160;if such person is successful on the merits or otherwise in defense of any action, suit or proceeding or (ii)&#160;if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. The power to indemnify applies to actions brought by or in the right of the corporation as well, but only to the extent of defense expenses (including attorneys&#8217; fees but excluding amounts paid in settlement), actually and reasonably incurred and not to any satisfaction of judgment or settlement of the claim itself, and with the further limitation that in such actions no indemnification shall be made in the event of any adjudication of negligence or misconduct in the performance of his duties to the corporation, unless a court believes that in light of all the circumstances indemnification should apply.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our bylaws provide that we may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Company) by reason of the fact that the person is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person&#8217;s conduct was unlawful. Our bylaws also provide that we may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Company to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the Company and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the Company unless and only to the extent that the Delaware Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Delaware Court of Chancery or such other court shall deem proper.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">51</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under our bylaws, expenses (including attorneys&#8217; fees) incurred by an officer or director in defending any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the Company in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the Company. Such expenses (including attorneys&#8217; fees) incurred by former directors and officers or other employees and agents may be so paid upon such terms and conditions, if any, as we deem appropriate.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The indemnification and advancement of expenses provided by our bylaws is not exclusive, both as to action in such person&#8217;s official capacity and as to action in another capacity while holding such office.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our bylaws also provide that we may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person&#8217;s status as such, whether or not the Company would have the power to indemnify such person against such liability under our bylaws. The Company maintains an insurance policy providing for indemnification of its officers, directors and certain other persons against liabilities and expenses incurred by any of them in certain stated proceedings and under certain stated conditions.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In October 2006, GeoVax and our subsidiary, GeoVax, Inc. entered into indemnification agreements with Messrs.&#160;McNally, Reynolds,&#160;Kollintzas and Spencer. Pursuant to these agreements, we have agreed to hold harmless and indemnify these directors and officers to the full extent authorized or permitted by applicable Illinois and Georgia law against certain expenses and other liabilities actually and reasonably incurred by these individuals in connection with certain proceedings if they acted in a manner they believed in good faith to be in or not opposed to the best interests of the Company and, with respect to any criminal proceeding, had no reasonable cause to believe that such conduct was unlawful. The agreements also provide for the advancement of expenses to these individuals subject to specified conditions. Under these agreements, we will not indemnify these individuals for expenses or other amounts for which applicable Illinois and Georgia law prohibit indemnification. The obligations under these agreements continue during the period in which these individuals are our directors or officers and continue thereafter so long as these individuals shall be subject to any proceeding by reason of their service to the Company, whether or not they are serving in any such capacity at the time the liability or expense incurred for which indemnification can be provided under the agreements.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;FOR SECURITIES ACT LIABILITIES</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the registrant pursuant to the foregoing provisions, the registrant has been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the event that a claims for indemnification against such liabilities (other than our payment of expenses incurred or paid by a director, officer or controlling person in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">52</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">WHERE YOU CAN FIND MORE INFORMATION</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are subject to the informational reporting requirements of the Exchange Act, which requires us to file annual, quarterly, and current reports, proxy statements and other information with the SEC.&#160;&#160;The SEC maintains an Internet site that contains such information regarding issuers that file electronically, such as GeoVax Labs, Inc.&#160;&#160;The public may inspect our filings over the Internet at the SEC&#8217;s home page at <font style="FONT-STYLE: italic; DISPLAY: inline; TEXT-DECORATION: underline">www.sec.gov</font>.&#160;&#160;The public may also read and copy any document we file at the Public Reference Room of the SEC at 100 F Street, N.E., Washington, DC 20549.&#160;&#160;Information on the operation of the Public Reference Room may be obtained by the public by calling the SEC at 1-800-SEC-0330.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">EXPERTS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The audited consolidated financial statements of GeoVax, Labs, Inc. and subsidiary for the years ended December 31, 2011 and 2010 and for the period of time considered part of the development stage from January 1, 2006 to December 31, 2011, included in the Registration Statement have been audited by Porter Keadle Moore LLC, an independent registered public accounting firm, as set forth in their report appearing herein.&#160;&#160;Such financial statements have been so included in reliance upon the reports of such firm given upon their authority as experts in accounting and auditing.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The audited consolidated financial statements of GeoVax Labs, Inc. and subsidiary for the year ended December 31, 2005 and for the period from inception of the development stage (June 27, 2001) to December 31, 2005, included in the Registration Statement have been audited by Tripp, Chafin &amp; Causey LLC, an independent registered public accounting firm, as set forth in their report appearing herein.&#160;&#160;Such financial statements have been so included in reliance upon the reports of such firm given upon their authority as experts in accounting and auditing.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">LEGAL MATTERS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The validity of the shares of our common stock offered by the selling stockholders will be passed upon by the law firm of Womble Carlyle Sandridge &amp; Rice, LLP, Atlanta, Georgia.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">53</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GEOVAX LABS, INC.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A DEVELOPMENT-STAGE ENTERPRISE)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INDEX TO 2011 CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#c0ffff">
<td valign="top" width="94%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reports of Independent Registered Public Accounting Firms on Financial Statements</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-2</font></font></td>
</tr><tr bgcolor="white">
<td valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="top" width="94%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consolidated Balance Sheets as of December 31, 2011 and 2010</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-4</font></font></td>
</tr><tr bgcolor="white">
<td valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="4%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="top" width="94%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consolidated Statements of Operations for the years ended December 31, 2011, 2010 and 2009 </font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">and for the Period from Inception (June 27, 2001) to December 31, 2011</font></font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-5</font></td>
</tr><tr bgcolor="white">
<td valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="top" width="94%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consolidated Statements of Stockholders&#8217; Equity (Deficiency) for the Period from </font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Inception (June 27, 2001) to December 31, 2011</font></font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-6</font></td>
</tr><tr bgcolor="white">
<td valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="top" width="94%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consolidated Statements of Cash Flows for the years ended December 31, 2011, 2010 and 2009 </font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">and for the Period from Inception (June 27, 2001) to December 31, 2011</font></font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-9</font></td>
</tr><tr bgcolor="white">
<td valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="top" width="94%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Notes to Consolidated Financial Statements</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-10</font></font></td>
</tr><tr bgcolor="white">
<td valign="top" width="94%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="top" width="94%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Financial Statement Schedule:</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="94%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font>&#160;Schedule II &#8211; Valuation and Qualifying Accounts for the years ended December 31, 2011, 2010 and 2009</font></font></td>
<td valign="top" width="2%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="4%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-19</font></font></td>
</tr></table>
</div>

<div align="left">&#160;</div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-1</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ON FINANCIAL STATEMENTS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To the Board of Directors</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">GeoVax Labs, Inc.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Atlanta, Georgia</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have audited the accompanying consolidated balance sheets of GeoVax Labs, Inc. and subsidiary (a development stage company) (the &#8220;Company&#8221;) as of December 31, 2011 and 2010, and the related consolidated statements of operations, stockholders&#8217; equity, and cash flows for each of the three years in the period ended December 31, 2011, and for the period of time considered part of the development stage from June 27, 2001 to December 31, 2011, except we did not audit the Company&#8217;s financial statements for the period from June 27, 2001 to December 31, 2005 which were audited by other auditors. Our audits also included the financial statement schedule of the Company listed in Item 15(a).&#160;&#160;These financial statements are the responsibility of the Company&#8217;s management.&#160;&#160;Our responsibility is to express an opinion on these financial statements based on our audit.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).&#160;&#160;Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.&#160;&#160;The Company is not required to have, nor were we engaged to perform an audit of its internal control over financial reporting.&#160;&#160;Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion of the effectiveness of the Company&#8217;s internal control over financial reporting.&#160;&#160;Accordingly, we express no such opinion.&#160;&#160;An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.&#160;&#160;We believe that our audits provide a reasonable basis for our opinion.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of GeoVax Labs, Inc. and subsidiary as of December 31, 2011 and 2010, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2011, and for the period of time considered part of the development stage from June 27, 2001 to December 31, 2011, in conformity with accounting principles generally accepted in the United States of America. Also, in our opinion, the financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly in all material respects the information set forth therein.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" nowrap valign="top" width="35%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/S/&#160;PORTER KEADLE MOORE LLC</font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Atlanta, Georgia</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">March 29, 2012</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ON FINANCIAL STATEMENTS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Board of Directors</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">GeoVax, Inc.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Atlanta, Georgia</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have audited the statements of operations, stockholders&#8217; deficiency and cash flows of GeoVax, Inc. (a Georgia corporation in the development stage) for the period from inception (June 27, 2001) to December 31, 2005.&#160;&#160;These financial statements are the responsibility of the Company&#8217;s management.&#160;&#160;Our responsibility is to express an opinion on these financial statements based on our audit.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States).&#160;&#160;Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.&#160;&#160;An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements.&#160;&#160;An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.&#160;&#160;We believe that our audit provides a reasonable basis for our opinion.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In our opinion, the financial statements of GeoVax, Inc. referred to above present fairly, in all material respects, the results of its operations, changes in stockholders&#8217; deficiency and cash flows for the period from inception (June 27, 2001) to December&#160;31, 2005, in conformity with accounting principles generally accepted in the United States of America.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>
</td>
<td align="left" nowrap valign="top" width="35%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/S/&#160;TRIPP, CHAFIN &amp; COMPANY, LLC</font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font><br>
&#160;</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Marietta, Georgia</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">February 8, 2006</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">RDGXBRLParseBegin</font></div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GEOVAX LABS, INC.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A DEVELOPMENT-STAGE ENTERPRISE)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSOLIDATED BALANCE SHEETS</font></div>
</div>

<div align="left">
<div align="left">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31,</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr>
<td align="left" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">ASSETS</font></div>
</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Current assets:</font></div>
</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 12pt"></font>1,167,980</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 12pt"></font>1,079,087</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Grant funds receivable</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">183,515</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">474,275</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepaid expenses and other current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">66,508</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">48,830</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="76%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,418,003</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,602,192</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="76%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Property and equipment, net of accumulated depreciation and amortization</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">176,206</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">248,441</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="76%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other assets:</font></div>
</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Licenses, net of accumulated amortization of $208,933 and $184,047 </font></font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">at December 31, 2011 and 2010 respectively</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">39,923</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">64,809</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred offering costs</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">430,402</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deposits and other assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,010</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">11,990</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total other assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">50,933</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">507,201</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total assets</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 12pt"></font>1,645,142</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 12pt"></font>2,357,834</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="76%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div>
</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="76%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Current liabilities:</font></div>
</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 12pt"></font>138,339</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 12pt"></font>96,892</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accrued expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">125,869</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">241,736</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amounts payable to Emory University (a related party)</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">677,327</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">182,980</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="76%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total current liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">941,535</font> </td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">521,608</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="76%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Commitments (Note 4)</font></div>
</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="76%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stockholders&#8217; equity:</font></div>
</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="76%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock, $.001 par value, 40,000,000 shares authorized; </font></font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,442,611 and 15,654,846 shares issued and outstanding at </font></font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31, 2011 and 2010, respectively</font></div>
</div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,443</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,655</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additional paid-in capital</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,319,166</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22,105,747</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deficit accumulated during the development stage</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(22,632,002</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(20,285,176</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total stockholders&#8217; equity</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">703,607</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,836,226</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total liabilities and stockholders&#8217; equity</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 12pt"></font>1,645,142</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 12pt"></font>2,357,834</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">&#160;</td>
</tr></table>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 2.7pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">See accompanying notes to consolidated financial statements.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GEOVAX LABS. INC. </font>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A DEVELOPMENT-STAGE ENTERPRISE) </font></font>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSOLIDATED STATEMENTS OF OPERATIONS</font></font></font></div>
</div>
</div>
</div>

<div>
<div>&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="40%">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">From Inception</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr>
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="10" valign="bottom" width="43%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Years Ended December 31,</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(June 27, 2001) to</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr>
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31, 2011</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Grant revenue</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,899,885</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,185,257</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,668,195</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,311,692</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Operating expenses:</font></div>
</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,276,375</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.3pt"></font>4,793,956</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,068,682</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 14.9pt"></font>25,630,676</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,972,555</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.3pt"></font>3,162,134</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,914,845</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 14.9pt"></font>17,647,659</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,248,930</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.3pt"></font>7,956,090</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,983,527</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 14.9pt"></font>43,278,335</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="40%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss from operations</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,349,045</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,770,833</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,315,332</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 6pt"></font>(22,966,643</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="40%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other income (expense):</font></div>
</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest income</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 23.15pt"></font>2,219</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 20.95pt"></font>23,505</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 16.45pt"></font>31,080</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 32.3pt"></font>340,310</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest expense</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 53.2pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36.75pt"></font>(5,669</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 23.15pt"></font>2,219</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 20.95pt"></font>23,505</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 16.45pt"></font>31,080</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 31.55pt"></font>334,641</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,346,826</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,747,328</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,284,252</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(22,632,002</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Basic and diluted:</font></div>
</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Loss per common share</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.15</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.18</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.22</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2.11</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="40%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted average shares outstanding</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,735,541</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,651,308</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,191,278</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 15.65pt"></font>10,704,803</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr></table>
</div>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="17" valign="top" width="92%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">See accompanying notes to consolidated financial statements.</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div>&#160;</div>

<div>
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GEOVAX LABS, INC. </font>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A DEVELOPMENT-STAGE ENTERPRISE) </font></font>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIENCY)</font></font></font></div>
</div>
</div>
</div>

<div>
<div>&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deficit</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accumulated</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">during the</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stockholders&#8217;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common Stock</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additional</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Subscription</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Development</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Equity</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amount</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Paid In Capital</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Receivable</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stage</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Deficiency)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="28%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Capital contribution at inception (June 27, 2001)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss for the period ended December 31, 2001</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.5pt"></font>(170,592</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 5.4pt"></font>(170,592</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="28%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at December 31, 2001</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 39.8pt"></font>10</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.5pt"></font>(170,592</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 2.1pt"></font>(170,582</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sale of common stock for cash</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,789,954</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 17.75pt"></font>2,790</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 14.25pt"></font>(2,320</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 52.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 37.65pt"></font>470</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of common stock for technology license</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.4pt"></font>704,534</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 27.75pt"></font>705</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 9.8pt"></font>148,151</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 52.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 14.3pt"></font>148,856</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss for the year ended December 31, 2002</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.5pt"></font>(618,137</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 5.4pt"></font>(618,137</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="28%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at December 31, 2002</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,494,488</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 17.75pt"></font>3,495</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 9.8pt"></font>145,841</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.5pt"></font>(788,729</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 5.4pt"></font>(639,393</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sale of common stock for cash</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,229,278</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 17.75pt"></font>1,229</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,458,380</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 52.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.3pt"></font>2,459,609</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss for the year ended December 31, 2003</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.5pt"></font>(947,804</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 5.4pt"></font>(947,804</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at December 31, 2003</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,723,766</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 17.75pt"></font>4,724</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,604,221</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,736,533</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 10.95pt"></font>872,412</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sale of common stock for cash and stock subscription </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">receivable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,482,605</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 17.75pt"></font>1,483</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,988,436</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,750,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 52.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 14.3pt"></font>239,919</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash payments received on stock subscription receivable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 9.8pt"></font>750,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 52.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 14.3pt"></font>750,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of common stock for technology license</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 11.05pt"></font>49,420</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 34.4pt"></font>49</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 16.45pt"></font>99,951</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 52.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 14.3pt"></font>100,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss for the year ended December 31, 2004</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,351,828</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,351,828</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="28%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at December 31, 2004</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,255,791</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 17.75pt"></font>6,256</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,692,608</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,000,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,088,361</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 5.4pt"></font>(389,497</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash payments received on stock subscription receivable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,500,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.3pt"></font>1,500,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss for the year ended December 31, 2005</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,611,086</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,611,086</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at December 31, 2005</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,255,791</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 17.75pt"></font>6,256</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,692,608</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 0.9pt"></font>(500,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(5,699,447</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 5.4pt"></font>(500,583</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash payments received on stock subscription receivable</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 9.8pt"></font>500,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 52.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 14.3pt"></font>500,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Conversion of preferred stock to common stock</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,550,851</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 17.75pt"></font>3,551</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,071,565</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 52.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.3pt"></font>1,075,116</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock issued in connection with merger</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,359,891</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 17.75pt"></font>4,360</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,708,489</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 52.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.3pt"></font>1,712,849</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of common stock for cashless warrant exercise</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 11.05pt"></font>56,825</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 34.4pt"></font>57</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 30.9pt"></font>(57</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 52.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 53.2pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss for the year ended December 31, 2006</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.5pt"></font>(584,166</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 5.4pt"></font>(584,166</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at December 31, 2006</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,223,358</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 11.05pt"></font>14,224</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8,472,605</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(6,283,613</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.3pt"></font>2,203,216</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sale of common stock for cash</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.4pt"></font>406,729</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 27.75pt"></font>407</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,162,543</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 52.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.3pt"></font>3,162,950</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of common stock upon stock option exercise</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 17.75pt"></font>2,471</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 41.05pt"></font>2</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 23.15pt"></font>4,998</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 52.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 27.65pt"></font>5,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based compensation expense</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,518,496</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 52.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.3pt"></font>1,518,496</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss for the year ended December 31, 2007</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,241,796</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(4,241,796</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="28%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at December 31, 2007</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,632,558</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 11.05pt"></font>14,633</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,158,642</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(10,525,409</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.3pt"></font>2,647,866</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Continued on following page</font></div>
</div>

<div>&#160;</div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GEOVAX LABS, INC. </font>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A DEVELOPMENT-STAGE ENTERPRISE) </font></font>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIENCY)</font></font></font></div>
</div>
</div>
</div>

<div>
<div>&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom">&#160;</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deficit</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr>
<td valign="bottom">&#160;</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accumulated</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr>
<td valign="bottom">&#160;</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">&#160;</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">during the</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom">&#160;</td>
<td colspan="2" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stockholders&#8217;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common Stock</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additional</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Subscription</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Development</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Equity</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amount</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Paid In Capital</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Receivable</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stage</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Deficiency)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="28%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at December 31, 2007</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,632,558</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 11.05pt"></font>14,633</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13,158,642</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(10,525,409</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.3pt"></font>2,647,866</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sale of common stock for cash in private </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">placement transactions</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.4pt"></font>176,129</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 27.75pt"></font>176</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,364,824</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 52.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.3pt"></font>1,365,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="28%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Transactions related to common stock purchase </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">agreement with Fusion Capital</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.4pt"></font>130,290</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 27.75pt"></font>130</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 9.8pt"></font>405,961</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 52.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 14.3pt"></font>406,091</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based compensation:</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="28%" style="TEXT-INDENT: 27pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock options</font></font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,798,169</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,798,169</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%" style="TEXT-INDENT: 27pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consultant warrants</font></font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">146,880</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">146,880</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of common stock for consulting services</font></font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">73,990</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">74,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss for the year ended December 31, 2008</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,728,187</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,728,187</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="28%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 446pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at December 31, 2008</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">14,948,977</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 11.05pt"></font>14,949</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,948,466</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(14,253,596</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.3pt"></font>2,709,819</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Transactions related to common stock purchase </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">agreement with Fusion Capital</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.4pt"></font>216,261</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 27.75pt"></font>216</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,519,784</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 52.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.3pt"></font>1,520,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="28%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sale of common stock for cash upon exercise of </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">stock purchase warrant</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.4pt"></font>462,826</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 27.75pt"></font>463</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,499,537</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 52.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.3pt"></font>1,500,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based compensation:</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock options</font></font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,221,764</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,221,764</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%" style="TEXT-INDENT: 27pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consultant warrants</font></font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">45,401</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">45,401</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of common stock for consulting services</font></font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31,495</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">31,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss for the year ended December 31, 2009</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,284,252</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,284,252</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="28%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at December 31, 2009</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,632,564</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 11.05pt"></font>15,633</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">21,266,447</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(17,537,848</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.3pt"></font>3,744,232</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of common stock in lieu of cash payment</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 11.05pt"></font>12,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 34.4pt"></font>12</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 16.45pt"></font>89,988</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 52.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 20.95pt"></font>90,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="28%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based compensation:</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="28%" style="TEXT-INDENT: 27pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock options</font></font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">575,662</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">575,662</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="28%" style="TEXT-INDENT: 27pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consultant warrants</font></font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">121,057</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">121,057</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 27pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Issuance of common stock for consulting services</font></font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10,500</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">10</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53,803</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">53,813</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Fractional share payout upon reverse split</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 18.85pt"></font>(218</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 14.25pt"></font>(1,210</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 52.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 18.75pt"></font>(1,210</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="28%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss for the year ended December 31, 2010</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,747,328</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,747,328</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="28%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at December 31, 2010</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,654,846</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 11.05pt"></font>15,655</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22,105,747</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(20,285,176</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.3pt"></font>1,836,226</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Continued on following page</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>
</div>

<div>&#160;</div>

<div>
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GEOVAX LABS, INC. </font>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A DEVELOPMENT-STAGE ENTERPRISE) </font></font>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIENCY)</font></font></font></div>
</div>
</div>
</div>
</div>

<div>
<div>&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deficit</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accumulated</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">during the</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stockholders&#8217;</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common Stock</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additional</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Subscription</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Development</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Equity</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Shares</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Amount</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Paid In Capital</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Receivable</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stage</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Deficiency)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="34%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at December 31, 2010</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">15,654,846</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 11.05pt"></font>15,655</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">22,105,747</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(20,285,176</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.3pt"></font>1,836,226</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="34%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Sale of common stock for cash in private </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">placement transaction</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.4pt"></font>658,520</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 27.75pt"></font>659</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 9.8pt"></font>440,551</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 52.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 14.3pt"></font>441,210</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="34%" style="PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based compensation:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="34%" style="TEXT-INDENT: 27pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock options</font></font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">463,752</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">463,752</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="34%" style="TEXT-INDENT: 27pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Consultant warrants</font></font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">159,245</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">159,245</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="34%" style="TEXT-INDENT: 27pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Common stock issued for services</font></font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">129,245</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">129</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">149,871</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">150,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="34%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss for the year ended December 31, 2011</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.3pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 48.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,346,826</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,346,826</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="34%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="34%" style="PADDING-BOTTOM: 4px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -18pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at December 31, 2011</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,442,611</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,443</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">23,319,166</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(22,632,002</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="8%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">703,607</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">See accompanying notes to consolidated financial statements.</font></div>
</div>

<div>&#160;</div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-8</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GEOVAX LABS. INC. </font>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A DEVELOPMENT-STAGE ENTERPRISE) </font></font>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></font></font></div>
</div>
</div>
</div>

<div>
<div>&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="40%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td colspan="2" valign="bottom" width="13%">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td colspan="2" valign="bottom" width="13%">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td colspan="2" valign="bottom" width="13%">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td colspan="2" valign="bottom" width="13%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">From Inception</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr>
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="10" valign="bottom" width="43%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Years Ended December 31,</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="2" valign="bottom" width="13%" style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(June 27, 2001) to</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr>
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td colspan="2" valign="bottom" width="13%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31, 2011</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr>
<td align="left" valign="bottom" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash flows from operating activities:</font></div>
</td>
<td valign="bottom" width="1%">&#160;</td>
<td colspan="2" valign="bottom" width="13%">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td colspan="2" valign="bottom" width="13%">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td colspan="2" valign="bottom" width="13%">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td colspan="2" valign="bottom" width="13%">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,346,826</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,747,328</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(3,284,252</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(22,632,002</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="MARGIN-LEFT: 18pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Adjustments to reconcile net loss to net cash </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">used in operating activities:</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Depreciation and amortization</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.55pt"></font>109,017</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 5.3pt"></font>119,773</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 11.95pt"></font>89,776</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 26.3pt"></font>565,637</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accretion of preferred stock redemption value</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.45pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 44.2pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 44.2pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 26.3pt"></font>346,673</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based compensation expense</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.55pt"></font>772,997</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 3.8pt"></font>750,532</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,298,665</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 16.3pt"></font>6,359,739</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Write-off of deferred offering costs</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.55pt"></font>430,402</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 42.7pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 44.2pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 26.3pt"></font>430,402</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 27pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Changes in assets and liabilities:</font></div>
</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Grant funds receivable</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.55pt"></font>290,760</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(153,954</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 9.75pt"></font>(8,953</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 17.4pt"></font>(183,515</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Prepaid expenses and other current assets</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 11.2pt"></font>19,122</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 9.75pt"></font>(4,215</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 5.3pt"></font>254,671</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 24.1pt"></font>(29,708</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deposits</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 27.9pt"></font>980</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 3.1pt"></font>(11,010</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 44.2pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 24.1pt"></font>(11,010</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts payable and accrued expenses</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.55pt"></font>419,927</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 11.95pt"></font>39,033</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 5.3pt"></font>224,943</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 16.3pt"></font>1,030,325</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total adjustments</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,043,205</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 5.3pt"></font>740,159</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,859,102</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 16.3pt"></font>8,508,543</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash used in operating activities</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(303,621</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,007,169</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,425,150</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 0.75pt"></font>(14,123,459</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash flows from investing activities:</font></div>
</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Purchase of property and equipment</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 2.35pt"></font>(11,896</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 9pt"></font>(4,706</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(270,246</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 17.4pt"></font>(538,490</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from sale of property and equipment</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.45pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 18.65pt"></font>5,580</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 44.2pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 39.65pt"></font>5,580</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash provided (used) by investing activities</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 2.35pt"></font>(11,896</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 28.65pt"></font>874</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(270,246</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 17.4pt"></font>(532,910</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="40%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash flows from financing activities:</font></div>
</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from sale of common stock</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.55pt"></font>404,410</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 44.2pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,020,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 9.65pt"></font>15,526,308</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Proceeds from sale of preferred stock</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.45pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 44.2pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 44.2pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 26.3pt"></font>728,443</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred offering costs</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 43.45pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(430,402</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 44.2pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 17.4pt"></font>(430,402</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net cash provided by financing activities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 4.55pt"></font>404,410</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(430,402</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,020,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 9.65pt"></font>15,824,349</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="40%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net increase (decrease) in cash and cash equivalents</font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 11.2pt"></font>88,893</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,436,697</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,324,604</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 16.3pt"></font>1,167,980</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents at beginning of period</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,079,087</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,515,784</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2,191,180</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 65.2pt"></font>-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">&#160;</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="40%">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right">&#160;</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="40%" style="PADDING-BOTTOM: 4px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -0.9pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Cash and cash equivalents at end of period</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,167,980</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,079,087</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3,515,784</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">&#160;</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">&#160;</td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,167,980</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">&#160;</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="40%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Supplemental disclosure of cash flow information</font></font></td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: -0.9pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Interest paid</font></font></div>
</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
<td align="left" valign="bottom" width="1%">&#160;</td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="12%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5,669</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left">&#160;</td>
</tr></table>
</div>

<div>&#160;</div>

<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#c0ffff">
<td align="left" colspan="9" valign="top" width="50%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: -2.3pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Supplemental disclosure of non-cash investing and financing activities:</font></div>
</td>
<td colspan="2" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td colspan="2" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="15%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="17" valign="top" width="90%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">In connection with the Merger discussed in Note 5, all of the outstanding shares of the Company&#8217;s mandatory redeemable convertible preferred stock were converted into shares of common stock as of September 28, 2006.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">See accompanying notes to consolidated financial statements.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-9</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GEOVAX LABS, INC.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(A DEVELOPMENT-STAGE ENTERPRISE)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Years Ended December 31, 2011, 2010 and 2009 and</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Period from Inception (June 27, 2001) to December 31, 2011</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Nature of Business</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">GeoVax Labs, Inc. (&#8220;GeoVax&#8221; or the &#8220;Company&#8221;), is a biotechnology company developing vaccines that prevent and fight Human Immunodeficiency Virus (&#8220;HIV&#8221;) infections. HIV infections result in Acquired Immunodeficiency Syndrome (&#8220;AIDS&#8221;). We have exclusively licensed from Emory University (&#8220;Emory&#8221;) vaccine technology which was developed in collaboration with the National Institutes of Health (&#8220;NIH&#8221;) and the Centers for Disease Control and Prevention (&#8220;CDC&#8221;). GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in Smyrna, Georgia (metropolitan Atlanta area).</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our current vaccines under development address the clade B subtype of the HIV virus that is most prevalent in the United States and the developed world.&#160;&#160;Our vaccines are being evaluated to determine their potential to (a) prevent HIV infection and (b) to serve as a therapy for individuals who are already infected with HIV.&#160;&#160;These vaccines are currently being evaluated in humans -- both in those infected with HIV and those who are not.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As discussed in Note 2, the Company is a development-stage enterprise and we are devoting substantially all of our present efforts to research and development.&#160;&#160;We have funded our activities to date almost exclusively from equity financings and government grants, and we will continue to require substantial funds to continue these activities.&#160;&#160;We anticipate that our existing cash resources, combined with the proceeds from the NIH grant discussed in Note 3 and the financing events discussed in Note 11, should be sufficient to fund our planned activities into the first quarter of 2013.&#160;&#160;In order to meet our operating cash flow requirements, we may plan additional offerings of our equity securities, debt or convertible debt instruments. We are also seeking additional funding for our research programs through government grant funding mechanisms.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Basis of Presentation and Principles of Consolidation</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our primary business is conducted by our wholly-owned subsidiary, GeoVax, Inc. The accompanying consolidated financial statements include the accounts of GeoVax, Inc. from inception together with those of GeoVax Labs, Inc. from September 28, 2006 (see Note 5).&#160;&#160;All intercompany transactions have been eliminated in consolidation.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Development-Stage Enterprise</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are devoting all of our present efforts to research and development and GeoVax is a development stage enterprise as defined by Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 915, <font style="FONT-STYLE: italic; DISPLAY: inline">Development Stage Entities</font>.&#160;&#160;All losses accumulated since inception (June 27, 2001) have been considered as part of our development stage activities.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Use of Estimates</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;&#160;Actual results may differ from those estimates.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-10</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cash and Cash Equivalents</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We consider all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.&#160;&#160;Our cash and cash equivalents consist primarily of bank deposits and money market accounts.&#160;&#160;The recorded values approximate fair market values due to the short maturities.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Fair Value of Financial Instruments and Concentration of Credit Risk</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Property and Equipment</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Property and equipment are stated at cost, less accumulated depreciation and amortization.&#160;&#160;The components of property and equipment as of December 31, 2011 and 2010 are as follows:</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="76%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Laboratory equipment</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">388,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">388,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Leasehold improvements</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">115,605</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">115,605</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other furniture, fixtures &amp; equipment</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28,685</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,789</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total property and equipment</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">532,290</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">520,394</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accumulated depreciation and amortization</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(356,084</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(271,953</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Property and equipment, net</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">176,206</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">248,441</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized.&#160;&#160;Depreciation is computed using the straight-line method over the estimated useful lives of the assets which range from three to five years.&#160;&#160;Amortization of leasehold improvements is computed using the straight-line method over the remaining term of the related lease.&#160;&#160;Depreciation and amortization expense was $84,131, $94,887, and $64,891 during the years ended December 31, 2011, 2010 and 2009, respectively.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Other Assets</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Other assets consist principally of license agreements for the use of technology obtained through the issuance of the Company&#8217;s common stock. These license agreements are amortized on a straight line basis over ten years. Amortization expense related to these agreements was $24,886 during each of the years ended December 31, 2011, 2010 and 2009 and is expected to be $19,923, $10,000, $10,000, $-0-, and $-0- for each of the next five years, respectively.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Impairment of Long-Lived Assets</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future net cash flows expected to be generated by such assets. If we consider such assets to be impaired, the impairment to be<font style="DISPLAY: inline; FONT-WEIGHT: bold"> </font>recognized is measured by the amount by which the carrying amount of the assets exceeds the expected future net cash flows from the assets.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Accrued Liabilities</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have not yet been billed by our third party vendors. This process involves identifying services and activities that have been performed by such vendors on our behalf and estimating the level to which they have been performed and the associated cost incurred for such service as of each balance sheet date in our financial statements. Examples of expenses for which we accrue include fees for professional services and fees owed to contract manufacturers in conjunction with the manufacture of vaccines for our clinical trials. We make these estimates based upon progress of activities related to contractual obligations and information received from vendors.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-11</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net Loss Per Share</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. All common share equivalents (which consist of options and warrants) are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, totaled 2,798,801, 2,013,522, and 1,866,550 at December 31, 2011, 2010 and 2009, respectively.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Revenue Recognition</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We recognize revenue in accordance with the SEC&#8217;s Staff Accounting Bulletin No. 101, <font style="FONT-STYLE: italic; DISPLAY: inline">Revenue Recognition in Financial Statements, </font>as amended by Staff Accounting Bulletin No. 104, <font style="FONT-STYLE: italic; DISPLAY: inline">Revenue Recognition, </font>(&#8220;SAB 104&#8221;). SAB 104 provides guidance in applying GAAP to revenue recognition issues, and specifically addresses revenue recognition for upfront, nonrefundable fees received in connection with research collaboration agreements.&#160;&#160;During 2011, 2010 and 2009, our revenue consisted of grant funding received primarily from the NIH (see Note 3).&#160;&#160;Revenue from this arrangement is approximately equal to the costs incurred and is recorded as income as the related costs are incurred.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and Development Expense</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research and development expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) fees paid to third-party service providers to perform, monitor and accumulate data related to our preclinical studies and clinical trials, (ii) costs related to sponsored research agreements, (iii) the costs to procure and manufacture materials used in clinical trials, (iv) laboratory supplies and facility-related expenses to conduct development, and (v) salaries, benefits, and share-based compensation for personnel.&#160;&#160;These costs are charged to expense as incurred.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Patent Costs</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our expenditures relating to obtaining and protecting patents are charged to expense when incurred, and are included in general and administrative expense.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Period to Period Comparisons</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as predictive of the results for future periods.&#160;&#160;Certain prior year amounts have been reclassified to conform to the current year financial statement presentation.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Income Taxes</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.&#160;&#160;Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled.&#160;&#160;Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Stock-Based Compensation</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date.&#160;&#160;Compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance.&#160;&#160;Compensation cost for stock options or warrants is estimated at the grant date based on each instrument&#8217;s fair-value as calculated by the Black-Scholes option pricing model.&#160;&#160;We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award.&#160;&#160;See Note 6 for additional stock-based compensation information.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-12</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Recent Accounting Pronouncements</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There have been no recent accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements, nor do we believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on our financial statements.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Government Grants</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NIH Grant</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In September 2007, the NIH awarded us an Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant to support our HIV/AIDS vaccine program.&#160;&#160;The project period for the grant covers a five-year period which commenced October 2007, with an aggregate award of $20.4 million.&#160;&#160;As of December 31, 2011, there is approximately $3.9 million of unused grant funds remaining and available for use through August 31, 2012 (the end of the original project period).&#160;&#160;We are utilizing this funding to further our HIV/AIDS vaccine development, optimization and production.&#160;&#160;We record revenue associated with the grant as the related costs and expenses are incurred and such revenue is reported as a separate line item in our statements of operations.&#160;&#160;During 2011, 2010, and 2009, we recorded $4,899,885, $4,940,778, and $3,668,195, respectively, of revenue associated with this grant.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">QTDP Grant</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In November 2010, we were awarded a one-time grant of $244,479 pursuant to the Qualifying Therapeutic Discovery Project (QTDP) program enacted as part of the Patient Protection and Affordable Care Act of 2010.&#160;&#160;The QTDP program was intended to provide incentive to smaller companies who are focusing on innovative therapeutic discoveries.&#160;&#160;We received the full amount of the grant during 2010, which is recorded as revenue for 2010 in the accompanying Consolidated Statement of Operations.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Commitments</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Lease Agreements</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We lease approximately 8,400 square feet of office and laboratory space located in Smyrna, Georgia (metropolitan Atlanta). Rent expense for the years ended December 31, 2011, 2010 and 2009 was $119,255, $118,988, and $63,350, respectively.&#160;&#160;Future minimum lease payments pursuant to the 62 month lease total $121,560 in 2012, $125,180 in 2013 and $128,920 in 2014.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Other Commitments</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In the normal course of business, we may enter into various firm purchase commitments related to production and testing of our vaccine material, conduct of clinical trials, and other research-related activities. As of December 31, 2011, we had approximately $478,000 of unrecorded outstanding purchase commitments to our vendors and subcontractors, of which we expect approximately $445,000 in 2012 and $33,000 in 2013.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2006 Merger and Recapitalization</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Company was originally incorporated in June 1988 under the laws of Illinois as Dauphin Technology, Inc. (&#8220;Dauphin&#8221;).&#160;&#160;Dauphin was unsuccessful and its operations were terminated in December 2003.&#160;&#160;In September 2006, Dauphin completed a merger (the &#8220;Merger&#8221;) with GeoVax, Inc. which was incorporated under the laws of Georgia in June 2001.&#160;&#160;As a result of the Merger, the shareholders of GeoVax, Inc. exchanged their shares of common stock for Dauphin common stock and GeoVax, Inc. became a wholly-owned subsidiary of Dauphin.&#160;&#160;Dauphin then changed its name to GeoVax Labs, Inc. and replaced its officers and directors with those of GeoVax, Inc.&#160;&#160;Subsequent to the Merger, the Company has not conducted any business other than GeoVax, Inc.&#8217;s business of developing human vaccines.&#160;&#160;The Merger was accounted for under the purchase method of accounting as a reverse acquisition in accordance with GAAP. Under this method of accounting, Dauphin was treated as the acquired company and, accordingly, all financial information prior to the date of Merger presented in the accompanying consolidated financial statements, or in the notes herein, as well as any references to prior operations, are those of GeoVax, Inc.&#160;&#160;In June 2008, the Company was reincorporated under the laws of the State of Delaware.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-13</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stockholders&#8217; Equity</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Common Stock Transactions</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In February 2010, we issued 12,000 shares of our common stock in settlement of an obligation accrued at December 31, 2009 in the amount of $90,000.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During December 2011, we sold an aggregate of 658,520 shares of our common stock to fifteen individual accredited investors (including members of our board of directors and management --see Note 9) for an aggregate purchase price of $441,210, $36,800 of which was received in January 2012 and is therefore reflected as a receivable (Other Current Asset) in the accompanying Consolidated Balance Sheet as of December 31, 2011.&#160;&#160;We also issued to the investors warrants to purchase an aggregate of 987,783 shares of common stock at a price of $1.00 per share, which expire in December 2016.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">From time to time, we issue shares of our common stock to consultants or others in exchange for services.&#160;&#160;During 2011, 2010 and 2009 we issued 129,245, 10,500, and 4,500, respectively, for such services; and we recorded general and administrative expense of $150,000, $53,813, and $31,500 during each respective period related to these issuances.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Stock Options</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In 2006, we adopted the GeoVax Labs, Inc. 2006 Equity Incentive Plan (the &#8220;Stock Option Plan&#8221;) for the granting of qualified incentive stock options (&#8220;ISO&#8217;s&#8221;), nonqualified stock options, restricted stock awards or restricted stock bonuses to employees, officers, directors, consultants and advisors of the Company.&#160;&#160;The exercise price for any option granted may not be less than fair value (110% of fair value for ISO&#8217;s granted to certain employees).&#160;&#160;Options granted under the Stock Option Plan have a maximum ten-year term and generally vest over three years.&#160;&#160;The Company has reserved 1,200,000 shares of its common stock for issuance under the Stock Option Plan.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A summary of activity under the Stock Option Plan as of December 31, 2011, and changes during the year then ended is presented below:</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of Shares</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted-</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Price</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted-</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Remaining</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractual</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Term (yrs)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aggregate</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intrinsic</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Value</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding at January 1, 2011</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,137,356</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.33</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">230,000</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>0.91</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>-</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Forfeited or expired</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(439,114</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>2.81</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding at December 31, 2011</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">928,242</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.43</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>6.5</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-0-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercisable at December 31, 2011</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">578,231</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.59</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>4.8</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-0-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Additional information concerning our stock options for the years ended December 31, 2011, 2010 and 2009 is as follows:</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="64%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted average fair value of options granted during the period</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.79</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.95</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.15</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intrinsic value of options exercised during the period</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="64%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total fair value of options vested during the period</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">540,339</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">499,557</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,143,326</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We use the Black-Scholes model for determining the grant date fair value of our stock option grants.&#160;&#160;This model utilizes certain information, such as the interest rate on a risk-free security with a term generally equivalent to the expected life of the option being valued and requires certain other assumptions, such as the expected amount of time an option will be outstanding until it is exercised or expired, to calculate the fair value of stock options granted.&#160;&#160;The significant assumptions we used in our fair value calculations were as follows:</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="64%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted average risk-free interest rates</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.4</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.8</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected dividend yield</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected life of option</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" valign="bottom" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7 yrs</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" valign="bottom" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.7 yrs</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" valign="bottom" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7 yrs</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected volatility</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">111.2</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">112.9</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">112.3</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-14</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Stock-based compensation expense related to the Stock Option Plan was $463,752, $575,662, and $1,221,764 during the years ended December 31, 2011, 2010 and 2009, respectively.&#160;&#160;Stock option expense is allocated to research and development expense or to general and administrative expense based on the related employee classifications and corresponds to the allocation of employee salaries.&#160;&#160;For the three years ended December 31, 2011, stock option expense was allocated as follows:</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="64%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General and administrative expense</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">284,352</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">369,161</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">917,110</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development expense</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">179,400</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">206,501</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">304,654</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total stock option expense</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">463,752</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">575,662</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,221,764</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As of December 31, 2011, there was $515,697 of unrecognized compensation expense related to stock-based compensation arrangements.&#160;&#160;The unrecognized compensation expense is expected to be recognized over a weighted average remaining period of 2.0 years.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Compensatory Warrants</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">From time to time, we issue stock purchase warrants to consultants or others in exchange for services. A summary of our compensatory warrant activity as of December 31, 2011, and changes during the year then ended is presented below:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of Shares</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted-</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Price</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted-</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Remaining</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractual</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Term (yrs)</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aggregate</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intrinsic</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Value</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding at January 1, 2011</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,400</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.00</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,400</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>1.40</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>-</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Forfeited or expired</font></div>
</td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,400</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>7.00</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding at December 31, 2011</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">64,400</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.00</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>0.6</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-0-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercisable at December 31, 2011</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">58,850</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.00</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>0.7</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-0-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Additional information concerning our compensatory warrants for the years ended December 31, 2011, 2010 and 2009 is as follows:</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="64%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted average fair value of warrants granted during the period</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.96</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.75</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intrinsic value of warrants exercised during the period</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="64%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total fair value of warrants vested during the period</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,780</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,238</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,413</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We use the Black-Scholes model for determining the grant date fair value of our compensatory warrants.&#160;&#160;The significant assumptions we used in our fair value calculations were as follows:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="64%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted average risk-free interest rates</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.98</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.54</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected dividend yield</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected life of warrant</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" valign="bottom" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.0 yrs</font></div>
</td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="3" valign="bottom" style="TEXT-ALIGN: right">
<div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.0 yrs</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected volatility</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">115.46</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">112.1</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Expense associated with compensatory warrants was $7,119, $121,057, and $45,401 during the years ended December 31, 2011, 2010 and 2009, respectively.&#160;&#160;All such expense was allocated to general and administrative expense.&#160;&#160;As of December 31, 2011, there was no unrecognized compensation expense related to compensatory warrant arrangements.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-15</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Investment Warrants</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In addition to outstanding stock options and compensatory warrants, as of December 31, 2011 we have a total of 1,806,159 outstanding stock purchase warrants issued to investors in connection with financing transactions.&#160;&#160;Warrants as to 987,783 have an exercise price of $1.00 per share and expire in December 2016; warrants as to 818,376 have an exercise price of $16.50 and expire in December 2014.&#160;&#160;During the fourth quarter of 2011, we recorded general and administrative expense of $152,126 associated with the extension of warrants which were due to expire in 2011 to 2013.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Retirement Plan</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We participate in a multi-employer defined contribution retirement plan (the &#8220;401k Plan&#8221;) administered by a third party service provider; and the Company contributes to the 401k Plan on behalf of its employees based upon a matching formula.&#160;&#160;During the years ended December 31, 2011, 2010 and 2009 our contributions to the 401k Plan were $56,928, $52,632, and $25,057, respectively.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Income Taxes</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At December 31, 2011, we have a consolidated federal net operating loss (&#8220;NOL&#8221;) carryforward of approximately $71.3 million, available to offset against future taxable income which expires in varying amounts in 2012 through 2031.&#160;&#160;Additionally, we have approximately $764,000 in research and development (&#8220;R&amp;D&#8221;) tax credits that expire in 2022 through 2031 unless utilized earlier.&#160;&#160;No income taxes have been paid to date.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As a result of the Merger discussed in Note 5, our NOL carryforward increased substantially due to the addition of historical NOL carryforwards for Dauphin Technology, Inc.&#160;&#160;However, Section 382 of the Internal Revenue Code contains provisions that may limit our utilization of NOL and R&amp;D tax credit carryforwards in any given year as a result of significant changes in ownership interests that have occurred in past periods or may occur in future periods.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&#160;&#160;Significant components of our deferred tax assets and liabilities included the following at December 31, 2011 and 2010:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred tax assets:</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 4%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net operating loss carryforward</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,875,119</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,116,958</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development tax credit carryforward</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">763,690</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">731,290</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based compensation expense</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,991,769</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,779,950</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total deferred tax assets</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,630,578</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,628,198</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="76%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred tax liabilities</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Depreciation</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(38,587</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(51,945</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 4%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total deferred tax liabilities</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(38,587</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(51,945</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="76%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net deferred tax assets</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,591,991</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,576,253</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Valuation allowance</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(27,591,991</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(27,576,253</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have established a full valuation allowance equal to the amount of our net deferred tax assets due to uncertainties with respect to our ability to generate sufficient taxable income to realize these assets in the future. <font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>A reconciliation of the income tax benefit on losses at the U.S. federal statutory rate to the reported income tax expense is as follows:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="64%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">U.S. federal statutory rate applied to pretax loss</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(797,921</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(934,092</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,116,646</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Permanent differences</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 32.15pt"></font>3,536</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(77,200</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 21.8pt"></font>169,469</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="64%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research and development credits</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 25.45pt"></font>32,400</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,959</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 21.8pt"></font>169,667</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change in valuation allowance</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 18.8pt"></font>761,985</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">951,333</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 21.8pt"></font>777,510</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reported income tax expense</font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-16</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Related Party Transactions</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We are obligated to reimburse Emory University (a significant stockholder of the Company) for ongoing costs in connection with the filing, prosecution and maintenance of patent applications subject to a license agreement for technology associated with the vaccines we are developing.&#160;&#160;The expense associated with these ongoing patent cost reimbursements to Emory amounted to $249,907, $193,674, and $85,673 for the years ended December 31, 2011, 2010, and 2009, respectively.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have entered into two subcontracts with Emory for the purpose of conducting research and development activities associated with our grant from the NIH (see Note 3).&#160;&#160;During 2011, 2010, and 2009, we recorded $1,172,758, $1,391,203, and $816,651, respectively, of expense associated with these subcontracts.&#160;&#160;All amounts paid to Emory under these subcontracts are reimbursable to us pursuant to the NIH grant.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Through November 2009, we leased office and laboratory space on a month-to-month basis from Emtech Biotechnology Development, Inc., a related party associated with Emory.&#160;&#160;Rent expense associated with this lease totaled $43,112 for the year ended December 31, 2009.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In March 2008, we entered into a consulting agreement with Donald Hildebrand, a former member of our Board of Directors and our former President &amp; Chief Executive Officer, pursuant to which Mr. Hildebrand provides business and technical advisory services to the Company.&#160;&#160;The term of the consulting agreement, as amended, began on April 1, 2008 and ends on December 31, 2012.&#160;&#160;During 2011, 2010, and 2009, we recorded $24,000, $57,600, and $57,600, respectively, of expense associated with the consulting agreement.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In December 2011, members of our management and Board of Directors participated in the private placement offering of our common stock and warrants described in Note 6, whereby they purchased an aggregate of 335,954 shares of our common stock for a total purchase price of $225,089 and received five-year warrants to purchase an additional 503,932 shares of our common stock exercisable at $1.00 per share.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Selected Quarterly Financial Data (unaudited)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A summary of selected quarterly financial data for 2011 and 2010 is as follows:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="14" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011 Quarter Ended</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 31</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">June 30</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">September 30</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="52%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenue from grants</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">893,002</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,753,033</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,297,006</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">956,844</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(606,282</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(211,344</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(375,852</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,153,348</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="52%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss per share</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.04</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.01</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.02</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.08</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="14" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010 Quarter Ended</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March 31</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">June 30</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">September 30</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December 31</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="52%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenue from grants</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,338,560</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,737,169</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,163,288</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">946,240</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(690,789</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(933,089</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(644,666</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(478,784</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="52%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net loss per share</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.04</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.06</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.04</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.03</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subsequent Events</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Private Placement of Common Stock and Warrants</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During January 2012, we sold an aggregate of 407,999 shares of our common stock to twelve individual accredited investors (including 45,000 shares sold to members of our board of directors and management) for an aggregate purchase price of $273,360.&#160;&#160;We also issued to the investors warrants to purchase an aggregate of 612,001 shares of common stock at a price of $1.00 per share, which expire in January 2017.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Issuance of Convertible Preferred Stock and Warrants</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 21, 2012, we sold shares of our Series A convertible preferred stock to certain institutional investors for an aggregate purchase price of $2.2 million.&#160;&#160;The preferred stock is convertible at any time into shares of our common stock at $0.75 per share (2,933,333 shares in the aggregate), subject to possible adjustment as provided in the certificate of designation.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-17</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the terms of the securities purchase agreement, the investors also received five-year Series A warrants to purchase an aggregate of 2,933,333 shares of our common stock at $1.00 per share.&#160;&#160;The Series A warrants are immediately exercisable.&#160; We also granted to the investors a one-year additional purchase right, evidenced in the form of Series B warrants, to purchase up to 2,933,333 of our common stock for one year with an exercise price of $0.75 per share, and five-year Series C warrants to purchase up to 2,933,333 shares of our common stock at $1.00 per share.&#160;&#160;The Series B warrants are immediately exercisable.&#160;&#160;The Series C warrants only vest and become exercisable at the time, and to the extent, that the Series B warrants are exercised.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-18</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GEOVAX LABS, INC.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SCHEDULE II &#8211; VALUATION AND QUALIFYING ACCOUNTS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For the Years Ended December 31, 2011, 2010 and 2009</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additions</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Description</font></div>
</td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Beginning</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Of Period</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Charged to</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Costs and</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expenses</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Charged to</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deductions</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance at</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">End</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Of Period</font></div>
</td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reserve Deducted in the Balance Sheet </font><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">From the Asset to Which it Applies:</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Allowance for Deferred Tax Assets</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 9pt"></font>Year ended December 31, 2011</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,576,253</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">889,322</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(873,584</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,591,991</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td align="left" valign="bottom" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 9pt"></font>Year ended December 31, 2010</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,091,338</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,160,405</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(675,490</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,576,253</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="40%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 9pt"></font>Year ended December 31, 2009</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,674,882</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,416,456</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,091,338</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Deductions represent the effect of expiring NOL carryforwards from prior years.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">F-19</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font color="white" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">RDGXBRLParseEnd</font></div>
</div>

<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PART II</font></div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">INFORMATION NOT REQUIRED IN PROSPECTUS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 90pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">ITEM 13.</font></font></div>
</td>
<td align="left">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Other Expenses of Issuance and Distribution.</font></font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following table sets forth the estimated costs and expenses of the Registrant in connection with the offering described in the registration statement.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#c0ffff">
<td valign="bottom" width="83%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">SEC registration fee&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right">1,257</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="83%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Legal fees and expenses&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">20,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="83%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounting fees and expenses&#160;&#160;&#160;&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="14%" style="TEXT-ALIGN: right">2,500</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="83%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Miscellaneous&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-0-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr bgcolor="#c0ffff">
<td valign="bottom" width="83%" style="PADDING-BOTTOM: 4px; PADDING-LEFT: 0pt; MARGIN-LEFT: 9pt">
<div style="MARGIN-LEFT: 18pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">TOTAL</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font></td>
<td valign="bottom" width="14%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">23,757</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 90pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 14.&#160;</font></div>
</td>
<td align="left">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Indemnification of Directors and Officers.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Section&#160;145 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), provides, among other things, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the corporation&#8217;s request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with the action, suit or proceeding. The power to indemnify applies (i)&#160;if such person is successful on the merits or otherwise in defense of any action, suit or proceeding or (ii)&#160;if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. The power to indemnify applies to actions brought by or in the right of the corporation as well, but only to the extent of defense expenses (including attorneys&#8217; fees but excluding amounts paid in settlement), actually and reasonably incurred and not to any satisfaction of judgment or settlement of the claim itself, and with the further limitation that in such actions no indemnification shall be made in the event of any adjudication of negligence or misconduct in the performance of his duties to the corporation, unless a court believes that in light of all the circumstances indemnification should apply.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our bylaws provide that we may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Company) by reason of the fact that the person is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person&#8217;s conduct was unlawful. Our bylaws also provide that we may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Company to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the Company and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the Company unless and only to the extent that the Delaware Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Delaware Court of Chancery or such other court shall deem proper.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Under our bylaws, expenses (including attorneys&#8217; fees) incurred by an officer or director in defending any civil, criminal, administrative or investigative action, suit or proceeding may be paid by the Company in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the Company. Such expenses (including attorneys&#8217; fees) incurred by former directors and officers or other employees and agents may be so paid upon such terms and conditions, if any, as we deem appropriate.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">II-1</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The indemnification and advancement of expenses provided by our bylaws is not exclusive, both as to action in such person&#8217;s official capacity and as to action in another capacity while holding such office.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our bylaws also provide that we may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Company, or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person&#8217;s status as such, whether or not the Company would have the power to indemnify such person against such liability under our bylaws. The Company maintains an insurance policy providing for indemnification of its officers, directors and certain other persons against liabilities and expenses incurred by any of them in certain stated proceedings and under certain stated conditions.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In October 2006, GeoVax and our subsidiary, GeoVax, Inc. entered into indemnification agreements with Messrs.&#160;McNally, Reynolds,&#160;Kollintzas and Spencer. Pursuant to these agreements, we have agreed to hold harmless and indemnify these directors and officers to the full extent authorized or permitted by applicable Illinois and Georgia law against certain expenses and other liabilities actually and reasonably incurred by these individuals in connection with certain proceedings if they acted in a manner they believed in good faith to be in or not opposed to the best interests of the Company and, with respect to any criminal proceeding, had no reasonable cause to believe that such conduct was unlawful. The agreements also provide for the advancement of expenses to these individuals subject to specified conditions. Under these agreements, we will not indemnify these individuals for expenses or other amounts for which applicable Illinois and Georgia law prohibit indemnification. The obligations under these agreements continue during the period in which these individuals are our directors or officers and continue thereafter so long as these individuals shall be subject to any proceeding by reason of their service to the Company, whether or not they are serving in any such capacity at the time the liability or expense incurred for which indemnification can be provided under the agreements.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the registrant pursuant to the foregoing provisions, the registrant has been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">II-2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 90pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 15.&#160;</font></div>
</td>
<td align="left">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Recent Sales of Unregistered Securities.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the quarter ended June&#160;30, 2009, we sold an aggregate of 74,692&#160;shares of our common stock to Fusion Capital Fund&#160;II, LLC (&#8220;Fusion Capital&#8221;) pursuant to a common stock purchase agreement (the &#8220;Purchase Agreement&#8221;) for an aggregate purchase price of $590,000. We also issued to Fusion Capital an additional 2,927&#160;shares of our common stock as a partial settlement of the commitment fee for entering into the Purchase Agreement.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On September&#160;4, 2009, we issued 2,250&#160;shares of our common stock to Equinox One Consulting, LLC (&#8220;Equinox One&#8221;) pursuant to a consulting agreement with the Company.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the quarter ended September&#160;30, 2009, we sold an aggregate of 27,837&#160;shares of our common stock to Fusion Capital pursuant to the Purchase Agreement for an aggregate purchase price of $210,000. We also issued to Fusion Capital an additional 1,042&#160;shares of our common stock as a partial settlement of the commitment fee for entering into the Purchase Agreement.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the quarter ended December&#160;31, 2009, we sold an aggregate of 58,182&#160;shares of our common stock to Fusion Capital pursuant to the Purchase Agreement for an aggregate purchase price of $480,000. We also issued to Fusion Capital an additional 2,381&#160;shares of our common stock as a partial settlement of the commitment fee for entering into the Purchase Agreement.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On each of December&#160;1, 2009, March&#160;1, 2010, and June 1, 2010, we issued 2,250&#160;shares of our common stock to Equinox One for services rendered pursuant to a consulting agreement with the Company.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For all of the aforementioned transactions with Fusion Capital and Equinox One, respectively, we relied on Section&#160;4(2) of the Securities Act and Rule&#160;506 promulgated thereunder. The shares were only offered to a single accredited investor who purchased for investment in a transaction that did not involve a general solicitation.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On September&#160;22, 2009 we issued 462,826&#160;shares of our common stock to Mr.&#160;Stavros Papageorgiou. The shares were issued to Mr.&#160;Papageorgiou pursuant to his exercise in full of a warrant granted on May&#160;15, 2006. The Company received $1,500,000 for the shares it sold. The Company relied on Section&#160;4(2) of the Securities Act to issue the common stock and warrant, inasmuch as the common stock was issued to a single accredited investor who purchased for investment in a transaction that did not involve a general solicitation.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In February 2010, we issued 12,000&#160;shares of our common stock to Dr.&#160;Daniel Kiddy to settle a lawsuit claiming he was entitled to such shares.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March&#160;15, 2010, we issued 6,000&#160;shares, in the aggregate, of our common stock to Ms.&#160;Dian Griesel and Mr.&#160;Kevin Moran, two individuals affiliated with The Investor Relations Group, our investor relations and public relations firm for services rendered to us.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the aforementioned transactions with Dr.&#160;Kiddy and the affiliates of IRG, we relied on Section&#160;4(2) of the Securities Act and Rule&#160;506 promulgated thereunder to issue the common stock. No advertising or general solicitation was employed in offering the shares. The shares were issued to accredited investors or to no less than 35 accredited investors who received specified information and had appropriate knowledge and experience. The shares were offered for investment purposes only and not for the purpose of resale or distribution.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 22, 2011, we issued an aggregate of 21,253 shares of our common stock to Gilford Securities, Incorporated and to Array Capital Management, LLC for financial advisory services.&#160;&#160;For this transaction the Company relied upon Section 4(2) of the Securities Act and Rule 506 promulgated thereunder to issue the common stock.&#160;&#160;The shares were offered to investors who acquired the shares for investment in a transaction that did not involve a general solicitation.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">For the quarter ended June 30, 2011, we issued an aggregate of 75,734 shares of our common stock to Gilford Securities Incorporated and to Array Capital Management, LLC for financial advisory services. For these transactions the Company relied upon Section 4(2) of the Securities Act and Rule 506 promulgated thereunder to issue the common stock.&#160;&#160;The shares were offered to investors who acquired the shares for investment in a transaction that did not involve a general solicitation.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">II-3</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On July 20, 2011, we issued an aggregate of 32,258 shares of our common stock to Gilford Securities, Incorporated and to Array Capital Management, LLC for financial advisory services.&#160;&#160;For this transaction the Company relied upon Section 4(2) of the Securities Act and Rule 506 promulgated thereunder to issue the common stock.&#160;&#160;The shares were offered to these investors who acquired the shares for investment in a transaction that did not involve a general solicitation.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On December 30, 2011, we sold to fourteen individual accredited investors 658,520 shares of our common stock, $.001 par value, and five-year warrants to purchase an aggregate of 987,783 shares of common stock at an exercise price of $1.00 per share for an aggregate purchase price of $441,208.&#160;&#160;No commissions were paid in connection with these sales.&#160; We relied on Rule 506 of Regulation D under the Securities Act to issue such securities, inasmuch as these were sold without any form of general solicitation or general advertising and sales were made only to accredited investors. A copy of the form of warrant issued to the investors was attached to our Form&#160;8-K filed January 5, 2012.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On January 31, 2012, we sold to eleven individual accredited investors 370,686 shares of our common stock, $.001 par value, and five-year warrants to purchase an aggregate of 556,031 shares of common stock at an exercise price of $1.00 per share for an aggregate purchase price of $248,360.&#160;&#160;No commissions were paid in connection with these sales.&#160;We relied on Rule 506 of Regulation D under the Securities Act to issue such securities, inasmuch as these were sold without any form of general solicitation or general advertising and sales were made only to accredited investors. A copy of the form of warrant issued to the investors was attached to our Form&#160;8-K filed February 6, 2012.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 16, 2012, we entered into a Securities Purchase Agreement with the certain purchasers identified therein providing for the issuance and sale to the purchasers of an aggregate of 2,200 shares of our Series A convertible preferred stock, and a Series A, B and C Warrant to each purchaser, for gross proceeds to the Company of $2.2 million, as described in our Form&#160;8-K filed March 22, 2012.&#160;&#160;The Company relied on an exemption from the registration requirements of the Securities Act afforded by Section&#160;4(2)&#160;thereof and Rule&#160;506 of Regulation D.&#160;&#160;Moody Capital, LLC acted as the exclusive placement agent for the private placement, and the Company paid the placement agent a fee equal to 8% of the aggregate $2,200,000 of gross proceeds raised in the private placement.&#160;&#160;For information regarding the terms of the Series A convertible preferred stock and the Series A, B and C Warrants, see &#8220;Description of Securities&#8221; in the prospectus accompanying this registration statement.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 90pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 16.&#160;</font></div>
</td>
<td align="left">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibits and Financial Statement Schedules</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Exhibit</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 45pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Number</font></font></div>
</td>
<td align="left">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Description</font></font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.1</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Agreement and Plan of Merger dated January 20, 2006 by and among GeoVax, Inc., GeoVax Acquisition Corp. and Dauphin Technology, Inc. (1)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.2</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">First Amendment to Agreement and Plan of Merger (2)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.3</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Second Amendment to Agreement and Plan of Merger (3)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.1</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certificate of Incorporation (6)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.1.1</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed April 13, 2010 (10)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.1.2</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed April 27, 2010 (11)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.1.3</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form of Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock, filed March 20, 2012 (14)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.2</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Bylaws (6)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.1 **</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Opinion of Womble Carlyle Sandridge &amp; Rice, LLP</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10.1 *</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Employment Agreement between GeoVax Labs, Inc. and Robert T. McNally effective as of April 1, 2008 (7)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10.2 *</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Employment Agreement between GeoVax, Inc. and Mark W. Reynolds Amended and Restated effective as of January 1, 2010 (9)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10.3 *</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Employment Agreement between GeoVax, Inc. and Harriet Robinson effective as of November 19, 2007 (9)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10.4 *</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">GeoVax Labs, Inc. 2006 Equity Incentive Plan (4)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10.5</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">License Agreement (as amended and restated) between GeoVax, Inc. and Emory University, dated August 23, 2002 (3)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10.6</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Technology Sale and Patent License Agreement between GeoVax, Inc. and MFD, Inc., dated December 26, 2004 (3)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10.7</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Office and Laboratory Lease between UCB, Inc. and GeoVax, Inc. (8)</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">II-4</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10.8 *</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Summary of the GeoVax Labs, Inc. Director Compensation Plan (9)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10.9</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form of Warrant dated December 30, 2011 (12)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10.10</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Consulting Agreement by and between Donald G. Hildebrand and GeoVax Labs, Inc., dated April 1, 2008 (13)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10.11</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form of Securities Purchase Agreement dated March 16, 2012 (14)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10.12</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form of Registration Rights Agreement dated March 16, 2012 (14)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10.13</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form of Series A Warrant issued March 21, 2012 (14)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10.13</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form of Series B Warrant issued March 21, 2012 (14)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">10.13</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Form of Series C Warrant issued March 21, 2012 (14)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">21.1</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Subsidiaries of the Registrant (5)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">23.1 **</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Consent of Porter Keadle Moore LLC</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">23.2 **</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Consent of Tripp, Chafin &amp; Company, LLC</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">23.3 **</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Consent of Womble Carlyle Sandridge &amp; Rice, LLP (contained in the opinion filed as Exhibit 5.1 hereof)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 45pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">24.1 **</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Power of Attorney (included on the signature page to this Registration Statement)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 45pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">101**,***</font></div>
</td>
<td align="left">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following financial information for GeoVax Labs, Inc., formatted in Extensible Business Reporting Language (XBRL): (i) Consolidated Balance Sheets as of December 31, 2011 and December 31, 2010, (ii) Consolidated Statements of Operations for the years ended December 31, 2011, 2010 and 2009 and for the period from inception (June 27, 2001) to December 31, 2011, (iii) Consolidated Statements of Stockholders&#8217; Equity (Deficiency) for the period from inception (June 27, 2001) to December 31, 2011, (iv) Consolidated Statements of Cash Flows for the years ended December 31, 2011, 2010 and 2009 and for the period from inception (June 27, 2001) to December 31, 2011, and (v) Notes to Condensed Consolidated Financial Statements.</font></font></div>
</div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">___________________</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 36pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">*&#160;</font></div>
</td>
<td align="left">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Indicates a management contract or compensatory plan or arrangement.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 36pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">**&#160;</font></div>
</td>
<td align="left">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Filed herewith.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 36pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">***</div>
</td>
<td align="left">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files in Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended and otherwise are not subject to liability under those sections.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Incorporated by reference from the registrant&#8217;s Current Report on Form 8-K filed January 24, 2006.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(2)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Incorporated by reference from the registrant&#8217;s Current Report on Form 8-K filed July 13, 2006.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(3)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Incorporated by reference from the registrant&#8217;s Current Report on Form 8-K filed October 4, 2006.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(4)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Incorporated by reference from the registrant&#8217;s definitive Information Statement (Schedule 14C) filed August 18, 2006.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(5)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Incorporated by reference from the registrant&#8217;s Annual Report on Form 10-K filed March 28, 2007.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(6)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Incorporated by reference from the registrant&#8217;s Current Report on Form 8-K filed June 23, 2008.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(7)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Incorporated by reference from the registrant&#8217;s Current Report on Form 8-K filed March 24, 2008.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(8)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Incorporated by reference from the registrant&#8217;s Quarterly Report on Form 10-Q filed November 6, 2009.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(9)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Incorporated by reference from the registrant&#8217;s Annual Report on Form 10-K filed March 8, 2010.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(10)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Incorporated by reference from the registrant&#8217;s Current Report on Form 8-K filed April 14, 2010.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(11)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Incorporated by reference from the registrant&#8217;s Current Report on Form 8-K filed April 28, 2010.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(12)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Incorporated by reference from the registrant&#8217;s Current Report on Form 8-K filed January 5, 2012.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(13)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Incorporated by reference from the registrant&#8217;s Current Report on Form 8-K filed March 24, 2008.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(14)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Incorporated by reference from the registrant&#8217;s Current Report on Form 8-K filed March 22, 2012.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Financial Statement Schedules.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Schedule II&#8212;Valuation and Qualifying Accounts for the years ended December 31, 2011, 2010 and 2009 (unaudited) is included in the Financial Statements at page F-19.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">All other financial statement schedules have been omitted because they are not applicable or not required or because the information is included elsewhere in the Consolidated Financial Statements or the Notes thereto.</font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">II-5</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 90pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">ITEM 17.&#160;</font></div>
</td>
<td align="left">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Undertakings.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(a)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The undersigned registrant hereby undertakes:</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">i.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To include any prospectus required by section&#160;10(a)(3) of the Securities Act of 1933;</font></div>
</td>
</tr></table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ii.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule&#160;424(b) if, in the aggregate, the changes in volume and price represent no more than 20&#160;percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement;&#160;and</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">iii.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.</font></div>
</td>
</tr></table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">That, for the purpose of determining any liability under the Securities Act of 1933, as amended, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <font style="FONT-STYLE: italic; DISPLAY: inline">bona fide </font>offering thereof.</font></div>
</td>
</tr></table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">3.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</font></div>
</td>
</tr></table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">4.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</font></div>
</td>
</tr></table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">i.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&#160;424;</font></div>
</td>
</tr></table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">ii.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</font></div>
</td>
</tr></table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">iii.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant;&#160;and</font></div>
</td>
</tr></table>
</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
</table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">iv.</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 27pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(b)</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Insofar as indemnification for liabilities arising under the Securities Act of 1933&#160;may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by us of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">II-6</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURES</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Smyrna, State of Georgia, on the&#160;2nd day of April, 2012.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td colspan="2" valign="top" width="38%">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">GEOVAX LABS, INC.</font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td align="left" valign="top" width="50%" style="BORDER-BOTTOM: #ffffff solid">&#160;</td>
<td valign="top" width="3%" style="BORDER-BOTTOM: #ffffff solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By: </font></div>
</td>
<td align="left" nowrap valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/&#160;Robert T. McNally</font></td>
<td valign="top" width="12%" style="BORDER-BOTTOM: #ffffff solid"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" nowrap valign="bottom" width="35%">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Robert T. McNally Ph.D.</font></font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">President and Chief Executive Officer</font></font></div>
</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%">&#160;</td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="35%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 216pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">POWER OF ATTORNEY</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">KNOW ALL MEN BY THESE PRESENTS</font>, that each person whose signature appears below constitutes and appoints Robert T. McNally and Mark W. Reynolds, and each of them, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place and stead in any and all capacities, to sign any or all amendments to this Registration Statement on Form S-1 (including post-effective amendments), and to file the same, with all exhibits thereto, and other documents in connection therewith with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully and to all intents and purposes as he might or could do in person, hereby ratifying and confirming that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Name</font></font></td>
<td width="2%">&#160;</td>
<td width="43%"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Title</font></td>
<td width="2%">&#160;</td>
<td width="23%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Date</font></font></td>
</tr><tr>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="23%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="33%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Robert T. McNally</font></td>
<td width="2%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td width="43%" style="PADDING-BOTTOM: 2px">Director</td>
<td width="2%" style="PADDING-BOTTOM: 2px">&#160;</td>
<td width="23%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">April 2, 2012</font></td>
</tr><tr>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Robert T. McNally</font></td>
<td width="2%">&#160;</td>
<td width="43%">President &amp; Chief Executive Officer</td>
<td width="2%">&#160;</td>
<td width="23%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%">&#160;</td>
<td width="43%">(Principal Executive Officer)</td>
<td width="2%">&#160;</td>
<td width="23%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="23%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="33%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Mark W. Reynolds</font></td>
<td width="2%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Financial Officer</font></td>
<td width="2%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="23%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">April 2, 2012</font></td>
</tr><tr>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Mark W. Reynolds</font></td>
<td width="2%">&#160;</td>
<td width="43%">(Principal Financial and Accounting Officer)</td>
<td width="2%">&#160;</td>
<td width="23%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%">&#160;</td>
<td width="43%">&#160;</td>
<td width="2%">&#160;</td>
<td width="23%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%">&#160;</td>
<td width="43%">&#160;</td>
<td width="2%">&#160;</td>
<td width="23%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="33%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ S<font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">teven S. Antebi</font></font></td>
<td width="2%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></td>
<td width="2%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="23%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">April 2, 2012</font></td>
</tr><tr>
<td width="33%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Steven S. Antebi</font></font></div>
</td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="23%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="23%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="23%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="33%" style="BORDER-BOTTOM: black 2px solid">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ David A. Dodd</font></font></div>
</td>
<td width="2%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></td>
<td width="2%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="23%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">April 2, 2012</font></td>
</tr><tr>
<td width="33%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">David A. Dodd</font></font></div>
</td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="23%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="23%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="23%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="33%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dean G. Kollintzas</font></font></td>
<td width="2%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></td>
<td width="2%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="23%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">April 2, 2012</font></td>
</tr><tr>
<td width="33%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dean G. Kollintzas</font></font></div>
</td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="23%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="23%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="23%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="33%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Harriet L. Robinson</font></font></td>
<td width="2%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></td>
<td width="2%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="23%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">April 2, 2012</font></td>
</tr><tr>
<td width="33%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Harriet L. Robinson</font></font></div>
</td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="23%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="23%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="33%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="23%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr><tr>
<td width="33%" style="BORDER-BOTTOM: black 2px solid"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">John N. Spencer, Jr.</font></font></td>
<td width="2%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Director</font></td>
<td width="2%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="23%" style="PADDING-BOTTOM: 2px"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">April 2, 2012</font></td>
</tr><tr>
<td width="33%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">John N. Spencer, Jr.</font></font></div>
</td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="43%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="2%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="23%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
</tr></table>
</div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">II-7</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">EXHIBIT INDEX</font></font></div>

<div>
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Exhibit</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 54pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Number</font></font></div>
</td>
<td align="left">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Description</font></font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">5.1 *</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Opinion of Womble Carlyle Sandridge &amp; Rice, LLP</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">23.1 *</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Consent of Porter Keadle Moore LLC</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">23.2 *</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Consent of Tripp, Chafin &amp; Company, LLC</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">23.3 *</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Consent of Womble Carlyle Sandridge &amp; Rice, LLP (contained in the opinion filed as Exhibit 5.1 hereof)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">24.1 *</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Power of Attorney (included on the signature page to this Registration Statement)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 54pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">101 *, **</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The following financial information for GeoVax Labs, Inc., formatted in Extensible Business Reporting Language (XBRL): (i) Consolidated Balance Sheets as of December 31, 2011 and December 31, 2010, (ii) Consolidated Statements of Operations for the years ended December 31, 2011, 2010 and 2009 and for the period from inception (June 27, 2001) to December 31, 2011, (iii) Consolidated Statements of Stockholders&#8217; Equity (Deficiency) for the period from inception (June 27, 2001) to December 31, 2011, (iv) Consolidated Statements of Cash Flows for the years ended December 31, 2011, 2010 and 2009 and for the period from inception (June 27, 2001) to December 31, 2011, and (v) Notes to Condensed Consolidated Financial Statements.</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">___________________</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td align="right" style="WIDTH: 36pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">*&#160;</font></div>
</td>
<td align="left">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Filed herewith.</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top" style="LINE-HEIGHT: 1.25;">
<td style="WIDTH: 36pt">
<div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">**</font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files in Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended and otherwise are not subject to liability under those sections.</font></div>
</td>
</tr></table>
</div>
</div>

<div>&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">&#160;</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
<head>
    <title>ex5-1.htm</title>
    <!--Licensed to: EdgarEdge-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibit 5.1</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><img src="ex5-10.jpg" alt=""></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">April 2, 2012</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">GeoVax Labs, Inc.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1900 Lake Park Dr.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Suite 380</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Smyrna, Georgia 30080</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>Re:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Registration Statement on Form S-1</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Ladies and Gentlemen:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have acted as counsel to GeoVax Labs, Inc., a Delaware corporation (the &#8220;Company&#8221;), in connection with the preparation of the Company&#8217;s above-referenced registration statement on Form S-1 (the &#8220;Registration Statement&#8221;), under the Securities Act of 1933, as amended (the &#8220;Act&#8221;), filed by the Company with the Securities and Exchange Commission (the &#8220;Commission&#8221;).&#160;&#160;The Registration Statement relates to up to 11,733,332 shares of common stock, $0.001 par value, of the Company (the &#8220;Common Stock&#8221;) that may be sold from time to time by the selling stockholders named in the Registration Statement, which includes up to 2,933,333 shares of Common Stock underlying shares of Series A convertible preferred stock, par value $0.01 per share, of the Company (the &#8220;Series A Preferred Stock&#8221;), and 8,799,999 shares of Common Stock issuable to the selling stockholders upon the exercise of Series A, B and C Warrants (collectively, the &#8220;Warrants&#8221;).&#160;&#160;This opinion is delivered to you pursuant to Item 16(a) of Form S-1 and Item 601(b) (5) of Regulation S-K of the Commission.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As the Company&#8217;s counsel, we have examined originals or copies, certified or otherwise identified to our satisfaction, of the Company&#8217;s certificate of incorporation and bylaws, each as amended to date, and minutes and records of the corporate proceedings of the Company relating to the filing of the Registration Statement and the issuance of the Common Stock and Warrants, as provided to us by the Company, certificates of public officials and of representatives of the Company, and statutes and other instruments and documents, as a basis for the opinions hereinafter expressed.&#160;&#160;In rendering this opinion, we have relied upon certificates of public officials and representatives of the Company with respect to the accuracy of the factual matters contained in such certificates.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In connection with such examination, we have assumed (a) the genuineness of all signatures and the legal capacity of all signatories; (b) the authenticity of all documents submitted to us as originals and the conformity to original documents of all documents submitted to us as certified or photostatic copies; (c) that the Warrants constitute the enforceable obligation of the parties thereto other than the Company; and (d) the proper issuance and accuracy of certificates of public officials and representatives of the Company.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div>&#160;</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Based on and subject to the foregoing, and having regard for such legal considerations as we deem relevant, it is our opinion that:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;With respect to the Common Stock to be issued upon conversion of the Series A Preferred Stock, when the Common Stock has been issued and delivered in accordance with the terms of the Series A Preferred Stock, such Common Stock will be validly issued, fully paid and nonassessable.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;With respect to Common Stock to be issued upon exercise of the Warrants, when (a)&#160;the Company has received the aggregate purchase prices for such Common Stock in accordance with the terms of the applicable Warrant, and (b) such Common Stock has been issued and delivered in accordance with the terms of the applicable Warrant, such shares of Common Stock will be validly issued, fully paid and nonassessable.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The opinions set forth in paragraphs 1 and 2 above are each subject to (a)&#160;the effect of any bankruptcy, insolvency, reorganization, moratorium, arrangement or similar laws affecting the rights and remedies of creditors&#8217; generally, including the effect of statutory or other laws regarding fraudulent transfers or preferential transfers, and (b)&#160;general principles of equity, including concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability of specific performance, injunctive relief or other equitable remedies regardless of whether enforceability is considered in a proceeding in equity or at law. We express no opinion regarding the effectiveness of (i)&#160;any waiver of stay, extension or usury laws or of unknown future rights; or (ii)&#160;provisions relating to indemnification, exculpation or contribution, to the extent such provisions may be held unenforceable as contrary to federal or state securities laws.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This opinion is limited to the Delaware General Corporation Law, as currently in effect as of the date of this opinion.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">This opinion is rendered as of the date hereof, and we undertake no obligation to advise you of any changes in applicable law or any other matters that may come to our attention after the date hereof.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to any reference to the name of our firm in the Registration Statement.&#160;&#160;In giving this consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the 1933 Act or the rules and regulations of the Commission thereunder.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div align="center">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td width="50%"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td width="50%">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Very truly yours,</font></font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/ Womble Carlyle Sandridge &amp; Rice, LLP</font></font></div>
</td>
</tr></table>
</div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">TCF</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CDR</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
<head>
    <title>ex23-1.htm</title>
    <!--Licensed to: EdgarEdge-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Exhibit 23.1</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We have issued our report dated March 29, 2012 included in the Annual Report of GeoVax Labs, Inc. on Form 10-K for the year ended December 31, 2011.&#160;&#160;We hereby consent to the use of said report in this Registration Statement on Form S-1 of GeoVax Labs, Inc. appearing in the Prospectus, which is a part of this Registration Statement.&#160;&#160;We also consent to the reference to our firm under the caption &#8220;Experts&#8221; in such Prospectus.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">/S/ PORTER KEADLE MOORE, LLP</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Atlanta, Georgia</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">April 3, 2012</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<html>
<head>
    <title>ex23-2.htm</title>
    <!--Licensed to: RDG-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Exhibit 23.2</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="right">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><br>
</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">We consent to the use in this Registration Statement on Form S-1 of our report dated February 8, 2006 relating to the financial statements of GeoVax, Inc. appearing in the Prospectus which is a part of the Registration Statement. We also consent to the reference to our firm under the caption &#8220;Experts&#8221; in the Registration Statement.</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">/S/ TRIPP, CHAFIN &amp; COMPANY, LLC</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">Marietta, Georgia</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: normal">April 3, 2012</font></font></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>govx-20111231.xml
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Tue Apr 03 16:11:41 UTC 2012 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:govx="http://geovax.com/20111231" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="govx-20111231.xsd"/>
  <context id="c0_AsOf31Dec2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c1_AsOf31Dec2010">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c2_From1Jan2011To31Dec2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c3_From1Jan2010To31Dec2010">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c4_From1Jan2009To31Dec2009">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c5_From27Jun2001To31Dec2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <startDate>2001-06-27</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c6_From27Jun2001To31Dec2001_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2001-06-27</startDate>
      <endDate>2001-12-31</endDate>
    </period>
  </context>
  <context id="c7_From27Jun2001To31Dec2001">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <startDate>2001-06-27</startDate>
      <endDate>2001-12-31</endDate>
    </period>
  </context>
  <context id="c8_From27Jun2001To31Dec2001_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2001-06-27</startDate>
      <endDate>2001-12-31</endDate>
    </period>
  </context>
  <context id="c9_AsOf31Dec2001_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2001-12-31</instant>
    </period>
  </context>
  <context id="c10_AsOf31Dec2001_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2001-12-31</instant>
    </period>
  </context>
  <context id="c11_AsOf31Dec2001">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <instant>2001-12-31</instant>
    </period>
  </context>
  <context id="c12_From1Jan2002To31Dec2002_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2002-01-01</startDate>
      <endDate>2002-12-31</endDate>
    </period>
  </context>
  <context id="c13_From1Jan2002To31Dec2002_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2002-01-01</startDate>
      <endDate>2002-12-31</endDate>
    </period>
  </context>
  <context id="c14_From1Jan2002To31Dec2002">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <startDate>2002-01-01</startDate>
      <endDate>2002-12-31</endDate>
    </period>
  </context>
  <context id="c15_From1Jan2002To31Dec2002_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2002-01-01</startDate>
      <endDate>2002-12-31</endDate>
    </period>
  </context>
  <context id="c16_AsOf31Dec2002_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2002-12-31</instant>
    </period>
  </context>
  <context id="c17_AsOf31Dec2002_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2002-12-31</instant>
    </period>
  </context>
  <context id="c18_AsOf31Dec2002_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2002-12-31</instant>
    </period>
  </context>
  <context id="c19_AsOf31Dec2002">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <instant>2002-12-31</instant>
    </period>
  </context>
  <context id="c20_From1Jan2003To31Dec2003_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2003-01-01</startDate>
      <endDate>2003-12-31</endDate>
    </period>
  </context>
  <context id="c21_From1Jan2003To31Dec2003_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2003-01-01</startDate>
      <endDate>2003-12-31</endDate>
    </period>
  </context>
  <context id="c22_From1Jan2003To31Dec2003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <startDate>2003-01-01</startDate>
      <endDate>2003-12-31</endDate>
    </period>
  </context>
  <context id="c23_From1Jan2003To31Dec2003_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2003-01-01</startDate>
      <endDate>2003-12-31</endDate>
    </period>
  </context>
  <context id="c24_AsOf31Dec2003_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2003-12-31</instant>
    </period>
  </context>
  <context id="c25_AsOf31Dec2003_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2003-12-31</instant>
    </period>
  </context>
  <context id="c26_AsOf31Dec2003_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2003-12-31</instant>
    </period>
  </context>
  <context id="c27_AsOf31Dec2003">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <instant>2003-12-31</instant>
    </period>
  </context>
  <context id="c28_From1Jan2004To31Dec2004_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2004-01-01</startDate>
      <endDate>2004-12-31</endDate>
    </period>
  </context>
  <context id="c29_From1Jan2004To31Dec2004_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2004-01-01</startDate>
      <endDate>2004-12-31</endDate>
    </period>
  </context>
  <context id="c30_From1Jan2004To31Dec2004_StockSubscriptionReceivableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">govx:StockSubscriptionReceivableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2004-01-01</startDate>
      <endDate>2004-12-31</endDate>
    </period>
  </context>
  <context id="c31_From1Jan2004To31Dec2004">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <startDate>2004-01-01</startDate>
      <endDate>2004-12-31</endDate>
    </period>
  </context>
  <context id="c32_From1Jan2004To31Dec2004_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2004-01-01</startDate>
      <endDate>2004-12-31</endDate>
    </period>
  </context>
  <context id="c33_AsOf31Dec2004_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2004-12-31</instant>
    </period>
  </context>
  <context id="c34_AsOf31Dec2004_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2004-12-31</instant>
    </period>
  </context>
  <context id="c35_AsOf31Dec2004_StockSubscriptionReceivableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">govx:StockSubscriptionReceivableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2004-12-31</instant>
    </period>
  </context>
  <context id="c36_AsOf31Dec2004_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2004-12-31</instant>
    </period>
  </context>
  <context id="c37_AsOf31Dec2004">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <instant>2004-12-31</instant>
    </period>
  </context>
  <context id="c38_From1Jan2005To31Dec2005_StockSubscriptionReceivableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">govx:StockSubscriptionReceivableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="c39_From1Jan2005To31Dec2005">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="c40_From1Jan2005To31Dec2005_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="c41_AsOf31Dec2005_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2005-12-31</instant>
    </period>
  </context>
  <context id="c42_AsOf31Dec2005_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2005-12-31</instant>
    </period>
  </context>
  <context id="c43_AsOf31Dec2005_StockSubscriptionReceivableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">govx:StockSubscriptionReceivableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2005-12-31</instant>
    </period>
  </context>
  <context id="c44_AsOf31Dec2005_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2005-12-31</instant>
    </period>
  </context>
  <context id="c45_AsOf31Dec2005">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <instant>2005-12-31</instant>
    </period>
  </context>
  <context id="c46_From1Jan2006To31Dec2006_StockSubscriptionReceivableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">govx:StockSubscriptionReceivableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="c47_From1Jan2006To31Dec2006">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="c48_From1Jan2006To31Dec2006_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="c49_From1Jan2006To31Dec2006_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="c50_From1Jan2006To31Dec2006_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="c51_AsOf31Dec2006_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="c52_AsOf31Dec2006_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="c53_AsOf31Dec2006_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="c54_AsOf31Dec2006">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <instant>2006-12-31</instant>
    </period>
  </context>
  <context id="c55_From1Jan2007To31Dec2007_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="c56_From1Jan2007To31Dec2007_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="c57_From1Jan2007To31Dec2007">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="c58_From1Jan2007To31Dec2007_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="c59_AsOf31Dec2007_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="c60_AsOf31Dec2007_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="c61_AsOf31Dec2007_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="c62_AsOf31Dec2007">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <instant>2007-12-31</instant>
    </period>
  </context>
  <context id="c63_From1Jan2008To31Dec2008_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="c64_From1Jan2008To31Dec2008_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="c65_From1Jan2008To31Dec2008">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="c66_From1Jan2008To31Dec2008_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="c67_AsOf31Dec2008_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="c68_AsOf31Dec2008_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="c69_AsOf31Dec2008_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="c70_AsOf31Dec2008">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="c71_From1Jan2009To31Dec2009_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c72_From1Jan2009To31Dec2009_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c73_From1Jan2009To31Dec2009_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="c74_AsOf31Dec2009_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="c75_AsOf31Dec2009_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="c76_AsOf31Dec2009_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="c77_AsOf31Dec2009">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="c78_From1Jan2010To31Dec2010_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c79_From1Jan2010To31Dec2010_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c80_From1Jan2010To31Dec2010_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="c81_AsOf31Dec2010_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c82_AsOf31Dec2010_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c83_AsOf31Dec2010_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="c84_From1Jan2011To31Dec2011_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c85_From1Jan2011To31Dec2011_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c86_From1Jan2011To31Dec2011_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="c87_AsOf31Dec2011_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c88_AsOf31Dec2011_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c89_AsOf31Dec2011_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="c90_AsOf30Mar2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <instant>2012-03-30</instant>
    </period>
  </context>
  <context id="c91_AsOf30Jun2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <unit id="usd">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="usdPerShare">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="shares">
    <measure>xbrli:shares</measure>
  </unit>
  <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="ftnt_0" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities: In connection with the Merger discussed in Note 5, all of the outstanding shares of the Company&apos;s mandatory redeemable convertible preferred stock were converted into shares of common stock as of September 28, 2006.</link:footnote>
    <link:loc xlink:type="locator" xlink:label="_CashAndCashEquivalentsPeriodIncreaseDecrease-c2_From1Jan2011To31Dec2011" xlink:href="#_CashAndCashEquivalentsPeriodIncreaseDecrease-c2_From1Jan2011To31Dec2011"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_CashAndCashEquivalentsPeriodIncreaseDecrease-c2_From1Jan2011To31Dec2011" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_CashAndCashEquivalentsPeriodIncreaseDecrease-c3_From1Jan2010To31Dec2010" xlink:href="#_CashAndCashEquivalentsPeriodIncreaseDecrease-c3_From1Jan2010To31Dec2010"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_CashAndCashEquivalentsPeriodIncreaseDecrease-c3_From1Jan2010To31Dec2010" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_CashAndCashEquivalentsPeriodIncreaseDecrease-c4_From1Jan2009To31Dec2009" xlink:href="#_CashAndCashEquivalentsPeriodIncreaseDecrease-c4_From1Jan2009To31Dec2009"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_CashAndCashEquivalentsPeriodIncreaseDecrease-c4_From1Jan2009To31Dec2009" xlink:to="ftnt_0" order="1"/>
    <link:loc xlink:type="locator" xlink:label="_CashAndCashEquivalentsPeriodIncreaseDecrease-c5_From27Jun2001To31Dec2011" xlink:href="#_CashAndCashEquivalentsPeriodIncreaseDecrease-c5_From27Jun2001To31Dec2011"/>
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="_CashAndCashEquivalentsPeriodIncreaseDecrease-c5_From27Jun2001To31Dec2011" xlink:to="ftnt_0" order="1"/>
  </link:footnoteLink>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c0_AsOf31Dec2011" decimals="0">1167980</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c1_AsOf31Dec2010" decimals="0">1079087</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:GrantsReceivable unitRef="usd" contextRef="c0_AsOf31Dec2011" decimals="0">183515</us-gaap:GrantsReceivable>
  <us-gaap:GrantsReceivable unitRef="usd" contextRef="c1_AsOf31Dec2010" decimals="0">474275</us-gaap:GrantsReceivable>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c0_AsOf31Dec2011" decimals="0">66508</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c1_AsOf31Dec2010" decimals="0">48830</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c0_AsOf31Dec2011" decimals="0">1418003</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c1_AsOf31Dec2010" decimals="0">1602192</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c0_AsOf31Dec2011" decimals="0">176206</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c1_AsOf31Dec2010" decimals="0">248441</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet unitRef="usd" contextRef="c0_AsOf31Dec2011" decimals="0">39923</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet unitRef="usd" contextRef="c1_AsOf31Dec2010" decimals="0">64809</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization unitRef="usd" contextRef="c0_AsOf31Dec2011" decimals="0">208933</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization unitRef="usd" contextRef="c1_AsOf31Dec2010" decimals="0">184047</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:DeferredFinanceCostsNoncurrentNet unitRef="usd" contextRef="c1_AsOf31Dec2010" decimals="0">430402</us-gaap:DeferredFinanceCostsNoncurrentNet>
  <us-gaap:DepositsAssetsNoncurrent unitRef="usd" contextRef="c0_AsOf31Dec2011" decimals="0">11010</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:DepositsAssetsNoncurrent unitRef="usd" contextRef="c1_AsOf31Dec2010" decimals="0">11990</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent unitRef="usd" contextRef="c0_AsOf31Dec2011" decimals="0">50933</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent unitRef="usd" contextRef="c1_AsOf31Dec2010" decimals="0">507201</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets unitRef="usd" contextRef="c0_AsOf31Dec2011" decimals="0">1645142</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c1_AsOf31Dec2010" decimals="0">2357834</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c0_AsOf31Dec2011" decimals="0">138339</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c1_AsOf31Dec2010" decimals="0">96892</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c0_AsOf31Dec2011" decimals="0">125869</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2010" decimals="0">241736</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:DueToRelatedPartiesCurrent unitRef="usd" contextRef="c0_AsOf31Dec2011" decimals="0">677327</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:DueToRelatedPartiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2010" decimals="0">182980</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c0_AsOf31Dec2011" decimals="0">941535</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c1_AsOf31Dec2010" decimals="0">521608</us-gaap:LiabilitiesCurrent>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c0_AsOf31Dec2011" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c1_AsOf31Dec2010" xs:nil="true"/>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c0_AsOf31Dec2011" decimals="0">16443</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c1_AsOf31Dec2010" decimals="0">15655</us-gaap:CommonStockValue>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPerShare" contextRef="c0_AsOf31Dec2011" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPerShare" contextRef="c1_AsOf31Dec2010" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c0_AsOf31Dec2011" decimals="INF">40000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c1_AsOf31Dec2010" decimals="INF">40000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c0_AsOf31Dec2011" decimals="INF">16442611</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c1_AsOf31Dec2010" decimals="INF">15654846</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c0_AsOf31Dec2011" decimals="INF">16442611</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c1_AsOf31Dec2010" decimals="INF">15632564</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:AdditionalPaidInCapitalCommonStock unitRef="usd" contextRef="c0_AsOf31Dec2011" decimals="0">23319166</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock unitRef="usd" contextRef="c1_AsOf31Dec2010" decimals="0">22105747</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage unitRef="usd" contextRef="c0_AsOf31Dec2011" decimals="0">22632002</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage unitRef="usd" contextRef="c1_AsOf31Dec2010" decimals="0">20285176</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c0_AsOf31Dec2011" decimals="0">703607</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c1_AsOf31Dec2010" decimals="0">1836226</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c0_AsOf31Dec2011" decimals="0">1645142</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c1_AsOf31Dec2010" decimals="0">2357834</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:RevenueFromGrants unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">4899885</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueFromGrants unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">5185257</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueFromGrants unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">3668195</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueFromGrants unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">20311692</us-gaap:RevenueFromGrants>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">4276375</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">4793956</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">4068682</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">25630676</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">2972555</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">3162134</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">2914845</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">17647659</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">7248930</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">7956090</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">6983527</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">43278335</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">-2349045</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">-2770833</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">-3315332</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">-22966643</us-gaap:OperatingIncomeLoss>
  <us-gaap:InvestmentIncomeInterest unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">2219</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">23505</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">31080</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">340310</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InterestExpense unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">5669</us-gaap:InterestExpense>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">2219</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">23505</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">31080</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">334641</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">-2346826</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">-2747328</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">-3284252</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">-22632002</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPerShare" contextRef="c2_From1Jan2011To31Dec2011" decimals="2">-0.15</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPerShare" contextRef="c3_From1Jan2010To31Dec2010" decimals="2">-0.18</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPerShare" contextRef="c4_From1Jan2009To31Dec2009" decimals="2">-0.22</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPerShare" contextRef="c5_From27Jun2001To31Dec2011" decimals="2">-2.11</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic unitRef="shares" contextRef="c2_From1Jan2011To31Dec2011" decimals="INF">15735541</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic unitRef="shares" contextRef="c3_From1Jan2010To31Dec2010" decimals="INF">15651308</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic unitRef="shares" contextRef="c4_From1Jan2009To31Dec2009" decimals="INF">15191278</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic unitRef="shares" contextRef="c5_From27Jun2001To31Dec2011" decimals="INF">10704803</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <govx:AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception unitRef="usd" contextRef="c6_From27Jun2001To31Dec2001_AdditionalPaidInCapitalMember" decimals="0">10</govx:AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception>
  <govx:AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception unitRef="usd" contextRef="c7_From27Jun2001To31Dec2001" decimals="0">10</govx:AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c8_From27Jun2001To31Dec2001_RetainedEarningsMember" decimals="0">-170592</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c7_From27Jun2001To31Dec2001" decimals="0">-170592</us-gaap:NetIncomeLoss>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c9_AsOf31Dec2001_AdditionalPaidInCapitalMember" decimals="0">10</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c10_AsOf31Dec2001_RetainedEarningsMember" decimals="0">-170592</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c11_AsOf31Dec2001" decimals="0">-170582</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c12_From1Jan2002To31Dec2002_CommonStockMember" decimals="INF">2789954</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c12_From1Jan2002To31Dec2002_CommonStockMember" decimals="0">2790</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c13_From1Jan2002To31Dec2002_AdditionalPaidInCapitalMember" decimals="0">-2320</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c14_From1Jan2002To31Dec2002" decimals="0">470</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets unitRef="shares" contextRef="c12_From1Jan2002To31Dec2002_CommonStockMember" decimals="INF">704534</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets unitRef="usd" contextRef="c12_From1Jan2002To31Dec2002_CommonStockMember" decimals="0">705</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets unitRef="usd" contextRef="c13_From1Jan2002To31Dec2002_AdditionalPaidInCapitalMember" decimals="0">148151</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets unitRef="usd" contextRef="c14_From1Jan2002To31Dec2002" decimals="0">148856</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c15_From1Jan2002To31Dec2002_RetainedEarningsMember" decimals="0">-618137</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c14_From1Jan2002To31Dec2002" decimals="0">-618137</us-gaap:NetIncomeLoss>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c16_AsOf31Dec2002_CommonStockMember" decimals="INF">3494488</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c16_AsOf31Dec2002_CommonStockMember" decimals="0">3495</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c17_AsOf31Dec2002_AdditionalPaidInCapitalMember" decimals="0">145841</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c18_AsOf31Dec2002_RetainedEarningsMember" decimals="0">-788729</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c19_AsOf31Dec2002" decimals="0">-639393</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c20_From1Jan2003To31Dec2003_CommonStockMember" decimals="INF">1229278</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c20_From1Jan2003To31Dec2003_CommonStockMember" decimals="0">1229</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c21_From1Jan2003To31Dec2003_AdditionalPaidInCapitalMember" decimals="0">2458380</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c22_From1Jan2003To31Dec2003" decimals="0">2459609</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c23_From1Jan2003To31Dec2003_RetainedEarningsMember" decimals="0">-947804</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c22_From1Jan2003To31Dec2003" decimals="0">-947804</us-gaap:NetIncomeLoss>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c24_AsOf31Dec2003_CommonStockMember" decimals="INF">4723766</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c24_AsOf31Dec2003_CommonStockMember" decimals="0">4724</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c25_AsOf31Dec2003_AdditionalPaidInCapitalMember" decimals="0">2604221</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c26_AsOf31Dec2003_RetainedEarningsMember" decimals="0">-1736533</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c27_AsOf31Dec2003" decimals="0">872412</us-gaap:StockholdersEquity>
  <govx:StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable unitRef="shares" contextRef="c28_From1Jan2004To31Dec2004_CommonStockMember" decimals="INF">1482605</govx:StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable>
  <govx:StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable unitRef="usd" contextRef="c28_From1Jan2004To31Dec2004_CommonStockMember" decimals="0">1483</govx:StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable>
  <govx:StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable unitRef="usd" contextRef="c29_From1Jan2004To31Dec2004_AdditionalPaidInCapitalMember" decimals="0">2988436</govx:StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable>
  <govx:StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable unitRef="usd" contextRef="c30_From1Jan2004To31Dec2004_StockSubscriptionReceivableMember" decimals="0">-2750000</govx:StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable>
  <govx:StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable unitRef="usd" contextRef="c31_From1Jan2004To31Dec2004" decimals="0">239919</govx:StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c30_From1Jan2004To31Dec2004_StockSubscriptionReceivableMember" decimals="0">750000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c31_From1Jan2004To31Dec2004" decimals="0">750000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets unitRef="shares" contextRef="c28_From1Jan2004To31Dec2004_CommonStockMember" decimals="INF">49420</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets unitRef="usd" contextRef="c28_From1Jan2004To31Dec2004_CommonStockMember" decimals="0">49</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets unitRef="usd" contextRef="c29_From1Jan2004To31Dec2004_AdditionalPaidInCapitalMember" decimals="0">99951</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets unitRef="usd" contextRef="c31_From1Jan2004To31Dec2004" decimals="0">100000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c32_From1Jan2004To31Dec2004_RetainedEarningsMember" decimals="0">-2351828</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c31_From1Jan2004To31Dec2004" decimals="0">-2351828</us-gaap:NetIncomeLoss>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c33_AsOf31Dec2004_CommonStockMember" decimals="INF">6255791</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c33_AsOf31Dec2004_CommonStockMember" decimals="0">6256</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c34_AsOf31Dec2004_AdditionalPaidInCapitalMember" decimals="0">5692608</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c35_AsOf31Dec2004_StockSubscriptionReceivableMember" decimals="0">-2000000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c36_AsOf31Dec2004_RetainedEarningsMember" decimals="0">-4088361</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c37_AsOf31Dec2004" decimals="0">-389497</us-gaap:StockholdersEquity>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c38_From1Jan2005To31Dec2005_StockSubscriptionReceivableMember" decimals="0">1500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c39_From1Jan2005To31Dec2005" decimals="0">1500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c40_From1Jan2005To31Dec2005_RetainedEarningsMember" decimals="0">-1611086</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c39_From1Jan2005To31Dec2005" decimals="0">-1611086</us-gaap:NetIncomeLoss>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c41_AsOf31Dec2005_CommonStockMember" decimals="INF">6255791</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c41_AsOf31Dec2005_CommonStockMember" decimals="0">6256</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c42_AsOf31Dec2005_AdditionalPaidInCapitalMember" decimals="0">5692608</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c43_AsOf31Dec2005_StockSubscriptionReceivableMember" decimals="0">-500000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c44_AsOf31Dec2005_RetainedEarningsMember" decimals="0">-5699447</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c45_AsOf31Dec2005" decimals="0">-500583</us-gaap:StockholdersEquity>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c46_From1Jan2006To31Dec2006_StockSubscriptionReceivableMember" decimals="0">500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c47_From1Jan2006To31Dec2006" decimals="0">500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities unitRef="shares" contextRef="c48_From1Jan2006To31Dec2006_CommonStockMember" decimals="INF">3550851</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities unitRef="usd" contextRef="c48_From1Jan2006To31Dec2006_CommonStockMember" decimals="0">3551</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities unitRef="usd" contextRef="c49_From1Jan2006To31Dec2006_AdditionalPaidInCapitalMember" decimals="0">1071565</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities unitRef="usd" contextRef="c47_From1Jan2006To31Dec2006" decimals="0">1075116</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions unitRef="shares" contextRef="c48_From1Jan2006To31Dec2006_CommonStockMember" decimals="INF">4359891</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions unitRef="usd" contextRef="c48_From1Jan2006To31Dec2006_CommonStockMember" decimals="0">4360</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions unitRef="usd" contextRef="c49_From1Jan2006To31Dec2006_AdditionalPaidInCapitalMember" decimals="0">1708489</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions unitRef="usd" contextRef="c47_From1Jan2006To31Dec2006" decimals="0">1712849</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <govx:StockIssuedDuringPeriodSharesCashlessWarrantExercise unitRef="usd" contextRef="c48_From1Jan2006To31Dec2006_CommonStockMember" decimals="0">56825</govx:StockIssuedDuringPeriodSharesCashlessWarrantExercise>
  <govx:StockIssuedDuringPeriodValueCashlessWarrantExercise unitRef="usd" contextRef="c48_From1Jan2006To31Dec2006_CommonStockMember" decimals="0">57</govx:StockIssuedDuringPeriodValueCashlessWarrantExercise>
  <govx:StockIssuedDuringPeriodValueCashlessWarrantExercise unitRef="usd" contextRef="c49_From1Jan2006To31Dec2006_AdditionalPaidInCapitalMember" decimals="0">-57</govx:StockIssuedDuringPeriodValueCashlessWarrantExercise>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c50_From1Jan2006To31Dec2006_RetainedEarningsMember" decimals="0">-584166</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c47_From1Jan2006To31Dec2006" decimals="0">-584166</us-gaap:NetIncomeLoss>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c51_AsOf31Dec2006_CommonStockMember" decimals="INF">14223358</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c51_AsOf31Dec2006_CommonStockMember" decimals="0">14224</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c52_AsOf31Dec2006_AdditionalPaidInCapitalMember" decimals="0">8472605</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c53_AsOf31Dec2006_RetainedEarningsMember" decimals="0">-6283613</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c54_AsOf31Dec2006" decimals="0">2203216</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c55_From1Jan2007To31Dec2007_CommonStockMember" decimals="INF">406729</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c55_From1Jan2007To31Dec2007_CommonStockMember" decimals="0">407</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c56_From1Jan2007To31Dec2007_AdditionalPaidInCapitalMember" decimals="0">3162543</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c57_From1Jan2007To31Dec2007" decimals="0">3162950</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c55_From1Jan2007To31Dec2007_CommonStockMember" decimals="INF">2471</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c55_From1Jan2007To31Dec2007_CommonStockMember" decimals="0">2</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c56_From1Jan2007To31Dec2007_AdditionalPaidInCapitalMember" decimals="0">4998</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c57_From1Jan2007To31Dec2007" decimals="0">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue unitRef="usd" contextRef="c56_From1Jan2007To31Dec2007_AdditionalPaidInCapitalMember" decimals="0">1518496</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue unitRef="usd" contextRef="c57_From1Jan2007To31Dec2007" decimals="0">1518496</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c58_From1Jan2007To31Dec2007_RetainedEarningsMember" decimals="0">-4241796</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c57_From1Jan2007To31Dec2007" decimals="0">-4241796</us-gaap:NetIncomeLoss>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c59_AsOf31Dec2007_CommonStockMember" decimals="INF">14632558</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c59_AsOf31Dec2007_CommonStockMember" decimals="0">14633</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c60_AsOf31Dec2007_AdditionalPaidInCapitalMember" decimals="0">13158642</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c61_AsOf31Dec2007_RetainedEarningsMember" decimals="0">-10525409</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c62_AsOf31Dec2007" decimals="0">2647866</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c63_From1Jan2008To31Dec2008_CommonStockMember" decimals="INF">176129</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c63_From1Jan2008To31Dec2008_CommonStockMember" decimals="0">176</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c64_From1Jan2008To31Dec2008_AdditionalPaidInCapitalMember" decimals="0">1364824</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c65_From1Jan2008To31Dec2008" decimals="0">1365000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesOther unitRef="shares" contextRef="c63_From1Jan2008To31Dec2008_CommonStockMember" decimals="INF">130290</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c63_From1Jan2008To31Dec2008_CommonStockMember" decimals="0">130</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c64_From1Jan2008To31Dec2008_AdditionalPaidInCapitalMember" decimals="0">405961</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c65_From1Jan2008To31Dec2008" decimals="0">406091</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition unitRef="usd" contextRef="c64_From1Jan2008To31Dec2008_AdditionalPaidInCapitalMember" decimals="0">1798169</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition unitRef="usd" contextRef="c65_From1Jan2008To31Dec2008" decimals="0">1798169</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued unitRef="usd" contextRef="c64_From1Jan2008To31Dec2008_AdditionalPaidInCapitalMember" decimals="0">146880</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued unitRef="usd" contextRef="c65_From1Jan2008To31Dec2008" decimals="0">146880</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation unitRef="shares" contextRef="c63_From1Jan2008To31Dec2008_CommonStockMember" decimals="INF">10000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c63_From1Jan2008To31Dec2008_CommonStockMember" decimals="0">10</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c64_From1Jan2008To31Dec2008_AdditionalPaidInCapitalMember" decimals="0">73990</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c65_From1Jan2008To31Dec2008" decimals="0">74000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c66_From1Jan2008To31Dec2008_RetainedEarningsMember" decimals="0">-3728187</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c65_From1Jan2008To31Dec2008" decimals="0">-3728187</us-gaap:NetIncomeLoss>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c67_AsOf31Dec2008_CommonStockMember" decimals="INF">14948977</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c67_AsOf31Dec2008_CommonStockMember" decimals="0">14949</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c68_AsOf31Dec2008_AdditionalPaidInCapitalMember" decimals="0">16948466</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c69_AsOf31Dec2008_RetainedEarningsMember" decimals="0">-14253596</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c70_AsOf31Dec2008" decimals="0">2709819</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesOther unitRef="shares" contextRef="c71_From1Jan2009To31Dec2009_CommonStockMember" decimals="INF">216261</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c71_From1Jan2009To31Dec2009_CommonStockMember" decimals="0">216</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c72_From1Jan2009To31Dec2009_AdditionalPaidInCapitalMember" decimals="0">1519784</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">1520000</us-gaap:StockIssuedDuringPeriodValueOther>
  <govx:StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant unitRef="shares" contextRef="c71_From1Jan2009To31Dec2009_CommonStockMember" decimals="INF">462826</govx:StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant>
  <govx:StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant unitRef="usd" contextRef="c71_From1Jan2009To31Dec2009_CommonStockMember" decimals="0">463</govx:StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant>
  <govx:StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant unitRef="usd" contextRef="c72_From1Jan2009To31Dec2009_AdditionalPaidInCapitalMember" decimals="0">1499537</govx:StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant>
  <govx:StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">1500000</govx:StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition unitRef="usd" contextRef="c72_From1Jan2009To31Dec2009_AdditionalPaidInCapitalMember" decimals="0">1221764</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">1221764</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued unitRef="usd" contextRef="c72_From1Jan2009To31Dec2009_AdditionalPaidInCapitalMember" decimals="0">45401</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">45401</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation unitRef="shares" contextRef="c71_From1Jan2009To31Dec2009_CommonStockMember" decimals="INF">4500</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c71_From1Jan2009To31Dec2009_CommonStockMember" decimals="0">5</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c72_From1Jan2009To31Dec2009_AdditionalPaidInCapitalMember" decimals="0">31495</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">31500</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c73_From1Jan2009To31Dec2009_RetainedEarningsMember" decimals="0">-3284252</us-gaap:NetIncomeLoss>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c74_AsOf31Dec2009_CommonStockMember" decimals="INF">15632564</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c74_AsOf31Dec2009_CommonStockMember" decimals="0">15633</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c75_AsOf31Dec2009_AdditionalPaidInCapitalMember" decimals="0">21266447</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c76_AsOf31Dec2009_RetainedEarningsMember" decimals="0">-17537848</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c77_AsOf31Dec2009" decimals="0">3744232</us-gaap:StockholdersEquity>
  <govx:StockIssuedDuringPeriodSharesInLieuOfCashPayment unitRef="shares" contextRef="c78_From1Jan2010To31Dec2010_CommonStockMember" decimals="INF">12000</govx:StockIssuedDuringPeriodSharesInLieuOfCashPayment>
  <govx:StockIssuedDuringPeriodValueInLieuOfCashPayment unitRef="usd" contextRef="c78_From1Jan2010To31Dec2010_CommonStockMember" decimals="0">12</govx:StockIssuedDuringPeriodValueInLieuOfCashPayment>
  <govx:StockIssuedDuringPeriodValueInLieuOfCashPayment unitRef="usd" contextRef="c79_From1Jan2010To31Dec2010_AdditionalPaidInCapitalMember" decimals="0">89988</govx:StockIssuedDuringPeriodValueInLieuOfCashPayment>
  <govx:StockIssuedDuringPeriodValueInLieuOfCashPayment unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">90000</govx:StockIssuedDuringPeriodValueInLieuOfCashPayment>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition unitRef="usd" contextRef="c79_From1Jan2010To31Dec2010_AdditionalPaidInCapitalMember" decimals="0">575662</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">575662</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued unitRef="usd" contextRef="c79_From1Jan2010To31Dec2010_AdditionalPaidInCapitalMember" decimals="0">121057</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">121057</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation unitRef="shares" contextRef="c78_From1Jan2010To31Dec2010_CommonStockMember" decimals="INF">10500</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c78_From1Jan2010To31Dec2010_CommonStockMember" decimals="0">10</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c79_From1Jan2010To31Dec2010_AdditionalPaidInCapitalMember" decimals="0">53803</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">53813</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits unitRef="shares" contextRef="c78_From1Jan2010To31Dec2010_CommonStockMember" decimals="INF">-218</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit unitRef="usd" contextRef="c79_From1Jan2010To31Dec2010_AdditionalPaidInCapitalMember" decimals="0">-1210</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">-1210</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c80_From1Jan2010To31Dec2010_RetainedEarningsMember" decimals="0">-2747328</us-gaap:NetIncomeLoss>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c81_AsOf31Dec2010_CommonStockMember" decimals="INF">15654846</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c81_AsOf31Dec2010_CommonStockMember" decimals="0">15655</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c82_AsOf31Dec2010_AdditionalPaidInCapitalMember" decimals="0">22105747</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c83_AsOf31Dec2010_RetainedEarningsMember" decimals="0">-20285176</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c84_From1Jan2011To31Dec2011_CommonStockMember" decimals="INF">658520</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c84_From1Jan2011To31Dec2011_CommonStockMember" decimals="0">659</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c85_From1Jan2011To31Dec2011_AdditionalPaidInCapitalMember" decimals="0">440551</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">441210</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition unitRef="usd" contextRef="c85_From1Jan2011To31Dec2011_AdditionalPaidInCapitalMember" decimals="0">463752</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">463752</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued unitRef="usd" contextRef="c85_From1Jan2011To31Dec2011_AdditionalPaidInCapitalMember" decimals="0">159245</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">159245</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation unitRef="shares" contextRef="c84_From1Jan2011To31Dec2011_CommonStockMember" decimals="INF">129245</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c84_From1Jan2011To31Dec2011_CommonStockMember" decimals="0">129</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c85_From1Jan2011To31Dec2011_AdditionalPaidInCapitalMember" decimals="0">149871</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">150000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c86_From1Jan2011To31Dec2011_RetainedEarningsMember" decimals="0">-2346826</us-gaap:NetIncomeLoss>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c87_AsOf31Dec2011_CommonStockMember" decimals="INF">16442611</us-gaap:SharesIssued>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c87_AsOf31Dec2011_CommonStockMember" decimals="0">16443</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c88_AsOf31Dec2011_AdditionalPaidInCapitalMember" decimals="0">23319166</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c89_AsOf31Dec2011_RetainedEarningsMember" decimals="0">-22632002</us-gaap:StockholdersEquity>
  <us-gaap:DepreciationDepletionAndAmortization unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">109017</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">119773</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">89776</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">565637</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">346673</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">772997</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">750532</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">1298665</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">6359739</us-gaap:ShareBasedCompensation>
  <us-gaap:AmortizationOfDeferredCharges unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">430402</us-gaap:AmortizationOfDeferredCharges>
  <us-gaap:AmortizationOfDeferredCharges unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">430402</us-gaap:AmortizationOfDeferredCharges>
  <us-gaap:IncreaseDecreaseInReceivables unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">-290760</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInReceivables unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">153954</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInReceivables unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">8953</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInReceivables unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">183515</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">-19122</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">4215</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">-254671</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">29708</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInDepositOtherAssets unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">-980</us-gaap:IncreaseDecreaseInDepositOtherAssets>
  <us-gaap:IncreaseDecreaseInDepositOtherAssets unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">11010</us-gaap:IncreaseDecreaseInDepositOtherAssets>
  <us-gaap:IncreaseDecreaseInDepositOtherAssets unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">11010</us-gaap:IncreaseDecreaseInDepositOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">419927</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">39033</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">224943</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">1030325</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">2043205</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
  <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">740159</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
  <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">1859102</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
  <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">8508543</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">-303621</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">-2007169</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">-1425150</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">-14123459</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">11896</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">4706</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">270246</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">538490</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">5580</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">5580</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">-11896</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">874</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">-270246</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">-532910</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">404410</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">3020000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">15526308</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">728443</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:PaymentsOfStockIssuanceCosts unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">430402</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">430402</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">404410</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">-430402</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">3020000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">15824349</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="_CashAndCashEquivalentsPeriodIncreaseDecrease-c2_From1Jan2011To31Dec2011" unitRef="usd" contextRef="c2_From1Jan2011To31Dec2011" decimals="0">88893</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="_CashAndCashEquivalentsPeriodIncreaseDecrease-c3_From1Jan2010To31Dec2010" unitRef="usd" contextRef="c3_From1Jan2010To31Dec2010" decimals="0">-2436697</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="_CashAndCashEquivalentsPeriodIncreaseDecrease-c4_From1Jan2009To31Dec2009" unitRef="usd" contextRef="c4_From1Jan2009To31Dec2009" decimals="0">1324604</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="_CashAndCashEquivalentsPeriodIncreaseDecrease-c5_From27Jun2001To31Dec2011" unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">1167980</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c77_AsOf31Dec2009" decimals="0">3515784</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c70_AsOf31Dec2008" decimals="0">2191180</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:InterestPaid unitRef="usd" contextRef="c5_From27Jun2001To31Dec2011" decimals="0">5669</us-gaap:InterestPaid>
  <dei:EntityRegistrantName contextRef="c2_From1Jan2011To31Dec2011">GeoVax Labs, Inc.</dei:EntityRegistrantName>
  <dei:DocumentType contextRef="c2_From1Jan2011To31Dec2011">S-1</dei:DocumentType>
  <dei:CurrentFiscalYearEndDate contextRef="c2_From1Jan2011To31Dec2011">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityCommonStockSharesOutstanding unitRef="shares" contextRef="c90_AsOf30Mar2012" decimals="INF">16850610</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityPublicFloat unitRef="usd" contextRef="c91_AsOf30Jun2011" decimals="0">8741870</dei:EntityPublicFloat>
  <dei:AmendmentFlag contextRef="c2_From1Jan2011To31Dec2011">false</dei:AmendmentFlag>
  <dei:EntityCentralIndexKey contextRef="c2_From1Jan2011To31Dec2011">0000832489</dei:EntityCentralIndexKey>
  <dei:EntityCurrentReportingStatus contextRef="c2_From1Jan2011To31Dec2011">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityVoluntaryFilers contextRef="c2_From1Jan2011To31Dec2011">No</dei:EntityVoluntaryFilers>
  <dei:EntityFilerCategory contextRef="c2_From1Jan2011To31Dec2011">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:EntityWellKnownSeasonedIssuer contextRef="c2_From1Jan2011To31Dec2011">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:DocumentFiscalYearFocus contextRef="c2_From1Jan2011To31Dec2011">2011</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus contextRef="c2_From1Jan2011To31Dec2011">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentPeriodEndDate contextRef="c2_From1Jan2011To31Dec2011">2011-12-31</dei:DocumentPeriodEndDate>
  <us-gaap:NatureOfOperations contextRef="c2_From1Jan2011To31Dec2011">&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;justify&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;1.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Nature&#xd;
        of Business&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;GeoVax&#xd;
        Labs, Inc. (&amp;#8220;GeoVax&amp;#8221; or the&#xd;
        &amp;#8220;Company&amp;#8221;), is a biotechnology company&#xd;
        developing vaccines that prevent and fight Human&#xd;
        Immunodeficiency Virus (&amp;#8220;HIV&amp;#8221;)&#xd;
        infections.&amp;#160;&amp;#160;HIV infections result in Acquired&#xd;
        Immunodeficiency Syndrome&#xd;
        (&amp;#8220;AIDS&amp;#8221;).&amp;#160;&amp;#160;We have exclusively&#xd;
        licensed from Emory University (&amp;#8220;Emory&amp;#8221;)&#xd;
        vaccine technology which was developed in collaboration&#xd;
        with the National Institutes of Health (&amp;#8220;NIH&amp;#8221;)&#xd;
        and the Centers for Disease Control and Prevention&#xd;
        (&amp;#8220;CDC&amp;#8221;).&amp;#160;&amp;#160;GeoVax is incorporated&#xd;
        under the laws of the State of Delaware and our principal&#xd;
        offices are located in Smyrna, Georgia (metropolitan&#xd;
        Atlanta area).&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Our&#xd;
        current vaccines under development address the clade B&#xd;
        subtype of the HIV virus that is most prevalent in the&#xd;
        United States and the developed world.&amp;#160;&amp;#160;Our&#xd;
        vaccines are being evaluated to determine their potential&#xd;
        to (a) prevent HIV infection and (b) to serve as a therapy&#xd;
        for individuals who are already infected with&#xd;
        HIV.&amp;#160;&amp;#160;These vaccines are currently being&#xd;
        evaluated in humans -- both in those infected with HIV and&#xd;
        those who are not.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;As&#xd;
        discussed in Note 2, the Company is a development-stage&#xd;
        enterprise and we are devoting substantially all of our&#xd;
        present efforts to research and development.&amp;#160;&amp;#160;We&#xd;
        have funded our activities to date almost exclusively from&#xd;
        equity financings and government grants, and we will&#xd;
        continue to require substantial funds to continue these&#xd;
        activities.&amp;#160;&amp;#160;We anticipate that our existing cash&#xd;
        resources, combined with the proceeds from the NIH grant&#xd;
        discussed in Note 3 and the financing events discussed in&#xd;
        Note 11, should be sufficient to fund our planned&#xd;
        activities into the first quarter of 2013.&amp;#160;&amp;#160;In&#xd;
        order to meet our operating cash flow requirements, we may&#xd;
        plan additional offerings of our equity securities, debt or&#xd;
        convertible debt instruments. We are also seeking&#xd;
        additional funding for our research programs through&#xd;
        government grant funding mechanisms.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;</us-gaap:NatureOfOperations>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c2_From1Jan2011To31Dec2011">&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;2.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Summary&#xd;
        of Significant Accounting Policies&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Basis&#xd;
        of Presentation and Principles of Consolidation&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Our&#xd;
        primary business is conducted by our wholly-owned&#xd;
        subsidiary, GeoVax, Inc. The accompanying consolidated&#xd;
        financial statements include the accounts of GeoVax, Inc.&#xd;
        from inception together with those of GeoVax Labs, Inc.&#xd;
        from September 28, 2006 (see Note 5).&amp;#160;&amp;#160;All&#xd;
        intercompany transactions have been eliminated in&#xd;
        consolidation.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Development-Stage&#xd;
        Enterprise&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;We&#xd;
        are devoting all of our present efforts to research and&#xd;
        development and GeoVax is a development stage enterprise as&#xd;
        defined by Financial Accounting Standards Board&#xd;
        (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification&#xd;
        (&amp;#8220;ASC&amp;#8221;) Topic 915, &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Development&#xd;
        Stage Entities&lt;/font&gt;.&amp;#160;&amp;#160;All losses accumulated&#xd;
        since inception (June 27, 2001) have been considered as&#xd;
        part of our development stage activities.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Use&#xd;
        of Estimates&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The&#xd;
        preparation of financial statements in conformity with&#xd;
        accounting principles generally accepted in the United&#xd;
        States of America (&amp;#8220;GAAP&amp;#8221;) requires us to make&#xd;
        estimates and assumptions that affect the reported amounts&#xd;
        of assets and liabilities and disclosure of contingent&#xd;
        assets and liabilities at the date of the financial&#xd;
        statements and the reported amounts of revenues and&#xd;
        expenses during the reporting period.&amp;#160;&amp;#160;Actual&#xd;
        results may differ from those estimates.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Cash&#xd;
        and Cash Equivalents&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;We&#xd;
        consider all highly liquid investments with a maturity of&#xd;
        three months or less when purchased to be cash&#xd;
        equivalents.&amp;#160;&amp;#160;Our cash and cash equivalents&#xd;
        consist primarily of bank deposits and money market&#xd;
        accounts.&amp;#160;&amp;#160;The recorded values approximate fair&#xd;
        market values due to the short maturities.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Fair&#xd;
        Value of Financial Instruments and Concentration of Credit&#xd;
        Risk&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Financial&#xd;
        instruments that subject us to concentration of credit risk&#xd;
        consist primarily of cash and cash equivalents, which are&#xd;
        maintained by a high credit quality financial institution.&#xd;
        The carrying values reported in the balance sheets for cash&#xd;
        and cash equivalents approximate fair values.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Property&#xd;
        and Equipment&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Property&#xd;
        and equipment are stated at cost, less accumulated&#xd;
        depreciation and amortization.&amp;#160;&amp;#160;The components of&#xd;
        property and equipment as of December 31, 2011 and 2010 are&#xd;
        as follows:&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2011&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2010&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;76%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Laboratory&#xd;
                equipment&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;388,000&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;388,000&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;76%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Leasehold&#xd;
                improvements&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;115,605&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;115,605&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;76%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Other&#xd;
                furniture, fixtures &amp;amp; equipment&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;28,685&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;16,789&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;76%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total&#xd;
                property and equipment&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;532,290&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;520,394&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;76%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Accumulated&#xd;
                depreciation and amortization&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(356,084&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(271,953&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;76%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Property&#xd;
                and equipment, net&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;176,206&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;248,441&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
        &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Expenditures&#xd;
        for maintenance and repairs are charged to operations as&#xd;
        incurred, while additions and improvements are&#xd;
        capitalized.&amp;#160;&amp;#160;Depreciation is computed using the&#xd;
        straight-line method over the estimated useful lives of the&#xd;
        assets which range from three to five&#xd;
        years.&amp;#160;&amp;#160;Amortization of leasehold improvements is&#xd;
        computed using the straight-line method over the remaining&#xd;
        term of the related lease.&amp;#160;&amp;#160;Depreciation and&#xd;
        amortization expense was $84,131, $94,887, and $64,891&#xd;
        during the years ended December 31, 2011, 2010 and 2009,&#xd;
        respectively.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Other&#xd;
        Assets&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Other&#xd;
        assets consist principally of license agreements for the&#xd;
        use of technology obtained through the issuance of the&#xd;
        Company&amp;#8217;s common stock.&amp;#160;&amp;#160;These license&#xd;
        agreements are amortized on a straight line basis over ten&#xd;
        years.&amp;#160;&amp;#160;Amortization expense related to these&#xd;
        agreements was $24,886 during each of the years ended&#xd;
        December 31, 2011, 2010 and 2009 and is expected to be&#xd;
        $19,923, $10,000, $10,000, $-0-, and $-0- for each of the&#xd;
        next five years, respectively.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Impairment&#xd;
        of Long-Lived Assets&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;We&#xd;
        review long-lived assets for impairment whenever events or&#xd;
        changes in circumstances indicate that the carrying amount&#xd;
        of an asset may not be&#xd;
        recoverable.&amp;#160;&amp;#160;Recoverability of assets to be held&#xd;
        and used is measured by a comparison of the carrying amount&#xd;
        of the assets to the future net cash flows expected to be&#xd;
        generated by such assets.&amp;#160;&amp;#160;If we consider such&#xd;
        assets to be impaired, the impairment to be&lt;font style=&quot;DISPLAY: inline; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;recognized&#xd;
        is measured by the amount by which the carrying amount of&#xd;
        the assets exceeds the expected future net cash flows from&#xd;
        the assets.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Accrued&#xd;
        Liabilities&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;As&#xd;
        part of the process of preparing our financial statements,&#xd;
        we estimate expenses that we believe we have incurred, but&#xd;
        have not yet been billed by our third party vendors. This&#xd;
        process involves identifying services and activities that&#xd;
        have been performed by such vendors on our behalf and&#xd;
        estimating the level to which they have been performed and&#xd;
        the associated cost incurred for such service as of each&#xd;
        balance sheet date in our financial statements. Examples of&#xd;
        expenses for which we accrue include fees for professional&#xd;
        services and fees owed to contract manufacturers in&#xd;
        conjunction with the manufacture of vaccines for our&#xd;
        clinical trials. We make these estimates based upon&#xd;
        progress of activities related to contractual obligations&#xd;
        and information received from vendors.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Net&#xd;
        Loss Per Share&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Basic&#xd;
        and diluted loss per common share are computed based on the&#xd;
        weighted average number of common shares outstanding. All&#xd;
        common share equivalents (which consist of options and&#xd;
        warrants) are excluded from the computation of diluted loss&#xd;
        per share since the effect would be anti-dilutive. Common&#xd;
        share equivalents which could potentially dilute basic&#xd;
        earnings per share in the future, and which were excluded&#xd;
        from the computation of diluted loss per share, totaled&#xd;
        2,798,801, 2,013,522, and 1,866,550 at December 31, 2011,&#xd;
        2010 and 2009, respectively.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Revenue&#xd;
        Recognition&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;We&#xd;
        recognize revenue in accordance with the SEC&amp;#8217;s Staff&#xd;
        Accounting Bulletin No. 101, &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Revenue&#xd;
        Recognition in Financial Statements,&lt;/font&gt; as amended by&#xd;
        Staff Accounting Bulletin No. 104, &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline&quot;&gt;Revenue&#xd;
        Recognition,&lt;/font&gt; (&amp;#8220;SAB 104&amp;#8221;). SAB 104&#xd;
        provides guidance in applying GAAP to revenue recognition&#xd;
        issues, and specifically addresses revenue recognition for&#xd;
        upfront, nonrefundable fees received in connection with&#xd;
        research collaboration agreements.&amp;#160;&amp;#160;During 2011,&#xd;
        2010 and 2009, our revenue consisted of grant funding&#xd;
        received primarily from the NIH (see Note&#xd;
        3).&amp;#160;&amp;#160;Revenue from this arrangement is&#xd;
        approximately equal to the costs incurred and is recorded&#xd;
        as income as the related costs are incurred.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Research&#xd;
        and Development Expense&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Research&#xd;
        and development expense primarily consists of costs&#xd;
        incurred in the discovery, development, testing and&#xd;
        manufacturing of our product candidates. These expenses&#xd;
        consist primarily of (i) fees paid to third-party service&#xd;
        providers to perform, monitor and accumulate data related&#xd;
        to our preclinical studies and clinical trials, (ii) costs&#xd;
        related to sponsored research agreements, (iii) the costs&#xd;
        to procure and manufacture materials used in clinical&#xd;
        trials, (iv) laboratory supplies and facility-related&#xd;
        expenses to conduct development, and (v) salaries,&#xd;
        benefits, and share-based compensation for&#xd;
        personnel.&amp;#160;&amp;#160;These costs are charged to expense as&#xd;
        incurred.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Patent&#xd;
        Costs&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Our&#xd;
        expenditures relating to obtaining and protecting patents&#xd;
        are charged to expense when incurred, and are included in&#xd;
        general and administrative expense.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Period&#xd;
        to Period Comparisons&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Our&#xd;
        operating results are expected to fluctuate for the&#xd;
        foreseeable future. Therefore, period-to-period comparisons&#xd;
        should not be relied upon as predictive of the results for&#xd;
        future periods.&amp;#160;&amp;#160;Certain prior year amounts have&#xd;
        been reclassified to conform to the current year financial&#xd;
        statement presentation.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Income&#xd;
        Taxes&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;We&#xd;
        account for income taxes using the liability method. Under&#xd;
        this method, deferred tax assets and liabilities are&#xd;
        recognized for the estimated future tax consequences&#xd;
        attributable to differences between the financial statement&#xd;
        carrying amounts of existing assets and liabilities and&#xd;
        their respective tax bases.&amp;#160;&amp;#160;Deferred tax assets&#xd;
        and liabilities are measured using enacted rates in effect&#xd;
        for the year in which temporary differences are expected to&#xd;
        be recovered or settled.&amp;#160;&amp;#160;Deferred tax assets are&#xd;
        reduced by a valuation allowance unless, in the opinion of&#xd;
        management, it is more likely than not that some portion or&#xd;
        all of the deferred tax assets will be realized.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Stock-Based&#xd;
        Compensation&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;We&#xd;
        account for stock-based transactions in which the Company&#xd;
        receives services from employees, directors or others in&#xd;
        exchange for equity instruments based on the fair value of&#xd;
        the award at the grant date.&amp;#160;&amp;#160;Compensation cost&#xd;
        for awards of common stock is estimated based on the price&#xd;
        of the underlying common stock on the date of&#xd;
        issuance.&amp;#160;&amp;#160;Compensation cost for stock options or&#xd;
        warrants is estimated at the grant date based on each&#xd;
        instrument&amp;#8217;s fair-value as calculated by the&#xd;
        Black-Scholes option pricing model.&amp;#160;&amp;#160;We recognize&#xd;
        stock-based compensation cost as expense ratably on a&#xd;
        straight-line basis over the requisite service period for&#xd;
        the award.&amp;#160;&amp;#160;See Note 6 for additional stock-based&#xd;
        compensation information.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Recent&#xd;
        Accounting Pronouncements&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;There&#xd;
        have been no recent accounting pronouncements or changes in&#xd;
        accounting pronouncements which we expect to have a&#xd;
        material impact on our financial statements, nor do we&#xd;
        believe that any recently issued, but not yet effective,&#xd;
        accounting standards if currently adopted would have a&#xd;
        material effect on our financial statements.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <govx:GovernmentGrantsTextBlock contextRef="c2_From1Jan2011To31Dec2011">&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;3.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Government&#xd;
        Grants&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;NIH&#xd;
        Grant&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In&#xd;
        September 2007, the NIH awarded us an Integrated&#xd;
        Preclinical/Clinical AIDS Vaccine Development (IPCAVD)&#xd;
        grant to support our HIV/AIDS vaccine&#xd;
        program.&amp;#160;&amp;#160;The project period for the grant covers&#xd;
        a five-year period which commenced October 2007, with an&#xd;
        aggregate award of $20.4 million.&amp;#160;&amp;#160;As of December&#xd;
        31, 2011, there is approximately $3.9 million of unused&#xd;
        grant funds remaining and available for use through August&#xd;
        31, 2012 (the end of the original project&#xd;
        period).&amp;#160;&amp;#160;We are utilizing this funding to&#xd;
        further our HIV/AIDS vaccine development, optimization and&#xd;
        production.&amp;#160;&amp;#160;We record revenue associated with&#xd;
        the grant as the related costs and expenses are incurred&#xd;
        and such revenue is reported as a separate line item in our&#xd;
        statements of operations.&amp;#160;&amp;#160;During 2011, 2010, and&#xd;
        2009, we recorded $4,899,885, $4,940,778, and $3,668,195,&#xd;
        respectively, of revenue associated with this grant.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;QTDP&#xd;
        Grant&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In&#xd;
        November 2010, we were awarded a one-time grant of $244,479&#xd;
        pursuant to the Qualifying Therapeutic Discovery Project&#xd;
        (QTDP) program enacted as part of the Patient Protection&#xd;
        and Affordable Care Act of 2010.&amp;#160;&amp;#160;The QTDP&#xd;
        program was intended to provide incentive to smaller&#xd;
        companies who are focusing on innovative therapeutic&#xd;
        discoveries.&amp;#160;&amp;#160;We received the full amount of the&#xd;
        grant during 2010, which is recorded as revenue for 2010 in&#xd;
        the accompanying Consolidated Statement of&#xd;
        Operations.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;</govx:GovernmentGrantsTextBlock>
  <us-gaap:CommitmentsDisclosureTextBlock contextRef="c2_From1Jan2011To31Dec2011">&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;4.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Commitments&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Lease&#xd;
        Agreements&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;We&#xd;
        lease approximately 8,400 square feet of office and&#xd;
        laboratory space located in Smyrna, Georgia (metropolitan&#xd;
        Atlanta). Rent expense for the years ended December 31,&#xd;
        2011, 2010 and 2009 was $119,255, $118,988, and $63,350,&#xd;
        respectively.&amp;#160;&amp;#160;Future minimum lease payments&#xd;
        pursuant to the 62 month lease total $121,560 in 2012,&#xd;
        $125,180 in 2013 and $128,920 in 2014.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Other&#xd;
        Commitments&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In&#xd;
        the normal course of business, we may enter into various&#xd;
        firm purchase commitments related to production and testing&#xd;
        of our vaccine material, conduct of clinical trials, and&#xd;
        other research-related activities. As of December 31, 2011,&#xd;
        we had approximately $478,000 of unrecorded outstanding&#xd;
        purchase commitments to our vendors and subcontractors, of&#xd;
        which we expect approximately $445,000 in 2012 and $33,000&#xd;
        in 2013.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;</us-gaap:CommitmentsDisclosureTextBlock>
  <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="c2_From1Jan2011To31Dec2011">&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;5.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;2006&#xd;
        Merger and Recapitalization&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;The&#xd;
        Company was originally incorporated in June 1988 under the&#xd;
        laws of Illinois as Dauphin Technology, Inc.&#xd;
        (&amp;#8220;Dauphin&amp;#8221;).&amp;#160;&amp;#160;Dauphin was&#xd;
        unsuccessful and its operations were terminated in December&#xd;
        2003.&amp;#160;&amp;#160;In September 2006, Dauphin completed a&#xd;
        merger (the &amp;#8220;Merger&amp;#8221;) with GeoVax, Inc. which&#xd;
        was incorporated under the laws of Georgia in June&#xd;
        2001.&amp;#160;&amp;#160;As a result of the Merger, the&#xd;
        shareholders of GeoVax, Inc. exchanged their shares of&#xd;
        common stock for Dauphin common stock and GeoVax, Inc.&#xd;
        became a wholly-owned subsidiary of&#xd;
        Dauphin.&amp;#160;&amp;#160;Dauphin then changed its name to GeoVax&#xd;
        Labs, Inc. and replaced its officers and directors with&#xd;
        those of GeoVax, Inc.&amp;#160;&amp;#160;Subsequent to the Merger,&#xd;
        the Company has not conducted any business other than&#xd;
        GeoVax, Inc.&amp;#8217;s business of developing human&#xd;
        vaccines.&amp;#160;&amp;#160;The Merger was accounted for under the&#xd;
        purchase method of accounting as a reverse acquisition in&#xd;
        accordance with GAAP. Under this method of accounting,&#xd;
        Dauphin was treated as the acquired company and,&#xd;
        accordingly, all financial information prior to the date of&#xd;
        Merger presented in the accompanying consolidated financial&#xd;
        statements, or in the notes herein, as well as any&#xd;
        references to prior operations, are those of GeoVax,&#xd;
        Inc.&amp;#160;&amp;#160;In June 2008, the Company was&#xd;
        reincorporated under the laws of the State of&#xd;
        Delaware.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
<!-- [WMV3][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTq1p9Q9BOYVi2GPRTHo+pgjoNP861n9NVRv7C2G88h/3wwhHkJLayCg9bVmJBkpG0p9Weoty0FgIB6TmIINIPVOJYJHlp2mrcMSbjWjnDb9i/IxkHtESS3GwUSoALGmW1U1bFJJ611RSS1I1y5WHtkvoUbFojlH0+NLql5XvCIwPdx0grEpuG2eTUZ51HgEIgWQ77J7Xx/+vw=] CSR-->
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c2_From1Jan2011To31Dec2011">&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;6.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Stockholders&amp;#8217;&#xd;
        Equity&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Common&#xd;
        Stock Transactions&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In&#xd;
        February 2010, we issued 12,000 shares of our common stock&#xd;
        in settlement of an obligation accrued at December 31, 2009&#xd;
        in the amount of $90,000.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;During&#xd;
        December 2011, we sold an aggregate of 658,520 shares of&#xd;
        our common stock to fifteen individual accredited investors&#xd;
        (including members of our board of directors and management&#xd;
        --see Note 9) for an aggregate purchase price of $441,210,&#xd;
        $36,800 of which was received in January 2012 and is&#xd;
        therefore reflected as a receivable (Other Current Asset)&#xd;
        in the accompanying Consolidated Balance Sheet as of&#xd;
        December 31, 2011.&amp;#160;&amp;#160;We also issued to the&#xd;
        investors warrants to purchase an aggregate of 987,783&#xd;
        shares of common stock at a price of $1.00 per share, which&#xd;
        expire in December 2016.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;From&#xd;
        time to time, we issue shares of our common stock to&#xd;
        consultants or others in exchange for&#xd;
        services.&amp;#160;&amp;#160;During 2011, 2010 and 2009 we issued&#xd;
        129,245, 10,500, and 4,500, respectively, for such&#xd;
        services; and we recorded general and administrative&#xd;
        expense of $150,000, $53,813, and $31,500 during each&#xd;
        respective period related to these issuances.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Stock&#xd;
        Options&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In&#xd;
        2006, we adopted the GeoVax Labs, Inc. 2006 Equity&#xd;
        Incentive Plan (the &amp;#8220;Stock Option Plan&amp;#8221;) for&#xd;
        the granting of qualified incentive stock options&#xd;
        (&amp;#8220;ISO&amp;#8217;s&amp;#8221;), nonqualified stock options,&#xd;
        restricted stock awards or restricted stock bonuses to&#xd;
        employees, officers, directors, consultants and advisors of&#xd;
        the Company.&amp;#160;&amp;#160;The exercise price for any option&#xd;
        granted may not be less than fair value (110% of fair value&#xd;
        for ISO&amp;#8217;s granted to certain&#xd;
        employees).&amp;#160;&amp;#160;Options granted under the Stock&#xd;
        Option Plan have a maximum ten-year term and generally vest&#xd;
        over three years.&amp;#160;&amp;#160;The Company has reserved&#xd;
        1,200,000 shares of its common stock for issuance under the&#xd;
        Stock Option Plan.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;A&#xd;
        summary of activity under the Stock Option Plan as of&#xd;
        December 31, 2011, and changes during the year then ended&#xd;
        is presented below:&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block&quot;&gt;&#xd;
                &amp;#160;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block&quot;&gt;&#xd;
                &amp;#160;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Number&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;of&#xd;
                Shares&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Weighted-&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Average&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Exercise&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Price&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Weighted-&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Average&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Remaining&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Contractual&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Term&#xd;
                (yrs)&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block&quot;&gt;&#xd;
                &amp;#160;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Aggregate&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Intrinsic&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Value&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Outstanding&#xd;
                at January 1, 2011&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,137,356&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;5.33&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Granted&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;230,000&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font id=&quot;TAB1-291&quot; style=&quot;MARGIN-LEFT: 36pt&quot;&gt;&lt;/font&gt;0.91&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Exercised&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font id=&quot;TAB1-292&quot; style=&quot;MARGIN-LEFT: 36pt&quot;&gt;&lt;/font&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Forfeited&#xd;
                or expired&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(439,114&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font id=&quot;TAB1-293&quot; style=&quot;MARGIN-LEFT: 36pt&quot;&gt;&lt;/font&gt;2.81&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;52%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Outstanding&#xd;
                at December 31, 2011&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;928,242&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;5.43&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font id=&quot;TAB1-294&quot; style=&quot;MARGIN-LEFT: 36pt&quot;&gt;&lt;/font&gt;6.5&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-0-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;52%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Exercisable&#xd;
                at December 31, 2011&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;578,231&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;7.59&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font id=&quot;TAB1-295&quot; style=&quot;MARGIN-LEFT: 36pt&quot;&gt;&lt;/font&gt;4.8&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-0-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
        &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Additional&#xd;
        information concerning our stock options for the years&#xd;
        ended December 31, 2011, 2010 and 2009 is as&#xd;
        follows:&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2011&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2010&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2009&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;64%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Weighted&#xd;
                average fair value of options granted during the&#xd;
                period&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;0.79&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2.95&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;6.15&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;64%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Intrinsic&#xd;
                value of options exercised during the period&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;64%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total&#xd;
                fair value of options vested during the&#xd;
                period&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;540,339&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;499,557&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,143,326&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
        &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;We&#xd;
        use the Black-Scholes model for determining the grant date&#xd;
        fair value of our stock option grants.&amp;#160;&amp;#160;This&#xd;
        model utilizes certain information, such as the interest&#xd;
        rate on a risk-free security with a term generally&#xd;
        equivalent to the expected life of the option being valued&#xd;
        and requires certain other assumptions, such as the&#xd;
        expected amount of time an option will be outstanding until&#xd;
        it is exercised or expired, to calculate the fair value of&#xd;
        stock options granted.&amp;#160;&amp;#160;The significant&#xd;
        assumptions we used in our fair value calculations were as&#xd;
        follows:&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2011&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2010&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2009&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;64%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Weighted&#xd;
                average risk-free interest rates&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1.4&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2.6&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2.8&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;64%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Expected&#xd;
                dividend yield&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;0.0&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;0.0&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;0.0&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Expected&#xd;
                life of option&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;3&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;div style=&quot;TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;7&#xd;
                yrs&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;3&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;div style=&quot;TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;6.7&#xd;
                yrs&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;3&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;div style=&quot;TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;7&#xd;
                yrs&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;64%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Expected&#xd;
                volatility&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;111.2&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;112.9&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;112.3&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
        &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Stock-based&#xd;
        compensation expense related to the Stock Option Plan was&#xd;
        $463,752, $575,662, and $1,221,764 during the years ended&#xd;
        December 31, 2011, 2010 and 2009,&#xd;
        respectively.&amp;#160;&amp;#160;Stock option expense is allocated&#xd;
        to research and development expense or to general and&#xd;
        administrative expense based on the related employee&#xd;
        classifications and corresponds to the allocation of&#xd;
        employee salaries.&amp;#160;&amp;#160;For the three years ended&#xd;
        December 31, 2011, stock option expense was allocated as&#xd;
        follows:&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2011&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2010&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2009&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;64%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;General&#xd;
                and administrative expense&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;284,352&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;369,161&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;917,110&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;64%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Research&#xd;
                and development expense&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;179,400&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;206,501&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;304,654&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;64%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total&#xd;
                stock option expense&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;463,752&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;575,662&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,221,764&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
        &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;As&#xd;
        of December 31, 2011, there was $515,697 of unrecognized&#xd;
        compensation expense related to stock-based compensation&#xd;
        arrangements.&amp;#160;&amp;#160;The unrecognized compensation&#xd;
        expense is expected to be recognized over a weighted&#xd;
        average remaining period of 2.0 years.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Compensatory&#xd;
        Warrants&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;From&#xd;
        time to time, we issue stock purchase warrants to&#xd;
        consultants or others in exchange for services. A summary&#xd;
        of our compensatory warrant activity as of December 31,&#xd;
        2011, and changes during the year then ended is presented&#xd;
        below:&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block&quot;&gt;&#xd;
                &amp;#160;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block&quot;&gt;&#xd;
                &amp;#160;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Number&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;of&#xd;
                Shares&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Weighted-&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Average&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Exercise&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Price&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Weighted-&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Average&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Remaining&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Contractual&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Term&#xd;
                (yrs)&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block&quot;&gt;&#xd;
                &amp;#160;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Aggregate&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Intrinsic&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Value&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Outstanding&#xd;
                at January 1, 2011&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;59,400&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;7.00&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Granted&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;7,400&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font id=&quot;TAB1-296&quot; style=&quot;MARGIN-LEFT: 36pt&quot;&gt;&lt;/font&gt;1.40&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Exercised&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font id=&quot;TAB1-297&quot; style=&quot;MARGIN-LEFT: 36pt&quot;&gt;&lt;/font&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Forfeited&#xd;
                or expired&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(2,400&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font id=&quot;TAB1-298&quot; style=&quot;MARGIN-LEFT: 36pt&quot;&gt;&lt;/font&gt;7.00&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;52%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Outstanding&#xd;
                at December 31, 2011&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;64,400&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;7.00&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font id=&quot;TAB1-299&quot; style=&quot;MARGIN-LEFT: 36pt&quot;&gt;&lt;/font&gt;0.6&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-0-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;52%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Exercisable&#xd;
                at December 31, 2011&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;58,850&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;7.00&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font id=&quot;TAB1-300&quot; style=&quot;MARGIN-LEFT: 36pt&quot;&gt;&lt;/font&gt;0.7&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-0-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
        &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Additional&#xd;
        information concerning our compensatory warrants for the&#xd;
        years ended December 31, 2011, 2010 and 2009 is as&#xd;
        follows:&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2011&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2010&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2009&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;64%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Weighted&#xd;
                average fair value of warrants granted during the&#xd;
                period&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;0.96&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;4.75&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;64%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Intrinsic&#xd;
                value of warrants exercised during the&#xd;
                period&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;64%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total&#xd;
                fair value of warrants vested during the&#xd;
                period&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,780&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;19,238&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;6,413&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
        &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;We&#xd;
        use the Black-Scholes model for determining the grant date&#xd;
        fair value of our compensatory warrants.&amp;#160;&amp;#160;The&#xd;
        significant assumptions we used in our fair value&#xd;
        calculations were as follows:&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2011&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2010&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2009&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;64%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Weighted&#xd;
                average risk-free interest rates&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;0.98&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1.54&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;64%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Expected&#xd;
                dividend yield&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;0.0&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;0.0&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Expected&#xd;
                life of warrant&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;3&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;div style=&quot;TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;3.0&#xd;
                yrs&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;3&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;div style=&quot;TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;3.0&#xd;
                yrs&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;64%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Expected&#xd;
                volatility&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;115.46&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;112.1&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;%&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
        &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Expense&#xd;
        associated with compensatory warrants was $7,119, $121,057,&#xd;
        and $45,401 during the years ended December 31, 2011, 2010&#xd;
        and 2009, respectively.&amp;#160;&amp;#160;All such expense was&#xd;
        allocated to general and administrative&#xd;
        expense.&amp;#160;&amp;#160;As of December 31, 2011, there was no&#xd;
        unrecognized compensation expense related to compensatory&#xd;
        warrant arrangements.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Investment&#xd;
        Warrants&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In&#xd;
        addition to outstanding stock options and compensatory&#xd;
        warrants, as of December 31, 2011 we have a total of&#xd;
        1,806,159 outstanding stock purchase warrants issued to&#xd;
        investors in connection with financing&#xd;
        transactions.&amp;#160;&amp;#160;Warrants as to 987,783 have an&#xd;
        exercise price of $1.00 per share and expire in December&#xd;
        2016; warrants as to 818,376 have an exercise price of&#xd;
        $16.50 and expire in December 2014.&amp;#160;&amp;#160;During the&#xd;
        fourth quarter of 2011, we recorded general and&#xd;
        administrative expense of $152,126 associated with the&#xd;
        extension of warrants which were due to expire in 2011 to&#xd;
        2013.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c2_From1Jan2011To31Dec2011">&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;7.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Retirement&#xd;
        Plan&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;We&#xd;
        participate in a multi-employer defined contribution&#xd;
        retirement plan (the &amp;#8220;401k Plan&amp;#8221;) administered&#xd;
        by a third party service provider; and the Company&#xd;
        contributes to the 401k Plan on behalf of its employees&#xd;
        based upon a matching formula.&amp;#160;&amp;#160;During the years&#xd;
        ended December 31, 2011, 2010 and 2009 our contributions to&#xd;
        the 401k Plan were $56,928, $52,632, and $25,057,&#xd;
        respectively.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c2_From1Jan2011To31Dec2011">&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;8.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Income&#xd;
        Taxes&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;At&#xd;
        December 31, 2011, we have a consolidated federal net&#xd;
        operating loss (&amp;#8220;NOL&amp;#8221;) carryforward of&#xd;
        approximately $71.3 million, available to offset against&#xd;
        future taxable income which expires in varying amounts in&#xd;
        2012 through 2031.&amp;#160;&amp;#160;Additionally, we have&#xd;
        approximately $764,000 in research and development&#xd;
        (&amp;#8220;R&amp;amp;D&amp;#8221;) tax credits that expire in 2022&#xd;
        through 2031 unless utilized earlier.&amp;#160;&amp;#160;No income&#xd;
        taxes have been paid to date.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;As&#xd;
        a result of the Merger discussed in Note 5, our NOL&#xd;
        carryforward increased substantially due to the addition of&#xd;
        historical NOL carryforwards for Dauphin Technology,&#xd;
        Inc.&amp;#160;&amp;#160;However, Section 382 of the Internal&#xd;
        Revenue Code contains provisions that may limit our&#xd;
        utilization of NOL and R&amp;amp;D tax credit carryforwards in&#xd;
        any given year as a result of significant changes in&#xd;
        ownership interests that have occurred in past periods or&#xd;
        may occur in future periods.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Deferred&#xd;
        income taxes reflect the net effect of temporary&#xd;
        differences between the carrying amounts of assets and&#xd;
        liabilities for financial reporting purposes and the&#xd;
        amounts used for income tax&#xd;
        purposes.&amp;#160;&amp;#160;Significant components of our deferred&#xd;
        tax assets and liabilities included the following at&#xd;
        December 31, 2011 and 2010:&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2011&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2010&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Deferred&#xd;
                tax assets:&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;76%&quot; style=&quot;TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 4%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;&#xd;
              &lt;div style=&quot;TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Net&#xd;
                operating loss carryforward&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;24,875,119&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;25,116,958&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;76%&quot; style=&quot;PADDING-LEFT: 4%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Research&#xd;
                and development tax credit carryforward&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;763,690&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;731,290&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;76%&quot; style=&quot;PADDING-BOTTOM: 2px; PADDING-LEFT: 4%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Stock-based&#xd;
                compensation expense&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,991,769&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,779,950&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;76%&quot; style=&quot;PADDING-LEFT: 4%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total&#xd;
                deferred tax assets&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;27,630,578&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;27,628,198&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;76%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;76%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Deferred&#xd;
                tax liabilities&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;76%&quot; style=&quot;PADDING-BOTTOM: 2px; PADDING-LEFT: 4%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Depreciation&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(38,587&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(51,945&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;76%&quot; style=&quot;PADDING-BOTTOM: 2px; PADDING-LEFT: 4%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Total&#xd;
                deferred tax liabilities&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(38,587&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(51,945&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;76%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;76%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Net&#xd;
                deferred tax assets&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;27,591,991&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;27,576,253&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;76%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Valuation&#xd;
                allowance&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(27,591,991&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(27,576,253&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;76%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
        &lt;/table&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;We&#xd;
        have established a full valuation allowance equal to the&#xd;
        amount of our net deferred tax assets due to uncertainties&#xd;
        with respect to our ability to generate sufficient taxable&#xd;
        income to realize these assets in the future. &lt;font style=&quot;DISPLAY: inline; FONT-WEIGHT: bold&quot;&gt;&amp;#160;&lt;/font&gt;A&#xd;
        reconciliation of the income tax benefit on losses at the&#xd;
        U.S. federal statutory rate to the reported income tax&#xd;
        expense is as follows:&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2011&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2010&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2009&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;64%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;U.S.&#xd;
                federal statutory rate applied to pretax&#xd;
                loss&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(797,921&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(934,092&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(1,116,646&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;64%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Permanent&#xd;
                differences&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font id=&quot;TAB1-301&quot; style=&quot;MARGIN-LEFT: 32.15pt&quot;&gt;&lt;/font&gt;3,536&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(77,200&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font id=&quot;TAB1-302&quot; style=&quot;MARGIN-LEFT: 21.8pt&quot;&gt;&lt;/font&gt;169,469&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;64%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Research&#xd;
                and development credits&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font id=&quot;TAB1-303&quot; style=&quot;MARGIN-LEFT: 25.45pt&quot;&gt;&lt;/font&gt;32,400&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;59,959&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font id=&quot;TAB1-304&quot; style=&quot;MARGIN-LEFT: 21.8pt&quot;&gt;&lt;/font&gt;169,667&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;64%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Change&#xd;
                in valuation allowance&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font id=&quot;TAB1-305&quot; style=&quot;MARGIN-LEFT: 18.8pt&quot;&gt;&lt;/font&gt;761,985&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;951,333&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font id=&quot;TAB1-306&quot; style=&quot;MARGIN-LEFT: 21.8pt&quot;&gt;&lt;/font&gt;777,510&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;64%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Reported&#xd;
                income tax expense&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 4px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
        &lt;/table&gt;&lt;br/&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c2_From1Jan2011To31Dec2011">&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;9.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Related&#xd;
        Party Transactions&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;We&#xd;
        are obligated to reimburse Emory University (a significant&#xd;
        stockholder of the Company) for ongoing costs in connection&#xd;
        with the filing, prosecution and maintenance of patent&#xd;
        applications subject to a license agreement for technology&#xd;
        associated with the vaccines we are&#xd;
        developing.&amp;#160;&amp;#160;The expense associated with these&#xd;
        ongoing patent cost reimbursements to Emory amounted to&#xd;
        $249,907, $193,674, and $85,673 for the years ended&#xd;
        December 31, 2011, 2010, and 2009, respectively.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;We&#xd;
        have entered into two subcontracts with Emory for the&#xd;
        purpose of conducting research and development activities&#xd;
        associated with our grant from the NIH (see Note&#xd;
        3).&amp;#160;&amp;#160;During 2011, 2010, and 2009, we recorded&#xd;
        $1,172,758, $1,391,203, and $816,651, respectively, of&#xd;
        expense associated with these subcontracts.&amp;#160;&amp;#160;All&#xd;
        amounts paid to Emory under these subcontracts are&#xd;
        reimbursable to us pursuant to the NIH grant.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Through&#xd;
        November 2009, we leased office and laboratory space on a&#xd;
        month-to-month basis from Emtech Biotechnology Development,&#xd;
        Inc., a related party associated with&#xd;
        Emory.&amp;#160;&amp;#160;Rent expense associated with this lease&#xd;
        totaled $43,112 for the year ended December 31,&#xd;
        2009.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In&#xd;
        March 2008, we entered into a consulting agreement with&#xd;
        Donald Hildebrand, a former member of our Board of&#xd;
        Directors and our former President &amp;amp; Chief Executive&#xd;
        Officer, pursuant to which Mr. Hildebrand provides business&#xd;
        and technical advisory services to the&#xd;
        Company.&amp;#160;&amp;#160;The term of the consulting agreement,&#xd;
        as amended, began on April 1, 2008 and ends on December 31,&#xd;
        2012.&amp;#160;&amp;#160;During 2011, 2010, and 2009, we recorded&#xd;
        $24,000, $57,600, and $57,600, respectively, of expense&#xd;
        associated with the consulting agreement.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;In&#xd;
        December 2011, members of our management and Board of&#xd;
        Directors participated in the private placement offering of&#xd;
        our common stock and warrants described in Note 6, whereby&#xd;
        they purchased an aggregate of 335,954 shares of our common&#xd;
        stock for a total purchase price of $225,089 and received&#xd;
        five-year warrants to purchase an additional 503,932 shares&#xd;
        of our common stock exercisable at $1.00 per share.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="c2_From1Jan2011To31Dec2011">&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;10.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Selected&#xd;
        Quarterly Financial Data (unaudited)&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;A&#xd;
        summary of selected quarterly financial data for 2011 and&#xd;
        2010 is as follows:&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;14&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2011&#xd;
                Quarter Ended&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;March&#xd;
                31&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;June&#xd;
                30&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;September&#xd;
                30&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;December&#xd;
                31&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;52%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Revenue&#xd;
                from grants&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;893,002&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,753,033&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,297,006&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;956,844&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;52%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Net&#xd;
                loss&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(606,282&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(211,344&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(375,852&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(1,153,348&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;52%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Net&#xd;
                loss per share&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(0.04&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(0.01&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(0.02&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(0.08&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
        &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;14&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;2010&#xd;
                Quarter Ended&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;March&#xd;
                31&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;June&#xd;
                30&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;September&#xd;
                30&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;December&#xd;
                31&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;52%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Revenue&#xd;
                from grants&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,338,560&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,737,169&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,163,288&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;946,240&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;52%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Net&#xd;
                loss&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(690,789&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(933,089&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(644,666&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(478,784&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;52%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Net&#xd;
                loss per share&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(0.04&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(0.06&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(0.04&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(0.03&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
        &lt;/table&gt;&lt;br/&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:SubsequentEventsTextBlock contextRef="c2_From1Jan2011To31Dec2011">&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;11.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subsequent&#xd;
        Events&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Private&#xd;
        Placement of Common Stock and Warrants&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;During&#xd;
        January 2012, we sold an aggregate of 407,999 shares of our&#xd;
        common stock to twelve individual accredited investors&#xd;
        (including 45,000 shares sold to members of our board of&#xd;
        directors and management) for an aggregate purchase price&#xd;
        of $273,360.&amp;#160;&amp;#160;We also issued to the investors&#xd;
        warrants to purchase an aggregate of 612,001 shares of&#xd;
        common stock at a price of $1.00 per share, which expire in&#xd;
        January 2017.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Issuance&#xd;
        of Convertible Preferred Stock and Warrants&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;On&#xd;
        March 21, 2012, we sold shares of our Series A convertible&#xd;
        preferred stock to certain institutional investors for an&#xd;
        aggregate purchase price of $2.2 million.&amp;#160;&amp;#160;The&#xd;
        preferred stock is convertible at any time into shares of&#xd;
        our common stock at $0.75 per share (2,933,333 shares in&#xd;
        the aggregate), subject to possible adjustment as provided&#xd;
        in the certificate of designation.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Pursuant&#xd;
        to the terms of the securities purchase agreement, the&#xd;
        investors also received five-year Series A warrants to&#xd;
        purchase an aggregate of 2,933,333 shares of our common&#xd;
        stock at $1.00 per share.&amp;#160;&amp;#160;The Series A warrants&#xd;
        are immediately exercisable.&amp;#160; We also granted to the&#xd;
        investors a one-year additional purchase right, evidenced&#xd;
        in the form of Series B warrants, to purchase up to&#xd;
        2,933,333 of our common stock for one year with an exercise&#xd;
        price of $0.75 per share, and five-year Series C warrants&#xd;
        to purchase up to 2,933,333 shares of our common stock at&#xd;
        $1.00 per share.&amp;#160;&amp;#160;The Series B warrants are&#xd;
        immediately exercisable.&amp;#160;&amp;#160;The Series C warrants&#xd;
        only vest and become exercisable at the time, and to the&#xd;
        extent, that the Series B warrants are exercised.&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="c2_From1Jan2011To31Dec2011">&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;SCHEDULE&#xd;
        II &amp;#8211; VALUATION AND QUALIFYING ACCOUNTS&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
        &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold&quot;&gt;For&#xd;
        the Years Ended December 31, 2011, 2010 and 2009&lt;/font&gt;&#xd;
      &lt;/div&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;6&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Additions&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block&quot;&gt;&#xd;
                &amp;#160;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block&quot;&gt;&#xd;
                &amp;#160;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Description&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Balance&#xd;
                at&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Beginning&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Of&#xd;
                Period&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Charged&#xd;
                to&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Costs&#xd;
                and&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Expenses&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Charged&#xd;
                to&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Other&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Accounts&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(1)&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Deductions&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; style=&quot;PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot; style=&quot;BORDER-BOTTOM: black 2px solid&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Balance&#xd;
                at&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;End&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;center&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Of&#xd;
                Period&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left; PADDING-BOTTOM: 2px&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Reserve&#xd;
                Deducted in the Balance Sheet&lt;/font&gt; &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;From&#xd;
                the Asset to Which it Applies:&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;Allowance&#xd;
                for Deferred Tax Assets&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td colspan=&quot;2&quot; valign=&quot;bottom&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;40%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font id=&quot;TAB1-307&quot; style=&quot;MARGIN-LEFT: 9pt&quot;&gt;&lt;/font&gt;Year&#xd;
                ended December 31, 2011&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;27,576,253&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;889,322&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(873,584&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;27,591,991&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr style=&quot;background-color: #C0FFFF;&quot;&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;40%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font id=&quot;TAB1-308&quot; style=&quot;MARGIN-LEFT: 9pt&quot;&gt;&lt;/font&gt;Year&#xd;
                ended December 31, 2010&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;27,091,338&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,160,405&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;(675,490&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;)&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;27,576,253&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
          &lt;tr&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;40%&quot;&gt;&#xd;
              &lt;div style=&quot;LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot; align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&lt;font id=&quot;TAB1-309&quot; style=&quot;MARGIN-LEFT: 9pt&quot;&gt;&lt;/font&gt;Year&#xd;
                ended December 31, 2009&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;25,674,882&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;1,416,456&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;-&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td align=&quot;left&quot; valign=&quot;bottom&quot; width=&quot;1%&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;$&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td valign=&quot;bottom&quot; width=&quot;9%&quot; style=&quot;TEXT-ALIGN: right&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;27,091,338&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td nowrap=&quot;nowrap&quot; valign=&quot;bottom&quot; width=&quot;1%&quot; style=&quot;TEXT-ALIGN: left&quot;&gt;&#xd;
              &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
        &lt;/table&gt;&lt;br/&gt;&lt;table align=&quot;center&quot; border=&quot;0&quot; cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; id=&quot;hangingindent-117&quot; width=&quot;100%&quot; style=&quot;FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman&quot;&gt;&#xd;
          &lt;tr valign=&quot;top&quot; style=&quot;LINE-HEIGHT: 1.25;&quot;&gt;&#xd;
            &lt;td style=&quot;WIDTH: 18pt&quot;&gt;&#xd;
              &lt;div&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;&amp;#160;&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td style=&quot;WIDTH: 18pt&quot;&gt;&#xd;
              &lt;div style=&quot;TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;(1)&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
            &lt;td&gt;&#xd;
              &lt;div align=&quot;left&quot;&gt;&#xd;
                &lt;font style=&quot;DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt&quot;&gt;Deductions&#xd;
                represent the effect of expiring NOL carryforwards&#xd;
                from prior years.&lt;/font&gt;&#xd;
              &lt;/div&gt;&#xd;
            &lt;/td&gt;&#xd;
          &lt;/tr&gt;&#xd;
        &lt;/table&gt;&lt;br/&gt;</us-gaap:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>govx-20111231.xsd
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Tue Apr 03 16:11:41 UTC 2012 -->
<xs:schema xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" targetNamespace="http://geovax.com/20111231" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:govx="http://geovax.com/20111231" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" elementFormDefault="qualified" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="govx-20111231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="govx-20111231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="govx-20111231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="govx-20111231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://geovax.com/role/ConsolidatedBalanceSheet" id="govx_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://geovax.com/role/ConsolidatedBalanceSheet_Parentheticals" id="govx_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://geovax.com/role/ConsolidatedIncomeStatement" id="govx_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://geovax.com/role/ShareholdersEquityType2or3" id="govx_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Consolidated Statements of Stockholders' Equity (Deficiency)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://geovax.com/role/ConsolidatedCashFlow" id="govx_ConsolidatedCashFlow">
        <link:definition>005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://geovax.com/role/Note" id="govx_Note">
        <link:definition>006 - Disclosure - Note 1 - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://geovax.com/role/Note0" id="govx_Note0">
        <link:definition>007 - Disclosure - Note 2 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://geovax.com/role/Note00" id="govx_Note00">
        <link:definition>008 - Disclosure - Note 3 - Government Grants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://geovax.com/role/Note000" id="govx_Note000">
        <link:definition>009 - Disclosure - Note 4 - Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://geovax.com/role/Note0000" id="govx_Note0000">
        <link:definition>010 - Disclosure - Note 5 - 2006 Merger and Recapitalization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://geovax.com/role/Note00000" id="govx_Note00000">
        <link:definition>011 - Disclosure - Note 6 - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://geovax.com/role/Note000000" id="govx_Note000000">
        <link:definition>012 - Disclosure - Note 7 - Retirement Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV3][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTq1p9Q9BOYVi2GPRTHo+pgjoNP861n9NVRv7C2G88h/3wwhHkJLayCg9bVmJBkpG0p9Weoty0FgIB6TmIINIPVOJYJHlp2mrcMSbjWjnDb9i/IxkHtESS3GwUSoALGmW1U1bFJJ611RSS1I1y5WHtkvoUbFojlH0+NLql5XvCIwPdx0grEpuG2edhfACeYvPkjMnG8aTABsq0=] CSR-->
      <link:roleType roleURI="http://geovax.com/role/Note0000000" id="govx_Note0000000">
        <link:definition>013 - Disclosure - Note 8 - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://geovax.com/role/Note00000000" id="govx_Note00000000">
        <link:definition>014 - Disclosure - Note 9 - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://geovax.com/role/Note000000000" id="govx_Note000000000">
        <link:definition>015 - Disclosure - Note 10 - Selected Quarterly Financial Data (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://geovax.com/role/Note0000000000" id="govx_Note0000000000">
        <link:definition>016 - Disclosure - Note 11 - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://geovax.com/role/Schedule" id="govx_Schedule">
        <link:definition>017 - Disclosure - Schedule II - Valuation and Qualifying Accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://geovax.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Disclosure - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-types-2011-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:element name="ConsolidatedBalanceSheetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_ConsolidatedBalanceSheetsAbstract"/>
  <xs:element name="CurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_CurrentAssetsAbstract"/>
  <xs:element name="CurrentLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_CurrentLiabilitiesAbstract"/>
  <xs:element name="ConsolidatedStatementsOfOperationsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_ConsolidatedStatementsOfOperationsAbstract"/>
  <xs:element name="OtherIncomeExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_OtherIncomeExpenseAbstract"/>
  <xs:element name="BasicAndDilutedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_BasicAndDilutedAbstract"/>
  <xs:element name="ConsolidatedStatementsOfStockholdersEquityDeficiencyAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_ConsolidatedStatementsOfStockholdersEquityDeficiencyAbstract"/>
  <xs:element name="AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="govx_AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception"/>
  <xs:element name="StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="govx_StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable"/>
  <xs:element name="StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable"/>
  <xs:element name="StockIssuedDuringPeriodValueCashlessWarrantExercise" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="govx_StockIssuedDuringPeriodValueCashlessWarrantExercise"/>
  <xs:element name="StockIssuedDuringPeriodSharesCashlessWarrantExercise" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_StockIssuedDuringPeriodSharesCashlessWarrantExercise"/>
  <xs:element name="StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="govx_StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant"/>
  <xs:element name="StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant"/>
  <xs:element name="StockIssuedDuringPeriodValueInLieuOfCashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="govx_StockIssuedDuringPeriodValueInLieuOfCashPayment"/>
  <xs:element name="StockIssuedDuringPeriodSharesInLieuOfCashPayment" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_StockIssuedDuringPeriodSharesInLieuOfCashPayment"/>
  <xs:element name="ConsolidatedStatementsOfCashFlowsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_ConsolidatedStatementsOfCashFlowsAbstract"/>
  <xs:element name="CashFlowsFromOperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_CashFlowsFromOperatingActivitiesAbstract"/>
  <xs:element name="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract"/>
  <xs:element name="ChangesInAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_ChangesInAssetsAndLiabilitiesAbstract"/>
  <xs:element name="CashFlowsFromInvestingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_CashFlowsFromInvestingActivitiesAbstract"/>
  <xs:element name="CashFlowsFromFinancingActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_CashFlowsFromFinancingActivitiesAbstract"/>
  <xs:element name="SupplementalDisclosureOfCashFlowInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_SupplementalDisclosureOfCashFlowInformationAbstract"/>
  <xs:element name="NatureOfOperationsTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_NatureOfOperationsTextBlockAbstract"/>
  <xs:element name="SignificantAccountingPoliciesTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_SignificantAccountingPoliciesTextBlockAbstract"/>
  <xs:element name="GovernmentGrantsTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_GovernmentGrantsTextBlockAbstract"/>
  <xs:element name="GovernmentGrantsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_GovernmentGrantsTextBlock"/>
  <xs:element name="CommitmentsDisclosureTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_CommitmentsDisclosureTextBlockAbstract"/>
  <xs:element name="MergersAcquisitionsAndDispositionsDisclosuresTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_MergersAcquisitionsAndDispositionsDisclosuresTextBlockAbstract"/>
  <xs:element name="StockholdersEquityNoteDisclosureTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_StockholdersEquityNoteDisclosureTextBlockAbstract"/>
  <xs:element name="PensionAndOtherPostretirementBenefitsDisclosureTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_PensionAndOtherPostretirementBenefitsDisclosureTextBlockAbstract"/>
  <xs:element name="IncomeTaxDisclosureTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_IncomeTaxDisclosureTextBlockAbstract"/>
  <xs:element name="RelatedPartyTransactionsDisclosureTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_RelatedPartyTransactionsDisclosureTextBlockAbstract"/>
  <xs:element name="QuarterlyFinancialInformationTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_QuarterlyFinancialInformationTextBlockAbstract"/>
  <xs:element name="SubsequentEventsTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_SubsequentEventsTextBlockAbstract"/>
  <xs:element name="ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlockAbstract"/>
  <xs:element name="PrivatePlacementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="govx_PrivatePlacementAxis"/>
  <xs:element name="PurchaseAgreementwithFushionCapitalAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="govx_PurchaseAgreementwithFushionCapitalAxis"/>
  <xs:element name="StockSubscriptionReceivableMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_StockSubscriptionReceivableMember"/>
  <xs:element name="PurchaseAgreementwithFushionCapitalMember" type="nonnum:domainItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_PurchaseAgreementwithFushionCapitalMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="govx_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>govx-20111231_cal.xml
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Tue Apr 03 16:11:41 UTC 2012 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_ConsolidatedBalanceSheet" roleURI="http://geovax.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_ConsolidatedIncomeStatement" roleURI="http://geovax.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_ConsolidatedCashFlow" roleURI="http://geovax.com/role/ConsolidatedCashFlow"/>
  <calculationLink xlink:type="extended" xlink:role="http://geovax.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrantsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrantsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_GrantsReceivable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://geovax.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
<!-- [WMV3][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTq1p9Q9BOYVi2GPRTHo+pgjoNP861n9NVRv7C2G88h/3wwhHkJLayCg9bVmJBkpG0p9Weoty0FgIB6TmIINIPVOJYJHlp2mrcMSbjWjnDb9i/IxkHtESS3GwUSoALGmW1U1bFJJ611RSS1I1y5WHtkvoUbFojlH0+NLql5XvCIwPdx0grEpuG2eW7Ek3n3DL+RCy3Cp2dYe5g=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromGrants" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueFromGrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromGrants" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://geovax.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDeferredCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfDeferredCharges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDeferredCharges" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>govx-20111231_def.xml
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Tue Apr 03 16:11:41 UTC 2012 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_ConsolidatedBalanceSheet" roleURI="http://geovax.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://geovax.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_ConsolidatedIncomeStatement" roleURI="http://geovax.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_ShareholdersEquityType2or3" roleURI="http://geovax.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_ConsolidatedCashFlow" roleURI="http://geovax.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note" roleURI="http://geovax.com/role/Note"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note0" roleURI="http://geovax.com/role/Note0"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note00" roleURI="http://geovax.com/role/Note00"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note000" roleURI="http://geovax.com/role/Note000"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note0000" roleURI="http://geovax.com/role/Note0000"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note00000" roleURI="http://geovax.com/role/Note00000"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note000000" roleURI="http://geovax.com/role/Note000000"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note0000000" roleURI="http://geovax.com/role/Note0000000"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note00000000" roleURI="http://geovax.com/role/Note00000000"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note000000000" roleURI="http://geovax.com/role/Note000000000"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note0000000000" roleURI="http://geovax.com/role/Note0000000000"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Schedule" roleURI="http://geovax.com/role/Schedule"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#DocumentAndEntityInformation" roleURI="http://geovax.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://geovax.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="govx_CurrentAssetsAbstract" xlink:href="govx-20111231.xsd#govx_CurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="govx_CurrentAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_CurrentAssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrantsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrantsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_CurrentAssetsAbstract" xlink:to="us-gaap_GrantsReceivable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_CurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_AssetsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_Assets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="govx_CurrentLiabilitiesAbstract" xlink:href="govx-20111231.xsd#govx_CurrentLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="govx_CurrentLiabilitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_CurrentLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_CurrentLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_CurrentLiabilitiesAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:to="us-gaap_StockholdersEquity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://geovax.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://geovax.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromGrants" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueFromGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromGrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OperatingExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="govx_OtherIncomeExpenseAbstract" xlink:href="govx-20111231.xsd#govx_OtherIncomeExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_OtherIncomeExpenseAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_OtherIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_OtherIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_OtherIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="govx_BasicAndDilutedAbstract" xlink:href="govx-20111231.xsd#govx_BasicAndDilutedAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_BasicAndDilutedAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_BasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_BasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://geovax.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="govx_StockSubscriptionReceivableMember" xlink:href="govx-20111231.xsd#govx_StockSubscriptionReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="govx_StockSubscriptionReceivableMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="govx_AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception" xlink:href="govx-20111231.xsd#govx_AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="govx_StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="govx_StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="govx_StockIssuedDuringPeriodValueInLieuOfCashPayment" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodValueInLieuOfCashPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueInLieuOfCashPayment" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="govx_StockIssuedDuringPeriodSharesInLieuOfCashPayment" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodSharesInLieuOfCashPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesInLieuOfCashPayment" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="govx_StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="govx_StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="govx_StockIssuedDuringPeriodValueCashlessWarrantExercise" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodValueCashlessWarrantExercise"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueCashlessWarrantExercise" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="govx_StockIssuedDuringPeriodSharesCashlessWarrantExercise" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodSharesCashlessWarrantExercise"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesCashlessWarrantExercise" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="32" xbrldt:closed="true"/>
  </definitionLink>
<!-- [WMV3][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTq1p9Q9BOYVi2GPRTHo+pgjoNP861n9NVRv7C2G88h/3wwhHkJLayCg9bVmJBkpG0p9Weoty0FgIB6TmIINIPVOJYJHlp2mrcMSbjWjnDb9i/IxkHtESS3GwUSoALGmW1U1bFJJ611RSS1I1y5WHtkvoUbFojlH0+NLql5XvCIwPdx0grEpuG2ecM0fUKeBVKnAeb1JvFLIFg=] CSR-->
  <definitionLink xlink:type="extended" xlink:role="http://geovax.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="govx_CashFlowsFromOperatingActivitiesAbstract" xlink:href="govx-20111231.xsd#govx_CashFlowsFromOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_CashFlowsFromOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_CashFlowsFromOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="govx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:href="govx-20111231.xsd#govx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_CashFlowsFromOperatingActivitiesAbstract" xlink:to="govx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDeferredCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfDeferredCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDeferredCharges" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="govx_ChangesInAssetsAndLiabilitiesAbstract" xlink:href="govx-20111231.xsd#govx_ChangesInAssetsAndLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="govx_ChangesInAssetsAndLiabilitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_ChangesInAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_ChangesInAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_ChangesInAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_ChangesInAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_ChangesInAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_CashFlowsFromOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="govx_CashFlowsFromInvestingActivitiesAbstract" xlink:href="govx-20111231.xsd#govx_CashFlowsFromInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_CashFlowsFromInvestingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="govx_CashFlowsFromFinancingActivitiesAbstract" xlink:href="govx-20111231.xsd#govx_CashFlowsFromFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_CashFlowsFromFinancingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_CashFlowsFromFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_CashFlowsFromFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_CashFlowsFromFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_CashFlowsFromFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="govx_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:href="govx-20111231.xsd#govx_SupplementalDisclosureOfCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_SupplementalDisclosureOfCashFlowInformationAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="govx_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://geovax.com/role/Note">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NatureOfOperations" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://geovax.com/role/Note0">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://geovax.com/role/Note00">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="govx_GovernmentGrantsTextBlock" xlink:href="govx-20111231.xsd#govx_GovernmentGrantsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_GovernmentGrantsTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://geovax.com/role/Note000">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://geovax.com/role/Note0000">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://geovax.com/role/Note00000">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://geovax.com/role/Note000000">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://geovax.com/role/Note0000000">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://geovax.com/role/Note00000000">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://geovax.com/role/Note000000000">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://geovax.com/role/Note0000000000">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://geovax.com/role/Schedule">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://geovax.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityRegistrantName" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentType" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityPublicFloat" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AmendmentFlag" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AmendmentDescription" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>govx-20111231_lab.xml
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Tue Apr 03 16:11:41 UTC 2012 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="govx_ConsolidatedBalanceSheetsAbstract" xlink:href="govx-20111231.xsd#govx_ConsolidatedBalanceSheetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_ConsolidatedBalanceSheetsAbstract_lbl" xml:lang="en-US">Consolidated Balance Sheets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConsolidatedBalanceSheetsAbstract" xlink:to="govx_ConsolidatedBalanceSheetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_ConsolidatedBalanceSheetsAbstract_lbl0" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConsolidatedBalanceSheetsAbstract" xlink:to="govx_ConsolidatedBalanceSheetsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">ASSETS [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="govx_CurrentAssetsAbstract" xlink:href="govx-20111231.xsd#govx_CurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_CurrentAssetsAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_CurrentAssetsAbstract" xlink:to="govx_CurrentAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_CurrentAssetsAbstract_lbl0" xml:lang="en-US">Current assets: [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_CurrentAssetsAbstract" xlink:to="govx_CurrentAssetsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrantsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrantsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US">Grant funds receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Other assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl0" xml:lang="en-US">Other assets: [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Licenses, net of accumulated amortization of $208,933 and $184,047 at December 31, 2011 and 2010 respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deposits and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="govx_CurrentLiabilitiesAbstract" xlink:href="govx-20111231.xsd#govx_CurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_CurrentLiabilitiesAbstract" xlink:to="govx_CurrentLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_CurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Current liabilities: [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_CurrentLiabilitiesAbstract" xlink:to="govx_CurrentLiabilitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Amounts payable to Emory University (a related party)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments (Note 4)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&#8217; equity: [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $.001 par value, 40,000,000 shares authorized; 16,442,611 and 15,654,846 shares issued and outstanding at December 31, 2011 and 2010, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_lbl" xml:lang="en-US">Deficit accumulated during the development stage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:to="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Licenses, accumulated amortization (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_ConsolidatedStatementsOfOperationsAbstract" xlink:href="govx-20111231.xsd#govx_ConsolidatedStatementsOfOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_ConsolidatedStatementsOfOperationsAbstract_lbl" xml:lang="en-US">Consolidated Statements of Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConsolidatedStatementsOfOperationsAbstract" xlink:to="govx_ConsolidatedStatementsOfOperationsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_ConsolidatedStatementsOfOperationsAbstract_lbl0" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConsolidatedStatementsOfOperationsAbstract" xlink:to="govx_ConsolidatedStatementsOfOperationsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromGrants" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueFromGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US">Grant revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromGrants" xlink:to="us-gaap_RevenueFromGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating expenses: [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_OtherIncomeExpenseAbstract" xlink:href="govx-20111231.xsd#govx_OtherIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_OtherIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_OtherIncomeExpenseAbstract" xlink:to="govx_OtherIncomeExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_OtherIncomeExpenseAbstract_lbl0" xml:lang="en-US">Other income (expense): [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_OtherIncomeExpenseAbstract" xlink:to="govx_OtherIncomeExpenseAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_BasicAndDilutedAbstract" xlink:href="govx-20111231.xsd#govx_BasicAndDilutedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_BasicAndDilutedAbstract_lbl" xml:lang="en-US">Basic and diluted:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_BasicAndDilutedAbstract" xlink:to="govx_BasicAndDilutedAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_BasicAndDilutedAbstract_lbl0" xml:lang="en-US">Basic and diluted: [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_BasicAndDilutedAbstract" xlink:to="govx_BasicAndDilutedAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Loss per common share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_ConsolidatedStatementsOfStockholdersEquityDeficiencyAbstract" xlink:href="govx-20111231.xsd#govx_ConsolidatedStatementsOfStockholdersEquityDeficiencyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_ConsolidatedStatementsOfStockholdersEquityDeficiencyAbstract_lbl" xml:lang="en-US">Consolidated Statements of Stockholders&apos; Equity (Deficiency)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConsolidatedStatementsOfStockholdersEquityDeficiencyAbstract" xlink:to="govx_ConsolidatedStatementsOfStockholdersEquityDeficiencyAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_ConsolidatedStatementsOfStockholdersEquityDeficiencyAbstract_lbl0" xml:lang="en-US">Consolidated Statements of Stockholders&apos; Equity (Deficiency) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConsolidatedStatementsOfStockholdersEquityDeficiencyAbstract" xlink:to="govx_ConsolidatedStatementsOfStockholdersEquityDeficiencyAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="govx_AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception" xlink:href="govx-20111231.xsd#govx_AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="govx_AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception_lbl" xml:lang="en-US">Represents increases in additional paid in capital attributable to capital contribution at inception.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception" xlink:to="govx_AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception_lbl0" xml:lang="en-US">Capital contribution at inception (June 27, 2001)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception" xlink:to="govx_AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Sale of common stock for cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Sale of common stock for cash (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl" xml:lang="en-US">Issuance of common stock for technology license</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl" xml:lang="en-US">Issuance of common stock for technology license (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="govx_StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable_lbl" xml:lang="en-US">Value of shares of stock issued during the period for cash and stock subscription receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable" xlink:to="govx_StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable_lbl0" xml:lang="en-US">Sale of common stock for cash and stock subscription receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable" xlink:to="govx_StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable_lbl0"/>
    <loc xlink:type="locator" xlink:label="govx_StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="govx_StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable_lbl" xml:lang="en-US">Number of shares of stock issued during the period for cash and stock subscription receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable" xlink:to="govx_StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable_lbl0" xml:lang="en-US">Sale of common stock for cash and stock subscription receivable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable" xlink:to="govx_StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Cash payments received on stock subscription receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of preferred stock to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of preferred stock to common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl" xml:lang="en-US">Common stock issued in connection with merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Common stock issued in connection with merger (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_StockIssuedDuringPeriodValueCashlessWarrantExercise" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodValueCashlessWarrantExercise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="govx_StockIssuedDuringPeriodValueCashlessWarrantExercise_lbl" xml:lang="en-US">Value of shares of stock issued during the period for cashless warrant exercise.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodValueCashlessWarrantExercise" xlink:to="govx_StockIssuedDuringPeriodValueCashlessWarrantExercise_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_StockIssuedDuringPeriodValueCashlessWarrantExercise_lbl0" xml:lang="en-US">Issuance of common stock for cashless warrant exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodValueCashlessWarrantExercise" xlink:to="govx_StockIssuedDuringPeriodValueCashlessWarrantExercise_lbl0"/>
    <loc xlink:type="locator" xlink:label="govx_StockIssuedDuringPeriodSharesCashlessWarrantExercise" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodSharesCashlessWarrantExercise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="govx_StockIssuedDuringPeriodSharesCashlessWarrantExercise_lbl" xml:lang="en-US">Number of shares of stock issued during the period for cashless warrant exercise.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodSharesCashlessWarrantExercise" xlink:to="govx_StockIssuedDuringPeriodSharesCashlessWarrantExercise_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_StockIssuedDuringPeriodSharesCashlessWarrantExercise_lbl0" xml:lang="en-US">Issuance of common stock for cashless warrant exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodSharesCashlessWarrantExercise" xlink:to="govx_StockIssuedDuringPeriodSharesCashlessWarrantExercise_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock upon stock option exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock upon stock option exercise (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Transactions related to common stock purchase agreement with Fusion Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Transactions related to common stock purchase agreement with Fusion Capital (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation - Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Stock-based compensation - Consultant warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation - Issuance of common stock for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation - Issuance of common stock for services (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="govx_StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant_lbl" xml:lang="en-US">Value of shares of stock issued during the period for cash upon exercise of stock purchase warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant" xlink:to="govx_StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant_lbl0" xml:lang="en-US">Sale of common stock for cash upon exercise of stock purchase warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant" xlink:to="govx_StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant_lbl0"/>
    <loc xlink:type="locator" xlink:label="govx_StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="govx_StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant_lbl" xml:lang="en-US">Number of shares of stock issued during the period for cash upon exercise of stock purchase warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant" xlink:to="govx_StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant_lbl0" xml:lang="en-US">Sale of common stock for cash upon exercise of stock purchase warrant (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant" xlink:to="govx_StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant_lbl0"/>
    <loc xlink:type="locator" xlink:label="govx_StockIssuedDuringPeriodValueInLieuOfCashPayment" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodValueInLieuOfCashPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="govx_StockIssuedDuringPeriodValueInLieuOfCashPayment_lbl" xml:lang="en-US">Value of shares of stock issued during the period in lieu of cash payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodValueInLieuOfCashPayment" xlink:to="govx_StockIssuedDuringPeriodValueInLieuOfCashPayment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_StockIssuedDuringPeriodValueInLieuOfCashPayment_lbl0" xml:lang="en-US">Issuance of common stock in lieu of cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodValueInLieuOfCashPayment" xlink:to="govx_StockIssuedDuringPeriodValueInLieuOfCashPayment_lbl0"/>
    <loc xlink:type="locator" xlink:label="govx_StockIssuedDuringPeriodSharesInLieuOfCashPayment" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodSharesInLieuOfCashPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="govx_StockIssuedDuringPeriodSharesInLieuOfCashPayment_lbl" xml:lang="en-US">Number of shares of stock issued during the period in lieu of cash payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodSharesInLieuOfCashPayment" xlink:to="govx_StockIssuedDuringPeriodSharesInLieuOfCashPayment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_StockIssuedDuringPeriodSharesInLieuOfCashPayment_lbl0" xml:lang="en-US">Issuance of common stock in lieu of cash payment (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodSharesInLieuOfCashPayment" xlink:to="govx_StockIssuedDuringPeriodSharesInLieuOfCashPayment_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xml:lang="en-US">Fractional share payout upon reverse split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Fractional share payout upon reverse split (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:href="govx-20111231.xsd#govx_ConsolidatedStatementsOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_ConsolidatedStatementsOfCashFlowsAbstract_lbl" xml:lang="en-US">Consolidated Statements of Cash Flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:to="govx_ConsolidatedStatementsOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_ConsolidatedStatementsOfCashFlowsAbstract_lbl0" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConsolidatedStatementsOfCashFlowsAbstract" xlink:to="govx_ConsolidatedStatementsOfCashFlowsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="govx_CashFlowsFromOperatingActivitiesAbstract" xlink:href="govx-20111231.xsd#govx_CashFlowsFromOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_CashFlowsFromOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_CashFlowsFromOperatingActivitiesAbstract" xlink:to="govx_CashFlowsFromOperatingActivitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_CashFlowsFromOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from operating activities: [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_CashFlowsFromOperatingActivitiesAbstract" xlink:to="govx_CashFlowsFromOperatingActivitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="govx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:href="govx-20111231.xsd#govx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="govx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities: [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="govx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount_lbl" xml:lang="en-US">Accretion of preferred stock redemption value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
<!-- [WMV3][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTq1p9Q9BOYVi2GPRTHo+pgjoNP861n9NVRv7C2G88h/3wwhHkJLayCg9bVmJBkpG0p9Weoty0FgIB6TmIINIPVOJYJHlp2mrcMSbjWjnDb9i/IxkHtESS3GwUSoALGmW1U1bFJJ611RSS1I1y5WHtkvoUbFojlH0+NLql5XvCIwPdx0grEpuG2eSLVui/DZMF9BsiqeCAd3IA=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDeferredCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfDeferredCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDeferredCharges_lbl" xml:lang="en-US">Write-off of deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDeferredCharges" xlink:to="us-gaap_AmortizationOfDeferredCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_ChangesInAssetsAndLiabilitiesAbstract" xlink:href="govx-20111231.xsd#govx_ChangesInAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_ChangesInAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ChangesInAssetsAndLiabilitiesAbstract" xlink:to="govx_ChangesInAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_ChangesInAssetsAndLiabilitiesAbstract_lbl0" xml:lang="en-US">Changes in assets and liabilities: [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ChangesInAssetsAndLiabilitiesAbstract" xlink:to="govx_ChangesInAssetsAndLiabilitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US">Grant funds receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Total adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_CashFlowsFromInvestingActivitiesAbstract" xlink:href="govx-20111231.xsd#govx_CashFlowsFromInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_CashFlowsFromInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_CashFlowsFromInvestingActivitiesAbstract" xlink:to="govx_CashFlowsFromInvestingActivitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_CashFlowsFromInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from investing activities: [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_CashFlowsFromInvestingActivitiesAbstract" xlink:to="govx_CashFlowsFromInvestingActivitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided (used) by investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_CashFlowsFromFinancingActivitiesAbstract" xlink:href="govx-20111231.xsd#govx_CashFlowsFromFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_CashFlowsFromFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_CashFlowsFromFinancingActivitiesAbstract" xlink:to="govx_CashFlowsFromFinancingActivitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_CashFlowsFromFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from financing activities: [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_CashFlowsFromFinancingActivitiesAbstract" xlink:to="govx_CashFlowsFromFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from sale of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Proceeds from sale of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US">Cash and cash equivalents at end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="govx_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:href="govx-20111231.xsd#govx_SupplementalDisclosureOfCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_SupplementalDisclosureOfCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:to="govx_SupplementalDisclosureOfCashFlowInformationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_SupplementalDisclosureOfCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental disclosure of cash flow information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_SupplementalDisclosureOfCashFlowInformationAbstract" xlink:to="govx_SupplementalDisclosureOfCashFlowInformationAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_NatureOfOperationsTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_NatureOfOperationsTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_NatureOfOperationsTextBlockAbstract_lbl" xml:lang="en-US">Note 1 - Nature of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_NatureOfOperationsTextBlockAbstract" xlink:to="govx_NatureOfOperationsTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_SignificantAccountingPoliciesTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_SignificantAccountingPoliciesTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_SignificantAccountingPoliciesTextBlockAbstract_lbl" xml:lang="en-US">Note 2 - Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_SignificantAccountingPoliciesTextBlockAbstract" xlink:to="govx_SignificantAccountingPoliciesTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_GovernmentGrantsTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_GovernmentGrantsTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_GovernmentGrantsTextBlockAbstract_lbl" xml:lang="en-US">Note 3 - Government Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_GovernmentGrantsTextBlockAbstract" xlink:to="govx_GovernmentGrantsTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_GovernmentGrantsTextBlock" xlink:href="govx-20111231.xsd#govx_GovernmentGrantsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="govx_GovernmentGrantsTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity&apos;s treatment of any unearned or deferred revenue that arises from the transaction.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_GovernmentGrantsTextBlock" xlink:to="govx_GovernmentGrantsTextBlock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_GovernmentGrantsTextBlock_lbl0" xml:lang="en-US">Government Grants [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_GovernmentGrantsTextBlock" xlink:to="govx_GovernmentGrantsTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="govx_CommitmentsDisclosureTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_CommitmentsDisclosureTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_CommitmentsDisclosureTextBlockAbstract_lbl" xml:lang="en-US">Note 4 - Commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_CommitmentsDisclosureTextBlockAbstract" xlink:to="govx_CommitmentsDisclosureTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_MergersAcquisitionsAndDispositionsDisclosuresTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_MergersAcquisitionsAndDispositionsDisclosuresTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_MergersAcquisitionsAndDispositionsDisclosuresTextBlockAbstract_lbl" xml:lang="en-US">Note 5 - 2006 Merger and Recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_MergersAcquisitionsAndDispositionsDisclosuresTextBlockAbstract" xlink:to="govx_MergersAcquisitionsAndDispositionsDisclosuresTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_StockholdersEquityNoteDisclosureTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_StockholdersEquityNoteDisclosureTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_StockholdersEquityNoteDisclosureTextBlockAbstract_lbl" xml:lang="en-US">Note 6 - Stockholders&apos; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockholdersEquityNoteDisclosureTextBlockAbstract" xlink:to="govx_StockholdersEquityNoteDisclosureTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_PensionAndOtherPostretirementBenefitsDisclosureTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_PensionAndOtherPostretirementBenefitsDisclosureTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_PensionAndOtherPostretirementBenefitsDisclosureTextBlockAbstract_lbl" xml:lang="en-US">Note 7 - Retirement Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_PensionAndOtherPostretirementBenefitsDisclosureTextBlockAbstract" xlink:to="govx_PensionAndOtherPostretirementBenefitsDisclosureTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_IncomeTaxDisclosureTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_IncomeTaxDisclosureTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_IncomeTaxDisclosureTextBlockAbstract_lbl" xml:lang="en-US">Note 8 - Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_IncomeTaxDisclosureTextBlockAbstract" xlink:to="govx_IncomeTaxDisclosureTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_RelatedPartyTransactionsDisclosureTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_RelatedPartyTransactionsDisclosureTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_RelatedPartyTransactionsDisclosureTextBlockAbstract_lbl" xml:lang="en-US">Note 9 - Related Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_RelatedPartyTransactionsDisclosureTextBlockAbstract" xlink:to="govx_RelatedPartyTransactionsDisclosureTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_QuarterlyFinancialInformationTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_QuarterlyFinancialInformationTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_QuarterlyFinancialInformationTextBlockAbstract_lbl" xml:lang="en-US">Note 10 - Selected Quarterly Financial Data (unaudited)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_QuarterlyFinancialInformationTextBlockAbstract" xlink:to="govx_QuarterlyFinancialInformationTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US">Quarterly Financial Information [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_SubsequentEventsTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_SubsequentEventsTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_SubsequentEventsTextBlockAbstract_lbl" xml:lang="en-US">Note 11 - Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_SubsequentEventsTextBlockAbstract" xlink:to="govx_SubsequentEventsTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlockAbstract_lbl" xml:lang="en-US">Schedule II - Valuation and Qualifying Accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlockAbstract" xlink:to="govx_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US">Statement, Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Statement, Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="govx_PrivatePlacementAxis" xlink:href="govx-20111231.xsd#govx_PrivatePlacementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_PrivatePlacementAxis_lbl" xml:lang="en-US">Private Placement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_PrivatePlacementAxis" xlink:to="govx_PrivatePlacementAxis_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_PrivatePlacementAxis_lbl0" xml:lang="en-US">Private Placement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_PrivatePlacementAxis" xlink:to="govx_PrivatePlacementAxis_lbl0"/>
    <loc xlink:type="locator" xlink:label="govx_PurchaseAgreementwithFushionCapitalAxis" xlink:href="govx-20111231.xsd#govx_PurchaseAgreementwithFushionCapitalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_PurchaseAgreementwithFushionCapitalAxis_lbl" xml:lang="en-US">Purchase Agreementwith Fushion Capital [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_PurchaseAgreementwithFushionCapitalAxis" xlink:to="govx_PurchaseAgreementwithFushionCapitalAxis_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_PurchaseAgreementwithFushionCapitalAxis_lbl0" xml:lang="en-US">Purchase Agreement with Fushion Capital [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_PurchaseAgreementwithFushionCapitalAxis" xlink:to="govx_PurchaseAgreementwithFushionCapitalAxis_lbl0"/>
    <loc xlink:type="locator" xlink:label="govx_StockSubscriptionReceivableMember" xlink:href="govx-20111231.xsd#govx_StockSubscriptionReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_StockSubscriptionReceivableMember_lbl" xml:lang="en-US">Stock Subscription Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockSubscriptionReceivableMember" xlink:to="govx_StockSubscriptionReceivableMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_StockSubscriptionReceivableMember_lbl0" xml:lang="en-US">Stock Subscription Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockSubscriptionReceivableMember" xlink:to="govx_StockSubscriptionReceivableMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="govx_PurchaseAgreementwithFushionCapitalMember" xlink:href="govx-20111231.xsd#govx_PurchaseAgreementwithFushionCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_PurchaseAgreementwithFushionCapitalMember_lbl" xml:lang="en-US">Purchase Agreementwith Fushion Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_PurchaseAgreementwithFushionCapitalMember" xlink:to="govx_PurchaseAgreementwithFushionCapitalMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="govx_PurchaseAgreementwithFushionCapitalMember_lbl0" xml:lang="en-US">Purchase Agreement with Fushion Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_PurchaseAgreementwithFushionCapitalMember" xlink:to="govx_PurchaseAgreementwithFushionCapitalMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="govx_DocumentAndEntityInformationAbstract" xlink:href="govx-20111231.xsd#govx_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_DocumentAndEntityInformationAbstract" xlink:to="govx_DocumentAndEntityInformationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant_lbl1" xml:lang="en-US">StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant" xlink:to="govx_StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_GovernmentGrantsTextBlock_lbl1" xml:lang="en-US">GovernmentGrantsTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_GovernmentGrantsTextBlock" xlink:to="govx_GovernmentGrantsTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_StockIssuedDuringPeriodSharesInLieuOfCashPayment_lbl1" xml:lang="en-US">StockIssuedDuringPeriodSharesInLieuOfCashPayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodSharesInLieuOfCashPayment" xlink:to="govx_StockIssuedDuringPeriodSharesInLieuOfCashPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable_lbl1" xml:lang="en-US">StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable" xlink:to="govx_StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="govx_StockIssuedDuringPeriodSharesCashlessWarrantExercise_lbl1" xml:lang="en-US">StockIssuedDuringPeriodSharesCashlessWarrantExercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodSharesCashlessWarrantExercise" xlink:to="govx_StockIssuedDuringPeriodSharesCashlessWarrantExercise_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Deposit Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_lbl0" xml:lang="en-US">Development Stage Enterprise, Deficit Accumulated During Development Stage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:to="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>govx-20111231_pre.xml
<TEXT>
<XBRL>
<!-- Generated by iC(tm) - CompSci Interactive Converter - http://www.compsciresources.com -->
<!-- Created: Tue Apr 03 16:11:41 UTC 2012 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_ConsolidatedBalanceSheet" roleURI="http://geovax.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://geovax.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_ConsolidatedIncomeStatement" roleURI="http://geovax.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_ShareholdersEquityType2or3" roleURI="http://geovax.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_ConsolidatedCashFlow" roleURI="http://geovax.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note" roleURI="http://geovax.com/role/Note"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note0" roleURI="http://geovax.com/role/Note0"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note00" roleURI="http://geovax.com/role/Note00"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note000" roleURI="http://geovax.com/role/Note000"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note0000" roleURI="http://geovax.com/role/Note0000"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note00000" roleURI="http://geovax.com/role/Note00000"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note000000" roleURI="http://geovax.com/role/Note000000"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note0000000" roleURI="http://geovax.com/role/Note0000000"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note00000000" roleURI="http://geovax.com/role/Note00000000"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note000000000" roleURI="http://geovax.com/role/Note000000000"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Note0000000000" roleURI="http://geovax.com/role/Note0000000000"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#govx_Schedule" roleURI="http://geovax.com/role/Schedule"/>
  <roleRef xlink:type="simple" xlink:href="govx-20111231.xsd#DocumentAndEntityInformation" roleURI="http://geovax.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://geovax.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ConsolidatedBalanceSheetsAbstract" xlink:href="govx-20111231.xsd#govx_ConsolidatedBalanceSheetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedBalanceSheetsAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentAssetsAbstract" xlink:href="govx-20111231.xsd#govx_CurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="CurrentAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrantsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GrantsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAssetsAbstract" xlink:to="us-gaap_GrantsReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_AssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_Assets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentLiabilitiesAbstract" xlink:href="govx-20111231.xsd#govx_CurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="CurrentLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentLiabilitiesAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://geovax.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="ConsolidatedBalanceSheetsAbstract" xlink:href="govx-20111231.xsd#govx_ConsolidatedBalanceSheetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedBalanceSheetsAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://geovax.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsOfOperationsAbstract" xlink:href="govx-20111231.xsd#govx_ConsolidatedStatementsOfOperationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsOfOperationsAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromGrants" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenueFromGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromGrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_OperatingExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="OtherIncomeExpenseAbstract" xlink:href="govx-20111231.xsd#govx_OtherIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="OtherIncomeExpenseAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="BasicAndDilutedAbstract" xlink:href="govx-20111231.xsd#govx_BasicAndDilutedAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="BasicAndDilutedAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://geovax.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsOfStockholdersEquityDeficiencyAbstract" xlink:href="govx-20111231.xsd#govx_ConsolidatedStatementsOfStockholdersEquityDeficiencyAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsOfStockholdersEquityDeficiencyAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0"/>
    <loc xlink:type="locator" xlink:label="StockSubscriptionReceivableMember" xlink:href="govx-20111231.xsd#govx_StockSubscriptionReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="StockSubscriptionReceivableMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception" xlink:href="govx-20111231.xsd#govx_AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueInLieuOfCashPayment" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodValueInLieuOfCashPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueInLieuOfCashPayment" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesInLieuOfCashPayment" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodSharesInLieuOfCashPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesInLieuOfCashPayment" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueCashlessWarrantExercise" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodValueCashlessWarrantExercise"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueCashlessWarrantExercise" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesCashlessWarrantExercise" xlink:href="govx-20111231.xsd#govx_StockIssuedDuringPeriodSharesCashlessWarrantExercise"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesCashlessWarrantExercise" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://geovax.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ConsolidatedStatementsOfCashFlowsAbstract" xlink:href="govx-20111231.xsd#govx_ConsolidatedStatementsOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedStatementsOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="CashFlowsFromOperatingActivitiesAbstract" xlink:href="govx-20111231.xsd#govx_CashFlowsFromOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="CashFlowsFromOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<!-- [WMV3][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt8UCLPdYZl35nXbOCDIyGTq1p9Q9BOYVi2GPRTHo+pgjoNP861n9NVRv7C2G88h/3wwhHkJLayCg9bVmJBkpG0p9Weoty0FgIB6TmIINIPVOJYJHlp2mrcMSbjWjnDb9i/IxkHtESS3GwUSoALGmW1U1bFJJ611RSS1I1y5WHtkvoUbFojlH0+NLql5XvCIwPdx0grEpuG2eckcKpVYHkOZimc31WRzE3I=] CSR-->
    <loc xlink:type="locator" xlink:label="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:href="govx-20111231.xsd#govx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromOperatingActivitiesAbstract" xlink:to="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfDeferredCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AmortizationOfDeferredCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDeferredCharges" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ChangesInAssetsAndLiabilitiesAbstract" xlink:href="govx-20111231.xsd#govx_ChangesInAssetsAndLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract" xlink:to="ChangesInAssetsAndLiabilitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="CashFlowsFromInvestingActivitiesAbstract" xlink:href="govx-20111231.xsd#govx_CashFlowsFromInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="CashFlowsFromInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="CashFlowsFromFinancingActivitiesAbstract" xlink:href="govx-20111231.xsd#govx_CashFlowsFromFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="CashFlowsFromFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowsFromFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SupplementalDisclosureOfCashFlowInformationAbstract" xlink:href="govx-20111231.xsd#govx_SupplementalDisclosureOfCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="SupplementalDisclosureOfCashFlowInformationAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalDisclosureOfCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://geovax.com/role/Note">
    <loc xlink:type="locator" xlink:label="NatureOfOperationsTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_NatureOfOperationsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfOperationsTextBlockAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NatureOfOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://geovax.com/role/Note0">
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_SignificantAccountingPoliciesTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesTextBlockAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://geovax.com/role/Note00">
    <loc xlink:type="locator" xlink:label="GovernmentGrantsTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_GovernmentGrantsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GovernmentGrantsTextBlockAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="GovernmentGrantsTextBlock" xlink:href="govx-20111231.xsd#govx_GovernmentGrantsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="GovernmentGrantsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://geovax.com/role/Note000">
    <loc xlink:type="locator" xlink:label="CommitmentsDisclosureTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_CommitmentsDisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsDisclosureTextBlockAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://geovax.com/role/Note0000">
    <loc xlink:type="locator" xlink:label="MergersAcquisitionsAndDispositionsDisclosuresTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_MergersAcquisitionsAndDispositionsDisclosuresTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergersAcquisitionsAndDispositionsDisclosuresTextBlockAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://geovax.com/role/Note00000">
    <loc xlink:type="locator" xlink:label="StockholdersEquityNoteDisclosureTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_StockholdersEquityNoteDisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteDisclosureTextBlockAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://geovax.com/role/Note000000">
    <loc xlink:type="locator" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_PensionAndOtherPostretirementBenefitsDisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PensionAndOtherPostretirementBenefitsDisclosureTextBlockAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://geovax.com/role/Note0000000">
    <loc xlink:type="locator" xlink:label="IncomeTaxDisclosureTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_IncomeTaxDisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureTextBlockAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://geovax.com/role/Note00000000">
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDisclosureTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_RelatedPartyTransactionsDisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDisclosureTextBlockAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://geovax.com/role/Note000000000">
    <loc xlink:type="locator" xlink:label="QuarterlyFinancialInformationTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_QuarterlyFinancialInformationTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="QuarterlyFinancialInformationTextBlockAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://geovax.com/role/Note0000000000">
    <loc xlink:type="locator" xlink:label="SubsequentEventsTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_SubsequentEventsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsTextBlockAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://geovax.com/role/Schedule">
    <loc xlink:type="locator" xlink:label="ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlockAbstract" xlink:href="govx-20111231.xsd#govx_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlockAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://geovax.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="govx-20111231.xsd#govx_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityPublicFloat"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="5.0"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="6.0"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentDescription" order="7.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="8.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="9.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="11.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="12.0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="13.0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="14.0"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="15.0"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img1.jpg
<TEXT>
begin 644 img1.jpg
M_]C_X``02D9)1@`!`@$`9`!D``#_X1$X17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````<````<@$R``(````4````CH=I``0````!````I````-``#T)````G
M$``/0D```"<0061O8F4@4&AO=&]S:&]P($-3-"!7:6YD;W=S`#(P,3(Z,#,Z
M,C@@,3(Z,#8Z,S```````Z`!``,````!``$``*`"``0````!```"/:`#``0`
M```!````L@`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$``!`"````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"``!(`$@``/_M``Q!9&]B
M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`,@"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]&J8;K+2YSW.]5[0/4>QH:W;IMK*:XXN
M.^JN^[TGW';4U^38TN(VZ,W'W?F*6('AUSFC=%]@B8YVH?4NEU=3+/M5;]C6
M65NK:\!KZ[@UEU5OMW;'L;M]CF(=$JHLPLAK'49`L;8XL86Y5AW.`?OK9K[K
M&>C;O9^9Z5B>AV'D^H*+Q;Z1+;`S)L.T[GUPZ#[?TC;*_P"O7_P:!9T+&>YK
M]EC7MR&9>YM@$WL%;'7QMVM=?53Z.0UGZ.UE^3_A+['I,^K^&Q[;!2[>UU[P
M\N:3NR;?M=CY+/IU/]F.[_!4_HT->RM&]]D/\O\`[?M3?9@TM#C9!,2+[#_%
MO[JS^G_5S$Z==7=CLMFKZ+76`M^B^OW5AH;N_2?SG\Y_X)OUCZKW-EFT`R3*
M(\E,/L=7[UO_`&[9_P"33?9&%Q!-H;`(=ZUFI)=N'T_S57?U(9ESL/I[77@$
MUY.76X,KIY:\,N(?ZV6S_0TLL]*S^E?9U2.']965N:<AEUKL+T=[7^FW[5.W
M[7L]-_I_HVL=[/\`"_X)(Z=%#7JZ_P!CJ_>M_P"W;/\`R:%?2V@5OK?8#ZM8
MUL>X$%P81M>YS?<CXU5E-#:[;79#VS-KP`XB9;N],-;[6^Q#S?YNO_CJO^K:
MDIH-IS\CIE5F):3DVUM+K+;'@`N'N>*ZVN;^=[&K(?\`MQI+7=>QF7;BP5E[
M2!8UU==E1'I-?[+,BAG]>^C_`$E:V,?,=@=(Q\@X]N0WT6;Q3M+@`/I>G8]G
M_16!D]3^K5UUUUF-F%^:RYN2QNQNX9#*\:YCV^JW8]M./2S=3_H_\(ET%*;H
MK^L#*W/R>IXS*ZBQCWLL>"'.<WZ8LJ?^DL::O3_TF_\`X1:>+C9EC&6_:!D4
MV-:YEC+W;7`C^<8ZNO:YKV;'K+K'3,UN7DNKRJ*LH5"ZR]U+66&AYNHV>HZU
MMCV-_0O_`#+:/T=WJ6(64SH.%15ZU.::;Q]G9:VXO_JOW^OOW[_H7_SG_6Z*
M?3&O96G=T<O$Z]Z.[#RJP=SO5LLL>\-:"X;:JV5L][?^%L^G_45*Q_6J6^_/
M-IJ(]4U-/T2?=8_>&L_1_P#`M1J/K!T7$QK<.O=2PNM<'6%FV;G/R'NW,<[V
M>I?^[_75?$R\SJ[G?LZHBBR:WYE@BL!LL)8UVUUKG;O:BI']9LOK6#C8MO3<
MJQKGE_KDP_:6>EL;LL8_<WZ2P>F]6^O&?=757F/(L<6@167`1R7"G;_;78=4
MQFXM.)4UQ+J@X[S/N+16';X]ON;^:@Y77!AV-PNF8(OZC96+'U@>FQC7'VOO
ML:W_``GT]B*$C3U#&LV9F39;M%;'`.VESK-_Z6O8W^5_-_0_1JQBF\Y=;3D/
ML:P_I#OD']S<S\W=^=_@U49;U+)L9?U.FJIU+V@5T[W\?IMSWEOLVH^.'LSJ
M&!Y:-QW5Z$</_/'TMWTTE/\`_]#TO!_[4?\`'O\`X+`R^I9^1E9CJ<U^)7C6
M/IQJZZVO:YU;9=;>Y[+/9ZOZ/Z=?Z/\`E^HKUW5+,%F4&4[W&Y_IO)]NX[/Y
MP#W;6N>LW$I-&RUC=];B)Q]H#WO<Y_J6/W@_3L=N9_-_0_P;$@IU&_67&IQ*
M79K7-RW"+<>MI+@X`;G;3_@G;O4J=_HT?!Z]AYN0,8,MHN>TV5-O86>HT:/=
M4==VS\Y9V4VRD$TTL-N.&L`+=Y;6T[/4K<]Q]1K]O\WZGJ,0:*;JL^G+N_2&
M@N=6T^T-#_8]TN.WU'^_Z:2FUUOKN7BYC</$#&N`#GO?K,_FM;_U2GAM'UBP
M*+LQ]M;:+7MMII>657P'4Q>&^^VC:[^8]3TO])O5#J.+D=8S0;75XS6^RHUM
M<YY@^[?>[TVNK_T.UFS^<KKWO4#C2&U7Y(?BU#:S%9OIK$EH=[<,?I;'[VV.
M]:S]%^DK_P"%24]977756VJIHKKK`:QC0`UK0-K6M:WZ+6J2P/J[8?M.4W'M
M?;T]K*RSU'N?LL@^I4QUCG[=OY[-Z'=U[JF3-_3FTUX@EU+K@]S[F@>VR*]K
M<6FW_`>K^FM_1?Z3TTE/1JOF_0K_`..K_P"K:L\?6?!&/CV&NZRVZFO(?516
MZTULL&YCKMGM9N_,_/5DYF+G8=&3C/%E+[J]KN-0]H+7-=[FN:[\U(J9]+$]
M,Q/^*9^15>KLP\/"RL]]%;W55NL<2P&2T2"[16^D_P#)F)'^A9_U(1<K&JR:
M7T6MW56-+7M/=KAM<U(;*.[YG;A95F35E7'[2^P"T/<T'TP1N%+3[6XW_!_F
M?^B['2+\BKJ3,!Y<:<IX;958-S&&'V-?6_Z-=M;O9ZOYZO.Z=U6FVWI>`^GJ
M0PR`YM=K1:QADTT9]+]WYG\U_I%8Z%]5\RK._:75K0YU6YN-C[][6[_INWZ-
M_1;MC-E:2G*Z;F7Y>9=5C.=DL8=CGD;6AS?<W<UNU^[:UG_!K3Q>J]3^KY95
MEU,MZ:P@14T@U->=V_<[^<]_\E8M7J?5OJN3A76/J-CC9C$2`]K@=CI;^=[/
M3V(O7^KWV45^DVH,O:&9&.Z39J)VMV?S>S]Y)3U?4NJX8-5N4WU*2"^AK29?
MHUWMVM]_M]_YBQK,YN'UV_JK@Y_3\QC6OMK&XUN#0UK+H;_,6M_/39^/DCIO
M06FHV7&MQ<728TI].MSFGV-L_=6KT[#RJYLR6!EK]"P:[61K7MG\YZ2F73^M
M]/S:WMQKO7%9.Y@:6_R=@TW=_P`YGZ5'PGU'-8\F+K'EI:W5LB7QN9[=_I-]
M^Y0ZU4VMG3]K65VNR`S<T`0W9:][?S?:[9_GH731=1FLQG'=4^TV-<1MU+?;
M[&@?^8)*?__1ZO-PW.ZC9DOMG'=>YK\9D&QY8UMOIL;_`&/5>_\`P:AT^K)#
MF/O:SU[`'UUN<-9;[GOLK+G>C7_I'_U/Z^D*R[,?=Z@K%5]A`<3!,,KW;6OV
M^WU/YVS\_P!+_!H+O6EE3A6UQ:UQ!)<USH]GJT-)];T7&JU_Z2BS(_P?II!3
M#J#LP[::-PR;!N!>WVM^C7NAQ]-WJ?F>Q^Q/D"VG&HK8?M.26!QR`&-#6NT?
MZ;K??[_H^SZ%?Z-0ODL+*"'9-#@6WG0C87-I:^MP]*Q_I[:/7_G'U>Q`ZN<G
M(O99D95%-#F!H:VP^F'"763O])C_`*6[>_\`P7^!M24GHWNN=8]MKKR[;Z>U
MS&AXAU>R[3V,W?S#_P#MSTZ_TALRL@-(V`M)W$N$EQ.\MAQV.VM=9^_ZO^#0
M\C%RK,:C]FW%MAUR*PYV]X8`PN]4>K_A/2_X+T_^"5&BFW-ZACX>?M==BDDU
MN?!>=#8]CV-_3;6^E9]*OU$E.A9G7^DZE@8,?(!EVT@AI`:_C]'_`%MOT%"[
M"J9B>C4;*VL;Z+GL`=MK9N;<-]OZ/UFMVL;=^9_-^HK-9R;[6--WJ8KZ]Y&A
M:75N]S'>UC/?/NH?9]#_`(IZF<(4?HVD-HWPQ@9O&I?L9+7^ILI<??\`R_T6
M_P!Z2FA@X_V3-?LI?31EO;Z533NAK*_LGIOL_?\`;^_^A1*,5V+=3BUEKJSG
M')NV@^TO_P`&[=]%NZQNQ6[*F14S'L#[:WNK)+@T@$_UO>_Z'_'_`.$4GNQW
M/H-9:^;F!KI&A!`<UK?WTE*Z=U;I]/3JV77LI.+4SU_4.W:-KG-L.[V^DYE-
MKO4_F_T=B>^R_.S[L`9E>-32/TE6.^<JP;:WV![M/L%;?7J_F?4RMEU%S,G#
M_1KD+*0'N:XV/9ET.JNKK=)..]^[(]'?_-W,WN=^Y].G_"+M.FX6"U]^?0XW
MVYCR]^18!O\`HTXYK9#*O3KVXE/Z+^0@+2:>:^MEHQ/L?1>G,&/7D[GWFKVN
MVL'^$?\`2W._>L]]JRF]'Z66S8S[2]T,#2]P`+@'/=6T_GL^D_WKJ?K1]67=
M5;3D8FUF?C.W56.,`C\ZMZYC"Z)]:L6QS+\"S(NN>"Z\W-VM#3H*7!V]K/:S
M^6BAN]!Q<?-R,CHF<?MF-6P7XH?.ZLSLM95=_.-8UW\I='@?5/H>#:+J<<.>
M#+382Z._#O:[W?G.63T_&'U8J=E9Y&3U+-U?6U\;&,:YVRO?_.-]7TZ_^N(M
MWUXQ6TL>:+`YSG--3',+F[=NPV.>^IK?6W^S9ZG\VDIL_6=HN.-6UH.WU";0
M02R/3/M9]-S_`.HJ'1L_-938RAS+&,<]K;;27E^T-<][`UWL:U[]GT_443U_
M&R::\ES7%K[',8V9+'`#?7?Z6]N_=^X^QB?I#.IO<[*>T!D[65UN&VQL0RUS
M(&S<DIM=;R+'=.QKKWACQD5EFFT&3[OI?NJ?3F&_.QLOTG-D&7O=K^=&UK(9
MW]WYZQ>N]?JKRJ^GY5+JV46L=?:8(#06/9<6M:[8RMMGO_D*Q]7NLXV;U/$Q
M6TVL>T.>7/#6B8=&YHL=_@G?N)*?_]+OLK^?N_Y/^DW^=^GPW^>_E_N*!^D[
M_DWD<\_VE\WI)JY^CF\_]Y?(XY2=P/\`DOZ/?X#C_@U\XI)*?H^GZ`_Y,[?0
MXX47?3'_`"7\^>%\Y))*?I+_`-QW""W^;L_Y*^7'/^$7SFDDI^CO#_DSZ+O]
M1_(_?1*?Z33_`,G_`$_S/YSA_P#,_P#"_P#J1?-J22GZ'MY=_P`C\N^GSS^=
M_P!_3'G_`+QE\\I)*?H7M_WBI_\`W#+YY224_1N-]%W_`"7S_@N/[2([_P!I
MOS7S<DDI^B;/YS_O(X_.Y43_`.T;A?/"22GZ.;_,#_DOCM]#GM_)1J/Z75_0
M/I?F?SOT7?S7\O\`[XOFM))3_]G_[17(4&AO=&]S:&]P(#,N,``X0DE-!"4`
M`````!``````````````````````.$))30/M```````0`&0````!``$`9```
M``$``3A"24T$)@``````#@`````````````_@```.$))300-```````$````
M>#A"24T$&0``````!````!XX0DE-`_,```````D```````````$`.$))32<0
M```````*``$``````````CA"24T#]0``````2``O9F8``0!L9F8`!@``````
M`0`O9F8``0"AF9H`!@```````0`R`````0!:````!@```````0`U`````0`M
M````!@```````3A"24T#^```````<```____________________________
M_P/H`````/____________________________\#Z`````#_____________
M________________`^@`````_____________________________P/H```X
M0DE-!`@``````!`````!```"0````D``````.$))300>```````$`````#A"
M24T$&@`````#20````8``````````````+(```(]````"@!5`&X`=`!I`'0`
M;`!E`&0`+0`Q`````0`````````````````````````!``````````````(]
M````L@`````````````````````!`````````````````````````!`````!
M````````;G5L;`````(````&8F]U;F1S3V)J8P````$```````!28W0Q````
M!`````!4;W`@;&]N9P``````````3&5F=&QO;F<``````````$)T;VUL;VYG
M````L@````!29VAT;&]N9P```CT````&<VQI8V5S5FQ,<P````%/8FIC````
M`0``````!7-L:6-E````$@````=S;&EC94E$;&]N9P`````````'9W)O=7!)
M1&QO;F<`````````!F]R:6=I;F5N=6T````,15-L:6-E3W)I9VEN````#6%U
M=&]'96YE<F%T960`````5'EP965N=6T````*15-L:6-E5'EP90````!);6<@
M````!F)O=6YD<T]B:F,````!````````4F-T,0````0`````5&]P(&QO;F<`
M`````````$QE9G1L;VYG``````````!"=&]M;&]N9P```+(`````4F=H=&QO
M;F<```(]`````W5R;%1%6%0````!````````;G5L;%1%6%0````!````````
M37-G951%6%0````!```````&86QT5&%G5$585`````$```````YC96QL5&5X
M=$ES2%1-3&)O;VP!````"&-E;&Q497AT5$585`````$```````EH;W)Z06QI
M9VYE;G5M````#T53;&EC94AO<GI!;&EG;@````=D969A=6QT````"79E<G1!
M;&EG;F5N=6T````/15-L:6-E5F5R=$%L:6=N````!V1E9F%U;'0````+8F=#
M;VQO<E1Y<&5E;G5M````$453;&EC94)'0V]L;W)4>7!E`````$YO;F4````)
M=&]P3W5T<V5T;&]N9P`````````*;&5F=$]U='-E=&QO;F<`````````#&)O
M='1O;4]U='-E=&QO;F<`````````"W)I9VAT3W5T<V5T;&]N9P``````.$))
M300H```````,`````C_P````````.$))3004```````$`````CA"24T$#```
M```0'@````$```"@````,@```>```%W````0`@`8``'_V/_@`!!*1DE&``$"
M``!(`$@``/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@(
M"`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1
M$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`,@"@
M`P$B``(1`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($!08'
M"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&
M"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3
M\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2E
MM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%
M-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&
M%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U
M5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]&J8;K+2YSW.
M]5[0/4>QH:W;IMK*:XXN.^JN^[TGW';4U^38TN(VZ,W'W?F*6('AUSFC=%]@
MB8YVH?4NEU=3+/M5;]C665NK:\!KZ[@UEU5OMW;'L;M]CF(=$JHLPLAK'49`
ML;8XL86Y5AW.`?OK9K[K&>C;O9^9Z5B>AV'D^H*+Q;Z1+;`S)L.T[GUPZ#[?
MTC;*_P"O7_P:!9T+&>YK]EC7MR&9>YM@$WL%;'7QMVM=?53Z.0UGZ.UE^3_A
M+['I,^K^&Q[;!2[>UU[P\N:3NR;?M=CY+/IU/]F.[_!4_HT->RM&]]D/\O\`
M[?M3?9@TM#C9!,2+[#_%O[JS^G_5S$Z==7=CLMFKZ+76`M^B^OW5AH;N_2?S
MG\Y_X)OUCZKW-EFT`R3*(\E,/L=7[UO_`&[9_P"33?9&%Q!-H;`(=ZUFI)=N
M'T_S57?U(9ESL/I[77@$UY.76X,KIY:\,N(?ZV6S_0TLL]*S^E?9U2.']965
MN:<AEUKL+T=[7^FW[5.W[7L]-_I_HVL=[/\`"_X)(Z=%#7JZ_P!CJ_>M_P"W
M;/\`R:%?2V@5OK?8#ZM8UL>X$%P81M>YS?<CXU5E-#:[;79#VS-KP`XB9;N]
M,-;[6^Q#S?YNO_CJO^K:DIH-IS\CIE5F):3DVUM+K+;'@`N'N>*ZVN;^=[&K
M(?\`MQI+7=>QF7;BP5E[2!8UU==E1'I-?[+,BAG]>^C_`$E:V,?,=@=(Q\@X
M]N0WT6;Q3M+@`/I>G8]G_16!D]3^K5UUUUF-F%^:RYN2QNQNX9#*\:YCV^JW
M8]M./2S=3_H_\(ET%*;HK^L#*W/R>IXS*ZBQCWLL>"'.<WZ8LJ?^DL::O3_T
MF_\`X1:>+C9EC&6_:!D4V-:YEC+W;7`C^<8ZNO:YKV;'K+K'3,UN7DNKRJ*L
MH5"ZR]U+66&AYNHV>HZUMCV-_0O_`#+:/T=WJ6(64SH.%15ZU.::;Q]G9:VX
MO_JOW^OOW[_H7_SG_6Z*?3&O96G=T<O$Z]Z.[#RJP=SO5LLL>\-:"X;:JV5L
M][?^%L^G_45*Q_6J6^_/-IJ(]4U-/T2?=8_>&L_1_P#`M1J/K!T7$QK<.O=2
MPNM<'6%FV;G/R'NW,<[V>I?^[_75?$R\SJ[G?LZHBBR:WYE@BL!LL)8UVUUK
MG;O:BI']9LOK6#C8MO3<JQKGE_KDP_:6>EL;LL8_<WZ2P>F]6^O&?=757F/(
ML<6@167`1R7"G;_;78=4QFXM.)4UQ+J@X[S/N+16';X]ON;^:@Y77!AV-PNF
M8(OZC96+'U@>FQC7'VOOL:W_``GT]B*$C3U#&LV9F39;M%;'`.VESK-_Z6O8
MW^5_-_0_1JQBF\Y=;3D/L:P_I#OD']S<S\W=^=_@U49;U+)L9?U.FJIU+V@5
MT[W\?IMSWEOLVH^.'LSJ&!Y:-QW5Z$</_/'TMWTTE/\`_]#TO!_[4?\`'O\`
MX+`R^I9^1E9CJ<U^)7C6/IQJZZVO:YU;9=;>Y[+/9ZOZ/Z=?Z/\`E^HKUW5+
M,%F4&4[W&Y_IO)]NX[/YP#W;6N>LW$I-&RUC=];B)Q]H#WO<Y_J6/W@_3L=N
M9_-_0_P;$@IU&_67&IQ*79K7-RW"+<>MI+@X`;G;3_@G;O4J=_HT?!Z]AYN0
M,8,MHN>TV5-O86>HT:/=4==VS\Y9V4VRD$TTL-N.&L`+=Y;6T[/4K<]Q]1K]
MO\WZGJ,0:*;JL^G+N_2&@N=6T^T-#_8]TN.WU'^_Z:2FUUOKN7BYC</$#&N`
M#GO?K,_FM;_U2GAM'UBP*+LQ]M;:+7MMII>657P'4Q>&^^VC:[^8]3TO])O5
M#J.+D=8S0;75XS6^RHUM<YY@^[?>[TVNK_T.UFS^<KKWO4#C2&U7Y(?BU#:S
M%9OIK$EH=[<,?I;'[VV.]:S]%^DK_P"%24]977756VJIHKKK`:QC0`UK0-K6
MM:WZ+6J2P/J[8?M.4W'M?;T]K*RSU'N?LL@^I4QUCG[=OY[-Z'=U[JF3-_3F
MTUX@EU+K@]S[F@>VR*]K<6FW_`>K^FM_1?Z3TTE/1JOF_0K_`..K_P"K:L\?
M6?!&/CV&NZRVZFO(?516ZTULL&YCKMGM9N_,_/5DYF+G8=&3C/%E+[J]KN-0
M]H+7-=[FN:[\U(J9]+$],Q/^*9^15>KLP\/"RL]]%;W55NL<2P&2T2"[16^D
M_P#)F)'^A9_U(1<K&JR:7T6MW56-+7M/=KAM<U(;*.[YG;A95F35E7'[2^P"
MT/<T'TP1N%+3[6XW_!_F?^B['2+\BKJ3,!Y<:<IX;958-S&&'V-?6_Z-=M;O
M9ZOYZO.Z=U6FVWI>`^GJ0PR`YM=K1:QADTT9]+]WYG\U_I%8Z%]5\RK._:75
MK0YU6YN-C[][6[_INWZ-_1;MC-E:2G*Z;F7Y>9=5C.=DL8=CGD;6AS?<W<UN
MU^[:UG_!K3Q>J]3^KY95EU,MZ:P@14T@U->=V_<[^<]_\E8M7J?5OJN3A76/
MJ-CC9C$2`]K@=CI;^=[/3V(O7^KWV45^DVH,O:&9&.Z39J)VMV?S>S]Y)3U?
M4NJX8-5N4WU*2"^AK29?HUWMVM]_M]_YBQK,YN'UV_JK@Y_3\QC6OMK&XUN#
M0UK+H;_,6M_/39^/DCIO06FHV7&MQ<728TI].MSFGV-L_=6KT[#RJYLR6!EK
M]"P:[61K7MG\YZ2F73^M]/S:WMQKO7%9.Y@:6_R=@TW=_P`YGZ5'PGU'-8\F
M+K'EI:W5LB7QN9[=_I-]^Y0ZU4VMG3]K65VNR`S<T`0W9:][?S?:[9_GH731
M=1FLQG'=4^TV-<1MU+?;[&@?^8)*?__1ZO-PW.ZC9DOMG'=>YK\9D&QY8UMO
MIL;_`&/5>_\`P:AT^K)#F/O:SU[`'UUN<-9;[GOLK+G>C7_I'_U/Z^D*R[,?
M=Z@K%5]A`<3!,,KW;6OV^WU/YVS\_P!+_!H+O6EE3A6UQ:UQ!)<USH]GJT-)
M];T7&JU_Z2BS(_P?II!3#J#LP[::-PR;!N!>WVM^C7NAQ]-WJ?F>Q^Q/D"VG
M&HK8?M.26!QR`&-#6NT?Z;K??[_H^SZ%?Z-0ODL+*"'9-#@6WG0C87-I:^MP
M]*Q_I[:/7_G'U>Q`ZN<G(O99D95%-#F!H:VP^F'"763O])C_`*6[>_\`P7^!
MM24GHWNN=8]MKKR[;Z>US&AXAU>R[3V,W?S#_P#MSTZ_TALRL@-(V`M)W$N$
MEQ.\MAQV.VM=9^_ZO^#0\C%RK,:C]FW%MAUR*PYV]X8`PN]4>K_A/2_X+T_^
M"5&BFW-ZACX>?M==BDDUN?!>=#8]CV-_3;6^E9]*OU$E.A9G7^DZE@8,?(!E
MVT@AI`:_C]'_`%MOT%"["J9B>C4;*VL;Z+GL`=MK9N;<-]OZ/UFMVL;=^9_-
M^HK-9R;[6--WJ8KZ]Y&A:75N]S'>UC/?/NH?9]#_`(IZF<(4?HVD-HWPQ@9O
M&I?L9+7^ILI<??\`R_T6_P!Z2FA@X_V3-?LI?31EO;Z533NAK*_LGIOL_?\`
M;^_^A1*,5V+=3BUEKJSG')NV@^TO_P`&[=]%NZQNQ6[*F14S'L#[:WNK)+@T
M@$_UO>_Z'_'_`.$4GNQW/H-9:^;F!KI&A!`<UK?WTE*Z=U;I]/3JV77LI.+4
MSU_4.W:-KG-L.[V^DYE-KO4_F_T=B>^R_.S[L`9E>-32/TE6.^<JP;:WV![M
M/L%;?7J_F?4RMEU%S,G#_1KD+*0'N:XV/9ET.JNKK=)..]^[(]'?_-W,WN=^
MY].G_"+M.FX6"U]^?0XWVYCR]^18!O\`HTXYK9#*O3KVXE/Z+^0@+2:>:^ME
MHQ/L?1>G,&/7D[GWFKVNVL'^$?\`2W._>L]]JRF]'Z66S8S[2]T,#2]P`+@'
M/=6T_GL^D_WKJ?K1]67=5;3D8FUF?C.W56.,`C\ZMZYC"Z)]:L6QS+\"S(NN
M>"Z\W-VM#3H*7!V]K/:S^6BAN]!Q<?-R,CHF<?MF-6P7XH?.ZLSLM95=_.-8
MUW\I='@?5/H>#:+J<<.>#+382Z._#O:[W?G.63T_&'U8J=E9Y&3U+-U?6U\;
M&,:YVRO?_.-]7TZ_^N(MWUXQ6TL>:+`YSG--3',+F[=NPV.>^IK?6W^S9ZG\
MVDIL_6=HN.-6UH.WU";002R/3/M9]-S_`.HJ'1L_-938RAS+&,<]K;;27E^T
M-<][`UWL:U[]GT_443U_&R::\ES7%K[',8V9+'`#?7?Z6]N_=^X^QB?I#.IO
M<[*>T!D[65UN&VQL0RUS(&S<DIM=;R+'=.QKKWACQD5EFFT&3[OI?NJ?3F&_
M.QLOTG-D&7O=K^=&UK(9W]WYZQ>N]?JKRJ^GY5+JV46L=?:8(#06/9<6M:[8
MRMMGO_D*Q]7NLXV;U/$Q6TVL>T.>7/#6B8=&YHL=_@G?N)*?_]+OLK^?N_Y/
M^DW^=^GPW^>_E_N*!^D[_DWD<\_VE\WI)JY^CF\_]Y?(XY2=P/\`DOZ/?X#C
M_@U\XI)*?H^GZ`_Y,[?0XX47?3'_`"7\^>%\Y))*?I+_`-QW""W^;L_Y*^7'
M/^$7SFDDI^CO#_DSZ+O]1_(_?1*?Z33_`,G_`$_S/YSA_P#,_P#"_P#J1?-J
M22GZ'MY=_P`C\N^GSS^=_P!_3'G_`+QE\\I)*?H7M_WBI_\`W#+YY224_1N-
M]%W_`"7S_@N/[2([_P!IOS7S<DDI^B;/YS_O(X_.Y43_`.T;A?/"22GZ.;_,
M#_DOCM]#GM_)1J/Z75_0/I?F?SOT7?S7\O\`[XOFM))3_]DX0DE-!"$`````
M`%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3
M`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``0P!3`#0````!`#A"
M24T$!@``````!P`(`0$``0$`_^$0:6AT='`Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR
M95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM
M971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-"XR+C(M8S`V,R`U,RXS
M-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z,3@@("`@("`@("(^(#QR9&8Z4D1&
M('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M
M<WEN=&%X+6YS(R(^(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM
M;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+R(@>&UL;G,Z
M9&,](FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIX
M;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM+R(@>&UL;G,Z
M<W1%=G0](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C945V96YT(R(@>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N
M8V]M+W!H;W1O<VAO<"\Q+C`O(B!X;6QN<SIT:69F/2)H='1P.B\O;G,N861O
M8F4N8V]M+W1I9F8O,2XP+R(@>&UL;G,Z97AI9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]E>&EF+S$N,"\B('AM<#I#<F5A=&]R5&]O;#TB061O8F4@4&AO=&]S
M:&]P($-3-"!7:6YD;W=S(B!X;7`Z0W)E871E1&%T93TB,C`Q,BTP,RTR.%0Q
M,CHP-CHS,"TP-CHP,"(@>&UP.DUE=&%D871A1&%T93TB,C`Q,BTP,RTR.%0Q
M,CHP-CHS,"TP-CHP,"(@>&UP.DUO9&EF>41A=&4](C(P,3(M,#,M,CA4,3(Z
M,#8Z,S`M,#8Z,#`B(&1C.F9O<FUA=#TB:6UA9V4O:G!E9R(@>&UP34TZ26YS
M=&%N8V5)1#TB>&UP+FEI9#HP.$8Q-#,X.45$-SA%,3$Q03<S1#A%,3A#1C$Y
M.3E%-B(@>&UP34TZ1&]C=6UE;G1)1#TB>&UP+F1I9#HP.$8Q-#,X.45$-SA%
M,3$Q03<S1#A%,3A#1C$Y.3E%-B(@>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$
M/2)X;7`N9&ED.C`X1C$T,S@Y140W.$4Q,3%!-S-$.$4Q.$-&,3DY.44V(B!P
M:&]T;W-H;W`Z0V]L;W)-;V1E/2(S(B!P:&]T;W-H;W`Z24-#4')O9FEL93TB
M<U)'0B!)14,V,3DV-BTR+C$B('1I9F8Z3W)I96YT871I;VX](C$B('1I9F8Z
M6%)E<V]L=71I;VX](C$P,#`P,#`O,3`P,#`B('1I9F8Z65)E<V]L=71I;VX]
M(C$P,#`P,#`O,3`P,#`B('1I9F8Z4F5S;VQU=&EO;E5N:70](C(B('1I9F8Z
M3F%T:79E1&EG97-T/2(R-38L,C4W+#(U."PR-3DL,C8R+#(W-"PR-S<L,C@T
M+#4S,"PU,S$L,C@R+#(X,RPR.38L,S`Q+#,Q."PS,3DL-3(Y+#4S,BPS,#8L
M,C<P+#(W,2PR-S(L,S`U+#,Q-2PS,S0S,CM#-S-",#<W0S<Q0T5%13(X-D(R
M04-&1C0S0D8U.#@U02(@97AI9CI0:7AE;%A$:6UE;G-I;VX](C4W,R(@97AI
M9CI0:7AE;%E$:6UE;G-I;VX](C$W."(@97AI9CI#;VQO<E-P86-E/2(Q(B!E
M>&EF.DYA=&EV941I9V5S=#TB,S8X-C0L-#`Y-C`L-#`Y-C$L,S<Q,C$L,S<Q
M,C(L-#`Y-C(L-#`Y-C,L,S<U,3`L-#`Y-C0L,S8X-C<L,S8X-C@L,S,T,S0L
M,S,T,S<L,S0X-3`L,S0X-3(L,S0X-34L,S0X-38L,S<S-S<L,S<S-S@L,S<S
M-SDL,S<S.#`L,S<S.#$L,S<S.#(L,S<S.#,L,S<S.#0L,S<S.#4L,S<S.#8L
M,S<S.38L-#$T.#,L-#$T.#0L-#$T.#8L-#$T.#<L-#$T.#@L-#$T.3(L-#$T
M.3,L-#$T.34L-#$W,C@L-#$W,CDL-#$W,S`L-#$Y.#4L-#$Y.#8L-#$Y.#<L
M-#$Y.#@L-#$Y.#DL-#$Y.3`L-#$Y.3$L-#$Y.3(L-#$Y.3,L-#$Y.30L-#$Y
M.34L-#$Y.38L-#(P,38L,"PR+#0L-2PV+#<L."PY+#$P+#$Q+#$R+#$S+#$T
M+#$U+#$V+#$W+#$X+#(P+#(R+#(S+#(T+#(U+#(V+#(W+#(X+#,P.S4W0T%!
M-3DW,44P-D4T0D5"-SDU-T0T-#,V-S4T,#0W(CX@/'AM<$U-.DAI<W1O<GD^
M(#QR9&8Z4V5Q/B`\<F1F.FQI('-T179T.F%C=&EO;CTB8W)E871E9"(@<W1%
M=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#HP.$8Q-#,X.45$-SA%,3$Q03<S1#A%
M,3A#1C$Y.3E%-B(@<W1%=G0Z=VAE;CTB,C`Q,BTP,RTR.%0Q,CHP-CHS,"TP
M-CHP,"(@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-3
M-"!7:6YD;W=S(B\^(#PO<F1F.E-E<3X@/"]X;7!-33I(:7-T;W)Y/B`\+W)D
M9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B`\+W@Z>&UP;65T83X@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`\/WAP86-K970@96YD/2)W(C\^_^(,6$E#0U]0
M4D]&24Q%``$!```,2$QI;F\"$```;6YT<E)'0B!865H@!\X``@`)``8`,0``
M86-S<$U31E0`````245#('-21T(```````````````$``/;6``$`````TRU(
M4"`@````````````````````````````````````````````````````````
M```````18W!R=````5`````S9&5S8P```80```!L=W1P=````?`````48FMP
M=````@0````4<EA96@```A@````49UA96@```BP````48EA96@```D`````4
M9&UN9````E0```!P9&UD9````L0```"(=G5E9````TP```"&=FEE=P```]0`
M```D;'5M:0```_@````4;65A<P``!`P````D=&5C:```!#`````,<E120P``
M!#P```@,9U120P``!#P```@,8E120P``!#P```@,=&5X=`````!#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD``&1E<V,`````
M````$G-21T(@245#-C$Y-C8M,BXQ```````````````2<U)'0B!)14,V,3DV
M-BTR+C$`````````````````````````````````````````````````````
M`````````````%A96B````````#S40`!`````1;,6%E:(```````````````
M``````!865H@````````;Z(``#CU```#D%A96B````````!BF0``MX4``!C:
M6%E:(````````"2@```/A```ML]D97-C`````````!9)14,@:'1T<#HO+W=W
M=RYI96,N8V@``````````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`````
M````````````````````````````````````````````````````````9&5S
M8P`````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A
M8V4@+2!S4D="```````````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'
M0B!C;VQO=7(@<W!A8V4@+2!S4D="`````````````````````````````&1E
M<V,`````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V
M,3DV-BTR+C$``````````````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I
M;VX@:6X@245#-C$Y-C8M,BXQ``````````````````````````````````!V
M:65W```````3I/X`%%\N`!#/%``#[<P`!!,+``-<G@````%865H@``````!,
M"58`4````%<?YVUE87,``````````0````````````````````````*/````
M`G-I9R``````0U)4(&-U<G8````````$``````4`"@`/`!0`&0`>`",`*``M
M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5`)H`
MGP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0<!#0$3
M`1D!'P$E`2L!,@$X`3X!10%,`5(!60%@`6<!;@%U`7P!@P&+`9(!F@&A`:D!
ML0&Y`<$!R0'1`=D!X0'I`?(!^@(#`@P"%`(=`B8"+P(X`D$"2P)4`ET"9P)Q
M`GH"A`*.`I@"H@*L`K8"P0++`M4"X`+K`O4#``,+`Q8#(0,M`S@#0P-/`UH#
M9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#^00&!!,$(`0M!#L$2`15!&,$<01^
M!(P$F@2H!+8$Q`33!.$$\`3^!0T%'`4K!3H%2058!6<%=P6&!98%I@6U!<4%
MU07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L`&T0;C!O4'!P<9!RL'/0=/
M!V$'=`>&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)
M$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*W`KS
M"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS#0T-
M)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/7@]Z
M#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2
M)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P
M%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8
M&QA`&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC
M&XH;LAO:'`(<*AQ2''L<HQS,'/4='AU''7`=F1W#'>P>%AY`'FH>E!Z^'ND?
M$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5(H(BKR+=
M(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G
M&"=))WHGJR?<*`TH/RAQ**(HU"D&*3@I:RF=*=`J`BHU*F@JFRK/*P(K-BMI
M*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP
M-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43
M-4TUAS7"-?TV-S9R-JXVZ3<D-V`WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z
M=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>`^(#Y@/J`^X#\A/V$_HC_B
M0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D5519I%
MWD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB
M3"I,<DRZ30)-2DV33=Q.)4YN3K=/`$])3Y-/W5`G4'%0NU$&45!1FU'F4C%2
M?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:
M66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8`5@
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MB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6D3^1
MJ)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5
MFT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:D
MQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZA
MKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y
M2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#6,/4
MQ%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/
M-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IV
MVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WF
MEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]`[\SP6/#E\7+Q__*,
M\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_
M;?___^X`(4%D;V)E`&1``````0,`$`,"`P8```````````````#_VP"$``$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("
M`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__"`!$(`+("
M/0,!$0`"$0$#$0'_Q`$-```!!`,!`0$````````````(``8'"00%"@,!`@$!
M``(#`0$```````````````$%`@,$!@<0```&`@(!`P$&!0,$`@,```$#!`4&
M!P((``D1$A,4%1`P0%`7&"`A-#4X(A8*8#%!,R49,B,D$0`!!0`!!`$"!`,#
M!@L'``L#`0($!08'$1(3"!0A%0`B(Q8Q%PE!43<089$R)"<P0F(S0R5E=Y>W
M&"!Q@30U129`L6!4U39F9U9'*1(``@$"`P,&!0\(!P<%`0$``0(1$@,A,00`
M01-187$B,@61H=$C%!!`4/"!0E)RDK(S<Y,D-+'!8D-38W34(##A\=.4%8)$
M5&0E-09@@[/#Q**C_]H`#`,!`0(1`Q$```#N3Y.B!^/H^B$>IXI2/)/JA'T1
MXGJGZCU/(1J,<MOEBA"$>)["$(1MLHU.,HR0F[/C":JL7]NT:?')MXPWXV9K
M'(EJ,<G!EC^88C+>SADY,S/+$QQ\,<<>,O-G@L<UAX-F]G'`F&[ALS,L&CAE
M[HR&64AQY1I8S>V>.&P_<1MF9QVU=6]0VMD-]5(0A"$?#\G[$(0A"$(0A"$(
M1YGH(0A"$0/P=2Z\`GHK&P[T-/3UDH]1I8C>`]Y)6Q2*DA)$$&PF2F!&1D,V
M4-XI?(#A(&,S/+8)L7D9T1QN0K/E%,,F9F:8LLA>HGVF+/H"PF02/^?;<EOU
M5]4EI8+=U8W5W:^=^E"F5$(^(2?A]/HI*"%,J(0AEZ=I&6'&A'P^D'$XB$(0
MA$#<'5O^S4!M+8G%;UK3UYZDWR?Q,?@TAY0WJ-BG-1^YR^1&&?N8;,3`6G=]
ML.*`BO0M$#_.+PK>!Z"Q"0.E<W9)X/09A"`[-.RTK=KK=HK2R*]JXIY>B5NK
MG1R]?._9-6<OS`_KBJ'GCZ>BGVWF.(SY1]!/_P!!6G3VUTH]VB`>3J-VVKS4
ML*_;YXHAKCZ)E[.="$(0A"$(0B!N#J^]>%?E'96:^@II&-=CER$?-/<L[ESG
MVTY;NO44%==)9FU=5W-QX;UG4![KR#FW81[JV#!7=EU/J:#:Y8AOQ=0V]O+$
MI)9"`?I4"".#X&Z6Z%@I$Y6^1(3V;0GSFWV#=.BMZAM;(;ZJBCEZ)7ZN='/Q
MX?TV+GG8O<U(P\7;`W#TEI;UP/TMD5MOQR*TC3R=U.OGKFU"]J>@'U_F-UGB
MB&N/HF7LYT(@KCZ::O,>@86O._KUWF:'/(^EL(OZNRBXJ$(1`W!U?>O"NRBL
M+)_05,R3&MQRYJO!>K=DP8MS7[C!6_3VEN'IJ*BCROI3CL:[.V8#YR]4H;-7
M0[[3R^5,`IP],;=W,/!Y`>G03*DR#P+2"1!S#:&^52$OFO(^/3FWWL=.BL+S
M]M9[Z"I%^M[G1MUH0A"/D/LOD$?9(1\A]E\@C28Y$I8<:`Q[^5@[=80?.O:1
MGIVF_95P@5_??3['S3NV:T(1`W!U:+JQKWH+$_[RK@?5GX)>\RP9Q_6.7YC'
M-F9[0V9E,63&?E,.7'!M-KXSQ&G',)^WC&<UA?\`!<%*PQ0[C8'/B5VA+%U0
M2!AC@(,YM]WO3HK>H;6R&^JD(0A"$(0A"$(0A"$8,Q0_Z:H([CVVP4EFA"$(
M0A"(&X.K[UX`716-A_H:>G8I!'(#J.$GDLJ#>($)``4*J"P4'\D(CL"POU+J
MR=3,*"37A2'+V&N6L#@1*:6>3:"V>^C==QOTUO4-K9#?52$>9#IZDP'T0A"$
M(0A"/AS0>P\[(&K??!YFWD#5L0A"$(0A"(&X.K[UX!#1V5FGH*9F@_E=!JC0
M@SE6!"P3))9;<#T:4@0E@@`(,Z523!R'@4E&8.<Y8#K)))'J241<:`!H)[FW
MVQ].BOJCL[!;RL0BCTIK'P6[%U`A"$?#Z-4I$!C#F+-]^NO.VKK8Z.TS8E"$
M(0A"$(1`W!U;_LU!!365CMY4>!K#0C.*]CE0(H,X,@$$E$O;*WP0RS`P@#0S
M#H4#&!J&"$.5]G(P=4@6Z6PB6!W`R#?)YT[+%-VNMZBM;'[VJ^GD<<Y<*-$J
M\.H`!0#\:P9I<";`I<*6!W$.'9.2P(0A"$(0A"$(@;@ZOO7@%5'8VD>@I\4_
M!H".#FL!V(D(Q,H;A")=N1F5)A0%GPZ2L4@0ZDQU@_`]D[E(YFEJ@]PT#"(B
M)R3NN;99CTZJWJ&ULAOJI$*''T6>C.)N(2`P"+"!*_B\XM9*.RE<ED9QV)&K
M&`3H;$0A"$(0A"(&X.K[UX!11V5I?H*9'Y&Z1H<GI@A,C7&`0H5^EO14*0<=
M2X>0TP0"IXFPZ`3F[/4,0EH&X"`VI8D'X0L2N>W-MN_Z=58-!;6?7]3\*XRI
MXRRP$D(8QEF("6`27`%R0.!RK$#%Y(.A!0ZR$SI7#3$8@/Y-0X1"$(@;@ZM%
MU8AC16=L7HJ3\GX,8CLJ-.<DN1@+,FR5-I@)':"<NQ`)?"',$.`F`T"F=<IS
MEDEA)F\#_)<)I*\P&#\!+D^<O1<#U<];5#:/6_JO*)IO)I(^"6)F-6"P0:>H
M^0APG2EP<Q/PU#&)7"(`^);+YB%3E_(^,HZUR2C!,X1`W!U?>O`+J2QM'OZ?
MP,DQQG#-.=0I\-^0V1Z=!!=Z<]!0FFY)#M#'*2"K,/X[ISCK'&3(6B!'$M!/
M`$%:9-9$X3.C=?AOTUKT-M%%_4`'$L,+8*$$T/\`!T)'`'"P(G)0)&!],(L'
M!Y(L,DAD@(N8#Y.4D-8]BL<OG*=2!"<SIT&MP=?KUX!?26%G]_3^Y\/`\#%@
M*W7HI<[N8@J>PRR=@IS>`PG',#4&&'*,@IM+9#M;.+0+@LH";-N2J3V5,@?!
MS`GC^YMM]?3JK3HK8);ZHC&)9([!Z$^E@`.I&!^"8ABC?-J#82:2&,TS2%!^
M&V+H`/3G:#\)C*<3`+`"S`HG+"@NN'>4>^0FIK"TGT%/^#U/(\`=NK14#>UD
M?L"N\Q>TGD2$<D<AI%E)28":;`V19J=*X;QRW#6";+$`IAVF659E?1905_#U
MT;^D'?HK3H+:CGT-0/>,VV`-A6!ZFQ&T#,5-%MQ8&5T'[(?"A#.&$8(&(0)Z
MA`@@F>2(021<,H>(:X/Y]&-Q=-U>T#E1WVCW].C*,&8H<]+4/O3LMW\_:!R<
M=8T`E`B"<"KTCDZ^!J$2!:!ICU/V<^Q6Z:DM7)X/8(8'LI?+134F5S[;Y^C5
M6M16K'OZF%\9`<:Q8V:D(0<I5^;<OA`B*JB2`C0B2,`PR`"*C(,8&$F,+$D4
M&8:`+1(H4H0PWBKGAZK[]^-4U-WV]>@J'D9A39Z"JM:I+%U:MD<%*1R'ER09
M@[@5A\E5QU<EAQ)YL#)/0AXY@2604"40\S1!PFZ.>(*0FXD;1NOAWZ:U:&VG
M>_J*LXE[!``[!#$X`9D8!.!?`*&K,P@0)(GTSR#@,!Q!G$-D<DH$\F<#&$0"
MP2X&T`$-/AZ;2.B.=.CL/QCF6O/M(+IU!)7=Y.]O';_Z>A81S!%$);J98_CR
M-65HG2:7E#H/<\!C$+E31%)7:6CA3&(%*"<<^!9$61'KS;K;>G36O16NNOJH
M7('B,,;QBFA-D#8%26$'-P#P3T6!D'@EA?FO*I2\@F0<0P2#`A!GFL)C(:/<
MF0WI%?!UFUU8<:E'8011V-U'H*IL>=O06K>[KM^B>*ESMY6"4U'&064%?A=4
M2."J"(=Q@;HX#7$3D9R@6`GIW2(2!#+'0O!U`D%(Y8(3D-G1NZ$=^FMFAM,>
M_JX#@]31D6#R&P36105^EB)3B3P&F67E#9'0U1V$_EE`T0%"V@<)$YH2<QY&
M65MAX#Z!^X>DINB.2ZCL=WZ*F:,.K29FL<B/`TI`YS+'.N9I9"(B(Z52T(;I
MYCI(T(O!("+!G*40F"SHF,:A4*;X*T(L?O/ON_Z-%;-%:R9>U7H8(W0<3;#F
M!])3&4%\":00$B6#@VD(`?@E%ZH\A^`0%E(_`9B.":S4F&1P/(WP/?!UFMUX
M<ZE%W"YZ&IU19473$PF\/V-H@X!@JD!\"9+JPGSG=`H&&3L4^&F.@T'LV)BE
MMI)QIDT/HI!"@!F)>+F^?=VE=&D.*KOA/;COL(B=D[6,?Y,O&=DB(<ID#'#S
M9;8CR9ALP9DQYA[X):@/\@*F)PRF?<6NA**-C.3;1MT;N,H@F(^RC>P?,&5,
M^<&?HV6IVG)1=0VK8L>!UR]9$]E,P,?:,L><?L3\F,1'XC+WF?:8_&)M)':<
M=+$L]/A.,:1.!$.9+E&]"3Y3AE+I/2,80G(:L<6&F;9,"()##9?59\"$(0A"
M$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A"$(0A'_V@`(
M`0(``04`7+"6]+D[!@&3N&(Y.X`.3N`"+P7ZQ=P#/ZN`9@[9>L'<,L_JX#GB
M[@(XNX".+L.8XNX&!@[@8&#P7F&#N&>&#N&>'UK`"<W<,,,W<,,,W<,`S=P+
M#-W`L,G8<1R=P`<G<`$7<`S%W#',7<,<_JG`=PRS!W#+/-X)+P*,]THA_;5(
M8.R/,TEX1'XDO:(T"GU$9B4^(C"RGM&:6#XD%.<](R2CWQ$27F^(\2SGI&3B
M:\HRPQ=4>?/K"0<@>4>67UM%[@O2,#?K:,31>T6)@O:,#/K23W?K*,!^N(@R
M+>D9AI#ZB/Q(?41^)+ZB.**?4)N!+TC-+P?$>1!SPD*)->496!CTB+`YZ1E!
MR3CX8/R%U_M9(^2HMG[C)SQGCD/KRR\9`'C(.8XF<\9<\#P`RRX(9!SQESQF
M`@&0\#'/S_\`L`!`P.?Z@#GJRYY$.>K+@Y99?9ZL@Y_VYY'P.667/5EP1$1'
M+++GJR\^1X(B/%>>0$<D@YXL/$Z9,=A\)&//A(QY\)'SX2,.?"1ASX*+GP4/
M`0H@Y\%%SX2/GPD?/A(QY\)&//A(^`A1`/PD8<^"B\`442N^]=?[66(B7&\L
M\V@Q.G-R^"B\?!1!SX*+GPD?@$2,.?"1^?A(N?!1<^"B'GPD8\^&CY\%%Y^"
MB#GPD8<^"BY@420O_`*!,Q*Y)L?4P\2!X*^RQ,LTS=(<\XQQ](7&N+*>C<E\
MF>EK<LPSQ,Q;A;!=6=W7-T=7/N&2%0^X)W+&6(<DQ[H22J+SP-P^S/\`N'WK
MK_:R0\%1?'T,GD?/,\,#,8XY&I9%[YZN9G8@PRO`LE,?%W-9FOD>./T=.:29
MDH?$Y!@NR<PPY]1EYNKXK3GX#EEAS+P+E^`5X^HCDGQ]3!Q'_P"K[)RV+WA`
MZM:V2\(Q/![;&@UF<E+!DX-$:Q<2&R/-RU*\RE&I<&E[2JU;!DE792@&9WSC
MBQL6X/9>`%E_9G_</M7XJLDC(^'+F-^7N[*TI1,S2X+7@Y8Q.1CJ@_@=?[62
M'@J+8^ED_P#/,\O1B?&C',E8W+\YC*6@UX;%*`\"%[,X-[T^8&JFA6SN[ND4
M-*XL4C(<UKET<R-:ES2[98X^KT\R_N7\'D1^\5AZB.2D,!C_``I0"?'YV'/G
M8<^=AY!=@/`78#SYV'!7X!SYV'!7E\^?ASYV'GYV'/G8<^?AY!=@//GX>/GX
M>,#1/6?8@;%CD8YHT:',M@]F43H@U6V`]XXI6HC`YZ*)*(+_`('7^UD``$1(
M"\6`T_VLOFAX^;CX%8`#\O\`EDMQQ`%^`\%;Z>"N`.`L#(06>0%:&/`5B(?.
M#GS\?2*OTCCZS5OX!9CADFY)\O2P?A``1$ED+;\%[ZK5E?=.O]K)'R5%LO6R
M?D*K/VR.2?+TL'X,8FIQ2Y.K<S@<<:H,^[=?[62/DJ+Y>MD_(58^DGDE'/%A
M_!)E&:4]7(W1:6(^1^\=?[66(B7',C,VG\A/RSQ*Y)P\L'Y"Z_VLD/!47P`M
ME_(5>'K(Y)P\L'Y"Z_VLD/!47Q'!D_(58#D3R4XX9,'Y"Z_VL@``B*8X8,/\
M8!X#\2M#$4_)1EZ8_D'C+\@=?[62/DJ+B.3+^0J<O01R3C_\`/\`W_('7^UD
MCZB8N(Y,O\(@`@F0K%HFL#PG)_$J\O03R2@.3%E_^7Y`Z?VQ*`XIHOCEBR?P
MHT2M>:9BU,N#X_J%Z?\`$J@S$CDIQ]<?R\#E^0.8`+8DQ]"2+AZ67[<<<LLB
M6,E&6L?C,R/Q:L/43R3X^M@R'SE^0.@"+8EQ]*:+8A@Q_:D>"&U(<><I-_&*
ML0S(Y)QQQ8,A]67Y`YB(-B?TB1%_3FQ,:U88L.4N6+1%EJMS:%;@YYR1A=U2
MU5^,5B`$\D^08L`^//Y`ZB(-9'_HBN?N,CVC<0E+^*9+'8D]-*&-^^0YRI$W
M(V[#[_\`\?>*LO01R3Y#BP#X\_D#I_;$XB*>*Y>MCX..(B(!D'XY4/@GDF#(
M6'\A=?`-9("!,6QRQ8_R%7B.1''M$:XM61[N(@<\<$YY\^\\>`.=^"<\\]YX
MX)SMY]YXY[SSSWGGGO._GWG?T@<[<$YUY[SSSW7KGO//@#GCQB<Z^`.>.`<\
M>0.>>`:[\]YXX)SQY]YY\B<[^GW77@G._`->//O.WJ`YX`50.ZE(GQSP(9TC
MHUH!-=^":[<`UUX)KEP#7+@&NG!-<O(&N?/=<O'NN?`-=//NN7/=<>"8Y\$U
MSX)KGY]US\^ZY^!-<N>ZZ>/==>>ZZ^?==//NNW@373GNN?CW7/S[KIY$USY[
MKKX]UU`1-<_'NNO,Q<SL?^B?_]H`"`$#``$%`$J8U6?BWCD(-XB`-XB`-XB'
MT[/T@W"./T\?3]/#TBWCCC]/'TBWB`"WB`"@#$,FX<!R;QQ')NS`<F\<<LF\
M<<OIN7KQ;QRRQ;QRRQ;Q$<6\<AQ;QR$$`"`-XB`-XB'T\?3]/$<?IXCC\#GT
M\0Q^GB&.+<9ED<7D2:8S+BLOIRKT9-BK'F3:JP'-I5X9&-:G#(YL4$Y_2%GK
M):U)QA38I-,P:5661+8H.YBUJ\^"U*<0S:U>'!;U(`+:H`L&E4.(-BGT`WJ<
MA^E*O1],4>WBV*LN?257C-M488&M2HK(YK4%":TJBL\VI3CF8V*"\@:%`J"F
MI29G@V*LQP;E.8X-:G/[&,/4[?D*'^M4AZ5+Z'I<_L`0$/\`0/,O1P/0(AZ!
MYY#S_I\CZ?LQR+$/Y<\XCS_0(?Z<0\XY#X#QX#S]@``<```````0#+[/`>0`
M`#G@.``!]J?#R;QE#$7;AYYV&7RE//E*>?+5>?E*>?*4\^2H\?*4\^4IX"I4
M`_*4ASY*GQ\I3SY2GGRU7GY2KGRE//E*N9&FFI?O4/\`6GACB<]AABX%G'%\
M^4JX*I3EP5:H0!4I#@JE0\^4IX"I2`?(4<!4IQY\E0/`5J@')4JRY\E3X^0H
M#GR5(<$S,Q%^`)]`F<9?[IQ3X]S[(9_K6LV&+[FSGI2TKEBH1)6-L3+B,L1Q
MR5"NR0.;6C6OR9KRP4$-&1S?E&U>*E*V'J2\\,L,OLQ_I/O4/]:I'U*7[+U.
M?@?',<LL,GQ+@J9<!+(BY>63S',S3CT[ZWI"T3#GEB['89`64U&F88MIP%%M
M"G+%N:$Z@O,,<<N8B(HOP"?(,3>,8^';BK_V?9%UR-N5-S@C9`-R+%L6N6#H
MB2O/P7)[%`8N=ER92SQU2G1.38<04ZX*$N,=P=6O!](7I<FG/+UY_9C_`$GV
MI,D^*AV:B$SHS(VMT=%'H]_)*UEI'QLQ:7#^!#_6J1]2E]R'-S_\<PQ]>9+V
M6@R3+$6$<87/%L6DJR\CDSFC5L[3F40XIG1L;E.#HF,P4.^"]"E?0P<T+@VX
M`/CSS'+_`/C_``"<?!G&,<@=>&E>\/Q,N?$RY\3/GQ,N?$RY\7+GQ,N?$RY\
M3/GQ,N?%RY\3+GQ,N?$SY\3+GQ,N?$RYE@)2;[%2Q.CP1*%*D!=<<X]$C"DZ
MX6P1/<3,R6HTTT[/^!#_`%JL<LE<@$W)V+*]S'XX\^,/!29!P",1Q^*(CDFR
MQX"8!#XX^D4WCF1'H$$N0\^/Y`"?//AY>L$W,\`*2_@$V6>)W&,/+M^$$0`#
MEYRG)(UD)\_ND/\`6J0]*E]Q]#G^,'^8?P)\?4;QC#R[?@RWXC,_%&M7"446
M27]VA_K5(>E2_8A@Y_D*?'U&<90Q%U_!'%`<6G94"40#P'WB'^M/#'$Y\#`'
M'\A)#'(SC((@Z_D*'^M4CZE+\(9.?Y`'CR0/@WC&/I=OR%#_`%JD?4I?LO6Y
M_D)&08G<8QR!U_(4/]:K'+)7(A,R=ONOY>/PR4<\3N,H>74!\A^0(?ZU2'I4
MOV(X.?Y"0`9&\8P$78!`0_($`>5RO'T*G[$<'/\`B/5)TH8.S8:;^)(`!-XQ
M^/JP>?'Y`D'PL6"`JWX<1<_X5"DA*7CDO<LFEI)2&?B4PX@9QCRQQ=@_F'Y`
MB_K5@@*M^S]QS^T1``-<LSLB&S$#/Q9.8X&\8\_;=0_F'Y`A_KE@@*M\'U.7
MVG(3E:@HHL@O\8G\`;QBQ];N'GQ^0(O'S5?D%;V(XNCHF2X)BR46;C($B9`Y
ME(4&$>=FLE*D_&)_4)O&,!R=OR%!_-<K``5OP"#HV*D?T-I`X]WD3:O7/GHS
M0QU6M5+C/P(@(?=I\1R-XR_R=/R%$`9+5>/I52`/2Z<'^8`(ASR/G\:G#U&<
M9!Q!U_(6\/4O5CCDJ?1`73\7_+^(@0`WC8H*2+Q+;O&1;?Y`MMX):#R);?Y]
MMOYD6@\B6W>!+1>1+0>`+0#P2V[R!;=X]MMY[;=Y$MN\"6V\]MN'F1:#P);=
MP"V[@EMW/;0>0+;?'MMO!+;_`#[;9SVV_GMM_/;;_3[;?X]MN\^VW^2!;R3U
M)@'*%Y[:N4^V@]7MM_`+;^"6W>0+0>1+;O&):#S[:#S[:#R!:'F1;?SVV[GM
MH/(%M_@"V[Q[:'Q[;?SVV[R):#GMH/`%(.>V@Y[;?Y`MO\>VW^!+;_'MMW/;
M0>?;;O(EH?'MH."6W\]M!S#X10_]$__:``@!`0`!!0#8&^*]UEJ-XW:"-HW3
M=D&U0Z[L@W+'7=D&Y8JW=8RY)GNR"1^SW9!(^I=U7DQWQW9!4^X;L@K?6K=D
M'%8U;L@XK$.ZCT\&M&[(2-&T;LA(D;#NZQOA4<W9"0L4<W9"0L6&^:+&`2/=
MD(\Q2/=D(\Q/N[(,2=WW9".HW?=D(ZC<]U'IK5NN[(-RQUW9!N6';L@1)<MV
M02/N6[()'W]WROX^.[(*WW'=D%;Z][N1F.M%8SYFM:MH;VCZF3]I:=]Z)<YQ
M7_8E0$_;X+VBZF3=/"^W/1^9ML+[8-,9A'HAVJZ>2EI0=KNM3A3EI=I&I%2Q
M*P^TO46NF!Y[5-36UCGW9EJ[`D\K[)=;(\U)^Q&A'->'9)K<H4LW9;K)*5:G
MLYU622%?V?ZHMCXE[4M/W"2/W:!JE$WUY[2]1HV^D]D.MQ\Q([-=73%JWMFT
MK9WR(=KFDDS?:W[E>OVRTT`[C-!I^@A/<#HA,X%$>W/1Z4-$0[0M3Y3&E/:G
MK,FI^?\`8UKK`(O,^RO6:(QJ<=D^M4)3NW8?K:@7\[>G7Z/UL_QB`"`B`C^`
M$XH#?X]IQ''6+5AV^O:Q=.#O]8Z_7-T=!3[D[XGL)$KMPPM^RIFQC3HE63K:
M<>D4^L^!O4-W1V1JQ4KW')M^UI3;;7)(E4$&-7Q(D')UAFM5FDOT>K>Y`D2#
M8N4K'.<NK?%JUJ7;7LS986@13O:O99WJ78>31%G?[2LFW$R!FL5FG-&O+P\E
MQNJ'M4OV6O&..MX&M$F@EF.LRB=>*(]9>:^&5*Y&RN:4-4EB+&>5.'^S*,I5
M)(*KK=EM']:HVQM<EIYL>5`8LU>+I`XK>=K+G)&GKHY7]65E,FG]!:,Y^@M&
M<_06C//Z"T9S]!:,Y^@E%^/T$HOGZ!T5ZOT#HH>?H+1G/T$HOGZ"T9S]!:,Y
M^@M&>?T%HP.?H+1G/T%HSB&$PR"W]]H@&0<GU*)YC9_\>U'^,-!.DG?*)ZK7
MF0NNC.=35;8`YZ7:=YYG:(:/*%&.G6HV&*+374%M1F:9:>G%D:&:-)LRM!M%
M"%G[+=.?7CJ+JA@EQU7UAQ#'5S67#''5G6/$UPU)U4=L#-3M6#BL=&=)\%5G
M:P:\LM[3W#6:*M^=CI7QNL_":06PH@K2L@Q-XQ<!WBUT+EUXV%5+4]-,?UKE
MH.C-KE&G<^A-/V-)9>K6DI$*;=KZB;(TC2Q.*A!(/+D#+,I(WEN"..PH^3&U
M>7):P'G;VU_6.MCE-!Z8C]G_`"G<,XGIYVU2&1]..?9_2FQ4SVEZ\;#I#;?8
MKN7WXO74N\6EV;7YJU'(U&'>K2GLDVDTVZ7K_P"Q%G>Z<N+L^9ZAW;0=]6L"
M_7^^.P2D:(L&/O[+*V'['S_(3[W:C_&'5AI^@ZQ=2;<;']`:V7?/;N.[0UO[
M7U1;#RK6?MV5JY1;7_(6GL::^M+OW8X#5M36_P!.VY>PLPVE[EFAM4]9E:3$
MEREEC=BM20F1J]\Z;?;&7=I.KBQ[WT[*;QHVQF)8Y.+)R_G)2W7C/8TA6/51
M&'2APL*,MTNC^KD[:#D6ND@5MKA;]=5Y(+!>-,);(VQFTHGF+S%].9HIYJ[I
M1!:MX4UB6EO&OFN:1!-/%K9!M+15.SQ)Y"^MD<:H4^HGU`+>_0;G;TU_5^MG
ME,@(1#[/^0CJKL]NWK=O;I;LWVW2."MMA-V^NGVA<JZ_MI;+ZU'O:?1GIO:]
MQZ[TLZP=0-C*2['.][6Z^=NNO+?JJ[DN?K:E^ONQZGO0,ZP.PC_Z8KETEV)8
M>TR-LZ>.QW['S_(3[=EV.\)!1G6'V-V9M%UP]KNU'85UQ=;=1$R7.K8=L5V#
MV+M!U,;Y/'8_I/\`P;4?XPZL-/T'6+JA8Q0=>U.-HMZ;CPO-:FFZNI*>;BQ^
M^=8=H7[O/[I="9=O[IU<E`6(1`=E>OK:'7+LV[-85:-Z:`;`];V]&]M#2?KY
MOFK'?7WK(L/2?:BU>F5S?.MK:K1S>M]7(16BBYM.^LS#;DB>3DQ<+>VP^*3:
MZ&YAA=#SU;/+4@\#P8%FPU=MKS+]?I:L3',<7898A0LS>45DI;DV!-LPE63(
M+4@I*`9:4[3'5J(.;@S.+-#ZX"4VBY1ESBUIOLUN#G<VV1MVZR>1.RRJ\2_N
M!8>?N!8>?N!8>?N!8>?N!8>?N!8.?N!8>?N!8>?N!8>?N!8>?N!8.?N!8>?N
M!8>?N!8>?N!8>?N!8>?N!8>,$L,L&\_LW.[`-5-!H+H/LOMMM2WPSKH>ZR[J
MO^3)7MHWOHT^;]?1JHT@K-+,NS"!U_`ZKB'\&U'^,.E[7&&/3OIV0QZ/=;3S
M?L,J)J6=J^E;>MCG;!I++7MR[%=968,>VG1[(S_[9M(`5*^VG1Y`G1]K&EJ_
M!JVRKA\:U6\E((1QWEHW/DR[+]3J\/@_9KJ39AC_`-@FN4594'9MJ(ZMQ.]-
M%'GWY<2:RK&G>PSP<]SC9-9&V2J:IG5Z#KCK=$:F0-Z,XMPET>?R7%LC)R2;
MU;89BI7LGL3#J,A>V?:E8TDC3+<NYUBM<'>]K3EM:TC8J:!U4[+61O66,P+K
M+NV(QITS9*_P<97SMZ=/I'6S^$<W-M96ZT>T^?[FSO3'J,H;6&<_=;4?XPZL
M.WU[6+J$4(Y-U^.;#@GRW%T=;Y!A,**?D3P[/3\VL:AC3KCFNOS%RU)!T^;Y
MK!INA89Q)-C:UAJXW9.G7B20=L;+(.["ZP0*H]`IG:T3N1LN=I_VK%K9=:V1
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MP43`0P29M3SMGGC5-S619)W.FFJ!Y-5?-W.UESDK3UT_;V?[SOU=)$&I,PF+
M-<^FUL4DT=6&[C[<S1_"`AD')C-([`V.]^Q6?9RAJWBV$BR#5CL/>7ARO2G(
MCLI36O/1UUT:KO;:WD-3?]YM1_C#03I)WRB>I=SE+MHYF@+-)/;TA6"ELS]]
MQ1$EGK$QQ*C>&U&.`U;<#;.9M(&:!LL*9L)<]'2%U00YRA#O#W$I7!GZ35`\
M4+<DXN6*WQ!);34WL6)+6Y9")CC5319-X$NJ>?[/E0MXH3L;MHA\UIW6JV[8
MEG(6X5%CW&ICC>?%ZW/GZ(B(,2?>ZIUMHU55=CNE,RFAFIL7D2M*PLQ$>9+>
M4JW:0&@::L@K8?<MD$*97(*:BBS&MCYPUL'.WIJ^L];.09"`>?"@SV4^TTKD
M=Z[;L2ZM1I&5V.S757%<,THH":5QL!%Y53]I=G#-"%S=VO2(U,R]O$U1O^I?
M;#!;4=&QR0NJ+G9S-U"-ZQAJP':'Q<I2B:'5Y:K*HN4*YG4/WVU'^,.K#3]!
MUBZ<&_!@Z_!]>7#`$S):G+.`_P!LDM_$HI)VD7&D3RG5%DC3I&-HJJC52Q^*
M`J>#IG6EEK)];,S<ZQB4FL@UFKSJN1HI+4&\]L5W%Y\Y6VSS<_7EID),J6TN
MSG.;]J_!XHUR*H71SB6NNR,AB@T_?K-<,/D!2B0NZ^;56XVR5M:T0N?2:7L\
MTC>Z>K;+&2-/=XC:<98CO!KYC'8_V$5$^.]8;#QA]<)8X-$;;UJ!^(E378LK
M7.[7*6-[<.=O35]8ZV?LV&L%75M0P-PC,]V$8&"&61+S(G`E5;4_!:5M>1R!
M!9%-HH/7JVSEZ+6AHLJ2555%0'2;=VB(]`)AU1W^BM"D.=ED6D;1.\3UX/9D
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MIF!-4CV%8EU:22?QN#%[".RG8)LZR(-$JEQ`0R#9M-4;G7UOLM3#+8>`.!M)
M7?J%K/3VT7:Q9-Y,C=IC:<O:91U8JVHC)'L%K))]'+U5WE5'V+G!`V)I+MA0
MD2D3%+(Q)_XMJ/\`&'2]KC#'IWTA-\:9NMO_`%CCEF&.1OD0.P4'%R5*:IRW
M;UB4W/&:I>YMKS.TSGF],TYO2TT;U;TZAR*NU.P=\B[1R$O<WG>LM&Q^"4GV
M`QXZ'6%J%*'R+,]!V+*9@PUQ=#JX3&28*W5I<[`AD..V`>X[;K1JXJDU>W37
M4//5'[3P/)INK76O'%PSD1ZN.K:[JJ4RJ5Q)D:VQ7#8<RM"]'&6\"M^X/&2J
MMUEDN;16]DV4Q6!)-4+V9,(.[-[>^+.=O[N+'UJ&[*OIEC3+=Q@CT$3RV7V_
ML/(:Z5.T*K2D)?$(W#KV8B%\K>B*<?GF$S)_:]C$3.P'1B%SN4M5LT[*U4I>
MZ5RC#K0;QD#I8_8-'(@P;E9[47XI@G7PA3EMNCE8H'UWU5A;*#C3#'JO826`
MW32!<+35>\M^^D/^B0?JS3S%DDW+[OFO]=(%<&]6SVWBZ/:H;/21-1]E6I2M
MB5%9$?MFO>)G1L6'_9M1_C#JP[?7M8NFETQ?.O\`\9!@'N`'#`$!/0JCE#U#
M\E[5V`]:I!TEC;Y9M,/[[L;D4K>=EY4DC$&HFRK!5=>?5Y&JI:$$:4(VKM4U
ME:I$IHI.KPL"'.S@WR^6[(LM:.T7N)!)HGO$19TM0-RFY87,-4W!]>[1J%$T
MJ8Y<R"1Y[(,ZZS(:_0'-7(8UK+#).VQ&,,6+_("HLE):XRG=#&#L60-Z?6C4
M&M%R2D[RH6"_[>A5AQ5USH&?32Q,>=PCIBT=:%WTTB9GBT*J5&12&HG^6M^N
MD!L,:]1`$SD,0@TBW!?+-K.H&BAWB=F4D[*JYC]L1"LJ(>X)84)K^)O,>)+3
MNF**'5"=.$\GI0:WJB/3Y_F":>*8U/FR-N$7J4%:*2LS'L-/V&+VKM]9T;I:
MY[D=WF;7S?+;?)NA-$KZO@[@N2M:"][7L'M#V.KVJJ]@D>Q6W5:CCV`'QD%N
MKMZP6D]!KTWMVWVOGCY46[=>K->>R#8&G)33=NQ>[X+M:8!.KFK+K]=UCZ:7
M/!\Z_P`X[+',`#$?;P`3<P)'X^`X8(R"4FT&Q^KVLD>L'<?J*VELILZN:36*
MF/K[INO9*5KU5,A>61CC\=CZ^0MXK+FJIBNR'[YZ^O=;2]JV;E;-,I;9[G:A
ML&L5<R,<]MFO'6-G)YK*K.Z[J-_W5<C*WKD`V7KI9DOV:IG6>3V%$:TU-BL'
M'&)H219(XV('2#QU68\8$HBB.U!>=']:-%(]"QU9C@2HQFF44L]"VPA],A]D
M\[B43LOZRMB=CI0GLN8J3I75-26@PP:"YKGF-(&%QS][7.822/*LI](5C<Z6
M<S92=QO%(N+D'^YX&Y1::PAV=[20WFFBD%KRX4]0)T$.;8YL`[KK0A:>^R8%
M+==9%5\NAUC0F!7E/IDQ(6R=L.<K6GF:P/,ZCM>:4UU"9>VMZ-I;]]Y<XQ?7
M#0-(EC<T?T+1K-#D<.>K5(WNF"Z7N.Z<SGD&H[11H8*FK&-M+%.J^W=J9VRJ
M;H]L<V05?V5VDHB>M.L"%V:]:>F].N:.OSU"`Y&E89``@(EB.&)I&6.S>V>O
M&G%8PN2]A/:T\]9?47KSI-:.Q>VL:H)HLSMMNMU?(GVE;*QMZ>.PG=>Q[%4;
M\;WI55!]N5Q"<ZI:,W;B6UG6]-*@?(B]6!5T?3/%U2LMMJ-ZDLFUKZ[YO<,C
MU]U,B>O!!+?X4;`,EAN=MZ\VW)*;6QS?HB72BLS(](G)MBK88@1%E$XY*R1Y
MV'QECRK_`%3=S,[)6G*D9>Q4A5PERUZEB*<3?G<4W"Y]9.QK]-HZ_P`*BO\`
M\CLH0Z4S2J>3V=%SCULHL3C9*"(O6"&;/4QMIIE]H06=[&SI!#W&?[)V\8X:
MTI;B*8FPJPHXYWFZ7++WN*W0E<D*"F;>+SH:7/\`:M@VFOA+@:D/AQ\@O!<S
MTY7+BEJ&1FU2X60IX9L%&CK19=MG4]+=-QI[;7TMKE(80CL-##WYSV;BM\U2
MOU9TQG%B7%W`5FAF%FZCL)+K$-;'U++\-S8-%I%4G679R2DH)VD7NZ6M']8F
ML&36OIT3E1CK_P`,LO'S,14>!Q%U<VUD:[0[=[`V3G6N73W"V"REQI>/-G[=
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MIE6.R'65<&^^QM7597%(01T,QR1R-<G`>T^P9W`ZWA#A+K%M>MH"WF3B;UK#
M#5)L1)!AB,:LQJ<D$/5_2[=8VUPF.A4S53BG6-H/.7(TF:U/BWYX9E)R\#<@
M*PQL!:]DY6DZWS--FFY+7*1DW$L8*UBFE-)/SWKXP4Z[I6EK:5C%*Z\:X8VC
M=,J:Y965(*);C8->3ZTG"Y17OMFM=`UK,L5O.X9<U-W6:T2$'F+))9=-Q[(V
MA7L)JN;JW!Y)J:8)MLIV36LNK/7=\I,:3MIIV"KG7]H?49T6I-T;F0O*EV%V
M63J-3IPDM1'225/;(;!(9#KN;ZQU@(-M(G2M5%I;6E:N$#C4_F*HEY&T8NVT
MW&]_&AI-S=FB0*OT2MZPX)--?'!RLZ5G-=6SN[[V:;`I!KD%#,-612FH818M
M2(;.F*BD%ZV3JK^UQAD+=:,J,J/V!,&)_P`38DVS]JG\XA\)/H[5QP:G;672
M5EK.R]7.M;:V^X5:XW;M0ET:Z9+^OC;_`$/M?;G=Q[[QNL[L`NW8O8MP-4Y9
MR(3"$W:U/4*_'2YSA4.L5*$K4XV$7,FV7N5H/D(<JT96\#;7(G\5D]]L)O\`
MN'J+8IQE432&9128C(D[+$WAJK,O*62%U0(%TF<GI8\N:S*T[6:6Q^0O,DN)
M2_Q5J=)17];M4C<H^UQ,M.ZQB`PV)-6\4F=E-64E,9NKDM!L[@>_NL3B#PE1
MV7#DOV=PCJ8R]9^R%@7LV3"EH).WV^KHG+RRV-)*/1NU>J7RQXTOUEA*6U'*
M#3R/:S7C;-+8):WO>L91C&=(]B6"UDRQ];HQ#[4W0M!9;9:R>NCI3RY6><RZ
M<2D^46!N#$*3:6C>1<L;:#V;9+M1;<VVK=*HK"JI#;LLU\()U].+OJ$15L@.
MY*VT(AKNME&S\SN'5G]`['ADI5J<K7&MY:Q6M5$V.:(7'Z_G!%U0=ND,6B-I
M+(H+75T:A+=-6>88S>^*D!=4.K;O_N#62"(+'DU-V[+=@9!O7==JP6,=<72;
MOGJ'KCU0(IM!MI?^01KKJMKYJ5&EY(XY2=CRD!?8CJ<JG]>2ZN'2D;(<;C71
M5G==M9'94UTPB;@Z.()+%CTYO"VI:VA1M8R>V+!U;IETKB/M"#!`43[6.3BX
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MRQL>+H<4'9#J%C@ZVC#'.O8YKG&:D=7.*[R5M`4E4;,&BWQ>%VCLI9O7WHF_
M5`BOC<+5344[8GLATDT_GUG]DFE53WC*IB0O-*L'Z*GL"P8:W-.5P0=-+K(N
M6*H9E/+5BD+1.MRI*RM/5&3D65!*DCZ*/-Q,K;YSA#-QZ#D]R3WL+USM9VT^
MM.E[;;T#&EKC8:7N%V-ZR@ILU8?9W`H79QZTG6ODE:2A#9E1Q23[`U!`[!K6
MQ*I8&UM@$QA5&RR'-=*P?&UI&U+DCCL*U/D.(ADZGV)5?5$]3U9+]9'>>V\B
MB\)>D!&C,D4R1A<,&6F;262R,JWV-[:1!1J_!+0G6[&D[36S0SV!'HPVQM_K
M&\%%I+YY"8U$H<SO$%JU;)7+8:2P^L%4'_VVL):`UND:R;V!;39&["K>5W+,
MSDD^EK+/94O:K8@+;3VO!RV7/5:U*\-^,3<U5I@I453JR@=FK6/3\YW3ZH6T
MB'*'RBL7*[J^U%VJLFG8E2MO,=LPPLHDO$HD!'+/#RXM!*DR;U$SR[EM]7.L
M\\6OO0PW2!1'NDU<R'Z_])[K!(G2.C-6U(AM6RZ<UOJ_M5VAZK=WZQW\OW5F
MS;P07SJW2]V=C&PO6OMY?5=1_2=6]5W5&B-7M]#;):HWE)]I+-P8MA(!L*R3
M,,]?ZBMI_I;6:BH`VS2HXLOEYVOZB+/^T4QZ_-:>R<V;4#/Z%U^["]=8MMJ[
MR#2ZU4LGE?7O:.Y_2G'*W!AYV!Z_2[:C3F:P+>F?LSY&=Z%47AVNVX[5$YU4
M^Z<VE[3K9N3E*F:@MYFC";4GO++)%CI[O!BN==;]VW*/R#6;<Q?$EFN&UBN,
MV=J3N_,*^1]:FT*'.ENO/L&I_&#4SO/#7B!UAMA7;HZN6ZSX@D%)[@R)V;>K
MW<-+`-<=.=]M;UEE43MU;,SANLNR=?P>:PW<>=OLKC&X$K0V(S=E<]0$%]E!
M:5:T[AGM,7KWLI:80GU+VP/+E-!;URICB=4[F15_LG7S<JU&EHUMVZ86*^-6
M=\+/4T3!E=84A3>@.^]%U?:?6UO5:,WAFBW8O%"H!I)V6Q8JMH)VFUF0$F[9
MLN$2SMG*P32SMU+)5R/MB5D&R/MCSQR?NVPU&K<>U;+BEX[5Q-2R'M>+S;G_
M`+849,M9^R>RHE^RN]QQ<-%+Z<\5/7'>2HM9US;#'E.'5!L0H='3J.V#6,4$
MZS=U*@(M'0CL5LZ11?K4WGC"JNM+.PJ",K+4O9BT"CB7:'BWEQ;M$QSLW3?:
M>Y74KJ8O7%7;/3AL]9[TS=9-\QYH>>IO9@6NF="]K8#9?_1/_]H`"`$"`@8_
M`+NLU$\!(JB)`+`3!(F)FE9=NRBLY53+]VZL"0#%HM$D`X(6)`(>2LB+9*R+
ME@WD7_3=878TP+1P8`DJ6FD`&E>)5P6+@K<9%NM;11W;K"6,"+1QP)$DD!`1
M1B](4W`'*FW?%I%'=NL)8P(M''`D220$!%&+TA3<`<J;=\6E5=!K"I!(;@N!
M`B29`8'MD(P#M0:58O9%U4;NW5@D$_1$@1%4E21(Z\`$E^&3;#\2QQ5MMW;J
MPQ!/T1($0&EE)$CKP`27X9-L.+ECBM:;NK5BZ`)%`(DR``X8VR9HF'(6L%B%
M2\;36U[MU98`'Z(@&9I@L0)/4D$@IQ!Q`G#O\)K:]VZLL`#]$0#,A89B!)ZD
M@D%.(#<""W?X3J>[=8"I@S:.&`)@@D.`*\4J#&V0A8W+`NNI[MU@*F#-HX8`
MF""0X`KQ2H,;9"%C<L"ZZ)W5K#<4Q!MA9,`P&9EMD#KBL/1*$!C79XI*=VZL
MB2!-HK,$@8.5@&4@M`BX"Q`MWS9+6^[=81)`FT5F"0,'*D!B4@M`BX"2!;OF
MR7]`U@M@D2;+[B1-,<0@]0B$)(<&/-W^$ES_`$W6!2`<;1!&\R)F1#R`"3PX
M4,;NGXR7/]-U@4@'&T01O,B9D0\@`D\.%#&[I^-QSW;K0*9`X+%B8P6D20Q(
M99,*"LLRI<LM<>Y_INL*@$X6B2=X@3,F4@$`CB0P4VM1P7N?Z;K"H!.%HDG>
M($S)E(!`(XD,%-K4<$-_INL*2,1:)@$@54S40`R,5"EX8@(7M7UM!KG=NL`D
M`Q:+1)`."%B0I#R5D1;)!(N6#>#7.[=8!(!BT6B2`<$+$A2'DK(BV2"1<L&\
MB_Z5K"6,86Q@8,`FJ(+*R5S0"`[,ME[=QT4=VZPEC`BT<<"1))`0$48O2%-P
M!RIMWQ:11W;K"6,"+1QP)$DD!`11B](4W`'*FW?%I5_TW64$$U<(QA!,B:@:
M"+@!63C:`.H4V0MMN[=8&()^B)`I@-)4D2.O`!)?ADVPXN6.*MMN[=8&()^B
M)`I@-)4D2.O`!)?ADVPXN6.+3_IVJXG)P_<[4T=OS?;_`'OX?SVS6U[MUA8`
M'Z(@&J0L%B!)ZD@D%.(#<""W?X36U[MUA8`'Z(@&J0L%B!)ZD@D%.(#<""W?
MX3W'T>J%M02Q-I@%7M5&8F4#/"RRT\-U6^R6FMW:2M2@P2"1(F"5+*8Y5)'(
M2,=KSV7N-:2[0&6V[JY`Q-LHK5J#*EA@&'(R%FM><#<0H#0Y!I"RP(!A`6BM
MJ5-+$$J*MK1`NK6S``V[@FDQ4>J0J&00S$`":H97"V31?0W'95#6;H/5,5'J
M0J$=8,Q`B9@HX4,4OK(<P;-WLHSB32A"UT5(K$.P9!0&=5-IW2_;=K7$*M9N
MR@QD/"E0W5("U&LTT5!T+67:WJ+;/:KI:S=E1CU6(4J'D$!:B7)6BH.A9[_`
MU(9;=5!LW`V,0H)4(S$F!2Y4P6JH5F&HN"W?=K:!J5LW*B2`0BRH6LU`4E@5
MZU=(1RNH<)?=[:!J5LW:FD"E5J55+F8I+`K#5TA'*FXMK4L1<5(%B\&EC!(#
M(I(02SQ)`@`%V16<BW?<K=6V0EFX3+&"1U0&51+,5+=6*:F=`SD)><K<"0MJ
MX223!*]7KJH!8E*L(B2Z!K-/%AV('FKHB-[2@I7'M&%P;&%:G3*J7B+KE0>%
M<`6!-35**4F!5E,GLI<*:8*E\\5RHFS=6F!)9JD4A,A5$3)[*7&2U;"7Z6ML
M]7!N`*%(`5I4,'?$HM,L`(Q>T'MV^'?I:TSU<&[2H4Y-U:@SXE%IZP`C%[0>
MW;"7RK6F>K@W`%"^]:5#!G$E%IE@!O>V'O(RWP$1&)X-V#7[T0E1=<"RQ*X[
MTN!+R-;OA4MHQ;@W8-9[`A:BZX%TIE03O2Z$O6C;OPB(T\&X0:S`0`*6+K@6
M6F1)S*70E\,E\!+E$\&ZU9B92E6++((D")C<]LOJ%:WJ`+=WA@\&ZP<TS-NA
M&+*""I:(J`]Z]MGO6N'?%%X6P39N4L2)J5@I!M@@AKAA5BHD(]MGLMPM2AN7
M&50UB\#U2!4>H0J,"&#N5$352R7%2T>%J4+W&4!K%X'JL!6>H0J,"&#N5$55
M4LEQ4XIM:E!-S!K%X&+>;0$,!Q!MS!<F@#BAD6PS6]0CO:XE+6;LJ`"2&*HR
MAL("U$N2M%0="UEVMWT=K=95K-RI1!)5J590V$!:C42M%0="UN\]N^C-;#T-
M:N5B3%)`4BL'-03U?.`FWU]M1=%N\[6TJI6U<J,@$**E45F0*205-5=(5RM]
MJ+[-;0,5%F[)J"E5$J!6:AU205ZU5(1RK0MYW#("JVKI;KB08*@FD27`EE(H
M(XA5"(2\YX]NUA;<"JY<%L-4P52BDRSAB`(B6>VK;=Z8Q-J,XF2!$UIG,1)J
MF.'=GAO[`]Y?P]SYAVM&9ZHY]W++3\H])SVT[U53<O&9JF;UPS5Q+M73Q;DG
M'B/-9V&!#3ARY^7Q[0TE_'M,&/;Y?'MD9]L;2H.$93RX>/+GV)@\^P,8;8`G
MVP/S#;$'"1Y1X\=J8/+XIGP>+88&3X]W]FP@''#:D`U?V>3Q;;Z<]_+GX0/=
M&QD,(GEYI_*)]S;&0I\?J#$^W^\^'8P<]CUCC[?SG:6))]0P3C[?S[8;1.&Q
MJ8F=LS_?GX=B2<=H+$[$R9V.)RV$DF-B3=B;MJ>M$S=01V[<S.51G*BY/#?;
MO4VYG@L,.0X-/5?"F9,"!)+VQYQ=KCW=/;9S=N22H),7&`F1N&&QG26L3\%?
M)L9TEK$_!7R;3Z):F9[*Y\N6PC26L#\%?)L(TEK`_!7R;?@[7R%\FWX.U\A?
M)MAH[7R%\FWX.U\A?)L?NEKY*^38_=+7R5\FQG26L3\%?)L9TEK$_!7R;3Z)
M:F9[*Y\N6TC1VI^(ODV$:2U@?@KY-H]#M1\1?)MITLVE139N9`#)K7)TG^N[
MR_A[GS#M;+352)\'0OY!T#+:T]TL;INWRT@@U<>Y,@I;(,S,V[>/ZM.R`]VP
MC,-Y4$\N\<NQ'H=J/B+Y-L-':^0ODV`]#M0/T%\FT>B6H^*ODVPTEKY*^3:?
M1+4_%7R;1Z):CXB^3;\':^0ODVQT=KY"^3:3I+4_%7R;'[K;QSZJX^+8GT.U
M)_07R;&-):Q_07R;8:2U\E?)M^#M?(7R;6UM6E0-9<]4`20]H8QG`)C#">?U
MC-J9KMS`DP;B`^\N0(,$P,)E[8\XNW>8HJ\W,1.1!GL/$1,P*8JKM1Q$V<3^
MMN?_`"/ZNAU6G-.H.H"D\JT.8R.\`SF(D$9CN[O'NIF2T]P(]HNQ1B1(@,2%
M)Q!C'$$09)N=Y=SW66[9TUF\%`GB!FNU0,Y@"5$5"09D2W>-E$+/I+3X3U79
MKRW,SG*P33.`QQQT-S36B=#9NJ+QDYN)"P)GJ`YB`70YTRKHP*,)!&1!R(Z=
MO_*;?>5X):LW'X1K*.L,\BW!!)$`#M$0`,#&R:[OFVQ5;E(DDM1`@F02W6J6
M<<`"&*]8:N[<T&I6Q;-EJ@0A8.ZP58D;XD3BIW&5#]UC27+FIH#@+!)!!QQ@
M""",6G>`<MM-K!IK_HSM2S0`$,%H,L)ZHK%,]6/?$*7T:6G>^EHW&@8!1$XY
M%\00@Q@@F)$I=ML#;8`@C(@X@^Z/5TOU-WYUGVY?V_UO>7\/<^8=K0B.J.;=
MR0L?)'0,MM,E,1<O"(IB+US"FBU3&4<*W&7#3L#=$>7U&1U!0C$'$';7:"^\
M:.^;AM@D0.'<N8B`($!U)S)426`D=UC4SZ+J;1NT'X++<5`1GV;:L<8KDP2,
M-$6`_P!-U0(68`5V(JC"20],$G!;E*X`QWKWO<8%<E@[D558#](W`5CE40.L
M9[W[L[S)&K%PW%!(,!HJ01N24(D9-F8G;77*`75)$[C(Z>3D.&!!!(/_`(\O
M<^H>SWD]NVURHO;ML2$F5N0'DEA%L&J2!U@&3O!!9=DTB*UUL``&J/5)(J("
MM5$`$03,@:6SHQQKMZWQ%@P*"##,3B`8(&!,@R!MH+:2SZ@,5&"Q2"2#41#2
M"H7.H$&-NXK&FT;3JB&,D`@`I*&2`#UP"2>8`XPK,M+$"1G!Y)&&'-ZEB09%
MBY!Z7M2/%S^L0*9BY:.4Y74,]BY$9R%$1-=L`W$V[T%,^:G*<B#/8>(SF!3%
M7$M1Q$V?ZV[_`/(_JZ71]WZ(W;BW@YQ0"*76)<C&2)CWL^YH=-JM"VFT%IP[
M%W0NQRA0A>($P6(Q,QU8;57_`$&XNF:Q;MJTI$HUQCU:J@L,(,8XX;=_:NS:
MKT^H".@6%-0-PLD$@#M8-@(B<0=M4=7Z2-?=J9K8?J\4XJ::J"J&D`U=E<]K
M>C[RTIMWK,JIE2&0$TD4LV0PQQ@`G/;OS7ZSN]UM:F]*$T$@5L1,,2,"-V&4
M[7-)I+!N7F=2(I$01C+%8]PSR1L=+8TS-JFX75E012Z,TFJ,`IR)DP,=E[S&
MBN>B#3JLRG:BX8BO](##"2<<)V'=Q[ON#5F^6B;>7!*3-8':W3)&)V'>5GN]
M-1IM2@1T<KYLD**C,X*$&"U34X`!`+);50%4```0!&X#<.0;O5TOU-WYUGVY
M?V^K?]"N4ZH*2N`,D#`8@@2<)@QG!RVUVLU6I8:NR6!A5D1BM(*BHM@L$8O(
M$8;:+6-KF;4M=57%-N.LK$@$(8I(B8,\DG:RURX3<9`22`#)`W`0.C'W=O\`
MR"S9[Q`]"I(#(A#AE9@&I52L!8D$G?&XKJKMFBY4RGD,;Q.(!Y#)!!$F)/\`
M0[R_A[GS#M:$1U1S;N2%CY(Z!EMID*TQ<O"(IB+]P13P[5,91PK<9<-.R"?4
M9J28W#$GHV[K>[9:U>M:NZ7!8!N#<NO<S4D,:32!N+L<(@Z#OBUW=</=]FR4
M)!0&0+@ZJEYI-2;A(JGL[</3#[[;<.F-..3">0J2>2H*=VW=O<Z6;[:2JJ[>
M5E#%@2XS8-+WH9C&4C&25[O[S[JLZC4D2+M=P$E<!%3L">J3`R!49SMJK%G2
MN]VZD!13,F#!DP(WXQA$[=S:!M$VF&EMJK7&="2:4!HH=S'5G'M8"01.W_D=
MC3Z>NWK;8".&4$,W$KK!B`M<@B9RC=MW;K$3BA-+P7II6#):H`Q@28@,`HQC
MDL:+T8M?M([VW5@2EZXY8IUB*K9)@DCLB8!R_P#&=0%&HU6D6+@J"RQ-DDRT
M`@<,@F*LC!DC9:HJC&,IYO4L&?U#_.MS^;\^[^B)/]9'#J\Y:W3$74,]BY$1
MG2(SKMQQ%V[SX@6F@''*0RE??IC,0)))@!+A\VVSVGL79XKG!&(AG9@9`,B#
MN]T#+;\/?SCZ-_#EET3M^'OYQ]&_ARRZ)V`X%[[-O)X\N?9?N]_']V_CP\>7
M/LOW>_C^[?QX>/+GV_#W\I^C;P99^T;?A[^7[-_!EGTQM^'OY3]&_@RSZ?<V
M/W>_G^R?R;-]WOX?NW\6']O-L1P+WV;^'+Q9\VWX>_G'T;^'++HG;\/?SCZ-
M_#EET3M'H]^9CZ-ORQ$;+]WOX_NW\>'CRY]@?1[_`-F_D_LY]@?1K_V;;O<_
MLVL.MJX$%IP2RE1):W`Q@S@?`>;U3;TMDD#-C@J_&;(?EVMV-/K1?OB>(5'4
M!P@*??;P3B,,\2!>U:!E[NN6N(5`A#>5@!5&$J?.K.)<DB*3.GTVGT]RY=%]
M7(1'<A0K@GJ`[R![NX8C36=+H]2=00BXV+JJDP"S$K`"B3F<1!WD?^1G6:2X
M=/J&MT5VW".%5P0:A2T<_+RX!;5BTJ6AD%``$F3`&&),]/\`1[R_A[GS#M9"
MQ30(\'2WY3TG/;1I:`X:O=`@@@+QGI`A[HB(B+MP$1#N.L8-FZPB95&8;]XG
M&!,<@G:KT/44_5/Y/;EGLS>C7X'[I\?%SC.,QL!Z-?F)^C;R;QCT9QL/NFHD
MS'FGW;\HCW=L=-J,_P!E<_.O]O-L?NNH^S?R;8Z+4C_VV]V,-VQ'HNHD?NVG
MP1.P"Z74$G]T_-.[=.Z?R2&]$U%,Y\-OS#^W8SI;\\G#8G\F[?.T^AZ@#ZI_
M)CR8;]I]$U$3^R?R;5>BZC[-\/%&_P`.>Q#:34"/W3\W-NGVR)2X;%U$2TXZ
MR,N+,D#&)P5H,;C!Q]8D7`"O%LG$QB+]HKFZ8U`0*C)CJ7/HVV[T-4>:C.,R
M!';29RB35-/#NSPW]:``23LNM[_/#LQ*V1]+<S`&Z@2)))F`<`2)&DLJ+'=X
MRMI@(RZQS8\I.?)_5]Y?P]SYAVM&9ZHY]W++3\H])SVT[23-R\9FJ9O7#-7$
MNS/+Q;DY\1^V?8$FJ)N6AG&=VV([=N9RBHS/8N?1MMWH:H\U&<9D".VDSE$F
MJ:>'=GAOZSTEZ\ZV4*%[MQS"I/92,RP`DCE8"8&SV>XK1?4P0=1<&/3;7(#I
M'ASV:[?N,]TYDF3_`%G>7\/<^8=K1F>J.?=RRT_*/2<]M,X8F;EXS-4S>N&:
MN)=JG,'BW)SXC]H^P(-4>=M;XSNH(FM,YB*NM--%R>&^W>I0D'@L#`DP<&]X
M^%,S@`!,O;'G%]96]1;52ZF14`PGE@X&,QR&#L+6IN6VM@S!MVR)RD!E(!YQ
MCS[$G^M[R_A[GS#M;+352)\'0OY!T#+:R]TL;INWBU6=7&N3,I;(,Y@V[9&1
MMIV1[`S;8@UH#&<&XH(BE\",^K@LDM;CB+MWIU9BW.4Y$&>P^43,"F)KM1Q$
M]@>\OX>Y\P[6A$=4<V[DA8^2.@9;:=!;IBY>PBF(O7!EP[4?%X5NG+AI%(]@
M>S,7+1RG*ZF,47,LYI$1-=N.(NW>F$Q:G*8@@S%#Y1,P*8GB6HXB>P/>7\/<
M^8=K0B.J.;=R0L?)'0,MM,A6F+EX1$1%ZX(IX=JF/@\*W&7#2*1[`@!9\Y:W
M3E=0SV+D1$S2(B:[<<1=N\@X!%`(DQB&4K'73&J(Q)F(2X?-M[`]Y?P]SYAV
MLA8IH$>#I;\IZ3GMHDMA1:!N!:3(I%UZ8(>Z"(C$7;@Y'?M'^F!ZZ`8"GBV<
MS&/&MD>_M^^B!)DQ"7#%MMN]35'FHSC,@1-=O/**C5,47)X;$<A]@>\OX>Y\
MP[6C,]4<^[EEI^4>DY[:9B]4O>,S5,WKAFKB7:IY>+<G/B/VC[`DG(W+0F:<
M[ML9UIGE%76FFBY/#?;O051-N,XS($8/;)F8BHU331<GAN9S]@>\OX>Y\P[6
MC,RHY]W++3\INDY[:9B]4O>,S5,WKAFKB7:IY>+<G/B/VC_1((PV8:33-=81
M(7$B>;/VX8[/?OZ%DM*))8J!NY^?W=T^N@:HF[:&<9W4PFM,\HJ-4TT7)X;[
M=Y`%_H\:"P)$B1U58P1(80`5D,R*2ZGI]O+^4^P/>6'^[W?F-MIPQ8L+:R6D
ML<!F2JDGEE5,YJ,MM,KLY<7+TERQ<GC7)+%E1BWPBR(Q,ED5I4?T18T=AKES
MFW<Y.0'.2-C:=/2>^`<2'86K9C""I4N<1(RS$C$;:70+<!LA%:X1A5<SB('5
M28`Y9F<_71"5SQ+4TD@P+ULGLJY*F(80`5)#,BRZ[=Z+$^;Y*LF!F.'<RSFD
M4Q57:CBHQ!,3OS]WV![SD'\-=R^K;VG;2H5@BVHB(B`,(H2.BA(^`N0TRT4P
M]X1%,1>N"*:+41$1PK<?LT[(]4*H)8F`!F3LFK[_`+QL63V;:P;KCF!P4;I/
MNQO]![MLC3=WC<IZ[<[OF9W@8<LY^O(H!\Y:W3E=0SV+F43-(C.NW'$7;O,%
M`WFY@B1@09BBYE$S2*8FNW'$5CRGI\>_V![RC/T>[\QN3;3J%@"VHB(C`812
MD=%"Q\%<AIDHI(N7A$4Q%^YA3P[5,<G"MQEPTBD>JBZ#1+_J)4AKS]8B3^K&
M0@;^<R#L][476>ZQDEB23[I]>E2LGB6B,)RNH9[%S(`F:1$37;(XB[=Z%E0C
MAY-3$D@#M.@!!@J:J@T%5=@$8GE/L#WE'_#W?F-M8H"A*!$0!$"(`)$<D$B,
MB<]K!MTHK7+\4!0H!OW(H"M<0*/>A7N(!`#,,3WQW;WEJ*]9IKH`P4`VV'4<
M0HF2&.\"0#,3MWKWHG>#TH+C611;Q1)AFZDFJ)W=6",\+'>&LNEKMPOA"@`*
M[*,E63`QW3LO<^GUYM6F4M-%MHBW5`!4$X[Y.&&&!V[R[NUH5K^F8BM1"MUF
M7$28/5P_VA[VIO7@+*A'$M=H*1C=0`]9E`8&*2#4&@JKM"-MWH6:%X<'&,R!
M$UIG,1)F8HNSPW,93[>3\@]@>\H_X>Y\QMK.,]0;YW<M33TU-/PCGM8>J:KM
M\S-4SJ+IFJNY/3Q+DY\1^T>[+VBZMC5Z=M/<;&`H)9R8PJH,J3C*QB)&W>EG
M!4&E=4$\BX`;S@,A)/CVT5K5]X6DO)Q"5)$@<1B,!C)!!B-XB9VT=Z]?-M;E
MH'J7#;*EK52B0P;(P09QD3N+6])9"!C).)+'E),D^'>8S]83/]:QKIFY:&<3
M-ZV(FNWGE%1JRHN3PVV[T(>D\*)F,R!G7;SRBHSE1<GAL8R]@>\L8^[W/F-M
M8),FA>?<-]3S\IOC',Z9ZJINWS,U3-^YC5Q+M4YSQ;DY\1^T=@2H)&6T$"(]
M?U5Q%RUOC.ZBQ-=O.8BHSE1<GAMMWG06!%N<"1@""02JN:2)#@@*4+!F1277
MV![RG+T>Y\QMK08F:1G,Y;Y`,\L@'F&6VF5V<N+EX$N6+DB_<DL72VY8^^+(
MC$S**94>P/5+AA<M'JE@<+MN9*JYI(D,("E20S(I+KMK=%8HXUQ8%1`4&09)
M*7,HD0M4@4LC0ZECW?IR2,?O#C'_`"N4S[1CCW?IO\P_\K[?%L:>[]+'\0_\
MK[>;;_MVFG^(?^5\7CV%7=VFY_O+\W_*]/BY,1'=^F_S#_E]%_-AS[&>[]-/
M\0_\KL8[NTT3_P`0^7^5.,^'FW?]OTW^8?\`EAL?^G:7_,/_`"NV/=^F(_B'
M'_YCLO\`T[31O^\/XONI_//-M_V_35?Q#QT_AO<CW9W;-/=VF&&'WASCNG[J
M,-B1W?IYC_B'SZ?1L1[@V'_3]+_F+G\K[>7;\!I?\Q<_EMO^WZ6?XA_Y79JN
M[]-.[[P_C^Z[+5W?IYG&-0^7-]VS\/YMA/=VF_S#\^[T7HW\O+ACW?IHC_B'
MS_RV4[">[]+_`)A_Y;\^QG0:;+]N^<8?[MR^+IP_[=II_B7_`)7EGVC$T]W:
M:/XA_P"5Y(V/_3]+'\0_N?[L/;NVP[OTU7\0\;_^5Y(\>P_Z?I\_^(?+?_NV
M?]VZ28[NTW^9?\GHOYQT;8Z#31_$/R_PW)X\.?9?^G:>G?\`>'GW/NO]\;IP
M$]WZ8K_$./\`\IVU&F]`TP-RVZSZ1<,5*0#'HPRF8G'+#:REP`7`@!@R)`$P
M0J`CD(1?BKD+>B]#TQI>X9%XK@[LX$+I544U0:552!U500`:=!IOMW_EMNKH
M=/\`;O[G^[]&[8SH-/\`;O\`D]&Z-X]V,33H;`/U['_\XVQT-C/]N_\`+^/Q
M;&=%I_MW_E]A&AL1]>_N_P"[_FVQT5C[=_Y<[?@;$_7O_+^WFV_!6(^N?^7]
MO+L*M%IX^O?^7V'W&Q]N_P#+\ODY]C]QL9?MVS_R_1MAHK$?7/\`X&V&BL?;
MO_+_`-W/MAHK$?7O_+].WX*Q3/[=_P"7\?BV,Z&Q/U[_`,OMAH;'V[_R_1L/
MN&GF?V[Y8_\`+='CV_`Z?[=_Y?9?N&GC?]X?W8^[=/M.'X#3Q]>_-/\`NW3X
MMOP&FGZ]^;_ENG'HPVZNATX_]]ST?[N.;8_<+$QAY]\_\ME[<=A&AL1]>_+_
M``_)S9["=#IX^O?F_P"7Z?%L8T-B-WGW_E^G;\!IY_B'Y!_RW+/N1M_V_3E?
MXAQR_P#+'F\>&W5T-B?KW]S_`'?;\!I_\P_+R>C<G/GLEJYH=.+9="QXQ8BF
MXCRJMIB"13@"5,XJZ-#+_P"B?__:``@!`P(&/P!-/9$W6F!CB0"8P!B8B3"C
M-BJ@D0NMTY)!B7"S`)S8`"13`:#+@&"ET6V/ING"@3VQBLX$"*L1)HCB`+#(
M&9%=B=;IQ`D]<<L&(!JCK8+42$E9#VN(Q.MTX@2>N.6#$`U1UL%J)"2LA[7$
M).KTX8$".(I,F8$@D'WLL"5%0E@$N\,NNMTY$@?2`$S,8&#!ZLD@!:Q731=X
M;.-9IR!^G!,S$`@''JY@4UBNFB[PQ<&OTYMDG&LSA!)I*AP(JB5!-)"@EK8<
M,VLTX$QVY(B)P4$P.MB`0U!IJKM<17.LTX!_3DB(F0`3AUL@:J#157:XBD:W
M3F1(ZXY8$R!3/5P:D@/+0$N\-2-;IS(D=<<L"9`IGJX-20'EH"7>&K-K].$(
MF:B<)B2JJ6'O3335#8KU+O#A];IY@'"X&B1/O9DCK2!)E($E[0N0VMTXP!,.
M#&$GL@S$-($F4@27M<2GTO3EX&`N+O$Q5-(]\#+1*Y]>UQ&7TW3D@Q@X@\D&
M(QE<3`%76CAWN&R^FZ<D&,'$'D@Q&,KB8`JZT<.]PZ!K=,<8GB`"-[28D`%3
M`EC5`4LEQ45?3=."3&+B!RR8C"&Q$@T]6>)9XBKZ;IP28Q<0.63$80V(D&GJ
MSQ+/$CTW3AH.;C.,IBG$A@"2$E9+!7M,\+K=.<"1+@3A([0$3*P#!EX,%+O#
MA=;IS@2)<"<)':`B96`8,O!@I=X;'T_3P!/:.(D20*9P4AJ>T02JJ;BNBL3K
M=.($GKCE@Q`-4=;!:B0DK(>UQ&)UNG$"3UQRP8@&J.M@M1(25D/:XA/INGJ!
M`BL3C(SBGM"@F8&%P^9(N;%EUNG(D#M@$S,8$`X]628"UBNFB[PRRZW3D2!V
MP"9F,"`<>K),!:Q731=X<^F6*.6OW>S%79ZW9_=_3>;V#-K=.!)';!(B)P`)
MPZT$2&H-%5=KB!FUNG`DCM@D1$X`$X=:")#4&BJNUQ%1=38+DP`+BDDY1A^D
M0LF`9K4M:#7%NV6[2,0<",08R8!AT$`C>`<-K27!;6ZUNLJUQ$9!(@.'9:20
M58`YJ>57"E_-P$#?26Y@S@!5);""@!8$A2`S`&YC:-*R8NVCRX"'ZS8=E9;%
M<.NE5P'A]59/G;>\$P.OUFP[*RV6'668#6FQ487+?:8*8Q8$A:H9@"@*L:BJ
MDBZ%N6717IJ6[;AIB&66#%<9)@4PU5)1PMQ>)995>D,+MN&RQ66#%>L))`IQ
M#4E6"I;FR2S$"+UHC#,DA\!SF!,+VB`;2<2RH=B)-VW`B99@&+!8$AH(;`)4
M64&S;+V5K8B3<2!$RQAB:8!(8`U845%E!"FY844,TF[;B%$P2&,%LDF`3.-*
ML56+EE5-LO)N6X``D!H8E68X`,%,XF%5B%^B$H7QNVA`'PI<4GD5H8P<(4QJ
M*[ED-;2J.+;);&*5I8RV9ISB/?/;#W:N%U%DQ=M',D0(<U-AV1+008ZRS<,V
MB%$X7+9F9P6'-38=D2V6'66;EQKED%;BI'$226&8ZU)5<*C.$\BN5N&NS4MQ
M4CBVY);>IJI*KA4:H62<DN%+C5VJEN*E/$0DEA,B&(*KA49PGD5RJ!3:J9B`
M.);G"3)Z^"F##'JG"":EFVX>R69V6GB6Y%/OCUHH;$*P)!@;GME[5P7+,LS"
M.(D@*.T9:`C8A6F"1^DE2$<+K(6QNVQ`'PI<4G]%H8P8&!BP0]DETJCBVQ2)
MB'J8!6@@P3D2.TCA;+UVB7M%X%Q*E`,4L"00YP(02QF`*@RK=6NRU"*QINVS
MVA-(ZP+.#*E5!,C"05)8<2RP"*TK=MD=9:J1UNLXQ!59,Q$AE+%`]EB`F*W;
M9$O'5[0EE.#Q-(!8FB&+HERRZBX%!6[;AIB"LL"5Q!+0`F-=)5@+P%RRR)<H
MJ%Q()Y5E@Q6#),`*)KI*L!P.-9HXM%?$6C(FK.JB`233,]2*^KM84O95;C%0
M3=MP(F6(#%J0%)D`U"FFHN@:V%X768J/.V]V9/7P7D8PID034LP.'DQDW+8'
M5,&35`GWL]H=994$[=9K:CA/<Q=2812T%5+,&:(52`9DF%5F7;0BF>OTY`GX
M+1&<P(SK2*U]@=']:GSAMJ%B(=L(B,3NI2.BA8^"N0NK`$6[0B(CS2811;B.
M2A/BC+U9!PV$P3[?)XN;;KQ&.?C_`"X[$B"0?'$>&,.C90(PR_-'CVB<=MU0
M_/\`W>+;&(P_L\>7J`*PCF]O,?!L)W;`R,L.C#^SQ;4X1E'1@?!EL!@!EY-L
MP2/%F/*/#M$83_;^7':8Q]7`;``8;``8;0P!'J3&.P`&'J##:`,/5A4!`2X<
MI_5N9BEM^,D89U(16NV@J`/G!$X8C$>^7&8C$XY*_8;9$2^P06TP!('8$X3S
MF><GEV_$7/E'GY^<^$[?B+GRCS\_.?"=I])N3\8\W/S#P#;\1<^4>;GYAX!M
M^(N?*/-S\P\`VCTAX^,?+SGP['[P^/Z1\O.=OQ#[_?'?GOW[]I&IN`_&/EV$
M:BY\H\W/S#P#:/2'CXQYN?F'@&WXBY\H\_/SGPG;\1<^4>?GYSX3M/I-R?C'
MGY^<^$[?B;GRCS<_,/`-OQ%SY1YN?F'@&WXFYE\(^7F&UWBW68BXL228D/,2
M=^$X>[R_UNC^M3YPVO!`*`QB,HG".L^'^TWQCF76T`+8M60(RC@V\NO<PY.N
MWQCGMYNXRX[B1S;CO_)M/I-R?C'R\YVZVHN'_:._/?L0=3<@_I'R[8:AQ_M'
MR\PVDZFY/QCY><[#[P^'Z1\O,-J1J'CXQZ.7DV/GW^4?+L"-1<!'Z1\NV.H?
MY1W9;]I&IN3\8]/+R["K4W#TL?+M3Z0]/QCY=L+[_*/EVPU#_*._/?M<-RX6
M874`DS`IN3&,XG/=ZQAQ(*OT2$8CWR;P(Q.,"E^PVVB`,$O&<9@B.TF>429R
MI>:&V6(^CMY?$7VGG]756W`-H6I@P1-2B8._=T3@1,:_0:\!G5*D>%#IU@N:
M@2,02"0L](V71=[6P;-V\]J2,;9"VX@X0"203(C/X1"Z%W847[BY4U(`A0YR
M5@R!D*CO,G66;S`:N[:)M3N"G$\TL`O+`;<3LRL(8&#MW`^BM5W;EL&X:000
M([9@@#$R33RQB3M<T7=MRW;!MU&,4#C$J*<A$'?CAS[:<#56&O-Q!207I*J9
M#+'))!R#`;L=AWBVK2W8XE!J##'`S@#(@[L9PC?MJ-(U^WZ0B5J)/76))&&$
M9&8,@@3&UF[(5+MT6TGWSG(<RS@6R'/!V9'$.#!'(1GZM[ZQ/R7.?\WNC?\`
MUNC^M3YPVU#3,NV,S.)WU//36T_";,W&JJFW:QF9\TF^NY/36WQB<3,8>HKH
M8<&0>0C;1ZNTH])L!$?`2:D4DF`"<62"<ZB1OVU_``%VRX0L,RTH6(.!S=EP
MP@`\DZE%$Z[3$,Q$2R`&)WGJU$[R5GEV[O[L1<0:C.9+GJX_!"01N%1.W=?>
M'=Y!TKI03$$LL]8[Y:&F0,5PPVT*@]5K@!!.!'(<1(Z<-N^W[UTRW-"&<6@H
M5BF)BDI/#"P,&(C&1B=M$URX$.I)%H&3400N,=D$F`<9Y(QVU-_4'AV;5SAL
M3B:S/5`&<1B9@#ERVUSW"%33L`^9,DQ@!F!VB?@XB=N];U[5+PK`(#`,1.,/
MAF(!(`QF"8&;!6J4'`Y2.7'''U+H@0+J].*OY/6)ZT2EP9QG;;#M)GR29RI?
ML-MH<<WC.)D$1VESRB3.5#S0VRXSYNW_`/&OY,O5U%_67PB-;I&#$S4I]ZIW
M`YGW,B-;?MZ@7]9<6E0JL$7&9)<!IY@,"(,@G:S:])4WA>9RO6F&5`),03U3
M(!PWXG#NC377"7K,HS&2*80*QP)R$$`YB8@X6/138.E2$#E.MPQ@9+*&#,))
MPB6C*-KFH[OU`>S<Q(AE(8]K-0(G$1R[=U:6QKZKEA(9(<22!E(@P01F!$9D
M[6]7J;X2TH.)J.8@0%!/3&POW[ZK97B&J#!E6`@03B2,(D#G&U[N_P!*4:MM
M15&,$2J@S3&YCG-,8XQLNM.M#:8Z:B:7[1,8BF8W[P=^!P3NY]<]C4V+C,KK
M40PQ,"*2"2S03R#$3&SM),DF3B3TGEY?5O?6)^2YS_F]T;_5M'5VZM//6`)!
MC>1!&(SC?ES[:/3Z.R#I;H!4U,9![4F?>XF5P(@[:K3>B'T4(Q6':HPRJ,9(
MQDDC'<`<,;HMVPJ!B`))P&&9)/3^;+;N:[<T)+:IF!IN$,M)483(ZU6\81AM
M=T:7*D`!$Y@'<T82.;`B",#_`$=']:GSAMJ&F9=L9F<3OJ>>FMI^$V9NL6F;
M=K&9GS2;ZGGIK?XS9G/U%4L%DYG(=,3MWBEEUN6[NGM40#2MU%1<B%&'6,D8
M@+OPVUO=]S6J-9=N!AA<.$I()"0#"M.>,1@3LQO&='<4J\;UZ(QQYLB<-M=W
MF[VEU$$6[;`D0>J1U1$*G568DF<(VUF@[QN6K1)JM!%(AA,E@JD9Y8CM-&&&
MVFOWKRK9MN"29Q`Y`!49Z.F-N^=<=2+[:AV9$4.,"685%U`':$XM`![1V[A:
MX]#Z-NL()J$J05C?`@@D#ID[:W2/%MGU/%61N.%)8`XC/<#CM?[P%X);N715
M;*F#;`[6$BL;AC,QE@>_],S-:L:GL&FH``M`I&()JP@P(@\NQC+U+R3^L0__
M`,O[?;AZP)JCJ7-\9VV$=I,^23.5+S0VVCI:"6(G/`J0?>MA$S@!$RR#KKLE
MQ+UNFA!BP!P10<,#@0=V,;Y6?IK7RU\O3X,,UGZ:U\M?+T^##-9^EM3\=?+'
M)X>8Q]-:^6OEZ/#CDT?36OEKY>CPXY-'TUJ/CC^_E\'.)^FM?+7R]/@PS6?I
MK7RU\O3X.=9^FM?+7R]'AQR:/IK7RU\O1X<<FCZ:U'QU\L\GAYC'TUKY:^7I
M\&&:S]-:^6OEZ?!AFL_2VI^.OEZ?!SK/TUKY:^7H\..31]-:^6OEZ/#CDT?3
M6OEKY?%GCE((%Q&N(2UQ3`96R#SE.4Q.`.Z<QZ@>^\3D-YZ/=($F`"1)$[-=
MNZ;AV2!2">MOF1X(YYB1#%+!9?3[=WA@F*Q99232<P)4*<X$`1.-V_J+UM+)
MM%99@)-2&(FHX<@Z,=K]V]J+/HZU-(NH:L32HAIEB(W0,R#MW(+-Y!J+/$#4
MLI922I6""2#F<(Y9RV:[>N,]PYEB23&&)..6']'1_6I\X;:HN36;C3.<R9GJ
MIC_LK\49#4-=)K*6ID$&>$F<JGS$^*,@Q%U`1N+`'P<^6QB]:.$]M3^0^YXQ
MACL?/VMWOA[<-OI[48>_&^?=W8X82-@WI-F#^FOEW09Z-H&HL%N3B)/3VL!T
MQR9[`F]:Q_>(/RD9;_=Y#!;TFR%!C%U&^-YY?!OC:HWK0'.ZCEYXW=&(YX7[
MQ9@Y=<<D^T9\T8["J_:`.\NO/SSNY-E'&M`D?#7RP.7^W#8,NILE2#$7%QB<
M(F9PY(Y]C%^U($GKKA$X''`X3C^7#8IZ18JS^D3+ES]L<XF#J;(QCMKGR9]&
M.1G`G9T:XC.;BP%8-`I:3@>4J.GH]8S;!DV[@,<AMN#[UL(SP&$FI.T-M#AD
M\Y3$`F>RV6<P(SK2*U]:$DX;>C]V++3!N'L*(G#`S(P!@B2"`PF#?N,UW5$X
MLV.4Q&<140))($"8`_J]']:GSAMJ%B(=L(B,3NI2.BA8^"N0NK33%NUA$1YI
M-U%N.BA(RI7+UZ1/]&*2>I<.4Y6VQ[+9<L89U)%:[:'#)YRF(!,]ELLY@1G6
MD5KZSU*H_$8&E$423!(+'"8)C*87&#CM;N=XW*+0@\)#OWAF!@[N7$5*5.`6
MU90+;48`"`/ZS1_6I\X;:A8B';"(C$[J4CHH6/@KD+BA8\W:PB(\TF$46XYA
M0D".JN0]@2*9ZCG*<K;8Q2V6<QAG4D5KMH*\N(/",1'67&8@29,"E^PWK)K;
M,P!C(P<YCH.1Y1(V)L(ZMRAW!R`C!A(P&!Z=@/ZW1_6I\X;7@@%`8Q&43A'6
M?#_:;XQS+"V!PQ9L@09$"S;R(=Q')UWP]\<_7@P_I0PPI?DB0C$9LN^(@DS`
MI?L-MH2&@UY]((^$LSE$F<J7FAO8'1_6I\X;:AIF7;&9G$[ZGGIK:?A-F;K`
MS-NUC-4^93&:GF<^V_QFS/L`)RV!F.I<WQG;<9U+GE%6,Q2\\-MM":HZ_1F"
M/A+,Y1)G*AYH;V!T?UJ?.&VH:9EVQF9Q.^IYZ:VGX39FXQ,S;M8S5/FDQFNY
M/RV^,<S[`J2T&FX!C&=M\)J3/*`<<J7!H;;1E"TU'LYP5(,=5MT[A\9.VOL#
MH_K4^<-M47)K-QIG.9,SU4Q_V5^*,A?:Z3Q#;LS,S]#;SE4,\O43'WJY#^JY
M_6YH)GAW,@3APGG)6@1,F(B>LG;7;1"">ON$G`$R.J^(S!@1G4D5J#$>P.C^
MM3YPVU"Q$.V$1&)W4I'10L?!7(75*Q%NSA$1YFWA%%N.BA/BKE_7C'UF!1/4
MN;IB+;F>R\1RP(SJ3MKMH:5DU\D[CCBCY9S3U<ZDBM00</8'1"8\ZGSAMJ4(
MB+C"(B()W4I'10D?!7(75*Q%NSA$1YFWA%%N.BA/BKE_34ZBZ$!RG:W:M:U7
M=F@!0Q_-&6.?3&/KH=630^X']6^.*MEG(`(B:D@NNVAJ52*\FIC(_"91/P<9
MJBE6:%(G/V!T1_?6_GKT>WERVU14*%XC12%"]H]D*S*!R!690,F(QVNE0H4V
M[44A0H\RF"A6=0.2&81O.?\`2-V_<"J`?=C$P-^U2Q9[OG>`7<8C(R%!,,K=
M!@@[7M5P@+C,U&):%)SD[V$;L!`SGUT2P4CAW,P")X;1FRB0<5,R&@JK-"G;
M1%VA*B#C&!!!';3.8B3,Q1<FA@?8'18QYY/G#VG?R8[:H@R#<;&9GK'?7<GI
MXCS\-LS=>J9MV<9F?,V\9KN3TUO.=1S_`*!),`;&QW9;XMSX7O%PF9PJP(RP
MQ$500!J-9=-[4;JHI&6``$9B>2<0%PCUV"#`*N#NSMN/A)F8&9F8I>:&VT3%
MRHKS!C`@@B0R9C"),S%+S0P/L#HIF.,F7QAT[:H@R#<;&9GK'?7<GIK>?AMF
M;K53*6L9F?-)C-3STUO/PFS/JW#JKY]"$4HN%61)8].`&8BH%9C9;5FV%MJ,
M`!`'KVHF(2YOC.VX^$F<Q$F9BE^PVV@62.ONG*#(ZJL8(P81!!(9E66`G/V!
MT4G#C)\X;:H,S%N(V+$ECB<6+*K$\I*J2<U!PVN5@L0EJ:JI,6D[1(1B3[XE
M48F20IV[MUNALA=->3'K%B'4PZG'`<F`;HPV[OT'H0J:A;G6?!W(F,8`4$;S
MC,Y;7]'I+<6D"[RQ,J&Q,D;]VP[TN:0/J`]/;8`BJF8!P.,SES9[=W]XZ9B+
M&H7LL065H!,$`2L&,IPQS`'KR%+#J7)BH&!;<GLJV!R:0%*R&90:AMH0!)KY
M)R!,]A\LYIPSJ2*U]@=%)_6I\X;:H`0.(V$1O.ZBW'10D?`7(70<(M61$`1%
ME!E2D8810D1%"F0-=9U()NV+R75$C$G`#$',@SS$GEC17&J>X;ZLQQ.;@ECG
M`DR?!.VI?3Z6XR-1UHP[(&>.`B"23$'&`-K]JTBW'6^PAE#@PP#8$$$#,,!&
M.>RW-5>+L!`R``Y`!``Z!ZRQ']61$]2X<IRMM^B\1G,81-2=M=M$U,P\Q$Y`
MGX+Y1,QAG4D5K[`Z,$?KD\3`[:E::8N,(B(Q.$4I$<E"1\%<A<7DM6<(B/,V
M\(I2(RBA(RH3LC8C8P3L#)D?F]?,*9\V^Z<D8SV7RB9@1G4D5KMHJD5A7$,`
M1)!`P+()!Q7&:H@,84^P.B'+>3YPVU)0*$-QH"@``28@!G`'(`S`#)CF;U--
M'#M$4@!1-I,!#,L#(!68#<S""?79G^E)`(HN9Q'T;@=IE$@P5@DAJ2JL0%.V
MFU-XMPD))I$G(B(KMS.1EHC,,)4]75WIY[*_X^/1AT[=767HY[*X_P#^^'3C
MT88XZR_]BON?K_;^01J[T1^R7/D^FRY_%L8U=ZGZE?\`'PCW9YMOQMZ8_8KG
M]OTX2>G84ZJ\5Y[2C_[CL8UEZ8P\RN?V^6QIU5TKA'FE'3^N/N?GV$:R]5]2
MO+R<?DG?GA)SV,ZJ\#]4I_\`N&QC67XC]BN?V^7Y.?=CJ[\S^Q7*?K\X\>WX
MR_\`8K_C[#[Y?I^I7_'VPU=Z?JE\'TW3CXCL8U=_[)?\;9OO=X<GFE/A'&'Y
M?=VZNKO3&^TN?VV(]P9<^`C67OL5_P`<<^[R$U:N_'U*^[^O_-S\P,:N_P#8
MK_C\NZ?=VPUEZ)_8KET\?/+=S<^PG5WY^I3_`!]L=7?CZE?<_7_W<^PC67H@
M_J5SW?K_``Y]&Q^]W_L4_P`?99UMXXX^94>#SYYMOQ5Z/JE_QMC]\O5Q^Q6)
M^W]O-L/OEZJ/V*Y]'''/OV/WN]'U2_DXWY]F^]WHC#S2^/SWE_-M8O>D7B$=
M6CA+N(/[7I'MPOW020SL<9G$DXRSF>EV/*S'$MJ3J=0K,J`CAAL515)EKY8@
MD$BHDXXDF23][O4_5+/_`,W]_-&)G57L\/-+E'UW+XN7;'5WH^J7G_?='C]U
M8UE^-_F5\7G^6-A.KO1]2O/^_P"CQX[8:N]/U*^Y^NZ,/'L:]7>CFLK_`(^_
MQ<^WXR\!'[%3C]N)'@V,ZN\!]2IY/WXY^3=MCJ[LS^R7GP^FZ,>G##'JZN][
MME?!]/ATX]&S?>[W-YE?'Y_Q^+#'\7>CZE>;]_T].&6X5:J]/U2\W[[I\7+A
MCJ[T_4K_`(_3ACT['[W=F/V*YX_ONC#IQ.WXN]]DO/\`ONC=ACB=OQEZ/J5Y
M_P!_T>,\VPC67@(_8J<?MQ(SY-OQEZ?J5\/T_1AXSL9UM[+]@N?+^(\7N3OV
M_%7OLEYOWW3XN7`_>[U/U2_XWMCGP,ZN]5]4O^-[<^;8_>[Q:?V2C?\`7'=X
M]C&KO$_4J/\`[S^3;\7?^R7D^NY?%OW;#[W>IQ_4KSQ^OZ)]WEPQU=Z/J5Y_
MW_1ANQQ.V&KN@Q^Q4XX?OQS^(\VQ^]WCA^Q48_;G#GGW-^W5UEZ(_8KS?O\`
MI\6>T>EWIY>$OY.-[N?-S[,]O57B]#``VPHEE*P66_,8\A'*K`E?_17_V@`(
M`0$!!C\`U7.'*]C]GXZPQ,X377*2Z2*ZFJ=!JZ/*DMV`O+BF6\)5EO&';45B
MS=%=.&D"CKK6YDP:R7$G:+U)]W8`"6^9H[-E/P$3D*913=!?9O.6)I==Q;J-
MS86]1CK`FL)9V%0*R@.@8.9.@FFPM-QS(V^=K1^I/NY:W>BF.S:557P&XL>C
MY"B9C475WAM%KI6IB<?5<.DT5929Y-LMP_C"VL]9"E5.GL*2KUEOG*2#%]2?
M=R\/J;:;2Y=]5P&YD.RF)1:W1T!KNQN-34U_&=3JJ^#EAAL-@7/0*N?O8$&Y
M-63<[R''Q5)!B^I/NY>'U-M-I<N^JX#<R'93$HM;HZ`UW8W&IJ:_C.IU5?!R
MPPV&P+GH%7/WL"#<FK)N=Y#CXJOHH/K3[KV]9;5UQ?UNRB^KO(==FRYC/3\?
M#N[JPC:./1Z[-6,>/:Z25#SEM50-?>`PM@E34SS7F$#KZC.6_J3[NU5A8U%K
M=S9#.`GZ2AS\/,S,9`V(;?58C4ZG,'M\\>UU#HM?7S)T_5AP-B;,!O!7_'[]
MG4YVW]2?=VJL+"HM+N;(9P&_2T6?AYJ9C8.Q#;:C$:G4YF3;YXUIJ'1:^OES
MI^K#@;$V8#>"T''S]I89:=Z4^\51LZBCIK>SSTKBC!6-0*=HI6QKJ/,U_+F<
MY:O.`]->2+6IS8)CZG63ZZC%NJ^;;2H%=1[J9D+;.U/J3[NVMA75-7=0I#N`
MWYNBT$/2S=E`QP:G4[;4Y?,Q[;0GJ\NZ5`L)<&=E`[ZN-IPT8L_R"_%VV=J/
M4GW=M;"OJ*N[A2'\!OS5%H(>EF;*#C@U.HV^IRV9C6^A-5Y=TJOL)<&?E`[Z
MN-IPT8L_R"_%W<&5ZD^[E&?+6T*EU#[7@-SX=;,6BR6COS4EC3ZFVK^3*G*U
M\[4C-88\NA@6D_!3X-,:SFZ+CR/M;N#*]2?=RC/EK:%2ZA]KP&Y\.MF+19+1
MWYJ2QI]3;5_)E3E:^=J1FL,>70P+2?@I\&F-9S=%QY'VNAJZ3TI]XK#59RQC
M4$C,SN*<#C16>G+G\GH)5+GN0^0N6\APW?UU<EAIH1-'%TI,@6PPT\$>V,M]
M@EV$N?G?4GW=G@';Z>DK&6_`3^/IE[,S]]I<Y7&B5W*6IPUA3U&QL!9,E986
MXJR`V!O(<Z::%"S/(TC$2YV=]2?=RP`RVTU+6,M^`W<?S+V907NDSE<:)7<H
MZG#6%/4[&P'DR5EA;BK(#(&\ASIQH4+,\C2,06T)ZT^Z]'E8UYHJF9IK[U=Y
M#B%C0,[H-'GR:87'D:/,YDM:.X467FUPX&:EV4ROW$,[(G3.<@)C*#1N]2?=
MS/U]W4T]U(CZ/@-U?>YV'/ATTZY#?Y8.IEZ8=MD@1M>V97Q8<N?,-A9`:L-@
M75\:,W5!HW>I/NYGZ^[J:>ZD1]'P&ZOO<[#GPZ:=<AO\L'4R],.VR0(VO;,K
MXL.7/F&PL@-6&P+J^-&;I_(4[U#]\Z^(_$%UE?EG^LF@M-_9WI,["M*?C-F+
MSUO<W=1M[W20]%GFGLQP,Y76.6),L[6!1:'$7&JO]&WU)]W-!7TE3<74>/G.
M`W6%[HH<"'<SJ8-!EC:F)IB6VM!)R#8=?*AQ)\,VZCAM`UY<IR6S"W^C;ZD^
M[F@KZ2IN+J/'SG`;K"]T4.!#N9U,&@RQM3$TQ+;6@DY!L.OE0XD^&;=1PV@:
M\N4Y+9A8UDOJ3[N6](70YNNFVM%P&ZQD566T.G'2GY&DY%NI'R#.SV:SNAS&
MALJB!3S-D.LTRQ0TA[O+;^HR$2=HO4GW<KP/MLS2V;*C@-W($RBF7][F\Y8F
MEUW%VIW-A<5..L":PEG85`K.`^!@YDZ":;"TW',C;Q)VB]2?=RO`^VS-+9LJ
M.`W<@3**9?WN;SEB:77<7:G<V%Q4XZP)K"6=A4"LX#X&#F3H)IL+3<<R-OG(
M#O2GWBG3=#8S*`@ZSBG`SHF=T[<C9VE'2Z.Y%RW]AA5VGY%S5UB0Z,4H^0K;
M>M#=V]M6XB^RVLOJ2#%]2?=R\/J;:;2Y=]5P&YD.RF)1:W1T!KNQN-34U_&=
M3JJ^#EAAL-@7/0*N?O8$&Y-63<[R''Q5)!B^I/NY>'U-M-I<N^JX#<R'93$H
MM;HZ`UW8W&IJ:_C.IU5?!RPPV&P+GH%7/WL"#<FK)N=Y#CXJMHW^I/NXZFM:
MFZNHNY#P&Z3FA0Z"_H'S@V5;'U)=[36Q^(]+'WD*OF4H)]E7CE96&$_)4&=A
M8]3G+?U)]W*JPL:FTNILAO`;M)19^'FIF-@[`-MJ<1J=3F9%MGCVFH=%KZ^9
M.GZL.!L39@-X+0<?/VE3G+?U)]W*JPL:FTNILAO`;M)19^'FIF-@[`-MJ<1J
M=3F9%MGCVFH=%KZ^9.GZL.!L39@-X+0<?/VG@_\`2?[C?NG_`/P[^45)\C_Z
M9]N__GO]]_R<_P`8_P#\$_\`YF_^:_\`R_\`PO\`_P`]_%MG*CU)]W+6PKJF
MKNH4AW`;LW1:"'I9FR@X\-3J=OJ<MF8]MH3U>7=*K["9!GY0.^KC:<-&+/\`
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M`%Y7-A7.=F7-G@BTO/E;8Q^:]%P;171O6;GRWQ^KN<E0\=V^BY#A:S*<>Z*D
MRG!4.PY"^VQ]SJ"T&8M#T-S,KYDNHKWV;L1-3,>SN+/R+R1O>.,G6;[T[]H\
M[.)^Q-%#I5Y$U!6\2SJOC;A_555G%NJS4:>335+:Q9C)Q84^DT$&IQ#SS.;L
M+8<C;GDS&9*CY#]8_8;-6IZWB[2&H[7E+2]>-9E?QUPK<5@UN(FLTLBGIX]=
M&LAV)H-A0:*#4.L6[;DK./'C>4.2IE?H?7_G3Y=)QOQAM]KAWZ[7FH>/KVKP
M)^09.-%,RN>OY-9K[N/H:"..H;97==`/CKD^EY8R%IJ^"(WL588[4^N?/G[D
MX^X^E0+";&!R3(S7'.DRF4U=P:`R-15;[0LG8'M*9<XEN'0T!K/+RIUYS#BM
M%?\`!W_J"N\#KO6SV!'KN,\*RNLI[X7*7[=XWT>9QFPFDK6QJ:J-9/E:PUG3
M.SR6P=!0&L]7RVS`>X$*?C.*,[RE=\2W?I;[+YWDPLG6Q:,F:XPSI[_C:MXP
MV/)]U.T`0QXE/I9U:^&"9<?._;]?/MXW*>JT-AS9+)Q-A\]L[O/1?6/V(I[6
M[L=C`I)F1XNRUIMN,\EB[+FNY/?#C2<D6VC75`>%:K=@K`T-Z:MY2MYMGS3>
MVW$V-S&IN\92^LWL-#TMU=;B'3R<3Q/ESZWC3+Y2QYQT,JZ;$+D#6D:[HY%?
M;K=`K`T%\6L?;5D;V6T]D/EK(<,+AJCTR]LZSDJ3K]+<AKKYU-Q]L>&LKJM1
M6<55;UL]:ZJC3I%+')"B."2VN:*NM+EZLY\V,^CYMR/`9:7">JWLCH+._P!I
MJ-,_/3[/CKNXOA5_+^)Q,,!+2XN,C(O8;()8`HCI=A>9^#;:"UI*SV*Y-3,\
MRX[@^?#XK]3/9?92+33:O0'J)^BPDJ+Q9'J.5^/,/40CW5S>Y25=P&5BPF1'
MS)]WGX-MPQ#H,E[17,7FKDJ_XW@W!_3OV@QU=QXS.9==!8<D\N#Y'XHQ=K@N
M&W6LJ!2#U!XI*IUI,.12)74>FL*3AEE?5>QLF!S7R!IL%4W=KZD^S.$K,/&R
M.0=J[ODSE).3.*\58X;AB,8\2L_=<B.ZG2:>29QFUU'I)]+PJ''1/8/4P><=
M[HL-2W4?U2]DL[5XN%EZ`MK;<G\H?OKB[)V&(X6'=/BT;=7(COIUM32E4R0:
M/23:7*TQW\[1ZO4<*;CGDVPL/5OV-I,YD,=CK<5/656[C7W&-7K,IM^3R,E%
MQ]/)JTF:-@X0XK72-%E`WV<K)\CG*NI;[A#><_6&VN?5_P!B\YF,/B<1:"K(
M==R('2<94^JQNTY)\<H^2J)=6V7H1BA,C-4^AR@;[-T5;<<R3Z^_X(VOL5.U
MK/6GV$AY_$\?9$T;[2'D*):<;0-;C]5RE6J>=CJR55MD:2(V"L1'%T>3%?\`
M(E9K3<YYBCXSPW%VTNMS<>K_`+$CRMG8\IS9$:)Q;G!1N,Y6KM^:\3$^-,TN
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MZMMF6$F#/SVDA5&`FLY/V>0-RC?\LU^'K=SPGS-0S+#'<-Z2THM3S;>%'A9U
M9@O7XE?32K9FUT4FHS\&OK[4=E)@3\_HX-0#D@O(VZQF9EPN9]##-N.#>::6
M0;C[A35%R%ARF=D?!V(:KCSD>]=%K\5-G$BFU>CFMR\$)-='GT$/+RY^XY'Q
M&BO^!@^QMW@=CP%SD'8<:<=FA%E"9RBS/\?Z'-X[46LA(L6CK2V3SZX]S1KG
M?NX='GC6F0OYTKG'%3M1P>[V`L\IK_5_V+'?<=8@5;=6!:_DR;G>,M%C\CLY
MCZ)X*:H):DEZPLZI=GDM@7U":R%RE^V/98^BE<$5W/%?P.'UAYH3G"SC75R'
M,T/%-?1GR8<5(YJO]%)$V%1??D;)HRMU#)"Y!?W!^.4M&>D]DM')XFXWI.2;
MO,T'J)[/`N+L>G@YN7FL#E;+5<49G%V?+5@?5QHTW,EMHUKG#1K1UZ*K!17I
MJWE6^APO87;67$>#J]O>8_(>J'LH317D^_B4AZ#B[*R])Q=F\A9<US)E^.'.
MR9K6-<YN3"M?OP:H-#>EK9#15_L/M=##UG"&2FX/">I_LK><@1S\YA2SJ[,6
M/D<6UUQ:0^.,W'FS=M&A#E6V3EUY*.=#'II$"CF'JJTO,&DL(_L)Q=ZT$6M]
M?.;JF@D<@<K<HTW$U9=TV]V>#RO'.IXNS.COH9+G5U-O.H8@K&K".2>??YZ%
M;?CVUF?>4HO)QQ%K/G.T?[6:7[WK<W3?:5L_YR\$?)2_^?\``^W??)GWCY/P
M/V_K?D_M2Z_]OHO7^*+]%5J]6JCD^K51>G5/JG\%3Z+]/QVJCT_.B-5.O1RM
M1"=>HU56LZIT7NZ(JIT^J*G7_P#0&@4HT.X;C-"KV^5PF.8QY6CZ]ZC8\C45
MW3HBN1/[4_X#V-<U5:YO`_+RM<BJBHJ<?:%45%3ZHJ+^/7*\^]?N/[SP/Q#;
M?N']S?O7[]]QX^STS[U^\OYV^R_[M^Z>;S_<_P"8_('S_)Y_W)>^3[I*P5PE
MPFA=<<Y>\$]EPNF_=/WU]C[R>Q<Q+-=G_.'V(72GM$.IQV"<@;99S2^;[_<]
MWW.0&2!T[MCAC?+2*QPB-F&F#:L9O?7.C+*`]JA>U[B#1%17L:BJCK?`<=:&
MU9*L_-26E^:1>4L:':D>`)<[1V%7#L&$)#B,)(G2!_*>SZ`1&M*A'U=?=6[_
M`+SOF2HM3919,A%O95H61!=:1ZX;C1K?14H+!LB-X&M<SPJPSN]51^=FP=7K
M;(4\-HQ)U8.X%G;\]=8V42RDQ!2QP[RNV,[[2;[C(C'=,8=Y3HCE<]67=K27
MUXXV*DBALM*JK4$*9H8XK(VDG6!W$'15<*CT46.%SX)8;TD=6*!K%>C<TZ?+
MU<?,6LZPK<]JZE]W(C:6&9XPS%C`KXU6@ZBXJQ&6$Q6^6*YCE"4[1]!V<2OV
ME]:3(*QI<ZGJ]$/72-74PV`+/BR)!(TTT2G``G^R.=$8YT@!'*HPD$UW'.+D
M7,HI;R4*R!B+RX28&WCM&>+;4]2>;*;&I+BY)*!,DJZ(8@WHK0-17J(E[K;X
M,:%R'53["EF&CTUB.1.@TQI;JZ9"B-#:3X`I!HS!)/6,TO>)S&#<X_0O'/(>
M>TNU!:KGZ^SI-E>'FU$[Y-W%@FCY_(#'$!)MZDD^*T!U*AIANC5Z#5'-2`'E
MRCLP1H8AVMK`""=:V\$7D:KWR94,)))#M(G<,1AH,11>9%&X2-"H:&OT$R/2
M$;66)M-`L(^B>!A9`L[=?'M8M-)FQO@`_4D-1WCD_5[D8U.T0K259TDZ#<6X
MH,>R+,D/MP`LG12399T8-YY@3^15B-58[@D&K.J-1QJ*JW.FJZOBZZBAC5E]
M/F&B_%T!FDB$S4HX>]!3+J0QJO\`&C#18_5XW&:O0LJQ@\@P8UH5MX>H`RRG
MUU86VLH\:8(H2U1FG"U2#61':\99$A4<B-[B%<^KX^S''>DM]+F8%(*RIYI2
M[2=!AS[N?%J8\+/1G5LY`:L@Y)4DK*ZUAA$26$?:U!%Y%V/\PXV!J8TH%=QN
M"?44<D'W=R1XK;&PN(]804-(T12&="E$0#T\C'].JALC61=`:I`XD$@Q9X[X
M,J!)IHF<HW,U$$<>%%``*(*VBHU6JT8WN8KU\HJ&UX<XNY+M[<-U.NK_`$NQ
MQSC<<_8J^)%I&&J;8,QH-"6GDR7JZOC,%-*PSY2%*JJXM<'7VFQ@6?A@V%UB
MZ"5#@0#R)+[.4S.TU9(@),+%M@C:KBN()KU%T=W%Z.)$S,C/MH"@[)PJ(-O9
MR_%.FW+IBR[&/)CU7V0D@U:U7L.OF&5%\GZ:L>;/G-+LZAP+RL+4E@V4<QFT
M[K2$6V'-,([9J1G,@=8XD5S6HJ*B"57-#[)U>J-8:*WSG-_*&?)E3NOLW<P`
M!W%@>QU%C=Q8UB^/GJFMD*^$<#XI4(]0M(YZHZ-!L=6E7'S<T=A<R$F5]F!U
M3GD?\U\3/5,?PP[V;=S($1X!&-)EA1SR-8([WH.]L<Q'JK[1:4DL!]?9QI,S
M/<:UED5BP:PE1`"._K)T(UF(_P`=66,E7EZ@\C.]S]<S44^ULYU0<;KB+5U$
MXE#`!I8@6Q-#$E:*AI;70U-Q<^4Y`RWRS3B.8T_C54<>VU3];<1:>KH?LOVH
M4A8Q`BSL.390I%F*7"@1?ACNY@T/6,5SI+VB+U5P5>2+-J!?*/H;0DN]DULB
M99-JJVW?)M8D:FA30D-,N9-94(YS9#X0QK(\;>SL$,;HM<*6&%$!34UR:VF]
M]S(#=M@C+$9(5&?$5IG]7PT:/XXA&:QPG=J"R!M;M+6ROW;8MW2YP)IL>7G@
MUT?0U%=6S8,5D8+:>,$I_C#0B,5&-;T<O1B%SH[=L$%_2A@_%CSY<.>9;$`&
M-,"'(:*1(CM(%[BJYW:T9D15^C5-)KJ9;S06%!JM59QK.!/MH<)33+E"2XEO
M7AG0HMS$BPU:V%)$A&^0CT5OC<]26N_@6%Y$V5&CJW[K9V]T:MG+H_)+'71X
ME&PI60TDL8X:`7MB"5RN7KU<ZEN5L@BKLUS7PO"DZVXOIU=-DQ])S'QQG79:
M@O@\M\.1F-EVEJE4V&MS.%>PR.@.H-,0G[8L_P`>WDK*2KV':$X>NZV2;.P9
M]C8NSES*@4^QCFC5O$/-\AM+,R,Z<&R,ZEB`C5SSF/?94+":>G_&@T.PXXPN
MJOY?)W,T:7=Z;(Y^]N94:IY>W-/5`D6=I6R)IH];40@18S'/5H(HAB9T8QJ)
M_@OQ/]?X_P"[K'_7^/\`V/\`\I?]/X_P7XG^O\?]W6/^O\?^Q_\`E+_I_'7^
M3'$_7KUZ_P`NLAUZ_3Z__1_X_E3_`$?C_!?B?Z?P_P!W6/\`I_#_`+'_`.2G
M^C\?X+\3_3^'^[K'_3^'_8__`"4_T?CI_);B;I_=_+G']/[?^QO\Z_A?]R_$
MWU_C_NYQ_P!?XI]?^I_K]%_"N_DMQ+W*G17?RYQW<J?7Z*OV;JJ?F7_3^/KP
MMQ,O^JO^'./_`.*J*W_[-_Q5:BI_<J?C_!?B?^S_`/UUC_[.G3_[/_9VI_H_
M'3^2_$_3IT_PZQ_\/I]/_H_\/RI_H_'^"_$_U_C_`+NL?]?X_P#8_P#RE_T_
MC_!?B?Z_Q_W=8_Z_Q_['_P"4O^G\=?Y,<3]>O7K_`"ZR'7K]?K_]'_C^9?\`
M3^/\%^)_I_#_`'=8_P#LZ=/_`+/_`&=J?Z/Q_@OQ/]/X?[NL?]/X?]C_`/)3
M_1^.G\E^)_[O\.L?_!41%3_Z/_<B?Z/Q@XV)R.8QT:ZX?YF/<@RM!59\%L>H
MVO`C*DMF.HA1&3BUC+B8D=Q5<H4E&[.GD?U_R]'(BIU1>BHBIU:J.:OU_M:Y
M$5/[E_R<8<MU6IM\GJ^.#3X1U@B'.KM9D;9JK:Y2X@R#B",,DR(\<EB*8*]>
MWZJBM_\`;]CO^X;E_P#\O=#^.%;K;2KZ=L[CB7CBTUTW50+"KT\S3V&.II=_
M*T=9;\->N=K77TBU,5\P$KCW"2`R%>PF=I7HM;&H+7:2+F;JK7V.]\YNLDZR
M%*J[N7H[#WY]BYMO-OZV\XCX$GQ[M+"00L@$C!XUXI*$$:DJ"(M8(\_D#C7B
M[=68D2`RQO,+FKPC:QA)<B)`86XBV<D48'W`R^'JT3"F*K$5'JJL(_U.]:7D
M&A6C(_@GBYSQM.QPS-8Y<LKFH8;E:Y$_UD547Z?B#,D>FGJF>76*5U;*-Z\<
M1%D5SI#B/.Z"=^/<6(IGE>KU&K>Y7*J]>J_@36>K'KBUH2N,%K>$.,FM$9[F
MO>42)F$097O8BJY.BJJ(O]GX-75_JIZW0*^0IW2(,+@WC"+#.Z2Y'R7&C`R[
M`%60]J*]7-7O5.J]?P,)?5'UK*$+`"$(G!?%[QB'&Z?&&-CLLK6,C]J=B(B(
MSI].GXDDC>F/JA'),&,4MX/77B`3Y0A!='$*2X>/:IQCCN5C6NZHC%5J?3Z?
MB+8@]+/4L-A!<Q\*<+URX>',AO&]Y!OBR68U#1W,(1SD5CD5%<JI]5_$A_\`
MZ3?6COED>66_^1'%O?**5RN(60[]J]3$(Y55SG=555^OXCP6>L/KRV%$\'Q8
M;>%N-FQ8WQG,=&^/'3-($/QW#:K.U$[%1.G3I^#HWUQX&:DI'I*1O$''J))0
MBHI$.B9[]9'JU.O=UZ]/Q'8SUTX)8R)'9$B,;Q%Q^UL:*-1JR-':F?1`QV*%
MBHQO1J*U/I]$_#3-]<^"&F81YF%;Q#Q\A6&)W*0K2)GN]I'J]W5R+U7JO]_X
M:.U]9?7RS&V2DQK+#ACCB8QLMK2M24ULG-D:DE&G>B/_`-;H]WU^J_CP&]:?
M7\H4:QJ!)PWQT\2-%Y%&WQNSBL[1J9_:G3Z=Z]/XK^/G,]//5EDW_P#?&^OO
M$K97^LU__P`PF10O^NU%_C_%$7\<00LUP'Q10U\GC#FB?:UF0Q65QOWB15ZS
M@"OJI$@6?JZTMM.H8MK)6(CN]0C,9B=K2N82P#K\5AA(L9WSH1<C5/%;0*RN
M:%#,%(@-AAFQZEG8KS*B$8-K`"?^1I'1\!7#SV.JDA*.)44M5`%2U+NHEDP!
MQQ(:6R;5`+XXZ-6-#ZO<O3Q]@$Y51E[M16(Y]9/N`7$SRCI*J2Z.(]9GV'$*
M1>U$.2D<@6.[7Q?(:.KD4HQT&YKRPJN-.AT)IF>BCC2#/J[*$0A)UC%K#F;%
M;!EM(YRJ)CX9R-(CNYBHVNG1A1'@D28D2.8)P(!\;K&=)>(SNLJ:I#(QZM8]
M@?,B.:W\KD+S!HJBHK@'C<A:F/8Q82BER[6%&U%M9%9)=9`M(;!R",/T>QSF
M!E(QSW*GT67E:Z-5U8Y6@+:A3D1V5U%_CJ>(2L?\K+Z1Q*U7T\J&J1IK@=SN
MUSD,H>Q7+9SZ.^@Y^?&BPKEP&5T7)9BRHW)8%KFRH-+9V<*[-EX3Y+&D;.AD
M<U5&1GC^H+6]*FAT%(Z`.N!50FU5_;R-`2+/?&L9%?::%D?R2#22E&QJ1`-[
M6%541[_'IGQZ[)276-'0019&IS]4V.KZ$X22M1HH,RKL_DZ+[I*"A'%,@4\,
MA$3H]6MJ==)I\X]31XIOLENKYE!`>H6R3V\,*+)A+:ME,:@W,=+\C7,0#VC&
MUK\/=*R?94_W0L_2T4`4!*R\?`C1+1+`E?,,\WW8,2`T""`]/D>5G<UR-1'Y
M'53`U3J@-0^:_P"X^:S<&IL22R%?,`^S@QXLQC6`:I6,11N5B=6]?(^_E`L)
MD[:-O;>)F:N743;"W@=9(R5IV3(Q(D<L@$!2$<S\C%;*<KG*YCE'77=M39PM
MPRO+(L0#A"G7;!$#)<2Q4DUPA12"`AWKY'*D7I^FQJHU!2@XOD7,W]543VOT
ME*_,U,2O+2V$^R=.LM($9Q,T%X0HF+Y&A:X30/54:XB)^*S&XJTL9[C\D<7Q
M[>]I9%Y(N"T=IRQD8U_6S*U_&G,LNPH28N9(!)D?:XT:'4N(1;W-QQETM;^/
M;:)]H6Z\7'$6S^&W-KJW`^R:W-W/WA*I.&N=UCKGO@?/^X_8X7V?XWS_`-P9
M+XW[KI?Q<)VJW_>MSNO1?^5SAR&Y7?P;]'*O5/\`,O\`;_'_`"\'<BY*=;X_
MD"3[/8K$2-KD+VZRFGE8^5QUR]:R,M,NL]:5,Z70FLXXY"QC.()#L1S6]R]'
M^GGN1Z;[#;X;CJYY5B\7^P?K1/WFRV?"7+&3G9ZTW+K8&3VVAT\?&[2/5Y^V
MCMN*KQ2W$E`*YSW"(V3;>[_]/#?:_-\O^LOJCZT>T\/B;.V-O&RGL1F.0.1_
M9"OWKM!CXM@.KT6J;Q[A(0_A%C&)=5ZGAMZR_B=UO[>8/.9<,ODWT<]/>5YM
M;2WLF_@\=\R<B;KVTJN;*=(RG;5UVY@V>;!2V\QD2/+FLJA.<Y[%:OX]1.5.
M-$M6>L/K7[$8R'[H6-5+>P5P;FO&WE;0X2PJU:'[G$S?%DRSOGN5SXX;>SHU
M5$,K',K+RFG1K.GN:^%;55E#(TT2PK;&,.9!G13-ZM+&EQ3,(QR?1S7(OX_K
M<9?W`Y>/QU@>(.5-9#]>ON/L'O>/]+QP.)NN;`VX_7VMJMW5W)-#4P*VJ0$*
MFAS##>.*%@5:9!'S_N)_4%X]Y?YA/1<LER^5F74NGSO-NCX0UEG1T?&>TU8=
MU*J#:"=*U=G)C!D2BBGRZ1(TM_F=^<W/%II?6#W1P7$_&,SU;T0.7*^PH>&O
MYG97F3D+*!S-YPSNH6O++GMJ].6#&OZLQ*^;]EE&:9HW%9'++]$Q>MG-?*'+
M$_@&?[`8`G%\SCZUC[REAR9U:/-"C:3697]L79[>EGB<>S-'K1"`,CI/4[!I
MPC[.CXD]@Q\+\F<NU_!')&W-G,:"I]>>5I]N:A3)\B_*VT>?>'%.&V2\^>CV
MT8-85ASO"5R1OQRAQC9?=]/K.!O7*]]N^>P43(_P^*/7?+R93+C6W$@Q%-:Z
MB9!K)TJJH(0C3;`,$CG+'8X+RTFHS=G$NL[I*BMOZ&XKRM/`MJ6XA!L:NSA'
M;^4T2?!DC*-Z?1S'HO\`EXO7_P#LUSO]>G_];^N7]O:O3KT_O3_W+_9_POL=
M_P!PW+__`)>Z'\>N5']E_;GV;@?B&I_;W[9_97V'[=Q]GH?V7]F_R2]:/VE]
MK\/@^V?RXX_^!X_!^VZ+Q_:XO&-.RG'GDJ^?O>.*E&F='D34KJCWC]A8;*0>
M.=Q#ZX+GFQGA4)*S]@XIT5K?C_8:=B?:X]R1$E"0=VX384U'I(KF_:ZPBPG^
M0QB%:,A'.&15>C@O8B/(C4=_DL:2[KXEK3VT*376=9/`.5"GP98G`E1)4<K7
M#,`X7JUS7(J*B_CVV]6N2KW15W"'MK;\Z<D>N,?5Z.YLLQF9O`7-7,F.G4>5
MD:.WFP\]G&4^#U$7X\9PPB91PQN8QW3N]*KWDG0ZZ_XZ]KN#=ASO&X<T-[=A
MPE1QV+%^QU/P=36F"%>.RY+4>'X]H[^<PL=[GW,\SWM5WT?P;IKP]F?U/_J!
M9&ZQ>#K-)>Z*UQ?!O/SY-'`,S#5=W=FSF5?;ZL-4QKHH0MC0M=+$)&#'V/\`
M<?W^U]F&PCR:F#E:V=47-E:PJ3"\"XT%)O0U^;D63:6)R3><J5US2SDCA%)G
M"HJN.KW.;T7^H?Z4>Z/GIO8?CSF2S]A<9F)5M(O(U+Q!RJM4=F+S%L0KHTG)
M8%EA2N@(!K6**Y=TZ=BL9[D:4H%#H\)P3OM9BM'"-(K]!D=-74Y70K_-W4"1
M#LZ:UBJOY31SB<J?15Z?C^BWB_Z>G,&\X<]K]3QMP/M_=&SY9W7+_'G$7+^3
MEX;CN/O6V.4YNN*/(^Q>TU.LEV3XG[+AVTJ:R2APR6C?&*GM;2Y[-:[DNO\`
M1C(4&V]K[S(NH4#QU6Z+*WFYCT6>@VMK!E[W:U.,H"VMC6Q$$V+%((;3EG$2
M'^.!^(.&GR.:>1O8S@ZP]F..JS-S(5-1-X$@?8AQN2=%H;YT5M17:.?H8\*I
MC-CGERYOD:08!!,8?I?GN/M`7D2S]\<AJ=_P'\"=1Y>%<Y7)9^)=S`SYVUM*
M"/`VE[86`:6HHRJR7,NU)&*L9H3%9_3-XLXA]>M9(TON[N:6^NJ'5W^%R>QK
MZ',TE'I]3P*M?HK5T',\CSI.D@1;*RL"`K(484H$<QI#U)#IK"XIRYVWGU5?
M,M<^>;"LC45E*B!/.IS6-<0U?/+627N`XX'N"56=S%5JHO\`DX9;#DLC2;'B
MWG&&/ZN84Y&[;UU(&*,Z*C8P)+U[#O7IT$Y4ZIU5'5'W>_-+O0W0+.'((3SN
MK:JNL06(G%?*F&KJUE),>JQHDB0U@QC(1"N>15*E_,FN/.D&=%%;K`D1*^73
MPSD`V2`JS0$ETDVPC+)E@E,<@Y#W*!1-$X;9>1TLIDGX$8UQ148)Q`R8KXC#
M+`L,G/8!H74[)L-1%9\N/$>)BC<J)U\>UXVTOFES.-)=E!S@2I'/&MJ5D^&W
M09;(VSW0K"4//R(OE=#.>0YA7-8%[@N[0W-+:&*C;0X[F@K+MZAEP*^9:R!,
M;+.J&BC0#!.2(WRO>]KE>U7*9%)RG+%8FS>TEZ[8NL`.A!96F/6Z:V2N)&MV
MV[(\0EB&Y&?S]KWE*Y1&"7ZM+D)DBCKM!IC59@3<]%#"O)A?+8?,-,G#B(4*
MSG1S_J`"=%>QR.11HU>MK4:?(,CP9$V-$CPYE8^KM)=+\IR.'!BCLY,2.`"N
M>.8PQ`$')*QK>U$>@HV?H,%)QN>*HX^@M(\F(Y"1GH-&Q_!,D2"V0IA8R"E2
M'(!(RN\3456]1QM(>JBV.N(9S&S9P3=\()'`L%K3"F3%BV,=MG%"9OZ06JY&
M#<QS&>-HXYUZ)VN2&5&._P#G6N$@2+&$7MDC'Y%>,K$7KU<UW=U3RWC+9C7`
MKX9YX7.0ST2PA13D-*E$B%9+:9%"@V(GF:TAF_E<BL1^@I]1'GC6I?\`MNJ4
M09!%-%+/:M.!]4,(2FL7LCM.I6=.Q.\GZ0V(5V^JM5%!<-JI["9P89,P#:^=
M<FEM$".?Y32QID'X_>66T[6%ZM[E&K$;'C0M!9#2>Z]CQ=-9T4R8V$YR.8R/
M77,B9*B)_P!8Q5ZD$IE*?XZO0?B_*S6V.4TUO`Q-H>);2*9LR%0S=#:NK#0K
M.SDJ!P)GVD1(_8T+1/[FE(YJJTK0,H*0V0=87E7RGZXVA"/S9=(,<.AYZXY/
M#M(T-W&'.I`-SPJUTIM@:H@K5,$L_P#<&747[GK?Q[:Q/M"W?BXXBVGPVYO]
MUN!]DUN;NOO"57\FN>/CKGO@?/\`N/V.']G^-\_]P9+XW[KI?Q<(O7K_`#7Y
MX7ZIT^CN<>1')_8GTZ+]/[T_R\4<&^KW".EY-UN8YWRO+-W9_NCC3'Y*-F:K
M$<F9J;"^[[7>YR;(T#;&_B*V,*(1C@D5RE3IV/\`5+B[D/B"P]4/4SA??1^6
MN9YG*6WX]T_,W)UU7P5S<;`<?9/AS9<C9G/UQ:.;9B-=6MV,BLL$(*)U`@Y/
M)VJ3@GD3/\07'K=PGPGF.13R^-&Y(VAXBY']BM7;**D@<AR]K`S<BBY*K!UL
MHU0Q3F\HU&)&M<7^IOS?AJ&PY+XH]I)W'?-?%6"RLS,5NI@[];KFN^Y*XDK(
M%];9O.U-=%T6QBFI9)CPZT==/&!Y$?$*OXYV=SB+W#S?L'SW$U7(>[X&C\X4
MTWCF'[`W1(%YDDIL'4<BRN*=!Q[QUI(5/"AO-9Q'2ZJA84C0&7Z<:\`^[G#.
MCXSY7X'J(_']-I;';\=[VFY!X[K5>S"RH=KAMGIY4&XRU!XJ>7%F!CIV00F$
M\B%>P/\`4GY_YY]7M!F.._;#F,F[X)V=O;<*:J5GZQFWY9TTJ5I(>?Y'T&AQ
M<ZQJ=5!9V1XYW%-U8]6]C5?O/7WUOXTL>3^4-MNN,9M=3Q-!B\O!@UN2V-9J
M;FPM[G;Z;,UL>,E;5$&)HWG(60]C/&K7*J'XAXSXFUNDY:U$3UR`SCY+?"55
MU2$P?)O&N\U:7MS<[JKR0EJZ?%3!=T>WD(>6\(Q.(TBO3`>[U?P'NI_KIF_1
MNQX1M-?'O^+!VG\Q;*XO]N*HC9&5R3$T9X`XUM'@%F+%0#;-'#ZN`/Y++'TQ
M'ZO:3^?DG^H/_P"H`>;3D;A#[&O%[Y(K9EF[4KRLVG;,8T2!^&ADDMD=.C&L
M12,MO=[#>KO&OMAP-[?\"\>\*<W<4\S:'"4^@X`OZ<%!50MG*J=F31YVZQU=
M45`?OD2C'9SRH2<R/'D/<%Y*'/PX-+5Q*.EJZ>+6YNK'1YVNCUD$$($&AI1$
M,*GI8@@(.+%:][8X&M&BJC>O^7B]?_[-<[_7I_\`UOZY?V]J].O3^]/_`'+_
M`&?Y>28?K9NH/'G.P,M;67%U]<9RBU6=D[&N@R)5)0:BFOP$CDSN@G#9$E&"
M0$F*POF&1?&HR<_<W>P/*MQ2>RG!NIY"PW*M308+CNCEX+84!73<'28S%2*2
M;#LYFSBV,&L9'MB322KIL@`7!5&JG"?/XO87.Z/V:F[SCG!<O!G\/\9EXODW
M&QR6XU&DCYJAC5\2XA"S=IGPU\*0MJ5),43RE&A"HX.,-K-G;;/2V^8JK:TU
M-A5YFGF&G7%;'G%^-5YRDJ:.+&ADD*T#%CD<C&IY'E7JJ_U:.*,;[79&EH_Z
M>=9Q!>\40MWZ_<>Z"NY%=R3Q-O.0+"EY9M,O+QUP"!73L6R.*92.K##9)<4@
MRJ/P+QY[.:;CX'&VMN+C4Y#6T-46;)RDO18ZT6MGWF)EV1#6,C+VJ.8\;#O*
M6+(0T9Q3J#SD_P#8]CO^X;E__P`O=#^/7*C^R_MS[-P/Q#4_M[]L_LK[#]NX
M^ST/[+^S?Y)>M'[2^U^'P?;/Y<<?_`\?@_;=%X_M<7`4`ZJ1GR5'L![PTHLR
MW*`R0ZI\;W5]@QEALR$[AWUN%0?9`A>'X0,'CCUZ]X&45,HB5$7<&\S3,M]F
M*U$YDQLQ.Q,1C*DKD>EE9O8TLNI*]J*]OY7(J([KWN_%E9@J[*[-7P94P5/3
MMAOMK1\8+S-@5K+&;70'SI2L[!(:0$:O5$<]J?7\>D>PT^-T'"N[X0]XO9N^
MY@AVVART'6W7J'SM["<N<VRJ^KT&&UVG@$G6-5>T\!L0<EQX[KBS&]C6,<A/
M53W?QGK%O[#UCX!X+O>']3>UNAX7K[-UPZD]@J.NE9'#S.5:V]L,N(G(E8HR
M>".]H%*K(Z]G:9V1XBCQ(WL=Q1R!B^6^`[*=90*5L'7U%H"MNH$J\ER0Q:R+
M+RMG++Y$(J)-B1GHCU8C5]5_2ZCQ_L!M.%6VU;L/9?V6XWY#PN0W,K49:?)V
M]58S9U[MZGD`VDY.]@R1]7H["IB'6-%`837.^8Y8_J;[Q>CN`]A/94F<K[7%
M^VA>4N<<-;6FMXMM1PJ./6YC4\Q<G4-E;V<+.V<YXJY8HHD6PJJ\J&_,YPO8
MGAOB#BS7[?D_G7AG3X;)Y:'/Q-(:EO\`2TO2$W6V^HV-!0U$2'()XI!0RY*,
M(U>SO;T<O])SU2D\#3O56C]'<)Q-5\Q^PO)?)/$MQ<@TN#XPP>#N0\(9#B/;
M<@W5V%\G($FP)MH2D:2:V&I0B&)[G?UH*/C#,_S.J?ZG>4C67$%X_44E5#X_
MY"U/%O(F#WU)RN70VL*TJL]5W^A':P9M5&M&&KC_`!F@;)$T)O33GS)$L>:<
MAP__`$YQ^D7+=;1V\:-IP[/.:2DV-#R-D*;;7]9`F9+2V3K&'(A-FCE5Z)&+
MVE8XZL]>?0W7\83^4M]ZR>N6DTW#_L[QEO:/+Z/%^W-]K7WTO"5E5L[ZGL3\
M1:JVMVND3R>(<*#5",T,>4V.Z)_1.YHJZVF]H>9?0NS"OLK`E\B4F$MMO>:;
M!\>TUYL:O8[!HH-M"K='D3K.D/`^SGC*R2V*0KGL%#6R9%'8K%CK/'!(4T(<
MU1,64R&:0(!RQ6G[D&Y[&/<SHJM1>J?Y.'BW(B^*?Q7SO!ARV0&6`H=@[9^N
M9([Y(NYIAL()I6,(WZ-(Y$?U:Y6//HJV+&/)?4F;HF6$$MITA@D.-.ME%,>)
M<^D0SVO.U.QRM"KQ.5%<XMMH9$RZ$0EM\.1%=(`&IB1ID6'*DGK)3)['2JED
MLA!#80:=#B>SJQ6?DNI5EHX@``JYHJ>]TM>18<LJ11L%!IX"3ON:"EM(IBQH
M[R)&:CGN:QR=(]>/.6-A:;#2A"ZIAGMY25D9EE#KZA;2"Z)'65,COCQ&HCR`
M^,`9!G&9K6HP`+N:L>7=SEIH%H41$D(XM?&K^R1"FE+\HT'\K7#1Z=7#?W?1
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M-L,_::2]EP#2%K8IIUC5`B,92(TBBA"AP?&U2*UG:02HHU5SF=PFY'E.>+3Y
M^7?'M`:BYG#*^)?K+:X1)TAA%8:2*$]H$8+L1W^JJ,5J^+2$XVMRVDRFLH\M
MV8WOR85))SS^D,537GE,#6M)(BN:@S,:C6.&BHKU[PKQIF3YET^3,WG%4?34
M<>I^ZOHFYOFGC[8,TDZC;QMS<MG5P+&F&>);"I8(*<T<D]UYF/"W4UGX]KXF
MJC4LNK'D\?8Q17\Z!70FZ.FY1PMOCI,:39<N\(QG7D/708)JP+;J8>39,`$%
M#JC/'E[C\:'+7_'W+YK"-R-RQ:I)SW%>STU-+K=1RAK]323H%U1UEA6S13:2
MY`94&57">Y1O:PC58G^'7/'^?_<=R2O3_10+U_M_A_=_G3K_`(=<\?Y_]QW)
M*]/]%`O7^W^']W^=.O\`ASSQU_[CN2/X_P!W5*#I_=]?X?7_`#+T_P`.N>/_
M``.Y)3_W?QH$Z=?I_I_S+T_PZYX_\#N24_\`=_&@3IU^G^G_`#+T_P`.N>/[
M^O\`(WDK_P#4N?1?[_\`1_G3K_AUSS_X'<D__'^%!_9]?]'^=.O^'7/'_@=R
M3_\`'_[!_9]?]'T_BG7_``ZYY_\``WDGZ_Z:!/\`-_I_S+T_PZYY_P#`[DE.
MO^F@3_-_I_S+T_PZYXZ?W_R-Y*_A_?T3/]?[O\_U_P`R]/\`#KGC_/\`[CN2
M5Z?Z*!>O]O\`#^[_`#IU_P`.N>/\_P#N.Y)7I_HH%Z_V_P`/[O\`.G7_``YY
MYZ_W?R.Y(_\`UK0=O]_]O]G^=.O^'7/'_@=R2G_N_C0)TZ_3_3_F7I_AUSS_
M`.!W)/\`_`/IU^G^G_,O3_#KGG_P.Y)_A_?]:!%_A_\`'Z_W]43'W=9B^2*2
MFS/$_+%7:6^TP6CQL!MGJ=?PG+I:V&;0Q("V$R9%RD\BM`PB#9&57JSO'W_Y
M(^W]D^3Z[+R;IRQ,-QW3!?IN6>3KASE%&HN.>.JI2Z+3V$J5VA\C!,A1WO;\
M@X6KW?CDGD_GSU$D^H_#MG.SA?6O/;[6K/Y]UF7+&LDT&BY<P<:`ROX\),.*
M(:N@N.DP8CO88;^QAR<B\V92FT=9Z@^P'`K.?M_D*(:P>'I_N3Q=R-C*/+IM
M,[':VDM=%*!J[#>U)CB64S1Q)4UCN\2*S)<)<%\3\N<R\IFY[X]WJY/BWB[>
M[HX,C4Y;E"IL+J=9YO-6M)`%#M)\<3A&DCD=3C5!N:]O=QCB^'O7KW*U'+&F
MD<4\:QPVGIC[)8_.<=??K'-9S5<@;O3;KBVHR\#-\=T\N78R/$6<LE\1HAC(
MPJ/_`!_6)N>8N%^2Y/"OM+:^K4;BD_*G"W*=-Q!S=FL-P_R-0\GP+"+L,=68
M754M46QC1G1;QA!&<;_9F$[W/?1\?<88G(\<8+,17P<UB,'FZ;(9#/022#2W
MPZ/-9Z%74U3%?+DD*HXX1L4A'.Z=7*J_^Q['?]PW+_\`Y>Z'\>IU+B8M#!QE
M/ZT\$U>1A96?7VF8AYBOXNRT2@BYRSJ.9?8RJL:&/5!$R&>+R%NXYHZ,>/17
M3%2RD\-5N0!0Q\96<P>Z<#*567("WST?/0_<KG^MITHI]#R[[`Q+*JA5C/%&
MDQ=QL(KHI$>EY;L1+23/D[+/<E1X<6F9K+J7E.*]SM*;/UK1NB';8SL?F)XP
MSX@*]ICQ^UQF!*)_8U"M8AZZ9NMZ&=%B0Y\F.W@SFR4\$">[QPYQ'0\#(&V'
M()U:TG=VJ[HWKU<Q'0<UG=YOK+1622G0:+^1'.,*VDMA>/Y2C@V7'T.0Y!H5
MJI^7]1JHYG<US7.D.MY_*M:.(QA))I?`O-(HXF/ZHU_ROV,L8H^K53O&][.J
M+]?H[I+&O(&_$Z#(2)+=*X$YVA##)>%TE@5+,XZCC>Y\9ODZM5S6LZN<J(UW
M:>$O(&[;)C2X$`XW\%\W,:.;:1RRZZ*IG<?H!2RXHE(G1RHUGYGJU$7H>5-Y
M`W\<$6955\E7\!<\.,";>1OF4T4T07'))@CV4+]<;7#1?"K7N[6O8KHI(FVY
M#*V;YOBJO`O.0E)\9&N.YS3<>C<$(F.1WD(C!.;T5KE1458%W49/G.?4VE>&
MUK9X.`.7U#.KI#!%!+C(['M*49A%1S41O<YO141>YO=VS:[F:*3Y`(BA+P'S
M%Y6R9)2``,C68Q_B:0PE:CW]HT7^+OHO0_BA<RF6,\8SL%P!S.\@R&<=@FO8
MF([F^1\8B=51&HK'(JIVNZ/B[?0<F9J0.<"L45EP/S4CUL)!EC!B,0&$/Y"N
M.G:O;U1G15<J(URI-%@-'R7K#5LAT6>*JX'YK4D4X_$I&%;*P<;J@VE:Y5;U
M;V*UR*K7C5P-)I#\L4F>DJ3PW<_@?F5E8]@FN<4ORAXDC&"&@W=7.Z(JIT3J
MJM116]9K=Y/J3^'X]I$X8Y</72$D/8P+H\T>,6,=KW/3ZL<O3^W^*=7110^9
M'R6IW/!_(/F1A!HI"!:A/)BV-&YQ1JG:JHY.BJJ(C7JWC_0XBGY`JJ'#<><O
MP-A/W&-U_%]0>5IM%Q$6BI&66NH:TDV7-C9.R,SXW7XZ`0I%1OU21GXNUQM+
M&F")5Z2^NYYP3;#+PXY+6YK*R'$;(B3KR-4*0<`35;`GRO*/Q,8KU9>UN-D1
M;F)`^!4Y8)8\BE@63P!8<UC<$J@R23LTV(5DB*XPI*E4;`G[F.['YS/:&[N.
M;]-41XDXD6S9,'QQBH.E8SXU351K:2.FGR+(2/>0XVR2M:UB-[WHQ'1)<*L@
M1-`<-?5VR1.D5I8D2%#0<(+)96$?)AN@C8,CD=)$QG:PS&]6N_YTK&B8]Z1R
ML5KR!(4;V*.6U4,2,)SW.\1&,Z$5R=J(J]O((72%G.7D[<)/5S3Q83:YEW=&
M!$4,DLP:05C&(-[T:)[BKU(WM1?'5RID*-4!-(@R+JF/*^3(&LL:7E5%B&60
MB2&2Y:KWH[N>-JO>URM7P-E9]DN?'L(KF-<,%=*`HB+\67'!)%\4B3OB-$JH
MU6D55[5<CF>-SPV-_H=%43IDT<*!-JQD-=`E,BN8>8D9%4LV%Y1C5'*-Z.[/
MR,>JM[JU_&5Q89VUR/8:]T-;?#ILLVM@R;:GN(LFZD)$)(NQUYH_R(<EKV.<
MH'>-RJKOP2TC[+;FKXUZ&TJ)YY5W237166CUE`@Y&8RNA2VVRRFJ9"QQ#-\A
M1C/W,\8(^MMZ;>R6V-:!&,6P.&)J3&\L:EC7L&"M(3,JDQ2H_P`Y&D<XGZBH
M-C?%8R_A!HY\T8`O-IIM3=EFB$.772HBAKH;`0A*>6,`_"Q)3/`-R^5K%&QM
M'0Z7M6),BQ=#26E5*D)8R(KOD3SUYY#8I71(DEKP,<1[AB1J=.]5:PL+B:QR
MT>[>Z*S0W%G8(*X"D8\E45L2?+B37_,JV*,@A*<K$$K1!\KFN5\6QSCXTRS1
M\*K`^QBI91&F-XQU,.[@M%'"P$.LC/\``\RN6,YZD3L7]1,_+Y!ML-<Q,CS%
MZS"I(U_7BIM!"GU_L?Q[;YF#$M+;E'B<ENH]0^!-BRR74J5,M8T:(*DU)"-S
MMC^/;67]W6D\O'$6K^8W2?M1Q_O>MS=+]G2U_G+P/\A=#\_X'V[[Y,^\?)^!
M^W];\G]J77_Z).M[BP@U-35PY%A9VEG+!`KJZ!#$^1+G3ILH@HT2'%`-SR%(
MYK&,:JN5$3K^-#ZD_P!'>L;R?R"&P)G^2_?K19F7:>F_K*R%_M]N>-=$KY<?
MF_D6;7PCPJBJK&.K%GR02"R311F;^)/L7RSI=;[C^[.B0<C6^V?L*^/IMI$E
MHY'I!XKSLA9=!Q%G(:(@XL:J;\H04\:R7"Z#;_P7L=_W#<O_`/E[H?QZY7GW
MK]Q_>>!^(;;]P_N;]Z_?ON/'V>F?>OWE_.WV7_=OW3S>?[G_`#'Y`^?Y//\`
MN2]\GW25@[V3:LU/SN=O>*P9=.T!]H*U/9^\'L%*'</U@.8O8MVA6=WM+\[^
M8&Q2<IEE?N"W<Y+63$0D2$1)(G5QHC!N4LMDMI!K&^.Z-'CLA'CHT;NO<JO<
MY6L&J/:NIU'&U3.I;`DILJ5E<FRID5Y7MD52VDROI58)M:8+JY#R(C'2%_*[
MJ`Z]JE!JK*JL(6LCS'!JW0X,"NI2S8T\('S<G:V]=(MRSOO;VK-A*>.X,)W2
M+WMZ>2KK[&]JFNB-N\<*KTE(.WJ$G7\5TA\MLR2X$!94F?Y8T27(:K4<`;QG
M^G05?!N:_1;BX)7V]7;TUY1Q`RRLKHT.3G*&)<3#CL]#%K)YG`ED)X9"PFMC
MG(K&L(,^[LLV/'W]+&-E.R))#:0H%@5@:ZVN+:*T4*X4TE\8#D5JHV.U4\1F
M(QS1QW4U+<<DW-K,;7I\NMLWFLM%"D1A>5@&!;.7[<8#_B_3J&(_\O:-.Q6;
MOERSRKK7[.&?,S`(HY5BX?W<RCE62G@F4<:P2:9#P0(_Q]PVF<9CU&^QB66C
MSU=CZZ>&):L!6V,Z96K)4XH,?K'K_@1`GC.18D<;1A<A'#>GZOY]1`J]Z*YK
M72YJ7L^]SEKG8*/GRSL@45"DN#+?99N,UCXS;,!'@&L5KRJBHX@HN@AQH?[=
M6K<R-*KVV$-W;9J6(*8X@GNEP6PHQU0(@JX+FNZ*Y&HWL;L,[B9%@#%0B1<X
M1AXPH#IKHC8\B1#MYH6'"09ZEGZ)W/>(W<Y5:WHHJBNL\_3$A5S=`\4[(202
M=/6RYMFM<]J7L,CJ:]',B%`P#)C02$:1L92%;^8NFP$N#:\H9R\LK6&>PMZ:
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M16;65,G7T2(O).V-"K*LTN,`$65<W(V!AJ^N%/<6?-&20@^YA1=J]JM"URLQ
MUH"LAV]?WQ3U$RA#/D18UK&LV54@(EKHC1VCK&(@SG[U1O8A%57>)6"G;1\R
M1#MI4$$>7;S^R!\6/&:Y#!\T^&<\B,8$1K!HOY2>1PG=R.3RZN4S5:_94.7N
MSCRE?!NH<.%;WP72O#1CSC6GC!;>=\<8"1V&:&($BM&Y2IY*39;?,U=E.D5D
M<20%48+R(&ZEQ;2QJZ?0&^W53142`\B2SQ$.?Q*OF:A2O=;!-7UUIG02*PI(
M=O%CRBF:<TET6M;(6!&2$0LAA""^,QPAJQO56=%<(+;^*>OR]Q*@T\:],&&T
M=>=B->ZA/&B59`I\Q',;Y2/81/&->Y.QS1YZ-F-#,I`6,@D#[QY*^$.)-6KN
MH%'#-)DT-B<?RY\D9T`)B/0P$5KD[!C7*3>3+P6QFQ89XT!E;%N9=Z5$.!"R
MY#XH_'*EV#F^61W!$YREZJCN]Z%HK&BJSRK*E+:6%R&KJRHL`,:`IJXL63!;
M&'8L"X+(Q$[7E1".<-'=R(:JMA6.GJ(&J)<-N8X(MQ9-GZFI@P;0%]G6#B3!
MS+=QSG$X<@;0->QWT\CG$7-2Z;92+ALGE3@FOO\`3EMG9@X36O,V,KDSQIIN
M4>#C*.\-:-KOMX[:8"P>U:W]O:=\AV8LOQ[:R_NZTGEXXBU?S&Z3]J./][UN
M;I?LZ6O\Y>!_D+H?G_`^W??)GWCY/P/V_K?D_M2Z_P`KS'*,(1-5Y"E>T8QL
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MJX\>,TIG)WE*K5*8BJ\CG/<KE_X/V._[AN7_`/R]T/X]<KS[U^X_O/`_$-M^
MX?W-^]?OWW'C[/3/O7[R_G;[+_NW[IYO/]S_`)C\@?/\GG_<E[Y/NDKC^XC7
M#;MUOSK[P6S]*[2)LA6Z2?>;V,E-M2:@G+WL,W41[1I?(6P;R%M"2U<IV7]U
MWK92"ODL[)QN\QCQ`%,\I58Z.0K`C$5_:\0V]W:O?VO[%5K51JG[P-D.&/PC
MAQ6R9@89+![!HWY<<3336CD*KFC,/\@_S(YR*J&2AU-9/.9TN>8%I6?;8EHA
M8+B-^*.]D4I20X+H[&D3M<[R,[FHTC7N[R6.%T5C"G7$VN=H#V%*:YIHD*%4
M_GD7$B+]IC2XY!#C@5RCFH96*Y&]5>1K22-("E#.&QSYYH4FSL.JDE--%FUU
MS2Q)\.HG%"H`1XJ]5$U7*UG_`$%;<WVC!:PZL"QYI;:O)*FO"UI)4A@95N66
M19X?&-PP"&B,1G>G:HW(*3G..[JJW6D#6%;!$^OD6]O!@W$*)=1KTLBR),/.
MH/!;/$8;>DU53],31*U"Q08K5[JM/:UD/7,FRX6;=1P])`,:`Z7*;;%9I85)
M764IPO+6QRQF%*T,IKW=5)9U&SY29R<YE5>ZJWNH^K'G<18ZBQ-(`^.*2IYT
M99%;$C-(D'RD9YT4BIT=U<R1GX5^.=:W91S(<*['7U-==2*V%WOE3(X7I7T!
M[.,^,YQ8DI"O\B^(9?U6CR\G1BL:6MM74#)$'1/EV%)+T,.(HJ6JC_&B5>L"
MHX[T@&1U=,\2-`J>4:J*MH[H<.P%3>68";&"\>5N;EE@E=!NXP+F#&FQKN!'
M&BGBE6.:!.&9!O>-G<&'9UM!I]#(JJBTN:D5/8A(;01M')#)G6=A)9+B5<6J
MHK%W=*7M;->C/RM1Q.AAW!8L/-Q-#2V,Y[;2N2ZQ5J>4H2A98Q)C`P;:L\D0
MCHX9#T&L@S%=W/*YY+*H9:3[2AU&;D66ML*?[%81K#43[-PUD%@R*^3986L9
M"(>!(KD"-[N]K`J5CE(2=2<;\;2[>^KSH*;8R,Y!=:409L9MAY@`ABDNML^]
MT%CI/C"?PR@(P:>/ZAL+K*XNUIM%KYL#+:BOTG@B75)10K4M:[0?`C4D:<U\
M303&NA1D'%DRHY7L*)G1OAI"<BT@OOEHQU*RE/%LZRQR$VK/!L(LIE/(&Z#5
MW$Z:(TRV2.`8W$1A6..J*%@%L3(2X><0H/E6,R-"DCCL0KS,*-K%0!3-\[/$
M1'--V)T:Y?,H$(C!"KHLB7&"%S7(]$$67\@J0GJ1[%(CV='F*1%[NJ?5#*YJ
M@4;SQ%89OYBHBE`07E"T,=%4I2>1R=S5;Y%Z=?IUAP5$YY6M,60=!)'`CV$"
M1>Q#,:I_*O5W<-'-<YO5$14[Q;0!X\5\$^\TKP`?,$V-\J+<6)SSKR4&&DZJ
M<L_M1CBN&-QAA5&JB.0=!>$I+4RY()P1!D5T*I@_><]*E%&$'Q15*_#4#8K$
M>)5!W]S@_E[![8M%DG%:/(V/CGM`%P)NF8(\9)EA):8;72IT8C5CQ1O>IR^-
MSE<TB/?PS35=A&M2+R=:;/23;NB9/CUR28EC$AK&CQCWC:M1.FK&*Q[VEBRH
MS>U'M=W$JJ:1+.*0.*TX9YH;A/M7&)$(H:Z,:"T;ZZ%'"5R-:(?<+JY_5Z*]
MU19!U]3&I9LJSB:#,'C>15DP40<&QK7*(#(=B!`L<8:H-HFJU[FM:B((M7JI
MM/:5<$LL-4>TC%A)<1I!1.401&03XXH:)XY"B^AFHB_D1?T\XZQION-2^U84
M,-T94@!$$4H08A@,B-=YHCR>,#'(C"M1W5SNQ1MCP*PL[+C)8QI`R"/`KK.6
M>&]RE8D>+W+##&16?(<YJ!./HU'/:[H4$#%:V-ED9/:H[UL*HN(0RPBJYLV7
M4A5AW?%KS.!VN*Z.]3-4G=^5#6DV9;5;J/77-]1X/13=)'\Z:FPE%"YKQEK(
MC4DF0KSQHL1Y.@A*YQ%\OG_&*KW.#5Z"RU/K[2Z7:3;7]HET&AO_`&`X[:2#
M4WS>4>'0WH]0'OBDJ6V;QS4.D,=)J4D+E[3\>WDK)R;N+:EX>NZV03/PI\^<
M_.W,J!3[&-(!6\1<W21T<W(SIP;,[J6("-6D.8]]E0C)IZ?_`"S.'\#8VF,(
M'\W(6C;#5U]/HY?9'CU&)2/)5&2K)Y5:\A5&5J?3L3\SFUW(/*F]7/56W2JG
MYG/67RIW*>TG=1'KP-)).CXY)0U8LP:HOG<_M1J]4[XV_P"--7M0"9&AGK*^
M?8E@7,,1J]9YP3V"L!$$^OF#8@&)]`N1CF_7Z/K^*^0+JXTFECT\N5'T=],?
M+G?-J7`C2J@TJ0:3)E,(+J\+RD55<U6IUZHYW_L]6JBIU5.J*BIU:JM<GT_M
M:Y%1?[E_R2M!I;`$&#%8YR-(>,*1+>U.J@A#DGCMD'[>KE:CDZ-17*J(BK^)
MU1D['['2UVC/3H?-M5XHD"7V@B6>FLVO-+$Z*Q5*5D9WTZ+VIU1>R-2%W-I9
MR8=E\B5,+:6%K."^2YCBADW2SGNF4@H[1O$-ZN5"$1O:OU1YJWE^SIIV:E6/
MVZ!=1U4>C@3I$L<>(LJ&:<K9--VE8A'_`)BMZH].O7M?LN'-;?[JEQ')=/#J
M[ZVXMWFBXXU\K/OL*^SF5M5M\C-KM!55VDA1%@V"1CC6962CQW+XS._!M1P1
MQKRSQMJY-8E++U6)]IO9["Z&=3)('+6HL+/!<NY8]A4NE"0KHAO)&<]$56?E
M;VPJR*2:6-`C!B`)96=E<V!!`&T;'S;:XESK6RDN:W\YY!BF([JY[G.55_X7
MV._[AN7_`/R]T/XX5NMM*OIVSN.)>.+373=5`L*O3S-/88ZFEW\K1UEOPUZY
MVM=?2+4Q7S`2N/<)(#(5["9VE>BUL:ALM7*NIFRN_8WWYL]--TT&QJ]$6_F>
M^GLO*O9-Y63N(N!;F%>GL3$?)%)PF,,.4YS24=0_I7`,R.1M?V]XS$$'Q$$U
M.PJL(CW/&9SVO57D[E8]%Z]'+VN:CGPD1A1163%4+)9I9E.BM8KVC,Y9/<KD
M(9S6]_D;^='='#&1D4AN[R&EE,1A#OBO5QO]J-)G!=W*U&@:%6M&UJ/5')VL
M4<^,$%6Z26P\D82N6.D6.&*(;F1!E?)AS[1P(0RN\B#:-7*[L<YJ(4[1EMG2
MV#%#B/OD(812)#:4`Q%',("0:6D;L1>HBO:T7<GYFN=JZJFLWMUQJL-9`?&A
MBM;JEL9P%ENN8-J0AY$=D,+UD.GN,;XCT&T32$Z(2OAYJQU&:V]E$FTFIY%;
MJ9\W*S2FAB%\5;UEA)$D$V.L!ND23E:&5*E%\SRN([M?FJ[D;5Z>]I=4&KD;
M"2TMG52`6%8&T'5YJ5Y(TN@JY*-?&-+"3PG[%$3N8U$$Z#IJG-&S:OCK\B*Z
M317[!7=HUER4["6\2+#'<+(="^X.DF)'Z->T:-&B,)5V=7#'-Q835\2RTVJK
MIL:U*BDE14O`5,E:AC<[XF"?)D`25-`SN^KGN0K\+)%-AVA;Z1KS7F'+%T!(
ME<29.(MK^X8$HT^GI8T$8@0)D,\N4,4A"26E<,;E=:YR/896AR^CSLG41*JP
ME@MM7/L;J(V)`A-M[1U2\=@!K6.5\.2CI!?(P34)V$TQM)&8IM(>W#<#T$:9
M63(9CM\5:&`59<4T(MK32_DA?T=$;&Z*XG?W-%+B)17HZLQJHAJBAU$29IMM
M70),B#4+9@))#"K\X-LKS%&Y0R5BL)W>`+'=,=7TVLR*;.=K*P]L>)*/5W-+
M8RH<>='KPWT"4RI;5U<&,HV1S>04H9#I&*/O5H4TDREL(LVYH,<RSN\';3+"
M3G)M5':69E)4F-;S:Y8LJ7$`^5,<J$1J,1PW,<J/*LNJQF%%>P(MGKZR2(L>
MLIBQ)`9JP<O$+W@K;'0J1KSF84KRR2(1'OZIWY"US<W96$FYS%K7`MYZ6Y[6
M45;D@83;NO@3S-L+B9<&`R/,(4*=@E8).CT,2K+N9D&P^W64>8P%YI)]E8'K
MZ\,HCKJM$:TK64T."C9"3AM\EBT@E8A$<]SV5MM]\@IKI2^#[/#LR38UQ9&=
M-K`L%-(1D0,V2*-(4C"^)PNQXVKW-7I)GNM1?(A1C,C!B69636@B?[1+?8Q)
M"($Z0@2/)VO:]'K]6]J=6C#?`-#=+C7^?^1!.V+(+-%*O(<>OL8L6(Y4DD[1
MB<^6U2]&M5K4?W-[].`MN"-+CZVTA3!$E5Z0KF3-NI9F1I`8[@UQI5.9JM49
M'^1J=O5I'*BD@OK&5((4DLH;2E2G'&*4WQ66`H0ZN0P+Q"AN'V(SM8Q6JJKT
M57OV8H?(3ZF)6Y^7=#S]:S[1()*K'R0C$2R2TCO'76"D<W\SFO%(;WM>SL3P
MY[4DCP*JQ):Z?!51KFZL-`D1VD6-'K2[&V@1;J1,"/1R94<JK,9'B*!RD<YS
MF]F*TE'?S[&ZA4#OWC>ML;"<MA,.P\8<MD`RG/(M'S9+O$5S0.`%I!-Z]4C_
M`(A5X+.@@W`2%=!)H#BGCC3HL6,(#A-ERWC0JO:QW4/<V.]&*-45J(6`[>ZJ
MMG9`LJL0LZF1(IJ2LB1DC?+27"+)C6OW&9VH+]%KHK6MZ^5[OSOK@>7:5\67
M%'"K[2?7,KXSC2I,:425\.5(+)A$C$8_JYKO!V-1.UAODLK)-9*JW3Y%HR%I
M[V2".*&UH8SV%KWW,HS+>&^81/TV([QD[NCG)_JM!AJZSHX]A.M(D#/4IY5E
M"7339H"NL*E'YHT>?V%'(\C?*B][!/>]BIT\5+27%3>P+S%CC;"MK8<MCX#M
MJICED3:R1%6-$G1J\L;H!S@C5R$5KVN5Q1MAVO?95=\W=</Y<4>GK)MYHI=#
M:<RXR%M9-O*KN+.7#T]03)3946Q&VGAQ(\)Q22+[-!&[0UOX]MH:4[;U1\<1
M;-(+LY^ZFB^R:W-W/W9U7_)KG?XS:#X'SUL?L<+[/\;Y_P"X,E\;]UTOY7=J
MIU5.J(YJKVJB(]/HJM15Z_16JO3^/X3N5%=T3N5$5J*O3ZJC55RHBK_9U7\'
M+W-9X@E)WO;WL9V,<[N<WR"[FMZ=53N;U3^U/X_BGL-@ZO>:;I97@SD1TB/7
MQJO.SVQ8/D"*2.3-F#\:/+^9CGD8C?HB)XLCG>;KJKQU[@K&)N,O(OX<,]O/
MJ$:^336=0:*=EA&'-&1G;%>WJQ'-8YJ_3RRLS,N6U'(BYZQG1#V9H<VLN:^,
M][JPN?>*8_SZ.4%[6$812(@W_P#&ZIY*8U8.VH=[:VD.?%B!D.CQ:6ML),A)
MI+282:R-/`,:L>UC5_,^5_Q_JTL#D"0=7V$"J&"\IQ%`ZP+?PHO9-CPFDD*A
M12I(7N$1S^B#ZJY?HOXT!:JM#-I@RXD&%*D*)IHIG1^TT2-'^0UL^U9+ZJYB
MKTZ(OT5$_3NGA)>6UG8SOABJ)X&105[E,9T<#'H6,^(26SJ)>SH-KF?G_O97
M6`J6WM,T#/%CQJB'&D_``KBL>.RM)DLA72+$9!^%&O[D57HG5_<BO'D.91Q<
M!:3!D=2Z*2\3*J7(8=&+66;A',R%(:$C%&5.K2JO1R(O1Q(T^N,,\&<-94*0
M)6**;&(J/;,CJU5\D<_D1S7_`/&1R._@J*OXH<_(GBO80*^4ZKS-,\PK*%=3
M8KD619&22`4=@8Z(=S_(U48C%7HB=1V5=.D.KZ%]!#TR133V2D)*5JGL*^XD
M^5&BCL<SQD(,;BM7IVC[D1HZP&>E39,:@L+"UMK"RK@I&F2)SG("FK5^0B7@
MA,1'D>]$[!E16]SG*I,9<-HHP*RRU5]`O^RSDNGJ.K0J,,:,&7U`(YE8J=HW
M,43D55>W_G>/])-I"9T]CG(7_5!2^98H8J.A1E:7R$<09X\=I&JY554=_;_%
M?^&]CO\`N&Y?_P#+W0_CURH_LO[<^S<#\0U/[>_;/[*^P_;N/L]#^R_LW^27
MK1^TOM?A\'VS^7''_P`#Q^#]MT7C^UQ<!4DJW4*T_.7N_6I0?84Q*TS:_P!Z
M_8R)]I_:3^)/75F9;5*)H/@+@</\-&>#]OTW3[;'[51>BO<USF_EZC5CE:K7
M-,CV*U51O=_'N1>B(B]4(B%031E$:0G>@GHQ&O8Y%*`R.8CQC:]/(U>K?IU1
M511E&3R/:1H2(CE,D8#X[WO9((Y)$=CAL>C7.&UZ*O;UZ?VI/$$4!DN'$51]
MI0J6+->%\>.I0..T+!2G':X841$(%_1Z-7L8^4*>A[#Y$1[8K121G97SX"JR
M84$5']8$B2(B@21YC*C7-<J]%ZD;7`ET([B5>3Z2^825'@DS=0L..]V@N;Q5
M#4OI<\RT`\`Q*]Y)+U7M<WJP\RAFPXAH3JLK7"84M78Z`<N(D*/8Q8UB]K+2
MI:"**((XC.7N:AFJYCF$'&D\<YF1B,Y+".O.*'GG6$>?=0*\?V")%--FQH];
M]RG(YO<)6N^:[O&1C^K69++PJ:R*EHEO$ERXL5"LK#"B0+Z\C72/DK%1@)+4
M58AA*KHS6KXV,8YXY3\E5/IX&.L$ISS;&-#B-TD0SG_N2T=<*D>("(V.USN@
MPD,$?:YB-0B-?49`4HEU8WH9,)9E''L`(E%'A3FV!11&$K[6.-DHHCQ(J=[R
M*PKVM>TJ]\&BT/A>.<8`*E\J<M=82KTE?')!GR6*^=H*:P>\BD8%["J%O5>Q
M%)Y'/8.?/'<Q[$%-?'L;F!92;.%7UL""X9I".<M5,)(;W.DHD=936/<Y@W,3
MPW&(UUCGK+4T49)MD=WVRNL@9NM$RUG3]?*MI;DO:^F>"-#"Q".<8!W=$85$
M4,D331F0M#$%-N249(4JNR-;-::III=Q#EJLC(@`$*!&1">033>)%0;G$!E:
M[D^H)"MMI*2*"OEV(9-/97<NN+*=//*'7QK2&2S5C1CGV(F_%L7C&\QAE:\F
M*A7T"#=TEH>HR%EB+D`(\J9*G.656P)4J($N>N;RI*CW?-\XBC"_M.ANWJ_D
M>9GZ^$X,C'W\V13,LH!)!#4D$\2502A`F^61(AP2O9&+':(X#/(O>G4:EC6>
M1XY=D)J4A`T69LKR9;<C6Q.LI]:W/CC6;)$9U@*O=*41#13RB,>YK5$]&AHK
M;.EL9&A'NXV<T69S\=]3<,T4DI8\^OTD.\M&1LI:1XM4_P":$`X]@`R-*Q2-
M1RBO9T.9!M"T<.%0&^Y6*"*>P9\I)4I+"9\:3/DP)]2:/)&:.CQ>!XT5B.8Q
MF,@27FCTZ7&=[+4S8DF/*B5]S$F@K6VEB60)9+5DM(D7QJ%/^B\KE<0G)%_M
M==/M(J[;4P\OF)MO-A0S7\?06D`Z>4$DBTT>$X:R(TMHX[&,?^7RM_YUN8BW
M_P!PS<VQF+5U,*V*Z62JDE%&L5I$0,B,0T-Y6NDN.0*]_D41RD>UCY"5MK2!
MF:?''&:&YGW^L+6VAP@GUTZO%806-B2U<\#5(K58UW<1&N:U!_S+P58I<Z84
M6MW5+EQ>2JL8Y63;&LK8$/X\MM7*KH]0-W?&C1S.[6$7]5LCQV><TMDW3\8P
MZK30XVJK)W?I*"3-6M?80+"CBOCGLJ@$=AT9."KD[QN84".<HQX[2V&HKKBN
MEP1$;20K>L#,,61%>@;>X%:R)%S`8WPH8+1*YD@I$8QKT55)4Y?+:.%(GV%L
MC!YR;:5TB3-BI'AQQEEACV*L[$2Q?,$![3.>-'([M(HT);8JR'#9<KHR#A':
M2$,<SO<422*F06:I91GB"I"-+_K->3L5K54CV71[+.40+!L]D/-P9)7,L+PI
M"MDG"!)B6@/G1QD<T8&L<V2U>QK$:G9G]]>0]#7$I&_[,RJBR)D]R])4)S)U
MFTIY,61(0C4609HU$QB]G3L<K`BSN<+'CW]-(/9?>9KGRII(J5`*ZRK99B/.
M>2=\F;'-VN&X2C5CO(QK&-+A:]]+K3`Y)]>[E\6EJ(VH%!/5<_X'1&L9,(O%
MW,\X4G/N@O,Z>.L`.N6$MBM[F/#^YZW\>VL/[,E[X^.(MG\%V<_=+1?9-;F[
MG[LM9_)KG?XR4'P/G_<?L</[/\;Y_P"X,E\;]UTO^39;>-5_<P4U5)):+\T4
M!*RJ-',&7<*8CV=_V_O:Y&-5'.54Z*GU5#:[?7\S"8>-<,FQ[ZCMN[2-J#R'
MS+*>DZ1(8L#JV.U&+XU4BJW^UOZ6GAVU!=:6"6ON8_%LS5ED@S&MK50L6E+6
M*XD6:"P@U:AEN[1JG4KOR?F_/(ICV-C5\AY><"@R-E'B22R`7$EDA9#\W#!+
M<.8![7?#*<JD9T*KD[G._/9<)[F]M)Y*7-15AS+J4ZTT=OL_"T^CJ03H9"#J
MXL13-4+BHOT[DZ_ZKB<DY6@#J(^?F5@=-4S:V8^P#151"'^/#F2CRW(K[:K&
MU>K".?W-;^9O3N'<V$05_9LSC@2A1K4\H,^ODRBM??.J50O2/,8(34&:0-&B
M1J*U47N4+,7-/%P[9D\<@FC5+"+4RV4<0<QN598&2$591OS++,/Z&*-6L7HU
M$%G,C1/FWY4;$K-T/25\%D2XC%E^(MI$FM,\(6P8[D>4:_G^O7M_-T+R!?\`
M%56RAR>9NI-<^F99,F5FR8TS72K])Y'J*!+@$7N`T;G>;R=B]57H6/QR2=>V
M5KQQ75KFV-_(4ME*@6"^9X2.^29_QX$MZ,#TZHX+D[NO\7_BNUY);(%#:5R+
M!D4[D;+)(A`8R4ET)Y72W>-HU[$"J-*UO57,1J^*^\-EIIF9!6Q;:Z.0T&(E
MMGAE^9;QV0D+-$V!$B">5\1B(4PVJGT?]!29,N6RM;&KHMG#LZX+?M#I4^1]
MO''I809!7I<$KX[%G1U1SAA?W(U5?^IC*I"ML02=+6`9IZTR3(Y:PT5\00B>
M$JADQS1W*A4:]2-5R]7/<O0N9RAI23BT-3&KWRD&@D,H47ZHQ%5&HU%Z?Q7^
M'\5_'DT6^RE#T'*,X=Q>5]>888;BH<A023C,%J>%RIWM:KNB]$ZHJ?B#34G-
MG'LZULB/#"@I?Q0'.4;T&YB-E*!&.5Z]$1RIW*B].O1>COMEI76/:CE=\&=&
ME]J,>HG*[XY2=$:1.U?[G?3^/_">QW_<-R__`.7NA_'KE1_9?VY]FX'XAJ?V
M]^V?V5]A^W<?9Z']E_9O\DO6C]I?:_#X/MG\N./_`('C\'[;HO']KB\>TJU3
MZ!*?G;W@KDHTSZ8W[#\+WD]D8CZA,?\`R;]>Q9U("B6.M<_C_$?#:BA^P4_;
M]MCH%KG+XVI]"%>8G:JN[5>\KWE=U5J_5RKUZ?AR)W(]OYNQJC\BM1[NWZ.5
M6HTW8J(JJGT_N5/HBJPA.CF/1K"*U.X7<0:JU2#8OY_I_G7IU^B=4,TSXKDF
M-)&)$D-E'"61X$(-!,BE84?>!?&4C^U$:B.1&HJH^S'8_#7NKX$9B/=-?)MH
MDD;`%AK'8YT2:Z("2Y&E"KY#Q->UPR=>A*"6/['29VMM='8Y>[SMW=55F6>&
MPHS5&>M9+P7)C4X:RRZ,AJ)S5#WL:YK'HTN:70F/3:/0QG!%6K<TTJ82C'<6
M%0][%29,^U"K)K%D1U`5&"E*YZJQ6JUAN.]Y&D;'B#/T$B/W:ZV.*UTEF6')
MJ3MB5\.2P-Q1BJHBJ20J-/T1ST0:#110(U:BF=<L!^U*:=:GSL:N%3N3X<FJ
MT,:5,L$KV"DM@,22T\Q3$9XRHQS%%K./[7!6>*DP)CZ2JY`D68;G+1PPE;!+
M5+7/,A7A2?4RF0VLBR&I'<U3/$AO$6PU$_86MI7MCI(K61R6]G>%N*N8^M6B
M"6JBI*J"K$E(>0R:LMB@$K0$>CG><R<E:VHP]Y*-<U\;5<>&^^2:J5(69(C7
M-5(O?DRJPUV`(W,DO9XTZE:SO_Z;>UF)ETD*MK//50%AT<N/\>]D(;0085JL
M6Q@BDP4+*[V-$A"M$CAJ0*=$%H#Z?_J[65KI.9O:P#+XF6O7B9+2<.U*Y[EK
M/-3,.D=DAK8JD:P9NP@U<#5ZM;T\V,/14.%JLQ61HD<KJFJ[QAL:^QJI1:1C
M:Z04CE[V^,XP/:\K.Y""I)<^FB'DBL93HEO</62WP&C%@`-V.ES2&-`BO>L3
MN<CFO(,1AOZHXL^DD5L>S^1#=)K/N33GL0P[%Y0S/+"D2)$>/4W3&-<UK?)V
M$:]$;^;H_P#?L-U/$T%'+AU9R'A5CS_;7S%IM'6!'"MEFE44(Z^5CV*XQ>US
M"N:1PRVU!F[5N>/608U5$CV$RP>RFE/9(-7$#7,&T`JP=D,8UC'81'HQ6L<S
MN_3T6]CT\:M?0S96CU\YOV@8[6QGS`2+NXMY`)U8ZR'YXYO')G$!*8!Z-8OC
MC=PJ_+5]KK-117LE)4^#;-B68Z<.GE"JJR!9,ES(CYJ&L4C3X4]ORB+/1K54
MZ-7LR1)%IV@K[F"HXTB-UNK&(U\:-,BR6`;*16";+8T`NUCT:Y[AIV=5=R7F
ML[R3MR:R)R#S&LDE$:&>CJ*6FY#OE6GN(UL84)U\0R]89G3VN4SW=HFE[7FI
M+?"PG)9Y^8")H9FBK(]I5%L+&M=*BR'2:NZ+9NJ/OK44LH7<K0C,]CVE5"$E
MYRS)$SNA"*&Z-/A%T7V:+95CC27QJ\ZS(!&R".1A0L(XC&LZ..153],]);FJ
M]3GY(NLJNLJ5Q_E34<QI9MD1\H44+7'(CP=C_*-0N[4;T_+8<E>OTC.T9)@+
M.5;%1U;`^X2I0A5MD,P12J]K)8"#$TZL\+R.")JQBN$X3+"CB8[CSE"PMK8:
M6U-F"ELY=K$@0FV=H+57LN*&SBRY,FN&R&2,4C2H-KFO:?N4N8T)*C&XO+4`
MK$\&774-=MMT"39ODDK[;0Q"R(;+6!FRRFL2/",XBM<Y%0B(8)(5%S9F\O"/
MG(5K3UO(69I+.*M<8,VJ6*/7M;:B9"J"HSYD@K8ZLB=K.YK$[R?B18746Q#0
M5]M6S*8PY\I8-A.;%&Y)T6U'8_!;&@/$B+XY/3K]58U!JT5L:!8+86UQL_F@
MKH,IL#'YR+7$L*VM?>MT`8<246P,C#(P1$:KW(Y.B#_1D1N7I;VV&96E^;39
MG2RH-5)T5GWV8T632642PD0H$1Y@A8UP`R@$:A6*B*%*9U(6WF97)\N</386
M*M,O#LZDKG\P<>6[M+#A-XRYKLIVAS)0?/=:$J8X:R*'Y[;W+/CNU%;^/;"+
MK(]%)JA9+(64<>BF0(-<S14W*&&N,=*":RY=X2C%NH6N@P35H&W4P\JQ&`(*
M'5&(/+W'X5R]>B(JKT17+T1.OT:U%<Y?\R)U7\6O%T#Y5AO>7YD+`9:JKX7W
M([;&Y-'41CPE$7N&UJM7R-:K@JK5ZHKFH[E`?)@LAN)4O+A?39_0PZZZC4.U
MI11AG#=/("0>//640*#8Y48YKNB=RO\`U)%[.I;"^M,#;7TV%%"U!F@`F.D0
M6Y''P@A3XE+6.ZL2(-[E,)%1_5G7Q6NLE<<YS!Z6VP8S5>.@U%971K"PK$.N
M@G#IOCA!5732L?X3.4;R/=W-1B]SA[;DC0;05=4Z;.RHN<R%-5-RUY53IWRW
M=^IDUT>&L^6JG<ACO[RR6N5']/X-I,C?T4NHTL2;6U6BT\2X@Q*&0V@,RNO+
M>!4FCHT>;C_#0KHXXS`>;L5@V]W4F35U_P".=K_#)Q=I@)9\^^=7"@B)(G;B
MQA(`U]63I+1(@Y#BC8T;6M1?X/W>?/(QMG<9.#3`RH'Y]LJ':WR2G@&ZGLCP
M>P4]5")SB#5WB5J*G55_5RUA,!%'<NMI4ZLCU%%9U%.L&UB25L[2XI31!SCV
M<@97D0[F(U_C5%Z-5RLI6X22-N<B.L![F_?'2%7V\*%(/(B@N*)XQN8IIKGB
M`]POS=CD^G:OAGUHK!`3M#G:B0B%1D$<NPE_[3\*$CXL<UI&*YQ"1F=SG#<O
M:UG\&L1R=>BHBIU16KT5.OU:Y$<U?\RIU3\3:;E,=*K;9AX%&::^+$N8DQS&
M'),H+`X22818[6-<\@E1/IVKW.5&K-F9O6"IXOVN?7#H*NY?,F#'5O6,:0X(
M&1SBGW"C8J2'%57.7ZN5'?JMKIUS6SH@R):'-HHIXM!,?)<@[8T(I((_D6WA
M5R/(UB/<GY2*U.K14VXI\G'U?*4!C1PQ'!`86N$KS-.:CDBC/;506?G5%8%K
MO^4QJ.5*7C#@.IML4?6/#\Z;EKFQ7:RY$&S#)6GK[>M97S*B,2/%7Y+V,8]P
M/(UR.:]S62=3SGMKK/6,P%5+2N9:'U%Q;)8SX\9!-DSDL9S(P1L$A>]6N>O1
MO;U_YS1;?*\ES;;)T9A$7>4LBN^)2QQL!*-.CQA1G3CS:IWC"Y1*7M(O:BN<
MOZN5T68Y:U]GDSA%<U-[3:K0QCV-2CNM@&U&U_B>,L9CGK'1HVL:/\JHY.]_
MW2PM9E])K)#$CW\\?9(N*^<IC`.Y>\CR-`]CAH]ZJYR)T7ZM5&_Y'S+*;$KX
M8U8A)4Z2&)&&I'H,://(>,3%>]R-3JOU5>B?B5E+W?UD2]AR(L>3#:A#>-)K
MAMC2/,)K@OBE\GT>URI].G\5:BG7.7]1>)&'',=U5/CSF"%*\OQGN?'(1B-,
M@7=J]?JB?^U['?\`<-R__P"7NA_'J=2XF+0P<93^M/!-7D865GU]IF(>8K^+
MLM$H(N<LZCF7V,JK&ACU01,AGB\A;N.:.C'CT5TQ4LI/$%-C8U/#R57RU[G5
M^6B9R7!LLY%ST#W<]B8M/&H+.JY8Y[JIU(&O8-L,T?=;0)HZ->.]MV*EA(3_
M`%6N_*KD^KVI]45[47]-5^G5$7HG]_3^S\+U4B_E3\K1O>U.B$<JHK!JJN<C
M>BIU7^")TZJG5C5:7N<7HUP'K^GT1ZM*155C58C4ZJUR.;W?3H[Z=2`\TR._
M]1K9$1(:/(U1#(I!_($<8>TCU&Q'?GZIU7JGYD>XT,Q8[C?`.LAQR0D4Y7L<
MH3C%%"&/(?W?)>7L&-Y&HQR_F0=I",H"G?%<'8"E_-$L<4.#9?M>TSL]IUC0
MK-%`0#T/'(Q6D:UCHKFHH];QON'Z/*XN#<RP9)M@"R.2-+=</DW]'(A/#;R;
M.4>?().M&3C5OB.5[U:Y['O.#]D7<:)I[VODMQ3+*FC6`I4JN)$?W0(#&2/N
M523HTK7G4II#%:K%>C4\V9S4ZT^^:/,,CNHJ@3)E)66EA'DPGS73ZZ)6]9-W
M/1_R*^.C4CC;V*4B/8U2WS]9G+AFL@PXEQ9B)42%N?F0IDUSVS[T*'+=S94N
M41QPU4MTOP$<[]8;5<VSJZ_D&SM#2)#YY+'.[*8]\VC<*;7YRGLJYHX)+N/6
M00D`4\PRCAJQ[.SIU04G5#D'Y$#`$[:$!6B?%J2W)'H^NIJ=L6$EM9:^NNC3
M!D,]PY!H9%:U@F->B-HZ\SV4-UG9=8.9(K0Q%H&U-42ONG8\CX*2W39<R*]R
MSV/<$QGA<A',[4+K*@4*)E9-M)^:0NKL%BU\RV9`-,H*R^L4K6R=!J+`<6-\
M:0)S5(QR,,1[H[/-8QHM(E5:3<W-C6517UM-#T5=;YV2\E=(51UDF'I85PX8
M&+*-V',X05:DEST5:'<UFAW]1`@%@+'SNWOD,S41Y56(<:SFT4%A'UFDG6DP
MH$*J`=\=[6L>UC5["9RST;:NOOZZ(?QV\S4$D$AQY,T;7YH9&#K:*KB24.TS
M)"-GF(1[$$'\RIH<Z"'`AR[B6QL6V""/+D:*+,CJ0J@B3ZX;0WB1FO:TCT,)
MQ>G>UP_(P6CAV>RU#?V[6Q[79ZB?.A5MZ;/0%2-9K8&FFLO*!D>+'&C0H*,B
M,\4=556M)(TV$NAS*R/#AK7R6U<J+(TM'=-^U1*NXEK*KIT*#'E,7XK0C>`8
MRA:K'M(BD!55K)E1>1+_`#\C/FL[*V//K83[#/1[-8%;-OXD6=G*-8Y&E0)'
M2WQD?&`=.WL6FV4B[D74B?-H!A/?V<NQ)2PY%E'B3@0IHQO^VN^Z2'#[N]C.
MQR#,U7?G%RM993.0'VD?;\@V4B3?EHI-+>7$S8VJ3G;:QFPYBC$3/SW*&*2.
MH%8-R!.)&$5D.PUY&VN90=`2#<Z'1`&.1/KI'RV5]+7U@W.8"EF$<Y&M;\H;
M`C:AE:,?CKB`T\^R4EYU@0#FCU8[2@\<J4*02J$MG8SGAJHXWHH4&5J,1S4>
MYS5?8EMQS?V#8K5&BRAW!#S(WP"L9,C3H1(QITM2.<(C5,@S-&Q6.[T1$(>F
M@58J^A&<01_$9"C#M7PV*R2P(11P1@6)XPW.>-6->4+6JYR>-"*6RCYD,$\W
MXM8^6`HAPYL>45\F+),7XJ6I2%-(8QXR,8JL:X:N[>BC4$6"E,<KW,\GPHL3
MJZ)(*^7(F,AQT89)*N_(Y%:,;5)T1%1WCLK672S8L4LV(V?7U_W'M,^/!M3U
MPX9XD0A*LZ28#7M:7HQ[F/:=I6D:+\7B#4VIK,C?NL84NL:P@GP(,)]A9R9$
MN4(L<?Q[&2D&:*6_XJ,$JM3M3L)E;3)6;*ZSL9F?D:?,Z2^;49"$!];(<]7I
M-KI>'N9=A(`C1M>$D9R%1["H[KWU-K*(:AGZG2WRRJW]N6%""D/"F'K/B3:^
MU@D&2+-;'1(D]SVK,CD:Y%>,Z$3CJTM;P%YFY//7KXZ3&WR1*B.>WI/8OCRY
MPLJAKK+DCA6OIKN#MHD4T%@K*1(DS0#CAH]*8K<U9?CVZGMM_LCEXU!7MF?N
M)<OYUN=7G*=*?[DG,G!2ROW"L_X'VW[W-^\?)^!^WM=\G]J75S"J7BE4E/8O
MJ+&%(DUI(B&B*0A9$&9%8020G-:K$(A2>16=R$1KE4=QNQ4<4,;-2YL'1PY5
MR))T8P7M^`Z*L>._Y\=/.QQ$:G=U?_J]/RDJ_8#1S;VVJZZ5:)E6.:=0LCFC
M,>EA7UC0*QD&M0_:"4YJ-5JIW?3HA+JI?C2P=S?VLRTMY'Q!3M)I,]9O=(AV
M);<(YE?6+^5512->1Z]$;]5_5%LKVR!6<>UEA57L@81@+:G98_6HAU!)#2N+
M92(:#?(.4J^0[^K41S?R?LH=!4\<5KYH-EK3;-@Z:]IJLTD8'W<F?X4D2&SE
M5%6&-W:C_JGC[7*+6\LWG/5E)R,JLJQTL6QMW!C3"J0!:&(@GM#Y(5Z(CF>=
M&=1#'T1?^,*YYR=)K=%@=M%NX=165\,EGH:J#J[9PHZU-<:`6-958'S$1Q!M
M&\D=/)V/15\L/'TE9>Y_8X6!76E^.Y=(EYZ72'`PGSBM<1K<_#&-44<7J3O5
M>J)]50E?H,[NXUZNQLK('[<BP8KXD^KB(AQ`K1%B.>!D*.?O,5/U".=U5SE=
M^KG-AI]/H:VM@VE)2L2\:Z>*^(&.D!Q'W$<CEC$1AO$OC08QHQ>J-5%4>J+4
M9W.R:V[BYI[;E)D:UK8Y7(HX-`.LCC%%&E9+8^45[U;V*Y%=TZ(H6V^ELLG#
M/G[&78]ES/($%*N9"H%T4"":L$^3#0<%KHH!.5$./L1R(G42U?'=18\P;ZL9
M!'=5]/#/';&D2#H4R'<P!(\>,.O[GM.KR-Z(G<JN5JO+RUIJP."RFFLQ5.&H
M0W<N=/HZU\P4<,B0#XJQ!EO"D10M3NZH3^#T5?)0DTL=EER*#"#V%A1@F?)N
M8\"&]L\[I`11XZ#M),-7D`)2O88K4:XG1W>^NDZF">WBQJR+7&I)U;/?254C
M1S5CP)UM8Q8Z1XUT-HU:H!-7HT3?(K$3]/DSCVFJV5-+2RZL.BM!23@M"UDF
MT%$6=7/DQ'K4Q?C*P:>)[6M1B(O;V_I9NPP6:C&B;#.3H^!DSJ+Y\Q2TU+->
MX97I%>8R6A"(,A$57/1S6JQ/X"/S%M*NXV,O7Y&GG0*$M<UF;FS[^2D<68FR
M&,FK#*"/(:HT:-I6J_JCOK^K2:'4YCDW.ZJ_B-I2<3PD9#X]R<]T620+HM5\
M<LRVA2C.:7O,-ZF<Y>O<J]"X'"X_C^MKM)-%)E6.BI+19E5J233PF@`U)(0M
MI&5X#.4Z*@VJO<U7)W=[HT(A:]:R9#N*Z?`C/FQ'5L2I`BQ`)7LCL@I6,>']
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M$<0/YOI^9$^O^7V._P"X;E__`,O=#^/7*\^]?N/[SP/Q#;?N']S?O7[]]QX^
MSTS[U^\OYV^R_P"[?NGF\_W/^8_('S_)Y_W)>^3[I*X^NTM%T"VW.GO#/_<"
MZ)->MPD[WG]D93[?]VNYB]A7:=EH]4-]P3?[GYO>AOO]RCON,CHB][D;T17J
MC>]R)]%<K&=&]R_QZ-^G]WX"KQQAIY2>1$(YR,4BO:,@7J$?<4KG(CFJUOU(
MO1R].C_PXJ/<JA[OR$(X`$1S!JY7.:->]K&HJHJHY$<J_P!WY4;\B2X,U$.`
M[0F%'(<W:2,0L88#=RQ7(JN8941.]7HU%:CPSHEBP<^28<J$2=\!$B"KANBR
M95<-SHS>R";J49/(1!N[&]%ZL_)4[?!2=!%;97`2,S9M;-,+3.A``DBN+]RA
MQHELE500PI$A'5YG%&Q$5'(J$O8]]CKW/QLM86<32W5<ZTGQ&'22W[3;5\2Y
MGVT0T.S!/C'`"&_S$;Y@-&B(Y"2*LF8L2:*EL6M/H:^C-H;.M/(`&9`T#TAP
M7**M$R*@3=S4E-0XV$8]7->XEEIJ!>0T31,AMPL"'<7MB:SL$@)6:"+2$@'-
M06TN2)\D1/,R*)B*P[W-8B,JLSC*&KAV5Z);:,6X!84,W#55F9+.PKCQZVMD
M1+=K3G?+.YP7L>>(K?RL3H+,Z_2?8-A8QEJ+2IENIY5?55LD9K&;9:EM+)BT
M5BV^N9#BL,E@KXS"B3Q='M3QRJ2+0CMHW:;+1\L!L,\.HCH@YID!+%%>SXLI
M([SJL9SFI)42-[57]:GW-'7MFAMII(=;$T-<297PILV*>+)D_'3X5N'_`*Q-
MV?\`5YQO"YZ.(WJG0L'!9UEY^SP)8`N*[1&FU-N+04K!B6-9CFQ(!:V5731.
M?$0JR1O"YQ(SG!(Y3ZFSI(F9;\]X76T&#5,L+*&*22L*.=.H*P4`D"6>/'>$
ML0QF>5!L5@U1BJ#2:9=3::BN@BSR'H[K*3,W0EM/&Z;,BT/[;'<2JRWK8A11
MECO8$=CX^YWU8OBUES:2ZW8P+XH8N!2B))@24J[`#RWK(4IT`[AFHX<L)FJJ
MQSA5BHWN_P"CI"0K7/YJ(:ILXFLHVCTDK2WE<6U2+764>+)<E#:TJ#,D(9+&
M3(CR)/4K7.4C!EU\JIMJVFD927FW+G[ZRT4[,1`28)30H:+4%EVT8FIE1OAB
MF25/&AD0*%3QHOFRB[5K7SJC1YZ?IU%3IH2^0]W2S:R0R4Z4R/!H*P<8X9\L
M9H+I$EI6O3L(KG9&!2ULNOJ8QJ^1&4E4ZL(`L.5#>8;XP3D-7R"F[#N#W/C@
M+T:O=^9H>5U8:36-T'+7)4*/1-<*YE0S?S`T]>YT2*UPHL>MEQW/;,:U!M\3
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ML6.5B1^Q6H-AE1G1$>UC@LBV_P!YB0A7N;K9`*"0QVQK+QEG41&D>L6"!8EJ
MQ#3'.E>,1FH$GYVIT7R8Z)&S+[<DLX])9K81[*WD2J>L(,\R32CKV(6*6MDG
M;)CB$J!00WL4?9W.)L29+;\D7>@XQHJO25IN7<E]MBVX[N1IG7E-G31:>$6?
M61(U"(5=,[Y+X0YC7JK6#$5>/.0MO!U/&"5/+'K_`)V@K["]K\Y]_?I^3L9`
MF_>S1.3^$QA;:#N_MH`!NIP]`X[(#:'3^=V5L_Q[?2GW2T##<8CJGV":3]JJ
M]EYJ<[2.JDM/YR<$_(6^;8?!2O\`ODW[O\GX'[?UOR?VI=6EKQHRTD5>WOM&
M:[EV6@F6[H@W2I#;_8GEV#YEG;1_*][QF<<SC,ZN4BOZJ)V@<^)#R\:\GASM
MI`9+&Y85"-D.7<:FHG1E;%21,:20%CAHZ6`S6M8WJK'_`+QKH_(U=KJNN>&I
MBU2A!7[.I$XCJ^#1U+0/=%J[=J*\[E$T?8]R?7JBF-R[/WIDA[N_^RGIQSEO
M-)+2!)2,T\4#X)10(T)SUBHU?TVKU<Y%3ZDG9DHFRJ'+ZFWLR8S3+&AY8E;F
MFNK:&#$OH(2,/JTD0N\H&O<QI'.1JM8B/%S!3:OCZJ7D4M\YL2SU@RU8ZNCI
MQ/CT0*8T".%6U$"*U&#0HG*=R_P_(WQ8CB/F?#/T#LG6UOD?2Q"R$8V$11N+
M66TM!G,^0TWC&-O<K?JC?&K.C8&OPU%(M\;H:2/046!5LA)F5`R)'JZ+(MIY
M(1#AV\=H6]7(Y.]Z=%1>]?(V_%4G!RY<PP#Y`PMBBS#AH:L9AS_GDGL49.P,
MH:&_,5[G&3L:]W1"?L:%;#F&N[!`X2%&CV1H@8]I(<2/#AE!'<M-#$Q7-D/:
MXK>WM[^JN5"`@:&Q2[FUVHM*FCF$EW0ZJ9IH4]6R($.#)JBF'!L(C'='R6#:
MU6+VN:Y.H;/.SLI!S9,Y>60ZM/FV08$DT:<4;ZH+:^$Y9]65886G)VKX$;V_
M16_I5^@V!'VF@)2P*O7UM96N9A0W&@:P(N^82M8/[+`>X32(%J/:K%5S&]OZ
M>IS''N&&#:I:64'0UU/!CPHNT+XI(UMV:(X/*RK.XKD"KT8Y$8OY515\D:ZY
M>HXE1QEB\^.AJJ"WB1C4EE=G4T.A)6SY,8L29.@&:U['HY5*OY6M5')Y;"/0
M9W4PKHZ%S?)W)U!46!IUF>P(\E%`IARN]@;65`1PO$UPA$:1R=R*3N)*L>*;
MT4O.3(M9JID6^`&1L:=T\+5GD;6RXSV5\\R@=T8=[NTB*C48C&JRY-)C1L]N
MGH*LI,OHV@;)L3UK/N`(VBG.8B?=K%XD/'A]4C-[41'M>B(.)O>0L]"IX/%M
MI>YB+:)75-M,8E\1,\,S*A@I`ZTL&TL!(02#*JQF$7M=V-:/(3;"+%TMA?6,
M"ZGPX],M?8-BM,R17T^;JOMICK(EPT0CU0;NUKT3NZN52Y/V+UL2ZXMS5?$H
M)]51QR(8\@YT$A`7`X@Y<AYSR'-CHCVJB(16HJ]R]]/(K9+ZVLL9D.+-JNU@
M#1RR"2G2):!;",2KB"DC$<W<1CE\?7N:C^\D?43)AQ!TE&"+#HR@"WXS!RF&
M)9*9`L.JSE`WM:JM1&HB*QO1J)-LII4#"KHDF=+,J*J"BQ`OD2"JB=55!B&J
M_P#P_%/Q3F4M<3F<E9W!<?6ECFDCCU\">VI-KR/6''1E[=@,]HU>G<&*1[6]
M51PDCX7CN9"M:C*193]#L85B:H09H<IA9IR61:USVWMQ9HX`O)U[F.7HYW7H
M;D;?<BPZOB3UZ!"K,S6UHSRSFU,&-^=9U,V*PD2?=6YT>-3D:TSE>YW5R/3S
M<9;O*U-S05<J+=EX_P`Q91_M=Y!S5:2I#+?;A8(KCFM!&;(Z*]7].WZ]%\GX
MS7,6X=.AYZHK'S#D$,3YNELY:A'&#2Q7-B(\TMZ(-K%^C/$]57\KFML,IP[^
MZL_FH\9T4'''&!)#+B4R4;_8)^HT+HWE!)0;NKD808T^O1K5;^E;(LG7Y^_A
MP:PME70MQ:+8I2C*1;"7<23?H6+#O=T(P7=V]G:YW14%^(5)O=!L=G60BPQW
M5#NHKT.ZO?/>`CJF2D=Y7,9"1K@O8Y55%1?S*JJ2IY`Q[R$I+4(E9Y>OECS/
M$Q\VO.GC8WY$`K^Q_3JBK]4^BHJ^R95:YR"X"YB(K6]O<Y&<=Z)RM;W.:WN5
M$^G543_/^/7*[^]?N3[SP/Q#:_N']S+M?OWW'C[/2_O7[R7FWV676_=/-Y_N
M?\Q^0/G^3S_N2\[_`+I*X_NTM?OZVO.?O#8)?NT7[P==?/\`>CV/DOM4UJ\P
M>PRZ=MFYWF^X?O\`W"34<AOO]SW_`'&0@F!.Y7,5WD&UO:WKW)T:\GZ7E:J=
M>C^C>G]JKT:J-:SHB][E5$:C4<KD5>J=47N>KE7KT7^WK_G9T:B>-%0:)]&L
M14[?RM3\J*C?HB].J(JHGT5?PCE\WC`-OY6M>]3$*[Q":C^Y7$(WM5%:O5%5
MZ*J]41?P1J/?W>4?D:UHU4<DGB>0XR)$4GE[2=4=T1&HOT[$3\K(4<<9H`'$
MDT0G.C""JL^5)=U8G;V*TK%8-&(UK51$[4Z*R#?^R?*O'?%>:L3RV1;GD8C(
M<&5XWJAPP9LFLD15GBE-5&!80;FL[58U>JL)F.'^+?8#$\L\P\NZO+TN9J.-
MLGK-);WFA@3B2!TZ@B8AU8.!91I,E9MD\R#A0AJ]7-8)'K9W%K2`J;NV+9@E
MRH9[>CB2)(#%CR*][Z.:/[I(C1Q=CSE`8DAQV=S6E1KG'UT>1$@0X\N+/J*>
MRJPG=Y&6,A"VE3/M$'\`]@KF&(IUGS"-<CW]A._Q(>N#,#30)-8#[7DG#HH1
MGO4WRCA;%8Y6PYI7H\HQ(U'D9]/"O>C(F8K1Q*J/4U(JR(,,`=>V-!#*20$1
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M\).YS.QFJ/F"3A55*9MMIJ.]HHI9E<V,9R&R-?4SBQ7&A_;)`[26=)'T0;D$
M!Q'M:6^JL/75U(.5IVT1=+$H8\>MG2YDJ#J8#274CY4R!\F(5W2.<*?,%(5_
MYW,>A,SEIOW"U:#91[&='B2S#JHM6>ZK`Z>I,"OB`C2?N'8044A.^*2,CRB2
M,XW0M7%ACC-&Q8B#)+JR*2+'ZL2<-[T9$D-.]L+M&-R-:-?S.1RC5!<_[J%\
MJ?CJSDKEV''JYTFRIX$\[-A<R)$9_P`Q@&0[.*3PL1%:4,D3$,W]-ZC;/S>I
MAASU5`NJ.R/>4<B=)M+V&#X0X\)M4(LF:E5Y@-`![$_47N7Q]BNBCI4E"9>V
MKX[U>RQAM-3TT;Y2OK88`*R0QLDLIS3&.Y54BN5>JJY5/`L;(401XLX;*NP&
MMDX$(,X<D!^Z.VKD&/&>`3&^-6.\BN[7HK.U2GG0VR(4BZ>6N%+CI)%.5`,6
MP=$M8X:QL<`/FL(7\_B8Q$(Y7M14(XMB9QJJ3%*2%(\$V5-D7`FC/^<KWTC&
M`%'6.Y&N8[M>UB*I.B/02"AL(C(Q!M*TO4SB-4+E4P6]D<Y1H=ZO+VN8U&)_
MQ/XBT=Y4WDFO^',C12P$B!F1;&UL*J[J:D;WR*^4`H#2SMZJC44B+T<JL;XV
M\<QY9JZ1HZ0AJ6YNDNA3?#?#M)J.GQ[`\>VB08\MT]!O#&>KT+W->Q$=VEL)
M!2$MK5(\N1%B5ZH2'+8@'0G!D./61YHZI@Y#4,\+OU7)_!_5?+Q-EKV!F[*J
M?>5]QH&B,*>D6IG&D,9FTER*P0PU,5@E5RHY[I##N:Q4^,A'<<5E>69E:"=S
M1PYG$=8[%U)+?/L^5\Z,U5"G'Y=X;,N=M6R0UD:J^[R&W7R61$S^J<1<Q9_C
MW##2V6UJIH>+4L"R\!<;*CO'U=5I\]:7L"PF83CCE2[D8BVI(<B+IH1ZN-36
M6;-.B6]OGZD\V^K=OB0&+=45">N7;ZR'7V4.SJC,F&A7-=6B*V'85!`F8B2H
M:HA57IY!H]O:_6@QO*4+:-<]D2SK[MM*TEL:Q*237WC50@F//4U[FQAPPM1O
M:/J_R*YST94ZL$EO)%8L7+9>_NJ:T<X]5,&\4ABB9-!GX%2JJX:22`5_:KE>
MY%<Y!UE7EZZVSM=:V(VNC4]V*?8VTDTI8MTROAR/EP:FOF(=Y'+#'%1GZBHK
M>]Z-E`U=OHZ&DR<J]/6XFEG18=A+T\66>HI],"SDNBV<N1:M8UY5D$(!6N1Z
MM<J,5]C/=1_9^0=G'1*#<RIT5X]I60SA8/+V,)$)75I(\9>K9<4,>25@VJQ[
MD:WOFQYV9SFOFPYD8>>I?ABK4F2DC0R-A9LMI.0\\<4J.:Z4-'HU%8O545J/
MKJ_EG+4LB+&D:BVE8K(9:5,LXVNHF&$*+=VT$BA^YND#7M,-/`U$>[JU'*C%
MWM5=QH>@L+HM`?&6$E/GR(ER^)'DBFN@,@CCU[7":JNG%\_8)ZC_`./V:^OS
M$0$K5V<>!+J;O-2G!DP8D\0EERH#;"3,GUS83.Y[6B>P1>CU4;5<3ML>/.(*
M^?-Y6B%E`LPGCU]K"H(<Z.A_WMH+!Q#O86</JR*`)48Q7-<C5>QJO^\<8<9U
M-/M*)LRM!4NMJR3-MH\\CHAIU8ITDVQYTZ4-3/&5S6B1&HQO1K%?F]OS+3Y2
MKTU'Y-#*J](:MACH*',2GS;2-(SL*1%K+&[FC:183G1I!&JYCE>_M:K^0="-
ME/`SD2\K).&R=G23FY_7#C@2<\)-"2<EX."UQB(C%DC1A2$^G158S-<=YZ_I
ML]F9/)&1GW$J^L%KZG&%F2EG0*<#I$H(BD<7O\$E2)X.KW.<WO?X[:!IKZD%
MQZ',76>;,QE6RP78VU722`4U275#@23!TML9B!2PCE^3'4K^BL55\=5AY$W8
M\>6O*\Z3<6LG53[:=?:V56E\PL_B"D(965=9%&,CWF0J]Z-Z]4\:/-Q]57TO
MBJ;56<ZQR.H;;2[W1<AV]>-#)]]2:;PQ0.1.HP(QCHW1K6M5>U"66#^VV$>G
MY%S%!<)(K8U%--7/JQ-=I-7);8!LVPEM`P7)X!M&Q%[$*B#:C_PDVNV3=';V
M5/=EA6EX7-SC4V726:""UMR!$T51WNCJP8XC!/1%?U[.YW875VDF+K+2FNX1
M#EK)M8R!!S!7C&<$>KD-BQ9@QM1Y!DDIYU5[T<Y7KU'=T%9`0-]JM0$V?F6<
M9MKF*[RH,^CC6JCDAMH-M94["H`1W(A2D51M;VO&V%65\8$.#`C!B1(L8?BC
M@`!B#&,0^KNQC6M^B*JK_>JK]?QKXU)<2JJ]TWBS\$5>!IIUE&F(]ME#$Y4\
MD0;HJ_G.-S'C7M1%57(UV[C6,RYSU[+;,H:_45<H3[JABN44JNAQAR2RP*Z0
MV(]A'&&5B,>U'.1J-=^*SD>VC3G9;E*^'#M)&D:P=L%LAIVSM#*Q\,PX)P%,
MUR@Z"57O<16L9WN<.?B2[[1;##$IZK94LD(\I1`PE]%C-L`5\['40X#;E9T&
M,UJ?*C.[.J]Z(Y2=O&M;M;<%UI:NWT]S/%!I8N7?19(#:>HJX)V0DCG,ZREL
M:0"!"WY!&$5W<]B,_'K=P>:SCUN6BY%.1PT$D7A!.L;DP65;;SL\,X`PL(BB
M8TK7(YB?3Z_J9K73=+FLI>:+YMY?ZX33%=]@DF6%%E/2?*,DN-$G_F\;6.>Y
MC6IWN5&H^[U7)/(,/E&Q$"^%57N$B5=-76=7`>&=#%&CM@!*X]HI&L(!7^`3
M&(J(UKO(M;RM8!HXU_E;JPC2(L:1638D>,27\NJAN)%49)JCC(C9:RE(J'>Y
M%1GYD;RKB9DZ<>71Z>#=BKSQE'&IP649P#QPG:YPGDDG&U[FMZ)W-<[IU<J)
MS+D*Q\^+8:3A[DALJ?'`!\0=;)Q>FBFC2CF:;P^16?5K6(5W<SL<BJC7^O%9
M?6.YM[RNX,XE@W5MR?=;;2<EV=M$P.?CV-CR'HN2^-N&>1[_`',V8-Y+:;H,
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MF>6,=Q7Q[7QR@):ZJ>,5C>6'A$05)CL]"%,O-GH+%Q&HVOK`2C/1.Y$Z-7JS
M?Y/1N]`_Z:%]$F1,G1ZCAGC[7^XGM-E)##UUQ>7^;YBHMYA^`L'=2(\TM))2
M(^\?7$%*#W(=A`^P?LQ98=])O-SRSRGB_6"ON;:_TMCP[ZWUUVW*P9;YEM.G
MK^_>74I3W,RRF-?.@U\T46(L49)8DLZL$BBM]&:SCBCU-\TTEN=A&*5P[B6M
M23[E:V;^]32H`E)(54<O^HYPV'Q5*&FLH\A]S6Q#S,T")I&WPI16Q)M7%'$=
M6`H[%CHCT:Y4FM<HG!Z#16N@P+W2[&.QP4O+:#I,C0QZNLC_``FKI<Q4WV:J
M8%#5P&22BD0I!3$DD>OD,Q6,1I;ML'E.T_E[#C1K$5::BQ*7CIT<2C2Y@%K\
M[35;*\H`N<Q#+)<G5CVO50BZU%HG(UM;U`P1*U17E+09&FE?]8LKV"(.IQ]2
MH'3/*H94!)3Y3Y,EJ.<QKWM9$9RZ"KOJ=Q6U<"R@QZ,<JW!%*04N-64DZO@7
MT%8[(K!.<0LN4YW<QSVC<_Q4^DT\^O2;(C5])7?"K0'O(\Z;)ENE9RU'%6-9
MT.DJ_BJI%[RRX_D,H216(Y&3[Z@A0_!;:(A*UV:FDMH=K67T!\N^@U\>RE>`
M:).C1W2J]Z1/']%B.<\;5*>D@1ILRM/67EK:DT!QE+I#QYY`7-16HV/*JF6L
M&H$B02QVPU"H^K(XR-\CZVFOI>C^VW)(F@S@)V.&.355#30E5UQ9&:`AH5\%
M2L?"=*5C'OCE=(5@G^<P-_?Q;6'F%CM;7-M=13"CBKK2.&DA:"H>\7W)81X:
MCL)DHY)CS2$5L@CR$1&-AU]31Y8+'/O3I4QZ_)6<-.^*V7'^X1+%]NP$IY([
MX1AS)*JJ/?V(UZLSP\<O531HT.W.6`>*)JI#Z>6EC+834J*^:\1#2@KXT"YI
M.@D1>T8D*2-*BJ`1V_[/'$59<4T<P3M=&\37"\GY^BM>U'HQ4[5;U?R>2U'5
MNS\_7[^##R[)D.R@W0Y6OL2/LB-`UTU+5U:<;1A*QXFN"SQHAE<I+.'KJ9TE
ME.,=S9ZPTL;J-OB#*CK!AJ^?%*G<)@AH0Z.\ZF8]Y.X:E=65&BS>CDTJCCP_
MW!]HB5<2GD2PSY4$=L:!->1K1N&[H^4BC>UROZN\CG#LU`LB3;74$$N5(;)E
MV56>`!"'KH[:^0=]=5.2<Q50P@=IG]RO7M4C6G6?!'(4A4:<X8A87^UH&.P"
M2X[ISCN5C^YZ,:[]0K%[AN5[D0Q*X8(XPO6$C@#CA0H6M,)K!,)-8%B>.0Y1
M-Z$8BO1B?5H_(LX"P4,<8F#F*R+%D,>SJPK5C/D&;%,WNZ^0:.5&(U51>J>2
MZ@EK':&+90(AYL6;+E_:ID(!C-C#EPBV0FQ:NME/^2=&/9&7Q`[NT+GO(3+2
MYT>RSKJVP,#10HM=4.H+(4J08DHA*WX%3;!OQL&XT1%-\7O_`$Q]KW>,4*-9
M/DUL:3)CVMC6QZI[_CP7Q1N&1S2NE5\TDE>A""<!B%*U'.0:O03*08H^GJY4
M1]WG,45``E1FY"76?.OY=Q719FL;'L;*X&7OFK\>&@%6)W(\P_QQ[3!M.08&
MYK^=>&KF9%S6TVU3=53ZSDB@E[.FKPX?C[E&TF\;2J-DB)?@E5]946&<GRXU
MI94=627=0?Q[C`2I2Z6-Q22V2([._NA(ZT6CH+M+G[9_)[G/XZYW[?\`<$L/
MLD+[0L;YW[@R7QOW536\:/F;EU);\A:P&PT]K"EYN-9206DJIMZVGR$>GS4K
M*UL@JN\$29719,9S_&X`G(YKJS,9:JMO#)MU^595];;37U?W%B-DV$DRR'@E
M19JHCPE_-XR,5>]',51\6YVWE9Q3Y/,H5T^<,%C9V\.9U?('-*,C9%L)82]#
M=%:HBJB_I^-6CC:3$0;*;0Z#4HS,7Q8HH!Z;/6!(8K&E@.GS4%'[V,[8QD8U
M>SI_#QH\-?\`<J,=G:P[2'BZ]]?!$/[1>1]`:!)B:.T";OE55=7(C`/8QC2]
M>[M5I/U'QM$W.8Z@@3$E`NX%6LR]N#1Y@PFI:9\F69L0D0;W)T%W*4#EZ*[K
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M2TK(BV`R4TE1PYSQ>2T16,,)O1C&$5K5>KOU;SU^OXUQ8U=[4DT=%<6$P?DB
M;:;WQ)M/3$D&BC6N/UZ#5",:%1JKNU6N08<%JLP-V8SC72='1CAR;F39YB!/
M=/B6DJ3,.A@W4=KO&+Q]S"JBM5R,:U`UF+XPXWNHG#G%U_3DLY&@K(1(,FTB
M6(37E=]E>XCD-<5$<@C*YG:$KDZHBHJ#R%3D<S7"Y'J+2;5X&SB")+-B(M@J
MS)S)C(DP4>-;.*[N>'O>]J=?J[N_4I0ZZHK,]96=8RPEZ^+4.2Z-H<\=J76T
MGV#YA:K,5DA[6E;$*K72G*GT7R?J0=A9UZ:7(OUVAN6:0-X1^EU<745#J:N,
MPK&!.*,V^MX[V1FO8QXVHQ'(CU>3'LXQI95;:S&#^?4W`G9U+&Z1&*:CL8Q)
M(&-HS*Q'?'$]5$G1?HY.H=)0?%KB6P='1`NLC`5+&MJJ6I1L^3+):"LP+!AQ
M4`WXK2-<YST1O1O_`$6EHBZYE,.]T$&V*\5=/'<U;Z^NFP8<16@E?]:+:6RA
M8\34[QC=^1CNU1#.,5WQ]:2H1YQS_/G)6.93P@N5))T9/11/>_\`UNY%5BHB
M=7*J(\E7K==!2HCPY$6IE5L]K:HMK;/'%*D1(A2?-<QI6(`/1WE3JG5W=VE%
MK\KDZ)LY5`%2ZZ1'=8Z/2B\LD1H0V3'.E$M80"'6(3J^.\;E[VK^HX>\YYF@
MW.LLSP,YE>'\I"F,@TA$[(C)-0?Y!&K<5'5Y%ZHBH]CE5S%3]+C^OX5C5D*\
MHLY)L[F]@"9#TN@JK-[VA9:&4\<LQT*.BC<PKAHU0=6*B,1&83FGV"1>1G6Q
M"WPJ:-+`^&*#1S4C5TFZ$Z<SX5;7S3JC1=CE/]6]?^C2IM&_>1'?\3"?:'P`
MQ17AI+`S(Y\P=SE<V/7J\+7HC5ZN3M^J._4I,=I*N)*Y%J:F9F+/);.4CL_;
MUL=ZV$6/'C17/;4,3N4W>[_G%>JKU1SFDY1S>_N8V)JOORNXZ^S3!/?)KC/^
M!KH)XM<UXWQ8SZZ&.*KW,(K2.*WJY.];[B_CN@;39.!IW6$[27!'EO+FR\:%
MEL2.0D2>WR."@5&C4Z(WOZ(J*@=?GMC2OK1V%M"T,KQU;*^35U1>Z!]P,54)
M(G1NYJ(,#NQXF_W-_*SD/C[BRO:6@HN&-1<Z;6RV_"%6V),]LGQ8\YJE'\F+
M-KAH@1O5W0A&]6]SO&OKU2I3KG4J.#N)JM,^N:7&+1)`P5!$2G7'KPSZXKDU
MK/%X/MB\>8/X'9X/V[2=GVV-QS0+6"STF'SO[PU<7.%H%QZ5CH'O1['A?2-R
M_P#)WUY;E'P&M\#:YV!PR0GHT'V"G[/MT<G>-7*T[G/8BN.J*J#(`?ZA.T14
M\C%_*KA-[57JW^Q\9C%<0;$<K5\@R._-^96M>)&^+M3\I%<@WO\`RHO5'=K$
M3O5J(K%3JCD1.G5'O<]?(Y4[>GT5557?5%_BEC<7L^!64]7$E3[:SLY4:OK*
MZLBC>>9.L9LXPHD2%"B,<0Q2/:QK&N<O1/I^-!ZW?T:N&X/MIR9232T&[]J]
M::;G?2#@F05'?(FV>^C>(W+&C@^-[PU=&CQR%:CQ&E-51/J?;'^H%RO<?U`_
M<]KFVM9M.4A#B\)<0%4@)2T?K[P<)29;+5E7*,YL::>.60J=#(R,1SD>%K[-
MKS=Q7H19(A1A@C=!JR?(E>:.TQ_CHQSD>I7>-SF*J*JML[6<CQ"K)\%T8L[[
MB`T"60[!_,-"*]J62Q$:225%8-HR(CVL5[40,*HJ9C[*-7;R;`Q26%S<SX>Z
M!<?-M9NM=(,@&&T4HM<7X,5QF`C5X7-0:,:B#^9I=K(JW22ENXM=39I8>@=+
MFQY5?$B:4H7,28`<F45`/`CDZ(K%[45K247RZ:$?D2LT"Q*G(/E2092Q0]N2
M*8NI8-D8-I<2:P\EQ6A<..4I6LD*]J)WRY.W@QKZ7G8K<Q8`F3+>=&J'"B&N
MHA;KX,YE-4G!7%8)CCC5'L5CF$>CE:6%B!A/26U5&+:MRNFA062Y%C<^/LL[
M:#*(5[)X;P2N>H$<11M1WC1'(HK)M9#6CMZIF9.^1GX]?;1(4J*>6677Q*62
M2`2#5.CM&OR"F%X9*?P&J*UE3+MKW54HI>@FT5Y30[9[YMC7QW=]9+D,C`F0
M26U>15DL+&EQ1G`I0.:\0D\.<U<B(2LJ3M\-C56<*HM(9"F^0RQK;R(LDY)K
M8"27,,%CRJBJKNY'.3R3[&XXWJ($@4$L2JGTY5%169GV!;8EF:')*G0T6T<9
MPB`8*0)AW,0DAA'*2%890TY(ZW,$<E]X&WL6S*J<4#[*&B2+\41A(PP2(<4A
MHY4(PK6'&5"=I:^:+&56IF9IL:#G_P!P/BQJ<%B4QH<NW;2T"1$F6$6.KOT9
M;W1WO8G1!$;Y`R(\:!3P!(4J1R5`&1`P8IQI#,Q@`*Q8L9&!>T86HK!=RN4B
M*U$8HHDI1JYZIX.X7ZK2C[&E5SQJ<)6*)7*K7.1S6.[6HJIV"''5KE>801L=
M(<Q%[E=(*=Z-ZO5I48B(]ZKY%7Z(O=^IH(UHT4V!=[_62X\JM&R4VD))O+"6
MP;H[#^<$`4DSBE;Y'D<XI%9W-:GDN;@<_2:'-@C('6R[9H`Q:V.0KV$951HT
M9K[R)!.L?Y?G5&O8WRJY_>]Q)E;6.&_/4]C`AQEF-\=Z;3LE2U@0YT:S'&DQ
M!I&*YPF*QYV":T94`P;'A%>S[JMOM)%D%!345=;08\@\.5YY#I$H3[4`FQX8
MHZ]S8_F,QK')XF-1.RVDRZ.-\J)(?'-#CS+&-8MZNCE^$Q9@'#8R(-.U&E:U
M9+W#&SIW.$TT6GSUI26"*ZMG9L<U)]L^7+''(C8%O"8""BN\K'&`XA"=G5%5
MSWL4L:MTFG>6PD&AU]*)[62)=Y:%AN/8QQ3%.<ISP'N\9E<HT&#\S_X+Y--K
M%NI]+**%NTTC)$^N.*)25$6;Y'U=A8/GR(9$KK8QTC,$_P`A&B1'.<BF?FX(
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M&]S`Y1D>J@NSES.E5$"MFFF%H,X0[I@84R:V2U+5URU$:BA5!/Z]%1B-ZBSN
M!G8'07\R9(9&I]1)>6+2U\=H3$CA,=LI9%9.A%$)6G<C&,8-43IT3Q9_):#$
MQ]%FZBGK;K6V_P!SD&G3=-8Q0G"L6U9,ADL*;,R)#W)TZ,,U6(JOZHA*VRRM
MI<;3B0E]4LH"V=L,,&AM8HW#V$:53QC/F(L4#WKY%,1$:G1JOZ_GSV8Q>ALK
M*AS\8!HL7+6$P*W^?``2%AF:L]D(,=9W?YCN\A'L5$1KNY?+?\Z\B9>GR+0P
MYU3@J#/6"VY#9LLTP\_<,"R0IC6A58D@I2N:HD12+VK^<?\`,2*V52RX]O,I
M;/,A=]Q@_MM@&U\VPL0SWMDOD/D(CC=CAH\?TZHU%\=#,Y.T.5/QS36&DL]7
M8LC("B&*?-+]MIA@8Q"/?*$UKFHC6^!$5J=JHJ,'H]$RB^7$F1VTYJ0SH5./
M+AC,CQIJ=97:C9@2^8@GD>Q&-1/U%<[OF8[/U=T_(R:F+))*S`'3.VYL&JZ#
M<$D@(0D2G>UO<88_R(WHKNO>JO'!T,*U?#71,T[KEKI-7$FHU'3,^.16_(BC
ME0PR/&:0U#O[P=53\R_J:O/6&ET.S<\,>UI!YJ,^'\W7SV.`:=3V5B>*:LJJ
MB8Y7%`JHUWB<J-1R?I2L%R=::*RT\&N=3BV19,99]O2![9`J:8AI:.>""\/:
M*1U"YG^JKD5JM%FHOKXE;C02H]Y+>3.EK8IM!KA,/'E9FVL8K!I%-:*WHTA!
M>1I/SN=^5%%54F9H9=K6BDRKP&LQUC\2QKK'1E+6F;'EEDR225%.8;NE2%=W
M->B(BJ[]2TSNNKM<&\KJJ'"O\U=J\$?55>8E(^ILBRCKXIZ3++\Y'J92/:Y4
M03^OZM&W:BAP\3&+&CMI([XC(S(,2?!-11JI@RE*K)Q8P$85_C>U1HJ.:WH\
MD7+8K`YNL^(:!5T4:;+%^\LS:UT,4>PG08T"Q*,C90X7YB&(Q@^G1RM5BN'I
MR7IX.(2J"&I/&JZR)^X+"EAB8.ZO/NP+84R;;CD"5K!E&YJ]Z*WIVH@[$4^1
M'!J)S($J'-NI=S37\N&!4LJR[G=([PQYH1",Q4=VJ5O1K45>QC8DNCS1-/H;
MJ?9NST!TZ3)+,H'%:M@S32"37QTDV4QPWB$Y'(2,]RIWN<ODI,--;AZ2^GS9
M5[O]'`2+;2<;"?'$X1(E&_SDAV[$481N7H]O<YR-7NZDH]Q82G83ASCR'7SV
M;S571WQ[^U4+84BTB5XK-HQFLFV;B#*K7HUXW]7(JH0E/G!0JZNNZ61!;B=:
M!L>6V383948YA0CU4AD,'W&.-Q%(5R_E8Y%:QR/05.+&18._S^6B6(=5I,V"
M13S,[":9OW"LF-+8Q2G&Y&N((J,<C7.5W1%^HJD>.X^U$.:,DC*\9PZZL`V)
M-HZ,L&N1]Z4,B0^4R&<[6M\C!]7.Z+W*O:O\P^9.0;FSM\Y8MMP8V<.=,J<N
MJN8])48[$;W5\,A4<1XU0G=]%ZM7N+I<C2::H2WTPI!*_144\,LMG#=%=)F3
MIV@FIU!7QVEZL1R+^=W3^"]355-JL=]FN:VVK,B>S@T-382](KBSF0=`\XIO
M^SV7R>KS&8O1_1'=O5BE_%Q47-UY;R[T=GJ:K54EH6X#9@#.EQ9;K1)Z!F4=
MB,#&1/$-&B5XE5O16M\-'29O69J-19H<::2FT<$+S6!FH8``&M(\MUA?FM#B
M[2N*T08[FM<C6=G07L=`V3L6?_\`!^<*,(<P5I1-@TN#M)\6BL98VJLV2&7,
MZA<12$#V]K.U'>-_KQ2K3KGEI^#.):M:!<W^S5HUK\#GXBTZY#^2_K=^U%K/
M#X?MO\N\%\'L\'[<I.S[9%P&)T/P^.X<;FWW3K:FMGXV5G8PI@?=KV(AOI1X
MY_!_K;^WIU42,D8=>'!Y44!@7`6FHWL)2PJ6TDKT^7XYJD^;#8]3'<6>P4>6
MRV<.0$D<P^U&$4*-<Y_4G17#&0D@+!?',L;XB&+7N53$:%#/$3Q*:N8UO=V$
M8KE:XB*UK>C&?GZ#*,K62FJC!R!H-RR%BG#(<6/XU:U7*Y6JU?IU[VKV[*Q]
MS_9C0V7H/F[S-EX;])>$BV_'M+R**!EZ8U[<^SNXA2(6CUSR;1L]D>GCE'$'
M%:)6F`YY1DS'%W$''^3XRX_RM<"NSN$Q%-!SN>IHH/\`56)%JHL:.I"/:CI9
M'(\AR.5[W/(]?)-,22P8AG8)A'/D!\)1&[3?I#(I3(J,:U6IV^4??T:K7KWM
MBM,ZP$?X9V01QV/\HQ2&"><T@`X[0QV%>C5$KGJKF*]SW-1SQZJ?$6YN<_55
M$V^@U:2V2609B1YE/53[B4T1))*YEO(<\$:/T.(<9?$SL`K!4E3CK6+1RL_3
MU[APXL,=3`F4SY$.BERX9T=(_2$C7BCA9$B2!2'M1[>K>T.!-I>/K&VVM36B
MC7!;M(.<B:"HKK4K\Q/HI)O]DNXDT]A\BP2NCB5CB*CQB,1.^/81)&OS6B)H
M,_-B4H+5A)\;75KI3(IZ^$ZW=,F6<*V"XG='(T)`$\;T*J(PIM+1.I:_0G2?
M-+/M9VLG6([^,.O#;=<O(L%G:6<*;)(CW2VE`%_=X4[7L4\";J0,U&;A1KAT
M*ZN;QDRQPWC?%CY^Q>3N?*AVDR-!<5X+%YU"X2$:HW,*@=#7V0J]MW,@2M16
MWIW4+["Z':QI8!$J(<.P5L4L,[6$D2'/1$<SR=S5ZM&5V,T6$B6T6;B1ZBVK
M+`EY<7+:I)D8D2#"!>4SI4^N&5'AFF*R4..GT(]6/5E3)OY+;NOLI(TA1HP+
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MK&,5@GN<2<#(QIU?8AQ4RWK9D6`=](E[*B(>BL6NHVBEV5F&(][.DU[&!"SL
M8KE8C@X;?ZZWL9I+.-6:4^SGL$<9R1D^)`!%K'#AS#%^YN>B><#7E1ZE5[&C
M'X16&JHJV)GDAVDX9H797337,0L1L"6$K3%CLA1`RC/["C0A7!&B^16*QOW^
M)%BR:]TJM%6$A&D65M91G*0<8XHS+(#X#H\4BJ;R@_281KFM>B->YUG<H.9H
M`R%GUAI2K+C.2KC2!3BUXY/1[[7I(1R&(XR_F<Y>O5&DTU;;4BR!S:^3&=3V
M*1TD3'F&67)[H-A+E"+7A$V.Y%=U8][U>US'="/TM1"IKB'C^.%!@<]875W3
MNAW3([5*^DE!+:Q'Z.\H0-:HYH4+XBO0?8US']MS5<0U,J`+,_#N-E2RNV[J
M)%L)3Q;%(,LQQ0)E#92([5D-8*/-`5@%'T%Y/'7"Y%SEUG+FKT%[H:JQ*9J&
MJXE460*%/M:6/-9`ARCR'M!%@?DDHURIVC(]X?Q3W%F>^V,:?R]P+>3:W15-
M7JUKZVLYDP-M`OZ*O9Q+SE9QJRDFC8?YI($5U+\7YKKW+J%VJK?Q[@2+FNQ=
MI$?Q>R$&+O:7%W]*RULM1G:ZBGUL#>\B\740MU4WDN/*S$P-E*N*[2A@2JBH
MT%L&%0V7(ERR5>U%M@)UI4)42ZVL@R8,D,PZ,D&6E::JM)4]PU<-L8A*Y&DZ
M,<K7^1K*_E.B=>Y*K\>4W%;61HM?,=4S!.>E9+CUT-6I,-#>([E8\?D:]JHU
M%:UCJN-1>O\`LM?5W#;'X-9!@2UL;8,6L>RD/*(I5=4U4:P:U6J/\[AM9U5W
MY?)D(-+O:3.\@<AUL]US;6595`J:*JH_&Q,N6`:MF5XY56(J"ZB:R43M;V^1
M6,[Z+AS&T0+K-R[Y:<^[;54]/2-X]J'_`"*L=&&+"!/^SR\ZK"1E(XQ3H9?(
M]W<_MV>*73ZSE&TE4E9\C)BIF+$B'DQD?+BPK!(@>]88!D;((_HUCGKU=_%!
MOTM?QD+'1GQ)-3/A7]]9AN/*TD\AZX->R:C),8L4*R/*BH[QN5.SZN[:R1QE
MR5R/-Y#Y#M9.HR^0H-&739VG<R,Q$K;/-V,>PC5&=>17>2,8:J!!-:K$Z-1\
M7`<E!I;WD[0W3RK:Y_-!K1V)+2"XOP+2#&#$AQTC`(@T+'$K41C%[5_)W\HQ
M<[Q<>FV5"^IF9O.5;7Z:-OI`OU11H23WE1Y2QGL\C>YK8Y&M=XNC!.?+XPY,
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ML2<R^/<,>!84.SFEG6M:18QVOD&"=KX_>UX?J@U?,@SXF=K+^KOI;)L*!O\`
M7'6X"[XS(K3R8\Q3+\,G5R@-VQTZJ]6-<KNV#D;F\K(32V!HD.9>Z?4VM?>R
MJYHI9Z81,^D%JVT$;'-:IA.:GZBO=WJ]6<B[SD+9N5]3-N:V/A-%*U<%]<2#
M8QAU0:IE/(KIHI%BX"D')3R'<_JY%ZJ]B-L..<5!S=A`!$BW%W:CEV-G+SA9
M`WV]9'D7+K*2>S>CF*Q'.<]6HSIW=&(72\D4F=Y`D2](-N<AQ4J7V<BJAV#Q
MV(I3991RHLB9)CN<C$-'(Y$1B#<JM'Y..;C9:@=!4UU,YVGP%*,=9><EY^R=
M&A4;=7I@UL:SHS4S98SJ*`8*(X+1N<X:N5U)D\CQ[OP\9X59"9O0R#68&7F@
M/'*6'`LY$B8(UD-)0_"V5)\K$5S^Y&HKNS*W8U9QU<4Y7AYKHKF3.?)T[9R(
M`DV5K922Y4HLMC?B@:-PX_0[OTV]7**MQ>/@T]I+KID6-(X]63:QDJXL./+/
M4W#I$0`+6S*%\8D=0J1X)$@C7*TCD5B8S[;FJ2MVUO555_584@#V=U.,&5$'
M/96BLXA8->Y)"(JJC%<-'-1O5O9WZ3DPQL[CM)MZ:V?GLR70Z#.?;-$V(GW&
MQTU'4SHU!*&"$<2B:^.]J,:QR+W(CG:*WL>2(L:OQ]I+RW&HXE754<V_DRI<
MLVG9%.M>LVWS\FJJ8O;(E.<57=C!/8BO*[8X0.>M;.!1UXJ+2V&K##R8WV\E
M\B0XX+B&)+*S=-9*038A$(![6N[T[7.1OVTH:K,V!J:O`Z[;J)4"1H),Y[/F
MTTB.QC*&#\U.O>^/"81&.56.;W=64;KZNDD)#B4D/$LC75B^B`*H5A0D9.&O
MGN;J`^4]Z%GM*0KGN1%[D[?Q<R)O*=1Q_D',E0K"KHZ6F/=R8\U#*T=K>/AD
MF5IO))1HDAM%T1[4_,1RJ^^^-I=<>JJS-@ZRIQXJ_0WU/1$GI)=9V%A;1K`M
M.*<!6M:&$UJA;V%155G5_LS)O;^`0I.'^>HE=11\Z#/NC6=/@-%8ULQ]I%B0
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MD'="W]Y4R)@R`^WO6D2N^.B%*0A^*_9?V%Y(39[OE,^[!-IJW'8O'9&@BXKD
M778^`M!5YVEC6I'S8E.%TI\J<?J3HH?$B?G7^G-QQ[(!XPX/T7!"<O55I'X9
MXNV>OSUQ'R5I=2,_"L-'3MKYM`6PHU&WY0GS!B>]B&5_4K?>GTR]AJK)Z3D7
MTCY*B9J-S=QGG+;(8_DO/SKR\JZM=#E)UOI1979A?2H0X(TP\0PW$<-HU`[N
M*6-XHQ4>@0&D&FJI5>1%5K46/T"B(O1RL>U@>O:]?JYK$'#*.V#X^WX@I\-G
M;)CB&<Q)$T,1Y!RBC\*N0+5:4JH1&N(U$6]R,W2.!6)70K&:R'(2T61.K]7X
MA!F-CP7O8Z!#L>K/`YQV"&U1C[$_4NIH]:ZJN[V3+T-P*9!F:M*GXKY0=`6[
MM9(21XE&(<>*8<B*PEB%Z-8%_P"4?ES>RE;,3=-&L2-XX;%JRSZ*1*OF*VDK
M&5[JD2YU;.M?'+9FC%$P+2*([T[>C,K4[Z$^7M+VGAVE_M4NH='`_>M?:>*;
M#6Z%`AM@/JZ:*V,D665C%9,7HCS(K_QD]#QP[#:357%/.K`0[;96LO04U6&,
M.;I9FRF&0^2G%CLB,&$HH8SL<]WD5Z/=VPYU1HI-OK=A+CQ]%86JS"RH\!(<
MR'!.,@_D09DR&I6HTK(;NT2=[$*B*K\JM!?+<651+#7NJL_7VD<7EM2R:6-H
MH#'S8OVR?3RHX6B"/K'E/>C7]I&A<Z+.8L2IOBSK"?,):9^/H:6PS;CC::)3
M45;Y115"*SD,)8"",X3M^.3O<QCGQ+;D&[N9KYD]&U+V4P*\<C-+/9,JI==$
ME2["2.G!!*"/&CD`-J(GD<!KW$<R-($%\EI'^:N<P@".6*D50_"`*2]KH*C,
MGZSG=2HI'_1$5_B,3M1PSJQ[2]7-.YSA_JK)"K1"8C5&U&HQO7JYRJB*KG*_
ML7JGD:K4(]S6]J?JN5'L<\B]Y%[?KT:UO\&JB='JJHG1KQ?IC_4(BF&C&!DM
M8A'!53/[D<WN14;T3ZJB.4E1*B%FF5[(X&HA5"9KW-"AE&QS2*Z?V1F#5PVR
M.[Z/1WY7@BV]RC/F3*U!Q1!/3#A(:6!UC6/4#A6$6PE/"US7,,]Y!HY&*Y"$
M\6X%^V6PK`/)&LO*6WLA&*&7+BZ&S8,WW$T17PQ>+N0CQ.'^5[E(@^U59,TL
M*,:66'8_&,R!&86)]]"QLZ9$/+8-R2G63!O1DH3'.4R."9S1F<K9U8[-6EGD
M+U])`C4.=E//(SA7VA@V/[H/#SAI@3_'()6189!5:O,-HSD>]'OK,]G+*W9)
MJ)5,8DIDU:^JB3BLD"B9R/!2RC%0A8C!.DBD!D1@>+HG14Z/957%Y*@L=`BQ
MX,4L5`1RK6PBAMQQ7)7`L%"\D@;8TH2L$X3AHG:U&$5\!*LD0)(1J(ED2;,J
MA/CDG!E>",9\X$QK94AG>3R=I'=Q%<5JO>QE3!F2)3)$)9EP:%97-X=0/EC6
M4\(#3DLI@1&$!_R`@>SN3\[E8YRHS[W2WC*H<.:E;;^8%PZ!,B3JJR9(.2&R
MK?-@UT544B.*O<V5$;^1SG,0=WA%DMU+8<"=(F@(%S\[!MIMZ`OG)>S!EDU)
M$Z_+8B-DL[!M:QOF$+KG[;C==EQV*[DP*T9H%C*EMM:N%9C#.E^78&MH$N!)
M#Y)%>XC%1%\3@J-$"-UNDRVEZ(<.6---86\ZUB#L+9RO0+)L>G9!8KVLBC4G
MB58[VI^1B(Q"+Q;E9,/CJT7^<_"%(&MN:_-:W*5EN[EG'1Z67%D\A<@<9P`[
M"+/>.QS<EME)N(FB#&ET]1=VH8]%._'M]-%<+1E?QB*M'.31_M92DNM5G:9E
M2EFO,O!"25T#IZ0/MWWR9]X^3\#]OZWY/[4NK.EX4KX$RZ#4QS7BFJ8\B-8.
MAF:Q)5Z44-\%MV(D?I$CL>J.1O\`K+T_)^Y=KL09>TLZJGD[W"XYL:5.O+6M
MA"#43G/AO=#C2NV1^HUK6)%<G8YO5.TF`XYAS+3*W9AU5?2;255ONH]_7RAL
M':'FG'&6-#2I>BH5I'$<\BJK55'+W0LS]Q`W.2=Q)N)]O*@L*23M2RU)`M*;
MR1R2Q5$@O:I5(1!HJI_KM=W$U&\F7T>+J>'`$S"9U+*&['6-(J.AY<\J&@D.
MLHH8[0J5"]Y9"=4^G_-;7E2^O:F'H8+IV;V50>$!D-]?=0R%DMN#J09@/&Y'
M/8J.;VN%_K)_!FJS_+EQ52,C:+#DXS3"8R%69NOMQ@@N^Y2P1@1Y!Y31-:QO
M1I$:J*G1&*@K?:>J]?'A\B?=)0L_<$AL/=7#3V$B5.GRSCBM1(NK$JDCD:)C
M/B%:J,Z.1"9?D/FJCI8_-5/7LEW7[9*>5=Q8D4#'U"5?;%)$22\CT^9T_45&
M=>Y.Y&EM*NPK*CCZ<QK:@;2RQ1K:]N1PQAG2J^MD,>`4R;$5I.\/>TCG_E3J
M[H6XT%<*7J34%.>1)/&"PME<D@1VD(I9;`@`8[NO>]45&M3JOT1%Z;.+Q3F*
MFRV,@QIT4T^0ECD,93RPH_Y$@#XZQ4MX)X[GC0*L>CVN541S5\=AM.4.3X>P
M?KJ=ZSKEDXK`6,6QFDB2Q4Q($5$B)!17(01!M\;6O3I^5WCI\UBZ:\MSW#&1
MW7^5T+"CGNDS/DQ(]*]8<N96UK6M5CBO<YO>KD3O[D0H]%+OWYBYL:'03%K+
M0,E]!0Q9KU'*D:6T$;_K.=+>[R..KF=$)].Y%ZEGU^7T-9JF8J8'.8>TPT:4
M69K=@/JVSH95A:^5PH,N0Y!/D*5%\;U7ZHJJ2U/NN%^6*>W;8P]/4:#(64B.
M*4IE58]5="2.-)#'O$U%=&5W</\`BK>W\A::]DTU;RH"YO;.#8GF@J!X^)=,
M8L6/XYD&(P=F6(UC5*5O>[Z].WM_2_:UY19(VZS_`-OO=0^F-%:#1)#D_;:Z
M1*^*(XHM?)5PG,(KU84PU1!_P&VNRU42ZJ;A%DZZ?#*)[QS2QNX\(&3CEC,2
MQ2U0J#:BN(Q2JWHBJO0N.O;(EO>Q=W&GUNGI-HX(/VC:Q"/F1(C^@E2/<B+V
MA7RB<K$-^7K]'&Y6Y)WNWD6=HEC22:K`%L&RH4>?'F.)$^V$BQ`A#!EM"(<I
M.O1GB[G.;W(YVZC_`&*NR_(@!O/B:Z60UQ028P0-F0;0DA@0.\@WL4B)U[U(
MU%_(C'(SD0W)'$F4C\=U_P`9L?9S9$6PUNBU"#:`I)5<2(^)7P&I'<K(XVA0
M+43Z-=VM';\QLY3A3XT+/'LJG%W%.<U@ZMBDDUTH:3*R&^.&JKQV:,CL5O>O
M?]5Z-0:<<:/5<,4CK:312*B6&S+\K344(:N6#;UZQP&3XMF:2U?+VD>1A'HJ
M_7J^QLKGD?NTU39+H)/%>>A/M;G3750K(5714LD:$MA51WB:TS7M(YQ'JYRJ
MG7R5-UG^)+6VU6XS.;O#0X4Z12U?&-57&=-M`D-&'%D2;:H<X`GM1S?G(Y/I
M^53.Q\6DM]8#2[V)(CR;\X4%:Y6VQH.Z;3K5I%"T;(TESC)((K7JQ6IW-5/T
MPR.2GW<6!QC>K*L;VOB+'U6[BL`-[GQ%MFHY+,A(R(X#&JC>WHU6_P#15FGU
MUM89VIVOQA\.LU%4Z#(CYE6,@SK>;`^W!1;5@I4-&E(GZ;/(UJ)U5B::+:<D
MNWEGN"/U->:89R_<CP)@I(J-Q!1Y'VS.&>1/[RF5[>U>B_JWLK+5D3CF\Y`H
M05XI-3`ACD7"1HC#&'.EF`:,9'2A.:I$&)[FKT;U<[]7V/L9<5E).H?7+FBM
MBE@6?WF,:%-XON>VWJ32G+'6::PB&"=A&H<8W(Y'.1S2,]=+[[RFC^]\$\16
M_P"X6Z5-FV^^Y<?YZ9]Y38-YK]E6ZM+3S>?[DG(V_2=Y//\`N2\[_N<K+[/)
M:K17E9>;CVGC$L:CD4FXB:<MA[M>R%G)CW%H[V.]L93J:R$9;)+6+LK<%E(,
MZ669=H<VINN"-90K4TA.4^`;KU1YMT59$F-JX66I5T6HON1;.#!J7GIRY[$:
MB&RME.60&/85/3R(B>-WMKQU5:*DH<I:^KW*.#PM3+GUPEMB0>+;V#B<G2S)
M0D;8V8X-<H1P!H27*ZL5@U>J*;@W-<W>Q_&/'.@X\'S;;Z_#7>@BLY,KWR.5
MMIH:F-`P;!$U,Z78T]D*5"9%BR'S/D#Z=R.[2\%\H<@[#5<1XKD_T:QVFD:#
M)<I:OA>_S4W1\::+39C#W/(V:T--=4.DF4MI#%952VK"2"F<)PW-[&#T&5]=
MN*Z7C6IUMY8Z_7R(7WJXT.SV$XJ//I-KK-!.N]=K;B3\E>AYTPY1#[F)T1.U
MA'PSODHDDD?X:J44+K$:V09\H+!M$5X)*_\`.!1CVHC6=51JJ-!JC@3SRA.'
M+C1J\$8(GL4GQ/D2!J-""CE8-S)"L5Z.=]$>]HWVILG55*7LZGO:BUT4"(1D
M>L!;@!%LI(``(]T.:LB,)OS"_*,)OYF-(-SU*]+.`4L&,^OB2B1]"IHL>W+)
MIPW;J98\)SKM)5B%5E$DB<R1'+_LSR-0CGKJ<G9V#S085&YL8CL]]I2NK!Q:
M2S??5LP1K>XR4>>^+.("(S[B[O>X2N0;4%4`TDH8,A0Z`51*J\P>R41IB2C.
MT<XU/;JS2+G2L&I1RPO:B"`;O<-XVJR?-N3BV\R'--;P9-S4ER4&LJ*]?@4C
MX[@P6RSH`K&(R<<S)+T>/JJC1$#%Q>%%`-.;:3+YFEH;=+_.V=;XF3I8=-)F
MI'A.8-AU8JPXK'!DD1CU,G?Y]!.M9<[Q6:GH]78QKH%+,;+@F5A)*,F1"V$6
M(*0!ST)&\Y"'[5&U>]$=0UD:SS,J3>R7W^0)97<S=R9-=6UT8X[F9!29Y15V
M5284\KJ!SCS2)'0;'N[R0*<K*VH@EC/F6N>'-)KR5;TC_;C1#Z2**J\$V`2$
MQAQ0.L1']O:@E9T&D5L<K0.4?:5!E1S&E5L@(A-?'$2.`/8J/5R*1CU3ZMZ)
MVO$-XG*)!-*QB,0C'^-.U3(/HUJO"C>U.UO1$^GTZ=)$B7()'8(;"=[R11=#
MJYQA0V/7JCI!$1&JWHYO9T5?XJJQ5J3@+-K9HFC*UDJ8EF60$\ID!Y(/?.6H
M(XST>1RR$[QH]'N150E@T=A''%G.`(=EYQQXKJU5?(M)RV46EDE'8VD;\L;M
M,G8O\7L>O<3-4Z6`R0;2URSJV^%+EW-JQTF[&"'7DKQI(@1R'"UXT&X;'>!$
M[W"5.H]KF8%5=/?6<@ZJ357I7PI1)[)EK*+8UM.9]3"?"K6U[FA5$(U7-3QH
MG<U?$R4696UDR781(US2G@5C8T!A),?OCU8PU\AI'PV_E^K2.1@W(YK^Q&BD
MV%=(KJ@$JAD4Y11209%ZXUH-P7Z%LN17*-E.@T8(C?$G:-SNUR]RH4^5I!2M
M!8&KP7C(>@GPR_;Q%,D>);!@P(=A\VET)1)X%8YL(IWL1CV.,_R#//@2LJ.W
MIGLA2K<S;8+K.NE11V<&6*<\BOE`24B.CE8A6D:].J-\97!B6TXAF6XQ+9%F
M!^W#@USCQ7V`H8XT&&K@R5:-!=$4@A#_`#*C6IV71)9Q5P9$PL>&MA9N:0\0
M,,@ZT$R:2"XSSA:U3L1Q&JBIU=V(-%#L./M,DR\B!JC`F&KXX7S%D";:!)#J
M8QBOC3"N[F`4B.ZJ5.B,1JJ-NN@5EM.AX'4W,=Y;:XN4GVR7)A-!)""EGUYF
M)'()RQE>Z4_M<KW-8JJTA9]>.>VSSM)0BCAC#KK$5)7K\1YF&'(@$99"LSND
M`89I&*CT<5?&]'M?)#,RN;L;*/9,F+:TN=AO<ZVF"=`Z&[)!U(R!/()Y?,IF
MNC(UW5K5(XB\)Z.GO96?RM1REPV\=-661Z"+7ATFSS.(+5VVCC\G\&Q#UMS.
MFLK1U1;::^QF.^`E#I4D?M:V_'MW)9;?97GXT#5-E_N1,K\AUYJ\Y2MI_NB\
MQ\%)(_<*V'P/MWWN;]X^3\#]O:[Y/[4NN9M%3:"T?6DB4I6&JJ>$IK2Z@#6-
M&CT$58\F2V76UC4<54>1J/9V_7MZL+ON)[JL?MKW/"GSJ?5WQ`7=`RWN9LS2
M'EO=%))>VWM"$=%:C!MANZC8Q$3M?(F<F;NJI>1+Z'#K\3*NXY:VSQ>::1D1
MQ8DQH90)\FV<Q%?*>USU3JG<J=R%Q'*H=[]^XT?45<FRI'"'::&ZV4=Y$C39
M+)=:L"KJ)49A&]C6JI5(U>CE>U"SLG(XVV4+-UDJ3H]C?Y*OD>1]O-ED,*MT
MMBY$%%=ERL?VC5Y!A*)?X*U%9><&>G^MSD*XH:A_W[67YK*AL['1%+\HY9%U
M#A$-;PZYS.TKG)VL5JL:C49T'&X[GI2\H\R1[ZOV%G<V-DD[.SJ*.OQ3#S-B
M1$?9@@K"3L9^5!/:J?3HOBXMKEN\O)Y(U\UC;>K+7R[&!DZTK@@BQ;:QJXJL
MAOKA]C)**-Z,>G:B=4:K\?4T$^5973I0TMDEQST&3O[62,L%U1FKPD=ZS:F3
M..GY#*Y7=41$=W*CS:AT:P@WO'6EJY?W-TZ=\8&B<1K)6>H((@,^\E0O6.)1
M(54[DZJ[J[RVV?H:`'"E=+RJ$LX0QI9:-I[:,\E>%Y&!8D-\@+.UC1HBKT7^
M"M[AR8V)X_NM-KJ\0729L&D.&B+-<\D:5]U=*!^5D!J>1'F5B.>]6_3LZ!C;
M+=;OBFOK8;(H87#N2EABR#S)PS3)D;2O="82KJK&3^A*<P;_``M<[L1JMZ"Q
M0<KQO3T%\F@E*VIS<R,)PR59VODPYI%`5!T<QCU>-_<]"H[JK55W4MU53XM?
M)T?(S8D.GK5NIH,K0"SPFV$R1</B5KSR1R&&>QP$5XY"]4>K^JH3&9ZCXJBA
MR]?9U&HM+REB%C9VCM62>H;BK.]@2S(<22C_`)K2%;Y&.</N553OR.GY4R%8
M/&2PW55D]$D($06TC*-D51YZ"V&)8SX"-&W\WC(TSNO5$;U99GT=)+RTC.R)
M_P!JCLKXYIVED"4R!K]+/-\97.SR!16F5.KFM7JUO1S19W+:/"W=/376CL94
MY7!(QNB@YZ4VWAT(Q0F?)L`J6L>_X_5P7O5O1CNU$;G]I;9N\H^/\H/Y4%]Y
M12Z6Q'.EE<^KKJ81HAWRXE>8CWM$-'_5%ZJJO;Y*?E8E?2W?#T.XA::8"_SS
MED7C+"1&#:3;22P"1XQ7#*GB'V=[E3^*J[H_DY,IP#%GY.'$R>EGZ/4B%4-3
M/F&AQUV>JV1'/L'WDT"A4@B?D&;ZN[7(\N?%41=5GYT+41G3Q1\]XZ,<*(1[
M'9@4`4<?QY=*T2(YJJURCZJY?RKV7MG9W+^%<6"0GVROH93*V?IIAY"M-ISQ
MV#CDC`ES',7M7R]JM7Z,3IXJ$_#\:OVTJ82NRU_7VHH]DV?3O,R78Z!+-XIC
MQF2?2QV2&(J#<-SQ]'(J,3$<@<;B!+Y)F50H6H;H;(<*CAP!Q7BLX.=AM".$
MK(KFJH5&JJ]%3MZ]W4@/872VDO>[G1U4"DFYYSVQA54TLADV&:!%KF&)/:(Y
M5^07M:Y7.15<]JJA(W,^CY%MZ;#4?'KX]+CLNV6.P)864B-/EQ)L5&*%[87P
M&N0_4JO\_1O1&J7\:?G#3S)L33Z0`(%+F*PXXE#G:8,884DEKA0PC316'15D
M.9T:GT5R*_H@K/8;351#YJKJH4S+4T\[#UE3J8Q_BAM)T")#^1,K`2@L4C?*
MOU[U<J=O5G-G#W)NXI=7RQ'>*BJ)0\V.-G\SEK0Y%T$##M=6#-,.6+`%V]6M
M>Q[?S]SGH-2U-O.=;9YA(P[*O?7L%I=$.GC"CUYHY1O:ZBJ(5>P3W1A>1YRH
M\BKU*B%V%[,^9/NIMA-GBFWZ$L[2)30$&R)%5Q6/!$C01D7QN%^F]'I]7K]7
M<]PL)FY2I9\+\O1I<B9VTZPROXNT=C9Z"*Z+)D29PQ1^GE:SM:8C^Y7=6JY/
M76];<_N-MUP5Q';)H?W-^]?OR6.`S\Q+G]Y)S3[))K?NB&\_W/\`F+OOG]_G
M_<=YW_<Y7&>F)";N[Z=R'[G.S>IEWYME"N8EM[J>P4ZP:S>@]E?9D=K)ERK7
MY_RC;>\=+;(66.POTD/T5Q89^^!!?J!2#46@`6+`!9(^(4>@+9TMH&)4E0E3
M4O:("24<DX07`,)ZO=W<>;61(KBTFZNBV]9"VDREMH5;!#816%NI#JJ%)C4-
MU8P[$?B!*7SE`=&_\ZU5.>QAP`QY\BRAL<LR"C8X:^S8V7U1!1'P2C4#E5LD
MHG.4:,ZJO5'%G"/#J9,)S6RVH^E01Q(IXTE"S`R(C'R`J9KGC5K.K>B=2/=U
M(Q7_`)F1XPY?1%D,8`<8JM*K5<D?Y`1QFA7L:S_FT5K456_ZBE/"0J24:P0I
M$=(\A&%1!L//1KE,-XVKW=K>US/HJM8Y.@Y2QV@B)(13));UE$G24:6*0#@I
M'(\HO*)G:@FN1!.3M8/IVDE!FQ37KYC_`(TFO$1P8H"-@/9(&DMX7(.:T#_H
M-&F$[N8KVHA41UM=Y;CX&@S]_5651:AK4GYRWS&KMY8:FAT<#14H`,@"B5TH
MHY('K8@D1@O8X94>[R5^'M,["K#G>O@M;F7IB6>.JIG2)H)4%(#"46ANJ^'_
M`+)(D/F2A2SC:X`W()B-G6N@T-=]SI"%BY[:2*IU*Z<"JK((812JL0%9;09T
M5>YU@A`O/Y%9^0S/TM#45D_/6L?.YJTA2(E-G#9R7<W@PC=3Z:[B4T>14U-2
M0X%"`TGM1Q.CG-8U5<QU7!D1%V9UO#1HRU[XSST\F1)6ROYT%1/B&C2+(H@V
M31#<WO>AV^9CE\D^BRL@TRX^4.^D5<V+`LHTNE5TH%@0+X2@EYX>6/,"$:2G
MI7G8G5JLZ^-U;JK=:F7IHT,1RQAY&F,*GL94(4.51@<=;642),C(BSFQG$ZE
MZ(UR=['DP<'V%YRQ_$]CR/M,QA,+B+:ZCWFWY$U.YT\?/Y`]'E*&'9;"?%/>
MA*A[$4;X,)K2/E'$T9%'5<5>P'.]1@=W)S51LY]2_.[[41L1A[K0+DZO=<J:
M'&972YKBG#W^H:L./::$M1!/(15:_H(CQ5?J_I>8H@>;]-+X]I(&/Q^2VVI;
M3WO-LH5;P]4ZO;Y7*W6`X_T',%K)`#,1KNQ@EMS%"HD>PB.1[R:9:GQL)54`
M)T)T2W@2V$BVT@EP)8IFJ@&L<-Q&H=HD:Y.Y4>ODGV4^TA5,:[$5@2V-A6CJ
MI1)$D1$D42M"T:)\-Z$8YZR5>/O1O1K?U(TY-7G[>TL1`M8E;GK$<T=A#'<1
M@EL)\BJ-$@5\9)$QL:4]S"L>Z1Y7"(YSD)]ID:UXM2\5!8F=)KI=)#J(`=-#
M!*@B:/NA-C1R*HGRU&R1&(,;U4;4ZILL+F+]T[5W-_L8D1\`$20>FE1+B4.P
M^1%^(LBDE0B`)';-:UR">B*]&J/],E-:PM+86L8;8L>(0$G1K&*T;A@"^+%#
M,+=SK!H'L&.0UQ2JU45KA]&"7%Y^ZY4V][N]5IKR7=U<@&E#4!DO-;R@5+'0
M6K0X\L0C8OC*0L:O<%7?E>5K'V6HS.CA4\JW#/U,2!'H)135T$NF/!O8H8=R
M)MA:NN6P6O,\W0,)[5=X$7QN?W:.P99^2NDGBUQ1U@HD*+/)7R73&+"@12R1
M6D@`6>4CNYI41%<QZD>X6<KY#)8+.0QJ^-CVQT@EENC$@N<%H9/8Q7]S%)X7
MKVIT5H_J+9^O_'7+V"Y/UG'&%H]YRS04VBK-94XW,2K:=4P(>ALZ]LW.5]\>
M1'5LZM9/;-KF/"X\<35<]G+&KXYYXP]#A^,,WMN8M`_09?:UM5*Q%#LJ'C:W
MO\%L)V=ILIR$#]ZWE93D-02;#R6!!!:B/*T*Z4O'7(,S5#STVMR^GCW.;T63
MY!S-K91))C5&LSNIR\&]H(ME'FK,BK)@O25'5"(1_P#TE0Y2:"+77-5]HFS2
MZ@,RLO4>P[ED/K`R#S0S02)H2*%[Y*NZ*YW8Q6M*T&?H:Z1QY51+$S[\,R-(
MUABPV5TR"$M<K'K.=>)(=YI*O:T`4:IRQVN:98TM]S]ON+/D[U\IG#'HQYE:
M@-MSSA`$JI%D[F#B(UB313)SZXD-UU/6[=(2&E'J$/\`MFV_'MY'I+/;U$UG
M&89I)O']QLZ*^^V5FJSEE>0ITW!\<<J79\39TL21%TL,]7&I;'.&G1+BWS]2
M:;?5N]Y)Y1Y)NK'CRPL1W*7,][`LQ4A9[@]D8U>GQ(`G&5H97BB,:3M;T1KD
M:U0S..H:<A:3EBX(6VNX0&-E5%>2'%+GB3$+$BQ(V=1IN^,UC!M<UZO7JKGD
M_%J'5T1N0BVLJO!.R]M.B09+K04EL>%8QIL.36VM;#@%8UZ@B&8PHG/1PVJ]
M_;G'OY"ETV>D9NJK[7'9<LRY=K[V,Q8;24^=ES'QZPH6]!.4*"4BN(]_14?T
MT/'3Z6=?<;6-#9@Y-\"'F3+,4]'1*RW<AB!MQFFO-XY?;XG-(B-5RN1KB2+'
MU9R,C!Y<]BR'R5K;N5,L)FIAWQFL#CJD%Y87,FMD3/,P0SPV#<C53NZJB.>/
M3T6/ON/!<:0)5[*K4GI\PD(;"1VF!6#EN9%$5Q7=D?\`485S&E[55K%<R;$Q
MM)@:BJ/#XYCAEP"3[G:$LQB28@X@S$96MFE.I7$&KD<-7M[D57*/4RXV5PM9
MEZ[.TT.KKM)^2XAW@8SR2)%-6/=$#6N5T+L19/E:Y[WN1R(K^WA_7ZCBFXMG
M4!UE:6UT5K(G`!:UG<&4:OP\6QB5(8PY@B#26X;GR&]SEZ=Q%'`XWJ>D'0S:
MB),IF0*XQOWA#>5QRP:>4\Y59$B"`H7/[V%81S.Q?TT4EM<.R=CG^%M'&%"M
M\Q`N"2+9MY6J<\LMA95MB2Y"QP48OA66UB/[4;U5J*3![`&KM,B*PV$.QM,>
ML^SG5%_]C(R;8U=QH;.=)N8K;;Q(GQ8YFB^K&._BU27'/'K;RL.AH(;3U5=7
M96BH-C\2U<P:&FSRVXID\,2.!5<\?:)K&J]7(W\W9"_<;QV>B@9"+83]'"C@
M"V[EQHB)*D1JMB"B5\Z6BN,Z(/QM9U5.B)U1E)B+E2["!(V\J'L\S3(<,ZMP
M,.R^+-EZ>[KCQ;BFFOCL5C``>A#/+T;U<B*,.?Y@XHL,/PKQ_&M8?%[QW=_`
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M1\.99DU<*!(O@)/\RE:8$D12JQK6N^C%=39B=H`UL>-#=79&TL]`YUI7O[`R
MXT=LD\MIK'XW@$GBDJ;N[6-7JY6]8)*V_N)%I%@1X\:Q#]JBB/&3I(<Q*E(0
MZ$(I96L[GI&4_8UK/)T3K^*O>:3E*Z'FJM7WK<I*?\^/3Z(B%BF)&<1?B,@L
MB$<PC%:K$<YZ^-%550F6XZUU(*TL_+86E[H*:#;PON+&1X!8`D'$;'KZ^-6`
M_.-&HYQGO57(KG*P\L\4V=K:2R2+4UTZLKH4'?T@DBQY&D@V!FV%C#BA(17/
M8O<XCCC>U55KAK8:?96>>JN/X]))E+6V)#3M'2U8)$D!QE1DM7G=.DC1S.]'
MN[7C[>K.G?TXLO=0*QTL6QBT\83*@%/7RCD&]U196YHJ%HU,PJ,%XS/>CD9V
M]7(Q5AT:$)!YCR%!64>M3/6UI8:N$5P4.VM&@9\3Y[2,.9I)+5))<+L[BN&U
M'-BYZOT.LK(]:RHAZX9-"^9/+6$8VP;$D2;&7)GI(L(BHA"@\<A@E(U'HG>C
M+:YR6'(;.VL<D:RL0VX];8:=)D)\Z/$KJVXMI,:'$"]JO.%JL1[E<CF]?)V^
MQD2?EH><NZOU]Y\=$=&=5RXS)#^+;NO0D)(DE65\F5&$Y3@8)88BHK>UKTZ.
M]<JN_LMY<WM;P/Q#`NK?E.[W&EY/M;:'Q]GH]E9<CZ/DWC/A7DF_WDZ8-Y;B
M;H<;DKR78.,6?35<IQ8(.,\;I[;DVZNZ7ESWA5"\@76NMN3])9/]S/8&ON":
M;5<H\-\(\BW>K?:!),LIEOEZV=,NW2G2X%79+(IZ^FCR>3)%K<[_`$\K*6CQ
M5&6#,J=77MFQZ:L:-<_:QJ0U0P<;\Q6!#XB/>-7O5Y4[)&7L8_(>1JBSW:^R
MMEC0;/1Y(J5*,O8L&55#L;"QCD60D@$89%"CR..147LCYGFBKIY47/3)D*AN
MHUY$GI,^0`$\+(DVI>&MM!-+-*".8L"+&D*UR*HVO(\=!M\Y,0N>NF64HEB4
M<2$1SXD]\&0CE%(4I9,A_;WJO:XB-84;&(K&*,;5:`#B/+\<OZ1$<15,?XTP
M1RMB]GY$"UAF,1G8B?E[5>0HVMCDD.1TUCG/*;KV-[&*04A&A,P+D3\JN1OT
M[55$15\+6(UPV(^.G3M7R,4K>QK.X/:B-']/S-0C%=T7M1R_@Z$1K8PQI\D$
M4(VH%#M(Z0UG:X;E<0;D5"/$1'*YZ.5K%5&,=;F8&%0J"'':T:2(")`>=K1-
MAE5T9A5A->A#&$T32]RH1JD,U),N?ASUK)TF==6#;>VN+&/)U1I+14VB[K*;
M8OJ7QIJBZ`A!^$60P/>%6NZ/=U95U_FT9)P,V`[FQ:^>*/9>:)4SZBR@,2).
MC26O6$UL>(5Q>AD,48T)I,9@(UQ%J*B2QH[*'Q^R%)J&6US&B/J7K82-#1ZB
MMSTB40C8X)$B6Z,52.:QT<;5+:VI:T0K68>MM:36V]D$#Z&?,[+2,V;C[.9?
MYNQ7O<<<*&4<*<_R#EH8+R/;8RL/EJ>FLILPMI:#*2<.-+ND86'&T=B*#:*T
M\@P&*SXSV_&#V.[D1'N0=MRYS[R7A>).+\T*J'IMWNY]!D\S62KF1$SM7)N[
MV7+9%=+M+><``D&1K#&D*GC7O3LX0C<4?U`OZ;E?R_Q/[0>MG+)>0N1N8L%5
MWL'BOB7DENRV>7S6GJ:72Z<,B?'&YT:J9XHD@C4:YS5<G?\`U!=5ZR?U%OZ8
MVPX]_J?>IW$?K/RG:\U>T+<CI?6F?QL/4Y:1N\AFZ/,[-O*-%;8?6R90JP$F
MJFQ[\`7NZ@3N)REEN'/ZB/\`3MY']8/9_FG^FGRGR;R1R+[-+F^:N)J_T*/Q
M%!W&;@8@&;TM7R*[D:DX=BR,R85M"933);V&:]HQ.=Z-Z2Y_J+^E>W]?O7_D
MGF;;\]<:V/.<$%GM\]R3B(E%69_-CJ@!!KN^^&,L^%9V$&(L4;U[%<8P7>O'
M''+7O7Z67_K+PA[T>S_-,[BR?[(W1ZV5ZJ\I005/'W$E`E=5P3EL*U@E=-IU
ML(%9\625K2&>0[$X)UV2]YO0W)\L<5>Z_+'*&DU=?[)Z^Z)/])[D=PS&<#T[
MRJ:7,G!C601I2MAQ(Z*A'EEJ9Y?Q4SN&MMQ9SWI*#3X@>NML'=T]QV6*7@04
MD2='&Z+`IH88U>8\9\=&_(9$:XS9*HKC;>/BI=M&F5W)7(==87EI5US2Q9LW
MD&QEO8*<-5/-S5H..\1D<WSA>UK7=6M!Y76=A+[<!5NL*O2V8*<-E?VME!?)
M-*J,]`3MDN^W68V#5'R&O+$57N>G8K'1MEA,[>Y;04MU(LMN9S>NJ=6W1(@"
M?,#96CC15L'>"4<<4@VO`SM8UC%4;75V7KZRQ:ZM'72EK^LB7,4,@=D1OW+[
MB1\JOFS7ND&8!SGH1"L<YBJ]@:0ET\SJP,6FB^*,R.H8]D5;`R.29%2=,E!9
MV(9G<B-&<;G_`/.^3\0I=;;&$"6"'/@%R4CJ0TQ]@089$N8RV/-CRDCRD#*&
MB&:9Z(]451B1?9>3RA['>N?KK2\H^E?$W`%SQ?F*O04/(6*Y,;(N];<:_<4&
M,P4C-.BWN8U<2;%LFS9MG(,@7&&TC6.)@?7K>^^'HWGX?J!P/=<;>NG(-;?\
MWZ*)S7MW>SWKWS1GI_(>+F</0BX'$%R/#+JZQC-D6)/N,]QVM>("*[VJ]I.<
M?:3U^R^@]AY?$LQF6XJT_)')U33U?&.9L*#XS]18\?XTLK6Z*;(:Y9HH`1PX
M1/'T1K5:/VQY3E^]GK1B?9C;>XN5Y[]9>0+F_P";XTS`8&'J\?;:FI?;5?'U
MB3(:*;05L\2AC1I,:R/(:R0=$$-X+WGGDGWN]9]%QQIO?FZY@U\.;J.=*G0Z
MKU,T/%U90ZKBV;0Y_CZ!G&S-5L<]'+.J1L96SPC$LB00?;&;?1_7GFZ#R-B@
M?U`9UOE#<`;'DZ.+"<)2^:>.==A>(YTD/$>JV@,]58F4\&HIFU(\O)STR3'L
M+JFK23+V!^.=?7[!!Q9MER9F:RFSC^0IM16Y"#:0]3074>WM["XX?YU;"^R+
M5K,CEA9UURR4`:U=E0V21+VMO\S><$>HT+.7<D`B5]-[F\U1D/GPN(=U-:(;
MT.*&84LM!N^2QH7M:CD5KNYRN@8W,\%>IN3IHX05<B5`]QN5CZ#[,$<:.U:N
MX/Z`*^ON11Q.\4@@Y+&.5O4;NU%2@I-KQ;P1N-#GKZ;H8>O-[V<T5L_YTB7\
MJ-_L3/0J5#<"']&M&5#,7L153IVM;GM0_ACUMJ14O;YZZM]WN8([3O"Z(:-,
M@R`^@0WUT]L@1%(_H5CVJSL8-6-5+'9[#AGUATUQ9BMX\@#?=+EV#7CBSY=B
M^O@1VL]`R2/MU/7DBA8([Y#BF$4SW]"^)F2DIQ7ZO_>L_I[S2V5C"]R.6846
MW),;8-I(3:<OH+.@!B5B%C*?S))))49.UX5)W-99CX>]5(E/-!8II*F1[C\O
M237TTP)OVN6Z6+T)C@C@KYAQ/(!X#J8:$8THE>CVN"WC?U<_;45U-]BJR>X/
M+9;&H6%85,NT(6X_]!3'V"38X9H8K4''-#\T=SSR%CO^1IJ1O''K^,^AGY_Q
M7$KWAY@FSJS/TQZB3)SZ(GH%%9+CSBQYB,(WXY0,.%%<7P*I9-)0<5>O&?TJ
MJ3[=MT]XN89EE71YRQ&V]3\`?H%!B2JB4$1&"8KF2`]1KYG>/HX59_Z=O5,>
MLJQ3X68Y#;[L\RATN;JI)S_&K8R0/06!#DLBPRJUSNP*$*]Y.UO7M76X;'<:
M>KN(35"K(!I,KW(YDT\84"O=-*Z80$CT2KIA=%*D'81TH<@`^[R=PGH_I^+$
M3.+O727#F*&##+,]T>3TMZBC=$LX5FZOE"_IZI6!V4]DB,5ENV$T(9`2/6$5
M#*UH0Q@>M\R+*OR2]+%J_;OF6DA7><<&H:E:""3T=M&5]\4P[%3V!7S`$'(C
M,'$#\5SCTEC'XA]7H];3S9!?VQ3^ZW-,"@-#<``HP?"3T-/-63WH1T@A#E8=
M$&C&`4?<NOO,]ZV^J\>ZV-_%NIU@/W:Y?C.`*#(!(@UL>*#T!;!^+&5CD=WB
M>XR+^=>G:C&UMGZW^J)H;2->X2^Z_,A7R&C<YR1SR"^A*R%!(Z-0O1Z.5O5O
M54^B["TL^%O7:U9MQVS;*ON/>'EN=`JVRX98-9"SP'_T_P#_`*NK:^.Y$5BJ
M\A%Z_G1JJUT_#3\1ZPVOSSND_<YWMWS(=D`R:R7<HVJKU]&ADC09="V)!DA-
M)E&>=AY(Y`T,D<<M<MB_5Z55+%H@5M:;V^Y=1T10MIGZF/(EO]#2$D5%U*%8
M_$CB0!H,>3'$21*6,XAQZC6\%>LL6)70(E?15N9]U.6*4U=&8#PSXQ9J>@$A
MYHLUQ'O1!M"03D:J/_*B(?#Y3@K@J$*7I(FHL-!-]]>8;;0VTZ':Q+.,"SD3
M/Z?RUYXD-(J"CL6,J!8B+T<J?@5Y<^MGJ7\D;01GE#[K\R,D$KHHY:LC,+_Z
M`E6,0L@[7.>WJC6(YO:Y7=R54.5ZQ^HXOM%S!NQ/9[J\R(LJ7"<Q$=.>GH*A
M)3B#`SJKU7JJJB]6]4>"J!A?5O(1`["!>_*S'N!RS#MW9X,B9\O.?--Z$2!?
M+2&<7Q9KQ$&(XU(6,=>SQBB2.-/4Z8UMM!D22D]ON71R)U1%#`$>(4O_`*"B
MJ*TEN'(<Z2G<!%>+MC-\:J^;7`]5_3<$FTCJ"=;-]R.5TLVN*U!GEQIAOZ?4
MMS9K1O?XG.;V#5&_E5J=J)A]%E/6?3Q#-?"D6:>Y'+]190Z./!1*BII'Q_0L
MZ04CVG1TDI%,Z3$$,+$!VJY12--P]P+JKN.6;.9:67OWSJQLV>8\U8P;.,+T
M*Z2Z@40XQ/`][WN4:N0C>]43C?)DXQ]9Z+(8:?;6UIG<W[K\TU8-;:2H\QM3
M*L)R>AQIPH];,>`CP.>=#,&]B/9Y'._$'D`_`'JGK>5:RLGU,7;Z7W8YG1QH
MDYP@])U;5^@\-DMT6O`T3/*4KNY7D[D>[JFP_='KUZ>OUU_(!.IM4'W/YU$:
MFL&18`WGE1(?HO`':`BS`&?$'U$\`'L"XA%&A5JHE)P5ZR56A@7>:O"W<3WG
MYS9"?*JS5C[U(U"WT/'#BAO@1Y#&M8Y'`\@U5Y/%^;DJZP6!]7>.=/R7E]%C
M9\Z3[><P:2GK,[J,-<92U@P*1OHO4/:4MA8#F#*DEJ":L@2,7S,>'AOC6?7T
ME3.X\XJX\PTVKS/[73-ULO)9&HH)-?GTQ'&'"6+2DAFKW#B?:,9D:OP-;\6E
MJ@>.""CXURW!OH%HS9'6\LWN0V-[[0<HXNPI*+E;FSE;EZ9G8^4X7_IT<:8F
MO6HC[JKK`K60JVK"E09T.M@PI4.LJ<3K7\(>B^1#F=7?3[>-G/=+V3;;Z')6
M=EGYD&O=;2?1=:R-OPQJ^:.9HBULH,U\D#TK`_'(V5E@%X9]!)S(6HG7NUDQ
MO<CV@KYVJ@EAY^#6P:@I?2FPC9:PK(\.Q1QRBM(<E9<=?A#6*Y9%6_2\2?T^
M=58CO/DW,ZO]L?9/,/7/#+2RH]9D'N])[^9D]!\MEJI;0QK,;AS(K!1`?#59
M%/7U'`'].R140ZJ_%85Q?<KVB:PE[93+:75V=&0OH_)^RUE;\J*P\,K9Q9+!
MR$'*C-D#;&AM/Z[?T\'L'7V(YGC]V?:$137!VV+*Z?#+_P"A%[X-?$82*AHK
MO.4_B-V2`>=OAA,=ZZ_T[GH"KFQ9*K[K>S;G2+-R3DK)XGG]##D'#BHZ'\B.
M53GDJ$RMDA\[?!-:?UZ_IP$.2,QE>8/N-[."9'FMD0^LFP$7T7D%L0.@#,-!
M-+'>A7C(I7-&X9),9_KG_3O4#ZZ$.*Q_NQ[/N<*W'\#[C,FD%Z(`)854OME^
M&&BA?'\P>XYO`[SD&SUS_IW!"*LK`U@F>['L^UL2VB?;OFS9:`]$(S)]9(44
MKP1$0)8_E#WR#^%WFF,-Z[?TX7SY,^ODME)[E^T+8R18K):GC2(O_H:60<KS
MK'>![9`@@0944)5*CASE@>MO].Z.];=TZG=+]W/:6:D2"7[BLF-:M#Z*0/O%
MB9QXZ_):L42*PRK'53-4-B>!ZT?TY8QB7$:?4OE>Z'LS+2'#"MDKQ63`^AD%
MMI=$64+I/&D1J*TRN`_S-\54^5ZU_P!.,ZQKHT^S6/[F^RL9TJ`0,(`X]4IO
M0J:E/:,$R2UTHGS!.0@D2.WQ.\M/&+ZW?TY'1X=L67:#A>YWLU#^;7.="<&-
M7/+Z'375MHQR2E)+/\X95*+_`&=OB?YOV%ROZ<_TM^3,/8V,5^JQVP]J.?-%
ME-#3UTJIF54)V>TW]/W050K.ME5[RCE2A3AM+X'L`QP%4L1A/Z3/]"YS!U\Q
MDQK-]LQI(ME^ZNJYL7__`)L/^%6Q"'B*>*_SDD((Z-.'Y#/`P4C^E/\`T-A@
M+36<>P;#Y#W\.0?02"3B5EM#EA_IS(^%515^&DB`]L@DEHCHR4!)">$+'_TO
M/Z*`W$J[EEG)C<J<F1Y1M%,C7\>HN*LC/Z=ZLJ*^K2PAJ2+VFD&=%*X4N,^0
MUP+%D?\`IE?T28Y)%;`6`XW(_)TL4;1HE)]ZL+$"_P!/H*6E#+='L%A5XW1#
M0$E1FNER6Q%23:V\'^GG_1BBR2UU2^B'*Y&Y/FQ*[1([.+II5G$%Z"00VN:M
M&P[1(%>!(,FL69%59DGX3DEZRB@_T_\`^CO"9=4L*'G;$G*?),BTS-P:#11=
M%8'E"_I[PUNZV8<-J:OC=(LB`^5"\DJ5\!R3+T'#/JU_3&XX\NQJKW*EH_8W
MG>N-6Y^MDV3UI=<3->B^:=NKA82PHX)[_@Q8K$FJD%_RAI%Y&TDS@[^G+"D;
M/9-O*6$;VF]E)\#/9N4NB)>45H*/Z6U/[ET%F:QAJRX:E>T*"EH^&;Y3/C6T
M2+P1Z$AR2ZFH?DL_5>XOL96RLMQY#GVTJPHELC^BEG`L=])$>)\?0A@08@#C
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MNRNXL"SKLS:+>WO]/^RMEJZ..^`U\$YY!3,BE:.4!#L^/&LR_P!/#^CL6QB9
MAE7':G+W+`Z=-'^ZDLC7TBJ_]`9"3ZL^8`&(Z`>024EDCYK9[0/6`L2=#],O
MZ1^#I*K/TT>NS&7Y*Y!#&GZV-(HF7EYJ+87]/V#:V.;LZIEN&/45[ZF1'+)@
M/-82AUY0SY\"I_IH_P!%?[F?-4U77Z.YY-Y(T%G`O8\:EC7]T85A_3R^--K[
M=L>P=&AL2,:"^4#K+/\`%7Y%Y'R'H7_1JS-Q.BY85);3N0.2]`RAEQ*VT)N)
MRPT]"*=;%VITLB(6`+RA#45<5T,C9[RME"Q!@^LW]/#AKB6KYUX^Y"T</A'F
M'26^C=CL=?\`[@[2Y3;?T]86$U7(\2XJZ6<&YCKF)ROK2I"EU%B>ONJ7_P#8
#G__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img02.jpg
<TEXT>
begin 644 img02.jpg
M_]C_X``02D9)1@`!`@$`9`!D``#_X0Q"17AI9@``34T`*@````@`"`$2``,`
M```!``$```$:``4````!````;@$;``4````!````=@$H``,````!``(```$Q
M``(````<````?@$R``(````4````F@$[``(````%````KH=I``0````!````
MM````.``#T)````G$``/0D```"<0061O8F4@4&AO=&]S:&]P($-3-"!7:6YD
M;W=S`#(P,3(Z,#,Z,C@@,3(Z,3`Z,S8`;FEC:P````.@`0`#`````0`!``"@
M`@`$`````0```F2@`P`$`````0```+4`````````!@$#``,````!``8```$:
M``4````!```!+@$;``4````!```!-@$H``,````!``(```(!``0````!```!
M/@("``0````!```*_`````````!(`````0```$@````!_]C_X``02D9)1@`!
M`@``2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$``P(
M"`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,
M$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`"\`
MH`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"!`4&
M!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'
M!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R62
M4_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3T
MI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&
M!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E
M!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/54E2ZGTK'Z
MDRMES[*Q47&:B&EP>Q]+ZWDM=^C=ZF_;_P`&S_!_HU5;]7*@TL=FY=C7!P=O
MMF0YKF1]'Z+?4<^O_1HT.Z->SKI+'=]6L=Q&_,S'L$'TWW%S206O=N#F_1L<
MS])7_-J5/U>IJL8_[9F.])S'L:;B&RPAS=[6!N_\ZI_[]3_^+2H=_P`%6>S;
MZG]O.+MZ>0+W65@N,2VO>S[2YC;/8ZWT/4]+?_A%0=D?6O>]K<7&VM&CW..N
MY[MFV+&[G54>EZ['MH9ZOJ^C=^B9Z^KDT_:,>VC>ZKU6.9ZE9VO;N&W?6\?0
ML;^8Y9W_`#=J+'M=FYCG.)<'&[Z)FM[',KV^@WTO1:VK]%[/^,_2(@CK7V*-
MJ;;]9C8&.HQ6-+O=;N>Z&^HYO\W['.?Z'IV-]_\`YA=Z>[/=B,=U!M;,ITFQ
ME4EC=?:QKG.=ZFUO^$_/_P!'7]!4S]7Z78[\9^3D6U6.H>1:_P!6/LY98UK?
M7%KMMUE6Z_\`\#]-:J!(Z*%J22202I)9G4>A8_4,RO,LNNJNH865>FYH#=V[
MU'"6.=^E:[9;_(0'_5C'LJ?39FYCZWC:YKKB9:6NKVOD>_VO^E_.?S:-#O\`
M@BSV=I))`S<4Y=(J]:RB'L?OJ.UWL<+-LD.]C]NVQOY]:"7)%OUN96/T-%C[
M'.G<=*RZP^D`UCJ=^+5B?3LW_:GY/^!]+^:+Z_UI$DXN*>88'N'YU;6^_P#.
M]OVA^_TZ_9Z7Z.NS]`D?JU0:F5NS<TN9'Z0WN+C'T_<?H>M-OJOJ]-_Z9_\`
M@_1](W[#H-F*^VZVX8=UN16VTM?-EA=LW6/8;]N*VQ[,;9;]#^=];]&GV/#[
M%M'Q^U$;OK,QVYU.-8QNQQ967!S@7N-U;'6V,8VRK';MKW_H[K[/\#6M820"
M1![A8_\`S99Z/IGJ.>7$%IL-^L'Z?MV^G^D_/]BM8G1L7$S!EU%VYF.S$JKT
MVLJK]S6MAN_=N_E(&OY!(MOI)))J7__0]525;J`RSB.&&2+]S-6[=VS>SU_3
M];]%ZOH>IZ7J_H_464,KZQO<,6P4TY37S7M+-MM;*XLOV6/=<[';F6XWVCTJ
MJ;:Z;/T=OJV?HTIWDESK,[ZQ9=>+=59BXQR@YHJ<YKB2U[KFV8SF.M;D?JE7
MH/\`?_A_M?\`VG]&Z]TY_5[<M[[[J+<!IR&,=20YSG"T>B'P-M;L2OUL*UG^
MFI]6S_1UI3J+%9TGK`:UKNH.`]S#])QV398P^H7-W9/J_9]]WIU5_9O7I]#^
M;MKVED=?ZAEX1QAC/#?5<X/EH=,;/'^LDI$>D]>ANSJ.R&U_2#G^YE?I./TF
M>HSUOUOW?TE_Z&ZST*=EFET['R,?%%618;;`YQDESH!)<VOU+9MLV-_/L6'T
MWK?4LC/QZ;;&FNP^\!@':T\_];:NF24I))))2DDEE]&LZL]U@ZA=1<*F,I=Z
M!!/KLWG)LMC^:?:VRG]7_P`%Z7_#)*;F?3=D8=U-%AJML:6LL:[:6GL[>`_:
ML]W2^L$R[J!<-[+"QH=6"1;OOKW[[7UX[\1C::JO?LL]6WU'K80,VU].'?;6
M8?76]S2==6M+FI*<D](Z\1#NHAX@@CWL+I?ZA_24O:ZM]W[]?]$IK^RX[/TE
MF0MJIKV5,98_U'M:`^R`-Q`]S]K?:W<N39]8>K$-FUNH;/L'>973=.NLOP,>
MZTS994Q[R!&I`)T24BS\/+R;J'8^0<>M@<VX`GW-<:S[&LV?IOT?Z.]S_P!#
MOL_06>IZE-%_2>MN#IZ@2\UEK;`7L&\6,=4]]+7.9Z;:*6>LVMU5N0^W*_34
MUV_HM;,L?5B7VL,/KK>YIYU#20L1W5^H"8L;IN_-'8!-E,1W9L/+SR@F)`HU
MJ[&%3DTMN%]GJ;[K'U&22*W'<RL[_P!Q64+&>ZS&JL?JY[&N<?,B45.8B*)'
M9__1]56)U86X_6\+J-F=BX>'7CY%#FWC](Y]IJL;Z+C977LW4566_G_H/3_[
M4_H-M5;,1S\^K*]=[6UM(]`$[7?2$EL[?\+[_9].K']]?Z3UDIY7I[_L]70F
M7=6Z<3TTV_;!6XD$/8^J@8<N_-:_T[?6_P"-_P"#6CT#J6'T_I[J.H]3P[KS
M??;OH]C(MM??]%[[/>[U/5L_T6_T?\'ZK][)J==CV5,L=4Y[2T6-Y:3^<.$#
M%PKJ+Q:[)LM;Z+:C6XDM):9;=[W6?I?=L]G\[_VH];TZO32D/_.+H7_<ZG_.
M6']9>H?;G8IZ5EX#Q47&P95EK/W(]/[/5?O^C_(V?R_\'URSLKI=^0[)+<VZ
MD9`:&BMQ!KV[/=5[O;_-_N_X2[UO6_P:4\?TJ[/Q^HXU^7D]+&/4X>H:;<A[
MX]\^FQ^/6QSOTG[ZZ[_G'T3_`+E-^YW_`)%::22G,_YQ]%_[DC_-?_Y!+_G'
MT;_N1_T'_P#D%II)*<S_`)Q]'_TY_P"V[/\`TFLWHG4J<%V><[*;:,G*?=1Z
M-%X(K<&AOK;J_P"?]OOV>Q=(J6'@7T.QW/RG7"FNQCP=T6&QU=GJG=;9_-NK
M?Z/^BJM]*M)2/_G%TG_26?\`;-W_`*25;J/7,._`R*<5[C?96YM?J49`9+AM
M_2.KH<]C?Y>WV+;5?*HLN?066^D*K-[FB??#7M:SVOK]FYV]W[^Q)3YXVOZP
MM#1MP?:&]L_\W_VGKK^E]:QL?IV-1E[_`+156UEGHX^4YDM&WV.?CM>[_-6G
M@8K\3&%#[WY):7$6VZN@F8<[\[_7_BU924XV=UO$OP[Z<<7&ZRMS6;\7*VR1
M'NV8[G+GG7=4/^#JUGBG/[Z?]P5V6?C'*Q7XXM=C^I`]6LEKVZ@_HW`MVO3X
M]%E5F0]]IL]=X>&F89#*ZBQFYS]K'>EZO]>Q,E`2W)^C8P<U/""(QB;-^H6Y
M^%UO&9BTU7LR/6:UK';,3++)^C[7OQF^W^6Y:ZHY&#FVY?K5YUE-(#=M#6M(
MW#U-[GO<-[F/_0?H_P#@K/\`3)\+!R<9S779MN5%>QXL#0'.]NVT;`W9[6_V
MT\,$C9)[FW__V?_M$2I0:&]T;W-H;W`@,RXP`#A"24T$!```````.!P"```"
M`*,<`E``!&YI8VL<`@4`(TUI8W)O<V]F="!7;W)D("T@,C`Q,B!&;W)M(%,M
M,2`M('8V.$))300E```````0K'O@6:/$VS1G+;0J^#VC-3A"24T#[0``````
M$`!D`````0`!`&0````!``$X0DE-!"8```````X`````````````/X```#A"
M24T$#0``````!````'@X0DE-!!D```````0````>.$))30/S```````)````
M```````!`#A"24TG$```````"@`!``````````(X0DE-`_4``````$@`+V9F
M``$`;&9F``8```````$`+V9F``$`H9F:``8```````$`,@````$`6@````8`
M``````$`-0````$`+0````8```````$X0DE-`_@``````'```/__________
M__________________\#Z`````#_____________________________`^@`
M````_____________________________P/H`````/__________________
M__________\#Z```.$))300(```````0`````0```D````)``````#A"24T$
M'@``````!``````X0DE-!!H``````VT````&``````````````"U```"9```
M`!P`,@`P`#$`,@`@`$8`;P!R`&T`(`!3`"T`,0`@`"T`(`!V`#8`(`!'`$4`
M3P!6`$$`6``M`#(`,@````$``````````````````````````0``````````
M```"9````+4``````````````````````0`````````````````````````0
M`````0```````&YU;&P````"````!F)O=6YD<T]B:F,````!````````4F-T
M,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M
M;&]N9P```+4`````4F=H=&QO;F<```)D````!G-L:6-E<U9L3',````!3V)J
M8P````$```````5S;&EC90```!(````'<VQI8V5)1&QO;F<`````````!V=R
M;W5P241L;VYG``````````9O<FEG:6YE;G5M````#$53;&EC94]R:6=I;@``
M``UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M````"D53;&EC951Y<&4`````
M26UG(`````9B;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L
M;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<```"U`````%)G
M:'1L;VYG```"9`````-U<FQ415A4`````0```````&YU;&Q415A4`````0``
M`````$US9V5415A4`````0``````!F%L=%1A9U1%6%0````!```````.8V5L
M;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%6%0````!```````):&]R
M>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F875L=`````EV
M97)T06QI9VYE;G5M````#T53;&EC959E<G1!;&EG;@````=D969A=6QT````
M"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP90````!.;VYE
M````"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L;VYG````````
M``QB;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E=&QO;F<`````
M`#A"24T$*```````#`````(_\````````#A"24T$%```````!`````(X0DE-
M!`P`````"Q@````!````H````"\```'@``!8(```"OP`&``!_]C_X``02D9)
M1@`!`@``2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$
M``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,
M#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(
M`"\`H`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"
M!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($
M`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#
M!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&
M!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S
M-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/54E2ZG
MTK'ZDRMES[*Q47&:B&EP>Q]+ZWDM=^C=ZF_;_P`&S_!_HU5;]7*@TL=FY=C7
M!P=OMF0YKF1]'Z+?4<^O_1HT.Z->SKI+'=]6L=Q&_,S'L$'TWW%S206O=N#F
M_1L<S])7_-J5/U>IJL8_[9F.])S'L:;B&RPAS=[6!N_\ZI_[]3_^+2H=_P`%
M6>S;ZG]O.+MZ>0+W65@N,2VO>S[2YC;/8ZWT/4]+?_A%0=D?6O>]K<7&VM&C
MW..NY[MFV+&[G54>EZ['MH9ZOJ^C=^B9Z^KDT_:,>VC>ZKU6.9ZE9VO;N&W?
M6\?0L;^8Y9W_`#=J+'M=FYCG.)<'&[Z)FM[',KV^@WTO1:VK]%[/^,_2(@CK
M7V*-J;;]9C8&.HQ6-+O=;N>Z&^HYO\W['.?Z'IV-]_\`YA=Z>[/=B,=U!M;,
MITFQE4EC=?:QKG.=ZFUO^$_/_P!'7]!4S]7Z78[\9^3D6U6.H>1:_P!6/LY9
M8UK?7%KMMUE6Z_\`\#]-:J!(Z*%J22202I)9G4>A8_4,RO,LNNJNH865>FYH
M#=V[U'"6.=^E:[9;_(0'_5C'LJ?39FYCZWC:YKKB9:6NKVOD>_VO^E_.?S:-
M#O\`@BSV=I))`S<4Y=(J]:RB'L?OJ.UWL<+-LD.]C]NVQOY]:"7)%OUN96/T
M-%C['.G<=*RZP^D`UCJ=^+5B?3LW_:GY/^!]+^:+Z_UI$DXN*>88'N'YU;6^
M_P#.]OVA^_TZ_9Z7Z.NS]`D?JU0:F5NS<TN9'Z0WN+C'T_<?H>M-OJOJ]-_Z
M9_\`@_1](W[#H-F*^VZVX8=UN16VTM?-EA=LW6/8;]N*VQ[,;9;]#^=];]&G
MV/#[%M'Q^U$;OK,QVYU.-8QNQQ967!S@7N-U;'6V,8VRK';MKW_H[K[/\#6M
M820"1![A8_\`S99Z/IGJ.>7$%IL-^L'Z?MV^G^D_/]BM8G1L7$S!EU%VYF.S
M$JKTVLJK]S6MAN_=N_E(&OY!(MOI)))J7__0]525;J`RSB.&&2+]S-6[=VS>
MSU_3];]%ZOH>IZ7J_H_464,KZQO<,6P4TY37S7M+-MM;*XLOV6/=<[';F6XW
MVCTJJ;:Z;/T=OJV?HTIWDESK,[ZQ9=>+=59BXQR@YHJ<YKB2U[KFV8SF.M;D
M?JE7H/\`?_A_M?\`VG]&Z]TY_5[<M[[[J+<!IR&,=20YSG"T>B'P-M;L2OUL
M*UG^FI]6S_1UI3J+%9TGK`:UKNH.`]S#])QV398P^H7-W9/J_9]]WIU5_9O7
MI]#^;MKVED=?ZAEX1QAC/#?5<X/EH=,;/'^LDI$>D]>ANSJ.R&U_2#G^YE?I
M./TF>HSUOUOW?TE_Z&ZST*=EFET['R,?%%618;;`YQDESH!)<VOU+9MLV-_/
ML6'TWK?4LC/QZ;;&FNP^\!@':T\_];:NF24I))))2DDEE]&LZL]U@ZA=1<*F
M,I=Z!!/KLWG)LMC^:?:VRG]7_P`%Z7_#)*;F?3=D8=U-%AJML:6LL:[:6GL[
M>`_:L]W2^L$R[J!<-[+"QH=6"1;OOKW[[7UX[\1C::JO?LL]6WU'K80,VU].
M'?;68?76]S2==6M+FI*<D](Z\1#NHAX@@CWL+I?ZA_24O:ZM]W[]?]$IK^RX
M[/TEF0MJIKV5,98_U'M:`^R`-Q`]S]K?:W<N39]8>K$-FUNH;/L'>973=.NL
MOP,>ZTS994Q[R!&I`)T24BS\/+R;J'8^0<>M@<VX`GW-<:S[&LV?IOT?Z.]S
M_P!#OL_06>IZE-%_2>MN#IZ@2\UEK;`7L&\6,=4]]+7.9Z;:*6>LVMU5N0^W
M*_34UV_HM;,L?5B7VL,/KK>YIYU#20L1W5^H"8L;IN_-'8!-E,1W9L/+SR@F
M)`HUJ[&%3DTMN%]GJ;[K'U&22*W'<RL[_P!Q64+&>ZS&JL?JY[&N<?,B45.8
MB*)'9__1]56)U86X_6\+J-F=BX>'7CY%#FWC](Y]IJL;Z+C977LW4566_G_H
M/3_[4_H-M5;,1S\^K*]=[6UM(]`$[7?2$EL[?\+[_9].K']]?Z3UDIY7I[_L
M]70F7=6Z<3TTV_;!6XD$/8^J@8<N_-:_T[?6_P"-_P"#6CT#J6'T_I[J.H]3
MP[KS??;OH]C(MM??]%[[/>[U/5L_T6_T?\'ZK][)J==CV5,L=4Y[2T6-Y:3^
M<.$#%PKJ+Q:[)LM;Z+:C6XDM):9;=[W6?I?=L]G\[_VH];TZO32D/_.+H7_<
MZG_.6']9>H?;G8IZ5EX#Q47&P95EK/W(]/[/5?O^C_(V?R_\'URSLKI=^0[)
M+<VZD9`:&BMQ!KV[/=5[O;_-_N_X2[UO6_P:4\?TJ[/Q^HXU^7D]+&/4X>H:
M;<A[X]\^FQ^/6QSOTG[ZZ[_G'T3_`+E-^YW_`)%::22G,_YQ]%_[DC_-?_Y!
M+_G'T;_N1_T'_P#D%II)*<S_`)Q]'_TY_P"V[/\`TFLWHG4J<%V><[*;:,G*
M?=1Z-%X(K<&AOK;J_P"?]OOV>Q=(J6'@7T.QW/RG7"FNQCP=T6&QU=GJG=;9
M_-NK?Z/^BJM]*M)2/_G%TG_26?\`;-W_`*25;J/7,._`R*<5[C?96YM?J49`
M9+AM_2.KH<]C?Y>WV+;5?*HLN?066^D*K-[FB??#7M:SVOK]FYV]W[^Q)3YX
MVOZPM#1MP?:&]L_\W_VGKK^E]:QL?IV-1E[_`+156UEGHX^4YDM&WV.?CM>[
M_-6G@8K\3&%#[WY):7$6VZN@F8<[\[_7_BU924XV=UO$OP[Z<<7&ZRMS6;\7
M*VR1'NV8[G+GG7=4/^#JUGBG/[Z?]P5V6?C'*Q7XXM=C^I`]6LEKVZ@_HW`M
MVO3X]%E5F0]]IL]=X>&F89#*ZBQFYS]K'>EZO]>Q,E`2W)^C8P<U/""(QB;-
M^H6Y^%UO&9BTU7LR/6:UK';,3++)^C[7OQF^W^6Y:ZHY&#FVY?K5YUE-(#=M
M#6M(W#U-[GO<-[F/_0?H_P#@K/\`3)\+!R<9S779MN5%>QXL#0'.]NVT;`W9
M[6_VT\,$C9)[FW__V3A"24T$(0``````50````$!````#P!!`&0`;P!B`&4`
M(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E`"``4`!H`&\`=`!O
M`',`:`!O`'``(`!#`%,`-`````$`.$))300&```````'``@!`0`!`0#_X1.`
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@8F5G:6X]
M(N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\>#IX;7!M
M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!8
M35`@0V]R92`T+C(N,BUC,#8S(#4S+C,U,C8R-"P@,C`P."\P-R\S,"TQ.#HQ
M,CHQ."`@("`@("`@(CX@/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W
M+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS>6YT87@M;G,C(CX@/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z9&,](FAT='`Z+R]P=7)L+F]R
M9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIX;7`](FAT='`Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"\B('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P9&8O,2XS+R(@>&UL;G,Z>&UP34T](FAT='`Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]M;2\B('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V5%=F5N=",B('AM;&YS.G-T4F5F/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V52968C
M(B!X;6QN<SIP:&]T;W-H;W`](FAT='`Z+R]N<RYA9&]B92YC;VTO<&AO=&]S
M:&]P+S$N,"\B('AM;&YS.G1I9F8](FAT='`Z+R]N<RYA9&]B92YC;VTO=&EF
M9B\Q+C`O(B!X;6QN<SIE>&EF/2)H='1P.B\O;G,N861O8F4N8V]M+V5X:68O
M,2XP+R(@9&,Z9F]R;6%T/2)I;6%G92]J<&5G(B!X;7`Z0W)E871E1&%T93TB
M,C`Q,BTP,RTR.%0Q,CHP.3HQ,2TP-CHP,"(@>&UP.D-R96%T;W)4;V]L/2)0
M4V-R:7!T-2YD;&P@5F5R<VEO;B`U+C(N,B(@>&UP.DUO9&EF>41A=&4](C(P
M,3(M,#,M,CA4,3(Z,3`Z,S8M,#8Z,#`B('AM<#I-971A9&%T841A=&4](C(P
M,3(M,#,M,CA4,3(Z,3`Z,S8M,#8Z,#`B('!D9CI0<F]D=6-E<CTB06-R;V)A
M="!$:7-T:6QL97(@.2XP+C`@*%=I;F1O=W,I(B!X;7!-33I$;V-U;65N=$E$
M/2)U=6ED.C0W-&4U9&4Q+6,Q9C`M-#AF.2UA8F8V+69E83(T869F-#=D."(@
M>&UP34TZ26YS=&%N8V5)1#TB>&UP+FEI9#I$.$,U-S$U,3`Q-SE%,3$Q03<S
M1#A%,3A#1C$Y.3E%-B(@>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/2)U=6ED
M.C0W-&4U9&4Q+6,Q9C`M-#AF.2UA8F8V+69E83(T869F-#=D."(@<&AO=&]S
M:&]P.D-O;&]R36]D93TB,R(@<&AO=&]S:&]P.DE#0U!R;V9I;&4](G-21T(@
M245#-C$Y-C8M,BXQ(B!T:69F.D]R:65N=&%T:6]N/2(Q(B!T:69F.EA297-O
M;'5T:6]N/2(Q,#`P,#`P+S$P,#`P(B!T:69F.EE297-O;'5T:6]N/2(Q,#`P
M,#`P+S$P,#`P(B!T:69F.E)E<V]L=71I;VY5;FET/2(R(B!T:69F.DYA=&EV
M941I9V5S=#TB,C4V+#(U-RPR-3@L,C4Y+#(V,BPR-S0L,C<W+#(X-"PU,S`L
M-3,Q+#(X,BPR.#,L,CDV+#,P,2PS,3@L,S$Y+#4R.2PU,S(L,S`V+#(W,"PR
M-S$L,C<R+#,P-2PS,34L,S,T,S([1C!&-#,S-T9!0C%$0C<T.41",3(P,#`T
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M.3DV+#0R,#$V+#`L,BPT+#4L-BPW+#@L.2PQ,"PQ,2PQ,BPQ,RPQ-"PQ-2PQ
M-BPQ-RPQ."PR,"PR,BPR,RPR-"PR-2PR-BPR-RPR."PS,#LQ,3-!0S4P04,Q
M1$8R,38T.$9"-D(S,$)$,S@Q13%"-"(^(#QD8SIC<F5A=&]R/B`\<F1F.E-E
M<3X@/')D9CIL:3YN:6-K/"]R9&8Z;&D^(#PO<F1F.E-E<3X@/"]D8SIC<F5A
M=&]R/B`\9&,Z=&ET;&4^(#QR9&8Z06QT/B`\<F1F.FQI('AM;#IL86YG/2)X
M+61E9F%U;'0B/DUI8W)O<V]F="!7;W)D("T@,C`Q,B!&;W)M(%,M,2`M('8V
M/"]R9&8Z;&D^(#PO<F1F.D%L=#X@/"]D8SIT:71L93X@/'AM<$U-.DAI<W1O
M<GD^(#QR9&8Z4V5Q/B`\<F1F.FQI('-T179T.F%C=&EO;CTB8V]N=F5R=&5D
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M=#II;G-T86YC94E$/2)X;7`N:6ED.D0X0S4W,34Q,#$W.44Q,3%!-S-$.$4Q
M.$-&,3DY.44V(B!S=$5V=#IW:&5N/2(R,#$R+3`S+3(X5#$R.C$P.C,V+3`V
M.C`P(B!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!0:&]T;W-H;W`@0U,T
M(%=I;F1O=W,B('-T179T.F-H86YG960](B\B+SX@/"]R9&8Z4V5Q/B`\+WAM
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M/"]R9&8Z1&5S8W)I<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@/#]X<&%C:V5T(&5N9#TB=R(_/O_B#%A)
M0T-?4%)/1DE,10`!`0``#$A,:6YO`A```&UN=')21T(@6%E:(`?.``(`"0`&
M`#$``&%C<W!-4T94`````$E%0R!S4D="```````````````!``#VU@`!````
M`-,M2%`@(```````````````````````````````````````````````````
M````````````$6-P<G0```%0````,V1E<V,```&$````;'=T<'0```'P````
M%&)K<'0```($````%')865H```(8````%&=865H```(L````%&)865H```)`
M````%&1M;F0```)4````<&1M9&0```+$````B'9U960```-,````AG9I97<`
M``/4````)&QU;6D```/X````%&UE87,```0,````)'1E8V@```0P````#')4
M4D,```0\```(#&=44D,```0\```(#&)44D,```0\```(#'1E>'0`````0V]P
M>7)I9VAT("AC*2`Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY``!D97-C
M`````````!)S4D="($E%0S8Q.38V+3(N,0``````````````$G-21T(@245#
M-C$Y-C8M,BXQ````````````````````````````````````````````````
M``````````````````!865H@````````\U$``0````$6S%A96B``````````
M````````````6%E:(````````&^B```X]0```Y!865H@````````8ID``+>%
M```8VEA96B`````````DH```#X0``+;/9&5S8P`````````6245#(&AT='`Z
M+R]W=W<N:65C+F-H```````````````6245#(&AT='`Z+R]W=W<N:65C+F-H
M````````````````````````````````````````````````````````````
M`&1E<V,`````````+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@``````````````+DE%0R`V,3DV-BTR+C$@1&5F875L
M="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``````````````````````````
M``!D97-C`````````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@
M245#-C$Y-C8M,BXQ```````````````L4F5F97)E;F-E(%9I97=I;F<@0V]N
M9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````````````````````````
M````=FEE=P``````$Z3^`!1?+@`0SQ0``^W,``03"P`#7)X````!6%E:(```
M````3`E6`%````!7'^=M96%S``````````$````````````````````````"
MCP````)S:6<@`````$-25"!C=7)V````````!``````%``H`#P`4`!D`'@`C
M`"@`+0`R`#<`.P!``$4`2@!/`%0`60!>`&,`:`!M`'(`=P!\`($`A@"+`)``
ME0":`)\`I`"I`*X`L@"W`+P`P0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'
M`0T!$P$9`1\!)0$K`3(!.`$^`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!
MH0&I`;$!N0'!`<D!T0'9`>$!Z0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=
M`F<"<0)Z`H0"C@*8`J("K`*V`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#
M3P-:`V8#<@-^`XH#E@.B`ZX#N@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C
M!'$$?@2,!)H$J`2V!,0$TP3A!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%
MM07%!=4%Y07V!@8&%@8G!C<&2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&0<K
M!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^`@+"!\(,@A&"%H(;@B"")8(J@B^"-((
MYPC["1`))0DZ"4\)9`EY"8\)I`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%
M"MP*\PL+"R(+.0M1"VD+@`N8"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,
M\PT-#28-0`U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!
M#UX/>@^6#[,/SP_L$`D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1
MZ!('$B8211)D$H02HQ+#$N,3`Q,C$T,38Q.#$Z03Q1/E%`84)Q1)%&H4BQ2M
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M--@U$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.%`XC#C(.04Y0CE_.;PY
M^3HV.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B`^8#Z@/N`_(3]A
M/Z(_XD`C0&1`ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%
M546:1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M3
M2YI+XDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1
MYE(Q4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]
M6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?
MLV`%8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H
M9SUGDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMN
MQ&\>;WAOT7`K<(9PX'$Z<95Q\')+<J9S`7-=<[AT%'1P=,QU*'6%=>%V/G:;
M=OAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_
M(W^$?^6`1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?
MB`2(:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0
MUI$_D:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\
MFFB:U9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:C
MYJ16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VX
MKBVNH:\6KXNP`+!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X
M6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'#`[,%GP>/"7\+;
MPUC#U,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.
M-LZVSS?/N-`YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-EL
MV?':=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SE
MA.8-YI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R
M\?_RC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^
M2_[<_VW____N`"%!9&]B90!D0`````$#`!`#`@,&````````````````_]L`
MA``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_P@`1
M"`"U`F0#`1$``A$!`Q$!_\0!&0`!``$$`P$!``````````````@!!PD*`P0&
M`@4!`0`"`@,!`0`````````````$!0,&`0('"`D0```%!`$`!P4&!04!````
M``0%!@<(`0(#"0`0(#`1$C<*0&`X&1HA,10U-CE0-!5%%G"`D!<8$Q$```<`
M`0$%`@8,"0<("`<``0(#!`4&!P@1`"$2$PDQ%$%1(B,5%B`P0&%Q,G,7M[AY
M"A#P@9&Q&'BY>J'!T7(D)QE08.%BLC.VEW#Q4H)C@S0VD\-%M49V-Q(``@$"
M!0$$!`<+!PH'`````0(#$00`(3$2!4%1(A,&87$R%"`P@9%"M!5`8+'!4B-U
M=K8'=Q"A8C.U%@A0@)#PT>%R@K(7\9)#<U0E-?_:``P#`0$"$0,1````W^``
M```````4!4````````````````H"H```````````````````-.CV+S/+MI^Q
M^6R]+@8,]GID:[L3/<N+G[W7M'"RA?C9.F=W1-N````````````LM,BZGGK'
MG65_4]B]Y@S^:R8NOSQ[7%EO]63H3WU7=&)E_!R]9'5D_)%KEV``````````
M```!Q\<:X'H^DW5AY\>6RTN2K6;R,MI"NS#S_I]._B<^*6U19<?/3,'J&S@`
M``````````0<NZF*UI7PEO*NT\R+>F!,D772[7S(]N,V*^L"5[+IENC%D8X=
MCH]CCSC=[GQI``````%N,^"I<6/GKR%FID6\L.4.%Q;*3@]OAS?N=.P```%J
M94>ZT60*%OL^&X6#,`````*$8K*!):MG=AR!T.>O?X[````=/GKX&1BN5&SC
MPV?%P.+@8,P%.%GYD7XY7/B2/U>.P````&K+ZAH$2[FLF_1VWOXV7I]UM9,>
MR<Z-+RFL<:&S4<O:>QD/73(4WE7-.EM=B3SO=0(#7M/AXW+6?=1\W5YXA]<U
MN0&@M_&9L><_0]NP2[YJ.R=YOO``````MC)CZ!GO_C^>[S_;[(SXOJ,.3TG3
MM::7&VR?)O1>5R`!A2W35HAW%;^IUY\'GP^8R]+[0)4L*JS_`'</:Q\^+Q.L
M#K^IOM`E>*SXY[Z]<P<OJG+CJ6Q9%==NP````(!W]-Z[#E\?EP^*S8N'MSZ+
M#WNW%D1UL(7M,6;U^#)9N;%O?!E^^P99-5M@!%BSKXW64*YD;-^_C[V<F1O>
M1\M.W-P8V;Q>?#.BCMP````!:R5&Q[[!3W5BY_V,??RF7'U>W'ML&:=M';``
M"`5]3>.SXO08\ER8F>V,J/Z#IDN1'S10MZ^;=!:Q(N:W\CMTE!56$%]@J<JF
MI[!B^VBARRZGL7[O3N``````````````````````````````````````````
M````````````````````````````````````````````````,$)(8_;(%F0T
M@87\.J=$S9@`````````^#7Y)+'I2$Y,$Z1&HOX>O,K@`!KPDQCOG@#QYY<]
M\9H2H```````````!@F([EV#]LN*83S(`1L,@)GK`````````!U35/,JQC&)
M8G@RV184ON3C,RH`*&JT9&3'X9*"WA"(O\9NBZ````````````!0`%2@!0^@
M`````````"@!4H`"H``*`%2@!4``````````````````````````````````
M````````'R8=3+<?O&*\GF7=(.EY#S!PGBR;X``!$0L^7.+<'O":Y4``````
M`A"=@F8=H```$+RUQ=PM07-)G@``M15[Q9*E]-]K+UKPL/:O12*:\MQYQ<*?
MJH````UVC$B9G3HF*LFX6H.Z7;(6GO#<!```-;8QDD^2$)+XVI@```````:8
M9^,;EAZD```&K80%,DYCC)ZFT:``#'UY]]<XI?+_`+RE5L_@T1-5^A[WW'F.
M3_T[X<F%MWSN````,?)YLM(7P.(A\9@#PAZ,\&7@+G@``&ML8R2?)"$E\;4P
M```````+'G@B4QS@```U;"`IDG,<9/4VC0``8^O/OKG%+Y?]Y2JV?P:(FJ_0
M][[CS')_Z=\.3"V[YW`````$`"*9,H@L92C"P9I3"V;$P```-;8QDD^2$)+X
MVI@```````0=(+F<H````U;"`IDG,<9/4VC0``8^O/OKG%+Y?]Y2JV?P:(FJ
M_0][[CS')_Z=\.3"V[YW`````&`(BN3-(*&4<PKF9\PR&Y````<!K5F,HGL0
MA)@FUD<H``````!@=(.&V(5```.$U8R`ADA,<Q/@VF#E``,>/GGU]B@\O^]I
M5;-X/$75?H:]UQYCE%].^&)E;C\Y`````#`.1N)?$%C(^8JS+,8B3;Y```(^
M&A&0B+^%@"4IO^$G@``````#!(0S-J<```$;#0@(AE]"-9,TWZ"3(`/DUZ?`
M?UPPX>0_HY=RV\^LS3>E^^GZCF_]J_,'-G[+^:M>0````'EC#6=0ZAUSKG7.
ML<!USK'7.N=<X3KG7.$XB@!0``H?0!\%`?1]`H``#Z*%#Y*`^CZ*%3Y*E"I0
MJ5!Q'R"AR%#)$9*0```")A;0E@=L[1]F+@GF6%)OG*<AR'(?9CJ)T&/`RE'T
M5````````,9QD'(T$P0``=(QZ$TBQ9+H```%#%\9%R*Y-,`^#B!R'"=DJ``#
M"D#-:`>)-2,V#C&>;&94`%#6^)@F&$W'P````````<1K,&=<P\FPV``#\@UR
M201YHSX````Z9J\&P,8BC8"!0U1RU))`L<7*-J(Y```4!4`'R`?0``/D`^@`
M```````#Y!4J``"A0`^@```4!0'T`6&+\%`#Z```````````````````````
M````````````````/__:``@!`@`!!0#W?!$'X5-XB/.I,0=%9!!V+2=N,GP(
MK'3.#2&6^T.G+!>"U-"+B@Q1E08L0BK<8/[?:2X+4<8*<+0ENP(<6+#@TGC'
M%PQ$#;!V1(A<H2]*X`9<+(,X,GM0HC(?84G8,$"T7FMH>$H`GK[;7NX;J!*'
M-I&JR].!2<82X<`E3%H(OSJQ-U-B14%9:(`*@FO`9%>4Y#,J5%0*I/C@L'!_
M:4X9!2@Z.AZ5,<MBT*Z!A5Y(5I3&O,-A[>?DA86WJDG!$>-5IR[#<K@_>FE,
M#*BW*9$6<VSFI2J,@VX)>+[6\**QA[0HJ\-2O?3HM+QUX/HI2M:A00P<)R8[
M\63L<X(8&P].8**#X^UM)3B_%6E:7=-+;JT[&VVZ^X6#%@,W0'#"1=X@**"9
M.FM>[@P`-+^!B\>,I?;?CO[,O!B3]OJ`RP5007$@Y+G.!-IP4;!$ZE+KB4+<
M76%:2$B\)64$A6!)20`NBS.6GQIE+RI/EUR3(\2L'`D^)1_2F@I4-.,J4#CE
M$<`T?B*E`6)LBX-3(,4>'01)6%ZG)R@`5EPK.$'.8.R9C7M`82\>+H*!9%C>
M7@`P3,DBTWS`028.\925$F5.T'%12A.LCBPH,K@"8!"AHTG30X;B+TT(5.,E
M+1]XHO1.4[5Y<&+,J5P*,1E7:B"'0D"5%!4G1*2)+E):6)0:282,@+!#@"[1
M"D0N>S.(5@H4+4?9E*F-R/`4GQD2Y3!3')D&,%<<F>`:L#LP"?Y4=4&XCPSP
M!L*Q/PX3"JCG`;WJ$TJ'#+`Z#!;%";669#8?E*^DK-<I9RBO/;30<?B!W!9\
M8#SK"K3K`9Y5`)RBC%1F!B%*C@047G:A'']W:`A@@N%YEHH,O"]3FA:%O4IW
MD,QZK-S`-<JS;\+D49GE*>L6*$258`BL.`V7$IAX<T+#LP*C$N4QB7@\:@$X
MQAL<CCG,!61J7EQD893,0"5IN`+JK$ZJ:8S@;B)\:[/;."16<6*QK8VPTRY,
MF;)_P+F)N#*\N1;$>,#53EM!-BW(K\656E&(27F08SQ>XZU_,1'Z2_OV'^1'
M?GB+_+/<=:_F(C])?W[#_(COSQ%_EGN.M?S$1^DO[]A_D1WYXB_RSW'6E]E3
M$1DQ_P")URXOZ[AR8_P0W)CJ=HN^RA;]_N.X:54^,TJBG'L*+$8YM@S"BG&M
M#Y48Y-1C=)L^[Z4[J?[A_P#_V@`(`0,``04`]B^_^"?;_"19Q3.=9#;$19,B
MIMPE8=0W7F654WUQ"5+CMORG=X?+4]Q4,02H_$AL:INN$^TCA%`@,B$U,[<J
MKP!LPI17A1@95A+PEBD$8Q-JAS"1P<XL$&559AM*<BDN#X`ZHQ5X5&@LR]NK
MWUH6DZC*[S-/#3D08!C3)GPD0X4*Q)X[H`-"`>-PC"$TH,L3ACC!F!%^)(2<
ML'`\WM)X"$F)86`U`"PW)<?7-AM-S!094EEN*;2@T'#K"`R$FEZ=.K;Z)S-P
M](A0\=C!&N$!B+C$BQ!:"+0W:VB@]^>X3@MS=-PP+:)Z*UI2@@6&"8++[,EG
M8XA8;/EZ<0C!FN[6IJ6VWTK2ZG36ZVEW8W76V6AA089BZ,N?"'MP"0XFSJ!1
MH49S.-!A:VWVWT[,8(Q%*P_$C\/,0PU"'A9F.SG`7B#H_P"7&>;\5D&J/`&R
M&)D:CA)F;"DJ.PC"H!:+,C<950FV1/!11QA4W2>B#$*6XU!G"DY:)4=X\G''
M9MP*=BPI26"5'<,(C,Q&#QV#&)#(8)CQ@>T%B+0@6H83A3=@P7E$8E".+L8H
M2>E=P\Q-<9W^%,#%64^RG54P\R`T%GPL.&"F1X%"7##S$0W&@T'9@&JFPK3@
MS,.L4.8EQ6I,H$%F`88F1@<X5`:VDGXT_#&F0U-C#$D`]<)&J\5^/$F\&`.2
M=F8D1<:YS$G`FF,&0%@',#39:!S!DV6`Q'^/EOX;(4@\N?,F2G/GS$!=G+Z$
MH'_ZYDR6"!%Q,`K?C+0F,PZ1Q=C'\JFRJX`&)\`:H8G"!"W*G2W*"QDV''@!
M$H0&),"S"96EA*$*:=H+"X1H;&ER?'P:0@!V>TB++``1/EP3/:GBZF>TD`8S
M'K#R7"89A"<+<]EY$$R@!I2$'@AA$$&";R;#<'+BP*68Q:9+Q@T$"Q`<(I.%
MPH;_`(R6?@,A8&R&-Z2*<G,`?$&#WI8ORUQX[,6/_@71S>*1=`,$875$*G_H
MY>?T41%QUPPX%'IQQY*KT:=H<Q]QXP?H\H^(:OE8;?JU*^6$F?UO[CQ@_1Y1
M\0U?*PV_5J5\L),_K?W'C!^CRCXAJ^5AM^K4KY829_6_N-]W(P!\]$@4`Q=)
M"5!#/^K3<&+HK4L"&4;"2^'->M?<>&;]L4*1&&4,*A#B9I+P4$IPTE'"T0=`
MI,0@JF9HO4T-MW^XC__:``@!`0`!!0#V+Q6UYWT[_P"`UK2G/%3GW_PAXI[`
MW-V3JF<2/UMJI:[J`""ABU>U\W44P%;NR4)@A7;V^HXJ-W!V+J1J%Z.V5I$#
M+..VYRUYV@0FZL>>NY3[O:)'NL$8J/VM)W!TU$\O-WC9M"NWAVO*AFY!LYNY
M94^8Q.;>G'3SO$>TQ=O#)%H]@*:=Z6QAO.11+!=:[:#5H6^:G<PES`1!:;#V
MS%#^VY*W4Y$2`FV^&`V:NJA]=C3CR\9J92[6S::UI'O+(5`:J-C0.)TT]84F
M9"(!\=9,ORN0":U(2O34;)7:PKGSU@08B%)!EG"I[3LACLZDM(80Z9':='=&
MFFEF3PQQFV(YQ24VJ*W1&LSF"9=`::,DI'%NL.6;PS4.=4^Q$D5P+4NXN$/L
MCUKNY)N3J2CK--`QA146Y6:TDVRA>Z)2T/:E#P-4?KXP=YK2IQ*5[Z<^[@Z0
MK)%CS]`@1@"8'0>YI66;M-*0B6*?[%%/DSSD+'HNNI;:DW::U>G?:5K2E#.:
M\/252!!88<&Z<IH78!W8F)B`*"]J'C:I]4AT+YSFX:HD;IV&P=XDZ;JTMHT[
M_LT^G')D0PK-"",])5,4]E7[GX<Q"P*W[YWDDVWN5$2,FZQ>SF&SB[%=AK;Q
M9=G8=M,"V36<TN?$]E#MK;MKU3*27,SY1/),:=+Z:,Y%HF1L(HRDL@Y:SWDP
M7[7YW*K5<R#U;`F]W"=.S!UI4LU$$AVMK1C8"1&>S;@II3P*DUL;F_>T^REX
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M)24'3):*2?DSA%ZBH2CXT,K`I%LQ8T4%&)8Z(:OU.1%6$<$?K_0:5;".>NQC
M(Z.K*B'J$ET40QU],A!`K[1[F<0T@VF2>EN`B9Q2$UEQ<D4Z)?K6A<61G8K5
MI$UAG`*M5D5@[DI_71&9)RRZM?NDEKR;:4"P=;4]$9RR!1ZUV26\9Y%0<8F3
M\?)"ZS&!D&[2D@`A#YHHJ0W9*':=?+3O%20$B8ZQW2T9T$[>IB)KR2+#:?8;
MA(R'D.&<4DLSC19!DYHVK9))I6M/M)\4UF,2Z83R*3G^FSRS=EDXVQ*1\L)(
MQU7T"YC.@\+T.UM,E(7PZC.93=S+UFYXS"FM69$_W-();/U-^0T3(B)N5<X8
MK39]DO\`NAK-&>TZU@XLL)4GLV8\;.FW<35HMYN;(D\EE5*I]H50LB2Z$WG'
M=*W8;(F4CPR)EO+'-**!LPG\7,CNK&R<D^YT.FO)8R'%[&82[%B-Z-=C*.3M
M/D[#6.4[I2C6CUKR?G3+8HV.S8FM%Q?TIW4]IV,_T1^C=#PFGZGVNVN1WF,B
M9`SMUYG:&T;PH3;)D+@9M?+N%VM9YX?KN/.Q\OUB2]*XR9DK(K8A/KV0=D$8
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MAZRB*F9'MP8C0YFM&^>S/"-B\1<$V.M7[*73<8RU?DVTZ*!\T_\`[R8&KGGF
MT2*R>3*AG['M,'-*]].W9S8I$E^I13/V%1/U_)\"-#&0'L+YZQ^QN#;M3B=<
MRN&<S#B'%KM.BA1"J>>D?DBHNLY#R(UJS<5.5B@:&_\`4[5?Y*$G6PXTK,YA
M,X4*1N7+33HE/9:,7B8QKM.K,.*Y4;M5>G1J3?.\6JI<(M&2Q%.XO&M8+7(W
M@-W=ANPF(@Z:NW],RW+-X![#:M*>E!C7(Q`Z4TG'J.RP9#9SU\GQD-I^WAC^
M/YV/(E[?-#V!1)!:MJK=B2KK/B*:&_1/8#/C4P?M5E/QNYOA'?OSMZTX?,50
M_"+7ST3WE\O?/&%'EIV-:=_"#4[K)3"KGY!=62W/8B:\`,09(C]=NK62RBV&
MPQ3LD8<QKUP%ZNEB*:AG$^Y["MO$W"BR]AV`;^/Q4R\,9",JH68:I6.7U\GQ
MD-I^WAC^/YV/(E[?-#V#_J)@6V3"+86&SB1<#!L`,-V`SXU,'[593\;N;X1W
M[\[>M.'S%4/PBU\]$]Y?+WSQA1Y:=IM;_;*].G^RKLT_;G]-?;2FD:67PK^E
M6^W27+2E*Q6]*O\`LF=AD^,AM/V\,?Q_.QY$O;YH>P;-:4KKF]-?2GR1>Q&?
M&I@_:K*?C=S?"._?G;UIP^8JA^$6OGHGO+Y>^>,*/+3M-KVRF,P)&Z)=DL:&
MIAMM8V11I1B?T+;(XV,A!2>>R>-+5.7Z>#91&>,^O'8'LOC*S+A^GNV21LBO
MKDZ^<4&#4$G!1@F(VAR3_+TQ'9+=/QUCPEN8MZ#@HSN;BSX,UW;[2=ED94^3
M:$=DT:67@Q3[:=?,(#AZF!H689GX#<J^5@4GY%6;N4Z)JQ*?4U*\[V8L^#-=
MU*UI3DX!H.KB*`S+JQ'_`*H65?)/&9;5OEV9EMSX0K%A;&V[Z5[3U!>I,%L[
MB9Z9?3P8P`C=OGU,%.TJ(WICM,YU!-C=W.JM.;3(B>E\TL*B$+9[KM7*6VDP
M^]+YI46D+4%UY0QT1TIV5?6!&\E>2*3.K+=,"8LAUI[TP<@CW5KNGQH<EU\;
MPD.X40HWA(N,MV^_74T5;/XB^F*TZ'$#X^T^RG7EG&].RI91Z(';SW%??'K#
MW6CXX$NM3>OB?VFJG<^&:D@@-O-23W1(CL'C$R_4NM\5-C\4)2%KH"8-[*0K
M/A87;2`2R((-[*`2:,X4[.J+36I&B0>6M*>&G9KE:I=M45D]1]I4QUO]21I5
MLY?ZE+2Q9R[U+.EVWEWJ7M,EO+O4R::K>7^IKTXVTN]3AIXIR[U.NH"G+O4]
MZB+:W>J`U(4Y=ZH74O3EWJB]3U.5]4?JEIR[U2FJRG+O5,ZMZ<N]4UK%Y=ZI
MK6I3GU2VN*O/JDM>%>?5':_;N?5%0+NY]4+!J[GU0$*:\^I[AS7GU.T2*\^I
MRBM=SZFR,MW*>IGCG=ROJ8F"KSZEUEKN?4K-7?SZDU`W<M]2&E<G/J."B[GU
M&6"_GU%0N[GU$1[=SZAI7W<^H2<&[GU!+J7\^H!>:_E-^[\7\^?A(F[E=],F
M;N?/CE9=RF]F863GSSYLW<IO$G7DY\[N?=>?.VV$7<^==L6NY7=1LFNI\Z#9
MK=SYS.T6[GSD=JMW/G%;9+N?.#VXW5^;WM_NY7;IN-NY=MLW0W\^:_NTR<^:
MAO(OY3:%O:R\^9EOFR<KLEWZ9.:_I&[`'^KV,JI;,]&0OBRX\+99%%C)LSCY
M8T33X^6M@VEG+V\;C!C`[/((CE`_BQ8F-+)1DE6TTHCNU&H^G*))*V\HF$U;
MRB>(+>4(R6WG])*;:/?LHCRR*^12Y;AQ$`C-ML4%LH:8L5.>&WH[O8"#:M'L
MP==;K9(-JD(D3D8F;%.L9&`4I+VOV:LFXKW.Z[C;,,V<=I=@)&*#L*UI;0NV
MH-J'>5<K=*-LCH;3I:.;^+HK7NY3)CK;>+#8KQ`H*%LNRX[+?QH3OI7OIUIP
M*,/''9AK8+39S9Q=+ED9FIVX3BW!K+2))1TXIOXT\/'!4@2>]/NZEWW-(_2#
M@FK]:R<#1IA&:-%D6S.>Q9\N,/A+9N1XV.2]ME*QIF;:B9#-&>R\ZR@/2U+D
M+!3596?TVMMY\,EE!*&SK*15S[[`P%6@03ZY2=YY?XI,-J,,=1[P)O/*/HNI
MWT>5//*WDKGA0.85)25JA309P(\MHY4D8ORZ13(Q-EWBNK?BZW=2O*4[J=3P
M4YX:<\-.OX:<\%.>&GLE;*5YX+>>&E.4^SK5MI7GAI7GAIREM*5["M._GAIS
MPTYX:=0-'!L<$D?#3NI;2G/!3G@M]T/_V@`(`0("!C\`^]_A)[+RY:7G(3JT
MDAF*"BM1D(W2)4;2#E6@QS'(\?!!%=V[(/=8EI4>SN0[B#F&KGG37`X&/EHF
MNDMVDE8*2L;#Z%:]XU(%1D*YXGY;C^8ANO!E$<BHK"C'HK-3?J`"!0URQ:<=
MR/.Q0<S.H*0['<BHJH=A15)'I/JQS,_)7PM[2RE\-RJ-*Q:M.ZJ_1%:DDC+U
M8YV]MN35["R4$/L8>(6T`4YJ>VN.(Y3WA=]Y<^$D>TU^D-]:Z;A3Y<+Q4'+Q
M3\T\JJL**P.UOINQ[J`:D5)VT/7'*30<PDEU9+65?"D5/2$D8!6(ST&=,9Z_
M=-C9#6:9$_\`,P'X\7DEIY/X]N(B50)&9=YJ`"=H</4,::5.N.)O[:^B/'7$
M;222$%5@">T'S-:&H`&9(.77%_RZ<Q''QD%QX8=T8;Q0$N!F<ZC:M-QZTQQ%
MIQETEU#>Q&2.2A0;5IN+!N\H`8',5-0*5RQRDW$\]%=7-DI:9`CH`JUW;'84
M>A#`4R--<QBSO>6YA;>2XCWQJ(I)`12H#.O=4FHR/;CAN4DG!>]9@D84[@`:
M`DZ&M00!VTUQ+P,?((98[?Q7?:0%.5$-3Z0=VE#IEB5;'F89>/@BWSSA7$<9
MJ1L`V[G;*HH*&NHQPLO'\@DT%]+X:%D>)@W:5?/;3.O7IKAH(^8\:_1]KQ^"
M\=-:LK-DR@BE<JU!`I]W"N+'WJWY!3;VXB0(T0'=!H2#N)SI\@Q;Q\79.UW)
M*IN7D`J8P:^''WLA4UW&E3\@'G#S2L$JV$SB()4"3\[0R!<S])@1V8M>(\OV
MLXM%N5GE:;;OD9"I5:+D%R`TT'KPWF:+C[IN;V#:CL@A60+M#94<@4K0D5.8
MP>5N9N0^UI'D>5$:,03,Y8Y@BH`W:$DY9''F"PY>QF6&\NO&I`4!`R(0;@0`
M".@ZF@&/+4HX^1.)L$/YM2/;^C3/,*:&IH:UR%<2^8KFW:5'=ZKEN`;)2,Z5
M44ZXD2SON5ED9@:3NOAJ.HH*ECH`2<@.OW59<E>1.\4)9J+2N[:0NI&A-?DQ
M<7<2<@MW+-N8L8BH!:KT49UI7;4TK2N6+K@QQ\B^6O=3&BC;XP?4R,:T)8DD
MBOX2,>6^'YN.X*S*UP3"4J"S54-NJ*%&IV@KEB*Z:R9>(CM#;)&"-R1DJ20=
M-QV`>KKEB^XSR_:W!%W032S,N[PP:E%"44$U(J:U!-1CD>(XT7LRW";56X:-
MDA]*4&ZH&F@J`:`UKY;DN^/N'O./1%"@H(B5"@N1FS'NU"U45R(.N/-]P(9!
M?<A18V%.X@)!!-:@[>SJ!CD>*O#<QB=PPE@8+(I%,LR*@T_G/;B.XN+KE7M%
M3)VD0S"3Z+*2-H4:4&>6HQQD%W)(.'X]&>:69T$\JF@"*$H6)(``%:Y'*A)N
M7L(V2Q,C>&&-2$KW:GMIK\='=O;.+5Z[7((5B-0"<B<27J6[FT0T9Z':#V%M
M`3V5Q7^63D5M7]Q5PIDIW0QT%?Y0`,\)9V=L\EVU:(HJ<A4_,`3AXI%I(I((
M[",B#Z1\5;W%Q:ND$P)1F!`<"E2I.H%1IV_`CEGMW2)_9+*5!IK0D"OR?'"9
M.*N6A(J&$;D$=H(%*896!#`T/K_URS^`6"G:.OQ2HBU=B`!VDY`?*<&WO;9X
MIP`2K@J:',&A[1I_+X5K;O))V*I8_,`3CPKNW>*7L<%3\Q`/P8/?+5XS(@=:
MBA*G0CT'#-:64LJCJB,WX!3+#Q2(5D4T((H0>RAS^<?&1<?:(7NX>0"*/0VW
M,_T1XAKZO1B3@@Q;RWQ$)DN-AH9[BC#74"H;0ZY#0$3\S;<![K=RSK!"/$D*
MDEAWP#J:;E.17*HSPWE\\&;N]6,;YFED1M[KW2JJ=H45!SUT.+3B;WA??.1:
M$/+(99$H3T15-!0]3TUQY(XI5=9+^9I91O<J$!!_JZ[0=A'>`![NN>/-EC#P
M[K;V4,CF8R/W76M$1:[=H*D58EF()ZXX-^1X=K[E>1[RIO=`B$+0#;F7.[6A
M'J`SBX^UL!X-M:"1F9V.R1>_O.>9(*@*>Z":T[?,GF0<>88;:T=R5FE!>1BU
M'W*5*[D&W8#0USU..%N.1XHW_*\@"X5G=%530J%"&K,=XS/6N+V%X2.'M[$S
MRH68^&QR"%J@]K`$Z#LQ<<Q9<4UM.ET(HV,C.T@R+%JG;6A.0&5-<O@6]OS5
MR(K`AJDG:"0#M!;Z(8T%<67#GBEL;?8\K2),TJRP@@`H7/=SR)-/:SK08O3`
ML$?(JP$'@W+W#2=X"L@]A,LZ:C\-KQ0XR2;FYK5`3XCA8Y'J`VVIJV[Z/LT4
M9=XX7B9[N0<7QEFADW2L069=U$+L5B5J"M*!1TJ!B(PF"#DC,H"P3O<@1%@&
M>0FH!`J:+J0!UQ[QQ'$I-Q[;56[2X=R'KW@Z>P"PT'2M,CEB">UC1K@-10ZA
MAN8%5.ULJ@FJU!&X`],<?QSR[C;6R[O_`'&S8T]("Y4ZD:?&VUC$#XDTBH/6
MQ`_'BVL+?F+A9[6+8(%!$!**?;92=*CZ&10"NF.6\U\]:"XGDOI(TA5BL>X,
M=S%EH2M0P'J';EY6>SM39->([RQ;F;;&E#N7>=PJ#E7(UJ-,>8;:UX0V\%G`
M[)/XLCL2E:%@3L[Y!(%-!IB*^L^/@O\`D$1FN(WF>.5`,_S:J0*#,[CD0,B<
M6/B\,K"]E.Y#*_?*#^MKJ*%5HH.VA^'R"\AX<E^JKX$+R^"LA)->^#6HH**-
M:^C+G+_D>/\`<K"SVJ8&FHIE*U"F9CW5;)JYFC`#'EVQXWPEY":>DZ02O-&L
M8J2=[?2H![.6NF(/+W%\;*LD=X=TQF>H6(,SH@!R`*T#D[Z@&HKCGO,/(R>)
M:K=-#"DUR4#;:49YG8N0![*BNA'05X:VCO$A@96-QX<CO$&`&Q5E<5&\U!;3
MU98MX8.#6V5RS)(D[S)+&:;-N[0C4Z',94H<74?"WK6EH=OCS5"(JK6FZ0T(
M]JNT$5I4Y"HLK:RD,L-JA0S'61C3<P_HG:3V$EB,CBVY_FK-KJ6YF*0Q!V0;
M16K%ES)R.6?2@[/+W$06;QQ20M/.K2,6"FI"$URVTVU%*]<\>9KFSL98S9?U
M<S2L=[DMM&SV=M:+GN)%"<\<#PU_Q4MWR]VJM(0[H(@Y%-JK4':*UW"E`U3I
M2[A0`0VR)"H&@V"K4IV,2*#L&.,LO[S7$<JNQ%LBE8WH2:,X.UJ]=XI3NUTQ
MRTEY"L=P)2I534#;W1WJ"M0*UI4UJ?C+BWXV<)'*034`D&E*J2#0TQ<2V<BG
MQEHZNH=7&?M`ZD5-#Z3VX@M+JY'@1R^(H557:V=*;0`%6O=6E!AH;EHMS`!G
M$:"1@*9%P*TRZ$8-I=-"28]AD\)/$9.PO0G0=*'''\AXL?O%K#X47<%%2A72
ME":$YG'*6L<J^'>&LIVC<<R<CT!)-?7BTLXKB.D`I&[(K.JY=T,14"@`RSIE
M7%YS:3(;Z=2K[E!4J=N6W(`=U?FH2<Z\M:H\:Q7NWQ`J*M=M***"BC(:>G%O
M:!H7$(I&SQ([QZ>PQ!(I04RQRJ^\[GO129F`+$9Y`]!F10#33%MP[R#W")RZ
MJ`*[C7,M2I]HZZ=IH/@3A;2WF22E5FC$@RTIH1_K7$?*K<H)DB\)5"`1B+7P
MP@--M<0TL;2$)('I%"J58?E$&I'HK3"\[=;#>!T8#;1:QTH-M=,@=<S7%_R8
M>-I+I:2HRAHW6E`"M=`,AGBSNEXZSC\$L0BPH$.X4.]?I9:`G+I3"V!CA@L`
MV[PX8Q&A;3<0"23\N))(+6WD9J&LD8<J0:C;73/.N(Y+Z.`3!JEDC"LV5.\U
M22!T'3XVWOK5@+F)@RD@$`C0T((_FQ(RW$<<KBA>.*-'(.HWA-WR@U].)+&/
MPI;-F+;)8UD4,?I`,-?EIUU)Q'S#7I]_044T6BK2FP+[.VG3$EFQBBM9#5UB
M18]YUJ^T5;/H33$MK$L$(D38[1Q(CNFE&8`'UXBX65HVLT%%)12ZK4':K$5`
MR&>M,JT^''#!96CNC%E=X5:12>Q\CE3+'(22O'<+=-NE65`ZN1H2N0J.E,AE
MED*6W+6]K;1SQ*554B"H`003M4BK4.18DC$O*6S(;QPX)85SD]IAF,\2\?X<
M%Q8O)O*31AUW&E6%2,\AV_SG$]X;"S<2(%,;0)X8`I3:H(H109UJ>M<127A4
M)&FU$10J(O8JC0?[ATQ'Q4,%LUFH.31!MU3NJU31B#U(_%CWF:&)&V@4C0(M
M!Z!UKUZX3C(O!:WC8M&7C5VC)ZINR!S.H)%30XN>8+1>_20>"3LR"99J*U#5
M%=Q)S)RSQ/PD946<LHD8T[Q8:9UTR&6+-A[N9H5"B0Q`R,H^BSUKM[=M"<ZG
M,XGO)V!N)'+L:9;F-3EV5Z=F"UM:645WMIXJP()#VU.8SZ]W$DTKEI78DDYD
MDZD_Z!CCH;MF#W4_A1T4GO"-Y34]!LC<_)AN0+R^[BQ][]@U\+?LK2N3;OHU
MQ):U?Q%NX[<]TT\26,2IG7V=FK=#E3!F627P_=KJ?V,]EG((ICKJ'("CZ0SP
MUH[2>,L]K">[D'NQ6+.OLD9L?H]<2S6I)1)I8C44.Z)VC?+LW*:'0C[R/(OZ
M5;ZE>8G_`%5/UHXN_P!8K+ZDF)/T'Y@^NIBX_3'`_P#2N.1_25[];E^\CR+^
ME6^I7F)_U5/UHXN_UBLOJ28D_0?F#ZZF+C],<#_TKCD?TE>_6Y?O(\B_I5OJ
M5YB?]53]:.+O]8K+ZDF)/T'Y@^NIBX_3'`_]*XY'])7OUN7[R/(Q#BGVJ_7L
MLKROS=<3KO&[^ZQ&O7WIA3UXNSXBT_O%9=1_\)<2=\?_`(?/]>V]2GSXN")%
MI]L<#U'15KCD07%?M.]&O7WJ4T]=,_5BHT^\?BYO*=HD\4UZ\H#*&%O(\$J3
M@UR$%RI#,#D)4'60#!C_`+O)X'V44($4?BB+QS)L]DGWC?5\JMX)_+Q(4X>#
M?]IVTE6CC*F1(B$<=T4@532;*A<Y9[\;$\O($%C>K1HH]P1I?SBZ4\9F-;<+
MF4ILJH.)">%A#^]\>25C0+NC2D)'=H4C!I=:KOSS6HP;WS;;+'-;7=R\2#;W
M[B61O&NGVBC=W;';TTC+M0[E(I_G$?_:``@!`P(&/P#[BR_R)I_DGE8KKFKB
MVM(B$18E+59<FK16^EN&@T&.,L[V622WF5CX\A%1UH10'3T"G7!Y66P=8&E"
M1@D!G!^G2F0R)H<Z8BL+OCI(!*A9&8J:@=2`3M^4XN;RSXF27C(FHTNY5T-"
M54YL!VXXZ"RM3-<W4>]066,!:5S9J"OHQQ%K/8E;RZ8C9N!V4U)(U^3'(V)@
M;9;0^(SU%-*[::UI@W\W'21<:L;,TA*TW`^RHK5JZ`Z$U'3''Q3<:T<%RU$.
M]&;T%HUS49C4_=5U=-I'&S?,I/XLO3BVCN?,EXO)2,3L4-MH,Z;MA&8%=?1K
MCD;.>U?WV%PJ(""9=WLD9"E:@DZ4.+7CCQDCWTL'B;593M/1230=#5M`,^N.
M0N;V!H'MI`CK7<:M4*%ID22#Z*9],6$7(\0]O#<L%C8NK5)I0%1F*U&NE:XN
M;7CN-,T<+[';Q$0UZT5LR!VXY*P6$A;4+N>HH214BGHS!/HKB/EGLG$;S>&J
MU%6'Y6GKR[1B,WG'21WDK[8HJJ6<4!W$UVHN>=34=F.26]M6BEM8][!660$=
M@9<MWHZ861^,,=HRU5_$1J^@JI)!]'SY_=QIK0_@_P!N+KP;BR*S2EV+B0G,
MU(&:@:GH<SB9[^Z46Z(1"B5H&/TG[=--/YZ^6N!>5#>1*7+9E/S8.RO7,*0<
MOPXNN0YFXC-RT#1((JA45@14;LZ]XGUX^Q)+R`<;NJ64,)&7=NI^2#7+(8^S
MH4L_L]558V8-XL:J`,B.N5?6=,<1><==QM);0^'^=!-30@MEJ2#_`##'.1^^
MH]]>/[9!H$ZUH,B1D!V8BX>WD".BK0T)4E<S4:T)[?3A6N+6QCB"4K$C;V-*
M5+'(>G+/Y/NJYLK5T662@JU:;=P+:5U`I\N(+:22R-M'%M7:'W$A:+4G*E:;
MLM*TQ#ROOJ-S8GWL37P]NFQ12M`,ACFN2XMH@T5(1XJM2@&96A!J&6NN==,2
M6RW2GD7N!,SD&A85R([,R?62<6M]S$\-+<$QQQAMN^F3,3F:4!RH:@9TRQ9\
MA?>ZQF)@S-"'5Y/0U213Y*]I..=2VO85M[QV8FAW][=1:Y`9-2N9`TQY;B:5
M/=;*K2+GWW-#ET(J.O:<67(6O@.\2E2DH)0@G7+/_>!AX8H+%9V;V`C",I3,
M-G4DXOI;55/)W9"1I$&:*,C5CNR`%:FN>5!V8MUNG#7(0;B!0%J9D#U_'26R
M3H9U%66HW#UCIA+9IE%PPJ%)[Q';3X`LS.OO14MLKWJ#K3^4DZ8:YN9U2`4[
MQ.69H,\+)&P*$5!'9\5-##.CRQD!@#4K72O96A^;X$B13*S+K0@TKVT^.,37
M\(D!H074&OJK7`(.7P`I(W'XIG8@*!4D]`-3@36LZR15(JI!%1J,NH_EWSRJ
MB=K$`?.2,>);SI(G:I!_!\&;W6=9/#?:U#6C#4'TC%+FZBC/])@/PFN`R,"A
MT(S!';ZOB\\27=R^VWDM"Q/_``Y4'I.S+$?+D`<SR,FR'<*B*&HSI\H&E:'/
M4@Q<9/R_CVT<32RG8@(`![A*Y``@'H:$5UP.7/*BWM3)W8A&K#:IH0S'.N1T
M.+GD+;E/=K(2%8TV(U0O5B<S7LKD=,>:.18J5M(1'&=B;M_>![U-Q&X'NDD"
MHQP5W)R@:6YD1?"$:YHV>]C2M:4K04`(QRB6G("SL;/)FVJQ9ANJ3NR"]TY5
M!^?)[V>]_.3W!10$&<9%-O;T8UURICA>%][$LD]PB]Z-"$0`5&T@AJ,V[<<^
MO3'*P6=_[G869V;@JLS,`:D[A15&TBGJQ!(DG_V,MUX2.%'?7\H"E,\A7I7$
M/&W7(B:)[<R.H15":@!:"M*@4)-2#GK\">;BX#)=BE`!N(%<SM^E0=!BYY$7
M[7<^]8U1HPC)(0:AE7,]M,].F+42/,]F1^=,D`A5<OH$]X]@KD3B?D#?+'Q<
M<[$#8I9T6AVUI0"GTM:DCZ(P+^*V0\A?W+*FV,5HO4A%!<BN5=37/7#F199;
M'PF),L2PGQ`I*J@]HJ6H,^E<>!R'(M'>`LS6[1*M4ID4;VJ`G,]:8FBG9A`<
MSM)4D#,BJD&A&1]&+N^2.@GF;;D?86M,S_2)^;XVXNG]F-&8_P#*"?Q8N;VX
MXR`Q3REC*Q'BJ&89*"*Z@_2ZZ9G''>7N)N##$EHCM(5#.%V@A0IJ`Q!4DGM(
MZ8Y^.YN/>EMF18Y***L]<FVBAH===/3CAI[CE?%FN9E5H=BA=K:[:#=W=">W
M#VMW>2VED[*L++&C(YZ[F.=3ED-*YXN=G)LONL8HVQ>[O-?#H<M":G6HQF<_
MA61LRZVC,?%D2,2,@`%.Z<J&IJ<Z4Z95XJULKLW-U<ECXHBJ5C!U$2ZL!W:9
M"H)..9NKXR-:11UB:6-8G+G*A1?HU(I45Q-S-_?QF-[<!8_#6E9"H5V)&>1J
M5`VT-*''$\+9(4G:`2RM%"&*AJFBQJH4$95)'4'MQR=P]LSRAAX.]`KE<]Q9
M%KF!0@4_'B>63E6GVT4HT2QO&XUKM[=0#IZZX@;D[9;BX4GPHZ;F9B*&BZ4Z
M%F%*^G%S<7("27#;A&*TC4:#UT/7,"@Z8GX?B[I;>."/=)(5#FII0`-D!0YX
MYKD9KE7=)A%"0J@$@T+=:[JUH=*''!07-ZCFY]N((**H"U.[VB3F2<LZ@98Y
M;D[3D$M^-MV944JK>(5!U8Z5-*4.IQ;RR'\[,6D8G4EC0$^M0#ZSB^N!PD+J
MR@&=B"ZURJJ$5%,@*$9U--<<=';2,\!C!!.1-<]*GXR">^B+/&*"A(%-:$`B
MH_WX@CNHS2,U4J2I7U$'3T>@=F)KB"$^(Z;&JQ-16IK6IJ>IJ:X66!9*`DA6
M<E`3U"Z?/7`G@60*'W!-[%`W;M_VU&+RT\-O"N)?$?O&I:H.O09:8X^=T.ZU
M'YOO9#*F8IGEBXN)(7!F/?4.P5CGWBH-"<R<P17IB#BS$PM8B"M&(92`0#7_
M`)C\_JQ83L':2V!\,EF.9U)KJ3VD]E`*8N+EA*AE-759&57/])1VUQQQ$!5+
M4UC4&B@]I'4^G$_)JA][D0*22=!3(#IH/F])^!$6N9HG2M#&Y776M-?E&6&X
M]HF,3/O+;CO+_E;M:X<^]7$A9"M7D+4![!D`<LC2HPW%0%A;%6!S[U'J3G37
M/LRQ9V6UPEN:QLK$.IZD,.WKEBXA-W<L9*59I6+BF8VME3YL->;Y9+PKMWR.
M78+K0$TRR[,(DT\R**Y(Y2M10UIKEAUM7E*$>RSEE&=<ET!)U/QLUI<*3#(M
M&`-,CZ1B,>%(Z(00K2.R@CKMW4_FPETWB1W(7;NC<H2HT4TZ?^&@P_&+;#W1
MM02:D_E%M:]F([D+)),GLM([.5_X=Q-#Z<)/+XLA1]RJ[LRJW:%+$8;E(PZW
M+&I`8A2:$5*UH30G+3K2N?PWEENKA590K*LA",HZ%?3U[<62HKPM;BD;1L59
M0=<_3\_SXFX^::>2&1@Q+.6<D$$9G09:#$?'S*WNRE<E-/8I0'(Y9:98BO-\
ML5TBA0T;E3M%<C0:9_BZ#$-NMW<@HQ8,)6WDGM;.H]&@Z8D6W#;W;<[,=S,>
MTG#W\TDPN3U5R*>J@R^0X,,<DCBI-78L<_2<\/?2&597%&".55Q_2`S/3J-,
M0\;1_=DF\7(T);/7+3.E,O7B#E&W&YC0H,\J'T4])Q<*3,(I6+%`YV!CF2%&
M7JK6F(K6):0H@4#T`4U[?3C;/<73V^ZOAM*Q3YO]?7A(HE"QJ``!H`,@/]`Q
MYVY+@(H6M?+_`!BW]WOD"$6[7MI8`Q@@[W]XO8`5%.Z6:O=(Q#Y/BM+$\T_F
M<<"![PH7[0-L+K:7I01>"?ZW3=E3KBUY\P6OV?-Y?O.97\\-QLK"\:QN&I3*
M03J0D>K+WJ@987CI;2P]Y/-<%Q65RM/>_,5F]]QJUI[#6\;&9](FHIJ3BWYZ
MWMK/[/EXCG>24F=0WNWEUBG)$K3VU8'P4_\`5Z$8X_B^>CC6[N>-LKY-CAQX
M%_:Q7=N21HQAF3>OT6)4YC[R/\5OZ@0_M3Y;QQ7\?4_L,8\O_P`&/-'[3RXM
M_P"*G[HOV9NL<+_#;][?UB;'DS]1?*_]@\?]Y'^*W]0(?VI\MXXK^/J?V&,>
M7_X,>:/VGEQ;_P`5/W1?LS=8X7^&W[V_K$V/)GZB^5_[!X_[R/\`%;^H$/[4
M^6\<5_'U/[#&/+_\&/-'[3RXM_XJ?NB_9FZQPO\`#;][?UB;'DS]1?*_]@\?
M]X^>/\5@,+U/D&W&AU?S1Y<*#35@"5'T@"17'%-[K)M_[]H:[6T^PP:Z:4SK
MI3'E]?=)=W_9GS0*;6U_O-*>SL(/JQ!6UDR_>G^Z,^RVB^6KH,=-%.3=AR..
M%!M)0?\`MO\`O:'LMJ;B6@TU-10=<>372)BH\A^5VJ`2-HX+CP6_X0<JZ5RU
M^\CS_P`7_B#\PS\5?<;Y8M;)Y(9'BDYFSM.6L+CBG78P=^5X.1&AMC'623C[
M@E@8[*1A[W_WAG^V&\_I<B1K^[%A[^.'2S6XKXX3[$%L!;EI/S/VB&)_,4.+
M)9?WF\NMK_<?FK14CO+\7(L+GD8VN;9P]PS_`&Q<31B3CJMN]V1C)^:$%&EN
M?WT7)N3YJ\L3EH>0NO!-U'8#W.4;I33C(8E"\R6[L=R&6Z(F,>+.&/\`>KR#
M6Z\!YP54FO;LW'@7UVTO)Q-68'WR[==WE]21+[MMV4DVX3RE_AVYB2[XGG>`
MX6WO;@[F2SX?C[.`\=P-JTCR2QGQMUYS`9M\EVEM"S`PS*_^<1__V@`(`0$!
M!C\`^XNG4.H=NG4.O\?\W_(7>/3X.W7K[?\`DGF[1=E]1/E%Q`P?$K#7<LR.
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MK5?:9AL!#Y^^BG4J@-KNEV<N8E&V+C'.FR46T!R=5PV,4J@^8@"W`[%=%XWS
MU;WGFI:[17Y',PT:J31<:C*6O'DL%FF+77&LS!VV/]RDB.VA&9D!7;D5\1DU
M$Q3'EEQI/G4F:`X>\<%=_P!,UKZQ-2QAW)(F"L"=#95P8H7)9)>#F%%@=&="
M3QM#D\KO*/9[RBO/%70<0XB5C-;O;[IR#M=QKTI#A<ZE.#%-<YSZJ-6#&UZ"
M]G`4201?)-FC893SV9`/[OYJG%^JWGB3:<_R[F39$:_A5T)L>6W71U&TD$::
MOV+0L4J+Z1L-&A)1&7;K*F6>*F:HG,;YT2^$?NG;MJ?&2!MDV3:'HQRK=Z:Y
MZ94I:P(M1)[53NUX\J12!WG,<`#O'ME%8U?U=>?58Y5ZA)VUXYR+/H"W,*-'
M1T2]G)./;-[U*8U)T9N#FI10.SJA,`V(=4$2=%`!,>6.(:'C%S8;_P`?-+J.
M8Y!C<-/(66W<HW6A+.PH,Q21:P3<()K+Q1&LD^]X(Y]Q:/$P\2S@Q$%,,XG/
M>(.@:!R1V;`PV)QEV8WZK3SFEV&1?6*.@J!+6.:85JL&;IK5ERK,3BSMFPBV
MI!5(5T`I`MROU7D9G-KXYV[AGIK;)=ARU218:3,.+M,RL_7ZO7:5,5]&/C++
M-S=CJLDQ,F44VS4[,SA1P#,?>`XQ4KD]P6T_C;G/,JV1M)X_Z-+Z9GMXEG]@
ML#F':UAI?<]KBI)ZB&E5;%'@N1T<5V7O0"9-0J:IB;#AG%7B1,[K7^/&BL,S
MV*Z2.X95E=@9S8RCB,L,C2LVN3TE@M=>K@L5S&=F4:%<F2$B90$2^+F)QFB:
M'(1M?X;0-2?7;7W5@9JP\U.V.%),OJ^RKQ8])RP&`(W>I++J.S@91B<?`4IR
M"-4YPSG'ZV,*]H/(];!Z!0D;<U?SUGB6PNCN-":O&U:[FY48MZ!(XC95919`
MI"J]%/$6M2>W<2=,S7<-JU13/>+G&I]=\_?:/KD(LPAW<=H%LE"23>I9)7D5
MY<K>3"0>.5(Y<HEZ*]#B7F'7^0N%3^.W'A?F+'6]#9T#0:7O]4G:Q*,XYS'0
M]=O-'69U_P"NKIQ+MFX,%U$TDU#*><X1]W<`E%WF>XFCD>$W6A*7G.=:;;[E
MNH!+G4D8A"-J=GI]253L52LTC$R:KP4U2*IM19+-US)K^`IONT/"`"/0?;_(
M'M^#V]MH-F^A^GI9B[[M<_M.AV'2:YR!L-L<S=C<@=XW8.8)Y4H]-BV(=51%
M$Z)S`NNH8RH@;NTF4Y0Z_487(J3GUAKW$++,O>6QO&P>ES;=4GYX]E4E(]$9
M6;1%%)(K%F9PV3:CY11^2L+ST@?3(EK?E,]O&/0LUN=@T(T-:)_(%"X/%S<?
MCS^ZM5V4/+OR/JU3U8^2#RDU5WCL3DZ^=T'5^67J`ZGE<KK%EXZVSC+D-/XY
MQEIC\_R*G7:$L$+8[5'KWP[R=>6MT6RO54?,65*FJ]6$RAB^0DWA?3:MFZ\7
M*YPV:S[I.XZ'G57T8>0]USV0O"MXDJJFC.B>B0SR4?+F(HN")CII%(F918A5
M`69<5:!5^"J/&:B4[.L]X]Z9H=<U9QR>P2J4VN5&)D#Q-@@5RPDQ//I"NK+%
M43,T;N$W`$=)'#KVX&[WQ:V7';#8.'_'%/C^O_6A97N=;R\B>)G(.1TL&U,,
MB_DYB3C9XW5([YL*2S-#Q'6()P[>I?5'N]9S>>3G/*],"I[+8RV2.CT,N^EF
M?UB8SK2-KRB]?E9VO2$LV1CHY)S'1Q#M4$U#)H`/:K<`,\NL5G\I1:KF#6`L
M+EJ[5K$G9<\*V>/"SK=DA[^6&L\R#A=51)(ZJ"RI5?+.)!3-%SFMXAZ:&95J
M%JCJ,7FN+&07&*UJTV/R&S-B[7M%D,PC:Y!"F59=T@W17575,4@"F0!'[JVK
MCGC=HJ=,NVKQ<!726*ZGF$X)G`)VR"E;2V5-!1\I(`O+5^.<,T^B!R=7'RN@
M=_:@9#<Y7T^I7',ER):CTZ,HU>WN*O<M,UNHFAZ`,[9YF5>0K./<SJ""\TY1
MBU%%$/.*@@0YR"3+.<SKD'2;3ZC\-R:C]AT.S6!S;FV`+Y6S1<QS;&*9`,X-
MU86,-$0C5HR;J'315,T7=(^8`E05#U".87#B1X_PSS%'M4X>P+#DE7;[)UF8
MA8N%3;7&6J$E2GC"092,-<*2#\`,(H.4)@"*$#PB4UFQYON%=F.7%_Y40_,C
M3-=L,*^3H-[U&,0M3(M4D8UDT-,HTINSN;Y=(WDF5&35.N*1"*"B3%>2G/;2
M^/95.*B$G8^.N+<=X*\H9Z&O.$FJL=HNE2=X77LDDA'R\6R=$CV+E(`,Q1`A
MDP\\KGCSROY$J\.,@FL)MCFX6Z[<0X'4:WI7(EZ08Y1C%Z*-H7+"DACK18%<
MF.+EV9N[<H@<2*%\OU*8'(^1''FIY3SYO.B7R5M\O!WUUN#-G93W)W7\X;R;
M9L%9J]<,2UFBY5VFWDG(1OC.Q!!8Q0+Z2.=N;EG:V*<`R2ERV&MC]/'?:;K3
MQI%2#.9K[,\$,:[B6EK9N5`%^=JL#9\L'@$3``<=N5V.FXZWN8Q2FV6@3F&\
MK:Y8K'D%PAK">=.68,WK:*[PDW'*SYSI^,"E*NV;+`8?),DK8:52,U],ZH:G
M9=`$9S,JID.B0''*>Q1S70C9>HV5)J]&S3]XF)1990[]=#Z.!F<$!;&Z&,;D
MA>\B@Z6_Y8<[[A2J)Q]X]\8J/>9?B]A4K$.W3JQZ%:%;YY\;`0\7$22KI5V_
M]V8MUCBDDDJ@H*;?,HW;K!"VO8F5&K+?4;'6X]**KTQ?21+4+4]@X]%NT2:Q
M"LSYWNY022ZI`4?`01\(?;;'E<'HU)F-,I[-K(6O/XRT0SVY5MB]3069O)RN
M-WBDM&-G*+M(Y#K)$*8JI!#\8.L%D4EH=+8:I9XMW-UW.'=FAV]WG(9BB]</
M9:*JZKLLR^CFJ$:Y.HLFB9,I6Z@B/0AN@#\?\,)QVD-/IK7<['6G-PA,K5FV
M@761K#0KTZ\TA"%.9S[D1.-<'`Q@*)B(*&`!*41#^!9RY62;MVZ9UEUUE")(
MHI)E$QU%55!*1-,A0ZB(B``':4UO5M#J="S*%(Q/*7BQS+-A7&@2CYO&1H#(
MG4%%51_(NTD$2$$QE%%`*4!'M!VNKRK*=K5EAXR?K\W&KD=1TQ"S+-*0BY-@
MY3$2.&;YBX353.'<8AP$/;]JT//:!I=)N5XR9^QB]-JE:L<7,3M#DI(S\C%C
M:HUBY6<PKMRI%N2%37*0WC0.7IU*8`_@$QA`"E#J(B(```'M$1'N``[62M4;
M1Z)<K#356J%N@ZK;H"PR]66>BL#1*Q1T3(.W<*JY%NH"97)$Q.)#=`'PCT^V
M"(^P.TC3YCE+Q\BK7$2[NORM<D]@H#"9C)R/=*,7T._8.IY)RSDF;U(R*J"A
M2J$5*)#`!@$.R#QFNBZ:.D4G#5TV537;N6ZZ9545VZZ1CI+(K)G`Q3%$2F*(
M"`_8-HQ9\S2D7A%%&;!1T@F\=)HE$ZRC9J<X+KD2*41,)2B!0#J/VI]+2CQK
M'1D8S<R$C(/5TFK)@P9HG<.WCQTN8B+9JU;IF.HH<P$(0HB(@`#V1O\`C>A5
M'3J2YD)"*;VJD3K"Q02TE%+>[R3).2C5EVQG+)?Y*A/%U*(AU]H?PFLNG7VF
M9W72*>2:>O%GA:K$`OX1,"`2,Z]8M!7$H=0(!_$(>P.QK+E.ATC2JZ1P+0\[
M0[5!VV)3=E*!SM57\"^?MD7)"F`13,8#@`^S[`1'V!VO'YH-$K6AES6Z2F=W
MI2LO??T:U=X42!*UN07*F5$)%CYA?,*0QRAU#O[,V>N[3E.7O9$@*Q[+0-!J
M=0>/D1,8@+M&D]+,'#A#QE$/&0HE`0$.O:/GJ[+1D]!RS1%_%3,*_:RD3)L7
M)`4;O(^18JKM'C5<@@)%$SF(8!Z@(A]K'M<MZTV<+6LKVC@9.:'8WG5,`<2>
M?1LC&C%,45E$R/[$_5R1)-HW*8IEW,FDF'>?OK'.U[7V,3Z@GJQZXPR#AP6]
MQS.=BN*W$H9*&>QTDA$R3=6&=R,U%SD4"15V8J*L3"Z/U.JX06I_#O2N=A>3
M&0Y1Q_O?*/DK-H8KD].LD*PC*C8O!F4XXKL6\<,V["0:Q,RT%!5B_P#(F$DU
M3G2\!`3YU(<U&7%/'9O19DV<<<:YB.8Z-#J9I0[`I%6!&Y76T,D;4_G;*$2]
M1*=%3J@8H*I%3`Q2$UCE!D/,1+AC@,+JDQ0N/V916*9AJKFSL*HNT9/K!IDU
M<6?THHK-+G(46;=;RTUEE"I`4I""IZUO)UY,4AY5N#&.UW"L6LQLJRMM9C:N
MXCI:.>*I:"G4OKQ,10:5`"J:$?2CN)*:33`&_0"]/2SV2X\O("9T3F?K>.4Z
M(XR,L2S5DRM.<7=HRE7UVO\`=$X)"61F9*/F(OWYO&-8UO%)2I11.15LH<_-
M:#P7EU$<&.*7I\)(U6\:`[S+/])G-&TIFWL[ZPS<R%]9*-H2D5M2K/$E$TG*
M7FMB('$BBC@P-Y[?M1Y%/&=OY(\K97':S68;,<[B4;QDMH2>5`^4QCIC!LW\
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MKDW+<I'W(OA_2>)E&S9VG#K.6[/'93W1GJEU7CY(2(M_>TC%<=`.X*"1EE6^
MH<H9;DE2,9X89#R@O#YE$AD=&L-QU7$\]<14K8,Z"9<Q#4M7J[2L-U4CV`IU
MYI:0>.`(J0C1/LIR@JN3T-SRF]2[F'?J;C#:@8738V8CZK799Q&(VZUQ.95.
M)LV]6FL24LN@P2D1>2$B[>`<RQP.J16Q)7%/9]FXV,,9LDU)3O)[C-G/#NR*
M[8VB)-S5:GE5>KXH6F5K4S.(M&RSJ72,1JV55.H)3D3,LIG/*SE-?,DWNMGN
M5FO/`70N)-'SV&D<^($FR@9C+M=3CT[A.QD$]5;+*.G#L5WJ:)_`DL@!G':^
MTC2YJWP>?/X<9"ZN:3=9Z@3;RL5]PA8)F'-:ZT^C)^-A9ME%G:216SE`[B/6
M61,<"*'Z\@N1L-7TJXVY$\C+A]3HM$7:K6-RW.U#QE6C&3E\JN\<I,I^9F6Y
ME%#&4/[N7S#&.`B'VS4-ALORH#+Z!;;]+I@H"1EV-4@WTVLU34$!`BSLK/RB
M"(?CG#MJ?(74>)O'BP4WDQLR6DV#E=8I6NS7)JGPU[TFM0_CS:F3U8C':7TC
M*QJP-Q96$3&;2:ZYVY$@653XD^EKP4UN3X_4NB<*<FVK3>1=SHU=O>KDI+NH
MP:-:IL52KFA)5QA8Y"/EHM9XY.8YT%GBA$C%(V^>]42!V/2VG,.,XA6_-LYP
M?9W=-J]%^LNG:2>?C24ZU%H+-G`2#2NO(Q9PX\L3NR_1RR8J^%=+RO3ST'2.
M:K/;K_RXW;.J)H'$UKBN40-1:0%Q-%.)N(H]B@H(+HHG4_IAM'*213HJG=N$
ME1.8HF34MF-;3R$V?@=@-SMU1H?#34*%QVRK7L6T.PRK<J;A75;S<H>6DV\M
M*RJS5%.-2433:BLI[P5LBF#A79E:9S2F:Z3A9F#4]9U!KB67SY,[)J+KW=7"
MXRL2+<U?DGZU9M<VDO/OR.)/Q-E0`A2^6!"$44,L<I"E,J8"@94Q2@!E#%(4
MI"F.(=1`H`'Q!]E@4AAB6@T#!YB?MCKD_P`DLNQNN[]<,;K$/'QAH`2YW:DU
MH!E"RZ[URJ[E7A?*;D:>$AP5$B3CA3BG';?9/F!M?,IS;[C#\GJAQL0EKA`X
M=7YQZ+N?KO&6G1C5G:-"A8V,D&AV2[5NDFI#.SNT4Q*8R?J'[CR1?:7,X-D&
M)'G>,FE\D<%S/CSK\SKKIH:-9L5\GI29&ZE6)8Y%$`-*HB94P-B$ZBJX22NW
MJ!\I.1^<RL#=>)L<TH7'=OA.<*)/KIMTQ3JQF^D7R;?P/N\V]>PMH5?O*TDP
M+#>ZKD1614!-?Q<'O3VXY51]G&G67C!4>27)/1.-G$:LZ7/T!*]$D9)U!9_Q
MGS^M0]`92KZ>,'TD_79)L6YGK<YNJIU1'F7H4SDUPUG1:U:ZPPXB.M*R2D9Y
MR`L=%D)1VQO-ON&!YTJ,*L^JD,9H[C(T""\>.C+@=-RBD4AM'MMQYI6KD7*U
M@L#5+[C&E<;*!QXTWCYJ":LDI8(JP1U+:LU).*DP:F19>;[P0AFJI!6\]-=)
M+-YWE]D\%R4UV'+9V?&KC8DPD[Q?=&LUR-#,))K6<O8JO8Z22>N*^T2/,2,<
MX2CP3.FW/YRPH+[=J.PPC',K=RDN<9?H_`(9RNXCL3J,<M8W5;JT@8ZITAL*
M;6S"DJ@7Q&9MVZ**A_/!4B=WX&<,]LKG&&K<<,N0T7D'O,OG-3U*=<V"7/$G
MBJ5!5N[MUZXSCFK.:9J+.3"18WB<")RE2(53U`.6=VU^IWVQT'::MQCXHV&K
M9S3(.MS=K:.H&OSVG1<6:)>!.C8V4T,^1@_.]:I';G113*B)2!Z:6>[!OF>7
M/^M\8%=9XUU/(Z>Q89M2J]%UGZQVI;0RQOUTE+$LW>NWCDZ)V$4WD6ZR#=$[
M4H=.=/,C$>3]#XM<0.(LW=J=FM6E\GI.A/-_F*&Q6-)*66TV9!*<JI+8Z59(
M1I(Q8BY5Y5%,A#*)>-3++I/BJO=^1-AO7(*Z/7)#%7?/;W8G;>`=B)QZG*]I
ML/'.>O0I1.N80#H/4>2&M?\`#HP_0JS9JE3ZK8^:EXN-,MVF9ZVE58ZLH2M+
MS:PHA:H96N/'Z2#(L3(-""[4]Y43$GF&'B[6<HN=DT&BR&;L;K#6VUPZM=FI
M0U^=O+C(%7KJCR1+!(,9&:5;HM2.'*:::0>%98!!4_VO-M)Y&YT_NUERQDK%
M5PJ-JL$%%.X9>62FUH:PQD._:-IV*4?D,(I+`/4JJA!$2G$.V?5/8ZE*)!DL
MVVG\NL=`L<I0+9G[]NBT;"6K3M=6:K1C)9LP;E,@!12*+=(Y`*HDF<MXU;-<
MUD"7;2<Y5RR]R]LN5KO*UKJSUPW=S@SJEOEYE>5F+,X;$&1>KG4<.2E!,3`G
M\CM&6K,X/4$8ZN3,G8:;F]BV?2+)DM+G9=NZ:2$O7LXD["M6RR2[=\L7SG:3
MHY/-,)!*8>O9+2LTKNFUY!C>F^F0V7-]FT?\RT+>V;Q.18V5EF`3Y*XX?1[]
M$BS<KLCE%!1,GED*!"@&_8,K3K8-`Y.ZHMLNT@70+4%AMMV6F8Z>\T]D&1^E
M642G)Q::A621RMP\2@>'YPP]N,6F6&HR"\_P_9N&6#LF]BF&M;J::\1&0B*K
MBOHNPCIEU&L(9J#51T10R!D"F#O#KVUC6+!0KFF_W!5:1U6E0>I7RO9?=[(J
MF[*6VV"@PTVR@Y6P-W+Y5RF9P15JF[.98$?,,<QLUX7S="FV>'9#/QMLSIA!
MW.PQ-IK-KC#6(Z5E:VQ![]+.)=P-LD?..X,J0_O1A\`"4G@XQ:!*15\M-LXB
M,;,UQB8N6FW:VN6#RWJ+K3\_9E9^9?K6^Q.G+@52O'YEE$3D3!/PE23*72],
M>0>JT]WM<A]*[54<TVG1<_SW7GYE7*RSC0*?7)UG'RWO*SQ8ZI$Q0(H9=43%
M$5#B;BQ(DS-&#8\,)5Q-<>ZM6Y:4@J?395R,>I]).*\Q=)LIY^B\BT715G@+
M*BZ`RIS'4.<3:)S#C*[)&WC3Z3`YU9+._L,P_8(5"NH1"+*)@J^Y=GAX--P,
M"U4<';HE.LJ0QQ'JHIXOX:@:3UKD)CLQ2',NO"63C[K4QE\RHG.I,D)-I,D:
MMY*&G6BR3`@)@[:*G;B)A1,F)S"-IXL/J#9']'NVA):_;+>^N\Z\U>>UU)($
M/SFR.@.EUI)>V*(B<AC>`&8D65+Y'10X#<U#[KRRUV2N=!G<V7E=NWVQWU:`
MK%@]S%Z%7BO=HJL1$XD=@D*$E[@H_1`HE!7P'4*>7X39TVML-C4Y4M*ITDY-
M9#+WEPQU<\^>VR/UJ%H0Y)HX6-<C9P"'^S)II%*7HF';">,RL-?*Y5>-$H:P
M8?>:?>7]=UC/K.L^6E'UEB+FS0$JLO)R2_GKBNU51.L1,X)E,FF)=/S-]NG+
MJ\J:LS@&<YHUZY&W:6TZ#3K$F$S"*4:R,%(EG2UV\D'C6/'LT??2!Y3KSDOD
M=I7>$+!L6T[O+5<*-^>;D+IDGI]]B*.5?WL*A`/%VL5%0\*+OJH8$695SB8P
M&4$IC`,/7M!T#=:=!13>::.8O'=:L68LK(SGVB;&196U&!,4+"S,T*9,B+CQ
M)E(JH'A$##VEZYAD]L2]4E&2+)I4=!U.P76I5E,LM)SCQ2HUE\*$+774O*RJ
MR[Q9N@55RH;J8W>/7[9?<4TQC(2=`TJO.ZM;HZ+EY&!?/H1^*?OC1&6B7#20
M9@X(3P'%-0HF((E'J4P@-6C9'.K_`*!5*2NS<U3/=2W#7M#S."7CP,#$S+/+
M)<GE0!-IXQ\"1V9T@`>GAZ"(##;;.QVBYOKT-4VM"+HV%Z?;\@L\C2&?GE;U
M27<U"19-G\2DBMY1?$D"Q42$3!0")IE+9.([7#H$,0N+U6:M,$L_F74]/6A1
M0BY+C*71U(JVUW;FZR1!1D#/!71*0"$,5,/!VK&K1T/HVGZ)0H\8G-;3NVJ7
M37WN81?D>ZE99XTM\H\B:KY;4`2(LV;E<D(4`*H'?UJFEV<^TZ>OG]Q4T#.J
M5K6Z:7HV:T"X&>&D$IRLTFRS[R+2=,G@@=L#GWDC<2E\!2@`!VG^9U6A[W6M
MCM[P96XHP>F7.-H%PG/HQ[%)3EIH+673K\^_:MGZAT2N4U&R+@07(B58/']D
M/::L]TV3E-4(BV5MG4;YFV7;Q8J;EU]KK-!=H:+LE-3;OFA$9!FZ41=F8'8J
M.B''S3&'O[<?XBOQ%_PF9XMPSFN85?L!O<CGV@42`?BH>2B6MC51G#23>37<
MKJN#O4G*ZJSEP<5/$X6$^A<5]`OW(G1:-J5@@['>[5H&UV2X:1/.J\_AY&.8
MA9YPCIK#0@.()#QL8]FU;''QF\('4,8:MQ@TJ.LC?'J@^H#N,KM3L"D`HLTS
M1L5I5X.1=E;NCNX-!%%+S$.A3*&23,!BF+U[5#>PL^VX;M=-I"&;,-.X[Z<]
MS*T/Z$T77<-:I,J%CYJ.?QC<[HX%,#<C@2"4HJ"5-,"TK)&&Y\N*<>BV:7MT
M=J53Y&75OK\M,SZ"[67^L]QF3S:5AC72"X@1FX:"T:>$ONJ:':VPN214\XF]
M&LSF[ZAHUZL;^Z:7IUQ>'6.XL5XM\H/ODL^$[E4Q"$*BV2,JH9-(AE5!/-<I
MKE9^1,+LLO[HFA9J)N%EJ)ZZT91*$,C'U'Z.2]ZK,<+-$?$@U53(9154PAU4
M-U6SVH6W5KM&KSK^PK3NQ:39-2MZCR119MU&H6*T.G+Q&+;HL2`BV3\"*9A.
M;IXSG,-AY,V!/5ZY=KY7V=9U:O9YJEBH=%V")8`W(V;Z5$5T6DK.)>0Q;)*H
MHOVK9RFV3!9)3H(CGG$9&%OQ<7SC;V_(%E$EN0IREDT!J,J5,;?)(QJ?TU!>
M[RQD1:%30+Y:*(`8!3`>U*YH33:R/]ESK+W^24M-:>,-,K]9DWLR]?NV-8!L
M"*5@=_3[E([OS>HHG`HE^000UZ,<$W)M0MCGI*VRV11>S6&,R2KW"56!=Y;*
MA1&:2<4A.@;J""DC])$9E$`;$2\"?@HF/4ABK%T?-Z-6\[JD>+DZCAE6:G!L
MZ]#-U'I?`LJY2C6*8'6[CG/U./RA[)L-&TCESIN7(2X33;!-`Y+WFPXRW=)N
M#NFJ)(!049]5G'K&ZH)JRB@)]``.[J`P-0J4+'5RK5:&C*]7*_#M46,3"0<,
MR1CHJ)C&3<I$&C"/8MR)))D*!2$(``'0/_1OKG!;`=?XH<0UL;S++[I7'G*O
M/K=HU]Y4R>B_6AU*/<6KD/J>0Q9,\H2<&C'R3M!S+2)))8W5`$^XGI4Y;:6&
M0/[IRTY`CB7(]W66-L?U1HM&X9>;W-2&1+S$C$S44T<6NKI^ZFE47BI&1Q34
M*93YSMS?XF\E&=.B.1/$+;&C9L-'B)2#K-\XWZQ76%UP71HMC-R\N_4DG,4L
M\C)GRU!;)R#'Y`@*@II^H[S8S".Q8<DR+DI3N/W"R2L%=L<NA;HFL:Q5,3VC
M5KZZC[?%L[55I>\SKTM>"-6CRIH19Q6.H)_DKRN]\NN#^RY9#UV5>SM8P/%+
ME3+JU>&0#Z*E5K/*\B=*C(^(9*D.+@BD8<5@^250@AXNS+6\4Y0>GMQ/S"^V
M>=0XY8/NE;F==Y`[%G4#8I"NQNB70\1OF1#05K\O%+NHZ+BX><,W9&2,HX5.
M<>C3@[QWOG&S!K-6<6B^0.[<H>6+IQ(9?FM1LUGD*;0\[J-#873.%;KJ=WDV
M"\@4KVPQ3%E#LEE/GUCD(7'YB3NO''E]RAY2\F\^XJ<9[ED\'.YI@,W<-IEC
MPU,MEYBT=!UR83K=$%D]=S98F8<'>)-R)(F;F.=5/BKQ8YP6?CUN5%YPQVM0
MV0ZK@.8W3%Y?,M<QVL1=[E*=>ZG<M)T]C9JK;JO(KDBY%F_;/2.V)O.:@0W4
M/N0/@Z#U_F`?Z>UST+,MIX*YQ6,ZY"W/-[MPAO5`TF6Y)T?/*%HCZI/W>EZ!
M':?'.:=I%DK<4K*1R)*4YAQ%PB45SD\9B\T^'6$-,G1L&3^GWG_(7`I"[UZP
MR*<CNUZN&GUJ/AKZO%V-D9U1GB]/8I"FS01=MA645`ZW0$A0]1O1RM*JRH.+
MW6U;M4062BW51US'D):`U+,F[61=K+LI931*ZYCXEJX4,X<%=-/QS+%$WI'9
MG8[/Q-PSD;SWJN^73;[-I&8WF9S3(S9[DT-LU4HS"LFURE2R%B:P\T2"E57,
MH<AI8ACHD\L`*?D?RPY;ZE@7*8,U9Q2V;Q'%N@S64L;!9)R4BJ55<[DY.U:O
MKC9:7N6CVB)9)O$C(A'(N#*&0<&\).U>4UWF5Z;UYCTVK][K7%_CG3['8=!S
M4%HQU[C%PNNN.0$RZGG$%.JMT7KF0I<<BX2(IY9$S&((;M$\=N27!OAEBF'[
MI>^-=0G>5$.\U#4^2VGY/*!`:38:?3&.V8=%U'+F%K.I$1;E%U.R$BJS67,F
MB!BH)\<O3KXU2.%0_)6^<:Y+D_O7(/1*A;;?DF?9U7)MEG93YWD<)=*[8;5-
M:'I9W01Z,A963>+C&9A45=JJ?-<N>"G+QCFK_D3Q/;9->6FIXS#3U4S79\<V
M^*EY&G61A2+3.V:>IMMK;Z#<,9ID,B_9@JHB+9PH'CZ?8[TXP_6>#^#%PKD'
M=<F7X4[E0-(LO(QU4,^F&D2>\:+<H/3*J^HH:0V*M(0ZD?3IB/09.4`%=R<B
MG76N$&7M\V:,HSTW[-R7S.<LT#-2+\FZ_G5B<[JK2RJL;$P1?4`/I8IW31!%
M%V8>HD<![!><O>0QH#,[Q@=<UFO<RZNR.=FSRC8>.+J>A=GACQKYZ\?1+99U
M6SRD:S<+JN/HZ1:E,<YS=1XU:]1I#B7B.F;NRG]6NLCJ6?ZI:/S5Y1:SMYK$
M:=7LM@K9!%NUZ>5202/8)&0LL*U9+$`K=FY\T10]4>K[\QQ*T;WZ<AK>R9:I
MC47:HO%M9<EP=;9:LD[J5AG92>K-IK)_*966+3EG!6ZBI"I+@(^,<$UN]\P/
M3IME,OM"KNC:)@N/YG;B[?6(^Q5\DB%>4EE>1-F;P4K#OGB2;A=W"G)T(8!2
M`3!TP%7+LBQN&X_7+E[QEX[W'2M*M$W9]`T-KN]FC8:5)F.<55O%1=/8U)`[
MM-Q+SLRLNX=E3*WC!1`ZY@#[JNF%\DO15W#F55Z\OYF$:WF<W@DFTER2$8S5
M/*0FCR>J9QJG'6?;3(JM77<EU20(N59=-0"!Z"-;Y`KS6ZZYQ7Y1V>]\E;R6
MU1]L7S>A2F/;#"U!C:+C+/&+Z].J8UL45`.))N5ZH]=("<IUB"58]0YG>G3E
M<AH.Z;'QRUG@CM;2$L4/6OH"O7IBZG^/W(*94G7S6/>(\?-,5<NG(HIF?.&+
MTJ`B9),OE.O3_P",.<2&SRF;TCC_`%.#I$8C`LI;2R4;7\[MFC2RC.RS#&"/
M)6M*.E91TBX>>%55<Y/$?Q=]HI>0^BY>_3V_.50YZOV[:R8MQ'S.`>Q;9FJY
M9URP/\3TV=MLE[Z_.!VC<S)9N#D`,<4P#QA<_2I8>D(R<<IE'<OGU4YPQ\-Q
MSAL0F#-KR=]4.64QM;>RI:]%VB*J":2IXTT4O83KMP:>$4U!(6*YC:+PFE?4
MFRZ_\)<HX^ST_5*=CNAZ_EV[9(_607NX4K8[)7Q^K>K5=RJ#N1BW1UVKHHIN
M`\M3J<=PS+CS#Y-=\Z]7BD^I[@_IU(W.D-0IV19_%P-<L6)1%GA9%SE=/T?6
MFL2]G$V#1Y]!1KM\F@*J:YE_!P8WFU\4-DXBX'P(<[3ITF^Y%N,Z97K8=9U>
MB,\WK%0HE.SV]WAQ'P%)9%?R$E,22S=NZ%1!%LFH;Q&+]R.56;<KMVD@LHV:
MF7!L5RX(D<R+<S@2*`@590`*)Q*;P`/7H/3M$O\`$/28WGB)ZE<1=ZBC1_4`
M7NV'T>G8PC!6R-5FKQ8MHRC4W-FWJDFJC5XW;0#R!DU71'@%]R1/X@#D5R"L
M54DE,DMW`/C?E$+IYAB6\19=+IVJ:A.6V$:QK>05DF;MC'3;9T<#-R-RD<%*
M0YA#IVT[A14<NDC^EARWY<8YZBNQ:&VF83ZKU*=IT?*S&_<8'L`[D2VI=#?=
MES2HS("S2*Q8L)-T4G?YH%]-+4YC@W,\]\!PJ=Y:J[?C416,@NZ9QTG'JW5\
MT?OJ;M%HJ]4F$V=R9E>IF,H<6IV'F%Z*`D!N6W$/C/Z;TEP+?!,9UH^<8AHM
M-P#*J%LM_H>DT?8%XQK%8M>+756Q;H&7MX!^^ERLTRF?H&4,=))0R7IPW["_
M2]GO32AN&.ER^E;=J=NK.`9B>0HR]#DJLYXR9E&XA:9V2TVO767DB*.WCALQ
MAF3./\POSS@$3>HMQ:NGH[_UU;3R4W[DAH?'WD56(#C<XIM_H6^RK^RT""V3
M4K_<(/1,GEL=GYM9%=91JH=J+;WJ,\8BDH?T]>4X9==^;:>4^FA!^GKR@KN,
MR]7=:O7IBK7$FGT_1:?$:'8Z@TT&IMIA\[A'!$GR4DDW10<BFH!C`7FUZCF\
MY+/<=QY(5/#<3Q7";O+U:9TVO9;AS"PG?7G25*1.V2KPLSH=DL0K-(A%ZY<Q
MS1KT<'\Q0"$^P'H'4>_NZ].O=[.O?T[2$55_1RW[&/46AI=A$8?S?B](PJD5
M[%YB)G40K&KN^3N9ZLQOESH%9;$"2^KB\.[=*%\2!8\KCIV8[Y>X9_:L^;>E
M?7L)LFXI-X2*K]LW5AN5)LL^P0@6CT)"+=S3"+=R94B-"LT4A%,JG4`+VWKC
M-D&<S4CZ>7JI:IQ^WWESH<7/PD1$8A-X_*'E^2M.3CEGZ=G</.6L'G\`S,Y9
M)F`KV3<@?YGQ@3.,M]/OC3H=_L6C&D:U8]FS.+RJR_U8:56T8)NC+069:;=J
M1$7N[3S)^HW@FCARE$M19JK.SF\M)!;7,CH/IG<NJ46KURTZ58HSD?8\"E;W
MS-UF\F<+Z,]GKD;;KJQL.F:.\!19^M8%8^'!-5-JFHBV(D@3@I9^,WI>7+T[
M)CC'R?SG;]>Y1Z#3<`Q67<XU2'*JUSX]52+Q.[6FU:@CK**Y6:J#I((%LBD8
MZQ^A_";#\7Q/@GR?V!MAW,[B=R3E]2IP8JEG=GIV4V1&XVV%JZUDUV`LZMF;
MMW)FA$G<8T;G>)&#S03\*AJO?[)E>@XG-V%&25?9AJ9*NG?:L+&9D8I!*P$I
M=FN%:*I*-6)'S<&TBX_V1TEYGEJ^-(GW3WAV]@=W;O[!W>SV?P>SXO\`)V]G
MWOC_`*>WL#V]?Y>WL^YO9[._M[.WL#NZ?Y!ZA_,/;O#K^'M[/X_>^+M[.W7H
M'7X^WL_CW?Z.W=]D'=[/9VZ]/X_@]G;KT[_C_@[P]G;V=O9_'_3_`,U^O01_
MZ/\`/V4NBETW&(RY"7D(1SM4YQ.Y-QN(M'D5,+0$BH[UM7*341LP9S#<Z"KD
M[T$$CE'QF+T'I`W&FV"%M=3M$1'S];LU<DV<U`3\'+-4GL9+PTO'+.&$G&2#
M-8BJ*Z*ATU4S`8HB`@/;^/\`G[NVOY1*26^SU@P*W+478YG/>*/)+3*)GUG:
MQC*9=QMBOM!S"Q51D=I%2"3A0PNO"5$WCZB7O[5K9L%T6KZGF-N;G<05OJ4D
MG(QS@Z"AD7L>Z(`$=Q4S%N2F0>,7::#QFX(9)=)-0IBAVS/@=H&H_5ODMKU8
MB;70:<^K-I"&FHZP/+?'5YH:\$ASTV/F[`_HDFBR8N'J;ITL@4B9#'53*:X<
MA.0MR;T+*Z,6(+.SRD?*3#LSVPS<?6X"'B(*$9R$W.3<W.RK9JU:-&ZRZJJH
M="]`$0#G-5KFY?<:1R.T[D:]*UNQLW9,WI<1,SEEF359W%HV<%XV/K[LPM0:
M"Y4,EX2$,8Q0%+=N+FA):)G)K%+5)X_/#3E:F(6S0B;-Q(05AK5ECXJ?@Y(K
M"2:NTTW+=,5F3M!=/Q)*IG-'>GF34B/.5\C6W=H#.X^N6>0:1S)C45;\X835
MN:1"U2A[`%*3+*!'.'J;P62Z"OE^%='Q_9"/Q=F^:"]LWUH<<FY+B.FE]7'`
MLOSPQ6*QF^NV8O/.\`5\,\ET5"ONG@,[$R'A\0=>T?L\?*7DU)D^+J/,!JLK
M2WJ<D.-+7!O1BO#QXN!4)8OI]R4ON'7Q^5U/XNG=VF\A!]:OKE7^254XI2"/
MU9<_1Y=<N6*0V_0K1)^*P$5@3YY/-U%7W0")NA,B(=2]>S&VR,G>"0\ABG)O
M?FQDJ8]5<CGG$C08K,MA<G;@X`Q95E:9A$K!KU\;Y`14*)0#IV>P4J_M9'[#
M6^-N)N"H5ARLD%YY6PT/.Y&@54JX`>,>,)QO[^Y`/"Q.(E,!A#MU^X-OX:9E
MIAYCD3QY3DW&FT-_5[5`BQ:P<M#P4\Z@IR:AV,#:V\#,6%@W>'C7+D&YWB/B
MZ%.41S^R<I]*4H#'4;2M3Z0@PJ]IN,K,RS1JF]DURP]0B)N2;0L.V62,\?*I
M$:-A72*<X&5(!F<BS4\YH_:MWK57PF)YK9TB1=!3P'`IR>-)0!Z"`"'7O^TU
M;,3O[6%JN/(?7N,$*C]6'7N2FJ8ACD_NMZ:N'GG>!"$0H-:=*-7@@)'+D"H@
M4!-U[&WTLI>S9Z7B;2N:8N`I3T9;\QU_LTC4JZ]",!R*HV968BU05CO%YB28
M`83=![3&6IOK.-K@^4L/P\?IC6W(,"[1.84MR*8,DGGF^%6NFS5$53/P#P%>
M?,>'Q=_9UH@REZ"ML^*^]\QUE!I3WWW\RO&ZUJTW3GI&?O7C-8VDTB)6<?U\
MQVF('*8`'IVDJM,/[426BN1^'<5G9$*RZ70#6N0M.K%ZSEFFL5;H>"<0%N9&
M>/0#RVBICD,`B0?L\SA+4I()OM:N[G/J>#%BH]36L;2DVZ_JI/U"&*#%H%>I
M+XP*FZ@*I2$]IP[.-$6>68*TUQ)3D"LJ6N.3/`SI.R&JAG)6@*^(TM]+%$/=
M>OC%/Y?7X.S^J>\3GTO':U2\4<D^AEO=PO%^IB-\KR!%_-\)XU2OKE,LX_%2
M5'P"`CV/,(O;.+,F:;UK)A&MN04"H<;[DQHFF*^6*O7Z0;3\BF5DA^,[2ZG*
M(`'3L]JKQU80EF-^P?-ERI0+A5`+1R-:HO,T2*L"@%,R=(+E]\6]C0?Q@'M+
M3=64=JL(6Y7>B/C/6BC-4)_/[/)U&PII)G$WFM4YF(6*DJ'<JF`&```?M=!F
M=JTG-J32X>T<E%+@XOUHKT-$-X5?:]$*\;RR<R];IG1>M%1)Y)BB*X'\!2F$
MP`/I]U:Q&VRE<=M^]1CDI+LL3H5T98;M-RX/R3C<],S^DUO0;O:\[CJC&2+Y
MHRFR1ZEAA'EAB7231DY#W@`'F!R1B'VQ5KCM>7V=TGBOBNT\DI?:M"SJLQ-?
M0<Z]+7&!BM=URA5UG=;U&LG%<(I)OIUDS1>D5511=`W[>ND]N%NJ]49H>HVZ
MD%W5EGXJ";(,&V&9R+AZLO*.FJ231`"CXU#"!"@`]1#M^\`\HN(-SDLUP79N
M=''B$XW:'4)%G5(.]728D\YS+E1=,=O\JW6J-=;:',S'N+2Y&4^AV+Q`SDRZ
M0-A.G$;MAC3DSDG$_)^.L[#V#*N1?,!75;+>^3-DL3-HPO%=H5(Y%;C$/ZA"
M9ZXE6LF^FGY&#N4<MEF+`3IE>%Y9Y'4Y@]7V*O>CYQ]V7CC=413(XI/(S'N9
M.B7C';"54Y%?(:_6V-19O#`43`P=K]`$>@=L<(A4)6&Q7@QQLG.6?*ZN2K5T
MR:MO4'>5&Z9SDF"OT`\*I0PJ3B[;;%TEEA%RJ,*99N4`$!5]O3_A4<JA_!_N
MPV7J`_?[<8>4>@,[$MQ3]1;TV<<M5JCX8J;GZ%YV<6^/U==UV+CCNQ:M(MQR
M:QQR2)9H@=99W8H$IS%!(QA2]%F_[.S%+E'RYKGJ9<M.4RZGO)3,=<V/%ZI.
M%H+9NZ*0T?%8]3OHNIM6Q"E3(2'$Y0ZJ&$?LXS]O?>O[JRA]J?\`X?Z/_6?A
M.VK_`+=3CS_=495VJ7[*7U\?US\Z[6G]I-Z%'Z-<Q^X>>?J1Y&@Z<Z'Z=OK0
M[MH.B14>1160OW#V_93AT#RCSULV2(<CIT:!C(RQ-A5$"(*U\QBB4QO%V]4#
MU(&KM&=XWYO!X_Q`X#2Z10,QM%2C.5&&.^4.UQ"R8"V?QV@:U64(2+>$.H*D
M3`"'R?,,4:?_`/U:O_\`[2T^T\>_VU_J6_W7VQ]EO\.)Q2_3M=>VE_XA#,O[
MHAYVG_\`#S^L9^L2[[7;]N7Z3GZL6!?9\"O[6,Y^JIR6[3?[)YY^G%QVN'[2
M'BQ^JY%]G?\`83]8S]:.J=K-_;,](#_PW&=M&_M0\K?T_P!_^U?#_)V;WB$X
M#<2FEL:2RLZSFSX3G;QVSFUG!W9Y=F#Z!<HM9,':AE"KIE*H0X^(H@/;C';J
MA;<H2#C3?[1>T\4Y`98OKW';5'=BICFFQJ]XI#"QU=RG8:"B\7=5^0(=Q]'.
M7"ARHB82F+OO.33+?QSS!U?\3KN8S>9<:\G:<<^-].J5&G'-N?:3<DY2TRGU
MLORQ@!%2<D?=`CXQ,Z!/FCF\+[D=(<2N'F\S>FR8VN1UQ7-\TTMIH,F@<L>K
M.N[&#*9B+6J"T=Y*JQSK@91$2G$3`/9;`*SH%&XX9Y1K)G6@.V<Q389[@DG1
M<@G&UJ=99K6?HR]-AG^&SC6,(27CR/&+<&Z!!,(I$.F?C9S_`"W#@]7X+#ZM
MKL32(WT]<.99Q4=L<:977N?2S[5-/:7FRFO59IX`Z5CH5)-1HTF">:97S$C`
M:>Y)O*51H?6#YHAG-CV)W&QK&TAE%>F']Q1JLM:URI+HT^)FW;B1%%14K9)8
MQE3=.G4+_/<:*SASC/-YN]UOVCSF-IT^2J&IWZU+*1M^LUBEJB9U#V:P3#IN
M="164445,H4Q5/E>(.S[CW'YOG=2XUQV>6*B2>7$B(N(R]AF,Q&2;:UUU_#*
M%2AF]5?1,B\*]34`$3(K*BH/01[9+5(*A\?]KX_Y1.U*=Q2,A6%+T+,:18\E
M%:&ILG0E8X9>OQLK10259ME&AP4:%\Q'J`"<HYYLMESVISNK9*QMD9F6@R<.
MS=VNBL+Y'(1-S:5F952,[B4+-&MR(/2I&*"Z10*;N^T1G[>^]?W5E#[4_P#P
M_P!'_K/PG;5_VZG'G^ZHRKM4OV4OKX_KGYUVM/[2;T*/T:YC]P[4\5H^:TRF
MZS)6[0M_=OHR#AJW=Y">KZ$1=[;I3E\5&,D?I*LQA$9%T^,)#M$NBH^`![0&
M#YWG6$WGAX]B&D96L[I<?4K-A\C#UZV?3K="'8P1GM6?-8R[10NC"D8_@DD#
M',/G%,/9NS:HIMVK5!)LV;HD!-%!!!,J2**29>A2)I)E`I0#N``Z?:>/?[:_
MU+?[K[8^RW^'$XI?IVNO;2_\0AF7]T0\[3_^'G]8S]8EWVNW[<OTG/U8L"^S
MX%?VL9S]53DMVF_V3SS].+CM</VD/%C]5R+[._["?K&?K1U3M9O[9GI`?^&X
MSMHW]J'E;^G^_P#VWG[_`&0.0?Z,+)VX!C\>66;]*V@]N=X_"'$#D9T_\I;9
MVX&B``'6F:D(]/[0&M?T]N2_]G_9?T=6/MQ?'X1M6^"/WQ_/C?.\>W)@![P_
MJ_;-^CFR=N+X_"-IWH1^_P#[[[Y]IC/V]]Z_NK*'VI_^'^C_`-9^$[:O^W4X
M\_W5&5=JE^RE]?']<_.NUI_:3>A1^C7,?N'G?U^#B!R,_1+:Q_I#MP,'IWC2
MM0Z_^?VL?T_:N/?[:_U+?[K[8^RW^'$XI?IVNO;2_P#$(9E_=$/.T_\`X>?U
MC/UB7?:[?MR_2<_5BP+[/@5_:QG/U5.2W:;_`&3SS].+CM</VD/%C]5R+[._
M["?K&?K1U3M9O[9GI`?^&XSMHW]J'E;^G^__`&WU!/34GW]QJ?(]?T[MQUFJ
M'M-9)$9YHT(_R^R*J0>?6Y2244L%JC6B:RSAL+1%+PM7!$EE56ZR9/2-]/.2
M>W2T<E=ZQ'1;/$UVBU;ZRPV?5F#OFI3J4_J\NC((*4^-GFD4X!B<K=T8?`!U
MP00426/S`].&Z/[I4>0NC^G?R)U7-7=@J+EAFNBQ_P":[1$W-4I]V%THG)75
MBRK[UTJV,V3:@FV.D5P9UT;CZ/G`>QO+I8>2')W/]MF:=6*-5ALD?4*U";=N
M4D>UZ9(DD6BM7@)$E?>D;*)HNU/]F455(DW**W:^>G7H+RYU;=]SX:;1I>5S
M<K6`;95<$R5#1(KZD1=V4DBG5T!7ZL.UB,09^0)?*3]X]X710/Z87#*YO;K9
M^0G*_0^04?GU$SBJGM[VMP;?<-`*I?-'%!\T4JE&!=NN4'@$<J^!JX6\GW=L
MX62N'IZZ:\O-0V_D'Q$VBZ9%8I6G+HY%<'GU*T&.1H+"_B]\H-`<GKK@Z;,S
M4&XBHW1%P#IVV;J^EIQ#OSJZS^\<P=-Y!0.84S/JP6U.(6+:[M=V;B\Z"8))
M@I6*.1\<Z0.R)NE3>[.5"HBBU<J)?9IBY<(-P662;(BNJFD"KA<P$103%0Q?
M&LL<>A2!U,8>X`[12Z\K&HHF]>_0!*LJ^;)I&!OZ6=!:+B50ZH$'R'2A4S]_
MR5#`4>@CT[5%(96-!0GH!L4#I^_-?&5<.3\('D&)YOB*J!N[PC\KKVU,Q9>+
M,57UTN/!TS%D&@E4(?TK\L:E,005Z'*9TF9,!#N%0HE]H=.U1*67BQ-_PJ?7
MI1\(2#03><[YFY\=HET!7KYCDJ1A3+[3@4>G7H/:V*(RD<LFGZD'H4N%%$GS
M90A&X9MF)17.8BHE*B!AZ>(?D]?A[+$1625,V5\AP5)0BAD%_*27\E8"B(I*
M^2N0_A-T'PG*/L$/N#F[Z;%I?W*H\BK+Z=V_ZM1G5EK)8O-]$C'F570#5BCW
M`\BHI-7-FT8NG"K46:;?P-%B$7.NF9#MZ0G`.<?7.S\D>2.>[7,5FKT*KA9X
M^C5R$VG9Y;ZRZG(I239:HPDJVBW/NJA4'9_"@958B3?HL(#][[0B#A=%`7"Q
M6Z`+*D2%=P<#&(@CXS%\Q8Y2"(%+U,(`/=W=N/:ZTBP20_XUGJ7J><H\;D2\
MM/TQM@:J'\PR@$\!'2A4Q'KT!0P%'O$`[+H?2<?YX?NY/%5`4??6WF^<GO5R
M241\OS/'YI%5"E$O3J!C``]XAVT@0FHD0/\`O!>9+DZ2+/Y:/_"1>,_.+\]\
MI+WSYKQ!W>9\G\;N[3Q`EHP3F_=[?6%;E(#]J)C.'7(IZ#5`I?-ZBLY$@@F7
M\8X@/0!Z=KP9"28+%+ZXOI,N3&2>-U"E;J\9<$32<&$B@@""BB9BE/\`BB8H
M@`]0[+%1625,W5\AP5)0BAD%P335%%8""(I*@DJ4WA-T'PF`?8(?8]X]/P]N
M!@@[;"!>5]D.8072$"D9\5^2B3LXB!^@%:J'`J@^PAA`!Z#VFR!(,A./I1/$
M0*#M`3"K^?-<GE`7S.HJ>/N\/MZ]W:X'"18B4?4@XL&`P.VXE$O]5^.)X@'S
M.GA\9#!U^,!#X.SKI(,1\7!;UAB!T=H=YW/*"K*-R!\YWG73*)B![3@`B'4.
MUF,608F+_7)](-3J5V@(>!.MQHJ'Z@IT\"8%'Q#[`Z=_;1"'<MR'-RGY6-BD
M,LF4QG!M[T!8J!2B8!%8R(>,"_C"7OZ=.W=W_;',MFK(D9RVX]L;'<L*L;$Q
M&$E;6;F(7+;<8E)`B?G*0M\;()BU`QB@WE6Z`^(B"KLJH<D^04!),>7O).IP
M0R\#9VZI)S$<B;J&D*EEXM7Z"<E`625;&:O["T/X%&CE-NQ.0AV1_$ZC*.BE
M$\K\.3G+GQMMQ9%"$.]EG[%)O:<NGY=5$P)U71HUFFD83'1*VE&[-P90J)%R
M*CROY.U9TSY=[K5F4=7Z[:471K#Q_P`06.G)1F?J,)-$CBLW&V._#(3C8H%4
M:)E;,E`361=$/*T6"/'UODME"SS0.,ND+'(P=P=Z:MBF<4Z1G$DC/F%0OZ+5
M)H]%,P`V<IM7OA,=H4HR',CE;3INO\K-8@'=,H%#MQ0"2PG%59,)-=BI%.$1
M<5^\:++I>]R"0J>8SCB(MP*BHX?D4L.<,00@N1&8%D-&XP:"#WZ(<5S4(]B8
M4*])2Y$%EV]1O::)&$CT_P#IS^0\)\ZT3[3G,7E_3'L-R?O\8^H.34"X)*K3
MN`9`VF'Z\XD:/?HB%<N>D6(57#@J!S^1$E3*4Y3/WQ#_`&=NQVX.Y2%+,A%S
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M>YN<G]%V'4[.Y][LFHZ_>7OTO>+E*+>6B"#11X)&$2R*4$HJ"8L6"0`DU3^X
M'A:*V+%\K<%;V&]<?+4S4282$VZ5AUDK+D<M*%0.X"MZ&U12*0`,3R)5LT5$
MY4?>"*CRGY&UV4CN6G(NH1#=&KVIJNC/X3C2;E62KV?*Q\D@1]7[59P,WDIU
MH<$U61B-F*B::K9<I@#XOM%@RR8EI6J3R<A!W;,-$KSD[*SY;KU%E&]ES;1J
MX\3`QDY"L6=BBHL@8#-Y!B9PR<D4;.5DSPRK#B9D+")8<WN6MKJ44PI%3E<X
MC]8T/CZU;[;IB+JW0KHD9QMV<L(K(4T9=0?!:W2C=8XO`8!VD8MQQ'C`ISCT
MWLWSPT"SRJGM-4>8J7D6;2(W.FK0]4+9PY:MM!9?3$D@N8KQ.GI^!?I(F;`5
MW/I<4\32M33U%*=I2L](9-E!<_+L;'`%Y2,OB;YK5`\SBBSJ[Y1.3,P/[G]:
M112*'TXF`D;Q"?#%@%?9\#^2,`A&/,HSQ>^(YFMR"EKY<*DI[K6A=GY*R=XF
MEI&H,T!^E5:<LW3C`]Z*X+VD+A9N)^<RJ+OFAP$D+K5ZU3:)&YK:;3C>9(L\
M/LZ9ZQ7!DU,!RF+E3_G%<HNRLB6069F_3W20$L+G3RV2^C7V4E;!H>R:K8O*
M&Q:OLM_E%K%HM^E?)2119H2LZ[,C&1Z92MX>%;,X]``;M4@#[#IVR>;XC5",
MOD7<=NM-U8L)V.8RL;BUSMN2W^OZVT=$?M5V;7)]XC':3R23<#[NUL,:4"""
MLDB3L,=_5XB@KZ?$UY6U8UM0J<I?`S]?9GMT=5WRRP:KLVV*614T@0C;_;0K
M8E`H^^`/:5.WQ+/U'X\H,2M[E[)TRAKUASH%9SA\UJ]G:&8UQNT'&X&$D1;6
M,2D\L)14@(@*XNA$K=GQOA2,T<*Y30(-YB@58)=&KO[^J6Z11BMHA(IM1EY1
MT=6ED3ZJ.(TQ3L0%L"O20<*X/4TGBVL\,W:[Z%I%/+7"SU%J+>*S"5:>7`K$
M-3Z:Q7`FAG*0S4)$3>/Q(>/L:_\`+^NMH"=R_5]ML-'KR8)-W%RV+0KG9$]&
MWZV-XYHPBI0H01D86F&(F"3>)6>N"%$'#4R0`'P?;+?HMWED8"F4*KS]SMTZ
MX2<KMX6LU>*=S<]++HLT7#M5&.BV*JQBI)G4,4@@4HCT#MT_KVT$X]W_`'=)
MUX_4!^$.F>_`'?V[N<50/^3S[8C_`,O=GGP]N[FI`*>S_NLSV4W7[P?[O0[P
M[=W,:.4_)Y;LAN[X![Z`'</;Y/+<JOL'YO)]@,/?^&C%]G;Y/*=ZI^3R'71`
M?O@(TLO=VZEY+3JOWDL;UHP_@[Z@7O[?)Y"VU7\GBFKF^#V]]5+W?Y^WR-TO
MJW=U^:P[5#?R=]:+WCV$"[%IRO0>G5+!]1,`_@'Z`#V=OD:AKROM_P"ZP#3C
M>SV!WPI>\WP=ODZ!MZOY/CSI9OY>^*#MU+;]^5_)<<](-U_!UCR^WM\FP<C%
M/]3C=HH_TM`]G8?#(<FE?R?&G01Z_%T\2)0[_@[?-I<K5OR7&.]&ZC[1#Y1R
M]X=OFH+F"X#OZ"AQ=N9@$`^$/$\)W#\';YND\UE_O(\5[88>OQ?*E"=_3O[?
M-YKSG5`?8*?%&T#U#X^^:+W=OF\AY[+?D^)MB'_M6$O;YO$/4$5#XT^)<X/\
MORK07N[?-\?/446^($N(TL/4?B#Q6\O?T[?-\9_4D5Z]X"GQ"D!ZA\(AUNQ>
MX.WS7%'U-5_B\KA\Y'J(^P`\5^)V^;X>>J*M^2X=&'KW]!_&T8H]P^WM\WPF
M]59;XO+X;)CU^+IXM-+[?@[?-\$O5F5_)\,FH]?CZ>+52^SM\WZ?WJ[+?DN%
MK`>OQ?C:V7N'X.WS?IU^L(M]Y/A3%C^'V["7V!V^;]-GUD5>[J'@X30_>'P#
MW[+[![#Y/IB>LRM[0#P\*80/$(>T`Z[)\';YGTK_`%GU?P<+H(.H>P!#_?$/
MP]NB/I-^M&L/P`'#.`+U'_S?'N^_V^:](SUI#]>\.O#F"#N_DUDW;YKT@/6?
M-_K<080G?\`?_P"H&]H=OFO1X]9@_P#K\2X9/N^/NT@_P]NB7HW>L@<?^MQ7
MAR=X^P/_`+^-[0[?->C)ZPYP_P"OQDB$_P`(_P#WJ;H`=OFO1:]7\_Q>+CA%
M$_!W_6PP=_;YKT4/5W/\7CX]Q:?7I[?_`.1G[P[?->B+ZMQ_O'PB-3'O]GLF
M3^WM\UZ'?JS'^+Q8I'$Z]/;_`/J!OY.P^5Z&7JO'^$/%D$>3J'_XYNWS7H4>
MJP8?@\>5L$^H_%[#?!V^:]!_U4#![1\>:L2=WP>QL?V]OF?05]44X]0Z>91&
M:0=?P_12G0.GP]OF?0+]3<P#W@*E79(]WW^L`?VC\'8/)]`'U)S_``=%(U@B
M/7V^T:L;N[?-_N_/J,B'7N\9HI+N]G7OJ/</7X.W5/\`=]?4+'[RDG#)=X^P
M.HTL0#M\W^[X<_1]H_.66`2Z`'</7Q4<>_KV^;_=[.=P_E+Q6T@[_P`7\:A#
M[/A^+MU3_=Z.;P^SIYNFU5'_`%NOBSTW3N[?-_N\?,T1^-78J>B'?[/;FYOY
M>WS?[N_R]$/_`(F\4A'X^O7Q9D(=.WS?[NWRK'XO-Y&T)'N_][+AZ#V'ROW=
M?DV(AT#YWE'GB("/P_C90/=T[`"?[NGR,'NZ_.\MLV2'^7Q9&/?U[?-_NY^^
MC^4YE9>EW_%\K(!Z=OF_W<W;O_F\V\I3[O@]N/>WK^'MT1_=S]:*(]P"MSER
M<H=?;W_[HRB`=.WS7[NOH1/A#WCG9E!>[[XAE`=!Z]@!+]WDLY!]G5;GCE@`
M'7\7N#+B]"_'V^;_`'?-ZEU[P%?GEF`_R=`S=/O_`,W;YOT!6J7WUN=^:F]O
MLZ@6A$'N^'M\WZ#$`C^7YRY^?_L4TG;2?Z\/!.'X7$K@5X<^^BMO@]B&]#(?
M27TZ#@8:*C`@_H0&[?IXP/YWO`].GA^U4BNZ%!7S2KOMDC/5/+\+R;/I+4]/
MU9>&B`DK>E#4V/(#0M9KL*Y34F)25<,85@FY1(Y<D.Y0(K>%LXQ6M56ZY/:O
MJ+LF/:CA4'GFNX_<EF*4LQ@;]3)6&,JP-.0+E&0CGC59Y&R3!<B[9PJ01$/F
M\CS%/H``'@H55+T`/8'R8H.X.WS>89X3I_[%*K9?;[?Q8P/;VZ$SRC$#V?)J
M4`7V>SV1X>SL=52C4E%)(AE%%#UF"3(FF0HF.<YQ8@4I"%`1$1[@#M7W#;*]
M+#!+9IC+':OS,'C@^#B#/Z-(VXV=QT.PV!-D<I:_(Z*7Z`;659@E5',H()I2
M9R&*H.J\@=.J<*SSO&J'9='NKF$I49+RR%:J<6XEY=2.BD&J:T@]*T;&\M(H
ME$YN@=0]O9K&UCB1R3S.&DJ26^0M]W#C$XS//9Z'<*PP,&D-:I!1VT?3$LSF
MTW;5N!0%=HDLH4>B8@/4M4K0?ZL%%A_0U[?)K-?#\$-'!_0V[?)KT&'X(E@'
ML_`W[?)@X</P1C(/Z$.W=#Q8>SV1[0/9[/8C\';NC(\`#XF38/\`\OMHM`0R
MWD+LI\/:,'W(6W<?\#L.I47`6\A!HVE-'2K'$@W3":9U)RE+NXJ&3F)9G&+)
MN%FR9#D$U;U6CV&LV3.+=6(^Z5NZ1;AHK7Y:JRD>258SK>0,!$2L%8]0%1,<
M2"F7J!P*("`9V,;6-XC,5V*^Q^7XYRRGL/LT1Q<U&^3,HX@JY!U;3%@%R@QM
MT\T48PLQ)1S""F'0%(S>K^:B*G4$TP^^!"_Y@[>P/Y@^XLUS"WYMRKQB+VZY
MM<VPW7MVXSZ=D>1:YI$@W>/86A5J?N45&V"$L]D8QKI>*0L$5"A)IM51;&5$
M"@:RW^_6*)J-*IT+(6&T6>==I,(>#A(MLH[?R,@[6$J:+9N@F(C[1$>@``F$
M`':U<-4OJK?!M4/D-U4OV>6C-7:]F^J=<NK=["P5S8Q-F5@)"OVEFNV<.V3,
MZY%`.5,4C)J'^R?RKT5BLXQDZD'9F[5T^<%:LT#N7`H,F*+E\\6!)(?"DBFH
MJH;H4A3&$`&AX38,KY3X39=B^LQ,(L'(WCO>\:INW/ZA!N+5/05%E;4W2?L;
M2VJ+)Q*DB9YI"R:[%LJ=-`QTS$"Z[%K]NBZ)FF>03NR7&V3(KBQB(EF!0.IY
M#-!T_?O72YR(-6C5%=V]=*IMVZ2JZB:9I>&C^._++(8YG`EL\%;N0&%3F45F
MZ0YWK-B7Z"4FGJLU%S)O?DE@BIQE$2QFWC4!L)45O+^T"(]>@`(]P"8>[O[@
M*`B(_>#O'MC>4Z?QRY>8)`<C=!5RG`=BV_'$:-GFE:0:,DIF%IJD6O9G6GY[
M/6V+AG:\2VM5=@UW16Z@&(F8A@"RWZ\S36NT^HP[Z>L<X]*N=O&Q4<B9=TZ.
MBU1<.W!B$+T(FBFHLJ<0(0IC"`#NR^35S5*TGQ]V5YB=P:ZWG\KF4\]L;6HU
M:[(2L=4K(9"VQT+(P%O9JHEEF,9(!XA\QLGW=?X1-XR^``,(GZAX0`G7Q]3=
M>@>'IW_%V0257134<F$C9,ZJ9#N#%+XC%0*8P"L8I>\0+U'IV*HZ71;IF.1(
MIUU$TBF44'PIIE,H8H"=0>X`#VCV$QS%*4OB$1,(%``*`B81$P@'0H!U'X@[
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M$X]>C34-2I4;FH2#445>.:^G*A#E+XW@(@';`<TX*<D^27*S@:3#=/BN3/YZ
M&<I;LOPV>I\-!-,$0R_7+/GU-F2W6?E2*1[ZN(2,JDE&)J.%&[<2%.4/P?8_
MS?T_R=O5EQWDZUO#/2]UY<;AR!P.`:YIH-R>\CLVV;+Z8TSZN9:[K-8G8VVR
M\+(Q*M:6C"+^\L%&H><DDW^<[<(/3SY&-+*CND]Q1LDC8JD6L6R4A6-=BG"(
MW.KS-\AX]U5H28KK2^-8U-FM((NW`I&]V(<"=0XT>G1PEYR;!R<R6B<C>/*D
M%DA^*;"O3V"8SD^UUG3Y&3Y(<@Y^H0!X2.S6!K"R$.T]PKUEEY4&K?HX3*X*
M'W$LNL(E212455,4AU!!-,@G.($3*90X@4H]Q0$1^`.O;$[/K]JL62\;^+.Z
MQ5TXLXY8LFVACJ'(KDLW;NJ93=PU$%Z$$7FN;9Z2QR+>KU]<Q7TF\D!E9)=L
M@BV9CR3J\E*S;?\`JK)0BFX+3N>7EK`1#.PU`+Y'KP4D\K7T;H+8M:$%E_H0
MTE[NIT24`%1*4?5.@(V?F"27('G/*ZMC"4G0]!@6M^SF*X[9!$/K5"R,[5HV
M,+&-Y.M/F_SZR*AU6QRE(/=U^RF[-,JK(0]>B)*<E5VS-Y(N$8V)9K/WRJ$?
M'-W4@^63:MS"5%!)194P`4A3&$`'&=_V&SS>34["[;>:MP<XQV'*M31T&W:7
MI44XS:1Y*[=/*4SZMU"2?TJ3?Q-5JQE@^AFDHY?R+L72B2+;D%4\"5UR1D^-
MG+;CDUW6+I&<V%"^*UW%=OQ?6-7-F,/<*;)Q&GKU2B+EGF9V4=/14BM&BW!%
MV8#-S56%XG<E^2'+3AD_XWZ-)\EK1OJL]8J=F^WL;;1$\61S.\V:@TM^CH=K
MB75B)8*RR57CV$>V275:M%O)`WVAT].BY<E:-UW1F[)NH[>+@@D=446C5'JJ
MY<J@7PIIE`3'.(`'>/;AUN7&G1><W(_9*5RVJ]@D>*?)SCWI,=QXPW.;V]<0
M>J:.!KGB.3M,3NN1460>*5>:=3LR^\SJQ11<@[.J7D3$/XC3V"'&?Z&_.3(R
M6-Z8:&F$)FJ$N:+G+G#:JO#;$@UBC>6X"MIR:B#P/=S%\X2E-ZH$.\K6RUM;
MD7SNM6U8R]NW'O>*#`W/,FN"X]`*69&S77-X&N0R2DS5G[=)K(.FCU95N()H
MF\1/%_`(?QZAWA_E[:OZ,D8I?'^1>HOR7K'*[+]!92$N1'*>),M-KZIS_P`F
M9S?G&0@&Y[=0'4'$-DUDRHM=(1\M$3%Z#S[H?-C2L7QQ[-ZVM6N&%@Y!\;>2
MVM6*#XMM\UJ,=E[[B%I&3;[FM<JTC6;:G+JR,=#L#V5.<)[P_67169I(\;>-
M7(ZC9KISN%X%9F]8\V^5V*<D-$C]^TU(!K,_2,MXY9_.0BE4W:PN&RMED`<3
M@VAL20(T(W<@@94G[OI0^1A-LL;"4OG+&'W>/FI73*Y*SU6J56UIA5*AKSA1
M\A8UZ=*QL#'Q[B.F7!DY%@'NJ_FD4.4S^T917:%R;L+)IQHSG/O3OT7+-L9W
M[+(VG/&#./M'`S6H-"5J->;23:R!*V5`\0\CU)".(+F88BB9`4SF(9,QR%,*
M9O#XDQ,'B$AO`8Q!,7KT'H(AU]GV8_?_`.C_`$=N@?Q^_P#A'['X>[[_`/I[
M=XB(?$(]?XCV]G7\/X.G3\'V8_?^_P!@]O=]\>WQ?@^Y/A_G_#_3U[?S?Y!Z
M_P`_7L'WNW3[+O\`YO\`3VZ?`'P?![>O7\/;X?O=X]WL]G\W;KW_`,>G^C[5
M\/\`'X/\O;X?A_R]OA[O_7]A+<K5F4O([!)Y)#XDTDI.7</H:M9_%6:4M[B.
MJ<&L46E?>6.>DBK2KA#HJ_!FU*H(E0(`=.G=_'^;V]OA'\/;^/QB/=\(=_;_
*`*1^]_H_YH?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img3.jpg
<TEXT>
begin 644 img3.jpg
M_]C_X``02D9)1@`!`@$`9`!D``#_X0Z/17AI9@``34T`*@````@`"`$2``,`
M```!``$```$:``4````!````;@$;``4````!````=@$H``,````!``(```$Q
M``(````<````?@$R``(````4````F@$[``(````%````KH=I``0````!````
MM````.``#T)````G$``/0D```"<0061O8F4@4&AO=&]S:&]P($-3-"!7:6YD
M;W=S`#(P,3(Z,#,Z,C@@,3(Z,3`Z-#@`;FEC:P````.@`0`#`````0`!``"@
M`@`$`````0```F*@`P`$`````0```3@`````````!@$#``,````!``8```$:
M``4````!```!+@$;``4````!```!-@$H``,````!``(```(!``0````!```!
M/@("``0````!```-20````````!(`````0```$@````!_]C_X``02D9)1@`!
M`@``2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$``P(
M"`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,
M$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`%(`
MH`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"!`4&
M!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'
M!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R62
M4_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3T
MI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&
M!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E
M!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/55FNZ3<<GU
MVY=@`=N%<N+='^ML_G/YO\S;_P"B_8KM][ZMNVI]NXQ[(TU`]V]S?WE7Q.JX
MN7Z7IBUOVAF^HV5/8'"-WTGM:WZ*2EK<#*=8+*\M])F7!K00[V^GKZA?^ZU_
ML_PG_7?4$>F9=K+&NZC8YEDQM`;M][;/T;V19[-GI?36FLZOZO\`2*SNKQPQ
MQ()<USPX[7MR6^\/W>V]GJ)*6=T[/)$]3M;+MT!C!/N]38V6GV[!Z?\`44F]
M.RA4YAS'N<2]S;"-6E_[ONV_HW^^K?O9_@_YM3JZ-TVK+^VLI'VF218YSG$%
MQM>[9O<YK-SLG(^A_I5=24T,7I^71<VRW.MO8T$.K>&@$D-:UWM_<V*^DJM>
M>QSVLNK?CE\[/4@3M&YWYQ\4E),JA]]/ILL-1EIWMY]I#_$?NJD[I&46B,^U
MMC9_2"9XJK:[:Y[JW;6T?G,_G7VV+2!!$CA#R,:G)K%=P):'->(<YIW,(LK=
MNK+7>U[=R2FD_I^4[:/VC8`&["`&C<Z6NWEWTM_L_,_TBC^RLAYWU]0M:PF0
M&F1!+W[6N<]WM_2N;_4_XNGTW9]6^BUT^@S&`J]-M.S>^`RLM=4T>_V^GL9L
M?]-6<7IN#ANW8M7I0STPUI=MVASK-OISZ?T[+'?1_/24OAXV1C[O6R79.[4%
MX`(U>[\SV_1<RO\`ZU^^K*2#=>ZMS&MJ?;N,2R(&L>[<6I*3*%K#94YC7%A<
M"`\<B>ZJU=7PK6,>SU8L:+&CT;9+2`0Z/3_E(U.;CW6>DPN#]N[:]CV$@':7
M-]5K-W*2FJW`O#'-.>]VL,)`]A(V;6[2/WO9ZBC9TW)>PU_M&QA<UH=8V`\B
MI[K-';MK-WJ^G?L9]#8E=]7>D79(R;*-S]SGD;W[7/?&Y[V;MKG?N?N;[%"O
MZK=#8QK#CEY;M][WO+B6?0>]^_WO_>?^?^>DITJ6/KK#7O-KI)+R`"9,\-_=
M1$DDE/\`_]#U&[(IQVM=<\,#W!C2>[CPU9>"(KZ*#R,?_P!%5J[1D76YV518
MUOI4>F:7`>X[V[G[I/[RI8/\UT7_`,+_`/HJM)3L))))*4DDDDI2S[GXN5GT
M,]EPJ]5KVD!VUP#/WOSEH*I<`,_%C32V?C#$E*Z4`.FXP`@"MH`&@`A6UE4W
MYV+TL6MIILJHJ+P1<9<UHW?F4V,W?U;'K524I))))2D.[(IHV>L\,]1P8R>[
MCPW\$1-`//;A)30Z:8IP02)^R-TEL\5=MOJ?^";$9_\`RE3_`,1=_P!7CJM@
M7U4XV#ZM@8/L;7:EP$-%.YW^@]N__C?^FK>1C66VUWU7&I[&N9]$.!#RQWYW
M_%)*;"2J_9\[_N7_`.!M2^SYW_<O_P`#:DIM)*I]GSO^Y?\`X&U2P;+7UO%S
M@]U=CV;@-LAI]OM24__1]`IPFW=4Z@^]A=274.KG</>QCMQ!GW>U[%#",U]%
M)Y./_P"BJU.BFNWJO4338^JUKL<7/8:S):PN;4YA]1[/9:UWO8S^0GQ<1F1T
MC`LWV4OJQV%CZG;2-U0:YON#VN_S$E.HDJ_3[++L#&MM.ZRRFMSS$2XM:YVF
MBL)*4DDDDI2HNHJIZC0:V[3;ZKWZDR3L\5>5%];F=1H+K'6;_5<`Z/:(9[&;
M6M]J2ELC<[H=W+G'&?IJ23L=^\RI[O\`MI6:,O%R"X8]S+2R"X,<"0'3MF/W
MMJ6(",6H'0[1R"/^J?<[_P`%>JN:[,Q;;\VFNNZH4-WM?8ZMP](VV>W;5<U^
M]MO\A)3H))@9$ITE*0KL>F_9ZK=WIN#VZD0X=]$5"OJ?;LVVOJV.#CLV^X#_
M``;][7^S^JDI#TX_Y*Q3/_:>LS_8:BXFW[)3MC;Z;8C;$0./2_1?]M_HT+IO
M_)6*?^Z]?']1J/C3]GJW3.QLSNF8_.]0-L_[<;O24D22224I4*;K,6Q]=U%@
M9=>[9<"PL]YFOBSUOY'\TKZJ=0^C1_Q]?_5)*?_2]0O]<`''#-Y<-Q?,;?SO
MH_G*OTO3H^)'_<:N/\QJM6/+&%P:7D?FMB3_`)VU9_3KKZNGX]!Q+;/2J96Y
MS'4EI+&BMVUWK_1]J2E=.Q',Z?AVXFREPQ&5[=D@^QAID-?5_,NW[?\`C;%<
MIR?4<UCZW4VN8+-CX^#V[FEW\TYS=ZH8S[L-K7MKR'85=41:^@@!NWT[&V>L
MWVMJW[][T=^;:US<AV-:VEK'!SB^H#W%A:_^D^E^;^=[_P#1_P"$24WTE4?G
M6UL+[,2YC&B7.<ZD``=S^L)/SK6-+GXES&CESG4`?^W"2FVJ+O7_`&C1ZH:&
M_I?3VS.V&?34SG/:6BS%MK#G!H<YU,2?A>7*&6^QN;0]M+K`P/;#2P$[Q/L]
M5]6[9Z?O24S`^R65,]6*-KAM<*VM&V7^W9Z.WV._<L_1U_X/Z=DNI`GIV4`)
M)IL@#4_1<@Y&3=96ZG['<'O8X,EU(/&TNGUG_O\`[B(,ZTO+!B7%[0"YNZB0
M#.TD?:/SMJ2DN/E8V0V<>YEP;&[TW!T3X[495!G6N+@W#N)88<`ZB08#H=^L
M?NN2&?8YSFMQ+BYFCVAU,B1N&[]824VT*[[1#?0#"=PW[YC;^=MV_GH#.H/>
M7-9BVO<PP\-?02T^#OUCVHE>6Y[7'T'M<QS6EA-9/N.W=^CLL;[$E,>EQ^S,
M2./0K_ZAJ:S$=3-F$&5%M3F>DVL$.CW41[Z/YMV_V[]GZ3_!H'3\B^O`QZQB
M6V;*F,WL=26G:T-W,=]H^BC'J#Q6;3BVBH`N+RZ@-#1J7%QR$E)FYF([;%]<
MNB!O:9W;MO?\[TK?^VWHRHY&2]]#V78=S:WC8YQ=1^=[/SKRWNF9EY%.\W8U
MVUSP*RY],^X-8UG\^WW.M^BDIOJKU#Z-'_'U_P#5)G9]C(WXEK9(`EU`DGAO
M](0<J^ZPT-=BV5_IJSN>ZD"`?=]&]SO\U)3_`/_3]53!K6MVM`#?`#35.DDI
MS\IG5VDUX3,1V.1M:RW>W:W;M@MK#V6>_P#,_1?HU)K.JO%;+F8PJ.\7!N]W
MMEOH-K:YK&_0W^KO5Y))3EO_`.<1;#ZL&UI9#V;K!)AV_P"E6]NQ[O3]CE>I
M;>^@-S6UFPD[FLES(GV_S@1DDE,7UUV`"QH>`9`<)U'?5.6M)!(!+=0?#MHH
M7WTX]3KKWBNI@E[W:`#S56KK?2;K6TU9=3[+#M8P.DD^`24V<AEI878^P9`$
M5OL!<!);N^B6O_-_>5.D==]<.MKPVUDM#RQUA>6@NGZ3&_FGV,1W=3Z>QSF.
MR&->P[7-)U!)]/4?UV[5+&S\++<YN-<VXL^EL,@:N9S_`%F.24UBWKPJ:Y@P
MQ>\/]7^<VA^GH.:[Z=K6?X7=Z>__`(-/C_MH9`]>K$;6XS:^MSRYWT@W:UU;
M?<UNSZ;D>_J6!CFUM][*S0UK[0XQM:\[*W._KN4GYN)6QSWVM:UC_3<XF`'Z
M>P_RO<DI*UC&DEK0TN,N($2?-)M;&N<YK0US]7$""?ZRK'JW30).36!,:N'(
M&_\`Z@[D7&R\;+87XU@M8T@%S=1)#7_]2]J2DK6M:T-:`UHT`&@"S\BOK+2Z
MK#9AG&(+6-LWMVMAH#7,K#V6>[?_`*):*22FB&]7?#;6XH9M=N'O?[]_Z&`X
M5^QM/NL_X9!=_P`XB?=5@O;[2&EUH(<(]VXUNW;;/>SVL6HDDI#2RU]3#EMK
M-S3)V26@S[2S>-R(^MCXWM#MI#FR)@CAP4DDE/\`_]3U5)?*J22GZJ27RJDD
MI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JD
ME\JI)*?JI)?*J22G_]G_[1-X4&AO=&]S:&]P(#,N,``X0DE-!`0``````#@<
M`@```@"C'`)0``1N:6-K'`(%`"--:6-R;W-O9G0@5V]R9"`M(#(P,3(@1F]R
M;2!3+3$@+2!V-CA"24T$)0``````$*Q[X%FCQ-LT9RVT*O@]HS4X0DE-`^T`
M`````!``9`````$``0!D`````0`!.$))300F```````.`````````````#^`
M```X0DE-!`T```````0```!X.$))3009```````$````'CA"24T#\P``````
M"0```````````0`X0DE-)Q````````H``0`````````".$))30/U``````!(
M`"]F9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H`
M```&```````!`#4````!`"T````&```````!.$))30/X``````!P``#_____
M________________________`^@`````____________________________
M_P/H`````/____________________________\#Z`````#_____________
M________________`^@``#A"24T$"```````$`````$```)````"0``````X
M0DE-!!X```````0`````.$))300:``````-M````!@`````````````!.```
M`F(````<`#(`,``Q`#(`(`!&`&\`<@!M`"``4P`M`#$`(``M`"``=@`V`"``
M1P!%`$\`5@!!`%@`+0`R`#,````!``````````````````````````$`````
M`````````F(```$X``````````````````````$`````````````````````
M````$`````$```````!N=6QL`````@````9B;W5N9'-/8FIC`````0``````
M`%)C=#$````$`````%1O<"!L;VYG``````````!,969T;&]N9P``````````
M0G1O;6QO;F<```$X`````%)G:'1L;VYG```"8@````9S;&EC97-6;$QS````
M`4]B:F,````!```````%<VQI8V4````2````!W-L:6-E241L;VYG````````
M``=G<F]U<$E$;&]N9P`````````&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG
M:6X````-875T;T=E;F5R871E9`````!4>7!E96YU;0````I%4VQI8V54>7!E
M`````$EM9R`````&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4
M;W`@;&]N9P``````````3&5F=&QO;F<``````````$)T;VUL;VYG```!.```
M``!29VAT;&]N9P```F(````#=7)L5$585`````$```````!N=6QL5$585```
M``$```````!-<V=E5$585`````$```````9A;'1486=415A4`````0``````
M#F-E;&Q497AT27-(5$U,8F]O;`$````(8V5L;%1E>'1415A4`````0``````
M"6AO<GI!;&EG;F5N=6T````/15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0`
M```)=F5R=$%L:6=N96YU;0````]%4VQI8V5697)T06QI9VX````'9&5F875L
M=`````MB9T-O;&]R5'EP965N=6T````115-L:6-E0D=#;VQO<E1Y<&4`````
M3F]N90````ET;W!/=71S971L;VYG``````````IL969T3W5T<V5T;&]N9P``
M```````,8F]T=&]M3W5T<V5T;&]N9P`````````+<FEG:'1/=71S971L;VYG
M```````X0DE-!"@```````P````"/_`````````X0DE-!!0```````0````"
M.$))300,``````UE`````0```*````!2```!X```F<````U)`!@``?_8_^``
M$$I&248``0(``$@`2```_^T`#$%D;V)E7T--``'_[@`.061O8F4`9(`````!
M_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.
M%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_
MP``1"`!2`*`#`2(``A$!`Q$!_]T`!``*_\0!/P```04!`0$!`0$`````````
M`P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)"@L0``$$
M`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T
M<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2D
MA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$
M`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#
M4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34
MY/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#U
M59KNDW')]=N78`';A7+BW1_K;/YS^;_,V_\`HOV*[?>^K;MJ?;N,>R--0/=O
M<W]Y5\3JN+E^EZ8M;]H9OJ-E3V!PC=])[6M^BDI:W`RG6"RO+?29EP:T$.]O
MIZ^H7_NM?[/\)_UWU!'IF7:RQKNHV.99,;0&[?>VS]&]D6>S9Z7TUIK.K^K_
M`$BL[J\<,<2"7-<\..U[<EOO#]WMO9ZB2EG=.SR1/4[6R[=`8P3[O4V-EI]N
MP>G_`%%)O3LH5.8<Q[G$O<VPC5I?^[[MOZ-_OJW[V?X/^;4ZNC=-JR_MK*1]
MIDD6.<YQ!<;7NV;W.:S<[)R/H?Z574E-#%Z?ET7-LMSK;V-!#JWAH!)#6M=[
M?W-BOI*K7GL<]K+JWXY?.SU($[1N=^<?%)23*H??3Z;+#49:=[>?:0_Q'[JI
M.Z1E%HC/M;8V?T@F>*JVNVN>ZMVUM'YS/YU]MBT@01(X0\C&IR:Q7<"6AS7B
M'.:=S"+*W;JRUWM>W<DII/Z?E.VC]HV`!NP@!HW.EKMY=]+?[/S/](H_LK(>
M=]?4+6L)D!ID02]^UKG/=[?TKF_U/^+I]-V?5OHM=/H,Q@*O3;3LWO@,K+75
M-'O]OI[&;'_35G%Z;@X;MV+5Z4,],-:7;=H<ZS;Z<^G].RQWT?STE+X>-D8^
M[ULEV3NU!>`"-7N_,]OT7,K_`.M?OJRD@W7NK<QK:GV[C$LB!K'NW%J2DRA:
MPV5.8UQ87`@/'(GNJM75\*UC'L]6+&BQH]&V2T@$.CT_Y2-3FX]UGI,+@_;N
MVO8]A(!VES?5:S=RDIJMP+PQS3GO=K#"0/82-FUNTC][V>HHV=-R7L-?[1L8
M7-:'6-@/(J>ZS1V[:S=ZOIW[&?0V)7?5WI%V2,FRC<_<YY&]^USWQN>]F[:Y
MW[G[F^Q0K^JW0V,:PXY>6[?>][RXEGT'O?O][_WG_G_GI*=*ECZZPU[S:Z22
M\@`F3/#?W41)))3_`/_0]1NR*<=K77/#`]P8TGNX\-67@B*^B@\C'_\`15:N
MT9%UN=E46-;Z5'IFEP'N.]NY^Z3^\J6#_-=%_P#"_P#Z*K24["2222E))))*
M4L^Y^+E9]#/9<*O5:]I`=M<`S][\Y:"J7`#/Q8TTMGXPQ)2NE`#IN,`(`K:`
M!H`(5M95-^=B]+%K::;*J*B\$7&7-:-WYE-C-W]6QZU4E*22224I#NR*:-GK
M/#/4<&,GNX\-_!$30#SVX24T.FF*<$$B?LC=);/%7;;ZG_@FQ&?_`,I4_P#$
M7?\`5XZK8%]5.-@^K8&#[&UVI<!#13N=_H/;O_XW_IJWD8UEMM=]5QJ>QKF?
M1#@0\L=^=_Q22FPDJOV?._[E_P#@;4OL^=_W+_\``VI*;22J?9\[_N7_`.!M
M4L&RU];Q<X/=78]FX#;(:?;[4E/_T?0*<)MW5.H/O874EU#JYW#WL8[<09]W
MM>Q0PC-?12>3C_\`HJM3HIKMZKU$TV/JM:['%SV&LR6L+FU.8?4>SV6M=[V,
M_D)\7$9D=(P+-]E+ZL=A8^IVTC=4&N;[@]KO\Q)3J)*OT^RR[`QK;3NLLIK<
M\Q$N+6N=IHK"2E))))*4J+J*J>HT&MNTV^J]^I,D[/%7E1?6YG4:"ZQUF_U7
M`.CVB&>QFUK?:DI;(W.Z'=RYQQGZ:DD['?O,J>[_`+:5FC+Q<@N&/<RTL@N#
M'`D!T[9C][:EB`C%J!T.T<@C_JGW._\`!7JKFNS,6V_-IKKNJ%#=[7V.K</2
M-MGMVU7-?O;;_(24Z"28&1*=)2D*['IOV>JW=Z;@]NI$.'?1%0KZGV[-MKZM
MC@X[-ON`_P`&_>U_L_JI*0]./^2L4S_VGK,_V&HN)M^R4[8V^FV(VQ$#CTOT
M7_;?Z-"Z;_R5BG_NO7Q_4:CXT_9ZMTSL;,[IF/SO4#;/^W&[TE)$DDDE*5"F
MZS%L?7=18&77NV7`L+/>9KXL];^1_-*^JG4/HT?\?7_U22G_TO4+_7`!QPS>
M7#<7S&W\[Z/YRK]+TZ/B1_W&KC_,:K5CRQA<&EY'YK8D_P"=M6?TZZ^KI^/0
M<2VSTJF5N<QU):2QHK=M=Z_T?:DI73L1S.GX=N)LI<,1E>W9(/L8:9#7U?S+
MM^W_`(VQ7*<GU'-8^MU-KF"S8^/@]NYI=_-.<W>J&,^[#:U[:\AV%75$6OH(
M`;M].QMGK-]K:M^_>]'?FVM<W(=C6MI:QP<XOJ`]Q86O_I/I?F_G>_\`T?\`
MA$E-])5'YUM;"^S$N8QHESG.I``'<_K"3\ZUC2Y^)<QHY<YU`'_MPDIMJB[U
M_P!HT>J&AOZ7T]LSMAGTU,YSVEHLQ;:PYP:'.=3$GX7ERAEOL;FT/;2ZP,#V
MPTL!.\3[/5?5NV>G[TE,P/LEE3/5BC:X;7"MK1ME_MV>CM]COW+/T=?^#^G9
M+J0)Z=E`"2:;(`U/T7(.1DW65NI^QW![V.#)=2#QM+I]9_[_`.XB#.M+RP8E
MQ>T`N;NHD`SM)'VC\[:DI+CY6-D-G'N9<&QN]-P=$^.U&509UKBX-P[B6&'`
M.HD&`Z'?K'[KDAGV.<YK<2XN9H]H=3(D;AN_6$E-M"N^T0WT`PG<-^^8V_G;
M=OYZ`SJ#WES68MKW,,/#7T$M/@[]8]J)7EN>UQ]![7,<UI8363[CMW?H[+&^
MQ)3'I<?LS$CCT*_^H:FLQ'4S9A!E1;4YGI-K!#H]U$>^C^;=O]N_9^D_P:!T
M_(OKP,>L8EMFRIC-['4EIVM#=S'?:/HHQZ@\5FTXMHJ`+B\NH#0T:EQ<<A)2
M9N9B.VQ?7+H@;VF=V[;W_.]*W_MMZ,J.1DO?0]EV'<VMXV.<74?G>S\Z\M[I
MF9>13O-V-=M<\"LN?3/N#6-9_/M]SK?HI*;ZJ]0^C1_Q]?\`U29V?8R-^):V
M2`)=0))X;_2$'*ONL-#78ME?Z:L[GNI`@'W?1O<[_-24_P#_T_54P:UK=K0`
MWP`TU3I)*<_*9U=I->$S$=CD;6LMWMVMV[8+:P]EGO\`S/T7Z-2:SJKQ6RYF
M,*CO%P;O=[9;Z#:VN:QOT-_J[U>224Y;_P#G$6P^K!M:60]FZP28=O\`I5O;
ML>[T_8Y7J6WOH#<UM9L).YK)<R)]O\X$9))3%]==@`L:'@&0'"=1WU3EK202
M`2W4'P[:*%]]./4ZZ]XKJ8)>]V@`\U5JZWTFZUM-674^RP[6,#I)/@$E-G(9
M:6%V/L&0!%;[`7`26[OHEK_S?WE3I'7?7#K:\-M9+0\L=87EH+I^DQOYI]C$
M=W4^GL<YCLAC7L.US2=02?3U']=NU2QL_"RW.;C7-N+/I;#(&KF<_P!9CDE-
M8MZ\*FN8,,7O#_5_G-H?IZ#FN^G:UG^%W>GO_P"#3X_[:&0/7JQ&UN,VOK<\
MN=](-VM=6WW-;L^FY'OZE@8YM;?>RLT-:^T.,;6O.RMSOZ[E)^;B5L<]]K6M
M8_TW.)@!^GL/\KW)*2M8QI):T-+C+B!$GS2;6QKG.:T-<_5Q`@G^LJQZMTT"
M3DU@3&KAR!O_`.H.Y%QLO&RV%^-8+6-(!<W420U__4O:DI*UK6M#6@-:-`!H
M`L_(KZRTNJPV89QB"UC;-[=K8:`US*P]EGNW_P"B6BDDIHAO5WPVUN*&;7;A
M[W^_?^A@.%?L;3[K/^&07?\`.(GW58+V^TAI=:"'"/=N-;MVVSWL]K%J))*0
MTLM?4PY;:S<TR=DEH,^TLWC<B/K8^-[0[:0YLB8(X<%)))3_`/_4]527RJDD
MI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JD
ME\JI)*?JI)?*J22GZJ27RJDDI__9`#A"24T$(0``````50````$!````#P!!
M`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E`"``
M4`!H`&\`=`!O`',`:`!O`'``(`!#`%,`-`````$`.$))300&```````'``@!
M`0`!`0#_X1.`:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K
M970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_
M/B`\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K
M/2)!9&]B92!835`@0V]R92`T+C(N,BUC,#8S(#4S+C,U,C8R-"P@,C`P."\P
M-R\S,"TQ.#HQ,CHQ."`@("`@("`@(CX@/')D9CI21$8@>&UL;G,Z<F1F/2)H
M='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS>6YT87@M;G,C(CX@
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL;G,Z9&,](FAT='`Z
M+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIX;7`](FAT='`Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM;&YS.G!D9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]P9&8O,2XS+R(@>&UL;G,Z>&UP34T](FAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T179T/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V5%=F5N=",B('AM;&YS
M.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S
M;W5R8V52968C(B!X;6QN<SIP:&]T;W-H;W`](FAT='`Z+R]N<RYA9&]B92YC
M;VTO<&AO=&]S:&]P+S$N,"\B('AM;&YS.G1I9F8](FAT='`Z+R]N<RYA9&]B
M92YC;VTO=&EF9B\Q+C`O(B!X;6QN<SIE>&EF/2)H='1P.B\O;G,N861O8F4N
M8V]M+V5X:68O,2XP+R(@9&,Z9F]R;6%T/2)I;6%G92]J<&5G(B!X;7`Z0W)E
M871E1&%T93TB,C`Q,BTP,RTR.%0Q,CHP.3HQ,2TP-CHP,"(@>&UP.D-R96%T
M;W)4;V]L/2)04V-R:7!T-2YD;&P@5F5R<VEO;B`U+C(N,B(@>&UP.DUO9&EF
M>41A=&4](C(P,3(M,#,M,CA4,3(Z,3`Z-#@M,#8Z,#`B('AM<#I-971A9&%T
M841A=&4](C(P,3(M,#,M,CA4,3(Z,3`Z-#@M,#8Z,#`B('!D9CI0<F]D=6-E
M<CTB06-R;V)A="!$:7-T:6QL97(@.2XP+C`@*%=I;F1O=W,I(B!X;7!-33I$
M;V-U;65N=$E$/2)U=6ED.C0W-&4U9&4Q+6,Q9C`M-#AF.2UA8F8V+69E83(T
M869F-#=D."(@>&UP34TZ26YS=&%N8V5)1#TB>&UP+FEI9#I$.4,U-S$U,3`Q
M-SE%,3$Q03<S1#A%,3A#1C$Y.3E%-B(@>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/2)U=6ED.C0W-&4U9&4Q+6,Q9C`M-#AF.2UA8F8V+69E83(T869F-#=D
M."(@<&AO=&]S:&]P.D-O;&]R36]D93TB,R(@<&AO=&]S:&]P.DE#0U!R;V9I
M;&4](G-21T(@245#-C$Y-C8M,BXQ(B!T:69F.D]R:65N=&%T:6]N/2(Q(B!T
M:69F.EA297-O;'5T:6]N/2(Q,#`P,#`P+S$P,#`P(B!T:69F.EE297-O;'5T
M:6]N/2(Q,#`P,#`P+S$P,#`P(B!T:69F.E)E<V]L=71I;VY5;FET/2(R(B!T
M:69F.DYA=&EV941I9V5S=#TB,C4V+#(U-RPR-3@L,C4Y+#(V,BPR-S0L,C<W
M+#(X-"PU,S`L-3,Q+#(X,BPR.#,L,CDV+#,P,2PS,3@L,S$Y+#4R.2PU,S(L
M,S`V+#(W,"PR-S$L,C<R+#,P-2PS,34L,S,T,S([-$(Y-3$P.#`Y,D1!1$)!
M,#)&045!,35$-#DW0T%%,C(B(&5X:68Z4&EX96Q81&EM96YS:6]N/2(V,3`B
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M+#0Q.3DU+#0Q.3DV+#0R,#$V+#`L,BPT+#4L-BPW+#@L.2PQ,"PQ,2PQ,BPQ
M,RPQ-"PQ-2PQ-BPQ-RPQ."PR,"PR,BPR,RPR-"PR-2PR-BPR-RPR."PS,#LT
M-#DR03$Q-S8V1#(W,30X-S,V0CA#13A&,C)!,#,R0B(^(#QD8SIC<F5A=&]R
M/B`\<F1F.E-E<3X@/')D9CIL:3YN:6-K/"]R9&8Z;&D^(#PO<F1F.E-E<3X@
M/"]D8SIC<F5A=&]R/B`\9&,Z=&ET;&4^(#QR9&8Z06QT/B`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B/DUI8W)O<V]F="!7;W)D("T@,C`Q,B!&;W)M
M(%,M,2`M('8V/"]R9&8Z;&D^(#PO<F1F.D%L=#X@/"]D8SIT:71L93X@/'AM
M<$U-.DAI<W1O<GD^(#QR9&8Z4V5Q/B`\<F1F.FQI('-T179T.F%C=&EO;CTB
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M=F5D(B!S=$5V=#II;G-T86YC94E$/2)X;7`N:6ED.D0Y0S4W,34Q,#$W.44Q
M,3%!-S-$.$4Q.$-&,3DY.44V(B!S=$5V=#IW:&5N/2(R,#$R+3`S+3(X5#$R
M.C$P.C0X+3`V.C`P(B!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!0:&]T
M;W-H;W`@0U,T(%=I;F1O=W,B('-T179T.F-H86YG960](B\B+SX@/"]R9&8Z
M4V5Q/B`\+WAM<$U-.DAI<W1O<GD^(#QX;7!-33I$97)I=F5D1G)O;2!S=%)E
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M<&UE=&$^("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@/#]X<&%C:V5T(&5N9#TB
M=R(_/O_B#%A)0T-?4%)/1DE,10`!`0``#$A,:6YO`A```&UN=')21T(@6%E:
M(`?.``(`"0`&`#$``&%C<W!-4T94`````$E%0R!S4D="```````````````!
M``#VU@`!`````-,M2%`@(```````````````````````````````````````
M````````````````````````$6-P<G0```%0````,V1E<V,```&$````;'=T
M<'0```'P````%&)K<'0```($````%')865H```(8````%&=865H```(L````
M%&)865H```)`````%&1M;F0```)4````<&1M9&0```+$````B'9U960```-,
M````AG9I97<```/4````)&QU;6D```/X````%&UE87,```0,````)'1E8V@`
M``0P````#')44D,```0\```(#&=44D,```0\```(#&)44D,```0\```(#'1E
M>'0`````0V]P>7)I9VAT("AC*2`Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP
M86YY``!D97-C`````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M$G-21T(@245#-C$Y-C8M,BXQ````````````````````````````````````
M``````````````````````````````!865H@````````\U$``0````$6S%A9
M6B``````````````````````6%E:(````````&^B```X]0```Y!865H@````
M````8ID``+>%```8VEA96B`````````DH```#X0``+;/9&5S8P`````````6
M245#(&AT='`Z+R]W=W<N:65C+F-H```````````````6245#(&AT='`Z+R]W
M=W<N:65C+F-H````````````````````````````````````````````````
M`````````````&1E<V,`````````+DE%0R`V,3DV-BTR+C$@1&5F875L="!2
M1T(@8V]L;W5R('-P86-E("T@<U)'0@``````````````+DE%0R`V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``````````````
M``````````````!D97-C`````````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ```````````````L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````````````
M````````````````=FEE=P``````$Z3^`!1?+@`0SQ0``^W,``03"P`#7)X`
M```!6%E:(```````3`E6`%````!7'^=M96%S``````````$`````````````
M```````````"CP````)S:6<@`````$-25"!C=7)V````````!``````%``H`
M#P`4`!D`'@`C`"@`+0`R`#<`.P!``$4`2@!/`%0`60!>`&,`:`!M`'(`=P!\
M`($`A@"+`)``E0":`)\`I`"I`*X`L@"W`+P`P0#&`,L`T`#5`-L`X`#E`.L`
M\`#V`/L!`0$'`0T!$P$9`1\!)0$K`3(!.`$^`44!3`%2`5D!8`%G`6X!=0%\
M`8,!BP&2`9H!H0&I`;$!N0'!`<D!T0'9`>$!Z0'R`?H"`P(,`A0"'0(F`B\"
M.`)!`DL"5`)=`F<"<0)Z`H0"C@*8`J("K`*V`L$"RP+5`N`"ZP+U`P`#"P,6
M`R$#+0,X`T,#3P-:`V8#<@-^`XH#E@.B`ZX#N@/'`],#X`/L`_D$!@03!"`$
M+00[!$@$501C!'$$?@2,!)H$J`2V!,0$TP3A!/`$_@4-!1P%*P4Z!4D%6`5G
M!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2`99!FH&>P:,!IT&KP;`!M$&
MXP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'^`@+"!\(,@A&"%H(;@B"
M")8(J@B^"-((YPC["1`))0DZ"4\)9`EY"8\)I`FZ"<\)Y0G["A$*)PH]"E0*
M:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@`N8"[`+R`OA"_D,$@PJ#$,,7`QU
M#(X,IPS`#-D,\PT-#28-0`U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.
MT@[N#PD/)0]!#UX/>@^6#[,/SP_L$`D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/
M$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3`Q,C$T,38Q.#$Z03Q1/E%`84
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MN#/Q-"LT932>--@U$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.%`XC#C(
M.04Y0CE_.;PY^3HV.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B`^
M8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#
M1$=$BD3.11)%546:1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*
M-TI]2L1+#$M32YI+XDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q
M4+M1!E%049M1YE(Q4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=7
M1%>25^!8+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:
M7FQ>O5\/7V%?LV`%8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UE
MDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(
M;6!MN6X2;FMNQ&\>;WAOT7`K<(9PX'$Z<95Q\')+<J9S`7-=<[AT%'1P=,QU
M*'6%=>%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!
M?:%^`7YB?L)_(W^$?^6`1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&
M#H9RAM>'.X>?B`2(:8C.B3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.
MCS:/GI`&D&Z0UI$_D:B2$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"8
M3)BXF229D)G\FFB:U9M"FZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&V
MHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6K
MZ:Q<K-"M1*VXKBVNH:\6KXNP`+!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!
MMGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'#`
M[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNV
MS#7,M<TUS;7.-LZVSS?/N-`YT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC7
M7-?@V&38Z-ELV?':=MK[VX#<!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;
MXV/CZ^1SY/SEA.8-YI;G'^>IZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O
M0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW
M_`?\F/TI_;K^2_[<_VW____N`"%!9&]B90!D0`````$#`!`#`@,&````````
M````````_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"`@$"
M`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P/_P@`1"`$X`F(#`1$``A$!`Q$!_\0`O@`!``,!`0$!`0$!````````
M``<("08%!`,*`@$!`0`````````````````````0``(!`P(%`P0"`@,`````
M``<(!@0%"0`#$$`"&3D@,#@!-3<8%C9@L(`3%1$``00"`0`&`PP%"04$"P``
M!0(#!`8!!P@`$1(3%`D0%7@@,$`AM!:6MG>WUSDB(S,7N'76&#B8V'F9N6`Q
M,C670M39.H!!4D,D)94F-C<9$@$```````````````````"P_]H`#`,!`0(1
M`Q$```#^_@`&<I6XY@T_(P.N/1/T.1)+*B$UG8GE'DD'%[R"SF3J#BR9RQH`
M`!0,XLZ0AD_<LR2H<`1"1>=>>:2N=8246!`````!6HB8D(XL\XF`A0GPIF:`
M$F`````&;Y1\[,M\3\9]$)$@E=BR1(96P[\BP_R?:73/1*PD6'R%^#3(```R
M((E)>/8*.EASN"`C[B:C@2&B1SFRW!J6`````"CIGT=H=F1^2Z?"0(>P74-`
M```````````````````````````````````````````````"NIPQ\!/1^YT!
M2<O$=.````````")2&#_`$=T0`?@3(6G````````*WGT$9$ND+GUG_3IBUP`
M```````!FT4M/;/+-`#(`[HW3)B````````.',:"F!/!:,H66O/,-LSJ````
M````9J%,#!TV=*HD^ECR9#7T````````````````````````````````````
M``````'FF*I.Y1HN:7%+,`````````%9BBA)A:TL6``````````9^E/RSI:8
M``EPZ,`````````'GF3YK@9`&OX`````````!$YBJ6!-@0``````````8Y%S
MBEQ=$`K(:M``````````\\RI-9C(`U_``````````(G*X$4&GP``````````
M,P#3\JL6I`,P33X`````````'GF5)K,9`&OX`````````!$Y7`B@T^``````
M````!F`:?E5BU(!F":?`````````%?CYRD1K,9`&OX`````````*X''',$4&
MGP`````````.9*S%<S4LJL6I`,P33X`````````IP?*5J-9C(`U_````````
M`!2P\4_8B@T^`````````!RIG&><:KE5BU(!F":?`````````_,_0\\RI-9C
M(`U_``````````(G*X$4&GP``````````,P#3\JL6I`,#RV(`````!9LM(`>
M>?R[G]3!YYE2:S&0!K^``````````1.5P.(.>`)S+F`````````S`-/RG!<<
M````````S!-/@#_)@\;QGGF5)K,9`&OX`````````!$Y7`D@L^`9@FGP````
M````,P#3\Q=+V%G3V0``````#,$T^`/A/YR#4PXPX4UF,@#7\`````````&>
MARI)QWQ:D`S!-/@```````1R90D@FL8!2XNB```````9@FGP!^1_*\?T_'GF
M:)K,9`&OX`````````.3(I(:.^+4@&8)I\```````#_)&)1`T_`*7%T0````
M``#,$T^`/C/YTS^C@\\RI-9C(`U_``````````(G*X'K%T0#,$T^````````
M!F`:?@%+BZ(``````!@D6O+;EASQS-@T_//,J368R`-?P`````````")RN!Z
MQ=$`P8++EZ29P```````9@&GX!4PMF```````?*?49@&GY_P_E!/Z@3F#/XU
MF,!36PL<`````````1V0V<`>L71`!'Y4`O\`@``````%8BJYJ*`56+4@````
M```&8!I^#$`OX<:0<:S%.C*H_H:`````````*@$<GO'0%QP`1^5`+_@`````
M`X<R]/=-70"L!9\````````S`-/P?S[G]!!YYE2:S`QQ-C@`````````1.5P
M.^+4@`^,R#(`-ER<```````9@&GX!6`L^````````9@&GYSYA";_`!YYE2:S
M`QQ-C@`````````1.5P.^+4@``J`2`3^``````#,`T_`*P%GP```````#,`T
M_`!YYE2:S`Q5-`2J)JN````````")RN!W!WI]!-0`*@$@$_@``````S`-/P"
MC!U1ZA:D```````S`-/P"K1#)$AK,#)$UN*RG-'P%S@``````"IQ"YV1=HYL
MIV7U`!4`D`G\`````'AF79_TU?``,TSN2^8``````,P#3\`@8]\SS-9@9(FM
MP!ET6?.E+`@`````$`'@$;%YP4X+C@`J`2`3^`````#P2`"K)J&``"FY<@``
M````&8!I^`#SS*DUF!DB:W``%3"V8``````(G*X%YP5_/`.V)I!')G,=\:0@
M`````&8!I^```4N!ZAYI<\````&8!I^`#SS*DUF!F>?"?[-.P"F9<P``````
M$3E<"\X`*<%QP````````9@&GX````*(D@%ACJ````9@&GX`(],VS68`&;YI
M``4S+F```````K>107G`!6HLJ````````<:9Y&GX````!%QP98T```&8!I^`
M#/(K"38#A3N@#PSW`>&?H>P".21@>:<^=D#ERYQ9DHX5,)7!PYW`/A/V/H!Q
MYV`!')(P.=/Q.H!P9H8021N>:`<*=T#R3U@#BSM`1Z=\?H?B<2=X#G3G38,`
M`H,7Y!3PM.>X#,<TX!2XLV=L#.@T7!&)2PTA!0PD8M:<V5J+<@HH7K!3XGTD
M0%$"]X!G0:+@S<)R+8@H@3@3^9RFC0!0`O\`@SX-!P"B1>T%)"SYWA\9D8:_
M@JH0N:)@```')'TG2'*G5'PG&GZ'Z'0'L```````')GT'0'-G4'.GGGXGADJ
M````````C`D\Y,ZP'('+DDG"DD`````````J.92E=";BQ!5@UK,_B-RLIVY8
MTVM)5`````!0PSA([.?-$3.PV:,EB-":R(SNC^D@``````P3*GGT%@"VA%!)
MY70I,2:?H:[F@@``````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M```/',&0"7S9\R7.1/).M($-#2]H,F"ZYEB:?$D$+%3"/RQ95(Z(AP_H7```
M````````````````````````````````````````````````/__:``@!`@`!
M!0#_`%W?_]H`"`$#``$%`/\`7=__V@`(`0$``04`]$M=&3A9S9BW;OQ(R=.2
M4M1P*B<K3"L5%T2<S(06PL&V1#<L6!TEEE=IFS9`^/1VF?95:.ENS4K]8RL\
MC7EM=#X(W"LEX`$:=!9II2V]ZE5O%R@^051"5)6AR"6&%P@6F0;FB@W3>1RD
M9[>[<,%8XC3Y*S-;:/<C*VR=9`NVB_L17>N6'D[VO)`'7_I):1JIC35:,B$=
M=4OQUUE#R-4\J5BJR%*1L1>Z,X'K-UCU\E2+%_A;N[)">;8=I@H6[NZZTZWG
M=VWR^NP:A^_PGEA2LV0)2Y#?Q0T(8-UH]PWGWH'I`@K8=$9F]E=M8I-&ZT\D
MK<9ZD;.C$\MA3:!`B7>5G@\6S)"3VC!@:D.-[(-3M*`H`7X`3ZGVR1"*RZLE
M2JH2HC5V,-&>W@$?7J5Q\'W<SVR_VJP""=19>%74LF*%/[<$S!&5_OJ4&:0#
M2%@.2P!OFH@-_9(\SQ733+`_#UEWK<5`JH18"PS3]([ZKK!695C?'U35"WRI
M>KY2=4N'IM/2[S<DL:+E$*L+HM]+2!8QWCR%<L!-1ZRX&)Y/C)TA4]0J51X>
M2FO)UEMQ.L[WV],#56+@H*^7$"BBWCTCV]9TO462*J20VJ<L%<@9$?3MAI))
M@N4:\Z4ZB%ZGBD97$JPFS`%1)2"7%4/;V(R6_<:H=4]\)I74^ZG7H%`@)XQF
M5W`]@M*8N`NDF:&@AUL+,2/!*MQKO#OG5=CDRU.LZG4Z^6=!PO:@-%_\?:II
M!0F81A;UKS-HU#7^6PGPFW'$578U3<SC<=1.Q$"'2B!V?)RKDG6F%2NCG40Y
M(=',6E>77)[5LM#/AQ\59.`SDK+P*)C.AR>I_<5`"^3E9#R68^Y(+O%'R+7M
M4)DN"@B:01F>]M?D%5],1L*V1%!=O+39$583N-GQ_P!<5TGP(?Y<6+VDR=`&
M/N#^3R[@0R-1CNE*)LF2JH'8QYRM+!2-?L@]`YA!')IDE)%,?&0&78SQ+BAD
M\>2Q?AA7A8,<B2KW-(Y!`6JKI@E[47Q<OBC3%31$VK/:>J@J;1+<H1MQ?-E=
M@UOH*>I*'<@RM.@Q4.A5WD5_BG(9>P0:6FQXL.G)8(6^-TQ:IJ4RR'I(7#)9
MT*!A'/`]MV/-Z1'?H<EC*6EI\%*JGU&L:'^+7FU4M]M$GO5YOJE+SOE&G9?'
M9GCV6U5[8RK?]]Q4IK!JYH;Y-T+73W=1:V^$&^SI;9!(X>)4^,%\852>58>J
MN%"=)Y_ZOUZ"$XU6$&X_;!6=?M@K.OVP5G7[8*SK]L%9U%)C$9W9>4NWVK`Y
M0T5%B!UA(^(G*GK\&8\7!<6.H`5LF[%`:`<LVH3#1ERQ]O9!=`5<T_)+8]O9
M!==O9!==O9!=8E8S&X4.N4NWVK!-X@-82/B)RIZ_!F+_`,:.9[Q@\L;/+MH.
ML;6E)C^.+O\`KG*7;[5@F\0&L)'Q$Y4]?@S%_P"-',]XP>6-GEVT'2B))>Q_
M'%W_`%SDSHQL0`&S'&-')"E^";Q`:PD?$3E)HSL(@Y'O9TB)H`N+_P`:.9[Q
M@\I-99:(##JQT1Q:*<MW"BNV6;0=J%RW6/XXN_ZYR;6K?-#[<1TJ_6,R7@F\
M0&L)'Q$Y0FK/.YNRE("[Z'0-B_\`&CF>\8/*3JPW.4PB.8_Y1:(@2K)2QK*O
MH.CT)1AC^.+O^N<EU[VUM]6KM]JP3>(#6$CXB<J>OP9B_P#&CF>\8/+&SR[:
M#J^T0S8_BKKIA=-)-WA4AUWA4AUWA4AUWA4AUWA4AUWA4AUWA4AUWA4AUWA4
MAUWA4AUWA4AUWA4AUWA4ATL;FKTX-+QNUMV+S:E,#JY"[,9J[?:L$WB`UA(^
M(G*GK\&8O_&CEWI8M6XV_P"%9H=?PK-#K^%9H=8]&%G;6I;R1L\NV@6O4T&3
M4<BG'SMX]7TZOKTKE1W"RY$]7;[5@F\0&L)'Q$Y4]?@S%_XT7/\`UL_6#CAA
M\8/)&SR[:L;A1]:L@S%.\`56OL<OUNE4?]]./G;QN=PV;3;5(9>%FG*8Z)AF
M`\O@1.9.F!VP3>(#6$CXB<H43C*MMJQL09Y,`'B_\:+N"X2&E5N.&'Q@\@89
MS4#`27$\GNR6*=7FJD64?BI0M+PX(GOIQ\[>._O[--L!P\"669J)'"(7,=_^
M$0NPUF";Q`:PD?$3E+E`H->9:4(+"(*!\7_C1=Q<JUN%6XX8?&#R'7T=&YT;
M01"]/%C9Y=N*E5AXJB)[Z<?.WC<;A16FW@N?;YHRA:NWVK!-X@-82/B)RIZ_
M!F+_`,:.1`!3EHTNXX8?&#R1L\NW%2C03"T1/?@KR*BI&03O/8P=+FV*YMO&
M]2&WU=VL`"7\ST!)U=OM6";Q`:PD?$3E3U^#,7_C1R(1P\2Y+N*2D%[$\5N\
M/6XUBM*X&V/LNO/(&SR[<5D8N]'B=>_3T-%2;NDE^;VNKIZ>OI7@0!*$YTR$
M4((*Z&V&X7360X)O$!K#PU2OCU>[*XJC229<G*2P/(5-Y>91P7@+B_\`&CD0
MGIP&"7>@L_BO$[XLO?V'+6FMM1CJ*>LRW<5M,0^*DWY%)?F]P%HR72PY5615
MN\F^3BI79B-RQ@F\0&I'CS1*7W_(^IJA+L0^3G:O7>2,780M/!4!L7_C1R!L
M+-%23CT%G\5XG?%E[Q)A>Z18+:,=Q+@VV0K'T1C*?Q76Z+M<9IR*2_-[@#6^
M/]RRU:NWVK!-X@.&7SZ63ZWWE#U^#,7_`(T7<8*B555O1<;?17:WT>#=*+/1
MMYB,6X0J:L=TN5[6SWC9Y=N*ZP0&0R:<BDOS>U+:^Z6J*XZ6:9V[GG5V^U8)
MO$!PR^4%NKK[RAZ_!F+_`,:+N$()"E5O5D)^`JG_`!9]XV>7;BNJ_P!E",TY
M%)?F]Z+M]JP3>(#AFK&$!,L?'J1JL*0EMCD`XVBQR1Z_!F+_`,:+R?K7]%.B
MS-KM.!>&V0`##['HR$_`53_BS[QL\NW&?8T$1)YA8A"5";&3I@<X\PH"]])?
MF]Q9N4E:%48@9*?S\RX)O$!PRO?>M-0)3:6X+:!4Y-*K:J])J']Q]\H2LP18
MW0XKD<A@3%_XT;E;+;>:"VCL?V:.N0O<PO"Y>C(3\!5/^+/N2?IOG7&I"SAQ
MC-MG]]_E&4STVU3'.@)O8H2/_*"K[R2_-[B9EJ$I]KZ`/C:'WW!-X@.&5[[U
MQ.PT/(:<^;&!BK`"P>9I+/[7[LJ6(13(JS<2CL4@;%_XT>#YW<_6-=/1D)^`
MJG_%GW)3&;--(Q84Z7^P1$S;.U3Y<?5D`#108)1O>27YO>B[?:L$WB`X97OO
M7IJEZK=]ZO>/7X,Q?^-'@T-4RE`%+I/&XV%V74B$0LA'@81E8#6)(GC\<"#Q
M:+)RY-CD_NFSR[>NC7!D:<\%)<&1G!>8A?F$+LG%#$R.^M[[22_-[T7;[5@F
M\0'#)R%CJ5X=^W.0W4#?(]?5CN-6$R3O9"_>/7X,Q?\`C1]&/PM%DZIQR1L\
MNWM'@@GX1&!BC0QPKM<(OMWE$.]A)?F]Z.@AP60W/!-X@/0U$6D]X?3C5VT]
M_7(7[Q#)8^)0%Q?^-'T)Z82"?UJY&:D."CBC-GEV]LX7:66$*I_)B;,U6]A)
M?F]Z`8N!&A9U!6,J-BN(]N\NZ[=Y=U.$_N0QZ.W>7==N\NZ[=Y=U3(M.:R1]
MN\NZ[=Y=U)D6G,+CT>1"?2ZP=N\NZ[=Y=T0%0ZA-U]N\NZ[=Y=U>$((T>M=0
MFE\I+YV[R[KMWEW56D\IH)&I5HC]J#>EX!\UH(H$L=M+:QKV[R[KMWEW5]3V
MZ1>7]N\NZ[=Y=U<T#)=DMM)CZ*=?2]N\NZ[=Y=UNIC?]B<=N\NZ[=Y=UV[R[
MJ#JAU$ZY=N\NZ[=Y=UUH],=N5PY)I20[%V[R[KMWEW4@4*OB=$N<6V8@'6U"
M)$(LC9U11K-;SV[R[KMWEW7;O+NNE/[EU$3MWEW7;O+NKXAQ`C-M[=Y=UV[R
M[KMWEW5H3>]2"8]N\NZ[=Y=T2E*WPQ'MG'J6*C:[=Y=U48^"K1T^ZH5?LTG;
MO+NNW>7=2U'IC`(R$$9'Z_M5Z5?$I$@\SX.!=YC;8O&*7:H8UP4E=6,$KB\'
M9&D_(T5&G1/]L<\'G@!)EDFX&NW[EU#FX/";>K_P/<+N5>S:EU<OO<:U,K-5
M2*(+)%IC1W+@U6[(KI+^#H"8UF49"&UR6R";@$AN7((RO%-X`2HT2.#>@B?F
MTNK7%I?LRS@1*F810I+!15U$&-/F$2:5O1-.N_7QK.#T`]CC#1<4P'1>%OTX
M.A'"#<J466.HC(QU<>C8W+?6!8P2];.#UP:_$Y*IW<9',V`]F;S^"#.P1^90
M^65.HI.H1/-G5SN=MLMN^A9%?UBL:*@PFE_FI.&PVZ8](;!+K![\EGL&A=7%
M)E$)Y9][>VJ?:ADWA9'C.I7+XG!+#=2,/K%](23AL2NDAG0)"+=Y"P&X+RNK
MU73V#6R8<+>08%=K_P!)Y!O7NW.YVVR6T?&,0EOIY)W0Y5GX#GO'B_-L"]R3
M3,IL1&.HGDWC4N1M4'7%K0OVA>3EC=B<A&764WFQ2G#H7GF*>9"Y#"K]C>S%
M4JNM#8WH&T$O2;Y)Y/?`3&93"@A[CV*WN-K3%9'LCMEI1@JF6D?WQ=,<&4$`
MJUCA61O@7,B=CPR6%6X7D-3:*M-1H[D&%[,.5CQR&GT$&).<J,L8&24#F0X[
MPU$LMU`,_=C>-$^6:-WM,,R?3>2QCQRF$*7&Y-,GM[8W(FNCPDB!@S'Z9[.O
M[:+D2V`AXF73*/1=2V8R<F`F!-&M^7H%V@#`QYC]"T)##'"*E_XJ2&ON-JL'
M=(RPZ[I&6'7=(RPZ`.0O(^43)JG=MA;1<1ME'OY%A!(R&D2`S0AY*KQ$OHM.
M4(\3X68WR/>BJK/!MGG?@%&E9"X8S(#+3DTREUTI;TSFX#!L%3B>DL/M\P\E
M6^U"[(032]O$S)P5!4I=U<V6=6W09291'8@2<DQ'LCC'+)*7)2H'^3__V@`(
M`0("!C\`.[__V@`(`0,"!C\`.[__V@`(`0$!!C\`]Q;=&[L#5YKC^0H.C+73
M-Z5X,2"P]5VO=-JW)1*QKO>L@I;C\>3'O%CTS-2%LT&&)&1YDJ.-G,(>>CRG
M]3TKYW\4R%5VCYC!+@\G&..VW8I\)71_&?9')I.P?6O]+20-)&7QFO%`/`^`
M882_+P0[W*&_`+\S*Q;#W;PKK^XN'&Q=MT?3=,(4^RU55YCZ1H079I.?;*:<
MY02K29>VJ./H!"$"I4%(4A%7,7DNES`]JB;NVF_6"MQ-Z<#[0/LT&L':W7I$
MZPUQJTCJ_7*R6M5]/]^VU/CCVTJ)2WITM.7&T-]\B.VSMS3LK43MEU^]32VZ
M$;'U_<[J);UTZ3"C=I7&J":;L_7,]J?KT),G6%,-R3)P2BCEPV\LNNH?31IK
M]THC6B':\EB]`X.I-J;&V]/NUI?(-:QCT0QKNQDH"QEG9&3WGHZJN1>89$.+
M5(2F:QEFE'*ML^/9AFP*_%M@"17JO=S:XM8F6@C2&;!;XHRM2IFNPZ;H(F"'
M)%@;&-,DXC\5S*7V7$)VI/7LG`&/K.G[)L5AO;^N]@V6B5YG6+:XE[(QS8H&
MQ7+T_K@FK"30H03>GQG&76'<,N(<RV88+;CC29=)B<?<7LTQK[94`$#7R:5%
MAZ4,F):JQ-&5P)L8A*1B.])F9C#U/(1-?9SG&5"])%=EB(FRS%DBTV"`S!.N
MQ/GC/KJ[8/J,RS,"G:H,M)&NH\5&'29S,R0A2<-MJ4M"5<2*!7MK<8M0:KY$
M2]P`K=L+D-0[.<C4$KJC6AW9[9=)Z!R%TO75B[1&',BD19.&G8DA69.)$G"D
MQ$U[<^^136FWS=_O>NPT'#9T['V(]4+G;*U7KOK,-&#KNIBJ[3K=4S9PT9T?
M@BR%DI7(1C#:W,UB?3]GQK6/MIT!5Q1&N5B[&QL2QV<G*#!05G(C:U)A4DM(
M)07VG(YER`[&RP[E[#:6UY3,#!-K,G3$6(,(Q10&G[`.$K$+,V2#4!QBD01-
M4F2K^&?LA2-$S,!H(16W)#65N)2XA60M-H6V7+7:SU.);`@5\-K[:,LJU3@F
MYI?'JPG"\--)P]7HU8W*.E`BJ"&(SHN1#DN2T,QXS[S>GK1Q[LE>MKEKY=\+
M=26EZQ4'8$@'8=-\B^3E'T-;K1J\^M-7$6:3#8M+[HXP+=.C<2HN6E,N9<2I
M%K):VL>;`Q1;[9M7W)A\.>KY2LWZG.QVK%6#(6S"PQB"0@)F,.IRMC#<B-(:
M?94XRZVXK<NG-"NZZ!N<;BVO0VV+9LH38+:T6N%WIM<VG%UE6:U5;13I(%Q[
M6=K&RWK-,G34CI!%A+80DA+F4UDCS4(T_CKM^:*L5ENNN1I&R7T/1:S#V!8J
M@&L$RUBZRVM=*F,"FNZL1"&'A3E=M[#,;':89JQ.G[)?/LWQO?::(ENC[#%X
MN)3C&9L=>W?70<@[4Q<1^ST8S423+PY;B)DA$-UZ,V\PC+N./W)R\66;JNO\
M@])`]Y5VKV.LWJ59(54EU"JVVS$FA,>G,'S-2I[-PA-OV%H>@.^W(8?;=[J0
MUE1:#I6]O[!2".6.M&"P:FWQNL#C]4&4HT8$RK<1J\*K-SO5&PA,F(CQG618
MD.+B=^F+*RQ[O47%@43U&UI6_P#%G=?(\R^1UU<9NT(C^F-D:&U=(J(VW1MN
MCJFTS9R6^HY-$YVNNY@L!W(F6)*IB9<388C:#`&B5.!R2VAQ?H0H=7[E8+6Y
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M5>1-&GU:F478II!B93==G6O#LT/908PR^UEV/,'2EOQUNMQI2F9[9`K<6WA\
M;7,ER,QJ3;TZ7+5M>-/ET<>&B0:+)DGSA",+?7*'P4R)XE+?_P`>S%Z\==;J
M^M]HNW,_;*>$OX8<"H.S9CN:6?V`3U9"LA5Q-,PQ71<38068*(+(KB^JI,1[
M$W$=+:U8'Z1IQRIG./Q/A5:>2<2[YJ]K"$9)NO;DJ%"9*A[B=F1*U;-:E:V?
M>EQIPZ$J*[EO#K<QYI6.K2NH-HUO6*^+W(Z@5LG2+[``6NI;.UGMO9+6SC&J
M]6WY)FXF0EH8N8/3YE#,R.)"28Q%V-!=CN*2Y*=Y*Z3FR];T;CCQOX?T7D*8
MV#.J-PNM[/F[?L;D7K6Q3F7@=P&"PU3UL9T#,Q(@)"DYY-:'<(DQL91V;(#(
M;!H2>.0SRR*)SA'[R8UQ=?&(<M=RMP.1>9]00=E&'J&BJU]@R@,F,P380ZXR
M[)5E/:3O#6K^+`X!T'HWCGN,YMR)2-A*KMQC[]@V\G`B`P42H$5#WVPP<1+'
MP_6$PJ5<,/QV(?6+D.N1JB#V<2*7*7G;J&:1#U?MYZ\XDZ&E4B'MX<_2TT+Y
MT1"]&=V2!5+ANQ$2E,%8[S3;C2^WTU^=UH<M1X7LYJ\O5*1-U7MBKKRG6QG-
M=NB;/%MM(!2Z"\&/8\%AL\V,<E2OU4=+J_B]]TEHRI8KL[=G(@C=4:^&6F9.
MB`AM2U<''6':E_+LBV'BA>%31)F"TP.CJC*)%2<*(Y+@LO.SHV[:-R"VWQ=E
M,Z6J^MYCUIU1=X[%J-6"P&[$`N\6V<?I%QV#L#4[H0^_71@T>Z0.J)RBB>YF
M.2'<P8LNTUC93MI'CBMT"%AM6HVQK);PI+7*PZ+W'.T$)49]Y!IJ?SA@*G.2
MQS+4=$UA:E82ZWE7'0;7;?I8_P`1^1NLKF?I5G&5*U$KR8OU>KX2T5P()V-%
MV6FB.`KS4"TPV/=Q7W7G(P*5'QG*G6Y+>R&>3NUM:#Z?/V)`%Z8DT;3.XPZ*
M[2+!>R.M:P[NB_R+!L:CL%SFPHK@*(05BMCIC\',I#:436H\8,`J)6^DC)JZ
MWW7J!LC2.\`TL):=9N#FKA&NC1S7(W.OQ<3):,J(3.^KAA9#R5P)$E&>UTU%
MQ7$DM1MZ5O\`Q9W5R/,/D==7*;M&+(TQLG0^K9-0&VV-MP=4VF;.2WU')HG.
MUUY4%@0Y$RQ(5,3+B0JSLNYR:P0FE]9@<RW:?>25;&%]R7)>O-6P+#<0U:(U
M&KOWF[H]5C_64Z+AZ8I".O&5H[6O#N\2]8J^][>;Y>/K"5ZG7:J44O2N-7*?
M9^D'C%7-619P!,GC:Q6P\LK!:.3)S#DIQ_+:&,9R@K#I90H0D!A=?-S4D:G;
MZRA0>U/'6*Z4@/6@"&9+P#&:W,6P[$4^A3"$/=?=/L+<][Y'R]G:H.[6T5NK
MC]IC1!BH!]8ESN)\'6Q7<US=(/GGSS04FP7F[_GQ'&FHK+L%P2PM#JG%+[OC
MC$J$O>UM":`YXV#F8@KM_4ABQ7VS!YO'G8G'*N:N(6,-:1C$J37JELAY[)V0
MP[)EN#(R7F5K>??Z>8]I^?6[BZ8YT[`W9>`!V)I&UH&ZX_?SK<%JRS#C`]ZZ
MKE6;YM@Z^U,@.,.PO$RW5-NI;;QA6=!:GLVN=RR)VJ(FL!]I)5[4TV.-M,/5
M4&,D,@;$)V*5(&>LRX(9)DI=4_V&T/-HSUJ0XDF"-:&WL4#&1\P46&3=9(D0
MR`TA'<B3H,MA9C*'HTJ,\IM:<XZE)5G&>FHM'#9?(LC)USM?7QJT'RFEYK4;
M:VBM83GP%0TA=8D>^.DY4=K5D(/`)$<3,I,%QKDQ^,F-,>@IU5<M7%MFOPAV
MK[%I#>`.P<5BDMNZ:XSR0W]R4H4O5KL'=(^-K.[5.P\@2HMZ21CV0?,'9Z\P
MT.H:4WS,XLUO]X+ND-_".2F-*C2_&BQYOFJK#RR/;%NFUW;]=T;DE#-C5P7>
M=GDYP*)!"`)49ES$>3*DI0A2>3-+DYN48KOK7?EVT<218X^6I8^LN\%BHLM/
M(D(KFQ4R2C>QG8"D,MMN,9&I5C*E2,XSUW[>P#72R6J=M[%A;PO%<N_#!-QY
M#5O;D6K`Z_+1J'D)*VQ!ATS7IB95A\MZ!-K)>9$PF2U!DQ%2$OL<6[]/U+>)
MNJ-'KW1#V'K:[:4+G7]H5O?&K#VF[G7L2(]JCB1T*-43[KS29$:4F3(_5.80
MWGM=-7ZM[VVVN=Q+VIB]\.[-NSBV;VT+13<5*WZRCZOY34B5M@%"W7&%ZKO$
MT3'-CIU>(>)9AD.PF9'4X]4=K6/6UN`6>O!X8*:7X[\;3N@6B=;GBR^;YKV?
M3QNV+53[#KNRV&Q3'AK)=B>9`,9PIHE(E..2,1=/@HST"E:[FZXJ6K3-&X09
MU[M^]Z#HMSK!V;JGE-MJ%N0R0VE(M-3JL4)/)`X%8S-[*YDUJ6\[E*)&T)P_
M;%OH4CCOR;T3\T0^@"=3+QT<C>=.VN9SQ.'/5L$U`C0*FWM-=<9CI:[;R(:9
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M=#\-Y41O*N)T`_%OY-GCWO#S%-K698?0MCA.VL5SVL6XK*L&"\;?9B`I#6\K
M=Q%G$B1B4V1;@1E=VQEQW">"8JD`\&MA<(^.R>(`J3R!X4$MW:FONA%UW382
M28+:W:WC0R`G=#9+18@E$,02\>%&3+F05Q7V7.]5R+J]F#63+&YN05QY`!"&
M=32M95JM#SU0UY26J5F*[8C<+Q4.-1V7V,14L,82\XVAM"&DY5[O>>P+B5W9
M&NT[CQRCXC:+OVF]+NB7]9:QY%%=76+-GP1GW4G'N%ZH=JU1`E#2C+8]B4TE
M.5QVUXSG--W!HKUQK;<T*C4;6.PH-GXDW'8&C;B#H]?<J`S8@O7`7D)K,[6]
MQCJS)?A0B/KN3"0,=P/DQY3:&WTW?<.WZWN38.P+;KX)Q_=)BM#NU4:2XZ@M
MTW;:C=5L8+%S*PI=P-`KBD"4GQ\QX<MJ)F2W%85(4TWMWERF@;$?J^P^+VH.
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ML+\OD>`>X\%4&K=IH+>:`4A6,Z><V<Y"B7*=1*&V,G);@/PWY<EV0G#:,X93
ML]]5/VI1AI6N:`(Z6M8G31,G?M5[EXVWZX[3UUL20Q/LR*X<'MW&[2&I0]*(
M^7AL?#7?8S(<RWR3V=7ZM?8-7W9P,HW"FN@R>DK%)/@':`>Y!6N!LJPE(=QA
MCS<HZ<Y!SL3H3$>-GL0&W$OY<><P@O6L1[PI1;RCZYY9"Y>=`V?&&2]>;M,!
MO;R6OW@YRL;*'6=2E!\JPZE]G'5+RE6>K>Z*28WG4+5OCC!Q/TH7LH?1!%,R
MM7#C'2['3)!JNR,7YB3&J.Q!M@4S*9Z\%H#&7<QI:'UM/1ZWR4'`MC2Z>.MG
M-6UD-=BN/ID%)AKY?!.)$'U2!*N;$+1?"4.=Q-AYP[(8RX1;-/J5AE;",.[S
MV()U?R:$4+?&SF+/K.O;%U`6HS.M4W=@++VS.D`K%D1:*H$N.S8SQF2R1AM/
MM*2M]+>$.XROWSCSN*L@;XK<W'\M<RVO;37=>*V%4W*OLH/$I^U->W<7&L-7
M*9'7&O0X[\5R)/C.P#`T?.5B4S&=@R>6EMOX#;8C9_)$IQ2M=<P"T`[8-=:Z
MNG#,Z2MFHYM@KEEN:).TZP=M$AARQAY:Q\>>/;7#2I&%Y>Z:]WA$HD41O`90
M]AZSV2(U-PX,ZDX_V2I7\I03K2ZIKB-NJUG@%EK1S7<%]9(@8+/EV5NQG/"L
M^&\)H?B5J.K\GZ).XP#-+-Z.VT7U6U9[)73^E&1@X383(]BR`6##MB!1YD(E
M':>B-.QR+S:>PC.$],U"(UOJNZXC:OTQ3J[5;)HV1:D4NZ:?WQ6=MR-CU[P5
MYKT=ZP;&K-=8KQ1V4EU<5B%'<B91WLQN0%Y!0J5L*%:]@,V$+RK""]-V5JJ;
M.`"7&X>DR-+%2;F\Y5;YKBOQ6H,@I)=EX)Q''V'VEIQ!<'Z\Y=4&A6Z.-UYQ
MAW#QQBT6WZ=MCTXHG<FSM$;,*6N0?"VUJ/$R!EZ*C1(\1,1SOVR#JUNH4TE*
MIV=P']LF'Y]GXR7D(,C\="JJSJ6R<=.8`KDO/9U:,<V2S(;C;8J5?$U,Q,)O
M2Y[306-(95V77XV=4UF;6MY7D+QS.\SK1HR3,TA(&DD6'F=LNY[$LY'8D=NZ
MR!5@9I</8!0)$B,-,QIT5Y,EU+<A",)N]+KM5O-&KY`B"/LU`J"MM>UR*-Y$
MI%GR6M05TNE\)5"'9),)M^2"AS_4XW#37A6TK=D+=_V?MW(C>+]K'ZIH++,R
MYGJE3+'>I5:$NY6E9PH'JT`D59"1G4I0])PTI#2W485_Q8Z'[#%,VRNRZ]I9
MSD6_2[O0K93=AEM(-QY4C.RZO2CXN$<M56ZXN652![4G#,AQEEWNW'V4KX][
M*T[8;-NS7_)L]+K&L[CI^E6/80%@^/%NFR0F\SJ]"EIU].%B(4Z1*:+XBN1F
MQDSO,)S'7C%GX[C[H&E;EIVOZUM&QT1N4C)L91K::-5\(>>C]?:S&?*`GFUX
MQUJ:PXPI>,8?:RK:]XN%EB!ZKI(#-L6S#3J7%PZS`'5I-OF-2G&TJPX18K;[
M$O,9':>[J7'SV?US?:![-K=A%GJ)9ZP)N5;LPJ8Q,%'JT>&QRX0J)F-.*8G1
M2X^6TY&4A6</8<3V>OKQT`\K*;^^F_:SL^T[-I<$%UYQ]W%?]L$]C4P[:ZY:
M@$/3U/IYK8TGU"1I!3,E]L<MAIB(I[*^ZZE9K5S'"[.$@6D(./0Q%UJYVDVX
M;&)Q6Y;,*RT^SP1ECK!N.V[A,F#.CL2XSN,MNMH6G*<?`MST6@VT?8K1Q]OP
MW66V!</*^]JUS+4&G[*A"GU*3A$C#E5O$!S+K65-ID=]'RKOH[R$7#A]/MY=
MO>E&XXS^5QRO1ZA9R`M>E!MZB:TF'A%B'#)8<X:;O4S`Q(>*ZZ6<E(6A$=64
M]-H[:JVSXE;J6CK&;J6[&]K!SNGK+IZQ`,)7/%;/J.S!U7LM'E+C.-O,)(Q8
M^9#+J%-]KM8QT<VH9`;3CA%%)@H8`5JN\,[!/NP!$ZPRY('7LL/&MQ&&Q714
MR>I:8F.S#AON9QA+:NK8/../=[/C0FJB]WK^PY;^N;Q&OU2L&MC,@)?`)G5[
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M1VY3>67%(<SA.<[;W3<R:Z$Q8P54+&M<UDUM)5=-6<Q"KM;8LD"BQ39`(R<L
M!%F#&=?:0VY*<PWUXSTN%3KQ@F#O^O1U>,WW6=^`%Z#L>G@[;'F2:O8#E.M,
M0:8CURP)&RT0R*&W(+[\.0TAW+L=Y"*M<]S70Q\SK38Y%43:=?5*P;0!UHS'
M#$+'AF[3:'".XI\>1709.>T_/PRRN&)G.]KLQ7<IT1JZZEKI8[_R6<FM:7K.
MKM=V[9\ZY*A`R5EZXZZ<,)Q8+4T`%G2XJY+C2)3$&0IK*NZ7U<@V]>%KO'L'
M%PTJO;MI%TUK=:/?*B7RV=S$B)J-E#CS)G!2369\:$Y";?:F2HCC3*EK3U=`
MO(WC>0MU@T]9R1T95;=::)::$S:5UDT0K1Z8`@VT:*($1HRR!Y@]R0EKN\2X
MCK>,YRC/P3DUQHT+48%OV;O.BN:]!,%[0%J(0)DA,C3W;":+&G4(R-@^K4MJ
M:CH>DK6\G*492E>4Z?WG8*-\TKOQF\M_;W#C7^E0NSZ_DMM396\:U3J/9;)>
MK3!G-T1C5M3%4]@@-@/R),I\@O,E;33\2*AS1O)CC5&9TSK@WBR[`YA\&E$Z
M[.IA[=`SCGMC7%(V%HTB'>;IE"O-CN5W2BS+0^@88BR$27>Z?C9[?$WG34]5
M4TC:\0]Y:LY3ZQ:LU0JAMGC[L.S#3%5K$J^N[.L=<V?8*`8J0,A7,Q1(=MF#
M&>:E/-R'WD/5'6`C7U4?JFT[G;]B[WN-ZR-OE-KJ92"Y2N:_,4"-L&@VJ]1T
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MH8K]ND#3T\>]`9D(8A8BM/-1TI:%<HWJUJ7>=LU?Y:>VN&T,*[L_%4L.\]S6
M_GK?^3X#:AHU,JDD:&`$ZH:',E,SGL$6%X<2TAU3+;2]D:_*Z$I''S;YOF9H
MCEYL@7+W72]M(YDD*)N,)MC8=.V39Z_K:G":S7I$*OP!-<A28\I$5H3!9E2%
MQTON.KUYL(C)WQ?J_3MY_,2E.7(;G-9D;IOLZ15-:@[=:)4(7&!:;UWW(YF2
M]G*,1Y$B-"5W&$-*\P6N:HJ@B/7^;O&D4@%Q^(7^MP$ZVYFW/69S2NX-CE;4
MF<JJRJ0:J$>"1DXB)DS91&6\M/\`P8:QY4UUKL<1I+E-PTK=#T#MV8Z=$6!4
MSC<<H$#3W(,.!/U^0X/,$"8VNP;15VWUN1HQ-B*J7%6ZTMI)`MH+7-,HNQ.,
MFY]'6KAW!L)8#+)'7=+'B<E-]<V)&VI"AZ]K]R`'R0@B)E@"!%P4Y&[6%.*?
M::`F;;49%#LI$>U(-4Z4:$V)^O3U95AX<LX">?$%.ZSCKP\PK*%ISCXL9Z\8
M^`<D>,^@:5"NFRM\4Q[7(E!6V`J<$K3<]Q)1RT'"AU]O#PR&\);C*8B(?EK<
MEH4EO*$.*3<>7>SZY;->N:A\L3;G%&MZ1U[MN*-V#?+3=T.3[`9)7JK,F*>&
M'1HPJ(R`[6"#D8@\Y+?0WAM"%<K>/VL.$%[UOO#;]XX%GS]XNO(OC.?T0_5N
M$\'6FM84"N?NN/%I%4V.?JFI69%B:EJEO'+!*<F=N+&:3%B^8!S/NM6N@*P[
M9\N6A<&=;\:=6;B"URZDXT7>)?:Q:Y7&_/QR6JX=T>M5S;%BU*Q.@0P;,QN1
M)0V2D);ETRS<`MA4L)>^6=RW-RBF6'=/&6RZN-4S<?#3>O$#P^D']>GR`];%
M53;V2A`&\Y,GP'FI$CQ*W)T-C'E1-KJD'DQ(X";2V99[WL[.Q*54+#<-5YU?
MLC0FE:(.CV\K%F$K=7J;+%F"CSO@Q:I1.7W&>^RZCI7.9(;7F-?)ML'D8!Y6
M\?\`]X%/(G=W!Q6][)R2X;SP%K#%T4R`=K5LNQ$*963>6C(MY^,GL,/*=<T1
MQ$Y(TX15MF:3);<B3IM<MX2Y5NSP-@[JV+MD85"SQ#GB(S4,??&H+[4MEA[Q
M45U24J:RVM7^RQ4)-=),0C(V<*EO!C)>NEV8I&*[$D.BK!7YPP^")-M/9RQ,
M@R8\R*[A+C+K;B4KQIPGJ8]?K.9QQVY9`>-IQ9N\VB>0Y?!+-3A7&5\L>M$L
MB\;O3<X">;CDK4^_'?B8)9GOKBOS,N6>08Q:LRQ\7GVK>V"6"&`JY*N6M$G<
M!O67>90$E3L<45%\!U#LJD-@^RV0REQ,9.-9;`G\.N<&VMAP:^,K.Y[QQZXV
M9M>F,[<%!0\VV":P?5>8CN7$-EXTER.IAO#&9/91UMX0K/J[_P#F[YKK/ZQU
MOQS_``][L=^KPK/>>)_>(K]6YV?T<]GX\YQTB[MU6,O`.MN7+8>OB(#9%:S4
M;K7[CJNZF]?7<"?K^9I'$"<'M->E1U8P\O&>[Z^OX)R:C22%J$HCZ*VB7:)4
MFU7&E6F'+`TTN<@/B+)02X.W0GDSAS?;;AR49E-=J.XEQEUQI>K3%<EGB5HL
MXKR]#G'$EW3SR)FJ5;(!2N<LL%)G-9&0QL[1!IURSIG9:D2L8$Y0E9".&[O;
MEL$9L_BZEQGUD6N?SR3:Y#6>6]8K6V9>_5DF;4XB5+LZYT2NY/NQ5>&DR_TL
MN*DYD*Z<6]_6<>/$V7>/'32.X+"+$]]ZJ&G-F:TK-T+#QGB%+D>KX<\TXVSV
MU97W:<=K.<]?P:P#=9V*Z?ODL_!7E!(`UD=;KE,&LV,*>U*SJHM6JA-+/T.K
M6R8;EET)G08D,@4Q&PF4Z^W"CX8M[^O/WB?T:GP?)F+H!,;&P<04\H96K^'E
M>XW*#QR75;XYQ.WG=K.!GIJ4C6;[C,U2DGTB7\<,N/\`M:ZZYI54W)Q3Y)['
MV45OI^OUHE$V5J2P<5A%23%+SR<$:PT21LBSH<CHQE$M;.5-YSX;/5_65T!_
MUDUU_./I_65T!_UDUU_./I_65T!_UDUU_./I_65T!_UDUU_./I_65T!_UDUU
M_./I'LE'M-<N5=EN/-13U4.#+$%DNQW,M2&XY01*F07G&'<92O"7,Y2K'5GJ
MS\%)_P`GS?DSG3@*J'#BQ,S=`UN=,S&CM,9ES79,]MV9)RTA&7Y3J&D)4XOK
M6K"<8SGXL>C:GM_^8]_&ONSX-N?[)]B_4\QTX-5^N>4SRIO]>!</.,P8#?`/
M('R]A`.[!AFEJ3"%VX,)M_+NO6P8)LD%A$R/'*#X)%EEY*),=EY*VTV#;>[?
M*?Y<ZZU33$#IEWO,C>?E^VB/5P\\O`#*+OUZD\N+';"S,621;RIF!!E2%)Z^
MRC/5GX/Y?X3<&I-8[6#.\-_,*E."-DT*JWD8Y*!;%X,>I)*X%H%%(JWP_P`X
M)_A5Y1VH_CI'=Y3WSG:_J/<0/[-.F/YE=.=^E;#P9X1(IW&^U<>@VO71W%G4
M$8R]#VAHBO['LF;%-=K,E@D\BPDW$QE-,Q\-1^RA6%JQV\_U'N(']FG3'\RN
MG]1[B!_9ITQ_,KI_4>X@?V:=,?S*Z<R*?3:^#J51J_F5<VP=9JU9$P`-<KH6
M!M#N8(<$$%1X@P0+A-8[+,>.TVTVGXDIQCX*3_D^;\F<Z>7W[.]7^5D_1M3V
M_P#S'OXU]V?!MS_9/L7ZGF.GEW^PQQ*^X+7_`$Y??9^%^O\`4/@_E^>QAYC_
M`-XO`#T<PM#R*I%#1.+MBTH#@61DL[-D7%&VM/A=H2),L8N!&:#*"/ELPT)0
M])P^A&',Y1G/8QZ><O\`B?<YOO4S\%)_R?-^3.=/+[]G>K_*R?HVI[?_`)CW
M\:^[/@VY_LGV+]3S'3R[_88XE?<%K_IR^^S\+]?ZA\'\OSV,/,?^\7@!Z.86
MNZ5K6+5-FZBL6E!^Z+^S7ZR,D;5)7/3X6W46?+-B59L%E54*7,8%(66QAR*A
MG#,?]0E/N.<O^)]SF^]3/P2/+M=>N1R`FD["V4>F5*+7)F*MK[5GS5^?%I)0
M35F`%C212;E"RT,!QRQN?E2D1(3[B>QFS:U`J-),1ANVU@BDZ!'9`79&D;Q!
MU/N=53FL3I,I]6KMFF(H,LB8Q"<Q,?0J.E^.I+^?+[]G>K_*R?HVI[?_`)CW
M\:^[/@J]<$Z[>)KL`QIVOV2UBAH)^L58WORX/4/5$`C'E6.%<2WSEM+7<.OA
MQ!.*+:[4D@[%BM//-;V>K0VT"/#:+,V\>S:A+`I^P4*_4JW/T2^A$1IY##E;
MMK0&=X;$C,>>TN(XW)C,.)[&?+O]ACB5]P6O^G+[[/POU_J'P6VWH_F5@%2Z
MR>MAO,&,N9-P(K@J48)9APV\X<E2L0X:^[;3GK6OJ3C_`']"K5AJ6Q`5GKTB
MYR;+1W(U&.V*OTO6]+UUL+86S9TVGWRR5"30Z=5-LUUV4[#*RI[LHK'@QHC\
M]UN,KR[BHV0W,'D^$GF+$($MG.<M2H4R_P#E^R8LAK.<8SEM]AQ*D]>,?%GT
M<PF-6P94??$:Q:43RBF/+N"HY`X[I\*YJ5<1)R8_5T)C:OS$;7ZD:8:RO&<R
ML*D]I6?3SE_Q/N<WWJ9^":QFU"YU>H/T1RT/12MCKQ:R$J7:#<JGR*QN36D2
M*=%@XVV]7_-V7@*Z7C$1BVRLIB3'=C/OM.FMB/6])8#7(/+'&M@;0S,4O$1S
M+WC6.2FZ57@LN4]#.J#;'J$:)5\0(@S$$(MUN=DC*6F2WY??L[U?Y63]&U/;
M_P#,>_C7W9\%HN[15[J8P74W*,H?)*TYXOLJ@#JR9+$+[5M4V)15H&$K?((&
M12#N2)D&4](@-1WF%(F#QKT3>&+':A-GD#N,T72]36$!3`++&K]+U#96*)(L
M34\T<61OI#%ZFJ+RXRX@YWL,)CPV.PXIWR[_`&&.)7W!:_Z<OOL_"_7^H?!;
MC6`IZ553-CJMA`B;1!;P[-K9,N(F#X!Z&TI:$NR@\J0B0VG*L84MO&.O'21`
MCW'7=2-D:_O'4CE:I=4MF=55?1G)$9H6#M@?2`=AN1&T#]F.'-#1;!`*2B<H
M8HL9*YFCY2YB),7RX*Y!<D.P:_P8\PP)#=EK;<E.Q15X\OJ!'<DK9:897(6R
MQC*\H0A.59SU)QCXO1S"O&O[_*LNW=F6+2DW?M)>/`24?6Q:JZ?"UG74*(%'
M"()FN)M%!BQR2T$94U<I;N7F5-,J2WCT\Y?\3[G-]ZF?@;*''6VUR',LL(6M
M*5/NI:=?RTRE6<9<<PPPM>4IZ\]A"L_[L9]!/^3YOR9SIY??L[U?Y63]&U/;
M_P#,>_C7W9\&W/\`9/L7ZGF.GEW^PQQ*^X+7_3E]]GX7Z_U#X/Y?GL8>8_\`
M>+P`]',+=T>_1;)+Y*V+2AJ?2F0K4"1KA>K-/A=:QX4LL@^2=/*M#`O!)"UP
MAN8Z'<-82_C'?*]/-34W(6N\G:O=3'F`<K=H!F:EP?YJ[BK1J@[)O#-DI-F#
M7[2_'[8-!+P3H60AY*8Q-UUGK[#R&W,93C]KR_\`\M#S*O[I'3]KR_\`\M#S
M*O[I'3]KR_\`\M#S*O[I'3]KR_\`\M#S*O[I'3]KR_\`\M#S*O[I'3]KR_\`
M\M#S*O[I'3]KR_\`\M#S*O[I'3]KR_\`\M#S*O[I'3]KR_\`\M#S*O[I'3]K
MR_\`\M#S*O[I'3]KR_\`\M#S*O[I'3]KR_\`\M#S*O[I'3]KR_\`\M#S*O[I
M'2_R=#V:XF']6GQE8V`$O^F-V:,M=8-&@S-@$1Y]-WMKO6UL5')!I"'V)+4)
MR*XG.<)<RK&<8]),/*7(;BE1\T;)<B/KBRFV)T9R*\N-);ZG(\A+;N<H6G])
M"NK./CQTEZEUN;2.&Z'+V*?KN!?I6[+/LRS6VV:2VU6+97`-OMW.2XU\S5J"
M+@FW),HCIL3*SW\3$4K+;>\4OH3_`)/F_)G.GE]^SO5_E9/T;4]O_P`Q[^-?
M=GP;<_V3[%^IYCIY=_L,<2ON"U_TY:Q;H<L%:KK^MXZ)9ZKU4=>#0R5FUUS(
M>3&J96Y:]@G8Z3.(^)+"C0Y68N7,H=PO"<9_K+>6!_8>Y6_^(3T_K+>6!_8>
MY6_^(3T_K+>6!_8>Y6_^(3TX^<A-GC:D(V%LVD*,7"!0X!@736CL$X7!3G*T
M,L)VSFQPB4Z*[UIB41G/,I7V%/N9QVL_`O+\]C#S'_O%X`>CG)O$\3J\NI\F
M;1H$W0QXB:6D6(3%U5HX#K.PMVZ)-"P!L"1,/"W'H6(<N>ER)E*G5,N9RUCX
M#YJ_VH<9/X>A/N%83G"593G"59QVL)5G'Q9RGKQVL8S_`.KK^/I9'M@<VN(5
M^V:0W%NNJNZ:"<1:5K[F$;K$.@V2T5FN'MQO<CK#L&9JF@@UH=B/*I3<69D4
MAIE],9Y#SO0G_)\WY,YT\OOV=ZO\K)^C:GM_^8]_&ONSX-N?[)]B_4\QT\N_
MV&.)7W!:_P"FW_Z7_P#5L^;\+]['_P">_P#(?7X?P?\`^L/_`+]_Y[X3_EOZ
M[_VOU?;]QQ!^S\U]?[?\#\OSV,/,?^\7@!Z.=M+Y!_TGFZULFU<6YG'O-;XR
M<N-XZQ<#_N%K`"Y*K5KU%J+8NNJ7&Q?\/I)H?FC^J7AQ]_'5A;F*]6]P+W:D
MI:!,@V(_=9Q2Y5<A!WJ^-,5`=]:'./VE]GA*_-\0C/9B$)$64XW^L2WEO.%=
M`5H#^/R(L@86>%Y*AR]>)^KC$)@A!]8@+!!%G@<_PTA/?0YT:/,C.=;;S3;B
M5(Q[_P":O]J'&3^'H3[@@4D-R7F!L&60?:AQW9<QUF''<D.-Q(C.%/2I*T-Y
MPVVC&5+5G&,?'GH8V;0N?G"S:%&WM$<K53T",Y$Q[)RU#/:_UEM"RDM91N.8
M6K/@:.,IJ$^,.GXMF*QBF:SASJPN2C"=<`($JW5C5R*-N7>&\-AZ_+5P;>*Q
M0-'3-519`^KPCHVRR[).*+V8J<\*'B7YQ*$'?CQY#,IV/'FD@5D/O$JUL<;Y
MACKM2?APFQ^N<\,N75&XU:S75W&(K!6.SM"BVF27,I(OS,2B<;#T',>/WC.?
M+[]G>K_*R?HVI[?_`)CW\:^[/@L2CD9%XI>G-2S..44[8*>7KC3M]V7R:O5H
MI%`KIZMRJU9[+8=?BS-9A0"N8+P10_)[$UQV;$C3'0^[6[I>)U\5:.&VOM^Y
ME$8H2.Y5;)O*D[B=M-"#^HAXYIJHUU=(B.C(\I+\^.W,6EV0ZG+?9\N_V&.)
M7W!:_P"FY=7;VV5%T_J2X5V"/NVRIM@K-5BU,:Q80Q!B>]8+BE59&)>)0V&.
MW+QW><N]G'Z2D^XX@_9^:^O]O^`[2V5#$/6"7KS7-WO,4#'4RB0;D5*LDS[`
MAA<B3#82\2='X93E;S2,*7CK6G'6K!"E&]@6X#LJI:NY3\B=G&79]!L@IW:F
MA*!Q2OM)TK020D%ZD3HJSA.0"R1$?EE1_MB94-DDN*EZ4_Y:5@G1VXDX[P,\
MP,S,BLI<0U&E$[EY>TV1':2\I;R6V7G\I3A><JQC'QYSGW'/0WM+,K(#<'-&
M9M+2.)-E8L"$ZA=XM\6]?M8APV9TQ54B_O*U_9<^K7$QUX<RN5W79E)<<]_\
MU?[4.,G\/0GW#TF0XAF/':<??>=5A+;3+2,N.N.*S\24(0G.<YS_`+L8Z:\H
M]3MU(4Y+WQO$K4J1KOF'QHDA)8^?Q3WE:&MCDN)6N]*M;066LXB>](D$B=R5
M+[<Y$Z8WG/4QTKDJW5"KVJ53K!#ME1DV,`)./U:TCT.MP++7'B<24X#L$%M]
M:69D;+4EI*U82O&,YZ7JW`ZA5PMKNT-EZYV<2`$CK#;G0HE0P,[9S4.(R2/N
M"1K:8\54MUW+#&,-H[*<=73R^_9WJ_RLGZ-J>W_YCW\:^[/@M9OQ>F5,K>Z7
M#.#J==25=#SK;4Q]F9C1[)!K-CE0W3`&'86(;*)S45YI$M#2,.X7A*<8Y`,4
MBG56G,V*B[7M-@9JM>$5YH[9S-4+O%[&8;$0X:"9XJZG"I,Q_"Y#ZL=:UJST
M\N_V&.)7W!:_Z;EXY#K7%H\W:E=@@X]KFB73L4,N'80QS,EX2Q/&.S4K0*RW
MV4OMYQE?7U_%U9]/$'[/S7U_M_P%3;B4K0M*D+0M.%(6A6,I4E258SA258SU
M9QGXLXZ!:,QJ'5[-)K=HA7>NT]J@51NK`+H-,KL8ZWA:^@2D2*M$"PN*GLD&
M&6Y;4U67TN8=SE73R_/8P\Q_[Q>`'N.>C>Z$7)-8@\T9D/CGFUP7(8]>A\<6
M^+<EA=%=7'8P0IO[WI-OQA].74^L\36^WUMY2GW_`,U?[4.,G\/0GW$XJ2D-
MPQXR')(3Y;V<X:BPH;*Y,J0[G&,YPVPPVI2NK&?BQTI=PHVT]'WO4#6W=QW.
MI#M<^:O2[DF962.AMLAH%[A^7MKS4(BO2[&4*V?LS24NW%#4./,=(34+=:5W
M/0G_`"?-^3.=/+[]G>K_`"LGZ-J>W_YCW\:^[/@VY_LGV+]3S'3R[_88XE?<
M%K_IOS06M'0+%YV751P:NNV<A(%@43(MI`&7<DB$2`3D1F?"#',84AAS.5]6
M.KJSUX]/$'[/S7U_M_P/R_/8P\Q_[Q>`'N.>E=V$W%0&T-S1F:7U/F,%R(6Y
MK-GBWQ;VBVY,DY_Y_*^?>T3V/&X^++>$,?\`N/@'F8@N1NY@&JBMROO'$Q6(
MIX99I7KD:.T(&A3I41X*#*1\IBRG4(6E2TKQVL9ZNK.,]/ZWVO\`_P"BW_\`
MFATL=MXX;:JVVJ_4+%BI6F=6ESDKKUE4)&GD!B\$G"'D($YT(8BRT)<:3WD>
M0VM.<I5C/H."H$QL?.)AR8^%/>BM36H,N9"?C1ICL)[&69;<9YQ*U-+_`$7,
M)[.?BSTU;;=S^8Z6Y.A]46ZYAJ]K=K1?'O5X=6W`VO+MKBQ1Y)O7=;B6=V;4
M:[8C.5C$2&TH<1A;V%89[/H)_P`GS?DSG3R^_9WJ_P`K)^C:GM_^8]_&ONSX
M-N?[)]B_4\QT\N_V&.)7W!:_Z;\KG&.1<HF^"M5',:WD:^M+E)N31A%I`/RE
M`;2T7`N!I60[4G"G,3&.TUE2.UGM=G/IU)QF/^6EMW8!;4`DW6)5UJ6\N/,6
MM6;"K98"L8N%CG;O`,,P)<0BA2$R66G<?]I.,_%T*&R7E3\@&!P8=-*SWL;V
MXRN99A#XSLN4[AM&P<K7EMAE6>K&,YSU=6.FAN1U3%&`55Y`:8U=NVLA+"F$
MD^&K^U:.#O884<2-E3AR3`\<>;9DX8?>9P\A786M/4K/P#R_/8P\Q_[Q>`'N
M.:-2+5P6!C\7>6<KCH!ECI<N2]:0L?CGQSW:FQET2<81#***;ME0<M,];7AX
M+2_^-:_@$UZ)#BQ7B4I,XB['CM,NSYJ8D6`F9-<;0E4J4F!!88PXYE2\,LH1
MU]E"<8Z><I[7_&W_`$U>%GH4A:4J0I.4J2K&%)4E6.I25)SUXRG.,_'CI.G:
M3X\T36!&O[DW2+V`3J'"L+#,M0[;H+<IM%F.<DB7,@T>IE?V%:1O>P7(.GQ<
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MWOBID1E[?4C7YZ09:%:CN,J3XROV:N./BCU*L,BOV(2S:`P9X[4[$S"?4.+P
M4R!D_##OAWW.[7V?+O\`88XE?<%K_IOR^\;<GL;PK=5'3->9K%0@WX]ZW=M(
M"')]6U`F#LL$X]ZIDR.MIR#(PE'6OLXRG"L>XV7]G]R^KA+IY:?L`<-_X==<
M_`"9L;M&"9%A[C=*,1E`:_;SWARVN(`PIL`MW(>O3I#U"I0\W">*6EM"JS!1
M-CY>GH[]KM^7K+B/LRHLKA5YC4B-)CNH?CR([^PO+_=9?8>:4IMYEYM6%)4G
M.4J3G&<9ZO<<Q:_1]<Q:$5T;RIE:=V87C0@D1>TM@L\>^/>S'-C2W!$:/)GR
MG*9LP,$[\AEV;W81",K[A#"4_`?.4]K_`(V_Z:O"STWJ]"9_+P+OZS6FSI,:
MI(TTICCBD$+UK<WH.\9M_@\?H;$T797[67@B81+8Y&-&($&41X;#N&XD6CW<
M)M^^5`S1;/I\D%K$9O6DFC#HU+W16-A76T#V+/J:\6-C8%AJP?(]IY$YN(K$
M*+'[$=A\BY*(WHV<K,FH4J#S?30O54@I(LEH1S?Y)4WE%;7;>,EB!XNH*U<<
MIJ0(YN%.-8.1'LSWECW,8A=/+[]G>K_*R?H-6JT\/^.-@LMC)S31XZ7U!1YQ
M4P7)2')9`F2FR`RWYDZ=*=4XZZM65N+5E2LYSG.>GE17'4G&O3NL;><\W/BS
M3FK+KO6]2K)KPA*B[R*K@RB0N$/E^JG90-EUQ&%+QEUEM78SE.,X^!ZOY`"-
MLWB,_4[_`!39VGDD:YEUP=2H.F]D4%56HCDW51:XBX]DM-MCSB['KR.F5A^4
M^EY+T8:VQNS-]EU%V0#XG5W0U914")DJR7IVBJAMA(.]'7#(*OK!V:Y8O[JY
M86.DA%%>%2ALE.[>7$^7?[#'$K[@M?\`3>W(778RKF;IK"KCS8`9=(18C5YD
MJ79P05QLQ"!FJZ6D1TQ2CBDX9FQU8<PG.59QC*<^XV7]G]R^KA+IY:?L`<-_
MX==<^_V6D,W&X4!5E'Y&KM]!D@X=O#L./LKE+"2[(`LX:-(F1FUQUK=@OJ2T
MZO+?8=[#B-D)J%ZJ=B:ND?DWJ<+`MN1M68K6D^4=6XIUPK9&<:SU17P6;QJY
M_C9XJ!76A+0\X@AEATT._1?9\MFM-R53$5[@EY@X-$M;>&5RD";KY?$!,E3*
M5N8:4_B/VLIPI6$YSU=>?]_N.73.B1W@;8(Y021?)]WPECB^L^1.-!:"GR"/
M>'G%Q)O7I2?2F.^%X2._4=C&/$HDYS\!\Y3VO^-O^FKPL].S>*)+DAJR'JD9
MN&\'&-'D=0PY.S[O6B&H]K3XXZL[,G\F[#?J[%U]:J.,)$/':NKP29%=:;%3
MI4:6U(E]"?\`)\WY,YT\OOV=ZO\`*R?I\I;URM25X\X[B?D-V<2?TC>-<<@_
M"H5X9*L=G+&7?VG4U\7QYZ^KX+N?[)]B_4\QT\N_V&.)7W!:_P"FY>01&@Q=
MHPM8UV":D4&:::KL6RHEV$,%Q">-/@+2U`2TLGA[MJ'R<9RUV>SCK[2?<3A1
M*.W,'DX<D?/B/8SEJ5"F,KC2H[N,9QG+;[#BDJZLX^+/2*(J]NYL4NM"XS`Z
MO4ZD\_N8=4IE3!P6DQA-9J-6";CAAJU6`,!IN+`'Q&6HL.(TVRTA+:$IQR@V
MQ1=P\^1EWU?QWW7L2G$I/F(<S"<<?:J5K6RV6O3GQI#<TB`09B%QC+BV'VUL
MNI3E*TY3G.,\>S1B?+*%R^C]3E"I.?(=ESB)(A0@$N=/FRGE+>DRY<IU3CCB
M\Y4M:LYSG.<^_P#E^>QAYC_WB\`/<<NB>G+E\Z[+L3E!)O?(8?\`.$<=^8N\
MUZ"T%47Z;X2!#BO5CL:EJ-2)^KI2GY./6?B>\[N2VA'P'SE/:_XV_P"FKPL]
M%F)@X:R)H=7S,\./;CO2W)Q2&.DR!\-N+'QF1)7*EMH1AM'Z:\JZD_'G'1FG
M<B^$O/N::W%(C*'<ON1W%WB#IU6N8`K65QN%CH6QC?'&WXGHU^S8:I`$4]<X
M3+).S"^&"4Q+F&,+Z$_Y/F_)G.GE]^SO5_E9/T^4LHA.3"5!\X[B?/'I4\PS
MXTBSKCD&VQ!3A_XWE.MO+5V$?K,]CKQ\6,_!=S_9/L7ZGF.GEW^PQQ*^X+7_
M`$W+L+D=0)6T])5BNP9NP:!"`@;/*LPEVPAH4:$R!LY<"!)*:*RH[W8DS&$8
MPUVL*RK&$Y]USA]D#DM]S%UZ<:OL`TW]W5<]_P#+\]C#S'_O%X`>XY=6D1=_
MG?(Y*\H)/(`\-\#$A_N_-/Z"T%IO-([V,2GN$>P+TW%*]^\B*[_\U[ON>PVA
MUWX#YRGM?\;?]-7A9[DG_)\WY,YT\OOV=ZO\K)^GRV-:;/K`^XT:W^:WQF#6
M*O$_$(BDAL[7.^HTN,I^&_%FQN^CNK1E;+K;G86K&%=6<]+_`,<=>Z:KM8TE
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MN+D"M[0%XPB:X*:++!S9B8#A%`Z1EG#G9RYAE?9Z^SGJ]QSA]D#DM]S%UZ<:
MOL`TW]W5<]_\OSV,/,?^\7@![@IO^\<:=?F=Q'+`"M9N^-^O1!8S9ZS`#BPE
M@*M!#(T<1,0AU?@L>(>86ZXU%;2XI6$XZ!+GR(T?6=HV>N`<5@(7-D++$D#P
M*2$TK@:R@(<%QU,X($7G>M:%+[3F?TNKJQ@!>ZI2'M=UP/:-BZL#U-XQ@[D?
M`TU?K'JN.ZV1Q#@J7'GMU'#[;:D96RVYA"EN*3E:O?\`SE/:_P"-O^FKPL]Q
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M6RRI<9*UYS'PS^I[:_?]=,U>U`;`!LY:K@86AX8:'%-G*S)*KC;>VS9;]-CS
MI-6@ZDKLUDP.;:0B&<DP_42NS/+P94;=J-C%PIZ39N(U2Y#`I`>OXK;=7#[[
MIFVU)UFIA)$GZ\BT>1KY?ABSJVI4UB;A#[?>,9>>\N_V&.)7W!:_Z3!1@?!*
MBR$=R+/&DHC$Z!.BO)REV-,ARFW8\F.ZG/4I"TJ2K'^_'0A3Q%%IPJI%LR5%
M:N-K`2#72>9K+4>9D@$BP6ADS,MAE"'>\:5WB$)PKKQC&.A&E\1*L%U[L<IO
MKAU;"#VO)(74\LA0M9\N=)7_`&XU-.B7*^F5%<TS7[$P]#<=5DE%?>@I0[XK
M+3GN.</L@<EON8NO3C5]@&F_NZKGOMA16)HL=95`RR:\0.,/20L`XJ!(P)FF
M(T=QE^0+BS\MKD(0M*UM)5C&<9SC/0A3Q-U$VW-2H7*;D"#WH2I8B,C=6M.*
M(_CLN736*L(<@5L?%O\`L/?$L,]:1F4M8"U1Y4"'XDJP5'^6M9O"^!^<7!#S
M!CO@N_\`$^#];W3R^"'A?$]S'\1X?Q'8[?=H[?5U]E/7U8]S#*:.YEZ-U#Q!
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M3_%NXN?4#>WN)_-'16DB7)N?LCCC5N-]AUG`OU'U0BB1-?[$M.QH%U?M-RF2
MU6!=F>NSD)$",/3B+B"IUQ_]8VWFE[#J7$XC>MP'I`9NUZ$:W'1J_,I#,^"2
MD%9#NQ2<)RKG\!)<2.QE,9M.9&96%HZDMJZ"P^X=>C]"[M("SEG>T;-V35=A
MV>)21!YBOL7))&L(C19@2;.F,(4XAKLQWGDM+5V\XQ[]`W0<B;`3>X'S'[?J
M/=>[*I2S/[M3L^S47YV:LJNP@NKKK\VCQ-^5'];AIW4XY^EVL83C'("/K^L1
M:ZR=UKL.:00S*(SNRTQ4#V!@08HI,G+!U&O-2'&A(2%F.'#L.*:@QH[2LHSY
M=_L,<2ON"U_Z5D.,S5H?VO\`OWX@P4MTX'&L1S]VA;EWHT3OA>!DL>39]3M:
M)FV19.1W7;A#$R)*%M+:2ZCW'.'V0.2WW,77IQJ^P#3?W=5SWVQTZQQGIM>M
M@$O63T.//(BI$L,>'R!92,P4$2X!8:\_!E+2F1%?9D,JSA;;B%X2K$:D(K-N
ML(.'9DVF,]L'<.YMGV1F0H36J]/KR;KL?8%JN?[N;!6JC!%%ZGF?FL&127H4
MX?(BRI3+WE[L,--L,,<+/,<99990EMIEIO8?E_H;::;1A*&VVT)QA*<8QC&,
M=6/=[:U#IDA%%;*MWS#^;<^:=E5J,QZAV;3+.8[TW":>DPN]`!92$]E.>\4K
M#>?B5G/O_G*>U_QM_P!-7A9[DG_)\WY,YT\OOV=ZO\K)^GRM/\6[BY]0-[>Z
M!\KL6T6D<*XF6KCTJBYANY-/S3^X:;LA%M00\3AA(N(Q6E0U,]SE>77DJ[>,
M8RG/OVY_LGV+]3S'3R[_`&&.)7W!:_\`399W$4-K&Q[\@G-=3*I7=Q'"]7U]
M8*]%V73W]H`BUF!!;(3KA(QJALY&%3T#IZ(1=R*\Y&?:0MI0ZZ".-VGR7)U[
MPGK/0<SD^;%ZM@=Y8W(4WPO(A''0B7(^%J^$D$==#8[Z4K,//83CQ6=;[&VW
MIXGQ_P!EVRN,DKKIDO8VK?/UZ>Q(D1I@!RT,A*V@^RVJ/AQF7ZOA*>8<0I3#
M2LY1CT;2TU:Y!*)5]MZYN^LK)*#/L1B\8!?:R3JIB0*DR8\R-'),CBKBF%N-
M.H0[A.5(5C&4YK5*JWG#<OQ=9I]?#5:NC/Z._EPS?5P*OCHPD1!\81X:2R$O
MP@^(VWWK[KKSG9[2UJ5G.<UPV=\V[E;=`@<\(*&*<9X]^7@,$6P4/(1Y9"LE
M258X@!+*/&GHC*XK[X^;#G--.J4P^T[A#B???+\]C#S'_O%X`>\+VE(\PG?L
M_5:KE.L2>,S^G^';6MT5R2Y(7%H";O$XZQ]XY`C4.H0W+S:,EUX:3ER6O.59
M5C8-&\PG?NE]>XE5I_.AZ=I_AW9J,I@,Q!:-0LVO9O'6[;8PS;W8KKDM6#^'
M8ZI*\0U1TI;P@(;U!SPWCQ2"#`.!9.G:MU3Q.OPBQE<$)LO-F($N0&@MM66&
M25$DMQ>XA38T'NHZ%=QWJG'%[QX@&AS99G0/'[C5LK.T9<B*Q8KX:W"2VZ`-
M9-5\0)%5T0J*YJQN5C,%MIA;DYQ"&6FVT)][\Y3VO^-O^FKPL]R3_D^;\F<Z
M>7W[.]7^5D_3Q.N7'S74';MQXR\X=(<ES.LG[O7=>%+I3:&!V)73@FLV:WJC
MU6*>;>NT>2E,^1%97%8?["U/8:9=_*2V!_;*XE?SPZ:&X]\A^"-[XYJY$N[-
M@:^O4[?.C=JAUFM6Z_)['-#2@C7!XF9@(E`A3B67UH[OOE)3_NSG*?37^1K<
MJ!C4`[AG<-)S(63+^"BMDF=W4:]#I2:_W/AG(":P!E(5,RYWB',X;PGJ5G./
M?MS_`&3[%^IYCIY=_L,<2ON"U_[G1&VMYP/5FV;M5R!*ZP/FZ]4_#$F+.>&L
M(^;LA"'A?6.A,9["L8SGK[7_`&O@?E^>QAYC_P!XO`#WN6<T%Y>LOD8]<*'5
MV+=N:M;OT+J<J\Z",VQL7KXU!V27#VDLS5H\Q4Z.\G#L!.#"D-*PZE]*://T
MEPYM/)R4>'GIEV%5S<^G]92]>R!<<"\*'NKV4<$Q[9(L+A&:VUD:IQ#"ARN]
MRG#[.<U>QGZD7H1PX!%E2])/2A,XU4R4Z&S(FUXK-`SB827/$R'%,.N1)#T=
M:T9RA:DYQGWGSE/:_P"-O^FKPL]S>*2#M@$K;J:-[=HKD(C&?+A&R,5_,-V?
M"0O+S3+RFU([?5E*74*;5G"TY3CR^_9WJ_RLG[GRM+&(KAXI7JA>N6\BVGAP
M@A.#5>.:XMVP0&?L12-'=@A&2Q9Y$6,J2MI+\A:6T94O.$^XKY=ARV_T7T<,
M[@-)M)*IQ1,[[<W=1I0)Q\)XS"UVW&O6B.&I7A\X3#RXWWF.UV<^_;_DZ_N=
M;N4<!KO9`8R]7"T,JT.)(I120F-)7$=<2COXSR'65_&V^TK"VU*1G&>GEW^P
MQQ*^X+7_`+G4VX=JZYE:DV#>@,PI9]<S81L=*JLV.=+#&H+T*QQH9N.IZ%!:
M?ZI#2%YP[UXQV<XS\"%$;Y;`-1@G#3%=$2CY&,-9(FGX)`K@?$7(6C#KS`8/
M,G/YQ^C&@0I$EW*&&'7$>7Y[&'F/_>+P`]\V^<H+<MZ]!=7;`+4MF!`]:SG;
M8.J9:97&X0SN9'K&6LPRSAMCNU]\O.$=E77U9X[6W=+!.+MVRZ:UX;V7&-!?
MFX78NY*L#I5E:)@/"P?4TY!5UW#L;N6NY7UI[*>KJ]Y\Y3VO^-O^FKPL]S#L
M-G'PHU-H3'F%,CSK92!(S>L\Y.85#Y-@<!AD.2^4#M:XKE.6(*K(MQ5RB3^%
M1$N1T=\IOCQQV\SGF+7*=H%@72/W4TS:&CCKVI8DR`@^`JQZ"]JTM8`4B2&(
MMRXS9):9#\5U#V.TA6%9_,]Y_P#TKTI^"W3\SWG_`/2O2GX+=*VYLKS@.8NO
M47*S#J74%WC;''6IHM5Q,8=4)J=;4>U,/P<LQ3##F8T"+WLI_"%=A"NK/3\S
MWG_]*]*?@MT_,]Y__2O2GX+=/S/>?_TKTI^"W0O3XGFN\XY5NKX<!83U6C;!
MT*_8P@"UR[$/JYPN$:T\HF-#V2?4"S$"2\TAF8\+EH94M49["/S/>?\`]*]*
M?@MT_,]Y_P#TKTI^"W0W;KCYKO..IU.M"YIRQV>S;!T*!KU?"C8ZY9$N;-%-
M/11HH6/BM*=?D/NMM--IRI2L8QG/0':ZIYK/.>SU:SAQEAK5EKU^T.:`6$`:
MA,$@QP&9&Z=DCBP<L.DMR(TF.XXR^RXE:%*2K&<_F>\__I7I3\%NGYGO/_Z5
MZ4_!;I6F]J><?RYUHNZ&FJW3D;`W%QNIJ[98GLM)9`UI-CU4-R=-.Y>1A,6+
MWKZLK3U)^/'3\SWG_P#2O2GX+=/S/>?_`-*]*?@MTGG+!YJ7.T&$%179Q0P8
MO.BA@L;"CIRM^9/(3=-L1(<5E&.M;CBTH3CX\YQTJ=8E^;OS-BV6_09Q.BUZ
M1M+CRR<N@T9%8FDB%3$N:D3/L<$?#E-//O0VWFVFG$J7G"58SG\SWG_]*]*?
M@MT_,]Y__2O2GX+=$4^?YM?->%;G*V7N2*M+V5Q_C6-=0K\L0//6I`1[4*":
MJV$GV"`Q+G8:\+&>FQT.+2IYO"AKE5Y063E_72YDR5$[JLUTH5_D%6''FH3H
M8?9];"@]5G"PLN"XVA+3:G&W5.)6O.<=6.AVL;8K2*T/5QHT9Q@>C0[",+R+
M(QJ85M,=9KL*E!W7TC`%E_>1A(QJ5W))"(JG),=A2DMXK5$T!YI_,J7JW44"
M)IFMB*#L_0UH!4B+JV'&IK6O5SX>J2SD8G28HIH?(BRGE38RV>P_C#G7T_,]
MY_\`TKTI^"W3\SWG_P#2O2GX+=*;KZS>;]S'KM^V+ZX_=]2#NU^.PBWWOYNQ
M$3[!\S:T0U-'-6?U%!<2],\$P_X5I6%N=E.>OI^9[S_^E>E/P6Z?F>\__I7I
M3\%NA`R9\TWGB(#B(,LF6+$[MHV`-&#8$=R7.($)TO3346%!A16EN.NN+2VV
MVG*E9QC&<](TZ#YHW/>;!FQV9<.9$N.D),67%DMI>CR8TAG3*V7X[[*\+0M&
M<I4G.,XSG&>GYGO/_P"E>E/P6Z?F>\__`*5Z4_!;I#UB_P";KS/9V40K\NV0
M->N[0X]-WB=5H$MF!.LL.IKU'@])K\.=);8=F(CJC-O.)0I>%*QC/YGO/_Z5
MZ4_!;I^9[S_^E>E/P6Z?F>\__I7I3\%NEN#:V\X[ESL(QK\T_6[X*H^XN-]L
M)4FQ19$F+)`VZ"!U5/E5LU'E0WFW(LQ++Z'&EIRG&4JQC\SWG_\`2O2GX+=/
MS/>?_P!*]*?@MTBT1SS9.;J+Q-`DK3"IJ]BZ"3:Y=8#3PXLQ8XM=5J#!>0!%
M$[$/C29B&<QV'YT=M:TK>;PJ/::!YM?->\UF7(G1(MBIVRN/]F!290R8^.)1
MHY<+J&:/>D#R$9QA]"7,J:>;4A>,*3G&/S/>?_TKTI^"W3\SWG_]*]*?@MTN
M)*U><'S#K0_70N$;V#/L&VN.@:%10I+,W`XO<91'4\9BL"R&1LC#$B:IAIWP
M[G95GL*ZJ>+B;SMW)$?)CS#@G<UV/56T'+F(L,^29%RTGZ2)"5@J)BPIJ&(+
MT6/A"HC;><J7GK7D5;*`)BV-<SC-RPXQ$0ZRHX-*#R>2[NCB`'8CTHO)BPYE
M9II32V&2\1A2R:H9/Q$-F4]&\)(XHWVU\K-@<5]L:>K%GX^:ROVMKY0Z--O;
MVZ&-9*L.OHD38P&PP+"6LA/3(M\?#BL^L%9CN81A6,JQC\SWG_\`2O2GX+=/
MS/>?_P!*]*?@MT_,]Y__`$KTI^"W1>H4^<!S%5MENLXNCFKT[8XZYV(BG9FI
M&XMBZ5C4WSE36<D5IC^/S&\+WV<([?:SU=/S/>?_`-*]*?@MT_,]Y_\`TKTI
M^"W1XS9/-6YTU\/'>A1WRIR^:($C6)!*=&&#F'IT_3D>*V]/)3&8["5*PIU]
MU#:<96I.,_F>\_\`Z5Z4_!;I^9[S_P#I7I3\%NGYGO/_`.E>E/P6Z6K78'S>
M>99O8%%CAY=WHPC:?'@E<:;%L+"Y0"3:JS#U*\:KT<Y&;4Y#7+893);3E3>5
M8QG/3\SWG_\`2O2GX+=/S/>?_P!*]*?@MT3;MP^<5R]U15%SHXQ%GV5M[CC1
M:\HE+PXJ*/2:M&J!8U4Z2EI66VL.]XO"<]6,]6>C3['F@\^WV'VT/,O,V[23
MC3S3B<+;=:<1I=2'&W$*QE*L9SC.,]>.GYGO/_Z5Z4_!;H_+E^:)SYBQ8K+L
MB3)D7#2+$>/'80IUY]]YW3"6V666TY4I2LX2E.,YSGJZ:_GO><'S#:@[9D#X
MFJYCNVN.C<39<HL%>L@J-K^0K4^&;E()UZ,Y/CH'9DJ>A-J?1C+2<JQ^9[S_
M`/I7I3\%NGYGO/\`^E>E/P6Z'+K>_-DYNTJFU@;),V6VVW8N@JW6:\(A-Y=F
M%3AXSJ"&*$C8C6,J=?D.MM-I^-2L8Z'"@_S(N1=FWCM>Q5W>.T=)W;:FDGS>
MZV*-2JMJH;8K50H-!%W"75H%(HPH0Y)')B,8:@HPISO>VI7N1H^V5B4%AZD"
M\AZO*MTB4.>&;3D[WWL$W'5B%0\',DEY(FDUH0MF>X48@K:*%W6(R'L-27?2
M,&4C2=TV;-NX>Z4"T7#7E?HMANVOM>62"*S;8-7B7@V%&KL%U5`B(@^,S)!,
M31[4PE&FHB,P)=>A,0)@IB&#$Q619&0F60&M1X$=IN!.E(?E(DS(:$8;=<PZ
MYA:TYSA2NOKSZ.5.T]Q$=<VP7N[3/&Y1;9-/`'Z_,NVR:'=N24%0[(HK;3<8
M+%H&MCX,=EAB*S'<@N#<I=D36RDF3Z-,2J5*V$X(UIOVK[2V+6=43*;`V+=*
MM6*3L2+60]6DWL?,KR90'<1>K6&0A;T)UV$$>0V]E2L,/4!&UWJ[(VDBDU5&
MRI%0:EL5-^_I!0,7%ZKL3UN3F:Z[8L250D/*4ZF-E&%YRKKSZ=8DM?:ZM%O;
M<UGOG6IXI3E`7Y4MC9!/2TB-J+8,2Q'`N!.C-L-4R0]9CP92+,'?`#L0'VVI
M,QJ1Z-K#V:S*N<F5KFZ-0ZC`B#IQ"RSOFX15!!CH9>3"%R"1.8E#,=,AYEG+
MRT]MQ">M6-1K1JVQ0XUUUKP;<*&RK]9CJU(2XV;<LNWMA5^],-FY,^*:,@K(
MR(@)%)(L22'?MN.MQV\NJ]%5NZM`%-QT(7P<YGT:^CHXFB3Q&Q"U[NG%DW3M
M(D8UP-#X9N9?P>M+'%9CD6O4J$O91*?:1(5U[-N.P-=WW6MXO.U7K'9PUX&U
MD/$FSFM;:UKL6=0QU=/V22W21X@!&%)?*R$E)Y4;.EK998D1VT]+57X,AN).
M.ULX&ARGE.(:C2B8R5"CR'5,I6\EMEY_"E91C*L8Q\6,YZ6*UVC7Y+5[#6L=
M*Z:CU8S(`/SR1K3"=A(L5UA8JY(L)5532KM&'B7W'FYLJ('PZMAEA4;"O13:
M`/X[[$V!3;J0U>1V/L?6L&EH.98U_M2'9J/3Y9X]<:O,!U^JV!3YPK+>:(*;
M$/RXHN-F>07,@>AJI:C/:Y@P6WB!JX5?8%;L9IJ^K"P<DJ57XD^OVJMJ%P8]
MNC1YLMIW#C9!49AAU:8F9;$K5X6YH'MW`1KNE"[8V):>8%-V4?6AD0Z@8S)E
MSY#(])1IW#*7'WEI;ZL*<7GK5GT;I*D/GO*KFQKG=MA7ZRV*91).M;)&(P:7
M5M$BM6PQ(^'?Q=DU[KNFMAC;9'*8BG&)#ZUS/%"W(OIO!"\ZZM%9&A-:4K6U
M=)6Y0&/#J[%8L]QD8U%IS%?.%)=JT941TR-(%'K$E=FGRY4C+SZ(.8(T9Z)U
M=H=;D!$WSR[.>F@I&YI"(42L5C86\#7&:+JH8?(#Y:[@YX=%&.3\*BP9*(K3
M*LI5AUY*%;\VG9J22UF/V_<:62K6OSSP5=C`P:/K.KZ_(R"\>M$"]?BI+&`#
MSL3$>4ZIR%AIQ>$97A&/1R=NM7XW638^8VK.+B:>QD33?46R=DU+9.VCSY<-
MF8?9G3R&K$V\&5DR)+,.6E0WLP'')#+.<`E%*O?*>7*6C:-C-`]DC*N$MB3=
MJVK=K*:+/@J:;L@`"#LA0L\2#P&R$Q^$'EQ6)+JY3;V?0K]WH28?^?/$SF-Q
M,;\!(BL_,R\<H?W$_,3:=B\;,A>'HE%_=01];2H?BBL;QK'A8K_;=['IJU2S
MQ@V(/U_7ML5_:4C=%.&Z_'UZ_;1QI9ZGQMB;`L";H/L+U3I5-<9JJHS@F8?)
MDH$%M*XP8:A)+T5F9IZP:SD`Z2V@U$UW=ZR?(.E]A2"T6#&N+A41:0*)'S5J
MLB6T.AN*:C,NS94EY$N2D:X.]-UJ%W5>7@,6<9,6`O?YM%GQ[GO"ZW^ZW[9N
MP-3*IH\<3A:MMKUJ9D,QC+;4B,ONF$1V93!-Z7Z-0677-;ODXO3KG8YDFX:F
M@U<]M*B1#6OK,!:E5:JWDR'IQ\79I\YD4<Q)5XV,%E2'1CT`GB(2A:YK<NO"
MZE+KU#J`.55`A"46"UF0)KX^`_7A!2:X[,)"PKD?,:/(>4IUYIM*UYRK.<^B
M<W)A>LHRX<E$@=W+,GQ["F5I=A>'D93'D>*;SEOL+SA"^UU*^+.>FC:1`U-:
M*N?MO$BD<;"4,XNKP)NC[C52=.F2SUTCC;!/3%I[D6J/O,R0CA)_+T.&WEA*
MWV<H]'+77-3J$B_6Z]\<-T5&G4V&T*=F6&XV'7E@%5,?#P<EP!+4Q=BE1E-.
MOOLML.)PYVT]G&<:]"*XI[3&4-^X:AVJ>V2!`:Y%R#^P1XAC`"?LNTL[%AFQ
M]?TV/PF*3A(@$B).3&:B1W<#6G6B'O+ULV1=JEKZK1Y@T<_9;O9`U4`,$#$Y
M@6(@O&3TV`.;F%24IJ/&:4YA;[[B6T84M6,9L,.K6NMV6943;U9MD6OG19F3
M6+)'CQIDBOV%@=*DNA3;$28RZN))PT^EMU"LHPE2<YZ&I-'N-5N<>N6(G4+"
M_5+"(L3(&V!.YP9JYIT1,F(%V(1F2WXJ$_EN3'[Q/>(3VL=?2<7,D((D2,B2
M)Y(H3EL0!P^#%:4]*FSILIQJ-$B1F496XXXI*$)QG.<XQCH$O>-EZ_S2+,ZR
MS6[EBY5S-5L#TE3R([02P^LO5!9U]<9S"$L/.95EM6,=?9SU&JK3MCT.V6BM
M0X1&Q5NM6^O'3X`>2FDAHZ>:#BR,HB*ASR(:8PRZ^VVAUZ(\A.<J:7A(A>Q=
MA4>@HL,R4/`+NML`U5)PA!'R2TV"(4=GP,$ID,5">DNM,]M;<=I;BL80E6<`
M[75#@>SU:SAQEAK5EKQ.$:`6$`:A,$@QP&9&OR1Q8.6'26Y$:3'<<9?9<2M"
ME)5C.??ZN/N-SJ=3GWBP,5.EPK+8@X*7;[5*C2)D:M5>,4F17K!8)$2&ZZB%
M$2])6VTM6$92E6<(L5'M5;N=?<F$1[9VJ'!EB#N$`\Z0++04$Q$J9"5,%DXC
ML>2UA?;8?;6VO"5ISC#K[[K;###:WGGGEI;:9:;3E;CKKB\I0VVVA.<J5G.,
M8QCKST%777EOJ]\IIUN0\$MM,/B;163#429('RG11X'+G"B#<:?$=8<4RZO"
M'FEHSU*3G&.D^TWBT5VFU@6WATG8[6;&UT".:4K"$N3RY>3#'Q&U+SC&,N.)
MQG.>KI7\F[W30^+:TIZJY*V<(/Q9F4143E.U_,N<SZY:3"<2]E4;O,8:5A?_
M``YQGH<7KG85'OZ*R4;!V1=)M@&U)KYIT?#+-"#B@4^?@24<%$8\E,=_NW<Q
MWVW,)["TYRVSMC<6J]8//!YUA9:V'L*I4IUT`,EPH!(XVW9"XQ:PX^<1CLOR
M<8RRTZ^VA2L*6G&?@%>@5;;NL+).MQ2W`ZI"`7ZJ&)=G-T!/;O@>O1AQ:2\:
M*4E'QEX\;#KPW'QR$M^@%KPE=*F/O]H%ECE9HTZQ!XEPL04"J.DZ7!5E^8V:
M+BPJI;6)<B.PXU&RZCO%)[6.OT6BJ"KO4"=HI$>#+NE;'V4--/U"(41+<&RK
M0'C37"(".1;@/J87+;:2]AES*,Y["NH&PC<VJ%OV8_`J=;93L2H*=L%I*RR(
M\76@;>#&5ECY*>'EL1X;&')+ST5Y"$94VO"2!DR0@B`XB#+)EBQ.7'@#1@V!
M'<ESB!"=+<:BPH,**TMQUUQ:6VVTY4K.,8SGH07JK:FM]FH$0P!`JO7UXK%S
M2,'VP>LM5IQ!5<*$L0H=E%-JDCW7.RB9'3EQG*T8Z_@;6J6J#"V8*-[NXO6&
MY4XHNM8$%]=ZSY+ZFVKL:*38M1(8*GM2Z/2)[#,7*EJDRGFFLX2A2W6SM2T'
MR3V02N0>+S*K]+/US?VR]/VRV!MA<*@6C>'U@V<;!V@#!M&PM);-U]6I<\W-
M7)EY>AR2<-+>9TJ&K:"Z-M3?X:WV,IO:S4)JW\RS5CBUNV3.*O%@5HEV3ZQV
MI:HL&EC.66O-B%9H*.J0&R'LL=MZ`[&??A0N6%@U5N(=I5_D%`Y.[&7,>V*3
M/AINV-K`N+$+1,F+2!F'0],OVMW=8;$BV0R,7$2_&LXCP\XIB)C`JXV[D;NO
M>^Q-+RM'ZT?UR-L6Z+4Y6ZMML+LO?<RUU4SK8GR!WD3)Q&-6[+K(UHD0-V)P
MR]7._)37ID.!)?YK4^K[2)6+5.\-9\H*76Z`G>=@K%9L`S8-;T6-XD5H'5E$
M`X;7[^E;K7+V1V#-1X%-I!'HT%[-C;[0Z)QNWE0ZO-MM%T_JC;.MBVA9IZN,
M&Q);9\O7!L3MZKDK/-D`3^U:JFAS:_,7.L,'$H5:BDC$]][&69D3D?QAU]"U
MG2HFJ.&&LRM>IVRZK0Z_9`%"Y!<M]F<CJW(K@N=#&E8Y2J<DH+D*22%*2NPP
MY\MIK#K4*1,JM8O8DKM"#0N;6C>0U$$3-]1]G%*CKH9PV?I.[*O$V'NJRA+E
M8')'*.WV.>#C$9"FF0$EE#2H;+3,%FGZLUAR8O&I96M_+HXV:#UCKC6&U2M$
M16MVZ?XZSM+[!"RK_4MS5D$&!V7<$,!>Q5HC5\O8GQ`MP:J:%9S,"GJ)K3;%
MTYO1@5TY"[DE5$MQKW35,['&:S+`N/!>DHMNU+!RPT);25EJ]H=NP\96&#9]
MN?$(O+9&3&QL!<?E19AO*?;\.H;#Q.E<>->1=C7NG>IJPJ\:JV-J@1;+=*W"
M]>:P7JE8IINCVZ-7(5',F!UDD2W+'.(]S,':;IMYDS)MVJ6JM>5FX3"%WLFS
M"$NT@:B(%6"3.V1<D-V_8,Q\M$>6Z;*I22++SF5)QAYU>/?>-U"FB"#E5J&]
M+'LBSW0.0KX^PZMDQ>,O(C7FNMETETQ*3,;V)0]O;)KQH)(B1I#D&2-S*SU*
M9;0[KNQ:\WC>[+;!PNH.;+$ZMW]L#450M5\%^97KCDEL6^C]<S[Z`H$-S:'%
MY=TK<J$O"O%O%D#9[[T7L2FM2DL7W>Y>OTO;8>\&0%SY:R]B$25"=\R78U^M
M]'L+UVVK8&;P[.\N6V":I`B%ILZ!%L(K.&I$=YB,4=)Z%J6\85"$UZ!J)":O
M6=FWJS-VRP0N2V]MF;^(:I+#KKIFT:QKNQM%7ZF@688^T4>0Y9JZ4?PX/Q-]
M=3N13_+;>>Z-X][<:$[I6YWC:D@Q7+'5']`:<J&R);FK8%P/@Z*5?W)KTV89
MA-QF845HYEZ%E+DT@RU2X>W[Z<VU2:US=X8[WL5<5R#L&&"C.E>8&_-I[;O=
M!@D3E<BTNBDN+%AU_5A%1CNCVDW*O/3TCHSB$'I-YW/$J$7<>MMHZ!USH^!0
MWR%1&JTS-H-HV$9,/!Q=GCCQTO7.XAM]B(LWAIC\YA^IBTM#)S;BEP^5NP-`
M5\;2M9[UWQ?3<6GA-]N:KIA'5^.%NH=-ZQ<8A4;)4A22=9W%J+"XDL>)9-P0
M,MAN,]$[^6B)"U=,"O[3M("A^;-INF6BU;AK9R<-U=RF+#ZYP]&VVZWFR1[G
M:Y]-UB"@1K.2F8(%<.,9<RZ2D+6M13;87DMN;]V+_+K1>RH6D*/M&;K!IWC<
M/W1J*^W*A$BH_?\`\V&[#2=/U^WTV:$%B1`2URS3$HA.+_JY@KA/JCDG<.<Y
M-0&$"FV=7';;P*'3[#%K/)C?+PE%\-C.6VHMK;C>O&EGJ?#M+?S7N<T7"%MO
MI0W)GS<N8$;0Y?['VAL'&Q*P?*-`=UW_`$S2#JJ\1NX&WD'+34ME&MKL5395
M-O0LK"&@Y5-#5RPTYG"ZL0B/RFS'ONQSNM;R1T:<W7JGE\W=*.*N9&HFZKR<
MNQJWCN/W(:B[$U`=;(5JP$J41&Q+<J-/=>EL!0V4Y;<BS6I1V;4MK[Z'%1_]
M+JV4LH4YH60M3E6J]^7MQ^UWQL$&JT4V@5CE`E,YS:SLUGDBY@E\*.@6%3S"
M7T39\-K6=[JVP2X*]Z%<YTU_0FQ+QR"+%;Y1!W)^G</YFD"9JT1"=JL%WJ&L
M-H:=M3EO$%9LW,T-)CP8T<S#?<C-6O9P;DON2Q:S_I@:2OM4UAJ[;)[4H3^C
MP&WOIZ^W`(2??WT&"3I59T36+M1WZTU6Q0>TSK-#GE72;K3<T+IZJ<)=RV6B
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M`?BST]V^L;,V"5/;ZY!W4'&I//Z-<-CP-JUS9%M,E[;I3CE&XQ;&U-IZ][.B
MU&JDA^XZ)L`F/!,/@1U?;LL6-C,."IWU?JZZZ)Y%<P=.T[&TMY'KT,Y!;/.;
M?M0.S6F_Z_MFE)].LHGG#M&EW[0VL-;A3%4DPI=GNL.1(*+DS:C+)XQ(%[S?
MY$6^YV^5>MCQ+=0G[SNRV;=/!JR>!L6<M4YL,G*50JIFB7*RD:[#75(`$47"
MAQ\EP5&E=Z[)_P#14.%!`9ZQ%AH<G/%U^/*8A2#I&'"?D0@S$V5C,:(\3DMI
M82ZY^@VI>%*^+&>G_E]N0']L[C;_`-PZ?^7VY`?VSN-O_<.G_E]N0']L[C;_
M`-PZ:]U]M?R5]T<?M<VNP,BK=N>P<J-$7,-KL2XP^ZY82-6K<)LZ;CLNM(;R
MS&5AW.7,9Q\6,^CEA%NM8U"+9XS"?5A!Y`+9D$>_<+YNNRU+2TUFPOD2`<^-
M,:?$0SY8?VA+`\H3BQIYD2-<<+1R&RQ5*UO*%U70%^V?,UFW=)J=J[>M=!!;
MXG%1>CV`<6WABT>`?T4X.(0G/&>!]<8<]8NOPD0R06OBR/$+95P(U;4<(1;*
MMR*V"-UR4SMCFKI;C47,EM?I!'AH$=5(.THTM@DS-/R9,N+,C8E1&6ULR./D
M(*K2]AE[2V6_HZQ&H!XA+KCM^E<CU<4!MPK4EPT,A1Z'$OZD6!T?'G6(X\*Z
MX#R!_6T9<TA+M36B[&5LNC-)$[CM=9D15*U,OFUZX'GD]FM516P(EH?UYJ$@
M6S'N;`T/@4B0,)O-&1C;2(;<.W6*YIOII>^>8(258F;B:V!`5$K/+O>-?`"0
M5QL(P(7.U6OUH=#@AW78,#"14>,A$6,A*6&_08UWH'RD-M<NM;#P]?GCMUU'
MDCIC6H4R0*#6I98.S5;I$>/17J_,6J,XZXKL/*3VD?HYZ`]E;LXV63C!M`EZ
M]]9Z)L]ZJU_.@O5DV5'%]_;ZDVU7I?KZ,RA]ONT_J4NX2OX\9Z#`D_R%M\"0
M4RP0Q<VU/<P>.TF*,$R"+<238'1S,#$Q^/"AKS)4RC/>J2GLX_2STF[!X^\7
M+1S!V-'L`$5&TQ4-@U'69F:))ONM%+"BTW9IX$U'`M(2XXRI/>O87U(^/'37
M=^VCJ4MHC8=LJXXU;].G;(&MYC7)N6C*IE6(V>O(;!G)0Y6.RJ1%QAE?7^CT
MUA:("*+&IUIM.QJM>;)?'"L053LA^.>[-J4,V\1@3H4.-!,;'UH*K[S4C.%S
M%G&F(J\2ULI<AQ*O`XPMEMA!05;TG5V]NFBETL>TKQPCKO+JID[K6Y(2N9K&
MOHLV5(!/L0Y!.=,1,9DXD1,Q'&YMEY7FZIK$K715J+-``+0^TU8K9ZYKK5&;
M?LP8W\[;9`&#+#(OHPH%'2%S'%,QX:7T#B3KBH[>R)`>X<81\&#L:11JO(L%
MN-N3M8#!FSBVO47;=XV(1B#7:C>((A)8/+8)@\I9(PVTMS&UYD]'[G*B<5T5
MH*4Y.VG94IOE'=;G*D0=+[JU?0HX?5_SNI(%66[N,V?'D0\S%BX8A_.8[(Q;
M3*$R*AH`*8T<!K+FX;U7YL$UDH];;A6]:5&V1C-%#>L+$&L:K]<K?ZN]6R/F
MT.@09Z&V(CUC&/))2I-EGLT+19FV!K[:WK^*VQB"Z#`4'^C*99UT%+:\L-SS
=7M\DT<@)'9%NDW7Y8ZED\OQ!WCU^IO\`:?\`_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img4.jpg
<TEXT>
begin 644 img4.jpg
M_]C_X``02D9)1@`!`@$`9`!D``#_X0_717AI9@``34T`*@````@`"`$2``,`
M```!``$```$:``4````!````;@$;``4````!````=@$H``,````!``(```$Q
M``(````<````?@$R``(````4````F@$[``(````%````KH=I``0````!````
MM````.``#T)````G$``/0D```"<0061O8F4@4&AO=&]S:&]P($-3-"!7:6YD
M;W=S`#(P,3(Z,#,Z,C@@,3(Z,3$Z,#``;FEC:P````.@`0`#`````0`!``"@
M`@`$`````0```FJ@`P`$`````0```04`````````!@$#``,````!``8```$:
M``4````!```!+@$;``4````!```!-@$H``,````!``(```(!``0````!```!
M/@("``0````!```.D0````````!(`````0```$@````!_]C_X``02D9)1@`!
M`@``2`!(``#_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$``P(
M"`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,
M$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(`$0`
MH`,!(@`"$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"!`4&
M!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'
M!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R62
M4_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3T
MI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&
M!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E
M!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`-+ZRN/_`#CR
MVE[F,+Z@X@G0&JG<Z)_-5.RFEM=CV9XL+![*QO#GDGM^;[6_377=4Q^B.ZE8
M,JBA^3;M=[VN+W#;L:?8?^#V*FVCZLN9ZC:,39I+B'-&H+F_3<WZ36.<KT.8
MB(Q%'0`?H]&K+#(RD=-23U>8IE[F,LN=4QSG;K"3H-H/[P1;JZ*V[J<XWN!;
M^C`>TF3#M2=OL7268_U:KK8ZVG#K8]S@PO.T$L.RW9OL;NV.]KT)Q^J#!O?^
MSFM$2XV-@:Q_I4?O$>TO^:CV)=X_BX-5=%N]U^:<=WJ/`:0YV@+8=[7>W=N>
MA60USF5WNL9-?Z22W4C])IN=]!RZBW&^KE=SZK<?%9:PNWM<UX(+1ZK_`,[_
M`$?O3_9?JV'BDTX?J/(:VN9<3KM]HL2^\1[2_P":KV)=Q_SGG+:,1M=CJ^I>
MH]@<65[7C<1]%K7ASF^]0J97:]WKY1QPUM>TG<[=+-?:UV[LNB97]5;!+:\*
M)CW$L,B/S;'L=^>U$=B_5PO#31B;RP.##.XM`V[FU[][OW4OO$?ZWGZ5>Q+^
MK_SGF+-C'O;1>^YH8^7F6@GML]SG?11J\?"<&^IU/TBX-+F[7NVDAI<-S'[?
M8YRZ/'P>@9#7/Q\7%M;$%S`2-?[?YRG^R>D?]P*/\UW_`)-+[Q'^M_S5>Q+^
MK_SGD:(L<QMU[J&;'$O))U!.UNW<-VY%MKHJ-9HS79+B\!S0US8;^_N<[][V
M[5U)Z3TB!^HT?YKO'^NG;TGI`<",&B9_==_Y-+[Q&]I>7I5[$NX_YSR==5#J
M&/?FFNTC6H[C$;_SFN_D,_[<3`-]7TOM#O0];;]HD@;(_G=KG+K/V1T?_N!1
M_FN_\FG_`&3TC;'V&B)F-KO#^NE]XCVE_P`U7L2\/^<\ED,J94759AN=H-HW
M-.H]W+OS$1M=-C[779AQW"PM:T[G2)'NT=[?I+J/V1T?_N!1_FN_\FG=TGI!
M<XG!H))))VN_\FE]XC_6\_2KV)?U?^<\?;+-S:[G6C8P[@XQN.USV?2_P;O8
MCVTXS"[T^H&R`Z-'"2!86#Z7NWOKJK]G^G]1=0.D](@_J-'^:[Q_KI?LGI'_
M`'`H_P`UW_DTOO$>TO\`FJ]B7<?\YY2EK+7$7Y1QVMKK+7&722&@MV[OW5>Z
M&UK.O=/%>0;PZRS<!N$16_;NW>UV^5O.Z3TC2<&C@#Z+NP_KHV!TWIE6;3;3
MATUV,<2U[000=KA[?>A+/$QD*EJ"/T>R8X9`@V-"#U?_T/0LK$#\QU^QAL&T
M->1[@``Z-T?O^Y`'3:PW8*J=L`;=HB!.T1L_-W.5G+IS'YH?7D^ECAH#Z0T$
MN=KN?O</;^C=_P!N,W_R+*[<;JK:2W[>UUOMBQ]37:@.]7VM]'VV.->S_1[$
M\'1;21N/:QL,+6CP:2!^`3^ED=W_`/2/]R+4VQM8%C_4?))=`')W-;`_<;[%
M-&RJFH["ESB65DN,DD`DG]X^W^2U-]@;(<:ZMS8VNVB1'T=KMNYNV%<5>_&N
MM<YS,NZ@$-`;6&0(#MWTVN_G-WN_J(654C^P-F?3IG03M;,#0?F)?80';@RH
M.+=I(`G;W9.WZ'\E$MQ;K+'/;FY%37&16ST=K?)GJ8UC_P#.>H?8LC_RPRO_
M``#_`-Y$;4NW%<V8#!/,:3]S4OLUGBW[_P#8E]BR/_+#*_\``/\`WD3?8LC_
M`,L,K_P#_P!Y$K4R^S60-6_?_L2&-9(U;]_^Q,W#O:]CSGY+PQVXUN]#:\:C
MT[-F*Q_IZ_F/8I/QK79'K-RK6-EI]$1L]HVZS^_]-*RJF/V:SQ;]_P#L3_9K
M(Y;SX_[%%F%>UX<[-N>`UHVNB"X!C3:[;_I&U_I&_0WV66U[$WV++(@]1N+-
MK6P&5@RT-&_U6M;;OMV;K?=_A$.(JH,OLUOBW[_]B<XUDG5O/C_L3,P\AK6C
M[;<YP)<YY#"73OTVN#JVM;ZC/;L_P-:A]@RR+66]1O>+""US0RMS=OYK/2:U
MON_.2XBJDGV:R#JW[_\`8F^S6>+?O_V)5XF6TM-F?;:&EI+?3K:#M=6^/T;0
M[WMKLJ=[O\.F;AY8:`[/M>X3)+6`0?*L5NW,_-<]Z7$54R.-9XMX'?\`V*>-
M18V]CC$`G@^1\E*FM]588^UUY'^$?&Z('.W:C5?SC?\`7LE:J?_1[O/SV5=3
M^QS8;;`US&L$B#[&^[<&M_2-51O6L9U)N#[0QNPF6ZQ9N]/:T./J?0=[:_TB
MU\C'<^Y[@X@&-(\@/%#^S/GZ9GX?[5("*"UI.Z@UN.W(+K16Y^P"#NDG8WV3
M]%VU"/6,=K#8Y]H:T;B-CI`ES9V_V/\`P2FS^;L6C]F(_/@_#_:G&.Z?YP_=
M_P"9(V$-!_5*F[RY]K2R"YI:=T%_I:-!]VQW\YL_P7Z5,WJU#F!Y?:T.9Z@#
MF/G;[?S:]_\`I6+0^SNG^<//A_YDE]G=!_2'[O\`S)*PIRF]>PW5"YEESJRX
MLW"M^D?2>X.VO]/^5M1/VQB&2+K(&V?98/I`N;`<T.?]#_!>IL_PBT?L[IGU
M#)Y,:_\`5)&A\_SI_'_R25A+GMZOCN:YS;+7@.->C'SO`W.8W<&[W;?]&G_:
M=09OW6Z[O;L=N]OI;O9]+Z.14Y7QCNU_2'B./_,DWV8_Z3\/_,DK"FF>H-#*
MWDW@6`N:!5<XP"6^_P!*NS9_;3#J-<CW9'_L/D?^D%=^S']_\/\`:D,;4>_\
M/]J5A&K2_:-?[V1_[#Y'_I!/^T:X^ED<_P#<?(\/^(5S[+_+_#_:E]F,?3[^
M'^U*PK5I?M&O][(_]A\C_P!()K.J4L#WN=D;6@N,8^23`U^B*%>^R_R_P_VI
M'&.XG?W\/]J5A6J$661.]W`/)"7J6?ON^\HWV70^_P##_:F^R_R_P_VI6%(S
M99I[W<#OY(F*]YR*P7$B3I/D4YQ?Y?8=O]JGCX^V]CMTP>(\CYH$BDO_TO0\
MK#;;G#(==:T,:&^BUT5F)=N>W]YS7^G_`,6@,Z6&TFK[7DP=LN%D'VAP/N^E
M^EW[K?=^8Q0ZI==5F[:L9V0'GWN:8#-K6?2]KOI_X-5ADY<6[L)P-8?LVN):
M\M>*F-8[T0_]-_/5N]/9Z*>!HMMUJ:O1J%9L?;!<=]A!=[G%^TN`;]#=L9_(
M4UG5N+Z6/<PU.<`75OC<TD"6/VRWVJ0`E'A5;?25`@2?BE`@I<*K;Z2H0$[@
M)^0_(EPJM-=CY=EN^K+=2S3]&&-<--N[W$_G;?\`P1,W&RA?78<QYK9J^K8V
M'F"/=^XW7=L8JMUIIK+Q4^XZC96)/""_-+:C:,3(=$_HPR'F"]HVL_E>G_X+
M6EPJMNUXO4VV[K.H;Z]K?8*&#W`;7GD[&N^FH,PNJ[`VSJA+I!+F8];#P&[6
M^YVUN[](JEG46UVLI=B93G.!U95N:"W87#?NV/;^F_G6_H_T=B7[1:+',&'E
MN+#$^@0UQG\RPGW-_P"$2X?%5MT8O4@-IZC(`<)-#-VK7-87/W?38_99_P`(
MINQLYWJ_KQ8'O)J#:F>QL[MFYWNL]OZ/>L_]H5>JVK[/E!SS#":"&D[3;]*?
MW&I?M$;6G['EFMPG<*C(/O\`T;J?YW=^B_J?I*OWTN'Q5;JBJ_T6,-Y]1K@7
MVAHES0[<ZK;^;OK_`$7J?VT+[-F[&M.<X.;])XJK.[VL9[A;ZFWWLLM]G^F5
M+[8W<!]GR(]VX^D9&W=^9_PFS]$AMZFU[#8_#RZC)ECJ22`!NW/<#L:E7BJW
M1^R9O_E@_P#[9I_\@GIQ\MEXLLS'75!KFFEU53`7$MV6>I4T6?H]K_;_`,(J
ME>0U]KJA3<-L38:X9K[OIS_U*"S/+HG"RJP>2^L`#X^]*OY4JW:4JOYQO^O9
M9=MI8YX%%MGIAL%C6$/W:?H=UC-WI_X7?Z?_`%Q3Q[G-RZFC'N=^E]+<&MVQ
MM>[[3_.?T;V[-_\`.^I_@4C'15O_T_1,K[-]H?O]3=I.W;'`_>0OU/\`X;_H
M+YK24@V&ZU^E?U./\-_T$OU/_AO^@OFI)'[5/TJ?L<G^>Y_D)?J<'^>_Z"^:
MDDOM0_2GZG_PW_03G['/^%[?N>"^:DDOM2_2H^R:QZW'\A+]4_X;_H+YJ22^
MU3]*_JD?X:/[*0^R2/Y[_H+YJ22^U3]*_JD'^>CO]%+]4C_#<_R5\U))?:I^
ME?U3_AO^@G/V7<?YZ9_DKYI22^U3]*_JD?X;_H)?JG_#?]!?-227VJ?I4_8_
M^%X'[BGC_9?79L]3=.F[;'!YA?,Z2!VZJ?_9_^T4P%!H;W1O<VAO<"`S+C``
M.$))300$```````X'`(```(`HQP"4``$;FEC:QP"!0`C36EC<F]S;V9T(%=O
M<F0@+2`R,#$R($9O<FT@4RTQ("T@=C8X0DE-!"4``````!"L>^!9H\3;-&<M
MM"KX/:,U.$))30/M```````0`&0````!``$`9`````$``3A"24T$)@``````
M#@`````````````_@```.$))300-```````$````>#A"24T$&0``````!```
M`!XX0DE-`_,```````D```````````$`.$))32<0```````*``$`````````
M`CA"24T#]0``````2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H`!@``
M`````0`R`````0!:````!@```````0`U`````0`M````!@```````3A"24T#
M^```````<```_____________________________P/H`````/__________
M__________________\#Z`````#_____________________________`^@`
M````_____________________________P/H```X0DE-!`@``````!`````!
M```"0````D``````.$))300>```````$`````#A"24T$&@`````#;0````8`
M`````````````04```)J````'``R`#``,0`R`"``1@!O`'(`;0`@`%,`+0`Q
M`"``+0`@`'8`-@`@`$<`10!/`%8`00!8`"T`,@`T`````0``````````````
M```````````!``````````````)J```!!0`````````````````````!````
M`````````````````````!`````!````````;G5L;`````(````&8F]U;F1S
M3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F
M=&QO;F<``````````$)T;VUL;VYG```!!0````!29VAT;&]N9P```FH````&
M<VQI8V5S5FQ,<P````%/8FIC`````0``````!7-L:6-E````$@````=S;&EC
M94E$;&]N9P`````````'9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N=6T`
M```,15-L:6-E3W)I9VEN````#6%U=&]'96YE<F%T960`````5'EP965N=6T`
M```*15-L:6-E5'EP90````!);6<@````!F)O=6YD<T]B:F,````!````````
M4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"
M=&]M;&]N9P```04`````4F=H=&QO;F<```)J`````W5R;%1%6%0````!````
M````;G5L;%1%6%0````!````````37-G951%6%0````!```````&86QT5&%G
M5$585`````$```````YC96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q497AT
M5$585`````$```````EH;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!;&EG
M;@````=D969A=6QT````"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R=$%L
M:6=N````!V1E9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````$453;&EC94)'
M0V]L;W)4>7!E`````$YO;F4````)=&]P3W5T<V5T;&]N9P`````````*;&5F
M=$]U='-E=&QO;F<`````````#&)O='1O;4]U='-E=&QO;F<`````````"W)I
M9VAT3W5T<V5T;&]N9P``````.$))300H```````,`````C_P````````.$))
M3004```````$`````CA"24T$#``````.K0````$```"@````1````>```'^`
M```.D0`8``'_V/_@`!!*1DE&``$"``!(`$@``/_M``Q!9&]B95]#30`!_^X`
M#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3
M&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0
M#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,_\``$0@`1`"@`P$B``(1`0,1`?_=``0`"O_$`3\```$%
M`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$``````````0`"
M`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&
M%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B
M9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>G
MM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"
M(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$
MP]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:
M``P#`0`"$0,1`#\`TOK*X_\`./+:7N8POJ#B"=`:J=SHG\U4[*:6UV/9GBPL
M'LK&\.>2>WYOM;]-==U3'Z([J5@RJ*'Y-NUWO:XO<-NQI]A_X/8J;:/JRYGJ
M-HQ-FDN(<T:@N;]-S?I-8YRO0YB(C$4=`!^CT:LL,C*1TU)/5YBF7N8RRYU3
M'.=NL).@V@_O!%NKHK;NISC>X%OZ,![29,.U)V^Q=)9C_5JNMCK:<.MCW.#"
M\[02P[+=F^QN[8[VO0G'ZH,&]_[.:T1+C8V!K'^E1^\1[2_YJ/8EWC^+@U5T
M6[W7YIQW>H\!I#G:`MAWM=[=VYZ%9#7.97>ZQDU_I)+=2/TFFYWT'+J+<;ZN
M5W/JMQ\5EK"[>US7@@M'JO\`SO\`1^]/]E^K8>*33A^H\AK:YEQ.NWVBQ+[Q
M'M+_`)JO8EW'_.><MHQ&UV.KZEZCV!Q97M>-Q'T6M>'.;[U"IE=KW>OE''#6
MU[2=SMTLU]K7;NRZ)E?U5L$MKPHF/<2PR(_-L>QWY[41V+]7"\--&)O+`X,,
M[BT#;N;7OWN_=2^\1_K>?I5[$OZO_.>8LV,>]M%[[FACY>9:">VSW.=]%&KQ
M\)P;ZG4_2+@TN;M>[:2&EPW,?M]CG+H\?!Z!D-<_'Q<6UL07,!(U_M_G*?[)
MZ1_W`H_S7?\`DTOO$?ZW_-5[$OZO_.>1HBQS&W7NH9L<2\DG4$[6[=PW;D6V
MNBHUFC-=DN+P'-#7-AO[^YSOWO;M74GI/2('ZC1_FN\?ZZ=O2>D!P(P:)G]U
MW_DTOO$;VEY>E7L2[C_G/)UU4.H8]^::[2-:CN,1O_.:[^0S_MQ,`WU?2^T.
M]#UMOVB2!LC^=VN<NL_9'1_^X%'^:[_R:?\`9/2-L?8:(F8VN\/ZZ7WB/:7_
M`#5>Q+P_YSR60RIE1=5F&YV@VC<TZCW<N_,1&UTV/M==F''<+"UK3N=(D>[1
MWM^DNH_9'1_^X%'^:[_R:=W2>D%SB<&@DDDG:[_R:7WB/];S]*O8E_5_YSQ]
MLLW-KN=:-C#N#C&X[7/9]+_!N]B/;3C,+O3Z@;(#HT<)(%A8/I>[>^NJOV?Z
M?U%U`Z3TB#^HT?YKO'^NE^R>D?\`<"C_`#7?^32^\1[2_P":KV)=Q_SGE*6L
MM<1?E'':VNLM<9=)(:"W;N_=5[H;6LZ]T\5Y!O#K+-P&X1%;]N[=[7;Y6\[I
M/2-)P:.`/HN[#^NC8'3>F59M-M.'378QQ+7M!!!VN'M]Z$L\3&0J6H(_1[)C
MAD"#8T(/5__0]"RL0/S'7[&&P;0UY'N``#HW1^_[D`=-K#=@JIVP!MVB($[1
M&S\W<Y6<NG,?FA]>3Z6.&@/I#02YVNY^]P]OZ-W_`&XS?_(LKMQNJMI+?M[7
M6^V+'U-=J`[U?:WT?;8XU[/]'L3P=%M)&X]K&PPM:/!I('X!/Z61W?\`](_W
M(M3;&U@6/]1\DET`<G<UL#]QOL4T;*J:CL*7.)962XR20"2?WC[?Y+4WV!LA
MQKJW-C:[:)$?1VNV[F[85Q5[\:ZUSG,R[J`0T!M89`@.W?3:[^<W>[^HA952
M/[`V9].F=!.ULP-!^8E]A`=N#*@XMVD@"=O=D[?H?R42W%NLL<]N;D5-<9%;
M/1VM\F>IC6/_`,YZA]BR/_+#*_\``/\`WD1M2[<5S9@,$\QI/W-2^S6>+?O_
M`-B7V+(_\L,K_P``_P#>1-]BR/\`RPRO_`/_`'D2M3+[-9`U;]_^Q(8UDC5O
MW_[$S<.]KV/.?DO#';C6[T-KQJ/3LV8K'^GK^8]BD_&M=D>LW*M8V6GT1&SV
MC;K/[_TTK*J8_9K/%OW_`.Q/]FLCEO/C_L4685[7ASLVYX#6C:Z(+@&--KMO
M^D;7^D;]#?99;7L3?8LLB#U&XLVM;`96#+0T;_5:UMN^W9NM]W^$0XBJ@R^S
M6^+?O_V)SC62=6\^/^Q,S#R&M:/MMSG`ESGD,)=._3:X.K:UOJ,]NS_`UJ'V
M#+(M9;U&]XL(+7-#*W-V_FL])K6^[\Y+B*J2?9K(.K?O_P!B;[-9XM^__8E7
MB9;2TV9]MH:6DM].MH.UU;X_1M#O>VNRIWN_PZ9N'EAH#L^U[A,DM8!!\JQ6
M[<S\USWI<153(XUGBW@=_P#8IXU%C;V.,0">#Y'R4J:WU5AC[77D?X1\;H@<
M[=J-5_.-_P!>R5JI_]'N\_/95U/['-AML#7,:P2(/L;[MP:W](U5&]:QG4FX
M/M#&["9;K%F[T]K0X^I]!WMK_2+7R,=S[GN#B`8TCR`\4/[,^?IF?A_M4@(H
M+6D[J#6X[<@NM%;G[`(.Z2=C?9/T7;4(]8QVL-CGVAK1N(V.D"7-G;_8_P#!
M*;/YNQ:/V8C\^#\/]J<8[I_G#]W_`)DC80T']4J;O+GVM+(+FEIW07^EHT'W
M;'?SFS_!?I4S>K4.8'E]K0YGJ`.8^=OM_-KW_P"E8M#[.Z?YP\^'_F27V=T'
M](?N_P#,DK"G*;U[#=4+F67.K+BS<*WZ1])[@[:_T_Y6U$_;&(9(NL@;9]E@
M^D"YL!S0Y_T/\%ZFS_"+1^SNF?4,GDQK_P!4D:'S_.G\?_))6$N>WJ^.YKG-
MLM>`XUZ,?.\#<YC=P;O=M_T:?]IU!F_=;KN]NQV[V^EN]GTOHY%3E?&.[7](
M>(X_\R3?9C_I/P_\R2L*:9Z@T,K>3>!8"YH%5SC`);[_`$J[-G]M,.HUR/=D
M?^P^1_Z05W[,?W_P_P!J0QM1[_P_VI6$:M+]HU_O9'_L/D?^D$_[1KCZ61S_
M`-Q\CP_XA7/LO\O\/]J7V8Q]/OX?[4K"M6E^T:_WLC_V'R/_`$@FLZI2P/>Y
MV1M:"XQCY),#7Z(H5[[+_+_#_:D<8[B=_?P_VI6%:H199$[W<`\D)>I9^^[[
MRC?9=#[_`,/]J;[+_+_#_:E84C-EFGO=P._DB8KWG(K!<2).D^13G%_E]AV_
MVJ>/C[;V.W3!XCR/F@2*2__2]#RL-MN<,AUUK0QH;Z+7168EVY[?WG-?Z?\`
MQ:`SI8;2:OM>3!VRX60?:'`^[Z7Z7?NM]WYC%#JEUU6;MJQG9`>?>YI@,VM9
M]+VN^G_@U6&3EQ;NPG`UA^S:XEKRUXJ8UCO1#_TW\]6[T]GHIX&BVW6IJ]&H
M5FQ]L%QWV$%WN<7[2X!OT-VQG\A36=6XOI8]S#4YP!=6^-S20)8_;+?:I`"4
M>%5M])4"!)^*4""EPJMOI*A`3N`GY#\B7"JTUV/EV6[ZLMU+-/T88UPTV[O<
M3^=M_P#!$S<;*%]=AS'FMFKZMC8>8(]W[C==VQBJW6FFLO%3[CJ-E8D\(+\T
MMJ-HQ,AT3^C#(>8+VC:S^5Z?_@M:7"JV[7B]3;;NLZAOKVM]@H8/<!M>>3L:
M[Z:@S"ZKL#;.J$ND$N9CUL/`;M;[G;6[OTBJ6=1;7:REV)E.<X'5E6YH+=A<
M-^[8]OZ;^=;^C_1V)?M%HL<P8>6XL,3Z!#7&?S+"?<W_`(1+A\56W1B]2`VG
MJ,@!PDT,W:M<UA<_=]-C]EG_``BF[&SG>K^O%@>\FH-J9[&SNV;G>ZSV_H]Z
MS_VA5ZK:OL^4'/,,)H(:3M-OTI_<:E^T1M:?L>6:W"=PJ,@^_P#1NI_G=WZ+
M^I^DJ_?2X?%5NJ*K_18PWGU&N!?:&B7-#MSJMOYN^O\`1>I_;0OLV;L:TYS@
MYOTGBJL[O:QGN%OJ;?>RRWV?Z94OMC=P'V?(CW;CZ1D;=WYG_";/T2&WJ;7L
M-C\/+J,F6.I)(`&[<]P.QJ5>*K='[)F_^6#_`/MFG_R">G'RV7BRS,==4&N:
M:755,!<2W99ZE319^CVO]O\`PBJ5Y#7VNJ%-PVQ-AKAFON^G/_4H+,\NB<+*
MK!Y+ZP`/C[TJ_E2K=I2J_G&_Z]EEVVECG@46V>F&P6-80_=I^AW6,W>G_A=_
MI_\`7%/'N<W+J:,>YWZ7TMP:W;&U[OM/\Y_1O;LW_P`[ZG^!2,=%6__3]$RO
MLWVA^_U-VD[=L<#]Y"_4_P#AO^@OFM)2#8;K7Z5_4X_PW_02_4_^&_Z"^:DD
M?M4_2I^QR?Y[G^0E^IP?Y[_H+YJ22^U#]*?J?_#?]!.?L<_X7M^YX+YJ22^U
M+]*C[)K'K<?R$OU3_AO^@OFI)+[5/TK^J1_AH_LI#[)(_GO^@OFI)+[5/TK^
MJ0?YZ._T4OU2/\-S_)7S4DE]JGZ5_5/^&_Z"<_9=Q_GIG^2OFE)+[5/TK^J1
M_AO^@E^J?\-_T%\U))?:I^E3]C_X7@?N*>/]E]=FSU-TZ;ML<'F%\SI(';JI
M_]D`.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`
M;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@
M`$,`4P`T`````0`X0DE-!`8```````<`"`$!``$!`/_A$W=H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB
M5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^(#QX.GAM<&UE=&$@>&UL;G,Z
M>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#0N
M,BXR+6,P-C,@-3,N,S4R-C(T+"`R,#`X+S`W+S,P+3$X.C$R.C$X("`@("`@
M("`B/B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N=S,N;W)G+S$Y
M.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B`\<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O
M,2XP+R(@>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O
M(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM
M+R(@>&UL;G,Z<W1%=G0](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C945V96YT(R(@>&UL;G,Z<W12968](FAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM;&YS.G!H
M;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W`O,2XP+R(@
M>&UL;G,Z=&EF9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]T:69F+S$N,"\B('AM
M;&YS.F5X:68](FAT='`Z+R]N<RYA9&]B92YC;VTO97AI9B\Q+C`O(B!D8SIF
M;W)M870](FEM86=E+VIP96<B('AM<#I#<F5A=&5$871E/2(R,#$R+3`S+3(X
M5#$R.C`Y.C$Q+3`V.C`P(B!X;7`Z0W)E871O<E1O;VP](E!38W)I<'0U+F1L
M;"!697)S:6]N(#4N,BXR(B!X;7`Z36]D:69Y1&%T93TB,C`Q,BTP,RTR.%0Q
M,CHQ,2TP-CHP,"(@>&UP.DUE=&%D871A1&%T93TB,C`Q,BTP,RTR.%0Q,CHQ
M,2TP-CHP,"(@<&1F.E!R;V1U8V5R/2)!8W)O8F%T($1I<W1I;&QE<B`Y+C`N
M,"`H5VEN9&]W<RDB('AM<$U-.D1O8W5M96YT240](G5U:60Z-#<T935D93$M
M8S%F,"TT.&8Y+6%B9C8M9F5A,C1A9F8T-V0X(B!X;7!-33I);G-T86YC94E$
M/2)X;7`N:6ED.D1!0S4W,34Q,#$W.44Q,3%!-S-$.$4Q.$-&,3DY.44V(B!X
M;7!-33I/<FEG:6YA;$1O8W5M96YT240](G5U:60Z-#<T935D93$M8S%F,"TT
M.&8Y+6%B9C8M9F5A,C1A9F8T-V0X(B!P:&]T;W-H;W`Z0V]L;W)-;V1E/2(S
M(B!P:&]T;W-H;W`Z24-#4')O9FEL93TB<U)'0B!)14,V,3DV-BTR+C$B('1I
M9F8Z3W)I96YT871I;VX](C$B('1I9F8Z6%)E<V]L=71I;VX](C$P,#`P,#`O
M,3`P,#`B('1I9F8Z65)E<V]L=71I;VX](C$P,#`P,#`O,3`P,#`B('1I9F8Z
M4F5S;VQU=&EO;E5N:70](C(B('1I9F8Z3F%T:79E1&EG97-T/2(R-38L,C4W
M+#(U."PR-3DL,C8R+#(W-"PR-S<L,C@T+#4S,"PU,S$L,C@R+#(X,RPR.38L
M,S`Q+#,Q."PS,3DL-3(Y+#4S,BPS,#8L,C<P+#(W,2PR-S(L,S`U+#,Q-2PS
M,S0S,CM$,T9$0C1%,D4S0S!#-#5&-3,V.3$T,T4X,T$S1C$V0B(@97AI9CI0
M:7AE;%A$:6UE;G-I;VX](C8Q."(@97AI9CI0:7AE;%E$:6UE;G-I;VX](C(V
M,2(@97AI9CI#;VQO<E-P86-E/2(Q(B!E>&EF.DYA=&EV941I9V5S=#TB,S8X
M-C0L-#`Y-C`L-#`Y-C$L,S<Q,C$L,S<Q,C(L-#`Y-C(L-#`Y-C,L,S<U,3`L
M-#`Y-C0L,S8X-C<L,S8X-C@L,S,T,S0L,S,T,S<L,S0X-3`L,S0X-3(L,S0X
M-34L,S0X-38L,S<S-S<L,S<S-S@L,S<S-SDL,S<S.#`L,S<S.#$L,S<S.#(L
M,S<S.#,L,S<S.#0L,S<S.#4L,S<S.#8L,S<S.38L-#$T.#,L-#$T.#0L-#$T
M.#8L-#$T.#<L-#$T.#@L-#$T.3(L-#$T.3,L-#$T.34L-#$W,C@L-#$W,CDL
M-#$W,S`L-#$Y.#4L-#$Y.#8L-#$Y.#<L-#$Y.#@L-#$Y.#DL-#$Y.3`L-#$Y
M.3$L-#$Y.3(L-#$Y.3,L-#$Y.30L-#$Y.34L-#$Y.38L-#(P,38L,"PR+#0L
M-2PV+#<L."PY+#$P+#$Q+#$R+#$S+#$T+#$U+#$V+#$W+#$X+#(P+#(R+#(S
M+#(T+#(U+#(V+#(W+#(X+#,P.S,R-3)#03%&1#<W1D,Y.$(X04-%.$(X,C<W
M,T(Q.39%(CX@/&1C.F-R96%T;W(^(#QR9&8Z4V5Q/B`\<F1F.FQI/FYI8VL\
M+W)D9CIL:3X@/"]R9&8Z4V5Q/B`\+V1C.F-R96%T;W(^(#QD8SIT:71L93X@
M/')D9CI!;'0^(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S
M;V9T(%=O<F0@+2`R,#$R($9O<FT@4RTQ("T@=C8\+W)D9CIL:3X@/"]R9&8Z
M06QT/B`\+V1C.G1I=&QE/B`\>&UP34TZ2&ES=&]R>3X@/')D9CI397$^(#QR
M9&8Z;&D@<W1%=G0Z86-T:6]N/2)C;VYV97)T960B('-T179T.G!A<F%M971E
M<G,](F9R;VT@87!P;&EC871I;VXO<&1F('1O(&%P<&QI8V%T:6]N+W9N9"YA
M9&]B92YP:&]T;W-H;W`B+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX](F1E<FEV
M960B('-T179T.G!A<F%M971E<G,](F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T
M:6]N+W9N9"YA9&]B92YP:&]T;W-H;W`@=&\@:6UA9V4O:G!E9R(O/B`\<F1F
M.FQI('-T179T.F%C=&EO;CTB<V%V960B('-T179T.FEN<W1A;F-E240](GAM
M<"YI:60Z1$%#-3<Q-3$P,3<Y13$Q,4$W,T0X13$X0T8Q.3DY138B('-T179T
M.G=H96X](C(P,3(M,#,M,CA4,3(Z,3$M,#8Z,#`B('-T179T.G-O9G1W87)E
M06=E;G0](D%D;V)E(%!H;W1O<VAO<"!#4S0@5VEN9&]W<R(@<W1%=G0Z8VAA
M;F=E9#TB+R(O/B`\+W)D9CI397$^(#PO>&UP34TZ2&ES=&]R>3X@/'AM<$U-
M.D1E<FEV961&<F]M('-T4F5F.FEN<W1A;F-E240](G5U:60Z.&8Q8F%A-#8M
M8S=D82TT86%E+6)D-C8M9F$X96-D.35B839A(B!S=%)E9CID;V-U;65N=$E$
M/2)U=6ED.C0W-&4U9&4Q+6,Q9C`M-#AF.2UA8F8V+69E83(T869F-#=D."(@
M<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/2)U=6ED.C0W-&4U9&4Q+6,Q9C`M
M-#AF.2UA8F8V+69E83(T869F-#=D."(O/B`\+W)D9CI$97-C<FEP=&EO;CX@
M/"]R9&8Z4D1&/B`\+W@Z>&UP;65T83X@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`\/WAP86-K970@96YD/2)W(C\^_^(,6$E#0U]04D]&24Q%``$!```,2$QI
M;F\"$```;6YT<E)'0B!865H@!\X``@`)``8`,0``86-S<$U31E0`````245#
M('-21T(```````````````$``/;6``$`````TRU(4"`@````````````````
M```````````````````````````````````````````````18W!R=````5``
M```S9&5S8P```80```!L=W1P=````?`````48FMP=````@0````4<EA96@``
M`A@````49UA96@```BP````48EA96@```D`````49&UN9````E0```!P9&UD
M9````L0```"(=G5E9````TP```"&=FEE=P```]0````D;'5M:0```_@````4
M;65A<P``!`P````D=&5C:```!#`````,<E120P``!#P```@,9U120P``!#P`
M``@,8E120P``!#P```@,=&5X=`````!#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W
M;&5T="U086-K87)D($-O;7!A;GD``&1E<V,`````````$G-21T(@245#-C$Y
M-C8M,BXQ```````````````2<U)'0B!)14,V,3DV-BTR+C$`````````````
M`````````````````````````````````````````````````````%A96B``
M``````#S40`!`````1;,6%E:(`````````````````````!865H@````````
M;Z(``#CU```#D%A96B````````!BF0``MX4``!C:6%E:(````````"2@```/
MA```ML]D97-C`````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`````````
M`````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`````````````````````````
M````````````````````````````````````9&5S8P`````````N245#(#8Q
M.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="````````
M```````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="`````````````````````````````&1E<V,`````````+%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$`````````
M`````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ``````````````````````````````````!V:65W```````3I/X`%%\N
M`!#/%``#[<P`!!,+``-<G@````%865H@``````!,"58`4````%<?YVUE87,`
M`````````0````````````````````````*/`````G-I9R``````0U)4(&-U
M<G8````````$``````4`"@`/`!0`&0`>`",`*``M`#(`-P`[`$``10!*`$\`
M5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5`)H`GP"D`*D`K@"R`+<`O`#!
M`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0<!#0$3`1D!'P$E`2L!,@$X`3X!
M10%,`5(!60%@`6<!;@%U`7P!@P&+`9(!F@&A`:D!L0&Y`<$!R0'1`=D!X0'I
M`?(!^@(#`@P"%`(=`B8"+P(X`D$"2P)4`ET"9P)Q`GH"A`*.`I@"H@*L`K8"
MP0++`M4"X`+K`O4#``,+`Q8#(0,M`S@#0P-/`UH#9@-R`WX#B@.6`Z(#K@.Z
M`\<#TP/@`^P#^00&!!,$(`0M!#L$2`15!&,$<01^!(P$F@2H!+8$Q`33!.$$
M\`3^!0T%'`4K!3H%2058!6<%=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(
M!ED&:@9[!HP&G0:O!L`&T0;C!O4'!P<9!RL'/0=/!V$'=`>&!YD'K`>_!]('
MY0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$`DE"3H)3PED"7D)CPFD
M";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*W`KS"PL+(@LY"U$+:0N`"Y@+
ML`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS#0T-)@U`#5H-=`V.#:D-PPW>
M#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1`F$$,0
M81!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#
M$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%>`6
M`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA`&&48BABO&-48^AD@
M&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:'`(<*AQ2''L<
MHQS,'/4='AU''7`=F1W#'>P>%AY`'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!
M(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D
M321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<*`TH/RAQ
M**(HU"D&*3@I:RF=*=`J`BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M
M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z
M,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXV
MZ3<D-V`WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG
M/&4\I#SC/2(]83VA/>`^(#Y@/J`^X#\A/V$_HC_B0"-`9$"F0.=!*4%J0:Q!
M[D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?`
M2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.
M)4YN3K=/`$])3Y-/W5`G4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J4_940E2/
M5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;
ME5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8`5@5V"J8/QA3V&B8?5B26*<
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MEHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6D3^1J)(1DGJ2XY--D[:4()2*
ME/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP<G(F<]YUDG=*>
M0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@
MJ%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[``L'6PZK%@L=:R
M2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;
MO16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#QT''
MO\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2/]+!
MTT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6WAS>
MHM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;
MZN7K<.O[[(;M$>V<[BCNM.]`[\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV
M^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X`(4%D;V)E`&1`
M`````0,`$`,"`P8```````````````#_VP"$``$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#
M`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__"`!$(`04":@,!$0`"$0$#$0'_Q`$?
M``$``@,!`0$!`0``````````!`4&!P@)`PH"`0$!``(#`0$!`0``````````
M``(#`00%!@<("1````,%!`<%"`$$`P$!``````(#`00%!@<@$Q0($1(R,Q46
M%S$T)34)$#!"0R8V*!D8(2)%-R-$.$<G$0``!@$!`P0*#04+"`H"`P`!`@,$
M!08'`!$2""`3TQ0AD[05-765-C<)$#$BDM)TE-1%M=46IK.VUG<Y,$%183(C
MA,2%EJES@\,T=A>WF'&!0C,DAL:'N!E#&%)F"A(``0("!`<,!P0(!00#`0``
M`1$"``,A,1($($%QD3,%-1!188&AL=$B,G*2$\%"HK+2<S0CLW0&,/!2@L*C
M%!7A4Y.T!V*#)19#)(3Q_]H`#`,!`0(1`Q$```#]SG;Y7X?OZ`?C@```9]SM
MW`>CI``;=XO4U%VN6`!GW.W<!Z.D`!MWB]347:Y8`&W>+U-1=KE@`9]SMW`>
MCI``#/N=NX#T=(`#;O%ZFHNURP`-N\7J:B[7+``S[G;N`]'2``V[Q>IJ+M<L
M`#]%GY@^^>V/P/[!ION\C\&7]%OQ.-H<GI8YM:]9;78U68IN:HV)S-[#][5R
MO2VOE+&.[6O$G';'&Z>HNUR\XY^Y\\X%1?5?ZUVO.GHYYSM[Y2C7V0_G.,_Y
MN]IKN<G/.=NP[(VE-G]8S?Z]VFNYR<]YV]!LK^\9?UA+A/7G3T,^YV]`LK']
MXSAN]J;#YF_\I8@65U%]5Q1;A^[J[EX?6Q;;UHED:JZK^2EOIW+P^MA^[JBE
MV*<AU;\#Z.EL/F;]+L4V55E+?3:TVX3OZ>Y>'UM:]7GY#JWQ)QQ_:HA3A^EC
M\J?H7W5_/'VG3?=Y'X,OZ+?B<>D_ROZ%]HYWQYWM[)Y>_P""/Z,^)#8G,WLE
MU-GVY^`_8M3=KE[&Y?0\9?NOR2OMKQC;U_?7\W_;\*Z&GA&_I^:GU;Y[J?L\
MK%]S7]S?SU]GW#Q.K@'2T?,WZQ\[T7Z'BZ:[G)]K?@OU_IKR?H^5?8^8X'^C
M>)U_T]#37<Y/LA\-^L[Q\]V=L\;J<7^\\CY<?7?FVO.GH>S/PKZWM/D=*PJL
MP+I:/B!]_P#CFP^9O^IGR#Z5N+A];D7VWE>G_(^C\*?T-\7W+P^MZ`?-?<]2
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ME&E&)..Y>'UM8];G1IQ^L<BLMKW+P^MJ[K\WYYQ_>,_:.::^K8?,W\,W]/\`
MO&1_.5=97N7A];4W9YGWCD?"48DX_I;_`"G^AO=7\\?:<!Z6C^:']6_GD```
M95I[.*[FL`!G_-WL`Z6B`!E6GLXKN:P`&?\`-WL`Z6B`!G_-WL`Z6B`!E6GL
MXKN:P``RK3V<5W-8`#/^;O8!TM$`#/\`F[V`=+1``RK3V<5W-8`#/^;O8!TM
M$`#UX^*?4_23Y7]!HKZ_-_Z)YD```6M4JJV(`%_1907U@`6M4JJV(`%_1907
MU@`7U%E#?6`!:U2JK8@`"UJE56Q``OZ+*"^L`"_HLH+ZP`+6J55;$`"_HLH+
MZP`.L_*]?HKSW3HKZ_-_Z)YD```6M4JJV(`%_19INR&5RQ78S?YQ,R4SB6PP
MJ.;_`#C(9!::]E!?7+RI<)!]C*J;*&^L`"UJE56Q``%K5*JMB`!?T64%]8`%
M_1907U@`6M4JJV(`%_1907U@`=9^5Z_17GNG17U_F-]KP>9*+.SMFKS>T[^H
M[Z]C3CINJ?4>Q7UAN:OGYO:8`T?;5Z8\W?XRYN]H2J?1ET/F7F<>:VAL=Y;M
M&%1EHZJ6P9XO<XZJ.73;5D<@SC2=<^U]FGOZ>*&^L`"UJE56Q``%K5*JMB`!
M?T64%]8`%_1907U@`6M4JJV(`%_1907U@`=9^5Z_17GNG17U^1_T#S8V3..C
M:Y[.G&=G'T(.,YY#-5;$`"_HLH+ZP`+6J6IY8V'/``OZ+,#NKO<@*;#-Z;*&
M^L`"UJE56Q``%K5*JMB`!?T64%]8`%_1907U@`6M4JJV(`%_1907U@`=9^5Z
M_17GNG17U^;_`-$\R```+6J55;$`"_HLH+ZP`+6J55;$`"_HLH+ZP`+ZBRAO
MK``M:I55L0`!:U2JK8@`7]%E!?6`!?T64%]8`%K5*JMB`!?T64%]8`'6?E>O
MT5Y[IU]D>8_2<D```2XRB2B`!80E7SB`!+C*)*(`%A"5?.(`%A7*OLB`!+CF
M)+```EQS$E@`"PA*OG$`"PA*OG$`"7',26``+"$J^<0`-P\G=V7S=N%.///>
MY@```E1E%E$`"="4&<0`)49191``G0E!G$`"="4&<0`).)1LQ``$G$HV8@`3
MH2@SB`!.A*#.(`$G$HV8@`3H2@SB`!M/F[FP-#9A3CY3]OG\XPSU!./$E<^J
MYQS7*K/CAV_+$640`)T)09Q`'E_59F^')T<^J%]?FSVN7\6!+C*)*(`$N,HD
MH@`??&?AG&B;ZOT&>?[/GG5/4F,_P7L<ZZRM394L4!381(3U+G&NL.Z[(X!A
MNJ6.::IZ8.HYQY]CG+LM@9QCL9=RVU\75RW?/&KHYTWC/;!W3?4`!M/F[FP-
M#9A3CY#]KGXSATI/''5<MCRQDIS['/<MD>A"+*(`$Z$H,X@#$69D,XI+&Q<I
M#`$Z$H,X@`3H2@SB`!)Q*-F(&ML9JR\,3A*[G&AQG-<XQ5FKPC0E.G&L-T2Q
MK;&<O8P"N>F,XZ4G&K,(QG,\J6&<QG'7>,]`RQS'#.<Y9O'.=V0``VGS=S8&
MALPIQYY[W,```$J,HLH@`3H2@SB`!*C*+*(`$Z$H,X@`3H2@SB`!)Q*-F(``
MDXE&S$`"="4&<0`)T)09Q``DXE&S$`"="4&<0`-I\W<V!H;-?9'F;T?*```$
MN.8DL``6$)5\X@`2XYB2P`!80E7SB`!85RK[(@`2XYB2P``)<<Q)8``L(2KY
MQ``L(2KYQ``EQS$E@`"PA*OG$`#;_)W=E<[:HKZ_-_Z)YD```6M4JJV(`%_1
M907U@`6M4JJV(`%_1907U@`7U%E#?6`!:U2JK8@`"UJE56Q``OZ+*"^L`"_H
MLH+ZP`+6J55;$`"_HLH+ZP`.L_*]?HKSW3HKZ_-_Z)YD```6M4JJV(`^.&2T
MV4%]8`%K5*JMB(.$[*!AEU-E!?6!\L/KE?464-]?PP^^4;"3E:U2JK8@`"UJ
ME56Q``OZ+*"^L`"_HLH+ZP`+6J55;$`"_HLH+ZP`.L_*]?HKSW3HKZ_R\^TX
M7-E-G>NW1Y=Z.QU5?7NNR',]-G4-]?I_L5>.VI?K*N6R[(P<,)C*LU[.E=ZC
M6M>:[&=/URZKV*\9IG>VP\[M._8TX[+LCSY3/KTT//':NS3B,9<]4SW9;#9-
M<^9\XV'+'H1N4<5ZUO.U-GIML58%UN=JN<``)\)0)Q``MZIU%L``+>J=1;`<
MDWT>\G,Z<]FUJE56Q``OZ+*"^L`#K/RO7Z*\]TZ*^ORJ^@^:&8SQK.N69SC1
MQSD4L?P9?7*JMB`!?T64%]?PP_DDY"UJE56Q&OH9V#/`OZ+*"^L#'XL@DOJ+
M*&^O'HLAD`M:I55L0`!:U2JK8@`7]%E!?6`!?T64%]8`%K5*JMB`!?T64%]8
M`'6?E>OT5Y[IT5]?F_\`1/,@``"UJE56Q``OZ+*"^L`"UJE56Q``OZ+*"^L`
M"^HLH;ZP`+6J55;$``6M4JJV(`%_1907U@`7]%E!?6`!:U2JK8@`7]%E!?6`
M!UGY7K]%>>Z<"R/,_H^4```)<,Q)X``L*Y5]D0`)<,Q)X``L*Y5]D0`+"N5?
M9$`"5',66``!*CF++``%A7*OLB`!85RK[(@`2HYBRP`!85RK[(@`;>Y.[LGG
M;4*<>>>]S```!*C*+*(`$Z$H,X@`2HRBRB`!.A*#.(`$Z$H,X@`2<2C9B``)
M.)1LQ``G0E!G$`"="4&<0`).)1LQ``G0E!G$`#:?-W-@:&S"G'R;[7/YMCGL
M&<>):Y],3CD^6@XYZ.E'L+*+*(`$Z$H,X@`2HRBRB`!.A*#.(`USC-E"4*<:
MX^IA^,[]E&AC*OEC+F!2LW3&@(RO,9W'.`Q=F[!=PSK*6/N9QG'^&%8S)C*R
MG&[8`$G$HV8@`3H2@SB`!M/F[FP-#9A3CY)=KGUYON6.)*Y;AEC)\J?#&#T8
MEB+*(`$Z$H,X@`2HRBRB`!.A*#.(`\.->W9$94\X[[EC0D<XQAUG9'SVJG@.
M,[]E'5F,Z>C+I2<=#PSUW+',^,[NEBR.U+(>=%4^\<XXEQG9DL>U5]6M\9\X
M:IU.,[CV:=!=?F`#[XS\,X')6WK>Z/#Z^^M>Z="4&<0`-I\W<V!H;,*<>>>]
MS```!*C*+*(`$Z$H,X@`2HRBRB`!.A*#.(`$Z$H,X@`?6,M?9QGF<``2<2C9
MB!&9^9=PS!G&L9LV`)T)09Q``DXE&S$`"="4&<0`-I\W<V!H;-=9'ESTW(``
M`$R$H<X@`6-<ZZR``$R$H<X@`6-<ZZR``%C7.NL@`!+A*).(``EPE$G$`"QK
MG760``L:YUUD``)<)1)Q``L:YUUD``-R\?>V?S=NBOK\W_HGF0``!:U2JK8@
M`7]%E!?6`!:U2JK8@`7]%E!?6`!?464-]8`%K5*JMB``+6J55;$`"_HLH+ZP
M`+^BR@OK``M:I55L0`+^BR@OK``ZS\KU^BO/=.BOK\U?H?F=7PE89Q21SF,\
M6K%!C.?3Q:U2JK8@`7]%E!?6`!:U2JK8@`7]%E!?6`!?464-]8`%K5*JMB``
M+6J55;$`"_HLH+ZP`+^BR@OK``M:I55L0`+^BR@OK``ZS\KU^BO/=.BOK\R_
MH?F?RF\'H^U?3U>6M>RVSCL/9J\<N;M>Y?4U.OIQJK8@`7]%E!?6`!:U2JK8
M@`7]%E!?6`!QUS]GSEJGT!=7O6V'.=%G/%4_0"V'$]<L1CGTDW:.(]:[6E>>
MAKH;<G'1M<\AEC9DXX-'.&0E_5%D[8JSJ>-Y60Y9HLZ-NAY1\[9[QW:(^,YM
M..ZK(<JT6]+RQ*MAYIZ5^^[89%+';NS5:V5:4VZ*;.-_TV\+;6MV[K;.O.#N
M^_GC?145]?F_]$\R`!_A_H+6J55;$`"_HLH+ZP`+6J55;$`"_HLH+ZP`,>U;
M=<6PM\KO.,7QF46]<M&$C+?]L-*URE$DSV.==RQ@<,Y]/$@_TV)5/6=L,BEC
M"89SF>)!@^K:OKSB>-5URW5;#!XRZ.8QJR.#QS=98]'.62CL*JR@OK``ZS\K
MU^BO/=.BOK\W_HGF0``!:U2JK8@`7]%E!?6`!:U2JK8@`7]%E!?6`!?464-]
M8`%K5*JMB``+6J55;$`"_HLH+ZP`+^BR@OK``M:I55L0`+^BR@OK``ZS\KU^
MBO/=.%..@N]S@``!)C*-*(`$V$H4X@`28RC2B`!-A*%.(`$V$H4X@`28RC2B
M``),91I1``FPE"G$`";"4*<0`),91I1``FPE"G$`#9W,V\\T=C__V@`(`0(`
M`04`EHA%)CY>@8Y>@8Y>@8Y>@8Y>@8Y>@8Y>@8Y>@8X!!>+\O0,<O0,<O0,<
MO0,<O0,&@4&YCY>@8Y>@8Y>@8Y>@8Y>@8>8!!61#EZ!CEZ!CEZ!CEZ!CEZ!B
M,0*#$5Y>@8Y>@8Y>@8Y>@8Y>@8C\"@R;CR]`QR]`QR]`QR]`QR]`Q&8#!20C
MEZ!CEZ!CEZ!CEZ!CEZ!CEZ!B#0&"GA'+T#'+T#'+T#'+T#'+T#$O0*#*0KEZ
M!CEZ!CEZ!CEZ!CEZ!B!P*#'2Y>@8Y>@8Y>@8Y>@8Y>@8<8#!3/7+T#'+T#'+
MT#'+T#'+T#$/@4&-%>7H&.7H&.7H&.7H&.7H&*]N+FXQ<2O]S>Q^F"`PQ5RB
M4.B1$'IU>FK1&'N[U[/\R\/#NZ(HQF#O#D:+PDCD5Z=C.Z2J2Z1_N8YR)D=(
MS!X@@E&(0NYGC$)3<')^<8D[O7F0<XQ"(BH[Q:%/B3I$'"((.;^XQ`D:WH=X
MQ"7M[=XG#7M9.-P95WAT<@L8;,7EXXQ"&Q!.)PU9\1BL+>%'&+0J*"-^3!:,
MPAV?31.&D?4XG#5GQVBD,?5A!/)GB,PAT?#Q.&IOI7IV,N[Q.&O;P);\H?8Q
M"(8H\1.&NBQGMU(\)O3LJL(#NHA%87"4WF*PMR(H]NJ)^,0EC^'#O3]$'"&(
M*Q>$HN9WUS2(]16%N+P(;YN]/;JXNY(Q"%'$T4AI7)==%V1*8IBYAO.1*_W-
M[*QL=4:?Q.(/KY4(DRJPYPA$=?(V^>S_`#,RO<$A\'=5(:\RJ[%:E$E#QQWI
M7*2C596/]S1@T-)#'A\AD;E>,D4>(BJXN,1A,D)O*,O/7F3V5W,ZN3[+D:BD
M60?'V#3"9X55IV_OS["8UO0XQ23HA/D#=G]9QE2%N,>C,HPJ&.:<Q>7B*Q23
MEJ@0M!],_P`)=VGAU-6OZ4QQOR83]$I*-'GY%ZXU"'=Z4B-/H+$'>:!!/)JA
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M1V=U3-22,UKN@90B"!#B`[I1W06:U%%I3H(*&8ZNS#AP[THBBL+A"[4=T%0U
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ML=>Y;#I6^7T'[KW+8Z]RV.O<MCKW+8Z]RV*ISM#YUB`=>\^X^=9;WFR;>65N
MVR\;NRMN;2.YLNVYLH=EE/;LI[ZS,.^#KWGW'SK+>\M43*W69I*<IFL:QOL4
M:PIV-8UC5$V&88K6^Q9K-;2SV-,PHTLTL:QH>-W96W-I'<V7;<V4.RRGMV4]
M]9F'?!U[R_$*9K'<BJY4TGIB3NB9)O>'IIKTRIVK$3,1Z1,D5YOG`7S@+YP%
M\X!%>'L4>3H'?53),?\`4/H34:1B#3I@YU]<RQCE28=C7@K%'UAC(O%ZO>-4
M>&G6:SB+XHJ0)'64.\,,U`S%FF2:;$O&[LK;FTCN;+MN;*'993V[*>^LS#O@
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MQ\=GYEENU9/:4V;)]FT39LI[%DEIG;9+MV7_`&@GO#G,1K5#L:TQ]+%3M9KM
M:#'U6WC&M*?6/\=GYEA8[2)J&;KWA@FUAF8*$#!0@8*$`SC!Q@H0,%"!@H0,
M%"!@H0#N,':S!0@8*$#!0@8*$#!0@&<H1JX*$![AT,2<PLUK$S-:QI3-:8IV
MZRC3!C6G5+I:"G:U4RS6'26;J:3:#G-JM;JF.9I6F4T!BAB@JA@J8UTW78UJ
MW]K5=##'.Q-1NAC%6Z2G,9J1FF2,8Q6$,V]LO^T$]XH1IP1/5,4NJPI#L+=_
MWG)K-N?ZZ-+?CL_,L-8QK#,9K-*QK+![2FS9/L^TQ6&9JET:&`I"M(TI6AA"
ML;H8T:I1J$TID)JZA=#2$:-#!JE:S0S04A6B[8QC2L,QI2M&H1@U2Z&$(UC2
ML:QA"L;VB[)JL(5C"L_Y++_M!/>>X^.S\RRW:LGM*;-D^S:)LV4]BR2TSMLE
MV[+_`+028UJN'7&'7&'7&'7&'7&'7&'7&'7%POKX=<8=<8=<8=<8=<7"U[AU
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MP[X)-:Q7$/`Q#P,0\#$/`Q#P,0\#$/`Q#P,0\:^(>!B'@8AX&(>!B'@7[Q>X
MAX&(>!B'@8AX&(>`UX>-;$/`Q#P,0\#$/`Q#P#KO#6XAX&(>!B'@8AX&(>`J
M\/#2XAX&(>!B'@8AX&(>`=X>&DQ#P,0\#$/`Q#P,0\#$/`(\/#"8AX&(>!B'
M@8AX&(>`DN\,)B'@8AX&(>!B'@8AX":[PQF(>!B'@8AX&(>!B'@%>'C3B'@8
MAX&(>!B'@8AX!5WAA\0\#$/`Q#P,0\#$/`B)U%#A/>>X^.S\RRW:LGM*;-D^
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M5!ABH,&/4%TXJ##%08.;[`R'>3NYU@7;LO\`M!/>>X^.S\RRW:LGM*;-D^PQ
MC"LLDV;*>Q9):9VV2[=E_P!H),:U7"/`PCP,(\#"/`PCP,(\#"/`PCP,*\7F
M$>!A'@81X&$>!A'@85>]PCP,(\#"/`PCP,(\!KJ\:^$>!A'@81X&$>!A'@*.
MJ[&X1X&$>!A'@81X&$>`JZKL+A'@81X&$>!A'@81X!W5=A,(\#"/`PCP,(\#
M"/`PCP".J[281X&$>!A'@81X&$>`DZKM)A'@81X&$>!A'@81X";JNUF$>!A'
M@81X&$>!A'@%=5VMPCP,(\#"/`PCP,(\`KJNT^$>!A'@81X&$>!A'@1)(Z1P
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M2$(=CLZZ$B$.K-KJZHJ!U[S[CYUEO>;)MY96[;+T0AB7*3`Q),IS$(9K4DF@
MJ293O*29TE7<BA2NR)4]0NMAT`QW0*S#H,*BFG=M=T&L4=DC%018BG<(ZUPC
M=H))G28[H,8U%)I3NSNH2Y2T*))*A%W0,S#H-(Q))AL.0H.1AV%01(U/;:QC
M67:;!J%UKLK&%*PA4]]9F'?!U[S[CYUEO>;)MY96[;+QN[*VYM([FR[;FRAV
M64]NRGOK,P[X)Z]Y]0#Z@'U`/J`?4`^H!]0#Z@'CVO\`4`^H!]0#Z@'U`/';
MSZ@'U`/J`?4`^H`WCVM]0#Z@'U`/J`?4`/QW3]0#Z@'U`/J`?4`4X[J_4`^H
M!]0#Z@'U`#\>U/J`?4`^H!]0#Z@'U`"<>U/J`?4`^H!]0#Z@"?'=7Z@'U`/J
M`?4`^H`3CNCZ@'U`/J`?4`^H`7CVGZ@'U`/J`?4`^H`7CNM]0#Z@'U`/J`?4
M`?L=KC__V@`(`0,``04`CIC$@G&8J.,Q4<9BHXS%1QF*CC,5'&8J.,Q4<8BG
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MOKW$H0[0IV]G^,@3M%7R)/!']"85VWCB0L*6J#,9&)S`7R*&E?C/Z+L_PJ/P
MPQ$7)-[>W&(S6=!6-._<G9JY7AZ=(Y"W"'*NSK%(,5%-.=7-T=8C"]V'IPF9
MSE"++NB3W,+^]PB&3)$']Y4@O?!#W"9TI-B"SJ5SB*S"/L]8-2"0KS02<XS2
M6$.BKOPN)+H$<IRBCFM`!%?-),<9HX5##H$AKR5]4D.;E$N&B.>94^=)B,>`
MM:0CN5[6I[,Y'T\DB+[R0G&./K_#,8U5WOWJ'0MSFA&4`^=WD^'1F*Q&)GB#
MT9(RKW-$@)OB)U"E*H_>6RXY1:)1-_;$#1:$JJFJ13IV=D(X_D8F_47\K$?\
MA]A%%$VM65:6_6:&KKM9[/\`&$.=-IE53&O5&'88S#-:UK2^1%,8ACK*J-:H
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MLFV+,-V`MNBG.4-.=K`U11K=+6AC6L&EK`UK6CX+/RK+-EIFM+83[-+='M:U
MK0EM64]NTIMV5=NRIVV3=EDVQ9ANP%MU[CX+/RK+-FRGV64MJRGMVE-NRKMV
M5.VR;LLFV+,-V`?^I+I(720NDA=)"Z2%TD+I(720NDM6Z2%TD+I(720NDA=)
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MR;LLFV+,-V`MNG9K0U0R:9C&2:<ZI3_T:F[M588K"ZISZ4?@0U[LK6Z3LUR'
M+>)LTG2.<Q$6ETF48T[$-9A3:Y'8VDP,QAD"%2:&()M*JPC5$FM8AJWI")DN
MV)I:I"J,2.0C$+LK6*,23418=A6G+I89C3E9_P`BK&%>-+-9K6-44QFOXB/$
M1XB/$1XB#MB6OXB/$1XB/$1XB%&Q+7\1'B(\1'B(\1!VQ+3XB/$08T38NS3H
M!NRR;8LPW8"VZ88S`TQFL&N?3I:&&,4:6AK6M'P6?E66;/LUFZOL3[/;I:U@
M2V@QK6-]J>W:4V[*NW94[;)NRR;8LPW8"VZ]Q\%GY5EFS93[+*6U93V[2FW9
M5V[*G;9-V63;%F&[`/\`U)=IB[3%VF+M,7:8NTQ=IB[3%VGJW:8NTQ=IB[3%
MVF+M/4NTQ=IB[3%VF+M,,33T7:8NTQ=IB[3%VF"IIB[3%VF+M,7:8NTP1-/3
M=IB[3%VF+M,7:8*FGK7:8NTQ=IB[3%VF+M,&33UKM,7:8NTQ=IB[3!TTVFNT
MQ=IB[3%VF+M,&33%VF+M,7:8NTQ=IAJ:>B[3%VF+M,7:8NTPU-/5NTQ=IB[3
M%VF+M,.I2E*#[/N/AL_#99V62VB]MDNU:-M63;5DUIO99;LV7;9!]DI=8:C-
M#&,T:A6-U=`872S4:-7^WX;/PV6=EDMG0UH*QK&M8U@8QK1H:-4S/87::S19
MU3`Q6Z?9H:WVFVM#1H;[=#09C=-EO99;LV7;9!]DIF%#3,:4S=+6F*UNM_:4
MVAFNW0T^DOPV?ALL[+);+&E:8K6:#M*UK6Z6Z6-8<S`S5T_VZYM4&:7234U=
M)6,9J:&-9IT_U_LUBZ@*UC%"Z-;^W0=I=.LP:6:0S1I.UFL9FDSPQ4Q</%!A
MXH,/%!AXH&N\5T8>*##Q0/3K%S$0*L1(-V;+ML@^S[CX;/PV6=EDMHO;9+M-
M:UMHVU9-M636F]EENS9=MD'_`*$O4Q>IB]3%ZF+U,7J8O4Q>IB]3U;U,7J8O
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MLFV+,-V`MNF:=+2FO];25)JAD6ZQRJZU^R\8U4I2F^"S\JRS9LI]EE(K&%:F
M728C+II6$*2[,&,(5-V1O#)I%8,,5IS$*PK7<K"F=RL!$B:QDRM*QW8T,0*U
MAD6,#46:I$RE>5&)M9AV:6(:6L80JA2$,F1)C6-830=)C#8?22Z*T%*P&0*P
M*)E85-/2>Z)KL3(TJA2D"A=0[P=1-)%5=0RRRY#I'.<C7A[TK'.1*`/+RL0+
M;KW'P6?E66;-E/LLHF:PVN<-.9I6&:P,.=@:<S6)',4Y%3%:U51IM+=%ZH&J
MJ-;>J-:H8VLQ51C2JG8U0[5#7A]%X?64.9AVJ*-&N=ABJJ%-KG!3G(%%5&"]
M4TZY]%X9H*;5#5#F8;L8W0W7,-9NC6:T-:UK3;%F&[`6W7N/@L_*LLV;*?99
M2VK*>W:4V[*NW94[;)NRR;8LPW8!M75\-'AH\-'AH\-'AH\-'AH\.U?#1X:/
M#1X:/#1X?J^&CPT>&CPT>&AG#M'AH\-'AH\-'AH+P\>&CPT>&CPT>&@O#]/A
MH\-'AH\-'AH+P[6\-'AH\-'AH\-'AH-P[6\-'AH\-'AH\-!N'Z?#1X:/#1X:
M/#0;AX\-'AH\-'AH\-#>':/#1X:/#1X:/#0WA^CPT>&CPT>&CPT.^'U1_]H`
M"`$!``$%`,P#T\N%!NN-81UQK".N-81UQK".N-81UQK".N-81UQK".M56^EW
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MN-81/-9JL(TUZXUA'7&L(ZXUA'7&L(ZXUA'HH3C-4XTN&8O_`,^>R3J(5HJ)
M#YND">Z?O,9EN8I=+"I#GB.RY[/_`)-!8)&IDBT5I15*!3<A2ZICS-JTO1]W
MCL2AL0@\0=O_`#VZ.CT_O4T4GJG)$9B-*ZGPB:G2EE3W^<YMDR<)!CDM_8#&
M-,V:Z5U0D-SCM,JDRM$9GDB=)(C,T27.,CO=(O+1&Z65/EF5XY3R?Y8A;[2&
MK,-CL^4=JY2Q.A'WN#4JJ@62'ZGL_0N5HK36HT"<IQIC4JG;*1?[8$)I55"/
M2DA3V?GJ4GZGL_0N5IAIU4&484*N_P"V('2FJ,S2LZT]GY]E-679@=X+&Z>S
M]+,#%?O]HRC2RI]0'*!T\G^9X2[RQ,CW`GZ7)AAD*%:?,I)IM46I;]+]-JBS
M8]N$M3'%',M+*GFDH3K]MR?(\ZU"C,/I;4V+S4YRE-<0>I<II4><(&)^_P!7
M2Y+,R3C&GFE=3W*<4:=U`>)MA$(BTP159%9W6]"O_4XS%_\`GSV>E*>8XIG@
MI])$H2KD8><O\,GJ<ZI4:E6D,K>S_P"39?I8J].]4IB<:@0#,I,*Q8E(+@Z4
M>C7J39GW)*'9D';_`,]TM0G][J)`Y5J)2#,;2AY<H)(L-G*<I#J=F_?)?BU=
M);^P)96CKM,DV2A7RD=.::QB5)2JS0Q"!PZ&9[9,DZ4JG4B\M$WTZS5R5DMK
M%,$F0N<LS%19OHQ2G,_4FHDTO]"/O<4WIUFMA62"I$9E%WDJID:(Z3UZ@19+
MB=!*1?[8&260<W+O1638M+9:15/CLO.,AYXZN21',N@J[_MC(U3_`#8MI%2E
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M>GMZ?EQ5W_;"$PQ]U=2Q!_(YJ1R-*N*\0?WE`5^_VBY3!'H:BE$XBB1*-1E%
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MG41&.02695A\0<(LX1.K-*X),T)FZ4X_%?9`W]QQ"\0<'5Y$;F67)937C,'=
M8DX1&'Q5WESS"S`_.K4<\ZLS-YQ9F#>V8AW2S$_)[.77R433]L^IW(DM3-$H
M7E'D2O\`F@DND-`<\L$H5E(RV3Q1*+(+.6:[.U,$\=>)HK3/\7KW3.C<UT_S
MV9CY-K_/-(_XW>KF/XW>KF/XW>KF/XW>KF,R.53UBIBHGD?IGFSI7EXK;,E$
M(?ZJ)J=5&3EVC54(]3R7<K4;J)2LU2:@YJ76I47S9U9GNC%%G*IKA%<W,HN5
M5_4FA\TS'ETS7IY@<T:M6IEJOG#?*@.LTR5!O5Q]1"KE>:8+4`J5F0K#43-=
M`INF#+3.LOYB8W-U`XM/?\PY<\PLP/SJU'/.K,S><69@WMF(=TLQ/R>SEU\E
M$T_;-0:'T6JT^RO0^BLD3J[NKLZ%A65?+#`9:A<AR/`H;'I7EF:4XC+DO1B(
MRU),F28W_"62?:]ET\L@E*Y(E^?;$#W3]+$!B4>]L$EZ#2XC+GF%F!^=6HYY
MU9F;SBS,&]LQ#NEF)^3V<NODHFG[9]Q_A+)/M>RZ>668'NK,N>868'YU:CGG
M5F9O.+,P;VS$.Z68GY/9RZ^2B+)IJPKEF5QRS*XY9E<<LRN.697'+,KCEF5Q
MRS*XY;EK`<LRN.697'+,KCEF5QRS*X9+LM\)Y9E<<LRN.697'+,KCEF5PC+<
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MSQF!S:P.B4YN6=*09UJ%2?-N]59S6?\`2LL\LL>K=F8F_+GDCS15:J"YS,;.
MEF">HG1"I,/JGEU><ZGJXI/'\U_5W'\U_5W#KG9]7HI?YK^KN/YK^KN/YK^K
MN/YK^KN/YK^KN'+.SZO15OYK^KN/YK^KN/YK^KN/YK^KN/YK^KN'7.SZO)7G
M^:_J[C*1ZBWJ?55SFCU5)IFVG^0VM4\U*I[5JAU9J@3Q6N)9GYS_`&+9X)QK
M;+"LI58CF8GU$J`QV.S&>B&9F>)JS^U-]1^:)"S&2UZG\?B<LQF=:S<A9B,S
ME?R45G297F@=9LW&8".T!GZLF>PE,)BF+U.JI.\\T+SRUC?7C/\`U7JU!O30
MJ+',XTFUCB_JPQ=TH;5CU-7NE,KY]\RN9^4_2ZS>U9C5*J>P+U$I\=:I46S7
MUGK1/?IT5DGRNGIAUDK_`)G*8R1)E<IU1KO9I_W,1+R[/1E;F3-<[9;\DSG0
MG,)ELH4;+[(%%,H%>*845B>2]^?<U68_*,>KU2GGTP)8A4:A5*GZ.54_Z5EG
MEEB?I!DJJDE1:1).F6!1FC%)YAEUT='2'NGM<MFS#N\67+OGMJO1ZF%<Y/+0
M2C990=*4TY<(9'LL=`XO+4P43I3-43@&6J@DJ3W':8T]F52)9>Z+1EZC.5S+
MG,,8AN3_`"O2BJ]Y9<OS]+DW93,MD_0]^E66HH^1++M1*,2>^4TD")2'.&4W
M+;-BL;R,4O@TH5-HW2VLTC3?0*C<_H0[)ME3A,#>\O-"XC*T<REY9HU1&=J4
MRM.U/)>RE9>8#,$5ACC&X7$,C>4"+44E[+-E[E*1BTVA[*C6:?\`<Q$O+O<?
M]*RSRRREW:RY;-F'=XLN7?+3[WRS$N^67_:LK[JR\]SLT_[F(L<B<+X]`QQZ
M!CCT#''H&./0,<>@8X]`QQZ!CCL%P''H&./0,<>@8X]`QQZ!AD<@W"N/0,<>
M@8X]`QQZ!CCT#",=@K77CT#''H&./0,<>@8X]`PX1R#')QZ!CCT#''H&./0,
M<>@8AD<@IWGCT#''H&./0,<>@8X]`PX1R"G?N/0,<>@8X]`QQZ!CCT#''H&'
M^.04C]QZ!CCT#''H&./0,<>@8BD<@R;[QZ!CCT#''H&./0,<>@8B,<@Q#\>@
M8X]`QQZ!CCT#''H&'B.04J/'H&./0,<>@8X]`QQZ!AZCD&*Y<>@8X]`QQZ!C
MCT#''H&*:OKF^N(FG[9]Q_A+)/M>RZ>668'NK,N>868'YU:CGG5F9O.+,P;V
MS$.Z68GY/9RZ^2B:?MGW'^$L.[T[/:9/M>RZ>6!K6%9#(I#(TXA"*PMZB$#W
M7M*\.YUQ+GF`6>G5W.'U]<H<ZB!^=6HYYU9F;SBS,&]LQ#NEF)^3V<NODHFG
M[9]5*$2T_O$AY<).S$YI*=TTI1G)@%!:"Y3I\R_*H1.`YHO4SE[*!--,*L16
MJ;Y6.CM#W>2<\O\`A/4-B67F'YKZ@P21RT\I+.[:(5OHA41URO9H9V<)5HOF
MXRTT7R\YD)OE:JD*EB1LM\YRMEUF;U!%J=396FFAZ'5[]72E[M)M)8'0:I,0
MI'G8J_5[-[+RL=]0C,U*U2<CT1K'`,LN<N5)%F'U#35!>,F>8N2\UE>B5]F/
M,SG7ZE5XJCE;C&<Z@.86N4W>HW!\RE39>GS*O.V>3,]E4C-4*$+YP7*BU2HK
M*$UR=.TJY=:A3`X'RNY/X[&9]],^`RM/\<IGDIDF<95BE:'GU,4Z@XWUGQC?
M6?&-]9\8WUGQC?6?$6??6EXKC?6?&-]9\8WUGQC?6?&-]9\1Y]]:CB>-]9\8
MWUGQC?6?&-]9\8WUGQ&7WUJ+S&^L^,;ZSXF^:/76<<WL*;%#0P1#NEF)^3V<
MNODHFG[9FNFE.9\>8+32G,M3&D@B@QQH?16%P9QE>688YS?2^FE0E6R]`&Q"
M#2W+LNC_``GLT,T^PGVN'EV1?'=R<G.&N?L=/+/8\4REM[J1[('NO;#)7@D&
MC`ESS`3-*L"G&&^V!^=6HYYU9F;SBS,&]LQ#NEF)^3V<NODHFG[9]Q_A+)/M
M>RZ>668'NK,N>868'YU:CGG5F9O.+,P;VS$.Z68GY/9RZ^2B*D(I"^`2X.`2
MX.`2X.`2X.`2X.`2X.`2X.`2X.!2]@.`2X.`2X.`2X.`2X.`2X&0.`<*X!+@
MX!+@X!+@X!+@X!+@1@4O,=>`2X.`2X.`2X.`2X.`2X'"!P`A.`2X.`2X.`2X
M.`2X.`2X(9`Y?(\\`EP<`EP<`EP<`EP<`EP.$"E\C]P"7!P"7!P"7!P"7!P"
M7!P"7`_P*7SOW`)<'`)<'`)<'`)<'`)<$4@<`.^\`EP<`EP<`EP<`EP<`EP1
M&!P`Y^`2X.`2X.`2X.`2X.`2X'B!2^9'@$N#@$N#@$N#@$N#@$N!Z@<`,Y<`
MEP<`EP<`EP<`EP<`EP4V<G!R<1$O+O<?]*RSRRREW:RY;-F'=XLN7?+3[WRS
M$N^67_:LK[JR\]SLT_[F(EY=G1S1S/E:-%?4!JQ&9VG^J->%XO*V?'-O.TC0
M;.*^U#?,PV;F'4:J`^>IK)R\:EW-(G,V<[_I66>664N[67+9L3%6&DDGQ&1*
MN4HGJ<:?U:I55EWG2N5%*;'?JUT;AD<E3-;E<GR*B:)TE.G$N27/<IU#A/LC
M4R2[+91'<UF6>5%8CF2R_E?/9.$[R73R!Q*)0^#P^&Q!UBT.B7?'NJ]+7`LO
MU-IU-GL:UC&.-29`BTMNU4J93#+$NS++DX06PONK+SW.S3_N8B7EV='+-4_,
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M_P"YB+J$1A/-<O#FN7AS7+PYKEX<UR\.:Y>'-<O#FN7AS3`.'\UR\.:Y>'-<
MO#FN7AS7+P+,\!X1S7+PYKEX<UR\.:Y>'-<O!&:8`UTYKEX<UR\.:Y>'-<O#
MFN7A#YG@*A.:Y>'-<O#FN7AS7+PYKEX0N9X"H\\UR\.:Y>'-<O#FN7AS7+PA
M\T0!1_YKEX<UR\.:Y>'-<O#FN7AS7+PB$T0!-_YKEX<UR\.:Y>'-<O#FN7A%
MIG@*3]S7+PYKEX<UR\.:Y>'-<O")3/`4S\UR\.:Y>'-<O#FN7AS7+P>9H@!4
M>:Y>'-<O#FN7AS7+PYKEX/<SP$CCS7+PYKEX<UR\.:Y>'-<O"F,3<8FX":?M
MGW'^$LD^U[+IY99@>ZLRYYA9@?G5J.>=69F\XLS!O;,0[I9B?D]G+KY*)I^V
M7Y^<H8Y'K]0A.$N=9Z/1&77C,;EZ=%H-4FG4QRY+<URM.4'?:JTRASD/\)9)
M]KV73RRS`]U9ESS"S`_.K4<\ZLS-YQ9F#>V8AW2S$_)[.77R433]LQU^@D,@
MDKU!I8[>G8>G;M)E8,X,"RRTGS_0>"2'1JJ^4-ZIQ#O3?GIXRFS)!\GE0JFU
M*I5_A+)/M>RZ>668'NK/.TXU%S/2]F<JE$I4IU6Z>F9SI.J1,N8VLU9GK,;2
MEYF:/UTJEFAS99X'_*G5+-AG'J#'8FY^J]4J6*-2!7RK\=J'*OJMSS,E0:7>
MJ=4R;A7[-U7)]I-(>:>HKM5:8?5%FR71-WJ/U"E2-TVSYS'%H=+&>::&U*S%
M9F9^K'Z450(AFZD_-RZ>J+$8O(TZ^HJ^29!)BFNL51\LM1JYUFI+F<KCF\G:
M4(M%ZM9IJDS9EPS;QJ/4SB'J9'E>N[<YM2):95.ID[0A:G?J-5(FXE*<VM3*
M@1G,EF5<Y.HLKG/S!)9>XEFFKI"JHY7:N5@K.XY5:P/=?<N>:BJM9Z1TSRQY
MA,T-8)KS'9E,VE**A9>JBU4JE3=^SJ>H&[1C,94FIE+J$^AYG.SI9J)$$T_;
M-DI2D+[/\)9)]KV73RRS`]U9?J5TZJ!'4,N="W5:`T4I1*]19HIQ(LZ/L8R_
MT1CZDMT/I))\_1RB%'JF3E7C*)3"L4KREDMRVRW2LDCR<G-*&3K*NZ/,N91L
MK\I2^YY4<L\.D]ZH51J"U%B.4G+)%H75')'0J=Y1RQY>Y>RW4?>,K.79ZF5?
M*UEW>:354H;22?9B@^4S+-`(<_Y>J&1:2)]R993JHTY;E_H@9VJI0BBM<D(_
MD9RBE?%LGV5IZD5PH11:%SH3*73B`(5$I\Y3^XR3E>R]4WC<0[I%X1#(_"4*
M/4L=D$)`DEUFQM)Y5A$(D^4X%(DJ1/R>SEU\D$T_;/N/\)9)]KV73RRS`]U9
MESS"S`_.K4<\ZLS-YQ9F#>V8AW2S$_)[.77R41+!<._'@?CP/QX'X\#\>!^/
M`_'@?CP/_P``PGX\#\>!^/`_'@?CP&=!>'?CP/QX'X\#\>!^/`2Z`8?\>!^/
M`_'@?CP/QX#GT%U?QX'X\#\>!^/`_'@.'02__'@?CP/QX'X\#\>`Y]`,7^/`
M_'@?CP/QX'X\#\>`^=`,7^/`_'@?CP/QX'X\"(=!<5^/`_'@?CP/QX'X\!^Z
M"ZWX\#\>!^/`_'@?CP%^@%U^/`_'@?CP/QX'X\!XZ"X7\>!^/`_'@?CP/QX$
MA\B80?_:``@!`@(&/P#4$N8T%CK[(!!J(,UH(.6-E2/`(V5(\`C94CP"-E2/
M`(V5(\`C94CP"-E2/`(V5(\`BQ_:Y%G^F5+`KMQLJ1X!&RI'@$;*D>`1LJ1X
M!&RI'@$2)?\`;)-C^B>4LA%\V6%C94CP"-E2/`(V5(\`C94CP"-E2/`(U8T:
MKD63YB]0?LB-E2/`(V5(\`C94CP"-E2/`(V5(\`C4@;JR2+5]:#U12/+FT<D
M;*D>`1LJ1X!&RI'@$;*D>`1LJ1X!$AS-620?ZVYBAHJ-\D`CC!(/`8V5(\`C
M94CP"-E2/`(V5(\`C94CP"-:O;JN0'"[32#8%!#'1LJ1X!&RI'@$;*D>`1LJ
M1X!&RI'@$;*D>`1JI[M5R"XW:42;`I)8V-E2/`(V5(\`C94CP"-E2/`(V5(\
M`B4Y^K))=YDZDM&*=,`Y(V5(\`C94CP"-E2/`(V5(\`C94CP"-8E^K))2^SP
M.J*A,*#BC94CP"-E2/`(V5(\`C94CP"-E2/`(UR#JN00+RT#J"@?T\@\Y)XX
MV5(\`C94CP"-E2/`(V5(\`C94CP"-?M=JR26MF2D%D4+)8:..-E2/`(V5(\`
MC94CP"-E2/`(V5(\`C4#+G=F2FNNSR0T`*;>--S\N_CKO]ZS==(UEKNZ7><&
MAQ;-G2Y;@TE`2'N!0D$`U$A!$R9JZ_R;PQCK+C+>UX:4!0EI*%""AI0@Q/%V
MO,N894PL?9<'6'@`ECD)LN`():4(!"BF+M<;Q?I++[.7RY;GM:^8E)L,)#G(
M*39!3'N__E_CB9>;U/9+N[`KG/<&M:-\N)``X28?K*[ZUNTS5S56:V:QTL)6
MKPXM"*%4PW63]:7<:N)033,8)9)*`!]JR5-%==$"^-O##="RW;#A8LHMJTMF
MRE*JB4K$N?(F-?)>T.:YI!:YI"@@B@@BD$4$4B+O^!F?>RX?,F/#9;0222@`
M%)))H``K,3[U<-:W:?=92VWRYK'M8@4VG-<0U!25(HB9K&3K2[/U>SM36S6&
M6U*U>'60BBLXX_NDS6EV;JS_`#C-8)5)32%UBNBNNBN&7O5U\E7BZ.5'RWM>
MPH4*.:2"AH*&@T1JK_N^Z-R\2M7ZUNT^;**/$N:QY8:NN&N);5C2+Q/NFL[O
M-DRNVYDQCFL0*;9:2&H`32E$?U5POLF?=E(MRWM>VBOK-)%&.FB)DRX7V5/E
ML>6.,M[7AKPA+26D@.`()::0HHIC47XYGW<W<GZONNM+M-O\I;<MDUCIC$*&
MTP.+FH2`5`IB\7>Z:PD39\KMM9,:YS*2.N`26T@BD"D$1>KY*UO=7721I'B;
M++)??<'66?O$1-;JG7%UO3I:6O)FRYEE52U8<Y%0HM:%*HN_XZY?[V[[AU2-
M:W;^ZHOD^:SS42UH[5NJFJJFJ)NKI6L)#M8,"NE"8TS&BBES`;0%(I(QC?B\
MRKOK*[S)LE?,#9C'&6A(-L`DM0@@VDI!B8-6ZSN]XL):\J8R99546P2BH46M
M#O1K?\+-]QVY*U;>-:W:7K&8EF4Z:QLQRU66%P<5Q((9JU^L)`UBX*)1F-$P
MA"5#%M$("5`J!WHFZNE:PD.U@P*Z4)C3,:**7,!M`4BDC&-^)]VN>L9$Z\2B
MCVLF,<YA!(ZS6DEM((I`I!%>YJC\+*]QL2-7WK6MVE7^:EB4^:QLQZE!987!
MSE-`0%31$O5LS6$ANL7A6RC,:)C@A*AA-HA`2H%0.]#KJV\,-Z:VT6!PM!JI
M:+54!:%1%HB?=+KK"1-O4KML9,:Y[*4ZS026TT4@4T;DGYL[[^9$B5K'6EVN
M\V:48V9-9++S5U0YP+J:*%B[W:]ZPD2KQ.*2V/F,:Y]('4:2"ZD@=4&D@1*N
MC[S+%[>"6L+@'N#4M%K54AJA2!0H6N)UWE7F6Z\2PTO:'`N:'6K)<T%6AUEU
ME0%LN2H[FL_QUX^\,,FZTUE=[M*<Y`Z;,9+!.\"\@$\`IB1,OFLKO*ES>P7S
M&-#UJLEQ`=Q+$B5-O,MLV:Y&`N`+RA<C02KBC24"E`34#`U4=:7;^Z$+Y/FL
M\U$5?+M6ZJ:JJ=S7?XIO^WN\&]:ROTF[W8%+<U[9;5-0M.("G+$O6,[6EW9J
M]Z69KIC!+<M2/+K)5"B'%$B9,O<ILN:YH82YH#R\@,#22CBXD!H"EQ(`4F+M
M=+[K*[R;U.*2V/F,8^851&-<07%2B-!IHW/S%\V5]PR)EZOMYER;JP*Y[W!C
M&C?+G$`<9C^Z2]:79VK?\X36&56FD#K%=%=<#63M8R!JXM7S3,9Y:;]M;*<*
MI$V\7F<V7=Y;2YSG$-:UH"ESG%``!222@%<!S2"TA0141'Y=_"O]_<_+OXZ[
M_>LW?S$\B6V\SOZ=JT!S[-YE.#5K=9%H@4H+1J6-7:FU5K[^GU?>M5.GN,H2
MG&8]LPACFN<UR]0;Y!8"F^/S%,E:R$MW_MCI`\MDJU-8^6Q&.?U6LMD&U>7V
MW-:PA'H&Q_Q/>];7ULW6`O\`K!CB;(=U6EC+0`;2B#LA:*%.[_\`E_CB\W_\
MPAAU9(+7D."@N:X%@#30YUM++36Y(O%ZU//$R2_\P76]WMLMCA)D2IDVB4I8
MT.$H-89I`L@D$=5(N%_O%D:@_P#;;V]KRGDV'W>Q*?:[`89ML->MFV:"L?T4
MS5M[.KGW:]S'3)?E@!OF/,@/MO8\2;*3"9;7ES0UH%DD'\N/=*<P_P!#(H<B
MT2VA:"0A11340J&B+O\`@9GWLN+],UQ8_M;99=-M]FPVDVM\45>M4A5(_P"3
MK]^67+?[ZV1,=)DL<!*D29K6]=&AOFS6.FO>&EPL@T]4F/S?K'5J._+)UQJ9
M]I@6262Y3?//5%E&N,KS/V2.LA$:\NE__,$FX7*\?F2\S+LZ9+ES)$X"6P-!
M$P&49=KS'-7JN>!9-H"+K=KW*NK9TI\QBW=C9<EX:\ALQC6@-`F!'&R`%)01
MJK_N^Z(O+;X0+H9;@]2@L(;2FA!952H01^>K[^69K1K!^I9]TNTB2QP)9*ET
MSGHVRKY@ELDV7%U@-M`$@#\Q/U&TONS?RSJ]DSRP4\UD]IF,<&CMME-FV@>L
M&FF@Q^?+SJN:\?EB]:QU4QTR2/L_)\A+R6D`M0$RVS,0/5>*Q&LY5\;+,FZ:
MPGW>0]C&L9-D2;+9<QH8`QP-+0Y@#2&T"@QJ+\<S[N;N21J6:R7/N5VFW61+
ME--J=->'%\QSFM+3)EMM`.<^T7DNJKU;(N$IYUC*_+6LY<X-!MMFNFS?+9,`
M"A[IB%K74DJ0*#$R[3)#9VH7?EZX2YS10PSY<RV&/LIUVV'6FFFR4(1U.L]9
M:LU=)NTF^3R6ME,8QGE2EE2W`,:&H\!TT&E?,K2+O^.N7^]N^YJ/5\B9*E7K
M5]Y>]Q8PNFS[S/H$IKFM*M827SB]P1`QO9*:BNDII_OLG7E_?/`'VC93F%'/
MHM6'`M`<>J5:`52-5RIEVG3/(_+VL&7MDNB:";P]&/H):]SJ6AP4H2`4,7S5
M]^OTN^RKMJF[MDSY:69<MQM&1,LT&8J(7=:Q+#@&AY$:W_"S?<=N:NU+?+Q*
MDWJ7>F7J\3&L+II+0DN3++6N/F3"&@@HUK!OD"-:W2S_`.<=^;+O-8$^T-U\
MHH]M%HRA+#@2%:U""D:@N:ENN)6O;^^\4),9)<P]=_K"606HX]4]4`U1JMDN
M=(O&KM6:NG2'7J0YSI4XS9[IC)8<6-:Y[+1<\-+VM-;[2-$:H_"RO<;%PU'>
MYLF3?_ZJ5>KQ-#"Z:DH`2Y+"UKG>=-1K0"C6RU)I<%_,MW:T_P!ZG:]N,V0T
MC[4R0WM,HM%C6AUHM4-`<J4Q^:)%Q?(;>INJI:M86!SYWF32]0*73`+)<JN1
M":$C_C^6QO\`]V[7+6#;Z`$>PF=U1.Q@N>06VJRI%1W)/S9WW\R&:DUI.D2=
M97[R[<YS2]TJ1+=:+@@<X.(M"4T`!SB2X@`F/S<)`<3>]4ZL_M]L),>T3&*)
M:@$O#R"]K>L"5(C\JVGR67Y^JYK9E+0]ST:&!_K%UD=4&E!11'_*$BY/DM:Y
MUQ(:PM`)$A_G$!M9$QQ\PBD/<;76.YK/\=>/O##Y.M1(_NM]DONTETP6A+8\
MBW-<`'.:QA1Q+6ESG!C1OBX/N,U\S47_`*E?KO=IDQI'F3FVF"S:`^TF!H,L
M`!SFI9%(C_A%VL#*EZV;=K$TOLMF#_ZK6M:\E')YI>&@T6RX#K$QJ#5TJ?)D
MWBX7LS7V&ETV?>9Q`9*:YK7*&OZT^V0@LM;44C7?XIO^WN\#6&O)$F;.%IDA
MLP!P,R8VR:"#0!VW(2&*E)0_\3"ZZP$_\L72;K"7.GO:6R739DAS@5F!H#/,
M?-8PN`I!%8,?\-3-:B7*UA+US="LQ&S&2/,FN<I<CFRP/++JFA&$U")3-6.N
M<W7MTO=VGS+NYJ3KP%#9+6.;9F.2W4PNH)!0*#+>]MEY:"1O$BD<4?F+YLK[
MAD3=:Z_E,?<[NX/:UP!M30"&-:TT%Q)-E00.U194?EV\:JO39NKQ^9)=YOI8
MUPN\DS6@^6VTQOV<H>6"2$!I5"`/S6^],EV':XFON=JSV'7R73(7$YOFD&77
M++CV28O\J[W.?.U(ZYF9YTETHR_,M@,$QQF->90:KDEM?;<6+U0X.U=-=*=+
M<Z1+):Y+358#9=9+FVA44<0M1(IC\N_A7^_N?EW\==_O6;H;-E-<!O@'GACV
MR6![0@*!0-X'$((%W8A*GJBL8ZJ^&`X7=EH%0;(4'?JKW?\`\O\`'%B8P.9O
M$`C,8=+9)8)9K```.48X\HRF^5^R@3-5'EE@\M$1*$WDJ2`UH1HB[_@9GWLN
M"Q[0YAK!"C-#A*DL:#6@`7*E<&4V4T2SB0)FJALMTAAEBH$!!D")`:T(T1JK
M_N^Z(+7`%I"$''!=*D,:Y$4-`*<0AP9+:T&M``N7?@RFRFB5O($S50&,:`P5
M`4#-&HOQS/NYNX'R[NQK]\-`.<"'.9+:'.K(`!.7?@B7+:T$J4`"GB@-:`&C
M%%W_`!UR_P![=]SS!=V"8JK9"KOJBK#I@EM$PBDH%.4UP]S9;0YU:`4Y=_C@
MB5*:T&M``N:-;_A9ON.W#,==Y9>M9:%SI`FF6WS0$5`J9:X=,$MOF$(2@4C>
M)@,EL#6C$`@Y-S5'X65[C8\Q]W89F^6@G.BP)IEM\P"@H%SUQYHD,$W]I`M-
M=*+3#GMEM#W5D`*<IQ[DGYL[[^9%N;=V.=OEH)Y1#"Z4TEM5`HR;W%`FNDL,
MW?0+152BP9C)+!,-9``--=->YK/\=>/O#`=-D,<1O@'G$,8932QM00(,@Q<4
M!\R2QSQ42`3G,>8+O+\Q56R%7?5%7<UW^*;_`+>[P!-E-<!4H!YX$GR6>4/5
M0)OU55PWS9+')4H!3(H@3#):9@J*!1QU[GYB^;*^X9%F;+:YJJA`(Y8=*;)8
M)1K``0Y15#9;Y+#+%0(!`R#%'E>6WRD1$")O)5""J/R[^%?[^YJJ_P`UI=+D
M7F5,(%9#'M<0.$@41LB_>%OQ1LB_>%OQ1LB_>%OQ1LB_>%OQ1LB_>%OQ1LB_
M>%OQ1LB_>%OQ1LB_>%OQ1_5?VF^V/)L)9:JVE_:JC9%^\+?BC9%^\+?BC9%^
M\+?BC9%^\+?BC9%^\+?BB5?_`.U7SRFW9TM++55SV.7M5(TQLB_>%OQ1LB_>
M%OQ1LB_>%OQ1LB_>%OQ1LB_>%OQ1<IXU3?;,NVO5:O6:@3K1LB_>%OQ1LB_>
M%OQ1LB_>%OQ1LB_>%OQ1LB_>%OQ1JUS-57P"3>6S"K6T@,>U!UJ^L(V1?O"W
MXHV1?O"WXHV1?O"WXHV1?O"WXHV1?O"WXHE29>JKX'-O-WF4M;5*O$J:X=JL
MAA`X2(V1?O"WXHV1?O"WXHV1?O"WXHV1?O"WXHV1?O"WXHOUU9JF^A\V2]@)
M:U`7-("]:JF-D7[PM^*-D7[PM^*-D7[PM^*-D7[PM^*-D7[PM^*-D7[PM^*+
MC=7ZIOI?*DL82&M0EK0"G6JHC9%^\+?BC9%^\+?BC9%^\+?BC9%^\+?BC9%^
M\+?BB7=IFJKX7A\PJ&M3KS'O'K;SJ>&-D7[PM^*-D7[PM^*-D7[PM^*-D7[P
MM^*-D7[PM^*+VV9JJ^$S+S-F!&MJ>\N`/6K"TQLB_>%OQ1LB_>%OQ1LB_>%O
MQ1LB_>%OQ1LB_>%OQ1K&8[5-](FS@\=5M`$J4RGK5JPG(1&R+]X6_%&R+]X6
M_%&R+]X6_%&R+]X6_%&R+]X6_%&M;R[55\+)[V$`-:HLRVL*];?&:-D7[PM^
M*-D7[PM^*-D7[PM^*-D7[PM^*-D7[PM^*-57K5]UG2F2)+F$3``22Y:$)HW+
MO\QO./T/[OIPF_+/.,*5Q\V%(^8.8X3?F,]]N%-[IYL.5W1S80RN]XX4WYCN
M?"G=[^%N%>,H]T85W[IY]R[_`#&\X_0_N^G";\L\XBRZ8T.WE$65%J"&N!(K
M2%!HW)9<4`7F@$&B+)>`[>4+!`<"17P;L@+3;',8`6G<"D"`%IB@PWYC/?;A
M3>Z>;#E=T<V$,KO>.%-^8[GPIW>_A;A7C*/=&%=^Z>?<N_S&\XBZFP"[S0*<
MAHJ-$7YKI3+:-(QTTE:A6:]_'`F3)0J`-%*@J1Q$)O5Q?7&6+39KTX$%&;%O
M&F+M)G-#GAY+7$*K;+L>^"B\*&+)T7E/([P+4XP%2-7V[0*TT&D^6Y<2&G-7
M#IA1P>*\83%DA9TLN98J!3''TCO&8^D=XS'TCO&8^D=XS#2;L0-\N49L<`R)
M1:VP><9HEVP$\IP-&,N8@RHJ1=F.?9G6G63O"FR#P5`B+PY[+,UTQ`-\V6A5
M2K&L7B[LL^8'*T$E$*8TQ%<6,0AHF"R@'9*]O-PU"F`'O))ESAF/4Q5EN>)3
M`YQ8]C37V4K'`HAC&EH)E.!)"UEO*BD<<3`QQTDMN464*]._$U"X,.^M8>1B
MJ4<B$Q):'%K2%!()4VBK:*$LHA*44Q=TKLTY?_Y%\<PD.;*;9RESE3,(O+6O
M*-F48J"`<;7+2L/E/?\`:N!3&M%01K4/+#E:DPF66\`!%NG@I7?!B]-3[,64
MRD4^C/#?F,]]N%-[IYL.5W1S80RN]XX4WYCN?"G=[^%N%>,H]T85W[IY]R[_
M`#&\X@&9+:XBI0#SP7MEM#S60`IX]QS1)8&FL($*5+#0&@`5<&3>@6@"A@$@
M**N"#9:`I6B/W?3A-^6><84KCYH<\#K'A/)B'%@R/F#F,!Q%(P"@AOS&>^W"
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M=$2UGNH=P</!'U#N3HCZAW)T1]0[DZ(^H=R=$?4.Y.B`L]W:;O?M#@CZAW)T
M1]0[DZ(^H=R=$?4.Y.B/J'<G1#P9[D0[W1'U#N3HCZAW)T1]0[DZ(^H=R=$?
M4.Y.B/J'<G1#`)[D0;W1'U#N3HCZAW)T1]0[DZ(^H=R=$?4.Y.B`!/<E.]OY
M(^H=R=$?4.Y.B/J'<G1'U#N3HCZAW)T0])[NT=[HCZAW)T1]0[DZ(^H=R=$?
M4.Y.B/J'<G1#_MW5\&\."/J'<G1'U#N3HCZAW)T1]0[DZ(^H=R=$3")[E*;V
M]DCZAW)T1]0[DZ(^H=R=$?4.Y.B/J'<G1$HS'EQ`-:>@#<E]X<_Z'BPAW?3A
M,X\)G>PAWF^\,)V3#;DPAQ\^$[O'"?E]`PG\7-A2\FY+[PYX8C05*5_X&'@,
M"-3'_A"-:#Q_X0X^6$!(-.]Q0RR*"4KJQ[T(BE">(0`VN'-`H&?,D<6$.[Z<
M%Y!1R&):5$\_Z\L60-_,(851I2-M_P`E_3&V_P"2_IC;?\E_3#5UYC_R7],;
M;_DOZ8VW_)?TQMO^2_IC;?\`)?TQMO\`DOZ8"Z\2D?\`POWQPQMO^2_IC;?\
ME_3&V_Y+^F-M_P`E_3&V_P"2_IARZ[H3_)?TQMO^2_IB7/DZQ6:10+)Z]/[-
M;>.C<<04(A[02EE<AAC7$VAR\/3$L4V2$J],-<TE;6<`&CDCM&P6K_C`825:
M::?UK_P@BFR110<73!:`#7R!:8)(Q`^(F+SUJ15X08EMM4VP#G](IAS2335T
M>G_^0U"4!"UTK17P5P19-8'!24@A*5=R4P]_JJ.($#IAS@:<20Q:`7T9C7QP
MQR"GI2"4_54R)$UU3@>#@RP$K)`A+/K$9@L(6IG]+0(:YQIIYX0NI#">,001
M6%S`=.%+R;DOO#GA@0("M,/*"R818FBA7$G/#7JF^.)(M`TH1G@H:"G)`<:Q
M'%A#N^G!((HAM$(11@L[V$.\WWAA.R8"."B"$H,`)#`10@@**H!#:8-%<-HJ
MJ@FR%CLBFCE@BS0:XI;`@@B@PB405;43"-0`U\(A'!1`4550!9%$$60AAS;(
MLK5Q"$@&R%5>/<L6!9WH`#0@B8<='-A2\FY+[PY_T/%A#N^G"9QX3.]A#O-]
MX83LF&W)A#CY\)W>.$_+Z!A/XN;"EY-R6!7:'/&A=F,:%V8QH79C&A=F,:%V
M8QH79C&A=F,:%V8QHG*F\8T+LQC0NS&-"[,8T+LQC0NS&`/*<MG>._&A=F,:
M%V8QH79C&A=F,:%V8PS[)V/$8T+LQC0NS&-"[,8T+LQC0NS&&+*=VMX\,:%V
M8QH79C&A=F,:%V8QH79C`64[M-Q']H1H79C&A=F,:%V8QH79C&A=F,/)DN1#
MB,:%V8QH79C&A=F,:%V8QH79C&A=F,,(DN1!B,:%V8QH79C&A=F,:%V8QH79
MC`(E.13B._&A=F,:%V8QH79C&A=F,:%V8PY)3NT<1C0NS&-"[,8T+LQC0NS&
M-"[,8?\`8NKWCO"-"[,8T+LQC0NS&-"[,8T+LQB8/*<JC$=Z-"[,8T+LQC0N
MS&-"[,8T+LQB6'L(*&O<N_S&\X_0_N^G";\L\XPI7'S84CY@YCA-^8SWVX4W
MNGFPY7='-A#*[WCA3?F.Y\*=WOX6X5XRCW1A7?NGGW+O\QO./T/[OIP:(;\L
M\XPI7'S;J@T;A"TQ(^8.8X";C?F,]]N`IW)O=/-ARNZ.;"&5WO'"F_,=SX4[
MO?PMPKQE'NC"N_=//N7?YC><1=:&EWFBO(>2+\Q[&>8C42E#33GKBW-E!:`0
M1C!4\0(Y(OSBQJMFO2JBA!_A%UDS!:1Q+75J++J"=\%,M!K@"?,:UQ[))`0[
MX7'$T@]:U*L=U1:_B7@KA\T$.#P5*!0B4*,71'[OIBY>:6I;<JI58=OXE3CB
M:'OLRS-%@F@@=52%Q*IR<$7B;/:&N:QH)J#J74@\-%&_1$UKRT%[0]`54U&L
M"L`)D,!["#.:UMH"L@JM%=!+3D3?B_,)!45T&FRRD9"N8B/-FM#9@Z@6A3P<
M!-7!3%YD/>&D=8(5K%-8Q$+5CB[N8YOF@$MWS50,H41,M@&U)%!3]IU";Z(2
M*XLSF@,DU$BA,1'"E?##"]S;,QJT.6D4;PK!`"?LQ+;,1B@TM*A:+(4@5[R4
MU0?,>`CY0(H0!PZ^:G(D7:P\^6YI;0G5<I0U95XHNS`6%]AX*UTV$XZTXTB8
M!-I#I+2J4BD%>*G@KA`XV`XHHJ()&(5)E)%,,:THTJA-()""R"T4A%.*E?V8
MDL+TFART5E00F2E3D$/EJ3)LNK%1#@$S'CKB5;F6;<V8'55`.2O>09XD36S!
M2P+57C]4X^&+M+=,'GMF,)WR;0"558\6*B'69S0++U?B*F@DU*,=:1?'H&ML
M*`*K0!*B@5E,6*'.F(.K3FBZ-8X%WEMSAN/C0&$#PT>6VT30+=JD'+2#CI$7
MHD(P@D#>%E#O5E3QP/-,VWP!J<ICM3LS>F.U.S-Z8[4[,WICM3LS>F.U.S-Z
M8EV73[-D)0W>RQVIV9O3':G9F],=J=F;TQVIV9O3':G9F],"PZ?94UAF^>&.
MU.S-Z8[4[,WICM3LS>F.U.S-Z8[4[,WIA]ET_MNK#*UIQU1VIV9O3':G9F],
M/)<^TM"I:JW@43+!2K<G=[^%N%>,H]T85W[IY]R[_,;SB`7,!3?$%P8`XXTI
MW"!+:AKH$``!!5P0+;`<H6`4"B"@`6/W?3A-^6><;J"K=E<?-NB8IM)OE,U2
M\->[(^8.8X!(%)W&_,9[[=Q'!1@3>Z>;#E=T<V$,KO>.%-^8[GPIW>_A;A7C
M*/=&%=^Z>?<N_P`QO./T/[OIPF_+/.,*5Q\V%(^8.8X3?F,]]N%-[IYL.5W1
MS80RN]XX4WYCN?"G=[^%N%>,H]T85W[IY]R604-H<\:=T:=T:=T:=T:=T:=T
M:=T:=T+Y[JHT[HT[HT[HT[HT[H!\]RV?3&G=&G=&G=&G=&G=#/MW8XT[HT[H
MT[HT[HT[HEK/=VNF-.Z-.Z-.Z-.Z-.Z`L]W:;[PC3NC3NC3NC3NC3NAX,]R(
M8T[HT[HT[HT[HT[HT[H8!/<B"-.Z-.Z-.Z-.Z-.Z`!/<E//&G=&G=&G=&G=&
MG=#DGN[1C3NC3NC3NC3NC3NA_P!NZOT"-.Z-.Z-.Z-.Z-.Z)A$]RE.:-.Z-.
MZ-.Z-.Z-.Z)9F/+BF/<E]X<_Z'BPAW?3A,X\)G>PAWF^\,)V3#;DPAQ\^$[O
M'"?E]`PG\7-A2\FY+[PYX;4A*1,L@$-2.J`1#R&CJDC-#$QE#P4+"`*4)XA!
M04!.6J"Q,2QQ80[OIPF<>$SO8-)$("%#F^\(*$&*7`0EH+"!X7+N.)WH45;M
M)W'*X45PSK#$-U2:-T<?/!I%$4'=4&B'%:%,*#1@OR^@83^+FPI>3<E]X<\,
M0B@K#W%+)A%B8+05Q)SPUZTX^&A(4%"A'$8:HH'HBW:-21Q80[OIPF<>$SO8
M+FA;:GC4PH7M`'.*<XY8(;1UC6#4IR0YK@I)/'^HA6BMU(.6L&'.)**Z@C?-
M!_7?Q0`:7**J,>>`'KV#GX8`4T/IR61Z88MI40TG/!LVK*'W:.6&T.0%IQ[Q
M7E2'HJTY$Z4B\HT]9$S1*=222%XA#$#K5/./1OPXM5?UXLD.%))SU\<`BI0N
M10O)![6D._4G,L`VM_?B:K:W#F%(R<\2P`AM\BE3QBG<HKA@<$1><P\V3VCB
MX3$MTZ47202K5LD\>*F-EO\`]0]$;+?_`*AZ(V6__4/1&RW_`.H>B'?^+?7_
M`)IWAP1LM_\`J'HC9;_]0]$3"_5Y:VP:W%ZTB@`BOAQ)#W7:46234"5_7)3E
MW'\7-A2\FY+[PY_T/%A#N^G"9QX3.]A#O-]X83LAA`,)N3"''S[BX#N\<)^7
MT#"?Q<V%+R;DH"LN'/&B,:(QHC&B,:(QHC&B,:(PGEE4],:(QHC&B,:(QHC`
M'EE;/IC1&-$8T1C1&-$88/+..-$8T1C1&-$8T1B6LLTNZ8T1C1&-$8T1C1&`
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M3UB`=\`T'C_QC]WTX3?EGG&%*X^;"D?,',<)\NE&F60*E5_^"98D7D.=Y?6)
M!2EJ@+1^RJ\*1>G.+BQK&$-%-9=4,:H##FFTU@:TC$2JUY$1(/VI<P-*D)::
MI<A3U@!0G!5O362WO+"V60042T7`N3'0%3$D.`:""*=^DV>*OCJACV4-;-<T
MBD*C'&G@)%&1<<6A+""7*=6?7*$+P;^.'L<`'-=[**#7CJRKO0QEAIM/:%!H
MZP<5&^EG@6'SB.H)339X2]S:^+-$V79LS!+>Y5Q"I$)0E5KHXXNL@-".E*N2
MR$3CB=U`;(:1312\LK2E$7DQ*2/+!-M[:T[+2Y<>\D*Z63]FU_5!)ZU")P5Y
M,5$%HEUSK%)/[%I43B2&WAI+7T5'_J`(BZ@N1AFO`!WK#CUDKZP41=7A@28&
MT8Q:(;F"\=4$V*5:,=;B@KH(X04/!!)!;-I0`BO%4N4C/#R'6@V0'$8B02J;
MRI$MLN7:>YI<!0*DH4D`&GBWHG$3*[R&XZB&DU.X<O#$EC6H]Q?621U'$5UT
MXMX+O0]CF`M#'.HI[**.$TXJHE/?9\EP%(K!(4#T+C*;]%WEN[3W(4X`7>A(
M8LL*X3**3V'6<0)*KB;$X.E$4_\`5O-'K,:.5>!*8>6DAR%"AWH+P27-DRW#
M_J+E!7-G,`BE9Q8G`&DKR+QQ)#B>O)M'@=15G.:)<PBDB+R)DX,"BE"<0WH!
ME7D/*U(1SQ:F7H,<M2$Q9ES;;=]$@'^N:O=,-8^99836D7=TF]ATQ#U$)*;]
MH4<10[EW^8WG'Z']WTX3?EGG&%*X^;"D?,',<)A<T$VV>^V`DL4!.+>ATQK`
M'FLP"YH)$4RQ4G$,63@@O:P!Y"+P1-<]@)#36./GAP#6AQ-:+P+BI2A89+,L
M$-:&TA:&U=,%UD6B$7@_4PU)3:""**B*LRQ9$IME$JQ5IRF&L$IMD`@!,1KS
MXXD/L"V&``[P040X&4U#71PKSTY8>&L`>5*HJ$A%Q4IPPQ@0N#0"414"<//%
MKRQ:M6N-$7*E&2!*\L>6,6*)9<P$M+DX*2(8!*:C:J*D*A..F',,L6"*0E$-
MEODM,MM02@<4-'EA`$'`-Z&^;+#D*A0L3"98)\QQXP:\L!ADML`JB8]^"\2Q
M;II3?KSI#6L:ULI5(`K*@@Y^"F!2C@5!X?UHR0TLE@$*G`M)SFN)W>_A;!!%
M!AO4%`0<$6[(M;\.#``3#6M'5`2+QE'NC"N_=//N7?YC><?H?W?3A-^6><84
MKCYL*1\P<QPF_,9[[<*;W3S8<KNCFPAE=[QPIOS'<^%.[W\+<*\91[HPKOW3
MS[DOR]):"95HY8];V(];V(];V(];V(];V(];V(];V(];V(]:VG_15'K>Q'K>
MQ'K>Q'K>Q'K>Q`[7F6?^FI>F/6]B/6]B/6]B/6]B/6]B&K:M4IV(];V(];V(
M];V(];V(];V(9;M+:H[-=/\`C'K>Q'K>Q'K>Q'K>Q'K>Q`\RU9M#]FM0G*D>
MM[$>M[$>M[$>M[$>M[$.MVK"%>Q5CCUO8CUO8CUO8CUO8CUO8CUO8AMBU80)
MV*L4>M[$>M[$>M[$>M[$>M[$#R[5E3^SOT\L>M[$>M[$>M[$>M[$>M[$.L6D
MM%>S7CCUO8CUO8CUO8CUO8CUO8A]FTJT]BM!Z$CUO8CUO8CUO8CUO8CUO8B9
M9M6E"]G>HY(];V(];V(];V(];V(];V(E_P!<MM*%2KBW/__:``@!`P(&/P#7
M#V.1XNLT@[Q$MR&-HSO$8VC.\1C:,[Q&-HSO$8VC.\1C:,[Q&-HSO$8VC.\1
MBU_<)MKS_P!H_LQM&=XC&T9WB,;1G>(QM&=XC&T9WB,3G_U\VW_5,"VBJ>6^
MB-HSO$8VC.\1C:,[Q&-HSO$8VC.\1B_DZPFJ+'K']J-HSO$8VC.\1C:,[Q&-
MHSO$8VC.\1C6I=?YI2ZN(ZQH-N73&T9WB,;1G>(QM&=XC&T9WB,;1G>(Q.#K
M_-(_I;R>T:Q=II!XB`1&T9WB,;1G>(QM&=XC&T9WB,;1G>(QJ]KK_-+3/E@]
M8_M"-HSO$8VC.\1C:,[Q&-HSO$8VC.\1C:,[Q&-8-;?YH:)\P#K']HQM&=XC
M&T9WB,;1G>(QM&=XC&T9WB,3&MO\T-\N5ZQQRF&-HSO$8VC.\1C:,[Q&-HSO
M$8VC.\1BY!M_FA;K)/:-98%,;1G>(QM&=XC&T9WB,;1G>(QM&=XC&K"+_-4R
M"3UC_G31S`1M&=XC&T9WB,;1G>(QM&=XC&T9WB,:G<+_`#;1ES%ZQI^U<(VC
M.\1C:,[Q&-HSO$8VC.\1C:,[Q&-<.O,]TQPGM`M%4ZNYKO\`"3ONW;HFW'55
MYG2B2`9<I[PH"D*UI"@%2*P(8R^W.;)>X*`]CF$A44!P"A00HQA(E&?(>P3&
M![;32+3"H#FJ`K204<*"AIHB?>Y-TFONLI+;VL<6,6JTX!&KB4A=W_O_`,$,
MD7>4Y\YQ0-:"YQ.\`%).2&7&=J^>R^NJENEO#RM2,(M'-#KBVX3C?17+L.MA
M`M+$M54U54P;LZ2\7@.LV$-JTJ6;-:K0B*M$/E36%LUI(((0@B@@@T@@T$&J
M)WXMGW<R&L8TEY*`"DDFH`8R8E7>^:NGRI\SLM?+>USEH%D.`)4[PAERFZOG
MMOCJI98X/*[S2+1J-0C^WLU?/-__`,L2W&94O82U53553#KM?;K,DWAJ*U[2
MQP6D*UP!"BD41K#]SWCN29E]U?/DRY@5A?+<P.[I<`'<2Q)E7BX3I<V9V`YC
MFERT=4$`NIHH6/Z>]W69*GT=5[7-=350X`TXJ(8R^769*>YH<`]KFDM*HX!P
M"M*%"*"AC6_X1WOR]R5?+QJ^?+N<SLS'2W-8Y:19<0&E1O&),Z\7*;+DS.PY
MS'-#L?5)`#J"M"Q=[M,U;>&WB;V&&6\.?W&D*[B!B6=8ZMO%W#UL^9+>RTB*
MEH!44*E2B)WX2]?[6=N?W'^WS_[>NE\MWEUIVTLUT5UT1+OLRYS6W-Y1LPL<
M&$TT!Q%DF@U'$=Z)$R=<9S)<WL%S'`/6JR2$<JBI:X9_77"=)M*GF,<Q414M
M`*BA4WQ&K?GR_?&Y,OTG5\]]R9VIC9;BQJ5J\"R$X3#K\VYS3<FE#,#'6`:`
MA>ED%2`BXQ$N^S+G-;<WE&S"QP8330'$62:#4<1WHDS[U<ITN3,"M<YCFM=0
MO5)`!H(-"T4[FLOGS/?,3;[=]7SYESEK:F-EN<QJ4FTX`M""DJ:(??F7.:;D
MTH9@8XL!H"%Z60:16<8AMX=)>+N7('(;)**@=4J4HJI$F\WBYS9=WF=ESF.:
MUV/JN(`-%-!.Y,^7*^Z9$V9<=7SYTN7VBR6YX;WBT$#CB?/N]RFS)$KMN:QS
MFLH7K$`AM`)I2@1,O+9#S=V$!SPTV02J`N1`2A132A2)4^9(>V2\D-<00UQ:
MEH-)"%+352I0M8W+C^$D^X(?+U?<9T^8T*1+8YY`WR&@D#AB;+NUQG3'R^T&
ML<XM[P`*<<39DN0]TN6%<0TD-"@*X@4!2`I2D@8X.L1J^?\`V\%/-\MWEUIV
MTLUT5UT;FJOD'[^=`N]QNDV=/(6S+:Y[DR-!/)$RY2M7SW7QO:EACB\)6K0+
M01<8B:QEWF.?+#BX!I):&@EQ<$H#0"7$U`$FJ)]YNMQG3+O*"O<QCG-8$57.
M`(:$II(HW-2_+F?>OAEWNLA\V\.*!K&ESCD:`2>(1_0/U?/%^_RS+<)F_P!A
M+55-4&XMN4TWU4\NPZVN]82TO`D2Y,B6Y\Y[@&M:"7.)H``%))-``I,%K@CA
M&NOGL]S<UW^$G?=NW=2M!>Z1+\XI26MM2)@)WFJ;(6A2@WHONL]8:G\Z^W?6
M`E`/,QH8US%<"`X)UCO`AY"[T:D9,N)>W_UT33;?,LRWM>]7M9UB^R"$D,LM
M)<.RI,?\B7;5UU,NY&YW-S0%(ZS@YR$EU"J:RF_1N_\`?_@B1<]3%PO\T%@+
M2A#7`AQ)%+196T=Y8D7?6<HLFMU->+O=W/<TS9LQDNF8@<X@S"YPEJ;1`(K6
M+Y<Y*G7'_KEV:6C2VFS[4QJ=JT)=DN;79%20+TR_787UL^[,#'VU+K#1-+;#
M'-,Q58`\M#2225`(UVP3&O']7-I"I2]QQ@&BHT5BA13$[\6S[N9%T9JRU_7N
M>!+L]JT:`F\::\5="+'Y"NFO@ESNIFL$V8]I,R;-ED]57$^7+>);6ER%2**1
M'Y;N5^5NOAJS6;;+RDT/?,/DBGK*YHF6-\'JT&-57BZ:FFWR]2=1R&3VL>]D
MZ42]Q)ZA$P/LV`4I#"5%DF+Q/NTR\.ES&L>D]Q?-87-!+'N<2XEA5M))0!8U
MA^Y[QB0Z[`_U(>VP@4VE%E!2I5$&./RE==>RW&YLUI)O$^=-<"`^8^B4U76D
M:PO=-5H%I4*!3J5FMG!L\Z]OKV6S3Y;I3@QP)]1TPR[)%!<**1'Y1D:PEM.O
M[O<M8.#)O;\WSED!P)M*1;+,:=9N(Q<)EV<_S;Q<I4Z:Q[BYTN=,M%[#:)<"
M*"6N)<%I,:W_``CO?E[DW^Z2WOE7J?+O$U\QP25+:0&L`)!$QY0D!MD-`;75
M?IU[F-_HIFO;@^47$672VRY=MS#46AE#B*`$!Q0R>R<Z7K<:YOCY1-+A*>RR
M7L5>J;0LN%"A05$7&XW^^S9\V[2@"Z8YSW>9,29,!+B3U"1+(H2Q5$[\)>O]
MK.W-;7R=+F3)%\D-:T/<&RY4B329A:2$<X`-E!K::7&L+K:\S'#^TS-4W-LH
MG1F8'!6MQ6P0XD"D(3OQ?YC)\MGFZZN3KNZ93+($EJO;2+3`VAQ::*`2*(NU
M]NET?=9D_6,XS93UM/>T61-9:I#$7L]6T\@DEH,:M^?+]\;E]UI=I,R;=WW=
MUWDL+@V6`XJ^8\$M%A@M$$*YS^`$QJZ\K_XEOY=GRW%>H+QYE+78A,+RT@'K
M&A%C7%ZKU9,U3<VR?V'36N[#,5L$.4#K"DI7&L'/E3I-]O\`?94UMWFM:V9*
M$N2UCWEH<XACK(#2X-+A4U*=S67SYGOF+YK6[RYLVY_T\R[R99<&RUF$VYCP
M7-'ERU<20KG/0"@%-13W.']KEZHO<N<0?LQ-)[+L5IQ+46DJ$Q1J"=>V3G7>
M7K%Z%P<6ME6)8:A-`8JAJ=55`IC\Y/>?_JS[U<S=2JM<!+ZQE8B`P$.LU4`U
MC<F?+E?=,AVM;A*FS+C=+=F6UP:)DU[4#2I:TM%!F$DD-"`$D"/RV9UD"[ZQ
MO_\`662K&$L=2]"18+00USJ"`@,?F&RV:ZZ-UA++*'%H:IM%N(-4]8BA:Z8_
M(,Z]-FES1>P7/M%`9K/+!)J!8T6!C8.K0-RX_A)/N"&S-7F=_;KK-;/F!A2V
MYJV98)+07/"M`<X-#2XG>-\;>Y;6:V_]CNLZ>QA!L2W(XVD)ZC"2'FEK2JF/
M^51<A,?JYT^U+#5+/J"26@*U?+#2XBFP`30!&N;[,DS)DF^782VVW`2Y4B4"
M73'-):A+>K*L@J5<<2QJKY!^_G0;GJF;-ERS9=-<PH0QAM"D$4KV0H!<BU*/
M^13>+F9.OKS+N3Y<EA#IHELFM:1U"3:L-8]P:300:B(_Y.9J\OF7)^K+P$8K
MF.FV);10U6EY/F!OK'K)CB8Z_MO4O5%YN\^4R>'?922BS2YI5C5L^N!2%"FD
M/:URM!(!WQOQJ7Y<S[U\2]7ZF>YEYG-+7.:HLRU!<212&A`J(O9QH==2=87<
MR[X=1OD74.<TSIHEE+9LN=UYAMD`%4H2@Q^7F7=S[3=6RVWE%[8NSZ)R8P[R
MP0^IX:.T!%SF3KU)EZU;>@SRIHF6[%DVK`#"WS"4;UW-L@.2D@B^RVS&O#9K
MQ::MER.(4*`4-84`I6!&NOGL]S<UW^$G?=NW29;RT\!(YH<TS7%I*D*4)WSO
MP#YSE`2LU;V2"TSGV2$K-6]N_P#?_@BTQY:[?!2`]TUQ>*B25'''F"8[S-]2
MN>N+8<;:JN-=]8))4F)WXMGW<R`YCB'#&*##2^:YQ%2DE,D"8Z8XOWU*YX+V
MS7!YK*E3QP22I,:P_<]XP'-*.$69DUSF\))YX!<\DBI2:(\PS'&9OJ5SP7/<
M2XXS3&M_PCO?E[EE\YY;O$DB&M<\EHJ!-62`7O)(WRL$DJ3$[\)>O]K.W+!G
M/L(B*4S0&%YL"H+1FAH<\D"JFK)O0/,F.<F^2>>-6_/E^^-RPV<\,WE*9H,L
M/-C>6C-`87FP*@M`XH+GN)=OFG<UE\^9[YBPV<\,WE*9H,L/-@XEHS1Y9FN\
MO>4IFJAK7/):*@M`R;DSY<K[ID663G-;O`D0X!Y`=72:<N_'EB:X2]Y2F:J`
MQTUQ8,1)3-N7'\))]P01+FN:.`D<T.<)CK1K*E3EWX+637!IQ`D"+!G/L(B*
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M=\,;1NN=WPQM&ZYW?#$R:_6%V(,B<R@NKF29DL'LU`N!/`L;1NN=WPQM&ZYW
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MD`!J4J!N3>Z>;]#QX1[PYCA/XL*9W?2,(]UWNG"9E&&_*<(Y!S#"9W1S84O)
MZ3A2LAY\*;EW)O=/-^AX\(]X<QA0TI"I1`4$13N/`%-$(:X4-*0"10=V8?\`
MI](W:!"XHI$'NN]TX3,HPWY3A'(.883.Z.;"EY/2<*5D//A3<NY-[IYHG=8@
M6#SB+N0]UE2N2C]1%EKRBKGJ.:+N`XH6-7/$V8PH"*1O%1R$+RB%';MM'%2L
M7FRB)OC]H0UM(+35O\,))F!K[5:+BCZQO@$?6-\`CZQO@$?6-\`AP%Z!.\&@
M&O?Q0EXF!SK0YCGAUG]L<Q6)I#5EH%X30I'3$L!RL#?2>6)4URV"$-2J..%]
M6E3C&]!LM``=+YNMRP]Q`M-<>-:H<X@H'@BG>!Y(:7`=EQR%5$,4!>#N@\=/
M1#S9!(*5I0@IIX:XF98D!U1>5X@$],2B6TEM.53PC$D->UO4%>+TF`AZ@#UX
MUL^A(DGUJ<RT>F#W7>Z<)F48;\IPCD',,)G='-A2\GI.%*R'GPIN7<F]T\T&
MRXA=XP&EQ+1B7<!,PJ.$P225-<4&"`:#`4K''A'O#F.$_B@-Q#!F=WTB",1P
M`L'NN]TX3,HPWY3A'(.883.Z.;"EY/2<*5D//A3<NY-[IYOT/'A'O#F.$_BP
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M0!;-(WM_CARFH0N)4@DU0"M)CCPN/!:HH6'+6D+DY8<$4B-D_P`UG1&R?YK.
MB-D_S6=$'_Q.+_-9T1LG^:SHC9/\UG1&R?YK.B-D_P`UG1&R?YK.B*-4XC_\
MK-[)&R?YK.B-D_S6=$;)_FLZ(V3_`#6=$;)_FLZ('_B?YK.B-D_S6=$/DS;B
MDL&M1U>.IW%3N`$40TE%5()%7-#M]8((Q<YBKK+!<*C`WP8!7>Y8H._R")5%
M!Z8<4HLDB`=ZN'*`I@%1Z8!7$.6&MQH><P!BAV_9],."U="P$,,%83I@\`6%
M7$#G*0J\W3!`%$&CU@(7>/3A.R[CLD&M4AM)40J0PTT""W-"8E6*133RP0*H
MX\+CP5%<&*\%V3".0\QPAEP%!IA5IBN'(8-,(M$5P::XKBN!35%!W`5IA<<!
M#B$*ZG>A0:8*&#3`*TP'+2GIA81:-RTM,$K3#1BPG9=QV3]#QX7'A'"=DPCD
M/,<(9<,Y?T@R#";D].$W"=EW'Y#';&>.V,\=L9X[8SQVQGCMC/';&>.V,\=L
M5[\=L9X[8SQVQGCMC/';&>#UQ7OQVQGCMC/';&>.V,\=L9X=UQGCMC/';&>.
MV,\=L9X[8SP[KBK?CMC/';&>.V,\=L9X[8SP>N*CCX#';&>.V,\=L9X[8SQV
MQGAO7%>_';&>.V,\=L9X[8SQVQGCMC/#NN*]^.V,\=L9X[8SQVQGCMC/';&>
M.V,\=L9X[8SQVQGCMC/`ZXJ&..V,\=L9X[8SQVQGCMC/#>N*M_A,=L9X[8SQ
MVQGCMC/';&>&=<9X[8SQVQGCMC/';&>.V,\/LD&G<F]T\WZ'CPCWAS'"?Q84
MSN^D81[KO=.$S*,-^4X1R#F&$SNCFPI>3TG"E9#SX4W+N3>Z>;]#QX1[PYCA
M/XMVG=F=WTC"/==[IPF91AORG".0<PPF=T<V%+R>DX4K(>?"FY=R;W3S1.I*
M6#5Q1=W-<ZPIS4>BJ++'G?XC_A%W`<4+&KGB<]I10A'"HY/\866TD8P`J\!A
ME%"/M9:4]"0UA!!&+$>'+''%XL+4*N\/1#+(5U@VN5%XDX^&);)9)!<:-ZKF
MIAA:#U2E50K&_P`,%KE#"2F\"$3TB+NY"$Z749DBPPDL[12FCI3EB5,:TG%5
MO5=$300;!(!Y>:B&V5"/-604YX5A5SZQS\O)#@T%6%*L1Z#SPXL5R$4&BC&:
M#BCJM6AZ'(>K$ZT!:!!RC&(FN-H-M-JXUXM^&DMH(>1P8QRT14+1`JWBA_7>
MJASB%(Q5%*::31O9M^)CK*L(_4^B&NHMJ,Q!/Z[U4/LM6RQI&4D+Z8F,+303
MFQ8Q$UP:?++7)P4&GT0%825:C=Y*\\26TDK2N\2*#RYX`9331$XN%%H\IZ("
M@DVBG=3T5C)$D"EP13OT]%$'RA*L<)<O((JDYW=$52<[NB*I.=W1%4G.[HBJ
M3G=T0Y1(53C=T15)SNZ(JDYW=$52<[NB*I.=W1%4G.[H@J)"H,;M[)%4G.[H
MBJ3G=T15)SNZ(JDYW=$52<[NB&J)'9&-W1%4G.[HBJ3G=T0P!K+*4HMFO&32
MN2`M>Y+R>DX4K(>?"FY=R;W3S10XB`"XIN`VBN6#37'5<1!"T128X\(]X<QP
MG\6[9H3ES[LSN^D8`&]N'NN]T[BBO`9E&&_*<(Y!S#"9W1S84O)Z3A2LAY\*
M;EW)O=/-^AX\(]X<QPG\6%,[OI&$>Z[W3A,RC#?E.$<@YAA,[HYL*7D])PI6
M0\^%-R[CP:D,:,1HQ&C$:,1HQ&C$:,1HQ&C%<:,1HQ&C$:,1HQ!'EA%C1B-&
M(T8C1B-&(=]F(T8C1B-&(T8C1B'?9BJ-&(T8C1B-&(T8@_9BH\QC1B-&(T8C
M1B-&(;]F*XT8C1B-&(T8C1B-&(=]F*XT8C1B-&(T8C1B-&/U$:,1HQ&C$:,1
MHQ`^S%0C1B-&(T8C1B-&(;]F*O28T8C1B-&(T8C1B&?9C]3&C$:,1HQ&C$:,
M0^RT"G<=D_0\>%QX1PG9,(Y#S'"&7#.7](,@PFY/3A-PG9=QV2'<`AJJIBFN
M&A32!#EWH7$J1PT\D6EQQQX7'A'"=DP:!"D4(>:*1%`BJ*6G<;EBG!"`TPZC
M=HP!1%6ZB0`E*#";D].$W"=EW'9(<HK$-%*B%AA0T""W%"8E6#OF+*8XX\+C
MPCA.R8+24LI"'>)YX!--`JWT@%I2$)Q?J(`3$*>*J"E28X-E.UR0:J6\J]$.
M1$CK(O\`CT0:E0\X2&JB1)I%%>>'C$`>>'5)_ATP%2`:`(IWCS0*NSRKT0B0
MRG$?31#E-%G]>7<IAQ!WH:%%0YH>)4P-F$4%%`XL<;1;_ICIC:+?],=,;1;_
M`*8Z8VBW_3'3`_\`(M_TQTQM%O\`ICIC:+?],=,2PR^AQM"IH:E=*@U<&.&M
MGS`Z:*R`FXW"=EW'9/T/'A<>$<)V3".0\QPAEA3A'+^D&083<GIPFX3LNX\F
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MGFW$L%<D`62L=@YH`+2L(0A@BR:MSCPCWAS'"?Q84SN^D81[KO=.$S*,-^4X
M1R#F&$SNCFPI>3TG"E9#SX4W+N3>Z>:`E<30&.M>6?=3>W^&N&O)Z[:.B+P:
M2C6\A'HB6)JA10[A4\AY*XF`=JT>>'-F--KRW`+6<?\`@(`;O#B*4B./"/>'
M,<)_%A3.[Z1A-=OAP/`C8F2D%JA#PH:.-.6)(``<7$$G@3I@$(221OBB!U`'
M$B@U&@4+BW^.N&%S6ARNH(K1*/1`*D(>*BF'!U98#D5P]'1"%Q[3QX0O+#7`
ME".7&(<ZT:`3F('I@2P>M;(7@0'TPQUI6V@,]=8X(G3"2H>F=>B)?6(5>1H=
MZ8!M'LM.<I"!P'6(IHJQPMJJ7:]I/U,&64+::\BQ-('6#&KEM"KBB<U3U5Y`
ML"FA"<P7B/!7E@(06>C'#0B$S$Y(<7N1H(&=:>2&"S_\2XJPO!^N]#W$J`&U
M4=H+5^O+#7`TEP%/"L/:TFV/0:?UQ1,<*FCT@>E8=UZ!9WO6"[^++$M'XN#?
M.\XPU418LD!"]PR`(D$?]`<O"H"0\@#JO3**?UXX<W$#$DRI)>ZFA0,9WX(F
MW8L"5J#S19EW4O:E=H#G@.F2K#MY5Y1"?T)3O"'/9+M/2JJ)HG78M9^TJ+Q5
M\=6Y-[IYOT/'A'O#F.$_BPIG=](PB`:++O=,'K&N`TGJB*#1%#C6L!I=U1#`
MUQ`40%)LC$J?J%@N#B"231OFN`%H@]<TPI>558+K94^B)C;1LET`VRHZ$YH:
MKB6A*.`4I#G8B24RPEHHB<6]!?:-K?AR&L!<P@DO--?-`<'&T,<%S7D..-8/
M6-,&RXC)#$<>R(+K95$XHLVBD$N)+T15Q0=XP0YQ(/HJB7D])A17!ZQIKBRM
M$"T5`@DUF)60\^%-R[DWNGF_0\>$>\.8X3^+"F=WTC"/==[IPF91AORG".0<
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MJ)BKC%[48O:C%[48O:C%[4._IT1::_3N?__:``@!`0$&/P#-KYFNJU>,\1Y)
M=-'*!Q36;N6]-F5D%T5"B!B*I*D`Q1#L@(;=>DJY>77W2Z])5R\NONEUZ2KE
MY=?=+KTE7+RZ^Z77I*N7EU]TNO25<O+K[I=>DJY>77W2Z])5R\NONEUUG_>-
M;^L??[F.>[^/><YG[N\YS6]SNW<W^SL_AUZ2KEY=?=+KTE7+RZ^Z77I*N7EU
M]TNO25<O+K[I=>DJY>77W2ZF'PY#MPO"9=K;0KGOV]YXK92FVM8Z`'YW>!(Z
MJ13"'M")0UZ2KEY=?=+KTE7+RZ^Z77I*N7EU]TNO25<O+K[I=>DJY>77W2ZR
M(N?(UO,LW^Z7,*&G'HG2YV87(IN&YW:7?*&P?X0UZ2KEY=?=+KTE7+RZ^Z77
MI*N7EU]TNO25<O+K[I=>DJY>77W2ZR\9QD.W+&:8BFG;85)MZ84')+13TR+I
M"*ON%2IJF`!#L[##KTE7+RZ^Z77I*N7EU]TNO25<O+K[I=>DJY>77W2Z])5R
M\NONEU-(N\AVUPD3$7$"[(FM-O3D*Y88&R2^9+@!E1`%6KQNFJ0?;*<@"'9#
M7I*N7EU]TNO25<O+K[I=>DJY>77W2Z])5R\NONEUZ2KEY=?=+K&S9QD:WK-W
M%^IR"Z*DV],FJBK88Y-5)0HJ[#$4(80$!]L!UZ2KEY=?=+KTE7+RZ^Z77I*N
M7EU]TNO25<O+K[I=>DJY>77W2Z])5R\NONEUDELWR-;T6[>_7%!!%.;>E321
M2L,BFDDF4%=A2)D*```>T`:])5R\NONEUZ2KEY=?=+KTE7+RZ^Z77I*N7EU]
MTNO25<O+K[I=2C9ID.W-D"P%".5%&;>D3`Z^/ZNNL8"E5``,JLH8QOX3"(Z]
M)5R\NONEUZ2KEY=?=+KTE7+RZ^Z77I*N7EU]TNO25<O+K[I=4,K;(=N0*OB+
M&3M8$IMZ0%7+FKLU%US@"ONE5E!$3#[8CKTE7+RZ^Z77I*N7EU]TNO25<O+K
M[I=>DJY>77W2Z])5R\NONEUBE1+(UO3.ZH,BNX,6;>@998N4<DMBJJ""ONC@
MW;IDVC_V2`'[VO25<O+K[I=>DJY>77W2Z])5R\NONEUZ2KEY=?=+KTE7+RZ^
MZ76$7*.0[<FN]@+L=VL2;>E4<'1R!.H)&5,"NTYDT2`4-OM%#9KTE7+RZ^Z7
M7I*N7EU]TNO25<O+K[I=>DJY>77W2Z])5R\NONEUFUS:K#+6!PSOU?0:+2SU
M9ZHW14KQU#I(F6,82$,?LB`>V/L9V_4WD_\`,F<]E&7Q_B'*%YB7#QW'(2=.
MH%KLT>O(,$$G+Y@B]A8EZV4>,FRY%%DBF$Z9#E,8``0'3%E?*5;:2\DVAI"-
M:6ZN3%;<R#`KE9F9ZQ0F6;)5VT*[;*)"JF!B`HF8NW>*(!#GL$!-01+#"M+)
M`'F8M]&%G*Z_6<MV,_#F>H(!)PKU=DL1)TAOH*'2.!3")3`%@N,)3+7,5&IB
MU"U6J*KLO(5RM"^4(BR"P3C1FM&0PO%E2D2ZRJGSAC`!=HB'L_\`N)_Z:TP@
M:[$2D_.2K@C.+AH6/=RLM).U-O-M6$<Q27>/'"FSW)$R&,/[P::8_F\:W^'O
ML@"0L*1*TZQ1]N>@N50Z`M*V[CD9ER"Q$3B3<1-O`41#VATO06V.KTXO35)5
M9S2D*C8%;:W10;`\657KB<>:8221:&!4QC(@!4QWA]SV=*59Q!S"%F1DS0JM
M=6C'J4ZE,E<]3-$J1!T"R!),KL.:%`4P5!3W.[O=C3^(EV#V*EHIZZC9.,DF
MJ[&0CI!BN=L]8/V3DB3EF]9N4C)JI*%*=,Y1*8`$!#4U^N6L?F1;M-F+%LX>
MOGKA%HS9M$5'+IVZ<J%1;MFS=$IUEW"ZQP(0A`$QC"```B.HBN73&E_J%AL'
M,]X8&T4VQ0$S-]863;M^]$7*QK1])<^NJ4A.9(?>.8`#:(@&F%$EL<7R+N\J
M5(\939&H6%E:I$BX*B@=A7G,<E+O"K`@<2"FB8#;AMGM#H,<,<<7Q[D,14`*
M&TJ%A<7,129FD%0"KHQQYP128%%<W\Q[E$!./N>SIU5[W5+)2K*Q(W4>UVVP
M4I7)QFF[0(Y:G=1,PU9OVY'+94JB8G3`#D,!@V@(#K)7_D[ZZ7T```B(B```
M!M$1'L```'9$1'4)(WG&]]ID?9DBK5M_:Z?8:ZSL")DTU2JPCJ7CF:$LD9)8
MA@,@90!*8!]H0U"0]FQ]>*[+68$AKD7.U.>B)&P`NJF@B,(RD&#=S*@LNL0A
M>8*IO'.`!V1#05VYU&SU&P"F@J$%9X"5@)D4G7^JJA%RK1H]%-S_`/C-N;#_
M`+VW3!A=*G9:@^E(IK.QC*T04I`.Y&$>JN$64RP;RS5HL[BG:S14B3A,#(J&
M2.!3")1V9F_4U.?G72_8B+O9,<7ROTNP&1)`6^;J%AB:O.&<HJ.&Y8B??QS>
M)DC+H(G.0$53B8A1$-H`(ZA)NRT:X5Z%LQ$U:W+SE9FHF+L":J"3I)2$?OV3
M=I*D5;+D4**!U`,F<I@[`@.J[5I'%^1(^S6\R9:E77M*LK6=M!E3E32+78A>
M,3D)LRASE*4&R:NT1``]O4:MD[%F1L<HS1W24.K?*19J@G+*,2H&>IQI[!&1
MY7YV9720J@D)Q3!0N]LW@VSGZFN(S_X]Y/\`8+DPV-[Z7&YU.9)D`U/L(4@R
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M;L%F[<6KJR)LC0S=R#AVDGN'6`V^J0NS:8`&.O4G1[?'4F87(UB;B^K4TTJT
MHY4ZSN-XZPN&2<2]7/U-;81)8QAYH_8]R;9#3UKHMRK$'8TDUJ],V&L3<+%3
MR*K5%\DK#2,DQ;,Y1)1DX36*9`YP%)0IP]R8!'63_P!8=U_.22U+WFMXVOU@
MI5?ZQW^N$'3K#+5:$ZH@1R[[[V!A'.(F-ZJV4*HISRQ-PA@,.P!VZ>WUE1[>
M[HT:OU61NC6M33BIL'//-V_5WMC29'AVJ_/NTB;BBQ3;ZI`V;3``M[(O!3"-
M==OCQ;6?5C'J<*YDDVX.SQS>5.@5BL^(U,"@HE4%0$QWMFSLZAK/9*/;Z_6[
M&!35ZPS=:FHJ#GBF1!R48:6?LD&$H!FX\X',**;2>Z]KL^Q*_P"SV/?^'54U
M,2="QQ?+O&UY,%I^0J-0L-E90:(I'6!68=PT<]0C$Q12,?>7,0-THC[0#J=G
MZU1KC88*KIG5LTU!UF:EHFNI)H+.E%)V28,G#.(3(U;J*"+@Z8`FF8P]@HB$
MC:&M>G'-9B'#%I+6)O$OUH*,=R9UTXUM(RZ;<T>R<2"C54J!%%"F5,F8"@(E
M'9%3TE`S4?!SRT@V@YE]%OFD5,N(E./5E6\5(KH)LY%:,2EFIG!$3G,B5RD)
MP`%";=8^_4UBO\U&6GD9CB@W7($E'M.OOX^DU:=M;YBQ`X)B\>-()@_7;-.<
M'=YPY2DV]C;J9856@W6ROJZ116P,J_5IV9=P2:*ATEE)EM','*T81)5,Q3"N
M4@%,40'LAJ9D8R`FY&/KK07]@?,(I\[9P3$';./%[,NFZ"B$8T!_(-T.<7,0
MG/+IDV[QR@)\E%QQ?#8Y35YA2_EJ%A&E$6%R5ES)[4$=WB*KUPX);HK[>=$"
M_P`H=GL8B_5Y)_\`%C)^DZ[0:?:;Q8%457"4%3Z_+669501`!663C(5H]>G1
M1`0WC`00+M[(ZD*+%8YO<G=XD%C2E.CZA8'MJC2M^:!P,A7FT>K+LP0%<F_S
MB)=W?+MV;0U+L8^L6%\]K[25D)]FSA9)RZ@V$$U<O9M[+MT6QUHUI#LV:RSI
M18"$;I)'.H)2E,(6"S5+']VM-;J2!W5JL%<JD[-P=9:IMU':CFP2T8P=,(9!
M-JD=4QW*B903*)A'8`C[&!_]GKU_Q%L&F%;J-?F[38I544(N`KD4_G)J27*F
M=4R+"*C&[I\\5!),QA*FF8=THC[0:+CMYCB^-,@&'86BN:A84+B811,XV%K"
ML<2;$>KD,I_W'\@!-[0;='H+>BW%>]I.P8*4I&L3:MM3?"4I@9'KA&)I@CL2
MG`>;%'?V"'8[.HV"@8N1FYN8?-8R(AXADYDI65DGRQ&S*/C8]FDL[?/GCA0J
M:221#**',!2@(B`:5;N$E$%T%#HKH+$,DLBLD82*)*IG`ITU$SE$#%$`$!#8
M.L[?K#KGYMJ>QG;]3>3_`,R9SV<$M$SS<C`5<N5Y11L0S]W#UTLQB2Z1SF1.
MB`J,H@LI(&:('6$$P76%$@B8VX&KWE?)&%1N]YQWQ(L,<QK:WN[O#(5JOR]8
M;O9Z-D(V.DXU-FFG.N#@(&32.G(+I"<1,`)FP0PDJ"M,MR^K+B\DN#6NR78\
M13;)"6:Q]?L436U#3,A8RU]H_1!O3HXT>T<.'R9@,U`YUA]9G6<95-U7J*XP
MGPM6"'9-RRCR-!65DV4Y.J1SQ\[E5%&B;HZZIR@Z7*@4#!O[I=OL_P#N)_Z:
MU`TG!JLJWR%<$)2MLG,.X58N&T3*QSAO85W,HW3.XB8M.%%<7;@FZ8C;?#:.
M]NC`US*L,XAI2(X'LS8.P7,66<B'.0,DV^I4LJ;J\&;LYR6<1J]S>34BC"D4
M6!ZLDF<A@YX#@%TI,(#Q;-@>K$P/7Y&OMSJDOJD_"96/-W>O*Q^^2=5GFM'.
MQ5>,1(+H6*?NDQ(&S06]E?\`&;6]QE]P958ZK6@+8J]?RJ=5A&F1WU>^[=;G
M8)_>SRB1XQ-.7<L46CA198Y^>*F9+/31&2CY=,F8,BJ@^C!>"S4,YMDJY.B0
M7[-@ZYUFHL**NU("\ZF;<$Y-TYIK]<M8_,BW:IS+%@2@Y%D9UG&4X80NV6+.
M21Q8,U(\X$.+9TF9P)BKANF;B'.@8@D`P>KMI_$*AS%*Q*]R15(S(=ZL<4Z>
MWG)60*-)R*IX(CB8?2'W-IEDCX1@P</"-E@<JICN!SJ92\+E#OP.8_B%0X5O
M6"PB<395C-[ZWL=ENDB;&K%3OBL673?S$,RFN]&T=KA%;>;B8B@".'K+3<'V
MO-=MHW`'B"L9@AJI:K74<GT%XYM,TZDWB*U1=M;RRM:446,;.2IE%RWCE5`6
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MZMD-4Y;*6_#DT7N'&4NV?.4IHSIXU1E',0&\551`P+M#"`D/K'LG5EYQ.6R5
M@S'&5LDUZR3\E89RF9-O19B3M%6DUIQW(6".>-2@W<*,Y!=9VB9T(G,(&+K,
MWZFIS\ZZ7[$J?+D9,34/EB^TG-&1[/>)IFE'T"GUYU'M(&I1T9(2;:1;7JU2
M0MUEFS=B+1"/1(AM!0P\W?9JYR$:E0[-ZP#@RM>/GTH\;&K\Q2XNE4U2S3U8
M<KK"P>0,?6$CI/'#8QD$4S$(J8H&*&F$^PF9"K9I9\<G$_9\>RCWFUK"TQM9
MZWWC=V*NFD`<'"!DN_3?J;Q`!0ZP0#I&!5':7'V/\AWRVY`EL6T]LA*3%TGY
MVQ3:=PO!&EOM\:Y>V&0?R":U:7>MH,Z1@1YLT1L$F]M,:<_4UQ&?_'O)_L9B
MO,S'66Q5[-]#A*]#H62<91=,QMB3&0*/WMPDHJ2DV!T):PM6"4=7D&+1050.
MJY6$W/)[^9+-)+(!AJS<'O"]`XY>KKD/4)&XQ<ZW!U#U\QE319[)&+M'IUVR
M/_BD2IK',4"@<=9&D&,_6(8MQXZ.%*PX.GK>H5[2WS%IBVO$=V*%`CYJC*5U
MA$@"+M5DN4B93IIG.3>)JJWJGT^;Q#(W[B8RM)Y!QQ;"O!EK3:H=BI#M\CUK
MOL<73:H]435*=-H4&H/Y,Z)U%C-DSZQA^L.E?G)&^Q>\N52%L%MK<]CF<PKB
MZJRDVSAZ2R82[XZ]GO=F82<E#,RU*KM5GBB2[<%W3N2/L'8F0Y]8TLP+$'#T
M=ZLO+-(L+TBY3U%CF92X(D>04ONJFC65SD+*^:K)(K@1VY$Z9TP-L#9FJUBF
M1YBJP\''#%"XJWU06JDY?HB:1$:[6]AU(Y:SLWS-X*S5`!=I`58YB;`..LC.
M7T7<:1>^(7.U`R)#X7R'$PT/=*`WI6-8RHV2TK1+2>E9..K4^I#I-H]=XA'N
M729@$C7F@,J;63_UAW7\Y)+5VS#6HVV6BE#C6ZX2Q33'4VTAJ4HO<73E:R7J
MQM964B(X:)2%'+URX72*N\>2?-I$'<14$O#[.KN&XXFK'!KQ,4_)<B@Z(I3F
M60W,H=+O585"*][$9V8DG#06I'.ZLZ.='F@,82AKASFKBRN<E7*YQ*VOF)*>
M;3CR+A:`K6::P@R,WC\BC6.JBS[K"#("&(T,OOD2]WO!KC>?O5@/4K]ESA:D
M^'QRLN"\'-LV%!+WY?4)455&+E"/KC=5%X9D)N9(<A%=T#DVZE?]GL>_\.JI
MIUF#'43<+10,-A:#U^B0TJWA8Z\Y&M<-WO:Q+@L@]B(I_#(*@V7F7"RRBK=F
MB5-$AE#E*'#`>9-'))8TXF.,8W%0%>>IKU:NR;ZK3PHO[<9JZ6:HUMW#,U4&
M#QX/5E$4A(10=NP>),4&MJDJ;&\1=+DZF04)=Y7XRO)KR:TZ]@RB52.91:,@
MX*9ZHANI%7.`JCOCKU<TU;&EM=N&#/B58OI:Q(3#A9E'O\B5S[ALW;^2(<[=
MF]J46GWH3.<"*1S<O5P%%,-FL??J:Q7^:C+364QL>YCC3$=J@\LWJ,JCHD8M
M:IJOHN$H*GQ[IPYBXV1L-D;*+LTD'KQ)HV9+N5S]C:16Z-;A&Q<'F0GK..'+
M)^7:O4)-O(!5J),#'3;\\H>->.S?=FJN9-9&35.<[5FX(J"QPW3"'K?TJ,E8
M9[&DA?U)VE,X%*3DZFLH?-4M)R,G!-6`+Q!WI:8R8K.ED`%0(Y%$Z@\R0@AF
M^^2<)9[/!9IQ>QID`C8I5C'4['6'\?LWSV>NDM$2<E%*(O).$,+.MA'MUS**
M&6<+@(&3!36(OU>2?_%C)^C4C#LQ:Z_%JFA;!DF9JKI9@NSK-9E"RK8#O$5V
M9E'RSY/=8-CKI).'O-[X@4@G)ZS52R4E:F<1&3:[PJVBB8RKDFSF\A1E)J^1
MX>*D&1$JP_DG"L\:L0D/)2*+)1;:18BO8(8H:];`RQN::L5&GN%'.#--C5!?
MRM8F\C#6*5$QZ:+6)%Q%R5L=/CS"3("E.[4!1T5+:!E0&0<Y$;Y7K>&<GXUS
M!CJIY7BI@RV/L6.P9+2-^DI^%D4Y.L1)7(0I0,>22;%%PD50@*'`JB;YLT<`
M[:MWCI!LZ#9L<MTESIHN`W1$NQ9,H&[`[.SK`_\`L]>O^(M@U&XVPC(2T1:;
MPP=0$O+Q2SAIWJIZR[-U89"3D&@`[80[=%H07!DCD.N78W`3<]S9\[062*T]
MK5X<\`=HQ-P]LYR8B'>4K\QID@LW^]TD6*FI4QK9>7"LLN1-%7GSH$%,2"9,
MYC<-3.M.9\74=PMTR$SVE'*20`6Q1^!+*H=CDDC<VP7<?,GA$SIR8;R,FFW*
M(`X*F`4J2G;73*OE]AE9O4T\>Y"C;FA:4ZTE".UIY:IQS.HR<(C<G\FH1D4\
ML\8@Q;H.=TO/*HJHWJ-0DH^90C[C9V2,Q$B\&+E4FDV^03DHT9%G'2`Q[XB8
M*H\^W06YLX;Z9#;2AG;]8=<_-M3V,[?J;R?^9,Y[)UHR0?1RJA.;458NUVBA
MT]X#<V<[=1,QB;Q0'8([-H:<M%I:35:O5A<O&RK]THW=N!.105W*)E1376%1
M(IMXP";>*`[=H!I,YIN7,=%NHT1,:2>"9)JJ!`5;)F%81(W4!,N\0-A1W0VA
MV`TJW4G)A1!=`C99`\F],BLV3*8A&ZJ9EA(H@0IQ`""`E`!'L>S_`.XG_IK0
M.8]XZ8.2E,0KAFX6:K@4X;#E!5`Y%`*8/;#;L'2#UU+2;EZU``;.W#]TLZ;@
M4PG*"#A14RJ0`<PB&Z(=D=NADR2+\LD8QC&D"O'!7QC&+N&,+L%`7$QB=@1W
MNR'8T#Y-TX3>E6ZP5X190KHK@3;XK@X*8%06WQV[VW>V]G;I1990ZJJIS**J
MJ&,=110YA,=10YA$QSG,(B(B(B(CJ:_7+6/S(MVDW3-PNT<HB)DG#991!=(P
M@)1,FLD8BA!$IA#:`AV!TW/(RTF_.T,8[4[U^Z=&;&.*8G,W,NJH*)C"D41$
MNP1$H?P!HD@O(OUI!/<%-\J\<*/$Q3_[L2.3J"L7F_WMANQ^]I=^A+R:+YR&
MQR]2?NTW;@.QV%W)%065#W(?RA'VM*++*'565.=5554YE%%5%#"8ZBAS")CG
M.81$1$1$1'62O_)WUTOI)=!51%=%0BJ*R1S)JI*IF`Z:J2A!`Z:B9P`2F`0$
M!#:&BMY.9E9%`B@+$0?2+MVB58I3D*J5-PLH0JA2*&`#`&T`,(?OCI!9W(/7
M2K8I"-E7+I==1N1,0%,B!U5#&2*00V@!1``_>T616D7RL@02&(^5=N%'A!3`
M"IB5T905RBF`;"[#=@/:THY=N%W3E8V\JX<JJ+KJFV`&\HJJ8RAS;``-HB.L
MS?J:G/SKI?L&:OYR8>M3B43MG<F]<MS"0P&()D5ESIF$A@`0VAV!#3=NZ>NW
M*#,G-M$%W*RR+5/8`<VW24.8B!-@!V"@`=C21G[UV],BF"*)G;E9R9)$O\E)
M(5CG%-,O[Q0V`&E%EU5%EE3&.JJJ<RBBAS#M,=10XB8YC#[8B.T=3GZFN(S_
M`./>3_8%@K.3"C`4BH"R4DWIV@H$``*B+8RXH\T4"@`%W=@;-),%7KM1B@<5
M4&2CE8[1%00,`J)-C'%%,X@<=H@4![(_PZ:HKOGBZ3$H$9)+.5U$V9`V;"M2
M'.8K<H;H=@@`'8TD:2D7T@9$HD1,^=N'8I$'9M(D*ZB@IE'=#L!L#L:QA^L.
ME?G)&^P5DWG9E!F5,R16B,H^2:E2,`@9(J!%RI`F8##M+LV#MT>.*]=ECU5`
M658E<K`S45+NB54[8#@B=0!(&PPEV]@-(,COGAF393GFS0SI<S5NM[K^=0;B
M<4DE/=#[HH`/9'1W+URX>.5-G..'2RCA<^Z`%+OJJF.H;=*&P-H]@/8R?^L.
MZ_G)):!BVG)ANR*0Z96:$F]2:E34$PJ$!NFN5("'$X[0V;!VCMTI'D>NR,%C
ME568E<K%9JJ%$IBJ*-@.")SE$H"`B41`0#01BLQ**1H$33"/4D'9V()HF*=%
M,&AEA;@1(Y"B4-W840`0]K3=JY>NW#5H`E:-EW*RJ#4H^V5NBH<R:(#_``%`
M/8E?]GL>_P##JJ:ZM'3<NP;@8QP;LI)XU1`YOY1^:063)O&V=D=FT=.TD9!Z
MDE(`(/TTG:Z9'H&WA$'9"J`5R`B<=N_O>V/\.C1B,M)I1QRJ$/'I/W2;(Y%A
M$52F:E5!`Q51,(F`2[#;>SI-B\EI-VR1YOF6;E^Z7:I<R04TN;;JJF1)S1!W
M2[`#=#L![&/OU-8K_-1EHZ49+RD<DH?G%$V$@[:)J*;H%WSD;JIE,?=``VB&
MW8&G3I*3D$W+T%"O7";UR1=V541%4KI8J@*.`4$?=`<1V_OZ59L):39-%C'.
MLU:/W39NJ=0A4E#*H(JD34,HF0"F$0$1*``/8#0L#SLR=B*/5A9FE'QF@MP+
MN`@+<5Q1%'<#9N[-W9V-GL8B_5Y)_P#%C)^E#1<E(1IE@*58S!XX9F5*01$A
M5!;J)B<"B8=@#MV;='E`EI()-0H$4D0?N@?'("940*=V"O6#%!(@%V";9N@`
M>T&EN]TO)Q_6#`=QU)^Z:\^<N]NG6YA5/G3%WQV";:(;1_ATJP3E)%-BN)Q6
M9$?.2M%A5V\X*K8JH(J"IM]UM`=O[_L8'_V>O7_$6P:,XC7[R/7,F*1EV+I=
MHL9(QBG,D95N=,XIF,0HB7;L$0#^#2,BXEI->0;%`C=\L_=*O$"%,<Q2(NCJ
MF72*4RIA`"F``$P_PCI=ZUEI-L\<@(.7;=^Z1=.`,8#F!=PFJ554!.4!'>$>
MR&W7?(KYX$CSHK]?!RL#WGS;1,MUH#\_SIA$=IM[:.A,81,8PB)C"(B(B([1
M$1'LB(CK.WZPZY^;:GL9)I<>X;-']OH-QJ[)T],8C-L[GZ[(Q39P[.0ISE;(
MK.RF4$`$0(`[`UZ5<.^5)G[-UZ5<.^5)G[-UZ5<.^5)G[-UZ5<.^5)G[-UZ5
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MWC%MQI<>X.!XXH=6:/[`FJL/M@B0P@`CL#7I5P[Y4F?LW7I5P[Y4F?LW7I5P
M[Y4F?LW7I5P[Y4F?LW7I5P[Y4F?LW5.L;O*&)%VL!:J]-N4&\E+F<+-XJ7:/
MEDD"FCBE%91-`0*`B`;PAKTJX=\J3/V;KTJX=\J3/V;KTJX=\J3/V;KTJX=\
MJ3/V;KTJX=\J3/V;KTJX=\J3/V;JXV-IE#$B#6?M5AFVR#B2ERN$6\K+NWR*
M2Y2QQB@LFFN`&`!$-X!UZ5<.^5)G[-UZ5<.^5)G[-UZ5<.^5)G[-UZ5<.^5)
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ME+`@Y4E[7*3:!V@A'"8Q$F[TI#[0#W8#^]KTJX=\J3/V;KTJX=\J3/V;KTJX
M=\J3/V;KTJX=\J3/V;KTJX=\J3/V;K)-<NMEJEE=6^U1,VR7JCEVY;MF[&(,
MQ42=F=MVYBK'4':4``0W?8L?B*7^KW'[C_:G]4Y3CQ\S^KWW*EOZ!W0;E3_B
M%QW;'\IQXBM/YLR_*A_&D?W6CRYCQI(=UK<I;XK%_53+E1?B&&[B3Y4'XK6^
MNICE5OXK)?6KKE6+QHU[D]BQ^(I?ZO<?N/\`:G]4Y3CQ\S^KWVBU"PY1QU`V
MTZK%`E7F;M6HNQ'7DP2-&HEA'TFA)&5D"KD%`H);50.7=V[0TWK(S\*%C=QR
MDPUKXRC$)MS$)*E15E&\4*_7UHY-8X$,N5,4@,(`)MHZG8VI7.IVF1J[I-C9
MH^N6*'FWM=>JJO6Z3.=:QCQTO$.E%XYP0J;@J9Q.@H`!M(8`*^BG[*39'5<H
M$>1[I!XU.LS<K,GB)7#911(RK1XW424*`[4U2&*;88H@&K/8+),1=?@8=HVD
M)>;FY!I$Q$6P;JG4</9&2?K-V3%H@0!,=14Y2%#LB(:92L4]:2<7)M&TA&R4
M>Y1>,)!@\1(Y9O63QL=1N[:.VZA5$U$S&(H0P&*(@(#I.E3.2\?Q%R54:))5
M*3N5<86915^F19BDG`NY)*5.H]15*=(H)"*A3`)=H"&K%`P5GKTU.5!TS8VR
M&B9J-DI6KO9%J#Z/9V*.9N5GD*Z?,AYY%-R1(ZJ7NR@)>S[,]&==:=\AJ[IZ
M$?UA'KPLR248@=V#3?Y\6I5E2D%3=W`,8`V[1#3%FZ>M&SN3560C6J[E%%S(
M+MVRKUPBQ04.55VJ@S;J*G*F!A*D0QAV%`1#4>K9+!"5]*6E&4'%*3<JPB4Y
M.;DCBE'0\>=^NW*\E'Z@"5%NF)EE3!L*41TPA74K&MIB52=+1<2N^:HR4DBP
M(51\JP8**E=/$F9#@94R9#`F`@)MFW0NXQ^SDFH.'C07+!T@\;@[CW:S!^U%
M9N=1,'#%\V416)MWDE4S$,`&*(`X\16G\V9?E0_C2/[K1Y<QXTD.ZUN4M\5B
M_JIERHOQ##=Q)\J#\5K?74QRJW\5DOK5URK%XT:]R>Q8_$4O]7N-<"4FZQUC
MR]6@W'+BRI,4;XT8H,Y"N3E)RA)S-2DK`>KVV19U>9D8%BY=MB,G2"[ADW.=
M$QDDS$]9[6KI@K`<3DYO4N%RY8\68QD;>(.O90L-?RM<5;0M-RV/*7)+%OUT
MB&:UM0Z@4LZW!1)Z=T50VF>5<JX*IH/FU9H6.[/!3-8A@L]?N^*[U#W6]XMF
MYE)GUJ0KU(R/5R03QB556-?(MWK?8HU<*E4]9G;IG$=%:V;!?&MQX(8IL,%7
MX>`E:1&5K%A8>GP$(^BF;59G6J0M8E9&#C2B#*)F$&SYJDDY;I*%X*^'/B*J
M47D;(>/<\W&Z8%SK9ZS'V*0R3@R`X:<^2[4\Q9WL88T=E/&>3HNM.)E`AB%<
MOFL--H?S_P#JJ-:F57$9A:'X">+C*]:E4';AF5/B7I%GPRTHDFV52V%3M50J
M$W)NX90H]8147<JHAO$$Q?5!_P"\=/*E?L2N1)V+OU>;8_RPG7;);YKU>6?7
MMIE'LBWJOW:N:$;>G:16QD%W01C=J[?*\TASRJ-]RO)N*AEF$SQ1[`YC\BLH
M$T/=\1)4F4KL9'8SD7S2>?P=BI4HP4*1DN1HV?I/HU<%S*`K[A&%X;<S0&"L
MAENT:^6NMDQW&9.CU:XA%2*<E!EK<LZ:-2.7[I=LH5SO[Z0("4`]V.OVE&)/
M^3FD?;NOVE&)/^3FD?;NOVE&)/\`DYI'V[K]I1B3_DYI'V[J]0U?X^*;?)M\
MTB21=5I.!*QAVTR3U.PQ"Z"D/DZ*L2$E3'$8=+K9GB!@5*F@8I0$3;!3KG%[
MG&NYPOZ=@C19R\'731R\,Q",D1/&R]E5%JYN;X#G#:\59-3ALW1%0-AQQ*XR
M&SK+R.:\#W$31+.K+5%2>:J7BZYKX1Y?']3?JDAGZ+VRV*J0DNI&-!$[A9J@
MX!,N[O@/!+1KWD9]BKB10RQQ,6'!5M>1LNXL6/*',)9-#AZHV0DD5S.)JFA"
MOH.!F8)X[10?H"+8`27(D=+BML60L=PN#LVYHXJ(.C5JK2(N8V%LEU;\.7#3
MCYS9(.UP]>DG#^@O;*TDYJ/DU&ACF:+"91(KLZJ.N+7A,QJUQ4QS/0\F/LL8
M4I-HLV1)K$,5CK*B-0L<_!OKVPQY`S"[FOWN4GUW+9G'"JV-*L=XO-*BIH(-
MZJG`97A8OA@<8OI=%D)YSAO+"UEL+!CQ6JO'4O!HN9"+IC95[U(7P(/HV-:-
M'@$35=J$&8JMPR1=KNRS!PK>N;J=_A9NK/!:/93&.:W4;P7+(1$95XR/A++;
ML-2TBI''012//,$B'`IP02W<#42.N&8I;%_$UP[85L<'--+9+1S/"4[AV&KK
MG*%:AP*@@^J['(-:?M$VQ=T3D?).$=I"G+N8QQE5)+',/,V[@2XI,27RQ7>A
M2MM3CG60<A<,LG7HN-=1[F(9HY,5J$')RD(+UTHD#..>?S0@(B7*\3CRWW9R
M+;C']6Q@Z??/H^9DFN0L=O\`AYBL7Y/F;6?O<HWGG;$L`Z<.9,53%CY1J*QC
ME-O`?.J,/.92C\<V!DJSKG^]&MVE%"*OE4XR,H87GX*.F*/755,75^P8OKK)
MPQ>QR3_JD.JQFW95'"SL3</M1B+E>,7UN^5L<B4^W6O'%RS*I;\I2'$%D27M
MN$YQYBPD55U:/%X13BFM<EIX8]@]@7993_PCQH/-@UZRSCY.=X!K=2Y!RC&.
M44Y2^.<UXSM<#7Y&619`S=6$U$B'#MLDLL*I6"!MW84-FO6)W?&\I886[XEX
M'N&F6X7G]?BOO'*-+AD?-&<X3*ZU:@'$7,-W,S/N:O4H]X*3<ZW5TFNT2""9
MR\:]-IU^FG-=Q-Q1,HS&$M.3D-4%G6+;3AG'MF.C&S]NX>LW(6B$9Y*>3[=L
M+=HSZH#<S?GS$1*F&2,&Y'R''-<Z9.J]]+C()")997>6B+9UEN7[F5*=J^%L
M`Q59N$M,[2LW#9FI.1RRA'C=RH8J1&EJ))PDG4\S9`MGJQ;7AB*:N'\L>DTS
M'.0,;R_%Q78NR`Y`IF%5BE[4E8%"JH!(QLHDDJ1?GP(?CMJKIH*6(X1SPV3=
M(6*<Y6Y,B6W&DTYRS'M6FZ5!LF$?&UF05,GV5W<FLH?:<QA%QXBM/YLR_*A_
M&D?W6CRYCQI(=UK<I;XK%_53+E1?B&&[B3Y4'XK6^NICE5OXK)?6KKE6+QHU
M[D]BQ^(I?ZO<:@Y+*N(,79,D:QS_`-VY#(-`J=S>U[K2K9PZ[QNK'$R2\3UE
M=DB=3JYD]\Z1!':)2B%BR32\08NJ&1;?WV^]E^J]`J<!=;/W_EF\]._>*TQ4
M2TG9KOU.M$GKOK*ZO67:1%E-Y0H&!0C5N@V(JNNZ5*W131*JY=*F7<N%"IE*
M!UW"QQ.<X[3',(B(B(ZME+@^''`T-3K[WB^_-3BL08]CJU=/NL_4E:S][()G
M7D8NQ?=V46.Y8=<26ZFX.*B6X<1'50AH2FU6&A\?@4*'$Q-?B8V,I0$AG]=(
M6IL&;1%K72DK\JY8@#0B(`T<*(A_-G,48Q*SUV"L:4+,,K##)ST1'RZ<3/QH
M+!'3D820;N"L)A@#A0$7*6XLD!S;I@VCMK\Q+P,-*2]3?NY6JRLC%L7TC692
M0AY&O/Y*OOG*"KF&?O8"7=L5EFQDU%6;I9$PBFH<IIH:?4:Q4QL<R\L=A&M0
M$5!#/6&0-OOYV:&+:->^DR^/V5G2_.+JCV3&'7]J?U3E./'S/ZO?<J6_H'=!
MM6W)L;'RAKI=6\<TG)*3M=MG6232+;I-FS2NU^<G)&N4UJL1`AG*<.T8$>K%
M!5P"JH;_`"9_Q"X[MC]05G>1R2M@K*4LVA)4IUT7;)I.HMT)AB)T%4@=1T@#
M-`ZK=8%$#+MD5=WG44CD]EZA#,2,RR4K(3<B?G5W#A_+2BXN'KYX[=*KNG*R
MAA`A=\X@DB0B28%23(0KCQ%:?S9E^5#^-(_NM'ES'C20[K6Y2WQ6+^JF7*B_
M$,-W$GRH/Q6M]=3'*K?Q62^M77*L7C1KW)[%C\12_P!7N/W'^U/ZIRG'CYG]
M7ON5+?T#N@W*G_$+CNV/Y3CQ%:?S9E^5#^-(_NM'ES'C20[K6Y2WQ6+^JF7*
MB_$,-W$GRH/Q6M]=3'*K?Q62^M77*L7C1KW)[$FDJ0%$E(]XFHF;>`JB9VRA
M3D,)1*8`,41`=@@.O-V.[9)?/]>;L=VR2^?Z\W8[MDE\_P!>;L=VR2^?Z\W8
M[MDE\_UYNQW;)+Y_KS=CNV27S_7F['=LDOG^MS[OQ^YUO>W.<D=W>YG9O?Z]
MMV[.Q[>S7F['=LDOG^O-V.[9)?/]>;L=VR2^?Z\W8[MDE\_UYNQW;)+Y_I1/
MO`PYH9%$XI\Y(;HJ%;+E*?\`U[>W@*80]O9V=>;L=VR2^?Z\W8[MDE\_UYNQ
MW;)+Y_KS=CNV27S_`%YNQW;)+Y_IX4*_'@4W5]\H*2.P^Q01+MVOA'W(_P`&
MS7F['=LDOG^O-V.[9)?/]>;L=VR2^?Z\W8[MDE\_UYNQW;)+Y_J1`D`P("D<
MJ10"J2'NTQ7;F$AMKX?<B8H#V-@]C7F['=LDOG^O-V.[9)?/]>;L=VR2^?Z\
MW8[MDE\_UYNQW;)+Y_I4R<!'IF&/ER"8JDAM%-6*>IJD]T^,&ZHD<2C^_L'L
M;![.O-V.[9)?/]>;L=VR2^?Z\W8[MDE\_P!>;L=VR2^?Z\W8[MDE\_TR.2OQ
MY#D=MC$.521VD.58@E,&U^(;2B&WLAKS=CNV27S_`%YNQW;)+Y_KS=CNV27S
M_7F['=LDOG^O-V.[9)?/]>;L=VR2^?Z>G/7X\YSNW)CG,I([3G,L<3&'8_`-
MIA';V`UYNQW;)+Y_KS=CNV27S_7F['=LDOG^O-V.[9)?/]>;L=VR2^?Z4.K`
M,%#\TT`3F4D-X0(T0(0/<OBA[DA0`.Q[0:\W8[MDE\_UYNQW;)+Y_KS=CNV2
M7S_7F['=LDOG^O-V.[9)?/\`305(!@<2QS$A1,I(>Y3(@4I"!NO@]R0H;`V]
MG7F['=LDOG^O-V.[9)?/]>;L=VR2^?Z\W8[MDE\_UYNQW;)+Y_I@!J_'F`C0
MY2`*DCL(07STXE+L?@.P3G$>SM[(Z\W8[MDE\_UYNQW;)+Y_KS=CNV27S_7F
M['=LDOG^O-V.[9)?/]19#0#`Q$TG0)D%20W4P,[5.8"['P#[HYA$=HCV=>;L
M=VR2^?Z\W8[MDE\_UYNQW;)+Y_KS=CNV27S_`%YNQW;)+Y_J3)',$&!%':)E
M"(&<&!0X([`,;K"ZX@(!V.P(>Q(?$G7Y!3]Q_I7^BY1_CR7<ZW*=_P"8_*#R
MGWQ%3\JARE/B,I]6.^4T^,H?E2<MW\97_*GY1_\`)MNYD>4U^(M/R0<IE\6/
MW8[Y4=_DW/=*G*D/C*7Y+V)#XDZ_(*:X;XVAX?H646'$!GBLX!6?6W-%@Q8[
MI]DM\-99^'F4XZ'PAEA&QP9(VH/@<B+F/727%`A$U2J**(\7U(KO"GA&R5SA
M`8XHN%LMTOQ<WNM/)C%F6!M,LUNXUICP<6LL4]H](J3R7GXQ-^_,B5(Z#%>0
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M4PY,T;N'B>";!AZ`9_[LAD3.FS*U1ULEV3Y9J)`23.8Q$_Z5_HN4?X\EW.MR
M>)FPXINKG'F7X/A^R;>:7<T8-U**P,A7(-RI&J1!UX>2@#3[Z2`J:/6AW&R8
M'7.7:5(#XH;X[<SL?1K)DG`6+K9<(-RDU&)CL^WA-Y)3[LCH&[V(5B:K14(!
MJL!>?*[R`BLES2[(I]1V!86G34C.HW+CIE&F3)6V1]/)?\.\'648>KQ5>C+J
M2EWMG#W?($19BM^NJ,.L"G#.E05;*K=<;XAS!28.R!%9&PK0,DU&M7*2=_>\
M(^WT:)M$!!VJ8G%GC[[R=6D4F[YR\455ZUOG5,8V\(KIM_4F]:;IK*D0<_\`
MV1<,R/6$2',5)?F3U43I<Z0`-NCV2[=@Z_8C?XD_#)^BFOV(W^)/PR?HIIWN
M>I"YP#-#E./_`-E/#$7FR"HD(J=FJ>[V"`!L#L]G7[$;_$GX9/T4U^Q&_P`2
M?AD_137[$;_$GX9/T4U^Q&_Q)^&3]%-?L1O\2?AD_131Q3]2%SIA:/RB7_[*
M>&(FPAV+@JJFTU4V#S28B?9[9MW8'9'7[$;_`!)^&3]%-?L1O\2?AD_137[$
M;_$GX9/T4U^Q&_Q)^&3]%-?L1O\`$GX9/T4TW,3U(F^<%TA(3_[*.&,N^8%"
MB4F\-4V%WA[&T?:U^Q&_Q)^&3]%-9&P=EWU=C^MXNB+21A.3\?DJKR+7`:/>
M5F\6C)'+$?&,L<9E4!=8AP:18MY1(KG8/.BD(#K/F2*!<+=0[UCZ"A[+4[/3
M+/-UB4CI4;)$0AQ<*0SYFG+QZL;,N"'9O2N&9E!(J*7/(HJ)\17#O4K+DMSC
M.)]7[<N)J!O:MZF).W8:RY4K=)5ZKP"=ZE9)[>IR.R0U9.I1LUEG4B@F-<?(
MF'JK@C8O#]A+B!D[G!9WIE(EKE)2E9L]KI6+N)G'I:I`RU=S#7*M7[`T@)<(
M>?DTH^UPKI!0T).*`@H16+>QBSO'\(QG\EK\/.1HK)>$!B97"N3*_B=GE.KM
MF-YI-\KN:9FEQV.KA)WH8BRPJ:$9,R`*),VHD*F?G0/B?/.$LB79A,QO%[:F
M,C1(66DEJWE'!'#;PV\0^1\F8,=4\RZU<=S>2+G@V63838LN^S)Z]0(1<S5(
M$CUJ*B<J7Q?AFO?`/;LKXZJU-NL[3823ER99HM%0R>G)TF4AY*4>2L)<'Z;#
MGW*Z#4B3=TB5-T4IDJUPX9!M>1O]Z?"QD"Z!E^T/,K7Y*;OE(B$R36*<D6:3
MCIN&+-PF<(2VQ4JHS=`XAXUY&S,(T2YJ//S-MITC-Y.=81S)@Y].XJA[WA/)
MV-:E4<A84O:D5,QM`O=VI58KF3#9;QO>FMB$T0ZDB)(P2YP7,B"8%OF&8*EX
MRR#%U^G\3SN+=5V]3X*0EXX:L/XMS$YJ62;0%6=QD%9[3#Y**F[@H^.D5ZZU
M(P>+/79I,63#*-HMN+8=!S6.''U:><JM'5Z5G'30\IZQ*8LV.Z]4+/(C%/G:
M4-CN]50'4E/),DDB0CPRAVJ8LU%5O7T-I7*UNC+;@:5&<Q'9*5:+=")XXG(W
MU;N!<Q1DA1FKV?E'L)#*9&FG$TM!KNGT899TLU5*Y:B)3\(6+$LF62IY/Q_Z
MRCA2X/>+BQUJQEB;ID6MSO$/!8A0</G\`BS?U1AQ+X@DB7DYF*[&1C"2+1%N
MKMWU29)Q-/VS)$U&<5%1B''#427R9DZ8?1V2(1T%4R%C2M3;BP.)*I*MBW"+
MM315DZ;O%(TLL<RA&<*F*'#\VIUQSD-/X?\`(6*V.:8YAC#+64JAEBG9@%3%
M<VRRUFYO2K#4Z++8<BK=&WTZDS86CEZ`([R1M]N*EZI9>'_/<>_JV4N'/$<+
ME"^8_<5K`-RGN)#+F.\1P\U3LB-9"36LT-0W^0B/IDA6C02IL5D2JD,(*!(8
ML9XAJ!+#3WW'+1K%>):4M3&NS=JX*L;8\R*C/4^G][3+NZ=DJ*R,S14`;`NK
M!R2#QD*STS05E>+CB48$:/,'L^([@:LEYJM_E9RP.L#\._$!P'<&V2K[/4AZ
MC,Q,:W8XWM>5'\[,D63!H6..^>)E+U8K5?/V=X"R2],OU>BEKSBR7Q=)6"CS
M;6NGO;&+I1GZJUF%&3E+!39`BSQ!RJ6+!P[``3_F$U]<)J\]*WK%N.,H^LAJ
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M[@O%`/>M)D!().PH@8^P$V[Q3=;*X;S)GC(ESM5WL33+:MLM4*Z:5F[V]S#9
MCR?4JS"PSBJ-Z^1C..DXZ.9L$HXC8ZZZ22(`(*&*:%IMJRHB>_8H]6AQ8<3U
MMR%7VT`UB[QQ(8+=XTBH2LR[6./U1=ECY6QN#SL60$VDFL\2YY("$%(.%NJ6
MROV:#6XNN$V\YKL%(D#A)1^'<DX27P,RL\*61*94K(]A99V08K-DS]5.ZKPN
M$2E57='5Y,A\92_)>Q(?$G7Y!37#M6D*UB&UT7$W$33<[WFL9=<OW4->&--K
M]PKR=#-7"4&Y0[MI,DN9W*CMYO$;J,B$!JMSPJ(\7]OBL8X`H^!>):NXNKT=
MC'%S$(9M&I8LC+E6%E[#3F..JK4G(Y+@[LLXDBHKG&/6:E;;T@187*/W"4M3
MRY-HJ2>1-1E)-`X2D'BF!<+QF),>/'Z[AV^G38[HR;6,-(NE5'<DLDH[7,9=
M=01X^J!)N<1R%FXO,[9[S94U6%QN7>*I?_L3%L*_.UFPOG&-$9!U]P8^.*Y:
M/&S0W?M9045$(TI`7/@[BIKM@C<:KQ%FGKWQ%X;KB[N=H64,D.,#Y)PO4,FQ
M<HYBZZLCD"K0V0%8MW)FC6:L]")MDWA=^,8E*VS#3)N(K60W_#?FSA*L,I-,
MEGK8N),YR]%LLM+QZ#9(ZKNS4^R8]:.&#10Z#5VF[<IJK)#S9PGHBE6%K$X]
MO%OX#K[.N7AY4]TI$]P`JXYCZ(QQT"9E6#2.R53,:1T/)&3<QI8A(7RR:$@I
M)K@C7\R9%B*>WO=`@[]1:9+4Y[.+'?TJ[3,')+]_@DF<:+991*M,A/'B,B@@
M[(=9%R'.;A?Z5_HN4?X\EW.MR;3C?)%6@[O0KO!R%:M]0LL>WEJ_9*_+-SM)
M.&F8QV11L^CGS90R:J2A1*<HB`AJW0L_6XB6BK<XC7EE8OFB:R$P\8)QK6/>
M/`,&TSR/1A6G5U0$%$#-DS$$IB%$(&HS6/:I(5JKKF<UZ%7AVO48=55-=%UU
M%(A"<RG(H.UDW9`'<=I+*$6!0IS`+5@P;-V3%DW1:,V;1%-NU:-&R946[9LW
M1*1)!N@B0"$(4`*4H````!R'WQ%3\JARE/B,I]6.^4T^,H?E2<ASC_+])@LA
MTAZZ;O']5LS47\'(+M2K%;C(1YCE;OTD>?,8$U@.GO[#;N\4HA;*%_N[K9JI
M?&Q65WBSM#J&M[0B!&I&MFD%%32DXW(S3!`I'*ZA0;AS0!S?N=5R':4^&194
M^O3-3JNQN)GE=K5A:M&4Y"PLF<YI..82C5@W(L1)8H'!NEM_[LF[3L?2>+JP
M_I>+[.E:,>5UR@Y5CZ=8XZ0<OHR;@"&<BHPDXIVX.HT6(;?:F-_-"36/IBPT
M:#E)+%,J><QTZ<(K`:GS*K1U'KRD*FDLFDW?.(Y^X;*JB43JM72Z)Q%-94IZ
MSDVLXHIM?OE,I+;&U3LL-%)QK^N8]9L4(UK1X8K0R3:/JC=HU2`D>FF5J!TB
M*;G.$*8+@O-TZ`?.\@5N(I]WD!CT4)2U56OKSKF#KTY*-00D9"'AU[1)';-U
M%131-(.-P`YY3>Q4^E<=U^0>8.<D>8B=NTG*SG'KM-B,4#JLKG<BJP<FB3G:
M&4`1.=HHHB8124.0UIL4UA/&LA8+LM:7-LG%JI$A,3SF\5."HES<R,DFW(]6
M<VNF5>-BY%3?`[QDQ025$Q$B`%K:UW!6-XUI=<;T[$EN9$K;-PQL>,*1&"RI
ME!F&+LKAH^JE3:.UDXUD<@H,BKJ\R4G.J;V0ZFZQ#13U_+A8HF56!(-L@.2B
M0D"RJL62^.T`3?6TC.LQZ,>4'ZJX"R3!$VU/:48N,N6&*+8V<-:ZO?8XDI$%
M751O5(A:W7*;=E'7.`[=W"J0=/BVT=)K'4?,DV"/,JD$@#JLR$G`Q,E(4M^M
M*U%_(,&SU[6I1S"25:<R4([<IJN(U^XKTR[9*+)&*H=JZ52$1(H8!R)C^6QM
M6Y.E9:F7-@R567[=9W$W69>+LG+Q]/M5UU"O5':L<ASH#L(H5(I3`)0V:#&$
MK48.8QZ$4UA!J$TQ3F(12*8BB9DS6:28.RKILU&Z9TA/O&3.F4Q1`Q0$*DI9
M,,T:96J-3L]9KCA]$@LZB8+(T=U#($>W="H#@Q+NS-N2QSF,I(!LY\R@@`ZE
M<=X"A\?X!H>3I2#B^(Z!K^,8JP'S7B:$Q_)8X2QJ9T^F&"-0<%K"C"-;3!$'
MZ["&8%8MT"%YA5LXQEE.BUV\X]=BRZY3+`Q*[KKPD=_J*#N+VD:NFK40`2)*
M%,F!BE'=VE*(8S0NV/:_:"8:EFD_BP\T@L^<42?80J]<:3M==JKBZ8S2%?=K
ML@=@<7`M7"R0G$BRH'J%98</N*$:_0&2L;2H<].B'#"KQZMZKN3A8PS=RW6(
MQ:)9%J,7.))DV$1E&"#E,"JIE,%OHTGB6@2E)OS1^PN5/E:S%R=7L;*5>*R4
MJUDX!^W<12Z$K)K&=.B\T`.'0\\IO*^[U6>'&0P9C0^!*^BT/#8>;U:-88Z8
M#&R\E(,02JD>BUB#$;23@[HI3I&+UL07$.=`IP3QNY26C8>.+65JT[9F(XD:
MO,4F1C)FESL4M)%>E/)5J9A6CE`RX*@<Z(`H!RF,`UZ\$Q#CT,AU_(%DS`VN
M,=7"QKY+,5XK*%0O>2XXAWCY:.LUMKB(Q[EP*RS@T<86IE3I&.!I*&E$.M1L
MNP>1DBV%15'K#%^W4:.T.=;J)+I<\W5,7>(8IR[=H"`]G1>&^5X=,4RF`R6(
M;8GA^2JK%_CQ&Q"HJN,JC5W95HI%<72ZBX@1,""X4.KN\X<QAHV,JQAG',!C
MW&:;I&@4R)JT4QKM2;/S'/(,X2+;MR-6;&1,<1<H%+S+CL<X4VP-A\L2SU29
MGPJRM+IZ*[1!!O2*J[?L92SQT6=,3*NG=OL,4V=/W"@@8Z;%F@4I2MQ,IR9#
MXRE^2]B0^).OR"G[C_2O]%RC_'DNYUN4[_S'Y0>4^^(J?E4.4I\1E/JQWRFG
MQE#\J3EN_C*_Y4_*/_DVW<R/*:_$6GY(.4R^+'[L=\J._P`FY[I4Y4A\92_)
M>Q)**&*0B<>\.<YA`I2$*W4,8QC&$`*4H!M$1[`:\,Q?R]KTNO#,7\O:]+KP
MS%_+VO2Z\,Q?R]KTNO#,7\O:]+KPS%_+VO2Z\,Q?R]KTNO#,7\O:]+K>[[QF
M[UO=WNO-=W>YG;N[>=V;=FO#,7\O:]+KPS%_+VO2Z\,Q?R]KTNO#,7\O:]+K
MPS%_+VO2Z44[[1O-A((D$_7FVX!Q;+F`N]SNS>$"B.S^#7AF+^7M>EUX9B_E
M[7I=>&8OY>UZ77AF+^7M>EUX9B_E[7I=/!"7C!*7J^\8'S787:H(!O#SO8VC
M[6O#,7\O:]+KPS%_+VO2Z\,Q?R]KTNO#,7\O:]+KPS%_+VO2ZD!)+1I@)'JG
M/NOFP[I`7;E$QMBO8*`F#L_QZ\,Q?R]KTNO#,7\O:]+KPS%_+VO2Z\,Q?R]K
MTNO#,7\O:]+I0"2T:<0CY8X@5\V,($3BGIU#"`*_R2$*)A']X`$=>&8OY>UZ
M77AF+^7M>EUX9B_E[7I=>&8OY>UZ77AF+^7M>ETR(27C#&,[;E*4KYJ)C&,L
M0`*``KM$1$=>&8OY>UZ77AF+^7M>EUX9B_E[7I=>&8OY>UZ77AF+^7M>EUX9
MB_E[7I=/2'EXPIBNW!3%,^:@8IBK'`2B`J[0$!#7AF+^7M>EUX9B_E[7I=>&
M8OY>UZ77AF+^7M>EUX9B_E[7I=*%/+1I#<TT$2G?-BF`#-$#%$0%7;L$H@(?
MQ#KPS%_+VO2Z\,Q?R]KTNO#,7\O:]+KPS%_+VO2Z\,Q?R]KTNF@'EHT@FCV1
MR[SYL&\0Z!3%,&U7LE,`]@?W]>&8OY>UZ77AF+^7M>EUX9B_E[7I=>&8OY>U
MZ77AF+^7M>ETP$9>,`#M#F((OFH`8H/GI!,4>=[(;Q1#_I#7AF+^7M>EUX9B
M_E[7I=>&8OY>UZ77AF+^7M>EUX9B_E[7I=1AC2T:!3I.A(87S8"G`':I3"41
M5V&`#!L'^/7AF+^7M>EUX9B_E[7I=>&8OY>UZ77AF+^7M>EUX9B_E[7I=21V
M;ML[*1VD4YFRZ2Y2&%':!3"F8P%$0_A]BQ^(I?ZO<?N/]J?U3E./'S/ZO?<J
M6_H'=!N5/^(7'=L?RG'B*T_FS+\J'\:1_=:/+F/&DAW6MREOBL7]5,N5%^(8
M;N)/E0?BM;ZZF.56_BLE]:NN58O&C7N3V+'XBE_J]Q^X_P!J?U3DF5:.$'21
M5G+8RK=5-9,KAFX59O$#'3,8H+-':!TE"[=Y-0ABF`#`(:<>/F?U>^Y4M_0.
MZ#>P)C"```"(B([```[(B(CV```TA)P\BPEHUSS@MI",=MW[%P"2IT%>8=M5
M%4%>:72,0VZ8=TY1`>R`^P_B6TDP<2L6BR<2<8@\;JR$<WDA=!'+OV2:AG+1
M%^+%;F#*%*57F3[HCN&V3_B%QW;'\A5J5=$SI!)%=9L54@KHHN3+D;K*H@85
M$TG!VJH$,(`!Q3,`;=T=FG'B*T_FS+^PU2<.4$%'JXM62:RR:1W;H&[AV+9J
M0YBF<+@T:*JB0FTW-IG-LV%$0TL^D';5@R;EWW#MZX2:M4";0+OK.%SD22+O
M&`-IA`-H^Q#^-(_NM'ES'C20[K6Y2WQ6+^JF7*B_$,-W$GRH/Q6M]=3'*K?Q
M62^M77*L7C1KW)[%C\12_P!7N-<"+A6"Q/-7A/CJQ4TKJ>4P8HQ2D6XI&4E9
M1E(/QC9:7;5Q=\W9G=`@@JF9=-`3E$P$$/6CT/)5`X:RY@=U#A6L-2?52+CK
M?$5;)#&%RE.QMT45GZU&3BLFTR"TCW4\0[;8Z5*"3D5><$HM\D9QP/4#3$9$
M4['%FJ=IJK)5_"9#P_?(FXW*N]\EF23J8JE4RW4F[=GNJJ1TBE''-S9VZQ@5
M]:?:[)CW#K]_B;C;X\);'UC0CJPQ<4HDCB\M1JRT/)1X-NHQP-[`\)$);W5D
MGNXNU*5RBDH3@>X?,OUQOEE*JYRNN2.&GB-D8=G;4[/AN(X6.(@"U*V7-XW6
M.SR]CNYJ0[@QD3<S+QY(R325.\0=E;PU>XF\N8<PK:YUPZC,*Y+RWDRJX[<X
MSLHB@[E\C8]=VNQ021+I78IL)FR[3G'0K"DB(E244'6=9"#D>_%H2SEZK4G!
MU*IJS"TS-X2F[IC57/\`)PQTFP.73*5A%;ZK9S1Y3M>\:!%'XE(F/-Y+SI79
MV@9KC\]UBSEM622UNBIY-Q#(T:4K<+`8M3O=20;O+'CIPQ14:H,9(%'T<\B1
M`RIP.8I/[4_JFO5EN\W/L-,H^)SGFR2MCG*;FE-V490G'!]Q&Q$9(6):V'(@
MRJ"^3'T.U05="5D:<6:)E'K1D0'.;/)EUC,+8UL'')AMQP.VJV3+&B7>EUP7
M?#=_O8M>'7=M<,I)C5'61D;C)H%:[&+NOK*F.0T8N4#<7>:^*NH47&5QQMP^
M<,U%LV:@BH6IU;-SUO>.)N00ME*L3_J[I;[^M'%=9/(U=<7#>98%9B"B39HJ
M;.-)RC+XK@97B<Q?5>+&$K=3RR2UK7O,S!I+4')#BM,K%5:(\8_?FLTR`4B6
M:)7J*Y(IX9)<Q6RV[`9&QZ^HM^XC<,8ZP=%<0U"Q^M$+99R;C?+EARK%YE<,
MZHB^<6ERZIL]9*'<T4'HG4;P<<S0YPJ3IN*GK<<5R\SB?(5QN_$%B268W)H-
M+NUA8R*7!K@V/>WZKKKIR2SF(H6=D)9ND<A#,6LRP<,SE*J19$$\[9LK%`Q5
MF6JQT7P=8]ELCQ,-0!M.8HQ[(0T^O4[`_:D>(8@NEY;G=1`-4SE+78UU)%0,
MDH8A>,WA?R+DFB8>D85<>)FMKU/)#:^3D!7\KU!W8\KS$4WLE)KDJ\E:[=:S
M(V1XT/"N@0:V%LL/.)+DV<(]UH=IQJIGNFT_)&:,&/2S-?&WVQ&%7Q].Q=:J
MZB:XR\M%Y>IB%F@&":(*(/`DG7,@8Q5!#*CS(#"DVXF5O5Q8?;,J%D>/KCV?
M@91YF7-,^_QJYKDP#E]$7F,Q(\B)>9B0(5^S:/RKJD!`Z:IEZEG^F0M3QWZO
M=26)0\J7.OP$76YFKR_5TL.V2HSCQDPBPL+&C*HQTN9H*"BEH3`H>[YL5)QG
MD^TX7BX_CVPK4LCU9K3LR)7926RIBJR2$3&2Q4)&I5`B3?(V'KI#Q$.JQ7DV
MD@6A'(@KO$_G<45S-">.^'YO:ZYF5]-9%P1>9G)-1:94KAJ@'#_C7[RY3Q+C
M]=R[R@\DI%,\6:(27E'39-@S6456`=/T<P9#@*&E5N('U2=(R'CF58U:.JU5
MK?$UC)Y(<8E?L#R28(R*T51G;F1?+NW"Z1H<L.4[@Q$4ER&X)'.-\@WR2Q?F
MW$F3>'1_!4U*N2;#!6;2V6R3%'RLW0+5Y!VU:LH:*F494LBY6:LW:#(W5]Q1
M8-<$N-X.0P%9LH/.&3B_H=VE,S/8-6U=:L;GA1;8TE)LL#%]]W.1Y1G$SKVL
MME$F0/2MI,61DB)K"3*T-`9N:NY>EY.]2]P[Y`L=ED*XFOE&N2;:R8JS5/WP
M'O/NAFX[&KU_:'RZ3A)6-48@[<*"U15`W&HP86VUJXOJ>#>)5[6'F1\?.RPU
M'RWAWB&KV.(2'CF%$K$A.?=F2J\H+ID45I:5G(I-O,D;I%<`VUCJCU2V2%7J
M-X6M[VHY.MD*ZS#1+%E2AK8GK`83K-WPECV=:Y*JT]68VP6$CQTTK;Y:2D91
MLIU=:MND`X<\9RN3HZJYQQWDB-NHQ]<3F7-UN<E::9;,?5?$<J_AV3@4:4^)
M<QL$LT=.$F20Q3)11,><$Y,F8H>R5ZFN'\^,.(62*%QI:$`WJ&5<-\0.-\=P
M-?@'+"'0(PA)ZBVM\^CP>R#UW8HQ!O,ID;HN`2#!#7)^5&.$5<Z\=_'UB[-:
MK]]3F+YKB/$>+<VDPO+-+-9V"Q:XQJDA7*6#-;9U8'L^@@J"BCI(JG#'G2L9
M?IS)S?\`!6/I&\)K2-2B5QR:SB^]612NHMSPZ9(4C)!K;&+E!VV[Y!U5VBJB
M*"!B"F'"QBF]91@V7$WBYL[M%P1JS28EKAD:XW+`^1<8-,>K2E=JD/'#0`4M
MKVUS"#A"*9L^]D:Y!BD50_,7)Y5N(C'%&B&.$.+B$R=QEUN9*>MY,D,FV)L]
MQ!=+A<'D+!5I&SXG!.1<R9F;Z39PQ?\`PZ#D"*\TGZPO*!65;Q=1U<!1-EQ#
M4L=A*)UBO9NQ#CF]6B?S#0'\S5Z:_=-[9:'%90:KGBVXNGE<.O\`SY5P66LE
MDS-WBIZ3O#*LG?D;%*,XZ"@)A_5"*R4>]E'RK1FDDTFU^8(<QB`<X%`.R(!K
M@(J^-+)!3-V<<*^#F4L9P\+,DCK3B;!=?"?B;,JT?=9C9.N9=C8N*F4%@.X;
M.U3MG"(',?=?,J[D:G8=A4.$_AF@\_6B^22]:J\IQ<1&<8.0MU`ND\LB[49S
MU_8-IJJV7^97F0+98X"I*JG;IFRI-2T8PIV/+YFN)LF',5Q3)ZPBL;5-E1,?
M5:T-8AI(0=9=-H6Z90K\[8V9#1S$QFLL14R")U3)EER<.\+P+/,5`DQ[PKYH
ML^?HW()UQ:)=\PEVE'J,K7$TBOM\$.97,(I;HGV&VAKS;]6#_?;BL_0#7FWZ
ML'^^W%9^@&O-OU8/]]N*S]`->;?JP?[[<5GZ`:\V_5@_WVXK/T`U)]8K?JO0
M<=\'G/@C=N*\406ZRISO-"?'X'%/?V[NT`'9[>O-OU8/]]N*S]`->;?JP?[[
M<5GZ`:\V_5@_WVXK/T`UYM^K!_OMQ6?H!KS;]6#_`'VXK/T`TKUNM>JZ!?J\
M?O`WN_%@*6YWO:\SL%7'Y3[PH[N]^]O;=G8V:\V_5@_WVXK/T`UYM^K!_OMQ
M6?H!KS;]6#_?;BL_0#7FWZL'^^W%9^@&O-OU8/\`?;BL_0#3#K-:]5T!N\\7
MS/,7?BP$.K=5)S`J<YC\!!<4]F^`>YV^UV->;?JP?[[<5GZ`:\V_5@_WVXK/
MT`UC.,BZ;PQR-%>4%HI=$*5(Y-5X<F[/[W2::SRT6^^5J+N4;DI-J`[&T$D]
M4&.Y@YT#B(;(XTVFP1F3,6HRR44LX<1B4D*!!>IQSAV@U=+L2.=X$CJ))J&)
ML$Q2CM`-0?BM;ZZF.56_BLE]:NN58O&C7N3V+'XBE_J]QJ->7B@4FYNX7G>\
M[JUU6"L3F)Y]1%5;O:O+L'BK'GE6Z9C<T)-XR91'LE#9+7&N4"DP%NG^O]_;
M3"U6"BK'-=]7Z4I*=]IQBP0DY+OE)H$<K\\J?GER%4/M.`#HY4$4D2J*JKG*
MDF1,#K+'%198X$``,JJH83&,/9,8=H]G4[7(S$&+HZO6GO7]YH)C0*FTAK%W
MD='?0O?V+;Q*;*7[T/5#+->L$4ZNJ83I[IA$=0$?&UV"CX^J;/NLQ8Q$>T9U
MK=CG407O`V0;IHP^[$OEVH=7*GL;K'3_`)!S%%DO?L=T6\+1J:J4<M;ZE`65
M5@DN8IUDV2DU'O3M4UCE`3`02@80`1U%RPP<.,K!L749"R8QC(9"'C7P-0>Q
M\6\YCK,>Q>`Q1!5)(Q$U`1)O`.X79(C7X"%@AF)%Q+RPPT4QC.^DL[-O.I.1
MZD@AUV1<F[*BZN\H<?;,.O[4_JGL[=@;1``$?WQ`-NP-O\`;1]EQX^9_5[[V
M%FJX',@X2.BJ4BJJ)C)J`)3E!5`Z:I-XH[-I3`.FD='-&S"/8-D&3%BR02:L
MV3-JD1!JT:-4")H-FS9!,I$TR%*0A"@```![,M_0.Z#>RRRF[=VUU8HR!&`B
MHM>\W`]$C$SF?<_-,<<]^@HJ-M=-9%5JI,=[QDA9F%`%@2$Q!]B?\0N.[8_D
M6"=C&AF;^TJ1[B<!)RY!D]>QK=1HC)=[16%@A*+M#D2<.4TR+.4T$2JF."*>
M[IQXBM/YLR_L$AK*P3EH?KS%^XBG(F-'R"L<X*\9HR;4!!*08I/4DUA05`R*
MATB[Y3`&P?9A_&D?W6CRYCQI(=UK<I;XK%_53+E1?B&&[B3Y4'XK6^NICE5O
MXK)?6KKE6+QHU[D]BQ^(I?ZO<?N/]J?U3E./'S/ZO?<J6_H'=!N5/^(7'=L?
MRG'B*T_FS+\J'\:1_=:/+F/&DAW6MREOBL7]5,N5%^(8;N)/E0?BM;ZZF.56
M_BLE]:NN58O&C7N3V))-4A5$U&#PBB9P$2*$,W4*<A@`0$2F*.P?XM>;T3VE
M;I]>;T3VE;I]>;T3VE;I]>;T3VE;I]>;T3VE;I]>;T3VE;I]>;T3VE;I]>;T
M3VE;I];O>"*W.M[VYS*N[O<SLWMG/_RMG8UYO1/:5NGUYO1/:5NGUYO1/:5N
MGUYO1/:5NGUYO1/:5NGTHGWAB^;&01.*?,J[@G!LN4#B'/;=X"F$/^@=>;T3
MVE;I]>;T3VE;I]>;T3VE;I]>;T3VE;I]>;T3VE;I]/"A`10%-U?>*"*NPVQ0
M1#>_G^SNC[6O-Z)[2MT^O-Z)[2MT^O-Z)[2MT^O-Z)[2MT^O-Z)[2MT^I`"0
M,60#QZI#@5%4-\@K-S"0W\\.THF*`_\`5KS>B>TK=/KS>B>TK=/KS>B>TK=/
MKS>B>TK=/KS>B>TK=/I04X&+3,,?+$$Q450$2*13U-0@[5A]RHF82C_$(Z\W
MHGM*W3Z\WHGM*W3Z\WHGM*W3Z\WHGM*W3Z\WHGM*W3Z9G)`11#E=MS$.5%4#
M$,58@E,417$-I1#:&O-Z)[2MT^O-Z)[2MT^O-Z)[2MT^O-Z)[2MT^O-Z)[2M
MT^O-Z)[2MT^GASP$4<YG;@QSF15$QS&6.)C&$%P#:81VCKS>B>TK=/KS>B>T
MK=/KS>B>TK=/KS>B>TK=/KS>B>TK=/I0RD#%J'YIJ`G.BJ)A`K1`I0V@L'8*
M4``/X@UYO1/:5NGUYO1/:5NGUYO1/:5NGUYO1/:5NGUYO1/:5NGTT$\#%G$L
M>R(43(JCND(B4I"!L6#W)"AL#7F]$]I6Z?7F]$]I6Z?7F]$]I6Z?7F]$]I6Z
M?7F]$]I6Z?3`#0$48"-#E(`HJ["%%\\.)2_S_8`3F$?^D1UYO1/:5NGUYO1/
M:5NGUYO1/:5NGUYO1/:5NGUYO1/:5NGU&%-`Q9B$2<@F045=U,#.U3&`@<]V
M`,81$?XQUYO1/:5NGUYO1/:5NGUYO1/:5NGUYO1/:5NGUYO1/:5NGU)$8,6K
M$AW:1E"-2&(50P([`,8#'.(B`=CV)#XDZ_(*?N/]*_T7*/\`'DNYUN4[_P`Q
M^4'E/OB*GY5#E*?$93ZL=\II\90_*DY;OXRO^5/RC_Y-MW,CRFOQ%I^2#E,O
MBQ^['?*CO\FY[I4Y4A\92_)>Q(?$G7Y!37#O),6&-5*KF?B#J&!K)8,C6B0J
M;&CGN,#;;`UN!Y!%JO'.(^.0IRR*J"ZC83J.4Q!4H%,!N,F,Q!7>'G)%"X0H
M[#%SFKI%9)LDNE/XYRB2USUKE4ONI!3[(EDQ11J@\D'4>BJN:673ZNB9N8Y1
M%JSP#4L49-8NZMC2P%=S5MG()LFVN^0J]!RTX$LRC9*+=P<-CIU+6-LDB8SV
M0"+(V3+O.DU"\3>0JC@/"\]"\*7$;Q+X*R(R-DRT0TD_BN'+&LE>!O,&+VKJ
MH*&OM@18P+>-'?4CUY(CM591NBON\-1\;5Z!;IY4SK8<`9JIE]?O8[)6",@4
M_"^3,V6FJ3L+"%DH\UGC8?&"K0B*RR;=RG+,9%!99DH05FV)Z]7FUQR(AP^9
MGXIIR#<S*4.FSP]@Z2I,#83ME"HO'2EDLECO[%I%$.B1D/,.CKKIBFFFM8)>
MMU(\EBFAV7@BK-TL+Q\[:6:0+Q\.**RQ!:<?Q*,<ZC+35Z^]R3$$EER.@35#
MO@5LH*\:H@M<.%&/J)N]=1X>X+-@Y)&715:3<C+Y+G\=/:O%12""@';P#NO+
M%=.S+@(/2J-P2`43FU_2O]%RC_'DNYUN4[_S'Y0>4^^(J?E4.2_B+;E+'-6E
MHM@O*R<78KO6821CHMJU0?.I)^RDY-LY9L&S)TDLHLH4J9$E"G$0*8!&]4:D
M9.Q[<KMC5-PQR-3ZK=*W8;30'L@QFT&#.[5^(DGDM573U>)=$13?HH'4.V5`
MH"*9]D\[Q7DS'V3&M6L$I4K.YQ_<ZY<V]<M4&]<QLU69Y:N24DG$6"'D6:S=
MTR<"FY;K)'(H0IBF`)9/(N8,6T$\#%.IV=)=,@5.K'A81BU1?/9B6+.2[$8Z
M*9L7":RKA;<1324*<Q@*8!%:L266L91]E;3C"L.*\^OE5:3C>RRJ1EXNO+1*
M\JF_2G))`HG;M#)@X6(`B0@AJ+@:/Q)8#N<Y.6.4I\+#53,6/+%*R]M@^^G?
MJK1<=$6)X\D+'#]Y'O6F*1#N6_4U^<(7FE-W4Y?[Y88NITJF1CRS6NSSCI-C
M#P%?A4#OY67DWBH@FV8L&:!U%#CV"E*(Z&=ILL6;A]L?S<BBTD&S1R26@(:S
MQSABJ_:-2OV;R#L#1<BZ'.(CSHDWN<(H0OL19[%/PL`6<FHZMPIIJ58Q19>Q
M3"AD8B`BQ?+H!(34HL42-FJ6^NN8!`A3#[&6"6_/>)*:E@J7@(#,<A<[Y7*C
M#8UG+16DKE7XBX3MDD(N&A9&5JBY)%)%9<J@M#E5$`*(#JN<QF?&DD%\R$RQ
MI3C0EQ@Y\EAO\VR=S454HX\(\D"*S;V'9JNR(B(&ZLF*H["!O>RXL]_M]7HU
M::*(HNK#<)^)K,&V6<GYMNDXEIIVR8(J+G]R0IE`$P]@-NGTM+/F<7%1C-S(
M24E(.46;"/8,T3N';UZ[<'3;M6C5!,QU%#F*0A"B(B`!IA*L3G58R;)K(,U%
M4'#511J\0(Y;G4:NTD'38YT5`$4U2$4(/8,4!`0T?_)MNYD=7,S_`"50&1<<
M2L7!9#,[N-=;%H<W-QD3-0L-<Q6D2!5Y67AY]@[:MWW,+.&SU!5,IB+)F-"&
MJMYJ=F1LJ$TXKCROS\9-1\^G6WP1MA"&D8URY82BL$_'F7B:"AU&RFT%"EV#
M[`B(@```B(B.P``/;$1_>`-,+C!W"O6*IRDT2NQUCK$HULT*]FALIZ<O'MY&
M!4D6JBL=9D56;T0-N,5D%NL"D"*HD7O,!D6B3E)B.O1<K<8>W5^3JT9)5QVM
M$6&.D+`RD%XED^@99JJU>HJ+%4:N$S)J@4Y1*#&R5*?A;1790BBL9/5V58S<
M+(I(KJM55&,I&+N6+LB3E`Z9A34,!3D,4>R`AR67Q8_=COE1W^3<]TJ<J0^,
MI?DO8D/B3K\@IKAN"EVS%E>K^#<_5;/DW%9%I%AN0W"4I\):*_&5I$L3::^R
MCXEVQN#M1P=9)RISR2.X`%`X&XL\S6&9P\_Q;Q*0&.:\RQK4,>S-?DZZSQ.C
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MQK<H*PX_CW,,X676C4>?=@X9N!53.CB(+%`8X''G#XTQ@RQ<PA*(T89&F6.(
MHFMJ8\@LDY".Y45E*52[S`IS[&$CFC%FI*1\6NJ(]2.DX#B;@<NY4FX!MPZ1
MF#6./[G>[A;50>L[]:K>O,R$Q,S;E"2@>KV,`;1JC80;R)#O`4%100#^E?Z+
ME'^/)=SK<IW_`)C\H/*??$5/RJ')XH,$5F&RI-\3L_G'/%OI-RA\7UC)5+X@
M*+E?,]GN=2@K)8;O2[Q2*[!4[#M\8UI5O,+0+]FM6$T8]<6:92JV[*F-H[*]
MHE%Y^:X=,Z6BW8UL5+D+_A^<X;L1Q,1Q"P<I&46CT^[6;$N:\4RITF]9:=35
M9624&-:I).V8GO5/P<RJN"W3;UA/&?>Y**XH.';,ZQ;%P[Y(XG\MWJA.,=Q+
M:[X.=1,W9*1.1CMG(+FE6K%,XHN6`+>X)G'A]XC,97#-<WDO+/$%*V*0''DG
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MWK6=[!<+CZJ'*U-LD5`N;;]]9?C=E*,V@7D+G(M<>I,Y`L]$*`E#'DC*QB\@
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M!.TXTTU9.44F;]51T8B8`]5#C"4A29VCKU3I7,K7%$75ZY-(87R#@NU93H+_
M`!K)4:Y3F5W];4SQ4\/Q;QJQ;Q-9B'2$VXD`?KKH*,UM?_Z!&M8POQ"3K+BP
MIN&H7AH1F:;DB[WO*\D'`M0<>/VB39\WG;X5:"O5?=1KQW-)MD&JQ$TSK!M*
M`<..:V1,JY2NF9^/SAER=F%[2<1Y'HD/0,=8FP[EK'<;/'HS<LY=<6(M$K:U
M[[O)J2,_,\<B8#-F[=-!MPOH5FN<8*6;J^QRK*3UA?R62:V<6-)XY<.1--K>
M3*FZ&"FK==;3PVN7[UB_M2[R,=5YC+E5:/)%VBX;<05AX=6^7'D[6)VUN\4Q
M*CF^4U5U!-+%78:SQSBON9TF)<H0LM033JE!4B'=:L#6;ZBM)@LD`O=9YJ;N
M!XB\K9!R=(S+_&E,O>)+JYS1%Q]@R/&6B*J;VGIV7+UZB8:I-$7J$:YL$JM(
MH1239%XMSVX*E/FZ:C+(5EWQ$\&\WE%K+PUEK<D&`4>*/$#_`#6A88*3:Q$Y
M$Q88R3DN_+:1;I)DBP=$=I\USA=6=F=7BP)#S/KD<S0$.^FXO-3G'4;P*6#@
M=DXF"D$#(H(U5EAN.XID8\\0]2,F+-R!W#)9-NHNL9K;W^<H2_A#1,^+2IV3
M)/$@O`3$O(4^4C($DP6SWV^1!8]G-/FZZIU(E\HD5$3HD!8J9B^LSC[5@!Z1
MMDOC7X+KW29VJV2P6><9Q%:P3P@0=^XE</6*3QW4GEVR-A.?J,C9HY1*,,9W
M<HAPR,W5!#:[X.(JN49.A9'3]:2[FGYG$9(P<UD+"C_-F<Y7).;+]!,$XIQ"
M7S.>!'LC:9EHJ@T:-[!,[AV;9(`9):/&X]CJW)RD@_:-99O9K?+T=L-<."II
M8K"?AJ1D!TA).@(1N4HQ^[S*RA@5(<A-O#1C;*=`F<4N<:WKB9R)/U))@]=H
M.&2N9LMH4&K2C25J,4[:M9%GD0M@8)-$DG*I(9BH0XHKK-]<4-NL.`<Z2LS&
M\<''+E>CXP:8*R.A?+94\P<665[YB>P4ZH2=682K^,G*7:63\56R0F8-E3$7
M!%4HI:<4KAO-D#A?R%(RF1I.HVKB!PNG%V:(O%URG.9%R%=Y?"4^^Y]C!V:Y
MV>;/',7RH*=3616`RA!344_:EX:_Y(J#^D&OVI>&O^2*@_I!K]J7AK_DBH/Z
M0:_:EX:_Y(J#^D&FN]ZTW#(@*!A('_Z0T$-PO67`"41^\'NA$X".W^/9K]J7
MAK_DBH/Z0:_:EX:_Y(J#^D&L;QM(]815\A3K3,M3DR%Q_B*`X;WU.:-X6U(.
M[M.WFM3CF5F*M&).NK.X0K=T21%XGO(G!/9JHUGB7RA5,Q9=BVG,6*_4^FJT
M>,F-W=ZOST4I)OTW;]`NTBKQ-)B1SL`_5DC;V]J._P`FY[I4Y4A\92_)>Q(?
M$G7Y!3]Q_I7^BY1_CR7<ZW*=_P"8_*#RGWQ%3\JARE/B,I]6.^4BBL0%$EE4
MTE2&_DG34.4AR#_$8HB&C5?'%5BJC!*/!D7#&+2.47D@+)C&]?D'2ZB[V1>A
M&QC9L"JZBBA6[9)(!!-,A2\EW\97_*GY#E@_:MWK%ZW6:/&;M%-PU=M7"9DG
M#9RW6*=)=!=(XE.0P"4Q1$!#9IA$QK<K6.BV36.8-2"<Q&S)D@FV:MR&4,=0
M2HH)%*`F$1V!V1'1_P#)MNYD?89SJ\>U6F(]F[8,)%5(JCIDSD%&RKY!JJ8!
M%N1X=FD*N[L$_-E`=H`'(:_$6GY(.4R^+'[L=\J._P`FY[I4Y4A\92_)>Q)J
MJ&`B:4<]44,/M%(1LJ8QA_B`H;=>%6WOC?!UX5;>^-\'7A5M[XWP=>%6WOC?
M!UX5;>^-\'7A5M[XWP=>%6WOC?!UX5;>^-\'6_WS;;G7-W>VFV;W,[=G\GV]
MFO"K;WQO@Z\*MO?&^#KPJV]\;X.O"K;WQO@Z\*MO?&^#I17OFWYL)%%,3[3;
M-\S9P8"_R?;$I1'7A5M[XWP=>%6WOC?!UX5;>^-\'7A5M[XWP=>%6WOC?!T]
M,$FV$I.K;P[3;`WE1`-ON?WQUX5;>^-\'7A5M[XWP=>%6WOC?!UX5;>^-\'7
MA5M[XWP=20DDVY@3CE5#[!-[D@+MBB8?<^T!C!KPJV]\;X.O"K;WQO@Z\*MO
M?&^#KPJV]\;X.O"K;WQO@Z5*G)MS&".F%!`!-V")1+U50W\GVB)D$1_B#7A5
MM[XWP=>%6WOC?!UX5;>^-\'7A5M[XWP=>%6WOC?!TQ3))MC'.[;$(4#&VB8R
MQ"E`/<^V(CKPJV]\;X.O"K;WQO@Z\*MO?&^#KPJV]\;X.O"K;WQO@Z\*MO?&
M^#I\F>3;%.1VY(<HF-M`Q5CE,`^Y]L!#7A5M[XWP=>%6WOC?!UX5;>^-\'7A
M5M[XWP=>%6WOC?!TH123;E,"+0PE$3;=AV:!RC_)_?*8!UX5;>^-\'7A5M[X
MWP=>%6WOC?!UX5;>^-\'7A5M[XWP=-`/)MRB:.8J%VB;LD40*8A@]S[1BCKP
MJV]\;X.O"K;WQO@Z\*MO?&^#KPJV]\;X.O"K;WQO@ZCS&DVP`HT.<@[QO=%!
M^^3$0]S[6^00_P"K7A5M[XWP=>%6WOC?!UX5;>^-\'7A5M[XWP=>%6WOC?!U
M%'-)MP*JBZ,F81-L,!7BI#"'N?WC%$->%6WOC?!UX5;>^-\'7A5M[XWP=>%6
MWOC?!UX5;>^-\'4HHQ<IN2).T2*&3$1`IA1W@`=H!V1#V+'XBE_J]Q^X_P!J
M?U3E./'S/ZO?<J6_H'=!N5/^(7'=L?RG'B*T_FS+\J'\:1_=:/+F/&DAW6MR
MEOBL7]5,N5%^(8;N)/E0?BM;ZZF.56_BLE]:NN58O&C7N3V+'XBE_J]QIY)2
M3QK'QT>U</I"0?.$FC)BR:)'<.GCQTX.F@V:MD$S'44.8I"$*(B(``CIO/J9
MKQ(2"=R+R(:S1\CTXL2YEH]LQ>R$6WD33(,UI%BSDVRJR!3BJDDX2,8H%4((
MS%OC\KXU?U.O+LVT_:&=ZJ[JNP;F071;,&\Q-(2AXV,7?.7*::)%E2&5.H4I
M0$3``G;NL\89;+I[O.(N,H4A%8F\4IR[Z:DX4Y=XA@$-H=D!`=2EQKU^I4[4
M8,CY2:M,-:8*4KD.G%M"R$F>4G&+]>,CR1S`P+KBJJ0$41`Y]A>SI&Q5"RP%
MJK[DS@C>=K<S'3D.N=HJ=!T1&3C'+IDJ9LNF8B@%.(D.40'8(#JN23W(-,;Q
MUPM+*CU1\:RQ!F=DN4B[58,:M!N2.S(R<^Y>HG2*T1$ZPJ$,&[M*.S7]J?U3
ME./'S/ZO?<J6_H'=!N5/^(7'=L?RG'B*T_FS+\J'\:1_=:/+F/&DAW6MREOB
ML7]5,N5%^(8;N)/E0?BM;ZZF.56_BLE]:NN58O&C7N3V+'XBE_J]QJ8DK*\B
MX^N1\5(/I]_..&C2$8PC1HLXE7DPZ?G38MHMLQ34.X46,5(B)3"<0*`ZX-Y"
M7S9PJACM'UGN'55ZZI%UYG:6C>#]8[6[3<E)&[NLLN(0R,)CB2CY>7,-?2*C
M6'+8Z_-MCI.#7[!$)0Z\I@OBU2;90A96'K3!:O05LAPBR9JAIGJ+%>+YNUUQ
MG'RL&LYW2GE';L4]\$Q`OJH:@HVPY1_O'GWB[N%HK\LO4HIS,/,H\-&:VS*9
MF6,HJFY=M[?E*:!E'F5***\JJFT;!S@)I!Q'V[@\5HMT=8:O->I.?^#VA6.O
M2SFW8"C,-8N0F7=?H3>9,2"ROCRU/I59F==H=2P`V>U]4.L+-E&G#',6L\)5
M\9J\'.%;#;7<P"58AV5>?8<K$K/R$^98&18]-5LLJH],MN&VF/SG9$=43*?"
M1E/'UCQZV];)P?YLRRRPZZAG^'>%NCP]$F\=H33IU$H*X_I;27;T\UCL3E0&
MZ#61F!!X`DYI9Q/3F3U22SJ+S#FBHT>[DB6T`.3,6U')%A@,>9$4@V39HPCS
M6.NLDA`[8A6K\B0/4"D1<ID+_:G]4Y3CQ\S^KWW*EOZ!W0;E3_B%QW;'\K/6
M&SJ7:!C,(8&Q[EC'U=HUL9TBQ9CG[@QS4M*&-85W#=,U5926/V$$9JX608=9
M<N!?;Z*B`EX9.-:-LF:V^+S16:;KEO&-WGZL=C<,%$S1CFB!>W];J,G9*_"2
M^#8#,+R8$S(Z+J59U7FCHHE72*EQNV^SSF8;]C+%?#EPGWW%>$L=QSZSE09Y
M7M7$Y!3TG6Z'"$3=72R6Z,Q!"R2*BHJ*MB.%DT1!,1$UJITDURYA6C4[%6#\
MI5&$>@[QGD*WR>19"Y.IE6T,-[[P1;.D*51")?0RVZD9TZ5!P50!2`)TY<Y7
MC,6+JKB/)L[;[KC"0IK#-.$YNVY.S5*5O+MFQ.!F<3F:C4FDH)5Q*-CWC5R1
M_3UEVL48S@Z<?FFAX?R7Q*7C'\[A'U>-KJ5^Q_E=Y5HC#J/%!>LUU"^YK2Q^
M[>I2UB8?<^J,9YO$BW=L(TT0J=V5%NJX,;"D`SKE5M[*X7S"4'88+OS)EN[:
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MU)A`\2&'\\94AK/74G4"BXR,PK!\%.VA7Y5H1K.HO4739-!(P:OW$;.0#!MB
M^L<#.$<KJ86CDG+E=3*%VXM>)OAQE'["YNI=JTB8965Q,T>+.7K%1-"*4*54
MZ`MUG2N<,5K4@N&LP0W"1Q?YO<6D+##R@HUC$<;78B@3%(6Q[>+:QKMJN(W]
MI+"DZF'CJ`*PW5FKE)\U<ZX'^&Y&N0=@/G'@_<YVM&3K-9YA6>1<8W5PM$6J
M,"#0AU"2$E8&62C.D7ZTAV7B0E51W-JAN(D&N-L?W4N(Z[A2ZUJ2KEUG6E8F
M8++G%_E;A*>Q`V)>MR(V22ILEBQ646?LFK1@[=.%HU(`(S+)/)J$0Q33+`^B
M.)3BUX<6Z"UKFZTTE9+AXX5[IQ5UZT+2I(.TK0K&PP-0[QO6Y6+]1-VXZVD<
M$T^KG+*W3#=LLJ,GPC<,7%C#P^!:Q9<DW$C/B#F9BIR.._NH@D9]-RE0F(8T
MBG(H';@\AS.5#LT.]RBKE_3HC%#>+->O61K\'B[^W7JU/)"`1>\"->XJ8:_*
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M[Q_*O84\\UQMWA(Z4<\\4STZB(IK<V!,9`_PU63S65*WQ^/XFKUR:R99@AYW
M@4XHJ]P]R#163I&*KY>[3'Y&96M"00"*I:SZ/49J%%!P1<.JDB+MP^S-1CV%
M16>QCB!K_%PG)S,NI<VL8WB4E.(K@IX6Z`1,6\RNX4,E9'#PJ;01(T43!PJU
MR1,4M].UNSMZ%='M>M$[2+$U9P,Y"U24F#BM$S,0V=*S$0JDT`6KE%)(57B>
MTQP2<%3D<E04M/62T80X`/5[9YJ$2(LVY\]Y8XB+)D.J9,9V3K0-^^W7C8_:
MQC-,Y44&DE+'=!O*<P*<%-QS"7L1I_UA^3N$%]BHJC%)A'89I6`LHY'B;TR:
M<Z4Q+"[G*(QE1?&$RJL9(BV$FZ)!+P_Q-FL%D=!Q/\`47Q2W:R(/&;=/$&:Y
M&7Q.,16ZLT;'!6*B')K_`"1&S`15:@%44!;?467%7#V89"/7BY.^4B*EY9DN
MT58F3F$P4CY=5%JL4BB+-U),U56X"&P4#D$!$!`1I%@P?PX37$W9WDH[C7U)
M@\AU3&[J+B5'4HNK/GF;<@O'N44'"*:(H$`%3"J!@[!1U8(7.O!!:.%VOQ=>
M[Z0]LG<T8\R6WL,SWR9-/NZC%4]JW>L%NI.%7/6%1%+=0$FS>,&DZMA7@&MO
M$I33UZ-E#Y%A,Z8UQTS2F';A^D^KHU^V,UY4RT8BV14,X`W-*`X`"]DIM-+;
MF3!<KPZW9>5E63C&DS=JYD%\SCV2Y4X^6-8ZLBA$*IRR0BH5(I=](`V&[.GC
M!KZIG(+Z-0DG#1M,DXI\*()/&*3HZ*,F5FI'"X13<(%!4$S>[*`[H]G5UR'B
M_%+W*N08.`!_&X]9V:#K3DZJA"=?=FG)U)6(%.N-SJ.E$S%_\25`4R>Z.&K(
MKQ)\'\QBNMMRM'4-G8LPPKE?O#T2.@(R:XML1FUS;E.U(F8DFQZ[%KB8WND=
MA0-JQ^(I?ZO<<HI2E`I2@!2E*``4I0#8!2@&P```#L![/]J?U3E./'S/ZO?<
MJ6_H'=!N5/\`B%QW;'\II*7&G0<[+PM:N;.(FG30J<Y&,7T&N^D(YA--A0E6
ML9)/(EJHY;$6!!R=LD*A#;A=D*JTQ52V:5<J$Q0(*.90S=G"1=)L2"K:?JS2
M`:@E")0<VDL/6V_5^;<&`IE`,8A!+9,MUZB0$/DJXQ47!6FYL6QT9R?A(,[M
M6#B)1T"G_BXV#4D'(LD#`*;07*W,@3G5-Z-E+/6(N6E8=-1"+EU43(2[!JNY
M:O'#)M*M#MY!*/=.F2*BS<%.95.D03E,)2[!6E\545XL:IP%"55-7(U)1Q1*
MLZFGU>H[H[=!(SNFQ#RQOU48M43L"G>*CS6TYML_E&K4"NP.0;3"P];L5LBV
M@M9:9K]>%V->@WZJ:@$7B:^,@YZ@W$O-,NLK<R4G.J;U4G\AXRI%UFX60KR4
M5*6:N1<P]8)PUNA[?#E;.'K=91,(BU0S61:]G:V>H%63W3AO:MK*+J.+JS>;
M9.L[&O?Y_%T;>'4=8AAW-.EKK'1??FL"CDE3'TJ^BV$\#H';`545#E<I-P;'
MQQB26Q33+[7L:X?Q-@^.=7RN1%FD9NAX4)`JX]CK*K)-%TYH("8KC:2;@N4Y
M4'X"LF!3&$1F[N2L09;?9:Y#5"P64(QIWZF:M7GD[(0=>DI`4NL/(B*?6>15
M00.84TSO%1`-IQU5'C+`&*V#NBSE6LM/<Q]0B6"]<GZ0RF8RFR\2JS004:/J
MK&6*0:QZA1VLVSU=)+=354*9>J5W`>*8RL.J=(8]=U]*EPBT,[HLK-V"RR-1
M=QSEJLT=5YW/VV5>':J$,B*\DZ/N[5U=ZK8^C,#XJBZ/2(6WUNI52+I,%&P-
M?KN01$U]K\;&L6:#9"#NR@@I+--T6\BJ4IW!%#E*8*_=X;&5+B+9C.NSF-<>
M3D7`L(YY2L?R#U`[ZF5GJ:2*4-6W9XUL*C1`I$3BV2VE_FB;MCA9#!.,%XNW
M)M$;.S"I12*<ZA'Y`FLKQ[:3,W024=-6&2[&_G4$C&%-&5>+.2`550QAOK&J
M8\QS2\AVIYD:VP.17M+5LJM6RQDNER-#G\IFB&EBJSR5LCRNR1VCLZ<DR7>,
MA,V.N5(QBZQYC=@,#,V6IXUQQCZTWZ'K!ZJM>CXWJ[:LQ<LYB'$[:'D4U,FD
MLNBP&2=HLU'2W-G$5#F,M<G&'Z0I:7&4$<V+3W>DA9(^76]>/4$<D"X(<I@N
M1*DJ:*Z^&QP,:/51-S'\WJ*P0MB"DGPU"22$O$XT"**2GL9%K)+S#5RA"IG*
MT`6LNY.[2*("1-SNJE`%"E,%$?7*AP5C?XH0(MC:1E$5G$C2G,O3&M6E'E>?
MBN#R/?2%;648++D/SRC195(3"150#46(A\%8P8QF,8^$BL>,4JE$F;TN,K-Q
M;Y!K3"N)JMU`BFE;N[1*5CDTMTK%ZF55`$S%`=6/&<OB:@R^.[='-XBR4:6K
M,9*5.8BV@(BVCW<`_;N(P6B"R!%BD*D4H.`Y[9SHB?5+Q!D+AVQ#;<58Y$#4
M3'$S1H)S2:D<$.K`>"K75"Q$>H5`1*!DT@,`&-L'W1MM,9?[J:(#3'M;CJ92
MFQ*Y&D1KM/B`:]ZZFP3(@4H5J..Q1.BP.!FJ:J1%"I@<H&"M-LS8GQWE1O39
MU&SU1#(%0@K:C7;`W+NI2\0G-L7I&+T"@`"=,`$P``&V@`:!P7`&/"+S5AA<
ML2ZB<4HF:3RB5@Q(3([[<<EZS>DR,4"DEC[7Y"HI@54`(4`A\8O\`8IE<>UZ
M]NLGP-.FJ;#S4!#9$?2SF>?W2,CI5L\096.0FWJ[QPZ3`JJ[EPJHH)CJJ"9Y
MD:.Q70F5\D"61-[;F]7B$I]PE<481"VHJ216H.11LZ=;8=\"`8"O!9I&5`QB
M`.JE1\:5C&&+L$1MQ4R;=<1U#%,''$NV2XNXUF^4VSDGV,BQ85]&%L\`=T^1
M")=N)-0R`%=-4D#IN((>N##62G66.N5)LJ;-!^O7K)&I.V0N`:+F3([CYB#D
MGL9((`HB=>.?+IIJHJ&(L2IV2B8AI-6G:(A?&M-E8B)3;/*RAE*;^\N2DX=4
M#&%D%]L8`_F!)L&1>E*NN)U2E,$'XK6^NIC4I`S;!K*PTW'/8B7C'R)'#*2C
M))LJS?L'C=0!37:O&BQTU"&`0,0P@/8'5):M\?U-%MC>&BZY1&R4*R(A5J_!
MD8$A82(1*D";>*AQBFIVK?8*3=5LDHF4JB9#`ZO;:JP:%Q>H=7=6-*.;DE5T
M^93;&,HZ*0#BN=HB1$RO_>G1(5,3"0I2A;F5`C(?'LO<VZS64L<!",RR*2;M
MR]<.EV9`,@BDZ14EGKAH!MYJW?N3N#(*B94BM;I588IQM=J<'%UV#8)``$:1
M<0S18LD?<@4#&*@@7>-LVF-M$>R.JW\5DOK5URK%XT:]R>Q8_$4O]7N/W'^U
M/ZIRG'CYG]7ON5+?T#N@W*G_`!"X[MC^4X\16G\V9?E0_C2/[K1Y<QXTD.ZU
MN4M\5B_JIERHOQ##=Q)\J#\5K?74QRJW\5DOK5URK%XT:]R>P_[X[O>_J3KK
M^_O[O4N84ZUO<U_.;O,;VW=]U_!V=?1?XBU]%_B+7T7^(M?1?XBU]%_B+7T7
M^(M?1?XBU]%_B+7T9U3K/_\`8-WK/->_V\U_U:^B_P`1:^B_Q%KZ+_$6OHO\
M1:^B_P`1:/L[V][NNI;_`(?W.N\PMS6W_P#)O<QO_P`6S^/7T7^(M?1?XBU]
M%_B+7T7^(M?1?XBTYYKO9U?^9ZSL^\&S^6/,[VWW7\OVMFOHO\1:^B_Q%KZ+
M_$6OHO\`$6OHO\1:>]3[V[O4E.N[O?\`_P!2YY#G-[?_`.SSVY[79VZ^B_Q%
MKZ+_`!%KZ+_$6OHO\1:^B_Q%I3J'>WG^I26_N]_]O4N]SKOCMYSW.[WOYW;_
M`-K9_)[.S7T7^(M?1?XBU]%_B+7T7^(M?1?XBTUZGWLZWUE#JN[]X-[K/.EY
MC=W_`'.]SNS9M[&OHO\`$6OHO\1:^B_Q%KZ+_$6OHO\`$6OHO\1:==<[V=;Z
MROUK>^\&]UGG3<_O;GN=[G=NW9V-?1?XBU]%_B+7T7^(M?1?XBU]%_B+1^^'
M>WK7-MM_?[_[W-]61ZO_`-W[G9U;<V?Q>WV=?1?XBU]%_B+7T7^(M?1?XBU]
M%_B+3?KO>W>ZDTZOO=__`/4N9+U39N?]GF=FS;V=GMZ^B_Q%KZ+_`!%KZ+_$
M6OHO\1:^B_Q%IGS_`'LYKJQNI[?O!LZMUMUO;NSL[O6^=]OL[=O[VS7T7^(M
M?1?XBU]%_B+7T7^(M?1?XBTPZQWMZKS:_4-O?_=YOK*G/[F[[K9UG>V[W[_M
M=C7T7^(M?1?XBU]%_B+7T7^(M?1?XBT_^XG5NJ=92Z_U;K^[UGFOYO>Z_P"Z
)WN:__CV/8__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex5-10.jpg
<TEXT>
begin 644 ex5-10.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8U+C`P`/_;`$,`#@H+#0L)
M#@T,#1`/#A$6)!<6%!06+"`A&B0T+C<V,RXR,CI!4T8Z/4X^,C)(8DE.5EA=
M7ETX169M95IL4UM=6?_;`$,!#Q`0%A,6*A<7*ED[,CM965E965E965E965E9
M65E965E965E965E965E965E965E965E965E965E965E965E96?_``!$(`&H!
M*@,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/1Z***`"BBB@#GY((=+\5PSK%&D>I1F)F"@8E7)'/\`M#/UVBJ\
M7DV/C(RQ01QVUXOV8NJ@?OE&[]02/JM:OB*QDOM(E6V_X^HB)H#Z2*<C\^GX
MU6U#2IY/#@AB(-_#BX1AWF!W'\SD?C0`TF(^('E@@B-TX\F-RO3:,R.3U/WE
M7ZC%6KF[O+.X@29H'BN'\I9%C(\MR/ER-QR#C'4=JA:QN;0Z?=1)Y\T"NLZ*
M0"_F8+$9XSN`./3-6+E9-0DMQY$D<,,@F8N`"Q7HH'UQS[4`-T?5OMNDFZN5
M6&6('SE'1<#.1[%2#^-48=9OIK"SN"+:!KB[>W970GRPI<9SN&3\GZT^UTRY
M$MF^SRHG@1+N-B,EH\;2,<'/(/MBJ\=E=K86<<EC(YBU"6=TRA^1FD(/7_;%
M`%O^U+S=$N(.;S[*SA25<;=VY>>/0CGD'GBK>K7=Q:FS%NT(\^<0DR(6QD$Y
MX(]*S)+&Z2[2:&S=;?[6DP@5E^0!&#-C.!DD<#TSWJSJHN+UK,#3IBD-RDCA
MS'\RX8'C=[B@#2M'G9Y5FFMY@I`!B0K@XR002?459JI9!5:54L6M5)#$G:`Y
MZ=%)[`5;H`\;>[N-[?Z1+U/\9IOVNY_Y^)O^^S4;_P"L;ZFFU[22/(NR;[7<
M_P#/Q-_WV:/M=S_S\3?]]FH:]$\%Z3!%I27DL(:>8DAG&2%S@8_G6=6:IQO8
MTIP<W:XWP/:7*6T]U=>9^]($?F$YVCJ>?7^E=5117F3ESRYCT81Y58***9--
M'!'OE;:,@#C))/0`=S4%#Z*BAN8IRPC8[D.&5E*D?4'FI<T`%%59=1M81,9'
M91`563Y&X)Z=N:F29)))(U)W1D!OE(`)&>O?B@"2BC(!`)&3TJNU[`ER;<E_
M-&TD"-B!N)`YQCD@_E0!8HHHS0`45"ERDES)`N=Z(KD]B&S@C_ODTDUW#!(L
M;LV]L<*I;&3@9P..?6@">B@,",@@CVHH`**`0<X(.**`"BBB@`HHHH`****`
M&RRQP1-+*ZQQJ,LS'``^M4)-9MXXS*T5UY(&3(+=\`>O3./?%5=7;S?$&CV<
MG,#F69E/1F0#:/PSG\!6W0`#D9HK#\1:@;54,=PL1M]MQ*NX`N@;E??(W'_@
M(I-7N(H=5L3-=20VLD,KN5E95.W;@\'W-`&[17.RR78TB!Y9IPQOHXT<DH[Q
M-*%&X#')4_Y-6]4E?3;R'4&DE:S/[J>/)(3/W7`^O!^N>U`&O16%<QSP+IK/
M-.LD]X/,7S6.%(8[.O;`_*IM?=H_[/*R3('NEC<1,P+*5;(X^@H`UZ*I:=L+
M3F,W6T,%Q.6/;.1NY[_I5V@#Q5_]8WU--J58GFN1%&I9W?:H'<DUW&F>"(87
MCEOIS,PP3$HPN?0GN/RKUYU8TUJ>7"G*;T+.B>%+"*SAENXO/G=0YW$[5SVQ
M_C72JH50J@``8`':E`P.**\J4W)W;/2C%15D%%%%24%5+^V><VTD6"]O+YH5
MC@-\I4C\F/XBK=5KZY:TC20(&0R*KDMC:"<9Z=LT`9]SIT]S>?:FCC&6B7RR
MW\"EB2>.IW8Q_C3;?3+I)86EY1``JI)CRR'9ACCH00#C^[CI5B#57F=T$*AT
MG,>-Q.4`SO''L:EBU6V=(BSX9UC;Y58J-_"\XZ$\<XH`COM,%W>AV(^SR1%)
MT_OXSM_+<WZ56ATN[6:"2XE\YMH\PJVW#AL[AQT(P/\`@(]:T#J5MOB56=O-
MD,:D(V,@$GG'^R>:0ZI:!`_FG:0"#L;Y@3@$<<C)'(]10!0M--N(KFWDD2)T
MB=L;B"P!4<YQR01UX)[U/=:?/<7US*LC0AX$CB=)#D,"YR5Z$?,/RJ_%<1SP
MM)"2P!(Q@@Y!P1@U2M=526U^T3;4CR!\A9]A[AN/E([YH`@;3[C(DCC2,(82
M(@_4JQ+'/N#CW[TR/29F8">.+:(Y5&')P6<E>,=@<5;75(HFN%NY$C\N5E4@
M'E0%))Z]-W)Z5*=4M`^S?(6RRX$3G)'4#CDT`9HTNY#1N((49$ME7#_=\MRS
MXX[@XJ[?VLTUW%+`H1TV[90^"!GY@P_B&.WKZ=:OQR+-"DL3!D=0RD="#TK-
M@U5IHQ^Y5)ED"O&S=%)P&!QR#_B.U`%6+1Y@L*%(XO*AE0.C<AR05?&.V#^=
M+_95P8X00P4;A)&)1R2`-RG'&,>QY)ZUH6EW/=I!.D*"VF&X,7^8*1D'&._'
M?O3WN94U"*`Q*8Y58JP;D8QU&.G/KZ4`,TZU>U-P&1!YDK2!E/+9YYJ[5&*\
MG(N]\,7^C@?<D)!;&2.@[8_.HY]3:.&)TA#,]NUPREL850,@<=?F%`&E159+
MO?>I`%!1X3*'S[@8Q^-6:`"BBB@`HK-^W7=S'+)I\$,D<;L@\V0J7*D@XP#C
MD$9-:#2*B!I65`<#YCW/`'Y\4`4M5TQ=12%EE:"YMW\R&9!DHWT[@]"*:8]7
M>$QF>SC8C'G+&Q/U"D]?Q-7_`#8Q*(MZ^81G9GG'KBF27,$3E))HT8#.&<`X
M]:`*MI8RQI<BYDCG,QX)0]-H&#SST_4U3M=&N8FT_P`ZYAF2TB>$@QGYT;`Y
MY[!0/>M6*[MIFVQ7$4C>BN":%O+5I/+6YA+YQM#C.?I0!EOHUR+);.*[3R8I
MXY8/,C+%%1@P0G/(R,`^E2W]C?WUG-;R7-LJN!@K"W!!!_O>U:#75NCLCSQ*
MZC)4N`0*2*[MIGVQ7$,C>BN":`*VHV=Q=BS,<L4;V\HE)9"0Q`(QU'J:@N[#
M4+M[=GN;9?(F650(6Y(!&#\WO^E:<L\4"AII4C4\9=@!47V^S*!_M<&PD@-Y
M@P:`%MUN@[FYDA=2!M$:%<>N<DY[5/4<-Q#."898Y,==C`X_*I*`.+T'PE<V
M^I1WE\R*L3;U13DD]LUVE%%7.;F[LB$%!604445!84444`%1W$"7-O+!(,I(
MI1OH14E%`%6/3X(IUFC#+(L(@!S_``CI^-5DT6)(U07%QA4B0?=Z1L67^'U-
M:=%`&<-(A$_FB20-YGF'&T`G#*<C&.0QR>O3TI&T>)HXT,TV(E5(SD950RMC
MISRJ]?2M*B@"G'IT"*VX>8QD:17<`LA8Y.TXXYJM<:'%<!_-N9RSC#-\OS8&
M!D8QGWZUJT4`9_\`9,8G,XGE\TLS;B%/W@H(QC&/E7\J5=+19%<3S;ED>0?=
MZL,'M5^B@"K9VCVB+"LS/!'$D<:L!D;<C.0.<C'Y5&-+AQ;EGD9[=B5<D`D9
MS@X&"/\``5>HH`JVMF+55CBFD\A.$B.,*/3.,X';FG&U/VS[0)Y0<!=F%VX_
M+/OUJQ10!6BLUBLWMP[G?N+.<;B6))/IWJ*73(I(8HS)(/+B,&X8RR$#(/'L
M*O44`0?95%XEP&8%(S$$&-N,@^F>P[U/110`4444`85SI-Y:237>BWGEF1C*
M]K,-T3L>3@]5S[57OKF36]*@^SV\V][=;E0F/DD(S'G)'0@G\!6HNCPJAB$]
MT;<_\L3*=N/3UQ[9Q5BVL8;625X=X\TY8%B0,``8';@`4`94RKK*Z==0.8)S
M"\L4G>-_DX/J.H(^M/@O!>W.)8Q'=0V\J31'G:V4Z>H/4'TJY:Z3;6CJT+3#
M:68`R$C+'+<>YYJ>2R@DN&G*8F:,Q%U.#M)SB@##CM8)O`]K)(`CPV*R1RCA
MHV"9#`]C5!I&E@U."YMU5KN>.-IFQM@=H(\$]Q@]/?'(KI(-(M8(8H1YKPQ`
M!(WE9E`'3@G!Q[T[^R[4F\WJSK>?ZY78E6X`Z=N`!0!4*!?$6T_,188)/4_/
M5*TM8)_`EFTH"M'8I(DHX:-@F0P/8BM9-)MXY5E#SF18O)#&5B=OIS_.BWT>
MT@@B@7S6@B`"1O*S*`.G&<''O0!1\.227BW-U>+F]5Q$5/6,!%.!Z9SG\:@U
M&Y2Z:U-O:F.2/4E1Q+@!G"'/(SVQS6S+IT+W1N8WE@G8!7>)L;P.F1T/UQFH
MGT:T=%4^:"LWG[A(P)DQC<3]*`)[1)@\S3PPQLS`+Y1SE<#J<#OFK-06]HEN
M[LLDSEP`?,D+8QZ9Z=:GH`****`"BBB@`HHHH`*9+-%"`99$C!X!9@,T^J.M
M0B?2;M!%YLAA=8P%R=Q4@8H`L_:8/):;S4,2Y+.&!`_&I000"#D&L&>.Y/VY
M%#I$Z-Y<20'#@QXY/8[L]>?PIEQ+?16M](99(A%"S1`1<8$>0<]`0P/!Y_"@
M#?:6-'1&=5>0D*">6(&>/PIU84B7$EY#DW+6RS[E<J=Z_NG#=NF2/S/:B"34
MFMT,@E%QLBVC;A2>-^[CCO\`AC%`&[17/[]3"'RC<,[)-]].F)!LQTYV;OTS
M6I9F3]V))9I,ASS%L&,C&<\Y'0>O-`%EI8T8AG52%W')Z#UH,\01',J!7("G
M<,-GTJA'D7.IF569MZ;-J[B$V+@@=\-O/YU2D@G_`+`,'DN9F\S8!%G?EB0&
M_N[N,],>U`&\S*N-Q`ST]Z8UQ"L:R-*BHW1BP`-9A6[76&EP6!**@VY41X^;
MYNQSD^^!U[-"R26D\,2$B6Z=(WQ_JU)^9O;!WX]\4`:PFB+J@D0LPW*-PR1Z
MBGA@20""1U'I6=<Q1B]LXUA<)"P<,D9(S@J!D=!R3^%.MTD2\U!HX\%V4H6!
M"M\H!YH`NM+&LBHSJ';HI/)I2R@X)&<9QGM67>K-)<V>(B9$D5G`3*$<Y.[M
M@$D>M5'M[YX;Z+:SO.)M^5QW_=A6[Y7CV]NX!N>?#Y7F^:GE_P![<,?G4E8?
MDR?;/M)AD^S?:2^S8<X\G;G;UZY'ZU<T^VN8M.M8Y)-KI$BL.N"`,T`:%%%%
M`!1110`4444`4Y=3MH;GR'9MV]8RP4E59ON@GU/'YCUJY7%7UPHUR[O\H6M;
MA(WL-V'F``VR`9^9LMP,<X]<8Z'P_+%/IXFCN#,TA+L#*7,>2<+R>,#C\*`*
ML;7T_B&_LAJ,T<44,<B;8X\@L6R.5Z<"GV.L2)IM]-J`WFPF>*22)>'50#NQ
MGT/(]0:SKFW2_P#$^K6\=X]M<-:1"-XI2I#9?L#SVXI9;^"3PAJMHT<=I>6U
MO(DUN.,-M/S#U!SD'WH`Z%[Z-61`DCS.N\1*`6`]3S@?B:AEU98?+$UK=(TD
M@B52JG+$9'(./7\JIZ=/'#K=\D[JK7(C>W8GAT"`$`]\-N./]JFZ]<P226$:
M7*HR7J!F5AE#M;UXS0!L6]P9V=3!-$5Q_K%QG/H0:FJG8M&'G1+W[4Y8,<LI
M*#``'';@_K5R@`HHHH`****`"BBB@`J"[NA:QJ[1NX9U0!,9R3@=2.Y%3U4U
M*U:\@2)=F!(CMNZ$*P./TH`E2ZB92681L!EE<@%1G&3S1)Y%U$\3,DB.-K*&
MZ\=/RK..ES)>"2)X3`D;1)$ZG`4A1@^O*_K[5/86,EI#%$S1RK$Y*NPRX4@]
M_7G&?2@![:A'%9R3B.1X(BPW+@\+U/)Z<'W-3272QW$4+(_[T[5?`QG!./7H
M#VK/%C++I`L,1@Q@QDR*>/[KJ?7H?KW&*L2V4DEW;2%TQ`<^9@^81C!7/H>O
M].]`$S7B>7,\:O(L)(8J.N.H'KC_`.MUJ5I0(?-C5I00"`F,MGTR<5FV]@=.
MWRH`^U74*@^:4LV1N]QTS[D\59CM)H=&BLXI0LJ0K$)/3``S0`UK^$0+>-;R
MA>5+8&4`;&3STSZ9JT;A!=K;8;>R&0''&`0#_,5!<6CFW@@MQ&L41'R/G!"_
M='Y@?E3C;R-J$=P67:L+1D=\D@Y_2@!UY<K:PF22.1D`RQ0#Y1Z]?Y<TY)8D
MF%M&O*J"0HX0=L_E56^T][BS-LD@(;/SRY9D/9E/J/\`)IK:8?[0:Y5ER\BR
M%_XQA0NT>QQ_/\`"PU_"(7E&YHU8("!]YB=N!Z\\>E2V\Z7$9=`1ABK!NH(.
M"*RH=$,,`B5T7RQ'M(!^<HX8,WOQC\3^&E96YMXY-Q!>21I&QT!)Z?@,"@"Q
M1110`4444`%%5+*>:6282QNBY#1DJ1\IXQ]>"<>XJC+-J*VX=?,8F5@!Y>2%
M`?DC'3A?KZ\B@#9HK+N+B[\J5H1()!YGR>7T`4E2..23M_,C%2%[E+J!"TA1
M@2Q"Y'WAC)"^F?2@#0HK-^T77D;BKEQ)@X7[RX_ARO'T/OS3C-/YSHQE6/>X
M#B/)'"X'3IRW/M0!>,49D$A12X&`V.<?6E5$0L555+')P,9-9T4]X)$\]&V'
M!;8GW3LR1[C/0COQ1%=7/[OSHY5(E(<+$2"I4L.@[<#ZB@#0\J,/O\M-W][`
MS0T4;DEHT8G@D@&H9972]B7YS$R-G"$C=E<9(''4U5-Q=JD+*DDA+NK*8\$C
M=A3TX['Z9H`O/!#)'Y<D4;Q_W64$?E0+>$($$,81>B[1@5G+->-:,Q,HE%JK
MC$763G(QCKTXI9Y;I))0C3,JP[D/E]6PW^S[+QF@#22-(\[$5<]=HQ3JKV;R
ML)/,+%0PV,R[21@9R/KFK%`!1110`4444`%%%%`!4-S<K;"-G5BKNJ9&,`DX
M&?QJ:H[B".Y@>&90\;C#"@"DFL020"98Y3'P&.!\N6*\\^H/X4?VQ!Y,LJQ2
MLD6[?@#Y0IY/7ISD>HYJS]BM_+N$\H;;C/FC^]QC^0I8[.WB,A2)1YH"O_M`
M#`_2@".#4(KB=X8T<LCLC=.,`<]>G(J%=8@9UC$<OF$,0N!G(?81UZYJ>+3[
M:$J8D*%51`58@[5Z#]?Q[TOV"V\[S?*&_P`SS<_[6W;G\J`(7U6%(Q*8Y/*9
MBBOP`QR1U)XY'?&:<-2BS=%TDCCM03)(P&T8`)Q@^A!I3IEL8WC_`'@C<DE!
M(=O.<\=.<FE73;95D0(VR0DNI=B&RNWD9Z8[4`(;\*^PV\PDVE]F!G:,9/7W
M`]:B75X9"/*CED5G$:LH&"2@<=^X(J8:=``HS*2JE0QE8MM.,C.>G`I%TNU1
M@41EPZR`!R`&"[1QGT`&*`)[6X6ZMTF0$*W9NH]14M16UO':PB*($(,D`L3U
M.>IJ6@`HHHH`****`"BBB@`HHHH`*@-V@C+[7P)1%VZE@OY9-3US+2R>?=KY
MC[1=)@9.!^^6@#<EOX8_-SN)B958#'\1P#SVS_(T)?Q2*&57*L4`.!_$,BN?
MNG98RRLP9@"2#R2+@8_G0\CI:OM=EP;8C!QCB@#H9+U4W8BD;;((SC'4XQU/
MN*=#=+-+)&JN&C.&W8X]/SZ_2L6.1S:LQ=B3>PY)/^S'6G9DG4=0&>`R<?\`
M`!0!,MVK(C!'*R$",\?/P3QSZ#/.*B;5+=%<L'&Q-Y!')PQ4@>X(Q6-#(_D(
M-[8CD4)S]WYV''IQQ]*9J!/V;=GYO(SGODK*3^=`&ZVI0)YV\.ODGYCCWQVI
MYO8_/>$*YD4XVX'/&<BLDG>SJWS*;J8$'D']V:73F+_8W<EG\U1N/)YM\F@#
M8M;E+J+S(PVP]">_^>GU!J:J6D$FQ)))/FR]?^NC5=H`****`"BBB@`HHHH`
F****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 3 - Government Grants<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_GovernmentGrantsTextBlock', window );">Government Grants [Text Block]</a></td>
        <td class="text"><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Government

        Grants</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">NIH

        Grant</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In

        September 2007, the NIH awarded us an Integrated

        Preclinical/Clinical AIDS Vaccine Development (IPCAVD)

        grant to support our HIV/AIDS vaccine

        program.&#160;&#160;The project period for the grant covers

        a five-year period which commenced October 2007, with an

        aggregate award of $20.4 million.&#160;&#160;As of December

        31, 2011, there is approximately $3.9 million of unused

        grant funds remaining and available for use through August

        31, 2012 (the end of the original project

        period).&#160;&#160;We are utilizing this funding to

        further our HIV/AIDS vaccine development, optimization and

        production.&#160;&#160;We record revenue associated with

        the grant as the related costs and expenses are incurred

        and such revenue is reported as a separate line item in our

        statements of operations.&#160;&#160;During 2011, 2010, and

        2009, we recorded $4,899,885, $4,940,778, and $3,668,195,

        respectively, of revenue associated with this grant.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">QTDP

        Grant</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In

        November 2010, we were awarded a one-time grant of $244,479

        pursuant to the Qualifying Therapeutic Discovery Project

        (QTDP) program enacted as part of the Patient Protection

        and Affordable Care Act of 2010.&#160;&#160;The QTDP

        program was intended to provide incentive to smaller

        companies who are focusing on innovative therapeutic

        discoveries.&#160;&#160;We received the full amount of the

        grant during 2010, which is recorded as revenue for 2010 in

        the accompanying Consolidated Statement of

        Operations.</font>

      </div><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_GovernmentGrantsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>govx_GovernmentGrantsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>govx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>18
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%\S-#`T-SAE.%\Q-&5C7S0T9&1?.3(S-%\V93`R
M,C=E,V9A-C0B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\S-#`T-SAE.%\Q-&5C7S0T9&1?.3(S-%\V
M93`R,C=E,V9A-C0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S0P
M-#<X93A?,31E8U\T-&1D7SDR,S1?-F4P,C(W93-F838T+U=O<FMB;V]K+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P@>&UL;G,Z=CTS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M
M8V]M.G9M;"(@>&UL;G,Z;STS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M8V]M
M.F]F9FEC93IO9F9I8V4B('AM;&YS.G@],T0B=7)N.G-C:&5M87,M;6EC<F]S
M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?06YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N='-?;V9?4W1O/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A
M=&5D7U-T871E;65N='-?;V9?0V%S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^3F]T95\Q7TYA='5R95]O9E]"=7-I;F5S<SPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5?,E]3=6UM
M87)Y7V]F7U-I9VYI9FEC86YT7SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/DYO=&5?,U]';W9E<FYM96YT7T=R86YT<SPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5?-%]#;VUM:71M
M96YT<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970Q,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO
M=&5?-5\R,#`V7TUE<F=E<E]A;F1?4F5C87!I=#PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,2YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5?-E]3=&]C:VAO;&1E<G-?17%U
M:71Y/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#$R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3F]T
M95\W7U)E=&ER96UE;G1?4&QA;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,RYH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/DYO=&5?.%]);F-O;65?5&%X97,\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.;W1E7SE?4F5L871E9%]087)T
M>5]4<F%N<V%C=&D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,34N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y.;W1E7S$P7U-E;&5C=&5D7U%U87)T97)L>5]&:6X\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,38N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.;W1E7S$Q7U-U8G-E<75E
M;G1?179E;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#$W+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^4V-H961U;&5?24E?5F%L=6%T:6]N7V%N9%]1=6%L/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#$X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@/"]X.D5X
M8V5L5V]R:W-H965T<SX-"B`@/'@Z4W1Y;&5S:&5E="!(4F5F/3-$(E=O<FMS
M:&5E=',O<F5P;W)T+F-S<R(O/@T*("`\>#I!8W1I=F53:&5E=#XP/"]X.D%C
M=&EV95-H965T/@T*("`\>#I0<F]T96-T4W1R=6-T=7)E/D9A;'-E/"]X.E!R
M;W1E8W13=')U8W1U<F4^#0H@(#QX.E!R;W1E8W17:6YD;W=S/D9A;'-E/"]X
M.E!R;W1E8W17:6YD;W=S/@T*(#PO>#I%>&-E;%=O<FMB;V]K/@T*/"]X;6P^
M/"%;96YD:69=+2T^#0H\+VAE860^#0H@(#QB;V1Y/@T*("`@/'`^5&AI<R!P
M86=E('-H;W5L9"!B92!O<&5N960@=VET:"!-:6-R;W-O9G0@17AC96P@6%`@
M;W(@;F5W97(N/"]P/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?,S0P-#<X93A?,31E8U\T-&1D7SDR,S1?-F4P,C(W93-F838T
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,T,#0W.&4X7S$T96-?
M-#1D9%\Y,C,T7S9E,#(R-V4S9F$V-"]7;W)K<VAE971S+U-H965T,#$N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$564D%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1O8W5M
M96YT($%N9"!%;G1I='D@26YF;W)M871I;VX@*%531"`D*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,P+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&]C=6UE;G0@
M86YD($5N=&ET>2!);F9O<FUA=&EO;B!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!296=I<W1R
M86YT($YA;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D=E;U9A
M>"!,86)S+"!);F,N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$;V-U;65N="!4>7!E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#Y3+3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-U<G)E;G0@1FES8V%L(%EE87(@16YD($1A
M=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/BTM,3(M,S$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N
M=&ET>2!#;VUM;VX@4W1O8VLL(%-H87)E<R!/=71S=&%N9&EN9SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L.#4P+#8Q,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%!U
M8FQI8R!&;&]A=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X
M+#<T,2PX-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%M96YD;65N="!&;&%G/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#YF86QS93QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-E;G1R86P@26YD97@@2V5Y/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XP,#`P.#,R-#@Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I
M='D@0W5R<F5N="!297!O<G1I;F<@4W1A='5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#Y997,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!6;VQU;G1A<GD@1FEL97)S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y.;SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($9I;&5R
M($-A=&5G;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y3;6%L
M;&5R(%)E<&]R=&EN9R!#;VUP86YY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@5V5L;"UK;F]W;B!396%S
M;VYE9"!)<W-U97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DYO
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y$;V-U;65N="!097)I;V0@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/D1E8R`S,2P-"@D),C`Q,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L
M(%EE87(@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C(P
M,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D1O8W5M96YT($9I<V-A;"!097)I;V0@1F]C=7,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/D99/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\S-#`T-SAE.%\Q-&5C7S0T9&1?.3(S-%\V93`R
M,C=E,V9A-C0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S0P-#<X
M93A?,31E8U\T-&1D7SDR,S1?-F4P,C(W93-F838T+U=O<FMS:&5E=',O4VAE
M970P,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14XS044^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O
M;F<^0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE971S("A54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$P/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-U<G)E;G0@87-S971S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,38W+#DX,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,2PP-SDL,#@W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y'<F%N="!F=6YD<R!R96-E:79A8FQE/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ.#,L-3$U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<T+#(W-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E
M>'!E;G-E<R!A;F0@;W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8V+#4P.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0X+#@S,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E
M;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0Q
M."PP,#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#8P,BPQ.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE="!O
M9B!A8V-U;75L871E9"!D97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<V+#(P-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T."PT-#$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^3W1H97(@87-S971S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y,:6-E;G-E<RP@;F5T(&]F(&%C8W5M=6QA
M=&5D(&%M;W)T:7IA=&EO;B!O9B`D,C`X+#DS,R!A;F0@)#$X-"PP-#<@870@
M1&5C96UB97(@,S$L(#(P,3$@86YD(#(P,3`@<F5S<&5C=&EV96QY/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.2PY,C,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-"PX,#D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R
M<F5D(&]F9F5R:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT,S`L-#`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$97!O<VET<R!A;F0@;W1H97(@87-S971S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PP,3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PY.3`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A
M;"!O=&AE<B!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4P+#DS,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4P-RPR,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!A<W-E=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-C0U+#$T,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S4W+#@S-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M=7)R96YT(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,S@L,S,Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.38L.#DR/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&5X
M<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C4L.#8Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C0Q+#<S-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06UO=6YT<R!P87EA8FQE('1O($5M;W)Y(%5N:79E<G-I='D@
M*&$@<F5L871E9"!P87)T>2D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8W-RPS,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ.#(L.3@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!L:6%B:6QI=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.30Q+#4S-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4R,2PV
M,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;6UI=&UE;G1S("A.;W1E(#0I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4W1O8VMH;VQD97)SXH"9(&5Q=6ET>3H\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"`D+C`P,2!P87(@
M=F%L=64L(#0P+#`P,"PP,#`@<VAA<F5S(&%U=&AO<FEZ960[(#$V+#0T,BPV
M,3$@86YD(#$U+#8U-"PX-#8@<VAA<F5S(&ES<W5E9"!A;F0@;W5T<W1A;F1I
M;F<@870@1&5C96UB97(@,S$L(#(P,3$@86YD(#(P,3`L(')E<W!E8W1I=F5L
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L-#0S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34L-C4U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!9&1I=&EO;F%L('!A:60M:6X@8V%P:71A;#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C,L,S$Y+#$V-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R+#$P-2PW-#<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9FEC:70@
M86-C=6UU;&%T960@9'5R:6YG('1H92!D979E;&]P;65N="!S=&%G93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C(L-C,R+#`P,BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,"PR.#4L
M,3<V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1O=&%L('-T;V-K:&]L9&5R<^*`F2!E<75I='D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<P,RPV,#<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@S-BPR,C8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A
M;"!L:6%B:6QI=&EE<R!A;F0@<W1O8VMH;VQD97)SXH"9(&5Q=6ET>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#8T-2PQ-#(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L,S4W
M+#@S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M,S0P-#<X93A?,31E8U\T-&1D7SDR,S1?-F4P,C(W93-F838T#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,T,#0W.&4X7S$T96-?-#1D9%\Y,C,T
M7S9E,#(R-V4S9F$V-"]7;W)K<VAE971S+U-H965T,#,N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$571T%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED871E9"!"
M86QA;F-E(%-H965T<R`H4&%R96YT:&5T:6-A;',I("A54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$P/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,
M:6-E;G-E<RP@86-C=6UU;&%T960@86UO<G1I>F%T:6]N("AI;B!$;VQL87)S
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,#@L.3,S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M.#0L,#0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V86QU92`H:6X@1&]L;&%R<R!P
M97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@875T:&]R:7IE9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,38L-#0R+#8Q,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#8U-"PX-#8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;6UO;B!S=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-BPT-#(L-C$Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34L-C,R+#4V-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S0P-#<X93A?,31E
M8U\T-&1D7SDR,S1?-F4P,C(W93-F838T#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S,T,#0W.&4X7S$T96-?-#1D9%\Y,C,T7S9E,#(R-V4S9F$V
M-"]7;W)K<VAE971S+U-H965T,#0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4Q14%'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/D-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F
M($]P97)A=&EO;G,@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,C8@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,#QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#`Y/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT(')E=F5N
M=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PX.3DL.#@U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`U+#$X-2PR-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#,L-C8X+#$Y-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C`L,S$Q+#8Y,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/
M<&5R871I;F<@97AP96YS97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PR-S8L,S<U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PW.3,L.34V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-"PP-C@L-C@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C4L-C,P+#8W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1V5N97)A;"!A;F0@861M:6YI<W1R871I
M=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.3<R+#4U-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M,38R+#$S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(L.3$T+#@T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$W+#8T-RPV-3D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X-"B`@("`@("`@/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#(T."PY,S`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#DU-BPP.3`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M+#DX,RPU,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT,RPR-S@L,S,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!F<F]M(&]P97)A=&EO;G,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L,S0Y+#`T-2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#<W,"PX
M,S,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,RPS,34L,S,R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#(R+#DV-BPV-#,I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R(&EN8V]M
M92`H97AP96YS92DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DEN=&5R97-T(&EN8V]M93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPR,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,RPU,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,2PP.#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-#`L,S$P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S
M="!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#8V
M.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X-"B`@("`@("`@/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#(Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(S+#4P-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,Q+#`X,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,S-"PV-#$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R+#,T-BPX,C8I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R+#<T-RPS
M,C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@S+#(X-"PR-3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@R,BPV,S(L,#`R*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY"87-I8R!A
M;F0@9&EL=71E9#H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&]S<R!P97(@8V]M;6]N('-H87)E("AI;B!$;VQL87)S('!E
M<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XQ
M-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B0@*#`N,3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@P+C(R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,BXQ,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@<VAA
M<F5S(&]U='-T86YD:6YG("AI;B!3:&%R97,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-2PW,S4L-30Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34L-C4Q+#,P.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#$Y,2PR-S@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,"PW,#0L.#`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\S-#`T-SAE.%\Q-&5C7S0T9&1?.3(S-%\V93`R,C=E,V9A-C0-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S0P-#<X93A?,31E8U\T-&1D
M7SDR,S1?-F4P,C(W93-F838T+U=O<FMS:&5E=',O4VAE970P-2YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P15!(2$L^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0V]N<V]L:61A
M=&5D(%-T871E;65N=',@;V8@4W1O8VMH;VQD97)S)R!%<75I='D@*$1E9FEC
M:65N8WDI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^0V]M;6]N(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D%D9&ET:6]N86P@4&%I9"UI;B!#87!I
M=&%L(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-T;V-K(%-U8G-C<FEP=&EO;B!296-E:79A8FQE(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E)E=&%I;F5D($5A<FYI;F=S
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E1O
M=&%L/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F,^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA
M;F-E(&%T($IU;BX@,C8L(#(P,#$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V%P:71A;"!C;VYT<FEB=71I;VX@870@:6YC97!T:6]N("A*
M=6YE(#(W+"`R,#`Q*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q-S`L-3DR*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$W,"PU.3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E(&%T($1E8RX@,S$L(#(P
M,#$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3<P+#4Y,BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M-S`L-3@R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4V%L92!O9B!C;VUM;VX@<W1O8VL@9F]R(&-A<V@\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-SDP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPS,C`I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y386QE
M(&]F(&-O;6UO;B!S=&]C:R!F;W(@8V%S:"`H:6X@4VAA<F5S*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPW.#DL.34T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O
M9B!C;VUM;VX@<W1O8VL@9F]R('1E8VAN;VQO9WD@;&EC96YS93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S`U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30X+#$U,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T."PX-38\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES
M<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@=&5C:&YO;&]G>2!L:6-E;G-E
M("AI;B!3:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M,#0L-3,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-C$X+#$S-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@V,3@L,3,W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92`H:6X@4VAA<F5S*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPT.30L-#@X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E
M(&%T($1E8RX@,S$L(#(P,#(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L-#DU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,30U+#@T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#<X."PW,CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C,Y+#,Y,RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-A;&4@;V8@8V]M
M;6]N('-T;V-K(&9O<B!C87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#(R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L-#4X+#,X,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L-#4Y+#8P.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V%L92!O9B!C;VUM;VX@
M<W1O8VL@9F]R(&-A<V@@*&EN(%-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,C(Y+#(W.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#DT-RPX,#0I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.30W+#@P-"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4@
M*&EN(%-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L
M-S(S+#<V-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0F%L86YC92!A="!$96,N(#,Q+"`R,#`S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT+#<R-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-C`T+#(R,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-S,V+#4S,RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M-S(L-#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y386QE(&]F(&-O;6UO;B!S=&]C:R!F;W(@8V%S:"!A;F0@<W1O
M8VL@<W5B<V-R:7!T:6]N(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L-#@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BPY.#@L-#,V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPW-3`L,#`P*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S.2PY,3D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-A;&4@;V8@8V]M;6]N('-T;V-K(&9O<B!C87-H(&%N9"!S=&]C:R!S=6)S
M8W)I<'1I;VX@<F5C96EV86)L92`H:6X@4VAA<F5S*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PT.#(L-C`U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H('!A>6UE;G1S(')E
M8V5I=F5D(&]N('-T;V-K('-U8G-C<FEP=&EO;B!R96-E:79A8FQE/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-3`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S
M=6%N8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!T96-H;F]L;V=Y(&QI8V5N<V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3DL.34Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!T96-H;F]L;V=Y(&QI
M8V5N<V4@*&EN(%-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0Y+#0R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#(L,S4Q+#@R."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@R+#,U,2PX,C@I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E("AI;B!3:&%R
M97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#(U-2PW.3$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D)A;&%N8V4@870@1&5C+B`S,2P@,C`P-#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-BPR-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU+#8Y,BPV,#@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#`P,"PP,#`I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PP.#@L,S8Q
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#,X.2PT.3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#87-H('!A>6UE;G1S(')E8V5I=F5D(&]N('-T;V-K('-U
M8G-C<FEP=&EO;B!R96-E:79A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#8Q,2PP.#8I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PV,3$L,#@V*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0F%L86YC92`H:6X@4VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-BPR-34L-SDQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E(&%T($1E8RX@,S$L(#(P,#4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,C4V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PV.3(L-C`X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3`P
M+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@U+#8Y.2PT-#<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-3`P+#4X,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@<&%Y;65N=',@<F5C96EV
M960@;VX@<W1O8VL@<W5B<V-R:7!T:6]N(')E8V5I=F%B;&4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)S
M:6]N(&]F('!R969E<G)E9"!S=&]C:R!T;R!C;VUM;VX@<W1O8VL\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-34Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP-S$L-38U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP-S4L
M,3$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VYV97)S:6]N(&]F('!R969E<G)E9"!S=&]C:R!T;R!C;VUM;VX@
M<W1O8VL@*&EN(%-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L-34P+#@U,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E9"!I;B!C;VYN96-T
M:6]N('=I=&@@;65R9V5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT+#,V,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L-S`X+#0X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-S$R+#@T.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E
M9"!I;B!C;VYN96-T:6]N('=I=&@@;65R9V5R("AI;B!3:&%R97,I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#,U.2PX.3$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E
M(&]F(&-O;6UO;B!S=&]C:R!F;W(@8V%S:&QE<W,@=V%R<F%N="!E>&5R8VES
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U-RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A
M;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@8V%S:&QE<W,@=V%R<F%N="!E>&5R
M8VES93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-38L.#(U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3@T+#$V
M-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@U.#0L,38V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0F%L86YC92`H:6X@4VAA<F5S*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,30L,C(S+#,U.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!$96,N
M(#,Q+"`R,#`V/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PR
M,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XX+#0W,BPV,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@V+#(X,RPV,3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR,#,L,C$V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y386QE(&]F(&-O;6UO
M;B!S=&]C:R!F;W(@8V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,RPQ-C(L-30S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,RPQ-C(L.34P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y386QE(&]F(&-O;6UO;B!S=&]C
M:R!F;W(@8V%S:"`H:6X@4VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#`V+#<R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K('5P
M;VX@<W1O8VL@;W!T:6]N(&5X97)C:7-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-"PY.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T
M;V-K('5P;VX@<W1O8VL@;W!T:6]N(&5X97)C:7-E("AI;B!3:&%R97,I/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#0W,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S
M960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L-3$X+#0Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L-3$X+#0Y-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0L,C0Q+#<Y-BD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T+#(T,2PW.38I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y"86QA;F-E("AI;B!3:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-"PV,S(L-34X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E(&%T($1E8RX@,S$L(#(P,#<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#8S,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#$U."PV
M-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q,"PU,C4L-#`Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(L-C0W+#@V-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V%L92!O9B!C;VUM;VX@<W1O8VL@
M9F]R(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,S8T+#@R-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L,S8U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4V%L92!O9B!C;VUM;VX@<W1O8VL@9F]R(&-A
M<V@@*&EN(%-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$W-BPQ,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1R86YS86-T:6]N<R!R96QA=&5D('1O(&-O;6UO;B!S=&]C
M:R!P=7)C:&%S92!A9W)E96UE;G0@=VET:"!&=7-I;VX@0V%P:71A;#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`U+#DV,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P-BPP.3$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1R86YS86-T:6]N<R!R96QA=&5D('1O(&-O;6UO;B!S=&]C:R!P=7)C:&%S
M92!A9W)E96UE;G0@=VET:"!&=7-I;VX@0V%P:71A;"`H:6X@4VAA<F5S*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,P+#(Y,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM
M8F%S960@8V]M<&5N<V%T:6]N("T@4W1O8VL@;W!T:6]N<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW.3@L,38Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW.3@L,38Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C
M:RUB87-E9"!C;VUP96YS871I;VX@+2!#;VYS=6QT86YT('=A<G)A;G1S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#8L.#@P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30V+#@X,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N("T@27-S=6%N8V4@;V8@8V]M;6]N
M('-T;V-K(&9O<B!S97)V:6-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW,RPY.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO
M;B`M($ES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@<V5R=FEC97,@*&EN
M(%-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L
M-S(X+#$X-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@S+#<R."PQ.#<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E("AI;B!3:&%R97,I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PY-#@L.3<W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E
M(&%T($1E8RX@,S$L(#(P,#@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$T+#DT.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$V+#DT."PT-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q-"PR-3,L-3DV*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S`Y+#@Q.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A
M;G-A8W1I;VYS(')E;&%T960@=&\@8V]M;6]N('-T;V-K('!U<F-H87-E(&%G
M<F5E;65N="!W:71H($9U<VEO;B!#87!I=&%L/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#4Q.2PW.#0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4R,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R86YS86-T
M:6]N<R!R96QA=&5D('1O(&-O;6UO;B!S=&]C:R!P=7)C:&%S92!A9W)E96UE
M;G0@=VET:"!&=7-I;VX@0V%P:71A;"`H:6X@4VAA<F5S*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C$V+#(V,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V%L92!O9B!C;VUM;VX@
M<W1O8VL@9F]R(&-A<V@@=7!O;B!E>&5R8VES92!O9B!S=&]C:R!P=7)C:&%S
M92!W87)R86YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-C,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#0Y.2PU,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-A;&4@;V8@8V]M;6]N('-T;V-K(&9O<B!C
M87-H('5P;VX@97AE<F-I<V4@;V8@<W1O8VL@<'5R8VAA<V4@=V%R<F%N="`H
M:6X@4VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8R
M+#@R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N("T@4W1O8VL@;W!T:6]N
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR,C$L-S8T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR
M,C$L-S8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX@+2!#;VYS=6QT86YT
M('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-2PT
M,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT-2PT,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B`M($ES<W5A;F-E
M(&]F(&-O;6UO;B!S=&]C:R!F;W(@<V5R=FEC97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS,2PT.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,2PU,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O
M;7!E;G-A=&EO;B`M($ES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@<V5R
M=FEC97,@*&EN(%-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#87-H('!A>6UE;G1S(')E8V5I=F5D(&]N('-T;V-K('-U
M8G-C<FEP=&EO;B!R96-E:79A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#`R,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@S+#(X-"PR-3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPR.#0L,C4R*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92`H
M:6X@4VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34L
M-C,R+#4V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0F%L86YC92!A="!$96,N(#,Q+"`R,#`Y/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PV,S,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,2PR-C8L-#0W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3<L-3,W+#@T
M."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS+#<T-"PR,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!I;B!L:65U
M(&]F(&-A<V@@<&%Y;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XX.2PY.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!I
M;B!L:65U(&]F(&-A<V@@<&%Y;65N="`H:6X@4VAA<F5S*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP
M96YS871I;VX@+2!3=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU-S4L-C8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3<U+#8V,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@8V]M<&5N
M<V%T:6]N("T@0V]N<W5L=&%N="!W87)R86YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3(Q+#`U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$R,2PP-3<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O
M;7!E;G-A=&EO;B`M($ES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@<V5R
M=FEC97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3,L.#`S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3,L.#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX@+2!)<W-U86YC92!O
M9B!C;VUM;VX@<W1O8VL@9F]R('-E<G9I8V5S("AI;B!3:&%R97,I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PU,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9R86-T:6]N86P@
M<VAA<F4@<&%Y;W5T('5P;VX@<F5V97)S92!S<&QI=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,2PR,3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PR,3`I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&<F%C=&EO;F%L('-H
M87)E('!A>6]U="!U<&]N(')E=F5R<V4@<W!L:70@*&EN(%-H87)E<RD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Q."D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#<T-RPS,C@I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPW-#<L
M,S(X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0F%L86YC92`H:6X@4VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,34L-C4T+#@T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!$96,N(#,Q+"`R
M,#$P/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PV-34\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,BPQ
M,#4L-S0W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,C`L,C@U+#$W-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#@S-BPR,C8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-A;&4@;V8@8V]M;6]N('-T
M;V-K(&9O<B!C87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT-#`L-34Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#0Q+#(Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4V%L92!O9B!C;VUM;VX@<W1O8VL@9F]R(&-A
M<V@@*&EN(%-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8U."PU,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B`M(%-T;V-K(&]P
M=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0V,RPW-3(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M-C,L-S4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX@+2!#;VYS=6QT86YT
M('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3DL
M,C0U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,34Y+#(T-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N("T@27-S=6%N
M8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!S97)V:6-E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,30Y+#@W,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A
M<V5D(&-O;7!E;G-A=&EO;B`M($ES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!F
M;W(@<V5R=FEC97,@*&EN(%-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$R.2PR-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@<&%Y;65N=',@<F5C96EV960@;VX@
M<W1O8VL@<W5B<V-R:7!T:6]N(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0P-"PT,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@R+#,T-BPX,C8I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPS-#8L.#(V*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L
M86YC92`H:6X@4VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,38L-#0R+#8Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!$96,N(#,Q+"`R,#$Q/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$V+#0T,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C,L,S$Y+#$V
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,C(L-C,R+#`P,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#<P,RPV,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S,T,#0W.&4X7S$T96-?-#1D9%\Y,C,T7S9E
M,#(R-V4S9F$V-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S-#`T
M-SAE.%\Q-&5C7S0T9&1?.3(S-%\V93`R,C=E,V9A-C0O5V]R:W-H965T<R]3
M:&5E=#`V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%6$1"1SX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!#87-H($9L;W=S("A5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#8^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(V($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CY$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/D1E8RX@,S$L(#(P
M,3`\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#(^1&5C+B`S,2P@,C`P.3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,CY$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@9FQO=W,@9G)O
M;2!O<&5R871I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,BPS-#8L.#(V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M,BPW-#<L,S(X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,RPR
M.#0L,C4R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,C(L-C,R
M+#`P,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M061J=7-T;65N=',@=&\@<F5C;VYC:6QE(&YE="!L;W-S('1O(&YE="!C87-H
M('5S960@:6X@;W!E<F%T:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#DL,#$W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3$Y+#<W,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C@Y+#<W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4V-2PV,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C
M8W)E=&EO;B!O9B!P<F5F97)R960@<W1O8VL@<F5D96UP=&EO;B!V86QU93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S0V+#8W,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@8V]M<&5N<V%T
M:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<W
M,BPY.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-3`L-3,R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR.3@L-C8U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-BPS-3DL-S,Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y7<FET92UO9F8@;V8@9&5F97)R960@;V9F97)I
M;F<@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0S,"PT
M,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT,S`L-#`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D-H86YG97,@:6X@87-S971S(&%N9"!L:6%B:6QI=&EE<SH\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1W)A;G0@9G5N9',@<F5C96EV86)L93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CDP+#<V,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$U,RPY-30I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH."PY-3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,3@S+#4Q-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.2PQ,C(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@T+#(Q-2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR-30L-C<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,CDL-S`X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P
M;W-I=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDX,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q+#`Q,"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q,2PP,3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O
M=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D(&5X<&5N<V5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT,3DL.3(W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,SDL,#,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C(T+#DT,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#,P
M+#,R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&%D
M:G5S=&UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`T
M,RPR,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-#`L,34Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX-3DL,3`R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^."PU,#@L-30S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@
M86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S`S
M+#8R,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#`P-RPQ-CDI
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PT,C4L,34P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$T+#$R,RPT-3DI/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@9FQO=W,@9G)O
M;2!I;G9E<W1I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4'5R8VAA<V4@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3$L.#DV*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#0L-S`V*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(W,"PR-#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-3,X+#0Y,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M;V-E961S(&9R;VT@<V%L92!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU+#4X,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-3@P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@<')O=FED960@
M*'5S960I(&)Y(&EN=F5S=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q,2PX.38I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.#<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C<P
M+#(T-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U,S(L.3$P*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H(&9L
M;W=S(&9R;VT@9FEN86YC:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@<V%L92!O9B!C;VUM;VX@<W1O
M8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P-"PT,3`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#`R,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-2PU,C8L,S`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F]C965D<R!F<F]M('-A;&4@;V8@<')E9F5R<F5D('-T;V-K/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,C@L-#0S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!O9F9E<FEN9R!C;W-T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-#,P+#0P,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T,S`L-#`R
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('!R
M;W9I9&5D(&)Y(&9I;F%N8VEN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT,#0L-#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-#,P+#0P,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS+#`R,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PX
M,C0L,S0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&EN
M8W)E87-E("AD96-R96%S92D@:6X@8V%S:"!A;F0@8V%S:"!E<75I=F%L96YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#@L.#DS/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S%=
M/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#0S-BPV
M.3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#,R-"PV,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L,38W+#DX,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S
M(&%T(&)E9VEN;FEN9R!O9B!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L,#<Y+#`X-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L-3$U+#<X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M,3DQ+#$X,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L
M96YT<R!A="!E;F0@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#$V-RPY.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#`W.2PP.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#4Q
M-2PW.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$V-RPY.#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5P<&QE
M;65N=&%L(&1I<V-L;W-U<F4@;V8@8V%S:"!F;&]W(&EN9F]R;6%T:6]N/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T('!A:60\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2PV-CD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$.3X\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1&EN;F5R1F]O=&YO
M=&4^#0H@("`@("`@(#QT9"!V86QI9VX],T1T;W`^6S%=/"]T9#X-"B`@("`@
M("`@/'1D(&-O;'-P86X],T0X('9A;&EG;CTS1'1O<#Y3=7!P;&5M96YT86P@
M9&ES8VQO<W5R92!O9B!N;VXM8V%S:"!I;G9E<W1I;F<@86YD(&9I;F%N8VEN
M9R!A8W1I=FET:65S.B!);B!C;VYN96-T:6]N('=I=&@@=&AE($UE<F=E<B!D
M:7-C=7-S960@:6X@3F]T92`U+"!A;&P@;V8@=&AE(&]U='-T86YD:6YG('-H
M87)E<R!O9B!T:&4@0V]M<&%N>2=S(&UA;F1A=&]R>2!R961E96UA8FQE(&-O
M;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:R!W97)E(&-O;G9E<G1E9"!I;G1O
M('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@87,@;V8@4V5P=&5M8F5R(#(X+"`R
M,#`V+CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S-#`T-SAE.%\Q-&5C
M7S0T9&1?.3(S-%\V93`R,C=E,V9A-C0-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO,S0P-#<X93A?,31E8U\T-&1D7SDR,S1?-F4P,C(W93-F838T
M+U=O<FMS:&5E=',O4VAE970P-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/DYO=&4@,2`M($YA='5R92!O9B!"=7-I;F5S<SQB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F%T=7)E
M(&]F($]P97)A=&EO;G,@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U
M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-
M"B`@("`@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^,2XF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#M.871U<F4-"B`@("`-"B`@("`@("`@;V8@0G5S:6YE<W,\+V9O;G0^#0H@
M("`-"B`@("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=,24Y%+4A%24=(
M5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^#0H@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY'96]687@-"B`@(`T*("`@("`@("!,86)S+"!);F,N("@F(S@R,C`[
M1V5O5F%X)B,X,C(Q.R!O<B!T:&4-"B`-"B`@("`@("`@)B,X,C(P.T-O;7!A
M;GDF(S@R,C$[*2P@:7,@82!B:6]T96-H;F]L;V=Y(&-O;7!A;GD-"B`@#0H@
M("`@("`@(&1E=F5L;W!I;F<@=F%C8VEN97,@=&AA="!P<F5V96YT(&%N9"!F
M:6=H="!(=6UA;@T*("`-"B`@("`@("`@26UM=6YO9&5F:6-I96YC>2!6:7)U
M<R`H)B,X,C(P.TA)5B8C.#(R,3LI#0H@("`@#0H@("`@("`@(&EN9F5C=&EO
M;G,N)B,Q-C`[)B,Q-C`[2$E6(&EN9F5C=&EO;G,@<F5S=6QT(&EN($%C<75I
M<F5D#0H@("`-"B`@("`@("`@26UM=6YO9&5F:6-I96YC>2!3>6YD<F]M90T*
M("`@(`T*("`@("`@("`H)B,X,C(P.T%)1%,F(S@R,C$[*2XF(S$V,#LF(S$V
M,#M792!H879E(&5X8VQU<VEV96QY#0H@(`T*("`@("`@("!L:6-E;G-E9"!F
M<F]M($5M;W)Y(%5N:79E<G-I='D@*"8C.#(R,#M%;6]R>28C.#(R,3LI#0H@
M("`@#0H@("`@("`@('9A8V-I;F4@=&5C:&YO;&]G>2!W:&EC:"!W87,@9&5V
M96QO<&5D(&EN(&-O;&QA8F]R871I;VX-"B`@("`-"B`@("`@("`@=VET:"!T
M:&4@3F%T:6]N86P@26YS=&ET=71E<R!O9B!(96%L=&@@*"8C.#(R,#M.24@F
M(S@R,C$[*0T*("`@("`-"B`@("`@("`@86YD('1H92!#96YT97)S(&9O<B!$
M:7-E87-E($-O;G1R;VP@86YD(%!R979E;G1I;VX-"B`@("`-"B`@("`@("`@
M*"8C.#(R,#M#1$,F(S@R,C$[*2XF(S$V,#LF(S$V,#M'96]687@@:7,@:6YC
M;W)P;W)A=&5D#0H@("`@#0H@("`@("`@('5N9&5R('1H92!L87=S(&]F('1H
M92!3=&%T92!O9B!$96QA=V%R92!A;F0@;W5R('!R:6YC:7!A;`T*(`T*("`@
M("`@("!O9F9I8V5S(&%R92!L;V-A=&5D(&EN(%-M>7)N82P@1V5O<F=I82`H
M;65T<F]P;VQI=&%N#0H@#0H@("`@("`@($%T;&%N=&$@87)E82DN/"]F;VYT
M/@T*(`T*("`@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M;&5F=#X-"B`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/D]U<@T*("`@("`-"B`@("`@("`@8W5R<F5N="!V86-C:6YE<R!U
M;F1E<B!D979E;&]P;65N="!A9&1R97-S('1H92!C;&%D92!"#0H@("`-"B`@
M("`@("`@<W5B='EP92!O9B!T:&4@2$E6('9I<G5S('1H870@:7,@;6]S="!P
M<F5V86QE;G0@:6X@=&AE#0H@("`-"B`@("`@("`@56YI=&5D(%-T871E<R!A
M;F0@=&AE(&1E=F5L;W!E9"!W;W)L9"XF(S$V,#LF(S$V,#M/=7(-"B`@("`@
M#0H@("`@("`@('9A8V-I;F5S(&%R92!B96EN9R!E=F%L=6%T960@=&\@9&5T
M97)M:6YE('1H96ER('!O=&5N=&EA;`T*(`T*("`@("`@("!T;R`H82D@<')E
M=F5N="!(258@:6YF96-T:6]N(&%N9"`H8BD@=&\@<V5R=F4@87,@82!T:&5R
M87!Y#0H@(`T*("`@("`@("!F;W(@:6YD:79I9'5A;',@=VAO(&%R92!A;')E
M861Y(&EN9F5C=&5D('=I=&@-"B`@("`-"B`@("`@("`@2$E6+B8C,38P.R8C
M,38P.U1H97-E('9A8V-I;F5S(&%R92!C=7)R96YT;'D@8F5I;F<-"B`@#0H@
M("`@("`@(&5V86QU871E9"!I;B!H=6UA;G,@+2T@8F]T:"!I;B!T:&]S92!I
M;F9E8W1E9"!W:71H($A)5B!A;F0-"B`@#0H@("`@("`@('1H;W-E('=H;R!A
M<F4@;F]T+CPO9F]N=#X-"B`@("`@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/@T*(`T*("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<^07,-"B`@("`-"B`@("`@("`@9&ES
M8W5S<V5D(&EN($YO=&4@,BP@=&AE($-O;7!A;GD@:7,@82!D979E;&]P;65N
M="US=&%G90T*("`@(`T*("`@("`@("!E;G1E<G!R:7-E(&%N9"!W92!A<F4@
M9&5V;W1I;F<@<W5B<W1A;G1I86QL>2!A;&P@;V8@;W5R#0H@("`@#0H@("`@
M("`@('!R97-E;G0@969F;W)T<R!T;R!R97-E87)C:"!A;F0@9&5V96QO<&UE
M;G0N)B,Q-C`[)B,Q-C`[5V4-"B`@("`@#0H@("`@("`@(&AA=F4@9G5N9&5D
M(&]U<B!A8W1I=FET:65S('1O(&1A=&4@86QM;W-T(&5X8VQU<VEV96QY(&9R
M;VT-"B`@#0H@("`@("`@(&5Q=6ET>2!F:6YA;F-I;F=S(&%N9"!G;W9E<FYM
M96YT(&=R86YT<RP@86YD('=E('=I;&P-"B`-"B`@("`@("`@8V]N=&EN=64@
M=&\@<F5Q=6ER92!S=6)S=&%N=&EA;"!F=6YD<R!T;R!C;VYT:6YU92!T:&5S
M90T*("`@(`T*("`@("`@("!A8W1I=FET:65S+B8C,38P.R8C,38P.U=E(&%N
M=&EC:7!A=&4@=&AA="!O=7(@97AI<W1I;F<@8V%S:`T*(`T*("`@("`@("!R
M97-O=7)C97,L(&-O;6)I;F5D('=I=&@@=&AE('!R;V-E961S(&9R;VT@=&AE
M($Y)2"!G<F%N=`T*("`@("`-"B`@("`@("`@9&ES8W5S<V5D(&EN($YO=&4@
M,R!A;F0@=&AE(&9I;F%N8VEN9R!E=F5N=',@9&ES8W5S<V5D(&EN#0H@#0H@
M("`@("`@($YO=&4@,3$L('-H;W5L9"!B92!S=69F:6-I96YT('1O(&9U;F0@
M;W5R('!L86YN960-"B`@(`T*("`@("`@("!A8W1I=FET:65S(&EN=&\@=&AE
M(&9I<G-T('%U87)T97(@;V8@,C`Q,RXF(S$V,#LF(S$V,#M);@T*("`@#0H@
M("`@("`@(&]R9&5R('1O(&UE970@;W5R(&]P97)A=&EN9R!C87-H(&9L;W<@
M<F5Q=6ER96UE;G1S+"!W92!M87D-"B`@#0H@("`@("`@('!L86X@861D:71I
M;VYA;"!O9F9E<FEN9W,@;V8@;W5R(&5Q=6ET>2!S96-U<FET:65S+"!D96)T
M(&]R#0H@("`-"B`@("`@("`@8V]N=F5R=&EB;&4@9&5B="!I;G-T<G5M96YT
M<RX@5V4@87)E(&%L<V\@<V5E:VEN9PT*("`@#0H@("`@("`@(&%D9&ET:6]N
M86P@9G5N9&EN9R!F;W(@;W5R(')E<V5A<F-H('!R;V=R86US('1H<F]U9V@-
M"B`-"B`@("`@("`@9V]V97)N;65N="!G<F%N="!F=6YD:6YG(&UE8VAA;FES
M;7,N/"]F;VYT/@T*("`@#0H@("`@("`\+V1I=CX\8G(O/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S0P-#<X93A?,31E8U\T
M-&1D7SDR,S1?-F4P,C(W93-F838T#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S,T,#0W.&4X7S$T96-?-#1D9%\Y,C,T7S9E,#(R-V4S9F$V-"]7
M;W)K<VAE971S+U-H965T,#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!1#X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY.;W1E(#(@+2!3=6UM87)Y(&]F(%-I9VYI9FEC86YT
M($%C8V]U;G1I;F<@4&]L:6-I97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I
M97,@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`@#0H@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@
M8F]L9"<^,BXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M3=6UM87)Y#0H@("`@(`T*
M("`@("`@("!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]F
M;VYT/@T*(`T*("`@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M
M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X-"B`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,
M13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^0F%S:7,-"B`@#0H@("`@
M("`@(&]F(%!R97-E;G1A=&EO;B!A;F0@4')I;F-I<&QE<R!O9B!#;VYS;VQI
M9&%T:6]N/"]F;VYT/@T*("`@(`T*("`@("`@/"]D:78^/&)R+SX\9&EV('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D]U<@T*("`@("`-"B`@("`@("`@<')I
M;6%R>2!B=7-I;F5S<R!I<R!C;VYD=6-T960@8GD@;W5R('=H;VQL>2UO=VYE
M9`T*("`@#0H@("`@("`@('-U8G-I9&EA<GDL($=E;U9A>"P@26YC+B!4:&4@
M86-C;VUP86YY:6YG(&-O;G-O;&ED871E9`T*("`@#0H@("`@("`@(&9I;F%N
M8VEA;"!S=&%T96UE;G1S(&EN8VQU9&4@=&AE(&%C8V]U;G1S(&]F($=E;U9A
M>"P@26YC+@T*(`T*("`@("`@("!F<F]M(&EN8V5P=&EO;B!T;V=E=&AE<B!W
M:71H('1H;W-E(&]F($=E;U9A>"!,86)S+"!);F,N#0H@("`@#0H@("`@("`@
M(&9R;VT@4V5P=&5M8F5R(#(X+"`R,#`V("AS964@3F]T92`U*2XF(S$V,#LF
M(S$V,#M!;&P-"B`@("`-"B`@("`@("`@:6YT97)C;VUP86YY('1R86YS86-T
M:6]N<R!H879E(&)E96X@96QI;6EN871E9"!I;@T*("`@#0H@("`@("`@(&-O
M;G-O;&ED871I;VXN/"]F;VYT/@T*(`T*("`@("`@/"]D:78^/&)R+SX\9&EV
M('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M1&5V96QO<&UE;G0M4W1A9V4-"B`@("`-"B`@("`@("`@16YT97)P<FES93PO
M9F]N=#X-"B`@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/@T*(`T*("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<^5V4-"B`@("`-"B`@("`@("`@87)E(&1E=F]T:6YG(&%L
M;"!O9B!O=7(@<')E<V5N="!E9F9O<G1S('1O(')E<V5A<F-H(&%N9`T*("`@
M(`T*("`@("`@("!D979E;&]P;65N="!A;F0@1V5O5F%X(&ES(&$@9&5V96QO
M<&UE;G0@<W1A9V4@96YT97)P<FES92!A<PT*("`@#0H@("`@("`@(&1E9FEN
M960@8GD@1FEN86YC:6%L($%C8V]U;G1I;F<@4W1A;F1A<F1S($)O87)D#0H@
M#0H@("`@("`@("@F(S@R,C`[1D%30B8C.#(R,3LI($%C8V]U;G1I;F<@4W1A
M;F1A<F1S($-O9&EF:6-A=&EO;@T*(`T*("`@("`@("`H)B,X,C(P.T%30R8C
M.#(R,3LI(%1O<&EC(#DQ-2P@/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@
M:71A;&EC.R!$25-03$%9.B!I;FQI;F4G/D1E=F5L;W!M96YT#0H@("`@(`T*
M("`@("`@("!3=&%G92!%;G1I=&EE<SPO9F]N=#XN)B,Q-C`[)B,Q-C`[06QL
M(&QO<W-E<R!A8V-U;75L871E9`T*("`@(`T*("`@("`@("!S:6YC92!I;F-E
M<'1I;VX@*$IU;F4@,C<L(#(P,#$I(&AA=F4@8F5E;B!C;VYS:61E<F5D(&%S
M#0H@("`@#0H@("`@("`@('!A<G0@;V8@;W5R(&1E=F5L;W!M96YT('-T86=E
M(&%C=&EV:71I97,N/"]F;VYT/@T*("`@#0H@("`@("`\+V1I=CX\8G(O/CQD
M:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*(`T*("`@("`@("`\9F]N="!S
M='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY5<V4-"B`@("`@#0H@("`@("`@(&]F($5S=&EM871E<SPO9F]N=#X-"B`@
M("`-"B`@("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=,24Y%+4A%24=(
M5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE
M9G0^#0H@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY4:&4-"B`@("`@#0H@("`@("`@('!R97!A<F%T:6]N(&]F(&9I;F%N
M8VEA;"!S=&%T96UE;G1S(&EN(&-O;F9O<FUI='D@=VET:`T*("`@#0H@("`@
M("`@(&%C8V]U;G1I;F<@<')I;F-I<&QE<R!G96YE<F%L;'D@86-C97!T960@
M:6X@=&AE(%5N:71E9`T*("`@#0H@("`@("`@(%-T871E<R!O9B!!;65R:6-A
M("@F(S@R,C`[1T%!4"8C.#(R,3LI(')E<75I<F5S('5S('1O(&UA:V4-"B`@
M("`@#0H@("`@("`@(&5S=&EM871E<R!A;F0@87-S=6UP=&EO;G,@=&AA="!A
M9F9E8W0@=&AE(')E<&]R=&5D(&%M;W5N=',-"B`@#0H@("`@("`@(&]F(&%S
M<V5T<R!A;F0@;&EA8FEL:71I97,@86YD(&1I<V-L;W-U<F4@;V8@8V]N=&EN
M9V5N=`T*("`@#0H@("`@("`@(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@870@
M=&AE(&1A=&4@;V8@=&AE(&9I;F%N8VEA;`T*("`@("`-"B`@("`@("`@<W1A
M=&5M96YT<R!A;F0@=&AE(')E<&]R=&5D(&%M;W5N=',@;V8@<F5V96YU97,@
M86YD#0H@("`@(`T*("`@("`@("!E>'!E;G-E<R!D=7)I;F<@=&AE(')E<&]R
M=&EN9R!P97)I;V0N)B,Q-C`[)B,Q-C`[06-T=6%L#0H@(`T*("`@("`@("!R
M97-U;'1S(&UA>2!D:69F97(@9G)O;2!T:&]S92!E<W1I;6%T97,N/"]F;VYT
M/@T*("`-"B`@("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=,24Y%+4A%
M24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^#0H@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z
M(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D-A<V@-"B`-"B`@("`@("`@
M86YD($-A<V@@17%U:79A;&5N=',\+V9O;G0^#0H@(`T*("`@("`@/"]D:78^
M/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E=E#0H@("`@#0H@
M("`@("`@(&-O;G-I9&5R(&%L;"!H:6=H;'D@;&EQ=6ED(&EN=F5S=&UE;G1S
M('=I=&@@82!M871U<FET>2!O9@T*(`T*("`@("`@("!T:')E92!M;VYT:',@
M;W(@;&5S<R!W:&5N('!U<F-H87-E9"!T;R!B92!C87-H#0H@("`@(`T*("`@
M("`@("!E<75I=F%L96YT<RXF(S$V,#LF(S$V,#M/=7(@8V%S:"!A;F0@8V%S
M:"!E<75I=F%L96YT<PT*("`@("`-"B`@("`@("`@8V]N<VES="!P<FEM87)I
M;'D@;V8@8F%N:R!D97!O<VET<R!A;F0@;6]N97D@;6%R:V5T#0H@("`@(`T*
M("`@("`@("!A8V-O=6YT<RXF(S$V,#LF(S$V,#M4:&4@<F5C;W)D960@=F%L
M=65S(&%P<')O>&EM871E(&9A:7(-"B`@("`-"B`@("`@("`@;6%R:V5T('9A
M;'5E<R!D=64@=&\@=&AE('-H;W)T(&UA='5R:71I97,N/"]F;VYT/@T*("`@
M(`T*("`@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4
M.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X-"B`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A
M;&EC.R!$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<^1F%I<@T*(`T*("`@("`@("!686QU
M92!O9B!&:6YA;F-I86P@26YS=')U;65N=',@86YD($-O;F-E;G1R871I;VX@
M;V8@0W)E9&ET#0H@(`T*("`@("`@("!2:7-K/"]F;VYT/@T*(`T*("`@("`@
M/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D9I;F%N
M8VEA;`T*(`T*("`@("`@("!I;G-T<G5M96YT<R!T:&%T('-U8FIE8W0@=7,@
M=&\@8V]N8V5N=')A=&EO;B!O9B!C<F5D:70@<FES:PT*("`@#0H@("`@("`@
M(&-O;G-I<W0@<')I;6%R:6QY(&]F(&-A<V@@86YD(&-A<V@@97%U:79A;&5N
M=',L('=H:6-H(&%R90T*(`T*("`@("`@("!M86EN=&%I;F5D(&)Y(&$@:&EG
M:"!C<F5D:70@<75A;&ET>2!F:6YA;F-I86P@:6YS=&ET=71I;VXN#0H@(`T*
M("`@("`@("!4:&4@8V%R<GEI;F<@=F%L=65S(')E<&]R=&5D(&EN('1H92!B
M86QA;F-E('-H965T<R!F;W(@8V%S:`T*("`@#0H@("`@("`@(&%N9"!C87-H
M(&5Q=6EV86QE;G1S(&%P<')O>&EM871E(&9A:7(@=F%L=65S+CPO9F]N=#X-
M"B`@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/@T*(`T*("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I
M=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY0<F]P97)T>0T*("`@("`-"B`@
M("`@("`@86YD($5Q=6EP;65N=#PO9F]N=#X-"B`@("`@#0H@("`@("`\+V1I
M=CX\8G(O/CQD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*(`T*("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^4')O<&5R='D-
M"B`@("`@#0H@("`@("`@(&%N9"!E<75I<&UE;G0@87)E('-T871E9"!A="!C
M;W-T+"!L97-S(&%C8W5M=6QA=&5D#0H@("`@#0H@("`@("`@(&1E<')E8VEA
M=&EO;B!A;F0@86UO<G1I>F%T:6]N+B8C,38P.R8C,38P.U1H92!C;VUP;VYE
M;G1S(&]F#0H@#0H@("`@("`@('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0@87,@
M;V8@1&5C96UB97(@,S$L(#(P,3$@86YD(#(P,3`@87)E#0H@("`-"B`@("`@
M("`@87,@9F]L;&]W<SH\+V9O;G0^#0H@("`-"B`@("`@(#PO9&EV/CQB<B\^
M/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@]
M,T0Q,#`E('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N)SX-"B`@("`-"B`@("`@("`@("`\='(^#0H@
M#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-
M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^
M#0H@("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/C(P,3$\+V9O;G0^#0H@(`T*("`@("`@("`@
M("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P
M>"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D
M/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@
M/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G/@T*("`@("`-"B`@("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(`T*("`@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXR,#$P/"]F;VYT/@T*("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*
M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G/@T*(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`\+W1R/@T*("`-"B`@("`@("`@("`\='(@<W1Y;&4],T0G8F%C:V=R;W5N
M9"UC;VQO<CH@(T,P1D9&1CLG/@T*(`T*("`@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W-B4^#0H@("`@#0H@
M("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[
M(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*(`T*
M("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY,86)O<F%T;W)Y#0H@("`@(`T*("`@("`@("`@("`@("`@(&5Q=6EP
M;65N=#PO9F]N=#X-"B`@("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*
M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X-
M"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/C,X."PP,#`\+V9O;G0^#0H@("`-"B`@("`@
M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@
M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X-"B`@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/C,X."PP,#`\+V9O;G0^#0H@("`-"B`@("`@("`@
M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@
M("`@("`\='(^#0H@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#<V)3X-"B`@("`-"B`@("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DQE87-E
M:&]L9`T*("`@(`T*("`@("`@("`@("`@("`@(&EM<')O=F5M96YT<SPO9F]N
M=#X-"B`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@
M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^,3$U+#8P-3PO9F]N=#X-"B`@(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@
M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@
M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/C$Q-2PV,#4\+V9O;G0^#0H@("`-"B`@("`@("`@("`@
M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@("`@
M("`\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T,P1D9&1CLG/@T*
M(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0W-B4@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^
M#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4
M.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^3W1H97(-"B`@("`@#0H@("`@("`@("`@("`@("`@9G5R
M;FET=7)E+"!F:7AT=7)E<R`F86UP.R!E<75I<&UE;G0\+V9O;G0^#0H@("`@
M#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T
M9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L
M:60[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-
M"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^#0H@
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/C(X+#8X-3PO9F]N=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*
M("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)SX-
M"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*
M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#DE('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@
M5$585"U!3$E'3CH@<FEG:'0G/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ-BPW.#D\+V9O;G0^#0H@
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^
M#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@("`@("`\='(^#0H@
M#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#<V)3X-"B`@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E1O=&%L#0H@("`@(`T*("`@
M("`@("`@("`@("`@('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+V9O;G0^#0H@
M(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D
M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-
M"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/C4S,BPR.3`\+V9O;G0^#0H@("`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T
M9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-
M"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^
M#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXU,C`L,SDT/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`\+W1D
M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@/"]T<CX-"B`@#0H@("`@("`@("`@/'1R
M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#,$9&1D8[)SX-"B`-"B`@
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-S8E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*("`-
M"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR
M-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@
M#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/D%C8W5M=6QA=&5D#0H@#0H@("`@("`@("`@("`@("`@9&5P<F5C
M:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX\+V9O;G0^#0H@("`@#0H@("`@("`@
M("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-
M"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M
M04Q)1TXZ(&QE9G0G/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@
M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^#0H@("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@S
M-38L,#@T/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-
M"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#)P>"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^*3PO9F]N=#X-"B`@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,G!X)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)SX-"B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'
M3CH@<FEG:'0G/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXH,C<Q+#DU,SPO9F]N=#X-"B`@("`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G/@T*("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/BD\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`\+W1R/@T*("`-"B`@("`@("`@("`\='(^#0H@#0H@("`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#<V)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX-"B`@#0H@("`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*(`T*("`@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY0<F]P97)T>0T*("`@#0H@("`@("`@("`@("`@("`@86YD(&5Q=6EP;65N
M="P@;F5T/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-
M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`T<'@G/@T*(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX-"B`@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)#PO9F]N=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(')I9VAT)SX-"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$W-BPR,#8\+V9O;G0^#0H@("`-
M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`T<'@G/@T*
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G
M/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE
M.R!415A4+4%,24=..B!L969T)SX-"B`@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X-"B`@#0H@
M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ
M(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/C(T."PT-#$\+V9O;G0^#0H@("`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`T<'@G/@T*("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-
M"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@/"]T<CX-
M"B`@#0H@("`@("`@(#PO=&%B;&4^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M
M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X-"B`@("`@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SY%>'!E;F1I='5R97,-"B`@("`-"B`@("`@("`@9F]R
M(&UA:6YT96YA;F-E(&%N9"!R97!A:7)S(&%R92!C:&%R9V5D('1O(&]P97)A
M=&EO;G,@87,-"B`@("`@#0H@("`@("`@(&EN8W5R<F5D+"!W:&EL92!A9&1I
M=&EO;G,@86YD(&EM<')O=F5M96YT<R!A<F4-"B`@("`@#0H@("`@("`@(&-A
M<&ET86QI>F5D+B8C,38P.R8C,38P.T1E<')E8VEA=&EO;B!I<R!C;VUP=71E
M9"!U<VEN9R!T:&4-"B`@("`@#0H@("`@("`@('-T<F%I9VAT+6QI;F4@;65T
M:&]D(&]V97(@=&AE(&5S=&EM871E9"!U<V5F=6P@;&EV97,@;V8@=&AE#0H@
M("`-"B`@("`@("`@87-S971S('=H:6-H(')A;F=E(&9R;VT@=&AR964@=&\@
M9FEV90T*(`T*("`@("`@("!Y96%R<RXF(S$V,#LF(S$V,#M!;6]R=&EZ871I
M;VX@;V8@;&5A<V5H;VQD(&EM<')O=F5M96YT<R!I<PT*(`T*("`@("`@("!C
M;VUP=71E9"!U<VEN9R!T:&4@<W1R86EG:'0M;&EN92!M971H;V0@;W9E<B!T
M:&4@<F5M86EN:6YG#0H@(`T*("`@("`@("!T97)M(&]F('1H92!R96QA=&5D
M(&QE87-E+B8C,38P.R8C,38P.T1E<')E8VEA=&EO;B!A;F0-"B`-"B`@("`@
M("`@86UO<G1I>F%T:6]N(&5X<&5N<V4@=V%S("0X-"PQ,S$L("0Y-"PX.#<L
M(&%N9"`D-C0L.#DQ#0H@("`-"B`@("`@("`@9'5R:6YG('1H92!Y96%R<R!E
M;F1E9"!$96-E;6)E<B`S,2P@,C`Q,2P@,C`Q,"!A;F0@,C`P.2P-"B`@("`@
M#0H@("`@("`@(')E<W!E8W1I=F5L>2X\+V9O;G0^#0H@("`@(`T*("`@("`@
M/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^3W1H97(-"B`@#0H@("`@("`@($%S<V5T<SPO9F]N
M=#X-"B`@(`T*("`@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M
M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X-"B`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/D]T:&5R#0H@(`T*("`@("`@("!A<W-E=',@8V]N<VES="!P
M<FEN8VEP86QL>2!O9B!L:6-E;G-E(&%G<F5E;65N=',@9F]R('1H90T*("`@
M("`-"B`@("`@("`@=7-E(&]F('1E8VAN;VQO9WD@;V)T86EN960@=&AR;W5G
M:"!T:&4@:7-S=6%N8V4@;V8@=&AE#0H@("`-"B`@("`@("`@0V]M<&%N>28C
M.#(Q-SMS(&-O;6UO;B!S=&]C:RXF(S$V,#LF(S$V,#M4:&5S92!L:6-E;G-E
M#0H@("`@(`T*("`@("`@("!A9W)E96UE;G1S(&%R92!A;6]R=&EZ960@;VX@
M82!S=')A:6=H="!L:6YE(&)A<VES(&]V97(@=&5N#0H@(`T*("`@("`@("!Y
M96%R<RXF(S$V,#LF(S$V,#M!;6]R=&EZ871I;VX@97AP96YS92!R96QA=&5D
M('1O('1H97-E#0H@(`T*("`@("`@("!A9W)E96UE;G1S('=A<R`D,C0L.#@V
M(&1U<FEN9R!E86-H(&]F('1H92!Y96%R<R!E;F1E9`T*("`-"B`@("`@("`@
M1&5C96UB97(@,S$L(#(P,3$L(#(P,3`@86YD(#(P,#D@86YD(&ES(&5X<&5C
M=&5D('1O(&)E#0H@("`-"B`@("`@("`@)#$Y+#DR,RP@)#$P+#`P,"P@)#$P
M+#`P,"P@)"TP+2P@86YD("0M,"T@9F]R(&5A8V@@;V8@=&AE#0H@#0H@("`@
M("`@(&YE>'0@9FEV92!Y96%R<RP@<F5S<&5C=&EV96QY+CPO9F]N=#X-"B`@
M#0H@("`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/@T*(`T*("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L
M:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY);7!A:7)M96YT#0H@(`T*("`@("`@
M("!O9B!,;VYG+4QI=F5D($%S<V5T<SPO9F]N=#X-"B`@#0H@("`@("`\+V1I
M=CX\8G(O/CQD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*(`T*("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^5V4-"B`@("`-
M"B`@("`@("`@<F5V:65W(&QO;F<M;&EV960@87-S971S(&9O<B!I;7!A:7)M
M96YT('=H96YE=F5R(&5V96YT<R!O<@T*("`-"B`@("`@("`@8VAA;F=E<R!I
M;B!C:7)C=6US=&%N8V5S(&EN9&EC871E('1H870@=&AE(&-A<G)Y:6YG(&%M
M;W5N=`T*("`-"B`@("`@("`@;V8@86X@87-S970@;6%Y(&YO="!B90T*(`T*
M("`@("`@("!R96-O=F5R86)L92XF(S$V,#LF(S$V,#M296-O=F5R86)I;&ET
M>2!O9B!A<W-E=',@=&\@8F4@:&5L9`T*(`T*("`@("`@("!A;F0@=7-E9"!I
M<R!M96%S=7)E9"!B>2!A(&-O;7!A<FES;VX@;V8@=&AE(&-A<G)Y:6YG(&%M
M;W5N=`T*("`@#0H@("`@("`@(&]F('1H92!A<W-E=',@=&\@=&AE(&9U='5R
M92!N970@8V%S:"!F;&]W<R!E>'!E8W1E9"!T;R!B90T*(`T*("`@("`@("!G
M96YE<F%T960@8GD@<W5C:"!A<W-E=',N)B,Q-C`[)B,Q-C`[268@=V4@8V]N
M<VED97(@<W5C:`T*("`@#0H@("`@("`@(&%S<V5T<R!T;R!B92!I;7!A:7)E
M9"P@=&AE(&EM<&%I<FUE;G0@=&\@8F4\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M5T5)1TA4.B!B;VQD)SXF(S$V,#L\+V9O;G0^<F5C
M;V=N:7IE9`T*("`@("`-"B`@("`@("`@:7,@;65A<W5R960@8GD@=&AE(&%M
M;W5N="!B>2!W:&EC:"!T:&4@8V%R<GEI;F<@86UO=6YT(&]F#0H@#0H@("`@
M("`@('1H92!A<W-E=',@97AC965D<R!T:&4@97AP96-T960@9G5T=7)E(&YE
M="!C87-H(&9L;W=S(&9R;VT-"B`@#0H@("`@("`@('1H92!A<W-E=',N/"]F
M;VYT/@T*("`@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/@T*(`T*("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+5-4
M64Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY!8V-R=65D#0H@("`@
M#0H@("`@("`@($QI86)I;&ET:65S/"]F;VYT/@T*("`@#0H@("`@("`\+V1I
M=CX\8G(O/CQD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*(`T*("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^07,-"B`@("`-
M"B`@("`@("`@<&%R="!O9B!T:&4@<')O8V5S<R!O9B!P<F5P87)I;F<@;W5R
M(&9I;F%N8VEA;"!S=&%T96UE;G1S+`T*("`-"B`@("`@("`@=V4@97-T:6UA
M=&4@97AP96YS97,@=&AA="!W92!B96QI979E('=E(&AA=F4@:6YC=7)R960L
M(&)U=`T*("`-"B`@("`@("`@:&%V92!N;W0@>65T(&)E96X@8FEL;&5D(&)Y
M(&]U<B!T:&ER9"!P87)T>2!V96YD;W)S+B!4:&ES#0H@#0H@("`@("`@('!R
M;V-E<W,@:6YV;VQV97,@:61E;G1I9GEI;F<@<V5R=FEC97,@86YD(&%C=&EV
M:71I97,@=&AA=`T*(`T*("`@("`@("!H879E(&)E96X@<&5R9F]R;65D(&)Y
M('-U8V@@=F5N9&]R<R!O;B!O=7(@8F5H86QF(&%N9`T*("`-"B`@("`@("`@
M97-T:6UA=&EN9R!T:&4@;&5V96P@=&\@=VAI8V@@=&AE>2!H879E(&)E96X@
M<&5R9F]R;65D(&%N9`T*("`-"B`@("`@("`@=&AE(&%S<V]C:6%T960@8V]S
M="!I;F-U<G)E9"!F;W(@<W5C:"!S97)V:6-E(&%S(&]F(&5A8V@-"B`@("`@
M#0H@("`@("`@(&)A;&%N8V4@<VAE970@9&%T92!I;B!O=7(@9FEN86YC:6%L
M('-T871E;65N=',N($5X86UP;&5S(&]F#0H@("`-"B`@("`@("`@97AP96YS
M97,@9F]R('=H:6-H('=E(&%C8W)U92!I;F-L=61E(&9E97,@9F]R('!R;V9E
M<W-I;VYA;`T*("`-"B`@("`@("`@<V5R=FEC97,@86YD(&9E97,@;W=E9"!T
M;R!C;VYT<F%C="!M86YU9F%C='5R97)S(&EN#0H@("`@(`T*("`@("`@("!C
M;VYJ=6YC=&EO;B!W:71H('1H92!M86YU9F%C='5R92!O9B!V86-C:6YE<R!F
M;W(@;W5R#0H@#0H@("`@("`@(&-L:6YI8V%L('1R:6%L<RX@5V4@;6%K92!T
M:&5S92!E<W1I;6%T97,@8F%S960@=7!O;@T*("`@("`-"B`@("`@("`@<')O
M9W)E<W,@;V8@86-T:79I=&EE<R!R96QA=&5D('1O(&-O;G1R86-T=6%L(&]B
M;&EG871I;VYS#0H@#0H@("`@("`@(&%N9"!I;F9O<FUA=&EO;B!R96-E:79E
M9"!F<F]M('9E;F1O<G,N/"]F;VYT/@T*("`@("`-"B`@("`@(#PO9&EV/CQB
M<B\^/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/DYE=`T*("`@("`-"B`@("`@("`@3&]S<R!097(@4VAA<F4\+V9O
M;G0^#0H@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G3$E.12U(
M14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/@T*(`T*("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P="<^0F%S:6,-"B`@#0H@("`@("`@(&%N9"!D:6QU=&5D(&QO<W,@
M<&5R(&-O;6UO;B!S:&%R92!A<F4@8V]M<'5T960@8F%S960@;VX@=&AE#0H@
M("`-"B`@("`@("`@=V5I9VAT960@879E<F%G92!N=6UB97(@;V8@8V]M;6]N
M('-H87)E<R!O=71S=&%N9&EN9RX@06QL#0H@#0H@("`@("`@(&-O;6UO;B!S
M:&%R92!E<75I=F%L96YT<R`H=VAI8V@@8V]N<VES="!O9B!O<'1I;VYS(&%N
M9`T*("`@#0H@("`@("`@('=A<G)A;G1S*2!A<F4@97AC;'5D960@9G)O;2!T
M:&4@8V]M<'5T871I;VX@;V8@9&EL=71E9"!L;W-S#0H@("`-"B`@("`@("`@
M<&5R('-H87)E('-I;F-E('1H92!E9F9E8W0@=V]U;&0@8F4@86YT:2UD:6QU
M=&EV92X@0V]M;6]N#0H@#0H@("`@("`@('-H87)E(&5Q=6EV86QE;G1S('=H
M:6-H(&-O=6QD('!O=&5N=&EA;&QY(&1I;'5T92!B87-I8PT*("`@#0H@("`@
M("`@(&5A<FYI;F=S('!E<B!S:&%R92!I;B!T:&4@9G5T=7)E+"!A;F0@=VAI
M8V@@=V5R92!E>&-L=61E9`T*(`T*("`@("`@("!F<F]M('1H92!C;VUP=71A
M=&EO;B!O9B!D:6QU=&5D(&QO<W,@<&5R('-H87)E+"!T;W1A;&5D#0H@("`@
M#0H@("`@("`@(#(L-SDX+#@P,2P@,BPP,3,L-3(R+"!A;F0@,2PX-C8L-34P
M(&%T($1E8V5M8F5R(#,Q+"`R,#$Q+`T*(`T*("`@("`@("`R,#$P(&%N9"`R
M,#`Y+"!R97-P96-T:79E;'DN/"]F;VYT/@T*("`@("`-"B`@("`@(#PO9&EV
M/CQB<B\^/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/E)E=F5N=64-"B`@("`-"B`@("`@("`@4F5C;V=N:71I;VX\
M+V9O;G0^#0H@("`-"B`@("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=,
M24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SY790T*("`@(`T*("`@("`@("!R96-O9VYI>F4@<F5V
M96YU92!I;B!A8V-O<F1A;F-E('=I=&@@=&AE(%-%0R8C.#(Q-SMS(%-T869F
M#0H@#0H@("`@("`@($%C8V]U;G1I;F<@0G5L;&5T:6X@3F\N(#$P,2P@/&9O
M;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI
M;F4G/E)E=F5N=64-"B`-"B`@("`@("`@4F5C;V=N:71I;VX@:6X@1FEN86YC
M:6%L(%-T871E;65N=',L/"]F;VYT/B!A<R!A;65N9&5D(&)Y#0H@(`T*("`@
M("`@("!3=&%F9B!!8V-O=6YT:6YG($)U;&QE=&EN($YO+B`Q,#0L(#QF;VYT
M('-T>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE
M)SY2979E;G5E#0H@(`T*("`@("`@("!296-O9VYI=&EO;BP\+V9O;G0^("@F
M(S@R,C`[4T%"(#$P-"8C.#(R,3LI+B!304(@,3`T#0H@("`@(`T*("`@("`@
M("!P<F]V:61E<R!G=6ED86YC92!I;B!A<'!L>6EN9R!'04%0('1O(')E=F5N
M=64@<F5C;V=N:71I;VX-"B`-"B`@("`@("`@:7-S=65S+"!A;F0@<W!E8VEF
M:6-A;&QY(&%D9')E<W-E<R!R979E;G5E(')E8V]G;FET:6]N(&9O<@T*("`-
M"B`@("`@("`@=7!F<F]N="P@;F]N<F5F=6YD86)L92!F965S(')E8V5I=F5D
M(&EN(&-O;FYE8W1I;VX@=VET:`T*("`@(`T*("`@("`@("!R97-E87)C:"!C
M;VQL86)O<F%T:6]N(&%G<F5E;65N=',N)B,Q-C`[)B,Q-C`[1'5R:6YG(#(P
M,3$L#0H@("`@(`T*("`@("`@("`R,#$P(&%N9"`R,#`Y+"!O=7(@<F5V96YU
M92!C;VYS:7-T960@;V8@9W)A;G0@9G5N9&EN9PT*("`-"B`@("`@("`@<F5C
M96EV960@<')I;6%R:6QY(&9R;VT@=&AE($Y)2"`H<V5E($YO=&4-"B`@("`@
M#0H@("`@("`@(#,I+B8C,38P.R8C,38P.U)E=F5N=64@9G)O;2!T:&ES(&%R
M<F%N9V5M96YT(&ES#0H@("`@#0H@("`@("`@(&%P<')O>&EM871E;'D@97%U
M86P@=&\@=&AE(&-O<W1S(&EN8W5R<F5D(&%N9"!I<R!R96-O<F1E9`T*(`T*
M("`@("`@("!A<R!I;F-O;64@87,@=&AE(')E;&%T960@8V]S=',@87)E(&EN
M8W5R<F5D+CPO9F]N=#X-"B`-"B`@("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL
M93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E)E<V5A
M<F-H#0H@("`@(`T*("`@("`@("!A;F0@1&5V96QO<&UE;G0@17AP96YS93PO
M9F]N=#X-"B`@("`@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G
M3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/@T*(`T*("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^4F5S96%R8V@-"B`@("`@#0H@("`@("`@(&%N9"!D
M979E;&]P;65N="!E>'!E;G-E('!R:6UA<FEL>2!C;VYS:7-T<R!O9B!C;W-T
M<PT*("`@("`-"B`@("`@("`@:6YC=7)R960@:6X@=&AE(&1I<V-O=F5R>2P@
M9&5V96QO<&UE;G0L('1E<W1I;F<@86YD#0H@("`@(`T*("`@("`@("!M86YU
M9F%C='5R:6YG(&]F(&]U<B!P<F]D=6-T(&-A;F1I9&%T97,N(%1H97-E(&5X
M<&5N<V5S#0H@("`@#0H@("`@("`@(&-O;G-I<W0@<')I;6%R:6QY(&]F("AI
M*2!F965S('!A:60@=&\@=&AI<F0M<&%R='D@<V5R=FEC90T*(`T*("`@("`@
M("!P<F]V:61E<G,@=&\@<&5R9F]R;2P@;6]N:71O<B!A;F0@86-C=6UU;&%T
M92!D871A(')E;&%T960-"B`-"B`@("`@("`@=&\@;W5R('!R96-L:6YI8V%L
M('-T=61I97,@86YD(&-L:6YI8V%L('1R:6%L<RP@*&EI*2!C;W-T<PT*("`-
M"B`@("`@("`@<F5L871E9"!T;R!S<&]N<V]R960@<F5S96%R8V@@86=R965M
M96YT<RP@*&EI:2D@=&AE(&-O<W1S#0H@#0H@("`@("`@('1O('!R;V-U<F4@
M86YD(&UA;G5F86-T=7)E(&UA=&5R:6%L<R!U<V5D(&EN(&-L:6YI8V%L#0H@
M(`T*("`@("`@("!T<FEA;',L("AI=BD@;&%B;W)A=&]R>2!S=7!P;&EE<R!A
M;F0@9F%C:6QI='DM<F5L871E9`T*("`-"B`@("`@("`@97AP96YS97,@=&\@
M8V]N9'5C="!D979E;&]P;65N="P@86YD("AV*2!S86QA<FEE<RP-"B`@("`-
M"B`@("`@("`@8F5N969I=',L(&%N9"!S:&%R92UB87-E9"!C;VUP96YS871I
M;VX@9F]R#0H@#0H@("`@("`@('!E<G-O;FYE;"XF(S$V,#LF(S$V,#M4:&5S
M92!C;W-T<R!A<F4@8VAA<F=E9"!T;R!E>'!E;G-E(&%S#0H@#0H@("`@("`@
M(&EN8W5R<F5D+CPO9F]N=#X-"B`-"B`@("`@(#PO9&EV/CQB<B\^/&1I=B!S
M='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E!A
M=&5N=`T*("`@#0H@("`@("`@($-O<W1S/"]F;VYT/@T*("`-"B`@("`@(#PO
M9&EV/CQB<B\^/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY/=7(-"B`@
M("`@#0H@("`@("`@(&5X<&5N9&ET=7)E<R!R96QA=&EN9R!T;R!O8G1A:6YI
M;F<@86YD('!R;W1E8W1I;F<@<&%T96YT<PT*(`T*("`@("`@("!A<F4@8VAA
M<F=E9"!T;R!E>'!E;G-E('=H96X@:6YC=7)R960L(&%N9"!A<F4@:6YC;'5D
M960@:6X-"B`-"B`@("`@("`@9V5N97)A;"!A;F0@861M:6YI<W1R871I=F4@
M97AP96YS92X\+V9O;G0^#0H@(`T*("`@("`@/"]D:78^/&)R+SX\9&EV('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^4&5R
M:6]D#0H@("`-"B`@("`@("`@=&\@4&5R:6]D($-O;7!A<FES;VYS/"]F;VYT
M/@T*("`@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G3$E.12U(
M14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/@T*(`T*("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P="<^3W5R#0H@("`@(`T*("`@("`@("!O<&5R871I;F<@<F5S=6QT
M<R!A<F4@97AP96-T960@=&\@9FQU8W1U871E(&9O<B!T:&4-"B`@("`@#0H@
M("`@("`@(&9O<F5S965A8FQE(&9U='5R92X@5&AE<F5F;W)E+"!P97)I;V0M
M=&\M<&5R:6]D(&-O;7!A<FES;VYS#0H@("`-"B`@("`@("`@<VAO=6QD(&YO
M="!B92!R96QI960@=7!O;B!A<R!P<F5D:6-T:79E(&]F('1H92!R97-U;'1S
M(&9O<@T*("`-"B`@("`@("`@9G5T=7)E('!E<FEO9',N)B,Q-C`[)B,Q-C`[
M0V5R=&%I;B!P<FEO<B!Y96%R(&%M;W5N=',@:&%V90T*("`@("`-"B`@("`@
M("`@8F5E;B!R96-L87-S:69I960@=&\@8V]N9F]R;2!T;R!T:&4@8W5R<F5N
M="!Y96%R(&9I;F%N8VEA;`T*("`-"B`@("`@("`@<W1A=&5M96YT('!R97-E
M;G1A=&EO;BX\+V9O;G0^#0H@("`@(`T*("`@("`@/"]D:78^/&)R+SX\9&EV
M('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M26YC;VUE#0H@("`-"B`@("`@("`@5&%X97,\+V9O;G0^#0H@(`T*("`@("`@
M/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E=E#0H@
M("`@#0H@("`@("`@(&%C8V]U;G0@9F]R(&EN8V]M92!T87AE<R!U<VEN9R!T
M:&4@;&EA8FEL:71Y(&UE=&AO9"X@56YD97(-"B`@#0H@("`@("`@('1H:7,@
M;65T:&]D+"!D969E<G)E9"!T87@@87-S971S(&%N9"!L:6%B:6QI=&EE<R!A
M<F4-"B`-"B`@("`@("`@<F5C;V=N:7IE9"!F;W(@=&AE(&5S=&EM871E9"!F
M=71U<F4@=&%X(&-O;G-E<75E;F-E<PT*(`T*("`@("`@("!A='1R:6)U=&%B
M;&4@=&\@9&EF9F5R96YC97,@8F5T=V5E;B!T:&4@9FEN86YC:6%L('-T871E
M;65N=`T*("`@#0H@("`@("`@(&-A<G)Y:6YG(&%M;W5N=',@;V8@97AI<W1I
M;F<@87-S971S(&%N9"!L:6%B:6QI=&EE<R!A;F0-"B`@("`-"B`@("`@("`@
M=&AE:7(@<F5S<&5C=&EV92!T87@@8F%S97,N)B,Q-C`[)B,Q-C`[1&5F97)R
M960@=&%X(&%S<V5T<PT*("`@("`-"B`@("`@("`@86YD(&QI86)I;&ET:65S
M(&%R92!M96%S=7)E9"!U<VEN9R!E;F%C=&5D(')A=&5S(&EN(&5F9F5C=`T*
M("`-"B`@("`@("`@9F]R('1H92!Y96%R(&EN('=H:6-H('1E;7!O<F%R>2!D
M:69F97)E;F-E<R!A<F4@97AP96-T960@=&\-"B`@(`T*("`@("`@("!B92!R
M96-O=F5R960@;W(@<V5T=&QE9"XF(S$V,#LF(S$V,#M$969E<G)E9"!T87@@
M87-S971S(&%R90T*(`T*("`@("`@("!R961U8V5D(&)Y(&$@=F%L=6%T:6]N
M(&%L;&]W86YC92!U;FQE<W,L(&EN('1H92!O<&EN:6]N(&]F#0H@(`T*("`@
M("`@("!M86YA9V5M96YT+"!I="!I<R!M;W)E(&QI:V5L>2!T:&%N(&YO="!T
M:&%T('-O;64@<&]R=&EO;B!O<@T*("`@#0H@("`@("`@(&%L;"!O9B!T:&4@
M9&5F97)R960@=&%X(&%S<V5T<R!W:6QL(&)E(')E86QI>F5D+CPO9F]N=#X-
M"B`@("`@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G3$E.12U(
M14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/@T*(`T*("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+5-464Q%
M.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY3=&]C:RU"87-E9`T*("`@
M#0H@("`@("`@($-O;7!E;G-A=&EO;CPO9F]N=#X-"B`@("`-"B`@("`@(#PO
M9&EV/CQB<B\^/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY790T*("`@
M(`T*("`@("`@("!A8V-O=6YT(&9O<B!S=&]C:RUB87-E9"!T<F%N<V%C=&EO
M;G,@:6X@=VAI8V@@=&AE($-O;7!A;GD-"B`-"B`@("`@("`@<F5C96EV97,@
M<V5R=FEC97,@9G)O;2!E;7!L;WEE97,L(&1I<F5C=&]R<R!O<B!O=&AE<G,@
M:6X-"B`@("`@#0H@("`@("`@(&5X8VAA;F=E(&9O<B!E<75I='D@:6YS=')U
M;65N=',@8F%S960@;VX@=&AE(&9A:7(@=F%L=64@;V8-"B`@#0H@("`@("`@
M('1H92!A=V%R9"!A="!T:&4@9W)A;G0@9&%T92XF(S$V,#LF(S$V,#M#;VUP
M96YS871I;VX@8V]S=`T*("`@(`T*("`@("`@("!F;W(@87=A<F1S(&]F(&-O
M;6UO;B!S=&]C:R!I<R!E<W1I;6%T960@8F%S960@;VX@=&AE('!R:6-E#0H@
M(`T*("`@("`@("!O9B!T:&4@=6YD97)L>6EN9R!C;VUM;VX@<W1O8VL@;VX@
M=&AE(&1A=&4@;V8-"B`@("`-"B`@("`@("`@:7-S=6%N8V4N)B,Q-C`[)B,Q
M-C`[0V]M<&5N<V%T:6]N(&-O<W0@9F]R('-T;V-K(&]P=&EO;G,@;W(-"B`-
M"B`@("`@("`@=V%R<F%N=',@:7,@97-T:6UA=&5D(&%T('1H92!G<F%N="!D
M871E(&)A<V5D(&]N(&5A8V@-"B`@#0H@("`@("`@(&EN<W1R=6UE;G0F(S@R
M,3<[<R!F86ER+79A;'5E(&%S(&-A;&-U;&%T960@8GD@=&AE#0H@("`-"B`@
M("`@("`@0FQA8VLM4V-H;VQE<R!O<'1I;VX@<')I8VEN9R!M;V1E;"XF(S$V
M,#LF(S$V,#M792!R96-O9VYI>F4-"B`-"B`@("`@("`@<W1O8VLM8F%S960@
M8V]M<&5N<V%T:6]N(&-O<W0@87,@97AP96YS92!R871A8FQY(&]N(&$-"B`@
M#0H@("`@("`@('-T<F%I9VAT+6QI;F4@8F%S:7,@;W9E<B!T:&4@<F5Q=6ES
M:71E('-E<G9I8V4@<&5R:6]D(&9O<@T*(`T*("`@("`@("!T:&4@87=A<F0N
M)B,Q-C`[)B,Q-C`[4V5E($YO=&4@-B!F;W(@861D:71I;VYA;"!S=&]C:RUB
M87-E9`T*(`T*("`@("`@("!C;VUP96YS871I;VX@:6YF;W)M871I;VXN/"]F
M;VYT/@T*("`-"B`@("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=,24Y%
M+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^#0H@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/3E0M4U19
M3$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E)E8V5N=`T*("`@#0H@
M("`@("`@($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',\+V9O;G0^#0H@(`T*
M("`@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q
M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-
M"B`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/E1H97)E#0H@(`T*("`@("`@("!H879E(&)E96X@;F\@<F5C96YT(&%C8V]U
M;G1I;F<@<')O;F]U;F-E;65N=',@;W(@8VAA;F=E<R!I;@T*("`@#0H@("`@
M("`@(&%C8V]U;G1I;F<@<')O;F]U;F-E;65N=',@=VAI8V@@=V4@97AP96-T
M('1O(&AA=F4@80T*("`@("`-"B`@("`@("`@;6%T97)I86P@:6UP86-T(&]N
M(&]U<B!F:6YA;F-I86P@<W1A=&5M96YT<RP@;F]R(&1O('=E#0H@("`-"B`@
M("`@("`@8F5L:65V92!T:&%T(&%N>2!R96-E;G1L>2!I<W-U960L(&)U="!N
M;W0@>65T(&5F9F5C=&EV92P-"B`@("`@#0H@("`@("`@(&%C8V]U;G1I;F<@
M<W1A;F1A<F1S(&EF(&-U<G)E;G1L>2!A9&]P=&5D('=O=6QD(&AA=F4@80T*
M("`@#0H@("`@("`@(&UA=&5R:6%L(&5F9F5C="!O;B!O=7(@9FEN86YC:6%L
M('-T871E;65N=',N/"]F;VYT/@T*(`T*("`@("`@/"]D:78^/&)R+SX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,T,#0W.&4X
M7S$T96-?-#1D9%\Y,C,T7S9E,#(R-V4S9F$V-`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\S-#`T-SAE.%\Q-&5C7S0T9&1?.3(S-%\V93`R,C=E
M,V9A-C0O5V]R:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^3F]T92`S("T@1V]V97)N;65N="!'<F%N
M=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=O
M=F5R;FUE;G0@1W)A;G1S(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR
M-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@
M#0H@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+5=%24=(5#H@8F]L9"<^,RXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF
M(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M';W9E
M<FYM96YT#0H@("`-"B`@("`@("`@1W)A;G1S/"]F;VYT/@T*("`@#0H@("`@
M("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[
M(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*(`T*
M("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY.24@-"B`@("`@#0H@("`@("`@($=R86YT/"]F
M;VYT/@T*("`-"B`@("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=,24Y%
M+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^#0H@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY);@T*("`@(`T*("`@("`@("!397!T96UB97(@,C`P-RP@
M=&AE($Y)2"!A=V%R9&5D('5S(&%N($EN=&5G<F%T960-"B`@#0H@("`@("`@
M(%!R96-L:6YI8V%L+T-L:6YI8V%L($%)1%,@5F%C8VEN92!$979E;&]P;65N
M="`H25!#059$*0T*("`@#0H@("`@("`@(&=R86YT('1O('-U<'!O<G0@;W5R
M($A)5B]!2413('9A8V-I;F4-"B`-"B`@("`@("`@<')O9W)A;2XF(S$V,#LF
M(S$V,#M4:&4@<')O:F5C="!P97)I;V0@9F]R('1H92!G<F%N="!C;W9E<G,-
M"B`-"B`@("`@("`@82!F:79E+7EE87(@<&5R:6]D('=H:6-H(&-O;6UE;F-E
M9"!/8W1O8F5R(#(P,#<L('=I=&@@86X-"B`@("`@#0H@("`@("`@(&%G9W)E
M9V%T92!A=V%R9"!O9B`D,C`N-"!M:6QL:6]N+B8C,38P.R8C,38P.T%S(&]F
M($1E8V5M8F5R#0H@#0H@("`@("`@(#,Q+"`R,#$Q+"!T:&5R92!I<R!A<'!R
M;WAI;6%T96QY("0S+CD@;6EL;&EO;B!O9B!U;G5S960-"B`@("`-"B`@("`@
M("`@9W)A;G0@9G5N9',@<F5M86EN:6YG(&%N9"!A=F%I;&%B;&4@9F]R('5S
M92!T:')O=6=H($%U9W5S=`T*("`-"B`@("`@("`@,S$L(#(P,3(@*'1H92!E
M;F0@;V8@=&AE(&]R:6=I;F%L('!R;VIE8W0-"B`@("`@#0H@("`@("`@('!E
M<FEO9"DN)B,Q-C`[)B,Q-C`[5V4@87)E('5T:6QI>FEN9R!T:&ES(&9U;F1I
M;F<@=&\-"B`@("`-"B`@("`@("`@9G5R=&AE<B!O=7(@2$E6+T%)1%,@=F%C
M8VEN92!D979E;&]P;65N="P@;W!T:6UI>F%T:6]N(&%N9`T*("`-"B`@("`@
M("`@<')O9'5C=&EO;BXF(S$V,#LF(S$V,#M792!R96-O<F0@<F5V96YU92!A
M<W-O8VEA=&5D('=I=&@-"B`@(`T*("`@("`@("!T:&4@9W)A;G0@87,@=&AE
M(')E;&%T960@8V]S=',@86YD(&5X<&5N<V5S(&%R92!I;F-U<G)E9`T*("`@
M("`-"B`@("`@("`@86YD('-U8V@@<F5V96YU92!I<R!R97!O<G1E9"!A<R!A
M('-E<&%R871E(&QI;F4@:71E;2!I;B!O=7(-"B`@(`T*("`@("`@("!S=&%T
M96UE;G1S(&]F(&]P97)A=&EO;G,N)B,Q-C`[)B,Q-C`[1'5R:6YG(#(P,3$L
M(#(P,3`L(&%N9`T*(`T*("`@("`@("`R,#`Y+"!W92!R96-O<F1E9"`D-"PX
M.3DL.#@U+"`D-"PY-#`L-S<X+"!A;F0@)#,L-C8X+#$Y-2P-"B`-"B`@("`@
M("`@<F5S<&5C=&EV96QY+"!O9B!R979E;G5E(&%S<V]C:6%T960@=VET:"!T
M:&ES(&=R86YT+CPO9F]N=#X-"B`@("`-"B`@("`@(#PO9&EV/CQB<B\^/&1I
M=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/E%41%`-"B`-"B`@("`@("`@1W)A;G0\+V9O;G0^#0H@(`T*("`@("`@/"]D
M:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DEN#0H@("`@
M#0H@("`@("`@($YO=F5M8F5R(#(P,3`L('=E('=E<F4@87=A<F1E9"!A(&]N
M92UT:6UE(&=R86YT(&]F("0R-#0L-#<Y#0H@("`-"B`@("`@("`@<'5R<W5A
M;G0@=&\@=&AE(%%U86QI9GEI;F<@5&AE<F%P975T:6,@1&ES8V]V97)Y(%!R
M;VIE8W0-"B`@("`@#0H@("`@("`@("A15$10*2!P<F]G<F%M(&5N86-T960@
M87,@<&%R="!O9B!T:&4@4&%T:65N="!0<F]T96-T:6]N#0H@("`@(`T*("`@
M("`@("!A;F0@069F;W)D86)L92!#87)E($%C="!O9B`R,#$P+B8C,38P.R8C
M,38P.U1H92!15$10#0H@("`@#0H@("`@("`@('!R;V=R86T@=V%S(&EN=&5N
M9&5D('1O('!R;W9I9&4@:6YC96YT:79E('1O('-M86QL97(-"B`-"B`@("`@
M("`@8V]M<&%N:65S('=H;R!A<F4@9F]C=7-I;F<@;VX@:6YN;W9A=&EV92!T
M:&5R87!E=71I8PT*(`T*("`@("`@("!D:7-C;W9E<FEE<RXF(S$V,#LF(S$V
M,#M792!R96-E:79E9"!T:&4@9G5L;"!A;6]U;G0@;V8@=&AE#0H@("`@(`T*
M("`@("`@("!G<F%N="!D=7)I;F<@,C`Q,"P@=VAI8V@@:7,@<F5C;W)D960@
M87,@<F5V96YU92!F;W(@,C`Q,"!I;@T*("`@#0H@("`@("`@('1H92!A8V-O
M;7!A;GEI;F<@0V]N<V]L:61A=&5D(%-T871E;65N="!O9@T*(`T*("`@("`@
M("!/<&5R871I;VYS+CPO9F]N=#X-"B`@(`T*("`@("`@/"]D:78^/&)R+SX\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,T,#0W
M.&4X7S$T96-?-#1D9%\Y,C,T7S9E,#(R-V4S9F$V-`T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\S-#`T-SAE.%\Q-&5C7S0T9&1?.3(S-%\V93`R
M,C=E,V9A-C0O5V]R:W-H965T<R]3:&5E=#$P+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F]T92`T("T@0V]M;6ET;65N=',\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UI
M=&UE;G1S($1I<V-L;W-U<F4@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q
M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-
M"B`@("`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXT+B8C,38P.R8C,38P.R8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.T-O;6UI=&UE;G1S/"]F;VYT/@T*("`-"B`@("`@(#PO9&EV/CQB<B\^/&1I
M=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P
M=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU2
M24=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/DQE87-E#0H@(`T*("`@("`@("!!9W)E96UE;G1S/"]F;VYT/@T*("`-"B`@
M("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR
M-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@
M#0H@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY7
M90T*("`@(`T*("`@("`@("!L96%S92!A<'!R;WAI;6%T96QY(#@L-#`P('-Q
M=6%R92!F965T(&]F(&]F9FEC92!A;F0-"B`@("`@#0H@("`@("`@(&QA8F]R
M871O<GD@<W!A8V4@;&]C871E9"!I;B!3;7ER;F$L($=E;W)G:6$@*&UE=')O
M<&]L:71A;@T*(`T*("`@("`@("!!=&QA;G1A*2X@4F5N="!E>'!E;G-E(&9O
M<B!T:&4@>65A<G,@96YD960@1&5C96UB97(@,S$L#0H@("`@#0H@("`@("`@
M(#(P,3$L(#(P,3`@86YD(#(P,#D@=V%S("0Q,3DL,C4U+"`D,3$X+#DX."P@
M86YD("0V,RPS-3`L#0H@("`@(`T*("`@("`@("!R97-P96-T:79E;'DN)B,Q
M-C`[)B,Q-C`[1G5T=7)E(&UI;FEM=6T@;&5A<V4@<&%Y;65N=',-"B`-"B`@
M("`@("`@<'5R<W5A;G0@=&\@=&AE(#8R(&UO;G1H(&QE87-E('1O=&%L("0Q
M,C$L-38P(&EN(#(P,3(L#0H@("`-"B`@("`@("`@)#$R-2PQ.#`@:6X@,C`Q
M,R!A;F0@)#$R."PY,C`@:6X@,C`Q-"X\+V9O;G0^#0H@("`@(`T*("`@("`@
M/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^3W1H97(-"B`@#0H@("`@("`@($-O;6UI=&UE;G1S
M/"]F;VYT/@T*("`@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G
M3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1L969T/@T*(`T*("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^26X-"B`@("`-"B`@("`@("`@=&AE(&YO<FUA;"!C
M;W5R<V4@;V8@8G5S:6YE<W,L('=E(&UA>2!E;G1E<B!I;G1O('9A<FEO=7,-
M"B`@("`@#0H@("`@("`@(&9I<FT@<'5R8VAA<V4@8V]M;6ET;65N=',@<F5L
M871E9"!T;R!P<F]D=6-T:6]N(&%N9"!T97-T:6YG#0H@("`-"B`@("`@("`@
M;V8@;W5R('9A8V-I;F4@;6%T97)I86PL(&-O;F1U8W0@;V8@8VQI;FEC86P@
M=')I86QS+"!A;F0-"B`@("`@#0H@("`@("`@(&]T:&5R(')E<V5A<F-H+7)E
M;&%T960@86-T:79I=&EE<RX@07,@;V8@1&5C96UB97(@,S$L(#(P,3$L#0H@
M("`-"B`@("`@("`@=V4@:&%D(&%P<')O>&EM871E;'D@)#0W."PP,#`@;V8@
M=6YR96-O<F1E9"!O=71S=&%N9&EN9PT*("`@(`T*("`@("`@("!P=7)C:&%S
M92!C;VUM:71M96YT<R!T;R!O=7(@=F5N9&]R<R!A;F0@<W5B8V]N=')A8W1O
M<G,L(&]F#0H@(`T*("`@("`@("!W:&EC:"!W92!E>'!E8W0@87!P<F]X:6UA
M=&5L>2`D-#0U+#`P,"!I;B`R,#$R(&%N9"`D,S,L,#`P#0H@(`T*("`@("`@
M("!I;B`R,#$S+CPO9F]N=#X-"B`@("`@#0H@("`@("`\+V1I=CX\8G(O/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S0P-#<X
M93A?,31E8U\T-&1D7SDR,S1?-F4P,C(W93-F838T#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S,T,#0W.&4X7S$T96-?-#1D9%\Y,C,T7S9E,#(R
M-V4S9F$V-"]7;W)K<VAE971S+U-H965T,3$N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!1#X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.;W1E(#4@+2`R,#`V($UE<F=E<B!A
M;F0@4F5C87!I=&%L:7IA=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^365R9V5R<RP@06-Q=6ES:71I;VYS(&%N9"!$:7-P
M;W-I=&EO;G,@1&ES8VQO<W5R97,@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4
M.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X-"B`@(`T*("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/C4N)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[,C`P-@T*("`-"B`@("`@("`@365R9V5R(&%N9"!296-A<&ET86QI>F%T
M:6]N/"]F;VYT/@T*("`@(`T*("`@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE
M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/E1H90T*("`@("`-"B`@("`@("`@0V]M<&%N
M>2!W87,@;W)I9VEN86QL>2!I;F-O<G!O<F%T960@:6X@2G5N92`Q.3@X('5N
M9&5R('1H90T*("`-"B`@("`@("`@;&%W<R!O9B!);&QI;F]I<R!A<R!$875P
M:&EN(%1E8VAN;VQO9WDL($EN8RX-"B`@(`T*("`@("`@("`H)B,X,C(P.T1A
M=7!H:6XF(S@R,C$[*2XF(S$V,#LF(S$V,#M$875P:&EN('=A<PT*("`-"B`@
M("`@("`@=6YS=6-C97-S9G5L(&%N9"!I=',@;W!E<F%T:6]N<R!W97)E('1E
M<FUI;F%T960@:6X@1&5C96UB97(-"B`@(`T*("`@("`@("`R,#`S+B8C,38P
M.R8C,38P.TEN(%-E<'1E;6)E<B`R,#`V+"!$875P:&EN(&-O;7!L971E9"!A
M#0H@(`T*("`@("`@("!M97)G97(@*'1H92`F(S@R,C`[365R9V5R)B,X,C(Q
M.RD@=VET:"!'96]687@L($EN8RX@=VAI8V@-"B`@("`-"B`@("`@("`@=V%S
M(&EN8V]R<&]R871E9"!U;F1E<B!T:&4@;&%W<R!O9B!'96]R9VEA(&EN($IU
M;F4-"B`@("`-"B`@("`@("`@,C`P,2XF(S$V,#LF(S$V,#M!<R!A(')E<W5L
M="!O9B!T:&4@365R9V5R+"!T:&4-"B`@("`-"B`@("`@("`@<VAA<F5H;VQD
M97)S(&]F($=E;U9A>"P@26YC+B!E>&-H86YG960@=&AE:7(@<VAA<F5S(&]F
M#0H@("`-"B`@("`@("`@8V]M;6]N('-T;V-K(&9O<B!$875P:&EN(&-O;6UO
M;B!S=&]C:R!A;F0@1V5O5F%X+"!);F,N#0H@("`-"B`@("`@("`@8F5C86UE
M(&$@=VAO;&QY+6]W;F5D('-U8G-I9&EA<GD@;V8-"B`@("`-"B`@("`@("`@
M1&%U<&AI;BXF(S$V,#LF(S$V,#M$875P:&EN('1H96X@8VAA;F=E9"!I=',@
M;F%M92!T;R!'96]687@-"B`-"B`@("`@("`@3&%B<RP@26YC+B!A;F0@<F5P
M;&%C960@:71S(&]F9FEC97)S(&%N9"!D:7)E8W1O<G,@=VET:`T*("`@(`T*
M("`@("`@("!T:&]S92!O9B!'96]687@L($EN8RXF(S$V,#LF(S$V,#M3=6)S
M97%U96YT('1O('1H92!-97)G97(L#0H@("`@(`T*("`@("`@("!T:&4@0V]M
M<&%N>2!H87,@;F]T(&-O;F1U8W1E9"!A;GD@8G5S:6YE<W,@;W1H97(@=&AA
M;@T*("`-"B`@("`@("`@1V5O5F%X+"!);F,N)B,X,C$W.W,@8G5S:6YE<W,@
M;V8@9&5V96QO<&EN9R!H=6UA;@T*("`-"B`@("`@("`@=F%C8VEN97,N)B,Q
M-C`[)B,Q-C`[5&AE($UE<F=E<B!W87,@86-C;W5N=&5D(&9O<B!U;F1E<B!T
M:&4-"B`-"B`@("`@("`@<'5R8VAA<V4@;65T:&]D(&]F(&%C8V]U;G1I;F<@
M87,@82!R979E<G-E(&%C<75I<VET:6]N(&EN#0H@#0H@("`@("`@(&%C8V]R
M9&%N8V4@=VET:"!'04%0+B!5;F1E<B!T:&ES(&UE=&AO9"!O9B!A8V-O=6YT
M:6YG+`T*("`@#0H@("`@("`@($1A=7!H:6X@=V%S('1R96%T960@87,@=&AE
M(&%C<75I<F5D(&-O;7!A;GD@86YD+`T*("`-"B`@("`@("`@86-C;W)D:6YG
M;'DL(&%L;"!F:6YA;F-I86P@:6YF;W)M871I;VX@<')I;W(@=&\@=&AE(&1A
M=&4@;V8-"B`@(`T*("`@("`@("!-97)G97(@<')E<V5N=&5D(&EN('1H92!A
M8V-O;7!A;GEI;F<@8V]N<V]L:61A=&5D(&9I;F%N8VEA;`T*("`@#0H@("`@
M("`@('-T871E;65N=',L(&]R(&EN('1H92!N;W1E<R!H97)E:6XL(&%S('=E
M;&P@87,@86YY#0H@("`@#0H@("`@("`@(')E9F5R96YC97,@=&\@<')I;W(@
M;W!E<F%T:6]N<RP@87)E('1H;W-E(&]F($=E;U9A>"P-"B`-"B`@("`@("`@
M26YC+B8C,38P.R8C,38P.TEN($IU;F4@,C`P."P@=&AE($-O;7!A;GD@=V%S
M#0H@(`T*("`@("`@("!R96EN8V]R<&]R871E9"!U;F1E<B!T:&4@;&%W<R!O
M9B!T:&4@4W1A=&4@;V8-"B`@("`-"B`@("`@("`@1&5L87=A<F4N/"]F;VYT
M/@T*(`T*("`@("`@/"]D:78^/&)R+SX\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S,T,#0W.&4X7S$T96-?-#1D9%\Y,C,T7S9E
M,#(R-V4S9F$V-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S-#`T
M-SAE.%\Q-&5C7S0T9&1?.3(S-%\V93`R,C=E,V9A-C0O5V]R:W-H965T<R]3
M:&5E=#$R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^3F]T92`V("T@4W1O8VMH;VQD97)S)R!%<75I='D\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K:&]L9&5R<R<@17%U
M:71Y($YO=&4@1&ES8VQO<W5R92!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T
M/@T*("`@("`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M5T5)1TA4.B!B;VQD)SXV+B8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C
M,38P.U-T;V-K:&]L9&5R<R8C.#(Q-SL-"B`-"B`@("`@("`@17%U:71Y/"]F
M;VYT/@T*("`@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/@T*(`T*("`@("`@("`\9F]N="!S='EL93TS1"=&3TY4+5-4
M64Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY#;VUM;VX-"B`@(`T*
M("`@("`@("!3=&]C:R!4<F%N<V%C=&EO;G,\+V9O;G0^#0H@("`@(`T*("`@
M("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U
M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-
M"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DEN
M#0H@("`@#0H@("`@("`@($9E8G)U87)Y(#(P,3`L('=E(&ES<W5E9"`Q,BPP
M,#`@<VAA<F5S(&]F(&]U<B!C;VUM;VX@<W1O8VL-"B`@#0H@("`@("`@(&EN
M('-E='1L96UE;G0@;V8@86X@;V)L:6=A=&EO;B!A8V-R=65D(&%T($1E8V5M
M8F5R(#,Q+"`R,#`Y#0H@("`-"B`@("`@("`@:6X@=&AE(&%M;W5N="!O9B`D
M.3`L,#`P+CPO9F]N=#X-"B`@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/@T*(`T*("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^1'5R:6YG#0H@("`-"B`@("`@("`@1&5C
M96UB97(@,C`Q,2P@=V4@<V]L9"!A;B!A9V=R96=A=&4@;V8@-C4X+#4R,"!S
M:&%R97,@;V8-"B`@("`@#0H@("`@("`@(&]U<B!C;VUM;VX@<W1O8VL@=&\@
M9FEF=&5E;B!I;F1I=FED=6%L(&%C8W)E9&ET960@:6YV97-T;W)S#0H@("`-
M"B`@("`@("`@*&EN8VQU9&EN9R!M96UB97)S(&]F(&]U<B!B;V%R9"!O9B!D
M:7)E8W1O<G,@86YD(&UA;F%G96UE;G0-"B`@(`T*("`@("`@("`M+7-E92!.
M;W1E(#DI(&9O<B!A;B!A9V=R96=A=&4@<'5R8VAA<V4@<')I8V4@;V8@)#0T
M,2PR,3`L#0H@(`T*("`@("`@("`D,S8L.#`P(&]F('=H:6-H('=A<R!R96-E
M:79E9"!I;B!*86YU87)Y(#(P,3(@86YD(&ES#0H@#0H@("`@("`@('1H97)E
M9F]R92!R969L96-T960@87,@82!R96-E:79A8FQE("A/=&AE<B!#=7)R96YT
M($%S<V5T*0T*(`T*("`@("`@("!I;B!T:&4@86-C;VUP86YY:6YG($-O;G-O
M;&ED871E9"!"86QA;F-E(%-H965T(&%S(&]F#0H@#0H@("`@("`@($1E8V5M
M8F5R(#,Q+"`R,#$Q+B8C,38P.R8C,38P.U=E(&%L<V\@:7-S=65D('1O('1H
M90T*("`@#0H@("`@("`@(&EN=F5S=&]R<R!W87)R86YT<R!T;R!P=7)C:&%S
M92!A;B!A9V=R96=A=&4@;V8@.3@W+#<X,PT*("`@#0H@("`@("`@('-H87)E
M<R!O9B!C;VUM;VX@<W1O8VL@870@82!P<FEC92!O9B`D,2XP,"!P97(@<VAA
M<F4L('=H:6-H#0H@("`-"B`@("`@("`@97AP:7)E(&EN($1E8V5M8F5R(#(P
M,38N/"]F;VYT/@T*(`T*("`@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/D9R;VT-"B`-"B`@("`@("`@=&EM92!T;R!T:6UE
M+"!W92!I<W-U92!S:&%R97,@;V8@;W5R(&-O;6UO;B!S=&]C:R!T;PT*(`T*
M("`@("`@("!C;VYS=6QT86YT<R!O<B!O=&AE<G,@:6X@97AC:&%N9V4@9F]R
M#0H@#0H@("`@("`@('-E<G9I8V5S+B8C,38P.R8C,38P.T1U<FEN9R`R,#$Q
M+"`R,#$P(&%N9"`R,#`Y('=E(&ES<W5E9`T*("`@(`T*("`@("`@("`Q,CDL
M,C0U+"`Q,"PU,#`L(&%N9"`T+#4P,"P@<F5S<&5C=&EV96QY+"!F;W(@<W5C
M:`T*("`@(`T*("`@("`@("!S97)V:6-E<SL@86YD('=E(')E8V]R9&5D(&=E
M;F5R86P@86YD(&%D;6EN:7-T<F%T:79E#0H@#0H@("`@("`@(&5X<&5N<V4@
M;V8@)#$U,"PP,#`L("0U,RPX,3,L(&%N9"`D,S$L-3`P(&1U<FEN9R!E86-H
M#0H@(`T*("`@("`@("!R97-P96-T:79E('!E<FEO9"!R96QA=&5D('1O('1H
M97-E(&ES<W5A;F-E<RX\+V9O;G0^#0H@(`T*("`@("`@/"]D:78^/&)R+SX\
M9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M="<^4W1O8VL-"B`@#0H@("`@("`@($]P=&EO;G,\+V9O;G0^#0H@("`@#0H@
M("`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N
M,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*
M(`T*("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M26X-"B`@("`-"B`@("`@("`@,C`P-BP@=V4@861O<'1E9"!T:&4@1V5O5F%X
M($QA8G,L($EN8RX@,C`P-B!%<75I='D-"B`@("`-"B`@("`@("`@26YC96YT
M:79E(%!L86X@*'1H92`F(S@R,C`[4W1O8VL@3W!T:6]N(%!L86XF(S@R,C$[
M*2!F;W(-"B`@(`T*("`@("`@("!T:&4@9W)A;G1I;F<@;V8@<75A;&EF:65D
M(&EN8V5N=&EV92!S=&]C:R!O<'1I;VYS#0H@("`-"B`@("`@("`@*"8C.#(R
M,#M)4T\F(S@R,3<[<R8C.#(R,3LI+"!N;VYQ=6%L:69I960@<W1O8VL@;W!T
M:6]N<RP-"B`@#0H@("`@("`@(')E<W1R:6-T960@<W1O8VL@87=A<F1S(&]R
M(')E<W1R:6-T960@<W1O8VL@8F]N=7-E<R!T;PT*("`@#0H@("`@("`@(&5M
M<&QO>65E<RP@;V9F:6-E<G,L(&1I<F5C=&]R<RP@8V]N<W5L=&%N=',@86YD
M(&%D=FES;W)S(&]F#0H@("`-"B`@("`@("`@=&AE($-O;7!A;GDN)B,Q-C`[
M)B,Q-C`[5&AE(&5X97)C:7-E('!R:6-E(&9O<B!A;GD@;W!T:6]N#0H@("`@
M#0H@("`@("`@(&=R86YT960@;6%Y(&YO="!B92!L97-S('1H86X@9F%I<B!V
M86QU92`H,3$P)2!O9B!F86ER('9A;'5E#0H@("`-"B`@("`@("`@9F]R($E3
M3R8C.#(Q-SMS(&=R86YT960@=&\@8V5R=&%I;@T*("`-"B`@("`@("`@96UP
M;&]Y965S*2XF(S$V,#LF(S$V,#M/<'1I;VYS(&=R86YT960@=6YD97(@=&AE
M(%-T;V-K#0H@#0H@("`@("`@($]P=&EO;B!0;&%N(&AA=F4@82!M87AI;75M
M('1E;BUY96%R('1E<FT@86YD(&=E;F5R86QL>2!V97-T#0H@("`-"B`@("`@
M("`@;W9E<B!T:')E92!Y96%R<RXF(S$V,#LF(S$V,#M4:&4@0V]M<&%N>2!H
M87,@<F5S97)V960-"B`@("`@#0H@("`@("`@(#$L,C`P+#`P,"!S:&%R97,@
M;V8@:71S(&-O;6UO;B!S=&]C:R!F;W(@:7-S=6%N8V4@=6YD97(@=&AE#0H@
M("`-"B`@("`@("`@4W1O8VL@3W!T:6]N(%!L86XN/"]F;VYT/@T*("`@("`-
M"B`@("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@
M,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M#0H@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY!#0H@("`-"B`@("`@("`@<W5M;6%R>2!O9B!A8W1I=FET>2!U;F1E<B!T
M:&4@4W1O8VL@3W!T:6]N(%!L86X@87,@;V8-"B`@#0H@("`@("`@($1E8V5M
M8F5R(#,Q+"`R,#$Q+"!A;F0@8VAA;F=E<R!D=7)I;F<@=&AE('EE87(@=&AE
M;B!E;F1E9`T*(`T*("`@("`@("!I<R!P<F5S96YT960@8F5L;W<Z/"]F;VYT
M/@T*(`T*("`@("`@/"]D:78^/&)R+SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P
M(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS1#$P,"4@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*
M("`@(`T*("`@("`@("`@(#QT<CX-"B`-"B`@("`@("`@("`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@
M("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!C
M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED)SX-"B`@("`@#0H@("`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K)SX-"B`-"B`@("`@("`@("`@("`@("`F
M(S$V,#L-"B`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/@T*(`T*("`@("`@("`@("`@
M("`@("8C,38P.PT*("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@
M#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/DYU;6)E<CPO9F]N=#X-"B`@("`-"B`@("`@("`@("`@("`@/"]D
M:78^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/F]F#0H@(`T*("`@("`@("`@("`@("`@(%-H
M87)E<SPO9F]N=#X-"B`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@
M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G/@T*(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#)P>"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X
M('-O;&ED)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^5V5I9VAT960M/"]F;VYT/@T*
M("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D%V97)A
M9V4\+V9O;G0^#0H@("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@
M("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[
M(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^#0H@
M("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^17AE<F-I<V4\+V9O;G0^#0H@#0H@("`@("`@("`@("`@(#PO
M9&EV/@T*("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%
M24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&-E;G1E<CX-"B`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY0<FEC93PO9F]N=#X-"B`@(`T*("`@("`@
M("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#)P>"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G/@T*("`@("`-"B`@("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(`T*
M("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY796EG:'1E9"T\+V9O;G0^#0H@(`T*("`@("`@("`@("`@("`\+V1I
M=CX-"B`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C
M96YT97(^#0H@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^079E<F%G93PO9F]N=#X-"B`@("`@#0H@("`@
M("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(`T*("`@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY296UA:6YI;F<\+V9O
M;G0^#0H@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M0V]N=')A8W1U86P\+V9O;G0^#0H@("`@#0H@("`@("`@("`@("`@(#PO9&EV
M/@T*("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(
M5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E
M;G1E<CX-"B`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY497)M#0H@("`@#0H@("`@("`@("`@("`@("`@
M*'ER<RD\+V9O;G0^#0H@("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R<'@@<V]L:60G/@T*("`@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VLG/@T*(`T*("`@("`@("`@("`@("`@("8C,38P.PT*("`-
M"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D%G9W)E9V%T
M93PO9F]N=#X-"B`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(`T*
M("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY);G1R:6YS:6,\+V9O;G0^#0H@(`T*("`@("`@("`@("`@("`\+V1I
M=CX-"B`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C
M96YT97(^#0H@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^5F%L=64\+V9O;G0^#0H@("`-"B`@("`@("`@
M("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R
M<'@G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T
M9#X-"B`@("`-"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@("`@("`\='(@
M<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T,P1D9&1CLG/@T*(`T*("`@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^#0H@
M(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q
M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-
M"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^3W5T<W1A;F1I;F<-"B`-"B`@("`@("`@("`@("`@("!A="!*
M86YU87)Y(#$L(#(P,3$\+V9O;G0^#0H@("`-"B`@("`@("`@("`@("`@/"]D
M:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/@T*("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/@T*("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*("`@("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/C$L,3,W+#,U-CPO9F]N=#X-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*
M("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-
M"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X-"B`@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@
M("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^-2XS,SPO9F]N=#X-"B`@("`@#0H@("`@("`@("`@("`\+W1D
M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@
M("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;3X-
M"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M/@T*(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-
M"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@/"]T<CX-"B`@#0H@("`@("`@("`@/'1R/@T*(`T*("`@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^#0H@(`T*("`@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^1W)A;G1E9#PO9F]N=#X-"B`@("`@#0H@("`@("`@("`@("`@(#PO9&EV
M/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X-"B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SX-"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@
M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR
M,S`L,#`P/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/@T*("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/@T*("`@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*
M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*("`@
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/CQF;VYT(&ED/3-$5$%",2TR.3$@<W1Y;&4],T0G34%21TE.+4Q%
M1E0Z(#,V<'0G/CPO9F]N=#XP+CDQ/"]F;VYT/@T*("`@("`-"B`@("`@("`@
M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$
M8F]T=&]M/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*
M("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@
M("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T
M;VT^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D
M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@
M("`-"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@("`@("`\='(@<W1Y;&4]
M,T0G8F%C:V=R;W5N9"UC;VQO<CH@(T,P1D9&1CLG/@T*(`T*("`@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^#0H@(`T*("`@
M("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^17AE<F-I<V5D/"]F;VYT/@T*("`-"B`@("`@("`@("`@("`@/"]D:78^
M#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/@T*("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/@T*("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*("`@("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BT\
M+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X-"B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SX-"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@
M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\
M9F]N="!I9#TS1%1!0C$M,CDR('-T>6QE/3-$)TU!4D=)3BU,1494.B`S-G!T
M)SX\+V9O;G0^+3PO9F]N=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@
M(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;3X-"B`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M/@T*(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M/"]T<CX-"B`@#0H@("`@("`@("`@/'1R/@T*(`T*("`@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>"<^#0H@("`@(`T*("`@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^1F]R9F5I=&5D#0H@("`@
M#0H@("`@("`@("`@("`@("`@;W(@97AP:7)E9#PO9F]N=#X-"B`@("`@#0H@
M("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G
M/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=.
M.B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^*#0S.2PQ,30\+V9O;G0^#0H@("`@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/@T*
M("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,G!X)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@
M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O
M;G0@:60],T1404(Q+3(Y,R!S='EL93TS1"=-05)'24XM3$5&5#H@,S9P="<^
M/"]F;VYT/C(N.#$\+V9O;G0^#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M
M0D]45$]-.B`R<'@G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)SX-"B`@("`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@
M(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U14
M3TTZ(#)P>"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@
M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G/@T*("`@("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@
M,G!X)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@/"]T<CX-"B`@#0H@("`@("`@("`@/'1R
M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#,$9&1D8[)SX-"B`-"B`@
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-3(E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/@T*("`-
M"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR
M-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@
M#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/D]U='-T86YD:6YG#0H@#0H@("`@("`@("`@("`@("`@870@1&5C
M96UB97(@,S$L(#(P,3$\+V9O;G0^#0H@("`@(`T*("`@("`@("`@("`@("`\
M+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX-"B`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@
M;&5F="<^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@
M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$.24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X
M(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/@T*("`@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^.3(X+#(T
M,CPO9F]N=#X-"B`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#1P>"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#1P>"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD
M/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@
M<FEG:'0G/@T*("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^-2XT,SPO9F]N=#X-"B`@("`@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@-'!X)SX-"B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX-"B`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!
M3$E'3CH@;&5F="<^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@
M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/@T*("`@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M/&9O;G0@:60],T1404(Q+3(Y-"!S='EL93TS1"=-05)'24XM3$5&5#H@,S9P
M="<^/"]F;VYT/C8N-3PO9F]N=#X-"B`@("`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`T<'@G/@T*("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/@T*(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T
M)SX-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)#PO9F]N=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*
M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#DE('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BTP+3PO9F]N=#X-"B`@
M("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`T<'@G
M/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@/"]T<CX-"B`@#0H@("`@("`@("`@/'1R/@T*
M(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0U,B4@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^
M#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4
M.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^17AE<F-I<V%B;&4-"B`-"B`@("`@("`@("`@("`@("!A
M="!$96-E;6)E<B`S,2P@,C`Q,3PO9F]N=#X-"B`@("`@#0H@("`@("`@("`@
M("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/@T*(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,
M24=..B!L969T)SX-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^#0H@("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXU
M-S@L,C,Q/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@-'!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@
M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@-'!X)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-
M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^#0H@("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B0\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,
M24=..B!R:6=H="<^#0H@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXW+C4Y/"]F;VYT/@T*("`@("`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`T<'@G/@T*("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/@T*
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@
M("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!4
M15A4+4%,24=..B!L969T)SX-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*
M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"="3U)$15(M0D]45$]-
M.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^#0H@("`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SX\9F]N="!I9#TS1%1!0C$M,CDU('-T>6QE/3-$)TU!4D=)3BU,1494
M.B`S-G!T)SX\+V9O;G0^-"XX/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<^#0H@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^#0H@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ
M(&QE9G0G/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O
M=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/@T*("`@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^+3`M/"]F;VYT
M/@T*("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#1P>"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@("`@/"]T
M86)L93X\8G(O/CQD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*("`@("`-
M"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D%D
M9&ET:6]N86P-"B`@#0H@("`@("`@(&EN9F]R;6%T:6]N(&-O;F-E<FYI;F<@
M;W5R('-T;V-K(&]P=&EO;G,@9F]R('1H92!Y96%R<PT*("`@#0H@("`@("`@
M(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$Q+"`R,#$P(&%N9"`R,#`Y(&ES(&%S
M#0H@("`-"B`@("`@("`@9F]L;&]W<SH\+V9O;G0^#0H@("`@(`T*("`@("`@
M/"]D:78^/&)R+SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG
M/3-$,"!W:61T:#TS1#$P,"4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*("`@(`T*("`@("`@
M("`@(#QT<CX-"B`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#)P>"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,G!X('-O;&ED)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,C`Q,3PO9F]N=#X-"B`@
M#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,G!X)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@
M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@("`@
M(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q
M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R
M/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/C(P,3`\+V9O;G0^#0H@(`T*("`@("`@("`@("`@("`\
M+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@
M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O
M;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R<'@@<V]L:60G/@T*("`@("`-"B`@("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(`T*("`@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR,#`Y
M/"]F;VYT/@T*("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G/@T*(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`\+W1R
M/@T*("`-"B`@("`@("`@("`\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO
M<CH@(T,P1D9&1CLG/@T*(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V-"4^#0H@("`@#0H@("`@("`@
M("`@("`@(#QD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M
M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T
M.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*(`T*("`@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY7
M96EG:'1E9`T*("`@#0H@("`@("`@("`@("`@("`@879E<F%G92!F86ER('9A
M;'5E(&]F(&]P=&EO;G,@9W)A;G1E9"!D=7)I;F<@=&AE#0H@("`@(`T*("`@
M("`@("`@("`@("`@('!E<FEO9#PO9F]N=#X-"B`-"B`@("`@("`@("`@("`@
M/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)#PO9F]N=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C`N-SD\+V9O;G0^#0H@
M("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD
M/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,BXY-3PO9F]N=#X-"B`@("`@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-
M"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@
M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O
M;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXV+C$U/"]F;VYT/@T*("`@("`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*
M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`\+W1R/@T*("`-
M"B`@("`@("`@("`\='(^#0H@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8T)3X-"B`@("`-"B`@("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/DEN=')I;G-I8PT*("`@(`T*("`@("`@("`@("`@("`@('9A;'5E(&]F(&]P
M=&EO;G,@97AE<F-I<V5D(&1U<FEN9R!T:&4@<&5R:6]D/"]F;VYT/@T*("`@
M(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D
M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-
M"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/BT\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-
M"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@
M(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@
M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/BT\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@
M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*
M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BT\+V9O
M;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M(#PO='(^#0H@(`T*("`@("`@("`@(#QT<B!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B`C0S!&1D9&.R<^#0H@#0H@("`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8T)3X-"B`@("`-"B`@
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@
M("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/E1O=&%L#0H@("`@(`T*("`@("`@("`@("`@("`@(&9A:7(@=F%L=64@
M;V8@;W!T:6]N<R!V97-T960@9'5R:6YG('1H90T*(`T*("`@("`@("`@("`@
M("`@('!E<FEO9#PO9F]N=#X-"B`-"B`@("`@("`@("`@("`@/"]D:78^#0H@
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXU-#`L,S,Y/"]F;VYT/@T*("`@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-
M"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@
M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-#DY+#4U-SPO9F]N=#X-"B`@
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@
M("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$L,30S+#,R-CPO9F]N=#X-
M"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M/"]T<CX-"B`@#0H@("`@("`@(#PO=&%B;&4^/&)R+SX\9&EV('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$;&5F=#X-"B`@("`@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY790T*("`@(`T*("`@("`@("!U<V4@=&AE
M($)L86-K+5-C:&]L97,@;6]D96P@9F]R(&1E=&5R;6EN:6YG('1H92!G<F%N
M="!D871E#0H@(`T*("`@("`@("!F86ER('9A;'5E(&]F(&]U<B!S=&]C:R!O
M<'1I;VX@9W)A;G1S+B8C,38P.R8C,38P.U1H:7,-"B`-"B`@("`@("`@;6]D
M96P@=71I;&EZ97,@8V5R=&%I;B!I;F9O<FUA=&EO;BP@<W5C:"!A<R!T:&4@
M:6YT97)E<W0-"B`@("`@#0H@("`@("`@(')A=&4@;VX@82!R:7-K+69R964@
M<V5C=7)I='D@=VET:"!A('1E<FT@9V5N97)A;&QY#0H@("`@#0H@("`@("`@
M(&5Q=6EV86QE;G0@=&\@=&AE(&5X<&5C=&5D(&QI9F4@;V8@=&AE(&]P=&EO
M;B!B96EN9R!V86QU960-"B`@#0H@("`@("`@(&%N9"!R97%U:7)E<R!C97)T
M86EN(&]T:&5R(&%S<W5M<'1I;VYS+"!S=6-H(&%S('1H90T*("`@("`-"B`@
M("`@("`@97AP96-T960@86UO=6YT(&]F('1I;64@86X@;W!T:6]N('=I;&P@
M8F4@;W5T<W1A;F1I;F<@=6YT:6P-"B`@(`T*("`@("`@("!I="!I<R!E>&5R
M8VES960@;W(@97AP:7)E9"P@=&\@8V%L8W5L871E('1H92!F86ER('9A;'5E
M(&]F#0H@(`T*("`@("`@("!S=&]C:R!O<'1I;VYS(&=R86YT960N)B,Q-C`[
M)B,Q-C`[5&AE('-I9VYI9FEC86YT#0H@#0H@("`@("`@(&%S<W5M<'1I;VYS
M('=E('5S960@:6X@;W5R(&9A:7(@=F%L=64@8V%L8W5L871I;VYS('=E<F4@
M87,-"B`@#0H@("`@("`@(&9O;&QO=W,Z/"]F;VYT/@T*("`@("`-"B`@("`@
M(#PO9&EV/CQB<B\^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN
M9STS1#`@=VED=&@],T0Q,#`E('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B`@("`-"B`@("`@
M("`@("`\='(^#0H@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`R<'@G/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@
M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#)P>"!S;VQI9"<^#0H@("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-0
M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P
M<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(P,3$\+V9O;G0^#0H@
M(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D
M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.
M1RU"3U143TTZ(#)P>"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G/@T*("`@
M("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@
M,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E
M<CX-"B`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXR,#$P/"]F;VYT/@T*("`-"B`@("`@("`@("`@("`@
M/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G/@T*
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@
M("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!C
M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED)SX-"B`@("`@#0H@("`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,C`P
M.3PO9F]N=#X-"B`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@
M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!0041$24Y'+4)/5%1/33H@,G!X)SX-"B`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@/"]T
M<CX-"B`@#0H@("`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L
M;W(Z("-#,$9&1D8[)SX-"B`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C0E/@T*("`@(`T*("`@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M5V5I9VAT960-"B`@(`T*("`@("`@("`@("`@("`@(&%V97)A9V4@<FES:RUF
M<F5E(&EN=&5R97-T(')A=&5S/"]F;VYT/@T*("`-"B`@("`@("`@("`@("`@
M/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-
M"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+C0\+V9O;G0^
M#0H@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B4\+V9O;G0^
M#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR+C8\+V9O;G0^#0H@("`@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B4\+V9O;G0^#0H@(`T*
M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR+C@\+V9O;G0^#0H@("`@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B4\+V9O;G0^#0H@(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@
M("`@("`\='(^#0H@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#8T)3X-"B`@("`-"B`@("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D5X<&5C
M=&5D#0H@("`-"B`@("`@("`@("`@("`@("!D:79I9&5N9"!Y:65L9#PO9F]N
M=#X-"B`@("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*
M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXP+C`\+V9O;G0^#0H@("`@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B4\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T
M9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-
M"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^
M#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXP+C`\+V9O;G0^#0H@("`@#0H@("`@("`@("`@("`\+W1D/@T*
M("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B4\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@
M("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Y)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXP+C`\+V9O;G0^#0H@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B4\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`\+W1R/@T*("`-"B`@("`@("`@("`\='(@<W1Y;&4],T0G8F%C
M:V=R;W5N9"UC;VQO<CH@(T,P1D9&1CLG/@T*(`T*("`@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^#0H@(`T*("`@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^17AP
M96-T960-"B`@(`T*("`@("`@("`@("`@("`@(&QI9F4@;V8@;W!T:6]N/"]F
M;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*
M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!C;VQS
M<&%N/3-$,R!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@
M<FEG:'0G/@T*("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H=#L@3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<^#0H@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXW#0H@#0H@("`@("`@("`@("`@
M("`@>7)S/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-
M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X-"B`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@
M/'1D(&-O;'-P86X],T0S('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!,24Y%+4A%24=(5#H@,2XR-3L@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"B`@#0H@("`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C8N-PT*("`@#0H@
M("`@("`@("`@("`@("`@>7)S/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`@
M(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X-"B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D(&-O;'-P86X],T0S('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!,24Y%+4A%24=(
M5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!
M4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"B`@#0H@("`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/C<-"B`-"B`@("`@("`@("`@("`@("!Y<G,\+V9O;G0^#0H@("`-"B`@("`@
M("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-
M"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@("`@("`\='(^#0H@#0H@("`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#8T)3X-"B`@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,
M24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D5X<&5C=&5D#0H@("`-"B`@("`@("`@
M("`@("`@("!V;VQA=&EL:71Y/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@
M("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@
M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@
M("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y
M)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ,3$N,CPO
M9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)3PO9F]N
M=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$Q,BXY/"]F;VYT/@T*
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXE/"]F;VYT/@T*("`-
M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^,3$R+C,\+V9O;G0^#0H@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B4\+V9O;G0^#0H@(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@
M("`@/"]T86)L93X\8G(O/CQD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N
M,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*
M("`@("`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/E-T;V-K+6)A<V5D#0H@("`-"B`@("`@("`@8V]M<&5N<V%T:6]N(&5X
M<&5N<V4@<F5L871E9"!T;R!T:&4@4W1O8VL@3W!T:6]N(%!L86X@=V%S#0H@
M#0H@("`@("`@("0T-C,L-S4R+"`D-3<U+#8V,BP@86YD("0Q+#(R,2PW-C0@
M9'5R:6YG('1H92!Y96%R<R!E;F1E9`T*(`T*("`@("`@("!$96-E;6)E<B`S
M,2P@,C`Q,2P@,C`Q,"!A;F0@,C`P.2P-"B`@#0H@("`@("`@(')E<W!E8W1I
M=F5L>2XF(S$V,#LF(S$V,#M3=&]C:R!O<'1I;VX@97AP96YS92!I<R!A;&QO
M8V%T960-"B`@("`@#0H@("`@("`@('1O(')E<V5A<F-H(&%N9"!D979E;&]P
M;65N="!E>'!E;G-E(&]R('1O(&=E;F5R86P@86YD#0H@(`T*("`@("`@("!A
M9&UI;FES=')A=&EV92!E>'!E;G-E(&)A<V5D(&]N('1H92!R96QA=&5D(&5M
M<&QO>65E#0H@#0H@("`@("`@(&-L87-S:69I8V%T:6]N<R!A;F0@8V]R<F5S
M<&]N9',@=&\@=&AE(&%L;&]C871I;VX@;V8-"B`-"B`@("`@("`@96UP;&]Y
M964@<V%L87)I97,N)B,Q-C`[)B,Q-C`[1F]R('1H92!T:')E92!Y96%R<R!E
M;F1E9`T*("`-"B`@("`@("`@1&5C96UB97(@,S$L(#(P,3$L('-T;V-K(&]P
M=&EO;B!E>'!E;G-E('=A<R!A;&QO8V%T960@87,-"B`@("`@#0H@("`@("`@
M(&9O;&QO=W,Z/"]F;VYT/@T*("`@("`-"B`@("`@(#PO9&EV/CQB<B\^/'1A
M8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0Q
M,#`E('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N)SX-"B`@("`-"B`@("`@("`@("`\='(^#0H@#0H@
M("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)
M3D<M0D]45$]-.B`R<'@G/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@
M("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4
M.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N
M=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/C(P,3$\+V9O;G0^#0H@(`T*("`@("`@("`@("`@
M("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^
M#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*
M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G/@T*("`@("`-"B`@("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(`T*("`@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR
M,#$P/"]F;VYT/@T*("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@
M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G/@T*(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#)P>"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X
M('-O;&ED)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G
M3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ
M(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@
M86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,C`P.3PO9F]N=#X-"B`@#0H@
M("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,G!X)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@
M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@/"]T<CX-"B`@#0H@("`@("`@
M("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#,$9&1D8[)SX-
M"B`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-C0E/@T*("`@(`T*("`@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^1V5N97)A;`T*("`-"B`@
M("`@("`@("`@("`@("!A;F0@861M:6YI<W1R871I=F4@97AP96YS93PO9F]N
M=#X-"B`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X-"B`@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-
M"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/C(X-"PS-3(\+V9O;G0^#0H@("`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T
M9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-
M"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X-"B`@#0H@("`@("`@("`@
M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/C,V.2PQ-C$\+V9O;G0^#0H@("`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-
M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X-"B`@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/CDQ-RPQ,3`\+V9O;G0^#0H@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@
M("`-"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@("`@("`\='(^#0H@#0H@
M("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#8T)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@
M#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N
M,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*
M(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY297-E87)C:`T*("`@#0H@("`@("`@("`@("`@("`@86YD(&1E
M=F5L;W!M96YT(&5X<&5N<V4\+V9O;G0^#0H@("`-"B`@("`@("`@("`@("`@
M/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@
M;&5F="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Y)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,3<Y+#0P,#PO
M9F]N=#X-"B`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U14
M3TTZ(#)P>"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#)P>"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^#0H@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I
M9VAT)SX-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^,C`V+#4P,3PO9F]N=#X-"B`@(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'
M3CH@;&5F="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Y)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,S`T+#8U
M-#PO9F]N=#X-"B`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#)P>"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@
M("`@("`\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T,P1D9&1CLG
M/@T*(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0V-"4@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P
M>"<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^5&]T86P-"B`@("`@#0H@("`@("`@("`@("`@("`@
M<W1O8VL@;W!T:6]N(&5X<&5N<V4\+V9O;G0^#0H@("`@(`T*("`@("`@("`@
M("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX-"B`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!
M3$E'3CH@;&5F="<^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^#0H@(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Y)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T
M<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^#0H@("`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT-C,L
M-S4R/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@-'!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@-'!X)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@;&5F="<^#0H@("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B0\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS
M1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=.
M.B!R:6=H="<^#0H@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXU-S4L-C8R/"]F;VYT/@T*("`@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@-'!X)SX-"B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX-"B`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$58
M5"U!3$E'3CH@;&5F="<^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^#0H@(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^#0H@("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ
M+#(R,2PW-C0\+V9O;G0^#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@
M("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU"3U143TTZ(#1P>"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`\+W1R/@T*
M("`-"B`@("`@("`@/"]T86)L93X\8G(O/CQD:78@<W1Y;&4],T0G3$E.12U(
M14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K
M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX]
M,T1L969T/@T*("`@("`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/D%S#0H@("`@#0H@("`@("`@(&]F($1E8V5M8F5R(#,Q
M+"`R,#$Q+"!T:&5R92!W87,@)#4Q-2PV.3<@;V8@=6YR96-O9VYI>F5D#0H@
M("`@(`T*("`@("`@("!C;VUP96YS871I;VX@97AP96YS92!R96QA=&5D('1O
M('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;@T*("`@("`-"B`@("`@("`@87)R
M86YG96UE;G1S+B8C,38P.R8C,38P.U1H92!U;G)E8V]G;FEZ960@8V]M<&5N
M<V%T:6]N#0H@#0H@("`@("`@(&5X<&5N<V4@:7,@97AP96-T960@=&\@8F4@
M<F5C;V=N:7IE9"!O=F5R(&$@=V5I9VAT960-"B`-"B`@("`@("`@879E<F%G
M92!R96UA:6YI;F<@<&5R:6]D(&]F(#(N,"!Y96%R<RX\+V9O;G0^#0H@("`@
M(`T*("`@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4
M.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X-"B`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A
M;&EC.R!$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<^0V]M<&5N<V%T;W)Y#0H@("`@#0H@
M("`@("`@(%=A<G)A;G1S/"]F;VYT/@T*("`@("`-"B`@("`@(#PO9&EV/CQB
M<B\^/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!
M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY&<F]M#0H@#0H@("`@
M("`@('1I;64@=&\@=&EM92P@=V4@:7-S=64@<W1O8VL@<'5R8VAA<V4@=V%R
M<F%N=',@=&\-"B`@(`T*("`@("`@("!C;VYS=6QT86YT<R!O<B!O=&AE<G,@
M:6X@97AC:&%N9V4@9F]R('-E<G9I8V5S+B!!('-U;6UA<GD-"B`-"B`@("`@
M("`@;V8@;W5R(&-O;7!E;G-A=&]R>2!W87)R86YT(&%C=&EV:71Y(&%S(&]F
M($1E8V5M8F5R(#,Q+`T*("`@(`T*("`@("`@("`R,#$Q+"!A;F0@8VAA;F=E
M<R!D=7)I;F<@=&AE('EE87(@=&AE;B!E;F1E9"!I<R!P<F5S96YT960-"B`-
M"B`@("`@("`@8F5L;W<Z/"]F;VYT/@T*("`@#0H@("`@("`\+V1I=CX\8G(O
M/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H
M/3-$,3`P)2!S='EL93TS1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;B<^#0H@("`@#0H@("`@("`@("`@/'1R/@T*
M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-
M"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*
M("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G
M/@T*("`@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%
M24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG
M/@T*(`T*("`@("`@("`@("`@("`@("8C,38P.PT*("`-"B`@("`@("`@("`@
M("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)
M3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:R<^#0H@#0H@("`@("`@("`@("`@("`@)B,Q-C`[#0H@(`T*("`@("`@
M("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^3G5M8F5R/"]F;VYT/@T*
M("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^;V8-
M"B`@#0H@("`@("`@("`@("`@("`@4VAA<F5S/"]F;VYT/@T*(`T*("`@("`@
M("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#)P>"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G/@T*("`@("`-"B`@("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(`T*
M("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY796EG:'1E9"T\+V9O;G0^#0H@(`T*("`@("`@("`@("`@("`\+V1I
M=CX-"B`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C
M96YT97(^#0H@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^079E<F%G93PO9F]N=#X-"B`@("`@#0H@("`@
M("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(`T*("`@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY%>&5R8VES93PO9F]N
M=#X-"B`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E!R
M:6-E/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,24=.
M.B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)SX-"B`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`R<'@G/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@
M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P
M>"!S;VQI9"<^#0H@("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E=E:6=H=&5D+3PO9F]N=#X-
M"B`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(`T*("`@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY!=F5R
M86=E/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*
M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U
M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*
M("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/E)E;6%I;FEN9SPO9F]N=#X-"B`@#0H@("`@("`@("`@("`@
M(#PO9&EV/@T*("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%
M+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&-E;G1E<CX-"B`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SY#;VYT<F%C='5A;#PO9F]N=#X-"B`@
M("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E1E<FT-
M"B`@("`-"B`@("`@("`@("`@("`@("`H>7)S*3PO9F]N=#X-"B`@("`@#0H@
M("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@,G!X)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@
M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@("`@(`T*
M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U
M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:R<^#0H@#0H@("`@
M("`@("`@("`@("`@)B,Q-C`[#0H@(`T*("`@("`@("`@("`@("`\+V1I=CX-
M"B`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT
M97(^#0H@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^06=G<F5G871E/"]F;VYT/@T*("`-"B`@("`@("`@
M("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DEN=')I;G-I8SPO9F]N=#X-
M"B`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(`T*("`@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY686QU
M93PO9F]N=#X-"B`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO
M='(^#0H@(`T*("`@("`@("`@(#QT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O
M;&]R.B`C0S!&1D9&.R<^#0H@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;3X-"B`@#0H@("`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/@T*(`T*("`@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY/=71S=&%N9&EN9PT*
M(`T*("`@("`@("`@("`@("`@(&%T($IA;G5A<GD@,2P@,C`Q,3PO9F]N=#X-
M"B`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^-3DL-#`P/"]F;VYT/@T*("`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*
M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXW+C`P/"]F;VYT/@T*("`@("`-
M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@
M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@
M=F%L:6=N/3-$8F]T=&]M/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@
M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@
M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI
M9VX],T1B;W1T;VT^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@("`@("`\
M='(^#0H@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;3X-"B`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/@T*(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY'<F%N=&5D/"]F;VYT/@T*("`@("`-"B`@
M("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@
M("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/C<L-#`P/"]F;VYT/@T*(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*
M("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;3X-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@
M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!I9#TS1%1!0C$M,CDV('-T>6QE
M/3-$)TU!4D=)3BU,1494.B`S-G!T)SX\+V9O;G0^,2XT,#PO9F]N=#X-"B`@
M("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*
M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X]
M,T0R('9A;&EG;CTS1&)O='1O;3X-"B`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-
M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@
M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@
M=F%L:6=N/3-$8F]T=&]M/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@
M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@
M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@/"]T<CX-"B`@#0H@("`@("`@
M("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#,$9&1D8[)SX-
M"B`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%
M24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^#0H@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/D5X97)C:7-E9#PO9F]N=#X-"B`@#0H@("`@("`@
M("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;3X-
M"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*
M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SX-"B`@("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-
M"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-
M"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXM/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^
M#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^
M#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^/&9O;G0@:60],T1404(Q+3(Y-R!S='EL93TS1"=-05)'
M24XM3$5&5#H@,S9P="<^/"]F;VYT/BT\+V9O;G0^#0H@(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B
M;W1T;VT^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@
M("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@
M(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O
M;3X-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@
M(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT<CX-"B`-"B`@
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*("`@("`-"B`@("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D9O
M<F9E:71E9`T*("`@(`T*("`@("`@("`@("`@("`@(&]R(&5X<&ER960\+V9O
M;G0^#0H@("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P
M>"<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4
M+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@
M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI
M9#L@5$585"U!3$E'3CH@<FEG:'0G/@T*("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@R+#0P,#PO9F]N=#X-
M"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI
M/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@("`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B
M;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^#0H@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^/&9O;G0@:60],T1404(Q+3(Y."!S='EL93TS1"=-05)'24XM3$5&
M5#H@,S9P="<^/"]F;VYT/C<N,#`\+V9O;G0^#0H@("`@(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`R<'@G/@T*(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^
M#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED
M)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$
M1$E.1RU"3U143TTZ(#)P>"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@
M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@
M(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G/@T*
M("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,G!X)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@
M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@/"]T<CX-"B`@#0H@("`@
M("`@("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#,$9&1D8[
M)SX-"B`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-3(E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`T
M<'@G/@T*("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%
M24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^#0H@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/D]U='-T86YD:6YG#0H@#0H@("`@("`@("`@("`@
M("`@870@1&5C96UB97(@,S$L(#(P,3$\+V9O;G0^#0H@("`@(`T*("`@("`@
M("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX-"B`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$58
M5"U!3$E'3CH@;&5F="<^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/@T*("`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^-C0L-#`P/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M0D]45$]-.B`T<'@G/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-
M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`T<'@G/@T*(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX-"B`@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)#PO9F]N=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M
M04Q)1TXZ(')I9VAT)SX-"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C<N,#`\+V9O;G0^#0H@("`@(`T*
M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<^#0H@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@
M("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^
M#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*
M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[
M(%1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/CQF;VYT(&ED/3-$5$%",2TR.3D@<W1Y;&4],T0G34%21TE.+4Q%
M1E0Z(#,V<'0G/CPO9F]N=#XP+C8\+V9O;G0^#0H@("`@#0H@("`@("`@("`@
M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!0041$24Y'+4)/5%1/33H@-'!X)SX-"B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX-"B`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'
M3CH@;&5F="<^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^#0H@(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Y)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@
M9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^#0H@("`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXM,"T\+V9O
M;G0^#0H@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/
M33H@-'!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@
M("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@
M(#QT<CX-"B`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-3(E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`T<'@G/@T*("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%
M+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^#0H@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/D5X97)C:7-A8FQE#0H@#0H@("`@("`@("`@
M("`@("`@870@1&5C96UB97(@,S$L(#(P,3$\+V9O;G0^#0H@("`@(`T*("`@
M("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@
M(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX-
M"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@
M5$585"U!3$E'3CH@;&5F="<^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-
M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0G/@T*("`@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^-3@L.#4P/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[
M(%!!1$1)3D<M0D]45$]-.B`T<'@G/@T*("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-
M"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`T<'@G/@T*(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`T<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX-
M"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)#PO9F]N=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@
M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%
M6%0M04Q)1TXZ(')I9VAT)SX-"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C<N,#`\+V9O;G0^#0H@("`@
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<^
M#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P
M>"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D
M/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B
M;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX-
M"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/CQF;VYT(&ED/3-$5$%",2TS,#`@<W1Y;&4],T0G34%21TE.
M+4Q%1E0Z(#,V<'0G/CPO9F]N=#XP+C<\+V9O;G0^#0H@("`@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@-'!X)SX-"B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX-"B`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!
M3$E'3CH@;&5F="<^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^#0H@(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Y)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T
M<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^#0H@("`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXM,"T\
M+V9O;G0^#0H@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/
M5%1/33H@-'!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@
M("`\+W1A8FQE/CQB<B\^/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR
M-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@
M("`@(`T*("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M="<^061D:71I;VYA;`T*("`-"B`@("`@("`@:6YF;W)M871I;VX@8V]N8V5R
M;FEN9R!O=7(@8V]M<&5N<V%T;W)Y('=A<G)A;G1S(&9O<B!T:&4-"B`@("`@
M#0H@("`@("`@('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$Q+"`R,#$P
M(&%N9"`R,#`Y(&ES(&%S#0H@("`@#0H@("`@("`@(&9O;&QO=W,Z/"]F;VYT
M/@T*("`@("`-"B`@("`@(#PO9&EV/CQB<B\^/'1A8FQE(&-E;&QP861D:6YG
M/3-$,"!C96QL<W!A8VEN9STS1#`@=VED=&@],T0Q,#`E('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P=#L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M)SX-"B`@("`-"B`@("`@("`@("`\='(^#0H@#0H@("`@("`@("`@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
M/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@("`@(`T*("`@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/C(P,3$\+V9O;G0^#0H@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@
M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@
M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R
M<'@@<V]L:60G/@T*("`@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&-E;G1E<CX-"B`@(`T*("`@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR,#$P/"]F;VYT/@T*("`-
M"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M
M0D]45$]-.B`R<'@G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)SX-"B`@("`@
M#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N
M,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^
M#0H@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^,C`P.3PO9F]N=#X-"B`@#0H@("`@("`@("`@("`@(#PO
M9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)SX-"B`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@/"]T<CX-"B`@#0H@("`@("`@("`@/'1R('-T>6QE/3-$
M)V)A8VMG<F]U;F0M8V]L;W(Z("-#,$9&1D8[)SX-"B`-"B`@("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C0E
M/@T*("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^5V5I9VAT960-"B`@(`T*("`@("`@("`@("`@("`@
M(&%V97)A9V4@9F%I<B!V86QU92!O9B!W87)R86YT<R!G<F%N=&5D(&1U<FEN
M9R!T:&4-"B`-"B`@("`@("`@("`@("`@("!P97)I;V0\+V9O;G0^#0H@#0H@
M("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@
M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T
M9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Y)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXP
M+CDV/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-
M"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@
M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^
M#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)#PO9F]N=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*
M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BT\+V9O
M;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T
M9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^-"XW-3PO9F]N=#X-"B`@
M("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@/"]T
M<CX-"B`@#0H@("`@("`@("`@/'1R/@T*(`T*("`@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V-"4^#0H@("`@
M#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N
M,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*
M(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY);G1R:6YS:6,-"B`@("`-"B`@("`@("`@("`@("`@("!V86QU
M92!O9B!W87)R86YT<R!E>&5R8VES960@9'5R:6YG('1H90T*("`@("`-"B`@
M("`@("`@("`@("`@("!P97)I;V0\+V9O;G0^#0H@#0H@("`@("`@("`@("`@
M(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^+3PO9F]N=#X-
M"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*
M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*
M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^+3PO9F]N=#X-"B`@#0H@
M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-
M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^+3PO9F]N=#X-"B`@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@
M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@/"]T<CX-"B`@#0H@("`@
M("`@("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#,$9&1D8[
M)SX-"B`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-C0E/@T*("`@(`T*("`@("`@("`@("`@("`\9&EV
M('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^5&]T86P-"B`@("`@
M#0H@("`@("`@("`@("`@("`@9F%I<B!V86QU92!O9B!W87)R86YT<R!V97-T
M960@9'5R:6YG('1H90T*("`-"B`@("`@("`@("`@("`@("!P97)I;V0\+V9O
M;G0^#0H@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@
M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^,2PW.#`\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D
M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@
M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G
M/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^,3DL,C,X/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T
M9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-
M"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^
M#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXV+#0Q,SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@("`@/"]T86)L93X\
M8G(O/CQD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*("`@("`-"B`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E=E#0H@("`@
M#0H@("`@("`@('5S92!T:&4@0FQA8VLM4V-H;VQE<R!M;V1E;"!F;W(@9&5T
M97)M:6YI;F<@=&AE(&=R86YT(&1A=&4-"B`@#0H@("`@("`@(&9A:7(@=F%L
M=64@;V8@;W5R(&-O;7!E;G-A=&]R>2!W87)R86YT<RXF(S$V,#LF(S$V,#M4
M:&4-"B`@#0H@("`@("`@('-I9VYI9FEC86YT(&%S<W5M<'1I;VYS('=E('5S
M960@:6X@;W5R(&9A:7(@=F%L=64-"B`@(`T*("`@("`@("!C86QC=6QA=&EO
M;G,@=V5R92!A<R!F;VQL;W=S.CPO9F]N=#X-"B`-"B`@("`@(#PO9&EV/CQB
M<B\^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@=VED
M=&@],T0Q,#`E('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N)SX-"B`@("`-"B`@("`@("`@("`\='(^
M#0H@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-
M"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G
M/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI
M9"<^#0H@("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M
M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(P,3$\+V9O;G0^#0H@(`T*("`@("`@
M("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#)P>"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G/@T*("`@("`-"B`@("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(`T*
M("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXR,#$P/"]F;VYT/@T*("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G/@T*(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#)P>"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N/3-$
M,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,G!X('-O;&ED)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,C`P.3PO9F]N=#X-
M"B`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,G!X)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@/"]T<CX-"B`@#0H@
M("`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#,$9&
M1D8[)SX-"B`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-C0E/@T*("`@(`T*("`@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^5V5I9VAT960-
M"B`@(`T*("`@("`@("`@("`@("`@(&%V97)A9V4@<FES:RUF<F5E(&EN=&5R
M97-T(')A=&5S/"]F;VYT/@T*("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=4
M15A4+4%,24=..B!R:6=H="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXP+CDX/"]F;VYT/@T*("`@("`-
M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)3PO9F]N=#X-"B`@#0H@
M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BT\+V9O;G0^#0H@(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/C$N-30\+V9O;G0^#0H@("`@(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXE/"]F;VYT/@T*("`-"B`@("`@("`@("`@
M(#PO=&0^#0H@("`@#0H@("`@("`@("`@/"]T<CX-"B`@#0H@("`@("`@("`@
M/'1R/@T*(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0V-"4^#0H@("`@#0H@("`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*(`T*("`@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY%>'!E8W1E9`T*
M("`@#0H@("`@("`@("`@("`@("`@9&EV:61E;F0@>6EE;&0\+V9O;G0^#0H@
M("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@
M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G
M/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^,"XP/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXE/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@
M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE
M9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@
M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$.24@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^+3PO9F]N=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*
M("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$.24@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,"XP
M/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXE
M/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@/"]T<CX-"B`@#0H@("`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U
M;F0M8V]L;W(Z("-#,$9&1D8[)SX-"B`-"B`@("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/@T*("`-"B`@("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D5X<&5C=&5D
M#0H@("`-"B`@("`@("`@("`@("`@("!L:69E(&]F('=A<G)A;G0\+V9O;G0^
M#0H@("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@
M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@
M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N
M/3-$,R!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/@T*("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=415A4+4%,
M24=..B!R:6=H=#L@3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<^#0H@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS+C`-"B`@(`T*("`@("`@("`@("`@
M("`@('ER<SPO9F]N=#X-"B`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^#0H@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^#0H@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@("`@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^+3PO9F]N
M=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/@T*("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@8V]L<W!A;CTS1#,@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!4
M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z
M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*("`-"B`@("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,RXP#0H@("`-
M"B`@("`@("`@("`@("`@("!Y<G,\+V9O;G0^#0H@("`-"B`@("`@("`@("`@
M("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`\+W1R/@T*("`-"B`@("`@("`@("`\='(^#0H@#0H@("`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8T
M)3X-"B`@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%
M24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&QE9G0^#0H@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/D5X<&5C=&5D#0H@("`-"B`@("`@("`@("`@("`@
M("!V;VQA=&EL:71Y/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@("`@/"]D
M:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ,34N-#8\+V9O;G0^
M#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXE/"]F;VYT/@T*
M("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@
M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G
M5$585"U!3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^+3PO9F]N=#X-"B`@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^,3$R+C$\+V9O;G0^#0H@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B4\+V9O;G0^#0H@(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@("`@
M/"]T86)L93X\8G(O/CQD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[
M(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*("`@
M("`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/D5X<&5N<V4-"B`@("`-"B`@("`@("`@87-S;V-I871E9"!W:71H(&-O;7!E
M;G-A=&]R>2!W87)R86YT<R!W87,@)#<L,3$Y+"`D,3(Q+#`U-RP-"B`@(`T*
M("`@("`@("!A;F0@)#0U+#0P,2!D=7)I;F<@=&AE('EE87)S(&5N9&5D($1E
M8V5M8F5R(#,Q+"`R,#$Q+"`R,#$P#0H@(`T*("`@("`@("!A;F0@,C`P.2P@
M<F5S<&5C=&EV96QY+B8C,38P.R8C,38P.T%L;"!S=6-H(&5X<&5N<V4@=V%S
M#0H@(`T*("`@("`@("!A;&QO8V%T960@=&\@9V5N97)A;"!A;F0@861M:6YI
M<W1R871I=F4-"B`@(`T*("`@("`@("!E>'!E;G-E+B8C,38P.R8C,38P.T%S
M(&]F($1E8V5M8F5R(#,Q+"`R,#$Q+"!T:&5R92!W87,@;F\-"B`@("`-"B`@
M("`@("`@=6YR96-O9VYI>F5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(')E;&%T
M960@=&\@8V]M<&5N<V%T;W)Y#0H@#0H@("`@("`@('=A<G)A;G0@87)R86YG
M96UE;G1S+CPO9F]N=#X-"B`@(`T*("`@("`@/"]D:78^/&)R+SX\9&EV('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^26YV
M97-T;65N=`T*("`-"B`@("`@("`@5V%R<F%N=',\+V9O;G0^#0H@("`@(`T*
M("`@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q
M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-
M"B`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/DEN#0H@("`@#0H@("`@("`@(&%D9&ET:6]N('1O(&]U='-T86YD:6YG('-T
M;V-K(&]P=&EO;G,@86YD(&-O;7!E;G-A=&]R>0T*("`@#0H@("`@("`@('=A
M<G)A;G1S+"!A<R!O9B!$96-E;6)E<B`S,2P@,C`Q,2!W92!H879E(&$@=&]T
M86P@;V8-"B`-"B`@("`@("`@,2PX,#8L,34Y(&]U='-T86YD:6YG('-T;V-K
M('!U<F-H87-E('=A<G)A;G1S(&ES<W5E9"!T;PT*("`@(`T*("`@("`@("!I
M;G9E<W1O<G,@:6X@8V]N;F5C=&EO;B!W:71H(&9I;F%N8VEN9PT*("`-"B`@
M("`@("`@=')A;G-A8W1I;VYS+B8C,38P.R8C,38P.U=A<G)A;G1S(&%S('1O
M(#DX-RPW.#,@:&%V92!A;@T*("`-"B`@("`@("`@97AE<F-I<V4@<')I8V4@
M;V8@)#$N,#`@<&5R('-H87)E(&%N9"!E>'!I<F4@:6X@1&5C96UB97(-"B`@
M("`@#0H@("`@("`@(#(P,38[('=A<G)A;G1S(&%S('1O(#@Q."PS-S8@:&%V
M92!A;B!E>&5R8VES92!P<FEC92!O9@T*("`@#0H@("`@("`@("0Q-BXU,"!A
M;F0@97AP:7)E(&EN($1E8V5M8F5R(#(P,30N)B,Q-C`[)B,Q-C`[1'5R:6YG
M('1H90T*("`@(`T*("`@("`@("!F;W5R=&@@<75A<G1E<B!O9B`R,#$Q+"!W
M92!R96-O<F1E9"!G96YE<F%L(&%N9`T*(`T*("`@("`@("!A9&UI;FES=')A
M=&EV92!E>'!E;G-E(&]F("0Q-3(L,3(V(&%S<V]C:6%T960@=VET:"!T:&4-
M"B`@(`T*("`@("`@("!E>'1E;G-I;VX@;V8@=V%R<F%N=',@=VAI8V@@=V5R
M92!D=64@=&\@97AP:7)E(&EN(#(P,3$@=&\-"B`-"B`@("`@("`@,C`Q,RX\
M+V9O;G0^#0H@(`T*("`@("`@/"]D:78^/&)R+SX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,T,#0W.&4X7S$T96-?-#1D9%\Y
M,C,T7S9E,#(R-V4S9F$V-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\S-#`T-SAE.%\Q-&5C7S0T9&1?.3(S-%\V93`R,C=E,V9A-C0O5V]R:W-H
M965T<R]3:&5E=#$S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^3F]T92`W("T@4F5T:7)E;65N="!0;&%N/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y096YS:6]N(&%N9"!/=&AE
M<B!0;W-T<F5T:7)E;65N="!"96YE9FET<R!$:7-C;&]S=7)E(%M497AT($)L
M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL
M93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^#0H@("`@(`T*("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O;&0G/C<N
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[4F5T:7)E;65N=`T*("`@#0H@("`@("`@
M(%!L86X\+V9O;G0^#0H@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4]
M,T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1L969T/@T*(`T*("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P="<^5V4-"B`@("`-"B`@("`@("`@<&%R=&EC:7!A
M=&4@:6X@82!M=6QT:2UE;7!L;WEE<B!D969I;F5D(&-O;G1R:6)U=&EO;@T*
M(`T*("`@("`@("!R971I<F5M96YT('!L86X@*'1H92`F(S@R,C`[-#`Q:R!0
M;&%N)B,X,C(Q.RD@861M:6YI<W1E<F5D#0H@("`@(`T*("`@("`@("!B>2!A
M('1H:7)D('!A<G1Y('-E<G9I8V4@<')O=FED97([(&%N9"!T:&4@0V]M<&%N
M>0T*("`@(`T*("`@("`@("!C;VYT<FEB=71E<R!T;R!T:&4@-#`Q:R!0;&%N
M(&]N(&)E:&%L9B!O9B!I=',@96UP;&]Y965S#0H@("`@#0H@("`@("`@(&)A
M<V5D('5P;VX@82!M871C:&EN9R!F;W)M=6QA+B8C,38P.R8C,38P.T1U<FEN
M9R!T:&4@>65A<G,-"B`@("`@#0H@("`@("`@(&5N9&5D($1E8V5M8F5R(#,Q
M+"`R,#$Q+"`R,#$P(&%N9"`R,#`Y(&]U<B!C;VYT<FEB=71I;VYS('1O#0H@
M("`-"B`@("`@("`@=&AE(#0P,6L@4&QA;B!W97)E("0U-BPY,C@L("0U,BPV
M,S(L(&%N9"`D,C4L,#4W+`T*("`@#0H@("`@("`@(')E<W!E8W1I=F5L>2X\
M+V9O;G0^#0H@("`@(`T*("`@("`@/"]D:78^/&)R+SX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,T,#0W.&4X7S$T96-?-#1D
M9%\Y,C,T7S9E,#(R-V4S9F$V-`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\S-#`T-SAE.%\Q-&5C7S0T9&1?.3(S-%\V93`R,C=E,V9A-C0O5V]R
M:W-H965T<R]3:&5E=#$T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^3F]T92`X("T@26YC;VUE(%1A>&5S/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@5&%X($1I<V-L
M;W-U<F4@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`@#0H@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(
M5#H@8F]L9"<^."XF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V
M,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M);F-O;64-"B`@("`-
M"B`@("`@("`@5&%X97,\+V9O;G0^#0H@(`T*("`@("`@/"]D:78^/&)R+SX\
M9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D%T#0H@("`@#0H@("`@("`@
M($1E8V5M8F5R(#,Q+"`R,#$Q+"!W92!H879E(&$@8V]N<V]L:61A=&5D(&9E
M9&5R86P@;F5T#0H@(`T*("`@("`@("!O<&5R871I;F<@;&]S<R`H)B,X,C(P
M.TY/3"8C.#(R,3LI(&-A<G)Y9F]R=V%R9"!O9@T*("`-"B`@("`@("`@87!P
M<F]X:6UA=&5L>2`D-S$N,R!M:6QL:6]N+"!A=F%I;&%B;&4@=&\@;V9F<V5T
M(&%G86EN<W0-"B`@("`@#0H@("`@("`@(&9U='5R92!T87AA8FQE(&EN8V]M
M92!W:&EC:"!E>'!I<F5S(&EN('9A<GEI;F<@86UO=6YT<R!I;@T*(`T*("`@
M("`@("`R,#$R('1H<F]U9V@@,C`S,2XF(S$V,#LF(S$V,#M!9&1I=&EO;F%L
M;'DL('=E(&AA=F4-"B`@(`T*("`@("`@("!A<'!R;WAI;6%T96QY("0W-C0L
M,#`P(&EN(')E<V5A<F-H(&%N9"!D979E;&]P;65N=`T*("`@(`T*("`@("`@
M("`H)B,X,C(P.U(F86UP.T0F(S@R,C$[*2!T87@@8W)E9&ET<R!T:&%T(&5X
M<&ER92!I;B`R,#(R#0H@#0H@("`@("`@('1H<F]U9V@@,C`S,2!U;FQE<W,@
M=71I;&EZ960@96%R;&EE<BXF(S$V,#LF(S$V,#M.;R!I;F-O;64-"B`@("`@
M#0H@("`@("`@('1A>&5S(&AA=F4@8F5E;B!P86ED('1O(&1A=&4N/"]F;VYT
M/@T*(`T*("`@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M;&5F=#X-"B`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/D%S#0H@("`@#0H@("`@("`@(&$@<F5S=6QT(&]F('1H92!-97)G
M97(@9&ES8W5S<V5D(&EN($YO=&4@-2P@;W5R($Y/3`T*("`@("`-"B`@("`@
M("`@8V%R<GEF;W)W87)D(&EN8W)E87-E9"!S=6)S=&%N=&EA;&QY(&1U92!T
M;R!T:&4@861D:71I;VX@;V8-"B`@(`T*("`@("`@("!H:7-T;W)I8V%L($Y/
M3"!C87)R>69O<G=A<F1S(&9O<B!$875P:&EN(%1E8VAN;VQO9WDL#0H@#0H@
M("`@("`@($EN8RXF(S$V,#LF(S$V,#M(;W=E=F5R+"!396-T:6]N(#,X,B!O
M9B!T:&4@26YT97)N86P-"B`@("`-"B`@("`@("`@4F5V96YU92!#;V1E(&-O
M;G1A:6YS('!R;W9I<VEO;G,@=&AA="!M87D@;&EM:70@;W5R#0H@("`@(`T*
M("`@("`@("!U=&EL:7IA=&EO;B!O9B!.3TP@86YD(%(F86UP.T0@=&%X(&-R
M961I="!C87)R>69O<G=A<F1S(&EN#0H@#0H@("`@("`@(&%N>2!G:79E;B!Y
M96%R(&%S(&$@<F5S=6QT(&]F('-I9VYI9FEC86YT(&-H86YG97,@:6X-"B`-
M"B`@("`@("`@;W=N97)S:&EP(&EN=&5R97-T<R!T:&%T(&AA=F4@;V-C=7)R
M960@:6X@<&%S="!P97)I;V1S(&]R#0H@#0H@("`@("`@(&UA>2!O8V-U<B!I
M;B!F=71U<F4@<&5R:6]D<RX\+V9O;G0^#0H@("`@(`T*("`@("`@/"]D:78^
M/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D1E9F5R<F5D#0H@
M("`@(`T*("`@("`@("!I;F-O;64@=&%X97,@<F5F;&5C="!T:&4@;F5T(&5F
M9F5C="!O9B!T96UP;W)A<GD-"B`@#0H@("`@("`@(&1I9F9E<F5N8V5S(&)E
M='=E96X@=&AE(&-A<G)Y:6YG(&%M;W5N=',@;V8@87-S971S(&%N9`T*("`@
M#0H@("`@("`@(&QI86)I;&ET:65S(&9O<B!F:6YA;F-I86P@<F5P;W)T:6YG
M('!U<G!O<V5S(&%N9"!T:&4-"B`-"B`@("`@("`@86UO=6YT<R!U<V5D(&9O
M<B!I;F-O;64@=&%X#0H@#0H@("`@("`@('!U<G!O<V5S+B8C,38P.R8C,38P
M.U-I9VYI9FEC86YT(&-O;7!O;F5N=',@;V8@;W5R(&1E9F5R<F5D#0H@#0H@
M("`@("`@('1A>"!A<W-E=',@86YD(&QI86)I;&ET:65S(&EN8VQU9&5D('1H
M92!F;VQL;W=I;F<@870-"B`-"B`@("`@("`@1&5C96UB97(@,S$L(#(P,3$@
M86YD(#(P,3`Z/"]F;VYT/@T*("`@(`T*("`@("`@/"]D:78^/&)R+SX\=&%B
M;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS1#$P
M,"4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86XG/@T*("`@(`T*("`@("`@("`@(#QT<CX-"B`-"B`@
M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@
M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-
M"B`@("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)SX-"B`@
M("`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT
M97(^#0H@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^,C`Q,3PO9F]N=#X-"B`@#0H@("`@("`@("`@("`@
M(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)SX-
M"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-
M"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@
M8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@("`@(`T*("`@("`@("`@("`@
M("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.
M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2
M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(P
M,3`\+V9O;G0^#0H@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO
M='(^#0H@(`T*("`@("`@("`@(#QT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O
M;&]R.B`C0S!&1D9&.R<^#0H@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;3X-"B`@#0H@("`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1L969T/@T*(`T*("`@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY$969E<G)E9`T*("`@
M#0H@("`@("`@("`@("`@("`@=&%X(&%S<V5T<SH\+V9O;G0^#0H@#0H@("`@
M("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT^#0H@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@
M(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;3X-"B`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT<CX-"B`-"B`@("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W-B4@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@5$585"U)3D1%3E0Z(#!P=#L@4$%$1$E.1RU,1494
M.B`T)3L@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G/@T*
M("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SY.970-"B`@(`T*("`@("`@("`@("`@("`@(&]P
M97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9#PO9F]N=#X-"B`@#0H@("`@("`@
M("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*
M("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B0\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@
M("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y
M)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR-"PX-S4L
M,3$Y/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@
M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@
M<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,C4L,3$V+#DU
M.#PO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`\+W1R/@T*("`-"B`@("`@("`@("`\='(@<W1Y;&4],T0G8F%C:V=R
M;W5N9"UC;VQO<CH@(T,P1D9&1CLG/@T*(`T*("`@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W-B4@<W1Y;&4]
M,T0G4$%$1$E.1RU,1494.B`T)2<^#0H@("`@#0H@("`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM
M4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*(`T*("`@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY297-E87)C:`T*
M("`@#0H@("`@("`@("`@("`@("`@86YD(&1E=F5L;W!M96YT('1A>"!C<F5D
M:70@8V%R<GEF;W)W87)D/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\
M+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T
M9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C<V,RPV.3`\+V9O
M;G0^#0H@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-
M"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXW,S$L,CDP/"]F
M;VYT/@T*("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@/"]T<CX-"B`@#0H@("`@("`@("`@/'1R/@T*(`T*("`@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W-B4@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>#L@4$%$1$E.1RU,1494.B`T
M)2<^#0H@("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M
M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^4W1O8VLM8F%S960-"B`-"B`@("`@("`@("`@
M("`@("!C;VUP96YS871I;VX@97AP96YS93PO9F]N=#X-"B`@("`@#0H@("`@
M("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@
M("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&QE9G0G/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^#0H@("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/C$L.3DQ+#<V.3PO9F]N=#X-"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*
M("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T
M.R!0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!L969T)SX-
M"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*
M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#DE('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@
M5$585"U!3$E'3CH@<FEG:'0G/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+#<W.2PY-3`\+V9O;G0^
M#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#)P>"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@("`@("`\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T,P1D9&1CLG/@T*(`T*
M("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0W-B4@<W1Y;&4],T0G4$%$1$E.1RU,1494.B`T)2<^#0H@("`@
M#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N
M,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM
M3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*
M(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SY4;W1A;`T*("`@("`-"B`@("`@("`@("`@("`@("!D969E<G)E
M9"!T87@@87-S971S/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I
M=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-
M"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C(W+#8S,"PU-S@\+V9O
M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D
M/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,C<L-C(X+#$Y.#PO
M9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`\+W1R/@T*("`-"B`@("`@("`@("`\='(^#0H@#0H@("`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S8E/@T*(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@
M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@
M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@
M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D
M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@/"]T<CX-"B`@#0H@("`@("`@("`@/'1R
M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#,$9&1D8[)SX-"B`-"B`@
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-S8E/@T*("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^1&5F97)R960-"B`@(`T*("`@("`@
M("`@("`@("`@('1A>"!L:6%B:6QI=&EE<SPO9F]N=#X-"B`@("`@#0H@("`@
M("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T
M9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@
M("`@("`@(#QT<CX-"B`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S8E('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@[(%!!1$1)3D<M3$5&5#H@-"4G/@T*("`@("`-"B`@("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/D1E<')E8VEA=&EO;CPO9F]N=#X-"B`@("`@#0H@("`@("`@("`@("`@(#PO
M9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE
M9G0G/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O
M;&ED.R!415A4+4%,24=..B!R:6=H="<^#0H@("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@S."PU.#<\+V9O
M;G0^#0H@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`R<'@G/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/BD\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T
M9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ
M(#)P>"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S
M;VQI9#L@5$585"U!3$E'3CH@;&5F="<^#0H@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"="3U)$15(M
M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX-
M"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^*#4Q+#DT-3PO9F]N=#X-"B`@(`T*("`@("`@("`@("`@/"]T
M9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^*3PO9F]N=#X-
M"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^
M#0H@(`T*("`@("`@("`@(#QT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R
M.B`C0S!&1D9&.R<^#0H@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<V)2!S='EL93TS1"=0041$24Y'
M+4)/5%1/33H@,G!X.R!0041$24Y'+4Q%1E0Z(#0E)SX-"B`@("`@#0H@("`@
M("`@("`@("`@(#QD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%
M6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@
M,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*(`T*("`@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY4;W1A;`T*("`@("`-"B`@("`@("`@("`@("`@("!D969E<G)E9"!T87@@
M;&EA8FEL:71I97,\+V9O;G0^#0H@("`@#0H@("`@("`@("`@("`@(#PO9&EV
M/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$
M15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G
M/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$.24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED
M.R!415A4+4%,24=..B!R:6=H="<^#0H@("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@S."PU.#<\+V9O;G0^
M#0H@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R
M<'@G/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/BD\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P
M>"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D
M/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI
M9#L@5$585"U!3$E'3CH@;&5F="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^*#4Q+#DT-3PO9F]N=#X-"B`@(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^*3PO9F]N=#X-"B`@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@
M(`T*("`@("`@("`@(#QT<CX-"B`-"B`@("`@("`@("`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0W-B4^#0H@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*
M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@
M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@
M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-
M"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@("`@("`\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@(T,P1D9&1CLG/@T*(`T*("`@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W-B4^
M#0H@("`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/@T*(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SY.970-"B`@(`T*("`@("`@("`@("`@("`@(&1E9F5R
M<F5D('1A>"!A<W-E=',\+V9O;G0^#0H@("`@#0H@("`@("`@("`@("`@(#PO
M9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D
M/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,C<L-3DQ+#DY,3PO
M9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-
M"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S
M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR-RPU-S8L,C4S
M/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT<CX-"B`-"B`@("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S8E
M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*("`-"B`@("`@("`@
M("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)
M3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E9A
M;'5A=&EO;@T*("`@(`T*("`@("`@("`@("`@("`@(&%L;&]W86YC93PO9F]N
M=#X-"B`@("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#)P>"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K
M(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^#0H@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I
M9VAT)SX-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^*#(W+#4Y,2PY.3$\+V9O;G0^#0H@(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M*3PO9F]N=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=.
M.B!L969T)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@
M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#DE('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P
M>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/@T*("`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,C<L-3<V
M+#(U,SPO9F]N=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/@T*("`-"B`@("`@("`@
M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@/"]T<CX-"B`@#0H@("`@("`@
M("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#,$9&1D8[)SX-
M"B`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W
M-B4@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^#0H@("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX-"B`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!
M3$E'3CH@;&5F="<^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^#0H@(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Y)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T
M<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^#0H@("`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXM/"]F
M;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-
M.B`T<'@G/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@
M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]4
M5$]-.B`T<'@G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T
M<'@@9&]U8FQE.R!415A4+4%,24=..B!L969T)SX-"B`@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N
M=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT
M)SX-"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/BT\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M=#L@4$%$1$E.1RU"3U143TTZ(#1P>"<^#0H@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`\+W1R
M/@T*("`-"B`@("`@("`@/"]T86)L93X\8G(O/CQD:78@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/@T*("`@("`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/E=E#0H@("`@#0H@("`@("`@(&AA=F4@97-T86)L
M:7-H960@82!F=6QL('9A;'5A=&EO;B!A;&QO=V%N8V4@97%U86P@=&\@=&AE
M#0H@("`@(`T*("`@("`@("!A;6]U;G0@;V8@;W5R(&YE="!D969E<G)E9"!T
M87@@87-S971S(&1U92!T;R!U;F-E<G1A:6YT:65S#0H@(`T*("`@("`@("!W
M:71H(')E<W!E8W0@=&\@;W5R(&%B:6QI='D@=&\@9V5N97)A=&4@<W5F9FEC
M:65N="!T87AA8FQE#0H@(`T*("`@("`@("!I;F-O;64@=&\@<F5A;&EZ92!T
M:&5S92!A<W-E=',@:6X@=&AE(&9U='5R92X@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+5=%24=(5#H@8F]L9"<^)B,Q-C`[/"]F;VYT
M/D$-"B`@("`-"B`@("`@("`@<F5C;VYC:6QI871I;VX@;V8@=&AE(&EN8V]M
M92!T87@@8F5N969I="!O;B!L;W-S97,@870@=&AE#0H@#0H@("`@("`@(%4N
M4RX@9F5D97)A;"!S=&%T=71O<GD@<F%T92!T;R!T:&4@<F5P;W)T960@:6YC
M;VUE('1A>`T*("`@#0H@("`@("`@(&5X<&5N<V4@:7,@87,@9F]L;&]W<SH\
M+V9O;G0^#0H@("`@#0H@("`@("`\+V1I=CX\8G(O/CQT86)L92!C96QL<&%D
M9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)2!S='EL93TS
M1"=&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;B<^#0H@("`@#0H@("`@("`@("`@/'1R/@T*(`T*("`@("`@("`@("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G/@T*("`@("`-"B`@("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(`T*
M("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXR,#$Q/"]F;VYT/@T*("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G/@T*(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#)P>"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N/3-$
M,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA
M8VL@,G!X('-O;&ED)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,C`Q,#PO9F]N=#X-
M"B`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$
M24Y'+4)/5%1/33H@,G!X)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@
M("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4
M.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N
M=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/C(P,#D\+V9O;G0^#0H@(`T*("`@("`@("`@("`@
M("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^
M#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*
M("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT<B!S='EL
M93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C0S!&1D9&.R<^#0H@#0H@("`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#8T)3X-"B`@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%
M+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO
M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG
M;CTS1&QE9G0^#0H@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/E4N4RX-"B`@("`-"B`@("`@("`@("`@("`@
M("!F961E<F%L('-T871U=&]R>2!R871E(&%P<&QI960@=&\@<')E=&%X#0H@
M(`T*("`@("`@("`@("`@("`@(&QO<W,\+V9O;G0^#0H@("`@#0H@("`@("`@
M("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*
M("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B0\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@
M("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y
M)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH-SDW+#DR
M,3PO9F]N=#X-"B`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M*3PO9F]N=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y
M;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^*#DS-"PP.3(\+V9O
M;G0^#0H@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BD\+V9O
M;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)#PO9F]N=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@Q+#$Q-BPV-#8\+V9O;G0^
M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BD\+V9O;G0^#0H@
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`\+W1R/@T*
M("`-"B`@("`@("`@("`\='(^#0H@#0H@("`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8T)3X-"B`@("`-"B`@
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@
M("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/E!E<FUA;F5N=`T*("`@(`T*("`@("`@("`@("`@("`@(&1I9F9E<F5N
M8V5S/"]F;VYT/@T*(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT(&ED/3-$5$%",2TS,#$@<W1Y;&4]
M,T0G34%21TE.+4Q%1E0Z(#,R+C$U<'0G/CPO9F]N=#XS+#4S-CPO9F]N=#X-
M"B`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH-S<L,C`P/"]F;VYT
M/@T*("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BD\+V9O;G0^
M#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT
M9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!I9#TS1%1!0C$M
M,S`R('-T>6QE/3-$)TU!4D=)3BU,1494.B`R,2XX<'0G/CPO9F]N=#XQ-CDL
M-#8Y/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-
M"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@("`@("`\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@(T,P1D9&1CLG/@T*(`T*("`@("`@("`@("`@
M/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V-"4^
M#0H@("`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G3$E.12U(14E'
M2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-
M05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L
M969T/@T*(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SY297-E87)C:`T*("`@#0H@("`@("`@("`@("`@("`@
M86YD(&1E=F5L;W!M96YT(&-R961I=',\+V9O;G0^#0H@("`-"B`@("`@("`@
M("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@
M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@
M("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Y)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N
M="!I9#TS1%1!0C$M,S`S('-T>6QE/3-$)TU!4D=)3BU,1494.B`R-2XT-7!T
M)SX\+V9O;G0^,S(L-#`P/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@
M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXU.2PY-3D\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T
M9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/CQF;VYT(&ED/3-$5$%",2TS,#0@<W1Y;&4],T0G34%21TE.
M+4Q%1E0Z(#(Q+CAP="<^/"]F;VYT/C$V.2PV-C<\+V9O;G0^#0H@("`@(`T*
M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@
M(`T*("`@("`@("`@(#QT<CX-"B`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-C0E('-T>6QE/3-$)U!!
M1$1)3D<M0D]45$]-.B`R<'@G/@T*("`-"B`@("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D-H86YG90T*(`T*("`@
M("`@("`@("`@("`@(&EN('9A;'5A=&EO;B!A;&QO=V%N8V4\+V9O;G0^#0H@
M(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D
M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@
M,G!X)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O
M;&ED.R!415A4+4%,24=..B!L969T)SX-"B`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0G/@T*
M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX\9F]N="!I9#TS1%1!0C$M,S`U('-T>6QE/3-$)TU!4D=)3BU,
M1494.B`Q."XX<'0G/CPO9F]N=#XW-C$L.3@U/"]F;VYT/@T*("`@("`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G/@T*("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@
M("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%
M6%0M04Q)1TXZ(&QE9G0G/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,G!X('-O;&ED.R!415A4+4%,24=..B!R:6=H="<^#0H@("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/CDU,2PS,S,\+V9O;G0^#0H@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!
M1$1)3D<M0D]45$]-.B`R<'@G/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-
M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI
M9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED.R!415A4
M+4%,24=..B!R:6=H="<^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CQF;VYT(&ED/3-$5$%",2TS,#8@
M<W1Y;&4],T0G34%21TE.+4Q%1E0Z(#(Q+CAP="<^/"]F;VYT/C<W-RPU,3`\
M+V9O;G0^#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#)P>"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@
M("`@("`\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T,P1D9&1CLG
M/@T*(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0V-"4@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#1P
M>"<^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^4F5P;W)T960-"B`@(`T*("`@("`@("`@("`@("`@
M(&EN8V]M92!T87@@97AP96YS93PO9F]N=#X-"B`@(`T*("`@("`@("`@("`@
M("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@-'!X)SX-"B`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$585"U!3$E'
M3CH@;&5F="<^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^#0H@(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Y)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@
M9&]U8FQE.R!415A4+4%,24=..B!R:6=H="<^#0H@("`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXM/"]F;VYT
M/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`T
M<'@G/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-
M.B`T<'@G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`T<'@@
M9&]U8FQE.R!415A4+4%,24=..B!L969T)SX-"B`@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X-
M"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX-
M"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/BT\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@
M("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU"3U143TTZ(#1P>"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#1P>"<^#0H@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*
M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@-'!X(&1O=6)L93L@5$58
M5"U!3$E'3CH@<FEG:'0G/@T*("`@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^+3PO9F]N=#X-"B`@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4
M15A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@-'!X)SX-"B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`\+W1A8FQE/CQB<B\^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S-#`T-SAE
M.%\Q-&5C7S0T9&1?.3(S-%\V93`R,C=E,V9A-C0-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO,S0P-#<X93A?,31E8U\T-&1D7SDR,S1?-F4P,C(W
M93-F838T+U=O<FMS:&5E=',O4VAE970Q-2YH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%$/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYO=&4@.2`M(%)E;&%T960@4&%R='D@
M5')A;G-A8W1I;VYS/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N<R!$:7-C;&]S=7)E
M(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@(`T*("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U714E'2%0Z(&)O
M;&0G/CDN)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[4F5L871E9`T*("`@("`-"B`@
M("`@("`@4&%R='D@5')A;G-A8W1I;VYS/"]F;VYT/@T*("`@("`-"B`@("`@
M(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY790T*
M("`@(`T*("`@("`@("!A<F4@;V)L:6=A=&5D('1O(')E:6UB=7)S92!%;6]R
M>2!5;FEV97)S:71Y("AA('-I9VYI9FEC86YT#0H@(`T*("`@("`@("!S=&]C
M:VAO;&1E<B!O9B!T:&4@0V]M<&%N>2D@9F]R(&]N9V]I;F<@8V]S=',@:6X@
M8V]N;F5C=&EO;@T*("`@#0H@("`@("`@('=I=&@@=&AE(&9I;&EN9RP@<')O
M<V5C=71I;VX@86YD(&UA:6YT96YA;F-E(&]F('!A=&5N=`T*("`@#0H@("`@
M("`@(&%P<&QI8V%T:6]N<R!S=6)J96-T('1O(&$@;&EC96YS92!A9W)E96UE
M;G0@9F]R('1E8VAN;VQO9WD-"B`@#0H@("`@("`@(&%S<V]C:6%T960@=VET
M:"!T:&4@=F%C8VEN97,@=V4@87)E#0H@("`@#0H@("`@("`@(&1E=F5L;W!I
M;F<N)B,Q-C`[)B,Q-C`[5&AE(&5X<&5N<V4@87-S;V-I871E9"!W:71H('1H
M97-E#0H@("`-"B`@("`@("`@;VYG;VEN9R!P871E;G0@8V]S="!R96EM8G5R
M<V5M96YT<R!T;R!%;6]R>2!A;6]U;G1E9"!T;PT*("`@(`T*("`@("`@("`D
M,C0Y+#DP-RP@)#$Y,RPV-S0L(&%N9"`D.#4L-C<S(&9O<B!T:&4@>65A<G,@
M96YD960-"B`@("`@#0H@("`@("`@($1E8V5M8F5R(#,Q+"`R,#$Q+"`R,#$P
M+"!A;F0@,C`P.2P@<F5S<&5C=&EV96QY+CPO9F]N=#X-"B`@("`@#0H@("`@
M("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[
M(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*(`T*
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^5V4-
M"B`@("`-"B`@("`@("`@:&%V92!E;G1E<F5D(&EN=&\@='=O('-U8F-O;G1R
M86-T<R!W:71H($5M;W)Y(&9O<B!T:&4-"B`@#0H@("`@("`@('!U<G!O<V4@
M;V8@8V]N9'5C=&EN9R!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@86-T:79I
M=&EE<PT*(`T*("`@("`@("!A<W-O8VEA=&5D('=I=&@@;W5R(&=R86YT(&9R
M;VT@=&AE($Y)2"`H<V5E($YO=&4-"B`@#0H@("`@("`@(#,I+B8C,38P.R8C
M,38P.T1U<FEN9R`R,#$Q+"`R,#$P+"!A;F0@,C`P.2P@=V4@<F5C;W)D960-
M"B`@#0H@("`@("`@("0Q+#$W,BPW-3@L("0Q+#,Y,2PR,#,L(&%N9"`D.#$V
M+#8U,2P@<F5S<&5C=&EV96QY+"!O9@T*("`@#0H@("`@("`@(&5X<&5N<V4@
M87-S;V-I871E9"!W:71H('1H97-E('-U8F-O;G1R86-T<RXF(S$V,#LF(S$V
M,#M!;&P-"B`@("`@#0H@("`@("`@(&%M;W5N=',@<&%I9"!T;R!%;6]R>2!U
M;F1E<B!T:&5S92!S=6)C;VYT<F%C=',@87)E#0H@("`@#0H@("`@("`@(')E
M:6UB=7)S86)L92!T;R!U<R!P=7)S=6%N="!T;R!T:&4@3DE((&=R86YT+CPO
M9F]N=#X-"B`@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@<W1Y;&4],T0G3$E.
M12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L
M;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI
M9VX],T1L969T/@T*(`T*("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<^5&AR;W5G:`T*("`@(`T*("`@("`@("!.;W9E;6)E<B`R
M,#`Y+"!W92!L96%S960@;V9F:6-E(&%N9"!L86)O<F%T;W)Y('-P86-E(&]N
M(&$-"B`-"B`@("`@("`@;6]N=&@M=&\M;6]N=&@@8F%S:7,@9G)O;2!%;71E
M8V@@0FEO=&5C:&YO;&]G>2!$979E;&]P;65N="P-"B`@(`T*("`@("`@("!)
M;F,N+"!A(')E;&%T960@<&%R='D@87-S;V-I871E9"!W:71H#0H@#0H@("`@
M("`@($5M;W)Y+B8C,38P.R8C,38P.U)E;G0@97AP96YS92!A<W-O8VEA=&5D
M('=I=&@@=&AI<R!L96%S90T*("`@(`T*("`@("`@("!T;W1A;&5D("0T,RPQ
M,3(@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+`T*(`T*("`@("`@
M("`R,#`Y+CPO9F]N=#X-"B`@#0H@("`@("`\+V1I=CX\8G(O/CQD:78@<W1Y
M;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)
M4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z
M(#!P="<@86QI9VX],T1L969T/@T*(`T*("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^26X-"B`@("`-"B`@("`@("`@36%R8V@@
M,C`P."P@=V4@96YT97)E9"!I;G1O(&$@8V]N<W5L=&EN9R!A9W)E96UE;G0@
M=VET:`T*("`@(`T*("`@("`@("!$;VYA;&0@2&EL9&5B<F%N9"P@82!F;W)M
M97(@;65M8F5R(&]F(&]U<B!";V%R9"!O9@T*("`@(`T*("`@("`@("!$:7)E
M8W1O<G,@86YD(&]U<B!F;W)M97(@4')E<VED96YT("9A;7`[($-H:65F($5X
M96-U=&EV90T*("`@(`T*("`@("`@("!/9F9I8V5R+"!P=7)S=6%N="!T;R!W
M:&EC:"!-<BX@2&EL9&5B<F%N9"!P<F]V:61E<R!B=7-I;F5S<PT*("`@#0H@
M("`@("`@(&%N9"!T96-H;FEC86P@861V:7-O<GD@<V5R=FEC97,@=&\@=&AE
M#0H@(`T*("`@("`@("!#;VUP86YY+B8C,38P.R8C,38P.U1H92!T97)M(&]F
M('1H92!C;VYS=6QT:6YG(&%G<F5E;65N="P-"B`@("`-"B`@("`@("`@87,@
M86UE;F1E9"P@8F5G86X@;VX@07!R:6P@,2P@,C`P."!A;F0@96YD<R!O;B!$
M96-E;6)E<B`S,2P-"B`@(`T*("`@("`@("`R,#$R+B8C,38P.R8C,38P.T1U
M<FEN9R`R,#$Q+"`R,#$P+"!A;F0@,C`P.2P@=V4@<F5C;W)D960-"B`@("`-
M"B`@("`@("`@)#(T+#`P,"P@)#4W+#8P,"P@86YD("0U-RPV,#`L(')E<W!E
M8W1I=F5L>2P@;V8@97AP96YS90T*("`@(`T*("`@("`@("!A<W-O8VEA=&5D
M('=I=&@@=&AE(&-O;G-U;'1I;F<@86=R965M96YT+CPO9F]N=#X-"B`@(`T*
M("`@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q
M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.
M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-
M"B`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/DEN#0H@("`@#0H@("`@("`@($1E8V5M8F5R(#(P,3$L(&UE;6)E<G,@;V8@
M;W5R(&UA;F%G96UE;G0@86YD($)O87)D(&]F#0H@(`T*("`@("`@("!$:7)E
M8W1O<G,@<&%R=&EC:7!A=&5D(&EN('1H92!P<FEV871E('!L86-E;65N="!O
M9F9E<FEN9R!O9@T*("`@#0H@("`@("`@(&]U<B!C;VUM;VX@<W1O8VL@86YD
M('=A<G)A;G1S(&1E<V-R:6)E9"!I;B!.;W1E(#8L('=H97)E8GD-"B`@#0H@
M("`@("`@('1H97D@<'5R8VAA<V5D(&%N(&%G9W)E9V%T92!O9B`S,S4L.34T
M('-H87)E<R!O9B!O=7(@8V]M;6]N#0H@("`-"B`@("`@("`@<W1O8VL@9F]R
M(&$@=&]T86P@<'5R8VAA<V4@<')I8V4@;V8@)#(R-2PP.#D@86YD(')E8V5I
M=F5D#0H@#0H@("`@("`@(&9I=F4M>65A<B!W87)R86YT<R!T;R!P=7)C:&%S
M92!A;B!A9&1I=&EO;F%L(#4P,RPY,S(@<VAA<F5S#0H@("`-"B`@("`@("`@
M;V8@;W5R(&-O;6UO;B!S=&]C:R!E>&5R8VES86)L92!A="`D,2XP,"!P97(@
M<VAA<F4N/"]F;VYT/@T*("`@#0H@("`@("`\+V1I=CX\8G(O/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S0P-#<X93A?,31E
M8U\T-&1D7SDR,S1?-F4P,C(W93-F838T#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+S,T,#0W.&4X7S$T96-?-#1D9%\Y,C,T7S9E,#(R-V4S9F$V
M-"]7;W)K<VAE971S+U-H965T,38N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!1#X-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY.;W1E(#$P("T@4V5L96-T960@475A<G1E<FQY
M($9I;F%N8VEA;"!$871A("AU;F%U9&ET960I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y1=6%R=&5R;'D@1FEN86YC:6%L($EN
M9F]R;6%T:6]N(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@(`T*("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P=#L@1D].5"U7
M14E'2%0Z(&)O;&0G/C$P+B8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P
M.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.R8C,38P.U-E;&5C=&5D
M#0H@(`T*("`@("`@("!1=6%R=&5R;'D@1FEN86YC:6%L($1A=&$@*'5N875D
M:71E9"D\+V9O;G0^#0H@("`-"B`@("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL
M93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY!#0H@("`-"B`@("`@("`@<W5M;6%R>2!O
M9B!S96QE8W1E9"!Q=6%R=&5R;'D@9FEN86YC:6%L(&1A=&$@9F]R(#(P,3$@
M86YD#0H@#0H@("`@("`@(#(P,3`@:7,@87,@9F]L;&]W<SH\+V9O;G0^#0H@
M#0H@("`@("`\+V1I=CX\8G(O/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L
M;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)2!S='EL93TS1"=&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0H@("`@
M#0H@("`@("`@("`@/'1R/@T*(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$
M24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@
M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P
M86X],T0Q-"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@8FQA8VL@,G!X('-O;&ED)SX-"B`-"B`@("`@("`@("`@("`@/&1I=B!S
M='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@
M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(`T*("`@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR,#$Q#0H@("`@
M#0H@("`@("`@("`@("`@("`@475A<G1E<B!%;F1E9#PO9F]N=#X-"B`@(`T*
M("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*
M("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#)P>"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@
M("`@(#QT<CX-"B`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U14
M3TTZ(#)P>"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@8FQA8VL@
M,G!X('-O;&ED)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4]
M,T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,
M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P
M="<@86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^36%R8V@-"B`@("`@#0H@
M("`@("`@("`@("`@("`@,S$\+V9O;G0^#0H@(`T*("`@("`@("`@("`@("`\
M+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@
M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O
M;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B!B;&%C:R`R<'@@<V]L:60G/@T*("`@("`-"B`@("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(`T*("`@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY*=6YE
M#0H@("`@#0H@("`@("`@("`@("`@("`@,S`\+V9O;G0^#0H@(`T*("`@("`@
M("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#)P>"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G/@T*("`@("`-"B`@("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(`T*
M("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY397!T96UB97(-"B`@("`-"B`@("`@("`@("`@("`@("`S,#PO9F]N
M=#X-"B`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@
M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0
M041$24Y'+4)/5%1/33H@,G!X)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-
M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^
M#0H@("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/D1E8V5M8F5R#0H@("`-"B`@("`@("`@("`@
M("`@("`S,3PO9F]N=#X-"B`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-
M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,
M24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)SX-"B`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@/"]T<CX-"B`@#0H@("`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U
M;F0M8V]L;W(Z("-#,$9&1D8[)SX-"B`-"B`@("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-3(E/@T*("`@(`T*
M("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U
M.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%
M1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-
M"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^4F5V96YU90T*("`-"B`@("`@("`@("`@("`@("!F<F]M(&=R86YT
M<SPO9F]N=#X-"B`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X-"B`@#0H@
M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/C@Y,RPP,#(\+V9O;G0^#0H@("`-"B`@("`@("`@("`@
M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X-"B`@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT
M)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/C$L-S4S+#`S,SPO9F]N=#X-"B`@("`@#0H@("`@("`@("`@
M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@
M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^#0H@(`T*("`@
M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXQ+#(Y-RPP,#8\+V9O;G0^#0H@("`@(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4
M15A4+4%,24=..B!L969T)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T*("`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^.34V+#@T-#PO9F]N=#X-"B`@(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@
M("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@
M(#QT<CX-"B`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-3(E/@T*("`@(`T*("`@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^3F5T#0H@("`-
M"B`@("`@("`@("`@("`@("!L;W-S/"]F;VYT/@T*("`@(`T*("`@("`@("`@
M("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@
M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*
M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@V,#8L
M,C@R/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXI/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@
M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M.24@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^*#(Q,2PS
M-#0\+V9O;G0^#0H@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/BD\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@
M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@
M("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y
M)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,S<U+#@U
M,CPO9F]N=#X-"B`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M*3PO9F]N=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)3X-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@
M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@Q+#$U,RPS
M-#@\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BD\
M+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`\+W1R/@T*("`-"B`@("`@("`@("`\='(@<W1Y;&4],T0G8F%C:V=R;W5N
M9"UC;VQO<CH@(T,P1D9&1CLG/@T*(`T*("`@("`@("`@("`@/'1D(&%L:6=N
M/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U,B4^#0H@("`@#0H@
M("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[
M(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&
M5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*(`T*
M("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY.970-"B`@(`T*("`@("`@("`@("`@("`@(&QO<W,@<&5R('-H87)E
M/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$
M;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q
M-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B@P+C`T/"]F;VYT/@T*(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/@T*("`-"B`@("`@("`@("`@
M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^*#`N,#$\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D
M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/BD\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-
M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Y)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXH,"XP,CPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^*3PO9F]N=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-
M"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D
M/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@P
M+C`X/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI
M/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@/"]T<CX-"B`@#0H@("`@("`@(#PO=&%B;&4^/&)R+SX\=&%B;&4@8V5L
M;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!W:61T:#TS1#$P,"4@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86XG/@T*("`@#0H@("`@("`@("`@/'1R/@T*(`T*("`@("`@("`@
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/
M33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@
M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D(&-O;'-P86X],T0Q-"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)SX-"B`-"B`@("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(`T*
M("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXR,#$P#0H@("`@#0H@("`@("`@("`@("`@("`@475A<G1E<B!%;F1E
M9#PO9F]N=#X-"B`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO
M='(^#0H@(`T*("`@("`@("`@(#QT<CX-"B`-"B`@("`@("`@("`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^
M#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT
M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@8FQA8VL@,G!X('-O;&ED)SX-"B`@("`@#0H@("`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M36%R8V@-"B`@("`@#0H@("`@("`@("`@("`@("`@,S$\+V9O;G0^#0H@(`T*
M("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*
M("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"
M3U143TTZ(#)P>"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G/@T*("`@("`-
M"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR
M-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,
M1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX-
M"B`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SY*=6YE#0H@("`@#0H@("`@("`@("`@("`@("`@,S`\+V9O
M;G0^#0H@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@
M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@
M4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-
M"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*
M("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G
M/@T*("`@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%
M24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[
M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS
M1&-E;G1E<CX-"B`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SY397!T96UB97(-"B`@("`-"B`@("`@("`@
M("`@("`@("`S,#PO9F]N=#X-"B`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*
M("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=415A4
M+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)SX-"B`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M
M0D]45$]-.B`R<'@G/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@
M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@8V]L<W!A;CTS
M1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L
M86-K(#)P>"!S;VQI9"<^#0H@("`@(`T*("`@("`@("`@("`@("`\9&EV('-T
M>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$
M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4
M.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D1E8V5M8F5R#0H@
M("`-"B`@("`@("`@("`@("`@("`S,3PO9F]N=#X-"B`@#0H@("`@("`@("`@
M("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X
M)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@/"]T<CX-"B`@#0H@("`@("`@("`@/'1R('-T
M>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#,$9&1D8[)SX-"B`-"B`@("`@
M("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-3(E/@T*("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)
M3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^4F5V96YU90T*("`-"B`@("`@("`@("`@
M("`@("!F<F]M(&=R86YT<SPO9F]N=#X-"B`-"B`@("`@("`@("`@("`@/"]D
M:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)#PO9F]N=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$L,S,X+#4V,#PO9F]N=#X-
M"B`@("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D
M/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B0\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS
M1"=415A4+4%,24=..B!R:6=H="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ+#<S-RPQ-CD\+V9O;G0^
M#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T
M9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,2PQ-C,L,C@X/"]F;VYT
M/@T*("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)#PO9F]N=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/CDT-BPR-#`\+V9O;G0^
M#0H@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`\
M+W1R/@T*("`-"B`@("`@("`@("`\='(^#0H@#0H@("`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R)3X-"B`@
M("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@
M,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M#0H@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/DYE=`T*("`@#0H@("`@("`@("`@("`@("`@;&]S<SPO9F]N
M=#X-"B`@("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S
M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N
M97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*
M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=415A4+4%,24=..B!R
M:6=H="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXH-CDP+#<X.3PO9F]N=#X-"B`@("`-"B`@("`@("`@
M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^*3PO9F]N=#X-"B`@#0H@("`@("`@("`@
M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@
M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B@Y,S,L,#@Y/"]F;VYT/@T*("`@(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/@T*("`-"B`@("`@("`@("`@
M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG
M:'0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^*#8T-"PV-C8\+V9O;G0^#0H@("`@#0H@("`@("`@("`@
M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/BD\+V9O;G0^#0H@(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@
M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H
M="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXH-#<X+#<X-#PO9F]N=#X-"B`@("`-"B`@("`@("`@("`@
M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^*3PO9F]N=#X-"B`@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT
M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C0S!&1D9&.R<^#0H@#0H@
M("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#4R)3X-"B`@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS
M1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/DYE=`T*("`@#0H@("`@("`@("`@
M("`@("`@;&]S<R!P97(@<VAA<F4\+V9O;G0^#0H@("`@#0H@("`@("`@("`@
M("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@
M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M.24@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^*#`N,#0\
M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BD\+V9O
M;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^
M#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,"XP-CPO9F]N=#X-
M"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T
M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^*3PO9F]N=#X-"B`@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-
M"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@P+C`T/"]F;VYT/@T*(`T*("`@
M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/@T*("`-"B`@("`@
M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L
M969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-
M"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G5$585"U!3$E'
M3CH@<FEG:'0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^*#`N,#,\+V9O;G0^#0H@#0H@("`@("`@("`@
M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,
M24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/BD\+V9O;G0^#0H@(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@("`@/"]T
M86)L93X\8G(O/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?,S0P-#<X93A?,31E8U\T-&1D7SDR,S1?-F4P,C(W93-F838T#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,T,#0W.&4X7S$T96-?-#1D
M9%\Y,C,T7S9E,#(R-V4S9F$V-"]7;W)K<VAE971S+U-H965T,3<N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5!1#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.;W1E(#$Q("T@
M4W5B<V5Q=65N="!%=F5N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-U8G-E<75E;G0@179E;G1S(%M497AT($)L;V-K73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=,
M24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&QE9G0^#0H@("`@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^,3$N)B,Q-C`[
M)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q-C`[)B,Q
M-C`[)B,Q-C`[)B,Q-C`[4W5B<V5Q=65N=`T*("`@(`T*("`@("`@("!%=F5N
M=',\+V9O;G0^#0H@("`-"B`@("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS
M1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!
M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T
M)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$)T9/
M3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/E!R:79A=&4-
M"B`@("`-"B`@("`@("`@4&QA8V5M96YT(&]F($-O;6UO;B!3=&]C:R!A;F0@
M5V%R<F%N=',\+V9O;G0^#0H@("`@(`T*("`@("`@/"]D:78^/&)R+SX\9&EV
M('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T
M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))
M1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D1U<FEN9PT*("`@#0H@("`@("`@
M($IA;G5A<GD@,C`Q,BP@=V4@<V]L9"!A;B!A9V=R96=A=&4@;V8@-#`W+#DY
M.2!S:&%R97,@;V8@;W5R#0H@("`-"B`@("`@("`@8V]M;6]N('-T;V-K('1O
M('1W96QV92!I;F1I=FED=6%L(&%C8W)E9&ET960@:6YV97-T;W)S#0H@("`-
M"B`@("`@("`@*&EN8VQU9&EN9R`T-2PP,#`@<VAA<F5S('-O;&0@=&\@;65M
M8F5R<R!O9B!O=7(@8F]A<F0@;V8-"B`@("`@#0H@("`@("`@(&1I<F5C=&]R
M<R!A;F0@;6%N86=E;65N="D@9F]R(&%N(&%G9W)E9V%T92!P=7)C:&%S92!P
M<FEC90T*(`T*("`@("`@("!O9B`D,C<S+#,V,"XF(S$V,#LF(S$V,#M792!A
M;'-O(&ES<W5E9"!T;R!T:&4@:6YV97-T;W)S#0H@(`T*("`@("`@("!W87)R
M86YT<R!T;R!P=7)C:&%S92!A;B!A9V=R96=A=&4@;V8@-C$R+#`P,2!S:&%R
M97,@;V8-"B`@(`T*("`@("`@("!C;VUM;VX@<W1O8VL@870@82!P<FEC92!O
M9B`D,2XP,"!P97(@<VAA<F4L('=H:6-H(&5X<&ER92!I;@T*("`@#0H@("`@
M("`@($IA;G5A<GD@,C`Q-RX\+V9O;G0^#0H@("`@(`T*("`@("`@/"]D:78^
M/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1D].5"U35%E,13H@:71A;&EC.R!$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P="<^27-S=6%N8V4-"B`@("`@#0H@("`@("`@(&]F($-O;G9E<G1I
M8FQE(%!R969E<G)E9"!3=&]C:R!A;F0@5V%R<F%N=',\+V9O;G0^#0H@("`@
M(`T*("`@("`@/"]D:78^/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4
M.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2
M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F
M=#X-"B`-"B`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/D]N#0H@("`@#0H@("`@("`@($UA<F-H(#(Q+"`R,#$R+"!W92!S;VQD
M('-H87)E<R!O9B!O=7(@4V5R:65S($$@8V]N=F5R=&EB;&4-"B`@#0H@("`@
M("`@('!R969E<G)E9"!S=&]C:R!T;R!C97)T86EN(&EN<W1I='5T:6]N86P@
M:6YV97-T;W)S(&9O<B!A;@T*(`T*("`@("`@("!A9V=R96=A=&4@<'5R8VAA
M<V4@<')I8V4@;V8@)#(N,B!M:6QL:6]N+B8C,38P.R8C,38P.U1H90T*("`@
M#0H@("`@("`@('!R969E<G)E9"!S=&]C:R!I<R!C;VYV97)T:6)L92!A="!A
M;GD@=&EM92!I;G1O('-H87)E<R!O9@T*(`T*("`@("`@("!O=7(@8V]M;6]N
M('-T;V-K(&%T("0P+C<U('!E<B!S:&%R92`H,BPY,S,L,S,S('-H87)E<R!I
M;@T*("`@("`-"B`@("`@("`@=&AE(&%G9W)E9V%T92DL('-U8FIE8W0@=&\@
M<&]S<VEB;&4@861J=7-T;65N="!A<R!P<F]V:61E9`T*("`-"B`@("`@("`@
M:6X@=&AE(&-E<G1I9FEC871E(&]F(&1E<VEG;F%T:6]N+CPO9F]N=#X-"B`-
M"B`@("`@(#PO9&EV/CQB<B\^/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@
M,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)
M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^
M#0H@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SY0=7)S=6%N=`T*("`@("`-"B`@("`@("`@=&\@=&AE('1E<FUS(&]F('1H
M92!S96-U<FET:65S('!U<F-H87-E(&%G<F5E;65N="P@=&AE#0H@("`-"B`@
M("`@("`@:6YV97-T;W)S(&%L<V\@<F5C96EV960@9FEV92UY96%R(%-E<FEE
M<R!!('=A<G)A;G1S('1O#0H@("`-"B`@("`@("`@<'5R8VAA<V4@86X@86=G
M<F5G871E(&]F(#(L.3,S+#,S,R!S:&%R97,@;V8@;W5R(&-O;6UO;@T*("`@
M(`T*("`@("`@("!S=&]C:R!A="`D,2XP,"!P97(@<VAA<F4N)B,Q-C`[)B,Q
M-C`[5&AE(%-E<FEE<R!!('=A<G)A;G1S#0H@("`@(`T*("`@("`@("!A<F4@
M:6UM961I871E;'D@97AE<F-I<V%B;&4N)B,Q-C`[(%=E(&%L<V\@9W)A;G1E
M9"!T;R!T:&4-"B`@("`@#0H@("`@("`@(&EN=F5S=&]R<R!A(&]N92UY96%R
M(&%D9&ET:6]N86P@<'5R8VAA<V4@<FEG:'0L(&5V:61E;F-E9`T*(`T*("`@
M("`@("!I;B!T:&4@9F]R;2!O9B!397)I97,@0B!W87)R86YT<RP@=&\@<'5R
M8VAA<V4@=7`@=&\-"B`@("`@#0H@("`@("`@(#(L.3,S+#,S,R!O9B!O=7(@
M8V]M;6]N('-T;V-K(&9O<B!O;F4@>65A<B!W:71H(&%N(&5X97)C:7-E#0H@
M("`-"B`@("`@("`@<')I8V4@;V8@)#`N-S4@<&5R('-H87)E+"!A;F0@9FEV
M92UY96%R(%-E<FEE<R!#('=A<G)A;G1S#0H@#0H@("`@("`@('1O('!U<F-H
M87-E('5P('1O(#(L.3,S+#,S,R!S:&%R97,@;V8@;W5R(&-O;6UO;B!S=&]C
M:R!A=`T*(`T*("`@("`@("`D,2XP,"!P97(@<VAA<F4N)B,Q-C`[)B,Q-C`[
M5&AE(%-E<FEE<R!"('=A<G)A;G1S(&%R90T*("`@("`-"B`@("`@("`@:6UM
M961I871E;'D@97AE<F-I<V%B;&4N)B,Q-C`[)B,Q-C`[5&AE(%-E<FEE<R!#
M('=A<G)A;G1S#0H@("`@#0H@("`@("`@(&]N;'D@=F5S="!A;F0@8F5C;VUE
M(&5X97)C:7-A8FQE(&%T('1H92!T:6UE+"!A;F0@=&\@=&AE#0H@("`@(`T*
M("`@("`@("!E>'1E;G0L('1H870@=&AE(%-E<FEE<R!"('=A<G)A;G1S(&%R
M92!E>&5R8VES960N/"]F;VYT/@T*(`T*("`@("`@/"]D:78^/&)R+SX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,T,#0W.&4X
M7S$T96-?-#1D9%\Y,C,T7S9E,#(R-V4S9F$V-`T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B\S-#`T-SAE.%\Q-&5C7S0T9&1?.3(S-%\V93`R,C=E
M,V9A-C0O5V]R:W-H965T<R]3:&5E=#$X+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%040^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4V-H961U;&4@24D@+2!686QU871I;VX@
M86YD(%%U86QI9GEI;F<@06-C;W5N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F(%9A;'5A=&EO;B!A;F0@
M475A;&EF>6EN9R!!8V-O=6YT<R!$:7-C;&]S=7)E(%M497AT($)L;V-K73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL93TS1"=,
M24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&-E;G1E<CX-"B`@("`@#0H@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^4T-(1415
M3$4-"B`@("`-"B`@("`@("`@24D@)B,X,C$Q.R!604Q5051)3TX@04Y$(%%5
M04Q)1EE)3D<@04-#3U5.5%,\+V9O;G0^#0H@("`@(`T*("`@("`@/"]D:78^
M/&)R+SX\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.
M1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@
M34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%
M24=(5#H@8F]L9"<^1F]R#0H@("`@#0H@("`@("`@('1H92!996%R<R!%;F1E
M9"!$96-E;6)E<B`S,2P@,C`Q,2P@,C`Q,"!A;F0@,C`P.3PO9F]N=#X-"B`@
M("`@#0H@("`@("`\+V1I=CX\8G(O/CQT86)L92!C96QL<&%D9&EN9STS1#`@
M8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)2!S='EL93TS1"=&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;B<^#0H@
M("`@#0H@("`@("`@("`@/'1R/@T*(`T*("`@("`@("`@("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@
M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0
M041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O
M;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)SX-"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@
M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,24=..B!L
M969T.R!0041$24Y'+4)/5%1/33H@,G!X)SX-"B`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@G/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@8V]L<W!A;CTS1#8@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S
M;VQI9"<^#0H@("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)
M3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D%D9&ET:6]N<SPO9F]N=#X-"B`@
M#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'
M+4)/5%1/33H@,G!X)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@
M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*("`-"B`@
M("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&
M3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@
M("`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R<'@G/@T*("`@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G/@T*
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@
M("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!C
M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.1RU"
M3U143TTZ(#)P>"<^#0H@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@
M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@
M;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@#0H@("`@("`@("`@("`@
M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ
M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O
M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO
M='(^#0H@(`T*("`@("`@("`@(#QT<CX-"B`-"B`@("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@#0H@("`@("`@("`@("`@(#QD
M:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P
M<'0[($1)4U!,05DZ(&)L;V-K)SX-"B`-"B`@("`@("`@("`@("`@("`F(S$V
M,#L-"B`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@
M("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%
M3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VLG/@T*(`T*("`@("`@("`@("`@("`@
M("8C,38P.PT*("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@
M("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4
M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P
M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M1&5S8W)I<'1I;VX\+V9O;G0^#0H@("`@#0H@("`@("`@("`@("`@(#PO9&EV
M/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1)3D<M0D]45$]-.B`R
M<'@G/@T*("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S
M;VQI9"<^#0H@("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)
M3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B
M;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L
M:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y
M;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W
M(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D)A;&%N8V4-"B`@#0H@("`@("`@
M("`@("`@("`@870\+V9O;G0^#0H@(`T*("`@("`@("`@("`@("`\+V1I=CX-
M"B`@#0H@("`@("`@("`@("`@(#QD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z
M(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'
M24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT
M97(^#0H@("`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^0F5G:6YN:6YG/"]F;VYT/@T*("`-"B`@("`@("`@
M("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D]F#0H@(`T*("`@("`@("`@
M("`@("`@(%!E<FEO9#PO9F]N=#X-"B`-"B`@("`@("`@("`@("`@/"]D:78^
M#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G/@T*(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@
M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N
M/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,G!X('-O;&ED)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^0VAA<F=E9`T*
M("`-"B`@("`@("`@("`@("`@("!T;SPO9F]N=#X-"B`@#0H@("`@("`@("`@
M("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,
M24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@
M8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A
M;&EG;CTS1&-E;G1E<CX-"B`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY#;W-T<PT*("`@("`-"B`@("`@
M("`@("`@("`@("!A;F0\+V9O;G0^#0H@("`-"B`@("`@("`@("`@("`@/"]D
M:78^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)
M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@
M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$
M8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/D5X<&5N<V5S/"]F;VYT/@T*(`T*("`@("`@
M("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*
M("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ
M(#)P>"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="
M3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@<V]L:60G/@T*("`@("`-"B`@("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(`T*
M("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY#:&%R9V5D#0H@(`T*("`@("`@("`@("`@("`@('1O/"]F;VYT/@T*
M("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@("`\
M9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@
M,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.
M+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D]T:&5R
M/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@("`@
M("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$58
M5"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P
M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(`T*
M("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SY!8V-O=6YT<SPO9F]N=#X-"B`-"B`@("`@("`@("`@("`@/"]D:78^
M#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G/@T*(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G4$%$1$E.
M1RU"3U143TTZ(#)P>"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@
M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N
M/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M8FQA8VL@,G!X('-O;&ED)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QD:78@
M<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`P<'0[
M($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'
M2%0Z(#!P="<@86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^*#$I/"]F;VYT
M/@T*(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`@
M(#QD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4
M.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'
M24XM4DE'2%0Z(#!P="<@86QI9VX],T1C96YT97(^#0H@("`-"B`@("`@("`@
M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M
M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^1&5D
M=6-T:6]N<SPO9F]N=#X-"B`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU"3U143TTZ(#)P>"<^#0H@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=0041$24Y'+4)/
M5%1/33H@,G!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C
M:R`R<'@@<V]L:60G/@T*("`@("`-"B`@("`@("`@("`@("`@/&1I=B!S='EL
M93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E3
M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@
M,'!T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(`T*("`@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY"86QA;F-E#0H@(`T*
M("`@("`@("`@("`@("`@(&%T/"]F;VYT/@T*("`-"B`@("`@("`@("`@("`@
M/"]D:78^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M
M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C
M:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N
M/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D5N9#PO9F]N=#X-"B`-"B`@("`@("`@
M("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D]F#0H@(`T*("`@("`@("`@
M("`@("`@(%!E<FEO9#PO9F]N=#X-"B`-"B`@("`@("`@("`@("`@/"]D:78^
M#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D<M0D]45$]-.B`R<'@G/@T*(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`\+W1R/@T*("`-"B`@("`@("`@("`\='(@<W1Y;&4],T0G8F%C
M:V=R;W5N9"UC;VQO<CH@(T,P1D9&1CLG/@T*(`T*("`@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT^#0H@(`T*("`@("`@("`@
M("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.
M1$5.5#H@+3EP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`Y<'0[
M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@(`T*("`@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY2
M97-E<G9E#0H@(`T*("`@("`@("`@("`@("`@($1E9'5C=&5D(&EN('1H92!"
M86QA;F-E(%-H965T/"]F;VYT/B`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^1G)O;0T*("`-"B`@("`@("`@("`@("`@("!T:&4@07-S970@
M=&\@5VAI8V@@:70@07!P;&EE<SH\+V9O;G0^#0H@("`@(`T*("`@("`@("`@
M("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M/@T*(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT^#0H@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V
M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@
M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@
M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9
M.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F
M;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;3X-"B`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO
M9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-
M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@8V]L
M<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M/@T*(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT
M/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%
M6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-
M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@
M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N
M/3-$,B!V86QI9VX],T1B;W1T;VT^#0H@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@
M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`\+W1R/@T*("`-"B`@
M("`@("`@("`\='(^#0H@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0
M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/
M3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D
M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS
M1&)O='1O;3X-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@
M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-
M"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D
M/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T
M=&]M/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T
M9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@
M("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-
M"B`@("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT^
M#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN
M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*
M("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-
M"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;3X-"B`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF
M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M/@T*(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@/"]T<CX-"B`@#0H@("`@("`@("`@/'1R('-T>6QE/3-$)V)A8VMG<F]U
M;F0M8V]L;W(Z("-#,$9&1D8[)SX-"B`-"B`@("`@("`@("`@(#QT9"!A;&EG
M;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M/@T*("`-"B`@("`@("`@("`@("`@
M/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z
M(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)
M3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@("`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/D%L;&]W86YC
M90T*("`@(`T*("`@("`@("`@("`@("`@(&9O<B!$969E<G)E9"!487@@07-S
M971S/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`@(#PO9&EV/@T*("`-"B`@
M("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N/3-$
M,B!V86QI9VX],T1B;W1T;VT^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T
M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@
M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'
M3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@
M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A
M;&EG;CTS1&)O='1O;3X-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@
M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)
M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@
M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$
M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[
M($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B
M;W1T;VT^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@
M("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@
M(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O
M;3X-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@
M(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT<CX-"B`-"B`@
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-#`E/@T*("`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$
M)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9
M.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G
M(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^/&9O;G0@:60],T1404(Q+3,P-R!S
M='EL93TS1"=-05)'24XM3$5&5#H@.7!T)SX\+V9O;G0^665A<@T*("`@#0H@
M("`@("`@("`@("`@("`@96YD960@1&5C96UB97(@,S$L(#(P,3$\+V9O;G0^
M#0H@("`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!
M3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X-"B`@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-
M"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL
M:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/C(W+#4W-BPR-3,\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D
M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L
M969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^
M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)
M1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^#0H@(`T*("`@("`@("`@
M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Y)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXX.#DL,S(R/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`\+W1D/@T*
M("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T
M)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@
M:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^
M#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O;G0^#0H@(`T*("`@("`@("`@("`@
M/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Y)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXM/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@
M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^
M)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@
M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@
M("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)#PO9F]N=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@
M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@("`@
M("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,
M63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B@X-S,L-3@T
M/"]F;VYT/@T*("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@
M("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@#0H@("`@
M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].
M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI
M/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B0\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR-RPU.3$L.3DQ/"]F
M;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M(#PO='(^#0H@(`T*("`@("`@("`@(#QT<B!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B`C0S!&1D9&.R<^#0H@#0H@("`@("`@("`@("`\=&0@86QI9VX]
M,T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)3X-"B`@("`-"B`@
M("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A%24=(5#H@,2XR-3L@
M5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494
M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&QE9G0^#0H@#0H@
M("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/CQF;VYT(&ED/3-$5$%",2TS,#@@<W1Y;&4],T0G34%21TE.+4Q%1E0Z
M(#EP="<^/"]F;VYT/EEE87(-"B`@(`T*("`@("`@("`@("`@("`@(&5N9&5D
M($1E8V5M8F5R(#,Q+"`R,#$P/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`@
M(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@("`\=&0@86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,
M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\
M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B0\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@
M("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL
M93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@#0H@("`@("`@("`@("`@(#QF
M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I
M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR-RPP.3$L,S,X/"]F
M;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\
M+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@
M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)3X-"B`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9
M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M
M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T
M9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@#0H@
M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@
M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^,2PQ-C`L-#`U/"]F;VYT
M/@T*("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[
M/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@
M("`@(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^#0H@("`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO
M=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)#PO9F]N=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@
M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BT\+V9O;G0^#0H@(`T*
M("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT
M('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S
M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L
M:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-
M"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S
M='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@#0H@("`@("`@("`@
M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)
M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT
M/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G5$585"U!
M3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^*#8W-2PT.3`\+V9O;G0^#0H@("`@#0H@
M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@
M<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@
M;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/BD\+V9O;G0^#0H@(`T*("`@
M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS
M1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@
M("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4
M+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C
M,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4]
M,T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\
M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T
M:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X-"B`@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ
M(')I9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E3
M4$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G/C(W+#4W-BPR-3,\+V9O;G0^#0H@#0H@("`@("`@
M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4
M+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@
M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@/"]T<CX-"B`@#0H@("`@
M("`@("`@/'1R/@T*(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0T,"4^#0H@("`@#0H@("`@("`@("`@
M("`@(#QD:78@<W1Y;&4],T0G3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$
M14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-
M05)'24XM4DE'2%0Z(#!P="<@86QI9VX],T1L969T/@T*(`T*("`@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N
M="!I9#TS1%1!0C$M,S`Y('-T>6QE/3-$)TU!4D=)3BU,1494.B`Y<'0G/CPO
M9F]N=#Y996%R#0H@("`-"B`@("`@("`@("`@("`@("!E;F1E9"!$96-E;6)E
M<B`S,2P@,C`P.3PO9F]N=#X-"B`@(`T*("`@("`@("`@("`@("`\+V1I=CX-
M"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D
M(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@
M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI
M;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@
M,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-"B`@
M("`-"B`@("`@("`@("`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`@("`@#0H@("`@("`@
M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&
M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F
M;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G5$58
M5"U!3$E'3CH@<FEG:'0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL
M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@
M<F]M86X[($9/3E0M4TE:13H@,3!P="<^,C4L-C<T+#@X,CPO9F]N=#X-"B`-
M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE
M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A
M;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-
M"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE
M.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/B8C,38P.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@
M#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@
M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-
M24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N
M=#X-"B`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(')I9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4]
M,T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/C$L-#$V+#0U-CPO9F]N=#X-"B`@("`@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O
M;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM
M97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N=#X-
M"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@
M86QI9VX],T1L969T('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@
M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN
M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@
M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B0\+V9O
M;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=415A4
M+4%,24=..B!R:6=H="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE
M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXM/"]F;VYT/@T*("`-"B`@("`@("`@
M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M
M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS
M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M
M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@
M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^#0H@("`-"B`@("`@("`@
M("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!
M34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P
M.SPO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@
M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G
M5$585"U!3$E'3CH@;&5F="<^#0H@("`@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)#PO9F]N=#X-"B`@#0H@
M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I
M9VAT)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G1$E34$Q!
M63H@:6YL:6YE.R!&3TY4+49!34E,63H@=&EM97,@;F5W(')O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G/BT\+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G5$585"U!3$E'3CH@;&5F
M="<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ
M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D
M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)3X-"B`@(`T*("`@("`@("`@("`@("`\9F]N
M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE
M<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*
M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=.
M.B!L969T)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@
M(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$.24@<W1Y;&4],T0G5$585"U!3$E'3CH@<FEG:'0G/@T*(`T*
M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[
M($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:13H@,3!P
M="<^,C<L,#DQ+#,S.#PO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@
M("`@#0H@("`@("`@("`@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G
M/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I
M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86X[($9/3E0M4TE:
M13H@,3!P="<^)B,Q-C`[/"]F;VYT/@T*(`T*("`@("`@("`@("`@/"]T9#X-
M"B`@("`-"B`@("`@("`@("`\+W1R/@T*("`-"B`@("`@("`@/"]T86)L93X\
M8G(O/CQT86)L92!A;&EG;CTS1&-E;G1E<B!B;W)D97(],T0P(&-E;&QP861D
M:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@:60],T1H86YG:6YG:6YD96YT+3$Q
M-R!W:61T:#TS1#$P,"4@<W1Y;&4],T0G1D].5"U&04U)3%DZ('1I;65S(&YE
M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!T:6UE<R!N97<@<F]M86XG/@T*("`-"B`@("`@("`@("`\
M='(@=F%L:6=N/3-$=&]P('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R<^
M#0H@#0H@("`@("`@("`@("`\=&0@<W1Y;&4],T0G5TE$5$@Z(#$X<'0G/@T*
M("`@#0H@("`@("`@("`@("`@(#QD:78^#0H@#0H@("`@("`@("`@("`@("`@
M/&9O;G0@<W1Y;&4],T0G1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/B8C,38P.SPO9F]N
M=#X-"B`@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@
M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('-T>6QE/3-$)U=)1%1(
M.B`Q.'!T)SX-"B`@(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`P<'0[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(
M5#H@,'!T)SX-"B`@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$
M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SXH,2D\+V9O;G0^#0H@#0H@("`@("`@("`@
M("`@(#PO9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@
M("`@("`@("`\=&0^#0H@("`-"B`@("`@("`@("`@("`@/&1I=B!A;&EG;CTS
M1&QE9G0^#0H@("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@<W1Y;&4],T0G
M1$E34$Q!63H@:6YL:6YE.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/D1E9'5C=&EO;G,-"B`@("`@#0H@("`@("`@
M("`@("`@("`@<F5P<F5S96YT('1H92!E9F9E8W0@;V8@97AP:7)I;F<@3D],
M(&-A<G)Y9F]R=V%R9',-"B`@#0H@("`@("`@("`@("`@("`@9G)O;2!P<FEO
M<B!Y96%R<RX\+V9O;G0^#0H@(`T*("`@("`@("`@("`@("`\+V1I=CX-"B`@
M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@
M(`T*("`@("`@("`\+W1A8FQE/CQB<B\^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\S-#`T-SAE.%\Q-&5C7S0T9&1?.3(S-%\V
M93`R,C=E,V9A-C0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S0P
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M:&5E=#`Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,BYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#,N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#`T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970P-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#8N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`W+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970P."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,#DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$P+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,2YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,3(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#$S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-"YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,34N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#$V+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970Q-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3@N
M:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'1087)T7S,T,#0W.&4X7S$T
=96-?-#1D9%\Y,C,T7S9E,#(R-V4S9F$V-"TM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
        <td class="text"><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Summary

        of Significant Accounting Policies</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Basis

        of Presentation and Principles of Consolidation</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our

        primary business is conducted by our wholly-owned

        subsidiary, GeoVax, Inc. The accompanying consolidated

        financial statements include the accounts of GeoVax, Inc.

        from inception together with those of GeoVax Labs, Inc.

        from September 28, 2006 (see Note 5).&#160;&#160;All

        intercompany transactions have been eliminated in

        consolidation.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Development-Stage

        Enterprise</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We

        are devoting all of our present efforts to research and

        development and GeoVax is a development stage enterprise as

        defined by Financial Accounting Standards Board

        (&#8220;FASB&#8221;) Accounting Standards Codification

        (&#8220;ASC&#8221;) Topic 915, <font style="FONT-STYLE: italic; DISPLAY: inline">Development

        Stage Entities</font>.&#160;&#160;All losses accumulated

        since inception (June 27, 2001) have been considered as

        part of our development stage activities.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Use

        of Estimates</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The

        preparation of financial statements in conformity with

        accounting principles generally accepted in the United

        States of America (&#8220;GAAP&#8221;) requires us to make

        estimates and assumptions that affect the reported amounts

        of assets and liabilities and disclosure of contingent

        assets and liabilities at the date of the financial

        statements and the reported amounts of revenues and

        expenses during the reporting period.&#160;&#160;Actual

        results may differ from those estimates.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Cash

        and Cash Equivalents</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We

        consider all highly liquid investments with a maturity of

        three months or less when purchased to be cash

        equivalents.&#160;&#160;Our cash and cash equivalents

        consist primarily of bank deposits and money market

        accounts.&#160;&#160;The recorded values approximate fair

        market values due to the short maturities.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Fair

        Value of Financial Instruments and Concentration of Credit

        Risk</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Financial

        instruments that subject us to concentration of credit risk

        consist primarily of cash and cash equivalents, which are

        maintained by a high credit quality financial institution.

        The carrying values reported in the balance sheets for cash

        and cash equivalents approximate fair values.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Property

        and Equipment</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Property

        and equipment are stated at cost, less accumulated

        depreciation and amortization.&#160;&#160;The components of

        property and equipment as of December 31, 2011 and 2010 are

        as follows:</font>

      </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

          <tr>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="76%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Laboratory

                equipment</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">388,000</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">388,000</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" width="76%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Leasehold

                improvements</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">115,605</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">115,605</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other

                furniture, fixtures &amp; equipment</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">28,685</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">16,789</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" width="76%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total

                property and equipment</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">532,290</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">520,394</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accumulated

                depreciation and amortization</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(356,084</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(271,953</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Property

                and equipment, net</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">176,206</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">248,441</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

        </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Expenditures

        for maintenance and repairs are charged to operations as

        incurred, while additions and improvements are

        capitalized.&#160;&#160;Depreciation is computed using the

        straight-line method over the estimated useful lives of the

        assets which range from three to five

        years.&#160;&#160;Amortization of leasehold improvements is

        computed using the straight-line method over the remaining

        term of the related lease.&#160;&#160;Depreciation and

        amortization expense was $84,131, $94,887, and $64,891

        during the years ended December 31, 2011, 2010 and 2009,

        respectively.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Other

        Assets</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Other

        assets consist principally of license agreements for the

        use of technology obtained through the issuance of the

        Company&#8217;s common stock.&#160;&#160;These license

        agreements are amortized on a straight line basis over ten

        years.&#160;&#160;Amortization expense related to these

        agreements was $24,886 during each of the years ended

        December 31, 2011, 2010 and 2009 and is expected to be

        $19,923, $10,000, $10,000, $-0-, and $-0- for each of the

        next five years, respectively.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Impairment

        of Long-Lived Assets</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We

        review long-lived assets for impairment whenever events or

        changes in circumstances indicate that the carrying amount

        of an asset may not be

        recoverable.&#160;&#160;Recoverability of assets to be held

        and used is measured by a comparison of the carrying amount

        of the assets to the future net cash flows expected to be

        generated by such assets.&#160;&#160;If we consider such

        assets to be impaired, the impairment to be<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>recognized

        is measured by the amount by which the carrying amount of

        the assets exceeds the expected future net cash flows from

        the assets.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Accrued

        Liabilities</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As

        part of the process of preparing our financial statements,

        we estimate expenses that we believe we have incurred, but

        have not yet been billed by our third party vendors. This

        process involves identifying services and activities that

        have been performed by such vendors on our behalf and

        estimating the level to which they have been performed and

        the associated cost incurred for such service as of each

        balance sheet date in our financial statements. Examples of

        expenses for which we accrue include fees for professional

        services and fees owed to contract manufacturers in

        conjunction with the manufacture of vaccines for our

        clinical trials. We make these estimates based upon

        progress of activities related to contractual obligations

        and information received from vendors.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Net

        Loss Per Share</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Basic

        and diluted loss per common share are computed based on the

        weighted average number of common shares outstanding. All

        common share equivalents (which consist of options and

        warrants) are excluded from the computation of diluted loss

        per share since the effect would be anti-dilutive. Common

        share equivalents which could potentially dilute basic

        earnings per share in the future, and which were excluded

        from the computation of diluted loss per share, totaled

        2,798,801, 2,013,522, and 1,866,550 at December 31, 2011,

        2010 and 2009, respectively.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Revenue

        Recognition</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We

        recognize revenue in accordance with the SEC&#8217;s Staff

        Accounting Bulletin No. 101, <font style="FONT-STYLE: italic; DISPLAY: inline">Revenue

        Recognition in Financial Statements,</font> as amended by

        Staff Accounting Bulletin No. 104, <font style="FONT-STYLE: italic; DISPLAY: inline">Revenue

        Recognition,</font> (&#8220;SAB 104&#8221;). SAB 104

        provides guidance in applying GAAP to revenue recognition

        issues, and specifically addresses revenue recognition for

        upfront, nonrefundable fees received in connection with

        research collaboration agreements.&#160;&#160;During 2011,

        2010 and 2009, our revenue consisted of grant funding

        received primarily from the NIH (see Note

        3).&#160;&#160;Revenue from this arrangement is

        approximately equal to the costs incurred and is recorded

        as income as the related costs are incurred.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research

        and Development Expense</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Research

        and development expense primarily consists of costs

        incurred in the discovery, development, testing and

        manufacturing of our product candidates. These expenses

        consist primarily of (i) fees paid to third-party service

        providers to perform, monitor and accumulate data related

        to our preclinical studies and clinical trials, (ii) costs

        related to sponsored research agreements, (iii) the costs

        to procure and manufacture materials used in clinical

        trials, (iv) laboratory supplies and facility-related

        expenses to conduct development, and (v) salaries,

        benefits, and share-based compensation for

        personnel.&#160;&#160;These costs are charged to expense as

        incurred.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Patent

        Costs</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our

        expenditures relating to obtaining and protecting patents

        are charged to expense when incurred, and are included in

        general and administrative expense.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Period

        to Period Comparisons</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our

        operating results are expected to fluctuate for the

        foreseeable future. Therefore, period-to-period comparisons

        should not be relied upon as predictive of the results for

        future periods.&#160;&#160;Certain prior year amounts have

        been reclassified to conform to the current year financial

        statement presentation.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Income

        Taxes</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We

        account for income taxes using the liability method. Under

        this method, deferred tax assets and liabilities are

        recognized for the estimated future tax consequences

        attributable to differences between the financial statement

        carrying amounts of existing assets and liabilities and

        their respective tax bases.&#160;&#160;Deferred tax assets

        and liabilities are measured using enacted rates in effect

        for the year in which temporary differences are expected to

        be recovered or settled.&#160;&#160;Deferred tax assets are

        reduced by a valuation allowance unless, in the opinion of

        management, it is more likely than not that some portion or

        all of the deferred tax assets will be realized.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Stock-Based

        Compensation</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We

        account for stock-based transactions in which the Company

        receives services from employees, directors or others in

        exchange for equity instruments based on the fair value of

        the award at the grant date.&#160;&#160;Compensation cost

        for awards of common stock is estimated based on the price

        of the underlying common stock on the date of

        issuance.&#160;&#160;Compensation cost for stock options or

        warrants is estimated at the grant date based on each

        instrument&#8217;s fair-value as calculated by the

        Black-Scholes option pricing model.&#160;&#160;We recognize

        stock-based compensation cost as expense ratably on a

        straight-line basis over the requisite service period for

        the award.&#160;&#160;See Note 6 for additional stock-based

        compensation information.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Recent

        Accounting Pronouncements</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">There

        have been no recent accounting pronouncements or changes in

        accounting pronouncements which we expect to have a

        material impact on our financial statements, nor do we

        believe that any recently issued, but not yet effective,

        accounting standards if currently adopted would have a

        material effect on our financial statements.</font>

      </div><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EN3AE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_CurrentAssetsAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 1,167,980<span></span></td>
        <td class="nump">$ 1,079,087<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grant funds receivable</a></td>
        <td class="nump">183,515<span></span></td>
        <td class="nump">474,275<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">66,508<span></span></td>
        <td class="nump">48,830<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">1,418,003<span></span></td>
        <td class="nump">1,602,192<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization</a></td>
        <td class="nump">176,206<span></span></td>
        <td class="nump">248,441<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Licenses, net of accumulated amortization of $208,933 and $184,047 at December 31, 2011 and 2010 respectively</a></td>
        <td class="nump">39,923<span></span></td>
        <td class="nump">64,809<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Deferred offering costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">430,402<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits and other assets</a></td>
        <td class="nump">11,010<span></span></td>
        <td class="nump">11,990<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other assets</a></td>
        <td class="nump">50,933<span></span></td>
        <td class="nump">507,201<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">1,645,142<span></span></td>
        <td class="nump">2,357,834<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">138,339<span></span></td>
        <td class="nump">96,892<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump">125,869<span></span></td>
        <td class="nump">241,736<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Amounts payable to Emory University (a related party)</a></td>
        <td class="nump">677,327<span></span></td>
        <td class="nump">182,980<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">941,535<span></span></td>
        <td class="nump">521,608<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments (Note 4)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#x2019; equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value, 40,000,000 shares authorized; 16,442,611 and 15,654,846 shares issued and outstanding at December 31, 2011 and 2010, respectively</a></td>
        <td class="nump">16,443<span></span></td>
        <td class="nump">15,655<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump">23,319,166<span></span></td>
        <td class="nump">22,105,747<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage', window );">Deficit accumulated during the development stage</a></td>
        <td class="num">(22,632,002)<span></span></td>
        <td class="num">(20,285,176)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#x2019; equity</a></td>
        <td class="nump">703,607<span></span></td>
        <td class="nump">1,836,226<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#x2019; equity</a></td>
        <td class="nump">$ 1,645,142<span></span></td>
        <td class="nump">$ 2,357,834<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_CurrentAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>govx_CurrentAssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>govx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_CurrentLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>govx_CurrentLiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>govx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br> -Section S99<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Publisher FASB<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 5<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net amount of long-term deferred finance costs capitalized at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 21<br><br><br><br> -Paragraph 16<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredFinanceCostsNoncurrentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepositsAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cumulative net losses reported during the development stage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 7<br><br><br><br> -Paragraph 11<br><br><br><br> -Subparagraph a<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 915<br><br><br><br> -SubTopic 210<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472335&amp;loc=d3e37729-110921<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 4<br><br><br><br> -Section 08<br><br><br><br> -Paragraph k<br><br><br><br> -Subparagraph 1<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 57<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph d<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DueToRelatedPartiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate sum of gross carrying value of a major finite-lived intangible asset class, less accumulated amortization and any impairment charges. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrantsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 4<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EXDBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="6">12 Months Ended</th>
        <th class="th" colspan="2">126 Months Ended</th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2009</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_CashFlowsFromOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (2,346,826)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (2,747,328)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (3,284,252)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (22,632,002)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">109,017<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">119,773<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">89,776<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">565,637<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount', window );">Accretion of preferred stock redemption value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">346,673<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump">772,997<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">750,532<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">1,298,665<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">6,359,739<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDeferredCharges', window );">Write-off of deferred offering costs</a></td>
        <td class="nump">430,402<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">430,402<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ChangesInAssetsAndLiabilitiesAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Grant funds receivable</a></td>
        <td class="nump">290,760<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(153,954)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(8,953)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(183,515)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">19,122<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(4,215)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">254,671<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(29,708)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Deposits</a></td>
        <td class="nump">980<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(11,010)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(11,010)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">419,927<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">39,033<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">224,943<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">1,030,325<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
        <td class="nump">2,043,205<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">740,159<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">1,859,102<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">8,508,543<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(303,621)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(2,007,169)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(1,425,150)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(14,123,459)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_CashFlowsFromInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(11,896)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(4,706)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(270,246)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(538,490)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">5,580<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">5,580<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided (used) by investing activities</a></td>
        <td class="num">(11,896)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">874<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(270,246)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(532,910)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_CashFlowsFromFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock</a></td>
        <td class="nump">404,410<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">3,020,000<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">15,526,308<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from sale of preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">728,443<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Deferred offering costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(430,402)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(430,402)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">404,410<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(430,402)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">3,020,000<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">15,824,349<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
        <td class="nump">88,893<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="num">(2,436,697)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">1,324,604<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">1,167,980<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
        <td class="nump">1,079,087<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">3,515,784<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">2,191,180<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
        <td class="nump">1,167,980<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">1,079,087<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">3,515,784<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">1,167,980<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_SupplementalDisclosureOfCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 5,669<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr>
        <td colspan="9"></td>
      </tr>
      <tr>
        <td colspan="9">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">Supplemental disclosure of non-cash investing and financing activities: In connection with the Merger discussed in Note 5, all of the outstanding shares of the Company's mandatory redeemable convertible preferred stock were converted into shares of common stock as of September 28, 2006.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>govx_AdjustmentsToReconcileNetLossToNetCashUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>govx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_CashFlowsFromFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>govx_CashFlowsFromFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>govx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_CashFlowsFromInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>govx_CashFlowsFromInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>govx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_CashFlowsFromOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>govx_CashFlowsFromOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>govx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_ChangesInAssetsAndLiabilitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>govx_ChangesInAssetsAndLiabilitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>govx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_SupplementalDisclosureOfCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>govx_SupplementalDisclosureOfCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>govx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDeferredCharges">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of amortization of deferred charges applied against earnings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDeferredCharges</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDepositOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or  income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInReceivables</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18, 19, 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of accretion of the preferred stock redemption discount during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockAccretionOfRedemptionDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 1 - Nature of Business<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
        <td class="text"><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Nature

        of Business</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">GeoVax

        Labs, Inc. (&#8220;GeoVax&#8221; or the

        &#8220;Company&#8221;), is a biotechnology company

        developing vaccines that prevent and fight Human

        Immunodeficiency Virus (&#8220;HIV&#8221;)

        infections.&#160;&#160;HIV infections result in Acquired

        Immunodeficiency Syndrome

        (&#8220;AIDS&#8221;).&#160;&#160;We have exclusively

        licensed from Emory University (&#8220;Emory&#8221;)

        vaccine technology which was developed in collaboration

        with the National Institutes of Health (&#8220;NIH&#8221;)

        and the Centers for Disease Control and Prevention

        (&#8220;CDC&#8221;).&#160;&#160;GeoVax is incorporated

        under the laws of the State of Delaware and our principal

        offices are located in Smyrna, Georgia (metropolitan

        Atlanta area).</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Our

        current vaccines under development address the clade B

        subtype of the HIV virus that is most prevalent in the

        United States and the developed world.&#160;&#160;Our

        vaccines are being evaluated to determine their potential

        to (a) prevent HIV infection and (b) to serve as a therapy

        for individuals who are already infected with

        HIV.&#160;&#160;These vaccines are currently being

        evaluated in humans -- both in those infected with HIV and

        those who are not.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As

        discussed in Note 2, the Company is a development-stage

        enterprise and we are devoting substantially all of our

        present efforts to research and development.&#160;&#160;We

        have funded our activities to date almost exclusively from

        equity financings and government grants, and we will

        continue to require substantial funds to continue these

        activities.&#160;&#160;We anticipate that our existing cash

        resources, combined with the proceeds from the NIH grant

        discussed in Note 3 and the financing events discussed in

        Note 11, should be sufficient to fund our planned

        activities into the first quarter of 2013.&#160;&#160;In

        order to meet our operating cash flow requirements, we may

        plan additional offerings of our equity securities, debt or

        convertible debt instruments. We are also seeking

        additional funding for our research programs through

        government grant funding mechanisms.</font>

      </div><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name Statement of Position (SOP)<br><br> -Publisher AICPA<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NatureOfOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EWGAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Licenses, accumulated amortization (in Dollars)</a></td>
        <td class="nump">$ 208,933<span></span></td>
        <td class="nump">$ 184,047<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">40,000,000<span></span></td>
        <td class="nump">40,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">16,442,611<span></span></td>
        <td class="nump">15,654,846<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">16,442,611<span></span></td>
        <td class="nump">15,632,564<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The accumulated amount of amortization of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 142<br><br> -Paragraph 45<br><br> -Subparagraph a(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 11 - Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
        <td class="text"><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subsequent

        Events</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Private

        Placement of Common Stock and Warrants</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During

        January 2012, we sold an aggregate of 407,999 shares of our

        common stock to twelve individual accredited investors

        (including 45,000 shares sold to members of our board of

        directors and management) for an aggregate purchase price

        of $273,360.&#160;&#160;We also issued to the investors

        warrants to purchase an aggregate of 612,001 shares of

        common stock at a price of $1.00 per share, which expire in

        January 2017.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Issuance

        of Convertible Preferred Stock and Warrants</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On

        March 21, 2012, we sold shares of our Series A convertible

        preferred stock to certain institutional investors for an

        aggregate purchase price of $2.2 million.&#160;&#160;The

        preferred stock is convertible at any time into shares of

        our common stock at $0.75 per share (2,933,333 shares in

        the aggregate), subject to possible adjustment as provided

        in the certificate of designation.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant

        to the terms of the securities purchase agreement, the

        investors also received five-year Series A warrants to

        purchase an aggregate of 2,933,333 shares of our common

        stock at $1.00 per share.&#160;&#160;The Series A warrants

        are immediately exercisable.&#160; We also granted to the

        investors a one-year additional purchase right, evidenced

        in the form of Series B warrants, to purchase up to

        2,933,333 of our common stock for one year with an exercise

        price of $0.75 per share, and five-year Series C warrants

        to purchase up to 2,933,333 shares of our common stock at

        $1.00 per share.&#160;&#160;The Series B warrants are

        immediately exercisable.&#160;&#160;The Series C warrants

        only vest and become exercisable at the time, and to the

        extent, that the Series B warrants are exercised.</font>

      </div><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EVRAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document And Entity Information (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Mar. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">GeoVax Labs, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">S-1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16,850,610<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 8,741,870<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000832489<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,
         2011<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2011<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCurrentReportingStatus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityPublicFloat</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityVoluntaryFilers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityWellKnownSeasonedIssuer</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>govx_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>govx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</a></td>
        <td class="text"><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SCHEDULE

        II &#8211; VALUATION AND QUALIFYING ACCOUNTS</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For

        the Years Ended December 31, 2011, 2010 and 2009</font>

      </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

          <tr>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Additions</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">

                &#160;

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">

                &#160;

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Description</font>

              </div>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance

                at</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Beginning</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Of

                Period</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Charged

                to</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Costs

                and</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expenses</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Charged

                to</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Other</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Accounts</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1)</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deductions</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Balance

                at</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">End</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Of

                Period</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 9pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reserve

                Deducted in the Balance Sheet</font> <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">From

                the Asset to Which it Applies:</font>

              </div>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Allowance

                for Deferred Tax Assets</font>

              </div>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" width="40%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-307" style="MARGIN-LEFT: 9pt"></font>Year

                ended December 31, 2011</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,576,253</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">889,322</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(873,584</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,591,991</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="40%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-308" style="MARGIN-LEFT: 9pt"></font>Year

                ended December 31, 2010</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,091,338</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,160,405</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(675,490</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,576,253</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" width="40%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-309" style="MARGIN-LEFT: 9pt"></font>Year

                ended December 31, 2009</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,674,882</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,416,456</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,091,338</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

        </table><br/><table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent-117" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

          <tr valign="top" style="LINE-HEIGHT: 1.25;">

            <td style="WIDTH: 18pt">

              <div>

                <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font>

              </div>

            </td>

            <td style="WIDTH: 18pt">

              <div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">

                <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(1)</font>

              </div>

            </td>

            <td>

              <div align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Deductions

                represent the effect of expiring NOL carryforwards

                from prior years.</font>

              </div>

            </td>

          </tr>

        </table><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for any allowance and reserve accounts (their beginning and ending balances, as well as a reconciliation by type of activity during the period). Alternatively, disclosure of the required information may be within the footnotes to the financial statements or a supplemental schedule to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 09<br><br> -Article 12<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e24092-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E1EAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1">126 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2009</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Grant revenue</a></td>
        <td class="nump">$ 4,899,885<span></span></td>
        <td class="nump">$ 5,185,257<span></span></td>
        <td class="nump">$ 3,668,195<span></span></td>
        <td class="nump">$ 20,311,692<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">4,276,375<span></span></td>
        <td class="nump">4,793,956<span></span></td>
        <td class="nump">4,068,682<span></span></td>
        <td class="nump">25,630,676<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">2,972,555<span></span></td>
        <td class="nump">3,162,134<span></span></td>
        <td class="nump">2,914,845<span></span></td>
        <td class="nump">17,647,659<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );"></a></td>
        <td class="nump">7,248,930<span></span></td>
        <td class="nump">7,956,090<span></span></td>
        <td class="nump">6,983,527<span></span></td>
        <td class="nump">43,278,335<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(2,349,045)<span></span></td>
        <td class="num">(2,770,833)<span></span></td>
        <td class="num">(3,315,332)<span></span></td>
        <td class="num">(22,966,643)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_OtherIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump">2,219<span></span></td>
        <td class="nump">23,505<span></span></td>
        <td class="nump">31,080<span></span></td>
        <td class="nump">340,310<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(5,669)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );"></a></td>
        <td class="nump">2,219<span></span></td>
        <td class="nump">23,505<span></span></td>
        <td class="nump">31,080<span></span></td>
        <td class="nump">334,641<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (2,346,826)<span></span></td>
        <td class="num">$ (2,747,328)<span></span></td>
        <td class="num">$ (3,284,252)<span></span></td>
        <td class="num">$ (22,632,002)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_BasicAndDilutedAbstract', window );"><strong>Basic and diluted:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per common share (in Dollars per share)</a></td>
        <td class="num">$ (0.15)<span></span></td>
        <td class="num">$ (0.18)<span></span></td>
        <td class="num">$ (0.22)<span></span></td>
        <td class="num">$ (2.11)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding (in Shares)</a></td>
        <td class="nump">15,735,541<span></span></td>
        <td class="nump">15,651,308<span></span></td>
        <td class="nump">15,191,278<span></span></td>
        <td class="nump">10,704,803<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_BasicAndDilutedAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>govx_BasicAndDilutedAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>govx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_OtherIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>govx_OtherIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>govx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cost of borrowed funds accounted for as interest that was charged against earnings during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-04.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 34<br><br><br><br> -Paragraph 21<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher OTS<br><br><br><br> -Name Federal Regulation (FR)<br><br><br><br> -Number Title 12<br><br><br><br> -Chapter V<br><br><br><br> -Section 563c.102<br><br><br><br> -Paragraph 9<br><br><br><br> -Subsection II<br><br><br><br> -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy.  It will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 115<br><br><br><br> -Paragraph 14<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 38<br><br><br><br> -Subparagraph a<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A7<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 130<br><br><br><br> -Paragraph 10, 15<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph 38<br><br><br><br> -Subparagraph d<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Emerging Issues Task Force (EITF)<br><br><br><br> -Number 87-21<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br><br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 28, 29, 30<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 7<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 141<br><br><br><br> -Paragraph 51<br><br><br><br> -Subparagraph g<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 2<br><br><br><br> -Paragraph 12, 13<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 86<br><br><br><br> -Paragraph 11, 12<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueFromGrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1448-109256<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 128<br><br><br><br> -Paragraph 171<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 128<br><br><br><br> -Paragraph 40<br><br><br><br> -Subparagraph a<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 128<br><br><br><br> -Paragraph 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Emerging Issues Task Force (EITF)<br><br><br><br> -Number 07-4<br><br><br><br> -Paragraph 4<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 6 - Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
        <td class="text"><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stockholders&#8217;

        Equity</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Common

        Stock Transactions</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In

        February 2010, we issued 12,000 shares of our common stock

        in settlement of an obligation accrued at December 31, 2009

        in the amount of $90,000.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">During

        December 2011, we sold an aggregate of 658,520 shares of

        our common stock to fifteen individual accredited investors

        (including members of our board of directors and management

        --see Note 9) for an aggregate purchase price of $441,210,

        $36,800 of which was received in January 2012 and is

        therefore reflected as a receivable (Other Current Asset)

        in the accompanying Consolidated Balance Sheet as of

        December 31, 2011.&#160;&#160;We also issued to the

        investors warrants to purchase an aggregate of 987,783

        shares of common stock at a price of $1.00 per share, which

        expire in December 2016.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">From

        time to time, we issue shares of our common stock to

        consultants or others in exchange for

        services.&#160;&#160;During 2011, 2010 and 2009 we issued

        129,245, 10,500, and 4,500, respectively, for such

        services; and we recorded general and administrative

        expense of $150,000, $53,813, and $31,500 during each

        respective period related to these issuances.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Stock

        Options</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In

        2006, we adopted the GeoVax Labs, Inc. 2006 Equity

        Incentive Plan (the &#8220;Stock Option Plan&#8221;) for

        the granting of qualified incentive stock options

        (&#8220;ISO&#8217;s&#8221;), nonqualified stock options,

        restricted stock awards or restricted stock bonuses to

        employees, officers, directors, consultants and advisors of

        the Company.&#160;&#160;The exercise price for any option

        granted may not be less than fair value (110% of fair value

        for ISO&#8217;s granted to certain

        employees).&#160;&#160;Options granted under the Stock

        Option Plan have a maximum ten-year term and generally vest

        over three years.&#160;&#160;The Company has reserved

        1,200,000 shares of its common stock for issuance under the

        Stock Option Plan.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A

        summary of activity under the Stock Option Plan as of

        December 31, 2011, and changes during the year then ended

        is presented below:</font>

      </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

          <tr>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">

                &#160;

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">

                &#160;

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of

                Shares</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted-</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Price</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted-</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Remaining</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractual</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Term

                (yrs)</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">

                &#160;

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aggregate</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intrinsic</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Value</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding

                at January 1, 2011</font>

              </div>

            </td>

            <td align="left" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,137,356</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.33</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font>

              </div>

            </td>

            <td align="left" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">230,000</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-291" style="MARGIN-LEFT: 36pt"></font>0.91</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font>

              </div>

            </td>

            <td align="left" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-292" style="MARGIN-LEFT: 36pt"></font>-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Forfeited

                or expired</font>

              </div>

            </td>

            <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(439,114</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-293" style="MARGIN-LEFT: 36pt"></font>2.81</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding

                at December 31, 2011</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">928,242</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">5.43</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-294" style="MARGIN-LEFT: 36pt"></font>6.5</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-0-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercisable

                at December 31, 2011</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">578,231</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.59</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-295" style="MARGIN-LEFT: 36pt"></font>4.8</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-0-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

        </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Additional

        information concerning our stock options for the years

        ended December 31, 2011, 2010 and 2009 is as

        follows:</font>

      </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

          <tr>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="64%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted

                average fair value of options granted during the

                period</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.79</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.95</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.15</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" width="64%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intrinsic

                value of options exercised during the period</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="64%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total

                fair value of options vested during the

                period</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">540,339</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">499,557</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,143,326</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

        </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We

        use the Black-Scholes model for determining the grant date

        fair value of our stock option grants.&#160;&#160;This

        model utilizes certain information, such as the interest

        rate on a risk-free security with a term generally

        equivalent to the expected life of the option being valued

        and requires certain other assumptions, such as the

        expected amount of time an option will be outstanding until

        it is exercised or expired, to calculate the fair value of

        stock options granted.&#160;&#160;The significant

        assumptions we used in our fair value calculations were as

        follows:</font>

      </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

          <tr>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="64%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted

                average risk-free interest rates</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.4</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.6</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2.8</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" width="64%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected

                dividend yield</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.0</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.0</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.0</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected

                life of option</font>

              </div>

            </td>

            <td align="left" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="3" valign="bottom" style="TEXT-ALIGN: right">

              <div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7

                yrs</font>

              </div>

            </td>

            <td align="left" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="3" valign="bottom" style="TEXT-ALIGN: right">

              <div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6.7

                yrs</font>

              </div>

            </td>

            <td align="left" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="3" valign="bottom" style="TEXT-ALIGN: right">

              <div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7

                yrs</font>

              </div>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" width="64%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected

                volatility</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">111.2</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">112.9</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">112.3</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>

            </td>

          </tr>

        </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Stock-based

        compensation expense related to the Stock Option Plan was

        $463,752, $575,662, and $1,221,764 during the years ended

        December 31, 2011, 2010 and 2009,

        respectively.&#160;&#160;Stock option expense is allocated

        to research and development expense or to general and

        administrative expense based on the related employee

        classifications and corresponds to the allocation of

        employee salaries.&#160;&#160;For the three years ended

        December 31, 2011, stock option expense was allocated as

        follows:</font>

      </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

          <tr>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="64%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">General

                and administrative expense</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">284,352</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">369,161</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">917,110</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research

                and development expense</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">179,400</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">206,501</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">304,654</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total

                stock option expense</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">463,752</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">575,662</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,221,764</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

        </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As

        of December 31, 2011, there was $515,697 of unrecognized

        compensation expense related to stock-based compensation

        arrangements.&#160;&#160;The unrecognized compensation

        expense is expected to be recognized over a weighted

        average remaining period of 2.0 years.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Compensatory

        Warrants</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">From

        time to time, we issue stock purchase warrants to

        consultants or others in exchange for services. A summary

        of our compensatory warrant activity as of December 31,

        2011, and changes during the year then ended is presented

        below:</font>

      </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

          <tr>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">

                &#160;

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">

                &#160;

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Number</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of

                Shares</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted-</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercise</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Price</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted-</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Average</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Remaining</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Contractual</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Term

                (yrs)</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">

                &#160;

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Aggregate</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intrinsic</font>

              </div>

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Value</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding

                at January 1, 2011</font>

              </div>

            </td>

            <td align="left" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,400</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.00</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Granted</font>

              </div>

            </td>

            <td align="left" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7,400</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-296" style="MARGIN-LEFT: 36pt"></font>1.40</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercised</font>

              </div>

            </td>

            <td align="left" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-297" style="MARGIN-LEFT: 36pt"></font>-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Forfeited

                or expired</font>

              </div>

            </td>

            <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(2,400</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-298" style="MARGIN-LEFT: 36pt"></font>7.00</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Outstanding

                at December 31, 2011</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">64,400</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.00</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-299" style="MARGIN-LEFT: 36pt"></font>0.6</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-0-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Exercisable

                at December 31, 2011</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">58,850</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">7.00</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-300" style="MARGIN-LEFT: 36pt"></font>0.7</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-0-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

        </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Additional

        information concerning our compensatory warrants for the

        years ended December 31, 2011, 2010 and 2009 is as

        follows:</font>

      </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

          <tr>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="64%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted

                average fair value of warrants granted during the

                period</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.96</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">4.75</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" width="64%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Intrinsic

                value of warrants exercised during the

                period</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="64%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total

                fair value of warrants vested during the

                period</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,780</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">19,238</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">6,413</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

        </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We

        use the Black-Scholes model for determining the grant date

        fair value of our compensatory warrants.&#160;&#160;The

        significant assumptions we used in our fair value

        calculations were as follows:</font>

      </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

          <tr>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="64%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Weighted

                average risk-free interest rates</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.98</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1.54</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" width="64%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected

                dividend yield</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.0</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">0.0</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected

                life of warrant</font>

              </div>

            </td>

            <td align="left" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="3" valign="bottom" style="TEXT-ALIGN: right">

              <div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.0

                yrs</font>

              </div>

            </td>

            <td align="left" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="3" valign="bottom" style="TEXT-ALIGN: right">

              <div style="TEXT-ALIGN: right; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">3.0

                yrs</font>

              </div>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" width="64%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Expected

                volatility</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">115.46</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">112.1</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">%</font>

            </td>

          </tr>

        </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Expense

        associated with compensatory warrants was $7,119, $121,057,

        and $45,401 during the years ended December 31, 2011, 2010

        and 2009, respectively.&#160;&#160;All such expense was

        allocated to general and administrative

        expense.&#160;&#160;As of December 31, 2011, there was no

        unrecognized compensation expense related to compensatory

        warrant arrangements.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Investment

        Warrants</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In

        addition to outstanding stock options and compensatory

        warrants, as of December 31, 2011 we have a total of

        1,806,159 outstanding stock purchase warrants issued to

        investors in connection with financing

        transactions.&#160;&#160;Warrants as to 987,783 have an

        exercise price of $1.00 per share and expire in December

        2016; warrants as to 818,376 have an exercise price of

        $16.50 and expire in December 2014.&#160;&#160;During the

        fourth quarter of 2011, we recorded general and

        administrative expense of $152,126 associated with the

        extension of warrants which were due to expire in 2011 to

        2013.</font>

      </div><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph d<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 1<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 5 - 2006 Merger and Recapitalization<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</a></td>
        <td class="text"><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2006

        Merger and Recapitalization</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The

        Company was originally incorporated in June 1988 under the

        laws of Illinois as Dauphin Technology, Inc.

        (&#8220;Dauphin&#8221;).&#160;&#160;Dauphin was

        unsuccessful and its operations were terminated in December

        2003.&#160;&#160;In September 2006, Dauphin completed a

        merger (the &#8220;Merger&#8221;) with GeoVax, Inc. which

        was incorporated under the laws of Georgia in June

        2001.&#160;&#160;As a result of the Merger, the

        shareholders of GeoVax, Inc. exchanged their shares of

        common stock for Dauphin common stock and GeoVax, Inc.

        became a wholly-owned subsidiary of

        Dauphin.&#160;&#160;Dauphin then changed its name to GeoVax

        Labs, Inc. and replaced its officers and directors with

        those of GeoVax, Inc.&#160;&#160;Subsequent to the Merger,

        the Company has not conducted any business other than

        GeoVax, Inc.&#8217;s business of developing human

        vaccines.&#160;&#160;The Merger was accounted for under the

        purchase method of accounting as a reverse acquisition in

        accordance with GAAP. Under this method of accounting,

        Dauphin was treated as the acquired company and,

        accordingly, all financial information prior to the date of

        Merger presented in the accompanying consolidated financial

        statements, or in the notes herein, as well as any

        references to prior operations, are those of GeoVax,

        Inc.&#160;&#160;In June 2008, the Company was

        reincorporated under the laws of the State of

        Delaware.</font>

      </div><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 9 - Related Party Transactions<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
        <td class="text"><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Related

        Party Transactions</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We

        are obligated to reimburse Emory University (a significant

        stockholder of the Company) for ongoing costs in connection

        with the filing, prosecution and maintenance of patent

        applications subject to a license agreement for technology

        associated with the vaccines we are

        developing.&#160;&#160;The expense associated with these

        ongoing patent cost reimbursements to Emory amounted to

        $249,907, $193,674, and $85,673 for the years ended

        December 31, 2011, 2010, and 2009, respectively.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We

        have entered into two subcontracts with Emory for the

        purpose of conducting research and development activities

        associated with our grant from the NIH (see Note

        3).&#160;&#160;During 2011, 2010, and 2009, we recorded

        $1,172,758, $1,391,203, and $816,651, respectively, of

        expense associated with these subcontracts.&#160;&#160;All

        amounts paid to Emory under these subcontracts are

        reimbursable to us pursuant to the NIH grant.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Through

        November 2009, we leased office and laboratory space on a

        month-to-month basis from Emtech Biotechnology Development,

        Inc., a related party associated with

        Emory.&#160;&#160;Rent expense associated with this lease

        totaled $43,112 for the year ended December 31,

        2009.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In

        March 2008, we entered into a consulting agreement with

        Donald Hildebrand, a former member of our Board of

        Directors and our former President &amp; Chief Executive

        Officer, pursuant to which Mr. Hildebrand provides business

        and technical advisory services to the

        Company.&#160;&#160;The term of the consulting agreement,

        as amended, began on April 1, 2008 and ends on December 31,

        2012.&#160;&#160;During 2011, 2010, and 2009, we recorded

        $24,000, $57,600, and $57,600, respectively, of expense

        associated with the consulting agreement.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In

        December 2011, members of our management and Board of

        Directors participated in the private placement offering of

        our common stock and warrants described in Note 6, whereby

        they purchased an aggregate of 335,954 shares of our common

        stock for a total purchase price of $225,089 and received

        five-year warrants to purchase an additional 503,932 shares

        of our common stock exercisable at $1.00 per share.</font>

      </div><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 3A<br><br> -Section 04<br><br> -Paragraph b<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 57<br><br> -Paragraph 1-4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph k<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 7 - Retirement Plan<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension and Other Postretirement Benefits Disclosure [Text Block]</a></td>
        <td class="text"><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Retirement

        Plan</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We

        participate in a multi-employer defined contribution

        retirement plan (the &#8220;401k Plan&#8221;) administered

        by a third party service provider; and the Company

        contributes to the 401k Plan on behalf of its employees

        based upon a matching formula.&#160;&#160;During the years

        ended December 31, 2011, 2010 and 2009 our contributions to

        the 401k Plan were $56,928, $52,632, and $25,057,

        respectively.</font>

      </div><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for pension and other postretirement benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 87<br><br> -Paragraph 264<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 158<br><br> -Paragraph 7, 21, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Staff Position (FSP)<br><br> -Number FAS106-2<br><br> -Paragraph 20, 21, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Implementation Guide (Q and A)<br><br> -Number FAS88<br><br> -Paragraph 63<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph h<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 30<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 03-2<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 8<br><br> -Subparagraph m<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 132R<br><br> -Paragraph 5<br><br> -Subparagraph q<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 106<br><br> -Paragraph 518<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 8 - Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
        <td class="text"><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Income

        Taxes</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">At

        December 31, 2011, we have a consolidated federal net

        operating loss (&#8220;NOL&#8221;) carryforward of

        approximately $71.3 million, available to offset against

        future taxable income which expires in varying amounts in

        2012 through 2031.&#160;&#160;Additionally, we have

        approximately $764,000 in research and development

        (&#8220;R&amp;D&#8221;) tax credits that expire in 2022

        through 2031 unless utilized earlier.&#160;&#160;No income

        taxes have been paid to date.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">As

        a result of the Merger discussed in Note 5, our NOL

        carryforward increased substantially due to the addition of

        historical NOL carryforwards for Dauphin Technology,

        Inc.&#160;&#160;However, Section 382 of the Internal

        Revenue Code contains provisions that may limit our

        utilization of NOL and R&amp;D tax credit carryforwards in

        any given year as a result of significant changes in

        ownership interests that have occurred in past periods or

        may occur in future periods.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Deferred

        income taxes reflect the net effect of temporary

        differences between the carrying amounts of assets and

        liabilities for financial reporting purposes and the

        amounts used for income tax

        purposes.&#160;&#160;Significant components of our deferred

        tax assets and liabilities included the following at

        December 31, 2011 and 2010:</font>

      </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

          <tr>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred

                tax assets:</font>

              </div>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td valign="bottom" width="76%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; PADDING-LEFT: 4%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">

              <div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net

                operating loss carryforward</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">24,875,119</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">25,116,958</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 4%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research

                and development tax credit carryforward</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">763,690</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">731,290</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 4%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Stock-based

                compensation expense</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,991,769</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,779,950</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="76%" style="PADDING-LEFT: 4%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total

                deferred tax assets</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,630,578</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,628,198</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td valign="bottom" width="76%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="76%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Deferred

                tax liabilities</font>

              </div>

            </td>

            <td valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 4%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Depreciation</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(38,587</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(51,945</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px; PADDING-LEFT: 4%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Total

                deferred tax liabilities</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(38,587</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(51,945</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

          </tr>

          <tr>

            <td valign="bottom" width="76%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="76%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net

                deferred tax assets</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,591,991</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">27,576,253</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Valuation

                allowance</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(27,591,991</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(27,576,253</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

        </table><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We

        have established a full valuation allowance equal to the

        amount of our net deferred tax assets due to uncertainties

        with respect to our ability to generate sufficient taxable

        income to realize these assets in the future. <font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>A

        reconciliation of the income tax benefit on losses at the

        U.S. federal statutory rate to the reported income tax

        expense is as follows:</font>

      </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

          <tr>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2009</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="64%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">U.S.

                federal statutory rate applied to pretax

                loss</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(797,921</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(934,092</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,116,646</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" width="64%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Permanent

                differences</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-301" style="MARGIN-LEFT: 32.15pt"></font>3,536</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(77,200</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-302" style="MARGIN-LEFT: 21.8pt"></font>169,469</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="64%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Research

                and development credits</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-303" style="MARGIN-LEFT: 25.45pt"></font>32,400</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">59,959</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-304" style="MARGIN-LEFT: 21.8pt"></font>169,667</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 2px">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Change

                in valuation allowance</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-305" style="MARGIN-LEFT: 18.8pt"></font>761,985</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">951,333</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font id="TAB1-306" style="MARGIN-LEFT: 21.8pt"></font>777,510</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="64%" style="PADDING-BOTTOM: 4px">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Reported

                income tax expense</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">-</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

        </table><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 136, 172<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 44, 45, 46, 47, 48, 49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 10 - Selected Quarterly Financial Data (unaudited)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Information [Text Block]</a></td>
        <td class="text"><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Selected

        Quarterly Financial Data (unaudited)</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">A

        summary of selected quarterly financial data for 2011 and

        2010 is as follows:</font>

      </div><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

          <tr>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="14" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2011

                Quarter Ended</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March

                31</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">June

                30</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">September

                30</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December

                31</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="52%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenue

                from grants</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">893,002</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,753,033</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,297,006</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">956,844</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" width="52%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net

                loss</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(606,282</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(211,344</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(375,852</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(1,153,348</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="52%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net

                loss per share</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.04</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.01</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.02</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.08</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

          </tr>

        </table><br/><table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">

          <tr>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="14" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">2010

                Quarter Ended</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">March

                31</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">June

                30</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">September

                30</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" style="PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">December

                31</font>

              </div>

            </td>

            <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="52%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Revenue

                from grants</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,338,560</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,737,169</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">1,163,288</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">$</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">946,240</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

          </tr>

          <tr>

            <td align="left" valign="bottom" width="52%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net

                loss</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(690,789</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(933,089</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(644,666</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(478,784</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

          </tr>

          <tr style="background-color: #C0FFFF;">

            <td align="left" valign="bottom" width="52%">

              <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

                <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Net

                loss per share</font>

              </div>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.04</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.06</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.04</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

            <td align="left" valign="bottom" width="1%">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font>

            </td>

            <td valign="bottom" width="9%" style="TEXT-ALIGN: right">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(0.03</font>

            </td>

            <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">

              <font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">)</font>

            </td>

          </tr>

        </table><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section G<br><br> -Subsection 1<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e725-108305<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 28<br><br> -Paragraph 23, 24<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6372559&amp;loc=d3e765-108305<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 28<br><br> -Paragraph 30<br><br> -Subparagraph a-j<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-K (SK)<br><br> -Number 229<br><br> -Section 302<br><br> -Paragraph a<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 270<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)-(j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952194&amp;loc=d3e1280-108306<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_QuarterlyFinancialInformationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EPHHK">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficiency) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Additional Paid-in Capital [Member]</div>
        </th>
        <th class="th">
          <div>Stock Subscription Receivable [Member]</div>
        </th>
        <th class="th">
          <div>Retained Earnings [Member]</div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 26, 2001</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception', window );">Capital contribution at inception (June 27, 2001)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(170,592)<span></span></td>
        <td class="num">(170,592)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2001</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(170,592)<span></span></td>
        <td class="num">(170,582)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock for cash</a></td>
        <td class="nump">2,790<span></span></td>
        <td class="num">(2,320)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">470<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock for cash (in Shares)</a></td>
        <td class="nump">2,789,954<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Issuance of common stock for technology license</a></td>
        <td class="nump">705<span></span></td>
        <td class="nump">148,151<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">148,856<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Issuance of common stock for technology license (in Shares)</a></td>
        <td class="nump">704,534<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(618,137)<span></span></td>
        <td class="num">(618,137)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares)</a></td>
        <td class="nump">3,494,488<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2002</a></td>
        <td class="nump">3,495<span></span></td>
        <td class="nump">145,841<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(788,729)<span></span></td>
        <td class="num">(639,393)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock for cash</a></td>
        <td class="nump">1,229<span></span></td>
        <td class="nump">2,458,380<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,459,609<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock for cash (in Shares)</a></td>
        <td class="nump">1,229,278<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(947,804)<span></span></td>
        <td class="num">(947,804)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares)</a></td>
        <td class="nump">4,723,766<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2003</a></td>
        <td class="nump">4,724<span></span></td>
        <td class="nump">2,604,221<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,736,533)<span></span></td>
        <td class="nump">872,412<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable', window );">Sale of common stock for cash and stock subscription receivable</a></td>
        <td class="nump">1,483<span></span></td>
        <td class="nump">2,988,436<span></span></td>
        <td class="num">(2,750,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">239,919<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable', window );">Sale of common stock for cash and stock subscription receivable (in Shares)</a></td>
        <td class="nump">1,482,605<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Cash payments received on stock subscription receivable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">750,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Issuance of common stock for technology license</a></td>
        <td class="nump">49<span></span></td>
        <td class="nump">99,951<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Issuance of common stock for technology license (in Shares)</a></td>
        <td class="nump">49,420<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,351,828)<span></span></td>
        <td class="num">(2,351,828)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares)</a></td>
        <td class="nump">6,255,791<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2004</a></td>
        <td class="nump">6,256<span></span></td>
        <td class="nump">5,692,608<span></span></td>
        <td class="num">(2,000,000)<span></span></td>
        <td class="num">(4,088,361)<span></span></td>
        <td class="num">(389,497)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Cash payments received on stock subscription receivable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,500,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,611,086)<span></span></td>
        <td class="num">(1,611,086)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares)</a></td>
        <td class="nump">6,255,791<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2005</a></td>
        <td class="nump">6,256<span></span></td>
        <td class="nump">5,692,608<span></span></td>
        <td class="num">(500,000)<span></span></td>
        <td class="num">(5,699,447)<span></span></td>
        <td class="num">(500,583)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Cash payments received on stock subscription receivable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
        <td class="nump">3,551<span></span></td>
        <td class="nump">1,071,565<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,075,116<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in Shares)</a></td>
        <td class="nump">3,550,851<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Common stock issued in connection with merger</a></td>
        <td class="nump">4,360<span></span></td>
        <td class="nump">1,708,489<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,712,849<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Common stock issued in connection with merger (in Shares)</a></td>
        <td class="nump">4,359,891<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueCashlessWarrantExercise', window );">Issuance of common stock for cashless warrant exercise</a></td>
        <td class="nump">57<span></span></td>
        <td class="num">(57)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesCashlessWarrantExercise', window );">Issuance of common stock for cashless warrant exercise</a></td>
        <td class="nump">56,825<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(584,166)<span></span></td>
        <td class="num">(584,166)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares)</a></td>
        <td class="nump">14,223,358<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2006</a></td>
        <td class="nump">14,224<span></span></td>
        <td class="nump">8,472,605<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(6,283,613)<span></span></td>
        <td class="nump">2,203,216<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock for cash</a></td>
        <td class="nump">407<span></span></td>
        <td class="nump">3,162,543<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,162,950<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock for cash (in Shares)</a></td>
        <td class="nump">406,729<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon stock option exercise</a></td>
        <td class="nump">2<span></span></td>
        <td class="nump">4,998<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon stock option exercise (in Shares)</a></td>
        <td class="nump">2,471<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,518,496<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,518,496<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(4,241,796)<span></span></td>
        <td class="num">(4,241,796)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares)</a></td>
        <td class="nump">14,632,558<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2007</a></td>
        <td class="nump">14,633<span></span></td>
        <td class="nump">13,158,642<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(10,525,409)<span></span></td>
        <td class="nump">2,647,866<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock for cash</a></td>
        <td class="nump">176<span></span></td>
        <td class="nump">1,364,824<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,365,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock for cash (in Shares)</a></td>
        <td class="nump">176,129<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Transactions related to common stock purchase agreement with Fusion Capital</a></td>
        <td class="nump">130<span></span></td>
        <td class="nump">405,961<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">406,091<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Transactions related to common stock purchase agreement with Fusion Capital (in Shares)</a></td>
        <td class="nump">130,290<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation - Stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,798,169<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,798,169<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Stock-based compensation - Consultant warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">146,880<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">146,880<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation - Issuance of common stock for services</a></td>
        <td class="nump">10<span></span></td>
        <td class="nump">73,990<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">74,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation - Issuance of common stock for services (in Shares)</a></td>
        <td class="nump">10,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3,728,187)<span></span></td>
        <td class="num">(3,728,187)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares)</a></td>
        <td class="nump">14,948,977<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2008</a></td>
        <td class="nump">14,949<span></span></td>
        <td class="nump">16,948,466<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(14,253,596)<span></span></td>
        <td class="nump">2,709,819<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Transactions related to common stock purchase agreement with Fusion Capital</a></td>
        <td class="nump">216<span></span></td>
        <td class="nump">1,519,784<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,520,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Transactions related to common stock purchase agreement with Fusion Capital (in Shares)</a></td>
        <td class="nump">216,261<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant', window );">Sale of common stock for cash upon exercise of stock purchase warrant</a></td>
        <td class="nump">463<span></span></td>
        <td class="nump">1,499,537<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,500,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant', window );">Sale of common stock for cash upon exercise of stock purchase warrant (in Shares)</a></td>
        <td class="nump">462,826<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation - Stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,221,764<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,221,764<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Stock-based compensation - Consultant warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">45,401<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">45,401<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation - Issuance of common stock for services</a></td>
        <td class="nump">5<span></span></td>
        <td class="nump">31,495<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,500<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation - Issuance of common stock for services (in Shares)</a></td>
        <td class="nump">4,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Cash payments received on stock subscription receivable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,020,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(3,284,252)<span></span></td>
        <td class="num">(3,284,252)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares)</a></td>
        <td class="nump">15,632,564<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2009</a></td>
        <td class="nump">15,633<span></span></td>
        <td class="nump">21,266,447<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(17,537,848)<span></span></td>
        <td class="nump">3,744,232<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueInLieuOfCashPayment', window );">Issuance of common stock in lieu of cash payment</a></td>
        <td class="nump">12<span></span></td>
        <td class="nump">89,988<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">90,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesInLieuOfCashPayment', window );">Issuance of common stock in lieu of cash payment (in Shares)</a></td>
        <td class="nump">12,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation - Stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">575,662<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">575,662<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Stock-based compensation - Consultant warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">121,057<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">121,057<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation - Issuance of common stock for services</a></td>
        <td class="nump">10<span></span></td>
        <td class="nump">53,803<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">53,813<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation - Issuance of common stock for services (in Shares)</a></td>
        <td class="nump">10,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit', window );">Fractional share payout upon reverse split</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,210)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(1,210)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Fractional share payout upon reverse split (in Shares)</a></td>
        <td class="num">(218)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,747,328)<span></span></td>
        <td class="num">(2,747,328)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares)</a></td>
        <td class="nump">15,654,846<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2010</a></td>
        <td class="nump">15,655<span></span></td>
        <td class="nump">22,105,747<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(20,285,176)<span></span></td>
        <td class="nump">1,836,226<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock for cash</a></td>
        <td class="nump">659<span></span></td>
        <td class="nump">440,551<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">441,210<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock for cash (in Shares)</a></td>
        <td class="nump">658,520<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation - Stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">463,752<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">463,752<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Stock-based compensation - Consultant warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">159,245<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">159,245<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation - Issuance of common stock for services</a></td>
        <td class="nump">129<span></span></td>
        <td class="nump">149,871<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">150,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation - Issuance of common stock for services (in Shares)</a></td>
        <td class="nump">129,245<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Cash payments received on stock subscription receivable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">404,410<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(2,346,826)<span></span></td>
        <td class="num">(2,346,826)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in Shares)</a></td>
        <td class="nump">16,442,611<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2011</a></td>
        <td class="nump">$ 16,443<span></span></td>
        <td class="nump">$ 23,319,166<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (22,632,002)<span></span></td>
        <td class="nump">$ 703,607<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents increases in additional paid in capital attributable to capital contribution at inception.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>govx_AdjustmentsToAdditionalPaidInCapitalCapitalContributionAtInception</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>govx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period for cash and stock subscription receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>govx_StockIssuedDuringPeriodSharesCashAndStockSubscriptionReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>govx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesCashlessWarrantExercise">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period for cashless warrant exercise.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>govx_StockIssuedDuringPeriodSharesCashlessWarrantExercise</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>govx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period for cash upon exercise of stock purchase warrant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>govx_StockIssuedDuringPeriodSharesForCashUponExerciseOfStockPurchaseWarrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>govx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesInLieuOfCashPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period in lieu of cash payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>govx_StockIssuedDuringPeriodSharesInLieuOfCashPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>govx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares of stock issued during the period for cash and stock subscription receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>govx_StockIssuedDuringPeriodValueCashAndStockSubscriptionReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>govx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodValueCashlessWarrantExercise">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares of stock issued during the period for cashless warrant exercise.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>govx_StockIssuedDuringPeriodValueCashlessWarrantExercise</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>govx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares of stock issued during the period for cash upon exercise of stock purchase warrant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>govx_StockIssuedDuringPeriodValueForCashUponExerciseOfStockPurchaseWarrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>govx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodValueInLieuOfCashPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares of stock issued during the period in lieu of cash payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>govx_StockIssuedDuringPeriodValueInLieuOfCashPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>govx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6576910&amp;loc=d3e11149-113907<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A91<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6576910&amp;loc=d3e11178-113907<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 39<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate adjustment to additional paid in capital for stock to account for a stock split in the case where the per-share par value or stated value is not reduced or increased proportionately such that the total par value or stated value remains the same for all shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Stock Split<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase in additional paid in capital due to warrants issued during the period. Includes also the proceeds of debt securities issued with detachable stock purchase warrants that are allocable to the warrants. These warrants qualify for equity classification and provide the holder with a right to purchase stock from the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Warrant<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528364<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 25<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6923874&amp;loc=d3e4724-112606<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 14<br><br> -Paragraph 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A3<br><br> -Appendix A<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period pursuant to acquisitions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 53<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period as a result of the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4, 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-30)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reduction in the number of shares during the period as a result of a reverse stock split.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued pursuant to acquisitions during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The gross value of stock issued during the period upon the conversion of convertible securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4, 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value stock issued during the period as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAD">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 4 - Commitments<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments Disclosure [Text Block]</a></td>
        <td class="text"><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Commitments</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Lease

        Agreements</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">We

        lease approximately 8,400 square feet of office and

        laboratory space located in Smyrna, Georgia (metropolitan

        Atlanta). Rent expense for the years ended December 31,

        2011, 2010 and 2009 was $119,255, $118,988, and $63,350,

        respectively.&#160;&#160;Future minimum lease payments

        pursuant to the 62 month lease total $121,560 in 2012,

        $125,180 in 2013 and $128,920 in 2014.</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Other

        Commitments</font>

      </div><br/><div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">

        <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">In

        the normal course of business, we may enter into various

        firm purchase commitments related to production and testing

        of our vaccine material, conduct of clinical trials, and

        other research-related activities. As of December 31, 2011,

        we had approximately $478,000 of unrecorded outstanding

        purchase commitments to our vendors and subcontractors, of

        which we expect approximately $445,000 in 2012 and $33,000

        in 2013.</font>

      </div><br/><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 25<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.(a)(19))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 17<br><br> -Article 9<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 7<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>37
<FILENAME>0001437749-12-003276-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-12-003276-xbrl.zip
M4$L#!!0````(`-QT@T`'F70WWW4``!/9!P`1`!P`9V]V>"TR,#$Q,3(S,2YX
M;6Q55`D``[]#>T^_0WM/=7@+``$$)0X```0Y`0``[%U;;]O&GG]?8+^#U@LL
M=H'C>.Z<\28&?)+V(-TV">)VSWDK9&IL<RN3.B3E./WT.T-:%CDBQ2$Y%&6#
MZ4,3B>+\_O?+W-[^V^GI[&\RE/$\E8O9]?=9\/X_T_O_FIW.WD?WJRL_F'T,
M4_6MGP8/4GT6/LA8_5M]?Y>FJ_.SLV_?OKWQU:.)'\0RB=:Q+Q/]P>ST]&*F
M__SKO[S5@[R/I1[B?/;K6LXN5_$,X!EDYQ">$SC[[=?W,P0@RG^D?O%X'2]G
MC_?+,'EW4AA(?_PFBF_/$`#X+`B3=![Z\B1_\EQ_&[1\?K']0?%A=I9_N7GT
M-GIX?'[P5D8/\T=-I'H40H@PW#RW3D[3[RNY17TS3ZZSEVZ^R7YR"N#I]D?+
M(/QC#VS]]?4\V<)>[GGX'S^KIPMH;N?S5248_44%EB")"(+>/B[F3VQ^\"3[
MYQ]4Z<+FV84TN)U(_XUB[9GZH@++XPYCON$,!Q1"G&7?/C^:5#VG\,*S?_SR
M\Y5_)^_GI\_RO\CU<C9[J]]QGF1??Y4WL^R=YUI.[TZ2X'ZUU$S//KN+Y<V[
M$ZT&IQN9OWE,%B=G%_F+_$B9R6,Z"Q;O3GSP^V7R^0;##]+7#V_'4P_*,`W2
M[Q?/'ZB/@H7^\"909I5!D25:-CQZ__%_3BZ`^L,Q(ER\/=O^K/C^L^T`FX]6
M,@ZB17G(C!7I1<9TB!33WYYM/GM^T_9W.8UG3T1NWE0F&I:(!L=--'!$-/K]
MQSBZAS_-0\W)7Z-CEKDB-$X_*"=\L3$UH!BP_70V*SXMP\7VV2=F;3[KR"Q<
M9!;8,NL8=:7$+-""6<`1LTB!64`\,PN((V<6$/;,4L^Z81;-F(6\G]::6[MV
M>,3L4KQBI\@[J"&R&G8!Y<,7BR`-HG"^_#(/%A_#]_-5D,Z7O\C[:QD?E)F:
M4?+V7FZ=<_99GI>=R\?5,O"#-`<V6P3JP43A?G?RE-N<7Z6*0_KG/_QSK7#J
M=#8*U3^3R\<@.;G8/+:7X+=GE<.5:#Y[1GD8+0"NM,"KU8+79#3.V,7KC>:K
M3.=!*!<_S.,P"&^3@K6\*ENIIK/62%Z^B8AB3FOG'5^5P$=SCMM4'3BK3X`A
MS,EJA[':(60'R[([Q@`U!-G%\A*@;<A!ORMAWT?A51KY?[Q6O=TA\4"!!K4H
M8)"C0`-QK:2GC'R4C'P4+2!U6G",#F]\=M%:HYEB^VMUE*R4"4R!<+#<#;E*
M8CQ#8E-`&Z&*<B9-;DAS\K0OQQ++[8RC3"H&(!N!8IJ`MVD"GH+'<,D!;I$<
M8$?)`8*UDIZ"SBA5U"A:@.JTX!@=WOCLPK5&,\7VU^HH22D3F`+A8+D;=I7$
M4$-B4T`;H8IR)DUF2'/RM"_'$LO]C*-,*H8@FQ?3!+)-$\@4/(9+#DB+Y("X
M2@Y$K:2GH#-*%36&%F!0JP69&5RMKQ,_#E::.U^E+X.'^?52OKJ5,'K%_WDC
MP7LTX36H`JQ3A6.,?>.S"]5:SI3FO=*8B7$I*9QRHL'2>.(HG\7$D-B4VXQ0
M4#N3)C6D.>4H!\U1AA`I,T0Z!<^7XUS+/9*CS!.'(+O4(Z';S(]._FC$FHFV
M2`BIJX10U*G",=K"Z.PBH-9R)K=_@)II%)F7-W70J68:*JQ31_&-($-B4\TT
M0LWD3)K8D.:4HXQ5,SD3*3%$.@7/E^-<RRV,H\P3AR";%3,_MLW\V.2/1JR9
M6(N$D+E*"+TZ53A&6QB?7;S6<J9,>K!*:11)BUI)3QGX*"LRQM`""FJU8$KS
M7JGETW*/9/+L@Z7QS%$^2Y$AL<E#C]`C<29-;$AS\K0OQQ++S9"C+"*&(+MT
M*H:W31.\*7@,EQQX+9(#SU5RP&HE/06=4<J"4;3`J]."8W1XX[.+UQK-%-M?
MJZ,L'WPQ!<+!<C?/41+#@"&Q*:"-4$4YDR8TI#EYVI=CB>5^QE$F%4.073H5
M@V_3!#X%C^&2`]XB.>"N+D,@M9*>@LXH5=0H6D#KM.`8'=[X[&*U1C/%]M?J
M*,N;.J9`.%CNQETE,=R0V!301JBBG$E3&-*</.V+L42OW,\XRJ1B"+)+)T<4
M;[&;@L=PR<$8-_!YJ%;24]`9I8H:10MPK19,P>JU6GYYF<7DV0=+1H2KJ$P-
MB4T>>H2RP)DTF2'-R=.^'$LLMU3$D9<%SL@NKL$HW00^!8_!DH-1;C'W1*VD
MIZ`S1EDPBA9P4*L%4[!ZI9;/2VL^)L\^6#*RE5C/J,R1(;')0Q^^+'`G36Q(
M<_*T+\<2BTM2(-S&2SAYT>&B)&P1):&K*$EK)3UYWU'RXU&T@-5JP>2U7ZOE
MEUH_DV<?+BI#5U&9&Q*;//0(^;$S:0I#FI.G?3&6*)Y6TX!?YK%Z[9%?9*QH
M!O@4@_YD/[54P$_K+$\X<K)52&4=R5Z'04[S.ED4+?!>SI-U+"^")"((>N>_
M77UX>[;Y<+9]G_Y]X=_%UWV1\=7=/)8GSW`6P8.BN$2%_L&G];V,YVD47\R*
MYM@(86LPYEO*[_\@P^@^"#??58VA33(X3S3<I(+.[2CFNYXYO:6M@3/Y(%NF
M-$"H?-DR"/\XOXFB-(Q2^;/ZQ^PQ^RC]OE*:I^2K4B:Y.'GZ-(Z697W40[V)
MXMLS!``^TU^?Z0=/M@ZG-$#IY0I=M(Y]V>;EFQ=M?K.<7\OENY.;-$Q_!^K#
M^Z7Z*+Q5R,/3WZY.+J[6J]4R<[#SI?*_B;^,-#-FT<TLC,)3?Y[<S8+P02:I
M<JNS>;B8W2B1A'[V+S]5DD@#F9S//H8SI>^A]'4HG7T+TKM9>B=GO\CX-G/L
MB;].$KE0[YI]TG32O\SFRZ4>1C\6K5-M30O]UEPLFV^TPY^'W_]COHJ2_TYF
M]^HAK1#?9[%<2'FO3Q'4`S_(.`WTWU>QO)&Q^G*6Z(QL]DW&SP]DPZ=1800_
MR]V>'IUG'UW)59I'(\3_,M-'6+QY>U:244D9<R9'?DEPZM\:I"&#W]\K9EZ&
M"_T_'<T>YDL=R+YD?N-CZ,=*#Z4*W-G_3WU45SYM7GNG2'UW\N_.7GMV4:F2
MEW&9N'GL;Q"HOS;HY-,39S=*5TY-W;Q10-RS)8VVZA[%"QF_.\EH.X#(<-V,
M4#^1U;_V98BLD2TCBHS4K>WK)[+ZU[X,D36R9421Y=U%Y&4)(W#G&?>\=X>P
M(Q5;,VOJY?:4_NSD.]O\==/PJ(1TF;Z?Q_%W%<'_=[Y<RYE.H[YJ,>AL=_:4
M"V<?^*!<I)[,%M(/[N?+Y-T).+F`D'F"JPR[U7@7KD$:,[TF2.`)P+V>(/\6
MJPHBV9Z'W(-I'%-(MW#,-V\%W&7L_;P@'D%>J[&_Q'(U#Q8_/*Y4N2\5VSZK
M5"^^5`EBFKQ?J^PM3+NS@C$*^!:-Q5@73M$U,(MS#/J@<\0E2"!7/FB+Q!C3
M%)DC\B$#"`ID/>R7.%)U=?K]BRI:4L4>;5LK7:U\DGV(]Q@"K"B%^E%VW%]7
M2/L9@P@G!':$]&.@AE7.^D&JF*#JJ%M="N6<[<4G+`0JJ,C^82Y<8=K/*$8X
M$.XQ7?K^^GZ]G*LB\?(^4L7DG_.LDNW,.P2XP';,JQG;C!9NT3?8*2>`>"[1
M?WBJRW_,V@?R?90H"46AGUM^+Y4@&!!0\"F-0^T8T`>YBI)`T9(KSO.S?;(8
MA;,(J7J`78_7!4J#+*$0G:`48I$+EE!0,HC*M^](IC6&_;R@P$,`6H"HBGX]
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M2V">IQJMV8%/+L`;4(RZ%F/N%4X?H'NXYQYH]D1RN4[OHCCX4RZV`)^F)JV9
M^/'3CRK1!?F?2H#F6/LDW1+7'IX-@>MCDJQ[\TI;(&*P6IC%<2JR@6Z(FKBD
M+5-5^<P)HL^%&=/!&548S"TV"Y9A1!GIC*UF<5?A+3TJ?(RA@*R85C6.MI/K
M]<+7D/0A"*A7K.+;X_L@'^0RRAI/RO?=RA_4Z/$J#O2DPXU>456H_C^L8R4$
M\Q<]^(N4\$&YL.^+YN*0Y#6(!R!.H<<&)"\3Z5VT7,@XR=?/=9>&!S`#!5W:
M??>.8V\W?%.2CIE2B*;Q:]-CE3>ZY,9.0=\TE&E8?:"U[`"TA?95*56XEGHF
M,9_*V8=ESW(,8]Y#",X+B>G.*+U@[%EB4"YR(*>(>D/!V#-M7FZL,\:A&(P;
M^Z:!#1^$(63%CDD5D!THB9S'OI[N+/B?IRDL)[J"/(:]$G?VC'CA")VM"A%/
M8$'9@='9:A8!C#..#HS.7N%40@>89\\]<]9:AC*>+]7#EXO[(`R2-)ZGP8-T
MJ'U(>(@62^B&,2NRSAXH;;400X9@T<L?%*6M-B(!5<4S%B^MM5)E8<1C5+3!
M69ZE6.GUT"HA>_K>2<CT],+UXF*!G5%ZP;#5-$\Y.R`&@V&K2DQP3(MM8[<P
MK'6%8*32JV*?M@I('92/H1_=RY^CQ(F&G"),!"!56+8#U;+%#HNMFIPBSP.\
M-,'G'(NMKIRJRIQBC(;$8JTPIP@)QAAIY(R!YV.VZEX'P_RIC[H:5)\XB7$(
M%IQ=W4@[T;<+)%O]464+H':8^H.RSM,A*,X,#0O*6J,P46F[%2P#4_ZQR\A)
M&2LI4FD$8_Q/41B5%=]EUE;2Z-JA*A*,3K`Z:O4>7/TQ=53J03'9ZS0FK+C^
M;:\$R[ADZCZJJA*J4*.4AJA2(5L(+8(I\3#B`T"PCZ&($T31`!#:A$ZS!6R"
M*"'8[/[=S,W]=9X$OBXL@^4Z+<[?U$\/6BD)4M#`F^)ZZX:1+YSCM-*D)YQ\
M1)Q6ZI;C1&A$G'8ZJ8&B-\6YLD:@9:1_E\'MG5XI^:!\VZW\M-8[#3_?[$QE
M9:]IF#RS4M6G:30/4UITKZUP[*8W+LFPTN3G"52(BVM4CH@,*T5_(@,*J(K(
MHR3#S@YR.H`'""_N(6A/1T[(;?3P>'ZY^+]UGL4FOT9U,Y6;"<LPC8/KM7[B
M4L<#N6I:[LQJZ`)-)YZ8^W[>GCE">UCZO5KZ#T)AZQR!U\NKYDP3(W6`'J!B
M7_;2#9<U'YL!])HM+5^;U%Z)VTRCMIR=!`:T;O)R/[]<OJ^W4EZ\$4`5A'S5
M3CXCG^_,S#W>)_DM^RII\+FP=,T,VNH4JC@_R_3"*I`(08F!NQ%2-3-W?Y:M
M=:L@I(*_':G05;(G3)5L0C(`?ER+OXUQJ>H1M2?&,2FDCI2=N<PN?&]A`E_6
ML7\W3^3G&W-C@WM+4-D(Q;:&8`)K(8)ZFIP:A5=L'+7!,Q0I;NP#$JX2X..B
MS-9<%'9.S35(W;!;)QR0UK+=+K`RR"'VG"="UDQK!F`ZE!9+;LO7Q-AX"4P$
M46(L"+&T\K9/@M$*3-;'%Z:)6^4;]H@\`U$[0Z6<F(;J-E/D!CP[A?8X]Y`8
M,E,L)]>["HV%^F^,3!$5[YP`>&MTV$+S(4*BU'88*U/L2@7(:1@]4T2P%G\;
M`T/*P#`?/_%%J(Z<7<""@=[\MY^PP;5\MO,4@G@<$.>ASYIAS0"ZASY4OJ'0
MQ@$0#V&ON%_!6>AK!R8K/)"9J;L-?8@:B%I9)@,$H>;8UPL@,P#:MDDPH[@Y
M^/1!5LX:3*56P9?`YC[)MK&Y-\P\G9N4;^A97R=^'&2]PZJ#B:KMH'CM&B!;
M8R0V(9%P)6OZU/'L"?3"@NC,-;:AN4(\'0G.ZQ>\GU9+?(<B5=22VLJ<!>=$
M;W]_.91C4$OYGC?6-*0\FF_.?$'DPSKR=];7"*$7_C@AS3SFR9=RD6@<^IWZ
M))G/-Y8;\QR*;R,\:UQ5!U;UH,16$IUP#M=)[!46B"`6/=RZ1J(M7:W[5#T\
M/[',V@])C1OG+H3HWDX<C#AKLX'&QOE#M!0QJN6\71**,(5\_^JTCLALV=8(
MH6M9A4LWS%EY"X8H]00<H*QJ!P9D4)JWR/9"1`Q$;4R5,H%*1\P,`9`:`-NG
M2^99%D.@9`9*.[LC@'/,!NW)XG+QMV-WF`LB&K>!.\U`2E&/;GT";2U;2$'O
M)*4?+:*.%C=(NZX)!K4LMNQ*,`@!W[MBNF-`L&58(X2N`8&4EXW040-".S"'
M"`@$&8B.+2`0;`!L'1!,4W3O=`DQ,-I9G6*?(*39&?=!5@ZG.U:G>$-YVZFP
M7BZ4%*^5!&SK$5AKR7;RL0XI\>HH<8&S16G]/KL>1]^[IM_R?)?.E?35HVG0
M."M)>*U(+.;C*07<HH*SA-IBB4@+LBN$UY%FD%%L6;`>#[6BEMIV"T\]O8;_
MI1%O:Z>*/`JAY?H@1^0]G:[G*U^;9'(8U%@)IH(+6V,MHK)V21ESJNEQ:H4$
M,\NVRP'(<&1>'N#978='0I6UW7@0<=L.935NN_F[I4R2O\]C?:[1#X\R]H.&
M#;7=M8LRCJRG%2M@7=@0]CRQ<4"Z/,NYEH/3Y,:$3OL1V'$_+*C%;ED(<%(Z
MA]+1.A=K`VX&T'V="RV7O#91"A*$,*:U:SS[%$3MX(`<3,-2ESYPD`&GC;)S
MXN6K'P8LORDV`%HN6D:ZT3GH,A=:+KI-G48(8+23S!UDE2<M+?GVMG;GV:1H
M@.VNCK59Y.EV46%7&K(C[,R6AL420\?H62WZ-@:F#VFCQ-3BPZ_PI%X=.16`
M!1UJ26JN<]F7G[/^3+*)G(U!H(]%(.+95BR5V-IEQPWD.;44<Q5>&TA#4^7&
M@H@0S0O6QR/2UJZH]1R_)1DVF[,SE;Z>J]_K2[1EF,SSGFA>/\DK&3\$OLS'
M_BK]Z#;,WM)X_X0CT4(*5=%7.CU]6)K,JX?&9*&MXHS-)/L:AM<JA>7<MKZC
M2`PPA6C-ZT8(G4N8\GXBFY@%B;[X8*`2IA4<D(-I2,5[P&'`@-/*B6!(.2,-
MR]'[H(,&.LL)<4!5YK>S5\9M;<7*Q9^ISX@1C[-1*AA6VKG#MS;';73?8_`(
M*IBN-.3G"8]=P3!2B[Z=?3'"=_H7AZ]@&*TC9Q>P?;+5L8+)+HT<U`(P0!8G
M8A30M$MT#0+<ZCZV9/X@N-UH/0%4["RS.R09MMI.``,6TW'[@%HGE'\U$\IB
MJ=*87!["5WF"P]*-FX<AK?+:J?&9:NTQ7Q;;GN9<S,1[.*TBC!<W:;?&V*'L
MM*?16LB.J=C?1:M4CD$#IM4FBGWHVB1@3?2YC:>VC:,QR')C8AX6MN=_C4*E
MK9%YQ+[-9T6'=8^#L5I!V-6KV$,<\KV']'1$9LN\1@A=NR^LO*/!RIT00;CP
MO"&Z+^W@@!Q,0Q^A#QQNP&D5&YG0%YHVM!CZH!,&.LON"T$44S'LRG>OW+<R
M]1EY0.55G1I`?>I.K[2#KG@.L<U,&63(HNX9KN[LBAYDV,<KV#Q4B[OEE(CP
MN&6W94N'0T)L;P>`%-GO6S4XWKPH[L<HUDNL?EM%X68.[/--]HO-%MBGW'1(
M8R`,99=`.(1K'OF\CVD=>.#4G@BS.2KDB$EW9))$"(IM%@6V8,4!V6!OT,#R
MD)`N(C^BOH@KO4!(WQKX4KHF`S/56LO&Y-IP;1A'.D4H`;!7CV98,JWOH'5!
MQ\#MIGZI`>W=;1JP7]$CZ%MNS1J#*#<FAN'NF;M'U&JRO\+-1@/M965__06N
M%8-EHZGY5K&NC1ZOO*#;QI`AU<MLB@')7:.G'1R0@QENF8U'#3BM3M"#B+'&
MK>9]T#$#G>UIF"HWYV38$P2\<L=NQQ8]0A"VO3BDN9K\&/X<R/7G&YUD?YE_
MUW&S2?&+:^]*5VA9G0K=F/;7XFI3U.TEJX+I'6G*DDR+*N;`U(A::EIMV!%"
MGUQ_9,397FHI+`O,.O3'5O0X$BKU*&/HA91$`[/45I5&Y-F`5:0;?8((`NJY
MF^IW2J.M@!T0<8@BLE?@!?VKR$$KKAX1^(AG\UUY;5RZ^?+8J+1VI)CO[+(=
MH.C/M?BKU">>Y%N<KE;+H/$0WU[V=8J@[5TGN\`Z>?KM[P^@@*?:1;:,@,_X
M.@9_*_JL[SCO2T"W#@8'M>RW//RV^6KVKAT,7MIL8A=%**-Z#<80'8QV</(.
M!FTX3J`/'&3`:=7!R!**`3L8'!OH++4)($YW]XL<9)<.+[8;2S>(VQQR23FU
M/B1]N'TN76G09V/2#E<9.49/:]&WFC@BP/I,N>&(L;J//D-;]OR6:(^M5G4E
M.X8].I7_[31H/)X-5QH[TB=(!2+T2,M_6P$[(.(`Y7^O^`E1F<1N]?^0-62/
MT&JS?W=_;3PH88XLC0AN<;+,>'3:6YO]6D['&Q<XJQ6%[54DA&7+-`>HQDKS
M?G9&S0A!#-8>_=ZKP&@%!^1@AIM/YMR`TZH:PQ@*..#&`2X,=);:A!A&`-A.
MYFX>^B!7L7I/9@KJ[TNI_W(9+B[OHS@-_G1GJ$``6"AA;<;=-8&^:*U[^%!X
M'AX;K>V2&KW?A[4'ZQ1K'I>0]]-:@]VC")11AKLH@GE\O;R1<2SS:_$N?3_.
M?OCYYJM<R/LL*_X0)'ZTWC\!;`U;^6I6U(@6X]=X\D'BH><A(<S-7XV=[\%Z
M]!X%M+2^9!@X]FMX!6>E0]SMYC=:`[)6*X;I_[-WY<UM&TO^JTQM\E)R%>GP
ME$AKGZNHR^8^17992K+9?[9`8$C.,XAA<$CB?OKM[L$Q`(8D1)&R#KHJ,4T"
M,SU]_/H88+I_U.Y7H*B0VFC6\65\%NOB*=P\V5*EH]WHZ,YDY82FIW<W);`R
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M!A3W.I[0L.L`7X<M+;RM/KUAD^8)+1+[:A_ESAE\$.6[(+UR2H'G"37UMA@_
MG/3*E@"T-UOM3G=COA=+QNJ%'-R&QT9L/H=AX,9P\=6UO!!\)6Z2S->],E1Y
MPZ/9TT]QJC[YSBBOG%4?-38G?`=T5X[YCAJMSH:4[X#LZCLB[5Y'/T3P01PO
M;(IDW76O+9=_&>]44;K=WI+6OFLF+_)[.V179_CF=%<"Q*%WRX,=^,\"I%2?
MO9K;?R#95;6D=]39C.:=,+MZ+:Z`)@^B?`>$5W>;W7:KWUSO\:OP_%%-PBO7
M4QJ=3G.)01HGW7(O\ZH'5S1:C^YE_BA"JQ<*NMW685NOO%8@M0*=A3UOSU%?
M</AQ>\0?M7JY9W\V(V6)1X]/^TK&.97!EC8B"GN1J^8K:^^&Q&V\4[J.NDKP
M=2$\N&GK3JX(!M5GK^;D'DAVY12QR..'T+T+PC=&M1]-^`-0KM?JM#OKLT,S
MZ07B\4:`$?P+P[U;"`2QCDI/CQ;KK$PX__R/_WW('?55^K\%J^GU>GT-,Q]"
M6E&*NV;$"HO:2JFFTSX\U)^`>B`OGEHO5MCI-JJI;8AA&YU'<.-)F;'*]K>S
M\7AXE-O2?1@[*O!B``CD^PL`F[6-%->=S=1M=G,'*E>:L!1</)[,-6>%-_N0
MEJYEZ3HRAS"C#^D(/G^]I<=,]7JM/KQFY`X7'\Z]4(2+;WPB@A!?PKFR9KPJ
M"'_\Q.4?UCV[M$9!C8'"O/_/7Y>-^5&?]$S:$89@-XMY]<FNZTTUO'YW;MC3
M"$)B+[P0@6VY?W'+/_><,RNL/D6]WFS5V_$TRT;[6&2>ED?$YZM'81!:G@/B
M7O.B0C_6KL9OE@\DM`RO)?2ZC4.,"*O-9Y3NUVCD"OO"E=;*`E(_?FF\0=I5
M=K)'G6;O*$>)-G!AX@$(R$$A7;C6I#+_QS`75Q/D!OA86M(I_.);[M!S^/V_
M^*+R#!CL]<`K]/HYCN9'^UAF8:P,W_@<G[+T)M>A%49!Y6G_XD%N/N-H1MG]
M(=W("RU_<2%<[E>?\4KJ$Q9&,<Y$/YV"@D^D7YVAUZ`?<!]+U\+PP5W+6^C3
MYX;^:)C[3^ZZ__+DG7<-KD9Z$+;B:S?^AJM=,MK',@!EQGT!WU3G+OX_#T:%
MD9;.I9SKPV:[^,LTES:2$5S5[P^%0/R_CH+&T<K%2=!?GW\9QSM1TJN^N%_<
M\-@1MRP(%R[_YR]_1S(\OAQ>G=<_GP\_?;[YP)KO6]UC=G/^WS?UX=79^15\
MU9B'Q^QL>/WU<O#7!S9R`0F/V6^#;Y^&5_7+\XODBOB;;VH<^$J-SBQ73+QX
M*MQ<%N.%^L<O$_COIWOG.+4/]0=I',-Z<D2F\PO/%1X_9A=?KF[J%X/?AI?P
MY8V80:)WQ>_8-SFSO/C7Z^'_G,.*B#KZXL]XD2/I.AD-S?>_6+/Y\4_-P\;Q
M4WQ2XDM7GBU<CME)%,#J@@!Y\"LR06=2<B7]"%*DW^#SR/\U^?@#9>OR<5@4
M[$Z%FDVF(J,BFY@6*K$#Q?]>J]5(+D^^:!XSZ;-PRDLT9[?$,*O=\Z[&1,`L
M-A(RY/;4DZZ<()"KZQ0IV5`.O^6NG"-BWUJVC3*&&2%"F/OP"[`%`@HV%I-I
MR#Y'L-C2`,/9+/*DP\?"%MRS%^P/X0.HZ<OZ//Q#I\^@8,(;<YL`PZCR,(!V
M"8-8)W)#^(;%6X-.F<,ELJX7G@/@8U)OG=;!\.Q:)]9(SY^<3:U;SOB][8)=
M``?+C(6(")_B!>;!K.Q\AM[T=T_@.57XZJ,^)_VXAD.Q<)@FTKNIL*?LS@H2
M(<)DP!-;NJXUD@J`#2/=B7"*2L6N+/6V)^@A@%\8A2!ZL/3/W'+A"IW`J^%G
M(WG:J*@F."C&4!B@C$%SST1`.?`IF)<O7;KFJU(K,VGZG*=GIVOE$"<>H.["
MLZ4_QT5GRJ`-'$%(1Y;$7.N.5HF?,=[B^(\S#E]#"$T4RL@'Y8<!Q=QRBY8G
MQZ!0P">\&#`)IT.>7\\6OF?5&!#D3X3%#F8<5CR7K@@3D\G&&(2XHVKA&!:L
MJPRH>SA=`J=?(M^D>[:*HS,`4^*.K8(VS"W'`=0(2.RV:SF<G90Q(XA&(::B
ML7H@ZMP2F!$@@I;-9*"`D=)Y%'P*SOHX8.:H%Z1>06H9F9'>2=]UC`J]9('I
MPE#M1AS!&FF(2/U""4.#S<T('J9<@/H"\H.-E=47KCVPWJ78GL-5(O1@]`XO
M"K@/\&:A&\&GSZUY&=_0P`4DF[?"B2!?`S221)[E@EH[BWA<7"W@C<$D86XC
M"VZF'"`CM^)8ONY"K;U$2L8+D,@4O53`ZG4(I@#&2$82"W$Z/;1R6&]I*'5M
MLA9/AB;[U!>RM]&"C0X"@[`=2%6B(%`2N@+M9*V:<A<J+%$1BV:P]2"T)B9?
M3>X%X#E08'W'25!PIZ2L$TP8:R"H^Z`N\#\T9JE95382&$&`1L#'H,IA@&J/
MWU@^.%4<6J-F21!@,E6*"\8(0,J36-EV#QHJ.AS+)1S1@@>*$<IJK0Y)&"<;
M-PI*)A)""(]`;8)5-8@C8T;<";=D\)A^"2_B:G44+.D\(DJ)LNQ"M#\#N[*%
M+`N)<$ATFB%7@(G+Y_>"GJY@MA5,B\0!N^$:<*<U#$]'>+I#%IW,XQUO%3]1
MO#+\K)9LXGM9P]HI\J8<9`1[0>[B(E%T;[-98\%41JX#D`,,&ZLP,D1.(<M4
MD`!NW#/%GIK,A0=W*!I\D/G?D>6#_J)20MK;-G)RZ)5'E#[%+Y+-.%>,E<G#
MGL19-G;E72)@VM6NH4;,K#)N(]7H#N.C/C"BX3YIE[*41.T"#K!+BZB!*8Q@
M5K],%V@-:&,H1BY7%PD()7VJ%`3OV9\\]@@!>A3^/<-NG5D9*<A97!&Z%J0D
M-4?0!1#\#!VQ+Z-)29&*-I&.-(-HV?)$,`O,.+X&Q;5-U5)EPW">`>"O`$7!
MQ^74&RAX\@[$@*`ZP0V_#T\0TE]*1<3D0GY@+:3UQ+60ZV@VL_R%"6K`3C11
MLTS6+!'V6XCIE?!N_KH$Z>$Q0<+6B'ED#'%B!2(HJ1SP_:ORV58:KWY5B9JK
M4E=(-`,0@:-27V/@]NKDL./<"D(MM`,VBNM_&*D!@CD1Q=*C!0$UQ,L0;M7E
MG=$=8KPA'`&C4((,&7M<^H)0'WQE7)DB5Y;*SS1.[,;!402869&3P<3?C1P*
M6V@L?.\/54&?J,A'BBC@1DX'U(!;G7!JJQO''I@!I"-HI3I#4$0C7<,X=!@5
M:_5JX-<;A^P`W)V*)+KFRL4@"=5RPPD,;F-^,-PS#:RXY$5AY8ASCW%70*87
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MCQ-7N8&4P8S[@%GY'<W!X&L.H>(:1<`B0O&9]=VX2IXH#8&W%021.DTPKL5;
M8RSF$ET^/7&""#"CX,^4-ECJU!8<RM6.HZ`JGPAL0"5([O%"506;:(BG,6S)
M((H,)]Y*TNI-EFM:F2:FI#Y57`*.0Q7Z2!%I9)`Z)"A@#AWPJXU#$J7'-,PP
M;(=12EFN%A>Y,/7,6@!/L":4%-XP'$[%843*5V?"NP3*4T,A%!4!OV?:LZ)O
M@M$[#2:3Z(`"R:F83`'57`$<1DS#M_Z4%5+69X'BAUCOA(1V7-HUF_J0SLV`
M^&F`3V2XF`??32$`F4<0@>(QE8AE(ZY5N0O6FLEUV;Z?JN.B)M`'[0[CEB>N
MC38C,3T7+I+-1I;W'>(<.C5*H0O0S!>P-/\[-\9P2<:\;"<.8,'&VK/#<(L-
MT6@^]^4]80$;6\*TKZ)F2VYPU-X#PE,P!71*^+PTZGI]2KY+-+E(99`1H1YF
M!WW(<I5A5I978",ANL:'79,PXA1B:!&6O,(W$7Q_"S6$K8DC[_GURDXF`(I@
M@FCT;PQAHF3W+2\/F^3!?.2_L<93,OZE\%&+'Q2R_-)S9#-+>.I4=4QM+0+)
M9.J_(4K0MA]!B43\F!`5EHJ:@F!AQR\W)+:?QC5Q"#FR7'S#$H"`8R2%VSPZ
M8.;]87$9)>B)9]E')(]5VN2@AV6/=:4'/^P?A=@N8WEZG@?6O2@Q<#"?L&40
MUE24L;I2XFBGQJM$23O]>:E/QP(SQ`4JT2@R9![37"0P4,_)V:K0W6YB,:;9
MI*OP!<0,7?(I$QBYZ\J[X,.F%9803_!C-G?=.>X4>Y-81HU8U/A+,+?L\B]W
MP@FG\7?-1N,?\=<EJTKD&I)</9"KOVI[LO3%DOL-CY)GC%%+#GV32J:_4M"5
M*?)(AJ&<&5;Q=7!V-KSZ5#_Y<G/SY;</K#6_7[%QN['>K^./-F>F>,MC!TWR
MH;.437M6E%EA2]3XA!>MF`W5&'3RY=O9^;>4/R/7LK\CEQAM&JU^_2$CX@?"
MN4VE^C*A13)W+%<$OU6!1TZH";*9+JDL=4_>^=8\7H;ZQX,D3P(97`X_77U@
MZ!./605C>?&VLH>-/6P\+]AH[&'CV=J*^MU?PG45LN76,`([F/@R\IPZF)?T
M/["?3AL7\.=X-4MBX9CSE!62T6/:H\-_K(DQGX'=K<Z^GD0_+M7+4-+\,%_R
MAZ].<G=GH(_2@:9!!5ZJ\57PV::EKT2KJIYI9_SY>3W:;YDO_75\\?%ESA^*
MV.U>K]9H&!WA4[JY1VO3B[>T/?9L9F-[[-EC#]MCSZY"['W4_`RB9GQS']LF
M+^418V(V]^6M>ICI:;/:O>,J<N0U.:X?QY\7X,":S6[ML-'=.[`?K5%[#-K,
MQO88M,>@,F_V&/0`KKW,.O56MMS>=E1.O6!7E;''D>\)/*J@QL;B'C\$ZK0X
M_.^%%[D?JC\OU;JWX4]7;]C&-K+*W[X1YAF=[4.89W3&3\R^5J]VV#-ZX^?L
MC"OM)+]\/=Q#W^ZL=P]];QWZFH>UHUY_#WW/20_W)?Z7D4S<R-#\BG+RQ_PN
MP+[2_Q+0?5]EV\#[/:\J6[?=JK7Z^ZWJ'ZY1>PS:S,;V&/3R,:C5J+7[G3T&
M/>-8>E_I?X7!^:#XXF]Y_I5O_^XK_,_8JO=EKGV9ZT'L.VAW#VN-GMD//VM'
M_`Q+7>^V6"[<P][N+'</>V\>]EI'S5J_V][#WO.`O6=3V5^)F)U]@E%!'8J'
M$Y6GSU7]:S"H^;&AEYQ3&%3EC?B'ZLX5>,0<&8U<7L&[/BW[GLD;;@]BVQ*_
M^L3;YD>'M5;C\,65]<INM2K8OR@3W@/?[BQX#WP;L>V5`%^KTZMU.L:CN_;`
M]RQW.=1O>`HD_>P^YW-%\^O:@/O5SQ8]Q_/_'7K4W]3Y!,_6I=-]N4='[F(L
MCXTCA!^WU)U:_D0=6R[3EH9Z$Q5M+.%1`UZ'#A)V>=JQ41TEK;\$K)\"JH]@
M6W,ZM/;_N+DGP9F^DT$-QF;S"`]#Q:9C$[W)LCYJ$/H68DH=&<EF/)Q*AV$G
M2#IL.&E9@(/P<>0R5]SRI/5WV>3C[@[JJ&3?\B8\Z7^`9[]CVT^XO:C;"V[Y
MYK/3!]I6#,[I)J]3Y_F5=+G36%5:^IIU^ASE;&J+C#VADY84/J>M)$7'>AFD
M32<T!NDKBKM/4//YGWN=6A,/A/VYWZGU>D>J'^W/A_"/?K/,:*U?!;&/<>J5
M6SI:MA:?*TL'S#;Z-9,&@.[/L7DU]M!],XV:%23LYBAH_?VBC(P!V<9*G_EJ
MN+M;3L8HHQW@CHUWJ-\.@H2PR:JL"6".`@C$\27P%ZDVA2&WIYYTY02&&,6'
MN<=M<LG(1!!$Y`*6(5_<@COITM,\.B8`GH&9!R$P?T67]IA@$W7:&J@'L$(/
M;(H-Z))"&B-(&V&[SQC1N%=B6D6433`I@3K5=2*ESD@:X5<+8>LP`29N@0.(
M45,#J-(HZP!+.<>`R++#I$-(F?T_-_NU?JL-\-ELX,DT^H=ZHQZC*7PB7="H
M*ZJSQ^]#\E**[-IZ='QUQKM+:!S.,'K2FN%EM(`\+J4WJ5\"JYT5:/GJ^+W3
M]CT^OQ5PKXN<=8FS,7JB'8A4&M2(AR-VQ,W=91EVL0GXA*N^:,*WHUD0(B3B
M%PYV68P;UH=Z#PO5B\LD:^R?CI10KRQ/AJE9Z[3;"&>8M1B!ZUORNW!5RZ%D
M;:J-T)2[Y?C+HTB6,&4&45SD)UT[J&&L+P(5:2Y?1'X5U#`WG93:ED6836"=
M/^LI;\:O;"#5+RYN!1Q$V&:$QC1WMA]C4_JT+1->OC005XQ08L;4@UQ9)G1%
M3'6=-#<57Y+"HO0F'GHK8SJ4YS_QD=B,_U+Y@T$&QK92J03XO<VY$ZC$)6&X
M61Z8E91#_72H?2O+1Z/1P+;]R-AOXS+K^_<VV+PUEJ[JSHK*"SFQC?U.X)^J
MP25:#K9M-?6WK)7T_R[+][/.B(3I=]@JUA7@&_`CM8[-ZAFCJ`SP=`FB^H*'
MJLLLB-S->IV'4^$[1/N"@<-Q),2F[&9:SN23)0GO5KI8>@#0\T(Q)E`(N'\K
M[*2]9=J(EF@N#I3UNYUS'YMZ:F@;4X!1-1(WXE/+'6L]([-18OXDN;>+[7`1
M1E/$6A@G,@T5HXW$:@%WJ%U-RE3RSD1:O,2X=0P&KB8TS?6$4ETTA;=4\N_9
M^3U@MLNSUC6Y-2:B1R+4PNZH+3S8<]HI?LSC"T!`8Q`0Y`Z&?I@Y`=$M\DXY
M0>P1ZH/(P/U[T1@^`$C[@=:,/1=Y2._?D4=-W)/V\ER_$5ES"P2"<2FB8.6E
MDA"8'D0I("T?N`$\^)-3WU25WFBM4D?4B3":2R,IL%Q(?)2-:1JGI4O)RB*8
M2XX`.519T!2)".HNJQ(O<)><XC,JF"4VL2_'/!XVK\Q=&R\E2/$K1%#74RRX
M+J^^OQHF;XNA)U8@[')!@/H`NU1VQ0[E"']I"61*Y0N?9Y5996;2,Y=3[C@6
M-A`Y,<"?@"^)J$Q`W86S(<$,HQ#3$.QI]9X-W%++P!P!>B.\`X5L21$)^YO/
MTWJ\@2`(1"VX[QVM`B)-1$$GJ6XGZTHKU3HCRH,A9Q1%JDL[!:RJ&?.=C%P'
M@W:83-1I&$"%]UA?FI6[V)>7E:P*1YG+$'TE%<84050DL@V0;_E8_`XTRN)N
M@RI\5O63Q!=H#"@25(4?V220D.#;T\8HL54[ZO=JO096A&J-9KO6;;44&<U:
M[_"PUNTVL,M;N8!4)"E?`-]7N[<-K]]4CVV#"+^I#'#IBS2OCLT[KN3$^732
MU1Q-%%L/^P[%?FE@='U^FBM#7X?6N)0V#[+&]2<11.;PB5W)]T`(V-&F.K1$
M*8P:@=1GK76OM;1$5Q6,>ZV9VMP:+4H^AY:V8BV=K:_%O)@"T0<)_UN-X^O!
M"1*2?M,\?O>>)5^:`\Q;R'$"-HF$$BR*>3YW*>/Y-!A\Q2`S40%?,[$"KW'+
M@@<*,A'RQ!C#7W`%EN-@!$M1:VD4#)]+*XWF@.OT]*KT?#Z./(?Z25)`G\:M
M6!:4GL>S,-VHQ`'X&O)0KJM:RM!.:;J98-Y559L*&KP7?$4>XC'O2986^W<,
M-<9L@BZ<(?VFG=YT)5E'X-2=70T_LX.`PP?PJ282VN^6E"@5&?%``O=Q:%^<
MZF_"E-!K'7J!`HX=A)/:(N:(098DQGLC27?Q4H9!E\H9)8_Z]K4:1CEY-93)
M$;XZ=-ZM$U1Z;=S$\W!C'N(-J;K`GJO\^JW$'D_%8D=C<;*+F5ERC`.!RB#@
MPZIG=)+@UQ$![3`L:OKH$+5BM0"+TIZQMIU5)JC^-B9``J-V(AN+T(`^6*&A
M@A>5'N)ZBP$+C#W*#\0[!;US2\0;M,)WZJJ8%E=<#&4T]"H^;0G$=:D:@XQ"
MA-*/RV?)J])8/[(2L"B5VV6\&IX65((P<D1<XRE466I`+%"K,US'V[1F$LQA
MH1(YGSJ(S"70(#!*BH`&FK!,B(4@I$$O#"&*$B7QKH^74EBNQZ44W[YC;MKN
MC`41.-]D?3`N;3;5<^PQ%<]4)8A$GM,='.4`9@@L%R3*@YI!["/N\;'X__:^
MA;EM(UGWK\S-=:J<.I!,\,TDZRK9LAWY.K9C*?;FG#JU-02&)!(08/"0Q/SZ
MVSUX$"`&)$61(D"V:M>A1'(PT]/]]7-Z@D1YHZMT%OG+Z%;!^#ROJG.>I8]*
MV%Y1;["`_TS]6B(QO$!=TA&[NLB<!T*51GPM>9HRW0\H"PJ5[9M%IIHS0A<9
MIW?CDIX8L1$K`K12X=>9W))B;%8M&Y@CS^0])&IZ:4C<3(/7RXE=._JH.84Y
M8,T.!A^20:FDY-%B!0#O*B)VL''16U%MEDSM4\)Q%W(6USJ#_("@A7:L3+(E
M#B,[Q`0(V!(K2N_@+5!'(G(E99A16D3@8+H8&IS)S3L+W+/H5:9"0Q%2]2<R
MY!D5DJ#P6W$2!YT?L%9,2\;\%I6\T<15WFY<,1`]5>V0OA8>(@K:9;`^K!2+
M"Q1\F?Y3IN@P(XA6$_=]<,737!%:8JE_A\CB!-&`:>:NF%5+@B6X,!_^*\T!
M"F;NHCY-.LQ%]KKA]^IJA:.C[EYCF#R*U$7%9U%L(D#*9NKT;2NIYXIJ],_9
M[XZI*`*6P93H(^B=C81TW&"TI!H(=:Z]*#59G*I0A%3-!*<R!QYB&,`1T0T3
M?X<"J]T*MD(`CL,PE&=K4(Y-:P1SD1\%F0_N4.QE(J68B"^RV5*Y4Y3SO[=B
M;[-D78XJ?0*/M+Q,LD.N`WV(D@A;D8!E?O8231=E7-$>"H=++>#)9#I@9)38
M*J)L3'")=?"QN()"3&?@>'GS'!V7U$N1;D.1%`MBH,\#+S@([-)C,@I>4?$&
M^&Y)<>`MM\,X4FG;[IT,RX:.+7QPT>)8@3L#ZTXFNPI+!4'A4<0//AW(TC?0
M<$#(OS#"%TRX(_66K+3Q429F6)"-8WG%I<($$B6FXOH["]Z7Y$A."I%6>#26
M76,%_]DK],!5[MO")5<3^^AH_60Z0AZ=B$,?X#@!E8TH1[\`#)"#Y.Q%$=V%
M/*V65B')*#P@C.W.!:9&3`L^$\C*+X^Y>-:DK`))W$?5S]'Q@;]#U$^6`\Y<
M&!V!R%8SL!$'Z$7($"HTD'5?=]PS65PL'64E,"2HMC6S(1^,W2AHAK.28_K9
M"@DDGCP\D>JTW#3!>#6*6:T86T)4NE'.*3=<_%U98K8H'EM*.R$^;K:6Q2ZG
MY1?%H%92>Y%?2X%ZB]5ERN2R<:QDNW+94=RLLVBSP%,PN&U$_2+CJN2BO+_"
M\]EGU\;$E05T<M:2EDBKJ6N6Q-Z^B86Y42CCR+"Y42`1]Q>G<CC:&7-Y_$?A
M%F1/.&:/`TF'!YC6MX!*245A[%4I@H@IARH7<AUGP5@W8KOX'*LT;-)E*,IP
M%JO*E+U1^./Q:1%#:4IFDN*?/=>!U\;Z.X:/AN*[HJZ,1ZBKFZ5#[[A2S<#3
M^8+>LQR]4;<LCLXH#+K2+Z:UMY'MB]Z%?#)7::@DTR'/=\"'W?+Z7\SC>\QT
M86B5*1W5>4MK%+1JO#X`'5E0$-5[IZ7=D7$/6E:9E\\L31;I205EC9(XAZQ%
M```%U(O*WO*K4ZPM+I);L;8MLA0_OPC]LS'GLQ^O@>=DF803+,3GLPOR"L[.
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M6V"IYNM9ZWR0C(\#A4[H*VND%_5L_J*#291LO.66'656@&#8Y"#I9G`1CD._
M&(Z+)]5DSV44U#$31]#UK+&%UGV\$<J:14ED=07<MZCN/PPLV_HG"O+"@N,:
MO$PP+Y>`\9`R2O;)%U.@]S5-6A>H#EG%53=E&Q4[99Z9U@MF3F1E2QCSSE%$
M=W55';;[3&I`LB5V9>%4><HKK>C%?431D>>TL<4#GN)#[I,^';AOT_A@ER(#
MEMI`T6&&I!_1VHI*63ZIJ;K51.64=R(M,63/L!_-0.OW.QJ^'K0;6J_7C]LK
MM+1NMZ_I@TZA!C];=*_A]$K('3&')&])X/+H5,,^]>YO-Y>?ER=!2G<G2O<C
M=I^*-`@*SYV(SL4D.I>#CR+.L`U<#!92;[3;6KLW*(KN+/0P:!8D>>#?0EAZ
M=,05'5`^$P"?!KM,RA'1HR_#XN>XZ3\D:C5-QV`6/'-2^#-@`RKSSW$MC/JP
M(TKUQ6B$)PQ0E;Q&/+LPY""X[%*=O>`[QHJJ7O:+D4W5S"@+'A<G(E3B>:5;
MF4?SI]RVB\I3%@$XF'NZF[@28$>N$66>9&3)<6^C^II@0;CE,9*R3JLD&19I
MA:@6/#H#9=N+!@1EY0QQ(#(%UH866QV9$FW<A@3Z4#'+PG554$"&X(QHL9(/
M7F.!I"T+1\W%:0E%/X1/&>#?PG'Y^<5JI_9E/,3/B<^,!].L0.H=Y$_;Q63@
M4?C`N0UY:C>X_<1N<&8;3T(Y[%/M?L#V@`53]"(M:#X)`N\U1R@;,"YY37VM
MW6@P_^]0*@7L@X!F\&AD18T[59"=K?*><?@<T$@"+-C8U].YYW"-O1.N-[8X
M>SX5@>?.`(,#7JCSO`AL0$G^PSG[DCU^D*UQ4+5H5*Q,U0--]E?3]8'6[*#9
MK>M];=!/C.YN2VMU&ALT=E0(_=NHQ`7K4J?A-*;JC,^GJJ+892.EV\3S`V"S
M1U^3)WEA<DU=ZW11J4EW4BNJ-OA(1]/[R4=:T3+T)BRJF?RQ364+>^N>N`;I
MCX_$>_4#4!(<S&;:>.C>B[I)#M$@E<5!=T+V-P-B"ZQR`M&YY9[EALKJJI'E
M35',C`F7QS32?<H>E5E$-*3@Q$>1BF(6'SM*PB9)"D5+3Z5@H<#R:9T2G)2E
M$>G1G.3L2Z;_R3G+A[R63^/G6SNP"3>70U[M7A_;-4;AKM1<SG1W4/D3*E+%
M!Y22ECY1B&68-&5QL:6CHBAC.=6V/+MV1\XN1K4XW-'"ORGJ#"2L;8E@BV34
M:L/Z9=X*_U5X8^'Y%T:4Y4?S_\(QX7LS-_YU,<9Q9*@.:9QWGM@X!RN@6^"S
M:,LE*WX1:6]P*D/;*LFO0KVXK$R:7TD4'-/@#H`3%JG&AN+[$.!5!X,LJIG*
MA`>RAN:=Q,<K&R;J8L#?9Y<\G$W@^S=IZV&-73G&>9&]L^T$XF_EV@DH`[SQ
MZ'>\>/`R=/S0P*YJV-!='B+'F/&B@;V,9&'?<UAQO,A\+B-OL#;4*=LK)Y^9
MZFKIDC&N80NI0HK%LA%;RS1$9MT1MV>7'06,P3S_RN\CRD4HKE`4=_%1^'3;
MTIU*=R8Q\^,-55KF#;TLV\/C`R5)>"V:K98+%64B]7B@$]O88[UA].S%&I)*
M0S,NX4[Z'"D:M>4*\]#7R-!W\09N</8)JI(/@V.7``RI`8>?N7?8_AJTIF^9
M%M9B*PO]XH>MY+X`3\PEZT$N<_!!H**C"2U+^0<^]&,RQ%<MV-R(OQEY<K%&
M7Q1NEO29""9N9(KE5JZJ9H-5RM+^U*^)]TZ%")EB4[!A?%D%$YM3LAW#/+7\
M8I,):[L+'%Z<4ER*N/CR*$ES8>AO$DX5HR3][DJ#L+%^0-Z/ZW#B8PY+,*6P
MIY+;$4;9"AX>L3DF7#$VF1H:BF./RUUIL&M)?(XC>VXC_P"%J9@!,3!1!8\#
MV5%P%";@Q?622'E@BV)'RV@B,#BFG;!R?E$RE.V]%QWCBO=_J;2UH'#C,U>+
M+@&Y.*V1C=,N'^%29NLT)@_#Q)X$'IK`K+#E:+C4.X&A9V3ZN8++/9$>D9">
M`:YB@>.:#(\O2\+R7I4)QE6LV0#V^EJ.\U4J!2>\$E]E8Z*@M&KX$ER*.YCN
MH\JWMC."7\9"_O/_.3MC__/MUZ^M__V??QNS\/X/IS,P_^G=CO^8.[]?AG?O
M>MZ@]_^:?_Y^,_?MWJWQ3\-^'_1_?_WAL_G'?]NMCO/OX:?7EU?S=S=_Z[/!
M;X-7G_[X:C7???YR\XO[7[/QG^['S_VN[@P^?OURVWO=?-?O3UZT[NXFO_SU
M_@.?OQX/AE^G[U_]-7O7F`V^"3>8-]Z.KUYU;Z975Q^O/G_]]/Z/][_8L^;4
M,WZ]'O[Y[4_G<CBP7ES=__5+\.;ZNO7N[O=K]^+#N^DW_7=]^/;]^ZZN?[F^
MUJ_T>>?;+\%?M^[OP[?NG_8OC?_Z^.%ON_/OV]=7=Y_-^\;8>S,+WS7%S>__
MW=%_&;^Y&G_[K==[W_OW_8O_NKW[U_^RU]=?SLX656]IM1RJEUB-O9$E\5@6
M?'Q)@`,Z&MTG=C2R6YI13<N8$>WV:42/]AF@RS9US%5T2</M)G/@Y53"H7N-
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M\Q/L==ST0-[X\L/R0"H;.U<+\2IN?7XM6Y_SQ<XI."")2I<6*MJ^FV!"Y`VH
MA#7>T,6Q-+2]$_HNL]6@W]-Z_9;"`4C!)N^MPQHRFZ2?PT9D^N7F(AR+P<3]
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M[OSVZO3%U?6G;,@S^WS977@Q?&[0HI$"TA^`E@S23R;'W[WB6T,7#U#XRLXA
MF6X`280YTQ=`RZ%WA&RWEB\[!B@BA)DH66E85MP+S[!22RRRU.;Q0A5;*HDO
MS,PU:0S[CD1M0S*=!I[K>N-[W*'%WXH3Q*<M;4'Z`&Q'%;6U*A`[)9(ZUQ2C
M0#K2(OJ708UET(@X-#KQ"8N[EQ5(@7"B8SORUEVD=ZQ5;+PFR%?=P18=<,?K
MA<MON+Q9BMMC!->[59_)`*.XT5AR!ZW`+R9;TBM!E]-^!4<^L^"3J6O:V9U7
M"LLYG$ZCK%12@3)?9KD<CV5\@E5.061Y)">UERY8CC)9F3M,,PZ!GTD)#(7M
MWOVXG=D=M9`RA&W/L*F",XY)V8AW!-_!,L7B.W>6&4SBO^F-QO?QGPNVP:;7
MTY?]H>3[*PNGHR5GKZ7/OA>_:R)@+?AMZ`8!&./%57R^N+R\^OCN[-6GFYM/
MO_[(FK/[PL/SPV_%GNOHDWFF^N[#LH6^",Q2,A$IBJ0P7.3XA!;-F`R;$>C5
MIR^7;[ZD]!EBVQ:D$I.Q@]5Q_L4D=H"ZY<B9/FA!NO*-2U&C_".G-MEM]9DA
MZS%7590]B<1\E'=:K7:>B*@/)*I"U2<_\J(WE;/Z8&)O#&".>^?Q6;S$Z)<'
M@9C<K(L/5^\^_LC0"ON);8#[M8=]TH#'I0%K#BG?XLL(SU9%$7,[2T"]GJH7
MT<V.:QQB(NL#R?HFCB_M0LT13:/'?I:=,E>5NVQ,4K(<R'(@R^%4@(,L![(<
M:D/6+TD',6+6'5+U=7SR-.0V17IV2MD;X4U+J<C8\[GG_[`KC""SC<PV,MLH
MBU!!&+Q(RDU);>^0JE>@M2W'MPRBZ@ZI^E66)5$@I;)J*'K?*Z%Z5,F16\,0
M5,S8<T/'/`/-Y7H_LO_[NO$6?GY:39)X<]151N4[4UT)6UTC]21\\&FY6T[Q
M^3Q(3V_$94]/+(T[WO`ZR-0#K=QEO%&8;2=("0\#:9M:L'NCA:[IK9[6ZG0W
M\BL/IJ(.3J=]\`PA1]V0X]EZV_GH$:-SWFH16%1'8(Y+CSXP6%1__X2D@*2`
MI("D8`,B;1+*H.C$TVWMN^ATX)-GY,AOJ)O?4`U*5,-_:+;D8=0-HG2D-"C:
M0*AQ:$I4`S72P2TSF>/%*_VL.=`5T\]9%*WN\C@I)1OG`W6V@)"(G#ARXLB)
M(RD@*2`I.%`H@ZHR*AKW2`[D*2,?%/:HAME.#DRU')@-#DR19J%X!\'%H2E1
M#;@HC7<T%=/?--Y!&%05[CLN(2,?CZ2`I("D@*2@$D4;#SYB6D+>TXYRO'6]
MD<`;3TH1BF%O[NBBBNH7@>R**>H@<P^T_E<?,HZ9?`4\$9D*9%([44]*J.?M
MUD#3];9:,BNBZ:IW]%+98((PJD["1QA5%XPJC?*T'A'E:9[W*U[54CW4HQ8P
M57*-]]`"IE;D(GDC>2-Y(WFK)-4V"6@=LG0G=W=0IZFZ.FAY=]H;8L!I!\0V
M:\92N(6J^I&QW&536_)+7:5Y`^VYECQ*C0$T8J8;#FVQWCD]`A6R&?D&CR9?
M677"DQ)PT.QKS793*=E/J(+7,N9ZO;PI\M>*%PD`]R?!1P&`3]/&Y@B!KW/>
MKD#O&\(]PCW"O5J1[TCPKS1?T58L;]-\1?>\<_`<+4$J02I!*IF23T>XLX:R
M&I]0K]J1;0I6UR-8'9]1Y2#\%*PF!5M?!4L^RV-C-KV^UFQM<BL`Z5KR,&I"
MM1,"0/(PMB1<[[PSH&!U5268<&]_`GP4N$>&W[Z"U1W%\C8-5K?/^Q2VJ2AW
M$Z3N#Q..`E+)E*1@];&@WJI@=?2>C'W&^FOHO4A>5BPNG%_7%M2_D=3_"-3_
MLNY>8=.T`LMUN%V@F.6,7&_*\5UFN(XA/,=RQLP-L90=5LS<&;[G,_@8"R:"
MS07W_"*("<<49C&L+/]M,.Z8\*(Q8);/N.+;(]>VW3O_QS5>6R[ZG-]<N>G,
M$+8]XR96:L<D;,2[@>_X,VX4W\F)5Z.A$K`',7W9'TJ^OP;A-DJ^T`$@(D61
M%(<_"T6W9)>EUO:75Z,C7=M0C6"#8*-:L*&\)XA@HUJR0K!!L%$IV&@H$U\$
M&Y60E561B\33J\P!\F[[^PV#;Q6+JSRQS'T3&*=<-$M4E-O="H^/!1MQRT/B
MAX*YHS2N,H[NTF1FZ&'@)9B(<I1C;"8\RU7U7*QXH=X))A,W"M5NJMN./3.P
M-O#_I$1IG/?J6$!R+'J2H.>1(D;04UOH:9X/2@X%$O00]!#T$/3LC2C=<YV@
MI]K1`7+X#^_P7SD!>.J^9932B!6]?)'<')GQ\\N=^1*ZDS]/FJVZ]*F!ACOT
M-7`GJ]L(?!XI7`0^!#X9HA#X;$,U`I_MA(O`A\`G0Q0"GP=0C7+^1Q@"N'&#
M]"B%@D"L)-5_*WQ5II^R_%426-*-IZ8;.^V&UFJI$_ZD(LD^K[R,$0;5'H/:
M@X'6Z?0(@P[-481!V\D885#M,4C7]'9+:S6[5`10R7!!]!XU-R@4X"LH&?I"
MIMA?X5&BLVMCXMHPW-0UA2T[&9@B$-[4<I)4O*S"9R8/1('L2[[\4F.$Z)O^
M>88'TE<W$\M?9H)H"F%@V=8_,"-#>`&WG&P;!HWYH3%AW)<3L_!@D?`#%5D]
MF"Z#*7``#_^OLY$G!/.%$7I6,`<1"F`0ALMD8^$(C]OV7$$I\7=HP>H$+#]P
MY2/%_4P8&*BPK9%<,_XQ7NU0(,4D-<P"I;#+@X?C>9F5N?!M#U;CA],H#));
MGVI9Z?/YU`UA6C@#X`88/IG%G67;,!78C/1B/@:?M.RBTK4"[#FQ*+^`O8?Q
M88:FANLUN&V$-M(1%YG;ZL+R\OTPXG,;)1L/&P$"8HTL`SZUS`,98K`[@;QJ
M,J04L%9F!LG4XH]Y8M$Y(\.<U#AC!9)2XXQ=F#$G1PHZREJ%HZS4.*,.LD*P
M0;!1+=B@QADUD!6"#8*-2L$&-<ZHL*Q0$<T1%M%LWCAC$=U*HF$R].4_K<12
M9FB9(I09.I7,T'E;'6"DE%`)Q;Y?CTT$/`0\!#SKNF&4)*,)>`AX*BM8!#Q'
M`#PUO.VH[L"SB9M/GOOA/?<W<8%&N><.]+%,X9AL;@F;.ES4!)=);]5>;S7.
ME>DOTEMD,%=8L`AX"'B6"$/`\Q!J$?!L)U@$/`0\2X0AX-F`6E5/R*])")/[
MOMI]3PY^1&<=JNZ^K]GL6L%ROABLM19Y'H3+&\E"892?V'[%8\7\]KR!O3+Q
MFWO*VA+B>>+YNO-\][Q7COO$]\3W1\KWA\=ZRFX=BWE\Z^*Q7-L*YFK3N$)X
M28$>"O0<2:!'UP%Z=D<7BO,\A%J$.]O)%>'.$>!.\UQU.(QPAW"GLG)%N',4
MN-,BW*E,7BMZC]JO+5']&KMBG0VYK_*8#7<Z$XXOFUC)OEZ.+Y@GL.&6F;0;
MDP.P3U%GK\\V=]@=+[1->];NMK1>IZFQ9YU>1^MVX16V&WNF:\VFKO6Z[>S%
M:G/!/9\)QTSFM!CH4AAB.A0>:^D:PR8S\M^&'`Q/@6N%??>$CP$!ZU;8<V6W
MK^ML.[ADD98/FP3;RC.1A.RHL'@8&.:)K=#@V::`\=W9%/NP)6.X'GXL;MZ&
MGRK,C9O8P\X//([S2[\H=P,[PR$Q$G*+Z<QVYZ+0=-ZPN>_+3F51JS&<C>%Z
MN&S7,?UDF^+5X!J3WFB+,9*QF<]M[EE"W0_O+2YH@JW6\"QO89-6[Y*OHC)P
MRH+,B_YH.4I3B[15:$<MTG9A6IP<*:AI216:EE"+M#K("L$&P4:U8(-:I-5`
M5@@V"#8J!1O4(JW"LK))=0FU2*M9*<J[*/136C&%H1IU"&@M/U%1RF%T=_V2
M-,]VF,X[FN1,L]_66AU5.0H=/'I222/LV4[&"'MJBSVM[D#3N\K0'V$/80]A
M#V'/WH@RT'N:KHX?$O94Q,U_$L]])T'(T_;NO\3U'^4!O9+"D`VDKW+N_4/Y
MI:X"N@M5N#ID'<O$*E5Y(L13ZLN'$$]]<O*)RSQ[`ZW=J)]&W2B:7G].)/#;
MG_P2^)TZ^#4;7:W3J%\H@\"/P.^1\DO@=^K@UVJTM6Y'?;,.@5^5(RS5*Z18
M";)M"L=LP$,W;I"66BB@@"E/H"B%M][!&`6WU%66]Z:2@4;,=,.A+3;0R2>9
MMG@0V4JT\=,2+CYA>`3J>%.\KY4($_#M3X()^+8BVY$`7WR@FH"OFB),P+<_
M"2;@VXIL1P)\:>^(C;PX`K]J!&&B]Z@/RQ+U+WP%)=V1JI5&,!%>U#OC64<'
MW3_HX0=#QQ.&.W:L?]0=2];U<O$7C6!RGU6-Q3V/.V.!12WJ5B$W$Y&;D&+$
MQ6B9GBLB;MZ*$QKB]-(!W%N@`6=W`I&GV!>&P]M\C-^8<LO!1C(SX5FNB91I
MGC>B;B7G:X`B%^:I-&.N8<J(RV[^^`!L9@4PF)&9S",9]76RDZXW5[#L-\D;
M@;HI\Q&2>E=D?0OPO/Q`Q&[9OP?^JP'K@X3XH8@#F;/0,R9<-M&)*`Z?+-HO
MANOXH1W(]UV/N8@=/LP5)`V^#3+,1O!G7WBWEB'\<W;!_'`ZY<G6YJ#(#;V%
M',/N)T]F'-LK6<&<`20M09:"0R(0DVV*Y`S\Y=9/^,*).@LA)LRPT9*CD/FA
ML-T[=5^@#=B,N@+1X70B18X41W%.?YTK#`]:D*Y\XU:F>TYSLC7O@/`Q1*6D
MMDN(J%L2->DEJ'CN]82#YEZ+3KO,KE++B6VH1AKPN#1@S2'E6^SBGZV/BQ)0
M;TS5BRA`LJN"%R)K]-@W]\(SK-TT;"&:1H_][%G&4Q^2(\MA&ZJ1Y4"60X6`
M@RP'LAQJ0]8O2::*F'6'5'T-`WO<"$)N4Z1GIY2]$=ZTE(J,/9][_@^[P@@R
MV\AL([.-L@@5A,&+\=@38QXH[2&BZI94O0*M;3F^91!5=TC5K]P.*9!2836T
MJDXRJ>0XY&'5ZDI8!0Z<?@H#/^`.E@Z5/9\'[#UW0N[-65R]^<32N.,-KX-,
M/=#*W:!OY0E2HJR^_VEIT2EMK541Y71P"E7AP!)AQJ$QXVE.$%4;*WKG)4WX
M""P.(C#'I4$?&":JOV="4D!20%)`4K`!D38)8E!<XNFV]AV>R1+FD^?BR&^H
MF]]0#4I4Q'\H"360PJ!(0S7DA!"C6HB1#FZ9R1PO7NEGS4%7,?V<-='J+H^3
M4E(_;U,8HT(\>%RB1@X<20%)`4D!20'58AQ5S",YAJ>,>E#(HQIF.SDPU7)@
M-C@F19J%XAT$%X>F1#7@HC3>T7M$O(,PJ"K<=UQ"1CX>20%)`4D!24$E"C8>
M?+"TA+RG'>5XZWHC8069_M[%";@>-M&VO!H4@.R**>H@<P^T_A][D2B1:<,K
M0Y^44,^;%3_/4KW#ELJ6$H1/=1(\PJ>ZX%-IA*?_B`A/]0_F5`_UJ.E+E=SB
M/31]J16Y2-Y(WDC>2-XJ2;5-@EF'+-O)W1;4:6YYGR<%P[9LOU*X/J_Z43&Z
M__6T[G\]'/F.Y![8;KL"836Z`9;@C^"OLLUKCA#VJA%8(]PCW"/<JQ7YC@3_
M2K,5`\7R-LU6-,Z[:DPE2#TX=Q.D[@\3C@)2R93<]B100UF'3ZA7[;@VA:KK
M$:J.3Z=R$'X*59."K:^")9_EL1W-^UJ_0Z'J:G(BP=_^Y/<HX(_\"PI5$^X1
M[IT:[I'9MY]0=0M0L;B\S4/5/0K:5)2["5+WAPE'`:ED2E*H^EA0;U6H.GI/
M1CYC_37T7B0O*Q85SJ]K"^K?2.I_!.I_67>+L&E:@>4ZW"Y0S')&KC?E^"XS
M7,<0GF,Y8^:&'OPZG0G'YX'KS=D=]_"B!Y_!QUDP$:HUS`7W?"8<4YC%\++\
MM\&X8\*+QH!9/N.^8H-'KFV[=_Z/:QRX7!@ZO\]R_YDA;'O&32S8CJF96#_X
MCC_C1O&=G*0U&BI9>Q#_E_VAY/MKP&ZC+`R=`R)2%$EQ^"-1=#UV68YM?PDV
M.MFU#=4(-@@VJ@4;&V3P"#8.+2L$&P0;E8*-QH!@H[*RLBJ(D7AZE3E'WFU_
MOV$<KF(AEB>6N6\"0Y:+?HF*NKM;X?&Q8"-N>4C\4#!WM(BMC*.[-)D9>AB$
M2<,LQ8%FPK-<5<_%BI?KG6!2<:.0[::*[=@S!&L3`$]*E,;YH.1\3J7C_\>B
M)`EZ'BEB!#VUA9Y#WU1!H$.@LYUP$>C4%G3:Y[T.V3N5#@J0GW]X/__*"<`_
M]RVCE$9,X=R+Y-+(@GNO'H%<?%)Y1T*?&J@^LK</S4H$/ML)%X$/@4^&*`0^
MVU"-P&<[X2+P(?#)$(7`YP%4HQJ`(XP-W+A!>LI"02!6EOJ_%;XJ\T]Q@4J)
M+&G'4]..NM;KJ^IO24&2=5YY^2+\J3_^#+1FJT\F.B%0Q2A""'0B"-35VGJ+
M+*#*A0BB]ZC70:$(7T')T!?H4[-7>)SH[-J8N#8,-W5-8<N&!J8(A#>UG-CW
MC@KQF<F#HAN>]]]+^R2<9[@@?76C<.M]H)PUL@Q\(/?]<#K#7@P^NQ,X:Q/(
M(1^R>&Q1@QC<-D*;)]_S!`RTJH]"\LU<@"#//]1#@8[R$2ERI*!3C54XU4@]
M%.H@*P0;!!O5@@WJH5`#62'8(-BH%&Q0#X4*RPK53QQA_<3F/10\R__K;.0)
M`8\$M!!^P#P>"/]I)982`\L4H<3`B20&&N<#96)2N7#*#<A'?K_#3"Y!SW:B
M1=!3>^BAFN5#LQ*!SW;"1>!3>_#1SSMMLGN>W.[9Q-TG#_[P'OR;^YDP5GKP
M0!_+%([)YI:P52<92NA*'CMIKNK2IP::JW%><B\FZ2WRURLK6`0\M0<>\M</
MS4H$/ML)%X%/[<&'K)Z*>NN'3,ZO20Z3"[_:A;>M4;9_P4;AL$,Z\6NVNU;`
MG"\-:ZW%G@<A\T;24!CE)[9?`5DQOSUO8`N41ZD4S#UEM0GQ_0&K0S>PS4Z0
M$F67:9^6&WAR-OPIPP6IR2?<P&JH24H1'HM_<>OB>6;;"N:5=RTH4D:1LB.)
ME.EZY[RMO/&,0F64(*RL9!'RU!YY#NT9U@MTJN`J$O@0^!P)^.AZ\US55H3P
MYS#YP>@]ZFRF\)H=7]7>C/N^:U@<&XC?6<%$W9$,7OCL64_3]8'&GNE-76MT
M>EH1K;ECLF?MCM9NZ)EVY&PNN.<SX9CPD$MAB.E0>*RE:PQ[\LA_&X6-Q*'P
M$+W&/.&CRV_="GNN;(UV8=O,#XT)$]$J<;;%\6S8/KG,P&5CX0B/V_(AW,3F
M;7[@<7Q$<4WQH.HG^YC(5"P)5NW)>8!$*X@>.IXPW+%C_2/,!<4MUTF7X`D[
MF6QV1Y8%-MX@)O\S%E,AV\>M"ICE@AV5%H\UHA'Q^LT?'X#9K0`&,S*3>:2X
M7#G84Q^I6>"C;[%(K(DM'0V9=T=2%?B8IB79'MC<#0,_`(%$T/`#6"1SXW:&
M**5%(6!%,?`U[%ZHDDALB3CAMX)Q>!0P"WQH>?6ZUF]T-;TS4,QD%GK&A$MD
MB0'1\OU0BJ=B59;D'A<@SW)@XHZ#Z`6+E/@ZLASN8._#`F<!`L$"Y4?5+2`3
MUL-%`L$&_9[6Z[?B=3F%\9)+(]G,LPQ9<?%,/V\T\!((YD\XMGH$P@+@6![V
M04B)IE).0,/N3XO51Q/HZWVMU>LF$R@^L+A1S_3N>:=1\F!\2ENY\LOBK9>+
M,4=NZ`%A_PZY%\`@L,X(@^\010W70ZV3`?SE?<_C?PK`DER=IJ8WNP4=F9E'
MEMP!?!'W.7LWQ]W$`L4D&VN:H4"J+=8M&3/AH!RM6TH,7X,M/[\(_;,QY[,?
MKY%I)ZYM"L]_\W=H!?./;B`N+=^P73_TQ`W,]17BR,MHT)^3+WZ.5G#AF)]0
M@WUV@2PB@.DB%+X"&HZLP%>,@UP>P"]?Q.A?WQG-_[P%*U!_SQU<X8W;TF&'
M\>5W+RN(?WEFV@,&QG_X%J]P"/NRF$-/R>_[>_4EW<XB!W^V`47*71E2:9NT
M"YX!"EF&-0.T0!GG;!K:@74FIC/;G0ML%PP:0%I]>!/P,$2X7Y[U0N;8#/:$
M/4<C.MK#?K/9^`G,Z[^BW4K^IO_T0PID@#6FBK6'<]1^$\LSY23GS!?>+0+U
MS'/Q4)WWD\1E?-9KT+;<F2N6ETY;2!6`'TYGPP#[AF+"[1%"H(7W%D>K%KYB
MI"''%L7AS)5$XH$Q08@?N1X0C*_1`I%'H5KD2B<C=2KBWLN+'?`SFCRCD7.K
MDR#^K-/5!LT^>$&@&[JMIA;Y/,U.B4>4=UZVLAD7N+XM/"_#_)4#YI2XX??'
M!N6'P_'^$^-XM(4*L8)=7=W'BF!\"<8O`@49%0BR<"%`1&0[1&D1CH0I34M'
M%)U%%VQM,"L!M$#*?/8\@^$?/WW(H;<!%N,<T`\L1W-A.F?,U!G`]+T%0`E(
MPI[U]/,6FUJV#7@`&'3++5NV74=':C3R1<#XF%N.'ZA`<A0&(/(LX/?R.Y;D
MI=A4C<Q3Z;K<<F^.<^=3-Y0^3T%1`6&:@)*>&XXG\$M+5T=)8B^/V_8\):,B
M>+2TPFY;:X"[`A.!^0#>P^00:TT!6.K.LB9,9I`LB;_(U_C_RQRI8=W,`"6)
M&BJ8\"!GDC>;RXO,KH^%CBU@)T,L,,'@#<S+MH2G7/='-R:M:@\"E-.(H89"
M.*"2+1GM0:92*0H2WS+Q51D7''D&#"\T1%"+_RJ\,1I?H.]"/[X:`7TBUM&D
M+8#2J-BDG%#"7GI"&BU^.,0`06`A1R=^'3XFC6>H?-^)A4$!RP"L@,?EQO;E
M31*7/)R!$<1NA#%Q7-L=S[5E2@+L*UGM%_<.Q,+3V'4<:VCUF\G:K[#%H9.Y
M67(QW!?XDA.BO6<*J?@1,B)[T(^L(A2/*9\SVYI:`9)*1:9(&GB\<KDZE-2,
M_&5D;FGA15`!PY.-P6!RI)6'L8;L;F;OO#`F&/14C>'>@;_O3ZQ9VN`Q7HL4
M.-<P0L^+N&#&_2"^%]-GKK<\$*Y=?AP_&^-F_.DMS;G3E=1+,1)>B7,2ZZ`(
M%3TQLH&/)?>"6F5B-,)?D9_!HW`]GL8`%P.8%GS($XX!WQ^*X`XQ%;\ON2VK
MQ6`4#A`0^(M@4'8<V^)#+!ZT1"24<;P.A-83\&BIS&>A-W-]X2?^4H&#XT?)
M2UAPD,7JEC^:#*64ZNLLKX-+YCHB7@%BEIDC9TZS9%:86Q#,PP[104+*1+>\
M2-($RV,4`ZB1ZZ0W5)?";,;T="\,M2<G4N1(09W:J]"IG>Z%J8.L$&P0;%0+
M-NA>F.K*RJH:,>HA4?$S7LN.8O'Q"Q]GU265NY?!3?;S]!1,_>&"CH:3%)`4
MD!1L0*1-+(NM@T'92%>ONTDQO\H02.RZ2/.WO]^N#<##&Q5$\WFJ/@5/;)1\
M%(J2J>1G*=&;37$\K9-`1[&V$[9Z',5ZMIZ9=DR7&AS!:K:U?J^#9U,.JP#K
M=0Z+SH$2^!#X/!Y\$'BZVJ"CNLZ.P*<:YO@A`WT;F/3+YOJ6EOAIQ0B_Q#6!
MY3;Y4K%@60G2ZGJ&')N1A4Y*LK+TJ8&R['5;6G>@[JA.NI(,]<K+&&%0_3&H
MI6M-PJ!*V^N',\$SE1#%,/JF@GW:AKD\?'XF3W>6/5_5\41MAE?=#G]H[5E=
MI787>G)UY5DL$ZOTZ(D03ZE$'T*\DH;]3TH^71L,=*W75<7DU?2ICJK=J#"N
M_MQ(`+@_&28`)`#L]0;:H%-R?QP!8*4]$,H8')]C<H.-W\H]"Y8>J,Q4%U-R
MH!XJ@P)S6ZC4:@7FFCVMVVIHG1YETH_!,2`0(A"J)P@U^YH^(!"JKG&^QMY^
MH&%=?YIM"5,GB4&$T;7'Z*H<>#I9C":\(;PAO"&\J9)-6+V`+45C=]#C(=.\
M[LD+1$B[D79[)'U(NY%V([PAO"&\(;RI"M5V$&&E`NQJ6]8S3^!U97BST%,;
MS514N`W5J*B0B@HW(=_S5E_K]'M*J:ZR[JQ@0>$/*B(2Z%5.;@GT3A[T.KHV
M:'<(]"H!>O4,QI.O486:ZK71?/)+ZJAE2$6?O(HFOZ1"*II`CT"OVL0[#M`C
MOZ1"H+>#M`85CF_&72>96J74\Q:03JEG2CT3WCQJ\80WA#<9XA#>/(!J]8Q5
MKXV(GG;(>>4]/-3"HSK21PKOU!1>LZ=U!K+S'RD\:N%1+8H0")T0"/6Z6K/3
M(A"JK-5=B:*/@AR3L;W,%E^Y'4:%Y&6&,X,IV^X==XR2%MX5M[0IO4GI34IO
MJM*;*ZWY2FO2X\QP$NX1[E6;>,>#>Z4.!.%>)2L[=AG%WZ67T5;0_PC@8/\:
M2$&XVE-MUQH(:,1,-QS:8@,5]+3DJ\A=T0\B6XGR>5K"G=5?YZ@PK_:R2XBW
M/]$EQ-N*;(1X!<(1XNTU>A^]QX&/Y-OPV]![D;RL6*`\OZXMJ'\CJ?\1J/]E
M#?6_"04E)_Q6,.$CM2Q_(D"#L%%HV\B(441]$3=GXN^0VRQP63`1JMGS*3@S
M`7-'S`T]8(A`5>?"S%#@&"&,Z`7<<N0QR^4MO+.""?.$/Q-&@)_&`:-#F7/\
M=2P<X?%`,#\<C2S#$O!8>(3<\N6A+,=PI_*1GH#=^$?@]'V13,=R\'=8=!!Z
MXOPA._`M9IJA:YMK>?Q"07M/&*YCP*(B0@/=<";)?(%B0UCFR`**.LQV8;H^
MX\&"^(N!?C^_/F<C80)-;)@X#\+`]>9,4BC:+GC6S/4"V(G%\$7]$]]QRBQX
MD,]&+NZ\_^/J?$DN3Y(7-2F"S!"V/>.F:3GCF)R-6#;P'7_&C>([.;!K-%1P
M]R`(*OM#R??7Z)J-<H/E2+Z+=%\=()I(422%X2+')[1HKM7ZFT<H5RN6Q20.
MJ/\,@&GAK3>`]UUYT=`W2!7M,@.\C;WWZ`!J[66%8(-@HUJPH;PDE6"C6K)"
ML$&P42G8:"@OER?8J(2L/'76]E$!^BY=H;P1?V`\9$4E:$FDA,]FMH6Q*I?-
M/+$(D!0'P&#,ZJA(CKVJ4T5ZL+1#Q;(VE3LJ49&T3+6.2#SO#7K:H*ETUJN=
M>SDHV2I7PTFH0ZA3(]09M-I:8]`DU"'4(=0AU'D:HCS7-5WO:MUV=W=,0Z"S
M`;4V"0"03W]XG_ZS\.`#P@E*:<28:8U&PA..H6S<3;XYZ:MZT:<&>BL=W#*3
M^5V\TL]:#5TQ]1SXM)KG>F=YJ)2Z+:W34JE")4%)&U:[H)R@C:"M?M#VO-?3
MF@UESI\PB,(`U94MPI[:8T^I6=543#UG5C7U\WZI5:5W!UJ[JZQ'4)*40(WJ
M#2@VL98_O@A?<,^8E)<8<<=DIK@5MCN;XF$5PQ.F5=+TE>(455,8I%"/5Z&V
MUBK4SGE[19RBJ;5+?`12J!2IJ('P$KC5'MPZ`VW0V:#*F!"($*B"$D8(5'L$
M*C6OVH^.5W2[Z@M;"=RJ$J]XDA#$3DYOG7:8XO6$.^-"\XCDQW)433_6&Q65
M"U`\E%/J*IJ[T++4,O:$6L:6*NG..B6M]U<HZ5Y7UP9]]07#U5;2%6Q$6UF_
MA%"54)5054&^04?76BUE$VX"O\-S(H'?_N27P._4P:_4I.RN,RE7QGUZO9[6
M4;?;41*=4+4ZT:#J5:^L1.]-F^*>=NCH2]P^M+S")=.V-&XC6L?BEH>R2ET%
M>6^*GEJ?4^OS"BKA8VI]3HA'B$>(1XA'B$>(1XA'B$>(=WR(MRK0$KVGN-[F
MYQ>A?S;F?/;CE73&;_C]I>4;MNN'GK@1]\$KC$*\C!_U<_+A+\+FX-I_YEXP
MO_&XXW,#:T!\Q7>9`6N"7[Z(T;^^,YK_>0LDT=]S!UOJW[@M_5(8^/*[EQ6,
MF"Q1\(%<L.Z:G?@/ZCMA!N<9UGB"5_&.JB*F<I=9=IO7!%ES`9H%KU5P@_>Z
MOXN'*:]1XIY@[A`FB'2/[AJRIL/0\P5[,\4.L[\[UJWP?+R_Z#EG/JS$&ED&
M3]O9+(;R`Z#+!/A'>,F50*_=Z8P[\Q_8R(6_.6/7<L8@BGYT?1'(I"/D7A95
MKKQ'2=YO9,&BQQJ;>:XOC#`J\G),-L4;F(0C[W>"I\U@_HL6.YGU86]<0]:&
M^<P/AW_&]S)Q!G^6=P;QL2>$/-N&DPR$,7%<VQW/"^OCON\:EJ13.KM;;ABP
M)SZ[$TA*!8'CPW.P!J4LW<`@R>U%B@?XHKBDA([1DB4Y%[N&"_%Q@='N13=;
MR9U5S.U9LSW0!HV>QI[I@Y;6[;4U2=MG_0[\THH(`A.<"^[Y3#BF6C0!/,5T
M"+O>TC6&,"K_;41C81MQ+;D1"UC)GI^3X.[L_C/L%"_OQL+;LNY<Y'#4=!Y`
MI!\Q4<0'\4X6>'H6>C.0*Y0@^)X9PA8!9WGQL=#"Z4]$WEMK<?%9N7#@O6=C
M`&N0*E"UDHL^7OW"GOL"7KA!<2:M'Y3R<1EZ.",U5]T)>169M^#+#&_KFMYK
M:KU.'[E;:PUTK=EH)?R-'>LZ>IXO-:!"4=I6"F>.WLKY7]BV2F0BN?1!ABUS
M(:VA@]A9'+D$6A*AE[>5X<UT/NZG'R+5X]O3D.9R&Y1"1Q)7(G$W$\\-QQ,%
MS3^ZMQ'6I1QH"^X#4[AXGY^0[&7SH>MQV9\=;XD3>`T>7Y[_%.8^.0O<,_F"
M#;EO^9&LO)FB$F*O+'>AC`!C4RG4BDP*9O,YL#9PA+2?@*W06%IBV>492)Y3
M,NT7E/5RQH>)RD4KR!.X`;?AD\_:+4W7FSD-$BF0G+98GA(2E3CU(9QZY2AV
MX5<)WD#,ON30G);@"/1^:$N@7]@^"P;)C73I.MPVV2\66'5#P!$3N0PV=0K[
M-XVV,;XU\Y7+/3.#H-E!+$!I$`=?2@=^.![A,\"O9>+C)>_A_]GKB25&[,V]
MM/5N53SV24J:I^7`[FYBP9)_]<XS<T6;\1;&]]DP]-%*\Q7V(7Q,BAD8B3;C
MYJWE2[D5WBT\Q,]?&KKX6FS8EIIT0/!I8@2KZ*TIUL6!/E,I(QH;BC%W$#<N
M9IYE,ZG[&GTY6_B$C^\4Y8CE)$EO[D*A+IF+6J,!7WC6Z6G=1OS-])=E79JF
MTU5++9K2*C*I344"@X>`0<HGT99'4NLG8@L#\G$$`;B92U*LDF'4+99AS7AT
M*:O<.V#26[R)9&:#NI.#N=C0%/=295/A@PUW"IHO<AKEH^^XAX:*#P:G;WC6
M,!H=;476!<Z<`(0-BTX9/'V.0&!,I!8&H>%CX!YT9W&)K59'&W3:S)^`"94N
M.GIV<5[19%!G\4B3I2/C"B-'\UFSV=$:_8&<,]!$`+^;R[L\@C^>29V7K@HO
M9TD&PUF:IH5.*3RC`V;IH-6,YZB@UJA(,'$O/,.*+#\>@(%[WFBP&6RR'&0K
ML5D$X1X05WN9\%H:E/LMA*\)SYZ_M=`YM[A]Y2#<2Q><XG&/B\?IC2<.R%T+
M&\1>X5ZEV\S2?6:7/.#L>>CP$'A;F,J.>@3>9>!]H<"C<#KE8(T``OCQ1K"_
M4\*/4L*;2'B$+909!*:B7:TWUE^.O<'6T,W8=$$CD2)'BOQ=E7K2-V`?EU56
MK+RW,A=5ZGII[CG55.R-#%\_;6DOW6CY`*IM4J-/"$T(_6!2T&W"AP?I7[-M
M1E5/;REO2R1HKI8H$:H0JE0(5=Z'CBJ\G/RTE`<Q"5.J)4B$*80I%<*4:S$+
M9(Z$@*7FTD3`0L!2(6!)$K'ECR<?J,*RM$EXJC(M)#I-N@!EL_80M\()B_4]
MR8\LR),%E'0Q:U65>?TZ<E?DL%^U.G'W!RVMT6AND*'9JWX[V8;9A#V/E#'"
MGMIBCZ[U.H`^)<TP"7\(?PA_"'_VB3_-00^LGY*+XPE_"'\(?PA_]M@*O*OU
MVVWRO2H<6Z1PX>'#A1^%HL5$\F.[?DE/$HH3DJZJ%WUJH+.>=QM=K=E7!PQ)
M:Y6137DJB]"'T*="]*D#^C1U76N5F,R$/H0^U94N0I_ZHT^KU]'Z';)]"'WJ
M)EV$/O5''UW3.RVP?OJ[(PZ!SP;4VB1,2"6(QQ937/3UH>AB/3"<=%S]=5SC
MO*%R[DF]D6U=6;DBW#D*W%&=`B+<(=RIK%P1[AP%[JC"B80[A#N5E2O"G:/`
M'0HC5B>,&+VGN*--$OAXNK\^N+Z2FDD0*8JDH.:OZTR//6\J=K8NC813\]?:
M2-0FJ2U":$+H!Y.".A\='J2I^6N=H9E0I4@*0I7#HPHU?R5,(4PA3-GEOE+S
M5P(6`A8"EIWO*S5_K36L;!*>HLKKFE5>4_/7BDO=498#4`,B90.T5JNO=;I*
MTUJY>BH'V)NT$?YL)V>$/S7&GUZKI^G=`>'/X:6-\&<[.2/\J3'^Z-V6UNRK
M2B'5JR?\(?PA_"'\V5$#V'97:[;5WA=A3S7BBQ0R/'S(D!K`5E6"CE)7T=&A
M54>'NH.&UNN7N.RDM>C@8F6EB]"G_N@S:+6T!J$/H4_MI(O0I_[HTVVWM6ZW
MY+XH0A]"G\I*%Z%/_=&GW>N#YT7-[RO5NH'J$(\UJ$@=8.L&XJ3DZJ_DJ`,L
M&==UDRO"G:/`'95?3[A#N%-9N2+<.0K<(7N'<*=6<D6X<Q2XTR+<J4P8,7I/
MT0'VYQ>A?S;F?/9CW%71GK^U'.X8%K>OG)'K37E@N<Z-N`]>843N9?S0GY.O
M78=#7_P="B=X<PO_^.DGF0&+@5^^B-&_OC.:_WD+)-#?<Z?9T/4;MZ5?"@-?
M?O>R@K%"MDR[!^[[C=SWC[#O7U9UNOT6+W#HVIFN"[I^GL&6)WBUV$+%ZJ-=
M588HDP_E(I,+UJK@OJ[9U&B7;O[X`-MD!3"8D9G,5AN]F,!GS[KE@:JWU6>;
M&V(*5&;NB+UVIU/78=<!2A!W3/:->V6'U=DQ[L&NZ'T9>I8S+EI.@$``=',&
MV-/4V)W`GB=@JCF,C\>>&,,6X3:T&SUM,!A$\7D?_^*&BC8?1K1;OMRMP&7!
MG;!O!4P=:&Z9(;<9-PQ/F%8@3/CKK8!/>GYQG.>68]@A-M]F[8[6:#22!\O)
MP<!3V6<DF0@`!O=,^$5E^IB6)PQ\C&0?(!(?2^[Z@0&:YQ<Z"SUCPGUXX5F&
M6-X>>-:S9J^EM;H-)2!]$[#7OLLLWP^%G&4P$855+L:[BSD9/YD^>9GP7=B5
M1D-?$'X-T7G`>#1].5_]'&B7)E9@?R>6,6'B?@9$@:FM9(?>^:G(V#YQ[@JX
M`<P'H6)-B6_`'UY@8<_YSYX8"0_$@^#NT63_Y"@TBVS1RIJZMH1V.51CU\*S
MX+<+--B2O2D([RS=JQ3L#/@LMQR8N1]808AF(@!>*O\QW"Q3H0Q](K@Y;[*I
M9=LPE!)R;B:B*,++4[/\[$HD0CAS:8K#Y&#>2]"284\@QC*X/&N<]SH+1&'/
MFQK6B+9:K62<!:ID)X50F"[U!XWYX?!/@&6)?:[O1S,S_PS]0&I^[L,R7-`9
MPBR0'DB,HR&YK9%EQ$!I"A\83QKG*MPB02FSPT(/`2I0;EJDPL`+FDKIP%]\
M88`E$:"$+)06[*O4J1I^I,B1"QF0"A+TL;!N@3]'\._97/",S&64HH*SR[1D
M@0EC48ZX5X$$"W[.:\@R*2M.4$4O%`AK.@7[!N9EST'/"L^P?'0S,P.SQ%"0
M79=22T$U8(9PS'5B6N&M)#&XI`21$0Z-"9084#;F,@O%,H/^*](F7LVK=#5:
MS@@)9QGR9^>SH'..P#$Y$>!@EDS.\LX*)KA/,0V4.)7`7!Y3-*GX"KSQ>HGT
M.3;-3WT-/Z2[OSS0`YEA03[<>>7^K64&Y<#+2\V-Z3HP&+*%)--0P)I$=G#D
M:BFU``$1*<OY2]P'L=3&7U*N+-U#<PMD70142B,C+Y<B*,9$F*$M/HV^<CN4
MB'[AF+^!]V"-YN`27!B&&\+W+RW?L%T_]$3M8BQE_1H/&6:Y?OW+F\O?/[Q1
ML-S5%8OXM-_4]9_8UXL/OU_<7'WZR"X^7K+??K_X</7VCZN/[]C%Z]>??O]X
M<UU+8W5]#\VGWI&WKJI#+XKI'X"+?G3?"TN:;K)69-=&_S:DY#<;C77-?E9L
MQA'=A*6H(%U3%$JM=8D415(\ILOP)@0Z`A)1RUV2L1W*6/=!S$.=O'>SKQ>Q
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MW%H1B:2`I("D@*2`I("D@*2`I("D@*2`I.!DI6"3.-&:T,^)R,^)+)-@@F""
MI("D@*2`I("D@*2`I("D@*2`I("D@*3@Y,M,CJO%S(5MNW>Y^VF*$\"^_I?)
MG2(W_#XJZ'CJ6FC"6,+8D\58D@*2`I("D@*2`I("D@*2`I("D@*2`I*"36(O
M.PZGY"YW:B=W.ZT5MM,.LZ2#6V;"E1>O]+-6HZ=@V.4C2_EA4G[!2\#*PBZ,
M"?7E8$\<M'D4<^D*WJJKH*Y75\JE5QO(GJFX::]T&:RCB[P(]:`JL-G3.KVN
MUNRT#JL"'\U.M1<U`I_MA(S`I[;@T^\/M%:SN8&6)^PA["'L(>S9'5'.=D@4
M`IUMJ$:@LYUP$>C4%G2>]WLMK=-O*RT>0I\RLJG:0Q+J$.H0ZFP<XQGHVF"@
MBJ<2Z%0C[W'(FE-*DNPR2=)7</8>DR0-2I*0`B4%NF<%V@`%VFKU28%2S*!:
M%"'P.7+PT35@&*W=Z*B#!H0_A#^$/X0_E"@AT"'0(=`Y#M!YWNUUM/9`'=L@
M]*%$":$.H0X5PU8"=.B`B$NYCSCW,5`PZ_YR'_`XRGV03B2=N$^=V-&ZO;;6
M[ZO*M$DG4AB`P(?`9W^YC[;>U=J=+N4^#B]MA#_;R1GA3VWQAW(?AQ8Q`IWM
MA(M`AT"'0(=`AT"'0(=*7&L@:JM2']%[?&B+)&H^]%XD+^7?<Y!E""<07DR[
MH>N9PHO?:<1_-(1MS[AI6LY8\8X_XT;QG334/^'.V,+_F?"<,UWOJ;:NT5!M
MWH/(7/:'DN\7<*68.LKS7>#.%%,L)G)6<UC,Z]DAOEU=WOP"7^[/%&!7DDS:
M<2KG1M+F(]#FRV-8>)^YE,=2K(@*N5S;QKFU58_:,^V?ZZJ"C;V1?!.BKDLT
M/CV1+H49&H'E.GZYO<"8)V:>\`&06#`13(Q&P@B8.V+B?F9Y@%;LXZ</S.">
M-Q^YWAWW3%])2OP9`9RPF6>Y'IL+[OGGZ^V%'6S25OC_\XO0/QMS/OOQVI@`
MG6SQ:?25VR%'>ETXYF\A[.=H#NN_,`PW=`+_TO(-V_5#3]R(^^`5YJ%?1E/Y
M^<7]T+-?RM?_'U!+`P04````"`#<=(-`5%(@>4H(``!84P``%0`<`&=O=G@M
M,C`Q,3$R,S%?8V%L+GAM;%54"0`#OT-[3[]#>T]U>`L``00E#@``!#D!``#E
M7%MSVC@4?M^9_0]>]F5W.M08-A<R36>(DQ"R-+`0DF9W.AUC"U!B6ZYD<^FO
M7\F8U("%C;$P;?M28F1]1^<[^J2C"^]^*Q:E.K`!UEQ@2/V9!-4_7.M/J2BI
MR'*Z.I0:MDN_U5TX!O29/0:8_DV_'[FN<R;+D\GDK4Z+$AUB0)"'=4#8`ZE8
M?"^Q?[_^\HZ!J!@PB#/IW@-2S<%2J2(IQV>*<O:7(O7N5:E<4LKSE^@;)K1?
M^AH!TM0R;7)>"(%-^]A\B_!0+I=*%7E1L#`O>39E#Y;*3RI^::5:K<K^MZ]%
M"8PJ2*M5Y(\?FEU]!"RM"&WB:K;.``@\(_[#)M(U%R([@5T2MP3[J[@H5F2/
MBDJY6%'>3HE1>#_WG"2]P\@$'3"0?-//W)D#S@L$6H[)+/*?C3`8G!>&:#RE
MM2B*4I[7\3M[\IDR1I`)#>;["\UD+>F.`'`+$JNXUVF\MF$(T%B;,NID]I7,
M?5-^G[UI#9OB@JY+/UO`WM*ZU9>9@9E;J&ID=&VBR7:FO;XE?V-4UTS=,_T`
M:E(3EHP#4Q?8!C`6YK$*MV=HT7X*9B)]"<!DH8OPHGY3ZP/SO."1XE#3G,\U
M0H!+5`]CGX2PBP(;_!@>:*3O!W+PGLQ<)P/3)8LGOC.+)26(Y]^C`>2%0J0P
ME7FV9OL.OOKBP;%FTAI)S54UC&?0'CYHI@=$-"$9L!SB($1X#2^W4</ZPD;Z
M<8GM=<4(2LC$LRR_MB*D$;]X?X"1%<.DB[;V'\(&P.<%I2!-`!R.7/:1MBT5
M976L48@.T`&%ZZ_VP6S86</X9NQ!TK#ND\#CY16/I^XH;0P<#1I74P?8!%#*
M6^X(8.$]/0GL-U$\5'H2.2]@K++.6"K"0A!WR-;%410-E+9W7T.;.KI)IXET
M0*93IB&DX1S4#H38'X.8>W1M)#(<97&NXXAP.IXNP0!02PP*RF8,*B)A\P11
M%0^Z+'$'35<"#V8MXI?`0032\7D/LL#%"H7<@?/#<Q9'J7>8*XN;)!_$S"7*
MO=&CWYHXI9^O(`=@=]:F"8U+1UPV.W4L<=*T$2]_5>+SL-E1\0IT6*WA]&[N
MW"I5;#6AUH<F="$0.?6-0-FE0]1T'7DT26AK,Y8AB,S.HY'RSF7YK"W)$L=-
M66:P%`-[P-A/&/'!<I_9)F:$YRV^.J6;'GG@'G6`R5;"VAH63,P&M'S'[&2T
M;'(6/Y5-1TS71?K+")FT5L+&)W<F@I`(E)V6%I%E(=NO5-PJXBI&OI'#YVEI
MS7#-,5E/_FJ&`9FIFMG6($V&5<V!KF:&@(4H;3QJSKE/,GZ2>(^KO"GSTC$P
MD3_K[+K:$%RQS4('0P)HD@QUZ-(QP+,\7VLN/0SMX>H;8C+8G:WZ'KIC%LY?
M%_QB^NE1:/RA^<A^M#\6\X!FKQN=$F9VPY2),X_]7EH658HC2?YFJ;RR6_I>
MX![JZCYRRE[0<MAI"MK;@ET#(6M$ZR#I1;P#"*"\L^W`D$`$%8LP?C-@WLN,
M//K"81SCLDP7[.?'<TP*53,L:$/B,OO&0"!!<9#YZDXBAF*]EG$*^FK47$6:
MB(CM]R&8>63YIZS^>_SP4/GTWT?=\:9/]E'5^'HR'C[-[-ZE-ZF?X.K)W^7G
MWOV,F"=C_6O)O'5/>VJS;3S]:U:.[(_]EGK9F-7OORA.]9_J1>OI`9;K[<[]
M#7KC#)_17?OT6+&K=P^=\8E:KI^>CN3*9#*Z>;EM:C-U6.T_6+<7+TZ]Y%0?
M`7)GI>MAX^+XWFHT[AKMA];MT^V-Z90MK'_H]I\?G^W+?A7*C>G+C7O5[5;J
MDUX7U9IUZU'I*?WKV]MC1>ETNTI#F1T]WK@O8]3K7Z-G\Z;TYJ[YQ3SZ.%8;
MD[8Q+0WQE>/5R^#QY.JE8E<NFV\ZZJRB.F7C"1P-SS]):K<3'$9+*8]C8'O@
MFL;@?+=>C"2N@N0];]D0T,M*N.:=&/4[X,9$*,NZ3!1W29CND(V6;1$HXWRP
M'82N88\!<=EP-Z_2/Q]*GXAH`!<KYW"*93$<5'R'9;UZLJA98$BM0N2^%+TE
M%2L.XO;N=)T;N&)'_V6`_+?S(AL<*:CA8MRP/^26;(BSS3/)O::PK^>-T^M[
MS7CVYG)%V#:!CFP=FF#)/_>(X;0Q&D-JY,6L1UCR_,IUC5T6\)<%Q"S69FA?
MVI6N2^!@H$.?/?K9!'ZPTES#0MB%7_WG@L[FQ./F?'!$0/RLG.Y)X/HXC=GZ
M#.W\R)>_?,7V-7W4UJ`##&`YOBF0^/O/@L[2)H;/?U`0'0!;D9'U0;SN2,/@
M0J/VLOM15/^%=74.4MX#I6AV>0[.^)!U6"U:@\6)3I6"#P4-6QL!<\YG1),:
MX^V`V[^R.*)#+<9`8UM@\_\;]LK!(#94K!U,$9,JI;+D!P^%M/P$,7(D)D:^
M7<#94RB$`7\ZQI>\'1![G$T*O@X67.%9B$[D59[]<)[(DI\N&)+Q$T3)B:@H
M">X,[#TF(G!_[/0MF>L#ND_75]U3K\SEN&2Q!?H..PL_X>+C#G&XXJ[#.UVS
M6_.R[<89[Y5SFC;?*,FK-T:A[[)BA'0`#,+V1;N:"5H#[G4=,2M&R>$/MB=O
MB(>5>U#)79WE;1":L`0=K*93!`SV2W%R]+S7C';D=PLW\_;SLI2I^;7?O&0J
M"CT;F6H0XK'[S*V!X./V\:`'*TD;N.=)$L>MF0I1)-S*.KEMS!\`]C-!^Z4V
MUI*\CW,((#O>^[Q)U4YC46O@U[ZPP_]M`I&C3R3>=]]]-SJ3=V4BR]^Q:@,,
MD;&:*XL@<BO\G/MI&E^MY'S;ICR'=(A14/,CIV$QXO0#-3]2$WB[C=P#/>]>
M?_'1+_4_4$L#!!0````(`-QT@T"'R`47KA0``.]@`0`5`!P`9V]V>"TR,#$Q
M,3(S,5]D968N>&UL550)``._0WM/OT-[3W5X"P`!!"4.```$.0$``.U=:7/;
M.+;]_JK>?]!XOKRI*;4D>[(XE4R5+"]1XE@:R4XZ,S65HDA(1D(1"DC*5O_Z
M!W"Q*8D+2.%R2:._M".)N)?G`#@7%]O;O[3;K2MD(:HYR&C--BT\^#]G^;=6
MNS4@R]54QZVAY;!O=0>O$?O,6B/*_LV^OW><U9M.Y^'AX3>=_=36,44V<:F.
M;/Y!J]W^9XO_][__\Y8;&5#$3;QIW;JHU5_15O>DU7OYIM=[\X]>Z^YVT#KN
M]H[]A]@3)K9^S#0;M1Z7IF6_.XH8>YQ1\S="%YWC;O>D$_[PR/_EFT?^P=;O
M'TZ\7_=.3T\[WK=//[5QW`]9L;W.[Y^NI_H]6FIM;-F.9NG<@(W?V-Z'UT37
M'$PL`;]:B;_@_VJ'/VOSC]J]X_9)[[='VWARD?W&<)[,1`MXT?&_//(`:[7>
M4F*B"9JWO'=\XVQ6Z-V1C9<KD[ON?79/T?S=T8*L'YFY7J]W[!O[*__D&Z/6
M)B8V.$EGFLE?>7J/D'/4X@7?389/7BP066N/G.,._ZJ3^&0'V+5O8XTBR[E'
M#M8UTR[NZ6Y!$(X/+>8&FCKL[R6SE<_9W8>Y@U(\G-ZS-[\GIH&H??'3Q<[F
MEA5Q3.A)MH,ISS+_9.,WT.S[2Y,\Y`/NZ2D/,2E.W1`'93OA_4I6/>*%=<5L
M=B6_:5?4;E<6Z7YIPF:[\AI#4*"XZ1!LJ=9SF._*K6%YK<NO:[D]D%WK\CL`
M4/\*.`%3$XLX(J].\@#,<$V!SO;IEW)`.">ZRV6V;QD7EL-T;6C-"5UZ(5^V
M,ZE/1QW4J"[J8T(0&<:`/'I\X;EN8&;:9I;:!IIKKLGBC,!,U.6G,K#E=-@C
MG>`WG?W'P^8%["Q9:M@J[*O_=*0S@O#VGA5!=7>&VD^6\SD<5P!X??"@:2_1
M<H9H3GRW'GWNY"#<U$PSGW/\@6>76&7%%N8-[)H9WW(+/3K(,I`1.L:?SC^2
M"7HT9LHD^E;Y)A\*$AH6;VHS9+X[<NWV0M-6WYXB=N87&K(_[5B`O-><:_;,
M>]?@X0[ODSK(=.SP$Z^7:G=[P2#QKRE6(O6JN-.WVBR!45D.^Q8ZS_`^,]FG
MVSXSYD-7@DH@5DN"9^:4+$5X<4@R$(2RH<Z[(Z:(?OU]HQ/+817LPO1^Q=H`
M6OACN_![D]C(>'?D4'?K+0OR,=61I5%,^H\8MAYM&0H40#HYL?UI*EE;]3&6
MJ&V$]OG:Y:,H(X&9.\M>(1W/,3+.`P4#8"71V-8;R"5G7YI3F8FKF5L$)0.6
M39)<BKYU2R<)FJ$PTH.AB`,6D-1+:TG%>.K;-G+L_LQV>(X9@IH="V!BLQ-J
M%9>=74CD@^\GUUS*DYYI!"2EY6*?!*OHV;C&OP/'-.U-1>2A6*7F64<V_./_
MXXG1M68R\W;?&6B4;K"U^*R9+DA@)6;X*7`NDZOL.A=M`X(("E!8B,`KJC%S
M$Z0C9AHH"-ZS44$#RD?*/BK975,A^,<4K31L7#RNF,0A5@]&SCVBOH.!MQ",
MB)B%C+ED\20$7T#=<2)U!\@Y($=Q;%2F.SGJZ;[`[S*1W(D5;$.$C:^<S=C4
M_%PDZT97//:X04"-)\5>Q3R)-)DTM.#"WTB%@8R!X\Q4&0AG$Q(+#$R?=<G?
M'5WC-9]G=S1K@9FV^::!VDJ&Q6HT1J!*1@G*0@UH7'^.YHCUFP8SS].S`V(S
M>\32_<X4B*]LHQ5W<(*<"8`'U]6=HQ6Q,7/0KR-/9F$(2[!59:<G3%(23C#=
M7\0M6%+B#568-LBJD0EZ%$.)]`&H;PDN@&X*["$.`MU2(9ROL3;#)GM[9+.H
M;^H0_<?6BC;(H$S8=K7Q@%C24AQ(N;U8=&0<]:%`/C/N\0J;2=ZJN9ONC$4#
M9JS9UW7B6HX]UC8\+P0Y_(^W5'E&,Z7J;75G"4"!R8BNLP*,B'>PW"08JSYI
M)LY/$EZ9"E0L*';1+9D@DZ\X&6L4F*$4:Q4GGP7Y28,K4U<.CA``F4EL--5%
M:9DU,T'^<W1JQ2;7R'*)G:4W'V09`V(YV%H@2V>F0:;44LQ5(CN'Q`="&,*E
M`,J-K],CZB;2=E!877@RF]458GFFX>:M=VU42%#^EK2-#MRR@KYA>$!HYEC#
MQM`::"OL:&;$!9"P+MMJM6MJ\M`E`B%4KN$<K9%)O%DE-J9>H`N^L79%L8W.
M&6@Z=ECTZ2Y=3W'/7<IZY-TG8%*E!WO5F,8J@P&1?E:6.I:CBI5'FM+:1;I6
M@D6D69)>1?*PVM@4AM)LG(4&Z6\[V_M%(EMPH#>2[&XT5_M*U+X2M:]$[2L)
M[:E])=DUL]I])2G+7B*:UE\2ZN`_@AW#\KDKX$43)A&+@`N3EX\,")EDCZCG
MO^&-\,>(>B>?`.=!$LTV@4@A^&"6LT1,>W;LONO<$XK_>`[=@!C;,U=I")Z;
MJ'VT`H).9"="]HP.;=LMB9[`5,5#WH+DA#@%Q/P#,M?K6QRY#C_^S&`CM%+H
MB=IK)D=;B`5$O<@BJN0AZ>YQ8C(&=6HDJD:B:B2J1J)J)%K22'2"ULART27S
MU]^8"4'-OI$&!+4QR$#-Z8U6_.1<IO7!'D#875R)QIHP)DR!"F8D.$$V8F_!
M]Y%'9A<"ZS"-)<U@I5M/LJKI=O-)Q0VH._,/H3:9T;ZQ9.AP__B9TX!\99FL
M<%Y;J.YN[<W/@@]JB?%>U2JEYZM6AG*S$P.2R"J[PPCQ1WG7Q(:E)&*F_F?K
MQ((CD.<J<L".MV7,MQ.>$)!G5TK*XY4NN$F#.?.]P3)70VN-;&]%JV_9N[6`
M?0)1]1-M55'_!:M:M!$D8P6W=C&T`2CGNR8JW'62EX\=;&#FM&Z(1;:[/T`R
MDHTUAI84O&`&+#?(@=7L;0.-R*_O8"*:4,^GU&>:C74>S&'3Y1/,>60ZZ=E:
MHYO^U@'(+^76[@N-6JPEV>$$\(YYB/J>9;*J36\9]2U:_S-1`TL!?T%X<<^]
M6[,^<(%N7/XRH_G>+)?G$01[^1RH4%9RT)D35,&T90G3ARF7_1PPRZ`F#]7D
MH;3)0[]:\FOKB.7M;(2>1(PU",86Q&QB/&1`&=X=8W#SB?&&2CB(6V0B,:V6
M;@E_/%HP!WA$5K%\VE(YH,4^GW8N%:DB0DZMC@E+?$)P@(Y1B=^<",=(NL$J
ML[G"Y&1@)GO>U[^8REOMY<YLG>(5-_Y\)'(<5TG76V664O$0,I,#43#`MJ9/
MD,-<0D8X2()K*0F6FM&!)<&4.>\A3^9A;MU(%'KX-4-"=VX<I/6B]V[D[[_Z
MQG?7S__;MR1I1WRX,=YR*)ZY'H(\$X=6^WM:$CHX"6;J/=$E`T>P:6"O7_87
MC/L[;,>(8N+OP;A!#]XW0,,C$<,-6$8FB*"`NLDDT$\55<'@KN5:9[CSHBBR
M!D!Z._3FH\IN@[[1)I,7Q0YL04%JQ2F;N*C5^B^R$8%.9"*OZ-`LH<9<$LKO
M$[IC0=;%(Z(ZMM%H[N]1=*E^K]GHBT;Y>F'QX=O!ENI+IDPX,R<4Y3'M5[)2
MJ,YKJLZ+M*5"&M#]2G[2):$J#JUKC-S1G#LXUC;+O4,Z"[3AN#)K'+06PRA@
MZG4YO7"PB54N6<F%UCK$*8A30-BI[,1S]D`V7'V`#)ZG0);MG;_@O<'(&\O:
M$_33Q39VT!31-=:1_S(3I).%#SQ,"KL<UVM=F4KG,<Q:@!QRF?T.@=+`'1N0
MWXGZ!G('`!O2+'DA:II,Q5?/LL?("5[4.8([!-R09]EGIZ?J6^5,I[I1V\SS
M0=B&1$L_TD5(>;R9PI6)86Z?R.=![?G-BVA(;5HF3'XCYENMJ8V>'2D_(1WC
M0HW':851#?F5M_1=2#$B<6$X[`>)N/([4?^(JP"P(<N2U]ZGBT7%'*=YT>"(
M*Q7<D.>4'!GL2'ZV&QQDCOK`+G\`]_G7T/J#6`OK6UJF3VY.EJ>MPE.ZXY>'
M'9RB%3!1XTA`"H(AKY(2@ME925A:A6W4.ATG!\5P78GL9?AC2G2$#)L?C\3]
MXX?3C^;`E\AD&ZTUHSFP"VF#NCXKJ;,@%A\S,,"X/_QOAQ^>/$4Z^Z4#=#?:
M80[57I8/Q#NL">6N#*M311#UJ,8J+0OSL#*4N\"LK_OA(1]]E-T!;-EN\#@N
M!LB0S)1<F_R&71&7,<:;VG''X1A2F996DS\P,I%M!W-M85)`RF@HKMS:LE4<
MJ9"TE`5E\M>M`/"67G"-5?$`M$+NDC-?TE4P7*`VFOMWB92MA'OVFYVZWH<S
MY#0YNR1?#BLD-<&!!L<X29"&Q":GE]1)5[`G79T`++'ZLUXTFJ.)Q-\K>0*1
MU`&^`6?_VIN:PQ]WT\U)YM[QI".0WOZEW6[]Y\NGSR?__<_O^LI]_&J].#7^
M>+5>?-U8=^?NP]4K>OKJX_'WN]N-;;Y:ZW]TS0_.Z[O!]=CX^F_SY(7U^VPT
M.!]NKFY_]E:G_SH]&WW]C(^OQI/;]^3OJ\5W<C-^_;)GG=Y\GJQ?#8ZO7K^^
M[YP\/-R___'A6ML,%J>SS\L/9S]65]W5Z1=$G$WW<C$\>WF['`YOAN//HP]?
M/[PW5\=+JG^:SKY_^6Z=STYQ9_CXX[US,9V>7#W<34G_^FKYI7?7FUU^^/"R
MUYM,I[UA;_/BRWOGQYK<S2[)=_-]]^\WUS_-%[^O!\.'L?'87="+E7MUC/1/
MW?G=1W3V^:/51[/>A_7E]?!R\>Z_K<%TTFX_XP=QSPP/`B]-\G!T0*I+G1"E
M3HA2U\NHZV74]3+E7"_C#>W#CMN;Z'HZ,[VO.WCM7[^=YX14X<+J/(#*"0O4
M?3-_CH%3H3J8/9:2=O?%_ND??,6-I6,3,<O<YBUA?WC[)6U^W=ZA34B6K:H.
MO"W"I5R0H1KD.5I1UB%[B['8WR;R(+7`;X`6LEL5W9*;1K1EB^$-=(+EF!&(
M*$7^PIV^KE//_&@^009:>BMXSK&M$W=W2ZNL133BYJOLN0'IS\4`W-E*Y6U=
M2MF(]JMQF[%I2?HRFFB7,9J?!Q5KP+Q8P*R223=8V>4Q@)1F0`QT\1(KWUKP
M#?3^-`93AVNLS;!98.@B5-(OU1KS("AR^%+1ZX)8S\ZZ@G/D_W\861H+TC;3
M#5;6-G-5Y>T[A5(!A#G`>-\HT^N5AHVPY8>W[EB&=PP4W,QM04]^!9[%((>Y
M8FK?&Q:C$QL[I=,=8[>RP:\\;N/0A`J/]JVS<)L'UO98V_!NA(^Z6`#NHNC[
ME,.ND">_0F,6@QSF(.?$X.(YM79+O-.)*%EC`QEGF\1(`R2<ENE?XSH'N>P(
M1')%\]45UI`<UJN+X0_,<^>E6-89+_N^^]>*2IHG2BNL6?-$J;!`B7=P8!S?
M3LR7NU/$J@BK%,YF;&J6PWH9OK)IM7_VGJ1$I;CUFK0[@;J[E8;,`2]8+OIY
M*^)4,]%H7B[%.<S79A8Q+\MY(`:<\8WKXF->I40%C;/>S):<!UYP!;W$EL;"
M.#D*FE98LQ0T%1:!'++:)@_0S@3J:K&=\])6::2;WIE)M`S_`\2^+)G>3$^J
M2V1()SP;=;!)VS!F"TXM#WT:$!LF)YEJK['-.!5$J-%,@DC'^%YB#!1GO28Q
M4$Y2\\";+;>%&`X.Q.'_XS'UFD7;/.OI;4[;S8I"<)S+?OVW;^:#$VX:-]Z/
M/JMNE&Y8S0([4T[,<`.V0PDB*'"=3H'M\.YJY>_,T$R^JHH5Z5+DWTC`^YJA
M-2=TZ2WNR#5,*5)NS4\Q*()4]JTXA6?N'!92V0X_/Q!F/BY2?G62=T#UW)YT
MBZ(E.`A)VFXH<2/=#7'0T<%;GO;JK-HWI_;-Y>5#[9M3^^;4OCG!L:KF>"H4
MS,$"'=858Z41ARO$H2.:\2E)<[MJM[I27:6Z2G65ZC9'=:=X83$[.I^6]Y=,
M\K.MB(EUC.Q;UFC/3*`Y'4'+C5!G413KIMB^9"O-5IJM-%MIMM+L>FNVE[R]
M(FM$+>[8%3\?-DFC$V80DI^N_<JFE!<77$)8FJH&LJIT5>FJTE6EJTI7ZZVK
M3TL&R'*)_9UAS].BH&/@#(MUUF11T(3V2Y>GS%R:E2PK65:RK&19R7(C9/D3
MH@M$MZX?ZEL&$QOO2`?^SV?A@4U9%_2D_LM>BT(LDL\N6^"[:NV7DG@E\4KB
ME<0W1N+WKX[AO7E)@W!QX[5=2U\`QVSI+ENWU?HQI=Q*N95R*^5ND'*/???#
M4S+'Q';XR>+4<_<,60RMTK+IA7VIO:X71[F&,J\6G2FA5T*OA%X)?9.$WC\=
M]59[+$G,4^TU8E%X.F*U6PH>U68ESDJ<E3@K<5;BW`QQGB"37QL]UJBSN:6:
M96OZSJPMJ%;G,=\(Z<Z%9TV57*UT4S*N9%S)N)+QQLCXOUPF.(B:F^`$2<V,
M',4%JN""EALAWJ(HUE6WU0(VI=Q*N95R*^5NCG)/W9F-?KK,MXLU2MZ5+8FB
M1&--V#"6`E5=]HI-]7MDN"92(VBEPTJ'E0XK'6Z,#@<]]VC.SW?WC["V##8B
M-/%\X]W(X%\+6];2\@/<J?^NL8/`KM/6L7.BN_QM^<5TEH.=321A\*>(`0R$
MO_EO/D$+S(]\MYP;;9D2!=A(_VU!UHP;['O+_MAU,K'4^E;M9"`D=UC<4%CM
M;MGO#D=ZJ[3:KFC=?V_I]U9Q$P.74F;ADO4\FOD5:?3",LZ97X?#G%ARK7.C
MZ9AD7C]5L#.)W%(WO=<HLD>N8SN:93!QD-6UI-JH/2<B.,F]I/[9ZMB=F5B_
M-(F6<M%M/C*B1=:Z"XI!0.0RI]Q(]YD7!O?DTM0D5/GMXFI\"U/,NPO<M'0(
MP.?(UBE>.9'QI`2<HZ76.VJ)!R+[JJ2B73NS1/G,FH$>/Z*-M-Y\I]@Z)S13
MP`A@?Y52UXOB[HOX!*T(Y8=,<Q?=E*%%3OCC2Z]Y1Y..3,#%:[G]CF_S,S'9
M`%>CFTML(BJ-AMUBF]$*]L`(D#^5WPH\"P/FUH)0:7W/=J$-"1UWD`@'4S*'
MJ;ZA+\@T/UKDP9HBS286,O@5ML_>'PI^4O$-H2$1G9"0C`V8A?(&_K6DTD:V
M\<76O>])`"/$/>U*Y>+(/X^A+]DG$OK]I()KKKR)>(3P2QRT;MORZ09!/UIT
MO6/^%$A"`M*&LVG9];<=;FFFV<A#X/\!4$L#!!0````(`-QT@T#BO'^N42D`
M`/P&`@`5`!P`9V]V>"TR,#$Q,3(S,5]L86(N>&UL550)``._0WM/OT-[3W5X
M"P`!!"4.```$.0$``.T]_7/<MK&_=Z;_`YIV.O94LG2V8UM.FIFS/IQ+%4N5
MY+AIIM.A2-P)"8^\D#Q)E[_^X8/DD4<`!$`2H-/W9OJL2,3N8G>QV%TL%E__
M:7\?O(<13+P,!N!V`]#QDVSY%.R#XWBYNO81F$49_JN?H7N(?Q?=PP3_-_[[
M79:MWAX</#P\///QIZF/$IC&Z\2'*?D%V-__!I#_^^,?OB9(CA-(4+P%-VL(
MIJL$'+X`DU=O)Y.W+R?@X\TQ>'XX><X&X1$ABGZY]5(('I=AE/[]BPJRQ]LD
M?!8GBX/GAX<O#HH/OV!?OGTDOZA]__""?CTY.CHZH'\M/TT1[T,,=G+PK^_/
MK_T[N/3V491F7N03!"EZF])?GL>^EZ$X4J`+"+\@_[5??+9/?K4_>;[_8O+L
M,0V^^(9Q#H"ODSB$5W`.*.EOL\T*_OV+%"U7(:&(_NXN@7,^)6&2')#Q!Q%<
M$.83+$<$R^05P?+G_-?GWBT,OP#DRX]7,^&DCFJPV*"#+:$A^<4Y)JA&*GS,
M8!3`H""6@)"PC6*@0BH!$]"Q7P,:$O['20&38O[[%XOX_O&_6$/3.$0!(?&=
M%Q+)7=]!F*73VS0C:ESG&AF#N3*93)XSSO]9$<I!H=R,0$)!C<1B+>C,&Z^K
M%.;",)C9?\/;D.HV'A8M,.NC_8_77WQ3'0?R@8"-_/J`(OBF/H]I4N>VE_@%
M/?C'EHGD7QSX,4:SRO;#ZG3F2;S4E5,6:\W_X)N>A1)VDL>AGD#`3\7@_VQE
M\_N1SB%;-EJK>IWN+SQO]=]IF@I7<3Y?.M>YE][2"><##\CJ/H!AEA:_H>M]
M_W"2V]H_"S#TKDG"Y<TG0+"<I]?7IS?75>VPJAYR<1!UD,QF"*/)6Y]B$GCK
MD7&4N_0^%\[2A66P6:Z3!$:9;&F)-DCNR`H1-C9$'@VB39!]"SSZ\=O*\K%O
M6V5,W]I3X>0.=JD><(L3$<'=UNHL%FQEGQV_#RL^KO:F=>RE=],H(/^<_KI&
M]UZ(<:33[-A+D@V*%C]XX9KOQW?<R]00VU$E+9I$ZQ</`EX4`)_\`+?#W=IJ
M+?E63;@Z+W0->X'A?>)AB%?0AQCZK2!:[*AE#1Q];P`R==I%+M`<^AF8KZ,@
M!4GYL:,-H$TX517ASJ^#+;I,X,I#P>GC"D8IQ,IWD=W!A!F\W/H-H2,J:`\:
M4<Z@FJ-`DD"9\I$`LJ$I-4DQ&0W\VO97ZI<+[=*0=%7A5-E2#8P,0K@!=8VG
M53U[I''FA>TQG%R+;@@0D<*X##HDRL%7`U-+%*]@DFTN,5<RK&=D!UPM,=P/
M<"`3),%G.R:5$2.T.FP(M3:P^'X/1#`#\1QXOK]>KD.:3@K@"F]RB&:GZ>?>
M,DXR]!O]A?.D@8K@ZQ:IA5?F.EBQ;4/FE'AH[">6.%0(5(U^V8R272B+1$)5
M'1'-S?:Z%M#!BY1K3!Y!RK<?CNOGH`J`9RA"&3Q']S"811GF%,+N+D,PT([0
M@M&R/RJG1K!2SY%/75#N-E"U^N1O?WE^^&;OZ,4+NB7\9?+FY=[AR]?`R\`)
M#B^6MU@;7TSVR`GLA'Z!?SC$P5*Z@O38-]RXUDPU#:DJJ0)/C?W8$SB'V`\*
M,`YRSG$<IQ@HG@1SC@92V7:DMBU>*T4"S2W&8<7$/Z!H`7PRU&G(I"S2JHZI
M,<#<1SF!JSA%V,HRM2TA#Z->`EQ6#E3;J!!J$ON\$H8WHBE'ZB277%V+)'/>
M6=.F+NZPNL-'U/MA4%OHS25#&H*/266DTA*X7UQEZ9":&2XG8U\;&%ZI^$>4
M>1&G7+I*]AQYMRA$&8(ICJ"OL]C_Y2X.`QPRDF@ZVPP9_2KC'L#A;@V*58D3
M^=^SZ;O9^>QF=GH-IA].P/7-Q?$_OKTX/SF]NO[KG]\\G[S^"IS^\^/LYD>W
M8;2N_*L:J,4BJXZ"#F6\$%Q=>B.*SVV)TJ1,JWJ(7L5E4%3"&^ZDLH1#2$MY
M2;@=,88:$XD@=@L?1'.U7VTBH$16<E)E^]CJ3KK+H%,%RM3WXW64I9?>AAPB
M#WGXQL=DM\:$3X2HE#+_&*S8UZX]0:FH:IZA>):F.5@,,EG#H**"PZJ*`)GE
MS*N0$+'&D._+\W^G.:M6D>VHC&2FYJG0-;R)KR#-.E]ZR<!Z(\%FL_)(3(9(
M;98U.P.R&)PNXV0#/D;H'GLBV/\"3SR0,)#XLR3;/'7M;;:+MI;%DO.DGP!V
M0-42VB++:0ME4U0O(JEX0(YW,35S)+%#AI6V\7*)LB6MHHR"XSC*4+2`D8\1
M#*$N,G26JVK%E`@OA)4CP),/<0;!RZ>.RVC;A5<KGFV9LJD/9#<Y)D^'V<V%
M:6>_J@.*?`FD`UW%O>I"K*J20D[+XEK6SV-)Y#"&0'@(H1QV.A0CMB..*(;A
M+E_LXK#IG.XBEVP"<012\MT>^,NSP\,)\3O!/1FS!UX>[AT>TO^!],Y+2*7S
M.KN+$_0;#+X"DU=[+U\^WWN5EXM,OMQ[]>7+O3<O7Q4?HS0E81(]EEUGY`)]
M0,[YI04G>_R*$U?[$4])=C>A!I^[)&J"`)%R'2^\]%`PBXZ]%<(>7@7-()%X
M.U:K>?UV>D0A5CD0D"+V?10!GXUU;OS4)5L+V-4XT<46GD"\TF):4'N=>0MX
M2CI]K!*4PA,X1S[*IMN2LI,UJ=39'3%,)4IGJGJSM[R6%T/Q4EPM18;7J[PI
M`)#=01!LH6!CCL$X+J/J2Z/J%3*]\+:#<6YZ)'8B`C<YB"8=TAQ$*O1!G9M>
ML=SD_F;'9$3;8:N+6HL!TA(ZR2PN35*UJJ2TJ(\X8C53E;?.@7RG3(:D^KEB
M*Z>5*O$A5-*`BO%4W@LH;*W&%Y;A/\$NZ4D<AEZ2.DZWF6N'8H6]C'?&1TT5
MS_?22RX2O+%C^#3VNH3)-0D\!P[FA6@M:ZT"24I1?QGO5W43K'!P3L/XIV.)
MP=O$+0C+I;SI0PTIM'1:)D8&5K\&.OL'#0)*E+2MD4=RG"A6$*1`L;C3-]VJ
M&W!G-'=F19=R5+8O#@GHT-$BEF!T[OBU"$^J/Y5)=SOVK$&]V*9;K:A0%9]S
M/:H0HZ-,E13U^#2*(U"I6NWRP+24M]+/D>ZA]+CU8GZQ(JV"L3-GWE"U!=P`
M<:IR7U4Y:2H-5K<0R+W;+0PGOI2A)+E-/1588VO]&]#6VH=5)#?^*>KO5XCF
MM_BOX#V,UO`,$\U:5PVQ_S21V'6"&_BE7<<2]K7S344HFNI.PI^:J3;DVA4M
M\G92PW99$2)S<;%,2(VHYTKQ?5E6_-9U[6>K]&H74J7SM7I\+"6%VXJER7N>
MQ?^\9="E[?853"$FFC2KK!RJY5B&L?`RA%:U24J*8#$78^B11>5PUG&R0TF,
M]=V@;>Y=*@_8BR,A!CX-EBA"1%=)W<^`>M6&TFKK4CDM(I^"C6)MW6KCW!XG
M*`JSUMM4@0$=CNL;UM"*T^'BA+5!A$!W'+=R$\E#NH7UXW_.(C]>PO,X'58)
M*FCZ[^^GK`5;*D3GE/A/@`@'Q,W4A&MGLRDJKG[L3-)D'Z*!,6VDPH`5/6]U
M4EJ2X79OJXL)D39Y1'0$>)([OD_?NDM1M4NBS&:T3-;B=74Y)>*^CPV^CR3%
MU)L0.MU7GT7W,*5W>QA\^OH<_LT0QEN(RVJ4(:)"L'B+/^=ZY-IXM\FK:L&E
M,^T23A2`!@P?=E'TF5A2KS+>H:)-17(3XSCV%$BGKAG->1E7:'R(H[CN*PRH
M%V)D0Z0>VQQ!(36M88$CW6B5555+Y+,SUQ>8#1LDU!$X*>FND2!0!OP-"/&?
MG68]N<*H*4%C)H8GW.^\%/DDO87"-2E4U/']16/MOPHJH$0@8OHU2TVR[YUV
MJ6J10.ENRN9H[[U/"14\9[_)ZC%<R.V+[UV.%$Z]),(6/"WJ,7?0#&&!VU#:
M3/ZVT")+W)#27#^O8")#V^IV7>WJBA*NFG45KG0(*S]!M+@C.GR/_8<%_+`F
M=Y`OYHV2*8IV"`W4(\!R0;D6<0(%+6``CP'A%-=1=65`'=^`,%*'JKKJ<TS;
M/946[S3O"[&KD##R!4U+-`OSE!#8K*[H3*U^]5ZMN8:WBM.O``,.GFS!.]+D
MWK2CM4Y,F;<V-M%>*-4L!E13@Q'T"1Z?3AP:FKUI\/.:90K3FUC4":%HB!!E
M";I=DR^F)#3$S&G<9Q08OQ[0]*WT0>RO"4&U:W?]LD98N;+"!%.E1Y&?0(^\
M;XDW;*_>60-L.VL`+V/PBZ:&Q>_]"F+2]`45J)\Y-);]Z52Y/'J2A<5#JWXH
MYAK0-MF#)]^M(PB>OR9]?PXG3UUF'D:K"[MG9X.[_HUT&D^VC<S@9Y(:'(2;
M.,Y&,=D-DTR6<>7?Z.=GBD+R?)1;YG;IE#$@FT\CZ7D8GYZ)"I,=I4:Z\'G2
MJ87-P)=+FS=*[;5-;+]$FHN?FX%PH@8MMT5Y5T3-.Q<Q.*PUTB5=5_1"_`?X
M0/\RR*&7&F++BJ)"DZCCJ8=]7!P-^I4;I&`>)]CI3>_<ZI*.B!M61HD=/6L?
MTVX7ZK>+V>J!G1YM)GK(S[`ZW.F49:^@ESS^F)]"R93_$HO\#L>_%_/AWL73
MPF^U($V',E$%$AY-]UN>HF;0OXOB,%YL0,C:)HW6?(H40=6*<MG5I=)-NC0<
MJJV``!?7+[4H[$=_/QNSVT&?)?PSR_'*ULTQWLN*KGC7Z]O43Q!-D5Q!'Z)[
MDFY4RN]V1-&_<]J:W>U&L4";Z6BBRL61[#S7YKQ-=Z6=+(NZM_Y$V7@1I!6,
M("E1/G-;RM*/$I5)O![8;[4)1G=ZN8\*2%W,5I5PF=@=G3[H]].0(69&>%CK
MJ(QC"$TW-9"J1(M*7VG]QO`F<BSK05>/VA:$%OO[OQ\IK1GI@>0!C*3S3.18
MU:-+9>EE$OL0!BGI85.X\!?S@9_0:$=JNR]>*T6B4BBBN2MOPRI?F*YBVU=J
M][CV>VVA5X,<-18-DUTZCB/ZZ&,<$8SDYXRT3KZ&/OXR&^C!NFX$V:R/[D2I
MN,@O'T=,]@KS%28)+$PTJ5RI6/'19J.4%4<U/:7&SJ[O9@CW@Q&M`U6*+#:G
M[(?B/A;$9Y/>ZG.!Z/!WB,/9J?_K&J6TBLCZAE##[>(-1`6Z%!K\%L$;J5B,
MHX@\+8?_]("R.["$R0(FXZ@&T5``5</>8)3QY5CIZG"DHQSD;EY,52&M#ST5
M&.`1::Q8'Y1-+5=GASA8"&&:?O(2TN/T]!$F/MKM#&!XFL"#:[T\W(#(WD\-
M"`[PP)``F&-Y-KHLAXI"*&>"17RU6-MM2"(ON24]_Q2*>,R)_P%E;-3O2"U=
MUK.ID@,>SW&GE,[^4_@M]FH\VJRD&.K)6*G-&E>.WJ;M^A\3MWG'?YF]I'^[
MH*GBM,`V3-VY-A&C*:;CDJ=;D;1>E3_&+#//4^DQQ0KM^J$:YHH9.%B-G6N]
MEE$QNFJ[@17\<PF+N^IZ&S.-DSLJ=Q8I\EL/XSJ.EZ3;FL?.;%FP#J]A<H]\
MR`B]@GZ\B"@4NCZ'6!>#TVSSK&OHR8CN$!!5VJ<PR5HK@8ZD8:0MM:PN/2N2
MZ/\DC<*F[7AM^U8,J>W2AE:*1$^*8Z\W]7SVI%<"V?/,N\=<J[RX&7B+!-)6
M%RP)>[:F!V6Y%HQSIVDJ@JH3M65;[^4.>3LDR^I9Q6JOUDR=J.%5U'EQF;Y>
M*+M!.^HZM.?S;M?<5]VP5M/OU`'J2+IMTVYI7KHNT3[K_Y3''NGGXAKUH[=&
M'E(/\C'?B52HS)-@P_5"T"?":DY*FSS]-4,:AZW#C&18\TQKZCP=9:P:NJN@
MR;L!TE$L`<9=;];3K'PJ1E0XQ*=07ZVE9PLILVC.WU,R5QCEO*N8G<,4&CG7
M<RD9XRH^LJKKXVGIVT%_U%.P<KWONUCI+$[(N=W'51P5"=^\]69Q#3O?:3J7
M+ZECZMU1Z531I$QW_S>CZ;%$>1)1#BP#]-SM&6,9@9ER*97)Z`G$DH?0+]7Z
MEP$5566<!7(CT)-#(_^YO2C"BGW5137`FNA6AM75QG:Y6VU@9,=C9@V53*V@
M1]O0CJ6::QRV=@Q7FCX/W3%MX2ZS_K/H','UQ9Q0<<GN&W=V87DPQU/1*B*Q
M-[\4JW.(@=.%4;G&/=*J>XD"*+D/(DZ.IOF.@$"M>E6!2,<:4`PDTR$:Z/1L
M?\1`Q]<B1]T&&?AMK49H/"K;J@AJ6ZG,$(W%XQK0%CDO-'`GXBY]:I2.4@E-
MUZL0#?+TN28%HZN)+$D3&*^SA%72>&'^4B)6V'B=L?`@@>1./P0I`?`Y'.@W
M5$'[7+[.KZ$Z>EPQQFZQV;\5SB%A;#T[FB1V5F+G=KBC>BB?P`AX9^0BBAXW
M(X;^+(P?TEX>4FQ"LYN,4:9+_WU$VB^,PG";?],69.O[=GSF6+S+K468YGN&
M6[%QWRS\O8K/_)IV"8YTB[O`L0X.O:+%%-OF>]H#2,].J`*S_[BJ(F6R[H%S
MJE9$N"`N(`"O!/'6::Y55XY;/=/AC+UG4#6HXK_8IR`PGHGX?0JNE[=*22%K
MY*,0?H`9>87N)L8_T&1["K$[WM5X](7+K@O2$]4"NU.!3JY+)`5\$.6O%I+?
MDI_9^5#*&BVU62>W3U)V5R/^NY0=F>_JH=)N9/-L7X]*(WCX^?\U2&AC#5,/
M)^2!8A_1O#?^.83T_=0HF"[C)$._#582JH379H9,A2"!L:P.I4W*O<H8YQ7Z
M.A*NI@R4&=)!^RZ+'JDT]S#U_81BN9A?P0`NZ>66$Y3Z\7KW+*FO+N/JZ.WW
M&U>F3;2'%V-XW6B3$@JX)P>%SON-:RM"O?.X'K,Z7,JU5S0ON0#2JQ;>P^0V
M;DF]]E+^OML(P=D;L6I%Z]*Z]#_^X>L_[>^#GSY]_\.+__ST+W^U?OPQ^O(H
M^.WU_>+'3?3Q9/WP_G5R]/H?SW_^>+-)P]?W_F^'X7?9FX_'YY?!C_\.7WP9
M_>OVXOADMGE_\^MD=?3/HW<7/_Z`GK^_O+KY-O[;:O%S_.'RS:M)=/3AAZO[
MU\?/W[]Y<W?PXN'A[MM?OCOW-L>+H]L?EM^]^V7U_G!U]`G&V>;P;#%[]^IF
M.9M]F%W^</'=C]]]&ZZ>+Q/_^^O;GS_]')W<'J&#V>,OWV:GU]<OWC]\O(ZG
MY^^7GR8?)[=GWWWW:C*YNKZ>S":;+S]]F_UR'W^\/8M_#K\]_-N'\U_#+_]U
M?SQ[N`P>#Q?)Z6K]_CF\/O]AC0Y._OW]V=&[%/T*CZ?!B]GT[_\!Q]=7^_OF
MFT)U@[F8G^0K^QB+8S%,^W(Y0KNW"&6D"-;;IP1E<#^>SXF=#PHSC_\;TE("
M/T['<$]01:BU$[A63AC7+V,@T8*<0;/G]K!/<XZ\6Q0:Y!V5(%D\*U.G2I1P
M9&-)8.;1T=2A#;?CG<;S6I+;)JR4^6&UU$V9+&Z>L55.HPFA!Q::>:O%683]
M1+S!GT#V[ZSR:M(@&XT<87\;S1'3O`@NR"&.S+&34B0P$>]IK?=\'07I>!XL
M4I)E=7]IGWF7^^5-Z#A$67DH*#:R4^8+8[6FO5>&>UO8D))Q**,*J0(MS8<6
M00>SCS$9!OPU!H95F!E.MS=LNRF*7*&5N=>OII_`59RBS+I><_#VED#LHL1-
MNL1Y1/)AZC1`UI&G7/T$\^Z0+FSBF/HTJ9->>AMBN$EZTO>3-:PZ"W:T3XF2
MWF-)A=R-&:GBG"(=2JKFZ(N;--W-1I>F=G2N@(Z6R'5:F76]]5&KG@UA>N(E
M9"=$M'(ZB>]1`(-W&^%!T2#YDC[IZ_W4/,Z\4+8>^J1>U'60T`"\+:(QU4/W
MI%#":ND^6-IAC\A/3ATM#0WL`V2%VE1?G3K1]265PWO7K9KT-:"JRYH\,BN2
MKE90S:)[F/95^R@#YK;V44*98NTC*B",L_9108[\$KHVSKBI?6RA2J7VD2NP
M\=4^#B4X@]K'\CP[?R_\)J8/^"40FR-L@++-)69XAKW.4_S;5?.*;4]E$>K8
M>]S$U$-L=?I$N:&B<04MC&!C:20#BX&NRR&TY5^KAM#CCVGZO/K<.^D?<C&W
MJZ4:Z.T7[RC3)DQ?,@C,DJ9Y>Y8V9753NJ.M!O72'3U6F9?N"#P[CA6W&!GP
ML(\G,N!0UQ89K'(0X`F)$9Z"VPW7#W!>D*"O#0I1@HA?W:.$,Q1Y.*KN)TJ0
M`7,;)4@H4XP2Y@6$<48)"G+D.YMMG'$3);10I1(E<`4VOBAA*,$=.CD4J.ZZ
M17^2BSE[/YW6;XJDQ_=+JFU-G%OVUKFUN2$2AG2J=>=AV*E<C@+V"XC_6*-U
M*,]9@Q*KA9!F-&HZT[62>*>GKMV4HUV1E1C7Y<RJB#GSGH<%YF-2?#IDCH*+
MK]=P3S\OP:-)>.3?5J[K,OT@$R8OX2"<>.]!&V=3M1BT\;"/)VCC4*<<M.%H
MC>>/.=9'?250B-5$;#)-AQ$<V+"2?TC&XA[O,J10@/;9V2TD&$)7M?#WWTJO
M35EUR).H*\H_!4^"_..GY!R2:C%)BM$?X!:!TUW=1"6JFJO-LR'RG*P-Y77F
M)9F^?*=XZ27)!J^R\L%684S($Q_P,G`+%RB*B$$B3ANEQFW&4VFJZO+D\JCW
M!<H8=QI)/1AE`B>Z0H2D^K8IOM^K`">F#;[7JU5(.RYY(;FQ&L;I.H';YDNS
M:!XG2WHI2BO]9P+7<G][?0I%]T\KD$!0@BK;K)+<$]XS2G`.>ZR:2WO;9M60
M;Q;;CAB2R'VG0%.V_$M0_TN"[I2SFD5XT<(T(WU/A_!9:_#M:"0/M<"0%)\`
M<HO">5J3)XMZL?+.A(P.G3YX&=6JO-XMCM(;^)B]"TG62&?#48%C\Z4J!7I$
M44><03`!^X"!(*;FW3I%$4R=53KJ2JJT(:I<,(V!F_`'R<HTL=@N\&B2(-*>
M4FFVGX*?"-<!9;N;XZUV>=42*/S)ZB?UV#Z&%A&:(Y\4=[#;%*0=<1PB'T%#
M8Z,)TMI1J1Y=,OOSG#R9OEXNO61#=*D"&&PA@P*TV\>7C.2[=7/T>=:AFX\2
MLB%LF")FVW9-C2Q1X"772K[9<],%2$ONM:Y`Z@PRM(_OXWN81,3/IQ?M#4UB
M.Q2KO2Y:R9$9OQ?8^&T!``;!7=2N+*#2IJG-WBQC)(3=34V</)DII$9T>EI+
M`'A;D[,B"W)#'S`D3SI$:TB[D>*E2U`_`[,Y?6$)(T+9!MQY*0C0G)Z'9VPL
M,5=D]/;79-JTTWL!$`LN2CWZED2ZQQYLVF*%GG\'<#`.$^2%="P96AD"4`H6
M,,(.51ANBDP&#"AI'BU12&N?$QJ7ZS!#JQ#3S?(`@#XHN,B;T#^A>!^])?YB
M#P0P1)B9U%LHQZV2.%C[&2:W?&H<CR&D)VAQQ[JVKE.8-T9X2O]22;(L/5++
M&6#CAQ<E^1N?XW3N:\SJ':'@&3S`,"3_WL4/](MT]Q.,)8"8:TL<7P4TF4R[
M$V*^W#1I@>1VX0H3"]!R%2<9V7=^7@<+QALZ&V]%2J:Q$#)(`C96]H$BG["#
M="\):2O_O%EMKAX5(3?0>F$:-_G`].BOWBI.OR)B@QZ]#$DG%VWP3*&7D/D0
MA2H._$LUNO.((!%I44'+4PC`BN0=/C;8:EK:#9R#AU*EM/!RBHVM1>"H?+8"
M,&W"3JK?$+O6N[6T9NZ((BB[_;>4:)(Y)B^Q8U*!XOK!%AUI59[[4.:"\74V
M.8Y!BB'D&"UE'M6H$;X15`X"%4='8)L<':0J";9V@MK."C-C]3U,%GA?H#?>
M4KJ/DYYQ&`=M0D/^<XO/,*;JB,+BB5LW2F4F[TML\C`!KP!#05VT*^BS%_%<
MMSSO41%*^]@#*[O4U9JA'\*D&E)BM6K<C$:!ON?`]D`5'%7X*L"*;1Y3AJN;
MWE0M=@>>&G?HI67$=W$88,2DT";;$./3U0G5AVI%><UHDQGI5^2TH`*01::`
MP75KG8TE6W]76)M375]G54$XR#F!,G*;CZ4H4R5[(H"GG(#J[UC=76U-:#S!
MJLPSTV<5+V&4LG=::-_%RQBO`9BAA"8)W\$(SE'W:+XS$GMVM2NI,C/[&IO9
MJQ(8(/T*W!K7OH1?VMI>N-?ESJ0A_B$LL3$M-@VS*9&BBY,,''5Z*4!0AP@*
MD*TFV\DUMH[:4[OBUH6QIL:<M4^\\1Z[&FPE0-;*8E2HD=G=-]CN,A@``W%<
M[J(CH]*N*G/`O+1%AF((\RC%9[N,14:,L-BW4*AV]]-15^-6>>[T+I:SP+`\
MY8J=F5YZ2;:YJ1R!=S51)G"M62P#XF0&[(@ZCNSLF<($5:`N3QP[2+<T;J;,
M,K=U&AB','TZZ&U;0@W:!!HK5E2%.-V%I330AJKAU.68H1W]YQHC@$FXR>^A
M>V'E`H^9"=4$:<UZZM$EO89Q2#*;,(0^T<@2+B@!@Q,O\\"3=>2M`X2_>>K2
MF)J)N+2C!FPS-Z%JR(:PGHJ8;1M.-;($RLK3S%GU5N)HW$H]N5?MI`:#3&^*
MK&]3^.L:!]BG]]"X$KH=BM6JHU9RI/9O0N^!%!```^%&@_1$5+G&JC)_XU(C
M(?A!#F>$R"P7&`D)$5Z1WU&AD9VSM`FQ=JXBG;MA&P;_#@9KTHR8='1@=ZJC
M`%N\$,TWM&40>P:H\XET#WAL7N3O3JY((7/(8#;#%JZ$3A//6_C%K2*'ES]Z
MU(RM2>R)K5WJC#K0,(AE[4".U8JC#H2V+85XWKX01AJ"]Z!--1/?D<E=%D:E
M!>SW<'D+DR'4O8G$;C.,!GY)33)61OHA^(E]ZEK7A`+:+3MN3M"TS<&U#R,O
M0?''*%U!'\T1#$[BI8>B84RA")EM)U-$B-"0L>_W0&4$^(F-&8&3V2;$N@62
MS=T\6LF\C)X@%_"GCVB0EAE\1'9+QC@4",O#\F_W0/$U^(E\[_K:N$Q<]5HO
MT60[%,-,@X#6VWHA:?$SBXY9T?UPNY(<H54W2TJ*Z*W:<@P@@_91!/)AO*W+
MB4(IB;3^TF8;'SH%`87:LOI$O&FNXHAV.!S:+'$1VG7D9:2TVZF\?'4[K&&P
M')LLF4BYIDO(ARX:=@4SCUSM/O42TM$U'<YX"3#9]:OY1`@/6MG'H/AZ+!ZV
M7&CULU/A?(VZT5TFZ!ZKXV7H^50GFW9(5*',&VBSWQR/`.'K%/134'Z[:SKL
MUQ%+V+ZM#1;-T.YU?Q$9_,=K6CC]F;':]&)_\?[E=)%`"O`!97=GZ_0.>Q:Y
M1Z&^TA1A62SY5Z.H[6W0VG"0C]]ZD*Z7J)X(MZJDP1SK3\%I$,==W@W1`179
MN5CUPTOOT,A/V]ZP(\=J?H)6)-JX@C[$%N@VA#Q_37;;4@K%[KE[&SFRJVJ@
M.A!L1[KVT/3$5;]"V<J+_M\(D3>`5R&*VQ-<5T*_&Q$=FE;6*-@1C96N#LU:
MR:$R21V]`(YRC7(W$6B9'IL&>.*JJSL@MPS*#D%#C+]7&1J]!D#1G.3-&\F#
MW+3=G>E3)$J`K!D*%6I$W2?SH?1LG@VN%WGRGIYPH%HZDBNU2IDO-LN/BL<%
M87"R)H\ELI>PKN\\C.8L3LA+&!]7<73Z"!,?I3!_CK!8()]HN\Q,]'Q1/]"=
M.X*=9\!W17IBN[TL@+0C(D_^P@&_@PZ0-ADO59=9=([@FCU:D[\::K0>.7#<
M._@:Q.HM,B'7QF)\\W?1)$&+D93;P8Y7Z.VTZ^F`*HO'I!(A3-/<_!>;@[$>
M<&"YO/=@0*Z^O(7\LUFX,Z7-P(_729*;'5ZDQ3[:`_EGKD^]:S1SZRB:DS((
MC`*(_LN\XTI](1/?Q3I+,QP88*F*3[=3Z#_#FG"`X;"#;?S#[GFV(@Y;N50U
M<@014QXD5:M(]P`;#"JC76F/GCB).FEPPW(QB\2R7,%[DG9AM*Y"E`D/5%AF
ME<$!#!!@D`JQ[8$<6EX3S."Y7OZ:T^>7P1APT*J,=1^'EKZ[3'^H@-G+Y0QF
MY7O;!2Q75ZI-YLV3K#[?K'=6%.D=_?_O,%T!*<N"44K3,5U6+_UW_Y:`!%68
M>X`\MA[/`8[OYQ"1]]\<73/MP!CM=2WCK^W[YWF<E][$M/-N`B^3>`63;$/:
M#-*T'/[M:BGQR0H(Y'F3'`8H@.S1;H79'LM=%I`<KVSU*?,DJ\LPR_7+/Z_3
M+*</AVR8&2B$>(VQ-DWG<8I_3\/[)+Y'`0S>;3YB-9Q%^9N+Y(Y3ANY1AJ!P
MMZ[@("(OL="EG+>W>D(P/25_IA:_P`9N-^`)00A0]!24.,$6J?/K&GURD!L1
M]"XAD_J+BD.)*4E(3X4`/OX#;GH+(G;`6JJ)%!+0$BFPCP']&N#/G11<M0IE
M)Q3@S-"F"W&.O%L44D5LB=HK7XXF=&]2SUNMHCE:OA)7KOW31^(NB&WSUJ06
M7SKMC-J@F\=CP>2L[IO8_O)L[BRZAZG:KD@V/\E>5T(2['4NI*,^:9[8=%DV
MGL3$<1R1N!J[W!=S]G.&;D-X#7W\J4S&*I'.%C@):RK@P1:^<R>G&WNTXQU%
MAH]AQ6OXP2TKOLV['=&*5W1==5DVGA5/_WA!S['2XH0C$*YR0:X"3+?/H!)1
M5[_+@T(P??`2;`QR5'N@0)9BE<A-A=,-69]+^LD-,:_M7HJ34EE4C5S,V1%-
M%Y-?EO]A@\^@C=O`[\Y=6\1\YNG7")-8IB@`8_!/H^#$RTH5,(]"^6`M1J%<
M`MHJ_/)D^"EY^PM_[BP*E0JEB$+%,[09A>ZFTF=1T:4'VV12KC"-`OR;!"MR
M)9@3+7?.,02QW&4;I!PF36?F4$$%K./$IADO>,N_"U>M'F/HG50(=G;')P[J
MAPHMYP8.%]UE`E<>"D[R9\?S4+YXQD2^QPH670ZRR&14'H<9R29KQ@6UY:;.
M3]T+[\1T3['=#HCM/@N]'NI&ZN#L>'D-O*+N+,4W@'SDR$`+>5[LI<V9V#X'
M%`1W>=/E'N+A$M+XXV'.I#7B82'+')OH;06GKB6NC'0M,>FTU$QK@P\F%K1P
M?F_P=_U%*Q2:#?]I%VE;8$*^<1Z-5'F]&X24D[";8Y`[-@T_Q5V-*O<H>C=X
M-PC?RXWK!):EXCTZ%%6H5LRG"'NK=U'YUDTXT2:-AJNQ.SO+9YH?XB@N,L>L
M]B%W<H7^165`66>2CWGJ/!@03H?K.<CGWBV3=H92WPM95N8,_T[244]W?VJ"
MMK8HA22T;5UL0)%:HT-<%GZW2FEW9^-/V/`605[$P&#^"+VDMX2K$++-&P,B
M(D1MIMGGA8J0`<W<JWT5:1-2H2'2V8[G\(UF++J<KU``XSTVH^1IGZ%4N.*H
M:*NXY5=[*UZAA*NLY<TVSG?=MNGPQ*+&@O&LGP_P@?ZITQDE!L*^<)\V59NL
M]H+:89.K"KUM&6][C5ZM6-IQF,B9`$\$PGF.YO(*K<I/:??J3BNF"F?<:Z9*
MJ?:R:;*K6SWY#W&XCC(OV9RA$)O4[HXE'ZSU>O(=`N3UY.7'@'WM3']:Y5(O
M*>=-TNYA?@8QS*PE$U!\5AP-NGXQO48T/PG-F9=9E,\$=;F^#9%_%L9>UM<*
MJX*TE8)N8)8O*_8AH%^Z2[())5!?2[NSLIN8+FZIY4V2B/7W\*R.XU2<KBXO
M\L5SL-TAR3!`QSD-P603XBVY=@;8]A"W!_<?\'3E-V:J=0[8>2^_=WN;@S<#
MKI,HGJKM8^WF\=\)7,78WS&O2\D!<*I0QG$@VIR@VKFHB#'=_$'J21Q[&5S$
M26^W"^M`[?<DJ>&7[UGT4U!\Z_A>(5<8]6VK.37MWO_-[#5)3@YR%+$%;*_J
M2$"!XCD$33(W3B$<'T,TY,,_A*C/U;8IYV?JGHO"^_S+OWK8JGU5O)LTS;($
MW:XS6L2;Q>#2J]]%=1;;MV8M1;/OU$[J$PS#?T3Q0W2-MX`X@@'-$DC>2=(S
MTR+P]@VV@!*YZ2:#]G\AHT`QC.6,$H>'0TJ"JYMTV>2MIKE/X#T,8]H;XSKS
M%O"4A,6K!!$O9(Y\E$U];&[6(=Y]\DS5[@B1JU;Y#M`/P1;V'LBA@PKX(NO7
M&.C4P^[.()[IZ(OMW1S!*[A`I)]SE'WPECT<.'.A6BM'X&&76Y/MMX!\[-R$
M\.51MQR<^75K7\A"P2L<:23D$($\`MB'4RB%;L\SE)'1TH`DKT0H!P$V:@2)
M8[G,=EJ2B*?>RWNA-]5^MH,\$,HPN'D1]*;HKLMU:?./P$_T,S=/@LD%PGW>
M<SNI7C3@'$5PAG\<]IG8+1;[0<XN">T*03X%]-L1O'8N%!17.^JS+"UU/@W\
MUU^*J>!?X?\B=_?HVOP_4$L#!!0````(`-QT@T"DP"^`/18```Z"`0`5`!P`
M9V]V>"TR,#$Q,3(S,5]P<F4N>&UL550)``._0WM/OT-[3W5X"P`!!"4.```$
M.0$``.U=:W/;NM'^WIGW/ZCNEW8ZCB2[N3B3G!E%OD0YCJ5:=GS23B=#D9"$
MA"(4D)2M_/H7X,6F))(B0(``?9@OL65J=_GL8O%@<7OWU\/#U@5P`#8\8+4F
MZQ;L_]U;_*-UV.JCQ7)LPM;`\<A?30^N`/G,60%,?B=_GWO>\FV[?7]__\(D
MC[HFQ,!%/C:!2S]H'1[^UJ+__N\O[ZB2/@94Q=O6C0]:O25N=8Y;W5=ON]VW
M_^JV;F_ZK:-.]RC\$OF&#9T?$\,%K8>%[;CO#Q+*'B;8?H'PK'W4Z1RWXP</
MPB??/M`/-IZ_/PZ>[IZ<G+2#OSX^ZL*T!XG8;ON/SY=C<PX6QB%T7,]P3*K`
MA6_=X,-+9!H>1$X!NUJ93]#?#N/'#NE'A]VCP^/NBP?7.O@M1*[5>H>1#:[!
MM!68_M9;+\'[`Q<NEC:U*/ALCL'T_<$,K1Z(E&ZW>Q3*^!O]Y!OQF(ML:%'L
M/Q@V?9/Q'`#OH$4%WUX/'M]A!M#*>*"N:],_M3._V?Y-KFG?1@8&CC<''C0-
MV^6W=%N0#,,'#C$#C#WR\X+H8C-V^\O40"$6CN?DS>?(M@!VSW[ZT%O?$!%'
M"!_O-S#GN\0^T?CU#7=^;J-[-N`>O]46UE"ND`?V&Q$\)2J.J+!.,9T=P6_:
M*:JW(\KIH;3":COB&D,DL+CJ&&RAVAG4=\1&&*MV\;'&;('HJ&,W0$+\<1@A
M)Q)Y#!$7DY176;Y=(-D^/BD&A%-D^K2;[3G6F>.1?FW@3!%>!$QNOS&YWTX:
MN"0TF#P7_.&2V+-A*7CP@&,!*[:5BF9G8(_-DZBSD;FAP:;<%.%8@6U,@/W^
M($N4VYNX'F7WI1C;DY0$$(5M\]W#F6$LOSWRH!MCLNW-"*&`04\-=Q+0Z.B+
M;6IH&]B>&W\2F'[8Z49L^F\9&N*(YK>4^!<,R(^N5&N?M&S"FXRT'MY\`0.;
ML4WDQXTPVQV*1$^TEP%?/C3GT'Z,T"E&"X;X\5"V0Q$FG/+]0?=%1TR<C$W@
M&!BBW@.4ZX`-15'/5"W^^6TD%?1-=#:QY\,]$GCKN$M@PBD$UBE:&-"1@GVF
MLO9O:II`H?#;\$0V7I$W.B\ZR22D=SPE<EUD_M&+!$MB#J>>ZV;V/V)B:$N#
M)DCO]!E)M+=!201*BQ@]!1@#ZS($,M.HP"*/#-]!\"1S@^_[F+Y-GH.R"$+J
M-Y5FS/2WH)AGO*82R&-K:6&#,$SZ'ZV]K`R;6.CVO+Z!\1HZLR^&[4NA1L44
M)UM[E>PC+R"3S:<@?/PNMF/O\F:]"VP0BZZ!"8AUDFCNC@XE#;"PTW8A29`5
M?O]PN6>$P=*`UMG#$C@N(*$T].8`A^\0O9`,CQ51JXKW%/9C(>P2U(';M27H
MAD0?IGE+8;_'$,F[!&3;73R=(?(,^[*<ST88+0'VUB,RX`P*+R2G+RF'N@*2
MFF&./N4>+=("\_`2D%6YO)@(/)EL/TV-6LJ_WV&IT/"GR$T"RN>M<^A`#US"
M%9V>]`QG!DF7')HHJ=7MT:AZO)\3ODE7[L--".?D\NAII(Q82.MV?>02DY!C
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M&3I3"$55]99JQQ3YHXAZNK7`4*)\W;M,RT5.8**\=1;;.A0O)V1MDYOX"""I
M?`S5LB"%R;!'!K0&3M]80I*Z$P9*H:K[M:I>8\;BSB(@"EF)P5O<7@$;!=.7
M8\^8@3.Z#W6)H0M.P12:T"/,VU_X`5$X]3'I'K:_(:<,7MJJ&K5X$3[@2.LG
M80@Y8$8%ER5DNZ]<36^M`9<6UH3R^W#EG'L?)5%1\E7-ON4X?S_2PJ8!@MU4
M[>WM5/$?Y&^SVMX^WNRZ:G9=-;NNFEU7N:`WNZZ:75<Z[[K*6::6X`.]!<(>
M_!5MC18?9QQ6:!.`.[U/P56`F?"*F.DK6^\B5&>(@U>T@M+.".#@'!C));!,
MM?7P=B$`E<T")JP+3'%[OC='&/YZXL62W+JC3O%0B-F;NW@)F0H4Y,>!Z_H5
M^3!2I;R2P>G!&*G(>\?EO"?(?4/?HT?*663$78D/D_KJZL@-S")O_DN`-ZNN
M+VR?^,:\\"TAZU&*.YP.E_0$1V(J?VEAC[@R]=>FPE"'"D.Q>&(J-325AJ;2
MT%0:='B9ZBL-UV`%'!^<$WO"'?XRPFA722V&&BG8*%SO&R5[9Q9M%I>[33=3
MF38-/]=U.6"IV0OQ%%,N("]+SS])3.1%5LII>WD*%6\+W!?2FZTQ%SEU.W?#
M@]EM8E?/6D`'TE>@Y[!+=.H^E4K94:$0WSA:9A^`.F7=2K*MZOZ1V84I,`G<
M:%C2=>%P_A*Y<IV74*,)G2S612;A*;&Z=\-I3`X+]@Z'5L0'X;"41W*^KL<H
M,=4->2_-7P@5M,9ZX*R`&ZSK#RT,;A<AG\AH/YFZU#2B_<&8;$390*E:=!U;
M()%];*M0-21@==46,!P=5.:25SY?72$';69AB5[+5E8/_^6`):K7XO0B\.0R
MC$T%-9D<VD*%?S:H)!O\8+C0I#P6VCY=U,'"++*^J[D+,E\Y<L)+-:6/,P,[
MI.VZ\:*++3-EM)Q]*I7PPST1F6Q$>R$3,S+F\^<=@+,Y?8$5R<HS<.4O)@`/
MISM3P8'1,KS+9H"J7H[!W8R(BMOV5<4$>\Z-9:PGGV=,A^[N<PCW4`#'S-@"
MS#CA7DB!B#G59@Z^-G/P+$'',"M?SBNA(?1N4.10,Z7/S:<JU*0*MG]2-1TN
M,>LD$HND/@.:SR6O)HN4Z#+!FA>)&6O)8IC2I^>%;$&7YXE\A9JTB*).V8->
MN082KAOT)ZZ)X9)J>;I;(,T]6??4[96BSV!M'^P%$!%W^@;G[+5GD*[8BL<E
M\MI1AJ:ZI;4LP!(5?O[Q]*8-\E:!I2O28VZEJ",RP$J4I?1XG^I6@/6L[WXX
M=>'>H*Q31N+#1AP/PXD?`$++>F"YN^<L(T$+4*.'9U)+;2)`5%G#";J<</]%
M>+K`"&"(PLU15^`^^(NDD4,1Q;JD^]Q*=T$,%1[2DV%A6%=2X>9MS?IP-!Y/
M[^"H_(RTO)`,9MVJ;M*ATGJ[.8F>RJUJN5%8M7>36C49W?(WX4WG\LQ5\M\M
MF1=TYPC3RQ)O"7<]>P#8A"Z("H\C'YMSPP5W!J8KU(L/F4MKTMG9@K#DGR[E
M75*<&YV51`&K*KVW`XC",XJ$5P(Z=&%)8>!<0N`/I_0=1L8ZV*A:MOFGR=2:
M@S,#%'GR=57+\G(C4+`+LX5J3KS808K<^$;1G1D%1OWQ>@U@T:(3<-P`[N!-
MA\'`W[T&/WWH0@^,`5Y!$X0O?0U,-'.@K#-]JC)=\XBKW)-1P)ZH&#`4><FH
MJY-W:`F[$3HSS!+0QG6@ZD^2RNLLTX.\ZC)!AA5ZD\PR\,;!H.`2]=Q.5WDX
MY)JA\81`*73C:!!1.)1';()9ZJ4-Y5PTQ69!#2*!%=,X"$K6%L7G!'H<`@FR
M)UNKGS%(,4'KX2DWKG$0E*Y!2IE"2'+?N'0BA32R&U$'TL@!;1P/I6J1$FB"
MXD#(LZ+6I#$7WC@8!)0CY98_)ML49^]`6=J-3M)M?BY,I)3?XL@L4UX562.G
M-</X`HSTA96E2^8%5&A-4<K"%[N<HQ3+V3/EIDRY'B^L0_/R9VD(8Z]SU#.%
M=$$CC$P`+)>>S4;?@UZZ,9Q*OEENOU+-W<Z`7KR$J?+S*W+S$7+H4(G`2:VE
M/WOTY/XQ,,F3GJ2K6\L95`-:4!+Q.%*T6]BH4[04M4AKJB`*]3AB]%P?V3-#
MKDL'757GDPW=M1[`ID`9N[U<85-\GE#D\!3E]>TLTI",_2VBABET1&@#UXTF
M9>.JBI!A8)I<C5W*!5/LU#*%2+&C/<'>S!>L=?_,!U7LT?+51.%=<;P.<S@-
M+^>JNCO>T5_WV85=0&/OEZK8B>^3%7H^PX!:L[$L4&/OEU]'V1R=)_OHO*,R
M:P?Y6^B?\DIVAL:6?J_V,4?=;!DV5<_`7MD^5?(%=+NWSFGOJM2+YDJ6K$2U
MJF^="MN5]IY*A2?V&$?)*&Q69XZUV:BJOE..\N]S&]T?<(1.UMECL4PQU\GM
M2N/O.)IS[.IVCEUF++%<)=?<)-?<)-?<)*?#RU1WCM!CXJ"SR8^7BO1,#ZZ"
M^1ZVOJFH,&VB)I7,%,>$__`?,2O^_RPC<-8HW3\>+WT;U;N_'AZV_GOW^<OQ
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M`&?RLPT"P!VKMT#8@[^D;70KI%=).`AN-\G460QL=7<WCF)M0=FA9YHXL'`X
MO0866`3+'D^A:R)_^V0&42L*BZM7UG5*#`\F^,4<H%>BHEK-?MB<+=#/RO=[
M-L%R5/I6`$\0[_E;CYLD$IEI.#V-]/>)L3,Y*P;S%:H93DIT^QY\!1RLQS9Z
MG1O.C!XR$TZ)DJ[I$AH3:',,70M)>C[MN"!R2@[3BX.-#-LP("GF%(3_#Q*;
M&*0TYGR%:AHS4XAOWIB8BQX':Q-\?^*N@810+`UHQ6DEOE;0L8*C'>6M)>&T
MI/8!40QO]3=M[EI.1B/(A5[E<9&B5TT-0%P0I$')P>(R7"[(WV1P08<1[LA8
MT_Q%QZ!DN.&#Y&M7$P&%+*E]9BB&-S_=VR;[O)DADQD]E7QO4'#V($8K:`'K
MPSJ3)DD9'HBTKUZ91JQK!-Y`RSO3HC",&+0K&J*4G*%AC8/RET67F"8-KXT7
M-$V:)ZQ&TZ2YF*B>-(@.GJ7G9M`]3AB04"/!Y:U'MN%X)*71I6K+W0-\!96)
MBVO7H?$6B.Z-(C`#MD+'G.6/'A@;-AA.JXT%!O5ZS+:SA@,+O@HOU<GH<U+>
MML+^/$U[#5,""[8Z].?GT#$(.173G^<)JU%_GHN)P!N2FO-C1#?6`M',=YH,
MQP2_D#F]=`NW)I\=*_P`D#]6'`)[+5%4#1(>%/LA5SG)'Q/1Z!:8V.P^<N44
MAW/UU3,5Y"*HN":<02I27K%"PI:F70?"QNAX%FSY:[ZE"%ML:G2\'?V/#B16
M9(A!R]3!+K'M,K:,0&#2K\EN@E2VQP>H*.\+]'V/Q"[&:Q*FTHZ?+::X%EMI
M"V+(7VY/W0<MMK5O62MG`RZ#SY^)UQ,[=3G.!TK9J,OJ];&_7-K!RQ@V73AJ
M(]?'X&ESX\"9(KP(T649G_/(U6-?8:I3N6`2>`<B[YP^$01<CYY7+6>F/B%?
M42HN$<";T_%)J$1M6*IFT_P5\L`!>V7GRO`"I*(Y/^2X-T3M!YN.,UF:>A$Y
MI4XL;;;&Z[HUGB&$&#;%-WOBFSWQS9YX'5ZFNCWQCV61G8PBI;2TJZ4FHXHT
M?,2PE4KI2H?G4)\QG#FDP9AT3CM<*TF/ZT,V-"'@Y"Z,(IOC?9X?A^&+JN:,
M'SWZGX;/-'Q&9SY3++M(B:UBFFO">XKB6$<N1,D04W!=H!7`#L7L@IY,SLE]
M]DLI=VAG0WETI3R%XX>%Y30\I^$Y#<_YL_&<S%12K@O2)RY264G.6PL^GK`Z
M$A*49!@/65XL8+C;\&GFC8^+%!35$)+G24C8(JEA);KT(@TK:5B)CJSD<0U6
M;EZ1LH0M7Z,V@95;;-D'FX@B2\7D)IQP8@JBSP#/""5+7M'8<RP"2'!V"_WU
M"1S.$DQ)%0)F%QHRI!T9$A-W3"2IX4@-1VHXD@XO4SU'XDLW,F*-TQ)-/)?+
MJ'A!%L"TJB9:'8ZER+M7F%%I98M*[%++LY2&3VG'I[B#JSB%:OA3PY\:_J3#
MRRA8X5,TO<AIVD65Z]'<<TD2`Y+"[C^IE!EQK7H>`<<-KX`)C@L>(=))`0_B
M`,\/P`%36'[^K;22ACD]0^8D*O0:(J5#Q]<0J89(Z4RD>+.-C&CCMD6/9)!+
ML_AQKBGK8EY?'9Z6?F,\E*55A00UF\J>'W-BB:!F*YD>_5G#CQI^I#,_RLLI
M,B(J5U]-MHWE8U;+S6)/E22F*+H&-CT0=&1@;WV##<<E/=#FO",?Q>&1VS">
MY\=X2L170X#TZ+`:`M00()T)$$.*D1%@+.IK0H^8$*TQ6^)8_?UOGX`"L+V.
M3N0V[,1)DGQ4B5%DPY*>'TOBBZJ&(.G1H34$J2%(.A.D8ME%1FP5U%P36E04
MQSHS(JYEVO[$!3]]8LW9"G"?.[1?2K/-_WFRG\+QT^SPUZ6+:BA/0WETICR9
M*45*.&4JTR:<<GE-#EAUVM(_-N?`\FW`7M2)OSF<TMMW0@<Y%J%[-IRN@TO7
M@J,E2T^*B=#3;.Y_EA1(7`0V._PUZ=,:CM1P)*TY$G_.D1-P_.9HXL-\EE4&
M[AIM^#]%ID_!("]WYGC06R>*9.S4+$\:$_<J)(@U,UL`?@NE78,9I$(<[\I8
MY)`K%Y@OB#UM\LVP:9`?MEM$IE0U8<[B`AKPV:"4K-%0P;$Q-^2Y\BAO2%/"
M*WC`W<1@JR]@1K3O8VK<.4D[AOT5&/C,L4Y)0BN/;J9D932;!^UL?!(W,'.P
MZ:=F0L_50TZPS7D\)[:[0]]S/<.Q2*\@*I/DZJB5/XI@EK@SN91G1O[$AN:Y
MC0Q/E".2(FN3<5+02%Q/S)5V>L0&B]IQ;AL"HGQ37)(4:P[M%@Z)RX'9F?V&
MO%/@FA@N`]HE#MZDU/K0D710(JQ?EZ`C43(BDC&=#;;`P^]@+2QG;XE5-?`N
MD:6W@8D@?\-1!4E(#7OD:[!$F-[W0\=??DX!BA'U=.DU2BGY*$4N..'.,*'X
M+\@FHU4#K\^A#;`P]+?%UB_F=X")1ST=WJXRE!N(ZQ/B.4-86(K9%%I#'KB%
M2HQUF2%F*/@.V/;O#KIWQL!PD0.L@>OZ`(L"/DM\#5V0B53LC",!X_T1P!!9
MPH:FZ6+KE&PR@(DQ/^9--K'<I_'N.?E$0'[/$ERCCC43FQCU$@/.3=FA5Z4@
MGQ1='P:?`T\,_LLG4IE1YW[7IC(GA@N"7_\?4$L#!!0````(`-QT@T#@*V16
MX0D``+5/```1`!P`9V]V>"TR,#$Q,3(S,2YX<V155`D``[]#>T^_0WM/=7@+
M``$$)0X```0Y`0``[5QM<^(X$OY^5?<?='RYV=IBC&'R`C5)%2$)(4<2)I!D
M<EM;4\(6H,26'$GF97[]23+FU38FR>8\M>R7#;*ZU?T\+:DE]>[7?^7SH(X(
M8E`@&W0G`-<^"?<WD`<UZGIM"X,&$?*K)?`0R38R1$S^EM\'0G@5PQB-1I\M
MV95;F"%.?68AKAI`/G\,U#___,=7-4B-(35$!71\!*H>`X42,/<KIEGY8H*[
M3@T4"V8Q$)(28U[AU@"Y$(Q=A_#*N,L<?)1;&%.U?*:L;Q0+A9*!"1>06"@W
M[4]\-[JW+9@A)AXR9`_$L)4#`K(^$M?01=R#%IJ)]1$=PK%R10YAFF:Q9(;:
MQWQ)^:@4&F(:WZ^:;6WXS!)*4AA#27YF4"#7I\-Q&EM\GE<JYA;U(.]J[>$7
M+9(OF/D%!QQ,GJ-\,,OELJ&_AEW7>BX#KSYW(9?`(P>YB(ASRMQ3U(.^(XYR
M+SYT<`\C.[?`HRUF^A9U[1G!Q]RQ#```5`A`0JB``E-RK`-)A9-N]SQ,>O0X
M;).MRHY*:,PMZ@'M1$4!<)3CV/4<%1NZ;<!0[RBG\,V'8/YP8/>SM##L`IG%
MJ(.2$3(\1CTY&["$>`Y#H&!->ADU]=F08R*G.3<Y9QR_FS\>0Q_NCQR3RP#0
M?*VX]7Y$V:CWX8[),3'!$6Z]EU,6=#[<*3FFY3N19"V[I7IWI"-`_7%WVXA:
ME+1&N3EPZF!;+?,GT%'+<7N`D,@!;`<>_XCM$FX5`"P./0?^6*ZM<L]IR^C2
MJXS>G^:ZP%09T-KX5V-5/$J[SY%]0X[UWZNQ.]4P[9(LNQP>JY(;!EZA845Z
MQH2Q1,7ZA'HS23]:D$D`!DA@:1)/P=FJ1`H*B^DI!)^6U?\6P>F.T!5"&T0V
MHQG",22N]EH'<HFT4A)ILP\<T!ZX\50>*<5V,S">L/9`!O:`.C9B_.S%QV*B
MQ(J4E1;X2N@4B>028U_2,]86U'J>CO-O$(P$/LG\#5L8$6L2->UV-*[.NQKD
M@W.'CF(FW.QSA/]+Q.VE)T[I!$KI;JK%<W1-!5K@1/],L4WM2^A/,;<<RGV&
MY`\E"%3^<0V%:I'XG_@<$\1CT-_!'\)?6,&_L'$2'$2BKU,'WW4AF^AU"_>)
M/%A:4,Z3JF51GPA,^J`E9XM<N'9S8@,I:ZP44FPKAY'$J/2@3H>($;UHU9FD
M9(?_)OS7"2ALRL/*D?!_"6[J7"STUA`)_`[W.>X1P`>QGX2]68C$7FW71;5=
M7"'61PQ`8H-;9$$/"^C@G]JWW4S8R$@4)844^[1I1K*RKY.H];1VE\ENXB&2
MB(T;MKJUCZ!!;>.W\O#.@F2V)0_W?P<&]%O''P]7]Z4___AN>?[XD>R5[9\'
MP_[CA-R=^J/Z`2L?_*?X=->9<.=@:/TL.)?B\*[6;-F/_W5*>^1[]Z9VVIC4
M.R^F5_Y6/KEYO,?%>NNV<T%_]_I/]+IUN&^2\O7][?"@5JP?'@Z,TF@TN'B^
M;,))K5_NWKN7)\]>O>"5'Q`5D\)YOW&RWW$;C>M&Z_[F\O'RPO&*+K.NVMVG
MAR=RVBUCHS%^OA!G[7:I/KIKTVJS[CZ8=V;W_/)RWS1OVVVS84[V'B[$\Y#>
M=<_IDW-1^/VZ^>+L?1_6&J.6/2[TV9GGUXO('O2J-?0X;#T_79'Z(>Q43_A+
MX>A/4&O?3I^$WARGT8&:(H<Q2Y&QJC*;X%8$=.!XESZF(R&&A4V)C/DEDH.R
M7B\<?=1M028FH"-32:X>'N/NDW:$K!`2QTB*#&<O^LRK$I\V<I"E:/GF0_7V
MZTS`.2:06!@ZX!0*"#[Y!/HVEGTB[XMV1*T1%<M4JL0GYH)"OY#X78Y>?+7E
MG@UC3P0[2H*K6&N`;-]9O".:-6V<,6OW%*$H:#3DKWOH^-H3?2SXIA_")^J.
M8GI=L2,F@9A3:ODJ;:P2^XP(F;PW2(\R5QL0D)788Q-WA;7S7*@.2'T@4`@6
M-/Y]$H*OQE)]15"*8:S58LQ*-+#K428`62N?2:K1"4I[FM32^A)$U*]\*)=7
M37FSF"^9G\?<GCU5;VF&<CQX+-_.C%#N568D%^7$&**-6)3L0^AI00,Y@L]T
MY>>Z9A9MB<QZ650:<%:E%#1E!8VY_W9#%DNBMC.&DNL$>U)8%%F6E#9<0@$U
M^-XZ#-,R*3WJ42[N<9U7NURHJKL<"(I(=`%<1;;)+:0AD*MF;0[`::^CG&"^
M*O_0O3SI.[4[6L[VV735)-AQ8%<5A@1]N<P4Y#KGJZ]U1GTO'$3F<6Z*]_^Y
MB2NPKGCH,_6.7^4\6UY%FF4<)WO1Q+"+':R*;C+G2I1M\?XLD#I_6+SIS5_P
M,^1?>EL39MJ-&"`6'/+/QAXB'&7'PP3;8AD\@1Q;,ELYQ8XO@<F.,W&&):\2
M,1PO7N0&U[CSVH3LN/PFZXWC>%BJ]I//@Y>=#JW:MDX*H=."V&Z06O#0$/Z+
M$NEY5]M:%3*8D!<XM0B.2PD2D$VBX.E!AV_`)_C6#3:!HYS%D+3H];"]@W>+
MR=<R=!K[!N<^LD]]%1(M[9(ZEB%5/"$C5'=1!V:+8:WN%ED(#Y4K68;MC9XE
MQ5N,:EV-Q+=%C6NI5V+VSN"D]B!VO=V$NH,X?X!,/7^?C1&S,/^E@RC*G:TG
MVQSUOQJ=ORQ<8G#8/D;.*5/Z[CQ*0D73#:+E,VL@#Y;387[5J$GO8$*6ELC'
M*R',WCJT)52OV>(:I(F1?]-3X[3@)"@'_C4#*\J55V]B&W')7K3$^+]=(AW6
MH/X"Y[IU4^.]#;N>,^I.SX.D7U7_L6+6#NEI+4U]')!)"R46=M`U$DW*98O\
M0R\K7-7X9QJ-]W(D/C`&D/35U)E>\!`[FU<WJ<Q,NC]<#*L&&2*>5<I36YHT
M`9:43!^A?P%WDRQ-W,E\SPL:H#-_KIJOD`LO5-GQ_#5&Q\[CH.!^\:ZO@\;B
MQ)';978\3F-D(LWS8O9Y+7M8RIY!?[>T-Y;<>=EX4#6>05<WFYB8H<>*AYX%
M_W>`B@C;/SCOC+<O<16>UYO/)W@&R4MI9R*#06DWKUHO/N8X>&U0=]O<H].?
M<]59#.`WVK_IJ+YTN:VJD#(=$-N;''_EU4*$JRV,V/KUID6EQ*S<^001U,,9
MGQYO]B`>G.`MJP/'F08@E96QN]>T6%77JBZ6JF;:Y=<8'8O`K!YT5@ZZD-ME
MT/DM[8V_YIW56`8EEAET=;.)R3>+TU+&F]ZLC%$N$_,BQK"&,=.Q_AY.).Q_
M+8:'<BZU'&CIYNH8\P]WVA85&[O!0MY86=ZC[$M*Z\*[YVJ?(=T^PF)P[O.!
MU#U]ALV<CRE-WO!R%?T6>(7<+F(KF;I-78C)_^-Z.-'(A#QE,T39<32]L0D3
M,ZDT.#NK4RHK]1:DRV^#XL/`Z?\!4$L!`AX#%`````@`W'2#0`>9=#??=0``
M$]D'`!$`&````````0```*2!`````&=O=G@M,C`Q,3$R,S$N>&UL550%``._
M0WM/=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`W'2#0%12('E*"```6%,`
M`!4`&````````0```*2!*G8``&=O=G@M,C`Q,3$R,S%?8V%L+GAM;%54!0`#
MOT-[3W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`-QT@T"'R`47KA0``.]@
M`0`5`!@```````$```"D@<-^``!G;W9X+3(P,3$Q,C,Q7V1E9BYX;6Q55`4`
M`[]#>T]U>`L``00E#@``!#D!``!02P$"'@,4````"`#<=(-`XKQ_KE$I``#\
M!@(`%0`8```````!````I('`DP``9V]V>"TR,#$Q,3(S,5]L86(N>&UL550%
M``._0WM/=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`W'2#0*3`+X`]%@``
M#H(!`!4`&````````0```*2!8+T``&=O=G@M,C`Q,3$R,S%?<')E+GAM;%54
M!0`#OT-[3W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`-QT@T#@*V16X0D`
M`+5/```1`!@```````$```"D@>S3``!G;W9X+3(P,3$Q,C,Q+GAS9%54!0`#
IOT-[3W5X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"```8W@``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>92</ContextCount>
  <ElementCount>110</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>4</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Disclosure - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Stockholders' Equity (Deficiency)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficiency)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 1 - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/role/Note</Role>
      <ShortName>Note 1 - Nature of Business</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 2 - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/role/Note0</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 3 - Government Grants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/role/Note00</Role>
      <ShortName>Note 3 - Government Grants</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 4 - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/role/Note000</Role>
      <ShortName>Note 4 - Commitments</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 5 - 2006 Merger and Recapitalization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/role/Note0000</Role>
      <ShortName>Note 5 - 2006 Merger and Recapitalization</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 6 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/role/Note00000</Role>
      <ShortName>Note 6 - Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 7 - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/role/Note000000</Role>
      <ShortName>Note 7 - Retirement Plan</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 8 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/role/Note0000000</Role>
      <ShortName>Note 8 - Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 9 - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/role/Note00000000</Role>
      <ShortName>Note 9 - Related Party Transactions</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 10 - Selected Quarterly Financial Data (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/role/Note000000000</Role>
      <ShortName>Note 10 - Selected Quarterly Financial Data (unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 11 - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/role/Note0000000000</Role>
      <ShortName>Note 11 - Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Schedule II - Valuation and Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/role/Schedule</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 001 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2009'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2008'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2007'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2006'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2005'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2004'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2003'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2002'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2001'</Log>
    <Log type="Info">Process Flow-Through: 002 - Statement - Consolidated Balance Sheets (Parentheticals)</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - Consolidated Statements of Operations</Log>
    <Log type="Info">	Process Flow-Through: Removing column '6 Months Ended
Dec. 31, 2001'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2008'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2007'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2006'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2005'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2004'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2003'</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2002'</Log>
    <Log type="Info">Process Flow-Through: 005 - Statement - Consolidated Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>govx-20111231.xml</File>
    <File>govx-20111231.xsd</File>
    <File>govx-20111231_cal.xml</File>
    <File>govx-20111231_def.xml</File>
    <File>govx-20111231_lab.xml</File>
    <File>govx-20111231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
